<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35926802</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-3348</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of vascular surgery. Venous and lymphatic disorders</Title><ISOAbbreviation>J Vasc Surg Venous Lymphat Disord</ISOAbbreviation></Journal><ArticleTitle>Systematic review of venous thromboembolism risk categories derived from Caprini score.</ArticleTitle><Pagination><StartPage>1401</StartPage><EndPage>1409.e7</EndPage><MedlinePgn>1401-1409.e7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvsv.2022.05.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-333X(22)00266-9</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Hospital-acquired venous thromboembolism (VTE, including pulmonary embolism [PE] and deep vein thrombosis [DVT]) is a preventable cause of hospital death. The Caprini risk assessment model (RAM) is one of the most commonly used tools to assess VTE risk. The RAM is operationalized in clinical practice by grouping several risk scores into VTE risk categories that drive decisions on prophylaxis. A correlation between increasing Caprini scores and rising VTE risk is well-established. We assessed whether the increasing VTE risk categories assigned on the basis of recommended score ranges also correlate with increasing VTE risk.</AbstractText><AbstractText Label="METHODS">We conducted a systematic review of articles that used the Caprini RAM to assign VTE risk categories and that reported corresponding VTE rates. A Medline and EMBASE search retrieved 895 articles, of which 57 fulfilled inclusion criteria.</AbstractText><AbstractText Label="RESULTS">Forty-eight (84%) of the articles were cohort studies, 7 (12%) were case-control studies, and 2 (4%) were cross-sectional studies. The populations varied from postsurgical to medical patients. There was variability in the number of VTE risk categories assigned by individual studies (6 used 5 risk categories, 37 used 4, 11 used 3, and 3 used 2), and in the cutoff scores defining the risk categories (scores from 0 alone to 0-10 for the low-risk category; from &#x2265;5 to &#x2265;10 for high risk). The VTE rates reported for similar risk categories also varied across studies (0%-12.3% in the low-risk category; 0%-40% for high risk). The Caprini RAM is designed to assess composite VTE risk; however, two studies reported PE or DVT rates alone, and many of the other studies did not specify the types of DVTs analyzed. The Caprini RAM predicts VTE at 30&#xa0;days after assessment; however, only 17 studies measured outcomes at 30&#xa0;days; the remaining studies had either shorter or longer follow-ups (0-180&#xa0;days).</AbstractText><AbstractText Label="CONCLUSIONS">The usefulness of the Caprini RAM is limited by heterogeneity in its implementation across centers. The score-derived VTE risk categorization has significant variability in the number of risk categories being used, the cutpoints used to define the risk categories, the outcome being measured, and the follow-up duration. This factor leads to similar risk categories being associated with different VTE rates, which impacts the clinical and research implications of the results. To enhance generalizability, there is a need for studies that validate the RAM in a broad population of medical and surgical patients, identify standardized risk categories, define risk of DVT and PE as distinct end points, and measure outcomes at standardized follow-up time points.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayssen</LastName><ForeName>Hilary</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Maryland, Baltimore, MD; Surgery Service, VA Medical Center, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cires-Drouet</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Maryland, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Englum</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Maryland, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Phuong</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Computer Science and Electrical Engineering, University of Maryland, Baltimore County, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahoo</LastName><ForeName>Shalini</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Maryland, Baltimore, MD; Surgery Service, VA Medical Center, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayorga-Carlin</LastName><ForeName>Minerva</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Maryland, Baltimore, MD; Surgery Service, VA Medical Center, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Surgery Service, VA Medical Center, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Surgery Service, VA Medical Center, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yesha</LastName><ForeName>Yelena</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Computer Science and Electrical Engineering, University of Maryland, Baltimore County, MD; Department of Computer Science, University of Miami, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorkin</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Gerontology and Palliative Care, University of Maryland School of Medicine, Baltimore, MD; Baltimore VA Geriatric Research, Education, and Clinical Center, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lal</LastName><ForeName>Brajesh K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Maryland, Baltimore, MD; Surgery Service, VA Medical Center, Baltimore, MD. Electronic address: blal@som.umaryland.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 RX000995</GrantID><Acronym>RX</Acronym><Agency>RRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028747</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000262</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Surg Venous Lymphat Disord</MedlineTA><NlmUniqueID>101607771</NlmUniqueID><ISSNLinking>2213-333X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Caprini score</Keyword><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Risk assessment model</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>Conflicts of interest: Hilary Hayssen, MD, none. Rafael Cires-Drouet, MD, none. Brian Englum, MD, none. Phuong Nguyen, PhD, none. Shalini Sahoo, MA, none. Minerva Mayorga-Carlin, MPH, none. Tariq Siddiqui, MS, none. Douglas Turner, MD, none. Yelena Yesha, PhD, none. John D Sorkin, MD PhD, none. Brajesh K Lal, MD, none</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35926802</ArticleId><ArticleId IdType="mid">NIHMS1827626</ArticleId><ArticleId IdType="pmc">PMC9783939</ArticleId><ArticleId IdType="doi">10.1016/j.jvsv.2022.05.003</ArticleId><ArticleId IdType="pii">S2213-333X(22)00266-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC. Impact of Blood Clots on the United States | CDC. Centers for Disease Control and Prevention. Published October 19, 2018. Accessed December 17, 2021. https://www.cdc.gov/ncbddd/dvt/infographic-impact.html</Citation></Reference><Reference><Citation>Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous Thromboembolism. Am J Prev Med. 2010;38(4):S495&#x2013;S501. doi:10.1016/j.amepre.2009.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2009.12.017</ArticleId><ArticleId IdType="pubmed">20331949</ArticleId></ArticleIdList></Reference><Reference><Citation>The Surgeon General&#x2019;s Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Published online 2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">20669525</ArticleId></ArticleIdList></Reference><Reference><Citation>Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17(3):304&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">1754886</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin M, Dengler N, Krauss ES, Segal A, Wei N, Daly M, et al. Completion of the Updated Caprini Risk Assessment Model (2013 Version). Clin Appl Thromb. 2019;25:107602961983805. doi:10.1177/1076029619838052</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029619838052</ArticleId><ArticleId IdType="pmc">PMC6714938</ArticleId><ArticleId IdType="pubmed">30939900</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett MA, Mauck KF, Stephenson CR, Ganesh R, Daniels PR. Perioperative Venous Thromboembolism Prophylaxis. Mayo Clin Proc. 2020;95(12):2775&#x2013;2798. doi:10.1016/j.mayocp.2020.06.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2020.06.015</ArticleId><ArticleId IdType="pubmed">33276846</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuck AK, Spirk D, Schaudt J, Kucher N. Risk assessment models for venous thromboembolism in acutely ill medical patients: A systematic review. Thromb Haemost. 2017;117(4):801&#x2013;808. doi:10.1160/TH16-08-0631</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH16-08-0631</ArticleId><ArticleId IdType="pubmed">28150851</ArticleId></ArticleIdList></Reference><Reference><Citation>Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2&#x2013;3):70&#x2013;78. doi:10.1016/j.disamonth.2005.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.disamonth.2005.02.003</ArticleId><ArticleId IdType="pubmed">15900257</ArticleId></ArticleIdList></Reference><Reference><Citation>Caprini JA. Risk assessment as a guide to thrombosis prophylaxis. Curr Opin Pulm Med. 2010;16(5):448&#x2013;452. doi:10.1097/MCP.0b013e32833c3d3e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCP.0b013e32833c3d3e</ArticleId><ArticleId IdType="pubmed">20592595</ArticleId></ArticleIdList></Reference><Reference><Citation>Krauss ES, Segal A, Cronin M, Dengler N, Lesser ML, Ahn S, et al. Implementation and Validation of the 2013 Caprini Score for Risk Stratification of Arthroplasty Patients in the Prevention of Venous Thrombosis. Clin Appl Thromb. 2019;25:107602961983806. doi:10.1177/1076029619838066</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029619838066</ArticleId><ArticleId IdType="pmc">PMC6714918</ArticleId><ArticleId IdType="pubmed">30939898</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. Published online March 29, 2021:n71. doi:10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen L, Li Y, Ding J, Yang J, Jiang G, Sihoe ADL. Implementation of a pulmonary thromboembolism prophylaxis program in Chinese lung surgery patients: compliance and effectiveness. J Thorac Dis. 2020;12(8):4307&#x2013;4314. doi:10.21037/jtd-20-690</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd-20-690</ArticleId><ArticleId IdType="pmc">PMC7475573</ArticleId><ArticleId IdType="pubmed">32944343</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong HS, Miller TJ, Davis K, Matthew A, Lysikowski J, Lazcano E, et al. Application of the Caprini Risk Assessment Model in Evaluation of Non&#x2013;Venous Thromboembolism Complications in Plastic and Reconstructive Surgery Patients. Aesthet Surg J. 2014;34(1):87&#x2013;95. doi:10.1177/1090820X13514077</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1090820X13514077</ArticleId><ArticleId IdType="pubmed">24327763</ArticleId></ArticleIdList></Reference><Reference><Citation>Obi AT, Pannucci CJ, Nackashi A, Abdullah N, Alvarez R, Bahl V, et al. Validation of the Caprini Venous Thromboembolism Risk Assessment Model in Critically Ill Surgical Patients. JAMA Surg. 2015;150(10):941. doi:10.1001/jamasurg.2015.1841</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2015.1841</ArticleId><ArticleId IdType="pubmed">26288124</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X, Zhang T, Zhou L, Yin X, Dong Q. Stratification of venous thromboembolism risk in stroke patients by Caprini score. Ann Palliat Med. 2020;9(3):631&#x2013;636. doi:10.21037/apm.2020.04.20</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm.2020.04.20</ArticleId><ArticleId IdType="pubmed">32312069</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NE, Conway-Pearson L, Kavanah M, Mendez J, Sachs TF, Drake FT, et al. Standardized Risk Assessment and Risk-Stratified Venous Thromboembolism Prophylaxis for Patients Undergoing Breast Operation. J Am Coll Surg. 2020;230(6):947&#x2013;955. doi:10.1016/j.jamcollsurg.2019.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2019.11.010</ArticleId><ArticleId IdType="pubmed">31809861</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi A, Huang J, Wang X, Li M, Zhang J, Chen Y, et al. Postoperative D-dimer predicts venous thromboembolism in patients undergoing urologic tumor surgery. Urol Oncol Semin Orig Investig. 2018;36(6):307.e15&#x2013;307.e21. doi:10.1016/j.urolonc.2018.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urolonc.2018.03.003</ArticleId><ArticleId IdType="pubmed">29599070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewes PD, Hachey KJ, Zhang XW, Tripodis Y, Rosenkranz P, Ebright MI, et al. Evaluation of the Caprini Model for Venothromboembolism in Esophagectomy Patients. Ann Thorac Surg. 2015;100(6):2072&#x2013;2078. doi:10.1016/j.athoracsur.2015.05.098</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2015.05.098</ArticleId><ArticleId IdType="pubmed">26279363</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz Rios LH, Minga I, Kwak E, Najib A, Aller A, Lees E, et al. Prognostic Value of Venous Thromboembolism Risk Assessment Models in Patients with Severe COVID-19. TH Open. 2021;05(02):e211&#x2013;e219. doi:10.1055/s-0041-1730293</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1730293</ArticleId><ArticleId IdType="pmc">PMC8219405</ArticleId><ArticleId IdType="pubmed">34179684</ArticleId></ArticleIdList></Reference><Reference><Citation>Heft J, Goulder A, Schneiter M, Adam R. Venous Thromboembolism Prediction in Postoperative Urogynecology Patients: The Utility of Risk Assessment Tools. Female Pelvic Med Reconstr Surg. 2020;26(8):e27&#x2013;e32. doi:10.1097/SPV.0000000000000780</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SPV.0000000000000780</ArticleId><ArticleId IdType="pubmed">31651538</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemoto H, Mo M, Ito T, Inoue Y, Obitsu Y, Kichikawa K, et al. Venous thromboembolism complications after endovenous laser ablation for varicose veins and role of duplex ultrasound scan. J Vasc Surg Venous Lymphat Disord. 2019;7(6):817&#x2013;823. doi:10.1016/j.jvsv.2019.06.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2019.06.014</ArticleId><ArticleId IdType="pubmed">31540837</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu JX, Dong J, Ren H, Chen XJ, Yang Y, Chen RX, et al. Incidence and risk assessment of venous thromboembolism in cancer patients admitted to intensive care unit for post- operative care. :7.</Citation></Reference><Reference><Citation>Moss SR, Jenkins AM, Caldwell AK, Herbst BF, Kelleher ME, Kinnear B, et al. Risk Factors for the Development of Hospital-Associated Venous Thromboembolism in Adult Patients Admitted to a Children&#x2019;s Hospital. Hosp Pediatr. 2020;10(2):166&#x2013;172. doi:10.1542/hpeds.2019-0052</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/hpeds.2019-0052</ArticleId><ArticleId IdType="pubmed">31924691</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber EL, Clarke-Pearson DL. The limited utility of currently available venous thromboembolism risk assessment tools in gynecological oncology patients. Am J Obstet Gynecol. 2016;215(4):445.e1&#x2013;445.e9. doi:10.1016/j.ajog.2016.04.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2016.04.034</ArticleId><ArticleId IdType="pmc">PMC5045759</ArticleId><ArticleId IdType="pubmed">27131583</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlpine K, Breau RH, Mallick R, Cnossen S, Cagiannos I, Morash C, et al. Current guidelines do not sufficiently discriminate venous thromboembolism risk in urology. Urol Oncol Semin Orig Investig. 2017;35(7):457.e1&#x2013;457.e8. doi:10.1016/j.urolonc.2017.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urolonc.2017.01.015</ArticleId><ArticleId IdType="pubmed">28214280</ArticleId></ArticleIdList></Reference><Reference><Citation>Taengsakul N, Saiwongse T, Sakornwattananon O, Kreesaeng P, Kantathavorn N. Incidence and Risk Factors for Venous Thromboembolism Following 2462 Major Abdomino-Pelvic Surgeries in Tertiary Hospital. Vasc Health Risk Manag. 2021;Volume 17:135&#x2013;143. doi:10.2147/VHRM.S304187</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/VHRM.S304187</ArticleId><ArticleId IdType="pmc">PMC8041647</ArticleId><ArticleId IdType="pubmed">33854322</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y, Zheng R, Fu Y, Xiang Q, Yue Z, Li J, et al. Assessing the thrombosis risk of peripherally inserted central catheters in cancer patients using Caprini risk assessment model: a prospective cohort study. Support Care Cancer. 2021;29(9):5047&#x2013;5055. doi:10.1007/s00520-021-06073-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-021-06073-4</ArticleId><ArticleId IdType="pubmed">33594508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrych J, Kvasnicka T, Fryba V, Komarc M, Malikova I, Burget F, et al. 28 day post-operative persisted hypercoagulability after surgery for benign diseases: a prospective cohort study. BMC Surg. 2016;16(1):16. doi:10.1186/s12893-016-0128-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12893-016-0128-3</ArticleId><ArticleId IdType="pmc">PMC4822325</ArticleId><ArticleId IdType="pubmed">27048604</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittelkow EM, DeBrock WC, Mailey B, Ballinger TJ, Socas J, Lester ME, et al. Evaluation of an Extended-duration Chemoprophylaxis Regimen for Venous Thromboembolism after Microsurgical Breast Reconstruction. Plast Reconstr Surg - Glob Open. 2021;9(8):e3741. doi:10.1097/GOX.0000000000003741</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/GOX.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC8345913</ArticleId><ArticleId IdType="pubmed">34377621</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroud W, Whitworth JM, Miklic M, Schneider KE, Finan MA, Scalici J, et al. Validation of a venous thromboembolism risk assessment model in gynecologic oncology. Gynecol Oncol. 2014;134(1):160&#x2013;163. doi:10.1016/j.ygyno.2014.04.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2014.04.051</ArticleId><ArticleId IdType="pubmed">24796634</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA, Caprini JA. A Validation Study of a Retrospective Venous Thromboembolism Risk Scoring Method. Ann Surg. 2010;251(2):344&#x2013;350. doi:10.1097/SLA.0b013e3181b7fca6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181b7fca6</ArticleId><ArticleId IdType="pubmed">19779324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachey KJ, Hewes PD, Porter LP, Ridyard DG, Rosenkranz P, McAneny D, et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg. 2016;151(1):37&#x2013;44.e1. doi:10.1016/j.jtcvs.2015.08.039</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2015.08.039</ArticleId><ArticleId IdType="pubmed">26386868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadesse TA, Kedir HM, Fentie AM, Abiye AA. Venous Thromboembolism Risk and Thromboprophylaxis Assessment in Surgical Patients Based on Caprini Risk Assessment Model. Risk Manag Healthc Policy. 2020;Volume 13:2545&#x2013;2552. doi:10.2147/RMHP.S272852</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/RMHP.S272852</ArticleId><ArticleId IdType="pmc">PMC7667181</ArticleId><ArticleId IdType="pubmed">33204195</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yu L, Yu T, Li F, Zhang Y, Yu Z, et al. Venous thromboembolism after adult thymus or thymic tumor resection: A single- center experience. Thorac Cancer. 2020;11(8):2291&#x2013;2296. doi:10.1111/1759-7714.13543</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1759-7714.13543</ArticleId><ArticleId IdType="pmc">PMC7396359</ArticleId><ArticleId IdType="pubmed">32558357</ArticleId></ArticleIdList></Reference><Reference><Citation>Yago H, Yamaki T, Sasaki Y, Homma K, Mizobuchi T, Hasegawa Y, et al. Application of the Caprini Risk Assessment Model for Evaluating Postoperative Deep Vein Thrombosis in Patients Undergoing Plastic and Reconstructive Surgery. Ann Vasc Surg. 2020;65:82&#x2013;89. doi:10.1016/j.avsg.2019.10.082</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.avsg.2019.10.082</ArticleId><ArticleId IdType="pubmed">31678541</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C, Shargall Y, Li H, Tian B, Chen S, Miao J, et al. Prevalence of venous thromboembolism after lung surgery in China: a single-centre, prospective cohort study involving patients undergoing lung resections without perioperative venous thromboembolism prophylaxis&#x2020;. Eur J Cardiothorac Surg. 2019;55(3):455&#x2013;460. doi:10.1093/ejcts/ezy323</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezy323</ArticleId><ArticleId IdType="pubmed">30289479</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgi K, Muthusamy A, Subair M, Srinivasan S, Kumar A, Ravi R, et al. Assessing the risk for development of Venous Thromboembolism (VTE) in surgical patients using Adapted Caprini scoring system. Int J Surg. 2016;30:68&#x2013;73. doi:10.1016/j.ijsu.2016.04.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2016.04.030</ArticleId><ArticleId IdType="pubmed">27109201</ArticleId></ArticleIdList></Reference><Reference><Citation>Macht R, Gardner I, Talutis S, Rosenkranz P, Doherty G, McAneny D. Evaluation of a Standardized Risk-Based Venous Thromboembolism Prophylaxis Protocol in the Setting of Thyroid and Parathyroid Surgery. J Am Coll Surg. 2017;224(6):1029&#x2013;1035. doi:10.1016/j.jamcollsurg.2016.12.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2016.12.054</ArticleId><ArticleId IdType="pubmed">28161482</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Razeq HN, Hijjawi SB, Jallad SG, Ababneh BA. Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience. J Thromb Thrombolysis. 2010;30(3):286&#x2013;293. doi:10.1007/s11239-010-0445-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-010-0445-9</ArticleId><ArticleId IdType="pubmed">20127272</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S, Chen S, Li H, Ke L, Liu Y, Jiang R, et al. Risk factors for venous thromboembolism and evaluation of the modified Caprini score in patients undergoing lung resection. J Thorac Dis. 2020;12(9):4805&#x2013;4816. doi:10.21037/jtd-20-1279</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd-20-1279</ArticleId><ArticleId IdType="pmc">PMC7578470</ArticleId><ArticleId IdType="pubmed">33145053</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi L, Spectre G, Nesichi O, Leader A, Raanani P, Reuven Y, et al. Implementation of a Novel Protocol for Preventing Venous Thromboembolism in Otolaryngology Patients. Otolaryngol Neck Surg. Published online July 13, 2021:019459982110249. doi:10.1177/01945998211024923</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01945998211024923</ArticleId><ArticleId IdType="pubmed">34255600</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Pan L, Deng H, Zhang J, Tong X, Huang H, et al. Risk Assessment in Chinese Hospitalized Patients Comparing the Padua and Caprini Scoring Algorithms. Clin Appl Thromb. 2018;24(9_suppl):127S&#x2013;135S. doi:10.1177/1076029618797465</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029618797465</ArticleId><ArticleId IdType="pmc">PMC6714840</ArticleId><ArticleId IdType="pubmed">30198321</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobastov K, Barinov V, Schastlivtsev I, Laberko L, Rodoman G, Boyarintsev V. Validation of the Caprini risk assessment model for venous thromboembolism in high-risk surgical patients in the background of standard prophylaxis. J Vasc Surg Venous Lymphat Disord. 2016;4(2):153&#x2013;160. doi:10.1016/j.jvsv.2015.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2015.09.004</ArticleId><ArticleId IdType="pubmed">26993860</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanh BM, Cuong LQ, Son NT, Duc DT, Hung TT, Hung DD, et al. Determination of Risk Factors for Venous Thromboembolism by an Adapted Caprini Scoring System in Surgical Patients. J Pers Med. 2019;9(3):36. doi:10.3390/jpm9030036</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm9030036</ArticleId><ArticleId IdType="pmc">PMC6789529</ArticleId><ArticleId IdType="pubmed">31319527</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, Wang L, Wu X, Tang Y, Yang J, Wang B, et al. Validation of a Venous Thromboembolism Risk Assessment Model in Hospitalized Chinese Patients: A Case-Control Study. J Atheroscler Thromb. 2014;21(3):261&#x2013;272. doi:10.5551/jat.20891</Citation><ArticleIdList><ArticleId IdType="doi">10.5551/jat.20891</ArticleId><ArticleId IdType="pubmed">24304962</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Liu C, Chen X, Wu W, Lu G. Comparison between Caprini and Padua risk assessment models for hospitalized medical patients at risk for venous thromboembolism: a retrospective study. Interact Cardiovasc Thorac Surg. 2016;23(4):538&#x2013;543. doi:10.1093/icvts/ivw158</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivw158</ArticleId><ArticleId IdType="pubmed">27297558</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant PJ, Greene MT, Chopra V, Bernstein SJ, Hofer TP, Flanders SA. Assessing the Caprini Score for Risk Assessment of Venous Thromboembolism in Hospitalized Medical Patients. Am J Med. 2016;129(5):528&#x2013;535. doi:10.1016/j.amjmed.2015.10.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2015.10.027</ArticleId><ArticleId IdType="pmc">PMC5331485</ArticleId><ArticleId IdType="pubmed">26551977</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo H, Li Y, Liu G, Ma Y, Li Z, Cao J, et al. Assessing the Risk for Development of Deep Vein Thrombosis among Chinese Patients using the 2010 Caprini Risk Assessment Model: A Prospective Multicenter Study. J Atheroscler Thromb. 2020;27(8):801&#x2013;808. doi:10.5551/jat.51359</Citation><ArticleIdList><ArticleId IdType="doi">10.5551/jat.51359</ArticleId><ArticleId IdType="pmc">PMC7458789</ArticleId><ArticleId IdType="pubmed">31852858</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilakis V, Klein GM, Trostler M, Mukit M, Marquez JE, Dagum AB, et al. Postoperative Venous Thromboembolism Prophylaxis Utilizing Enoxaparin Does Not Increase Bleeding Complications After Abdominal Body Contouring Surgery. Aesthet Surg J. 2020;40(9):989&#x2013;995. doi:10.1093/asj/sjz274</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/asj/sjz274</ArticleId><ArticleId IdType="pubmed">31639195</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamoun N, Matta S, Aderian SS, Salibi R, Salameh P, Tayeh G, et al. A Prospective Observational Cohort of Clinical Outcomes in Medical Inpatients prescribed Pharmacological Thromboprophylaxis Using Different Clinical Risk Assessment Models(COMPT RAMs). Sci Rep. 2019;9(1):18366. doi:10.1038/s41598-019-54842-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-54842-3</ArticleId><ArticleId IdType="pmc">PMC6892868</ArticleId><ArticleId IdType="pubmed">31797897</ArticleId></ArticleIdList></Reference><Reference><Citation>Golemi I, Salazar Adum JP, Tafur A, Caprini J. Venous thromboembolism prophylaxis using the Caprini score. Dis Mon. 2019;65(8):249&#x2013;298. doi:10.1016/j.disamonth.2018.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.disamonth.2018.12.005</ArticleId><ArticleId IdType="pubmed">30638566</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannucci CJ, Swistun L, MacDonald JK, Henke PK, Brooke BS. Individualized venous thromboembolism risk stratification using the 2005 caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: A meta-analysis. Ann Surg. 2017;265(6):1094&#x2013;1103. doi:10.1097/SLA.0000000000002126</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000002126</ArticleId><ArticleId IdType="pubmed">28106607</ArticleId></ArticleIdList></Reference><Reference><Citation>Seruya M, Venturi ML, Iorio ML, Davison SP. Efficacy and Safety of Venous Thromboembolism Prophylaxis in Highest Risk Plastic Surgery Patients: Plast Reconstr Surg. 2008;122(6):1701&#x2013;1708. doi:10.1097/PRS.0b013e31818dbffd</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e31818dbffd</ArticleId><ArticleId IdType="pubmed">19050522</ArticleId></ArticleIdList></Reference><Reference><Citation>Darzi AJ, Karam SG, Charide R, Etxeandia-Ikobaltzeta I, Cushman M, Gould MK, et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood. 2020;135(20):1788&#x2013;1810. doi:10.1182/blood.2019003603</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2019003603</ArticleId><ArticleId IdType="pmc">PMC7242782</ArticleId><ArticleId IdType="pubmed">32092132</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn SR. The Post-Thrombotic Syndrome. Published online 2010:5.</Citation></Reference><Reference><Citation>Piazza G. Chronic Thromboembolic Pulmonary Hypertension. N Engl J Med. Published online 2011:10.</Citation><ArticleIdList><ArticleId IdType="pubmed">21268727</ArticleId></ArticleIdList></Reference><Reference><Citation>Cote LP, Greenberg S, Caprini JA, Tafur A, Choi C, Mu&#xf1;oz FJ, et al. Comparisons Between Upper and Lower Extremity Deep Vein Thrombosis: A Review of the RIETE Registry. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2017;23(7):748&#x2013;754. doi:10.1177/1076029616663847</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029616663847</ArticleId><ArticleId IdType="pubmed">27572888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn S, Elman E, Bornais C, Blostein M, Wells P. Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults. Thromb Haemost. 2005;93(03):499&#x2013;502. doi:10.1160/TH04-10-0640</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH04-10-0640</ArticleId><ArticleId IdType="pubmed">15735801</ArticleId></ArticleIdList></Reference><Reference><Citation>Cires-Drouet RS, Durham F, Sharma J, Cheeka P, Strumpf Z, Cranston E, et al. Prevalence and clinical outcomes of hospitalized patients with upper extremity deep vein thrombosis. J Vasc Surg Venous Lymphat Disord. Published online June 2021. doi:10.1016/j.jvsv.2021.05.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2021.05.007</ArticleId><ArticleId IdType="pmc">PMC9000923</ArticleId><ArticleId IdType="pubmed">34089941</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucher N. Deep-Vein Thrombosis of the Upper Extremities. N Engl J Med. 2011;364(9):861&#x2013;869. doi:10.1056/NEJMcp1008740</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp1008740</ArticleId><ArticleId IdType="pubmed">21366477</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuman AG, Hu HM, Pannucci CJ, Jackson CR, Bradford CR, Bahl V. Stratifying the Risk of Venous Thromboembolism in Otolaryngology. Otolaryngol Neck Surg. 2012;146(5):719&#x2013;724. doi:10.1177/0194599811434383</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599811434383</ArticleId><ArticleId IdType="pmc">PMC4496153</ArticleId><ArticleId IdType="pubmed">22261490</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarlagadda BB, Brook CD, Stein DJ, Jalisi S. Venous thromboembolism in otolaryngology surgical inpatients receiving chemoprophylaxis: Venous Thromboembolism in Patients Receiving Chemoprophylaxis. Head Neck. 2014;36(8):1087&#x2013;1093. doi:10.1002/hed.23411</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hed.23411</ArticleId><ArticleId IdType="pubmed">23804491</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterbling HM, Rosen AK, Hachey KJ, Vellanki NS, Hewes PD, Rao SR, et al. Caprini Risk Model Decreases Venous Thromboembolism Rates in Thoracic Surgery Cancer Patients. Ann Thorac Surg. 2018;105(3):879&#x2013;885. doi:10.1016/j.athoracsur.2017.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.10.013</ArticleId><ArticleId IdType="pubmed">29397103</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu ZQ, Li KX, Zhu Q, Li HZ, Tang ZY, Wang Z. Application value of D-dimer testing and Caprini risk assessment model (RAM) to predict venous thromboembolism (VTE) in Chinese non-oncological urological inpatients: a retrospective study from a tertiary hospital. Transl Androl Urol. 2020;9(5):1904&#x2013;1911. doi:10.21037/tau-20-320</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tau-20-320</ArticleId><ArticleId IdType="pmc">PMC7658137</ArticleId><ArticleId IdType="pubmed">33209654</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl V, Shuman AG, Hu HM, Jackson CR, Pannucci CJ, Alaniz C, et al. Chemoprophylaxis for Venous Thromboembolism in Otolaryngology. JAMA Otolaryngol Neck Surg. 2014;140(11):999. doi:10.1001/jamaoto.2014.2254</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoto.2014.2254</ArticleId><ArticleId IdType="pubmed">25275427</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y, Liu Y, Chen S, Jin Y, Jiang H. The combination of Caprini risk assessment scale and thrombotic biomarkers to evaluate the risk of venous thromboembolism in critically ill patients. Medicine (Baltimore). 2018;97(47):e13232. doi:10.1097/MD.0000000000013232</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000013232</ArticleId><ArticleId IdType="pmc">PMC6392726</ArticleId><ArticleId IdType="pubmed">30461624</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Tian S, Wang Y, Zhao J, Pei M, Zhao M, et al. Evaluation of Risk Factors for Venous Thromboembolism in Patients Who Underwent Gynecological Surgery and Validation of a Fast-Rating Assessment Table. Med Sci Monit. 2019;25:8814&#x2013;8819. doi:10.12659/MSM.920198</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.920198</ArticleId><ArticleId IdType="pmc">PMC6882298</ArticleId><ArticleId IdType="pubmed">31751319</ArticleId></ArticleIdList></Reference><Reference><Citation>Tham T, Costantino P. Comparison of venous thromboembolism risk stratification models in a high risk otolaryngology patient cohort. J Perioper Pract. 2019;29(5):129&#x2013;134. doi:10.1177/1750458919826794</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1750458919826794</ArticleId><ArticleId IdType="pubmed">30672371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Lv B, Li W, Wang S, Ding W. Diagnostic Performance of the Caprini Risk Assessment Model Combined With D-Dimer for Preoperative Deep Vein Thrombosis in Patients With Thoracolumbar Fractures Caused by High-Energy Injuries. World Neurosurg. 2022;157:e410&#x2013;e416. doi:10.1016/j.wneu.2021.10.106</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2021.10.106</ArticleId><ArticleId IdType="pubmed">34673239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazeltine MD, Guber RD, Buettner H, Dorfman JD. Venous thromboembolism risk stratification in trauma using the Caprini risk assessment model. Thromb Res. 2021;208:52&#x2013;57. doi:10.1016/j.thromres.2021.10.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2021.10.016</ArticleId><ArticleId IdType="pubmed">34715509</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian B, Li H, Cui S, Song C, Li T, Hu B. A novel risk assessment model for venous thromboembolism after major thoracic surgery: a Chinese single-center study. J Thorac Dis. 2019;11(5):1903&#x2013;1910. doi:10.21037/jtd.2019.05.11</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2019.05.11</ArticleId><ArticleId IdType="pmc">PMC6588735</ArticleId><ArticleId IdType="pubmed">31285883</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y, Fu Y, Xiang Q, Xie L, Yu C, Li J. Plasminogen activator inhibitor-1 gene promoter 4G/5G polymorphism and risks of peripherally inserted central catheter&#x2013;related venous thrombosis in patients with lung cancer: a prospective cohort study. Support Care Cancer. 2021;29(11):6431&#x2013;6439. doi:10.1007/s00520-021-06207-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-021-06207-8</ArticleId><ArticleId IdType="pubmed">33893843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta Y, Arai M, Nakagawa T, Akizue N, Ishikawa K, Hamanaka S, et al. Comparison of a novel predictor of venous thromboembolic complications in inflammatory bowel disease with current predictors. J Gastroenterol Hepatol. 2019;34(5):870&#x2013;879. doi:10.1111/jgh.14472</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.14472</ArticleId><ArticleId IdType="pubmed">30225931</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Huang J, Liu J, Deng H, Pan L. Venous thromboembolism risk factors and prophylaxis of elderly intensive care unit patients in a Chinese general hospital. Ann Palliat Med. 2021;10(4):4453&#x2013;4462. doi:10.21037/apm-21-464</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-21-464</ArticleId><ArticleId IdType="pubmed">33894730</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber B, Seal A, McGirr J, Fielding K. Case series of elective instrumented posterior lumbar spinal fusions demonstrating a low incidence of venous thromboembolism: Elective posterior lumbar spinal fusion. ANZ J Surg. 2016;86(10):796&#x2013;800. doi:10.1111/ans.12702</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.12702</ArticleId><ArticleId IdType="pubmed">24897952</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33857326</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Thrombolytic therapy for pulmonary embolism.</ArticleTitle><Pagination><StartPage>CD004437</StartPage><MedlinePgn>CD004437</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD004437</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD004437.pub6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Thrombolytic therapy is usually reserved for people with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and may reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhage. This is the fourth update of the Cochrane review first published in 2006.</AbstractText><AbstractText Label="OBJECTIVES">To assess the effects of thrombolytic therapy for acute pulmonary embolism.</AbstractText><AbstractText Label="SEARCH METHODS">The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases and the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 17 August 2020. We undertook reference checking to identify additional studies.</AbstractText><AbstractText Label="SELECTION CRITERIA">We included randomised controlled trials (RCTs) that compared thrombolytic therapy followed by heparin versus heparin alone, heparin plus placebo, or surgical intervention for people with acute PE (massive/submassive). We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS">Two review authors (ZZ, QH) assessed the eligibility and risk of bias of trials and extracted data. We calculated effect estimates using the odds ratio (OR) with a 95% confidence interval (CI) or the mean difference (MD) with a 95% CI. The primary outcomes of interest were death, recurrence of PE and haemorrhagic events. We assessed the certainty of the evidence using GRADE criteria.</AbstractText><AbstractText Label="MAIN RESULTS">We identified three new studies for inclusion in this update. We included 21 trials in the review, with a total of 2401 participants. No studies compared thrombolytics versus surgical intervention. We were not able to include one study in the meta-analysis because it provided no extractable data. Most studies carried a high or unclear risk of bias related to randomisation and blinding. Meta-analysis showed that, compared to control (heparin alone or heparin plus placebo), thrombolytics plus heparin probably reduce both the odds of death (OR 0.58, 95% CI 0.38 to 0.88; 19 studies, 2319 participants; low-certainty evidence), and recurrence of PE (OR 0.54, 95% CI 0.32 to 0.91; 12 studies, 2050 participants; low-certainty evidence). Effects on mortality weakened when six studies at high risk of bias were excluded from analysis (OR 0.71, 95% CI 0.45 to 1.13; 13 studies, 2046 participants) and in the analysis of submassive PE participants (OR 0.61, 95% CI 0.37 to 1.02; 1993 participants). Effects on recurrence of PE also weakened after removing one study at high risk of bias for sensitivity analysis (OR 0.60, 95% CI 0.35 to 1.04; 11 studies, 1949 participants). We downgraded the certainty of evidence to low because of 'Risk of bias' concerns. Major haemorrhagic events were probably more common in the thrombolytics group than in the control group (OR 2.84, 95% CI 1.92 to 4.20; 15 studies, 2101 participants; moderate-certainty evidence), as were minor haemorrhagic events (OR 2.97, 95% CI 1.66 to 5.30; 13 studies,1757 participants; low-certainty evidence). We downgraded the certainty of the evidence to moderate or low because of 'Risk of bias' concerns and inconsistency. Haemorrhagic stroke may occur more often in the thrombolytics group than in the control group (OR 7.59, 95% CI 1.38 to 41.72; 2 studies, 1091 participants). Limited data indicated that thrombolytics may benefit haemodynamic outcomes, perfusion lung scanning, pulmonary angiogram assessment, echocardiograms, pulmonary hypertension, coagulation parameters, composite clinical outcomes, need for escalation and survival time to a greater extent than heparin alone. However, the heterogeneity of the studies and the small number of participants involved warrant caution when interpreting results. The length of hospital stay was shorter in the thrombolytics group than in the control group (mean difference (MD) -1.40 days, 95% CI -2.69 to -0.11; 5 studies, 368 participants). Haemodynamic decompensation may occur less in the thrombolytics group than in the control group (OR 0.36, 95% CI 0.20 to 0.66; 3 studies, 1157 participants). Quality of life was similar between the two treatment groups. None of the included studies provided data on post-thrombotic syndrome or on cost comparison.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS">Low-certainty evidence suggests that thrombolytics may reduce death following acute pulmonary embolism compared with heparin (the effectiveness was mainly driven by one trial with massive PE). Thrombolytic therapy may be helpful in reducing the recurrence of pulmonary emboli but may cause more major and minor haemorrhagic events, including haemorrhagic stroke. More studies of high methodological quality are needed to assess safety and cost effectiveness of thrombolytic therapy for people with pulmonary embolism.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Zhiliang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Jirong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Bi Rong</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Taixiang</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guan J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Cochrane China, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Qiukui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00680628</AccessionNumber><AccessionNumber>NCT00639743</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>ETM/442</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Cochrane Database Syst Rev. 2018 Dec 18;12:CD004437. doi: 10.1002/14651858.CD004437.pub5.</RefSource><PMID Version="1">30560579</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Zhiliang Zuo: none known.&#x2028;Jirong Yue: none known.&#x2028;Birong Dong: none known.&#x2028;Taixiang Wu: none known.&#x2028;Guan Jian Liu: none known.&#x2028;Qiukui Hao: none known.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>17</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33857326</ArticleId><ArticleId IdType="pmc">PMC8092433</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD004437.pub6</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Ahmed 2018 {published data only}</Title><Reference><Citation>Ahmed MA, Abdelsalam SI, Elmorsy RA. Value of thrombolytic therapy for submassive pulmonary embolism patients. Egyptian Journal of Chest Diseases and Tuberculosis 2018;67:413-8.</Citation></Reference></ReferenceList><ReferenceList><Title>Becattini 2010 {published data only}</Title><Reference><Citation>Becattini C, Agnelli G, Salvi A, Grifoni S, Pancaldi LG, Enea I, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thrombosis Research 2010;125(3):e82-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19833379</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dalla&#x2010;Volta 1992 {published data only}</Title><Reference><Citation>Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, et al. PAIMS2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of Cardiology 1992;20(3):520-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512328</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dotter 1979 {published data only}</Title><Reference><Citation>Dotter CT, Seamon AJ, Rosch J, Porter J. Streptokinase and heparin in the treatment of major pulmonary embolism: a randomised comparison. Vascular Surgery 1979;13(1):42-52.</Citation></Reference></ReferenceList><ReferenceList><Title>Fasullo 2011 {published data only}</Title><Reference><Citation>Fasullo S, Scalzo S, Maringhini G, Ganci F, Cannizzaro S, Basile I, et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. American Journal of the Medical Sciences 2011;341(1):33-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20890176</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 1993 {published data only}</Title><Reference><Citation>Goldhaber SZ, Haire WD, Fekdstein ML, Miller M, Toltzis R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341(8844):507-11.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094768</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jerjes&#x2010;S&#xe1;nchez 1995 {published data only}</Title><Reference><Citation>Jerjes-S&#xe1;nchez C, Ram&#xed;rez-Rivera A, De Lourdes-Garc&#xed;a M, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. Journal of Thrombosis and Thrombolysis 1995;2(3):227-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10608028</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kline 2014 {published data only}</Title><Reference><Citation>Kline J, Hernandez J, Kabrhel C, Courtney DM, Jones AE, Nordenholtz K, et al. Randomized trial of tenecteplase or placebo with low molecular weight heparin for acute submassive pulmonary embolism: assessment of patient-oriented cardiopulmonary outcomes at three months. Journal of the American College of Cardiology 2013;61(10 Suppl 1):E2074.</Citation></Reference><Reference><Citation>Kline JA, Hernandez J, Hogg MM, Jones AE, Courtney DM, Kabrhel C, et al. Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. Emergency Medicine Australasia 2013;25(6):515-26. [DOI: 10.1111/1742-6723.12159]</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1742-6723.12159</ArticleId><ArticleId IdType="pubmed">24224521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline JA, Hernandez J, Kabrhel C, Courtney DM, Nordenholtz KE, Diercks DB, et al. Randomized trial of tenecteplase or placebo with low molecular weight heparin for acute submassive pulmonary embolism: assessment of patient-oriented cardiopulmonary outcomes at three months. Academic Emergency Medicine 2013;20(5 Suppl 1):S7.</Citation></Reference><Reference><Citation>Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. Journal of Thrombosis and Haemostasis 2014;12(4):459-68. [NCT00680628]</Citation><ArticleIdList><ArticleId IdType="pubmed">24484241</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT00680628. Randomized trial of tenecteplase to treat severe submassive pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00680628?cond=pulmonary+embolism&amp;rank=42 (first received 20 May 2008).</Citation></Reference><Reference><Citation>Stewart LK, Nordenholz KE, Courtney M, Kabrhel C, Jones AE, Rondina MT, et al. Comparison of acute and convalescent biomarkers of inflammation in patients with acute pulmonary embolism treated with systemic fibrinolysis vs. placebo. Blood Coagulation &amp; Fibrinolysis 2017;28(8):675-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">28957940</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Konstantinides 2002 {published data only}</Title><Reference><Citation>Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. New England Journal of Medicine 2002;347(15):1143-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374874</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kucher 2014 {published data only}</Title><Reference><Citation>Kucher N, Boekstegers P, Muller O, Kupatt C, Beyer-Westendorf J, Heitzer T, et al. Randomized controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014;129(4):479-86. [NCT01166997]</Citation><ArticleIdList><ArticleId IdType="pubmed">24226805</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levine 1990 {published data only}</Title><Reference><Citation>Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98(6):1473-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2123152</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ly 1978 {published data only}</Title><Reference><Citation>Arnesen BL, Eie H, Hol R. A prospective study of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Medica Scandinavica Supplement 1978;621:15.</Citation><ArticleIdList><ArticleId IdType="pubmed">352100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly B, Arneson H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Medica Scandinavica 1978;203(6):465-70.</Citation><ArticleIdList><ArticleId IdType="pubmed">352100</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Marini 1988 {published data only}</Title><Reference><Citation>Giuntini C, Marini C, Di Ricco G, Palla R, Giacomelli V, Rindi M. A controlled clinical trial on the effect of heparin infusion and two regimens of urokinase in acute pulmonary embolism. Giornale Italiano di Cardiologia 1984;14(Suppl 1):26-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">6398781</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988;54(3):162-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">3073463</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meyer 2014 {published data only}</Title><Reference><Citation>Barco S, Russo M, Vicaut E, Becattini C, Bertoletti L, Beyer-Westendorf J, et al. Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Clinical Research in Cardiology 2019;108(7):772-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584226</ArticleId><ArticleId IdType="pubmed">30564950</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. Journal of the American College of Cardiology 2017;69(12):1536-44.</Citation><ArticleIdList><ArticleId IdType="pubmed">28335835</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. New England Journal of Medicine 2014;370(15):1402-11. [NCT00639743]</Citation><ArticleIdList><ArticleId IdType="pubmed">24716681</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT00639743. PEITHO Pulmonary Embolism Thrombolysis Study. clinicaltrials.gov/ct2/show/NCT00639743?term=thrombolysis&amp;rank=14 (first received 20 March 2008).</Citation></Reference><Reference><Citation>PEITHO Steering Committee. Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. American Heart Journal 2012;163(1):33-8. [NCT00639743]</Citation><ArticleIdList><ArticleId IdType="pubmed">22172434</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>PIOPED 1990 {published data only}</Title><Reference><Citation>PIOPED Investigation Committee. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED investigators. Chest 1990;97(3):528-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">2106408</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sharifi 2013 {published data only}</Title><Reference><Citation>Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the "mOPETT" Trial). American Journal of Cardiology 2013;111(2):273-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23102885</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sinha 2017 {published data only}</Title><Reference><Citation>Sinha SK, Sachan M, Goel A, Singh K, Mishra V, Jha MJ, et al. Efficacy and safety of thrombolytic therapy in acute submassive pulmonary embolism: follow-up study. Journal of Clinical Medicine Research 2017;9(2):163-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215020</ArticleId><ArticleId IdType="pubmed">28090232</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Taherkhani 2014 {published data only}</Title><Reference><Citation>Taherkhani M, Taherkhani A, Hashemi SR, Langroodi TF, Sadeghi R, Beyranvand M. Thrombolytic-plus-anticoagulant therapy versus anticoagulant-alone therapy in submassive pulmonary thromboembolism (TVASPE study): a randomized clinical trial. Journal of Tehran University Heart Center 2014;9(3):104-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393831</ArticleId><ArticleId IdType="pubmed">25870626</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tibbutt 1974 {published data only}</Title><Reference><Citation>Tibbutt DA, Davies JA, Anderson JA, Fletcher EW, Hamill J, Thomas ML, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. British Medical Journal 1974;1(904):343-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1633603</ArticleId><ArticleId IdType="pubmed">4594580</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>UPETSG 1970 {published data only}</Title><Reference><Citation>Sasahara AA, Hyers TM, Cole CM, Ederer F, Murray JA, Wenger NK, et al. The urokinase pulmonary embolism trial. Circulation 1973;47(2 Suppl):7-21.</Citation></Reference><Reference><Citation>Sharma GV, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. New England Journal of Medicine 1980;303(15):842-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7412801</ArticleId></ArticleIdList></Reference><Reference><Citation>UPET. Urokinase pulmonary embolism trial. Phase 1 results: a co-operative study. JAMA 1970;214(12):2163-71.</Citation><ArticleIdList><ArticleId IdType="pubmed">5536580</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zhang 2018 {published data only}</Title><Reference><Citation>Zhang LY, Gao BA, Jin Z, Xiang GM, Gong Z, Zhang TT, et al. Clinical efficacy of low dose recombinant tissue type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism. Saudi Medical Journal 2018;39(11):1090-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6274653</ArticleId><ArticleId IdType="pubmed">30397707</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Abdelsamad 2011 {published data only}</Title><Reference><Citation>Abdelsamad AA, El-Morsi AS, Mansour AE. Efficacy and safety of high dose versus low dose streptokinase for treatment of submassive pulmonary embolism. Egyptian Heart Journal 2011;63:67-72.</Citation></Reference></ReferenceList><ReferenceList><Title>Agnelli 1997 {published data only}</Title><Reference><Citation>Agnelli G, Iorio A, Parise P, Goldhaber SZ, Levine MN. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. Blood Coagulation &amp; Fibrinolysis 1997;8(4):216-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9199818</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Alexandru Ion 2017 {published data only}</Title><Reference><Citation>Alexandru Ion A, Andrei C, Raducan M, Sinescu C. The bleeding risk in thrombolysed patients with intermediary-high risk pulmonary embolism. European Journal of Heart Failure 2017;19(Suppl 1):34-5.</Citation></Reference></ReferenceList><ReferenceList><Title>Allen 2020 {published data only}</Title><Reference><Citation>Allen S, Porcaro K, Chan L, Masic D, Morris S, Haines J, et al. Comparison of outcomes in catheter-directed versus ultrasound-assisted thrombolysis for treatment of pulmonary embolism. Journal of the American College of Cardiology 2020;75(11):2266.</Citation></Reference></ReferenceList><ReferenceList><Title>Avgerinos 2018 {published data only}</Title><Reference><Citation>Avgerinos E, Ali AA, Toma C, Wu B, Saadeddin Z, McDaniel B, et al. Catheter-directed thrombolysis versus suction thrombectomy in the management of acute pulmonary embolism. Journal of Vascular Surgery 2018;67(2):e28.</Citation><ArticleIdList><ArticleId IdType="pubmed">30902560</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Barrios 2017 {published data only}</Title><Reference><Citation>Barrios D, Chavant J, Rosa-Salazar V, Muriel A, Viallon A, Yusen RD, et al. Treatment of right heart thrombi associated with acute pulmonary embolism. American Journal of Medicine 2017;130:588-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">28011316</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bell 1974 {published data only}</Title><Reference><Citation>Bell WR, Simon TL, Stengle JM, Sherry S. The urokinase-streptokinase pulmonary embolism trial (phase II) results. Circulation 1974;50(6):1070-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">4430106</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bell 1976 {published data only}</Title><Reference><Citation>Bell WR. Streptokinase and urokinase in the treatment of pulmonary thromboemboli; from a national co-operative study. Thrombosis and Haemostasis 1976;35(1):57-69.</Citation><ArticleIdList><ArticleId IdType="pubmed">785689</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bell 1977 {published data only}</Title><Reference><Citation>Bell WR. Thrombolytic therapy: differences between streptokinase and urokinase. Vascular Surgery 1977;11(6):378-83.</Citation><ArticleIdList><ArticleId IdType="pubmed">616152</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bhardwaj 2010 {published data only}</Title><Reference><Citation>Bhardwaj S, Krishna CK, Mukherjee N, Sambi RS, Aggarwal KK, Kapoor N, et al. Treatment of massive pulmonary embolism by tenecteplase. Indian Heart Journal 2010;62(5):454-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23189890</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bin 2019 {published data only}</Title><Reference><Citation>Bin H, Binxia S, Xufeng C, Lin L, Jinsong Z. Effects of the combination of alteplase or urokinase with low molecular weight heparin anticoagulant therapy in the treatment of elderly patients with acute submassive pulmonary embolism. Acta Medica Mediterranea 2019;35(3):1287-92.</Citation></Reference></ReferenceList><ReferenceList><Title>Carroll 2018 {published data only}</Title><Reference><Citation>Carroll BJ, Goldhaber SZ, Liu PY, Piazza G. Catheter-directed, ultrasound-facilitated fibrinolysis in obese patients with massive and submassive pulmonary embolism. Journal of Thrombosis and Thrombolysis 2018;45(2):257-63.</Citation><ArticleIdList><ArticleId IdType="pubmed">29322296</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Charbonnier 1984 {published data only}</Title><Reference><Citation>Charbonnier B, Raynaud P, Griguier P, Brochier M. Potentializing effects of a defibrillating agent on therapeutic thrombolysis in pulmonary embolism [Effets potentialisateurs d'un agent defibrinant sur la thrombolyse therapeutique dans l'embolie pulmonaire]. Archives des Maladies du Coeur et des Vaisseaux 1984;77:1426.</Citation></Reference></ReferenceList><ReferenceList><Title>Chen 2009 {published data only}</Title><Reference><Citation>Chen Z. Evaluation of effect of rt-PA therapy and different dose in acute pulmonary embolism [Abstract]. American Thoracic Society 2009 International Conference; 2009 May 15-20; San Diego. In: American Journal of Respiratory and Critical Care Medicine. Vol. 179 (Meeting Abstracts). 2009:A3294.</Citation></Reference></ReferenceList><ReferenceList><Title>Cimen 2019 {published data only}</Title><Reference><Citation>Cimen P, Alizoroglu D, Unlu M, Kirakli C, Ediboglu O, Erbaycu AE. Safety and effectiveness of thrombolytic therapy compared with standard anticoagulation in subjects with submassive pulmonary embolism. Erciyes Medical Journal 2019;41(2):175-9.</Citation></Reference></ReferenceList><ReferenceList><Title>Comerota 2009 {published data only}</Title><Reference><Citation>Comerota AJ. The ATTRACT trial: rationale for early intervention for iliofemoral DVT. Perspectives in Vascular Surgery and Endovascular Therapy 2009;21(4):221-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20047905</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>De Takats 1973 {published data only}</Title><Reference><Citation>De Takats G. The urokinase pulmonary embolism trial. American Journal of Surgery 1973;126(3):311-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">4580749</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Er 2018 {published data only}</Title><Reference><Citation>Er M. Recombinant tissue plasminogen activator treatment of pulmonary embolism also improves deep venous thrombosis. Journal of Investigative Medicine 2018;66(7):1045-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29880534</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Erkan 2002 {published data only}</Title><Reference><Citation>Erkan L, Findik S, Atici AG, Uzun O. Thrombolytic therapy in massive pulmonary thromboembolism. European Respiratory Journal 2002;20:237s.</Citation></Reference></ReferenceList><ReferenceList><Title>Francois 1986 {published data only}</Title><Reference><Citation>Francois G, Charbonnier B, Raynaud P, Garnier LF, Griguer P, Brochier M. Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen-urokinase. 67 cases [Traitemente de l'embolie pulmonaire aigue par urokinase comparee a l'association plasminogene-urokinase. A propos de 67 cas]. Archives des Maladies du Coeur et des Vaisseaux 1986;79(4):435-42.</Citation><ArticleIdList><ArticleId IdType="pubmed">3090961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 1989 {published data only}</Title><Reference><Citation>Goldhaber SZ. Tissue plasminogen activator in acute pulmonary embolism. Chest 1989;95(5 Suppl):282S-9S.</Citation><ArticleIdList><ArticleId IdType="pubmed">2495913</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ. TPA versus urokinase in acute pulmonary embolism: results of a randomized controlled trial. Vasa - Supplementum 1989;27:292-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2516368</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 1992 {published data only}</Title><Reference><Citation>Goldhaber SZ, Kessler CM, Heit JA, Elliot CG. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. Journal of the American College of Cardiology 1992;20(1):24-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">1607532</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 1994 {published data only}</Title><Reference><Citation>Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomised trial. Chest 1994;106(3):718-24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8082347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>IRCT201104245625N2 {published data only}</Title><Reference><Citation>IRCT201104245625N2. Comparative efficacy and complications of two-hour versus 24-hour regimen of streptokinase in acute pulmonary embolism In Tehran Heart Center. en.irct.ir/trial/6153 (first posted 28 August 2011).</Citation></Reference></ReferenceList><ReferenceList><Title>Jin 2012 {published data only}</Title><Reference><Citation>Jin J, Ding WB, Yuan RF. Thrombolytic treatment of acute pulmonary thromboembolism: comparison between catheter-directed thrombolysis and venous thrombolysis. Journal of Interventional Radiology 2012;21:667-71.</Citation></Reference></ReferenceList><ReferenceList><Title>Jing 2018 {published data only}</Title><Reference><Citation>Jing X, Zhang G, Zhang B, Dai L, Wang X, Jia L, et al. Efficacy and safety of low-dose urokinase for the treatment of hemodynamically stable AECOPD patients with acute pulmonary thromboembolism. Clinical Respiratory Journal 2018;12(5):1882-90.</Citation><ArticleIdList><ArticleId IdType="pubmed">29227032</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Konstantinides 1998 {published data only}</Title><Reference><Citation>Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. American Journal of Cardiology 1998;82(8):966-70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9794353</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lehnert 2017 {published data only}</Title><Reference><Citation>Lehnert P, Moller CH, Mortensen J, Kjaergaard J, SkovOlsen P, Carlsen J, et al. Surgical embolectomy compared to thrombolysis in acute pulmonary embolism: morbidity and mortality. European Journal of Cardio-thoracic Surgery 2017;51(2):354-61.</Citation><ArticleIdList><ArticleId IdType="pubmed">28186234</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Liu 2012 {published data only}</Title><Reference><Citation>Liu FY, Wang MQ, Duan F, Wang ZJ, Song P, Wang Y, et al. Management of acute massive with interventional techniques. Zhonghua Yi Xue Za Zhi 2012;92(19):1343-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22883125</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Marder 1978 {published data only}</Title><Reference><Citation>Marder VJ, Donahoe JF, Bell WR, Cranley JJ, Kwaan HC, Sashara AA, et al. Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism. Journal of Laboratory Clinical Medicine 1978;92(5):721-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">712206</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meneveau 1997 {published data only}</Title><Reference><Citation>Meneveau N, Schiele F, Vuillemenot A, Valette B, Grollier G, Bernard Y, et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. European Heart Journal 1997;18(7):1141-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9243149</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meneveau 1998 {published data only}</Title><Reference><Citation>Meneveau N, Schiele F, Metz D, Valette B, Attali P, Vuillemenot A, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. Journal of the American College of Cardiology 1998;31(5):1057-63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562007</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meyer 1992 {published data only}</Title><Reference><Citation>Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al. Comparison of the effect of an intravenous infusion of urokinase or alteplase on total pulmonary resistance in acute massive pulmonary embolism. A European, multi-center, double-blind study [Vergleich der wirkung einer intravenosen infusion von urokinase oder alteplase auf den pulmonalen en gesamtwiderstand bei akuter massiver lungenembolie. Eine Europapaische multicenter-doppelblindestudie]. Intensivmedizin und Notfallmedizin 1992;29:339-47.</Citation></Reference><Reference><Citation>Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. Journal of the American College of Cardiology 1992;19(2):239-45.</Citation><ArticleIdList><ArticleId IdType="pubmed">1732347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Miller 1971 {published data only}</Title><Reference><Citation>Miller GA, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. British Medical Journal 1971;763(2):681-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796248</ArticleId><ArticleId IdType="pubmed">5556052</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Muhl 2007 {published data only}</Title><Reference><Citation>Muhl D, Furedi R, Gecse K, Ghosh S, Falusi B, Bogar L, et al. Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism. Blood Coagulation &amp; Fibrinolysis 2007;18(7):661-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890954</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>NCT00968929 {published data only}</Title><Reference><Citation>NCT00968929. Recombinant streptokinase versus urokinase in pulmonary embolism in China (RESUPEC). clinicaltrials.gov/ct2/show/NCT00968929 (first posted 31 August 2009).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT01956955 {published data only}</Title><Reference><Citation>NCT01956955. Comparison of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in combination with thrombolytic treatment of acute massive pulmonary thromboembolism. clinicaltrials.gov/ct2/show/NCT01956955 (first posted 8 October 2013).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT03581877 {published data only}</Title><Reference><Citation>NCT03581877. Peripheral systemic thrombolysis versus catheter directed thrombolysis for submassive PE. clinicaltrials.gov/show/NCT03581877 (first posted 10 July 2018).</Citation></Reference></ReferenceList><ReferenceList><Title>Ohayon 1986 {published data only}</Title><Reference><Citation>Ohayon J, Colle JP, Tauzin-Fin P, Lorient-Roudaut MF, Besse P. Hemodynamic course during fibrinolysis in severe pulmonary embolism [&#xc9;volution h&#xe9;modynamique au cours des fibrinolyses de l'embolie pulmonaire grave]. Archives des Maladies du Coeur et des Vaisseaux 1986;79(4):445-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">3090962</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Palla 1997 {published data only}</Title><Reference><Citation>Palla A, Pazzagli M, Manganelli D, De Nitto P, Marini C, Rossi G, et al. Resolution of pulmonary embolism: effect of therapy and putative age of emboli. Respiration 1997;64(1):50-3.</Citation><ArticleIdList><ArticleId IdType="pubmed">9044475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Pang 2007 {published data only}</Title><Reference><Citation>Pang BS, Wang C, Lu Y, Yang YH, Xing GH, Mao YL, et al. Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2007;87:3074-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18261355</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Petolat 2019 {published data only}</Title><Reference><Citation>Petolat E, Laine M, Ammar C, Pinto J, Gaubert M, Resseguier N, et al. Right ventricular systolic dysfunction in intermediate high-risk pulmonary embolism treated by ultrasound-assisted catheter-directed thrombolysis. Archives of Cardiovascular Diseases Supplements 2019;11(2):191-2.</Citation></Reference></ReferenceList><ReferenceList><Title>Prandoni 1985 {published data only}</Title><Reference><Citation>Prandoni P, Zambon G, Scatigna M. Diagnostic approaches and results in the medical treatment of pulmonary thromboembolism [Aspetti diagnostici e risultati della terapia medica nella tromboembolia polmonare]. Minerva Medica 1985;76(38):1727-37.</Citation><ArticleIdList><ArticleId IdType="pubmed">4047457</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Research Group on Urokinase and PE 1984 {published data only}</Title><Reference><Citation>Research Group on Urokinase and Pulmonary Embolism. Multicenter study of 2 urokinase protocols in severe pulmonary embolism [&#xc9;tude multicentrique sur deux protoocles d'ukokinase dans l'embolie pulmonaire grave]. Archives des Maladies du Coeur et des Vaisseaux 1984;77(7):773-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">6433840</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Saponjski 2002 {published data only}</Title><Reference><Citation>Saponjski JD, Saponjski MD, Vukcevic VP. Massive pulmonary embolism and thrombolysis in the first week after major surgery. European Respiratory Journal 2002;20(Suppl 38):239s.</Citation></Reference></ReferenceList><ReferenceList><Title>Sasahara 1975 {published data only}</Title><Reference><Citation>Sasahara AA, Bell WR, Simon TL, Stengle JM, Sherry S. The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study. Thrombosis et Diathesis Haemorrhagica 1975;33(3):464-76.</Citation><ArticleIdList><ArticleId IdType="pubmed">1098216</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sharma 2000 {published data only}</Title><Reference><Citation>Sharma GV, Folland ED, McIntyre KM, Sasahara AA. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism. Vascular Medicine 2000;5(2):91-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10943585</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sors 1994 {published data only}</Title><Reference><Citation>Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994;106(3):712-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8082346</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tapson 2018 {published data only}</Title><Reference><Citation>Tapson VF, Sterling K, Jones N, Elder M, Tripathy U, Brower J, et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial. JACC Cardiovascular Interventions 2018;23(11):1401-10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30025734</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tebbe 1999 {published data only}</Title><Reference><Citation>Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. American Heart Journal 1999;138(7):39-44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10385761</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tebbe 2009 {published data only}</Title><Reference><Citation>Tebbe U, Bramlage P, Graf A, Lechleitner P, Bode C, Riess FC, et al. Desmoteplase in acute massive pulmonary thromboembolism. Thrombosis and Haemostasis 2009;101(3):557-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">19277420</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>UKEP Study Group 1987 {published data only}</Title><Reference><Citation>The UKEP Study Research Group. The UKEP Study: multicentre clinical trial on two local regimes of urokinase in massive pulmonary embolism. European Heart Journal 1987;8(1):2-10.</Citation><ArticleIdList><ArticleId IdType="pubmed">3545842</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>UPET Study Group 1974 {published data only}</Title><Reference><Citation>The Urokinase Pulmonary Embolism Trial Study Group. Urokinase streptokinase embolism trial. Phase 2 results. A co-operative study. Journal of the American Medical Association 1974;229:1606-13.</Citation></Reference></ReferenceList><ReferenceList><Title>Verstraete 1988 {published data only}</Title><Reference><Citation>Verstraete M, Miller GA, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988;77(2):353-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">3123091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wang 2009 {published data only}</Title><Reference><Citation>Wang Y, Yang Y, Wu Y, Wang C. The echocardiographic changes of pre and after treatments of recombinant streptokinase and urokinase on pulmonary embolism [Abstract]. Respirology 2009;14:A137.</Citation></Reference></ReferenceList><ReferenceList><Title>Wang 2010 {published data only}</Title><Reference><Citation>Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010;137:254-62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126994</ArticleId><ArticleId IdType="pubmed">19741062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Zhai Z, Yang Y, Yuan Y, Cheng Z, Liang L, et al. Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial [Abstract]. Respiratory Research 2009;10:128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806365</ArticleId><ArticleId IdType="pubmed">20040086</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wang 2018 {published data only}</Title><Reference><Citation>Wang W, Zhao X, Ren Y, Qiao P. Therapeutic effect evaluation of reteplase on acute pulmonary embolism. Pakistan Journal of Pharmaceutical Sciences 2018;31(3):899-905.</Citation><ArticleIdList><ArticleId IdType="pubmed">29716871</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wu 2010 {published data only}</Title><Reference><Citation>Wu YQ, Tao LB, Lu C, Hu YH. An economic evaluation of low dose recombinant human tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2010;90(2):103-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20356492</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Xu 2016 {published data only}</Title><Reference><Citation>Xu, QH, Li WL, Cai ZM, Lin YC, Huang SP. Effect of 50 mg alteplase to intermediate-risk pulmonary embolism with right ventricular dysfunction [&#x963f;&#x66ff;&#x666e;&#x9176;50mg&#x65b9;&#x6848;&#x5bf9;&#x4f34;&#x53f3;&#x5fc3;&#x529f;&#x80fd;&#x4e0d;&#x5168;&#x7684;&#x4e2d;&#x5371;&#x80ba;&#x6813;&#x585e;&#x60a3;&#x8005;&#x7684;&#x7597;&#x6548;]. Chung Hua I Hsueh Tsa Chih 2016;96:3062-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27784446</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yang 2007 {published data only}</Title><Reference><Citation>Yang D, Zhao G, Wu H, Zhou H, Ji Y, Zhang Z. Comparison of local and systemic thrombolytic treatment for acute massive pulmonary embolism [Abstract]. European Respiratory Journal 2007;30:544s.</Citation></Reference></ReferenceList><ReferenceList><Title>Yang 2009 {published data only}</Title><Reference><Citation>Wang C. The clinical features of 516 patients with acute pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2006;86(31):2161-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17064498</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YH, Zhai ZG, Wang F, Xie WM, Wang C. Changes in deep venous thrombosis after thrombolytic anticoagulant therapies in acute pulmonary thromboembolism. Chinese Journal of Internal Medicine 2009;48(5):371-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19615152</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yang 2011 {published data only}</Title><Reference><Citation>Yang Y, Wang Y, Ma Z, Qiu C, Wu H, Zhang X, et al. Efficacy and safety of two-hour regimen of recombinant streptokinase versus urokinase in massive and submassive pulmonary embolism [Abstract]. Respirology 2011;16:309.</Citation></Reference></ReferenceList><ReferenceList><Title>Yilmaz 2019 {published data only}</Title><Reference><Citation>Yilmaz ES, Uzun O. Comparison of low dose thrombolytic therapy and low molecular weight heparin therapy in patients with submassive pulmonary thromboembolism. Turkish Thoracic Journal 2019;20(Suppl 1):S58.</Citation></Reference></ReferenceList><ReferenceList><Title>Yilmazel 2018 {published data only}</Title><Reference><Citation>Yilmazel U, Araz EO, Kerget B, Yilmaz N, Akgun M, Saglam L. Comparison of long-term outcomes of 50 and 100 mg rt-PA in the management of acute pulmonary thromboembolism. Clinical Respiratory Journal 2018;12:1628&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">29044967</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zhao 2018 {published data only}</Title><Reference><Citation>Zhao T, Ni J, Hu X, Wang Y, Du X. The efficacy and safety of intermittent low-dose urokinase thrombolysis for the treatment of senile acute intermediate-high-risk pulmonary embolism: a pilot trial. Clinical and Applied Thrombosis/Hemostasis 2018;24(7):1067-72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6714758</ArticleId><ArticleId IdType="pubmed">29552916</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zhu 2008 {published data only}</Title><Reference><Citation>Zhu L, Wang C, Yang Y, Wu Y, Zhai Z, Dai H, et al. Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism. Journal of Thrombosis and Thrombolysis 2008;26(3):251-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17705052</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to ongoing studies</Title><ReferenceList><Title>EudraCT: 2005&#x2010;001070&#x2010;27 {published data only}</Title><Reference><Citation>EudraCT 2005-001070-27. Open, randomised, monosite pilot trial for comparison of thrombolytic efficacy of tenecteplase and alteplase in patients with acute pulmonary embolism. clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001070-27 (first posted 7 July 2005).</Citation></Reference></ReferenceList><ReferenceList><Title>EudraCT: 2017&#x2010;005075&#x2010;91&#x2010;DK {published data only}</Title><Reference><Citation>EudraCT2017-005075-91. Low dose thrombolysis, ultrasound assisted thrombolysis or heparin for intermediate high risk pulmonary embolism. clinicaltrialsregister.eu/ctr-search/search?query=2017-005075-91 (first posted 07 September 2018).</Citation></Reference><Reference><Citation>NCT04088292. Low dose thrombolysis, ultrasound assisted thrombolysis or heparin for intermediate high risk pulmonary embolism (STRATIFY). clinicaltrials.gov/show/NCT04088292 (first posted 12 September 2019).</Citation></Reference></ReferenceList><ReferenceList><Title>IRCT2014042017343N1 {published data only}</Title><Reference><Citation>IRCT2014042017343N1. Thrombolytic therapy plus anticoagulant versus anticoagulant alone in sub massive pulmonary thrombo embolism: (a randomized clinical trial). who.int/trialsearch/Trial2.aspx?TrialID=IRCT2014042017343N1 (first posted 18 May 2014).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT01531829 {published data only}</Title><Reference><Citation>NCT01531829. Low dose Rt-PA for acute normotensive pulmonary embolism with RVD. clinicaltrials.gov/ct2/show/NCT01531829 (first posted 13 February 2012).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT02604238 {published data only}</Title><Reference><Citation>NCT02604238. Efficacy and safety of half dose alteplase added to heparin, in patients with moderate pulmonary embolism (MONALYSE). clinicaltrials.gov/ct2/show/NCT02604238 (first posted 13 November 2015).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT03218410 {published data only}</Title><Reference><Citation>NCT03218410. Surgical pulmonary embolectomy versus catheter-directed thrombolysis in the treatment of pulmonary embolism: a non-inferiority study (Lungembolism). clinicaltrials.gov/ct2/show/NCT03218410 (first posted 14 July 2017).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT03854266 {published data only}</Title><Reference><Citation>NCT03854266. Low dose catheter directed thrombolysis for acute pulmonary embolism (BETULA). clinicaltrials.gov/show/NCT03854266 (first posted 26 February 2019).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT03988842 {published data only}</Title><Reference><Citation>NCT03988842. Standard-dose apixaban AFtEr very low-dose thromboLYSis for acute intermediate-high risk acute pulmonary Embolism (SAFE-LYSE). Clinicaltrials.gov/show/NCT03988842 (first posted 18 June 2019).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT04430569 {published data only}</Title><Reference><Citation>NCT04430569. Pulmonary Embolism International THrOmbolysis study-3 (PEITHO-3). clinicaltrials.gov/show/NCT04430569 (first posted 12 June 2020).</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Barco 2019</Title><Reference><Citation>Barco S, Russo M, Vicaut E, Becattini C, Bertoletti L, Beyer-Westendor J, et al. Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. Clinical Research in Cardiology 2019;108(7):772-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584226</ArticleId><ArticleId IdType="pubmed">30564950</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bottiger 1994</Title><Reference><Citation>Bottiger BW, Bohrer H, Bach A, Motsch J, Martin E. Bolus injection of thrombolytic agents during cardiopulmonary resuscitation for massive pulmonary embolism. Resuscitation 1994;28(1):45-54.</Citation><ArticleIdList><ArticleId IdType="pubmed">7809485</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Browse 1962</Title><Reference><Citation>Browse NL, James DC. Streptokinase and pulmonary embolism. Lancet 1962;2(7368):1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">14206016</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cao 2014</Title><Reference><Citation>Cao Y, Zhao H, Gao W, Wang Y, Cao J. Systematic review and meta-analysis for thrombolysis treatment in patients with acute submassive pulmonary embolism. Patient Preference and Adherence 2014;28(8):275-82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945048</ArticleId><ArticleId IdType="pubmed">24611003</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chatterjee 2014</Title><Reference><Citation>Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA 2014;311(23):2414-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24938564</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chesterman 1969</Title><Reference><Citation>Chesterman CN, Biggs JC, Morgan J, Hickie JB. Streptokinase therapy in acute major pulmonary embolism. Medical Journal of Australia 1969;2(22):1096-100.</Citation><ArticleIdList><ArticleId IdType="pubmed">5374043</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Duffett 2020</Title><Reference><Citation>Duffett L, Castellucci LA, Forgie MA. Pulmonary embolism: update on management and controversies. BMJ 2020;370:m2177.</Citation><ArticleIdList><ArticleId IdType="pubmed">32759284</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Eberle 2018</Title><Reference><Citation>Eberle H, Lyn R, Knight T, Hodge E, Daley M. Clinical update on thrombolytic use in pulmonary embolism: a focus on intermediate-risk patients. American Journal of Health-system Pharmacy 2018;75(17):1275-85.</Citation><ArticleIdList><ArticleId IdType="pubmed">29895520</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gao 2015</Title><Reference><Citation>Gao GY, Yang P, Liu M, Ding M, Liu GH, Tong YL, et al. Thrombolysis for acute intermediate-risk pulmonary embolism: a meta-analysis. Thrombosis Research 2015;136(5):932-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26384442</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Genton 1968</Title><Reference><Citation>Genton E, Wolf P. Urokinase therapy in pulmonary thromboembolism. American Heart Journal 1968;76(5):628-37.</Citation><ArticleIdList><ArticleId IdType="pubmed">5698419</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 1988</Title><Reference><Citation>Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GV, Dawley D, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2(8606):293-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2899718</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 2002</Title><Reference><Citation>Goldhaber SZ. Thrombolysis for pulmonary embolism. New England Journal of Medicine 2002;347(15):1131-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374871</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>GRADEpro GDT [Computer program]</Title><Reference><Citation>GRADEpro GDT. Version version accessed 2 October 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available from gradepro.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Gupta 2018</Title><Reference><Citation>Gupta R, Fortman DD, Morgenstern DR, Cooper CJ. Short- and long-term mortality risk after acute pulmonary embolism. Current Cardiology Reports 2018;20(12):135.</Citation><ArticleIdList><ArticleId IdType="pubmed">30311090</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hepburn&#x2010;Brown 2019</Title><Reference><Citation>Hepburn-Brown M, Darvall J, Hammerschlag G. Acute pulmonary embolism: a concise review of diagnosis and management. Internal Medicine Journal 2019;49(1):15-27. [DOI: 10.1111/imj.14145]</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.14145</ArticleId><ArticleId IdType="pubmed">30324770</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2011</Title><Reference><Citation>Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Hirsh 1971</Title><Reference><Citation>Hirsh J, McDonald IG, Hale GA, O'Sullivan EF, Jelinek VM. Comparison of the effects of streptokinase and heparin on the early rate of resolution of major pulmonary embolism. Canadian Medical Association Journal 1971;104(6):488-91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1930899</ArticleId><ArticleId IdType="pubmed">5549989</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hyers 1970</Title><Reference><Citation>Hyers TM, Stengle JM, Sherry S. Treatment of pulmonary embolism with urokinase. Results of clinical trial (phase 1). Circulation 1970;42(6):979-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">5492546</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jaff 2011</Title><Reference><Citation>Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011;123(16):1788-830.</Citation><ArticleIdList><ArticleId IdType="pubmed">21422387</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kearon 2016</Title><Reference><Citation>Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016;149(2):315-52.</Citation><ArticleIdList><ArticleId IdType="pubmed">26867832</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Konstantinides 1999</Title><Reference><Citation>Konstantinides S, Geibel A, Kasper W. Submassive and massive pulmonary embolism: a target for thrombolytic therapy? Thrombosis and Haemostasis 1999;82(Suppl 1):104-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10695497</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Konstantinides 2020</Title><Reference><Citation>Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal 2020;41(4):543-603.</Citation><ArticleIdList><ArticleId IdType="pubmed">31504429</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lefebvre 2011</Title><Reference><Citation>Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Liu 2014</Title><Reference><Citation>Liu Y, Lu Y, Song J, Li D, Liu H, Yang J, et al. Recombinant tissue plasminogen activator for hemodynamically stable patients experiencing an acute pulmonary embolism: a meta-analysis. Thrombosis Research 2014;134(1):50-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24824292</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Marti 2014</Title><Reference><Citation>Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. European Heart Journal 2014;36(10):605-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352209</ArticleId><ArticleId IdType="pubmed">24917641</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meneveau 2006</Title><Reference><Citation>Meneveau N, S&#xe9;ronde MF, Blonde MC, Legalery P, Didier-Petit K, Briand F, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006;129(4):1043-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16608956</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nakamura 2014</Title><Reference><Citation>Nakamura S, Takano H, Kubota Y, Asai K, Shimizu W. Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a meta-analysis. Journal of Thrombosis and Haemostasis 2014;12(7):1086-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">24829097</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>NCT00680628</Title><Reference><Citation>NCT00680628. Randomized trial of tenecteplase to treat severe submassive pulmonary embolism. clinicaltrials.gov/ct2/show/NCT00680628?cond=pulmonary+embolism&amp;rank=42 (first received 20 May 2008).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT04088292</Title><Reference><Citation>NCT04088292. Low dose thrombolysis, ultrasound assisted thrombolysis or heparin for intermediate high risk pulmonary embolism (STRATIFY). clinicaltrials.gov/show/NCT04088292 (first posted 12 September 2019).</Citation></Reference></ReferenceList><ReferenceList><Title>NICE 2012</Title><Reference><Citation>National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. nice.org.uk/guidance/cg144 2012 (accessed August 2015).</Citation></Reference></ReferenceList><ReferenceList><Title>Perlroth 2007</Title><Reference><Citation>Perlroth DJ, Sanders GD, Gould MK. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Archives of Internal Medicine 2007;167(1):74-80.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210881</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Review Manager 2020 [Computer program]</Title><Reference><Citation>Review Manager (RevMan). Version 5.4. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.</Citation></Reference></ReferenceList><ReferenceList><Title>Ryan 2016</Title><Reference><Citation>Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group, available at cccrg.cochrane.org/author-resources. Version 1.0 June 2016.</Citation></Reference></ReferenceList><ReferenceList><Title>Sasahara 1967</Title><Reference><Citation>Sasahara AA, Cannilla JE, Belko JS, Morse RL, Criss AJ. Urokinase therapy in clinical pulmonary embolism. A new thrombolytic agent. New England Journal of Medicine 1967;277(22):1168-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">6058604</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sasahara 1973</Title><Reference><Citation>Sasahara AA, Hyers TM, Cole CM, Ederer F, Murray JA, Wenger NK, et al. The urokinase pulmonary embolism trial: a national co-operative study. Circulation 1973;47(2 Suppl):7-21.</Citation><ArticleIdList><ArticleId IdType="pubmed">4266893</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sautter 1967</Title><Reference><Citation>Sautter RD, Emanuel RA, Fletcher FW, Wenzel FJ, Matson JI. Urokinase for the treatment of acute pulmonary thromboembolism. Journal of the American Medical Association 1967;202(3):215-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">6072357</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sista 2017</Title><Reference><Citation>Sista AK, Kuo WT, Schiebler M, Madoff DC. Stratification, imaging, and management of acute massive and submassive pulmonary embolism. Radiology 2017;284(1):5-24.</Citation><ArticleIdList><ArticleId IdType="pubmed">28628412</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stambaugh 1981</Title><Reference><Citation>Stambaugh RL, Alexander MR. Therapeutic use of thrombolytic agents. American Journal of Hospital Pharmacy 1981;38(6):817-24.</Citation><ArticleIdList><ArticleId IdType="pubmed">7018230</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stewart 2020</Title><Reference><Citation>Stewart LK, Kline JA. Fibrinolytics for the treatment of pulmonary embolism. Translational Research 2020;225:82-94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7487055</ArticleId><ArticleId IdType="pubmed">32434005</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tapson 2017</Title><Reference><Citation>Tapson VF, Friedman O. Systemic thrombolysis for pulmonary embolism: who and how. Techniques in Vascular and Interventional Radiology 2017;20(3):162-74.</Citation><ArticleIdList><ArticleId IdType="pubmed">29029710</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tow 1967</Title><Reference><Citation>Tow DE, Wagner HN Jr, Holmes RA. Urokinase in pulmonary embolism. New England Journal of Medicine 1967;277(22):1161-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">6058603</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yamasawa 1992</Title><Reference><Citation>Yamasawa F, Okada Y, Asano K, Mori M, Fujita H, Hasegawa N, et al. The role of recombinant human tissue-type plasminogen activator in the treatment of acute pulmonary thromboembolism. Internal Medicine 1992;31(7):885-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1450496</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to other published versions of this review</Title><ReferenceList><Title>Dong 2002</Title><Reference><Citation>Dong B, Pineo G, Mulrooney T. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No: CD004437. [DOI: 10.1002/14651858.CD004437]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004437</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dong 2006</Title><Reference><Citation>Dong BR, Yue J, Liu GJ, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No: CD004437. [DOI: 10.1002/14651858.CD004437.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004437.pub2</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dong 2009</Title><Reference><Citation>Dong BR, Hao Q, Yue J, Wu T, Liu GJ. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD004437. [DOI: 10.1002/14651858.CD004437.pub3]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004437.pub3</ArticleId><ArticleId IdType="pubmed">19588357</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hao 2015</Title><Reference><Citation>Hao Q, Dong BR, Yue J, Wu T, Liu GJ. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2015, Issue 9. Art. No: CD004437. [DOI: 10.1002/14651858.CD004437.pub4]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004437.pub4</ArticleId><ArticleId IdType="pubmed">26419832</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hao 2018</Title><Reference><Citation>Hao Q, Dong BR, Yue J, Wu T, Liu GJ. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2018, Issue 12. Art. No: CD004437. [DOI: 10.1002/14651858.CD004437.pub5]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004437.pub5</ArticleId><ArticleId IdType="pmc">PMC6516871</ArticleId><ArticleId IdType="pubmed">30560579</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23543562</PMID><DateCompleted><Year>2013</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2013</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Thromboprophylaxis for trauma patients.</ArticleTitle><Pagination><StartPage>CD008303</StartPage><MedlinePgn>CD008303</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD008303</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD008303.pub2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Trauma is a leading causes of death and disability in young people. Venous thromboembolism (VTE) is a principal cause of death. Trauma patients are at high risk of deep vein thrombosis (DVT). The incidence varies according to the method used to measure the DVT and the location of the thrombosis. Due to prolonged rest and coagulation abnormalities, trauma patients are at increased risk of thrombus formation. Thromboprohylaxis, either mechanical or pharmacological, may decrease mortality and morbidity in trauma patients who survive beyond the first day in hospital, by decreasing the risk of VTE in this population.A previous systematic review did not find evidence of effectiveness for either pharmacological or mechanical interventions. However, this systematic review was conducted 10 years ago and most of the included studies were of poor quality. Since then new trials have been conducted. Although current guidelines recommend the use of thromboprophylaxis in trauma patients, there has not been a comprehensive and updated systematic review since the one published.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the effects of thromboprophylaxis in trauma patients on mortality and incidence of deep vein thrombosis and pulmonary embolism. To compare the effects of different thromboprophylaxis interventions and their effects according to the type of trauma.</AbstractText><AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">We searched The Cochrane Injuries Group Specialised Register (searched April 30 2009), Cochrane Central Register of Controlled Trials 2009, issue 2 (The Cochrane Library), MEDLINE (Ovid) 1950 to April (week 3) 2009, EMBASE (Ovid) 1980 to (week 17) April 2009, PubMed (searched 29 April 2009), ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) (1970 to April 2009), ISI Web of Science: Conference Proceedings Citation Index-Science (CPCI-S) (1990 to April 2009).</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomized controlled clinical trials involving people of any age with major trauma defined by one or more of the following criteria: physiological: penetrating or blunt trauma with more than two organs and unstable vital signs, anatomical: people with an Injury Severity Score (ISS) higher than 9, mechanism: people who are involved in a 'high energy' event with a risk for severe injury despite stable or normal vital signs. We excluded trials that only recruited outpatients, trials that recruited people with hip fractures only, or people with acute spinal injuries.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Four authors, in pairs (LB and CM, EF and RC), independently examined the titles and the abstracts, extracted data, assessed the risk of bias of the trials and analysed the data. PP resolved any disagreement between the authors.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Sixteen studies were included (n=3005). Four trials compared the effect of any type (mechanical and/or pharmacological) of prophylaxis versus no prophylaxis. Prophylaxis reduced the risk of DVT in people with trauma (RR 0.52; 95% CI 0.32 to 0.84). Mechanical prophylaxis reduced the risk of DVT (RR = 0.43; 95% CI 0.25 to 0.73). Pharmacological prophylaxis was more effective than mechanical methods at reducing the risk of DVT (RR 0.48; 95% CI 0.25 to 0.95). LMWH appeared to reduce the risk of DVT compared to UH (RR 0.68; 95% CI 0.50 to 0.94). People who received both mechanical and pharmacological prophylaxis had a lower risk of DVT (RR 0.34; 95% CI 0.19 to 0.60)</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">We did not find evidence that thromboprophylaxis reduces mortality or PE in any of the comparisons assessed. However, we found some evidence that thromboprophylaxis prevents DVT. Although the strength of the evidence was not high, taking into account existing information from other related conditions such as surgery, we recommend the use of any DVT prophylactic method for people with severe trauma.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Barrera</LastName><ForeName>Luis M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Universidad de Antioquia, Medellin, Colombia. luismbarrera@cable.net.co</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perel</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ker</LastName><ForeName>Katharine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Cirocchi</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Farinella</LastName><ForeName>Eriberto</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Morales Uribe</LastName><ForeName>Carlos Hernando</ForeName><Initials>CH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>doi: 10.1002/14651858.CD008303</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058128" MajorTopicYN="N">Compression Bandages</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>None known.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23543562</ArticleId><ArticleId IdType="pmc">PMC12107512</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD008303.pub2</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Anglen 1998 {published data only}</Title><Reference><Citation>Anglen JO, Bagby C, George R. A randomised comparison of sequential&#x2010;gradient calf compression with intermittent plantar compression for prevention of venous thrombosis in orthopedic trauma patients: preliminary results. American journal of orthopedics 1998;27(1):53&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9452837</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cohn 1999 {published data only}</Title><Reference><Citation>Cohn SM, Moller BA, Feinstein, AJ, Burns GA, Ginzburg E, Hammers LW. Prospective trial of low&#x2010;molecular&#x2010;weight heparin versus unfractionated heparin in moderately injured patients. Vascular Surgery 1999;33(2):219&#x2010;23.</Citation></Reference></ReferenceList><ReferenceList><Title>Dennis 1993 {published data only}</Title><Reference><Citation>Dennis JW, Menawat S, Thron J, Fallon Jr WF, Vinsant GO, Laneve LM, et al. Efficacy of deep venous thrombosis prophylaxis in trauma patients and identification of high&#x2010;risk groups. The Journal of Trauma&#x2010;injury and Critical Care 1993;35(1):132&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8331703</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Elliot 1999 {published data only}</Title><Reference><Citation>Elliott CG, Dudney TM, Egger M, Orme JF, Clemmer TP, Horn SD, et al. Calf&#x2010;thigh sequential pneumatic compression compared with plantar venous pneumatic compression to prevent deep&#x2010;vein thrombosis after non&#x2010;lower extremity trauma. The Journal of Trauma&#x2010;injury and Critical Care 1999;47(1):25&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10421182</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fisher 1995 {published data only}</Title><Reference><Citation>Fisher CG, Blachut PA, Salvian AJ, Meek RN, O'Brien PJ. Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients [Abstract]. Journal of Bone and Joint Surgery &#x2010; British Volume 1991;73 Suppl 1:49&#x2010;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">7714648</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher CG, Blachut PA, Salvian AJ, Meek RN, O'Brien PJ. Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomised study of compression alone versus no prophylaxis. Journal of orthopaedic trauma 1995;9(1):1&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7714648</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fuchs 2005 {published data only}</Title><Reference><Citation>Fuchs S, Heyse T, Rudofsky G, Gosheger G, Chylarecki C. Continuous passive motion in the prevention of deep&#x2010;vein thrombosis: a randomised comparison in trauma patients. The Journal of bone and joint surgery. British volume. 2005;87(8):1117&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16049250</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Geerts 1996 {published data only}</Title><Reference><Citation>Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low&#x2010;dose heparin with low&#x2010;molecular&#x2010;weight heparin as prophylaxis against venous thromboembolism after major trauma. The New England journal of medicine 1996;335(10):701&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8703169</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ginzburg 2003 {published data only}</Title><Reference><Citation>Ginzburg E, Cohn SM, Lopez J, Jackowski J, Brown M, Hameed SM, Miami Deep Vein Thrombosis Study Group. Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma. British Journal of Surgery 2003;90(11):1338&#x2010;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598411</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Knudson 1992 {published data only}</Title><Reference><Citation>Knudson MM, Collins JA, Goodman SB, McCrory DW. Thromboembolism following multiple trauma. The Journal of Trauma&#x2010;injury and Critical Care 1992;32:2&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">1732568</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Knudson 1994 All groups {published data only}</Title><Reference><Citation>Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous thromboembolism in trauma patients. The Journal of Trauma&#x2010;injury and Critical Care 1994;37(3):480&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Knudson 1994 group I {published data only}</Title><Reference><Citation>Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous thromboembolism in trauma patients. The Journal of Trauma&#x2010;injury and Critical Care 1994;37(3):480&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Knudson 1994 group II {published data only}</Title><Reference><Citation>Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous thromboembolism in trauma patients. The Journal of Trauma&#x2010;injury and Critical Care 1994;37(3):480&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Knudson 1994 group III {published data only}</Title><Reference><Citation>Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous thromboembolism in trauma patients. The Journal of Trauma&#x2010;injury and Critical Care 1994;37(3):480&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Knudson 1996 {published data only}</Title><Reference><Citation>Knudson MM, Morabito D, Paiement GD, Shackleford S. Use of low molecular weight heparin in preventing thromboembolism in trauma patients.. Journal of Trauma&#x2010;Injury Infection and Critical Care 1996;41(3):446&#x2010;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kurtoglu 2004 {published data only}</Title><Reference><Citation>Kurtoglu M, Yanar H, Bilsel Y, Guloglu R, Kizilirmak S, Buyukkurt D, Granit V. Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin. World journal of surgery 2004;28(8):807&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">15457363</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stannard 2001 {published data only}</Title><Reference><Citation>Stannard JP, Riley RS, McClenney MD, Lopez Ben RR, Volgas DA, Alonso JE. Mechanical prophylaxis against deep&#x2010;vein thrombosis after pelvic and acetabular fractures.. Journal of Bone and Joint Surgery &#x2010; American Volume 2001;83 A(7):1047&#x2010;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11451974</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stannard 2006 {published data only}</Title><Reference><Citation>Stannard JP, Lopez&#x2010;Ben RR, Volgas DA, Anderson ER, Busbee M, Karr DK, McGwin GR, Alonso JE. The Journal of bone and joint surgery. American volume. Prophylaxis against deep&#x2010;vein thrombosis following trauma: a prospective, randomised comparison of mechanical and pharmacologic prophylaxis 2006;88(2):261&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16452735</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Velmahos 2005 {published data only}</Title><Reference><Citation>Velmahos GC, Petrone P, Chan LS, Hanks SE, Brown CV, Demetriades D. Electrostimulation for the prevention of deep venous thrombosis in patients with major trauma: a prospective randomised study. Surgery. 2005;137(5):493&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15855919</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yanar 2007 {published data only}</Title><Reference><Citation>Yanar H, Kurtoglu M, Taviloglu K, Guloglu R, Ertekin C. Is intermittent pneumatic compression make low molecular weight heparin more efficient in the prophylaxis of venous thromboembolism in trauma patients. European Journal of Trauma and Emergency Surgery 2007;33(3 Suppl 2):79&#x2010;80.</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Breyer 1986 {published data only}</Title><Reference><Citation>Breyer HG, Al&#x2010;Therib J, Bacher P, Werner B. Thrombosis prophylaxis with low molecular weight heparin in trauma surgery [Abstract]. Thrombosis Research Supplement 1986;VI:84.</Citation></Reference></ReferenceList><ReferenceList><Title>Greenfiel 1997 {published data only}</Title><Reference><Citation>Greenfield LJ, Proctor MC, Rodriguez JL, Luchette FA, Cipolle MD, Cho J. Posttrauma thromboembolism prophylaxis. The Journal of Trauma&#x2010;injury and Critical Care 1997;42(1):100&#x2010;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">9003265</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Haas 2003 {published data only}</Title><Reference><Citation>Haas S, Lassen MR, Wolf H, Brom J, Weidinger G, Fareed J. Prevention of venous thromboembolism in orthopedic trauma patients receiving heparin thromboprophylaxis &#x2010; a substudy analysis of autopsy&#x2010;confirmed fatal pulmonary embolism. Journal of Thrombosis &amp; Haemostasis 2003;1(Suppl 1):Abstract no: P1442.</Citation></Reference></ReferenceList><ReferenceList><Title>Holzheimer 2004 {published data only}</Title><Reference><Citation>Holzheimer RG. Prophylaxis of thrombosis with low molecular weight heparin. European Journal of Medical Research 2004;9:150&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">15096326</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Murakami 2003 {published data only}</Title><Reference><Citation>Murakami M, McDill TL, Cindrick&#x2010;Pounds L, Loran DB, Woodside KJ, Mileski WJ, et al. Deep venous thrombosis prophylaxis in trauma: improved compliance with a novel miniaturized pneumatic compression device. Journal of vascular surgery 2003;38(5):923&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">14603195</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Reilmann 1986 {published data only}</Title><Reference><Citation>Reilmann H, Creutzig H, Tscherne H, Reilmann L. Langenbecks Archiv fur Chirurgie. Medicamental prophylaxis of thromboembolic complications with heparin and dihydroergotamine in trauma surgery 1986;369:753.</Citation></Reference></ReferenceList><ReferenceList><Title>Wolf 1992 {published data only}</Title><Reference><Citation>Wolf H, Kujath P, Spannagel U. Prevention of Thromboembolic Complications in Traumatized Patients &#x2010; a Comparison Between Low&#x2010;Molecular&#x2010;Weight Heparin and Low&#x2010;Dose Heparin. Perfusion 1992;5(7):210.</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Acosta 1998</Title><Reference><Citation>Acosta JA, Yang JC, Winchell RJ, Simons RK, Fortlage DL, Hollingsworth&#x2010;Fridlund P, et al. Lethal injuries and time to death in a level I trauma center. Journal of the American College of Surgeons 1998;186:528&#x2010;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9583692</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bani&#x2010;Hani 2011</Title><Reference><Citation>Bani&#x2010;Hani M, Titi MA, Jaradat I, Al&#x2010;Khaffaf H. Interventions for preventing venous thromboembolism following abdominal aortic surgery. Cochrane Database of Systematic Reviews 2011, Issue 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006878</ArticleId><ArticleId IdType="pubmed">18254082</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bauer 1944</Title><Reference><Citation>Bauer G. Thrombosis following leg injuries. Acta Chirurgica Scandinavica 1944;90:229&#x2010;48.</Citation></Reference></ReferenceList><ReferenceList><Title>Cipolle 2002</Title><Reference><Citation>Cipolle MD, Wojcik R, Seislove E, Wasser TE, Pasquale MD. The role of surveillance duplex scanning in preventing venous thromboembolism in trauma patients. Journal of Trauma&#x2010;Injury Infection &amp; Critical Care 2002;52:453&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11901319</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cohn 1999</Title><Reference><Citation>Cohn SM, Moller BA, Feinstein AJ, Burns GA, Ginzburg E, Hammers LW. Prospective trial of low&#x2010;molecular&#x2010;weight heparin versus unfractionated heparin in moderately injured patients. Vascular and Endovascular Surgery 1999;33:219&#x2010;23.</Citation></Reference></ReferenceList><ReferenceList><Title>Elliott 1999</Title><Reference><Citation>Elliott CG, Dudney TM, Egger M, Orme JF, Clemmer TP, Horn SD, et al. Calf&#x2010;thigh sequential pneumatic compression compared with plantar venous pneumatic compression to prevent deep&#x2010;vein thrombosis after non&#x2010;lower extremity trauma. Journal of Trauma&#x2010;Injury Infection &amp; Critical Care 1999;47:25&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10421182</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Evans 2003</Title><Reference><Citation>Evans SA, Airey MC, Chell SM, Connelly JB, Rigby AS, Tennant A. Disability in young adults following major trauma: 5 year follow up of survivors. BioMed Central Public Health 2003;3:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149229</ArticleId><ArticleId IdType="pubmed">12546708</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fisher 1995</Title><Reference><Citation>Fisher CG, Blachut PA, Salvian AJ, Meek RN, O'Brien PJ. Effectiveness of leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: a prospective, randomised study of compression alone versus no prophylaxis. Journal of Orthopedics Trauma 1995;9:1&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7714648</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Frezza 1996</Title><Reference><Citation>Frezza EE, Siram SM, Thiel DH, Mezghebe MH. Venous thromboembolism after penetrating chest trauma is not a cause of early death. Journal of Cardiovascular Surgery 1996;37:521&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8941696</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Geerts 1994</Title><Reference><Citation>Geerts WH, Code KI, Jay RM, Chen RE, Szalai JP. A prospective study of venous thromboembolism after major trauma. The New England Journal of Medicine 1994;331:1601&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969340</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Geerts 1996</Title><Reference><Citation>Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, et al. A comparison of low&#x2010;dose heparin with low&#x2010;molecular&#x2010;weight heparin as prophylaxis against venous thromboembolism after major trauma. The New England Journal of Medicine 1996;335:701&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8703169</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Geerts 2008</Title><Reference><Citation>Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American college of chest physicians evidence&#x2010;based clinical practice guidelines (8th edition). Chest 2008;133(6 Suppl):381&#x2010;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">18574271</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Haentjens 1996</Title><Reference><Citation>Haentjens P. Thromboembolic prophylaxis in orthopaedic trauma patients: a comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium). Injury 1996;27:385&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8881132</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Handoll 2008</Title><Reference><Citation>Handoll HHG, Farrar MJ, McBirnie J, Tytherleigh&#x2010;Strong GM, Milne AA, Gillespie WJ. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD000305]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD000305</ArticleId><ArticleId IdType="pubmed">12519540</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2008</Title><Reference><Citation>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane&#x2010;handbook.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Hirsh 2004</Title><Reference><Citation>Hirsh J, Raschke R. Heparin and Low&#x2010;Molecular&#x2010;Weight Heparin. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Supplement):188&#x2010;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15383472</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hoffman 2001</Title><Reference><Citation>Hoffman M, Monroe D. A cell&#x2010;based model of haemostasis. Thrombosis and Haemostasis&#xa0; 2001;85:958&#x2010;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">11434702</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kahn 2012</Title><Reference><Citation>Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence&#x2010;Based Clinical Practice Guidelines. Chest 2012 Feb;141((2 Suppl)):195S&#x2010;226S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278052</ArticleId><ArticleId IdType="pubmed">22315261</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kakkos 2008</Title><Reference><Citation>Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby GP, Reddy DJ. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high&#x2010;risk patients. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD005258.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005258.pub2</ArticleId><ArticleId IdType="pubmed">18843686</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kelsey 2000</Title><Reference><Citation>Kelsey LJ, Fry DM, VanderKolk WE. Thrombosis risk in the trauma patient: prevention and treatment. Hematology/Oncology Clinics of North America April 2000; Vol. 14, issue 2:417&#x2010;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806564</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Knudson 1994</Title><Reference><Citation>Knudson MM, Lewis FR, Clinton A, Atkinson K, Megerman J. Prevention of venous thromboembolism in trauma patients. Journal of Trauma&#x2010;Injury Infection &amp; Critical Care 1994;37:480&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Knudson 1996</Title><Reference><Citation>Knudson MM, Morabito D, Paiement GD, Shackleford S. Use of low molecular weight heparin in preventing thromboembolism in trauma patients. Journal of Trauma&#x2010;Injury Infection &amp; Critical Care 1996;41:446&#x2010;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>McMurty 1999</Title><Reference><Citation>McMurtry AL, Owings JT, Anderson JT, Battistella FD, Gosselin R. Increased use of prophylactic vena cava filters in trauma patients failed to decrease overall incidence of pulmonary embolism. Journal of the American College of Surgeons 1999;189:314&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">10472933</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meissner 2003</Title><Reference><Citation>Meissner MH, Chandler WL, Elliott JS. Venous thromboembolism in trauma: a local manifestation of systemic hypercoagulability?. Journal of Trauma&#x2010;Injury Infection &amp; Critical Care 2003;54:224&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12579044</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nijkeuter 2004</Title><Reference><Citation>Nijkeuter M, Huisman MV. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review. Current Opinion in Pulmonary Medicine 2004;10(5):338&#x2010;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">15316429</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>O'Malley 1990</Title><Reference><Citation>O'Malley KF, Ross SE. Pulmonary embolism in major trauma patients. Journal of Trauma&#x2010;Injury Infection &amp; Critical Care 1990;30:748&#x2010;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">2352304</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>RevMan 2008 [Computer program]</Title><Reference><Citation>The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.</Citation></Reference></ReferenceList><ReferenceList><Title>Rogers 1993</Title><Reference><Citation>Rogers FB, Shackford SR, Wilson J, Ricci MA, Morris CS. Prophylactic vena cava filter insertion in severely injured trauma patients: indications and preliminary results. Journal of Trauma&#x2010;Injury Infection &amp; Critical Care 1993;35:637&#x2010;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">8411290</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rogers 1995</Title><Reference><Citation>Rogers FB. Venous thromboembolism in trauma patients. Surgical Clinics of North America 1995; Vol. 75:279&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">7899998</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rogers 2002</Title><Reference><Citation>Rogers FB, Cipolle MD, Velmahos G, Rozycki G, Luchette FA. Practice Management Guidelines for the Prevention of Venous Thromboembolism in Trauma Patients: The EAST Practice Management Guidelines Work Group. Journal of Trauma&#x2010;Injury, Infection and Critical Care 2002;53(1):142&#x2010;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12131409</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sauaia 1995</Title><Reference><Citation>Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, et al. Epidemiology of trauma deaths: a reassessment. Journal of Trauma&#x2010;Injury Infection &amp; Critical Care 1995;38(2):185&#x2010;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">7869433</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sevitt 1961</Title><Reference><Citation>Sevitt S, Gallagher N. Venous thrombosis and pulmonary embolism: a clinico&#x2010;pathological study in injured and burned patients. British Journal of Surgery 1961;48:475&#x2010;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">13750445</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shackford 1988</Title><Reference><Citation>Shackford SR, Moser KM. Deep venous thrombosis and pulmonary embolism in trauma patients. Journal of Intensive Care Medicine 1988;3:87&#x2010;98.</Citation></Reference></ReferenceList><ReferenceList><Title>Smith 1994</Title><Reference><Citation>Smith RM, Airey M, Franks AJ. Death after major trauma: can we affect it? The changing cause of death in each phase after injury [abstract]. Injury 1994;25:SB23&#x2010;4.</Citation></Reference></ReferenceList><ReferenceList><Title>Smith 2011</Title><Reference><Citation>Smith TO, Taylor R, Hing CB. Thromboprophylaxis following major skeletal trauma:a systematic review. European Journal of Trauma and Emergency Surgery 2011;37:479&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">26815419</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Spaniolas 2008</Title><Reference><Citation>Spaniolas K, Velmahos GC, Wicky S, Nussbaumer K, Petrovick L, Gervasini A, et al. Is upper extremity deep venous thrombosis underdiagnosed in trauma patients?. American Surgeon 2008;74(2):124&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18306861</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Velmahos 2000</Title><Reference><Citation>Velmahos GC, Kern J, Chan LS, Oder D, Murray JA, Shekelle P. Prevention of venous thromboembolism after injury: an evidence&#x2010;based report: Part I. Analysis of risk factors and evaluation of the role of vena caval filters. Journal of Trauma&#x2010;Injury Infection &amp; Critical Care 2000;49:132&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10912869</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Velmahos 2000a</Title><Reference><Citation>Velmahos GC, Kern J, Chan LS, Oder D, Murray JA, Shekelle P. Prevention of venous thromboembolism after injury: an evidence&#x2010;based report: Part II. Analysis of risk factors and evaluation of the role of vena caval filters. Journal of Trauma&#x2010;Injury Infection &amp; Critical Care 2000;49:140&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10912870</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>WHO 2008</Title><Reference><Citation>World Health Organization. The global burden of disease: 2004 update. Vol. 1, Switzerland: WHO Library and cataloguing&#x2010;data, 2008.</Citation></Reference></ReferenceList><ReferenceList><Title>Wille&#x2010;J&#xf8;rgensen 2008</Title><Reference><Citation>Wille&#x2010;J&#xf8;rgensen P, Rasmussen MS, Andersen BR, Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. The Cochrane Library 2008, Issue 4. [DOI: 10.1002/14651858.CD001217]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001217</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37606428</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2076-3271</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>Medical sciences (Basel, Switzerland)</Title><ISOAbbreviation>Med Sci (Basel)</ISOAbbreviation></Journal><ArticleTitle>Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">49</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medsci11030049</ELocationID><Abstract><AbstractText>Venous thromboembolism (VTE), comprising pulmonary embolism (PE) and deep vein thrombosis (DVT), poses a significant risk during and after hospitalization, particularly for surgical patients. Among various patient groups, those undergoing major orthopedic surgeries are considered to have a higher susceptibility to PE and DVT. Major lower-extremity orthopedic procedures carry a higher risk of symptomatic VTE compared to most other surgeries, with an estimated incidence of ~4%. The greatest risk period occurs within the first 7-14 days following surgery. Major bleeding is also more prevalent in these surgeries compared to others, with rates estimated between 2% and 4%. For patients undergoing major lower-extremity orthopedic surgery who have a low bleeding risk, it is recommended to use pharmacological thromboprophylaxis with or without mechanical devices. The choice of the initial agent depends on the specific surgery and patient comorbidities. First-line options include low-molecular-weight heparins (LMWHs), direct oral anticoagulants, and aspirin. Second-line options consist of unfractionated heparin (UFH), fondaparinux, and warfarin. For most patients undergoing knee or hip arthroplasty, the initial agents recommended for the early perioperative period are LMWHs (enoxaparin or dalteparin) or direct oral anticoagulants (rivaroxaban or apixaban). In the case of hip fracture surgery, LMWH is recommended as the preferred agent for the entire duration of prophylaxis. However, emerging factor XI(a) inhibitors, as revealed by a recent meta-analysis, have shown a substantial decrease in the occurrence of VTE and bleeding events among patients undergoing major orthopedic surgery. This discovery poses a challenge to the existing paradigm of anticoagulant therapy in this specific patient population and indicates that factor XI(a) inhibitors hold great promise as a potential strategy to be taken into serious consideration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Aaryana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Horani</LastName><ForeName>Rami A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0001-9146-2662</Identifier><AffiliationInfo><Affiliation>Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R16 GM149412</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>SC3 GM131986</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R16GM149412</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>SC3GM131986</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Med Sci (Basel)</MedlineTA><NlmUniqueID>101629322</NlmUniqueID><ISSNLinking>2076-3271</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.27</RegistryNumber><NameOfSubstance UI="D015945">Factor XIa</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015945" MajorTopicYN="N">Factor XIa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="Y">Arthroplasty, Replacement, Hip</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="Y">Arthroplasty, Replacement, Knee</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LMWHs</Keyword><Keyword MajorTopicYN="N">VTE</Keyword><Keyword MajorTopicYN="N">abelacimab</Keyword><Keyword MajorTopicYN="N">aspirin</Keyword><Keyword MajorTopicYN="N">factor XIa</Keyword><Keyword MajorTopicYN="N">milvexian</Keyword><Keyword MajorTopicYN="N">oral anticoagulants</Keyword><Keyword MajorTopicYN="N">orthopedic</Keyword><Keyword MajorTopicYN="N">osocimab</Keyword><Keyword MajorTopicYN="N">thromboprophylaxis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37606428</ArticleId><ArticleId IdType="pmc">PMC10443384</ArticleId><ArticleId IdType="doi">10.3390/medsci11030049</ArticleId><ArticleId IdType="pii">medsci11030049</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cohen A.T., Tapson V.F., Bergmann J.F., Goldhaber S.Z., Kakkar A.K., Deslandes B., Huang W., Zayaruzny M., Emery L., Anderson F.A., Jr., et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional study. Lancet. 2008;371:387&#x2013;394. doi: 10.1016/S0140-6736(08)60202-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(08)60202-0</ArticleId><ArticleId IdType="pubmed">18242412</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp&#xf3;sito-Ruiz M., Arcelus J.I., Caprini J.A., L&#xf3;pez-Espada C., Bura-Riviere A., Amado C., Loring M., Mastroiacovo D., Monreal M., RIETE Investigators Timing and characteristics of venous thromboembolism after noncancer surgery. J. Vasc. Surg. Venous Lymphat. Disord. 2021;9:859&#x2013;867e2. doi: 10.1016/j.jvsv.2020.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2020.11.017</ArticleId><ArticleId IdType="pubmed">33248295</ArticleId></ArticleIdList></Reference><Reference><Citation>Falck-Ytter Y., Francis C.W., Johanson N.A., Curley C., Dahl O.E., Schulman S., Ortel T.L., Pauker S.G., Colwell C.W., Jr. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141((Suppl. S2)):e278S&#x2013;e325S. doi: 10.1378/chest.11-2404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2404</ArticleId><ArticleId IdType="pmc">PMC3278063</ArticleId><ArticleId IdType="pubmed">22315265</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson D.R., Morgano G.P., Bennett C., Dentali F., Francis C.W., Garcia D.A., Kahn S.R., Rahman M., Rajasekhar A., Rogers F.B., et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: Prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3:3898&#x2013;3944. doi: 10.1182/bloodadvances.2019000975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019000975</ArticleId><ArticleId IdType="pmc">PMC6963238</ArticleId><ArticleId IdType="pubmed">31794602</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt G.H., Akl E.A., Crowther M., Gutterman D.D., Schu&#xfc;nemann H.J. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141((Suppl. S2)):7S&#x2013;47S. doi: 10.1378/chest.1412S3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.1412S3</ArticleId><ArticleId IdType="pmc">PMC3278060</ArticleId><ArticleId IdType="pubmed">22315257</ArticleId></ArticleIdList></Reference><Reference><Citation>Douketis J.D., Spyropoulos A.C., Murad M.H., Arcelus J.I., Dager W.E., Dunn A.S., Fargo R.A., Levy J.H., Samama C.M., Shah S.H., et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162:e207&#x2013;e243. doi: 10.1016/j.chest.2022.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2022.07.025</ArticleId><ArticleId IdType="pubmed">35964704</ArticleId></ArticleIdList></Reference><Reference><Citation>Douketis J.D., Spyropoulos A.C., Murad M.H., Arcelus J.I., Dager W.E., Dunn A.S., Fargo R.A., Levy J.H., Samama C.M., Shah S.H., et al. Executive Summary: Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162:1127&#x2013;1139. doi: 10.1016/j.chest.2022.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2022.08.004</ArticleId><ArticleId IdType="pubmed">35964703</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., Ray J.G. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126((Suppl. S2)):338S&#x2013;400S. doi: 10.1378/chest.126.3_suppl.338S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.126.3_suppl.338S</ArticleId><ArticleId IdType="pubmed">15383478</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkar V.V., Adams P.C. Preventive and therapeutic approach to venous thromboembolic disease and pulmonary embolism--can death from pulmonary embolism be prevented? Am. Coll. Cardiol. 1986;8((Suppl. S6)):146B&#x2013;158B. doi: 10.1016/S0735-1097(86)80016-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(86)80016-X</ArticleId><ArticleId IdType="pubmed">3537067</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepard R.M., Jr., White H.A., Shirkey A.L. Anticoagulant prophylaxis of thromboembolism in postsurgical patients. Am. J. Surg. 1966;112:698&#x2013;702. doi: 10.1016/0002-9610(66)90107-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9610(66)90107-3</ArticleId><ArticleId IdType="pubmed">4162520</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskeland G., Solheim K., Skj&#xf6;rten F. Anticoagulant prophylaxis, thromboembolism and mortality in elderly patients with hip fractures. A controlled clinical trial. Acta Chir. Scand. 1966;131:29.</Citation><ArticleIdList><ArticleId IdType="pubmed">5332064</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y., Mei J., Wang L., Shao M., Zhang J., Wu H., Zhao J. Investigation of the Incidence of Perioperative Pulmonary Embolism in Patients with Below-Knee Deep Vein Thrombosis after Lower Extremity Fracture and Evaluation of Retrievable Inferior Vena Cava Filter Deployment in These Patients. Ann. Vasc. Surg. 2019;60:45&#x2013;51. doi: 10.1016/j.avsg.2019.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.avsg.2019.02.027</ArticleId><ArticleId IdType="pubmed">31075462</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan M., Eusebio I.D., Haigh K., Panti J.P., Omari A., Hang J.R. Prevalence of Deep Vein Thrombosis in Low-Risk Patients After Elective Foot and Ankle Surgery. Foot Ankle Int. 2019;40:330&#x2013;335. doi: 10.1177/1071100718807889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1071100718807889</ArticleId><ArticleId IdType="pubmed">30577712</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts W.H., Heit J.A., Clagett G.P., Pineo G.F., Colwell C.W., Anderson F.A., Wheeler H.B. Prevention of venous thromboembolism. Chest. 2001;119((Suppl. S1)):132S&#x2013;175S. doi: 10.1378/chest.119.1_suppl.132S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.119.1_suppl.132S</ArticleId><ArticleId IdType="pubmed">11157647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen A.B., Mehnert F., Johnsen S.P., Husted S., Sorensen H.T. Venous thromboembolism in patients having knee replacement and receiving thromboprophylaxis: A Danish population-based follow-up study. J. Bone Joint Surg. Am. 2011;93:1281&#x2013;1287. doi: 10.2106/JBJS.J.00676.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.J.00676</ArticleId><ArticleId IdType="pubmed">21792493</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen A.B., Sorensen H.T., Mehnert F., Overgaard S., Johnsen S.P. Risk factors for venous thromboembolism in patients undergoing total hip replacement and receiving routine thromboprophylaxis. J. Bone Joint Surg. Am. 2010;92:2156&#x2013;2164. doi: 10.2106/JBJS.I.00882.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.I.00882</ArticleId><ArticleId IdType="pubmed">20844157</ArticleId></ArticleIdList></Reference><Reference><Citation>Warwick D., Williams M.H., Bannister G.C. Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. J. Bone Joint Surg. Br. 1995;77:6&#x2013;10. doi: 10.1302/0301-620X.77B1.7822397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.77B1.7822397</ArticleId><ArticleId IdType="pubmed">7822397</ArticleId></ArticleIdList></Reference><Reference><Citation>Flevas D.A., Megaloikonomos P.D., Dimopoulos L., Mitsiokapa E., Koulouvaris P., Mavrogenis A.F. Thromboembolism prophylaxis in orthopaedics: An update. EFORT Open Rev. 2018;3:136&#x2013;148. doi: 10.1302/2058-5241.3.170018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/2058-5241.3.170018</ArticleId><ArticleId IdType="pmc">PMC5941651</ArticleId><ArticleId IdType="pubmed">29780621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn S.R., Shivakumar S. What&#x2019;s new in VTE risk and prevention in orthopedic surgery. Res. Pract. Thromb. Haemost. 2020;4:366&#x2013;376. doi: 10.1002/rth2.12323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12323</ArticleId><ArticleId IdType="pmc">PMC7086463</ArticleId><ArticleId IdType="pubmed">32211571</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf8;rnar&#xe5; B.T., Gudmundsen T.E., Dahl O.E. Frequency and timing of clinical venous thromboembolism after major joint surgery. J. Bone Joint Surg. Br. 2006;88:386&#x2013;391. doi: 10.1302/0301-620X.88B3.17207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.88B3.17207</ArticleId><ArticleId IdType="pubmed">16498018</ArticleId></ArticleIdList></Reference><Reference><Citation>Januel J.M., Chen G., Ruffieux C., Quan H., Douketis J.D., Crowther M.A., Colin C., Ghali W.A., Burnand B., IMECCHI Group Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: A systematic review. JAMA. 2012;307:294&#x2013;303. doi: 10.1001/jama.2011.2029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2011.2029</ArticleId><ArticleId IdType="pubmed">22253396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill J., Treasure T., National Clinical Guideline Centre for Acute and Chronic Conditions Reducing the risk of venous thromboembolism in patients admitted to hospital: Summary of NICE guidance. BMJ. 2010;340:c95. doi: 10.1136/bmj.c95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c95</ArticleId><ArticleId IdType="pubmed">20106897</ArticleId></ArticleIdList></Reference><Reference><Citation>Cionac Florescu S., Anastase D.M., Munteanu A.M., Stoica I.C., Antonescu D. Venous thromboembolism following major orthopedic surgery. Maedica. 2013;8:189&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3865129</ArticleId><ArticleId IdType="pubmed">24371484</ArticleId></ArticleIdList></Reference><Reference><Citation>Deitelzweig S.B., McKean S.C., Amin A.N., Brotman D.J., Jaffer A.K., Spyropoulos A.C. Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin. J. Med. 2008;75((Suppl. S3)):S27&#x2013;S36. doi: 10.3949/ccjm.75.Suppl_3.S27.</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.75.Suppl_3.S27</ArticleId><ArticleId IdType="pubmed">18494224</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenny J.Y., Bulaid Y., Boisrenoult P., Bonin N., Henky P., Tracol P., Chouteau J., Courtin C., Henry M.P., Schwartz C., et al. French Society of Orthopaedic Surgery, Traumatology (SofCOT). Bleeding and thromboembolism risk of standard antithrombotic prophylaxis after hip or knee replacement within an enhanced recovery program. Orthop. Traumatol. Surg. Res. 2020;106:1533&#x2013;1538. doi: 10.1016/j.otsr.2020.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2020.02.026</ArticleId><ArticleId IdType="pubmed">33127330</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsheikh K., Hilabi A., Aleid A., Alharbi K.G., Alangari H.S., Alkhamis M., Alzahrani F., AlMadani W. Efficacy and Safety of Thromboprophylaxis Post-Orthopedic Surgery. Cureus. 2021;13:e19691. doi: 10.7759/cureus.19691.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.19691</ArticleId><ArticleId IdType="pmc">PMC8684043</ArticleId><ArticleId IdType="pubmed">34934566</ArticleId></ArticleIdList></Reference><Reference><Citation>Etscheidt J., Shahien A., Gainey M., Kronenfeld D., Niu R., Freccero D., Smith E. Review of Therapeutic Options for the Prevention of VTE in Total Joint Arthroplasty. Geriatrics. 2020;5:18. doi: 10.3390/geriatrics5010018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/geriatrics5010018</ArticleId><ArticleId IdType="pmc">PMC7151331</ArticleId><ArticleId IdType="pubmed">32197389</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull R.D., Pineo G.F., Francis C., Bergqvist D., Fellenius C., Soderberg K., Holmqvist A., Mant M., Dear R., Baylis B., et al. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: A double-blind, randomized comparison. The North American Fragmin Trial Investigators. Arch. Intern. Med. 2000;160:2199&#x2013;2207. doi: 10.1001/archinte.160.14.2199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.160.14.2199</ArticleId><ArticleId IdType="pubmed">10904464</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull R.D., Pineo G.F., Stein P.D., Mah A.F., MacIsaac S.M., Dahl O.E., Ghali W.A., Butcher M.S., Brant R.F., Bergqvist D., et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: A systematic review. Arch. Intern. Med. 2001;161:1952&#x2013;1960. doi: 10.1001/archinte.161.16.1952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.161.16.1952</ArticleId><ArticleId IdType="pubmed">11525697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkar A.K., Brenner B., Dahl O.E., Eriksson B.I., Mouret P., Muntz J., Soglian A.G., Pap A.F., Misselwitz F., Haas S., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial. Lancet. 2008;372:31&#x2013;39. doi: 10.1016/S0140-6736(08)60880-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(08)60880-6</ArticleId><ArticleId IdType="pubmed">18582928</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., Prins M.H., Hettiarachchi R., Hantel S., Schnee J., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949&#x2013;956. doi: 10.1016/S0140-6736(07)61445-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61445-7</ArticleId><ArticleId IdType="pubmed">17869635</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen M.R., Gallus A., Raskob G.E., Pineo G., Chen D., Ramirez L.M. ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. 2010;363:2487&#x2013;2498. doi: 10.1056/NEJMoa1006885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1006885</ArticleId><ArticleId IdType="pubmed">21175312</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson D.R., Dunbar M., Murnaghan J., Kahn S.R., Gross P., Forsythe M., Pelet S., Fisher W., Belzile E., Dolan S., et al. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. N. Engl. J. Med. 2018;378:699&#x2013;707. doi: 10.1056/NEJMoa1712746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1712746</ArticleId><ArticleId IdType="pubmed">29466159</ArticleId></ArticleIdList></Reference><Reference><Citation>Planes A., Vochelle N., Darmon J.Y., Fagola M., Bellaud M., Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996;348:224&#x2013;228. doi: 10.1016/S0140-6736(96)01453-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)01453-5</ArticleId><ArticleId IdType="pubmed">8684199</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergqvist D., Benoni G., Bj&#xf6;rgell O., Fredin H., Hedlundh U., Nicolas S., Nilsson P., Nylander G. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N. Engl. J. Med. 1996;335:696&#x2013;700. doi: 10.1056/NEJM199609053351002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199609053351002</ArticleId><ArticleId IdType="pubmed">8703168</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahl O.E., Andreassen G., Aspelin T., M&#xfc;ller C., Mathiesen P., Nyhus S., Abdelnoor M., Solhaug J.H., Arnesen H. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin) Thromb. Haemost. 1997;77:26&#x2013;31. doi: 10.1055/s-0038-1655901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1655901</ArticleId><ArticleId IdType="pubmed">9031444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen M.R., Borris L.C., Anderson B.S., Jensen H.P., Skej&#xf8; Bro H.P., Andersen G., Petersen A.O., Siem P., H&#xf8;rlyck E., Jensen B.V., et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. Thromb. Res. 1998;89:281&#x2013;287. doi: 10.1016/S0049-3848(98)00018-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0049-3848(98)00018-8</ArticleId><ArticleId IdType="pubmed">9669750</ArticleId></ArticleIdList></Reference><Reference><Citation>Comp P.C., Spiro T.E., Friedman R.J., Whitsett T.L., Johnson G.J., Gardiner G.A., Jr., Landon G.C., Jov&#xe9; M., Enoxaparin Clinical Trial Group Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J. Bone Joint Surg. Am. 2001;83:336&#x2013;345. doi: 10.2106/00004623-200103000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-200103000-00004</ArticleId><ArticleId IdType="pubmed">11263636</ArticleId></ArticleIdList></Reference><Reference><Citation>White R.H., Romano P.S., Zhou H., Rodrigo J., Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch. Intern. Med. 1998;158:1525&#x2013;1531. doi: 10.1001/archinte.158.14.1525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.158.14.1525</ArticleId><ArticleId IdType="pubmed">9679793</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelboom J.W., Quinlan D.J., Douketis J.D. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: A meta-analysis of the randomised trials. Lancet. 2001;358:9&#x2013;15. doi: 10.1016/S0140-6736(00)05249-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)05249-1</ArticleId><ArticleId IdType="pubmed">11454370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull R.D., Pineo G.F., Stein P.D., Mah A.F., MacIsaac S.M., Dahl O.E., Butcher M., Brant R.F., Ghali W.A., Bergqvist D., et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: A systematic review. Ann. Intern. Med. 2001;135:858&#x2013;869. doi: 10.7326/0003-4819-135-10-200111200-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-135-10-200111200-00006</ArticleId><ArticleId IdType="pubmed">11712876</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobieraj D.M., Lee S., Coleman C.I., Tongbram V., Chen W., Colby J., Kluger J., Makanji S., Ashaye A.O., White C.M. Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: A systematic review. Ann. Intern. Med. 2012;156:720&#x2013;727. doi: 10.7326/0003-4819-156-10-201205150-00423.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-156-10-201205150-00423</ArticleId><ArticleId IdType="pubmed">22412039</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher W.D., Agnelli G., George D.J., Kakkar A.K., Lassen M.R., Mismetti P., Mouret P., Turpie A.G. Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery&#x2014;the SAVE-HIP3 study. Bone Joint J. 2013;95:459&#x2013;466. doi: 10.1302/0301-620X.95B4.30730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.95B4.30730</ArticleId><ArticleId IdType="pubmed">23539696</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell M., Linkins L.A., Kearon C., Julian J., Hirsh J. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty: A systematic review. Arch. Intern. Med. 2003;163:1362&#x2013;1366. doi: 10.1001/archinte.163.11.1362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.163.11.1362</ArticleId><ArticleId IdType="pubmed">12796074</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster R., Stewart M. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. Cochrane Database Syst. Rev. 2016;3:CD004179. doi: 10.1002/14651858.CD004179.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004179.pub2</ArticleId><ArticleId IdType="pmc">PMC10332795</ArticleId><ArticleId IdType="pubmed">27027384</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit J.A., Elliott C.G., Trowbridge A.A., Morrey B.F., Gent M., Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 2000;132:853&#x2013;861. doi: 10.7326/0003-4819-132-11-200006060-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-132-11-200006060-00002</ArticleId><ArticleId IdType="pubmed">10836911</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., Bandel T.J., Beckmann H., Muehlhofer E., Misselwitz F., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 2008;358:2765&#x2013;2775. doi: 10.1056/NEJMoa0800374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0800374</ArticleId><ArticleId IdType="pubmed">18579811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong C.S., Marcum J.A., Zehr K.J., Cameron D.E. A Century of Heparin. Ann. Thorac. Surg. 2019;108:955&#x2013;958. doi: 10.1016/j.athoracsur.2019.03.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2019.03.104</ArticleId><ArticleId IdType="pubmed">31077659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogwood J., Mulloy B., Lever R., Gray E., Page C.P. Pharmacology of Heparin and Related Drugs: An Update. Pharmacol. Rev. 2023;75:328&#x2013;379. doi: 10.1124/pharmrev.122.000684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pharmrev.122.000684</ArticleId><ArticleId IdType="pubmed">36792365</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu M., Huang S., Luo C., Wu Z., Liang B., Huang H., Ci Z., Zhang D., Han L., Lin J. Pharmacological and clinical application of heparin progress: An essential drug for modern medicine. Biomed. Pharmacother. 2021;139:111561. doi: 10.1016/j.biopha.2021.111561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111561</ArticleId><ArticleId IdType="pubmed">33848775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandrotas R.J. Heparin pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 1992;22:359&#x2013;374. doi: 10.2165/00003088-199222050-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-199222050-00003</ArticleId><ArticleId IdType="pubmed">1505142</ArticleId></ArticleIdList></Reference><Reference><Citation>King C.S., Holley A.B., Jackson J.L., Shorr A.F., Moores L.K. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis. Chest. 2007;131:507&#x2013;516. doi: 10.1378/chest.06-1861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.06-1861</ArticleId><ArticleId IdType="pubmed">17296655</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther M.A., Warkentin T.E. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: Focus on new anticoagulant agents. Blood. 2008;111:4871&#x2013;4879. doi: 10.1182/blood-2007-10-120543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2007-10-120543</ArticleId><ArticleId IdType="pubmed">18309033</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsh J., Anand S.S., Halperin J.L., Fuster V., American Heart Association Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994&#x2013;3018. doi: 10.1161/01.CIR.103.24.2994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.103.24.2994</ArticleId><ArticleId IdType="pubmed">11413093</ArticleId></ArticleIdList></Reference><Reference><Citation>Joy M., Tharp E., Hartman H., Schepcoff S., Cortes J., Sieg A., Mariski M., Lee Y., Murphy M., Ranjbar G., et al. Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients. Pharmacotherapy. 2016;36:740&#x2013;748. doi: 10.1002/phar.1775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.1775</ArticleId><ArticleId IdType="pubmed">27265806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T.F., Milligan P.E., Wong C.A., Deal E.N., Thoelke M.S., Gage B.F. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb. Haemost. 2014;111:88&#x2013;93. doi: 10.1160/TH13-01-0042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH13-01-0042</ArticleId><ArticleId IdType="pmc">PMC4505726</ArticleId><ArticleId IdType="pubmed">24136071</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia D.A., Baglin T.P., Weitz J.I., Samama M.M. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141((Suppl. S2)):e24S&#x2013;e43S. doi: 10.1378/chest.11-2291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2291</ArticleId><ArticleId IdType="pmc">PMC3278070</ArticleId><ArticleId IdType="pubmed">22315264</ArticleId></ArticleIdList></Reference><Reference><Citation>PROTAMINE SULFATE- Protamine Sulfate Injection, Solution.  [(accessed on 11 June 2023)]; Available online:  https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=94d4f57f-940e-c0a8-e053-2a95a90ae3af&amp;type=display.</Citation></Reference><Reference><Citation>Arepally G.M. Heparin-induced thrombocytopenia. Blood. 2017;129:2864&#x2013;2872. doi: 10.1182/blood-2016-11-709873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-11-709873</ArticleId><ArticleId IdType="pmc">PMC5445568</ArticleId><ArticleId IdType="pubmed">28416511</ArticleId></ArticleIdList></Reference><Reference><Citation>McGarry L.J., Stokes M.E., Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thromb. J. 2006;4:17. doi: 10.1186/1477-9560-4-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-9560-4-17</ArticleId><ArticleId IdType="pmc">PMC1624807</ArticleId><ArticleId IdType="pubmed">17005045</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R., PENTATHALON 2000 Study Steering Committee Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A randomised double-blind trial. Lancet. 2002;359:1721&#x2013;1726. doi: 10.1016/S0140-6736(02)08648-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)08648-8</ArticleId><ArticleId IdType="pubmed">12049860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer K.A., Eriksson B.I., Lassen M.R., Turpie A.G., Steering Committee of the Pentasaccharide in Major Knee Surgery Study Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. 2001;345:1305&#x2013;1310. doi: 10.1056/NEJMoa011099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa011099</ArticleId><ArticleId IdType="pubmed">11794149</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B.I., Bauer K.A., Lassen M.R., Turpie A.G., Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N. Engl. J. Med. 2001;345:1298&#x2013;1304. doi: 10.1056/NEJMoa011100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa011100</ArticleId><ArticleId IdType="pubmed">11794148</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong K., Song Y., Li X., Ding J., Gao Z., Lu D., Zhu Y. Pentasaccharides for the prevention of venous thromboembolism. Cochrane Database Syst Rev. 2016;10:CD005134. doi: 10.1002/14651858.CD005134.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005134.pub3</ArticleId><ArticleId IdType="pmc">PMC6463830</ArticleId><ArticleId IdType="pubmed">27797404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen M.R., Bauer K.A., Eriksson B.I., Turpie A.G., European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: A randomised double-blind comparison. Lancet. 2002;359:1715&#x2013;1720. doi: 10.1016/S0140-6736(02)08652-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)08652-X</ArticleId><ArticleId IdType="pubmed">12049858</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie A.G., Bauer K.A., Eriksson B.I., Lassen M.R. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med. 2002;162:1833&#x2013;1840. doi: 10.1001/archinte.162.16.1833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.162.16.1833</ArticleId><ArticleId IdType="pubmed">12196081</ArticleId></ArticleIdList></Reference><Reference><Citation>Colwell CWJr Kwong L.M., Turpie A.G., Davidson B.L. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J. Arthroplast. 2006;21:36&#x2013;45. doi: 10.1016/j.arth.2005.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2005.05.023</ArticleId><ArticleId IdType="pubmed">16446183</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer-Westendorf J., L&#xfc;tzner J., Donath L., Radke O.C., Kuhlisch E., Hartmann A., Weiss N., Werth S. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: Findings from the ORTHO-TEP registry. J. Thromb. Haemost. 2012;10:2045&#x2013;2052. doi: 10.1111/j.1538-7836.2012.04877.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2012.04877.x</ArticleId><ArticleId IdType="pubmed">22882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki H., Ishida K., Shibanuma N., Tei K., Tateishi H., Toda A., Yamashiro Y., Matsumoto T., Kuroda R., Kurosaka M. Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty. Int. Orthop. 2014;38:525&#x2013;529. doi: 10.1007/s00264-013-2132-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00264-013-2132-x</ArticleId><ArticleId IdType="pmc">PMC3936088</ArticleId><ArticleId IdType="pubmed">24100922</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B.I., Lassen M.R., PENTasaccharide in HIp-FRActure Surgery Plus Investigators Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: A multicenter, randomized, placebo-controlled, double-blind study. Arch. Intern. Med. 2003;163:1337&#x2013;1342. doi: 10.1001/archinte.163.11.1337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.163.11.1337</ArticleId><ArticleId IdType="pubmed">12796070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsh J., Fuster V., Ansell J., Halperin J.L., American Heart Association/American College of Cardiology Foundation American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J. Am. Coll. Cardiol. 2003;41:1633&#x2013;1652. doi: 10.1016/S0735-1097(03)00416-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(03)00416-9</ArticleId><ArticleId IdType="pubmed">12742309</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S., Singh R., Preuss C.V., Patel N. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. Warfarin.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark N.P., Cho S.E., Delate T., Witt D.M. Thromboembolic and bleeding outcomes of low-intensity warfarin thromboprophylaxis following elective total hip arthroplasty. Thromb. Res. 2013;131:390&#x2013;395. doi: 10.1016/j.thromres.2013.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2013.02.017</ArticleId><ArticleId IdType="pubmed">23522854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S.E., Delate T., Witt D.M., Clark N.P. Thromboembolic and bleeding outcomes of extended duration low-intensity warfarin following elective total knee arthroplasty. Thromb. Res. 2015;135:267&#x2013;271. doi: 10.1016/j.thromres.2014.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2014.11.033</ArticleId><ArticleId IdType="pubmed">25555318</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordstrom B.L., Kachroo S., Fraeman K.H., Nutescu E.A., Schein J.R., Fisher A., Bookhart B.K. Warfarin prophylaxis in patients after total knee or hip arthroplasty--international normalized ratio patterns and venous thromboembolism. Curr. Med. Res. Opin. 2011;27:1973&#x2013;1985. doi: 10.1185/03007995.2011.614938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007995.2011.614938</ArticleId><ArticleId IdType="pubmed">21919556</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers P.J., Gent M., Jay R.M., Julian D.H., Turpie A.G., Levine M., Hirsh J. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch. Intern. Med. 1989;149:771&#x2013;774. doi: 10.1001/archinte.1989.00390040013003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1989.00390040013003</ArticleId><ArticleId IdType="pubmed">2650646</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G.K., Mitchell J.R. Warfarin sodium in prevention of deep venous thrombosis and pulmonary embolism in patients with fractured neck of femur. Lancet. 1976;2:869&#x2013;872. doi: 10.1016/S0140-6736(76)90536-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(76)90536-5</ArticleId><ArticleId IdType="pubmed">62111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey J.P., Kruger M.P., Solano F.X., Zajko A.B., Rubash H.E. Prospective randomized trial of sequential compression devices vs low-dose warfarin for deep venous thrombosis prophylaxis in total hip arthroplasty. J. Arthroplast. 1991;6:S29&#x2013;S35. doi: 10.1016/S0883-5403(08)80053-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0883-5403(08)80053-8</ArticleId><ArticleId IdType="pubmed">1774568</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.W., Pellegrini VDJr Marder V.J., Totterman S., Harris C.M., Gabriel K.R., Azodo M.V., Leibert K.M. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. JAMA. 1992;267:2911&#x2013;2915. doi: 10.1001/jama.1992.03480210073035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1992.03480210073035</ArticleId><ArticleId IdType="pubmed">1583760</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiement G., Wessinger S.J., Waltman A.C., Harris W.H. Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J. Arthroplast. 1987;2:23&#x2013;26. doi: 10.1016/S0883-5403(87)80027-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0883-5403(87)80027-X</ArticleId><ArticleId IdType="pubmed">3572408</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaempffe F.A., Lifeso R.M., Meinking C. Intermittent pneumatic compression versus coumadin. Prevention of deep vein thrombosis in lower-extremity total joint arthroplasty. Clin. Orthop. Relat. Res. 1991;269:89&#x2013;97. doi: 10.1097/00003086-199108000-00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003086-199108000-00014</ArticleId><ArticleId IdType="pubmed">1864061</ArticleId></ArticleIdList></Reference><Reference><Citation>Deitelzweig S., Jaff M.R. Medical management of venous thromboembolic disease. Tech. Vasc. Interv. Radiol. 2004;7:63&#x2013;67. doi: 10.1053/j.tvir.2004.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.tvir.2004.02.003</ArticleId><ArticleId IdType="pubmed">15252762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull R.D., Pineo G.F., Francis C., Bergqvist D., Fellenius C., Soderberg K., Holmqvist A., Mant M., Dear R., Baylis B., et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch. Intern. Med. 2000;160:2208&#x2013;2215. doi: 10.1001/archinte.160.14.2208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.160.14.2208</ArticleId><ArticleId IdType="pubmed">10904465</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoudi M., Sobieraj D.M. The cost-effectiveness of oral direct factor Xa inhibitors compared with low-molecular-weight heparin for the prevention of venous thromboembolism prophylaxis in total hip or knee replacement surgery. Pharmacotherapy. 2013;33:1333&#x2013;1340. doi: 10.1002/phar.1269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.1269</ArticleId><ArticleId IdType="pubmed">23625693</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson C.M., Hall C., Davis S., Schillig J.M. Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients. J. Thromb. Thrombolysis. 2021;52:577&#x2013;583. doi: 10.1007/s11239-020-02360-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02360-9</ArticleId><ArticleId IdType="pubmed">33400099</ArticleId></ArticleIdList></Reference><Reference><Citation>Enoxaparin Label.  [(accessed on 11 June 2023)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020164s110lbl.pdf.</Citation></Reference><Reference><Citation>Dranitsaris G., Stumpo C., Smith R., Bartle W. Extended dalteparin prophylaxis for venous thromboembolic events: Cost-utility analysis in patients undergoing major orthopedic surgery. Am. J. Cardiovasc. Drugs. 2009;9:45&#x2013;58. doi: 10.1007/BF03256594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03256594</ArticleId><ArticleId IdType="pubmed">19178131</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalteparin Label.  [(accessed on 11 June 2023)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020287s069lbl.pdf.</Citation></Reference><Reference><Citation>Nadroparin Label.  [(accessed on 11 June 2023)].  Available online:  https://pdf.hres.ca/dpd_pm/00066611.PDF.</Citation></Reference><Reference><Citation>Karathanos C., Chatzis D., Latzios P., Papakostas I., Goumas K., Giannoukas A.D., SeVEN EXT Collaborators Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study&#x2014;The SeVEN EXTension study. Phlebology. 2021;36:423&#x2013;431. doi: 10.1177/0268355520947300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0268355520947300</ArticleId><ArticleId IdType="pubmed">33407054</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy S.M., Scott L.J., Plosker G.L. Tinzaparin sodium: A review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis. Drugs. 2010;70:1319&#x2013;1347. doi: 10.2165/11203710-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11203710-000000000-00000</ArticleId><ArticleId IdType="pubmed">20568836</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji T., Ochi T., Niwa S., Fujita S. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: Two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin. J Orthop Sci. 2008;13:442&#x2013;451. doi: 10.1007/s00776-008-1264-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00776-008-1264-0</ArticleId><ArticleId IdType="pubmed">18843459</ArticleId></ArticleIdList></Reference><Reference><Citation>Leclerc J.R., Geerts W.H., Desjardins L., Jobin F., Laroche F., Delorme F., Haviernick S., Atkinson S., Bourgouin J. Prevention of deep vein thrombosis after major knee surgery&#x2014;A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb. Haemost. 1992;67:417&#x2013;423. doi: 10.1055/s-0038-1648463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1648463</ArticleId><ArticleId IdType="pubmed">1321509</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine M.N., Gent M., Hirsh J., Weitz J., Turpie A.G., Powers P., Neemeh J., Willan A., Skingley P. Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Arch. Intern. Med. 1996;156:851&#x2013;856. doi: 10.1001/archinte.1996.00440080039005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1996.00440080039005</ArticleId><ArticleId IdType="pubmed">8774203</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie A.G., Levine M.N., Hirsh J., Carter C.J., Jay R.M., Powers P.J., Andrew M., Hull R.D., Gent M. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N. Engl. J. Med. 1986;315:925&#x2013;929. doi: 10.1056/NEJM198610093151503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198610093151503</ArticleId><ArticleId IdType="pubmed">3531851</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf8;rgensen P.S., Knudsen J.B., Broeng L., Josephsen L., Bjerregaard P., Hagen K., J&#xf8;rgensen P.K., T&#xf8;rholm C. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study. Clin. Orthop. Relat. Res. 1992;278:95&#x2013;100. doi: 10.1097/00003086-199205000-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003086-199205000-00015</ArticleId><ArticleId IdType="pubmed">1314147</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor A., Ellis A., Shaffer N., Gurwitz J., Chandramohan A., Saulino J., Ishak A., Okubanjo T., Michota F., Hylek E., et al. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: A network meta-analysis. J. Thromb. Haemost. 2017;15:284&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5305416</ArticleId><ArticleId IdType="pubmed">28102615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull R., Raskob G., Pineo G., Rosenbloom D., Evans W., Mallory T., Anquist K., Smith F., Hughes G., Green D., et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N. Engl. J. Med. 1993;329:1370&#x2013;1376. doi: 10.1056/NEJM199311043291902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199311043291902</ArticleId><ArticleId IdType="pubmed">8413432</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman R.J., Davidson B.L., Heit J., Kessler C., Elliott C.G., Cabanas V., Chenault C., Dall D., Chandler D.R., Drennan D., et al. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group. J. Bone Joint Surg. Am. 1994;76:1174&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pubmed">8056798</ArticleId></ArticleIdList></Reference><Reference><Citation>Leclerc J.R., Geerts W.H., Desjardins L., Laflamme G.H., L&#x2019;Esp&#xe9;rance B., Demers C., Kassis J., Cruickshank M., Whitman L., Delorme F. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann. Intern. Med. 1996;124:619&#x2013;626. doi: 10.7326/0003-4819-124-7-199604010-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-124-7-199604010-00001</ArticleId><ArticleId IdType="pubmed">8607589</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald RHJr Spiro T.E., Trowbridge A.A., Gardiner GAJr Whitsett T.L., O&#x2019;Connell M.B., Ohar J.A., Young T.R., Enoxaparin Clinical Trial Group Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J. Bone Joint Surg. Am. 2001;83:900&#x2013;906. doi: 10.2106/00004623-200106000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-200106000-00012</ArticleId><ArticleId IdType="pubmed">11407799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamuly&#xe1;k K., Lensing A.W., van der Meer J., Smid W.M., van Ooy A., Hoek J.A. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. Thromb. Haemost. 1995;74:1428&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8772214</ArticleId></ArticleIdList></Reference><Reference><Citation>Mismetti P., Laporte S., Zufferey P., Epinat M., Decousus H., Cucherat M. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: A meta-analysis. J. Thromb. Haemost. 2004;2:1058&#x2013;1070. doi: 10.1111/j.1538-7836.2004.00757.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2004.00757.x</ArticleId><ArticleId IdType="pubmed">15219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskob G.E., Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003;124((Suppl. S6)):379S&#x2013;385S. doi: 10.1378/chest.124.6_suppl.379S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.124.6_suppl.379S</ArticleId><ArticleId IdType="pubmed">14668421</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.W., Pellegrini VDJr Totterman S., Boyd ADJr Marder V.J., Liebert K.M., Stulberg B.N., Ayers D.C., Rosenberg A., Kessler C., Johanson N.A. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J. Bone Joint Surg. Am. 1997;79:1365&#x2013;1372. doi: 10.2106/00004623-199709000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-199709000-00011</ArticleId><ArticleId IdType="pubmed">9314399</ArticleId></ArticleIdList></Reference><Reference><Citation>Colwell C.W., Jr., Collis D.K., Paulson R., McCutchen J.W., Bigler G.T., Lutz S., Hardwick M.E. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J. Bone Joint Surg. Am. 1999;81:932&#x2013;940. doi: 10.2106/00004623-199907000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-199907000-00005</ArticleId><ArticleId IdType="pubmed">10428124</ArticleId></ArticleIdList></Reference><Reference><Citation>Samama C.M., Vray M., Barr&#xe9; J., Fiessinger J.N., Rosencher N., Lecompte T., Potron G., Basile J., Hull R., Desmichels D., et al. Extended venous thromboembolism prophylaxis after total hip replacement: A comparison of low-molecular-weight heparin with oral anticoagulant. Arch. Intern. Med. 2002;162:2191&#x2013;2196. doi: 10.1001/archinte.162.19.2191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.162.19.2191</ArticleId><ArticleId IdType="pubmed">12390061</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine M.N., Hirsh J., Gent M., Turpie A.G., Leclerc J., Powers P.J., Jay R.M., Neemeh J. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann. Intern. Med. 1991;114:545&#x2013;551. doi: 10.7326/0003-4819-114-7-545.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-114-7-545</ArticleId><ArticleId IdType="pubmed">1848054</ArticleId></ArticleIdList></Reference><Reference><Citation>Karthikeyan G., Eikelboom J.W., Turpie A.G., Hirsh J. Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br. J. Haematol. 2009;146:142&#x2013;149. doi: 10.1111/j.1365-2141.2009.07734.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2009.07734.x</ArticleId><ArticleId IdType="pubmed">19438502</ArticleId></ArticleIdList></Reference><Reference><Citation>Imperiale T.F., Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA. 1994;271:1780&#x2013;1785. doi: 10.1001/jama.1994.03510460072036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1994.03510460072036</ArticleId><ArticleId IdType="pubmed">7515115</ArticleId></ArticleIdList></Reference><Reference><Citation>Westrich G.H., Bottner F., Windsor R.E., Laskin R.S., Haas S.B., Sculco T.P. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J. Arthroplast. 2006;21((Suppl. S2)):139&#x2013;143. doi: 10.1016/j.arth.2006.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2006.05.017</ArticleId><ArticleId IdType="pubmed">16950076</ArticleId></ArticleIdList></Reference><Reference><Citation>Drescher F.S., Sirovich B.E., Lee A., Morrison D.H., Chiang W.H., Larson R.J. Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: A systematic review and meta-analysis. J. Hosp. Med. 2014;9:579&#x2013;585. doi: 10.1002/jhm.2224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jhm.2224</ArticleId><ArticleId IdType="pubmed">25045166</ArticleId></ArticleIdList></Reference><Reference><Citation>CRISTAL Study Group. Camporese G.S., Kelly T.L., Pratt N., Graves S.E., Buchbinder R., Adie S., Cashman K., Ackerman I., Bastiras D., et al. Effect of Aspirin vs. Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. JAMA. 2022;328:719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9399863</ArticleId><ArticleId IdType="pubmed">35997730</ArticleId></ArticleIdList></Reference><Reference><Citation>Camporese G., Bernardi E., Prandoni P., Noventa F., Verlato F., Simioni P., Ntita K., Salmistraro G., Frangos C., Rossi F., et al. Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: A randomized trial. Ann. Intern. Med. 2008;149:73&#x2013;82. doi: 10.7326/0003-4819-149-2-200807150-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-149-2-200807150-00003</ArticleId><ArticleId IdType="pubmed">18626046</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitto R.P., Hamer H., Heiss-Dunlop W., Kuehle J. Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. J. Bone Joint Surg. Br. 2004;86:639&#x2013;642. doi: 10.1302/0301-620X.86B5.14763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.86B5.14763</ArticleId><ArticleId IdType="pubmed">15274256</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone M.H., Limb D., Campbell P., Stead D., Culleton G. A comparison of intermittent calf compression and enoxaparin for thromboprophylaxis in total hip replacement. A pilot study. Int. Orthop. 1996;20:367&#x2013;369. doi: 10.1007/s002640050099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002640050099</ArticleId><ArticleId IdType="pubmed">9049766</ArticleId></ArticleIdList></Reference><Reference><Citation>Warwick D., Harrison J., Glew D., Mitchelmore A., Peters T.J., Donovan J. Comparison of the use of a foot pump with the use of low-molecular-weight heparin for the prevention of deep-vein thrombosis after total hip replacement. A prospective, randomized trial. J. Bone Joint Surg. Am. 1998;80:1158&#x2013;1166. doi: 10.2106/00004623-199808000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-199808000-00009</ArticleId><ArticleId IdType="pubmed">9730125</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard J., Meuwly J.Y., Leyvraz P.F., Miron M.J., Bounameaux H., Hoffmeyer P., Didier D., Schneider P.A. Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. J. Bone Joint Surg. Br. 1999;81:654&#x2013;659. doi: 10.1302/0301-620X.81B4.0810654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.81B4.0810654</ArticleId><ArticleId IdType="pubmed">10463739</ArticleId></ArticleIdList></Reference><Reference><Citation>Tun H.N., Kyaw M.T., Rafflenbeul E., Su&#xe1;stegui X.L. Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis. Eur. Cardiol. 2022;17:e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127635</ArticleId><ArticleId IdType="pubmed">35620356</ArticleId></ArticleIdList></Reference><Reference><Citation>Haykal T., Adam S., Bala A., Zayed Y., Deliwala S., Kerbage J., Ponnapalli A., Malladi S., Samji V., Ortel T.L. Thromboprophylaxis for orthopedic surgery; An updated meta-analysis. Thromb. Res. 2021;199:43&#x2013;53. doi: 10.1016/j.thromres.2020.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.12.007</ArticleId><ArticleId IdType="pubmed">33422802</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradaxa Label.  [(accessed on 11 June 2023)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf.</Citation></Reference><Reference><Citation>Xalerto Label.  [(accessed on 11 June 2023)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215859s000lbl.pdf.</Citation></Reference><Reference><Citation>Eliquis Label.  [(accessed on 11 June 2023)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf.</Citation></Reference><Reference><Citation>Nieto J.A., Espada N.G., Merino R.G., Gonz&#xe1;lez T.C. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials. Thromb. Res. 2012;130:183&#x2013;191. doi: 10.1016/j.thromres.2012.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2012.02.011</ArticleId><ArticleId IdType="pubmed">22425218</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman M.V., Quinlan D.J., Dahl O.E., Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ. Cardiovasc. Qual. Outcomes. 2010;3:652&#x2013;660. doi: 10.1161/CIRCOUTCOMES.110.957712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.110.957712</ArticleId><ArticleId IdType="pubmed">20923996</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann I., Rada G., Claro J.C., Carrasco-Labra A., Thorlund K., Akl E.A., Bates S.M., Guyatt G.H. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: A systematic review and meta-analysis. Ann. Intern. Med. 2012;156:710&#x2013;719. doi: 10.7326/0003-4819-156-10-201205150-00421.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-156-10-201205150-00421</ArticleId><ArticleId IdType="pubmed">22412038</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Outes A., Terleira-Fern&#xe1;ndez A.I., Su&#xe1;rez-Gea M.L., Vargas-Castrill&#xf3;n E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: Systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344:e3675. doi: 10.1136/bmj.e3675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e3675</ArticleId><ArticleId IdType="pmc">PMC3375207</ArticleId><ArticleId IdType="pubmed">22700784</ArticleId></ArticleIdList></Reference><Reference><Citation>Loke Y.K., Kwok C.S. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. J. Clin. Pharm. Ther. 2011;36:111&#x2013;124. doi: 10.1111/j.1365-2710.2010.01162.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2710.2010.01162.x</ArticleId><ArticleId IdType="pubmed">21198726</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam S.S., McDuffie J.R., Lachiewicz P.F., Ortel T.L., Williams J.W., Jr. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: A systematic review. Ann. Intern. Med. 2013;159:275&#x2013;284. doi: 10.7326/0003-4819-159-4-201308200-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-159-4-201308200-00008</ArticleId><ArticleId IdType="pubmed">24026260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen M.R., Ageno W., Borris L.C., Lieberman J.R., Rosencher N., Bandel T.J., Misselwitz F., Turpie A.G., RECORD3 Investigators Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N. Engl. J. Med. 2008;358:2776&#x2013;2786. doi: 10.1056/NEJMoa076016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa076016</ArticleId><ArticleId IdType="pubmed">18579812</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie A.G., Lassen M.R., Davidson B.L., Bauer K.A., Gent M., Kwong L.M., Cushner F.D., Lotke P.A., Berkowitz S.D., Bandel T.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial. Lancet. 2009;373:1673&#x2013;1680. doi: 10.1016/S0140-6736(09)60734-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)60734-0</ArticleId><ArticleId IdType="pubmed">19411100</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B.I., Borris L.C., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., Muehlhofer E., Dierig C., Misselwitz F., K&#xe4;lebo P., et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374&#x2013;2381. doi: 10.1161/CIRCULATIONAHA.106.642074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.642074</ArticleId><ArticleId IdType="pubmed">17116766</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie A.G., Fisher W.D., Bauer K.A., Kwong L.M., Irwin M.W., K&#xe4;lebo P., Misselwitz F., Gent M., OdiXa-Knee Study Group BAY 59-7939, an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J. Thromb. Haemost. 2005;3:2479&#x2013;2486. doi: 10.1111/j.1538-7836.2005.01602.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01602.x</ArticleId><ArticleId IdType="pubmed">16241946</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B.I., Borris L., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., Misselwitz F., K&#xe4;lebo P., ODIXa-HIP Study Investigators Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost. 2006;4:121&#x2013;128. doi: 10.1111/j.1538-7836.2005.01657.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01657.x</ArticleId><ArticleId IdType="pubmed">16409461</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie A.G., Lassen M.R., Eriksson B.I., Gent M., Berkowitz S.D., Misselwitz F., Bandel T.J., Homering M., Westermeier T., Kakkar A.K. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb. Haemost. 2011;105:444&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">21136019</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B.I., Dahl O.E., Ahnfelt L., K&#xe4;lebo P., Stangier J., Nehmiz G., Hermansson K., Kohlbrenner V. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J. Thromb. Haemost. 2004;2:1573&#x2013;1580. doi: 10.1111/j.1538-7836.2004.00890.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2004.00890.x</ArticleId><ArticleId IdType="pubmed">15333033</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B.I., Dahl O.E., B&#xfc;ller H.R., Hettiarachchi R., Rosencher N., Bravo M.L., Ahnfelt L., Piovella F., Stangier J., K&#xe4;lebo P., et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost. 2005;3:103&#x2013;111. doi: 10.1111/j.1538-7836.2004.01100.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2004.01100.x</ArticleId><ArticleId IdType="pubmed">15634273</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolowacz S.E., Roskell N.S., Plumb J.M., Caprini J.A., Eriksson B.I. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb. Haemost. 2009;101:77&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">19132192</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., K&#xe4;lebo P., Christiansen A.V., Hantel S., Hettiarachchi R., et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J. Thromb. Haemost. 2007;5:2178&#x2013;2185. doi: 10.1111/j.1538-7836.2007.02748.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2007.02748.x</ArticleId><ArticleId IdType="pubmed">17764540</ArticleId></ArticleIdList></Reference><Reference><Citation>RE-MOBILIZE Writing Committee. Ginsberg J.S., Davidson B.L., Comp P.C., Francis C.W., Friedman R.J., Huo M.H., Lieberman J.R., Muntz J.E., Raskob G.E., et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplast. 2009;24:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18534438</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji T., Wang C.J., Fujita S., Kawai Y., Nakamura M., Kimura T., Ibusuki K., Ushida H., Abe K., Tachibana S. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: The STARS E-3 trial. Thromb. Res. 2014;134:1198&#x2013;1204. doi: 10.1016/j.thromres.2014.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2014.09.011</ArticleId><ArticleId IdType="pubmed">25294589</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji T., Fujita S., Kawai Y., Abe Y., Kimura T., Fukuzawa M., Abe K., Tachibana S. A randomized, open-label trial of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. Thromb. J. 2015;13:6. doi: 10.1186/s12959-014-0034-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-014-0034-9</ArticleId><ArticleId IdType="pmc">PMC4316611</ArticleId><ArticleId IdType="pubmed">25653574</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull R.D., Liang J., Bergqvist D., Yusen R.D. Benefit-to-harm ratio of thromboprophylaxis for patients undergoing major orthopaedic surgery. A systematic review. Thromb. Haemost. 2014;111:199&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">24154501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.M., Moon Y.W., Lim S.J., Kim D.W., Park Y.S. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty. Thromb. Haemost. 2016;115:600&#x2013;607. doi: 10.1160/th15-07-0527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/th15-07-0527</ArticleId><ArticleId IdType="pubmed">26790579</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin K.A., Beyer-Westendorf J., Davidson B.L., Huisman M.V., Sandset P.M., Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J. Thromb. Haemost. 2021;19:1874&#x2013;1882. doi: 10.1111/jth.15358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15358</ArticleId><ArticleId IdType="pubmed">34259389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Portman R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med. 2009;361:594&#x2013;604. doi: 10.1056/NEJMoa0810773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0810773</ArticleId><ArticleId IdType="pubmed">19657123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen M.R., Davidson B.L., Gallus A., Pineo G., Ansell J., Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost. 2007;5:2368&#x2013;2375. doi: 10.1111/j.1538-7836.2007.02764.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2007.02764.x</ArticleId><ArticleId IdType="pubmed">17868430</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Hornick P., ADVANCE-2 investigators Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial. Lancet. 2010;375:807&#x2013;815. doi: 10.1016/S0140-6736(09)62125-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)62125-5</ArticleId><ArticleId IdType="pubmed">20206776</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai Y., Fuji T., Fujita S., Kimura T., Ibusuki K., Abe K., Tachibana S. Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: Pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials. Thromb. J. 2016;14:48. doi: 10.1186/s12959-016-0121-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-016-0121-1</ArticleId><ArticleId IdType="pmc">PMC5134224</ArticleId><ArticleId IdType="pubmed">27980462</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen A.T., Hamilton M., Mitchell S.A., Phatak H., Liu X., Bird A., Tushabe D., Batson S. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS ONE. 2015;10:e0144856. doi: 10.1371/journal.pone.0144856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0144856</ArticleId><ArticleId IdType="pmc">PMC4696796</ArticleId><ArticleId IdType="pubmed">26716830</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenny J.Y., Pabinger I., Samama C.M., ESA VTE Guidelines Task Force European guidelines on perioperative venous thromboembolism prophylaxis: Aspirin. Eur. J. Anaesthesiol. 2018;35:123&#x2013;129. doi: 10.1097/EJA.0000000000000728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000728</ArticleId><ArticleId IdType="pubmed">29112548</ArticleId></ArticleIdList></Reference><Reference><Citation>Major Extremity Trauma Research Consortium (METRC) O&#x2019;Toole R.V., Stein D.M., O&#x2019;Hara N.N., Frey K.P., Taylor T.J., Scharfstein D.O., Carlini A.R., Sudini K., Degani Y., et al. Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. N. Engl. J. Med. 2023;388:203&#x2013;213. doi: 10.1056/NEJMoa2205973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2205973</ArticleId><ArticleId IdType="pubmed">36652352</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson D.R., Dunbar M.J., Bohm E.R., Belzile E., Kahn S.R., Zukor D., Fisher W., Gofton W., Gross P., Pelet S., et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: A randomized trial. Ann. Intern. Med. 2013;158:800&#x2013;806. doi: 10.7326/0003-4819-158-11-201306040-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-158-11-201306040-00004</ArticleId><ArticleId IdType="pubmed">23732713</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary Embolism Prevention (PEP) trial Collaborative Group Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295&#x2013;1302. doi: 10.1016/S0140-6736(00)02110-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)02110-3</ArticleId><ArticleId IdType="pubmed">10776741</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J., Huang R., Restrepo C., Chen A.F., Austin M.S., Hozack W.J., Lonner J.H. Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembolism Following Total Joint Arthroplasty: A Preliminary Analysis. J. Bone Jt. Surg. Am. 2017;99:91&#x2013;98. doi: 10.2106/JBJS.16.00147.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.16.00147</ArticleId><ArticleId IdType="pubmed">28099298</ArticleId></ArticleIdList></Reference><Reference><Citation>Azboy I., Groff H., Goswami K., Vahedian M., Parvizi J. Low-Dose Aspirin Is Adequate for Venous Thromboembolism Prevention Following Total Joint Arthroplasty: A Systematic Review. J. Arthroplast. 2020;35:886&#x2013;892. doi: 10.1016/j.arth.2019.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2019.09.043</ArticleId><ArticleId IdType="pubmed">31733981</ArticleId></ArticleIdList></Reference><Reference><Citation>Matharu G.S., Kunutsor S.K., Judge A., Blom A.W., Whitehouse M.R. Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern. Med. 2020;180:376&#x2013;384. doi: 10.1001/jamainternmed.2019.6108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.6108</ArticleId><ArticleId IdType="pmc">PMC7042877</ArticleId><ArticleId IdType="pubmed">32011647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkos S.K., Caprini J.A., Geroulakos G., Nicolaides A.N., Stansby G.P., Reddy D.J. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst. Rev. 2008;9:CD005258.</Citation><ArticleIdList><ArticleId IdType="pubmed">18843686</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak H.S., Cho J.H., Kim J.T., Yoo J.J., Kim H.J. Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty. Clin. Orthop. Surg. 2017;9:37&#x2013;42. doi: 10.4055/cios.2017.9.1.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.4055/cios.2017.9.1.37</ArticleId><ArticleId IdType="pmc">PMC5334025</ArticleId><ArticleId IdType="pubmed">28261425</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull R.D., Raskob G.E., Gent M., McLoughlin D., Julian D., Smith F.C., Dale N.I., Reed-Davis R., Lofthouse R.N., Anderson C. Effectiveness of intermittent pneumatic leg compression for preventing deep vein thrombosis after total hip replacement. JAMA. 1990;263:2313&#x2013;2317. doi: 10.1001/jama.1990.03440170035032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1990.03440170035032</ArticleId><ArticleId IdType="pubmed">2182917</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson N.V., Das S.K., Kakkar V.V., Maurice H.D., Smibert J.G., Thomas E.M., Nixon J.E. Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V Impulse System. J. Bone Jt. Surg. Br. 1992;74:50&#x2013;52. doi: 10.1302/0301-620X.74B1.1732265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.74B1.1732265</ArticleId><ArticleId IdType="pubmed">1732265</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna R., Galante J., Bachmann F., Wallace D.L., Kaushal P.S., Meredith P. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br. Med. J. 1980;280:514&#x2013;517. doi: 10.1136/bmj.280.6213.514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.280.6213.514</ArticleId><ArticleId IdType="pmc">PMC1601413</ArticleId><ArticleId IdType="pubmed">6989432</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher C.G., Blachut P.A., Salvian A.J., Meek R.N., O&#x2019;Brien P.J. Effectiveness of pneumatic leg compression devices for the prevention of thromboembolic disease in orthopaedic trauma patients: A prospective, randomized study of compression alone versus no prophylaxis. J. Orthop. Trauma. 1995;9:1&#x2013;7. doi: 10.1097/00005131-199502000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005131-199502000-00001</ArticleId><ArticleId IdType="pubmed">7714648</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui A.C., Heras-Palou C., Dunn I., Triffitt P.D., Crozier A., Imeson J., Gregg P.J. Graded compression stockings for prevention of deep-vein thrombosis after hip and knee replacement. J. Bone Jt. Surg. Br. 1996;78:550&#x2013;554. doi: 10.1302/0301-620X.78B4.0780550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.78B4.0780550</ArticleId><ArticleId IdType="pubmed">8682818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pour A.E., Keshavarzi N.R., Purtill J.J., Sharkey P.F., Parvizi J. Is venous foot pump effective in prevention of thromboembolic disease after joint arthroplasty: A meta-analysis. J. Arthroplast. 2013;28:410&#x2013;417. doi: 10.1016/j.arth.2012.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2012.08.003</ArticleId><ArticleId IdType="pubmed">23102505</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakai T., Izumi M., Kumagai K., Kidera K., Yamaguchi T., Asahara T., Kozuru H., Jiuchi Y., Mawatari M., Osaki M., et al. Effects of a Foot Pump on the Incidence of Deep Vein Thrombosis After Total Knee Arthroplasty in Patients Given Edoxaban: A Randomized Controlled Study. Medicine. 2016;95:e2247. doi: 10.1097/MD.0000000000002247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000002247</ArticleId><ArticleId IdType="pmc">PMC4706251</ArticleId><ArticleId IdType="pubmed">26735531</ArticleId></ArticleIdList></Reference><Reference><Citation>Windisch C., Kolb W., Kolb K., Gr&#xfc;tzner P., Venbrocks R., Anders J. Pneumatic compression with foot pumps facilitates early postoperative mobilisation in total knee arthroplasty. Int. Orthop. 2011;35:995&#x2013;1000. doi: 10.1007/s00264-010-1091-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00264-010-1091-8</ArticleId><ArticleId IdType="pmc">PMC3167399</ArticleId><ArticleId IdType="pubmed">20652250</ArticleId></ArticleIdList></Reference><Reference><Citation>Fordyce M.J., Ling R.S. A venous foot pump reduces thrombosis after total hip replacement. J. Bone Jt. Surg. Br. 1992;74:45&#x2013;49. doi: 10.1302/0301-620X.74B1.1732264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.74B1.1732264</ArticleId><ArticleId IdType="pubmed">1732264</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranks G.J., MacKenzie N.A., Grover M.L., Fail T. The A-V Impulse System reduces deep-vein thrombosis and swelling after hemiarthroplasty for hip fracture. J. Bone Jt. Surg. Br. 1992;74:775&#x2013;778. doi: 10.1302/0301-620X.74B5.1527133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.74B5.1527133</ArticleId><ArticleId IdType="pubmed">1527133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachiewicz P.F., Soileau E.S. Mechanical calf compression and aspirin prophylaxis for total knee arthroplasty. Clin. Orthop. Relat. Res. 2007;464:61&#x2013;64. doi: 10.1097/BLO.0b013e3181468951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BLO.0b013e3181468951</ArticleId><ArticleId IdType="pubmed">17632417</ArticleId></ArticleIdList></Reference><Reference><Citation>Comerota A.J., Katz M.L., White J.V. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am. J. Surg. 1992;164:265&#x2013;268. doi: 10.1016/S0002-9610(05)81083-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(05)81083-9</ArticleId><ArticleId IdType="pubmed">1415927</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornwell E.E., 3rd, Chang D., Velmahos G., Jindal A., Baker D., Phillips J., Bonar J., Campbell K. Compliance with sequential compression device prophylaxis in at-risk trauma patients: A prospective analysis. Am. Surg. 2002;68:470&#x2013;473. doi: 10.1177/000313480206800515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000313480206800515</ArticleId><ArticleId IdType="pubmed">12017149</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami M., McDill T.L., Cindrick-Pounds L., Loran D.B., Woodside K.J., Mileski W.J., Hunter G.C., Killewich L.A. Deep venous thrombosis prophylaxis in trauma: Improved compliance with a novel miniaturized pneumatic compression device. J. Vasc. Surg. 2003;38:923&#x2013;927. doi: 10.1016/S0741-5214(03)00792-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0741-5214(03)00792-4</ArticleId><ArticleId IdType="pubmed">14603195</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Horani R.A. Targeting factor XI(a) for anticoagulation therapy: A patent landscape. Pharm. Pat. Anal. 2020;9:3&#x2013;5. doi: 10.4155/ppa-2020-0002.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/ppa-2020-0002</ArticleId><ArticleId IdType="pubmed">32057285</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Horani R.A. Factor XI(a) inhibitors for thrombosis: An updated patent review (2016-present) Expert Opin. Ther. Pat. 2020;30:39&#x2013;55. doi: 10.1080/13543776.2020.1705783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543776.2020.1705783</ArticleId><ArticleId IdType="pmc">PMC7515655</ArticleId><ArticleId IdType="pubmed">31847619</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Horani R.A., Afosah D.K. Recent advances in the discovery and development of factor XI/XIa inhibitors. Med. Res. Rev. 2018;38:1974&#x2013;2023. doi: 10.1002/med.21503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21503</ArticleId><ArticleId IdType="pmc">PMC6173998</ArticleId><ArticleId IdType="pubmed">29727017</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco A., Laudani C., Spagnolo M., Agnello F., Faro D.C., Finocchiaro S., Legnazzi M., Mauro M.S., Mazzone P.M., Occhipinti G., et al. Pharmacology and Clinical Development of Factor XI Inhibitors. Circulation. 2023;147:897&#x2013;913. doi: 10.1161/CIRCULATIONAHA.122.062353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.062353</ArticleId><ArticleId IdType="pubmed">36913497</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredenburgh J.C., Weitz J.I. Factor XI as a Target for New Anticoagulants. Hamostaseologie. 2021;41:104&#x2013;110. doi: 10.1055/a-1384-3715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1384-3715</ArticleId><ArticleId IdType="pubmed">33860518</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu C., Hutt E., Bloomfield D.M., Gailani D., Weitz J.I. Factor XI Inhibition to Uncouple Thrombosis from Hemostasis: JACC Review Topic of the Week. J. Am. Coll. Cardiol. 2021;78:625&#x2013;631. doi: 10.1016/j.jacc.2021.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.06.010</ArticleId><ArticleId IdType="pmc">PMC8552338</ArticleId><ArticleId IdType="pubmed">34353538</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera V., Wang Z., Luettgen J., Li D., DeSouza M., Cerra M., Seiffert D. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin. Transl. Sci. 2022;15:330&#x2013;342. doi: 10.1111/cts.13148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.13148</ArticleId><ArticleId IdType="pmc">PMC8841437</ArticleId><ArticleId IdType="pubmed">34558200</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera V., Wang Z., Lubin S., Ueno T., Shiozaki T., Chen W., Xu X., Seiffert D., DeSouza M., Murthy B. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants. Sci. Rep. 2022;12:5165. doi: 10.1038/s41598-022-08768-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-08768-y</ArticleId><ArticleId IdType="pmc">PMC8956633</ArticleId><ArticleId IdType="pubmed">35338177</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitz J.I., Strony J., Ageno W., Gailani D., Hylek E.M., Lassen M.R., Mahaffey K.W., Notani R.S., Roberts R., Segers A., et al. Milvexian for the Prevention of Venous Thromboembolism. N. Engl. J. Med. 2021;385:2161&#x2013;2172. doi: 10.1056/NEJMoa2113194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2113194</ArticleId><ArticleId IdType="pmc">PMC9540352</ArticleId><ArticleId IdType="pubmed">34780683</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D., Kanefendt F., Schwers S., Unger S., Yassen A., Boxnick S. First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa. J. Thromb. Haemost. 2021;19:2407&#x2013;2416. doi: 10.1111/jth.15439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15439</ArticleId><ArticleId IdType="pmc">PMC8518835</ArticleId><ArticleId IdType="pubmed">34192419</ArticleId></ArticleIdList></Reference><Reference><Citation>Mailer R.K., Renn&#xe9; T. Commentary on &#x201c;Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor Xia&#x201d;: Small molecule factor XIa inhibitor asundexian allows for safer anticoagulation. J. Thromb. Haemost. 2022;20:1309&#x2013;1311. doi: 10.1111/jth.15722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15722</ArticleId><ArticleId IdType="pubmed">35596514</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitmeier S., Visser M., Tersteegen A., Dietze-Torres J., Glunz J., Gerdes C., Laux V., Stampfuss J., Roehrig S. Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa. J. Thromb. Haemost. 2022;20:1400&#x2013;1411. doi: 10.1111/jth.15700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15700</ArticleId><ArticleId IdType="pmc">PMC9313898</ArticleId><ArticleId IdType="pubmed">35289054</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini J.P., Caso V., Connolly S.J., Fox K.A.A., Oldgren J., Jones W.S., Gorog D.A., Durdil V., Viethen T., Neumann C., et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): A multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022;399:1383&#x2013;1390. doi: 10.1016/S0140-6736(22)00456-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00456-1</ArticleId><ArticleId IdType="pubmed">35385695</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer M., Buchmueller A., Dittmer F., Stra&#xdf;burger J., Wilmen A. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J. Mol. Biol. 2019;431:4817&#x2013;4833. doi: 10.1016/j.jmb.2019.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2019.09.008</ArticleId><ArticleId IdType="pubmed">31655039</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitz J.I., Bauersachs R., Becker B., Berkowitz S.D., Freitas M.C.S., Lassen M.R., Metzig C., Raskob G.E. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020;323:130&#x2013;139. doi: 10.1001/jama.2019.20687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.20687</ArticleId><ArticleId IdType="pmc">PMC6990695</ArticleId><ArticleId IdType="pubmed">31935028</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhamme P., Yi B.A., Segers A., Salter J., Bloomfield D., B&#xfc;ller H.R., Raskob G.E., Weitz J.I., ANT-005 TKA Investigators Abelacimab for Prevention of Venous Thromboembolism. N. Engl. J. Med. 2021;385:609&#x2013;617. doi: 10.1056/NEJMoa2105872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105872</ArticleId><ArticleId IdType="pubmed">34297496</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., L&#xf6;wenberg E.C., Crosby J.R., MacLeod A.R., Zhao C., Gao D., Black C., Revenko A.S., Meijers J.C., Stroes E.S., et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: A novel antithrombotic strategy with lowered bleeding risk. Blood. 2010;116:4684&#x2013;4692. doi: 10.1182/blood-2010-04-277798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-04-277798</ArticleId><ArticleId IdType="pubmed">20807891</ArticleId></ArticleIdList></Reference><Reference><Citation>Younis H.S., Crosby J., Huh J.I., Lee H.S., Rime S., Monia B., Henry S.P. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood. 2012;119:2401&#x2013;2408. doi: 10.1182/blood-2011-10-387134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-10-387134</ArticleId><ArticleId IdType="pubmed">22246038</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu R.Z., Kim T.W., Hong A., Watanabe T.A., Gaus H.J., Geary R.S. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 2007;35:460&#x2013;468. doi: 10.1124/dmd.106.012401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.106.012401</ArticleId><ArticleId IdType="pubmed">17172312</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Yu R.Z., Henry S., Geary R.S. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides. Expert Opin Drug Metab. Toxicol. 2019;15:475&#x2013;485. doi: 10.1080/17425255.2019.1621838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425255.2019.1621838</ArticleId><ArticleId IdType="pubmed">31144994</ArticleId></ArticleIdList></Reference><Reference><Citation>Willmann S., Marostica E., Snelder N., Solms A., Jensen M., Lobmeyer M., Lensing A.W.A., Bethune C., Morgan E., Yu R.Z., et al. PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients. CPT Pharmacomet. Syst. Pharmacol. 2021;10:890&#x2013;901. doi: 10.1002/psp4.12663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.12663</ArticleId><ArticleId IdType="pmc">PMC8376138</ArticleId><ArticleId IdType="pubmed">34085768</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;ller H.R., Bethune C., Bhanot S., Gailani D., Monia B.P., Raskob G.E., Segers A., Verhamme P., Weitz J.I., FXI-ASO TKA Investigators Factor XI antisense oligonucleotide for prevention of venous thrombosis. N. Engl. J. Med. 2015;372:232&#x2013;240. doi: 10.1056/NEJMoa1405760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1405760</ArticleId><ArticleId IdType="pmc">PMC4367537</ArticleId><ArticleId IdType="pubmed">25482425</ArticleId></ArticleIdList></Reference><Reference><Citation>Presume J., Ferreira J., Ribeiras R., Mendes M. Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery-Systematic review and meta-analysis. J. Thromb. Haemost. 2022;20:2930&#x2013;2938. doi: 10.1111/jth.15890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15890</ArticleId><ArticleId IdType="pmc">PMC9828034</ArticleId><ArticleId IdType="pubmed">36128769</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37304917</PMID><DateRevised><Year>2023</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1923-2829</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Cardiology research</Title><ISOAbbreviation>Cardiol Res</ISOAbbreviation></Journal><ArticleTitle>Ultrasound-Accelerated Catheter-Directed Thrombolysis.</ArticleTitle><Pagination><StartPage>161</StartPage><EndPage>166</EndPage><MedlinePgn>161-166</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14740/cr1490</ELocationID><Abstract><AbstractText>Venous thromboembolism is a very common presentation in the hospital setting. In patients with high-risk pulmonary embolism (PE) or PE and hemodynamic instability, systemic thrombolytic treatment is generally indicated. In those with contraindications to systemic thrombolysis, catheter-directed local thrombolytic therapy and surgical embolectomy are currently considered. In particular, catheter-directed thrombolysis (CDT) is a drug delivery system coupling the endovascular drug administration nearby in the thrombus and the local facilitating effect of ultrasounds. The applications of CDT are currently debated. Here we provide a systematic review of the clinical utilization of CDT.</AbstractText><CopyrightInformation>Copyright 2023, Alsamman et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alsamman</LastName><ForeName>Mrhaf</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5488-8696</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, UCF College of Medicine, Orlando, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, HCA Florida Ocala Hospital, Internal Medicine Residency Program, Ocala, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudhry</LastName><ForeName>Ali Mohsin</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, UCF College of Medicine, Orlando, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, HCA Florida Ocala Hospital, Internal Medicine Residency Program, Ocala, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>AlSaadi</LastName><ForeName>Abdulaziz Mheir</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, UCF College of Medicine, Orlando, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, HCA Florida Ocala Hospital, Internal Medicine Residency Program, Ocala, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prashad</LastName><ForeName>Rakesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, UCF College of Medicine, Orlando, FL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, HCA Florida Ocala Hospital, Internal Medicine Residency Program, Ocala, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Cardiol Res</MedlineTA><NlmUniqueID>101557543</NlmUniqueID><ISSNLinking>1923-2829</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Catheter-directed thrombolysis</Keyword><Keyword MajorTopicYN="N">Deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">Embolectomy</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>The authors affirm that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37304917</ArticleId><ArticleId IdType="pmc">PMC10257504</ArticleId><ArticleId IdType="doi">10.14740/cr1490</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Giordano NJ, Jansson PS, Young MN, Hagan KA, Kabrhel C. Epidemiology, pathophysiology, stratification, and natural history of pulmonary embolism. Tech Vasc Interv Radiol. 2017;20(3):135&#x2013;140. doi: 10.1053/j.tvir.2017.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.tvir.2017.07.002</ArticleId><ArticleId IdType="pubmed">29029707</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, Meyer G. et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015;36(10):605&#x2013;614. doi: 10.1093/eurheartj/ehu218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu218</ArticleId><ArticleId IdType="pmc">PMC4352209</ArticleId><ArticleId IdType="pubmed">24917641</ArticleId></ArticleIdList></Reference><Reference><Citation>Maturana MA, Seitz MP, Pour-Ghaz I, Ibebuogu UN, Khouzam RN. Invasive Strategies for the Treatment of pulmonary embolism. Where are we in 2020? Curr Probl Cardiol. 2021;46(3):100650. doi: 10.1016/j.cpcardiol.2020.100650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2020.100650</ArticleId><ArticleId IdType="pubmed">32839040</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia MJ. Endovascular management of acute pulmonary embolism using the ultrasound-enhanced EkoSonic system. Semin Intervent Radiol. 2015;32(4):384&#x2013;387. doi: 10.1055/s-0035-1564707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0035-1564707</ArticleId><ArticleId IdType="pmc">PMC4640907</ArticleId><ArticleId IdType="pubmed">26622102</ArticleId></ArticleIdList></Reference><Reference><Citation>Notten P, de Smet A, Tick LW, van de Poel MHW, Wikkeling ORM, Vleming LJ, Koster A. et al. CAVA (Ultrasound-Accelerated Catheter-Directed Thrombolysis on Preventing Post-Thrombotic Syndrome) trial: long-term follow-up results. J Am Heart Assoc. 2021;10(11):e018973. doi: 10.1161/JAHA.120.018973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.018973</ArticleId><ArticleId IdType="pmc">PMC8483549</ArticleId><ArticleId IdType="pubmed">34032127</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia MJ, Sterling KM, Kahn SR, Comerota AJ, Jaff MR, Ouriel K, Weinberg I. et al. Ultrasound-accelerated thrombolysis and venoplasty for the treatment of the postthrombotic syndrome: results of the ACCESS PTS study. J Am Heart Assoc. 2020;9(3):e013398. doi: 10.1161/JAHA.119.013398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.013398</ArticleId><ArticleId IdType="pmc">PMC7033890</ArticleId><ArticleId IdType="pubmed">31983322</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucher N, Boekstegers P, Muller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, Tebbe U. et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014;129(4):479&#x2013;486. doi: 10.1161/CIRCULATIONAHA.113.005544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.005544</ArticleId><ArticleId IdType="pubmed">24226805</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijver AM, van Leersum M, Fioole B, Reijnen MM, Hoksbergen AW, Vahl AC, de Vries JP. Dutch randomized trial comparing standard catheter-directed thrombolysis and ultrasound-accelerated thrombolysis for arterial thromboembolic infrainguinal disease (DUET) J Endovasc Ther. 2015;22(1):87&#x2013;95. doi: 10.1177/1526602814566578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1526602814566578</ArticleId><ArticleId IdType="pubmed">25775686</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza G, Hohlfelder B, Jaff MR, Ouriel K, Engelhardt TC, Sterling KM, Jones NJ. et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. JACC Cardiovasc Interv. 2015;8(10):1382&#x2013;1392. doi: 10.1016/j.jcin.2015.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2015.04.020</ArticleId><ArticleId IdType="pubmed">26315743</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapson VF, Sterling K, Jones N, Elder M, Tripathy U, Brower J, Maholic RL. et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial. JACC Cardiovasc Interv. 2018;11(14):1401&#x2013;1410. doi: 10.1016/j.jcin.2018.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2018.04.008</ArticleId><ArticleId IdType="pubmed">30025734</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37753655</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-1140</ISSN><JournalIssue CitedMedium="Internet"><Volume>279</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Annals of surgery</Title><ISOAbbreviation>Ann Surg</ISOAbbreviation></Journal><ArticleTitle>An Updated Systematic Review and Meta-analysis of the Impact of Graduated Compression Stockings in Addition to Pharmacological Thromboprophylaxis for Prevention of Venous Thromboembolism in Surgical Inpatients.</ArticleTitle><Pagination><StartPage>29</StartPage><EndPage>36</EndPage><MedlinePgn>29-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SLA.0000000000006096</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To compare the rate of venous thromboembolism (VTE) in surgical inpatients with pharmacological thromboprophylaxis and additional graduated compression stockings (GCSs) versus pharmacological thromboprophylaxis alone.</AbstractText><AbstractText Label="BACKGROUND">Surgical inpatients have elevated VTE risk; recent studies cast doubt on whether GCS confers additional protection against VTE, compared with pharmacological thromboprophylaxis alone.</AbstractText><AbstractText Label="METHODS">The review followed "Preferred Reporting Items for Systematic Reviews and Meta-analyses" guidelines using a registered protocol (CRD42017062655). The MEDLINE and Embase databases were searched up to November 2022. Randomized trials reporting VTE rate after surgical procedures, utilizing pharmacological thromboprophylaxis, with or without GCS, were included. The rates of deep venous thrombosis (DVT), pulmonary embolism, and VTE-related mortality were pooled through fixed and random effects.</AbstractText><AbstractText Label="RESULTS">In a head-to-head meta-analysis, the risk of DVT for GCS and pharmacological thromboprophylaxis was 0.85 (95% CI: 0.54-1.36) versus for pharmacological thromboprophylaxis alone (2 studies, 70 events, 2653 participants). The risk of DVT in pooled trial arms for GCS and pharmacological thromboprophylaxis was 0.54 (95% CI: 0.23-1.25) versus pharmacological thromboprophylaxis alone (33 trial arms, 1228 events, 14,108 participants). The risk of pulmonary embolism for GCS and pharmacological prophylaxis versus pharmacological prophylaxis alone was 0.71 (95% CI: 0.0-30.0) (27 trial arms, 32 events, 11,472 participants). There were no between-group differences in VTE-related mortality (27 trial arms, 3 events, 12,982 participants).</AbstractText><AbstractText Label="CONCLUSIONS">Evidence from head-to-head meta-analysis and pooled trial arms demonstrates no additional benefit for GCS in preventing VTE and VTE-related mortality. GCS confer a risk of skin complications and an economic burden; current evidence does not support their use for surgical inpatients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Benedict R H</ForeName><Initials>BRH</Initials><AffiliationInfo><Affiliation>Department of Surgery and Cancer, Section of Vascular Surgery, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machin</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Salih</LastName><ForeName>Marwah</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jasionowska</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lawton</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Siracusa</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Gwozdz</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Shalhoub</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Alun H</ForeName><Initials>AH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg</MedlineTA><NlmUniqueID>0372354</NlmUniqueID><ISSNLinking>0003-4932</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053828" MajorTopicYN="N">Stockings, Compression</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>A.H.D. is supported by an NIHR Senior Investigator award. The remaining authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>27</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37753655</ArticleId><ArticleId IdType="pmc">PMC10727201</ArticleId><ArticleId IdType="doi">10.1097/SLA.0000000000006096</ArticleId><ArticleId IdType="pii">00000658-202401000-00007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624298</ArticleId><ArticleId IdType="pubmed">26076949</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AT, Agnelli G, Anderson FA, et al. . Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">17938798</ArticleId></ArticleIdList></Reference><Reference><Citation>Assareh H, Chen J, Ou L, et al. . Incidences and variations of hospital-acquired venous thromboembolism in Australian hospitals: a population-based study. BMC Health Serv Res. 2016;16:511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5034410</ArticleId><ArticleId IdType="pubmed">27659903</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation. 2004;110(suppl 1):IV4&#x2013;IV12.</Citation><ArticleIdList><ArticleId IdType="pubmed">15598646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AT, Tapson VF, Bergmann JF, et al. . Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371:387&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">18242412</ArticleId></ArticleIdList></Reference><Reference><Citation>Grosse SD, Nelson RE, Nyarko KA, et al. . The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4706477</ArticleId><ArticleId IdType="pubmed">26654719</ArticleId></ArticleIdList></Reference><Reference><Citation>
NICE . Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE NG89, 2018. Accessed August 1, 2023. https://www.nice.org.uk/guidance/ng89/chapter/recommendations
</Citation></Reference><Reference><Citation>
NICE . Venous thromboembolism in adults. NICE QS201. 2021. Accessed August 1, 2023. http://www.nice.org.uk/guidance/qs201
</Citation></Reference><Reference><Citation>Anderson DR, Morgano GP, Bennett C, et al. . American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3:3898&#x2013;3944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6963238</ArticleId><ArticleId IdType="pubmed">31794602</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaboration CT, Dennis M, Sandercock PA, et al. . Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet. 2009;373:1958&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692021</ArticleId><ArticleId IdType="pubmed">19477503</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandavia R, Shalhoub J, Head K, et al. . The additional benefit of graduated compression stockings to pharmacologic thromboprophylaxis in the prevention of venous thromboembolism in surgical inpatients. J Vasc Surg Venous Lymphat Disord. 2015;3:447&#x2013;455. e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">26992625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, Xu C. Arcsine-based transformations for meta-analysis of proportions: pros, cons, and alternatives. Health Sci Rep. 2020;3:e178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384291</ArticleId><ArticleId IdType="pubmed">32728636</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AT, Skinner JA, Warwick D, et al. . The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br. 2007;89:887&#x2013;892.</Citation><ArticleIdList><ArticleId IdType="pubmed">17673580</ArticleId></ArticleIdList></Reference><Reference><Citation>Colwell CW, Jr, Froimson MI, Mont MA, et al. . Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin. J Bone Joint Surg Am. 2010;92:527&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">20194309</ArticleId></ArticleIdList></Reference><Reference><Citation>Du W, Zhao C, Wang J, et al. . Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. J Orthop Surg Res. 2015;10:78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4455337</ArticleId><ArticleId IdType="pubmed">25998624</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson BI, Borris LC, Dahl OE, et al. . A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374&#x2013;2381.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116766</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel DP, Buckley R, deVries G, et al. . Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial. J Bone Joint Surg Br. 2009;91:388&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">19258618</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard A, Zaccagnini D, Ellis M, et al. . Randomized clinical trial of low molecular weight heparin with thigh-length or knee-length antiembolism stockings for patients undergoing surgery. Br J Surg. 2004;91:842&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pubmed">15227689</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo JL, Liu M, Liu B, et al. . A comparison of indobufen and low-molecular-weight heparin in the prevention of deep vein thrombosis in patients after total hip arthroplasty: a prospective randomized controlled study. Int J Clin Exp Med. 2019;12:2720&#x2013;2728.</Citation></Reference><Reference><Citation>Jiang H, Meng J, Guo T, et al. . Comparison of apixaban and low molecular weight heparin in preventing deep venous thrombosis after total knee arthroplasty in older adults. Yonsei Med J. 2019;60:626&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6597473</ArticleId><ArticleId IdType="pubmed">31250576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkar AK, Brenner B, Dahl OE, et al. . Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">18582928</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen MR, Dahl OE, Mismetti P, et al. . AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery&#x2014;TREK: a dose-ranging study. J Thromb Haemost. 2009;7:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">19187076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen MR, Davidson BL, Gallus A, et al. . The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5:2368&#x2013;2375.</Citation><ArticleIdList><ArticleId IdType="pubmed">17868430</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen MR, Fisher W, Mouret P, et al. . Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2, and SAVE-KNEE. J Thromb Haemost. 2012;10:822&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pubmed">22429800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen MR, Raskob GE, Gallus A, et al. . Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">20206776</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitto RP, Hamer H, Heiss-Dunlop W, et al. . Mechanical prophylaxis of deep-vein thrombosis after total hip replacement a randomised clinical trial. J Bone Joint Surg Br. 2004;86:639&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">15274256</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskob G, Cohen AT, Eriksson BI, et al. . Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010;104:642&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">20589317</ArticleId></ArticleIdList></Reference><Reference><Citation>Samama CM, Laporte S, Rosencher N, et al. . Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. N Engl J Med. 2020;382:1916&#x2013;1925.</Citation><ArticleIdList><ArticleId IdType="pubmed">32223113</ArticleId></ArticleIdList></Reference><Reference><Citation>Selby R, Geerts WH, Kreder HJ, et al. . A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures. J Orthop Trauma. 2015;29:224&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">25900749</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie AG, Lassen MR, Davidson BL, et al. . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673&#x2013;1680.</Citation><ArticleIdList><ArticleId IdType="pubmed">19411100</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhamme P, Yi BA, Segers A, et al. . Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021;385:609&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">34297496</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitz JI, Bauersachs R, Becker B, et al. . Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020;323:130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990695</ArticleId><ArticleId IdType="pubmed">31935028</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitz JI, Cao C, Eriksson BI, et al. . A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010;104:1150&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">20886185</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntupalli SR, Brennecke A, Behbakht K, et al. . Safety and efficacy of apixaban versus enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open. 2020;3:e207410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320298</ArticleId><ArticleId IdType="pubmed">32589230</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang CQ, Zhao N, Zhang J, et al. . Different combination strategies for prophylaxis of venous thromboembolism in patients: a prospective multicenter randomized controlled study. Sci Rep. 2018;8:8277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5974317</ArticleId><ArticleId IdType="pubmed">29844423</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu R, Nansubuga F, Yang J, et al. . Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery. Medicine (Baltimore). 2020;99:e20928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7310966</ArticleId><ArticleId IdType="pubmed">32569239</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes M, Ramacciotti E, Henriques AC, et al. . Generic versus branded enoxaparin in the prevention of venous thromboembolism following major abdominal surgery: report of an exploratory clinical trial. Clin Appl Thromb Hemost. 2011;17:633&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">21949036</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkar AK, Agnelli G, Fisher W, et al. . Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. Ann Surg. 2014;259:1073&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">24374549</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. . Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006;4:2384&#x2013;2390.</Citation><ArticleIdList><ArticleId IdType="pubmed">16881934</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YH, Qiu H, He XL, et al. . Prevention of venous thromboembolism after resection of primary liver cancer with low molecular weight heparin and its association with P-selectin, lysosomal granule glycoprotein, platelet-activating factor, and plasma D-dimer. Eur Rev Med Pharmacol Sci. 2018;22:4657&#x2013;4662.</Citation><ArticleIdList><ArticleId IdType="pubmed">30058703</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalhoub J, Lawton R, Hudson J, et al. . Graduated compression stockings as adjuvant to pharmaco-thromboprophylaxis in elective surgical patients (GAPS study): randomised controlled trial. BMJ. 2020;369:m1309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219517</ArticleId><ArticleId IdType="pubmed">32404430</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainwright TW, Gill M, McDonald DA, et al. . Consensus statement for perioperative care in total hip replacement and total knee replacement surgery: Enhanced Recovery After Surgery [ERAS(R)] Society recommendations. Acta Orthop. 2020;91:3&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7006728</ArticleId><ArticleId IdType="pubmed">31663402</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Wu Y, Ning R. The deep vein thrombosis of lower limb after total hip arthroplasty: what should we care. BMC Musculoskelet Disord. 2021;22:547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8207610</ArticleId><ArticleId IdType="pubmed">34130675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus Schmitz J, Lindgren V, Janarv PM, et al. . Deep venous thrombosis and pulmonary embolism after anterior cruciate ligament reconstruction: incidence, outcome, and risk factors. Bone Joint J. 2019;101-B:34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30601041</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalhoub J, Norrie J, Baker C, et al. . Graduated compression stockings as an adjunct to low dose low molecular weight heparin in venous thromboembolism prevention in surgery: a multicentre randomised controlled trial. Eur J Vasc Endovasc Surg. 2017;53:880&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pubmed">28396238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziaja D, Kocelak P, Chudek J, et al. . Compliance with compression stockings in patients with chronic venous disorders. Phlebology. 2011;26:353&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">21810940</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner BRH, Machin M, Jasionowska S, et al. . Systematic review and meta-analysis of the additional benefit of pharmacological thromboprophylaxis for endovenous varicose vein interventions. Ann Surg. 2023;278:166&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10321513</ArticleId><ArticleId IdType="pubmed">36205129</ArticleId></ArticleIdList></Reference><Reference><Citation>Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51:70&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">15900257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkos S, Kirkilesis G, Caprini JA, et al. . Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst Rev. 2022;1:CD005258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8796751</ArticleId><ArticleId IdType="pubmed">35089599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36925330</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-6771</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>British journal of anaesthesia</Title><ISOAbbreviation>Br J Anaesth</ISOAbbreviation></Journal><ArticleTitle>Norepinephrine versus phenylephrine for treating hypotension during general anaesthesia in adult patients undergoing major noncardiac surgery: a multicentre, open-label, cluster-randomised, crossover, feasibility, and pilot trial.</ArticleTitle><Pagination><StartPage>519</StartPage><EndPage>527</EndPage><MedlinePgn>519-527</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bja.2023.02.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0007-0912(23)00062-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Intraoperative hypotension is associated with postoperative complications. The use of vasopressors is often required to correct hypotension but the best vasopressor is unknown.</AbstractText><AbstractText Label="METHODS">A multicentre, cluster-randomised, crossover, feasibility and pilot trial was conducted across five hospitals in California. Phenylephrine (PE) vs norepinephrine (NE) infusion as the first-line vasopressor in patients under general anaesthesia alternated monthly at each hospital for 6 months. The primary endpoint was first-line vasopressor administration compliance of 80% or higher. Secondary endpoints were acute kidney injury (AKI), 30-day mortality, myocardial injury after noncardiac surgery (MINS), hospital length of stay, and rehospitalisation within 30 days.</AbstractText><AbstractText Label="RESULTS">A total of 3626 patients were enrolled over 6 months; 1809 patients were randomised in the NE group, 1817 in the PE group. Overall, 88.2% received the assigned first-line vasopressor. No drug infiltrations requiring treatment were reported in either group. Patients were median 63 yr old, 50% female, and 58% white. Randomisation in the NE group vs PE group did not reduce readmission within 30 days (adjusted odds ratio=0.92; 95% confidence interval, 0.6-1.39), 30-day mortality (1.01; 0.48-2.09), AKI (1.1; 0.92-1.31), or MINS (1.63; 0.84-3.16).</AbstractText><AbstractText Label="CONCLUSIONS">A large and diverse population undergoing major surgery under general anaesthesia was successfully enrolled and randomised to receive NE or PE infusion. This pilot and feasibility trial was not powered for adverse postoperative outcomes and a follow-up multicentre effectiveness trial is planned.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION">NCT04789330 (ClinicalTrials.gov).</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Legrand</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA; INI-CRCT Network, Nancy, France. Electronic address: Matthieu.Legrand@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kothari</LastName><ForeName>Rishi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA; Department of Anesthesiology and Perioperative Medicine, Thomas Jefferson University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA; School of Medicine, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palaniappa</LastName><ForeName>Nandini</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boldt</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Lee-Lynn</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurien</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabel</LastName><ForeName>Eilon</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturgess-DaPrato</LastName><ForeName>Jillene</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harhay</LastName><ForeName>Michael O</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirracchio</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bokoch</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>VEGA-1 trial investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04789330</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Anaesth</MedlineTA><NlmUniqueID>0372541</NlmUniqueID><ISSNLinking>0007-0912</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1WS297W6MV</RegistryNumber><NameOfSubstance UI="D010656">Phenylephrine</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010656" MajorTopicYN="N">Phenylephrine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007022" MajorTopicYN="Y">Hypotension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000768" MajorTopicYN="N">Anesthesia, General</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="Y">Acute Kidney Injury</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute kidney injury</Keyword><Keyword MajorTopicYN="N">cluster-randomised crossover trial</Keyword><Keyword MajorTopicYN="N">intraoperative hypotension</Keyword><Keyword MajorTopicYN="N">noncardiac surgery</Keyword><Keyword MajorTopicYN="N">norepinephrine</Keyword><Keyword MajorTopicYN="N">phenylephrine</Keyword><Keyword MajorTopicYN="N">postoperative outcomes</Keyword><Keyword MajorTopicYN="N">vasopressor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>16</Day><Hour>23</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36925330</ArticleId><ArticleId IdType="doi">10.1016/j.bja.2023.02.004</ArticleId><ArticleId IdType="pii">S0007-0912(23)00062-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28820759</PMID><DateCompleted><Year>2018</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1159</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Spine</Title><ISOAbbreviation>Spine (Phila Pa 1976)</ISOAbbreviation></Journal><ArticleTitle>Thromboprophylaxis in Spinal Surgery.</ArticleTitle><Pagination><StartPage>E474</StartPage><EndPage>E481</EndPage><MedlinePgn>E474-E481</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/BRS.0000000000002379</ELocationID><Abstract><AbstractText Label="STUDY DESIGN">Systematic review and meta-analysis.</AbstractText><AbstractText Label="OBJECTIVE">Determine the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in spinal surgery patients receiving no thromboprophylaxis, mechanoprophylaxis, and chemoprophylaxis.</AbstractText><AbstractText Label="SUMMARY OF BACKGROUND DATA">The incidence of thromboembolic complications after spinal surgery is not well established. Although a variety of effective mechanical and chemical thromboprophylaxis interventions exist, their role in spinal surgery remains unclear. Spine surgeons are faced with the difficult decision of balancing the risk of death from a thromboembolic complication against the risk of permanent neurological damage from an epidural hematoma (EDH).</AbstractText><AbstractText Label="METHODS">The Medline database was queried using combinations of the terms related to the aforementioned subject matter. Articles meeting our predetermined inclusion criteria were reviewed and relevant data extracted. Meta-analyses were created using a random-effects model for incidence of DVT and PE by type of thromboprophylaxis, method of screening, and study type.</AbstractText><AbstractText Label="RESULTS">Twenty-eight articles were included in the final analyses. The higher mean incidence of DVT and PE in the mechanoprophylaxis group (DVT: 1%, PE: 0.81%) compared to the chemoprophylaxis group (DVT: 0.85%, PE: 0.58%) was not observed to be statistically significant. Six percent of PEs was fatal; the rate of EDHs was 0.3%. The incidence of DVT was higher in prospective studies (1.4%) compared to retrospective studies (0.61%); the incidence of DVT was not affected by whether the study screened only symptomatic patients.</AbstractText><AbstractText Label="CONCLUSION">Although the incidence of DVT and PE was relatively low regardless of prophylaxis type, the true incidence is difficult to determine given the heterogeneous nature of the small number of studies available in the literature. Our findings suggest there may be a role for chemoprophylaxis given the relatively high rate of fatal PE. Future studies are needed to determine which patient population would benefit most from chemoprophylaxis.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE">2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mosenthal</LastName><ForeName>William P</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Rehabilitation Medicine, University of Chicago Medicine Division of Biological Sciences, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landy</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Rehabilitation Medicine, University of Chicago Medicine Division of Biological Sciences, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyajian</LastName><ForeName>Haroutioun H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Rehabilitation Medicine, University of Chicago Medicine Division of Biological Sciences, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Idowu</LastName><ForeName>Olumuyiwa A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Rehabilitation Medicine, University of Chicago Medicine Division of Biological Sciences, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Lewis L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Rehabilitation Medicine, University of Chicago Medicine Division of Biological Sciences, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Edwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgery, Section of Neurosurgery, University of Chicago Medicine Division of Biological Sciences, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Rehabilitation Medicine, University of Chicago Medicine Division of Biological Sciences, Chicago, IL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Spine (Phila Pa 1976)</MedlineTA><NlmUniqueID>7610646</NlmUniqueID><ISSNLinking>0362-2436</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018890" MajorTopicYN="N">Chemoprevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013122" MajorTopicYN="N">Spinal Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28820759</ArticleId><ArticleId IdType="doi">10.1097/BRS.0000000000002379</ArticleId><ArticleId IdType="pii">00007632-201804150-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141:e278S&#x2013;e325S.</Citation></Reference><Reference><Citation>Glotzbecker MP, Bono CM, Harris MB, et al. Surgeon practices regarding postoperative thromboembolic prophylaxis after high-risk spinal surgery. Spine (Phila Pa 1976) 2008; 33:2915&#x2013;2921.</Citation></Reference><Reference><Citation>Glotzbecker MP, Bono CM, Wood KB, et al. Postoperative spinal epidural hematoma: a systematic review. Spine (Phila Pa 1976) 2010; 35:E413&#x2013;E420.</Citation></Reference><Reference><Citation>Al-Dujaili TM, Majer CN, Madhoun TE, et al. Deep venous thrombosis in spine surgery patients: incidence and hematoma formation. Int Surg 2012; 97:150&#x2013;154.</Citation></Reference><Reference><Citation>Cox JB, Weaver KJ, Neal DW, et al. Decreased incidence of venous thromboembolism after spine surgery with early multimodal prophylaxis: clinical article. J Neurosurg Spine 2014; 21:677&#x2013;684.</Citation></Reference><Reference><Citation>Gerlach R, Raabe A, Beck J, et al. Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery. Eur Spine J 2004; 13:9&#x2013;13.</Citation></Reference><Reference><Citation>Schizas C, Neumayer F, Kosmopoulos V. Incidence and management of pulmonary embolism following spinal surgery occurring while under chemical thromboprophylaxis. Eur Spine J 2008; 17:970&#x2013;974.</Citation></Reference><Reference><Citation>Glotzbecker MP, Bono CM, Wood KB, et al. Thromboembolic disease in spinal surgery: a systematic review. Spine (Phila Pa 1976) 2009; 34:291&#x2013;303.</Citation></Reference><Reference><Citation>Du W, Zhao C, Wang J, et al. Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. J Orthop Surg Res 2015; 10:78.</Citation></Reference><Reference><Citation>Gruber UF, Rem J, Meisner C, et al. Prevention of thromboembolic complications with miniheparin-dihydroergotamine in patients undergoing lumbar disc operations. Eur Arch Psychiatry Neurol Sci 1984; 234:157&#x2013;161.</Citation></Reference><Reference><Citation>Nelson LD Jr, Montgomery SP, Dameron TB Jr, et al. Deep vein thrombosis in lumbar spinal fusion: a prospective study of antiembolic and pneumatic compression stockings. J South Orthop Assoc 1996; 5:181&#x2013;184.</Citation></Reference><Reference><Citation>Nicol M, Sun Y, Craig N, et al. Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients. Eur Spine J 2009; 18:1548&#x2013;1552.</Citation></Reference><Reference><Citation>Otero-Fernandez R, Gomez-Outes A, Martinez-Gonzalez J, et al. Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice. Clin Appl Thromb Hemost 2008; 14:75&#x2013;83.</Citation></Reference><Reference><Citation>Rokito SE, Schwartz MC, Neuwirth MG. Deep vein thrombosis after major reconstructive spinal surgery. Spine (Phila Pa 1976) 1996; 21:853&#x2013;858. discussion 9.</Citation></Reference><Reference><Citation>Voth D, Schwarz M, Hahn K, et al. Prevention of deep vein thrombosis in neurosurgical patients: a prospective double-blind comparison of two prophylactic regimen. Neurosurg Rev 1992; 15:289&#x2013;294.</Citation></Reference><Reference><Citation>Zhi-jian S, Yu Z, Giu-xing Q, et al. Efficacy and safety of low molecular weight heparin prophylaxis for venous thromboembolism following lumbar decompression surgery. Chin Med Sci J 2011; 26:221&#x2013;226.</Citation></Reference><Reference><Citation>Akeda K, Matsunaga H, Imanishi T, et al. Prevalence and countermeasures for venous thromboembolic diseases associated with spinal surgery: a follow-up study of an institutional protocol in 209 patients. Spine (Phila Pa 1976) 2014; 39:791&#x2013;797.</Citation></Reference><Reference><Citation>Dearborn JT, Hu SS, Tribus CB, et al. Thromboembolic complications after major thoracolumbar spine surgery. Spine (Phila Pa 1976) 1999; 24:1471&#x2013;1476.</Citation></Reference><Reference><Citation>Epstein NE. Efficacy of pneumatic compression stocking prophylaxis in the prevention of deep venous thrombosis and pulmonary embolism following 139 lumbar laminectomies with instrumented fusions. J Spinal Disord Tech 2006; 19:28&#x2013;31.</Citation></Reference><Reference><Citation>Epstein NE. Intermittent pneumatic compression stocking prophylaxis against deep venous thrombosis in anterior cervical spinal surgery: a prospective efficacy study in 200 patients and literature review. Spine (Phila Pa 1976) 2005; 30:2538&#x2013;2543.</Citation></Reference><Reference><Citation>Ferree BA. Deep venous thrombosis following lumbar laminotomy and laminectomy. Orthopedics 1994; 17:35&#x2013;38.</Citation></Reference><Reference><Citation>Ferree BA, Wright AM. Deep venous thrombosis following posterior lumbar spinal surgery. Spine (Phila Pa 1976) 1993; 18:1079&#x2013;1082.</Citation></Reference><Reference><Citation>Ferree BA, Stern PJ, Jolson RS, et al. Deep venous thrombosis after spinal surgery. Spine (Phila Pa 1976) 1993; 18:315&#x2013;319.</Citation></Reference><Reference><Citation>Piasecki DP, Poynton AR, Mintz DN, et al. Thromboembolic disease after combined anterior/posterior reconstruction for adult spinal deformity: a prospective cohort study using magnetic resonance venography. Spine (Phila Pa 1976) 2008; 33:668&#x2013;672.</Citation></Reference><Reference><Citation>Schulte LM, O&#x2019;Brien JR, Bean MC, et al. Deep vein thrombosis and pulmonary embolism after spine surgery: incidence and patient risk factors. Am J Orthop (Belle Mead NJ) 2013; 42:267&#x2013;270.</Citation></Reference><Reference><Citation>Smith MD, Bressler EL, Lonstein JE, et al. Deep venous thrombosis and pulmonary embolism after major reconstructive operations on the spine. A prospective analysis of three hundred and seventeen patients. J Bone Joint Surg Am 1994; 76:980&#x2013;985.</Citation></Reference><Reference><Citation>Takahashi H, Yokoyama Y, Iida Y, et al. Incidence of venous thromboembolism after spine surgery. J Orthop Sci 2012; 17:114&#x2013;117.</Citation></Reference><Reference><Citation>West JL 3rd, Anderson LD. Incidence of deep vein thrombosis in major adult spinal surgery. Spine (Phila Pa 1976) 1992; 17:S254&#x2013;S257.</Citation></Reference><Reference><Citation>Wood KB, Kos PB, Abnet JK, et al. Prevention of deep-vein thrombosis after major spinal surgery: a comparison study of external devices. J Spinal Disord 1997; 10:209&#x2013;214.</Citation></Reference><Reference><Citation>Lee HM, Suk KS, Moon SH, et al. Deep vein thrombosis after major spinal surgery: incidence in an East Asian population. Spine (Phila Pa 1976) 2000; 25:1827&#x2013;1830.</Citation></Reference><Reference><Citation>Namboothiri S. Incidence of deep vein thrombosis after major spine surgeries with no mechanical or chemical prophylaxis. Evid Based Spine Care J 2012; 3:29&#x2013;33.</Citation></Reference><Reference><Citation>Oda T, Fuji T, Kato Y, et al. Deep venous thrombosis after posterior spinal surgery. Spine (Phila Pa 1976) 2000; 25:2962&#x2013;2967.</Citation></Reference><Reference><Citation>Catre MG. Anticoagulation in spinal surgery. A critical review of the literature. Can J Surg 1997; 40:413&#x2013;419.</Citation></Reference><Reference><Citation>Cheng JS, Arnold PM, Anderson PA, et al. Anticoagulation risk in spine surgery. Spine (Phila Pa 1976) 2010; 35:S117&#x2013;S124.</Citation></Reference><Reference><Citation>Bono CM, Watters WC 3rd, Heggeness MH, et al. An evidence-based clinical guideline for the use of antithrombotic therapies in spine surgery. Spine J 2009; 9:1046&#x2013;1051.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30843269</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-8191</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of cardiac surgery</Title><ISOAbbreviation>J Card Surg</ISOAbbreviation></Journal><ArticleTitle>AngioVac for extraction of venous thromboses and endocardial vegetations: A meta-analysis.</ArticleTitle><Pagination><StartPage>170</StartPage><EndPage>180</EndPage><MedlinePgn>170-180</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jocs.14009</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">AngioVac is a new device for filtering intravascular thrombi and emboli. Publications on the device are limited and underpowered to objectively estimate its safety and efficacy. We aimed to overcome this by performing a meta-analysis on the results of AngioVac for treating venous thromboses and endocardial vegetations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature review was performed to identify all articles reporting cardiac vegetation and/or thrombosis extraction using AngioVac. Endpoints were successful removal, operative mortality, conversion to open surgery, hospital stay, recurrent thromboembolism, and follow-up mortality. Random effect model was used, and pooled event rates (PERs) and incidence rate (IR) were calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 42 studies with 182 patients (81 vegetation and 101 thrombosis) were included. Overall mean follow-up times were 3.1 and 0.7 years in vegetation and thrombosis patients, respectively. The PERs for successful removal were 74.5 (confidence interval [CI]: 48.2-90.2), 80.5 (CI: 70.0-88.0), and 32.4 (CI: 17.0-52.8) in vegetation, right atrial/caval venous thrombi, and pulmonary emboli (PE) patients, respectively. The PERs for operative mortalities were 14.6 (CI: 7.7-25.8), 14.8 (CI: 8.5-24.5), and 32.3 (CI: 15.1-56.3), respectively. The PERs for conversion to open surgery were 25.0 (CI: 9.3-51.9) and 12.3 (CI: 5.4-25.6) in vegetation and thrombosis patients, respectively. The IR of recurrent thromboembolism was 0.18 per person per year (PPY) (CI: 0.00-14.69) in vegetation and 0.19 PPY (CI: 0.08-0.48) in thrombosis patients. IR of follow-up mortality was 0.37 PPY (CI: 0.11-1.21) in thrombosis patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">AngioVac is a viable option for extracting right-sided vegetations and right atrial/caval venous thrombi. Rates of successful extraction and mortality are significantly worse for PE.</AbstractText><CopyrightInformation>&#xa9; 2019 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hameed</LastName><ForeName>Irbaz</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Faiza M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wingo</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahouma</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leonard</LastName><ForeName>Jeremy R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-1680-2097</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Franco</LastName><ForeName>Antonino</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worku</LastName><ForeName>Berhane M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salemi</LastName><ForeName>Arash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girardi</LastName><ForeName>Leonard N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaudino</LastName><ForeName>Mario</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4680-0815</Identifier><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Card Surg</MedlineTA><NlmUniqueID>8908809</NlmUniqueID><ISSNLinking>0886-0440</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016206" MajorTopicYN="N">Databases, Bibliographic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057505" MajorTopicYN="Y">Embolic Protection Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004697" MajorTopicYN="N">Endocarditis, Bacterial</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017131" MajorTopicYN="N">Thrombectomy</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AngioVac</Keyword><Keyword MajorTopicYN="N">percutaneous</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword><Keyword MajorTopicYN="N">vegetation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30843269</ArticleId><ArticleId IdType="doi">10.1111/jocs.14009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35717948</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2567-689X</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Thrombosis and haemostasis</Title><ISOAbbreviation>Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Systematic Review and Meta-Analysis of Thromboprophylaxis with Heparins Following Intracerebral Hemorrhage.</ArticleTitle><Pagination><StartPage>1159</StartPage><EndPage>1168</EndPage><MedlinePgn>1159-1168</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0042-1744541</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">&#x2003;The efficacy and safety of pharmacological thromboprophylaxis in patients with intracerebral hemorrhage (ICH) remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">&#x2003;A literature search was performed to collect studies comparing the effect of thromboprophylaxis in patients with ICH. The primary endpoints were deep vein thrombosis (DVT), pulmonary embolism (PE), and hematoma expansion or rebleeding. A meta-analytic approach was employed to estimate the relative risk (RR) by fitting fixed-effects (FE) and random-effects (RE) models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">&#x2003;A total of 28 studies representing 3,697 hospitalized patients with ICH were included. Thromboprophylaxis was initiated within 4 days following hospital presentation and continued for 10 to 14 days in most of studies. Compared with control, thromboprophylaxis was associated with a reduced risk of DVT (47/1,399 [3.4%] vs. 202/1,377 [14.7%]; FE: RR, 0.24; 95% CI, 0.18-0.32; RE: RR, 0.27; 95% CI, 0.19-0.39) as well as PE (9/953 [0.9%] vs. 37/864 [4.3%]; FE: RR, 0.33; 95% CI, 0.19-0.57; RE: RR, 0.37; 95% CI, 0.21-0.66). Thromboprophylaxis was not associated with increased risk of hematoma expansion or rebleeding (32/1,319 [2.4%] vs. 37/1,301 [2.8%]; FE: RR, 0.75; 95% CI, 0.48-1.18; RE: RR, 0.80; 95% CI, 0.49-1.30) or mortality (117/925 [12.6%] vs. 139/904 [15.4%]; FE: RR, 0.82; 95% CI, 0.65-1.03; RE: RR, 0.83; 95% CI, 0.66-1.04).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">&#x2003;Thromboprophylaxis was effective in preventing DVT and PE without increasing the risk of hematoma expansion or bleeding among ICH patients. Future studies should explore the long-term effects of thromboprophylaxis in this population, particularly on the functional outcomes.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chi</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8371-1689</Identifier><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jane J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Trial Design and Development, Baim Institute for Clinical Research, Boston, Massachusetts, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheng</LastName><ForeName>Shi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marszalek</LastName><ForeName>Jolanta</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Thromb Haemost</MedlineTA><NlmUniqueID>7608063</NlmUniqueID><ISSNLinking>0340-6245</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006406" MajorTopicYN="N">Hematoma</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>19</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35717948</ArticleId><ArticleId IdType="doi">10.1055/s-0042-1744541</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35730378</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1751-1402</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The European journal of general practice</Title><ISOAbbreviation>Eur J Gen Pract</ISOAbbreviation></Journal><ArticleTitle>A systematic review and meta-analysis of diagnostic delay in pulmonary embolism.</ArticleTitle><Pagination><StartPage>165</StartPage><EndPage>172</EndPage><MedlinePgn>165-172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13814788.2022.2086232</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Diagnostic delay in patients with pulmonary embolism (PE) is typical, yet the proportion of patients with PE that experienced delay and for how many days is less well described, nor are determinants for such delay.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This study aimed to assess the prevalence and extent of delay in diagnosing PE.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A systematic literature search was performed to identify articles reporting delays in diagnosing PE. The primary outcome was mean delay (in days) or a percentage of patients with diagnostic delay (defined as PE diagnosis more than seven&#x2009;days after symptom onset). The secondary outcome was determinants of delay. Random-effect meta-analyses were applied to calculate a pooled estimate for mean delay and to explore heterogeneity in subgroups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The literature search yielded 10,933 studies, of which 24 were included in the final analysis. The pooled estimate of the mean diagnostic delay based on 12 studies was 6.3&#x2009;days (95% prediction interval 2.5 to 15.8). The percentage of patients having more than seven&#x2009;days of delay varied between 18% and 38%. All studies assessing the determinants of coughing (<i>n</i>&#x2009;=&#x2009;3), chronic lung disease (<i>n</i>&#x2009;=&#x2009;6) and heart failure (<i>n</i>&#x2009;=&#x2009;8) found a positive association with diagnostic delay. Similarly, all studies assessing recent surgery (<i>n</i>&#x2009;=&#x2009;7) and hypotension (<i>n</i>&#x2009;=&#x2009;6), as well as most studies assessing chest pain (<i>n</i>&#x2009;=&#x2009;8), found a negative association with diagnostic delay of PE.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Patients may have symptoms for almost one week before PE is diagnosed and in about a quarter of patients, the diagnostic delay is even longer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Maanen</LastName><ForeName>R</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4981-692X</Identifier><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinks-Roerdink</LastName><ForeName>E M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-0535-9253</Identifier><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutten</LastName><ForeName>F H</ForeName><Initials>FH</Initials><Identifier Source="ORCID">0000-0002-5052-7332</Identifier><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geersing</LastName><ForeName>G J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0001-6976-9844</Identifier><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Gen Pract</MedlineTA><NlmUniqueID>9513566</NlmUniqueID><ISSNLinking>1381-4788</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="Y">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">delay</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>4</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>6</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35730378</ArticleId><ArticleId IdType="pmc">PMC9246192</ArticleId><ArticleId IdType="doi">10.1080/13814788.2022.2086232</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe - the number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">17938798</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber S, Visani L, De Rosa M.. Acute pulmonary embolism clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER. Lancet. 1999;353(9162):1386&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83(03):416&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744147</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gal G, Righini M, Roy P-M, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med. 2006;144(3):165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461960</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017;390(10091):289&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">28549662</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda LA, Hathwar VS, Grant BJB.. Clinical suspicion of fatal pulmonary embolism. Chest. 2001;120(3):791&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">11555511</ArticleId></ArticleIdList></Reference><Reference><Citation>Barais M, Morio N, Cuzon Breton A, et al. &#x201c;I can't find anything wrong: it must be a pulmonary embolism&#x201d;: diagnosing suspected pulmonary embolism in primary care, a qualitative study. PLoS One. 2014;9(5):e98112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026480</ArticleId><ArticleId IdType="pubmed">24840333</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer G, Roy P-M, Gilberg S, et al. Pulmonary embolism. BMJ. 2010;340:c1421.</Citation><ArticleIdList><ArticleId IdType="pubmed">20388676</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">22007046</ArticleId></ArticleIdList></Reference><Reference><Citation>IntHout J, Ioannidis JPA, Rovers MM, et al. Plea for routinely presenting prediction intervals in Meta-analysis. BMJ Open. 2016;6(7):e010247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947751</ArticleId><ArticleId IdType="pubmed">27406637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageno W, Agnelli G, Imberti D, et al. Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry. Thromb Res. 2008;121(6):751&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">17920107</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso Mart&#xed;nez JL, Echegaray Agara M, Urbieta Echezarreta MA, et al. Embolismo pulmonar agudo. Un registro de 10 a&#xf1;os: de Mayo de 1992 a Mayo de 2002. Rev Clin Esp. 2004;204(10):521&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">15456603</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott CG, Goldhaber SZ, Jensen RL.. Delays in diagnosis of deep vein thrombosis and pulmonary embolism. Chest. 2005;128(5):3372&#x2013;3376.</Citation><ArticleIdList><ArticleId IdType="pubmed">16304286</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyard C, C&#xf4;t&#xe9; B, Looten V, et al. Determinants and prognostic implication of diagnostic delay in patients with a first episode of pulmonary embolism. Thromb Res. 2018;171:190&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">30190113</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriksen JMT, Koster-Van Ree M, Morgenstern MJ, et al. Clinical characteristics associated with diagnostic delay of pulmonary embolism in primary care: a retrospective observational study. Br Med J Open. 2017;7(3):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5353317</ArticleId><ArticleId IdType="pubmed">28279993</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x130;lvan A, &#xc7;elikdemir M, Ayrik C, et al. [Misdiagnosis of pulmonary embolism and causes]. Tuberk Toraks. 2015;63(1):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">25849051</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenab Y, Alemzadeh-Ansari MJ, Fehri SAF, et al. Effect of delay in hospital presentation on clinical and imaging findings in acute pulmonary thromboembolism. J Emerg Med. 2014;46(4):465&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">24462027</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez Castro D, Sueiro A, D&#xed;az G, et al. Prognostic significance of delays in diagnosis of pulmonary embolism. Thromb Res. 2007;121(2):153&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayhan S, &#xdc;nsal M, &#x130;nce &#xd6;, et al. Delays in diagnosis of acute pulmonary thromboembolism: clinical outcomes and risk factors. Electron J Gen Med. 2012;9(2):124&#x2013;129.</Citation></Reference><Reference><Citation>Men&#xe9;ndez R, Nauffal D, Cremades MJ.. Prognostic factors in restoration of pulmonary flow after submassive pulmonary embolism: a multiple regression analysis. Eur Respir J. 1998;11(3):560&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">9596102</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozlem B, Gokhan E, Baris G, et al. The diagnosis of pulmonary embolism in patients with normal d-dimer levels. Acta Medica Mediterr. 2016;32:171&#x2013;177.</Citation></Reference><Reference><Citation>Ozsu S, Oztuna F, Bulbul Y, et al. The role of risk factors in delayed diagnosis of pulmonary embolism. Am J Emerg Med. 2011;29(1):26&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">20825770</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Mart&#xed;nez JL, S&#xe1;nchez FJA, Echezarreta MAU.. Delay and misdiagnosis in sub-massive and non-massive acute pulmonary embolism. Eur J Intern Med. 2010;21(4):278&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">20603035</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasha SM, Klok FA, van der Bijl N, et al. Right ventricular function and thrombus load in patients with pulmonary embolism and diagnostic delay. J Thromb Haemost. 2014;12(2):172&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">24283792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimi-Rad MH, Rahimi-Rad S, Zarrin S.. Delays in diagnosis and treatment of venous thromboembolism in a developing country setting. Tuberk Toraks. 2013;61(2):96&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">23875586</ArticleId></ArticleIdList></Reference><Reference><Citation>Walen S, Damoiseaux RAMJ, Uil SM, et al. Diagnostic delay of pulmonary embolism in primary and secondary care: a retrospective cohort study. Br J Gen Pract. 2016;66(647):e444&#x2013;e450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4871310</ArticleId><ArticleId IdType="pubmed">27114207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zyci&#x144;ska K, Wiktorowicz M, Tomasik D, et al. Clinical presentation of pulmonary embolism in general practice. Fam Med Prim Care Rev. 2013;15(3):430&#x2013;433.</Citation></Reference><Reference><Citation>Aranda C, Peralta L, Gagliardi L, et al. A significant decrease in D-dimer concentration within one month of anticoagulation therapy as a predictor of both complete recanalization and risk of recurrence after initial pulmonary embolism. Thromb Res. 2021;202:31&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">33711756</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydo&#x1e7;du M, Do&#x1e7;an N&#xd6;, Sinano&#x1e7;lu NT, et al. Delay in diagnosis of pulmonary thromboembolism in emergency department: is it still a problem? Clin Appl Thromb. 2013;19(4):402&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">22496086</ArticleId></ArticleIdList></Reference><Reference><Citation>Berghaus TM, Von Scheidt W, Schwaiblmair M.. Time between first symptoms and diagnosis in patients with acute pulmonary embolism: are patients with recurrent episodes diagnosed earlier? Clin Res Cardiol. 2011;100(2):117&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">20821017</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulbul Y, Ozsu S, Kosucu P, et al. Time delay between onset of symptoms and diagnosis in pulmonary thromboembolism. Respiration. 2009;78(1):36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulbul Y, Ayik S, Oztuna F, et al. The relationship between socio-demographic characteristics of patients and diagnostic delay in acute pulmonary thromboembolism. Ups J Med Sci. 2011;116(1):72&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039763</ArticleId><ArticleId IdType="pubmed">21070094</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan TF, Ngian VJJ, Hsu K, et al. Pulmonary embolism: clinical presentation and diagnosis in the oldest old. Intern Med J. 2020;50(5):627&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">32431035</ArticleId></ArticleIdList></Reference><Reference><Citation>den Exter PL, van Es J, Erkens PMG, et al. Impact of delay in clinical presentation on the diagnostic management and prognosis of patients with suspected pulmonary embolism. Am J Respir Crit Care Med. 2013;187(12):1369&#x2013;1373.</Citation><ArticleIdList><ArticleId IdType="pubmed">23590273</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C, De Wit K, Parpia S, et al. Diagnosis of pulmonary embolism with d-dimer adjusted to clinical probability. N Engl J Med. 2019;381(22):2125&#x2013;2134.</Citation><ArticleIdList><ArticleId IdType="pubmed">31774957</ArticleId></ArticleIdList></Reference><Reference><Citation>Geersing GJ, Erkens PMG, Lucassen WAM, et al. Safe exclusion of pulmonary embolism using the wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ. 2012;345(7880):e6564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3464185</ArticleId><ArticleId IdType="pubmed">23036917</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosendaal FR, Raskob GE.. On world thrombosis day. Lancet. 2014;384(9955):1653&#x2013;1654.</Citation><ArticleIdList><ArticleId IdType="pubmed">25319500</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, van der Hulle T, den Exter PL, et al. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev. 2014;28(6):221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">25168205</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32151576</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-6259</ISSN><JournalIssue CitedMedium="Internet"><Volume>110</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Annals of thoracic surgery</Title><ISOAbbreviation>Ann Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Surgical Pulmonary Embolectomy Outcomes for Acute Pulmonary Embolism.</ArticleTitle><Pagination><StartPage>1072</StartPage><EndPage>1080</EndPage><MedlinePgn>1072-1080</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.athoracsur.2020.01.075</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0003-4975(20)30345-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Acute pulmonary embolism (PE) is associated with significant mortality. Surgical embolectomy is a viable treatment option; however, it remains controversial as a result of variable outcomes. This review investigates patient outcomes after surgical embolectomy for acute PE.</AbstractText><AbstractText Label="METHODS">An electronic search was performed to identify articles reporting surgical embolectomy for treatment of PE. 32 studies were included comprising 936 patients. Demographic, perioperative, and outcome data were extracted and pooled for systematic review.</AbstractText><AbstractText Label="RESULTS">Mean patient age was 56.3 years (95% confidence interval [CI], 52.5, 60.1), and 50% were male (95% CI, 46, 55); 82% had right ventricular dysfunction (95% CI, 62, 93), 80% (95% CI, 67, 89) had unstable hemodynamics, and 9% (95% CI, 5, 16) experienced cardiac arrest. Massive PE and submassive PE were present in 83% (95% CI, 43, 97)] and 13% (95% CI, 2, 56) of patients, respectively. Before embolectomy, 33% of patients (95% CI, 14, 60) underwent systemic thrombolysis, and 14% (95% CI, 8, 24) underwent catheter embolectomy. Preoperatively, 47% of patients were ventilated (95% CI, 26; 70), and 36% had percutaneous cardiopulmonary support (95% CI, 11, 71). Mean operative time and mean cardiopulmonary bypass time were 170 minutes (95% CI, 101, 239) and 56 minutes (95% CI, 42, 70), respectively. Intraoperative mortality was 4% (95% CI, 2, 8). Mean hospital and intensive care unit stay were 10 days (95% CI, 6, 14) and 2 days (95% CI, 1, 3), respectively. Mean postoperative systolic pulmonary artery pressure (sPAP) was significantly decreased from the preoperative period (sPAP 57.8, mm Hg; 95% CI, 53, 62.7) to the postoperative period (sPAP, 31.3 mm Hg; 24.9, 37.8); P &lt; .01). In-hospital mortality was 16% (95% CI, 12, 21). Overall survival at 5 years was 73% (95% CI, 64, 81).</AbstractText><AbstractText Label="CONCLUSIONS">Surgical embolectomy is an acceptable treatment option with favorable outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jae Hwan</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maynes</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Antonio</LastName><ForeName>Nicholas D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellado</LastName><ForeName>Mart&#xed;n</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Frances M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Pulmonary/Allergy, and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galanis</LastName><ForeName>Taki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, Thomas Jefferson Vascular Center, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonsalves</LastName><ForeName>Carin F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Division of Vascular and Interventional Radiology, Thomas Jefferson University Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marhefka</LastName><ForeName>Gregary D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awsare</LastName><ForeName>Bharat K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Pulmonary/Allergy, and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merli</LastName><ForeName>Geno J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Thomas Jefferson Vascular Center, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchantchaleishvili</LastName><ForeName>Vakhtang</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: vakhtang.tchantchaleishvili@jefferson.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ann Thorac Surg</MedlineTA><NlmUniqueID>15030100R</NlmUniqueID><ISSNLinking>0003-4975</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Thorac Surg. 2020 Sep;110(3):1080-1081. doi: 10.1016/j.athoracsur.2020.03.042.</RefSource><PMID Version="1">32315644</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Thorac Surg. 2021 Jul;112(1):344. doi: 10.1016/j.athoracsur.2020.08.112.</RefSource><PMID Version="1">33253668</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Thorac Surg. 2021 Jul;112(1):344-345. doi: 10.1016/j.athoracsur.2020.11.084.</RefSource><PMID Version="1">33621548</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017128" MajorTopicYN="N">Embolectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32151576</ArticleId><ArticleId IdType="doi">10.1016/j.athoracsur.2020.01.075</ArticleId><ArticleId IdType="pii">S0003-4975(20)30345-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27749350</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-7598</ISSN><JournalIssue CitedMedium="Internet"><Volume>123</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Anesthesia and analgesia</Title><ISOAbbreviation>Anesth Analg</ISOAbbreviation></Journal><ArticleTitle>Spine Surgery and Blood Loss: Systematic Review of Clinical Evidence.</ArticleTitle><Pagination><StartPage>1307</StartPage><EndPage>1315</EndPage><MedlinePgn>1307-1315</MedlinePgn></Pagination><Abstract><AbstractText>Spine surgery has been growing rapidly as a neurosurgical operation, with an increase of 220% over a 15-year period. Intraoperative blood transfusion is a major outcome determinant of spine procedures. Various approaches, including pharmacologic and nonpharmacologic therapies, have been tested to decrease both intraoperative and postoperative blood loss. The aim of this systematic review is to report clinical evidence on the relationship between intraoperative blood loss (primary outcome) and on transfusion requirements and postoperative complications (secondary outcomes) in patients undergoing spine surgery. A literature search of PubMed database was performed using 5 key words: spine surgery and transfusion; spine surgery and blood loss; spine surgery and blood complications; spine surgery and deep vein thrombosis; and spine surgery and pulmonary embolism. Clinical reports (randomized controlled trials, prospective and retrospective studies, and case reports) were selected. A total of 473 articles were examined; 450 were excluded, and 24 were selected for this systematic review. Selected articles were categorized into 3 subchapters: (1) drugs active on coagulation (12 studies): tranexamic acid, aminocaproic acid, aprotinin, and recombinant activated factor VII; (2) drugs not active on coagulation (5 studies): ketorolac, epoetin alfa, magnesium sulfate, propofol/sevoflurane, and omega-3 and fish oil; (3) nonpharmacologic approaches (7 studies): surgical tips, patient positioning, and general or spinal anesthesia. Several studies have shown a significant reduction in intraoperative bleeding during spine surgery and in the requirement for blood transfusion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willner</LastName><ForeName>Dafna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>From the *Department of Anesthesia and Critical Care Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; and &#x2020;Department of Anesthesia and Critical Care, Umberto I, La Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spennati</LastName><ForeName>Valeria</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Stohl</LastName><ForeName>Shelly</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tosti</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Aloisio</LastName><ForeName>Simone</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bilotta</LastName><ForeName>Federico</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anesth Analg</MedlineTA><NlmUniqueID>1310650</NlmUniqueID><ISSNLinking>0003-2999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013122" MajorTopicYN="N">Spinal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27749350</ArticleId><ArticleId IdType="doi">10.1213/ANE.0000000000001485</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35638051</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-0801</ISSN><JournalIssue CitedMedium="Print"><Volume>77</Volume><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of medicine and surgery (2012)</Title><ISOAbbreviation>Ann Med Surg (Lond)</ISOAbbreviation></Journal><ArticleTitle>Evidence-based perioperative diagnosis and management of pulmonary embolism: A systematic review.</ArticleTitle><Pagination><StartPage>103684</StartPage><MedlinePgn>103684</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103684</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amsu.2022.103684</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The diagnosis and treatment of pulmonary embolism have multi-modal approach based on specificity, sensitivity, availability of the machine, and associated risks of imaging modalities.</AbstractText><AbstractText Label="AIM" NlmCategory="UNASSIGNED">This review aimed to provide shreds of evidence that improve perioperative diagnosis and management of suspected pulmonary embolism.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline 2020. After a clear criteria has been established an electronic searching database was conducted using PubMed, Google Scholar, Cochrane library, and Cumulative Index of Nursing and Allied Health Literature (CINAHL), with Key search terms included:('pulmonary embolism' AND' anesthesia management ', 'anticoagulation' AND 'pulmonary embolism', 'thrombolysis 'AND 'pulmonary embolism', 'surgery' AND' pulmonary embolism'), were used to draw the evidence.The quality of literatures were categorized based on WHO 2011 level of evidence and degree of recommendation, in addition, the study is registered with research registry unique identifying number (UIN) of reviewregistry1318." and has high quality based on AMSTAR2 assessment criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A totally of 27 articles were included [guidelines (n&#xa0;=&#xa0;3), Cochrane (=5), systemic reviews (n&#xa0;=&#xa0;7), meta-analyses (=2), RCT (n&#xa0;=&#xa0;4), cohort studies (n&#xa0;=&#xa0;3), and cross-sectional study (n&#xa0;=&#xa0;3) and illegible articles identified from searches of the electronic databases were imported into the ENDNOTE software version X7.1 and duplicates were removed.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Currently divergent and contradictory approaches are implemented in diagnosis and management for patients suspected of pulmonary embolism.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">All perioperative patients, especially trauma victims, prostate or orthopedic surgery, malignancy, immobility, and obesity; smokers; and oral contraceptive users, antipsychotic medications are at increased risk of venous thromboembolism and need special caution during surgery and anesthesia<b>.</b></AbstractText><CopyrightInformation>&#xa9; 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abate</LastName><ForeName>Lamesgen Geta</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, College of Medicine and Health Science, Debre Markos University, Debre Markos, Ethiopia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Advanced Clinical Anesthesia and Critical Care, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayable</LastName><ForeName>Samuel Debas</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, College of Medicine and Health Science, Debre Markos University, Debre Markos, Ethiopia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Advanced Clinical Anesthesia and Critical Care, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fetene</LastName><ForeName>Melaku Bantie</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, College of Medicine and Health Science, Debre Berhan University, Debre Berhan, Ethiopia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Advanced Clinical Anesthesia and Critical Care, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med Surg (Lond)</MedlineTA><NlmUniqueID>101616869</NlmUniqueID><ISSNLinking>2049-0801</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anesthesia management</Keyword><Keyword MajorTopicYN="N">Anticoagulation</Keyword><Keyword MajorTopicYN="N">CASP, Critical Appraisal Skills Programmed</Keyword><Keyword MajorTopicYN="N">CTPA, Computed Tomography Pulmonary Angiography</Keyword><Keyword MajorTopicYN="N">DVT, Deep Venous Thrombosis</Keyword><Keyword MajorTopicYN="N">PE, Pulmonary Embolism</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Thrombolysis</Keyword><Keyword MajorTopicYN="N">WHO, World Health Organization</Keyword></KeywordList><CoiStatement>The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>31</Day><Hour>14</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35638051</ArticleId><ArticleId IdType="pmc">PMC9142630</ArticleId><ArticleId IdType="doi">10.1016/j.amsu.2022.103684</ArticleId><ArticleId IdType="pii">S2049-0801(22)00444-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bajc M., Sch&#xfc;michen C., Gr&#xfc;ning T., Lindqvist A., Le Roux P.-Y., Alatri A., et al. EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. Eur. J. Nucl. Med. Mol. Imag. 2019;46(12):2429&#x2013;2451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813289</ArticleId><ArticleId IdType="pubmed">31410539</ArticleId></ArticleIdList></Reference><Reference><Citation>Doundoulakis I., Antza C., Karvounis H., Giannakoulas G. Non-vitamin K antagonist oral anticoagulants in pulmonary embolism: an overview of systematic reviews. Curr. Pharmaceut. Des. 2020;26(23):2686&#x2013;2691.</Citation><ArticleIdList><ArticleId IdType="pubmed">32310040</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson L., Kesteven P., McCaslin J.E. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Cochrane Database Syst. Rev. 2015;(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6463831</ArticleId><ArticleId IdType="pubmed">26636644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramlakhan R., Rajkumar A., Andronikou S. The prevalence and radiological findings of pulmonary embolism in HIV-positive patients referred for computed tomography pulmonary angiography in the Western Cape of South Africa. Cardiovasc. J. Africa. 2017;28(4):221&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642032</ArticleId><ArticleId IdType="pubmed">28218770</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrer&#xed;a Palacios P. 2020. TEP no sospechado en Urgencias.</Citation></Reference><Reference><Citation>Raynal P.-A., Cachanado M., Truchot J., Damas-Perrichet C., Feral-Pierssens A.-L., Goulet H., et al. Prevalence of pulmonary embolism in emergency department patients with isolated syncope: a prospective cohort study. Eur. J. Emerg. Med. 2019;26(6):458&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">31609876</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.-J., Harjola V.-P., et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) Eur. Heart J. 2020;41(4):543&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">31504429</ArticleId></ArticleIdList></Reference><Reference><Citation>Desciak M.C., Martin D.E. Perioperative pulmonary embolism: diagnosis and anesthetic management. J. Clin. Anesth. 2011;23(2):153&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">21377083</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavorini F., Di Bello V., De Rimini M.L., Lucignani G., Marconi L., Palareti G., et al. Diagnosis and treatment of pulmonary embolism: a multidisciplinary approach. Multidiscipl. respirat. med. 2013;8(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3878229</ArticleId><ArticleId IdType="pubmed">24354912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Q., Dong B., Yue J., Wu T., Liu G. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst. Rev. 2015</Citation><ArticleIdList><ArticleId IdType="pubmed">26419832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayalew M.B., Horsa B.A., Zeleke M.T. Appropriateness of pharmacologic prophylaxis against deep vein thrombosis in medical wards of an Ethiopian referral hospital. Int. J. Vasc. Med. 2018;2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6076918</ArticleId><ArticleId IdType="pubmed">30105097</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellhaa&#xdf; A., Walther A., Konstantinides S., B&#xf6;ttiger B.W. The diagnosis and treatment of acute pulmonary embolism. Deutsches &#xc4;rzteblatt Int. 2010;107(34&#x2013;35):589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936787</ArticleId><ArticleId IdType="pubmed">20838451</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford F., Andras A., Welch K., Sheares K., Keeling D., Chappell F.M. D&#x2010;dimer test for excluding the diagnosis of pulmonary embolism. Cochrane Database Syst. Rev. 2016;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6457638</ArticleId><ArticleId IdType="pubmed">27494075</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int. J. Surg. 2021;88:105906.</Citation><ArticleIdList><ArticleId IdType="pubmed">33789826</ArticleId></ArticleIdList></Reference><Reference><Citation>CASP U. 2013. Critical Appraisal Skills Programme (CASP) Systematic Review Checklist. Oxford, UK.</Citation></Reference><Reference><Citation>Casp U. Critical appraisal skills programme (CASP) Qualit. res. checklist. 2017;31(13):449.</Citation></Reference><Reference><Citation>Horntvedt M.-E.T., Nordsteien A., Fermann T., Severinsson E. Strategies for teaching evidence-based practice in nursing education: a thematic literature review. BMC Med. Educ. 2018;18(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6064179</ArticleId><ArticleId IdType="pubmed">30055612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bro&#x17c;ek J., Akl E., Compalati E., Kreis J., Terracciano L., Fiocchi A., et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. Allergy. 2011;66(5):588&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">21241318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapner S.T., Kearon C. Diagnosis and management of pulmonary embolism. Bmj. 2013:346.</Citation><ArticleIdList><ArticleId IdType="pubmed">23427133</ArticleId></ArticleIdList></Reference><Reference><Citation>Antic D., Lefkou E., Otasevic V., Banfic L., Dimakakos E., Olinic D., et al. Position paper on the management of pregnancy-associated superficial venous thrombosis. Balkan working group for prevention and treatment of venous thromboembolism. Clinic. Appl. Thromb./Hemostasis. 2022;28 1076029620939181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8864277</ArticleId><ArticleId IdType="pubmed">35187959</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsh J., Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals from the council on thrombosis (in consultation with the council on cardiovascular radiology), American Heart Association. Circulation. 1996;93(12):2212&#x2013;2245.</Citation><ArticleIdList><ArticleId IdType="pubmed">8925592</ArticleId></ArticleIdList></Reference><Reference><Citation>Somasundaram K., Ball J. Medical emergencies: pulmonary embolism and acute severe asthma. Anaesthesia. 2013;68:102&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">23210560</ArticleId></ArticleIdList></Reference><Reference><Citation>Mclintock C., Brighton T., Chunilal S., Dekker G., Mcdonnell N., Mcrae S., et al. Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period. Aust. N. Z. J. Obstet. Gynaecol. 2012;52(1):14&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">21972999</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapson V.F. Advances in the diagnosis and treatment of acute pulmonary embolism. F1000 med. rep. 2012;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357009</ArticleId><ArticleId IdType="pubmed">22619694</ArticleId></ArticleIdList></Reference><Reference><Citation>Shonyela F.S., Yang S., Liu B., Jiao J. Postoperative acute pulmonary embolism following pulmonary resections. Ann. Thorac. Cardiovasc. Surg. 2015:15&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4904848</ArticleId><ArticleId IdType="pubmed">26354232</ArticleId></ArticleIdList></Reference><Reference><Citation>Members A.T.F., Konstantinides S.V., Torbicki A., Agnelli G., Danchin N., Fitzmaurice D., et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European society of cardiology (ESC) endorsed by the European respiratory society (ERS) Eur. Heart J. 2014;35(43):3033&#x2013;3080.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutts B.A., Dasgupta D., Hunt B.J. New directions in the diagnosis and treatment of pulmonary embolism in pregnancy. Am. J. Obstet. Gynecol. 2013;208(2):102&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">22840412</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti C., John G., Konstantinides S., Combescure C., Sanchez O., Lankeit M., et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur. Heart J. 2015;36(10):605&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352209</ArticleId><ArticleId IdType="pubmed">24917641</ArticleId></ArticleIdList></Reference><Reference><Citation>Birhan A., Assefa T., Beyene A., Ndayishimiye P., Woldu M.A. Outcome of acute deep venous thrombosis using standard treatment versus thrombolytics: a literature review. Int. J. Hematol. Oncol. Stem Cell Res. 2019;13(4):201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6925367</ArticleId><ArticleId IdType="pubmed">31871595</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Chatterjee S., Desai N.R., Kirtane A.J., Desai M.M., Bracken M.B., et al. Inferior vena cava filters to prevent pulmonary embolism: systematic review and meta-analysis. J. Am. Coll. Cardiol. 2017;70(13):1587&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412839</ArticleId><ArticleId IdType="pubmed">28935036</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators E.P. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 2012;366(14):1287&#x2013;1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">22449293</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew J., Stevens J., Slatore C. Refractory hypoxemia in a patient with submassive pulmonary embolism and an intracardiac shunt: a case report and review of the literature. Perm. J. 2018;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5882180</ArticleId><ArticleId IdType="pubmed">29616915</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37851108</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1435-2451</ISSN><JournalIssue CitedMedium="Internet"><Volume>408</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>Langenbeck's archives of surgery</Title><ISOAbbreviation>Langenbecks Arch Surg</ISOAbbreviation></Journal><ArticleTitle>A systematic review of venous thromboembolism mechanical prophylaxis devices during surgery.</ArticleTitle><Pagination><StartPage>410</StartPage><MedlinePgn>410</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">410</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00423-023-03142-6</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Hospitalisation and surgery are major risk factors for venous thromboembolism (VTE). Intermittent pneumatic compression (IPC) and graduated compression stockings (GCS) are common mechanical prophylaxis devices used to prevent VTE. This review compares the safety and efficacy of IPC and GCS used singularly and in combination for surgical patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Ovid Medline and Pubmed were searched in a systematic review of the literature, and relevant articles were assessed against eligibility criteria for inclusion along PRISMA guidelines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This review is a narrative description and critical analysis of available evidence. Fourteen articles were included in this review after meeting the criteria. Results of seven studies comparing the efficacy of IPC versus GCS had high heterogeneity but overall suggested IPC was superior to GCS. A further seven studies compared the combination of IPC and GCS versus GCS alone, the results of which suggest that combination mechanical prophylaxis may be superior to GCS alone in high-risk patients. No studies compared combination therapy to IPC alone. IPC appeared to have a superior safety profile, although it had a worse compliance rate and the quality of evidence was poor. The addition of pharmacological prophylaxis may make mechanical prophylaxis superfluous in the post-operative setting.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IPC may be superior to GCS when used as a single prophylactic device. A combination of IPC and GCS may be more efficacious than GCS alone for high-risk patients. Further high-quality research is needed focusing on clinical relevance, safety and comparing combination mechanical prophylaxis to IPC alone, particularly in high-risk surgical settings when pharmacological prophylaxis is contraindicated.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herring</LastName><ForeName>Brianna</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Melbourne, Epping, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowen</LastName><ForeName>Darren</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia &amp; Perioperative Medicine, Northern Health, Epping, VIC, 3076, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Critical Care, Melbourne Medical School, The University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Prahlad</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Haematology, Northern Health, Epping, VIC, 3076, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Australian Centre for Blood Diseases, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Northern Health, University of Melbourne, Heidelberg, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodgson</LastName><ForeName>Russell</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4772-516X</Identifier><AffiliationInfo><Affiliation>Department of Surgery, University of Melbourne, Epping, Australia. russell.hodgson@nh.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Northern Health, Epping, VIC, 3076, Australia. russell.hodgson@nh.org.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Langenbecks Arch Surg</MedlineTA><NlmUniqueID>9808285</NlmUniqueID><ISSNLinking>1435-2443</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048228" MajorTopicYN="N">Intermittent Pneumatic Compression Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053828" MajorTopicYN="N">Stockings, Compression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Graduated compression stockings</Keyword><Keyword MajorTopicYN="N">Intermittent pneumatic compression</Keyword><Keyword MajorTopicYN="N">Mechanical prophylaxis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>18</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>18</Day><Hour>11</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37851108</ArticleId><ArticleId IdType="pmc">PMC10584699</ArticleId><ArticleId IdType="doi">10.1007/s00423-023-03142-6</ArticleId><ArticleId IdType="pii">10.1007/s00423-023-03142-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fletcher J, Baker R, Fisher C, Gallus A, Matthews G, Stacey M, et al. The burden of venous thromboembolism in Australia: access Economics; 2008 [Available from: https://www.safetyandquality.gov.au/wp-content/uploads/2018/10/Access-Economics_The-burden-of-VTE-inAustralia_2008.pdf (viewed May 2022)</Citation></Reference><Reference><Citation>National Health and Medical Research Council . Venous thromboembolism prevention clinical care standard. Melbourne: NHMRC; 2020.</Citation></Reference><Reference><Citation>Assareh H, Chen J, Ou L, Hillman K, Flabouris A. Incidences and variations of hospital acquired venous thromboembolism in Australian hospitals: a population-based study. BMC Health Serv Res. 2016;16(1):511. doi: 10.1186/s12913-016-1766-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-016-1766-y</ArticleId><ArticleId IdType="pmc">PMC5034410</ArticleId><ArticleId IdType="pubmed">27659903</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (London, England) 2008;371(9610):387&#x2013;394. doi: 10.1016/S0140-6736(08)60202-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(08)60202-0</ArticleId><ArticleId IdType="pubmed">18242412</ArticleId></ArticleIdList></Reference><Reference><Citation>Eppsteiner RW, Shin JJ, Johnson J, van Dam RM. Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis. World J Surg. 2010;34(1):10&#x2013;19. doi: 10.1007/s00268-009-0284-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-009-0284-z</ArticleId><ArticleId IdType="pubmed">20020289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkos SK. Mechanical thromboprophylaxis is effective in reducing postoperative venous thromboembolism. Br J Surg. 2022;109(8):667&#x2013;668. doi: 10.1093/bjs/znac156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bjs/znac156</ArticleId><ArticleId IdType="pubmed">35594525</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitelaw GP, Oladipo OJ, Shah BP, DeMuth KA, Coffman J, Segal D. Evaluation of intermittent pneumatic compression devices. Orthopedics. 2001;24(3):257&#x2013;261. doi: 10.3928/0147-7447-20010301-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/0147-7447-20010301-17</ArticleId><ArticleId IdType="pubmed">11300290</ArticleId></ArticleIdList></Reference><Reference><Citation>Benko T, Cooke EA, McNally MA, Mollan RA. Graduated compression stockings: knee length or thigh length. Clin Orthop Relat Res. 2001;383:197&#x2013;203. doi: 10.1097/00003086-200102000-00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003086-200102000-00022</ArticleId><ArticleId IdType="pubmed">11210954</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism London: NICE; 2018 [updated 2019]. Available from: https://www.nice.org.uk/guidance/ng89. Accessed May 2022</Citation><ArticleIdList><ArticleId IdType="pubmed">32924386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroiwa M, Takahira N, Ujihashi Y, Miida K, Arai Y, Kawatani H. Reduction in the soles of graduated compression stockings prevents falls without reducing the preventive effect for venous stasis. Thromb Res. 2015;135(5):877&#x2013;881. doi: 10.1016/j.thromres.2015.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2015.02.028</ArticleId><ArticleId IdType="pubmed">25743882</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3(23):3898&#x2013;3944. doi: 10.1182/bloodadvances.2019000975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019000975</ArticleId><ArticleId IdType="pmc">PMC6963238</ArticleId><ArticleId IdType="pubmed">31794602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S&#x2013;e277. doi: 10.1378/chest.11-2297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2297</ArticleId><ArticleId IdType="pmc">PMC3278061</ArticleId><ArticleId IdType="pubmed">22315263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkum E, Klotz R, Seide S, Huttner FJ, Kowalewski KF, Nickel F, et al. Systematic reviews in surgery-recommendations from the Study Center of the German Society of Surgery. Langenbecks Arch Surg. 2021;406(6):1723&#x2013;1731. doi: 10.1007/s00423-021-02204-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00423-021-02204-x</ArticleId><ArticleId IdType="pmc">PMC8481197</ArticleId><ArticleId IdType="pubmed">34129108</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedegana LR, Burgess EM, Moore AJ, Carpenter ML. Prevention of thromboembolic disease by external pneumatic compression in patients undergoing total hip arthroplasty. Clin Orthop Relat Res. 1977;128:190&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">598154</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Arsdalen KN, Barnes RW, Clarke G, Smith MJ, Koontz WW., Jr Deep vein thrombosis and prostatectomy. Urology. 1983;21(5):461&#x2013;463. doi: 10.1016/0090-4295(83)90040-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-4295(83)90040-7</ArticleId><ArticleId IdType="pubmed">6857882</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucci MN, Papadopoulos SM, Chen JC, Campbell JA, Hoff JT. Mechanical prophylaxis of venous thrombosis in patients undergoing craniotomy: a randomized trial. Surg Neurol. 1989;32(4):285&#x2013;288. doi: 10.1016/0090-3019(89)90231-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-3019(89)90231-0</ArticleId><ArticleId IdType="pubmed">2675364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarmiento A, Goswami AD. Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty. J Bone Joint Surg Am. 1999;81(3):339&#x2013;346. doi: 10.2106/00004623-199903000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-199903000-00005</ArticleId><ArticleId IdType="pubmed">10199271</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Westrich G, Potter H, Sharrock N, Maun L, Macaulay W, et al. Effect of mechanical compression on the prevalence of proximal deep venous thrombosis as assessed by magnetic resonance venography. J Bone Joint Surg Am. 2002;84(11):1998&#x2013;2004. doi: 10.2106/00004623-200211000-00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-200211000-00014</ArticleId><ArticleId IdType="pubmed">12429761</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbersack Y, Taute BM, Hein W, Podhaisky H (2004) Prevention of deep-vein thrombosis after total hip and knee replacement. Low-molecular-weight heparin in combination with intermittent pneumatic compression. J Bone Joint Surg Br 86(6):809&#x2013;12.&#xa0;10.1302/0301-620x.86b6.13958</Citation><ArticleIdList><ArticleId IdType="pubmed">15330019</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin PL, Amin MS, Yang KY, Yeo SJ, Lo NN. Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial. J Orthop Surg (Hong Kong) 2009;17(1):1&#x2013;5. doi: 10.1177/230949900901700101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/230949900901700101</ArticleId><ArticleId IdType="pubmed">19398783</ArticleId></ArticleIdList></Reference><Reference><Citation>Chibbaro S, Cebula H, Todeschi J, Fricia M, Vigouroux D, Abid H, et al. Evolution of prophylaxis protocols for venous thromboembolism in neurosurgery: results from a prospective comparative study on low-molecular-weight heparin, elastic stockings, and intermittent pneumatic compression devices. World Neurosurg. 2018;109:e510&#x2013;e516. doi: 10.1016/j.wneu.2017.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2017.10.012</ArticleId><ArticleId IdType="pubmed">29033376</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Zhang ZY, Li Z, Liu CD, Zhan YX, Qiao BL, et al. Two mechanical methods for thromboembolism prophylaxis after gynaecological pelvic surgery: a prospective, randomised study. Chin Med J (Engl) 2012;125(23):4259&#x2013;4263.</Citation><ArticleIdList><ArticleId IdType="pubmed">23217397</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobastov K, Sautina E, Alencheva E, Bargandzhiya A, Schastlivtsev I, Barinov V, et al. Intermittent pneumatic compression in addition to standard prophylaxis of postoperative venous thromboembolism in extremely high-risk patients (IPC SUPER): a randomized controlled trial. Ann Surg. 2021;274(1):63&#x2013;69. doi: 10.1097/SLA.0000000000004556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000004556</ArticleId><ArticleId IdType="pubmed">33201130</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell J, Schenk G, Taute BM, Scheller C, Marquart C, Strauss C, et al (2018) Reduced risk of venous thromboembolism with the use of intermittent pneumatic compression after craniotomy: a randomized controlled prospective study. J Neurosurg 130(2): 622&#x2013;28. 10.3171/2017.9.JNS17533</Citation><ArticleIdList><ArticleId IdType="pubmed">29600912</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang CQ, Zhao N, Zhang J, Wang SZ, Guo SL, Li SH, et al. Different combination strategies for prophylaxis of venous thromboembolism in patients: a prospective multicenter randomized controlled study. Sci Rep. 2018;8(1):8277. doi: 10.1038/s41598-018-25274-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-25274-2</ArticleId><ArticleId IdType="pmc">PMC5974317</ArticleId><ArticleId IdType="pubmed">29844423</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Hirsch DR, MacDougall RC, Polak JF, Creager MA, Cohn LH. Prevention of venous thrombosis after coronary artery bypass surgery (a randomized trial comparing two mechanical prophylaxis strategies) Am J Cardiol. 1995;76(14):993&#x2013;996. doi: 10.1016/S0002-9149(99)80282-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9149(99)80282-3</ArticleId><ArticleId IdType="pubmed">7484878</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie AG, Hirsh J, Gent M, Julian D, Johnson J (1989) Prevention of deep vein thrombosis in potential neurosurgical patients. a randomized trial comparing graduated compression stockings alone or graduated compression stockings plus intermittent pneumatic compression with control. Arch Intern Med 149(3):679&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pubmed">2645846</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaboration CT, Dennis M, Sandercock PA, Reid J, Graham C, Murray G, et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet (London, England) 2009;373(9679):1958&#x2013;1965. doi: 10.1016/S0140-6736(09)60941-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)60941-7</ArticleId><ArticleId IdType="pmc">PMC2692021</ArticleId><ArticleId IdType="pubmed">19477503</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu DS, Newbold R, Stevens S, Wong E, Fong J, Mori K, et al. Early versus postoperative chemical thromboprophylaxis is associated with increased bleeding risk following abdominal visceral resections: a multicenter cohort study. J Gastrointest Surg Off J Soc Surg Aliment Tract. 2022;26(7):1495&#x2013;1502. doi: 10.1007/s11605-022-05301-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11605-022-05301-4</ArticleId><ArticleId IdType="pmc">PMC9296430</ArticleId><ArticleId IdType="pubmed">35318594</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu DS, Stevens S, Wong E, Fong J, Mori K, Ward S, et al. Pre-operative and intra-operative chemical thromboprophylaxis increases bleeding risk following elective cholecystectomy: a multicentre (PROTECTinG) study. ANZ J Surg. 2020;90(12):2449&#x2013;2455. doi: 10.1111/ans.15998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.15998</ArticleId><ArticleId IdType="pubmed">32516851</ArticleId></ArticleIdList></Reference><Reference><Citation>Doughtie CA, Priddy EE, Philips P, Martin RC, McMasters KM, Scoggins CR (2014) Preoperative dosing of low-molecular-weight heparin in hepatopancreatobiliary surgery. Am J Surg 208(6):1009&#x2013;15 discussion 15.&#xa0;10.1016/j.amjsurg.2014.08.012</Citation><ArticleIdList><ArticleId IdType="pubmed">25435300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 2013;128(9):1003&#x2013;1020. doi: 10.1161/CIRCULATIONAHA.113.002690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.002690</ArticleId><ArticleId IdType="pubmed">23852609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachdeva A, Dalton M, Lees T. Graduated compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev. 2018;11(11):CD001484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6477662</ArticleId><ArticleId IdType="pubmed">30390397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkos S, Kirkilesis G, Caprini JA, Geroulakos G, Nicolaides A, Stansby G, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst Rev. 2022;1(1):CD005258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8796751</ArticleId><ArticleId IdType="pubmed">35089599</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta I, Ball CG, Rudmik L, Hameed SM, Kortbeek JB. Complications related to deep venous thrombosis prophylaxis in trauma: a systematic review of the literature. J Trauma Manag Outcomes. 2010;4:1. doi: 10.1186/1752-2897-4-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-2897-4-1</ArticleId><ArticleId IdType="pmc">PMC2823661</ArticleId><ArticleId IdType="pubmed">20205800</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartelli M, Catena F, Ansaloni L, Coccolini F, Griffiths EA, Abu-Zidan FM, et al. WSES guidelines for the management of acute left sided colonic diverticulitis in the emergency setting. World J Emerg Surg. 2016;11:37. doi: 10.1186/s13017-016-0095-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13017-016-0095-0</ArticleId><ArticleId IdType="pmc">PMC4966807</ArticleId><ArticleId IdType="pubmed">27478494</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenall R, Davis RE. Intermittent pneumatic compression for venous thromboembolism prevention: a systematic review on factors affecting adherence. BMJ Open. 2020;10(9):e037036. doi: 10.1136/bmjopen-2020-037036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-037036</ArticleId><ArticleId IdType="pmc">PMC7473613</ArticleId><ArticleId IdType="pubmed">32883726</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao JM, He ML, Xiao ZM, Li TS, Wu H. Jiang H (2014) Different types of intermittent pneumatic compression devices for preventing venous thromboembolism in patients after total hip replacement. Cochrane Database Syst Rev. 2014;12:CD009543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7100582</ArticleId><ArticleId IdType="pubmed">25528992</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajid MS, Desai M, Morris RW, Hamilton G. Knee length versus thigh length graduated compression stockings for prevention of deep vein thrombosis in postoperative surgical patients. Cochrane Database Syst Rev. 2012;5:CD007162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11694892</ArticleId><ArticleId IdType="pubmed">22592717</ArticleId></ArticleIdList></Reference><Reference><Citation>Segers AE, Prins MH, Lensing AW, Buller HR. Is contrast venography a valid surrogate outcome measure in venous thromboembolism prevention studies? J Thromb Haemost. 2005;3(5):1099&#x2013;1102. doi: 10.1111/j.1538-7836.2005.01317.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01317.x</ArticleId><ArticleId IdType="pubmed">15869620</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest. 2009;135(2):513&#x2013;520. doi: 10.1378/chest.08-2655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.08-2655</ArticleId><ArticleId IdType="pubmed">19201714</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost. 2007;5(7):1438&#x2013;1443. doi: 10.1111/j.1538-7836.2007.02571.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2007.02571.x</ArticleId><ArticleId IdType="pubmed">17425687</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsh J, Ginsberg JS, Chan N, Guyatt G, Eikelboom JW. Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. Thromb Haemost. 2014;111(1):10&#x2013;13. doi: 10.1160/TH13-07-0562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH13-07-0562</ArticleId><ArticleId IdType="pubmed">24108360</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Eikelboom JW, Gould MK, Garcia DA, Crowther M, Murad MH, et al. Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e185S&#x2013;e194. doi: 10.1378/chest.11-2289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2289</ArticleId><ArticleId IdType="pmc">PMC3278047</ArticleId><ArticleId IdType="pubmed">22315260</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan NC, Stehouwer AC, Hirsh J, Ginsberg JS, Alazzoni A, Coppens M, et al. Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. Thromb Haemost. 2015;114(5):1049&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">26134342</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskob GE, Spyropoulos AC, Cohen AT, Weitz JI, Ageno W, De Sanctis Y, et al. Association between asymptomatic proximal deep vein thrombosis and mortality in acutely ill medical patients. J Am Heart Assoc. 2021;10(5):e019459. doi: 10.1161/JAHA.120.019459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.019459</ArticleId><ArticleId IdType="pmc">PMC8174250</ArticleId><ArticleId IdType="pubmed">33586478</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ, et al. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost. 2005;93(1):76&#x2013;79. doi: 10.1160/TH04-05-0323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH04-05-0323</ArticleId><ArticleId IdType="pubmed">15630494</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalayci A, Gibson CM, Chi G, Yee MK, Korjian S, Datta S, et al. Asymptomatic deep vein thrombosis is associated with an increased risk of death: insights from the APEX trial. Thromb Haemost. 2018;118(12):2046&#x2013;2052. doi: 10.1055/s-0038-1675606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1675606</ArticleId><ArticleId IdType="pubmed">30419597</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (2015) Guideline on clinical investigation of medicinal products for prevention of venous thromboembolism (VTE) in patients undergoing high VTE-risk surgery. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-productsprevention-venous-thromboembolism-vte-patients_en.pdf. Accessed May 2022</Citation></Reference><Reference><Citation>Morris RJ, Woodcock JP. Intermittent pneumatic compression or graduated compression stockings for deep vein thrombosis prophylaxis? A systematic review of direct clinical comparisons. Ann Surg. 2010;251(3):393&#x2013;396. doi: 10.1097/SLA.0b013e3181b5d61c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181b5d61c</ArticleId><ArticleId IdType="pubmed">20083996</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda H. Bilateral peroneal nerve palsy caused by intermittent pneumatic compression. Intern Med. 2006;45(2):93&#x2013;94. doi: 10.2169/internalmedicine.45.1459.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.45.1459</ArticleId><ArticleId IdType="pubmed">16484746</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachmann EA, Rook JL, Tunkel R, Nagler W. Complications associated with intermittent pneumatic compression. Arch Phys Med Rehabil. 1992;73(5):482&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">1580778</ArticleId></ArticleIdList></Reference><Reference><Citation>Nouh T, Alsabahi T, Altoijry A, Altuwaijri T. Can intermittent pneumatic compression cause compartment syndrome? Saudi J Anaesth. 2018;12(3):488&#x2013;490. doi: 10.4103/sja.SJA_191_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/sja.SJA_191_18</ArticleId><ArticleId IdType="pmc">PMC6044165</ArticleId><ArticleId IdType="pubmed">30100856</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra RO, Farber R, Feigl A. Pressure necrosis from intermittent-pneumatic-compression stockings. N Engl J Med. 1989;321(23):1615. doi: 10.1056/NEJM198912073212316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198912073212316</ArticleId><ArticleId IdType="pubmed">2586562</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi YM, Al-Hameed F, Burns KEA, Mehta S, Alsolamy SJ, Alshahrani MS, et al. Adjunctive intermittent pneumatic compression for venous thromboprophylaxis. N Engl J Med. 2019;380(14):1305&#x2013;1315. doi: 10.1056/NEJMoa1816150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1816150</ArticleId><ArticleId IdType="pubmed">30779530</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaboration CT, Dennis M, Sandercock P, Reid J, Graham C, Forbes J, et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet (London, England) 2013;382(9891):516&#x2013;524. doi: 10.1016/S0140-6736(13)61050-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61050-8</ArticleId><ArticleId IdType="pubmed">23727163</ArticleId></ArticleIdList></Reference><Reference><Citation>Barakat-Johnson M, Barnett C, Wand T, White K. Medical device-related pressure injuries: an exploratory descriptive study in an acute tertiary hospital in Australia. J Tissue Viability. 2017;26(4):246&#x2013;253. doi: 10.1016/j.jtv.2017.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtv.2017.09.008</ArticleId><ArticleId IdType="pubmed">29050901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalodiki EP, Hoppensteadt DA, Nicolaides AN, Fareed J, Gill K, Regan F et al (1996) Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. Int Angiol 15(2):162&#x2013;168</Citation><ArticleIdList><ArticleId IdType="pubmed">8803642</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz SL, Stechemesser B, Seeberger U, Meyer D, Kesselring C. Graduated compression stockings for the prevention of venous thromboembolism in surgical patients in the age of low molecular weight heparins. J Thromb Haemost. 2005;3(10):2363&#x2013;2365. doi: 10.1111/j.1538-7836.2005.01574.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01574.x</ArticleId><ArticleId IdType="pubmed">16194216</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalhoub J, Lawton R, Hudson J, Baker C, Bradbury A, Dhillon K, et al. Graduated compression stockings as adjuvant to pharmaco-thromboprophylaxis in elective surgical patients (GAPS study): randomised controlled trial. BMJ. 2020;369:m1309. doi: 10.1136/bmj.m1309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1309</ArticleId><ArticleId IdType="pmc">PMC7219517</ArticleId><ArticleId IdType="pubmed">32404430</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalhoub J. Contracting role of graduated compression stockings in prevention of perioperative venous thromboembolism. Br J Surg. 2022;109(8):669&#x2013;670. doi: 10.1093/bjs/znac157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bjs/znac157</ArticleId><ArticleId IdType="pubmed">35594526</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32321692</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-3348</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of vascular surgery. Venous and lymphatic disorders</Title><ISOAbbreviation>J Vasc Surg Venous Lymphat Disord</ISOAbbreviation></Journal><ArticleTitle>A systematic review on internal jugular vein thrombosis and pulmonary embolism.</ArticleTitle><Pagination><StartPage>662</StartPage><EndPage>666</EndPage><MedlinePgn>662-666</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvsv.2020.03.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-333X(20)30183-9</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Whereas the internal jugular vein is the most common site of thrombosis in patients with deep venous thrombosis (DVT) of the upper extremity, the association between internal jugular vein thrombus and pulmonary embolism (PE) has not been clearly characterized. The objective of this paper was to determine the risk of embolization of an isolated internal jugular vein thrombus causing a clinically overt PE, with the secondary objective of assessing the value of therapeutic anticoagulation in patients with isolated internal jugular vein thrombosis (IJVT) in improving clinical outcomes.</AbstractText><AbstractText Label="METHODS">The National Center for Biotechnology Information, Cochrane Library, Web of Science, and Cumulative Index to Nursing and Allied Health Literature were searched for articles. The relevant articles included were selected according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies were included if they specifically examined incidence of IJVT and incidence of PE and were excluded if they did not report on these rates specifically or failed to specify the exact site of upper extremity DVT.</AbstractText><AbstractText Label="RESULTS">Of the 274 articles screened, 25 were selected for full review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses inclusion criteria. Seven of those provided adequate data and were included in the review. There were only two studies demonstrating IJVT before PE that could probably establish causality, but this might be confounded by the presence of concomitant upper extremity DVT in one of the cases and radiologic findings compatible with resolving PE in another that might have preceded the presence of internal jugular vein thrombus. In the patients who were found to have PE in the setting of IJVT, the overall observed mortality attributed to PE was low. In specific studies, the use of anticoagulation did not reduce the mortality in those with isolated IJVT or affect the rate of thrombus resolution while carrying the risk of bleeding complications in these patients, who often have severe comorbidities.</AbstractText><AbstractText Label="CONCLUSIONS">Despite the proximity of the jugular vein to the right side of the heart and the pulmonary vasculature, there is little proof of propagation of the thrombus to cause a clinically overt PE. Whereas current practice is to treat the patients with IJVT in the same way as patients with lower extremity DVTs are treated, the lack of any survival benefit in those with isolated IJVT and the risk of bleeding complications warrant further studies to characterize the need of medical management in this population of patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Society for Vascular Surgery. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Drakos</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Surgery, Vascular and Endovascular Surgery Division, Stony Brook University Hospital, Stony Brook, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Benjamin C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Surgery, Vascular and Endovascular Surgery Division, Stony Brook University Hospital, Stony Brook, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labropoulos</LastName><ForeName>Nicos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Surgery, Vascular and Endovascular Surgery Division, Stony Brook University Hospital, Stony Brook, NY. Electronic address: nlabrop@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Surg Venous Lymphat Disord</MedlineTA><NlmUniqueID>101607771</NlmUniqueID><ISSNLinking>2213-333X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007601" MajorTopicYN="Y">Jugular Veins</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Jugular veins</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Upper extremity deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">Venous thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32321692</ArticleId><ArticleId IdType="doi">10.1016/j.jvsv.2020.03.003</ArticleId><ArticleId IdType="pii">S2213-333X(20)30183-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40320917</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-1489</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>May</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of intensive care medicine</Title><ISOAbbreviation>J Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Risk Factors for Mortality in Patients with Pulmonary Embolism-A Meta-Analysis.</ArticleTitle><Pagination><StartPage>8850666251326539</StartPage><MedlinePgn>8850666251326539</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/08850666251326539</ELocationID><Abstract><AbstractText>BackgroundIn recent years, although there have been many domestic and international reports on risk factors for pulmonary embolism (PE), there has not yet been a comprehensive and systematic analysis of risk factors for death from PE In this study, we conducted a meta-analysis of the research literature on PE published from June 2012 to January 2024.AimThe aim of this study was to systematically and comprehensively assess the risk factors, association strength, and quality of evidence for death in patients with pulmonary embolism.MethodsThe search strategy was developed in accordance with the PICOS principles (P: Participant, ie, study subject; I: Intervention, ie, intervention; C: Comparison, ie, control group; O: ie, Outcome study endpoints; S: Study design, ie, study design), and the search strategy was developed through computerized searches of English databases (including PubMed, Web of Science, Cochrane Library,EMbase) and Chinese databases, including China Biomedical Literature Database (CBM), Wanfang Data Medical Journals Repository, Wipo Database and China Knowledge Network. The search period was from the construction of the database to January 2024.ResultsTwenty-four papers met the nadir criteria, and the total number of cases and controls were 8769 and 8,830, respectively. Meta-analysis showed that the Odds ratio (OR) for the risk of death from PE were: age &gt;70 years (1.65, 95% confidence interval 1.62 to 1.68), hyponatremia (2.68, 2.25 to 3.19), D-dimer(1.51, 1.38 to 1.67), Troponin I (3.56, 1.83 to 6.90), Malignancy (3.67, 3.01 to 4.48), Diabetes mellitus (1.58, 1.33 to 1.88), and S protein factor activity (0.72, 0.65 to 0.81). (See Table 3).ConclusionThe results of this study showed that age over 70, hyponatremia, D-dimer, troponin I, malignancy, diabetes, and decreased protein S activity are independent risk factors for acute death in patients with pulmonary embolism. However, controlling certain risk factors alone may not reduce the mortality of PE. First, many of the risk factors for PE death are not modifiable (age, diabetes, malignancy). Secondly, the association between a risk factor and mortality is not always causal. Efforts to address a risk factor may not result in improved outcomes if there is no causal link. Therefore, these risk factors can be tracked in future randomized controlled trial studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>You</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-0812-8933</Identifier><AffiliationInfo><Affiliation>Emergency Department Intensive Care Unit, Zigong Fourth People's Hospital, Zigong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Xiao-Yu</ForeName><Initials>XY</Initials><Identifier Source="ORCID">0000-0003-3871-2831</Identifier><AffiliationInfo><Affiliation>Department of General Surgery, Zigong Fourth People's Hospital, Zigong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6634-0089</Identifier><AffiliationInfo><Affiliation>Department of Nursing, Zigong Fourth People's Hospital, Zigong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xue-Lian</ForeName><Initials>XL</Initials><Identifier Source="ORCID">0000-0002-9339-5827</Identifier><AffiliationInfo><Affiliation>Emergency Department Intensive Care Unit, Zigong Fourth People's Hospital, Zigong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0004-9139-7708</Identifier><AffiliationInfo><Affiliation>Emergency Department Intensive Care Unit, Zigong Fourth People's Hospital, Zigong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Chen-Cong</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0002-5895-1429</Identifier><AffiliationInfo><Affiliation>Department of Nursing, Zigong Fourth People's Hospital, Zigong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0009-0006-5105-6276</Identifier><AffiliationInfo><Affiliation>Emergency Department Intensive Care Unit, Zigong Fourth People's Hospital, Zigong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Intensive Care Med</MedlineTA><NlmUniqueID>8610344</NlmUniqueID><ISSNLinking>0885-0666</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">case-control</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">risk factors for death</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>5</Day><Hour>3</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40320917</ArticleId><ArticleId IdType="doi">10.1177/08850666251326539</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28370756</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0347</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Head &amp; neck</Title><ISOAbbreviation>Head Neck</ISOAbbreviation></Journal><ArticleTitle>Systematic review and meta-analysis of venous thromboembolism in otolaryngology-head and neck surgery.</ArticleTitle><Pagination><StartPage>1249</StartPage><EndPage>1258</EndPage><MedlinePgn>1249-1258</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/hed.24758</ELocationID><Abstract><AbstractText Label="BACKGROUND">The purpose of this study was to present our systematic review and meta-analysis of the data on venous thromboembolism (VTE; deep venous thrombosis [DVT] and/or pulmonary embolism [PE]) in otolaryngology-head and neck surgery (OHNS).</AbstractText><AbstractText Label="METHODS">PubMed and Scopus databases were searched for studies reporting VTE in OHNS. Incidence of VTE and bleeding is reported and meta-analyzed overall and for chemoprophylaxis and squamous cell carcinoma (SCC)/free flap subgroups.</AbstractText><AbstractText Label="RESULTS">A total of 23 studies were included with a total of 618,264 patients. Incidence of VTE was 0.4%. The incidence of bleeding complications was 0.9%. The addition of chemoprophylaxis did not result in a decreased VTE incidence (odds ratio [OR], 0.86), but produced an increased risk of bleeding (OR, 3.78). The overall OR for VTE in SCC/free flap cases was 6.28.</AbstractText><AbstractText Label="CONCLUSION">Chemoprophylaxis may not be necessary in the OHNS non-SCC or free flap patient population and must be balanced against an increased risk of bleeding. &#xa9; 2017 Wiley Periodicals, Inc. Head Neck 39: 1249-1258, 2017.</AbstractText><CopyrightInformation>&#xa9; 2017 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moubayed</LastName><ForeName>Sami P</ForeName><Initials>SP</Initials><Identifier Source="ORCID">0000-0002-6835-2155</Identifier><AffiliationInfo><Affiliation>Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eskander</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4326-1393</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mourad</LastName><ForeName>Moustafa W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, New York Eye and Ear Infirmary of Mount Sinai, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Most</LastName><ForeName>Sam P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology - Head and Neck Surgery, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Head Neck</MedlineTA><NlmUniqueID>8902541</NlmUniqueID><ISSNLinking>1043-3074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006258" MajorTopicYN="N">Head and Neck Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010038" MajorTopicYN="N">Otorhinolaryngologic Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010039" MajorTopicYN="N">Otorhinolaryngologic Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013517" MajorTopicYN="N">Otorhinolaryngologic Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">otolaryngology</Keyword><Keyword MajorTopicYN="N">thromboembolic</Keyword><Keyword MajorTopicYN="N">thromboembolism</Keyword><Keyword MajorTopicYN="N">thromboprophylaxis</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28370756</ArticleId><ArticleId IdType="doi">10.1002/hed.24758</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36512031</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1863-9941</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European journal of trauma and emergency surgery : official publication of the European Trauma Society</Title><ISOAbbreviation>Eur J Trauma Emerg Surg</ISOAbbreviation></Journal><ArticleTitle>Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1247</StartPage><EndPage>1258</EndPage><MedlinePgn>1247-1258</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00068-022-02180-x</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Anemia is one of the most common complications after hip fracture surgery. Tranexamic acid (TXA) has been considered effective in preventing anemia in total hip arthroplasty, but its role in hemiarthroplasty is debated. The aim of this systematic review was to investigate the efficacy and safety of perioperative TXA for hip hemiarthroplasty.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature search was performed to identify studies comparing adult patients who underwent hemiarthroplasty for a hip fracture with and without perioperative TXA. The primary outcome was transfusion rate. Secondary outcomes included postoperative hemoglobin, length of hospital stay, adverse events (i.e., deep venous thromboses and pulmonary embolism), and 30-day mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 13 articles were included, comprising 54,843 patients of whom 14.1% received perioperative TXA. TXA was applied intravenous in ten studies, topical in two studies, one study investigated both. Pooled results showed a significant reduction in transfusion rate (pooled RR: 0.48, 95% CI 0.40-0.58, p&#x2009;&lt;&#x2009;0.01). Postoperative hemoglobin and length of stay were investigated in nine studies, pooled results showed significant improvement of both outcomes for patients that received TXA. Eleven studies investigated thromboembolic events, and there was no statistical difference in deep venous thromboses (pooled RR: 0.67, 95% CI 0.18-2.56, p&#x2009;=&#x2009;0.56) or pulmonary embolism (pooled RR: 1.10, 95% CI 0.45-2.68, p&#x2009;=&#x2009;0.83)&#xa0;among the two groups. There was a significant reduction in 30-day mortality for patients that received TXA.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TXA can be considered effective and safe for&#xa0;patients undergoing hip hemiarthroplasty, with a reduction in transfusion rate and increase in postoperative hemoglobin, without increasing adverse events. Optimal timing, dosage, and type of administration of TXA remain unclear.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Augustinus</LastName><ForeName>Simone</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0625-4349</Identifier><AffiliationInfo><Affiliation>Department of Trauma Surgery, OLVG Hospital, Jan Tooropstraat 164, 1061 AE, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulders</LastName><ForeName>Marjolein A M</ForeName><Initials>MAM</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, OLVG Hospital, Jan Tooropstraat 164, 1061 AE, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardenbroek</LastName><ForeName>Tjibbe J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, OLVG Hospital, Jan Tooropstraat 164, 1061 AE, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goslings</LastName><ForeName>J Carel</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, OLVG Hospital, Jan Tooropstraat 164, 1061 AE, Amsterdam, The Netherlands. j.c.goslings@olvg.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Trauma Emerg Surg</MedlineTA><NlmUniqueID>101313350</NlmUniqueID><ISSNLinking>1863-9933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="Y">Tranexamic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="Y">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062785" MajorTopicYN="Y">Hemiarthroplasty</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000740" MajorTopicYN="Y">Anemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="Y">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hemiarthroplasty</Keyword><Keyword MajorTopicYN="N">Hip fracture</Keyword><Keyword MajorTopicYN="N">Systematic review and meta-analysis</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>13</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36512031</ArticleId><ArticleId IdType="doi">10.1007/s00068-022-02180-x</ArticleId><ArticleId IdType="pii">10.1007/s00068-022-02180-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA. 2009;302(14):1573&#x2013;9. https://doi.org/10.1001/jama.2009.1462 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.1462</ArticleId><ArticleId IdType="pubmed">19826027</ArticleId><ArticleId IdType="pmc">4410861</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpintero P, Caeiro JR, Carpintero R, Morales A, Silva S, Mesa M. Complications of hip fractures: a review. World J Orthop. 2014;5(4):402&#x2013;11. https://doi.org/10.5312/wjo.v5.i4.402 .</Citation><ArticleIdList><ArticleId IdType="doi">10.5312/wjo.v5.i4.402</ArticleId><ArticleId IdType="pubmed">25232517</ArticleId><ArticleId IdType="pmc">4133447</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss NB, Kristensen MT, Kehlet H. Anaemia impedes functional mobility after hip fracture surgery. Age Ageing. 2008;37(2):173&#x2013;8. https://doi.org/10.1093/ageing/afm161 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afm161</ArticleId><ArticleId IdType="pubmed">18349013</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosk CA, Mus M, Vroemen JP, et al. Dementia and delirium, the outcomes in elderly hip fracture patients. Clin Interv Aging. 2017;12:421&#x2013;30. https://doi.org/10.2147/CIA.S115945 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S115945</ArticleId><ArticleId IdType="pubmed">28331300</ArticleId><ArticleId IdType="pmc">5354532</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113(15):3406&#x2013;17. https://doi.org/10.1182/blood-2008-10-167643 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-10-167643</ArticleId><ArticleId IdType="pubmed">19188662</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuesta-Peredo D, Arteaga-Moreno F, Belenguer-Varea &#xc1;, et al. Influence of hospital adverse events and previous diagnoses on hospital care cost of patients with hip fracture. Arch Osteoporos. 2019;14(1):88. https://doi.org/10.1007/s11657-019-0638-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-019-0638-6</ArticleId><ArticleId IdType="pubmed">31402396</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillingham YA, Ramkumar DB, Jevsevar DS, et al. The safety of tranexamic acid in total joint arthroplasty: a direct meta-analysis. J Arthroplasty. 2018;33(10):3070-3082.e1. https://doi.org/10.1016/j.arth.2018.03.031 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2018.03.031</ArticleId><ArticleId IdType="pubmed">29699826</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, Ma X-L, Ma J-X. Efficiency and safety of intravenous tranexamic acid in simultaneous bilateral total knee arthroplasty: a systematic review and meta-analysis. Orthop Surg. 2016;8(3):285&#x2013;93. https://doi.org/10.1111/os.12256 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/os.12256</ArticleId><ArticleId IdType="pubmed">27627710</ArticleId><ArticleId IdType="pmc">6584435</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Jt Surg Br. 2011;93(1):39&#x2013;46. https://doi.org/10.1302/0301-620X.93B1.24984 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.93B1.24984</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Zhang H, Zhang Z, Ma C, Feng X. Comparison of bipolar hemiarthroplasty and total hip arthroplasty for displaced femoral neck fractures in the healthy elderly: a meta-analysis. BMC Musculoskelet Disord. 2015;16:229. https://doi.org/10.1186/s12891-015-0696-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-015-0696-x</ArticleId><ArticleId IdType="pubmed">26316274</ArticleId><ArticleId IdType="pmc">4552391</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GH, Tsang J, Molyneux SG, White TO. The hidden blood loss after hip fracture. Injury. 2011;42(2):133&#x2013;5. https://doi.org/10.1016/j.injury.2010.02.015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2010.02.015</ArticleId><ArticleId IdType="pubmed">20236640</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss NB, Kehlet H. Hidden blood loss after surgery for hip fracture. J Bone Jt Surg Br. 2006;88(8):1053&#x2013;9. https://doi.org/10.1302/0301-620X.88B8.17534 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.88B8.17534</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C, Freeman R, Edmondson M, Rogers BA. The efficacy of tranexamic acid in hip hemiarthroplasty surgery: an observational cohort study. Injury. 2015;46(10):1978&#x2013;82. https://doi.org/10.1016/j.injury.2015.06.039 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2015.06.039</ArticleId><ArticleId IdType="pubmed">26190627</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak DK, Jang CY, Kim DH, Rhyu SH, Hwang JH, Yoo JH. Topical tranexamic acid in elderly patients with femoral neck fractures treated with hemiarthroplasty: efficacy and safety? A case-control study. BMC Musculoskelet Disord. 2019;20(1):1&#x2013;9. https://doi.org/10.1186/s12891-019-2615-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-019-2615-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7): e1000097. https://doi.org/10.1371/journal.pmed.1000097 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId><ArticleId IdType="pmc">2707599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https://doi.org/10.1136/bmj.l4898 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712&#x2013;6. https://doi.org/10.1046/j.1445-2197.2003.02748.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1445-2197.2003.02748.x</ArticleId><ArticleId IdType="pubmed">12956787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. https://doi.org/10.1186/1471-2288-14-135 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-135</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId><ArticleId IdType="pmc">4383202</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539&#x2013;58. https://doi.org/10.1002/sim.1186 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1186</ArticleId><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Narkbunnam R, Chompoonutprapa A, Ruangsomboon P, Udomkiat P, Chareancholvanich K, Pornrattanamaneewong C. Blood loss and transfusion rate compared among different dosing regimens of tranexamic acid administration in patients undergoing hip hemiarthroplasty for femoral neck fracture: a randomized controlled trial. Injury. 2021;52(10):2986&#x2013;90. https://doi.org/10.1016/j.injury.2021.08.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2021.08.001</ArticleId><ArticleId IdType="pubmed">34384597</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaou VS, Masouros P, Floros T, Chronopoulos E, Skertsou M, Babis GC. Single dose of tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients undergoing surgery for hip fracture: a randomized controlled trial. Bone Joint J. 2021;103-B(3):442&#x2013;448. https://doi.org/10.1302/0301-620X.103B3.BJJ-2020-1288.R1</Citation></Reference><Reference><Citation>Thipparampall AK, Gurajala I, Gopinath R. The effect of different dose regimens of tranexamic acid in reducing blood loss during hip surgery. Indian J Anaesth. 2017;61(3):235&#x2013;9. https://doi.org/10.4103/ija.IJA_495_16 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ija.IJA_495_16</ArticleId><ArticleId IdType="pubmed">28405037</ArticleId><ArticleId IdType="pmc">5372404</ArticleId></ArticleIdList></Reference><Reference><Citation>Emara WM, Moez KK, Elkhouly AH. Topical versus intravenous tranexamic acid as a blood conservation intervention for reduction of post-operative bleeding in hemiarthroplasty. Anesth Essays Res. 2014;8(1):48&#x2013;53. https://doi.org/10.4103/0259-1162.128908 .</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0259-1162.128908</ArticleId><ArticleId IdType="pubmed">25886103</ArticleId><ArticleId IdType="pmc">4173581</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashkenazi I, Schermann H, Gold A, et al. Tranexamic acid in hip hemiarthroplasty. Injury. 2020;51(11):2658&#x2013;62. https://doi.org/10.1016/j.injury.2020.07.061 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2020.07.061</ArticleId><ArticleId IdType="pubmed">32763019</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung ZB, Anthony SG, Forsh DA, et al. Utilization, effectiveness, and safety of tranexamic acid use in hip fracture surgery: a population-based study. J Orthop. 2020;20:167&#x2013;72. https://doi.org/10.1016/j.jor.2020.01.040 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jor.2020.01.040</ArticleId><ArticleId IdType="pubmed">32025142</ArticleId><ArticleId IdType="pmc">6997115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahan JB, Morris J, Li D, Moran J, O&#x2019;Connor MI. Expanded use of tranexamic acid is safe and decreases transfusion rates in patients with geriatric hip fractures. OTA Int Open Access J Orthop Trauma. 2021;4(4): e147. https://doi.org/10.1097/OI9.0000000000000147 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/OI9.0000000000000147</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rijckevorsel VAJIM, Roukema GR, Kuijper TM, de Jong L. Clinical outcomes of tranexamic acid in acute hip hemiarthroplasties in frail geriatric patients. Orthop Traumatol Surg Res. 2022;108(5):103219. https://doi.org/10.1016/j.otsr.2022.103219 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2022.103219</ArticleId><ArticleId IdType="pubmed">35093562</ArticleId></ArticleIdList></Reference><Reference><Citation>Viberg B, Gundtoft PH, Sch&#xf8;nnemann JO, et al. Is tranexamic acid use in patients with a hip fracture safe? Bone Jt J. 2021;103-B(3):449&#x2013;55. https://doi.org/10.1302/0301-620X.103B3.BJJ-2020-1375.R2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.103B3.BJJ-2020-1375.R2</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Hu Q, Huang Q, Chen G, Zhou Z, Pei F. Efficacy and safety of tranexamic acid in geriatric hip fracture with hemiarthroplasty: a retrospective cohort study. BMC Musculoskelet Disord. 2019;20(1):1&#x2013;9. https://doi.org/10.1186/s12891-019-2670-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-019-2670-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Hui H, Zhang Y, Lin W, Fan Y. Intra-articular tranexamic acid injection during the hip hemi-arthroplasty in elderly patients: a retrospective study. Geriatr Orthop Surg Rehabil. 2018;9:215145931880385. https://doi.org/10.1177/2151459318803851 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2151459318803851</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillingham YA, Ramkumar DB, Jevsevar DS, et al. Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and. Reg Anesth Pain Med. 2019;44(1):7&#x2013;11. https://doi.org/10.1136/rapm-2018-000024 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rapm-2018-000024</ArticleId><ArticleId IdType="pubmed">30640647</ArticleId></ArticleIdList></Reference><Reference><Citation>Shichman I, Shaked O, Ashkenazi I, Schwarzkopf R, Warschawski Y, Snir N. Tranexamic acid in non-elective primary total hip arthroplasty. Injury. 2021;52(6):1544&#x2013;8. https://doi.org/10.1016/j.injury.2020.10.056 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2020.10.056</ArticleId><ArticleId IdType="pubmed">33092856</ArticleId></ArticleIdList></Reference><Reference><Citation>Haj-Younes B, Sivakumar BS, Wang M, An VV, Lorentzos P, Adie S. Tranexamic acid in hip fracture surgery: a systematic review and meta-analysis. J Orthop Surg (Hong Kong). 2020;28(1):2309499019887995. https://doi.org/10.1177/2309499019887995 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2309499019887995</ArticleId><ArticleId IdType="pubmed">31835969</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrow LS, Smith TO, Ashcroft GP, Myint PK. A systematic review of tranexamic acid in hip fracture surgery. Br J Clin Pharmacol. 2016;82(6):1458&#x2013;70. https://doi.org/10.1111/bcp.13079 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13079</ArticleId><ArticleId IdType="pubmed">27492116</ArticleId><ArticleId IdType="pmc">5099561</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y-M, Wang H-P, Li Y-J, et al. The efficacy and safety of intravenous tranexamic acid in hip fracture surgery: a systematic review and meta-analysis. J Orthop Transl. 2019;19:1&#x2013;11. https://doi.org/10.1016/j.jot.2019.03.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jot.2019.03.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing F, Chen W, Long C, Huang F, Wang G, Xiang Z. Postoperative outcomes of tranexamic acid use in geriatric trauma patients treated with proximal femoral intramedullary nails: a systematic review and meta-analysis. Orthop Traumatol Surg Res. 2020;106(1):117&#x2013;26. https://doi.org/10.1016/j.otsr.2019.10.015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2019.10.015</ArticleId><ArticleId IdType="pubmed">31928976</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Huang H, Tang X. Efficacy and safety of tranexamic acid for reducing blood loss in elderly patients with intertrochanteric fracture treated with intramedullary fixation surgery: a meta-analysis of randomized controlled trials. Acta Orthop Traumatol Turc. 2020;54(1):4&#x2013;14. https://doi.org/10.5152/j.aott.2020.01.88 .</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/j.aott.2020.01.88</ArticleId><ArticleId IdType="pubmed">32175891</ArticleId><ArticleId IdType="pmc">7243694</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruah RK, Borah PJ, Haque R. Use of tranexamic acid in dynamic hip screw plate fixation for trochanteric fractures. J Orthop Surg (Hong Kong). 2016;24(3):379&#x2013;82. https://doi.org/10.1177/1602400322 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1602400322</ArticleId><ArticleId IdType="pubmed">28031511</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon B-H, Kim T-Y, Ko YS, Lee Y-K, Ha Y-C, Koo K-H. Optimal use of tranexamic acid for total hip arthroplasty: a network meta-analysis. PLoS&#xa0;One. 2018;13(10): e0206480. https://doi.org/10.1371/journal.pone.0206480 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0206480</ArticleId><ArticleId IdType="pubmed">30379905</ArticleId><ArticleId IdType="pmc">6209331</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong H, Liu Y, Zeng Y, Wu Y, Shen B. The efficacy and safety of combined administration of intravenous and topical tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2018;19(1):321. https://doi.org/10.1186/s12891-018-2181-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-018-2181-9</ArticleId><ArticleId IdType="pubmed">30193586</ArticleId><ArticleId IdType="pmc">6129000</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z-J, Fu X, Xing D, Zhang H-F, Zang J-C, Ma X-L. Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc. 2013;22(9):1950&#x2013;7. https://doi.org/10.1007/s00586-013-2774-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00586-013-2774-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Porter SB, Spaulding AC, Duncan CM, Wilke BK, Pagnano MW, Abdel MP. Tranexamic acid was not associated with increased complications in high-risk patients with hip fracture undergoing arthroplasty. J Bone Jt Surg Am. 2021;103(20):1880&#x2013;9. https://doi.org/10.2106/JBJS.21.00172 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.21.00172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jules-Elysee KM, Tseng A, Sculco TP, et al. Comparison of topical and intravenous tranexamic acid for total knee replacement: a randomized double-blinded controlled study of effects on tranexamic acid levels and thrombogenic and inflammatory marker levels. J Bone Jt Surg Am. 2019;101(23):2120&#x2013;8. https://doi.org/10.2106/JBJS.19.00258 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.19.00258</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiganti M, Pipitone O, Than J, Stanley R, Passanise A, Krumrey J. A single dose versus two doses of tranexamic acid for extracapsular hip fractures. Cureus. 2022;14(1): e21239. https://doi.org/10.7759/cureus.21239 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.21239</ArticleId><ArticleId IdType="pubmed">35174034</ArticleId><ArticleId IdType="pmc">8841038</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Zhang W, Chang Q, Li Y. Combination effect of intraoperative and postoperative intravenous tranexamic acid in hip hemiarthroplasty. A propensity score matched analysis. Injury. 2022;53(10):3401&#x2013;6. https://doi.org/10.1016/j.injury.2022.07.033 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2022.07.033</ArticleId><ArticleId IdType="pubmed">35922338</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson JL, Stanworth SJ, Dennis JA, et al. Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev. 2021;12:CD002042. https://doi.org/10.1002/14651858.CD002042.pub5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002042.pub5</ArticleId><ArticleId IdType="pubmed">34932836</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim YE, Sim S-ED, Seng C, Howe TS, Koh SB, Abdullah HR. Preoperative anemia, functional outcomes, and quality of life after hip fracture surgery. J Am Geriatr Soc. 2018;66(8):1524&#x2013;31. https://doi.org/10.1111/jgs.15428 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.15428</ArticleId><ArticleId IdType="pubmed">30091139</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37839150</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2472</ISSN><JournalIssue CitedMedium="Internet"><Volume>231</Volume><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Thrombosis research</Title><ISOAbbreviation>Thromb Res</ISOAbbreviation></Journal><ArticleTitle>Anticoagulation in chronic thromboembolic pulmonary hypertension: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>91</StartPage><EndPage>98</EndPage><MedlinePgn>91-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.thromres.2023.10.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-3848(23)00280-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Life-long anticoagulation is the recommended management for chronic thromboembolic pulmonary hypertension (CTEPH). Evidence regarding the use of direct oral anticoagulants (DOAC) for CTEPH is yet to be established. We performed a systematic review and meta-analysis to clarify the outcomes of CTEPH in patients who used DOAC or vitamin K antagonists (VKA).</AbstractText><AbstractText Label="METHODS">We reviewed literature in PubMed and EMBASE through March 2023. We included studies involving patients with CTEPH where DOAC and VKA were compared. We collected data including intervention history for CTEPH, bleeding events, recurrence of VTE (venous thromboembolism), and mortality. We performed a meta-analysis using the Mantel-Haenszel method with a fixed-effects model.</AbstractText><AbstractText Label="RESULTS">We included one randomized clinical trial and six observational studies, with a total of 2969 patients. Six studies investigated major bleeding outcomes, and seven investigated all bleeding outcomes. There were no differences in major bleeding (RR 0.59, 95&#xa0;% CI [0.34-1.02], I<sup>2</sup>&#xa0;=&#xa0;0&#xa0;%) and all-bleeding (RR 0.87, 95&#xa0;% CI [0.67-1.13], I<sup>2</sup>&#xa0;=&#xa0;0&#xa0;%). Based on the five studies we included, DOAC was associated with a lower risk of mortality (RR 0.54, 95&#xa0;% CI: 0.37-0.79, I<sup>2</sup>&#xa0;=&#xa0;5&#xa0;%). However, a higher risk of recurrent pulmonary embolism (PE) was seen in three studies (RR 3.80, 95&#xa0;% CI: [1.93-7.50], I<sup>2</sup>&#xa0;=&#xa0;11&#xa0;%). No significant differences were noted in terms of VTE.</AbstractText><AbstractText Label="CONCLUSION">DOAC compared to VKA was associated with a significantly lower mortality and higher risk of recurrent PE. Since most of the included studies are observational, we must consider the existence of multiple biases and confounding factors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishisaka</LastName><ForeName>Yoshiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine, Mount Sinai Beth Israel, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Atsuyuki</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Mount Sinai Beth Israel, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Hisato</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiger</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuno</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA; Division of Cardiology, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY, USA. Electronic address: tkuno@montefiore.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Thromb Res</MedlineTA><NlmUniqueID>0326377</NlmUniqueID><ISSNLinking>0049-3848</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12001-79-5</RegistryNumber><NameOfSubstance UI="D014812">Vitamin K</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001777" MajorTopicYN="N">Blood Coagulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014812" MajorTopicYN="N">Vitamin K</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic thromboembolic pulmonary hypertension</Keyword><Keyword MajorTopicYN="N">Direct oral anticoagulants</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword><Keyword MajorTopicYN="N">Vitamin K antagonists</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>16</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>15</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37839150</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2023.10.003</ArticleId><ArticleId IdType="pii">S0049-3848(23)00280-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36788620</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-799X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of orthopaedic surgery and research</Title><ISOAbbreviation>J Orthop Surg Res</ISOAbbreviation></Journal><ArticleTitle>Venous thromboembolism after arthroscopic shoulder surgery: a systematic review.</ArticleTitle><Pagination><StartPage>103</StartPage><MedlinePgn>103</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13018-023-03592-0</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To summarize the incidence, risk factors, diagnosis methods, prophylaxis methods, and treatment of venous thromboembolism (VTE) following arthroscopic shoulder surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Literature on VTE after arthroscopic shoulder surgeries was summarized, and all primary full-text articles reporting at least 1 case of deep vein thrombosis (DVT) or pulmonary embolism (PE) after arthroscopic shoulder surgeries were included. Articles were critically appraised and systematically analyzed to determine the incidence, risk factors, diagnosis, prophylaxis, and management of VTE following arthroscopic shoulder surgeries.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This study included 42 articles in which the incidence of VTE ranges from 0 to 5.71% and the overall incidence was 0.26%. Most VTE events took place between the operation day and the 14th day after the operation (35/51). Possible risk factors included advanced age (&gt;&#x2009;70&#xa0;years), obesity (BMI&#x2009;&#x2265;&#x2009;30&#xa0;kg/m<sup>2</sup>), diabetes mellitus, thrombophilia, history of VTE, prolonged operation time, hormone use, and immobilization after surgery. The most common prophylaxis method was mechanical prophylaxis (13/15). No statistical difference was detected when chemoprophylaxis was applied. The management included heparinization followed by oral warfarin, warfarin alone and rivaroxaban, a direct oral anticoagulant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Based on the included studies, the incidence rate of VTE after arthroscopic shoulder surgeries is relatively low. The risk factors for VTE are still unclear. CT/CTA and ultrasound were the mainstream diagnosis methods for PE and DVT, respectively. Current evidence shows that chemical prophylaxis did not deliver significant benefits, since none of the existing studies reported statistically different results. High-quality studies focusing on the prophylaxis and management of VTE population undergoing arthroscopic shoulder surgeries should be done in the future.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, No. 37, Guoxue Road, Wuhou District, Chengdu, 610041, Sichuan Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Yinghao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, No. 37, Guoxue Road, Wuhou District, Chengdu, 610041, Sichuan Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linmin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>West China School of Medicine, Sichuan University, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Long</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, No. 37, Guoxue Road, Wuhou District, Chengdu, 610041, Sichuan Province, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, No. 37, Guoxue Road, Wuhou District, Chengdu, 610041, Sichuan Province, People's Republic of China. tangxin9388@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, West China Hospital, West China School of Nursing, Sichuan University, No. 37, Guoxue Road, Wuhou District, Chengdu, Sichuan Province, People's Republic of China. zhu-jing2008@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82072514</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2021YFS0238</GrantID><Agency>Science &amp; Technology Department of Sichuan Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Orthop Surg Res</MedlineTA><NlmUniqueID>101265112</NlmUniqueID><ISSNLinking>1749-799X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber><NameOfSubstance UI="D014859">Warfarin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NDF7JZ4M3</RegistryNumber><NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012782" MajorTopicYN="N">Shoulder</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Arthroscopic shoulder surgery</Keyword><Keyword MajorTopicYN="N">Prophylaxis</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36788620</ArticleId><ArticleId IdType="pmc">PMC9927062</ArticleId><ArticleId IdType="doi">10.1186/s13018-023-03592-0</ArticleId><ArticleId IdType="pii">10.1186/s13018-023-03592-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Urwin M, Symmons D, Allison T, Brammah T, Busby H, Roxby M, et al. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. Ann Rheum Dis. 1998;57(11):649&#x2013;655. doi: 10.1136/ard.57.11.649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.57.11.649</ArticleId><ArticleId IdType="pmc">PMC1752494</ArticleId><ArticleId IdType="pubmed">9924205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropars M, Thomazeau H, Huten D. Clavicle fractures. Orthop Traumatol Surg Res. 2017;103(1s):S53&#x2013;S59. doi: 10.1016/j.otsr.2016.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2016.11.007</ArticleId><ArticleId IdType="pubmed">28043849</ArticleId></ArticleIdList></Reference><Reference><Citation>Launonen AP, Lepola V, Saranko A, Flinkkil&#xe4; T, Laitinen M, Mattila VM. Epidemiology of proximal humerus fractures. Arch Osteoporos. 2015;10:209. doi: 10.1007/s11657-015-0209-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-015-0209-4</ArticleId><ArticleId IdType="pubmed">25675881</ArticleId></ArticleIdList></Reference><Reference><Citation>Thigpen CA, Shaffer MA, Gaunt BW, Leggin BG, Williams GR, Wilcox RB., 3rd The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. J Shoulder Elbow Surg. 2016;25(4):521&#x2013;535. doi: 10.1016/j.jse.2015.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2015.12.018</ArticleId><ArticleId IdType="pubmed">26995456</ArticleId></ArticleIdList></Reference><Reference><Citation>Best MJ, Tanaka MJ. Multidirectional instability of the shoulder: treatment options and considerations. Sports Med Arthrosc Rev. 2018;26(3):113&#x2013;119. doi: 10.1097/JSA.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JSA.0000000000000199</ArticleId><ArticleId IdType="pubmed">30059445</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakoc Y, Atalay &#xcf;B. Comparison of mini-open versus all-arthroscopic rotator cuff repair: retrospective analysis of a single center. Pan Afr Med J. 2020;37:132. doi: 10.11604/pamj.2020.37.132.19491.</Citation><ArticleIdList><ArticleId IdType="doi">10.11604/pamj.2020.37.132.19491</ArticleId><ArticleId IdType="pmc">PMC7757326</ArticleId><ArticleId IdType="pubmed">33425165</ArticleId></ArticleIdList></Reference><Reference><Citation>Black EM, Austin LS, Narzikul A, Seidl AJ, Martens K, Lazarus MD. Comparison of implant cost and surgical time in arthroscopic transosseous and transosseous equivalent rotator cuff repair. J Shoulder Elbow Surg. 2016;25(9):1449&#x2013;1456. doi: 10.1016/j.jse.2016.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2016.01.003</ArticleId><ArticleId IdType="pubmed">27068378</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein WJ, Pean CA, Colvin AC. Shoulder arthroscopy in adults 60 or older: risk factors that correlate with postoperative complications in the first 30 days. Arthroscopy. 2017;33(1):49&#x2013;54. doi: 10.1016/j.arthro.2016.05.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2016.05.035</ArticleId><ArticleId IdType="pubmed">27496681</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields E, Thirukumaran C, Thorsness R, Noyes K, Voloshin I. An analysis of adult patient risk factors and complications within 30 days after arthroscopic shoulder surgery. Arthroscopy. 2015;31(5):807&#x2013;815. doi: 10.1016/j.arthro.2014.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2014.12.011</ArticleId><ArticleId IdType="pubmed">25661861</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen AR, Cha PS, Devana SK, Ishmael C, Di Pauli von Treuheim T, D&#x2019;Oro A, et al. Evaluation of the trends, concomitant procedures, and complications with open and arthroscopic rotator cuff repairs in the medicare population. Orthop J Sports Med. 2017 doi: 10.1177/2325967117731310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2325967117731310</ArticleId><ArticleId IdType="pmc">PMC5639972</ArticleId><ArticleId IdType="pubmed">29051905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly BC, Constantinescu DS, Vap AR. Arthroscopic and open or mini-open rotator cuff repair trends and complication rates among American board of orthopaedic surgeons part II examinees (2007&#x2013;2017) Arthroscopy. 2019;35(11):3019&#x2013;3024. doi: 10.1016/j.arthro.2019.06.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2019.06.022</ArticleId><ArticleId IdType="pubmed">31699252</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp CM, Shields EJ, Wiater BP, Wiater JM. Venous thromboembolism after shoulder arthoplasty and arthroscopy. J Am Acad Orthop Surg. 2019;27(8):265&#x2013;274. doi: 10.5435/JAAOS-D-17-00763.</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/JAAOS-D-17-00763</ArticleId><ArticleId IdType="pubmed">30480588</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn SR. The post-thrombotic syndrome. Hematol Am Soc Hematol Educ Program. 2016;2016(1):413&#x2013;418. doi: 10.1182/asheducation-2016.1.413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/asheducation-2016.1.413</ArticleId><ArticleId IdType="pmc">PMC6142466</ArticleId><ArticleId IdType="pubmed">27913509</ArticleId></ArticleIdList></Reference><Reference><Citation>Essien EO, Rali P, Mathai SC. Pulmonary embolism. Med Clin N Am. 2019;103(3):549&#x2013;564. doi: 10.1016/j.mcna.2018.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2018.12.013</ArticleId><ArticleId IdType="pubmed">30955521</ArticleId></ArticleIdList></Reference><Reference><Citation>Lung BE, Kanjiya S, Bisogno M, Komatsu DE, Wang ED. Risk factors for venous thromboembolism in total shoulder arthroplasty. JSES Open Access. 2019;3(3):183&#x2013;188. doi: 10.1016/j.jses.2019.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jses.2019.07.003</ArticleId><ArticleId IdType="pmc">PMC6834973</ArticleId><ArticleId IdType="pubmed">31709360</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunutsor SK, Barrett MC, Whitehouse MR, Blom AW. Venous thromboembolism following 672,495 primary total shoulder and elbow replacements: meta-analyses of incidence, temporal trends and potential risk factors. Thromb Res. 2020;189:13&#x2013;23. doi: 10.1016/j.thromres.2020.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.02.018</ArticleId><ArticleId IdType="pubmed">32135385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolz JM, Aibinder WR, Adams RA, Cofield RH, Sperling JW. Symptomatic thromboembolic complications after shoulder arthroplasty: an update. J Bone Joint Surg Am. 2019;101(20):1845&#x2013;1851. doi: 10.2106/JBJS.18.01200.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.18.01200</ArticleId><ArticleId IdType="pubmed">31626009</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashjian RZ, Lilly DT, Isaacson AM, Georgopoulos CE, Bettwieser SP, Burks RT, et al. Incidence of and risk factors for symptomatic venous thromboembolism after shoulder arthroplasty. Am J Orthop (Belle Mead, NJ) 2016;45(6):E379&#x2013;E385.</Citation><ArticleIdList><ArticleId IdType="pubmed">27737296</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann RW, Pugely AJ, Ries Z, Amendola A, Martin CT, Gao Y, et al. Causes and predictors of 30-day readmission after shoulder and knee arthroscopy: an analysis of 15,167 cases. Arthroscopy. 2015;31(6):1035&#x2013;40.e1. doi: 10.1016/j.arthro.2015.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2015.03.029</ArticleId><ArticleId IdType="pubmed">26048765</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein WJ, Lansdown DA, Feeley BT, Ma CB, Zhang AL. The impact of body mass index on complications after shoulder arthroscopy: Should surgery eligibility be determined by body mass index cutoffs? Arthroscopy. 2019;35(3):741&#x2013;746. doi: 10.1016/j.arthro.2018.10.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2018.10.136</ArticleId><ArticleId IdType="pubmed">30704887</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill JR, McKnight B, Pannell WC, Heckmann N, Sivasundaram L, Mostofi A, et al. Risk factors for 30-day readmission following shoulder arthroscopy. Arthroscopy. 2017;33(1):55&#x2013;61. doi: 10.1016/j.arthro.2016.06.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2016.06.048</ArticleId><ArticleId IdType="pubmed">27641638</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancienne JM, Burrus MT, Diduch DR, Werner BC. High altitude is an independent risk factor for venous thromboembolism following arthroscopic rotator cuff repair: a matched case-control study in medicare patients. J Shoulder Elbow Surg. 2017;26(1):7&#x2013;13. doi: 10.1016/j.jse.2016.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2016.06.005</ArticleId><ArticleId IdType="pubmed">27528541</ArticleId></ArticleIdList></Reference><Reference><Citation>Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712&#x2013;716. doi: 10.1046/j.1445-2197.2003.02748.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1445-2197.2003.02748.x</ArticleId><ArticleId IdType="pubmed">12956787</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Yamamoto N, Nagamoto H, Sano H, Tanaka M, Itoi E. Venous thromboembolism after elective shoulder surgery: a prospective cohort study of 175 patients. J Shoulder Elbow Surg. 2014;23(5):605&#x2013;612. doi: 10.1016/j.jse.2014.01.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2014.01.054</ArticleId><ArticleId IdType="pubmed">24745310</ArticleId></ArticleIdList></Reference><Reference><Citation>Imberti D, Dentali F, Ivaldo N, Murena L, Paladini P, Castagna A, et al. Venous thromboembolism in patients undergoing shoulder arthroscopy: findings from the RECOS registry. Clin Appl Thromb Hemost. 2015;21(5):486&#x2013;488. doi: 10.1177/1076029614567311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029614567311</ArticleId><ArticleId IdType="pubmed">25616489</ArticleId></ArticleIdList></Reference><Reference><Citation>Brislin KJ, Field LD, Savoie Iii FH. Complications after arthroscopic rotator cuff repair. Arthrosc J Arthrosc Relat Surg. 2007;23(2):124&#x2013;128. doi: 10.1016/j.arthro.2006.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2006.09.001</ArticleId><ArticleId IdType="pubmed">17276218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoxie SC, Sperling JW, Cofield RH. Pulmonary embolism following rotator cuff repair. Int J Shoulder Surg. 2008;2(3):49&#x2013;51. doi: 10.4103/0973-6042.42576.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0973-6042.42576</ArticleId><ArticleId IdType="pmc">PMC2840827</ArticleId><ArticleId IdType="pubmed">20300313</ArticleId></ArticleIdList></Reference><Reference><Citation>Randelli P, Castagna A, Cabitza F, Cabitza P, Arrigoni P, Denti M. Infectious and thromboembolic complications of arthroscopic shoulder surgery. J Shoulder Elbow Surg. 2010;19(1):97&#x2013;101. doi: 10.1016/j.jse.2009.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2009.04.009</ArticleId><ArticleId IdType="pubmed">19559629</ArticleId></ArticleIdList></Reference><Reference><Citation>Jameson SS, James P, Howcroft DWJ, Serrano-Pedraza I, Rangan A, Reed MR, et al. Venous thromboembolic events are rare after shoulder surgery: analysis of a national database. J Shoulder Elbow Surg. 2011;20(5):764&#x2013;770. doi: 10.1016/j.jse.2010.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2010.11.034</ArticleId><ArticleId IdType="pubmed">21420324</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin CT, Gao Y, Pugely AJ, Wolf BR. 30-day morbidity and mortality after elective shoulder arthroscopy: a review of 9410 cases. J Shoulder Elbow Surg. 2013;22(12):1667&#x2013;75.e1. doi: 10.1016/j.jse.2013.06.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2013.06.022</ArticleId><ArticleId IdType="pubmed">24060598</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubenstein WJ, Lansdown DA, Feeley BT, Ma CB, Zhang AL. The impact of body mass index on complications after shoulder arthroscopy: Should surgery eligibility be determined by body mass index cutoffs? Arthrosc J Arthrosc Relat Surg. 2019;35(3):741&#x2013;746. doi: 10.1016/j.arthro.2018.10.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2018.10.136</ArticleId><ArticleId IdType="pubmed">30704887</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeung M, Shin JJ, Lesniak BP, Lin A. Complications of arthroscopic versus open biceps tenodesis in the setting of arthroscopic rotator cuff repairs: an analysis of the American board of orthopaedic surgery database. J Am Acad Orthop Surg. 2019;28:113&#x2013;120. doi: 10.5435/JAAOS-D-19-00252.</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/JAAOS-D-19-00252</ArticleId><ArticleId IdType="pubmed">31977611</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanigan DC, Muchow R, Orwin J, Graf B. Arthroscopy on anticoagulated patients: a retrospective evaluation of postoperative complications. Orthopedics. 2010;33(2):82&#x2013;86. doi: 10.3928/01477447-20100104-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/01477447-20100104-8</ArticleId><ArticleId IdType="pubmed">20192141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangan A, Brealey SD, Keding A, Corbacho B, Northgraves M, Kottam L, et al. Management of adults with primary frozen shoulder in secondary care (UK FROST): a multicentre, pragmatic, three-arm, superiority randomised clinical trial. Lancet. 2020;396(10256):977&#x2013;989. doi: 10.1016/S0140-6736(20)31965-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31965-6</ArticleId><ArticleId IdType="pubmed">33010843</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone AV, Agarwalla A, Gowd AK, Jacobs CA, Macalena JA, Lesniak BP, et al. Oral contraceptive pills are not a risk factor for deep vein thrombosis or pulmonary embolism after arthroscopic shoulder surgery. Orthop J Sports Med. 2019;7(1):1&#x2013;5. doi: 10.1177/2325967118822970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2325967118822970</ArticleId><ArticleId IdType="pmc">PMC6350148</ArticleId><ArticleId IdType="pubmed">30729148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzayan R, McCrum CL, Butler RK, Alluri RK. Risk factors for biceps related complications following arthroscopic tenotomy of the long head of the biceps tendon. Orthop J Sports Med. 2018;6(7):1&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7052466</ArticleId><ArticleId IdType="pubmed">32166093</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens BD, Williams AE, Wolf JM. Risk factors for surgical complications in rotator cuff repair in a veteran population. J Shoulder Elbow Surg. 2015;24(11):1707&#x2013;1712. doi: 10.1016/j.jse.2015.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2015.04.020</ArticleId><ArticleId IdType="pubmed">26164483</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager B, Ahn J, Tran J, Khazzam M. Timing and risk factors for venous thromboembolism after rotator cuff repair in the 30-day perioperative period. Arthrosc J Arthrosc Relat Surg. 2019;35(11):3011&#x2013;3018. doi: 10.1016/j.arthro.2019.05.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2019.05.045</ArticleId><ArticleId IdType="pubmed">31629586</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuremsky MA, Cain EL, Jr, Fleischli JE. Thromboembolic phenomena after arthroscopic shoulder surgery. Arthrosc J Arthrosc Relat Surg. 2011;27(12):1614&#x2013;1619. doi: 10.1016/j.arthro.2011.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2011.06.026</ArticleId><ArticleId IdType="pubmed">21925830</ArticleId></ArticleIdList></Reference><Reference><Citation>Duralde XA, McClelland WB., Jr The clinical results of arthroscopic transtendinous repair of grade III partial articular-sided supraspinatus tendon tears. Arthroscopy. 2012;28(2):160&#x2013;168. doi: 10.1016/j.arthro.2011.08.286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2011.08.286</ArticleId><ArticleId IdType="pubmed">22078003</ArticleId></ArticleIdList></Reference><Reference><Citation>Schick CW, Westermann RW, Gao Y, Wolf BR, Group A. Thromboembolism following shoulder arthroscopy: a retrospective review. Orthop J Sports Med. 2014 doi: 10.1177/2325967114559506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2325967114559506</ArticleId><ArticleId IdType="pmc">PMC4555560</ArticleId><ArticleId IdType="pubmed">26535285</ArticleId></ArticleIdList></Reference><Reference><Citation>Alyea E, Gaston T, Austin LS, Wowkanech C, Cypel B, Pontes M, et al. The effectiveness of aspirin for venous thromboembolism prophylaxis for patients undergoing arthroscopic rotator cuff repair. Orthopedics. 2019;42(2):E187&#x2013;E192. doi: 10.3928/01477447-20181227-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/01477447-20181227-05</ArticleId><ArticleId IdType="pubmed">30602049</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhart SS. Deep venous thrombosis after shoulder arthroscopy. Arthrosc J Arthrosc Relat Surg Off Publ Arthrosc Assoc N Am Int Arthrosc Assoc. 1990;6(1):61&#x2013;63. doi: 10.1016/0749-8063(90)90100-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0749-8063(90)90100-R</ArticleId><ArticleId IdType="pubmed">2178620</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T, Tamai K, Akutsu M, Tomizawa K, Sukegawa T, Nohara Y. Pulmonary embolism after arthroscopic rotator cuff repair: a case report. Case Rep Orthop. 2013;2013:801752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600284</ArticleId><ArticleId IdType="pubmed">23533883</ArticleId></ArticleIdList></Reference><Reference><Citation>Polzhofer GK, Petersen W, Hassenpflug J. Thromboembolic complication after arthroscopic shoulder surgery. Arthroscopy. 2003;19(9):E129&#x2013;E132. doi: 10.1016/j.arthro.2003.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2003.09.016</ArticleId><ArticleId IdType="pubmed">14608339</ArticleId></ArticleIdList></Reference><Reference><Citation>Cort&#xe9;s ZE, Hammerman SM, Gartsman GM. Pulmonary embolism after shoulder arthroscopy: Could patient positioning and traction make a difference? J Shoulder Elbow Surg. 2007;16(2):e16&#x2013;e17. doi: 10.1016/j.jse.2006.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2006.05.009</ArticleId><ArticleId IdType="pubmed">17097309</ArticleId></ArticleIdList></Reference><Reference><Citation>Creighton RA, Cole BJ. Upper extremity deep venous thrombosis after shoulder arthroscopy: a case report. J Shoulder Elbow Surg. 2007;16(1):e20&#x2013;e22. doi: 10.1016/j.jse.2006.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2006.04.002</ArticleId><ArticleId IdType="pubmed">16945557</ArticleId></ArticleIdList></Reference><Reference><Citation>Bongiovanni SL, Ranalletta M, Guala A, Maignon GD. Case reports: heritable thrombophilia associated with deep venous thrombosis after shoulder arthroscopy. Clin Orthop Relat Res. 2009;467(8):2196&#x2013;2199. doi: 10.1007/s11999-009-0895-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-009-0895-6</ArticleId><ArticleId IdType="pmc">PMC2706365</ArticleId><ArticleId IdType="pubmed">19452233</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariri A, Nourissat G, Dumontier C, Doursounian L. Pulmonary embolism following thrombosis of the brachial vein after shoulder arthroscopy. A case report. Orthop Traumatol Surg Res. 2009;95(5):377&#x2013;379. doi: 10.1016/j.otsr.2009.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2009.03.016</ArticleId><ArticleId IdType="pubmed">19576863</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Molin FF, Dal Molin SF. Thromboembolic complication after arthroscopic shoulder surgery. Rev Bras Ortop. 2010;45(3):312&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4799102</ArticleId><ArticleId IdType="pubmed">27022559</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo R, Notarnicola A, Moretti L, Moretti B, Marini S, Castagna A. Deep vein thromboembolism after arthroscopy of the shoulder: two case reports and a review of the literature. BMC Musculoskel Disord. 2010;11:65. doi: 10.1186/1471-2474-11-65.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2474-11-65</ArticleId><ArticleId IdType="pmc">PMC2858720</ArticleId><ArticleId IdType="pubmed">20377851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SJ, Yoo KY, Lee HG, Kim WM, Jeong CW, Lee HJ. Fatal pulmonary embolism caused by thrombosis of contralateral axillary vein after arthroscopic right rotator cuff repair. Korean J Anesthesiol. 2010;59:S172&#x2013;S175. doi: 10.4097/kjae.2010.59.S.S172.</Citation><ArticleIdList><ArticleId IdType="doi">10.4097/kjae.2010.59.S.S172</ArticleId><ArticleId IdType="pmc">PMC3030029</ArticleId><ArticleId IdType="pubmed">21286433</ArticleId></ArticleIdList></Reference><Reference><Citation>Delos D, Rodeo SA. Venous thrombosis after arthroscopic shoulder surgery: pacemaker leads as a possible cause: pacemaker leads as a possible cause. HSS J Musculoskel J Hosp Spec Surg. 2011;7(3):282&#x2013;285. doi: 10.1007/s11420-011-9215-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11420-011-9215-2</ArticleId><ArticleId IdType="pmc">PMC3192900</ArticleId><ArticleId IdType="pubmed">23024627</ArticleId></ArticleIdList></Reference><Reference><Citation>Laubscher PH, Ferguson MC. Venous thrombotic events in arthroscopic shoulder surgery&#x2014;a case report and review of the literature. SA Orthop J. 2011;10(2):78&#x2013;80.</Citation></Reference><Reference><Citation>Edgar R, Nagda S, Huffman R, Namdari S. Pulmonary embolism after shoulder arthroscopy. Orthopedics. 2012;35(11):e1673&#x2013;e1676. doi: 10.3928/01477447-20121023-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/01477447-20121023-31</ArticleId><ArticleId IdType="pubmed">23127464</ArticleId></ArticleIdList></Reference><Reference><Citation>Durant TJS, Cote MP, Arciero RA, Mazzocca AD. Fatal pulmonary embolism after arthroscopic rotator cuff repair: a case series. Muscles Ligaments Tendons J. 2014;4(2):232&#x2013;237. doi: 10.32098/mltj.02.2014.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.32098/mltj.02.2014.25</ArticleId><ArticleId IdType="pmc">PMC4187592</ArticleId><ArticleId IdType="pubmed">25332941</ArticleId></ArticleIdList></Reference><Reference><Citation>Durant TJS, Swanson BT, Cote MP, Allen DA, Arciero RA, Mazzocca AD. Upper extremity deep venous thromboembolism following arthroscopic labral repair of the shoulder and biceps tenodesis: a case report. Int J Sports Phys Ther. 2014;9(3):377&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060316</ArticleId><ArticleId IdType="pubmed">24944857</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber NH, Lee CS. Isolated pulmonary embolism following shoulder arthroscopy. Case Rep Ortho. 2014;2014:279082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273471</ArticleId><ArticleId IdType="pubmed">25548699</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwark JY, Koh J-S, Park HB. Pulmonary embolism after arthroscopic rotator cuff repair&#x2014;a case report. Clin Shoulder Elbow. 2014;17(1):31&#x2013;35. doi: 10.5397/CiSE.2014.17.1.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.5397/CiSE.2014.17.1.31</ArticleId></ArticleIdList></Reference><Reference><Citation>Manaqibwala MI, Ghobrial IE, Curtis AS. Upper extremity thrombosis presenting as medial elbow pain after shoulder arthroscopy. Case Rep Orthop. 2014;2014:653146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977502</ArticleId><ArticleId IdType="pubmed">24772360</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews JM, Wessel SS, Pate RC, Chong AC. Pulmonary embolism after arthroscopic bankart and rotator cuff repair. Kansas J Med. 2017;10(2):43&#x2013;46. doi: 10.17161/kjm.v10i2.8652.</Citation><ArticleIdList><ArticleId IdType="doi">10.17161/kjm.v10i2.8652</ArticleId><ArticleId IdType="pmc">PMC5733415</ArticleId><ArticleId IdType="pubmed">29472967</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagnatovsky M, Dai AZ, Zacchilli M, Jazrawi LM. Acute pulmonary embolism after arthroscopic glenoid labral repair and subacromial decompression: case report and review of the literature. Phys Sportsmed. 2018;46(1):135&#x2013;138. doi: 10.1080/00913847.2018.1419776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00913847.2018.1419776</ArticleId><ArticleId IdType="pubmed">29287491</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Nagase Y, Tamai K, Tanaka S. Pulmonary embolism associated with upper extremity deep venous thrombosis after shoulder arthroscopy: a case report. J Orthop Sci. 2019;24(4):746&#x2013;749. doi: 10.1016/j.jos.2017.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jos.2017.01.008</ArticleId><ArticleId IdType="pubmed">28209398</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan A, Villacis D, Boente R, Romeo AA. Venous thromboembolism after arthroscopic rotator cuff repair in a patient with a negative presurgical SARS-CoV-2 test who developed symptomatic COVID-19 three days after surgery. J Shoulder Elbow Surg. 2021;30(5):e251&#x2013;e255. doi: 10.1016/j.jse.2021.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2021.02.003</ArticleId><ArticleId IdType="pmc">PMC7901276</ArticleId><ArticleId IdType="pubmed">33636325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji L, Lyu C, Feng M, Qiang H. Asymptomatic pulmonary embolism after shoulder arthroscopy: case report and literature review. Orthop Surg. 2021;13(3):1119&#x2013;1125. doi: 10.1111/os.12982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/os.12982</ArticleId><ArticleId IdType="pmc">PMC8126936</ArticleId><ArticleId IdType="pubmed">33719207</ArticleId></ArticleIdList></Reference><Reference><Citation>Dattani R, Smith CD, Patel VR. The venous thromboembolic complications of shoulder and elbow surgery: a systematic review. Bone Joint J. 2013;95(1):70&#x2013;74. doi: 10.1302/0301-620X.95B1.29854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.95B1.29854</ArticleId><ArticleId IdType="pubmed">23307676</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene JW, Deshmukh AJ, Cushner FD. Thromboembolic complications in arthroscopic surgery. Sports Med Arthrosc Rev. 2013;21(2):69&#x2013;74. doi: 10.1097/JSA.0b013e31828a7e76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JSA.0b013e31828a7e76</ArticleId><ArticleId IdType="pubmed">23649153</ArticleId></ArticleIdList></Reference><Reference><Citation>Aibinder WR, Sanchez-Sotelo J. Venous thromboembolism prophylaxis in shoulder surgery. Orthop Clin N Am. 2018;49(2):257. doi: 10.1016/j.ocl.2017.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ocl.2017.11.012</ArticleId><ArticleId IdType="pubmed">29499826</ArticleId></ArticleIdList></Reference><Reference><Citation>Heil J, Miesbach W, Vogl T, Bechstein WO, Reinisch A. Deep vein thrombosis of the upper extremity. Deutsches Arzteblatt Int. 2017;114(14):244&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5415909</ArticleId><ArticleId IdType="pubmed">28446351</ArticleId></ArticleIdList></Reference><Reference><Citation>Afshari A, Ageno W, Ahmed A, Duranteau J, Faraoni D, Kozek-Langenecker S, et al. European guidelines on perioperative venous thromboembolism prophylaxis: executive summary. Eur J Anaesthesiol. 2018;35(2):77&#x2013;83. doi: 10.1097/EJA.0000000000000729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000729</ArticleId><ArticleId IdType="pubmed">29112553</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandor A, Tonkins M, Goodacre S, Sworn K, Clowes M, Griffin XL, et al. Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review. BMJ Open. 2021;11(7):e045672. doi: 10.1136/bmjopen-2020-045672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-045672</ArticleId><ArticleId IdType="pmc">PMC8323381</ArticleId><ArticleId IdType="pubmed">34326045</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;nemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198&#x2013;3225. doi: 10.1182/bloodadvances.2018022954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2018022954</ArticleId><ArticleId IdType="pmc">PMC6258910</ArticleId><ArticleId IdType="pubmed">30482763</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3(23):3898&#x2013;3944. doi: 10.1182/bloodadvances.2019000975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019000975</ArticleId><ArticleId IdType="pmc">PMC6963238</ArticleId><ArticleId IdType="pubmed">31794602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693&#x2013;4738. doi: 10.1182/bloodadvances.2020001830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001830</ArticleId><ArticleId IdType="pmc">PMC7556153</ArticleId><ArticleId IdType="pubmed">33007077</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38652521</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-5733</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Blood coagulation &amp; fibrinolysis : an international journal in haemostasis and thrombosis</Title><ISOAbbreviation>Blood Coagul Fibrinolysis</ISOAbbreviation></Journal><ArticleTitle>Aspirin versus low-molecular-weight heparin for thromboprophylaxis after orthopaedic surgery: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>187</StartPage><EndPage>195</EndPage><MedlinePgn>187-195</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MBC.0000000000001300</ELocationID><Abstract><AbstractText>The article aimed to compare the efficiency and safety of aspirin with low-molecular-weight heparin (LMWH) for thromboprophylaxis in orthopaedic surgery patients. According to the inclusion and exclusion criteria, PubMed, Embase and Cochrane Library database were searched for studies comparing aspirin and LMWH in venous thromboembolism (VTE) prophylaxis until 25 April 2023. The outcome measures included deep venous thrombosis(DVT)/Pulmonary embolism(PE) events, major bleeding events, wound complications, wound infection and death. Six studies met the requirements of our meta-analysis, including 12&#x200a;470 patients in the aspirin group and 10&#x200a;857 patients in the LMWH group. The meta-analysis showed that results showed that LMWH was superior to aspirin in preventing VTE events (odds ratio (OR) 1.44, 95% CI 1.24-1.68, P &#x200a;&lt;&#x200a;0.00001), whereas there was no significant difference between them in bleeding events (OR 0.95, 95% CI 0.86-1.05, P &#x200a;=&#x200a;0.33), wound complication (OR 0.58, 95% CI 0.28-1.17, P &#x200a;=&#x200a;0.13), wound infection (OR 1.12, 95% CI 0.86-1.47, P &#x200a;=&#x200a;0.39) and mortality (OR 1.04, 95% CI 0.70-1.55, P &#x200a;=&#x200a;0.83). In addition, subgroup analysis showed that compared with aspirin, LMWH was more likely to reduce the incidence of DVT events in orthopaedic surgery patients (OR 1.59, 95% CI 1.33-1.91, P &#x200a;&lt;&#x200a;0.00001), whereas there was no advantage in reducing the incidence of PE events (OR 1.22, 95% CI 0.62-2.40, P &#x200a;=&#x200a;0.56). Despite the similar safety profiles, this meta-analysis showed that LMWH was significantly superior to aspirin in thromboprophylaxis after orthopaedic surgery. LMWH was still the first-line drug for thrombosis prevention in patients who underwent major orthopaedic surgeries.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Haichao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Taizhou Municipal Hospital, Taizhou.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Long</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Siyuan</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Blood Coagul Fibrinolysis</MedlineTA><NlmUniqueID>9102551</NlmUniqueID><ISSNLinking>0957-5235</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="Y">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="Y">Aspirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019637" MajorTopicYN="Y">Orthopedic Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>6</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>23</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>23</Day><Hour>11</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38652521</ArticleId><ArticleId IdType="pmc">PMC11064920</ArticleId><ArticleId IdType="doi">10.1097/MBC.0000000000001300</ArticleId><ArticleId IdType="pii">00001721-202406000-00006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Majima T, Oshima Y. Venous thromboembolism in major orthopedic surgery. J Nippon Med School 2021; 88:268&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">33867423</ArticleId></ArticleIdList></Reference><Reference><Citation>Memtsoudis SG, Pumberger M, Ma Y, Chiu YL, Fritsch G, Gerner P, et al. . Epidemiology and risk factors for perioperative mortality after total hip and knee arthroplasty. J Orthopaed Res 2012; 30:1811&#x2013;1821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3407319</ArticleId><ArticleId IdType="pubmed">22517400</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon SJ, Patell R, Zwicker JI, Kazi DS, Hollenbeck BL. Venous Thromboembolism in Total Hip and Total Knee Arthroplasty. JAMA Netw Open 2023; 6:e2345883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10692868</ArticleId><ArticleId IdType="pubmed">38039005</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinov P, Tanchev PP, Ellis M, Volpin G. Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations. Int Orthopaed 2014; 38:169&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3890144</ArticleId><ArticleId IdType="pubmed">24114249</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart DW, Freshour JE. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. Ann Pharmacother 2013; 47:63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">23324504</ArticleId></ArticleIdList></Reference><Reference><Citation>Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. . Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: (2 Suppl): e278S&#x2013;e325S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278063</ArticleId><ArticleId IdType="pubmed">22315265</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang A, Sicat CS, Singh V, Rozell JC, Schwarzkopf R, Long WJ. Aspirin use for venous thromboembolism prevention is safe and effective in overweight and obese patients undergoing revision total hip and knee arthroplasty. J Arthroplasty 2021; 36 (7S):S337&#x2013;S344.</Citation><ArticleIdList><ArticleId IdType="pubmed">33376036</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckmann ND, Piple AS, Wang JC, Richardson MK, Mayfield CK, Oakes DA, et al. . Aspirin for venous thromboembolic prophylaxis following total hip and total knee arthroplasty: an analysis of safety and efficacy accounting for surgeon selection bias. J Arthroplasty 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">36870517</ArticleId></ArticleIdList></Reference><Reference><Citation>Farey JE, An VVG, Sidhu V, Karunaratne S, Harris IA. Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: a systematic review and meta-analysis [J]. Orthopaed Traumatol Surg Res 2021; 107:102606.</Citation><ArticleIdList><ArticleId IdType="pubmed">32631716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Hu N. Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis. J Thromb Thrombolysis 2021; 52:553&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">33387203</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidhu VS, Kelly TL, Pratt N, Graves SE, Buchbinder R, Adie S, et al. . Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL Randomized Trial. JAMA 2022; 328:719&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9399863</ArticleId><ArticleId IdType="pubmed">35997730</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;toole RV, Stein DM, O&#x2019;hara NN, Frey KP, Taylor TJ, Scharfstein DO, et al. . Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture. New Engl J Med 2023; 388:203&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">36652352</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372:n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, et al. . Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med 2013; 158:800&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">23732713</ArticleId></ArticleIdList></Reference><Reference><Citation>Westrich GH, Bottner F, Windsor RE, Laskin RS, Haas SB, Sculco TP. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. J Arthroplasty 2006; 21: (6 Suppl 2): 139&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950076</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou LB, Wang CC, Zhang LT, Wu T, Zhang GQ. Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study. BMC Musculoskelet Disord 2023; 24:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9811690</ArticleId><ArticleId IdType="pubmed">36600227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y, Tian S, Wang Y, Sun K. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagul Fibrinolysis 2014; 25:660&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">24695091</ArticleId></ArticleIdList></Reference><Reference><Citation>Rexiti P, Wutiku M, Wulamu W, Bai F, Cao L. Pulmonary hypertension could be a risk for deep vein thrombosis in lower extremities after joint replacement surgery. Revista da Associacao Medica Brasileira (1992) 2019; 65:946&#x2013;950.</Citation><ArticleIdList><ArticleId IdType="pubmed">31389502</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;astous J, Liederman Z, Douketis JD. Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery. Postgrad Med 2021; 133: (Suppl 1): 20&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">33779472</ArticleId></ArticleIdList></Reference><Reference><Citation>Guti&#xe9;rrez Guisado J. Thromboembolism prophylaxis in orthopaedic surgery and trauma. Revista clinica espanola 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">32532463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim PK, Ahn J, Scolaro JA. Venous thromboembolism prophylaxis after pelvic and acetabular fractures: a survey of orthopaedic surgeons&#x2019; current practices. J Am Acad Orthopaed Surgeons 2020; 28:750&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">32235242</ArticleId></ArticleIdList></Reference><Reference><Citation>Segon YS, Summey RD, Slawski B, Kaatz S. Surgical venous thromboembolism prophylaxis: clinical practice update. Hospital Pract (1995) 2020; 48:248&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">32589468</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder MA, Sympson AN, Scheuerman CM, Gregg JL, Hussain LR. Efficacy in deep vein thrombosis prevention with extended mechanical compression device therapy and prophylactic aspirin following total knee arthroplasty: a randomized control trial. J Arthroplasty 2017; 32:1478&#x2013;1482.</Citation><ArticleIdList><ArticleId IdType="pubmed">28159420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Best AJ, Rudge SJ, Chatterji U. Clinical effectiveness of aspirin as multimodal thromboprophylaxis in primary total hip and knee arthroplasty: a review of 6078 cases. J Arthroplasty 2019; 34:1359&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">30982759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist DE, Stewart DW, Brewster A, Waldroup C, Odle BL, Burchette JE, El-Bazouni H. Comparison of postoperative bleeding in total hip and knee arthroplasty patients receiving rivaroxaban, enoxaparin, or aspirin for thromboprophylaxis. Clin Applied Thrombosis/Hemostasis 2018; 24:1315&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6714764</ArticleId><ArticleId IdType="pubmed">29716395</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovik O, Amlie EJ, Jenssen KK. No Increased risk of venous thromboembolism in high-risk patients continuing their dose of 75&#x200a;mg aspirin compared to healthier patients given low-molecular-weight heparin. J Arthroplasty 2021; 36:3589&#x2013;3592.</Citation><ArticleIdList><ArticleId IdType="pubmed">34176693</ArticleId></ArticleIdList></Reference><Reference><Citation>Yhim HY, Lee J, Lee JY, Lee JO, Bang SM. Pharmacological thromboprophylaxis and its impact on venous thromboembolism following total knee and hip arthroplasty in Korea: a nationwide population-based study. PLoS One 2017; 12:e0178214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5443574</ArticleId><ArticleId IdType="pubmed">28542415</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts PJ, Kopstein M, Harkness W, Cornett B, Dziadkowiec O, Jenkins P, et al. . A retrospective analysis comparing post-operative bleeding with various doses of aspirin after lower extremity joint arthroplasty or revision. Pharmacotherapy 2021; 41:616&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">34050970</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang A, Zak SG, Waren D, Iorio R, Slover JD, Bosco JA, Schwarzkopf R. Low-dose aspirin is safe and effective for venous thromboembolism prevention in patients undergoing revision total knee arthroplasty: a retrospective cohort Study. J Knee Surg 2022; 35:553&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">32898907</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29727761</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-4529</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><PubDate><Year>2018</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of clinical anesthesia</Title><ISOAbbreviation>J Clin Anesth</ISOAbbreviation></Journal><ArticleTitle>Systematic review and meta-analyses of tranexamic acid use for bleeding reduction in prostate surgery.</ArticleTitle><Pagination><StartPage>32</StartPage><EndPage>38</EndPage><MedlinePgn>32-38</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jclinane.2018.04.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0952-8180(18)30215-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Prostate cancer and benign prostatic hyperplasia have an increased incidence with aging. The most effective treatments are radical prostatectomy and transurethral resection of the prostate. To reduce perioperative bleeding in these surgeries, an approach is the use of tranexamic acid (TXA). Studies show that TXA is effective in reducing the blood loss and the need for transfusion in cardiac, orthopedic, and gynecological surgeries. In prostate surgeries, its efficacy and safety have not been established yet.</AbstractText><AbstractText Label="STUDY OBJECTIVE">To determine whether there are differences between TXA versus placebo in terms of intraoperative blood loss, transfusion requirements, hemoglobin levels and the incidence of thromboembolic events.</AbstractText><AbstractText Label="DESIGN">Systematic review with meta-analyses.</AbstractText><AbstractText Label="SETTING">Anesthesia for prostate surgery.</AbstractText><AbstractText Label="PATIENTS">We searched the Medline, Cochrane, EBSCO, and Web of Science databases up to 2017 for randomized controlled trials that compared TXA administration with a control group in patients who submitted to prostate surgery.</AbstractText><AbstractText Label="MEASUREMENTS">The primary outcomes were the intraoperative blood loss and transfusion rate. Data on hemoglobin levels and the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) were also collected.</AbstractText><AbstractText Label="RESULTS">Nine comparative studies were included in the meta-analyses. The estimated blood loss and transfusion rate were lower in patients receiving TXA, with a standardized mean difference of -1.93 (95% CI&#x202f;=&#x202f;-2.81 to -1.05, I<sup>2</sup>&#x202f;=&#x202f;96%), and a risk ratio of 0.61 (95% CI&#x202f;=&#x202f;0.47 to 0.80, I<sup>2</sup>&#x202f;=&#x202f;0%), respectively. The hemoglobin levels and the incidence of DVT and PE did not differ between the groups.</AbstractText><AbstractText Label="CONCLUSIONS">TXA reduced intraoperative blood loss and the need for transfusion, without increasing the risk of DVT and PE in prostate surgeries. Due to the limited number of studies and the high heterogeneity of the results, more clinical trials with a large number of patients are necessary to confirm these findings.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Longo</LastName><ForeName>Marcelo A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital, Federal University of Santa Catarina, Florian&#xf3;polis, Santa Catarina, Brazil. Electronic address: marceloarent@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavalheiro</LastName><ForeName>B&#xe1;rbara T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital, Federal University of Santa Catarina, Florian&#xf3;polis, Santa Catarina, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira Filho</LastName><ForeName>Get&#xfa;lio R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Department of Surgery, University Hospital, Federal University of Santa Catarina, Florian&#xf3;polis, Santa Catarina, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Anesth</MedlineTA><NlmUniqueID>8812166</NlmUniqueID><ISSNLinking>0952-8180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="N">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011468" MajorTopicYN="N">Prostatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011470" MajorTopicYN="N">Prostatic Hyperplasia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="N">Tranexamic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anesthesia</Keyword><Keyword MajorTopicYN="N">Blood loss</Keyword><Keyword MajorTopicYN="N">Prostate</Keyword><Keyword MajorTopicYN="N">Review</Keyword><Keyword MajorTopicYN="N">Surgical</Keyword><Keyword MajorTopicYN="N">Systematic</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29727761</ArticleId><ArticleId IdType="doi">10.1016/j.jclinane.2018.04.014</ArticleId><ArticleId IdType="pii">S0952-8180(18)30215-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30560579</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2018</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Thrombolytic therapy for pulmonary embolism.</ArticleTitle><Pagination><StartPage>CD004437</StartPage><MedlinePgn>CD004437</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD004437</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD004437.pub5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and may reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhage. This is the third update of the Cochrane review first published in 2006.</AbstractText><AbstractText Label="OBJECTIVES">To assess the effects of thrombolytic therapy for acute pulmonary embolism.</AbstractText><AbstractText Label="SEARCH METHODS">The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, and CINAHL databases and the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 16 April 2018. We undertook reference checking to identify additional studies.</AbstractText><AbstractText Label="SELECTION CRITERIA">We included randomised controlled trials (RCTs) that compared thrombolytic therapy followed by heparin versus heparin alone, heparin plus placebo, or surgical intervention for patients with acute PE. We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS">Two review authors (JY, QH) assessed the eligibility and quality of trials and extracted data. We calculated effect estimates using the odds ratio (OR) with 95% confidence interval (CI) or the mean difference (MD) with 95% CI. We assessed the quality of the evidence using GRADE criteria.</AbstractText><AbstractText Label="MAIN RESULTS">We identified no new studies for inclusion in this 2018 update. We included in the review 18 trials with a total of 2197 participants. We were not able to include one study in the meta-analysis because it provided no data that we could extract. Most of the studies carried a high risk of bias because of high or unclear risk related to randomisation and blinding. Meta-analysis showed that, compared with heparin alone, or heparin plus placebo, thrombolytics plus heparin can reduce the odds of death (OR 0.57, 95% CI 0.37 to 0.87, 2167 participants, P = 0.01, low-quality evidence) and recurrence of PE (OR 0.51, 95% CI 0.29 to 0.89, 1898 participants, P = 0.02, low-quality evidence). Effects on mortality weakened when we excluded from analysis four studies at high risk of bias (OR 0.66, 95% CI 0.42 to 1.06, 2054 participants, P = 0.08). The incidence of major and minor haemorrhagic events was higher in the thrombolytics group than in the control group (OR 2.90, 95% CI 1.95 to 4.31, 1897 participants, P &lt; 0.001, low-quality evidence; OR 3.09, 95% CI 1.58 to 6.06, 1553 participants, P = 0.001, very low-quality evidence, respectively). We downgraded the quality of the evidence to low or very low because of design limitations, potential influence of pharmaceutical companies, and small sample sizes. Length of hospital stay (mean difference (MD) -0.89, 95% CI -3.13 to 1.34) and quality of life were similar between the two treatment groups. Limited information from a small number of trials indicated that thrombolytics may improve haemodynamic outcomes, perfusion lung scanning, pulmonary angiogram assessment, echocardiograms, pulmonary hypertension, coagulation parameters, clinical outcomes, and survival time to a greater extent than heparin alone. However, the heterogeneity of the studies and the small number of participants involved warrant caution when results are interpreted. Similarily, fewer participants from the thrombolytics group required escalation of treatment. None of the included studies reported on post-thrombotic syndrome or compared the costs of different treatments.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS">Low-quality evidence suggests that thrombolytics reduce death following acute pulmonary embolism compared with heparin. The included studies used a variety of thrombolytic drugs. Thrombolytic therapy may be helpful in reducing the recurrence of pulmonary emboli but may cause major and minor haemorrhagic events and stroke. More high-quality, blinded randomised controlled trials assessing safety and cost-effectiveness of therapies for pulmonary embolism are required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Qiukui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Bi Rong</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Jirong</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Taixiang</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guan J</ForeName><Initials>GJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ETM/442</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Cochrane Database Syst Rev. 2015 Sep 30;(9):CD004437. doi: 10.1002/14651858.CD004437.pub4.</RefSource><PMID Version="1">26419832</PMID></CommentsCorrections><CommentsCorrections RefType="UpdateIn"><RefSource>Cochrane Database Syst Rev. 2021 Apr 15;4:CD004437. doi: 10.1002/14651858.CD004437.pub6.</RefSource><PMID Version="1">33857326</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Qiukui Hao: none known.&#x2028;
Birong Dong: none known.&#x2028;
Jirong Yue: none known.&#x2028;
Taixiang Wu: none known.&#x2028;
Guan Jian Liu: none known.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30560579</ArticleId><ArticleId IdType="pmc">PMC6516871</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD004437.pub5</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Becattini 2010 {published data only}</Title><Reference><Citation>Becattini C, Agnelli G, Salvi A, Grifoni S, Pancaldi LG, Enea I, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thrombosis Research 2010;125(3):e82&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19833379</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dalla&#x2010;Volta 1992 {published data only}</Title><Reference><Citation>Dalla&#x2010;Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, et al. PAIMS2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Journal of the American College of Cardiology 1992;20(3):520&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512328</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dotter 1979 {published data only}</Title><Reference><Citation>Dotter CT, Seamon AJ, Rosch J, Porter J. Streptokinase and heparin in the treatment of major pulmonary embolism: a randomised comparison. Vascular Surgery 1979;13(1):42&#x2010;52.</Citation></Reference></ReferenceList><ReferenceList><Title>Fasullo 2011 {published data only}</Title><Reference><Citation>Fasullo S, Scalzo S, Maringhini G, Ganci F, Cannizzaro S, Basile I, et al. Six&#x2010;month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. American Journal of the Medical Sciences 2011;341(1):33&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20890176</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 1993 {published data only}</Title><Reference><Citation>Goldhaber SZ, Haire WD, Fekdstein ML, Miller M, Toltzis R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right&#x2010;ventricular function and pulmonary perfusion. The Lancet 1993;341(8844):507&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094768</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jerjes&#x2010;S&#xe1;nchez 1995 {published data only}</Title><Reference><Citation>Jerjes&#x2010;S&#xe1;nchez C, Ram&#xed;rez&#x2010;Rivera A, Lourdes&#x2010;Garc&#xed;a M, Arriaga&#x2010;Nava R, Valencia S, Rosado&#x2010;Buzzo A, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. Journal of Thrombosis and Thrombolysis 1995;2(3):227&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10608028</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kline 2014 {published data only}</Title><Reference><Citation>Kline J, Hernandez J, Kabrhel C, Courtney DM, Jones AE, Nordenholtz K, et al. Randomized trial of tenecteplase or placebo with low molecular weight heparin for acute submassive pulmonary embolism: assessment of patient&#x2010;oriented cardiopulmonary outcomes at three months. Journal of the American College of Cardiology 2013;61(10 Suppl 1):E2074.</Citation></Reference><Reference><Citation>Kline JA, Hernandez J, Hogg MM, Jones AE, Courtney DM, Kabrhel C, et al. Rationale and methodology for a multicentre randomised trial of fibrinolysis for pulmonary embolism that includes quality of life outcomes. Emergency Medicine Australasia 2013;25(6):515&#x2010;26. [DOI: 10.1111/1742-6723.12159]</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1742-6723.12159</ArticleId><ArticleId IdType="pubmed">24224521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline JA, Hernandez J, Kabrhel C, Courtney DM, Nordenholtz KE, Diercks DB, et al. Randomized trial of tenecteplase or placebo with low molecular weight heparin for acute submassive pulmonary embolism: assessment of patient&#x2010;oriented cardiopulmonary outcomes at three months. Academic Emergency Medicine 2013;20(5 Suppl 1):S7.</Citation></Reference><Reference><Citation>Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double&#x2010;blind, placebo&#x2010;controlled randomized trial. Journal of Thrombosis and Haemostasis 2014;12(4):459&#x2010;68. [NCT00680628]</Citation><ArticleIdList><ArticleId IdType="pubmed">24484241</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Konstantinides 2002 {published data only}</Title><Reference><Citation>Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. New England Journal of Medicine 2002;347(15):1143&#x2010;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374874</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kucher 2014 {published data only}</Title><Reference><Citation>Kucher N, Boekstegers P, Muller O, Kupatt C, Beyer&#x2010;Westendorf J, Heitzer T, et al. Randomized controlled trial of ultrasound&#x2010;assisted catheter&#x2010;directed thrombolysis for acute intermediate&#x2010;risk pulmonary embolism. Circulation 2014;129(4):479&#x2010;86. [NCT01166997]</Citation><ArticleIdList><ArticleId IdType="pubmed">24226805</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levine 1990 {published data only}</Title><Reference><Citation>Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98(6):1473&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2123152</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ly 1978 {published data only}</Title><Reference><Citation>Arnesen BLH, Eie H, Hol R. A prospective study of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Medica Scandinavica Supplement 1978; Vol. 621:15.</Citation><ArticleIdList><ArticleId IdType="pubmed">352100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ly B, Arneson H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Medica Scandinavica 1978;203(6):465&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">352100</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Marini 1988 {published data only}</Title><Reference><Citation>Giuntini C, Marini C, Ricco G, Palla R, Giacomelli V, Rindi M. A controlled clinical trial on the effect of heparin infusion and two regimens of urokinase in acute pulmonary embolism. Giornale Italiano di Cardiologia 1984;14(Suppl 1):26&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">6398781</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini C, Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988;54(3):162&#x2010;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">3073463</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meyer 2014 {published data only}</Title><Reference><Citation>Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer&#x2010;Westendorf J, et al. Impact of thrombolytic therapy on the long&#x2010;term outcome of intermediate&#x2010;risk pulmonary embolism. Journal of the American College of Cardiology 2017;69(12):1536&#x2010;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">28335835</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer&#x2010;Westendorf J, et al. Fibrinolysis for patients with intermediate&#x2010;risk pulmonary embolism. New England Journal of Medicine 2014;370(15):1402&#x2010;11. [NCT00639743]</Citation><ArticleIdList><ArticleId IdType="pubmed">24716681</ArticleId></ArticleIdList></Reference><Reference><Citation>NCT00639743. PEITHO Pulmonary Embolism Thrombolysis Study. http://clinicaltrials.gov/ct2/show/NCT00639743?term=thrombolysis&amp;rank=14 (accessed April 2009).</Citation></Reference><Reference><Citation>PEITHO Steering Committee. Single&#x2010;bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury: rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial. American Heart Journal 2012; Vol. 163, issue 1:33&#x2010;8. [NCT00639743]</Citation><ArticleIdList><ArticleId IdType="pubmed">22172434</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>PIOPED 1990 {published data only}</Title><Reference><Citation>PIOPED Investigation Committee. Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED investigators. Chest 1990;97(3):528&#x2010;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">2106408</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sharifi 2013 {published data only}</Title><Reference><Citation>Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the "mOPETT" Trial). American Journal of Cardiology 2013;111(2):273&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23102885</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Taherkhani 2014 {published data only}</Title><Reference><Citation>Taherkhani M, Taherkhani A, Hashemi SR, Langroodi TF, Sadeghi R, Beyranvand M. Thrombolytic&#x2010;plus&#x2010;anticoagulant therapy versus anticoagulant&#x2010;alone therapy in submassive pulmonary thromboembolism (TVASPE study): a randomized clinical trial. Journal of Tehran University Heart Center 2014;9(3):104&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393831</ArticleId><ArticleId IdType="pubmed">25870626</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tibbutt 1974 {published data only}</Title><Reference><Citation>Tibbutt DA, Davies JA, Anderson JA, Fletcher EW, Hamill J, Thomas ML, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life&#x2010;threatening pulmonary embolism. British Medical Journal 1974;1(904):343&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1633603</ArticleId><ArticleId IdType="pubmed">4594580</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>UPETSG 1970 {published data only}</Title><Reference><Citation>Sasahara AA, Hyers TM, Cole CM, Ederer F, Murray JA, Wenger NK, et al. The urokinase pulmonary embolism trial. Circulation 1973;47(2 Suppl):7&#x2010;21.</Citation></Reference><Reference><Citation>Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary&#x2010;capillary blood volume in patients with pulmonary embolism. New England Journal of Medicine 1980;303(15):842&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7412801</ArticleId></ArticleIdList></Reference><Reference><Citation>UPET. Urokinase pulmonary embolism trial. Phase 1 results: a co&#x2010;operative study. JAMA 1970;214(12):2163&#x2010;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">5536580</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Abdelsamad 2011 {published data only}</Title><Reference><Citation>Abdelsamad AA, El&#x2010;Morsi AS, Mansour AE. Efficacy and safety of high dose versus low dose streptokinase for treatment of submassive pulmonary embolism. Egyptian Heart Journal 2011;63:67&#x2010;72.</Citation></Reference></ReferenceList><ReferenceList><Title>Agnelli 1997 {published data only}</Title><Reference><Citation>Agnelli G, Iorio A, Parise P, Goldhaber SZ, Levine MN. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt&#x2010;PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. Blood Coagulation and Fibrinolysis 1997;8(4):216&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9199818</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Alexandru Ion 2017 {published data only}</Title><Reference><Citation>Alexandru Ion A, Andrei C, Raducan M, Sinescu C. The bleeding risk in thrombolysed patients with intermediary&#x2010;high risk pulmonary embolism. European Journal of Heart Failure 2017;19(Suppl 1):34&#x2010;5.</Citation></Reference></ReferenceList><ReferenceList><Title>Barrios 2017 {published data only}</Title><Reference><Citation>Barrios D, Chavant J, Rosa&#x2010;Salazar V, Muriel A, Viallon A, Yusen RD, et al. Treatment of right heart thrombi associated with acute pulmonary embolism. American Journal of Medicine 2017;130:588&#x2010;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">28011316</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bell 1974 {published data only}</Title><Reference><Citation>Bell WR, Simon TL, Stengle JM, Sherry S. The urokinase&#x2010;streptokinase pulmonary embolism trial (phase II) results. Circulation 1974;50(6):1070&#x2010;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">4430106</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bell 1976 {published data only}</Title><Reference><Citation>Bell WR. Streptokinase and urokinase in the treatment of pulmonary thromboemboli; from a national co&#x2010;operative study. Thrombosis and Haemostasis 1976;35(1):57&#x2010;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">785689</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bell 1977 {published data only}</Title><Reference><Citation>Bell WR. Thrombolytic therapy: differences between streptokinase and urokinase. Vascular Surgery 1977;11:378&#x2010;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">616152</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bhardwaj 2010 {published data only}</Title><Reference><Citation>Bhardwaj S, Krishna CK, Mukherjee N, Sambi RS, Aggarwal KK, Kapoor N, et al. Treatment of massive pulmonary embolism by tenecteplase. Indian Heart Journal 2010;62(5):454&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23189890</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Carroll 2018 {published data only}</Title><Reference><Citation>Carroll BJ, Goldhaber SZ, Liu PY, Piazza G. Catheter&#x2010;directed, ultrasound&#x2010;facilitated fibrinolysis in obese patients with massive and submassive pulmonary embolism. Journal of Thrombosis and Thrombolysis 2018;45:257&#x2010;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">29322296</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Charbonnier 1984 {published data only}</Title><Reference><Citation>Charbonnier B, Raynaud P, Griguier P, Brochier M. Potentializing effects of a defibrillating agent on therapeutic thrombolysis in pulmonary embolism [Effets potentialisateurs d'un agent defibrinant sur la thrombolyse therapeutique dans l'embolie pulmonaire]. Archives des Maladies du Coeur et des Vaisseaux 1984; Vol. 77:1426.</Citation></Reference></ReferenceList><ReferenceList><Title>Chen 2009 {published data only}</Title><Reference><Citation>Chen Z. Evaluation of effect of rt&#x2010;PA therapy and different dose in acute pulmonary embolism [Abstract]. American Thoracic Society 2009 International Conference; 2009 May 15&#x2010;20; San Diego. American Journal of Respiratory and Critical Care Medicine. 2009; Vol. 179 (Meeting Abstracts):A3294.</Citation></Reference></ReferenceList><ReferenceList><Title>Comerota 2009 {published data only}</Title><Reference><Citation>Comerota AJ. The ATTRACT trial: rationale for early intervention for iliofemoral DVT. Perspectives in Vascular Surgery and Endovascular Therapy 2009;21:221&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20047905</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>De Takats 1973 {published data only}</Title><Reference><Citation>Takats G. The urokinase pulmonary embolism trial. American Journal of Surgery 1973;126(3):311&#x2010;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">4580749</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Erkan 2002 {published data only}</Title><Reference><Citation>Erkan L, Findik S, Atici AG, Uzun O. Thrombolytic therapy in massive pulmonary thromboembolism. European Respiratory Journal 2002; Vol. 20:237s.</Citation></Reference></ReferenceList><ReferenceList><Title>Francois 1986 {published data only}</Title><Reference><Citation>Francois G, Charbonnier B, Raynaud P, Garnier LF, Griguer P, Brochier M. Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen&#x2010;urokinase. 67 cases [Traitemente de l'embolie pulmonaire aigue par urokinase comparee a l'association plasminogene&#x2010;urokinase. A propos de 67 cas]. Archives des Maladies du Coeur et des Vaisseaux 1986;79(4):435&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">3090961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 1989 {published data only}</Title><Reference><Citation>Goldhaber SZ. TPA versus urokinase in acute pulmonary embolism: results of a randomized controlled trial. Vasa &#x2010; Supplementum 1989;27:292&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2516368</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ. Tissue plasminogen activator in acute pulmonary embolism. Chest 1989;95(5 Suppl):282S&#x2010;9S.</Citation><ArticleIdList><ArticleId IdType="pubmed">2495913</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 1992 {published data only}</Title><Reference><Citation>Goldhaber SZ, Kessler CM, Heit JA, Elliot CG. Recombinant tissue&#x2010;type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. Journal of the American College of Cardiology 1992;20(1):24&#x2010;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">1607532</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 1994 {published data only}</Title><Reference><Citation>Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomised trial. Chest 1994;106(3):718&#x2010;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8082347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>IRCT201104245625N2 {published data only}</Title><Reference><Citation>IRCT201104245625N2. Comparative efficacy and complications of two&#x2010;hour versus 24&#x2010;hour regimen of streptokinase in acute pulmonary embolism In Tehran Heart Center. en.irct.ir/trial/6153 (first posted 28 August 2011).</Citation></Reference></ReferenceList><ReferenceList><Title>Jin 2012 {published data only}</Title><Reference><Citation>Jin J, Ding WB, Yuan RF. Thrombolytic treatment of acute pulmonary thromboembolism: comparison between catheter&#x2010;directed thrombolysis and venous thrombolysis. Journal of Interventional Radiology 2012;21:667&#x2010;71.</Citation></Reference></ReferenceList><ReferenceList><Title>Jing 2018 {published data only}</Title><Reference><Citation>Jing X, Zhang G, Zhang B, Dai L, Wang X, Jia L, et al. Efficacy and safety of low&#x2010;dose urokinase for the treatment of hemodynamically stable AECOPD patients with acute pulmonary thromboembolism. Clinical Respiratory Journal 2018;12:1882&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">29227032</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Konstantinides 1998 {published data only}</Title><Reference><Citation>Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. American Journal of Cardiology 1998;82(8):966&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9794353</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lehnert 2017 {published data only}</Title><Reference><Citation>Lehnert P, Moller CH, Mortensen J, Kjaergaard J, SkovOlsen P, Carlsen J, et al. Surgical embolectomy compared to thrombolysis in acute pulmonary embolism: Morbidity and mortality. European Journal of Cardio&#x2010;thoracic Surgery 2017;51:354&#x2010;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">28186234</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Liu 2012 {published data only}</Title><Reference><Citation>Liu FY, Wang MQ, Duan F, Wang ZJ, Song P, Wang Y, et al. Management of acute massive with interventional techniques. Zhonghua Yi Xue Za Zhi 2012;92(19):1343&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22883125</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Marder 1978 {published data only}</Title><Reference><Citation>Marder VJ, Donahoe JF, Bell WR, Cranley JJ, Kwaan HC, Sashara AA, et al. Changes in the plasma fibrinolytic system during urokinase therapy: comparison of tissue culture urokinase with urinary source urokinase in patients with pulmonary embolism. Journal of Laboratory Clinical Medicine 1978;92(5):721&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">712206</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meneveau 1997 {published data only}</Title><Reference><Citation>Meneveau N, Schiele F, Vuillemenot A, Valette B, Grollier G, Bernard Y, et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. European Heart Journal 1997;18(7):1141&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9243149</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meneveau 1998 {published data only}</Title><Reference><Citation>Meneveau N, Schiele F, Metz D, Valette B, Attali P, Vuillemenot A, et al. Comparative efficacy of a two&#x2010;hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one&#x2010;year follow&#x2010;up. Journal of the American College of Cardiology 1998;31(5):1057&#x2010;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562007</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meyer 1992 {published data only}</Title><Reference><Citation>Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al. Comparison of the effect of an intravenous infusion of urokinase or alteplase on total pulmonary resistance in acute massive pulmonary embolism. A European, multi&#x2010;center, double&#x2010;blind study [Vergleich der wirkung einer intravenosen infusion von urokinase oder alteplase auf den pulmonalen en gesamtwiderstand bei akuter massiver lungenembolie. Eine Europapaische multicenter&#x2010;doppelblindestudie]. Intensivmedizin und Notfallmedizin 1992;29:339&#x2010;47.</Citation></Reference><Reference><Citation>Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double&#x2010;blind trial. The European Cooperative Study Group for Pulmonary Embolism. Journal of the American College of Cardiology 1992;19(2):239&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">1732347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Miller 1971 {published data only}</Title><Reference><Citation>Miller GAH, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. British Medical Journal 1971;763(2):681&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796248</ArticleId><ArticleId IdType="pubmed">5556052</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Muhl 2007 {published data only}</Title><Reference><Citation>Muhl D, Furedi R, Gecse K, Ghosh S, Falusi B, Bogar L, et al. Time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism. Blood Coagulation and Fibrinolysis 2007;18(7):661&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890954</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>NCT00680628 {published data only}</Title><Reference><Citation>NCT00680628. Randomized trial of tenecteplase to treat severe submassive pulmonary embolism. http://clinicaltrials.gov/ct2/show/NCT00680628?cond=pulmonary+embolism&amp;rank=42 (accessed January 2015).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT00968929 {published data only}</Title><Reference><Citation>NCT00968929. Recombinant streptokinase versus urokinase in pulmonary embolism in China (RESUPEC). clinicaltrials.gov/ct2/show/NCT00968929 (first posted 31 August 2009).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT01956955 {published data only}</Title><Reference><Citation>NCT01956955. Comparison of low&#x2010;molecular&#x2010;weight heparin (LMWH) and unfractionated heparin (UFH) in combination with thrombolytic treatment of acute massive pulmonary thromboembolism. clinicaltrials.gov/ct2/show/NCT01956955 (first posted 8 October 2013).</Citation></Reference></ReferenceList><ReferenceList><Title>Ohayon 1986 {published data only}</Title><Reference><Citation>Ohayon J, Colle JP, Tauzin&#x2010;Fin P, Lorient&#x2010;Roudaut MF, Besse P. Hemodynamic course during fibrinolysis in severe pulmonary embolism [&#xc9;volution h&#xe9;modynamique au cours des fibrinolyses de l'embolie pulmonaire grave]. Archives des Maladies du Coeur et des Vaisseaux 1986;79(4):445&#x2010;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">3090962</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Palla 1997 {published data only}</Title><Reference><Citation>Palla A, Pazzagli M, Manganelli D, Nitto P, Marini C, Rossi G, et al. Resolution of pulmonary embolism: effect of therapy and putative age of emboli. Respiration 1997;64(1):50&#x2010;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">9044475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Pang 2007 {published data only}</Title><Reference><Citation>Pang BS, Wang C, Lu Y, Yang YH, Xing GH, Mao YL, et al. Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2007;87:3074&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18261355</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Prandoni 1985 {published data only}</Title><Reference><Citation>Prandoni P, Zambon G, Scatigna M. Diagnostic approaches and results in the medical treatment of pulmonary thromboembolism [Aspetti diagnostici e risultati della terapia medica nella tromboembolia polmonare]. Minerva Medica 1985;76(38):1727&#x2010;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">4047457</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Research Group on Urokinase and PE 1984 {published data only}</Title><Reference><Citation>Research Group on Urokinase and Pulmonary Embolism. Multicenter study of 2 urokinase protocols in severe pulmonary embolism [&#xc9;tude multicentrique sur deux protoocles d'ukokinase dans l'embolie pulmonaire grave]. Archives des Maladies du Coeur et des Vaisseaux 1984;77(7):773&#x2010;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">6433840</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Saponjski 2002 {published data only}</Title><Reference><Citation>Saponjski JD, Saponjski MD, Vukcevic VP. Massive pulmonary embolism and thrombolysis in the first week after major surgery. European Respiratory Journal 2002;20(Suppl 38):239s.</Citation></Reference></ReferenceList><ReferenceList><Title>Sasahara 1975 {published data only}</Title><Reference><Citation>Sasahara AA, Bell WR, Simon TL, Stengle JM, Sherry S. The phase II urokinase&#x2010;streptokinase pulmonary embolism trial: a national cooperative study. Thrombosis et Diathesis Haemorrhagica 1975;33(3):464&#x2010;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">1098216</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sharma 2000 {published data only}</Title><Reference><Citation>Sharma GV, Folland ED, McIntyre KM, Sasahara AA. Long&#x2010;term benefit of thrombolytic therapy in patients with pulmonary embolism. Vascular Medicine 2000;5(2):91&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10943585</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sors 1994 {published data only}</Title><Reference><Citation>Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2&#x2010;h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994;106(3):712&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8082346</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tebbe 1999 {published data only}</Title><Reference><Citation>Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. American Heart Journal 1999;138(7):39&#x2010;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10385761</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tebbe 2009 {published data only}</Title><Reference><Citation>Tebbe U, Bramlage P, Graf A, Lechleitner P, Bode C, Riess FC, et al. Desmoteplase in acute massive pulmonary thromboembolism. Thrombosis and Haemostasis 2009;101:557&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">19277420</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>UKEP Study Group 1987 {published data only}</Title><Reference><Citation>The UKEP Study Research Group. The UKEP Study: multicentre clinical trial on two local regimes of urokinase in massive pulmonary embolism. European Heart Journal 1987;8(1):2&#x2010;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">3545842</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>UPET Study Group 1974 {published data only}</Title><Reference><Citation>The Urokinase Pulmonary Embolism Trial Study Froup. Urokinase streptokinase embolism trial. Phase 2 results. A co&#x2010;operative study. Journal of the American Medical Association 1974;229:1606&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Verstraete 1988 {published data only}</Title><Reference><Citation>Verstraete M, Miller GA, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, et al. Intravenous and intrapulmonary recombinant tissue&#x2010;type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988;77(2):353&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">3123091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wang 2006 {published data only}</Title><Reference><Citation>Wang C. The clinical features of 516 patients with acute pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2006;86(31):2161&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17064498</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang YH, Zhai ZG, Wang F, Xie WM, Wang C. Changes in deep venous thrombosis after thrombolytic anticoagulant therapies in acute pulmonary thromboembolism. Chinese Journal of Internal Medicine 2009;48:371&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19615152</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wang 2009 {published data only}</Title><Reference><Citation>Wang Y, Yang Y, Wu Y, Wang C. The echocardiographic changes of pre and after treatments of recombinant streptokinase and urokinase on pulmonary embolism [Abstract]. Respirology 2009;14:A137.</Citation></Reference></ReferenceList><ReferenceList><Title>Wang 2010 {published data only}</Title><Reference><Citation>Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, et al. Efficacy and safety of low dose recombinant tissue&#x2010;type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010;137:254&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126994</ArticleId><ArticleId IdType="pubmed">19741062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Zhai Z, Yang Y, Yuan Y, Cheng Z, Liang L, et al. Efficacy and safety of 2&#x2010;hour urokinase regime in acute pulmonary embolism: a randomized controlled trial [Abstract]. Respiratory Research 2009;10:128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806365</ArticleId><ArticleId IdType="pubmed">20040086</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Wu 2010 {published data only}</Title><Reference><Citation>Wu YQ, Tao LB, Lu C, Hu YH. An economic evaluation of low dose recombinant human tissue&#x2010;type plasminogen activator for the treatment of acute pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2010;90:103&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20356492</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Xu 2016 {published data only}</Title><Reference><Citation>Xu, QH, Li WL, Cai ZM, Lin YC, Huang SP. Effect of 50 mg alteplase to intermediate&#x2010;risk pulmonary embolism with right ventricular dysfunction [&#x963f;&#x66ff;&#x666e;&#x9176;50mg&#x65b9;&#x6848;&#x5bf9;&#x4f34;&#x53f3;&#x5fc3;&#x529f;&#x80fd;&#x4e0d;&#x5168;&#x7684;&#x4e2d;&#x5371;&#x80ba;&#x6813;&#x585e;&#x60a3;&#x8005;&#x7684;&#x7597;&#x6548;]. Chung Hua I Hsueh Tsa Chih 2016;96:3062&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27784446</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yang 2007 {published data only}</Title><Reference><Citation>Yang D, Zhao G, Wu H, Zhou H, Ji Y, Zhang Z. Comparison of local and systemic thrombolytic treatment for acute massive pulmonary embolism [Abstract]. European Respiratory Journal 2007;30:544s.</Citation></Reference></ReferenceList><ReferenceList><Title>Yang 2011 {published data only}</Title><Reference><Citation>Yang Y, Wang Y, Ma Z, Qiu C, Wu H, Zhang X, et al. Efficacy and safety of two&#x2010;hour regimen of recombinant streptokinase versus urokinase in massive and submassive pulmonary embolism [Abstract]. Respirology 2011;16:309.</Citation></Reference></ReferenceList><ReferenceList><Title>Yilmazel 2018 {published data only}</Title><Reference><Citation>Yilmazel U, Araz EO, Kerget B, Yilmaz N, Akgun M, Saglam L. Comparison of long&#x2010;term outcomes of 50 and 100 mg rt&#x2010;PA in the management of acute pulmonary thromboembolism. Clinical Respiratory Journal 2018;12:1628&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">29044967</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zhu 2008 {published data only}</Title><Reference><Citation>Zhu L, Wang C, Yang Y, Wu Y, Zhai Z, Dai H, et al. Value of transthoracic echocardiography in therapy regimens evaluation in pulmonary embolism. Journal of Thrombosis and Thrombolysis 2008;26:251&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17705052</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to ongoing studies</Title><ReferenceList><Title>EUCTR2017&#x2010;005075&#x2010;91&#x2010;DK {published data only}</Title><Reference><Citation>EUCTR2017&#x2010;005075&#x2010;91. Low dose thrombolysis, ultrasound assisted thrombolysis or heparin for intermediate high risk pulmonary embolism. clinicaltrialsregister.eu/ctr&#x2010;search/trial/2017&#x2010;005075&#x2010;91/DK (first posted 25 May 2018).</Citation></Reference></ReferenceList><ReferenceList><Title>EudraCT: 2005&#x2010;001070&#x2010;27 {published data only}</Title><Reference><Citation>EudraCT 2005&#x2010;001070&#x2010;27. Open, randomised, monosite pilot trial for comparison of thrombolytic efficacy of tenecteplase and alteplase in patients with acute pulmonary embolism. clinicaltrialsregister.eu/ctr&#x2010;search/search?query=eudract_number:2005&#x2010;001070&#x2010;27 (first posted 7 July 2005).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT01531829 {published data only}</Title><Reference><Citation>NCT01531829. Low dose Rt&#x2010;PA for acute normotensive pulmonary embolism with RVD. clinicaltrials.gov/ct2/show/NCT01531829 (first posted 13 February 2012).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT02604238 {published data only}</Title><Reference><Citation>NCT02604238. Efficacy and safety of half dose alteplase added to heparin, in patients with moderate pulmonary embolism (MONALYSE). clinicaltrials.gov/ct2/show/NCT02604238 (first posted 13 November 2015).</Citation></Reference></ReferenceList><ReferenceList><Title>NCT03218410 {published data only}</Title><Reference><Citation>NCT03218410. Surgical pulmonary embolectomy versus catheter&#x2010;directed thrombolysis in the treatment of pulmonary embolism: a non&#x2010;inferiority study (Lungembolism). clinicaltrials.gov/ct2/show/NCT03218410 (first posted 14 July 2017).</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Bottiger 1994</Title><Reference><Citation>Bottiger BW, Bohrer H, Bach A, Motsch J, Martin E. Bolus injection of thrombolytic agents during cardiopulmonary resuscitation for massive pulmonary embolism. Resuscitation 1994;28(1):45&#x2010;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">7809485</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Browse 1962</Title><Reference><Citation>Browse NL, James DC. Streptokinase and pulmonary embolism. The Lancet 1962;2:1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">14206016</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cao 2014</Title><Reference><Citation>Cao Y, Zhao H, Gao W, Wang Y, Cao J. Systematic review and meta&#x2010;analysis for thrombolysis treatment in patients with acute submassive pulmonary embolism. Patient Preference and Adherence 2014;28(8):275&#x2010;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3945048</ArticleId><ArticleId IdType="pubmed">24611003</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chatterjee 2014</Title><Reference><Citation>Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of all&#x2010;cause mortality, major bleeding, and intracranial hemorrhage: a meta&#x2010;analysis. Journal of the American Medical Association 2014;311(23):2414&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24938564</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chesterman 1969</Title><Reference><Citation>Chesterman CN, Biggs JC, Morgan J, Hickie JB. Streptokinase therapy in acute major pulmonary embolism. Medical Journal of Australia 1969;2(22):1096&#x2010;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">5374043</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Eberle 2018</Title><Reference><Citation>Eberle H, Lyn R, Knight T, Hodge E, Daley M. Clinical update on thrombolytic use in pulmonary embolism: a focus on intermediate&#x2010;risk patients. American Journal of Health&#x2010;system Pharmacy 2018;75(17):1275&#x2010;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">29895520</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gao 2015</Title><Reference><Citation>Gao GY, Yang P, Liu M, Ding M, Liu GH, Tong YL, et al. Thrombolysis for acute intermediate&#x2010;risk pulmonary embolism: a meta&#x2010;analysis. Thrombosis Research 2015;136(5):932&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26384442</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Genton 1968</Title><Reference><Citation>Genton E, Wolf P. Urokinase therapy in pulmonary thromboembolism. American Heart Journal 1968;76(5):628&#x2010;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">5698419</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 1988</Title><Reference><Citation>Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GVRK, Dawley D, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. The Lancet 1988;2(8606):293&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2899718</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Goldhaber 2002</Title><Reference><Citation>Goldhaber SZ. Thrombolysis for pulmonary embolism. New England Journal of Medicine 2002;347(15):1131&#x2010;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374871</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>GRADEpro GDT 2015 [Computer program]</Title><Reference><Citation>McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 6 November 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.</Citation></Reference></ReferenceList><ReferenceList><Title>Gupta 2018</Title><Reference><Citation>Gupta R, Fortman DD, Morgenstern DR, Cooper CJ. Short&#x2010; and long&#x2010;term mortality risk after acute pulmonary embolism. Current Cardiology Reports 2018;20(12):135.</Citation><ArticleIdList><ArticleId IdType="pubmed">30311090</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hepburn&#x2010;Brown 2018</Title><Reference><Citation>Hepburn&#x2010;Brown M, Darvall J, Hammerschlag G. Acute pulmonary embolism: a concise review of diagnosis and management. Internal Medicine Journal 2018; Vol. doi:10.1111/imj.14145. [DOI: 10.1111/imj.14145]</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.14145</ArticleId><ArticleId IdType="pubmed">30324770</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2011</Title><Reference><Citation>Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Wiley&#x2010;Blackwell.</Citation></Reference></ReferenceList><ReferenceList><Title>Hirsh 1971</Title><Reference><Citation>Hirsh J, McDonald IG, Hale GA, O'Sullivan EF, Jelinek VM. Comparison of the effects of streptokinase and heparin on the early rate of resolution of major pulmonary embolism. Canadian Medical Association Journal 1971;104(6):488&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1930899</ArticleId><ArticleId IdType="pubmed">5549989</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hyers 1970</Title><Reference><Citation>Hyers TM, Stengle JM, Sherry S. Treatment of pulmonary embolism with urokinase. Results of clinical trial (phase 1). Circulation 1970;42(6):979&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">5492546</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jaff 2011</Title><Reference><Citation>Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011;123(16):1788&#x2010;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">21422387</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Konstantinides 1999</Title><Reference><Citation>Konstantinides S, Geibel A, Kasper W. Submassive and massive pulmonary embolism: a target for thrombolytic therapy?. Thrombosis and Haemostasis 1999;82(Suppl 1):104&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10695497</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lefebvre 2011</Title><Reference><Citation>Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Liu 2014</Title><Reference><Citation>Liu Y, Lu Y, Song J, Li D, Liu H, Yang J, et al. Recombinant tissue plasminogen activator for hemodynamically stable patients experiencing an acute pulmonary embolism: a meta&#x2010;analysis. Thrombosis Research 2014;134(1):50&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24824292</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Marti 2014</Title><Reference><Citation>Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta&#x2010;analysis. European Heart Journal 2014;36(10):605&#x2010;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4352209</ArticleId><ArticleId IdType="pubmed">24917641</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Meneveau 2006</Title><Reference><Citation>Meneveau N, S&#xe9;ronde MF, Blonde MC, Legalery P, Didier&#x2010;Petit K, Briand F, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006;129(4):1043&#x2010;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16608956</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nakamura 2014</Title><Reference><Citation>Nakamura S, Takano H, Kubota Y, Asai K, Shimizu W. Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a meta&#x2010;analysis. Journal of Thrombosis and Haemostasis 2014;12(7):1086&#x2010;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">24829097</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>NICE 2012</Title><Reference><Citation>National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. nice.org.uk/guidance/cg144 2012 (accessed August 2015).</Citation></Reference></ReferenceList><ReferenceList><Title>Perlroth 2007</Title><Reference><Citation>Perlroth DJ, Sanders GD, Gould MK. Effectiveness and cost&#x2010;effectiveness of thrombolysis in submassive pulmonary embolism. Archives of Internal Medicine 2007;167(1):74&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210881</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Review Manager 2014 [Computer program]</Title><Reference><Citation>The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.</Citation></Reference></ReferenceList><ReferenceList><Title>Sasahara 1967</Title><Reference><Citation>Sasahara AA, Cannilla JE, Belko JS, Morse RL, Criss AJ. Urokinase therapy in clinical pulmonary embolism. A new thrombolytic agent. New England Journal of Medicine 1967;277(22):1168&#x2010;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">6058604</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sasahara 1973</Title><Reference><Citation>Sasahara AA, Hyers TM, Cole CM, Ederer F, Murray JA, Wenger NK, et al. The urokinase pulmonary embolism trial: a national co&#x2010;operative study. Circulation 1973;47(2 Suppl):7&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">4266893</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sautter 1967</Title><Reference><Citation>Sautter RD, Emanuel RA, Fletcher FW, Wenzel FJ, Matson JI. Urokinase for the treatment of acute pulmonary thromboembolism. Journal of the American Medical Association 1967;202(3):215&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">6072357</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sista 2017</Title><Reference><Citation>Sista AK, Kuo WT, Schiebler M, Madoff DC. Stratification, imaging, and management of acute massive and submassive pulmonary embolism. Radiology 2017;284(1):5&#x2010;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">28628412</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tapson 2017</Title><Reference><Citation>Tapson VF, Friedman O. Systemic thrombolysis for pulmonary embolism: who and how. Techniques in Vascular and Interventional Radiology 2017;20(3):162&#x2010;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">29029710</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tow 1967</Title><Reference><Citation>Tow DE, Wagner HN Jr, Holmes RA. Urokinase in pulmonary embolism. New England Journal of Medicine 1967;277(22):1161&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">6058603</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yamasawa 1992</Title><Reference><Citation>Yamasawa F, Okada Y, Asano K, Mori M, Fujita H, Hasegawa N, et al. The role of recombinant human tissue&#x2010;type plasminogen activator in the treatment of acute pulmonary thromboembolism. Internal Medicine 1992;31(7):885&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1450496</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to other published versions of this review</Title><ReferenceList><Title>Dong 2002</Title><Reference><Citation>Dong B, Pineo G, Mulrooney T. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD004437]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004437</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dong 2006</Title><Reference><Citation>Dong BR, Yue J, Liu GJ, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004437.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004437.pub2</ArticleId><ArticleId IdType="pmc">PMC6516871</ArticleId><ArticleId IdType="pubmed">30560579</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dong 2009</Title><Reference><Citation>Dong BR, Hao Q, Yue J, Wu T, Liu GJ. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD004437.pub3]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004437.pub3</ArticleId><ArticleId IdType="pubmed">19588357</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hao 2015</Title><Reference><Citation>Hao Q, Dong BR, Yue J, Wu T, Liu GJ. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD004437.pub4]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004437.pub4</ArticleId><ArticleId IdType="pubmed">26419832</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28331932</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2567-689X</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>Thrombosis and haemostasis</Title><ISOAbbreviation>Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Pulmonary embolism and in situ pulmonary artery thrombosis in paediatrics. A systematic review.</ArticleTitle><Pagination><StartPage>1199</StartPage><EndPage>1207</EndPage><MedlinePgn>1199-1207</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1160/TH16-07-0529</ELocationID><Abstract><AbstractText>Data on paediatric pulmonary embolism (PE) are scarce. We sought to systematically review the current literature on childhood PE and conducted a search on paediatric PE via PubMed (1946-2013) and Embase (1980-2013). There was significant heterogeneity in reported data. Two patterns were noted: classic thromboembolic PE (TE-PE) and in situ pulmonary artery thrombosis (ISPAT). Mean age of presentation for TE-PE was 14.86 years, and 51&#x2009;% of cases were males. The commonest method for diagnosis of TE-PE was contrast CT with angiography (74&#x2009;% of patients). The diagnosis of TE-PE was often delayed. Although 85&#x2009;% of children with TE-PE had an elevated D-dimer at presentation, it was non-discriminatory for the diagnosis. In paediatric TE-PE, the prevalence of central venous catheters was 23&#x2009;%, immobilisation 38&#x2009;%, systemic infection 31&#x2009;% and obesity 13&#x2009;%, elevated Factor VIII or von Willebrand factor levels 27&#x2009;%, Protein C deficiency 17&#x2009;%, Factor V Leiden 14&#x2009;% and Protein S deficiency 7&#x2009;%. In patients with TE-PE, pharmacologic thrombolysis was used in 29&#x2009;%; unfractionated heparin was the most common initial anticoagulant treatment in 64&#x2009;% and low-molecular-weight heparins the most common follow-up treatment in 83&#x2009;%. Duration of anticoagulant therapy was variable and death was reported in 26&#x2009;% of TE-PE patients. In contrast to TE-PE, patients with ISPAT were not investigated systematically for presence of thrombophilia, had more surgical interventions as the initial management and were often treated with anti-platelet medications. This review summarises important data and identifies gaps in the knowledge of paediatric PE, which may help to design future studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajpurkar</LastName><ForeName>Madhvi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Madhvi Rajpurkar, 3901 Beaubien St, Detroit, MI, 48201, USA, Tel.: +1 313 745 551, E-mail: mrajpurk@med.wayne.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biss</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Amankwah</LastName><ForeName>Ernest K</ForeName><Initials>EK</Initials></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Suzan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Van Ommen</LastName><ForeName>C Heleen</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Goldenberg</LastName><ForeName>Neil A</ForeName><Initials>NA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Thromb Haemost</MedlineTA><NlmUniqueID>7608063</NlmUniqueID><ISSNLinking>0340-6245</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000792" MajorTopicYN="N">Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011029" MajorTopicYN="N">Pneumoradiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011651" MajorTopicYN="N">Pulmonary Artery</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">children</Keyword><Keyword MajorTopicYN="N">paediatrics</Keyword><Keyword MajorTopicYN="N">pulmonary artery thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28331932</ArticleId><ArticleId IdType="doi">10.1160/TH16-07-0529</ArticleId><ArticleId IdType="pii">16-07-0529</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31008951</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>16</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Efficacy of rivaroxaban for pulmonary embolism.</ArticleTitle><Pagination><StartPage>e15224</StartPage><MedlinePgn>e15224</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e15224</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000015224</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous clinical trials have addressed that rivaroxaban is effective for the treatment of patients with pulmonary embolism (PE). This study will systematically assess its efficacy and safety for PE.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We will carry out this study by searching the following electronic databases from inception to March 1, 2019 without language restrictions: Cochrane Library, EMBASE, PUBMED, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. In addition, we will also search clinical trial registries, dissertations, and conference abstracts to avoid any missing potential studies. All randomized controlled trials of rivaroxaban for patients with PE will be fully considered. Two researchers will independently perform literature selection, data collection, and methodological quality assessment. If it is appropriate, outcome data will be pooled by using a fixed-effect model or random-effect model, and meta-analysis will be considered for operation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All efficacy and safety of rivaroxaban for PE will be assessed through all primary and secondary outcomes. The primary outcomes are all-cause mortality and major bleeding. The secondary outcomes are recurrent venous thromboembolism, duration of hospital stay, quality of life, patient satisfaction, and adverse events.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings of this study will summarize updated evidence on the efficacy and safety of rivaroxaban for patients with PE.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">It is not necessary to inquire ethical approval for this study, because it will not analyze any individual patient data. The results of this study will be published through peer-reviewed journals.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION" NlmCategory="BACKGROUND">PROSPERO CRD42019126095.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Shi-Min</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Critical Medicine, Yulin No. 2 Hospital, Yulin, Shaanxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065427">Factor Xa Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NDF7JZ4M3</RegistryNumber><NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D065427" MajorTopicYN="N">Factor Xa Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31008951</ArticleId><ArticleId IdType="pmc">PMC6831236</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000015224</ArticleId><ArticleId IdType="pii">00005792-201904190-00032</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coon WW. Venous thromboembolism. Prevalence, risk factors, and prevention. Clin Chest Med 1984;5:391&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">6386288</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartholomew JR. Update on the management of venous thromboembolism. Cleve Clin J Med 2017;84Suppl 3:39&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">29257737</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Tang L, Hu Y. Progress in the research on venous thromboembolism. J Huazhong Univ Sci Technol Med Sci 2017;37:811&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">29270736</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter MP, Schernthaner GH, Lang IM. Chronic complications of venous thromboembolism. J Thromb Haemost 2017;15:1531&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">28762624</ArticleId></ArticleIdList></Reference><Reference><Citation>White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12814979</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med 2013;126:832e813&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">23830539</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012;379:1835&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">22494827</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521222</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995;108:978&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">7555172</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson FA, Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2025141</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C. Natural history of venous thromboembolism. Circulation 2003;107: I22-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">12814982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S&#x2013;33S.</Citation><ArticleIdList><ArticleId IdType="pubmed">15383473</ArticleId></ArticleIdList></Reference><Reference><Citation>Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011;378:41&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21703676</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondag W, Mos ICM, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011;9:1500&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21645235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1768813</ArticleId><ArticleId IdType="pubmed">15772203</ArticleId></ArticleIdList></Reference><Reference><Citation>White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167:239&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">17296878</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins MH, Bamber L, Cano SJ, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res 2015;135:281&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25483215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e419S&#x2013;96S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278049</ArticleId><ArticleId IdType="pubmed">22315268</ArticleId></ArticleIdList></Reference><Reference><Citation>Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 2010;30:376&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20139357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarich TC, Peters G, Berkowitz SD, et al. Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Ann NY Acad Sci 2013;1291:42&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">23701516</ArticleId></ArticleIdList></Reference><Reference><Citation>The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">21128814</ArticleId></ArticleIdList></Reference><Reference><Citation>The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">22449293</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohn CG, Fermann GJ, Peacock WF, et al. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies. Curr Med Res Opin 2017;33:1697&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">28665208</ArticleId></ArticleIdList></Reference><Reference><Citation>Groetzinger LM, Miller TJ, Rivosecchi RM, et al. Apixaban or rivaroxaban versus warfarin for treatment of submassive pulmonary embolism after catheter-directed thrombolysis. Clin Appl Thromb Hemost 2018;24:908&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6714714</ArticleId><ArticleId IdType="pubmed">29455567</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen ZF. Clinical efficacy and safety of rivaroxaban in the treatment of acute pulmonary embolism. Chin Community Physician 2018;34:47&#x2013;8.</Citation></Reference><Reference><Citation>Cai XY, Sun J. Clinical observation of rivaroxaban in the treatment of middle-risk pulmonary embolism. World Med Inf Dig 2018;18:101&#x2013;4.</Citation></Reference><Reference><Citation>Liang S. Therapeutic effect of comprehensive nursing intervention combined with rivaroxaban in patients with acute pulmonary thromboembolism combined with deep venous thrombosis of lower extremity. Heilongjiang Med 2018;42:1025&#x2013;6.</Citation></Reference><Reference><Citation>Liang LD, Lin MK, Zhou W, et al. The effect of rivaroxaban combined with low-division heparin calcium in the treatment of advanced lung cancer with pulmonary embolism. Chin J Gerontol 2018;38:4385&#x2013;7.</Citation></Reference><Reference><Citation>Sun GL, Qiao W, Gao SJ. Clinical effect of rivaroxaban in the treatment of pulmonary embolism. Chin Prescr Drugs 2018;16:66&#x2013;7.</Citation></Reference><Reference><Citation>Ye GS. Effect of rivaroxaban on pulmonary embolization anticoagulant therapy, incidence of adverse reactions and effects on vascular endothelial function in patients. Chin Pract Med 2018;13:93&#x2013;4.</Citation></Reference><Reference><Citation>Wei XL, Guli KD. Observing the clinical efficacy of rivaroxaban in the treatment of patients with pulmonary embolism. Chin Foreign Med Treat 2018;37:105&#x2013;6.</Citation></Reference><Reference><Citation>Huang H, Huang XD, Lin CQ. Therapeutic effect of rivaroxaban on acute pulmonary embolism. China Mod Pharm Appl 2018;12:88&#x2013;90.</Citation></Reference><Reference><Citation>Tian H, Wang H, Wang YP, et al. Clinical observation of rivaroxaban in the treatment of venous thromboembolism. Chin Foreign Med Res 2018;16:45&#x2013;7.</Citation></Reference><Reference><Citation>Tang KW, Mo GQ, Pan YC. Clinical efficacy of low molecular weight heparin combined with rivaroxaban in the treatment of acute pulmonary embolism. J Clin Ration Drug Use 2018;11:55&#x2013;6.</Citation></Reference><Reference><Citation>Ren JF, Si QJ. Study on the efficacy and safety of different regimens of rivaroxaban in the prevention and treatment of elderly patients with thromboembolic diseases. Chin J Geriatr Cardiovasc Cerebrovasc Dis 2018;20:367&#x2013;70.</Citation></Reference><Reference><Citation>Jiang G, Zhang WD, Peng ML. Clinical significance of rivaroxaban in the treatment of acute intermediate-risk pulmonary thromboembolism combined with deep venous thrombosis of lower extremity. Chin J Respir Crit Care 2018;17:172&#x2013;7.</Citation></Reference><Reference><Citation>Wu X, Cui WN, Wang SM, et al. Effects of rivaroxaban on D-dimer level and quality of life in patients with acute pulmonary embolism. Chin Lab Diagn 2018;22:230&#x2013;3.</Citation></Reference><Reference><Citation>Huang XG, Wang LY, Chen XL. Therapeutic effect of rivaroxaban on acute pulmonary embolism after stroke. Chin J Pract Nerv Dis 2017;20:32&#x2013;5.</Citation></Reference><Reference><Citation>Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.</Citation><ArticleIdList><ArticleId IdType="pubmed">25555855</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28495379</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6795</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography</Title><ISOAbbreviation>J Am Soc Echocardiogr</ISOAbbreviation></Journal><ArticleTitle>Transthoracic Echocardiography for Diagnosing Pulmonary Embolism: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>714</StartPage><EndPage>723.e4</EndPage><MedlinePgn>714-723.e4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.echo.2017.03.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0894-7317(17)30182-7</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Pulmonary embolism (PE) is a common diagnosis with significant mortality if not appropriately treated. The use of transthoracic echocardiography in patients with PE is common; however, its diagnostic capabilities in this use are unclear. With the increased use of ultrasonography in medical settings, it is important to understand the strengths and limitations of echocardiography for the diagnosis of PE.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a systematic review of PubMed, CINAHL, and EMBASE through 2016 for articles assessing the diagnostic accuracy of transthoracic echocardiography for PE. Two authors independently abstracted relevant data from the studies. We assessed quality using the QUADAS-2 tool for diagnostic studies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Undefined "right heart strain" was the most common sign used, and it had a sensitivity of 53% (95% CI, 45%-61%) and a specificity of 83% (95% CI, 74%-90%). Eleven other distinct signs were identified: ventricle size ratio, abnormal septal motion, tricuspid regurgitation, 60/60 sign, McConnell's sign, right heart thrombus, right ventricle hypokinesis, pulmonary hypertension, right ventricular end-diastolic diameter, tricuspid annular plane systolic excursion, and right ventricular systolic pressure.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Studies show a consistently high specificity and low sensitivity for echocardiography in the diagnosis&#xa0;of PE, making it potentially adequate as a rule-in test at the bedside in critical care settings such as the emergency department and intensive care unit for patients with a suspicion of PE, especially those unable&#xa0;to get other confirmatory studies. Future research may continue to clarify the role of bedside echocardiography in conjunction with other tests and imaging in the overall management of PE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fields</LastName><ForeName>J Matthew</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. Electronic address: matthewfields@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girson</LastName><ForeName>Lily</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Au</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Potts</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>Charity J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vetter</LastName><ForeName>Imelda</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Lister Hill Library, University of Alabama at Birmingham, Birmingham, Alabama; Dell Medical School, University of Texas at Austin, Austin, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riesenberg</LastName><ForeName>Lee Ann</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, Birmingham, Alabama.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Soc Echocardiogr</MedlineTA><NlmUniqueID>8801388</NlmUniqueID><ISSNLinking>0894-7317</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Critical care</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Ultrasonography</Keyword><Keyword MajorTopicYN="N">Ultrasound</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28495379</ArticleId><ArticleId IdType="doi">10.1016/j.echo.2017.03.004</ArticleId><ArticleId IdType="pii">S0894-7317(17)30182-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37865011</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Injury</Title><ISOAbbreviation>Injury</ISOAbbreviation></Journal><ArticleTitle>The effectiveness of venous thromboembolism prophylaxis interventions in trauma patients: A systematic review and network meta-analysis.</ArticleTitle><Pagination><StartPage>111078</StartPage><MedlinePgn>111078</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.injury.2023.111078</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0020-1383(23)00782-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Venous thromboembolism (VTE) is a major complication of trauma. Currently, there are few studies summarising the evidence for prophylaxis in trauma settings. This review provides evidence for the use of VTE prophylactic interventions in trauma patients to produce evidence-based guidelines.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A PRISMA-compliant review was conducted from Sep 2021 to June 2023, using Embase, Medline and Google Scholar. The inclusion criteria were: randomized-controlled trials (RCTs) in English published after 2000 of adult trauma patients comparing VTE prophylaxis interventions, with a sample size higher than 20. The network analysis was conducted using RStudio. The results of the pairwise comparisons were presented in the form of a league table. The quality of evidence and heterogeneity sensitivity were assessed. The primary outcome focused on venous thromboembolism (VTE), and examined deep vein thrombosis (DVT) and pulmonary embolism (PE) as separate entities. The secondary outcomes included assessments of bleeding and mortality. PROSPERO registration: CRD42021266393.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 7,948 search results, 23 studies with a total of 21,312 participants fulfilled screening criteria, which included orthopaedic, spine, solid organ, brain, spinal cord, and multi-region trauma. Of the eight papers comparing chemical prophylaxis medications in patients with hip or lower limb injuries, fondaparinux and enoxaparin were found to be significantly superior to placebo in respect of prevention of DVT, with no increased risk of bleeding. Regarding mechanical prophylaxis, meta-analysis of two studies of inferior vena cava filters failed to provide significant benefits to major trauma patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Enoxaparin and fondaparinux are safe and effective options for VTE prevention in trauma patients, with fondaparinux being a cheaper and easier administration option between the two. Inconclusive results were found in mechanical prophylaxis, requiring more larger-scale RCTs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine, Faculty of Medical and Health Sciences, The University of Auckland Te Waipapa Taumata Rau, Auckland, New Zealand. Electronic address: NotSerenaPeng@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Mandy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine, Faculty of Medical and Health Sciences, The University of Auckland Te Waipapa Taumata Rau, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, Faculty of Medical and Health Sciences, The University of Auckland Te Waipapa Taumata Rau, Auckland, New Zealand; Department of Surgery, Te Whatu Ora - Counties Manukau, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacCormick</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>School of Medicine, Faculty of Medical and Health Sciences, The University of Auckland Te Waipapa Taumata Rau, Auckland, New Zealand; Department of Surgery, Te Whatu Ora - Counties Manukau, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Injury</MedlineTA><NlmUniqueID>0226040</NlmUniqueID><ISSNLinking>0020-1383</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>J177FOW5JL</RegistryNumber><NameOfSubstance UI="D000077425">Fondaparinux</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077425" MajorTopicYN="N">Fondaparinux</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="Y">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Network, analysis</Keyword><Keyword MajorTopicYN="N">Prophylaxis</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">Trauma</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The author of this article/document hereby declares that they have no relevant financial ties, affiliations, or interests, personal or professional, that could be perceived as a potential conflict of interest in relation to the subject matter discussed. All data, statements, and opinions presented are solely those of the author and are not influenced by any third-party organizations or individuals.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>5</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>21</Day><Hour>18</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37865011</ArticleId><ArticleId IdType="doi">10.1016/j.injury.2023.111078</ArticleId><ArticleId IdType="pii">S0020-1383(23)00782-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36600747</PMID><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2229-5097</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Surgical neurology international</Title><ISOAbbreviation>Surg Neurol Int</ISOAbbreviation></Journal><ArticleTitle>Antifibrinolytics use during surgery for oncological spine diseases: A systematic review.</ArticleTitle><Pagination><StartPage>567</StartPage><MedlinePgn>567</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">567</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.25259/SNI_837_2022</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Data exist of the benefits of antifibrinolytics such as tranexamic acid (TXA) in general spine surgery. However, there are limited data of its use in oncological spine patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, Cochrane, OVID, and Embase databases were searched. Search terms: "<i>tranexamic acid"</i>, "<i>aprotinin</i>," "<i>aminocaproic acid</i>," "<i>spine surgery</i>," "<i>spine tumors</i>," and "<i>spine oncology</i>." Included studies were full text publications written in English with patients treated with either agent or who had surgery for oncological spine disease (OSD).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Seven hundred results were reviewed form the different databases, seven were selected. A total of 408 patients underwent spine surgery for OSD and received antifibrinolytics. There was a male predominance (55.2%) and mean age ranged from 43 to 62 years. The most common tumor operated was metastatic renal cancer, followed by breast and lung. Most studies administered TXA as a bolus followed by an infusion during surgery. Median blood loss was of 667 mL (253.3-1480 mL). Patients with TXA required 1-2 units less of transfusion and had 56-63 mL less of postoperative drainage versus no TXA. The median incidence of deep venous thrombosis (DVT) was 2.95% (0-7.9%) and for pulmonary embolism (PE) was 4.25% (0-14.3%). The use of TXA reduced intraoperative blood loss, transfusions and reduced postoperative surgical drainage output compared to no TXA use in patients with OSD.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In this review, we found that TXA may diminish intraoperative blood loss, the need for transfusion and postoperative drainage from surgical drains when used in OSD without major increase in rates of DVT or PE.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Surgical Neurology International.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Avila</LastName><ForeName>Mauricio J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Arizona, Tucson, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orenday-Barraza</LastName><ForeName>Jos&#xe9; Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Arizona College of Medicine, Phoenix, Arizona, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavagnaro</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Arizona, Tucson, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strouse</LastName><ForeName>Isabel M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Arizona College of Medicine, Phoenix, Arizona, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhadi</LastName><ForeName>Dara S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Arizona College of Medicine, Phoenix, Arizona, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Naushaba</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Arizona College of Medicine, Phoenix, Arizona, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Amna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Arizona College of Medicine, Phoenix, Arizona, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baaj</LastName><ForeName>Ali A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, University of Arizona College of Medicine, Phoenix, Arizona, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Neurol Int</MedlineTA><NlmUniqueID>101535836</NlmUniqueID><ISSNLinking>2152-7806</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antifibrinolytics</Keyword><Keyword MajorTopicYN="N">Metastatic spine disease</Keyword><Keyword MajorTopicYN="N">Spine oncology</Keyword><Keyword MajorTopicYN="N">Spine surgery</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>5</Day><Hour>2</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36600747</ArticleId><ArticleId IdType="pmc">PMC9805626</ArticleId><ArticleId IdType="doi">10.25259/SNI_837_2022</ArticleId><ArticleId IdType="pii">10.25259/SNI_837_2022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Avila MJ, Walter CM, Baaj AA. Outcomes and complications of minimally invasive surgery of the lumbar spine in the elderly. Cureus. 2016;8:e519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829395</ArticleId><ArticleId IdType="pubmed">27081580</ArticleId></ArticleIdList></Reference><Reference><Citation>Bednar DA, Bednar VA, Chaudhary A, Farrokhyar F, Farroukhyar F. Tranexamic acid for hemostasis in the surgical treatment of metastatic tumors of the spine. Spine (Phila Pa 1976) 2006;31:954&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16622388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzetti F. Forcing the vicious circle: Sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol. 2017;28:2107&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">28911059</ArticleId></ArticleIdList></Reference><Reference><Citation>Damade C, Tesson G, Gilard V, Vigny S, Foulongne E, Gauth&#xe9; R, et al. Blood loss and perioperative transfusions related to surgery for spinal tumors. Relevance of tranexamic acid. Neurochirurgie. 2019;65:377&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">31202780</ArticleId></ArticleIdList></Reference><Reference><Citation>Elwatidy S, Jamjoom Z, Elgamal E, Zakaria A, Turkistani A, El-Dawlatly A. Efficacy and safety of prophylactic large dose of tranexamic acid in spine surgery: A prospective, randomized, double-blind, placebo-controlled study. Spine (Phila Pa 1976) 2008;33:2577&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">19011538</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima N, Barra ME, Roberts RJ, Massaad E, Hadzipasic M, Shankar GM, et al. Advances in surgical hemostasis: A comprehensive review and meta-analysis on topical tranexamic acid in spinal deformity surgery. Neurosurg Rev. 2021;44:163&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">31938967</ArticleId></ArticleIdList></Reference><Reference><Citation>Godersky JC, Smoker WR, Knutzon R. Use of magnetic resonance imaging in the evaluation of metastatic spinal disease. Neurosurgery. 1987;21:676&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">3696401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hockley A, Ge D, Vasquez-Montes D, Moawad MA, Passias PG, Errico TJ, et al. Minimally invasive versus open transforaminal lumbar interbody fusion surgery: An analysis of opioids, nonopioid analgesics, and perioperative characteristics. Glob Spine J. 2019;9:624&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693068</ArticleId><ArticleId IdType="pubmed">31448196</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clin Trials. 1996;17:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17918266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar N, Zaw AS, Khine HE, Maharajan K, Wai KL, Tan B, et al. Blood loss and transfusion requirements in metastatic spinal tumor surgery: Evaluation of influencing factors. Ann Surg Oncol. 2016;23:2079&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">26819232</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sun TW, Luo G, Zhang C. Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: A meta-analysis. Eur Spine J. 2017;26:140&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">27671279</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ZJ, Fu X, Xing D, Zhang HF, Zang JC, Ma XL. Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials. Eur Spine J. 2013;22:1950&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3777050</ArticleId><ArticleId IdType="pubmed">23657623</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu VM, Kerezoudis P, Gilder HE, McCutcheon BA, Phan K, Bydon M. Minimally invasive surgery versus open surgery spinal fusion for spondylolisthesis: A systematic review and meta-analysis. Spine. 2017;42:E177&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">27285899</ArticleId></ArticleIdList></Reference><Reference><Citation>Moussazadeh N, Laufer I, Yamada Y, Bilsky MH. Separation surgery for spinal metastases: Effect of spinal radiosurgery on surgical treatment goals. Cancer Control. 2014;21:168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">24667404</ArticleId></ArticleIdList></Reference><Reference><Citation>National Heart L and Blood Institute, National Institutes of Health, US Department of Health and Human Services. Study Quality Assessment Tools. 2019.  Available from:  https://www.nhlbinih.gov/health-topics/study-quality-assessmen-tools [Last accessed on 2022 Sep 11]</Citation></Reference><Reference><Citation>Orenday-Barraza JM, Cavagnaro MJ, Avila MJ, Strouse IM, Dowell A, Kisana H, et al. 10-year trends in the surgical management of patients with spinal metastases: A scoping review. World Neurosurg. 2021;157:170&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">34655822</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennington Z, Ehresman J, Schilling A, Feghali J, Hersh AM, Hung B, et al. Influence of tranexamic acid use on venous thromboembolism risk in patients undergoing surgery for spine tumors. J Neurosurg Spine. 2021;35:663&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">34388705</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchyk KM, Schiff BA, Newkirk KA, Krowiak E, Deeb ZE. Metastatic renal cell carcinoma to the head and neck. Laryngoscope. 2002;112:1598&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">12352670</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman T, Varlotta C, Vasquez-Montes D, Buckland AJ, Errico TJ. The use of tranexamic acid in adult spinal deformity: Is there an optimal dosing strategy? Spine J. 2019;19:1690&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31202836</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothrock RJ, Barzilai O, Reiner AS, Lis E, Schmitt AM, Higginson DS, et al. Survival trends after surgery for spinal metastatic tumors: 20-Year cancer center experience. Neurosurgery. 2021;88:402&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803433</ArticleId><ArticleId IdType="pubmed">32970144</ArticleId></ArticleIdList></Reference><Reference><Citation>The SCRINIO Working Group. Bozzetti F, Mariani L, Lo Vullo S, Amerio ML, Biffi R, et al. The nutritional risk in oncology: A study of 1,453 cancer outpatients. Support Care Cancer. 2012;20:1919&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390688</ArticleId><ArticleId IdType="pubmed">22314972</ArticleId></ArticleIdList></Reference><Reference><Citation>Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23908465</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsantes AG, Trikoupis IG, Papadopoulos DV, Goumenos S, Piovani D, Nikolopoulos GK, et al. The safety and efficacy of tranexamic acid in oncology patients undergoing endoprosthetic reconstruction and a ROTEM-based evaluation of their hemostatic profile: A pilot study. Cancers (Basel) 2021;13:3951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8392365</ArticleId><ArticleId IdType="pubmed">34439106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GA, Shea B, O&#x2019;Connell D, Peterson J, Welch V, Losos M, et al. Oxford: University of Ottawa; 2000. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses.</Citation></Reference><Reference><Citation>Wright E, Ricciardi F, Arts M, Buchowski JM, Chung CK, Coppes M, et al. Metastatic spine tumor epidemiology: Comparison of trends in surgery across two decades and three continents. World Neurosurg. 2018;114:e809&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">29572177</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonezawa N, Murakami H, Demura S, Kato S, Yoshioka K, Shinmura K, et al. Perioperative complications and prognosis of curative surgical resection for spinal metastases in elderly patients. World Neurosurg. 2020;137:e144&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">31982597</ArticleId></ArticleIdList></Reference><Reference><Citation>Zairi F, Arikat A, Allaoui M, Marinho P, Assaker R. Minimally invasive decompression and stabilization for the management of thoracolumbar spine metastasis. J Neurosurg Spine. 2012;17:19&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">22607222</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HZ, Dong L, Wang HM, Hu F, Shao Q, Chen X, et al. Safety and efficacy of tranexamic acid in spinal canal tumors: A retrospective cohort study. Br J Neurosurg. 2020;34:313&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">31994911</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27718446</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1874-1754</ISSN><JournalIssue CitedMedium="Internet"><Volume>225</Volume><PubDate><Year>2016</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of cardiology</Title><ISOAbbreviation>Int J Cardiol</ISOAbbreviation></Journal><ArticleTitle>Catheter-directed treatment for acute pulmonary embolism: Systematic review and single-arm meta-analyses.</ArticleTitle><Pagination><StartPage>128</StartPage><EndPage>139</EndPage><MedlinePgn>128-139</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2016.09.036</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0167-5273(16)32292-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We sought to estimate the efficacy and safety outcomes of catheter-directed treatment (CDT) for patients with acute pulmonary embolism (PE).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched SCOPUS for studies reporting outcomes after CDT for acute PE. Studies were categorized in three groups for analyses due to heterogeneity in the classification of acute PE: 1) patients with PE causing right ventricular dysfunction and haemodynamic instability: unstable haemodynamic status, 2) patients with PE causing right ventricular dysfunction where study outcomes were not stratified by haemodynamic status: stable and unstable haemodynamic status, and 3) patients with PE causing right ventricular dysfunction who remained haemodynamically stable: stable haemodynamic status. Efficacy and safety outcomes were estimated and presented as point estimates with 95% confidence intervals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 35 studies with 1253 patients, 1277 CDTs were performed. The in-hospital mortality rates for the unstable haemodynamic status, stable and unstable haemodynamic status, and stable haemodynamic status groups were 18.1% (7.3-38.2%), 7.1% (5.0-10.1%), and 2.6% (0.8-7.3%), respectively. The major bleeding rates across the groups were estimated to be 4.5, 8.5 and 3.9 per 100 CDTs, respectively. Minor bleeding occurred in 6.2, 11.9 and 9.1 per 100 CDTs, respectively. After CDT, all groups had improvements in mean pulmonary artery pressure and right ventricular function.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We provide descriptive measures of efficacy and safety for patients who underwent CDT for acute PE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bajaj</LastName><ForeName>Navkaranbir S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA; Department of Epidemiology, Ryals School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, USA; Division of Cardiovascular Medicine and Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Rajat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ather</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guichard</LastName><ForeName>Jason L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lancaster</LastName><ForeName>W Jake</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Nirav</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Garima</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Solaiman</LastName><ForeName>Firas</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>D Trey</ForeName><Initials>DT</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Cardiology, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dell'Italia</LastName><ForeName>Louis J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA; Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leesar</LastName><ForeName>Massoud A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>James E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGiffin</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Division of Cardiothoracic Surgery, Department of Surgery, Alfred Hospital and Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Mustafa I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama, USA; Division of Cardiology, Baptist Princeton, Birmingham, Alabama, USA. Electronic address: musiahm@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Cardiol</MedlineTA><NlmUniqueID>8200291</NlmUniqueID><ISSNLinking>0167-5273</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Respir Crit Care Med. 2017 Nov 1;196(9):1213-1216. doi: 10.1164/rccm.201704-0719RR.</RefSource><PMID Version="1">28853904</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002404" MajorTopicYN="N">Catheterization</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018497" MajorTopicYN="N">Ventricular Dysfunction, Right</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Catheter-directed treatment</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Thrombolysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27718446</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2016.09.036</ArticleId><ArticleId IdType="pii">S0167-5273(16)32292-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35964047</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-799X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of orthopaedic surgery and research</Title><ISOAbbreviation>J Orthop Surg Res</ISOAbbreviation></Journal><ArticleTitle>Simultaneous versus staged bilateral total hip arthroplasty: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>392</StartPage><MedlinePgn>392</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">392</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13018-022-03281-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Total hip arthroplasty is a common orthopedic surgery for treating primary or secondary hip osteoarthritis. Bilateral total hip replacement could be performed in a single stage or two separate stages. Each surgical procedure's reliability, safety, and complications have been reported controversially. This study aimed to review the current evidence regarding the outcomes of simultaneous and staged bilateral total hip arthroplasty.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a meta-analysis using MEDLINE, EMBASE, Web of Science, and Scopus databases. Eligible studies compared complications and related outcomes between simultaneous and staged bilateral THA. Two reviewers independently screened initial search results, assessed methodological quality, and extracted data. We used the Mantel-Haenszel method to perform the meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In our study, we included 29,551 patients undergoing simBTHA and 74,600 patients undergoing stgBTHA. In favor of the simBTHA, a significant reduction in deep vein thrombosis (DVT) and systemic, local, and pulmonary complications was documented. However, we evidenced an increased pulmonary embolism (PE) and periprosthetic fracture risk in simBTHA. In the simBTHA, total blood loss, length of hospital stay, and total cost were lower.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This meta-analysis shows that simultaneous bilateral THA accompanies fewer complications and lower total cost. Well-designed randomized controlled trials are needed to provide robust evidence.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramezani</LastName><ForeName>Akam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Orthopedic Department, Orthopedic Surgery Research Center (OSRC), Sina University Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaseminejad Raeini</LastName><ForeName>Amirhossein</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Orthopedic Department, Orthopedic Surgery Research Center (OSRC), Sina University Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharafi</LastName><ForeName>Amirmohammad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Orthopedic Department, Orthopedic Surgery Research Center (OSRC), Sina University Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikhvatan</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Orthopedic Department, Orthopedic Surgery Research Center (OSRC), Sina University Hospital, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Heidelberg Medical Hospital, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortazavi</LastName><ForeName>Seyed Mohammad Javad</ForeName><Initials>SMJ</Initials><AffiliationInfo><Affiliation>Joint Reconstruction Research Center (JRRC), Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shafiei</LastName><ForeName>Seyyed Hossein</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Orthopedic Department, Orthopedic Surgery Research Center (OSRC), Sina University Hospital, Tehran University of Medical Sciences, Tehran, Iran. dr_hshafiei@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Orthop Surg Res</MedlineTA><NlmUniqueID>101265112</NlmUniqueID><ISSNLinking>1749-799X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="Y">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bilateral total hip replacement</Keyword><Keyword MajorTopicYN="N">Complications</Keyword><Keyword MajorTopicYN="N">Cost&#x2013;benefit analysis</Keyword><Keyword MajorTopicYN="N">Functional outcomes</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Total hip arthroplasty</Keyword></KeywordList><CoiStatement>The authors have no relevant financial or non-financial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>13</Day><Hour>23</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35964047</ArticleId><ArticleId IdType="pmc">PMC9375332</ArticleId><ArticleId IdType="doi">10.1186/s13018-022-03281-4</ArticleId><ArticleId IdType="pii">10.1186/s13018-022-03281-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip replacement. Lancet. 2007;370:1508&#x2013;1519. doi: 10.1016/s0140-6736(07)60457-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(07)60457-7</ArticleId><ArticleId IdType="pubmed">17964352</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780&#x2013;785. doi: 10.2106/jbjs.f.00222.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/jbjs.f.00222</ArticleId><ArticleId IdType="pubmed">17403800</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am. 2018;100:1455&#x2013;1460. doi: 10.2106/jbjs.17.01617.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/jbjs.17.01617</ArticleId><ArticleId IdType="pubmed">30180053</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavernia CJ, Hernandez VH, Rossi MD. Payment analysis of total hip replacement. Curr Opin Orthop. 2007;18:23&#x2013;27. doi: 10.1097/BCO.0b013e328011a270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCO.0b013e328011a270</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiridis E, Pavlou G, Charity J, Tsiridis E, Gie G, West R. The safety and efficacy of bilateral simultaneous total hip replacement: an analysis of 2063 cases. J Bone Joint Surg Br. 2008;90:1005&#x2013;1012. doi: 10.1302/0301-620x.90b8.20552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620x.90b8.20552</ArticleId><ArticleId IdType="pubmed">18669954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarmiento A. Sir John Charnley and his legacy to total hip arthroplasty, 1970&#x2013;1993. Curr Orthop Pract. 2014;25:115&#x2013;118. doi: 10.1097/BCO.0000000000000084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCO.0000000000000084</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H, Chen CL, Maltenfort MG, Restrepo C, Rothman RH, Chen AF. Bilateral total hip arthroplasty: 1-stage or 2-stage? A meta-analysis. J Arthroplasty. 2017;32:689&#x2013;695. doi: 10.1016/j.arth.2016.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2016.09.022</ArticleId><ArticleId IdType="pubmed">27776901</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Xu T, Li P, Xu Y, Xia L, Zhao Z. Comparison of mortality and complications between bilateral simultaneous and staged total hip arthroplasty: a systematic review and meta-analysis. Medicine. 2019;98:e16774. doi: 10.1097/md.0000000000016774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000016774</ArticleId><ArticleId IdType="pmc">PMC6775426</ArticleId><ArticleId IdType="pubmed">31574793</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org/handbook.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed) 2009;339:b2535. doi: 10.1136/bmj.b2535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan&#x2014;a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. doi: 10.1186/s13643-016-0384-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-016-0384-4</ArticleId><ArticleId IdType="pmc">PMC5139140</ArticleId><ArticleId IdType="pubmed">27919275</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz-Henry J. The ASA classification and peri-operative risk. Ann R Coll Surg Engl. 2011;93:185&#x2013;187. doi: 10.1308/rcsann.2011.93.3.185a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1308/rcsann.2011.93.3.185a</ArticleId><ArticleId IdType="pmc">PMC3348554</ArticleId><ArticleId IdType="pubmed">21477427</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GA SB, O&#x2019;Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses - 2011. Available from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Available from URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</Citation></Reference><Reference><Citation>Simunovic N, Devereaux PJ, Sprague S, Guyatt GH, Schemitsch E, Debeer J, Bhandari M. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. Can Med Assoc J. 2010;182:1609&#x2013;1616. doi: 10.1503/cmaj.092220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.092220</ArticleId><ArticleId IdType="pmc">PMC2952007</ArticleId><ArticleId IdType="pubmed">20837683</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter SD, Yao X. Effect sizes can be calculated for studies reporting ranges for outcome variables in systematic reviews. J Clin Epidemiol. 2007;60:849&#x2013;852. doi: 10.1016/j.jclinepi.2006.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2006.11.003</ArticleId><ArticleId IdType="pubmed">17606182</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 2003;327:557&#x2013;560. doi: 10.1136/bmj.327.7414.557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed) 1997;315:629&#x2013;634. doi: 10.1136/bmj.315.7109.629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhan S, Pankaj A, Malhotra R. One- or two-stage bilateral total hip arthroplasty: a prospective, randomised, controlled study in an Asian population. J Bone Joint Surg Br. 2006;88:298&#x2013;303. doi: 10.1302/0301-620x.88b3.17048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620x.88b3.17048</ArticleId><ArticleId IdType="pubmed">16498000</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheriazam A, Mohseni G, Esmailiejah AA, Safdari F, Abrishamkarzadeh H. Bilateral total hip arthroplasty: one-stage versus two-stage procedure. HIP Int. 2019;29:141&#x2013;146. doi: 10.1177/1120700018773427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1120700018773427</ArticleId><ArticleId IdType="pubmed">29756496</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih CH, Ho WB. One-stage versus two-stage bilateral autophor ceramic total hip arthroplasty. Clin Orthop Relat Res. 1985;193:141&#x2013;145. doi: 10.1097/00003086-198503000-00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003086-198503000-00018</ArticleId><ArticleId IdType="pubmed">3971613</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggli S, Huckell CB, Ganz R. Bilateral total hip arthroplasty: one stage versus two stage procedure. Clin Orthop Relat Res. 1996;328:108&#x2013;118. doi: 10.1097/00003086-199607000-00019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003086-199607000-00019</ArticleId><ArticleId IdType="pubmed">8653943</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenze M, Huo MH, Zatorski LE, Keggi KJ. A comparison of the cost effectiveness of one-stage versus two-stage bilateral total hip replacement. Orthopedics. 1998;21:1249&#x2013;1252. doi: 10.3928/0147-7447-19981201-04.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/0147-7447-19981201-04</ArticleId><ArticleId IdType="pubmed">9867298</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuben JD, Meyers SJ, Cox DD, Elliott M, Watson M, Shim SD. Cost comparison between bilateral simultaneous, staged, and unilateral total joint arthroplasty. J Arthroplasty. 1998;13:172&#x2013;179. doi: 10.1016/s0883-5403(98)90095-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0883-5403(98)90095-x</ArticleId><ArticleId IdType="pubmed">9526210</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaro-Adri&#xe1;n J, Bayona F, Rech JA, Murray DW. One- or two-stage bilateral total hip replacement. J Arthroplasty. 1999;14:439&#x2013;445. doi: 10.1016/s0883-5403(99)90099-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0883-5403(99)90099-2</ArticleId><ArticleId IdType="pubmed">10428224</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J, Tarity TD, Sheikh E, Sharkey PF, Hozack WJ, Rothman RH. Bilateral total hip arthroplasty: one-stage versus two-stage procedures. Clin Orthop Relat Res. 2006;453:137&#x2013;141. doi: 10.1097/01.blo.0000246529.14135.2b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.blo.0000246529.14135.2b</ArticleId><ArticleId IdType="pubmed">17312590</ArticleId></ArticleIdList></Reference><Reference><Citation>Berend KR, Lombardi AV, Jr, Adams JB. Simultaneous vs staged cementless bilateral total hip arthroplasty: perioperative risk comparison. J Arthroplasty. 2007;22:111&#x2013;115. doi: 10.1016/j.arth.2007.03.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2007.03.043</ArticleId><ArticleId IdType="pubmed">17823028</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper GJ, Hooper NM, Rothwell AG, Hobbs T. Bilateral total joint arthroplasty: the early results from the New Zealand National Joint Registry. J Arthroplasty. 2009;24:1174&#x2013;1177. doi: 10.1016/j.arth.2008.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2008.09.022</ArticleId><ArticleId IdType="pubmed">19056233</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghayev E, Beck A, Staub LP, Dietrich D, Melloh M, Orljanski W, R&#xf6;der C. Simultaneous bilateral hip replacement reveals superior outcome and fewer complications than two-stage procedures: a prospective study including 1819 patients and 5801 follow-ups from a total joint replacement registry. BMC Musculoskelet Disord. 2010;11:245. doi: 10.1186/1471-2474-11-245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2474-11-245</ArticleId><ArticleId IdType="pmc">PMC2987971</ArticleId><ArticleId IdType="pubmed">20973941</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S, Tokuhashi Y, Ishii T, Mori S, Hosaka K, Taniguchi S. One- versus two-stage bilateral total hip arthroplasty. Orthopedics. 2010 doi: 10.3928/01477447-20100625-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/01477447-20100625-07</ArticleId><ArticleId IdType="pubmed">20704112</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston LR, Clift BA, Abboud RJ. Bilateral simultaneous hip replacement versus bilateral sequential hip replacement. A 7-year data review. Orthop Nurs. 2011;30:119&#x2013;123. doi: 10.1097/NOR.0b013e31820f5155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NOR.0b013e31820f5155</ArticleId><ArticleId IdType="pubmed">21422893</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg-Larsen M, Joergensen CC, Husted H, Kehlet H. Simultaneous and staged bilateral total hip arthroplasty: a Danish nationwide study. Arch Orthop Trauma Surg. 2013;133:1601&#x2013;1605. doi: 10.1007/s00402-013-1829-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-013-1829-z</ArticleId><ArticleId IdType="pubmed">23912419</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasouli MR, Maltenfort MG, Ross D, Hozack WJ, Memtsoudis SG, Parvizi J. Perioperative morbidity and mortality following bilateral total hip arthroplasty. J Arthroplasty. 2014;29:142&#x2013;148. doi: 10.1016/j.arth.2013.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2013.04.001</ArticleId><ArticleId IdType="pubmed">23664280</ArticleId></ArticleIdList></Reference><Reference><Citation>Garland A, Rolfson O, Garellick G, K&#xe4;rrholm J, Hailer NP. Early postoperative mortality after simultaneous or staged bilateral primary total hip arthroplasty: an observational register study from the Swedish Hip Arthroplasty Register. BMC Musculoskelet Disord. 2015;16:77. doi: 10.1186/s12891-015-0535-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-015-0535-0</ArticleId><ArticleId IdType="pmc">PMC4393879</ArticleId><ArticleId IdType="pubmed">25887667</ArticleId></ArticleIdList></Reference><Reference><Citation>Quadri TA, Rashid RH, Zubairi AJ, Umer M, Hashmi PM. Single stage bilateral total hip replacement: Is it an option or a risk? J Pak Med Assoc. 2015;65:S91&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">26878546</ArticleId></ArticleIdList></Reference><Reference><Citation>Seol JH, Park KS, Yoon TR. Postoperative complications and cost-effectiveness of simultaneous and staged bilateral total hip arthroplasty using a modified minimally invasive two-incision technique. Hip Pelvis. 2015;27:77&#x2013;82. doi: 10.5371/hp.2015.27.2.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.5371/hp.2015.27.2.77</ArticleId><ArticleId IdType="pmc">PMC4972630</ArticleId><ArticleId IdType="pubmed">27536607</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Gupta G, Sharma RK. Comparison between single stage and two stage bilateral total hip replacement- our results and review of literature. Acta Orthop Belg. 2016;82:484&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">29119888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamath AF, Monteiro EL, Spranger A, Impellizzeri F, Leunig M. Simultaneous versus staged bilateral direct anterior Total Hip Arthroplasty: Are early patient-centered outcomes equivalent? Acta Orthop Belg. 2016;82:497&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">29119890</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GR, Marsh JD, Vasarhelyi EM, Howard JL, Lanting BA. A cost analysis of single-stage bilateral versus two-stage direct anterior total hip arthroplasty. HIP Int. 2016;26:15&#x2013;19. doi: 10.5301/hipint.5000292.</Citation><ArticleIdList><ArticleId IdType="doi">10.5301/hipint.5000292</ArticleId><ArticleId IdType="pubmed">26391260</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafyllopoulos GK, Memtsoudis SG, Zhang W, Ma Y, Sculco TP, Poultsides LA. Same-day surgery does not increase deep infection risk in bilateral total hip arthroplasty patients. J Arthroplasty. 2016;31:237&#x2013;241. doi: 10.1016/j.arth.2016.01.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2016.01.069</ArticleId><ArticleId IdType="pubmed">27067464</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown ML, Plate JF, Holst DC, Bracey DN, Bullock MW, Lang JE. A retrospective analysis of the merits and challenges associated with simultaneous bilateral THA using the direct anterior approach. HIP Int. 2017;27:169&#x2013;174. doi: 10.5301/hipint.5000449.</Citation><ArticleIdList><ArticleId IdType="doi">10.5301/hipint.5000449</ArticleId><ArticleId IdType="pubmed">27886354</ArticleId></ArticleIdList></Reference><Reference><Citation>Houdek MT, Wyles CC, Watts CD, Wagner ER, Sierra RJ, Trousdale RT, Taunton MJ. Single-anesthetic versus staged bilateral total hip arthroplasty: a matched cohort study. J Bone Joint Surg Am. 2017;99:48&#x2013;54. doi: 10.2106/jbjs.15.01223.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/jbjs.15.01223</ArticleId><ArticleId IdType="pubmed">28060233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SC, Lim YW, Jo WL, Park DC, Lee JW, Kang WW, Kim YS. Surgical accuracy, function, and quality of life of simultaneous versus staged bilateral Total hip Arthroplasty in patients with Osteonecrosis of the femoral head. BMC Musculoskelet Disord. 2017;18:266. doi: 10.1186/s12891-017-1605-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-017-1605-2</ArticleId><ArticleId IdType="pmc">PMC5474000</ArticleId><ArticleId IdType="pubmed">28623889</ArticleId></ArticleIdList></Reference><Reference><Citation>Poultsides LA, Triantafyllopoulos GK, Memtsoudis SG, Do HT, Alexiades MM, Sculco TP. Perioperative morbidity of same-day and staged bilateral total hip arthroplasty. J Arthroplasty. 2017;32:2974&#x2013;2979.e2971. doi: 10.1016/j.arth.2017.05.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2017.05.028</ArticleId><ArticleId IdType="pubmed">28629904</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlegelmilch M, Rashiq S, Moreau B, Jarr&#xed;n P, Tran B, Chuck A. Cost-effectiveness analysis of total hip arthroplasty performed by a Canadian short-stay surgical team in Ecuador. Adv Orthop. 2017;2017:5109895. doi: 10.1155/2017/5109895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/5109895</ArticleId><ArticleId IdType="pmc">PMC5748297</ArticleId><ArticleId IdType="pubmed">29403664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Z, Cao G, Wang G, Zhou Z, Pei F. Total hospital cost, length of stay, and complications between simultaneous and staged bilateral total hip arthroplasty: a nationwide retrospective cohort study in China. Medicine. 2019;98:e14687. doi: 10.1097/md.0000000000014687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000014687</ArticleId><ArticleId IdType="pmc">PMC6426474</ArticleId><ArticleId IdType="pubmed">30882631</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabro L, Yong M, Whitehouse SL, Hatton A, de Steiger R, Crawford RW. Mortality and implant survival with simultaneous and staged bilateral total hip arthroplasty: experience from the Australian Orthopedic Association National Joint Replacement Registry. J Arthroplasty. 2020;35:2518&#x2013;2524. doi: 10.1016/j.arth.2020.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2020.04.027</ArticleId><ArticleId IdType="pubmed">32402580</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo SJ, Shao HY, Huang Y, Yang DJ, Zheng HL, Zhou YX. Retrospective cohort study comparing complications, readmission, transfusion, and length of stay of patients undergoing simultaneous and staged bilateral total hip arthroplasty. Orthop Surg. 2020;12:233&#x2013;240. doi: 10.1111/os.12617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/os.12617</ArticleId><ArticleId IdType="pmc">PMC7031578</ArticleId><ArticleId IdType="pubmed">31958880</ArticleId></ArticleIdList></Reference><Reference><Citation>Partridge TCJ, Charity JAF, Sandiford NA, Baker PN, Reed MR, Jameson SS. Simultaneous or staged bilateral total hip arthroplasty? An analysis of complications in 14,460 patients using national data. J Arthroplasty. 2020;35:166&#x2013;171. doi: 10.1016/j.arth.2019.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2019.08.022</ArticleId><ArticleId IdType="pubmed">31521445</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa JM, Pannu TS, Higuera CA, Suarez JC, Patel PD, Barsoum WK. Hospital adverse events and perioperative outcomes in bilateral direct anterior approach total hip arthroplasty. J Arthroplasty. 2020;35:762&#x2013;766. doi: 10.1016/j.arth.2019.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2019.10.005</ArticleId><ArticleId IdType="pubmed">31706645</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou JF, Hu C, Zhang Y, Tian LQ, Liu YZ, Zhang C, Li J. Cost analysis of staged versus simultaneous bilateral total knee and hip arthroplasty using a propensity score matching. BMJ Open. 2021;11:e041147. doi: 10.1136/bmjopen-2020-041147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-041147</ArticleId><ArticleId IdType="pmc">PMC7929812</ArticleId><ArticleId IdType="pubmed">33653742</ArticleId></ArticleIdList></Reference><Reference><Citation>Mou P, Zeng WN, Chen Y, Zhou Z. Synchronous or sequential cementless bilateral total hip arthroplasty for osseous ankylosed hips with ankylosing spondylitis. BMC Musculoskelet Disord. 2021;22:302. doi: 10.1186/s12891-021-04142-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-021-04142-7</ArticleId><ArticleId IdType="pmc">PMC7988988</ArticleId><ArticleId IdType="pubmed">33761925</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue D, Grace TR, Restrepo C, Hozack WJ. Outcomes of simultaneous bilateral total hip arthroplasty for 256 selected patients in a single surgeon's practice. Bone Joint J. 2021;103-b:116&#x2013;121. doi: 10.1302/0301-620x.103b7.bjj-2020-2292.r1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620x.103b7.bjj-2020-2292.r1</ArticleId><ArticleId IdType="pubmed">34192915</ArticleId></ArticleIdList></Reference><Reference><Citation>Panchal S, Jogani AD, Mohanty SS, Rathod T, Kamble P, Keny SA. Is bilateral sequential total hip replacement as safe an option as staged replacement? A matched pair analysis of 108 cases at a tertiary care centre. Indian J Orthop. 2021;55:1250&#x2013;1255. doi: 10.1007/s43465-021-00536-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43465-021-00536-w</ArticleId><ArticleId IdType="pmc">PMC8586291</ArticleId><ArticleId IdType="pubmed">34824726</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh GS, Sutton RM, D'Amore T, Baker CM, Clark SC, Courtney PM. A time-driven activity-based costing analysis of simultaneous versus staged bilateral total hip and knee arthroplasty. J Arthroplasty. 2022 doi: 10.1016/j.arth.2022.01.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2022.01.048</ArticleId><ArticleId IdType="pubmed">35093545</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvati EA, Hughes P, Lachiewicz P. Bilateral total hip-replacement arthroplasty in one stage. J Bone Joint Surg Am. 1978;60:640&#x2013;644. doi: 10.2106/00004623-197860050-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-197860050-00008</ArticleId><ArticleId IdType="pubmed">681382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt MC, Hozack JW, Frampton C, Rothwell A, Hooper GJ. Is single-anaesthetic bilateral primary total hip replacement still safe? A 16-year cohort study from the New Zealand Joint Registry. ANZ J Surg. 2018;88:1289&#x2013;1293. doi: 10.1111/ans.14864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.14864</ArticleId><ArticleId IdType="pubmed">30347492</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp D, van den Bekerom MP, Harmse I, Schafroth MU. One stage bilateral total hip arthroplasty, is it safe? A meta-analysis. HIP Int. 2010;20:440&#x2013;446. doi: 10.1177/112070001002000405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/112070001002000405</ArticleId><ArticleId IdType="pubmed">21157747</ArticleId></ArticleIdList></Reference><Reference><Citation>Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27:302&#x2013;345. doi: 10.1128/CMR.00111-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00111-13</ArticleId><ArticleId IdType="pmc">PMC3993098</ArticleId><ArticleId IdType="pubmed">24696437</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;27:61&#x2013;65.e61. doi: 10.1016/j.arth.2012.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2012.02.022</ArticleId><ArticleId IdType="pubmed">22554729</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunutsor SK, Whitehouse MR, Blom AW, Beswick AD, Tea I. Re-infection outcomes following one- and two-stage surgical revision of infected hip prosthesis: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0139166&#x2013;e0139166. doi: 10.1371/journal.pone.0139166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0139166</ArticleId><ArticleId IdType="pmc">PMC4583275</ArticleId><ArticleId IdType="pubmed">26407003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KL, Kurtz SM, Lau E, Bozic KJ, Berry DJ, Parvizi J. Prosthetic joint infection risk after total hip arthroplasty in the medicare population. J Arthroplasty. 2009;24:105&#x2013;109. doi: 10.1016/j.arth.2009.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2009.04.027</ArticleId><ArticleId IdType="pubmed">19493644</ArticleId></ArticleIdList></Reference><Reference><Citation>Hailer NP, Garellick G, K&#xe4;rrholm J. Uncemented and cemented primary total hip arthroplasty in the Swedish Hip Arthroplasty Register. Acta Orthop. 2010;81:34&#x2013;41. doi: 10.3109/17453671003685400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17453671003685400</ArticleId><ArticleId IdType="pmc">PMC2856202</ArticleId><ArticleId IdType="pubmed">20180715</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Shao L, Xu W, Chen H, Huang W. Comparison of morphological changes of gluteus medius and abductor strength for total hip arthroplasty via posterior and modified direct lateral approaches. Int Orthop. 2019;43:2467&#x2013;2475. doi: 10.1007/s00264-019-04331-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00264-019-04331-z</ArticleId><ArticleId IdType="pubmed">31053885</ArticleId></ArticleIdList></Reference><Reference><Citation>van Stralen KJ, Le Cessie S, Rosendaal FR, Doggen CJ. Regular sports activities decrease the risk of venous thrombosis. J Thromb Haemost. 2007;5:2186&#x2013;2192. doi: 10.1111/j.1538-7836.2007.02732.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2007.02732.x</ArticleId><ArticleId IdType="pubmed">17697136</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA., Jr Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (London, England) 2008;371:387&#x2013;394. doi: 10.1016/s0140-6736(08)60202-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(08)60202-0</ArticleId><ArticleId IdType="pubmed">18242412</ArticleId></ArticleIdList></Reference><Reference><Citation>Pannucci CJ, Laird S, Dimick JB, Campbell DA, Henke PK. A validated risk model to predict 90-day VTE events in postsurgical patients. Chest. 2014;145:567&#x2013;573. doi: 10.1378/chest.13-1553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.13-1553</ArticleId><ArticleId IdType="pmc">PMC4502716</ArticleId><ArticleId IdType="pubmed">24091567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor A, Ellis A, Shaffer N, Gurwitz J, Chandramohan A, Saulino J, Ishak A, Okubanjo T, Michota F, Hylek E, Trikalinos TA. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost. 2017;15:284&#x2013;294. doi: 10.1111/jth.13566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13566</ArticleId><ArticleId IdType="pmc">PMC5305416</ArticleId><ArticleId IdType="pubmed">28102615</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett MC, Whitehouse MR, Blom AW, Kunutsor SK. Host-related factors for venous thromboembolism following total joint replacement: a meta-analysis of 89 observational studies involving over 14 million hip and knee replacements. J Orthop Sci. 2020;25:267&#x2013;275. doi: 10.1016/j.jos.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jos.2019.04.003</ArticleId><ArticleId IdType="pubmed">31029528</ArticleId></ArticleIdList></Reference><Reference><Citation>Malcolm TL, Knezevic NN, Zouki CC, Tharian AR. Pulmonary complications after hip and knee arthroplasty in the United States, 2004&#x2013;2014. Anesth Analg. 2020;130:917&#x2013;924. doi: 10.1213/ane.0000000000004265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0000000000004265</ArticleId><ArticleId IdType="pubmed">31206434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Goswami K, Shohat N, Aalirezaie A, Manrique J, Parvizi J. Longer operative time results in a higher rate of subsequent periprosthetic joint infection in patients undergoing primary joint arthroplasty. J Arthroplasty. 2019;34:947&#x2013;953. doi: 10.1016/j.arth.2019.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2019.01.027</ArticleId><ArticleId IdType="pubmed">30765229</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffer AK, Barsoum WK, Krebs V, Hurbanek JG, Morra N, Brotman DJ. Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty. Mayo Clin Proc. 2005;80:732&#x2013;738. doi: 10.1016/s0025-6196(11)61526-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0025-6196(11)61526-7</ArticleId><ArticleId IdType="pubmed">15945526</ArticleId></ArticleIdList></Reference><Reference><Citation>Horlocker TT, Hebl JR, Gali B, Jankowski CJ, Burkle CM, Berry DJ, Zepeda FA, Stevens SR, Schroeder DR. Anesthetic, patient, and surgical risk factors for neurologic complications after prolonged total tourniquet time during total knee arthroplasty. Anesth Analg. 2006;102:950&#x2013;955. doi: 10.1213/01.ane.0000194875.05587.7e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ane.0000194875.05587.7e</ArticleId><ArticleId IdType="pubmed">16492857</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohl DD, Ondeck NT, Darrith B, Hannon CP, Fillingham YA, Della Valle CJ. Impact of operative time on adverse events following primary total joint arthroplasty. J Arthroplasty. 2018;33:2256&#x2013;2262.e2254. doi: 10.1016/j.arth.2018.02.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2018.02.037</ArticleId><ArticleId IdType="pubmed">29551302</ArticleId></ArticleIdList></Reference><Reference><Citation>Surace P, Sultan AA, George J, Samuel LT, Khlopas A, Molloy RM, Stearns KL, Mont MA. The association between operative time and short-term complications in total hip arthroplasty: an analysis of 89,802 surgeries. J Arthroplasty. 2019;34:426&#x2013;432. doi: 10.1016/j.arth.2018.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2018.11.015</ArticleId><ArticleId IdType="pubmed">30528133</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi N, Anis HK, Gold PA, Garbarino LJ, Scuderi GR, Cushner FD, Higuera CA, Mont MA. Operative times can predict and are correlated with lengths-of-stay in primary total knee arthroplasty: a nationwide database study. J Arthroplasty. 2019;34:1328&#x2013;1332. doi: 10.1016/j.arth.2019.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2019.03.024</ArticleId><ArticleId IdType="pubmed">31000402</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyers SJ, Reuben JD, Cox DD, Watson M. Inpatient cost of primary total joint arthroplasty. J Arthroplasty. 1996;11:281&#x2013;285. doi: 10.1016/S0883-5403(96)80079-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0883-5403(96)80079-9</ArticleId><ArticleId IdType="pubmed">8713907</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy P, Heal JM, Blumberg N. Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions. Transfusion. 1991;31:212&#x2013;217. doi: 10.1046/j.1537-2995.1991.31391165169.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1537-2995.1991.31391165169.x</ArticleId><ArticleId IdType="pubmed">2003322</ArticleId></ArticleIdList></Reference><Reference><Citation>Innerhofer P, Walleczek C, Luz G, Hobisch-Hagen P, Benzer A, St&#xf6;ckl B, Hessenberger G, Nussbaumer W, Schobersberger W. Transfusion of buffy coat-depleted blood components and risk of postoperative infection in orthopedic patients. Transfusion. 1999;39:625&#x2013;632. doi: 10.1046/j.1537-2995.1999.39060625.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1537-2995.1999.39060625.x</ArticleId><ArticleId IdType="pubmed">10378843</ArticleId></ArticleIdList></Reference><Reference><Citation>Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. Br J Anaesth. 2005;95:33&#x2013;42. doi: 10.1093/bja/aeh290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeh290</ArticleId><ArticleId IdType="pubmed">15486006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosencher N, Kerkkamp HEM, Macheras G, Munuera LM, Menichella G, Barton DM, Cremers S, Abraham IL, Investigation FTO. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe*. Transfusion. 2003;43:459&#x2013;469. doi: 10.1046/j.1537-2995.2003.00348.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1537-2995.2003.00348.x</ArticleId><ArticleId IdType="pubmed">12662278</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Schleck C, Harmsen S, Lewallen D. Clinically important improvement thresholds for Harris Hip Score and its ability to predict revision risk after primary total hip arthroplasty. BMC Musculoskelet Disord. 2016;17:1&#x2013;8. doi: 10.1186/s12891-015-0856-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-015-0856-z</ArticleId><ArticleId IdType="pmc">PMC4901425</ArticleId><ArticleId IdType="pubmed">27286675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso CA, Jout J, Salvati EA, Sculco TP. Fulfillment of patients' expectations for total hip arthroplasty. JBJS. 2009;91:2073&#x2013;2078. doi: 10.2106/JBJS.H.01802.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.H.01802</ArticleId><ArticleId IdType="pubmed">19723982</ArticleId></ArticleIdList></Reference><Reference><Citation>Konyves A, Bannister G. The importance of leg length discrepancy after total hip arthroplasty. J Bone Joint Surg Br. 2005;87:155&#x2013;157. doi: 10.1302/0301-620X.87B2.14878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.87B2.14878</ArticleId><ArticleId IdType="pubmed">15736733</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28918384</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-8486</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of neurointerventional surgery</Title><ISOAbbreviation>J Neurointerv Surg</ISOAbbreviation></Journal><ArticleTitle>Systematic review and meta-analysis of effectiveness of preoperative embolization in surgery for metastatic spine disease.</ArticleTitle><Pagination><StartPage>596</StartPage><EndPage>601</EndPage><MedlinePgn>596-601</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/neurintsurg-2017-013350</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Preoperative embolization (PE) may decrease intraoperative blood loss (IBL) in decompressive surgery of hypervascular spinal metastases. However, no consensus has been found in other metastases and no meta-analysis which reviewed the benefit of PE in spinal metastases has been conducted.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess IBL in spinal metastases surgery in a randomized controlled trial (RCT) and cohort studies comparing PE and a control group of non-embolized patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search of relevant publications in PubMed and EMBASE was undertaken. Inclusion criteria were RCTs and observational studies in patients with spinal metastases who underwent spine surgery and reported IBL. Meta-analysis was performed using standardized mean difference (SMD) and mean difference (MD) of IBL. Heterogeneity was assessed using the I<sup>2</sup> statistic.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 265 abstracts (126 from PubMed and 139 from Embase) were identified through database searching. The reviewers selected six studies for qualitative synthesis and meta-analysis. The pooled SMD of the included studies was 0.58 (95% CI -0.10 to 1.25, p=0.09). Sensitivity analysis revealed that, if the study by Rehak <i>et al</i> was omitted, the pooled SMD was significantly changed to 0.88 (95% CI 0.39 to 1.36, p&lt;0.001) and PE reduced the IBL significantly. The pooled MD was 708.3&#x2009;mL (95%&#x2009;CI -224.4 to 1640.9&#x2009;mL, p=0.14). If the results of the Rehak <i>et al</i> study were omitted, the pooled MD was significantly changed to 1226.9&#x2009;mL (95%&#x2009;CI 345.8 to 2108.1&#x2009;mL, p=0.006).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PE can be effective in reducing IBL in spinal metastases surgery in both renal cell carcinoma and mixed primary tumor groups.</AbstractText><CopyrightInformation>&#xa9; Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luksanapruksa</LastName><ForeName>Panya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buchowski</LastName><ForeName>Jacob M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-8880-8490</Identifier><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Washington University School of Medicine, St Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tongsai</LastName><ForeName>Sasima</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office for Research and Development, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singhatanadgige</LastName><ForeName>Weerasak</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jennings</LastName><ForeName>Jack W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Radiology, Washington University School of Medicine, St Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurointerv Surg</MedlineTA><NlmUniqueID>101517079</NlmUniqueID><ISSNLinking>1759-8478</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004621" MajorTopicYN="N">Embolization, Therapeutic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011300" MajorTopicYN="N">Preoperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013125" MajorTopicYN="N">Spinal Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">epidural</Keyword><Keyword MajorTopicYN="N">metastatic</Keyword><Keyword MajorTopicYN="N">neoplasm</Keyword><Keyword MajorTopicYN="N">spine</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28918384</ArticleId><ArticleId IdType="doi">10.1136/neurintsurg-2017-013350</ArticleId><ArticleId IdType="pii">neurintsurg-2017-013350</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26424340</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1092-0684</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Neurosurgical focus</Title><ISOAbbreviation>Neurosurg Focus</ISOAbbreviation></Journal><ArticleTitle>Lumbar spine surgery positioning complications: a systematic review.</ArticleTitle><Pagination><StartPage>E16</StartPage><MedlinePgn>E16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2015.7.FOCUS15268</ELocationID><Abstract><AbstractText>OBJECT There are a variety of surgical positions that provide optimal exposure of the dorsal lumbar spine. These include the prone, kneeling, knee-chest, knee-elbow, and lateral decubitus positions. All are positions that facilitate exposure of the spine. Each position, however, is associated with an array of unique complications that result from excessive pressure applied to the torso or extremities. The authors reviewed clinical studies reporting complications that arose from positioning of the patient during dorsal exposures of the lumbar spine. METHODS MEDLINE, Scopus, and Web of Science database searches were performed to find clinical studies reporting complications associated with positioning during lumbar spine surgery. For articles meeting inclusion criteria, the following information was obtained: publication year, study design, sample size, age, operative time, type of surgery, surgical position, frame or table type, complications associated with positioning, time to first observed complication, long-term outcomes, and evidence-based recommendations for complication avoidance. RESULTS Of 3898 articles retrieved from MEDLINE, Scopus, and Web of Science, 34 met inclusion criteria. Twenty-four studies reported complications associated with use of the prone position, and 7 studies investigated complications after knee-chest positioning. Complications associated with the knee-elbow, lateral decubitus, and supine positions were each reported by a single study. Vision loss was the most commonly reported complication for both prone and knee-chest positioning. Several other complications were reported, including conjunctival swelling, Ischemic orbital compartment syndrome, nerve palsies, thromboembolic complications, pressure sores, lower extremity compartment syndrome, and shoulder dislocation, highlighting the assortment of possible complications following different surgical positions. For prone-position studies, there was a relationship between increased operation time and position complications. Only 3 prone-position studies reported complications following procedures of less than 120 minutes, 7 studies reported complications following mean operative times of 121-240 minutes, and 9 additional studies reported complications following mean operative times greater than 240 minutes. This relationship was not observed for knee-chest and other surgical positions. CONCLUSIONS This work presents a systematic review of positioning-related complications following prone, knee-chest, and other positions used for lumbar spine surgery. Numerous evidence-based recommendations for avoidance of these potentially severe complications associated with intraoperative positioning are discussed. This investigation may serve as a framework to educate the surgical team and decrease rates of intraoperative positioning complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shriver</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine;</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Spine Health, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeer</LastName><ForeName>Valerie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine;</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Spine Health, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alentado</LastName><ForeName>Vincent J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Case Western Reserve University School of Medicine;</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Spine Health, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mroz</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Center for Spine Health, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benzel</LastName><ForeName>Edward C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Center for Spine Health, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinmetz</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Center for Spine Health, and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosurg Focus</MedlineTA><NlmUniqueID>100896471</NlmUniqueID><ISSNLinking>1092-0684</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016206" MajorTopicYN="N">Databases, Bibliographic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008159" MajorTopicYN="N">Lumbar Vertebrae</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019635" MajorTopicYN="N">Neurosurgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016684" MajorTopicYN="N">Prone Position</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013118" MajorTopicYN="N">Spinal Cord Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ASIS = anterior superior iliac spine</Keyword><Keyword MajorTopicYN="N">DVT = deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">PE = pulmonary embolism</Keyword><Keyword MajorTopicYN="N">PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses</Keyword><Keyword MajorTopicYN="N">knee-chest</Keyword><Keyword MajorTopicYN="N">lumbar spine surgery</Keyword><Keyword MajorTopicYN="N">positioning complications</Keyword><Keyword MajorTopicYN="N">prone</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26424340</ArticleId><ArticleId IdType="doi">10.3171/2015.7.FOCUS15268</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40035126</PMID><DateCompleted><Year>2025</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>A Systemic Review and Meta-Analysis of the Risk of Venous Thromboembolic Events in Parkinson's Patients.</ArticleTitle><Pagination><StartPage>e70047</StartPage><MedlinePgn>e70047</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70047</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.70047</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Parkinson's disease (PD) is a common neurodegenerative disorder affecting more than 10 million people worldwide. The actual prevalence and relative risk of venous thromboembolism (VTE) in PD have not been systematically examined, especially in various study designs and surgical settings. To address this gap in knowledge, we conducted a meta-analysis on the risk of VTE and in PD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched PubMed, Embase, and Cochrane from inception to 22 June 2024 to identify cross-sectional, cohort, and case-control studies comparing the frequency of VTE, deep vein thrombosis (DVT) and pulmonary embolism (PE) events in PD and non-PD patients. We computed risk ratios (RR) with 95% confidence intervals (CIs) for each study and pooled results using a random-effects meta-analysis. Quality assessment was performed using Joanna Briggs Institute Critical Appraisal Tools.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 758 studies screened initially, 13 studies involving 775,144 patients were included. VTE risk was elevated (RR 1.73, 95% CI 1.47-2.04) when comparing PD patients to non-PD patients. In subgroup analysis comparing neurological and non-neurological surgeries, there was no significant (p&#x2009;=&#x2009;0.11) difference in VTE risk. Cross-sectional studies had a higher elevated VTE risk (RR 5.43, 95% CI 3.40-8.67) when compared to case-control (RR 1.58, 95% CI 1.14-2.20) and cohort (RR 1.50, 95% CI 1.22-1.84) studies (p&#x2009;&lt;&#x2009;0.01).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our meta-analysis showed an elevated risk of VTE events in PD patients. There was no significant difference between neurological and non-neurological surgeries in the incidence of VTE. Greater vigilance should be exercised to detect VTE events early in PD patients due to impaired mobility.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jia Dong James</ForeName><Initials>JDJ</Initials><Identifier Source="ORCID">0009-0009-0400-6999</Identifier><AffiliationInfo><Affiliation>Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Claire Kar Min</ForeName><Initials>CKM</Initials><Identifier Source="ORCID">0000-0002-0265-2809</Identifier><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chua</LastName><ForeName>Wei Yu</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Yinxia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Singapore General Hospital Campus, National Neuroscience Institute, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Behavioral Disorders, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Ling-Ling</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Singapore General Hospital Campus, National Neuroscience Institute, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Behavioral Disorders, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng-King</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Singapore General Hospital Campus, National Neuroscience Institute, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience and Behavioral Disorders, Duke-NUS Medical School, Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OF-LCG000207</GrantID><Agency>EKT</Agency><Country/></Grant><Grant><Agency>National Medical Research Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neurodegenerative disorder</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">venous thromembolism events</Keyword></KeywordList><CoiStatement>The authors have nothing to report. The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40035126</ArticleId><ArticleId IdType="pmc">PMC11876857</ArticleId><ArticleId IdType="doi">10.1111/ene.70047</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wendelboe A. and Weitz J. I., &#x201c;Global Health Burden of Venous Thromboembolism,&#x201d; Arteriosclerosis, Thrombosis, and Vascular Biology 44, no. 5 (2024): 1007&#x2013;1011, 10.1161/ATVBAHA.124.320151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.124.320151</ArticleId><ArticleId IdType="pubmed">38657032</ArticleId></ArticleIdList></Reference><Reference><Citation>Flinterman L. E., van Hylckama V. A., Cannegieter S. C., and Rosendaal F. R., &#x201c;Long&#x2010;Term Survival in a Large Cohort of Patients With Venous Thrombosis: Incidence and Predictors,&#x201d; PLoS Medicine 9, no. 1 (2012): e1001155, 10.1371/journal.pmed.1001155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001155</ArticleId><ArticleId IdType="pmc">PMC3254666</ArticleId><ArticleId IdType="pubmed">22253578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball N., Teo W. P., Chandra S., and Chapman J., &#x201c;Parkinson's Disease and the Environment,&#x201d; Frontiers in Neurology 10 (2019): 218, 10.3389/fneur.2019.00218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00218</ArticleId><ArticleId IdType="pmc">PMC6433887</ArticleId><ArticleId IdType="pubmed">30941085</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua W. Y., Wang J. D. J., Chan C. K. M., Chan L.&#x2010;L., and Tan E.&#x2010;K., &#x201c;Risk of Aspiration Pneumonia and Hospital Mortality in Parkinson Disease: A Systematic Review and Meta&#x2010;Analysis,&#x201d; European Journal of Neurology 31, no. 12 (2024): e16449, 10.1111/ene.16449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.16449</ArticleId><ArticleId IdType="pmc">PMC11555015</ArticleId><ArticleId IdType="pubmed">39236309</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe4;ckstr&#xf6;m D., Gran&#xe5;sen G., Domell&#xf6;f M. E., et&#xa0;al., &#x201c;Early Predictors of Mortality in Parkinsonism and Parkinson Disease: A Population&#x2010;Based Study,&#x201d; Neurology 91, no. 22 (2018): e2045&#x2013;e2056, 10.1212/wnl.0000000000006576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000006576</ArticleId><ArticleId IdType="pmc">PMC6282235</ArticleId><ArticleId IdType="pubmed">30381367</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsby I. J. and Claus K., &#x201c;26&#x2014;Prevention and Management of Deep Vein Thrombosis and Pulmonary Embolism,&#x201d; in Perioperative Medicine, 2nd ed., eds. Newman M. F., Fleisher L. A., Ko C., and Mythen M. (Amsterdam: Elsevier, 2022), 428&#x2013;434.</Citation></Reference><Reference><Citation>Page M. J., McKenzie J. E., Bossuyt P. M., et&#xa0;al., &#x201c;The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews,&#x201d; BMJ 372 (2021): n71, 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Porritt K., Gomersall J., and Lockwood C., &#x201c;JBI's Systematic Reviews: Study Selection and Critical Appraisal,&#x201d; AJN the American Journal of Nursing 114, no. 6 (2014): 47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">24869584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J., Ioannidis J. P., Terrin N., Schmid C. H., and Olkin I., &#x201c;The Case of the Misleading Funnel Plot,&#x201d; BMJ 333, no. 7568 (2006): 597&#x2013;600, 10.1136/bmj.333.7568.597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.333.7568.597</ArticleId><ArticleId IdType="pmc">PMC1570006</ArticleId><ArticleId IdType="pubmed">16974018</ArticleId></ArticleIdList></Reference><Reference><Citation>Berreta R. S., Zhang H., Alsoof D., et&#xa0;al., &#x201c;Adult Spinal Deformity Correction in Patients With Parkinson Disease: Assessment of Surgical Complications, Reoperation, and Cost,&#x201d; World Neurosurgery 178 (2023): e331&#x2013;e338, 10.1016/j.wneu.2023.07.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2023.07.064</ArticleId><ArticleId IdType="pubmed">37480985</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitti F. L., Ramayya A. G., McShane B. J., Yang A. I., Vaughan K. A., and Baltuch G. H., &#x201c;Long&#x2010;Term Outcomes Following Deep Brain Stimulation for Parkinson's Disease,&#x201d; Journal of Neurosurgery 132, no. 1 (2020): 205&#x2013;210, 10.3171/2018.8.Jns182081.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2018.8.Jns182081</ArticleId><ArticleId IdType="pubmed">30660117</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K., Katsumi K., Ohashi M., et&#xa0;al., &#x201c;Surgical Outcomes of Spinal Fusion for Osteoporotic Thoracolumbar Vertebral Fractures in Patients With Parkinson's Disease: What is the Impact of Parkinson's Disease on Surgical Outcome?,&#x201d; BMC Musculoskeletal Disorders 20, no. 1 (2019): 103, 10.1186/s12891-019-2473-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-019-2473-8</ArticleId><ArticleId IdType="pmc">PMC6408814</ArticleId><ArticleId IdType="pubmed">30851739</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchand K. B., Vakharia R., Sodhi N., et&#xa0;al., &#x201c;Impact of Parkinson's Disease on Complications, Readmission Rates, and Costs of Care Following Primary Total Knee Arthroplasty,&#x201d; Journal of Knee Surgery 35, no. 1 (2022): 21&#x2013;25, 10.1055/s-0040-1710546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1710546</ArticleId><ArticleId IdType="pubmed">32462645</ArticleId></ArticleIdList></Reference><Reference><Citation>S. McClelland, 3rd , Baker J. F., Smith J. S., et&#xa0;al., &#x201c;Complications and Operative Spine Fusion Construct Length in Parkinson's Disease: A Nationwide Population&#x2010;Based Analysis,&#x201d; Journal of Clinical Neuroscience 43 (2017): 220&#x2013;223, 10.1016/j.jocn.2017.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2017.05.006</ArticleId><ArticleId IdType="pubmed">28599840</ArticleId></ArticleIdList></Reference><Reference><Citation>Umemura A., Jaggi J. L., Hurtig H. I., et&#xa0;al., &#x201c;Deep Brain Stimulation for Movement Disorders: Morbidity and Mortality in 109 Patients,&#x201d; Journal of Neurosurgery 98, no. 4 (2003): 779&#x2013;784, 10.3171/jns.2003.98.4.0779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.2003.98.4.0779</ArticleId><ArticleId IdType="pubmed">12691402</ArticleId></ArticleIdList></Reference><Reference><Citation>Voges J., Hilker R., B&#xf6;tzel K., et&#xa0;al., &#x201c;Thirty Days Complication Rate Following Surgery Performed for Deep&#x2010;Brain&#x2010;Stimulation,&#x201d; Movement Disorders 22, no. 10 (2007): 1486&#x2013;1489, 10.1002/mds.21481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.21481</ArticleId><ArticleId IdType="pubmed">17516483</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini M. L., Deutsch B. C., Neifert S. N., and Caridi J. M., &#x201c;A National Snapshot Detailing the Impact of Parkinson's Disease on the Cost and Outcome Profiles of Fusion Procedures for Cervical Myelopathy,&#x201d; Neurosurgery 86, no. 2 (2020): 298&#x2013;308, 10.1093/neuros/nyz087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuros/nyz087</ArticleId><ArticleId IdType="pubmed">30957147</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T., Koreki A., Kokubun S., et&#xa0;al., &#x201c;Deep Vein Thrombosis and Its Risk Factors in Neurodegenerative Diseases: A Markedly Higher Incidence in Parkinson's Disease,&#x201d; Journal of the Neurological Sciences 457 (2024): 122896, 10.1016/j.jns.2024.122896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2024.122896</ArticleId><ArticleId IdType="pubmed">38290377</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y. F., Chou Y. C., Yeh C. C., et&#xa0;al., &#x201c;Outcomes After Non&#x2010;Neurological Surgery in Patients With Parkinson's Disease: A Nationwide Matched Cohort Study,&#x201d; Medicine (Baltimore) 95, no. 12 (2016): e3196, 10.1097/md.0000000000003196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/md.0000000000003196</ArticleId><ArticleId IdType="pmc">PMC4998413</ArticleId><ArticleId IdType="pubmed">27015218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheppalli N. S., Senthil T., Sakthivelnathan V., Menedal A., Mounasamy V., and Sambandam S., &#x201c;Complications During the Hospital Stay, Length of Stay, and Cost of Care in Parkinson Patients Undergoing Total Knee Arthroplasty: A Propensity Matched Database Study,&#x201d; Journal of the American Academy of Orthopaedic Surgeons. Global Research &amp; Reviews 6, no. 7 (2022): e22.00121, 10.5435/JAAOSGlobal-D-22-00121.</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/JAAOSGlobal-D-22-00121</ArticleId><ArticleId IdType="pmc">PMC9273370</ArticleId><ArticleId IdType="pubmed">35802778</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah N. V., Beyer G. A., Solow M., et&#xa0;al., &#x201c;Spinal Fusion in Parkinson's Disease Patients: A Propensity Score&#x2010;Matched Analysis With Minimum 2&#x2010;Year Surveillance,&#x201d; Spine (Phila Pa 1976) 44, no. 14 (2019): E846&#x2013;E851, 10.1097/brs.0000000000002998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/brs.0000000000002998</ArticleId><ArticleId IdType="pubmed">30817740</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann L., Eysel P., Hantscher J., et&#xa0;al., &#x201c;The Influence of Parkinson Disease on Lumbar Decompression Surgery: A Retrospective Case Control Study,&#x201d; World Neurosurgery 108 (2017): 513&#x2013;518, 10.1016/j.wneu.2017.09.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2017.09.028</ArticleId><ArticleId IdType="pubmed">28919560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bou&#xe7;a&#x2010;Machado R., Maetzler W., and Ferreira J. J., &#x201c;What Is Functional Mobility Applied to Parkinson's Disease?,&#x201d; Journal of Parkinson's Disease 8, no. 1 (2018): 121&#x2013;130, 10.3233/jpd-171233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jpd-171233</ArticleId><ArticleId IdType="pmc">PMC5836402</ArticleId><ArticleId IdType="pubmed">29480225</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Li G., and Liu J., &#x201c;Autonomic Dysfunction in Parkinson's Disease: Implications for Pathophysiology, Diagnosis, and Treatment,&#x201d; Neurobiology of Disease 134 (2020): 104700, 10.1016/j.nbd.2019.104700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104700</ArticleId><ArticleId IdType="pubmed">31809788</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata M., Morita Y., Shimizu T., Takahashi K., and Suzuki N., &#x201c;Cardiac Parasympathetic Dysfunction Concurrent With Cardiac Sympathetic Denervation in Parkinson's Disease,&#x201d; Journal of the Neurological Sciences 276, no. 1 (2009): 79&#x2013;83, 10.1016/j.jns.2008.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.09.005</ArticleId><ArticleId IdType="pubmed">18838148</ArticleId></ArticleIdList></Reference><Reference><Citation>Reber E., Gomes F., D&#xe4;hn I. A., Vasiloglou M. F., and Stanga Z., &#x201c;Management of Dehydration in Patients Suffering Swallowing Difficulties,&#x201d; Journal of Clinical Medicine 8, no. 11 (2019): 1923, 10.3390/jcm8111923.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8111923</ArticleId><ArticleId IdType="pmc">PMC6912295</ArticleId><ArticleId IdType="pubmed">31717441</ArticleId></ArticleIdList></Reference><Reference><Citation>Steidl E., Ribeiro C. S., Gon&#xe7;alves B. F., Fernandes N., Antunes V., and Mancopes R., &#x201c;Relationship Between Dysphagia and Exacerbations in Chronic Obstructive Pulmonary Disease: A Literature Review,&#x201d; International Archives of Otorhinolaryngology 19, no. 1 (2015): 74&#x2013;79, 10.1055/s-0034-1376430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0034-1376430</ArticleId><ArticleId IdType="pmc">PMC4392502</ArticleId><ArticleId IdType="pubmed">25992155</ArticleId></ArticleIdList></Reference><Reference><Citation>Branchford B. R. and Carpenter S. L., &#x201c;The Role of Inflammation in Venous Thromboembolism,&#x201d; Frontiers in Pediatrics 6 (2018): 142, 10.3389/fped.2018.00142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2018.00142</ArticleId><ArticleId IdType="pmc">PMC5974100</ArticleId><ArticleId IdType="pubmed">29876337</ArticleId></ArticleIdList></Reference><Reference><Citation>Linari S. and Castaman G., &#x201c;Hemostatic Abnormalities in Gaucher Disease: Mechanisms and Clinical Implications,&#x201d; Journal of Clinical Medicine 11, no. 23 (2022): 6920, 10.3390/jcm11236920.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11236920</ArticleId><ArticleId IdType="pmc">PMC9735904</ArticleId><ArticleId IdType="pubmed">36498496</ArticleId></ArticleIdList></Reference><Reference><Citation>Hongge L., Kexin G., Xiaojie M., Nian X., and Jinsha H., &#x201c;The Role of LRRK2 in the Regulation of Monocyte Adhesion to Endothelial Cells,&#x201d; Journal of Molecular Neuroscience 55, no. 1 (2015): 233&#x2013;239, 10.1007/s12031-014-0312-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-014-0312-9</ArticleId><ArticleId IdType="pubmed">24788225</ArticleId></ArticleIdList></Reference><Reference><Citation>Afsin E., Co&#x15f;gun Z., Kurul R., and T&#xfc;rko&#x11f;lu &#x15e;. A., &#x201c;The Incidence of Deep Venous Thrombosis in Parkinson's Disease,&#x201d; Neurological Research 45, no. 11 (2023): 1050&#x2013;1054, 10.1080/01616412.2023.2257441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01616412.2023.2257441</ArticleId><ArticleId IdType="pubmed">37699515</ArticleId></ArticleIdList></Reference><Reference><Citation>Meknas D., Br&#xe6;kkan S. K., Hansen J. B., and Morelli V. M., &#x201c;Surgery as a Trigger for Incident Venous Thromboembolism: Results From a Population&#x2010;Based Case&#x2010;Crossover Study,&#x201d; TH Open 7, no. 3 (2023): e244&#x2013;e250, 10.1055/a-2159-9957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-2159-9957</ArticleId><ArticleId IdType="pmc">PMC10511275</ArticleId><ArticleId IdType="pubmed">37736074</ArticleId></ArticleIdList></Reference><Reference><Citation>Rethinasamy R., Alias A., Kandasamy R., Raffiq A., Looi M. C., and Hillda T., &#x201c;Deep Vein Thrombosis and the Neurosurgical Patient,&#x201d; Malaysian Journal of Medical Sciences 26, no. 5 (2019): 139&#x2013;147, 10.21315/mjms2019.26.5.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.21315/mjms2019.26.5.13</ArticleId><ArticleId IdType="pmc">PMC6839661</ArticleId><ArticleId IdType="pubmed">31728126</ArticleId></ArticleIdList></Reference><Reference><Citation>Setia M. S., &#x201c;Methodology Series Module 3: Cross&#x2010;Sectional Studies,&#x201d; Indian Journal of Dermatology 61, no. 3 (2016): 261&#x2013;264, 10.4103/0019-5154.182410.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0019-5154.182410</ArticleId><ArticleId IdType="pmc">PMC4885177</ArticleId><ArticleId IdType="pubmed">27293245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. D. J., Leow Y. J., Vipin A., Kumar D., and Kandiah N., &#x201c;Impact of White Matter Hyperintensities on Domain&#x2010;Specific Cognition in Southeast Asians,&#x201d; Alzheimer's &amp; Dementia 19, no. S24 (2023): e082267, 10.1002/alz.082267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.082267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J. D. J., Leow Y. J., Vipin A., et&#xa0;al., &#x201c;Association of Blood&#x2010;Based Biomarkers: GFAP, Amyloid 42/40 and Perivascular Spaces in Relation to Cognitive Domains in Vascular Cognitive Impairment Participants,&#x201d; Alzheimer's &amp; Dementia 20 (2024): e092210.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">31815829</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-2291</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of orthopaedic trauma</Title><ISOAbbreviation>J Orthop Trauma</ISOAbbreviation></Journal><ArticleTitle>Ability of Thromboelastography to Detect Hypercoagulability: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>278</StartPage><EndPage>286</EndPage><MedlinePgn>278-286</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/BOT.0000000000001714</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To review the current literature on the use of viscoelastic hemolytic assays, such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM), during the perioperative period of patients and determine the ability of TEG and ROTEM to detect hypercoagulability and identify increased risk of the development of venous thromboembolism (VTE).</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">PubMed, EMBASE, and Cochrane online databases were queried through February 11, 2018, by pairing the terms "thromboelastography," "viscoelastic hemostatic assays," and "rotational thromboelastometry" with "venous thromboembolism," "deep vein thrombosis," "pulmonary embolism," and "hypercoagulability."</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">Inclusion and exclusion criteria were established to determine relevance and quality of data, of which 2.54% of initially identified studies met.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS" NlmCategory="METHODS">Articles and citations were reviewed for relevance by 2 independent individuals following PRISMA guidelines as well as a quality assessment of data as established by Zaza et al. In studies that separated patients postoperatively by VTE development or no VTE development, data were pooled utilizing a modified DerSimmion and Laird random effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One thousand eight hundred ninety-three articles were assessed for eligibility, yielding 370 abstracts. Of the 370 abstracts, 35 studies were included, and of these, only 5 were included in the meta-analysis. Studies included postsurgical patients in a variety of surgical fields, encompassing a total of 8939 patients, with 717 thrombotic events reported. Elevated maximum amplitude (MA) was a statistically significant indicator of hypercoagulability across at least 1 perioperative time point in 17 (50%) of the articles reviewed, consisting of 6348 (72%) patients. The pooled mean MA value for defining hypercoagulability was greater than 66.70 mm. Using a prepublished value for hypercoagulability of 65 mm, the combined effect of MA on the development of VTE in postsurgical patients was determined to be 1.31 (95% confidence, 0.74-2.34, P = 0.175) and was 46% sensitive and 62% specific in predicting a postoperative VTE.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Only 1 parameter, MA, was consistently used to both define hypercoagulability and be predictive of VTE after traumatic injury and surgical intervention; however, there remains a broad variability in the definition of hypercoagulability as determined by MA and thus limits its predictive ability. In addition, when hypercoagulability was measured throughout the perioperative period, TEG consistently demonstrated hypercoagulability starting on post-op day 1 (POD1).</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Diagnostic Level III. See Instructions for Authors for a complete description of levels of evidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Wesley</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Medical College of Georgia, Augusta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunati</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Emory University Orthopaedics, Atlanta, GA; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maceroli</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Emory University Orthopaedics, Atlanta, GA; and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grady Memorial Hospital, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Emory University Orthopaedics, Atlanta, GA; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staley</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Emory University Orthopaedics, Atlanta, GA; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Emory University Orthopaedics, Atlanta, GA; and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grady Memorial Hospital, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schenker</LastName><ForeName>Mara</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Emory University Orthopaedics, Atlanta, GA; and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grady Memorial Hospital, Atlanta, GA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Orthop Trauma</MedlineTA><NlmUniqueID>8807705</NlmUniqueID><ISSNLinking>0890-5339</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013916" MajorTopicYN="N">Thrombelastography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="Y">Thrombophilia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31815829</ArticleId><ArticleId IdType="doi">10.1097/BOT.0000000000001714</ArticleId><ArticleId IdType="pii">00005131-202006000-00002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Plotkin AJ, Wade CE, Jenkins DH, et al. A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries. J Trauma. 2008;64(2 suppl):S64&#x2013;S68.</Citation></Reference><Reference><Citation>Duraj L, Stasko J, Hasko M, et al. Monitoring of hemostasis by rotational thrombelastometry during normal pregnancy and postpartum. Acta Med Martiniana. 2015;15:5&#x2013;12.</Citation></Reference><Reference><Citation>Gibbs NM, Crawford GPM, Michalopoulos N. Thrombelastographic patterns following abdominal aortic surgery. Anaesth Intensive Care. 1994;22:534&#x2013;538.</Citation></Reference><Reference><Citation>Hajek R, Fluger I, Zezula R, et al. Coagulation patterns during and after cardiopulmonary bypass detected with thrombelastography. International J Artif Organs. Conference: 43rd annual european society for artificial organs, ESAO congress Poland. 2016;39:367. Available at: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/202/CN-01361202/frame.html.</Citation></Reference><Reference><Citation>Krzanicki D, Sugavanam A, Mallett S. Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography. Liver Transpl. 2013;19:852&#x2013;861.</Citation></Reference><Reference><Citation>Mallett SV. Clinical utility of viscoelastic tests of coagulation (TEG/ROTEM) in patients with liver disease and during liver transplantation. Seminars Thromb Hemost. 2015;41:527&#x2013;537.</Citation></Reference><Reference><Citation>Mathur A, Li B, Emond J, et al. Rotational thromboelastometry predicts thromboembolic complications after orthotopic liver transplant. Transplantation. 2015;99:262.</Citation></Reference><Reference><Citation>Moopanar D, Naidu S, Moodley J, et al. Thromboelastography in abruptio placentae. J Obstet Gynaecol. 1997;17:229&#x2013;233.</Citation></Reference><Reference><Citation>White AE, Edelman JJ, Lott N, et al. Characterization of the hypercoagulable state following severe orthopedic trauma. J Trauma Acute Care Surg. 2014;77:231&#x2013;237.</Citation></Reference><Reference><Citation>Nielsen VG, Cohen BM, Cohen E. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand. 2005;49:222&#x2013;231.</Citation></Reference><Reference><Citation>Othman M, Kaur H. Thromboelastography (TEG). Methods Mol Biol. 2017;1646:533&#x2013;543.</Citation></Reference><Reference><Citation>Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 suppl):S495&#x2013;S501.</Citation></Reference><Reference><Citation>Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.</Citation></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.</Citation></Reference><Reference><Citation>Zaza S, Wright-De Aguero LK, Briss PA, et al. Data collection instrument and procedure for systematic reviews in the guide to community preventive services. Task force on community preventive services. Am J Prev Med. 2000;18(1 suppl):44&#x2013;74.</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45(pt A):139&#x2013;145.</Citation></Reference><Reference><Citation>Suurmond R, van Rhee H, Hak T. Introduction, comparison, and validation of Meta-Essentials: a free and simple tool for meta-analysis. Res Synth Methods. 2017;8:537&#x2013;553.</Citation></Reference><Reference><Citation>Review Manager (RevMan) [Computer Program]. Version 5.3. Copenhagen, Denmark: The Nordic Cochrane Centre, The Cochrane Collaboration. 2014.</Citation></Reference><Reference><Citation>Brill JB, Badiee J, Zander AL, et al. The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography. J Trauma Acute Care Surg. 2017;83:413&#x2013;419.</Citation></Reference><Reference><Citation>Allen CJ, Murray CR, Meizoso JP, et al. Coagulation profile changes due to thromboprophylaxis and platelets in trauma patients at high-risk for venous thromboembolism. Am Surg. 2015;81:663&#x2013;664.</Citation></Reference><Reference><Citation>Cotton BA, Minei KM, Radwan ZA, et al. Admission rapid thrombelastography predicts development of pulmonary embolism in trauma patients. J Trauma Acute Care Surg. 2012;72:1470&#x2013;1475. discussion 1475-1477.</Citation></Reference><Reference><Citation>McCrath DJ, Cerboni E, Frumento RJ, et al. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100:1576&#x2013;1583.</Citation></Reference><Reference><Citation>Van Haren RM, Valle EJ, Thorson CM, et al. Hypercoagulability and other risk factors in trauma intensive care unit patients with venous thromboembolism. J Trauma Acute Care Surg. 2014;76:443&#x2013;449.</Citation></Reference><Reference><Citation>Gary JL, Schneider PS, Galpin M, et al. Can thrombelastography predict venous thromboembolic events in patients with severe extremity trauma? J Orthop Trauma. 2016;30:294&#x2013;298.</Citation></Reference><Reference><Citation>Jennings S, Cass AJ, Heather BP, et al. Coagulation changes during major surgery and relationship to post-operative deep vein thrombosis. J Cardiovasc Surg. 1981;22:327&#x2013;329.</Citation></Reference><Reference><Citation>Abrahams JM, Torchia MB, McGarvey M, et al. Perioperative assessment of coagulability in neurosurgical patients using thromboelastography. Surg Neurol. 2002;58:5&#x2013;11. discussion 11-12.</Citation></Reference><Reference><Citation>Barton JS, Riha GM, Differding JA, et al. Coagulopathy after a liver resection: is it over diagnosed and over treated? HPB. 2013;15:865&#x2013;871.</Citation></Reference><Reference><Citation>Branco BC, Inaba K, Ives C, et al. Thromboelastogram evaluation of the impact of hypercoagulability in trauma patients. Shock. 2014;41:200&#x2013;207.</Citation></Reference><Reference><Citation>De Pietri L, Montalti R, Begliomini B, et al. Thromboelastographic changes in liver and pancreatic cancer surgery: hypercoagulability, hypocoagulability or normocoagulability? Eur J Anaesthesiol. 2010;27:608&#x2013;616.</Citation></Reference><Reference><Citation>Kupcinskiene K, Trepenaitis D, Petereit R, et al. Monitoring of hypercoagulability by thromboelastography in bariatric surgery. Med Sci Monit. 2017;23:1819&#x2013;1826.</Citation></Reference><Reference><Citation>Pommerening MJ, Rahbar E, Minei K, et al. Splenectomy is associated with hypercoagulable thrombelastography values and increased risk of thromboembolism. Surgery. 2015;158:618&#x2013;626.</Citation></Reference><Reference><Citation>Thorson CM, Van Haren RM, Ryan ML, et al. Persistence of hypercoagulable state after resection of intra-abdominal malignancies. J Am Coll Surg. 2013;216:580&#x2013;589. discussion 589-590.</Citation></Reference><Reference><Citation>Traverso CI, Arcelus JI, Gomez E, et al. Prospective assessment of the risk of deep vein thrombosis in elective abdominal surgery. Predictive role of thromboelastography. Thromb Haemorrh Disord. 1993;7:9&#x2013;15.</Citation></Reference><Reference><Citation>Watters JM, Sambasivan CN, Zink K, et al. Splenectomy leads to a persistent hypercoagulable state after trauma. Am J Surg. 2010;199:646&#x2013;651.</Citation></Reference><Reference><Citation>Parameswaran A, Krishnamoorthy VP, Oommen AT, et al. Is pre-operative assessment of coagulation profile with Thrombelastography (TEG) useful in predicting venous thromboembolism (VTE) following orthopaedic surgery? J Clin Orthop Trauma. 2016;7(suppl 2):225&#x2013;229.</Citation></Reference><Reference><Citation>Forfori F, Ferro B, Mancini B, et al. Role of thrombolestagrophy in monitoring perioperative coagulation status and effect of thromboprophylaxis in bariatric surgery. Obes Surg. 2012;22:113&#x2013;118.</Citation></Reference><Reference><Citation>Hincker A, Feit J, Sladen RN, et al. Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery. Crit Care. 2014;18:549.</Citation></Reference><Reference><Citation>Lee BY, Butler G, Al-Waili N, et al. Role of thrombelastograph haemostasis analyser in detection of hypercoagulability following surgery with and without use of intermittent pneumatic compression. J Med Eng Technol. 2010;34:166&#x2013;171.</Citation></Reference><Reference><Citation>McCully BH, Connelly CR, Fair KA, et al. Onset of coagulation function recovery is delayed in severely injured trauma patients with venous thromboembolism. J Am Coll Surg. 2017;225:42&#x2013;51.</Citation></Reference><Reference><Citation>Yang Y, Yao Z, Dai W, et al. Changes of thrombelastography in patients undergoing elective primary total knee and total hip replacement with low molecular heparin prophylaxis. J Orthop Surg Res. 2014;9:52.</Citation></Reference><Reference><Citation>Kashuk JL, Moore EE, Sabel A, et al. Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients. Surgery. 2009;146:764&#x2013;772. discussion 772-764.</Citation></Reference><Reference><Citation>Liu C, Guan Z, Xu Q, et al. Relation of thromboelastography parameters to conventional coagulation tests used to evaluate the hypercoagulable state of aged fracture patients. Med (Baltim). 2016;95:e3934.</Citation></Reference><Reference><Citation>Park MS, Martini WZ, Dubick MA, et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma. 2009;67:266&#x2013;275. discussion 275-266.</Citation></Reference><Reference><Citation>Schreiber MA, Differding J, Thorborg P, et al. Hypercoagulability is most prevalent early after injury and in female patients. J Trauma. 2005;58:475&#x2013;481.</Citation></Reference><Reference><Citation>Wilson D, Cooke EA, McNally MA, et al. Changes in coagulability as measured by thrombelastography following surgery for proximal femoral fracture. Injury. 2001;32:765&#x2013;770.</Citation></Reference><Reference><Citation>Ng KF, Lo JW. The development of hypercoagulability state, as measured by thrombelastography, associated with intraoperative surgical blood loss. Anaesth Intensive Care. 1996;24:20&#x2013;25.</Citation></Reference><Reference><Citation>Taura P, Rivas E, Martinez-Palli G, et al. Clinical markers of the hypercoagulable state by rotational thrombelastometry in obese patients submitted to bariatric surgery. Surg Endosc. 2014;28:543&#x2013;551.</Citation></Reference><Reference><Citation>Mahla E, Lang T, Vicenzi MN, et al. Thromboelastography for monitoring prolonged hypercoagulability after major abdominal surgery. Anesth Analg. 2001;92:572&#x2013;577.</Citation></Reference><Reference><Citation>Bell CRW, Cox DJA, Murdock PJ, et al. Thrombelastographic evaluation of coagulation in transurethral prostatectomy. Br J Urol. 1996;78:737&#x2013;741.</Citation></Reference><Reference><Citation>Burke GW III, Ciancio G, Figueiro J, et al. Hypercoagulable state associated with kidney-pancreas transplantation. Thromboelastogram-directed anti-coagulation and implications for future therapy. Clin Transpl. 2004;18:423&#x2013;428.</Citation></Reference><Reference><Citation>Caprini JA, Arcelus JI, Laubach M, et al. Postoperative hypercoagulability and deep-vein thrombosis after laparoscopic cholecystectomy. Surg Endosc. 1995;9:304&#x2013;309.</Citation></Reference><Reference><Citation>Kolbenschlag J, Daigeler A, Lauer S, et al. Can rotational thromboelastometry predict thrombotic complications in reconstructive microsurgery? Microsurgery. 2014;34:253&#x2013;260.</Citation></Reference><Reference><Citation>Grant AL, Letson HL, Morris JL, et al. Tranexamic acid is associated with selective increase in inflammatory markers following total knee arthroplasty (TKA): a pilot study. J Orthop Surg Res. 2018;13:149.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27849664</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1140</ISSN><JournalIssue CitedMedium="Internet"><Volume>265</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Annals of surgery</Title><ISOAbbreviation>Ann Surg</ISOAbbreviation></Journal><ArticleTitle>Perioperative Pharmacological Thromboprophylaxis in Patients With Cancer: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>1087</StartPage><EndPage>1093</EndPage><MedlinePgn>1087-1093</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SLA.0000000000002074</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To compare the relative effects between pharmacological thromboprophylaxis and no anticoagulation.</AbstractText><AbstractText Label="BACKGROUND">The efficacy and safety of pharmacological thromboprophylaxis in cancer patients undergoing surgery need to be quantified to guide management.</AbstractText><AbstractText Label="METHODS">We searched multiple electronic databases (up to March 31, 2016) for trials of cancer patients undergoing surgery that assessed the relative benefits and harms of perioperative pharmacological thromboprophylaxis. Relative risks (RRs) with 95% confidence intervals (CI) were estimated.</AbstractText><AbstractText Label="RESULTS">A total of 39 studies were enrolled in this review. Patients with pharmacological thromboprophylaxis had a relatively reduced incidence of deep venous thrombosis (DVT) compared with those without (0.5% vs 1.2%, RR 0.51, 95% CI 0.27-0.94; P = 0.03) but a significantly increased incidence of bleeding events (RR 2.51, 95% CI 1.79-3.51; P &lt; 0.0001). The incidence of pulmonary embolism (PE) (RR 1.77, 95% CI 0.76-4.14; P = 0.19) and mortality related to venous thromboembolism (VTE) (1/2,811 vs 2/3,380) were similar between the pharmacological thromboprophylaxis group and the no pharmacological thromboprophylaxis group. Low-molecular-weight heparin (LMWH) reduced the incidence of DVT compared with unfractionated heparin (UFH) (RR 0.81, 95% CI 0.66-1.00; P = 0.05), and standard extended thromboprophylaxis after cancer surgery significant decreased the incidence of DVT as compared with conventional thromboprophylaxis (RR 0.57, 95% CI 0.39-0.83; P = 0.003).</AbstractText><AbstractText Label="CONCLUSIONS">Routine pharmacological thromboprophylaxis for cancer patients undergoing surgery needs to be carefully considered, because although thromboprophylaxis is associated with lower VTE events, there is a higher incidence of clinically significant bleeding events. If pharmacological thromboprophylaxis is to be used, extended thromboprophylaxis started preoperatively with LWMH might be the most effective strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, West China Hospital, Sichuan University, Chengdu , Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Bin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jichun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yukui</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Ding</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Xiaojiong</ForeName><Initials>X</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg</MedlineTA><NlmUniqueID>0372354</NlmUniqueID><ISSNLinking>0003-4932</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27849664</ArticleId><ArticleId IdType="doi">10.1097/SLA.0000000000002074</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38182827</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1496-8975</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Canadian journal of anaesthesia = Journal canadien d'anesthesie</Title><ISOAbbreviation>Can J Anaesth</ISOAbbreviation></Journal><ArticleTitle>Perioperative clinical practice recommendations for pediatric tonsillectomy: a systematic review.</ArticleTitle><Pagination><StartPage>187</StartPage><EndPage>200</EndPage><MedlinePgn>187-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12630-023-02668-z</ELocationID><Abstract><AbstractText Label="PURPOSE">Tonsillectomy is one of the most common surgical procedures performed in children. Since most clinical practice guidelines (CPGs) are designed to support surgical decisions, none are specifically designed for the perioperative management of children undergoing tonsillectomy. We aimed to identify and analyze the existing CPGs with recommendations for the perioperative management of children undergoing tonsillectomy by conducting a systematic review.</AbstractText><AbstractText Label="SOURCE">We searched Embase, MEDLINE, MEDLINE ePub Ahead of Print, and CINAHL for relevant articles published from inception to 3 August 2022. The inclusion criteria were: 1) CPG of perioperative recommendations for tonsillectomy under general anesthesia in children, 2) CPG that include at least one evidence-based recommendation, 3) peer-reviewed CPG published in English after 2000. We extracted data on baseline characteristics of each CPG and general recommendations for perioperative interventions or complications.</AbstractText><AbstractText Label="PRINCIPAL FINDINGS">Out of five eligible CPGs, AGREE II and REX confirmed that two CPGs were high quality while only one of the two was recommended for implementation without modifications. Most of the recommendations were for pain management. Acetaminophen was the only medication recommended in all five CPG. Except for the oldest CPG, the CPG all supported of the use of nonsteroidal anti-inflammatory drugs and steroids as a pain adjunct.</AbstractText><AbstractText Label="CONCLUSIONS">Acetaminophen, nonsteroidal anti-inflammatory drugs, and steroids are recommended in the perioperative management of pediatric tonsillectomy. Future CPG should further clarify the safe use of opioids based on severity of obstructive sleep apnea and in the context of opioid-sparing techniques, such as dexmedetomidine, high-dose dexamethasone, and gabapentinoids.</AbstractText><AbstractText Label="STUDY REGISTRATION">PROSPERO (CRD42021253374); first submitted 18 June 2021.</AbstractText><CopyrightInformation>&#xa9; 2024. Canadian Anesthesiologists' Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Albornoz</LastName><ForeName>Alfonso E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rana</LastName><ForeName>Mehwish</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Englesakis</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Library and Information Services, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>Maisie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Reshma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Child Health Evaluative Sciences, SickKids Research Institute, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilfoyle</LastName><ForeName>Elaine</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Child Health Evaluative Sciences, SickKids Research Institute, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petre</LastName><ForeName>Maria-Alexandra</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Montreal Children's Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campisi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Otolaryngology - Head and Neck Surgery, The Hospital for Sick Children, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoyama</LastName><ForeName>Kazuyoshi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7502-0896</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON, Canada. kazu.aoyama@utoronto.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Child Health Evaluative Sciences, SickKids Research Institute, Toronto, ON, Canada. kazu.aoyama@utoronto.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, 555 University Ave, #2211, Toronto, ON, M5G 1X8, Canada. kazu.aoyama@utoronto.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Perioperative Services Summer Studentship Program 2021</GrantID><Agency>Hospital for Sick Children</Agency><Country/></Grant><Grant><GrantID>Outcomes Research Award 2020-2021</GrantID><Agency>Hospital for Sick Children</Agency><Country/></Grant><Grant><GrantID>Department of Anesthesia</GrantID><Agency>Hospital for Sick Children</Agency><Country/></Grant><Grant><GrantID>Pain Medicine</GrantID><Agency>Hospital for Sick Children</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Directives de pratique clinique p&#xe9;riop&#xe9;ratoires pour l&#x2019;amygdalectomie p&#xe9;diatrique : une revue syst&#xe9;matique.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Anaesth</MedlineTA><NlmUniqueID>8701709</NlmUniqueID><ISSNLinking>0832-610X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>362O9ITL9D</RegistryNumber><NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D014068" MajorTopicYN="Y">Tonsillectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019990" MajorTopicYN="Y">Perioperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000768" MajorTopicYN="N">Anesthesia, General</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000082" MajorTopicYN="N">Acetaminophen</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059408" MajorTopicYN="N">Pain Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText Label="UNLABELLED">R&#xe9;SUM&#xe9;: OBJECTIF: L&#x2019;amygdalectomie est l&#x2019;une des interventions chirurgicales les plus courantes pratiqu&#xe9;es chez les enfants. &#xc9;tant donn&#xe9; que la plupart des lignes directrices de pratique clinique sont con&#xe7;ues pour soutenir les d&#xe9;cisions chirurgicales, aucune n&#x2019;est sp&#xe9;cifiquement con&#xe7;ue pour la prise en charge p&#xe9;riop&#xe9;ratoire des enfants b&#xe9;n&#xe9;ficiant d&#x2019;une amygdalectomie. Notre objectif &#xe9;tait d&#x2019;identifier et d&#x2019;analyser les lignes directrices de pratique clinique existantes comportant des recommandations pour la prise en charge p&#xe9;riop&#xe9;ratoire des enfants b&#xe9;n&#xe9;ficiant d&#x2019;une amygdalectomie en r&#xe9;alisant une revue syst&#xe9;matique.</AbstractText><AbstractText Label="SOURCES">Nous avons recherch&#xe9; des articles pertinents dans Embase, MEDLINE, MEDLINE ePub Ahead of Print et CINAHL, publi&#xe9;s depuis la cr&#xe9;ation de ces bases de donn&#xe9;es jusqu&#x2019;au 3 ao&#xfb;t 2022. Les crit&#xe8;res d&#x2019;inclusion &#xe9;taient les suivants : 1) lignes directrices de pratique clinique comportant des recommandations p&#xe9;riop&#xe9;ratoires pour l&#x2019;amygdalectomie sous anesth&#xe9;sie g&#xe9;n&#xe9;rale chez les enfants, 2) lignes directrices de pratique clinique incluant au moins une recommandation fond&#xe9;e sur des donn&#xe9;es probantes, et 3) lignes directrices de pratique clinique &#xe9;valu&#xe9;es par des pairs et publi&#xe9;es en anglais apr&#xe8;s 2000. Nous avons extrait des donn&#xe9;es sur les caract&#xe9;ristiques de base de chacune des lignes directrices de pratique clinique et des recommandations g&#xe9;n&#xe9;rales pour les interventions p&#xe9;riop&#xe9;ratoires ou les complications.</AbstractText><AbstractText Label="CONSTATATIONS PRINCIPALES">Sur les cinq lignes directrices de pratique clinique admissibles, AGREE II et REX ont confirm&#xe9; que deux lignes directrices de pratique clinique &#xe9;taient de haute qualit&#xe9;, tandis qu&#x2019;une seule des deux a &#xe9;t&#xe9; recommand&#xe9;e pour une mise en &#x153;uvre sans modifications. La plupart des recommandations portaient sur la prise en charge de la douleur. L&#x2019;ac&#xe9;taminoph&#xe8;ne &#xe9;tait le seul m&#xe9;dicament recommand&#xe9; dans les cinq lignes directrices de pratique clinique. &#xc0; l&#x2019;exception des lignes directrices de pratique clinique les plus anciennes, les autres ont toutes soutenu l&#x2019;utilisation d&#x2019;agents anti-inflammatoires non st&#xe9;ro&#xef;diens et de st&#xe9;ro&#xef;des comme adjuvants pour la douleur.</AbstractText><AbstractText Label="CONCLUSION">L&#x2019;ac&#xe9;taminoph&#xe8;ne, les agents anti-inflammatoires non st&#xe9;ro&#xef;diens et les st&#xe9;ro&#xef;des sont recommand&#xe9;s pour la prise en charge p&#xe9;riop&#xe9;ratoire de l&#x2019;amygdalectomie p&#xe9;diatrique. &#xc0; l&#x2019;avenir, les lignes directrices de pratique clinique devraient clarifier davantage l&#x2019;utilisation s&#xe9;curitaire des opio&#xef;des en fonction de la gravit&#xe9; de l&#x2019;apn&#xe9;e obstructive du sommeil et dans le contexte des techniques d&#x2019;&#xe9;pargne des opio&#xef;des, telles que la dexm&#xe9;d&#xe9;tomidine, la dexam&#xe9;thasone &#xe0; forte dose et les gabapentino&#xef;des. ENREGISTREMENT DE L&#x2019;&#xe9;TUDE: PROSPERO (CRD42021253374); soumise pour la premi&#xe8;re fois le 18 juin 2021.</AbstractText><CopyrightInformation>&#xa9; 2024. Canadian Anesthesiologists' Society.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical practice guidelines</Keyword><Keyword MajorTopicYN="N">general anesthesia</Keyword><Keyword MajorTopicYN="N">pediatric tonsillectomy</Keyword><Keyword MajorTopicYN="N">perioperative care</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>6</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>5</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38182827</ArticleId><ArticleId IdType="doi">10.1007/s12630-023-02668-z</ArticleId><ArticleId IdType="pii">10.1007/s12630-023-02668-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hall MJ, Schwartzman A, Zhang J, Liu X. Ambulatory surgery data from hospitals and ambulatory surgery centers: United States, 2010; 2017. Available from URL: https://www.cdc.gov/nchs/data/nhsr/nhsr102.pdf (accessed October 2023).</Citation></Reference><Reference><Citation>Patel HH, Straight CE, Lehman EB, Tanner M, Carr MM. Indications for tonsillectomy: a 10 year retrospective review. Int J Pediatr Otorhinolaryngol 2014; 78: 2151&#x2013;5. https://doi.org/10.1016/j.ijporl.2014.09.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijporl.2014.09.030</ArticleId><ArticleId IdType="pubmed">25447951</ArticleId></ArticleIdList></Reference><Reference><Citation>Belyea J, Chang Y, Rigby MH, Corsten G, Hong P. Post-tonsillectomy complications in children less than three years of age: a case&#x2013;control study. Int J Pediatr Otorhinolaryngol 2014; 78: 871&#x2013;4. https://doi.org/10.1016/j.ijporl.2014.02.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijporl.2014.02.029</ArticleId><ArticleId IdType="pubmed">24680134</ArticleId></ArticleIdList></Reference><Reference><Citation>Steward DL, Grisel J, Meinzen-Derr J. Steroids for improving recovery following tonsillectomy in children. Cochrane Database Syst Rev 2011; 2011: CD003997. https://doi.org/10.1002/14651858.cd003997.pub2</Citation></Reference><Reference><Citation>Lescanne E, Chiron B, Constant I, et al. Pediatric tonsillectomy: clinical practice guidelines. Eur Ann Otorhinolaryngol Head Neck Dis 2012; 129: 264&#x2013;71. https://doi.org/10.1016/j.anorl.2012.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anorl.2012.03.003</ArticleId><ArticleId IdType="pubmed">23078979</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell RB, Archer SM, Ishman SL, et al. Clinical practice guideline: tonsillectomy in children (update)&#x2014;executive summary. Otolaryngol Head Neck Surg 2019; 160: 187&#x2013;205. https://doi.org/10.1177/0194599818807917</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599818807917</ArticleId><ArticleId IdType="pubmed">30921525</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, Mckenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. https://doi.org/10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId><ArticleId IdType="pmc">8005924</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston A, Kelly SE, Hsieh SC, Skidmore B, Wells GA. Systematic reviews of clinical practice guidelines: a methodological guide. J Clin Epidemiol 2019; 108: 64&#x2013;76. https://doi.org/10.1016/j.jclinepi.2018.11.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2018.11.030</ArticleId><ArticleId IdType="pubmed">30529647</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839&#x2013;42. https://doi.org/10.1503/cmaj.090449</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.090449</ArticleId><ArticleId IdType="pubmed">20603348</ArticleId><ArticleId IdType="pmc">3001530</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers MC, Spithoff K, Kerkvliet K, et al. Development and validation of a tool to assess the quality of clinical practice guideline recommendations. JAMA Netw Open 2020; 3: e205535. https://doi.org/10.1001/jamanetworkopen.2020.5535</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.5535</ArticleId><ArticleId IdType="pubmed">32459354</ArticleId><ArticleId IdType="pmc">7254179</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldamluji N, Burgess A, Pogatzki-Zahn E, Raeder J, Beloeil H. PROSPECT guideline for tonsillectomy: systematic review and procedure-specific postoperative pain management recommendations. Anaesthesia 2021; 76: 947&#x2013;61. https://doi.org/10.1111/anae.15299</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.15299</ArticleId><ArticleId IdType="pubmed">33201518</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell RB, Archer SM, Ishman SL, et al. Clinical practice guideline: tonsillectomy in children (update). Otolaryngol Head Neck Surg 2019; 160: S1&#x2013;42. https://doi.org/10.1177/0194599818801757</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599818801757</ArticleId><ArticleId IdType="pubmed">30798778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ericsson E, Brattwall M, Lundeberg S. Swedish guidelines for the treatment of pain in tonsil surgery in pediatric patients up to 18 years. Int J Pediatr Otorhinolaryngol 2015; 79: 443&#x2013;50. https://doi.org/10.1016/j.ijporl.2015.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijporl.2015.01.016</ArticleId><ArticleId IdType="pubmed">25677565</ArticleId></ArticleIdList></Reference><Reference><Citation>Constant I, Ayari Khalfallah S, Brunaud A, et al. How to replace codeine after tonsillectomy in children under 12 years of age? Guidelines of the French Oto-Rhino-Laryngology-Head and Neck Surgery Society (SFORL). Eur Ann Otorhinolaryngol Head Neck Dis 2014; 131: 233&#x2013;8. https://doi.org/10.1016/j.anorl.2014.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anorl.2014.06.001</ArticleId><ArticleId IdType="pubmed">25106698</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbani CC, Pflum ZE, Ye MJ, et al. Intraoperative ketorolac for pediatric tonsillectomy: Effect on post-tonsillectomy hemorrhage and perioperative analgesia. Int J Pediatr Otorhinolaryngol 2020; 138: 110341. https://doi.org/10.1016/j.ijporl.2020.110341</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijporl.2020.110341</ArticleId><ArticleId IdType="pubmed">32891944</ArticleId></ArticleIdList></Reference><Reference><Citation>Lammers CR, Schwinghammer AJ, Hall B, et al. Comparison of oral loading dose to intravenous acetaminophen in children for analgesia after tonsillectomy and adenoidectomy: a randomized clinical trial. Anesth Analg 2021; 133: 1568&#x2013;76. https://doi.org/10.1213/ane.0000000000005678</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0000000000005678</ArticleId><ArticleId IdType="pubmed">34304234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hii J, von Ungern-Sternberg BS, Sommerfield A, Sommerfield D. Perioperative pediatric tonsillectomy analgesia: a single-center review of practice and cost-effectiveness analysis. Paediatr Anaesth 2021; 31: 497&#x2013;8. https://doi.org/10.1111/pan.14134</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pan.14134</ArticleId><ArticleId IdType="pubmed">33484060</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann GE, Flamer SZ, Nair S, et al. Opioid-free anesthesia for adenotonsillectomy in children. Int J Pediatr Otorhinolaryngol 2021; 140: 110501. https://doi.org/10.1016/j.ijporl.2020.110501</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijporl.2020.110501</ArticleId><ArticleId IdType="pubmed">33290925</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz AM, Dahl JP, Huang H, et al. The development of an opioid sparing anesthesia protocol for pediatric ambulatory tonsillectomy and adenotonsillectomy surgery&#x2014;a quality improvement project. Paediatr Anaesth 2019; 29: 682&#x2013;9. https://doi.org/10.1111/pan.13662</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pan.13662</ArticleId><ArticleId IdType="pubmed">31077491</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler AC, Daszkowski A, Tan JC, et al. The association of dexmedetomidine on perioperative opioid consumption in children undergoing adenotonsillectomy with and without obstructive sleep apnea. Anesth Analg 2021; 133: 1260&#x2013;8. https://doi.org/10.1213/ane.0000000000005410</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0000000000005410</ArticleId><ArticleId IdType="pubmed">33591119</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, Miao S, Gu T, Wang D, Zhang H, Liu J. Dexmedetomidine for the prevention of emergence delirium and postoperative behavioral changes in pediatric patients with sevoflurane anesthesia: a double-blind, randomized trial. Drug Des Devel Ther 2019; 13: 897&#x2013;905. https://doi.org/10.2147/dddt.s196075</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/dddt.s196075</ArticleId><ArticleId IdType="pubmed">30936683</ArticleId><ArticleId IdType="pmc">6421876</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YZ, Wang X, Wu JM, Song CY, Cui XG. Optimal dexmedetomidine dose to prevent emergence agitation under sevoflurane and remifentanil anesthesia during pediatric tonsillectomy and adenoidectomy. Front Pharmacol 2019; 10: 1091. https://doi.org/10.3389/fphar.2019.01091</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2019.01091</ArticleId><ArticleId IdType="pubmed">31607927</ArticleId><ArticleId IdType="pmc">6761387</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiotou AG, Malisiova A, Kouptsova E, Mavri M, Anagnostopoulou M, Kalliardou E. Dexmedetomidine for the reduction of emergence delirium in children undergoing tonsillectomy with propofol anesthesia: a double-blind, randomized study. Paediatr Anaesth 2018; 28: 632&#x2013;8. https://doi.org/10.1111/pan.13397</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pan.13397</ArticleId><ArticleId IdType="pubmed">29752853</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunkens A, Vermeulen K, Peters M, Fieuws S, Van de Velde M, Rex S. Bupivacaine infiltration in children for postoperative analgesia after tonsillectomy: a randomised controlled trial. Eur J Anaesthesiol 2019; 36: 206&#x2013;14. https://doi.org/10.1097/eja.0000000000000950</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/eja.0000000000000950</ArticleId><ArticleId IdType="pubmed">30640245</ArticleId></ArticleIdList></Reference><Reference><Citation>Loy KA, Lam AS, Franz AM, et al. Impact of eliminating local anesthesia on immediate postoperative analgesia in pediatric ambulatory adenotonsillectomy. Pediatr Qual Saf 2021; 6: e405. https://doi.org/10.1097/pq9.0000000000000405</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/pq9.0000000000000405</ArticleId><ArticleId IdType="pubmed">33977193</ArticleId><ArticleId IdType="pmc">8104218</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrette LX, Harris J, De Ravin E, Balar E, Moreira AG, Rajasekaran K. Clinical practice guidelines for pain management after tonsillectomy: systematic quality appraisal using the AGREE II instrument. Int J Pediatr Otorhinolaryngol 2022; 156: 111091. https://doi.org/10.1016/j.ijporl.2022.111091</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijporl.2022.111091</ArticleId><ArticleId IdType="pubmed">35240561</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih MC, Long BD, Pecha PP, et al. A scoping review of randomized clinical trials for pain management in pediatric tonsillectomy and adenotonsillectomy. World J Otorhinolaryngol Head Neck Surg 2022; 9: 9&#x2013;26. https://doi.org/10.1002/wjo2.54</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wjo2.54</ArticleId><ArticleId IdType="pubmed">37006744</ArticleId><ArticleId IdType="pmc">10050970</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes J, Zuercher M, Gai N, Roy Chowdhury A, Kazuyoshi Aoyama D. The Fragility Index of randomized controlled trials in pediatric anesthesiology. Can J Anesth 2023; 70: 1449&#x2013;60. https://doi.org/10.1007/s12630-023-02513-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-023-02513-3</ArticleId><ArticleId IdType="pubmed">37286747</ArticleId></ArticleIdList></Reference><Reference><Citation>Peker K, Polat R. Effects of intravenous and mask induction on post-operative emergence delirium in pediatric patients undergoing tonsillectomy with or without adenoidectomy. Ir J Med Sci 2020; 189: 1061&#x2013;8. https://doi.org/10.1007/s11845-020-02197-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-020-02197-4</ArticleId><ArticleId IdType="pubmed">32048203</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng A, Dodson KM, Thacker LR, Kierce J, Shapiro J, Baldassari CM. Use of laryngeal mask airway in pediatric adenotonsillectomy. Arch Otolaryngol Head Neck Surg 2011; 137: 42&#x2013;6. https://doi.org/10.1001/archoto.2010.230</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archoto.2010.230</ArticleId><ArticleId IdType="pubmed">21242545</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalwani K, Richins S, Aliason I, Milczuk H, Fu R. The laryngeal mask airway for pediatric adenotonsillectomy: predictors of failure and complications. Int J Pediatr Otorhinolaryngol 2013; 77: 25&#x2013;8. https://doi.org/10.1016/j.ijporl.2012.09.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijporl.2012.09.021</ArticleId><ArticleId IdType="pubmed">23063385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri D, Neubauer AG, Ranieri DM, do Nascimento P Jr. The use of disposable laryngeal mask airway for adenotonsillectomies. Rev Bras Anestesiol 2012; 62: 788&#x2013;98. https://doi.org/10.1016/s0034-7094(12)70179-4</Citation></Reference><Reference><Citation>Nghiem J, Brown SC, Aoyama K. Is there a role for pregabalin as premedication in pediatric anesthesia? J Anesth 2021; 35: 775&#x2013;7. https://doi.org/10.1007/s00540-021-02929-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00540-021-02929-5</ArticleId><ArticleId IdType="pubmed">33837480</ArticleId></ArticleIdList></Reference><Reference><Citation>Petre MA, Levin DN, Englesakis M, Maynes JT, Pechlivanoglou P, Aoyama K. Dexmedetomidine vs. total intravenous anaesthesia in paediatric emergence delirium: a network meta-analysis. Eur J Anaesthesiol 2021; 38: 1111&#x2013;23. https://doi.org/10.1097/eja.0000000000001490</Citation></Reference><Reference><Citation>Gan TJ, Belani KG, Bergese S, et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth Analg 2020; 131: 411&#x2013;48. https://doi.org/10.1213/ane.0000000000004833</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0000000000004833</ArticleId><ArticleId IdType="pubmed">32467512</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37928990</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-6391</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>JSES reviews, reports, and techniques</Title><ISOAbbreviation>JSES Rev Rep Tech</ISOAbbreviation></Journal><ArticleTitle>Venous thromboembolism following surgical management of proximal humerus fractures: a systematic review.</ArticleTitle><Pagination><StartPage>494</StartPage><EndPage>498</EndPage><MedlinePgn>494-498</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xrrt.2023.06.003</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Currently, there is limited information on the incidence of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) after surgical treatment of proximal humerus fractures (PHFs). Therefore, the purpose of this systematic review is to evaluate the incidence of VTE, DVT, and PE following surgery for PHFs.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A comprehensive search of several databases was performed from inception to May 27, 2022. Studies were screened and evaluated by 2 reviewers independently utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Only original, English studies that evaluated the incidences of VTE following surgical management of PHFs were included. Surgical procedures consisted of shoulder arthroplasty (SA) including both hemiarthroplasty (Hemi) and reverse shoulder arthroplasty (RSA) in addition to open reduction and internal fixation (ORIF). A pooled incidence for postoperative DVT, PE, and overall VTE was reported.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Twelve studies met the inclusion and exclusion criteria, encompassing a total of 18,238 patients. The overall DVT, PE, and VTE rates were 0.14%, 0.59%, and 0.7%, respectively. VTE was more frequently reported after SA than ORIF, (1.27% vs. 0.53%, respectively). Among SA patients, a higher rate of DVT was seen with RSA (1.2%) with the lowest DVT rate was observed for ORIF with 0.03%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Symptomatic VTEs following surgical treatment of PHFs, are rare, yet still relevant as a worrisome postoperative complication. Among the various procedures, VTE was the most frequently reported after SA when compared to ORIF, with RSA having the highest VTE rate.</AbstractText><CopyrightInformation>&#xa9; 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marigi</LastName><ForeName>Erick M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>John W</ForeName><Initials>JW</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marinis</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shoulder and Elbow Unit, Hospital Dr. S&#xf3;tero del R&#xed;o, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Puneet</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassett</LastName><ForeName>Leslie C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soza</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Sotelo</LastName><ForeName>Joaquin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JSES Rev Rep Tech</MedlineTA><NlmUniqueID>9918316187406676</NlmUniqueID><ISSNLinking>2666-6391</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Hemiarthroplasty</Keyword><Keyword MajorTopicYN="N">Open reduction internal fixation</Keyword><Keyword MajorTopicYN="N">Proximal humerus fracture</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Reverse total shoulder arthroplasty</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>6</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37928990</ArticleId><ArticleId IdType="pmc">PMC10624987</ArticleId><ArticleId IdType="doi">10.1016/j.xrrt.2023.06.003</ArticleId><ArticleId IdType="pii">S2666-6391(23)00067-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andres-Cano P., Galan A., Arenas J., Del Aguila B., Guerado E. Results of uncemented hemiarthroplasty as primary treatment of severe proximal humerus fractures in the elderly. Eur J Orthop Surg Traumatol. 2015;25:273&#x2013;280. doi: 10.1007/s00590-014-1487-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-014-1487-z</ArticleId><ArticleId IdType="pubmed">24871876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancienne J.M., Burrus M.T., Diduch D.R., Werner B.C. High altitude is an independent risk factor for venous thromboembolism following arthroscopic rotator cuff repair: a matched case-control study in Medicare patients. J&#xa0;Shoulder Elbow Surg. 2017;26:7&#x2013;13. doi: 10.1016/j.jse.2016.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2016.06.005</ArticleId><ArticleId IdType="pubmed">27528541</ArticleId></ArticleIdList></Reference><Reference><Citation>Chand M.R., Meiyappan A., Villa J.M., Kanwar S., Sabesan V.J., Gilot G. Ninety-day readmission following shoulder arthroplasty. J&#xa0;Shoulder Elbow Arthroplasty. 2018;2 doi: 10.1177/2471549218810016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2471549218810016</ArticleId></ArticleIdList></Reference><Reference><Citation>Crous-Bou M., Harrington L.B., Kabrhel C. Environmental and genetic risk factors associated with venous thromboembolism. Semin Thromb Hemost. 2016;42:808&#x2013;820. doi: 10.1055/s-0036-1592333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0036-1592333</ArticleId><ArticleId IdType="pmc">PMC5146955</ArticleId><ArticleId IdType="pubmed">27764878</ArticleId></ArticleIdList></Reference><Reference><Citation>Delegates&#x2217; TI-VSE Recommendations from the ICM-VTE: Shoulder &amp; Elbow. J&#xa0;Bone Joint Surg Am. 2022;104:252&#x2013;266. doi: 10.2106/JBJS.21.01258.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.21.01258</ArticleId><ArticleId IdType="pubmed">35315613</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillon M.T., Ake C.F., Burke M.F., Singh A., Yian E.H., Paxton E.W., et al. The Kaiser Permanente shoulder arthroplasty registry: results from 6,336 primary shoulder arthroplasties. Acta Orthop. 2015;86:286&#x2013;292. doi: 10.3109/17453674.2015.1024565.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17453674.2015.1024565</ArticleId><ArticleId IdType="pmc">PMC4443451</ArticleId><ArticleId IdType="pubmed">25727949</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekhtiari S., Horner N.S., de Sa D., Simunovic N., Hirschmann M.T., Ogilvie R., et al. Arthrofibrosis after ACL reconstruction is best treated in a step-wise approach with early recognition and intervention: a systematic review. Knee Surg Sports Traumatol Arthrosc. 2017;25:3929&#x2013;3937. doi: 10.1007/s00167-017-4482-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00167-017-4482-1</ArticleId><ArticleId IdType="pubmed">28260199</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyer J.H., Parker R.L., Lynch T., Parry T., Neviaser A.S. Rate of venous thromboembolism after surgical treatment of proximal humerus fractures. Arch Orthop Trauma Surg. 2021;141:403&#x2013;409. doi: 10.1007/s00402-020-03505-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-020-03505-4</ArticleId><ArticleId IdType="pubmed">32504179</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoxie S.C., Sperling J.W., Cofield R.H. Pulmonary embolism after operative treatment of proximal humeral fractures. J&#xa0;Shoulder Elbow Surg. 2007;16:782&#x2013;783. doi: 10.1016/j.jse.2006.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2006.12.004</ArticleId><ArticleId IdType="pubmed">17531514</ArticleId></ArticleIdList></Reference><Reference><Citation>Imberti D., Ivaldo N., Murena L., Paladini P., Castagna A., Barillari G., et al. Venous thromboembolism in patients undergoing shoulder surgery: findings from the RECOS Registry. Thromb Res. 2014;134:273&#x2013;277. doi: 10.1016/j.thromres.2014.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2014.05.014</ArticleId><ArticleId IdType="pubmed">24916548</ArticleId></ArticleIdList></Reference><Reference><Citation>Jameson S.S., James P., Howcroft D.W., Serrano-Pedraza I., Rangan A., Reed M.R., et al. Venous thromboembolic events are rare after shoulder surgery: analysis of a national database. J&#xa0;Shoulder Elbow Surg. 2011;20:764&#x2013;770. doi: 10.1016/j.jse.2010.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2010.11.034</ArticleId><ArticleId IdType="pubmed">21420324</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissin E., Al-Tawil K., Tavakkolizadeh A., Sinha J., Colegate-Stone T. Impact of intravenous tranexamic acid on patients undergoing shoulder arthroplasty surgery. Shoulder Elbow. 2022;14:249&#x2013;253. doi: 10.1177/1758573220970907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1758573220970907</ArticleId><ArticleId IdType="pmc">PMC9121286</ArticleId><ArticleId IdType="pubmed">35599712</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolz J.M., Aibinder W.R., Adams R.A., Cofield R.H., Sperling J.W. Symptomatic thromboembolic complications after shoulder arthroplasty: an update. J&#xa0;Bone Joint Surg Am. 2019;101:1845&#x2013;1851. doi: 10.2106/JBJS.18.01200.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.18.01200</ArticleId><ArticleId IdType="pubmed">31626009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lex J.R., Evans S., Cool P., Gregory J., Ashford R.U., Rankin K.S., et al. Venous thromboembolism in orthopaedic oncology. Bone Joint J. 2020;102-B:1743&#x2013;1751. doi: 10.1302/0301-620X.102B12.BJJ-2019-1136.R3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.102B12.BJJ-2019-1136.R3</ArticleId><ArticleId IdType="pubmed">33249908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lung B.E., Kanjiya S., Bisogno M., Komatsu D.E., Wang E.D. Risk factors for venous thromboembolism in total shoulder arthroplasty. JSES Open Access. 2019;3:183&#x2013;188. doi: 10.1016/j.jses.2019.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jses.2019.07.003</ArticleId><ArticleId IdType="pmc">PMC6834973</ArticleId><ArticleId IdType="pubmed">31709360</ArticleId></ArticleIdList></Reference><Reference><Citation>McCully B.H., Connelly C.R., Fair K.A., Holcomb J.B., Fox E.E., Wade C.E., et al. Onset of coagulation function recovery is delayed in severely injured trauma patients with venous thromboembolism. J&#xa0;Am Coll Surg. 2017;225:42&#x2013;51. doi: 10.1016/j.jamcollsurg.2017.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2017.03.001</ArticleId><ArticleId IdType="pmc">PMC5592971</ArticleId><ArticleId IdType="pubmed">28315812</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore E.E., Moore H.B., Kornblith L.Z., Neal M.D., Hoffman M., Mutch N.J., et al. Trauma-induced coagulopathy. Nat Rev Dis Primers. 2021;7:30. doi: 10.1038/s41572-021-00264-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00264-3</ArticleId><ArticleId IdType="pmc">PMC9107773</ArticleId><ArticleId IdType="pubmed">33927200</ArticleId></ArticleIdList></Reference><Reference><Citation>Na S.-S., Kim D.-H., Choi B.-C., Cho C.-H. Incidence, characteristics, and risk factors of venous thromboembolism in shoulder arthroplasty-a systematic review. Int Orthop. 2022;46:2081&#x2013;2088. doi: 10.1007/s00264-022-05496-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00264-022-05496-w</ArticleId><ArticleId IdType="pubmed">35761099</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro R.A., Inacio M.C.S., Burke M.F., Costouros J.G., Yian E.H. Risk of thromboembolism in shoulder arthroplasty: effect of implant type and traumatic indication. Clin Orthop Relat Res. 2013;471:1576&#x2013;1581. doi: 10.1007/s11999-013-2829-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-013-2829-6</ArticleId><ArticleId IdType="pmc">PMC3613522</ArticleId><ArticleId IdType="pubmed">23392993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ollendorf D.A., Vera-Llonch M., Oster G. Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients. Am J Health Syst Pharm. 2002;59:1750&#x2013;1754. doi: 10.1093/ajhp/59.18.1750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajhp/59.18.1750</ArticleId><ArticleId IdType="pubmed">12298113</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrotta C., Chahla J., Badariotti G., Ramos J. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database Syst Rev. 2020;5 doi: 10.1002/14651858.CD005259.pub4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005259.pub4</ArticleId><ArticleId IdType="pmc">PMC7202465</ArticleId><ArticleId IdType="pubmed">32374919</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrigliano F.A., Bezrukov N., Gamradt S.C., SooHoo N.F. Factors predicting complication and reoperation rates following surgical fixation of proximal humeral fractures. J&#xa0;Bone Joint Surg Am. 2014;96:1544&#x2013;1551. doi: 10.2106/JBJS.M.01039.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.M.01039</ArticleId><ArticleId IdType="pubmed">25232078</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce A., Pittet J.-F. Inflammatory response to trauma: implications for coagulation and resuscitation. Curr Opin Anaesthesiol. 2014;27:246&#x2013;252. doi: 10.1097/ACO.0000000000000047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0000000000000047</ArticleId><ArticleId IdType="pmc">PMC4124829</ArticleId><ArticleId IdType="pubmed">24419158</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager B., Ahn J., Tran J., Khazzam M. Timing and risk factors for venous thromboembolism after rotator cuff repair in the 30-day perioperative period. Arthroscopy. 2019;35:3011&#x2013;3018. doi: 10.1016/j.arthro.2019.05.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arthro.2019.05.045</ArticleId><ArticleId IdType="pubmed">31629586</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh J., El-Othmani M.M., Saleh K.J. Deep vein thrombosis and pulmonary embolism considerations in orthopedic surgery. Orthop Clin North Am. 2017;48:127&#x2013;135. doi: 10.1016/j.ocl.2016.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ocl.2016.12.003</ArticleId><ArticleId IdType="pubmed">28336037</ArticleId></ArticleIdList></Reference><Reference><Citation>Santana D.C., Emara A.K., Orr M.N., Klika A.K., Higuera C.A., Krebs V.E., et al. An update on venous thromboembolism rates and prophylaxis in hip and knee arthroplasty in 2020. Medicina (Kaunas) 2020;56:416. doi: 10.3390/medicina56090416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina56090416</ArticleId><ArticleId IdType="pmc">PMC7558636</ArticleId><ArticleId IdType="pubmed">32824931</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahi A., Chen A.F., Tan T.L., Maltenfort M.G., Kucukdurmaz F., Parvizi J. The incidence and economic burden of in-hospital venous thromboembolism in the United States. J&#xa0;Arthroplasty. 2017;32:1063&#x2013;1066. doi: 10.1016/j.arth.2016.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2016.10.020</ArticleId><ArticleId IdType="pubmed">27866951</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahi A., Bradbury T.L., Guild G.N., 3rd, Saleh U.H., Ghanem E., Oliashirazi A. What are the incidence and risk factors of in-hospital mortality after venous thromboembolism events in total hip and knee arthroplasty patients? Arthroplast Today. 2018;4:343&#x2013;347. doi: 10.1016/j.artd.2018.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.artd.2018.02.014</ArticleId><ArticleId IdType="pmc">PMC6123180</ArticleId><ArticleId IdType="pubmed">30186919</ArticleId></ArticleIdList></Reference><Reference><Citation>Slim K., Nini E., Forestier D., Kwiatkowski F., Panis Y., Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712&#x2013;716. doi: 10.1046/j.1445-2197.2003.02748.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1445-2197.2003.02748.x</ArticleId><ArticleId IdType="pubmed">12956787</ArticleId></ArticleIdList></Reference><Reference><Citation>Triplet J.J., Schuette H.B., Cheema A.N., Marigi E.M., Hassett L.C., Barlow J.D., et al. Venothromboembolism following shoulder arthroscopy: a systematic review. JSES Rev Rep Tech. 2022;2:464. doi: 10.1016/j.xrrt.2022.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xrrt.2022.05.003</ArticleId><ArticleId IdType="pmc">PMC10426627</ArticleId><ArticleId IdType="pubmed">37588470</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren J.A., Sundaram K., Kamath A.F., Molloy R.M., Krebs V.E., Mont M.A., et al. Venous thromboembolism rates did not decrease in lower extremity revision total joint arthroplasty from 2008 to 2016. J&#xa0;Arthroplasty. 2019;34:2774&#x2013;2779. doi: 10.1016/j.arth.2019.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2019.05.012</ArticleId><ArticleId IdType="pubmed">31153709</ArticleId></ArticleIdList></Reference><Reference><Citation>Widmer B.J., Bassora R., Warrender W.J., Abboud J.A. Thromboembolic events are uncommon after open treatment of proximal humerus fractures using aspirin and compression devices. Clin Orthop Relat Res. 2011;469:3332&#x2013;3336. doi: 10.1007/s11999-011-1942-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-011-1942-7</ArticleId><ArticleId IdType="pmc">PMC3210257</ArticleId><ArticleId IdType="pubmed">21656313</ArticleId></ArticleIdList></Reference><Reference><Citation>Zee A.A., van Lieshout K., van der Heide M., Janssen L., Janzing H.M. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization. Cochrane Database Syst Rev. 2017;8 doi: 10.1002/14651858.CD006681.pub4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD006681.pub4</ArticleId><ArticleId IdType="pmc">PMC6483324</ArticleId><ArticleId IdType="pubmed">28780771</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Dyer G.S.M., Earp B.E. Venous thromboembolism after total shoulder arthroplasty: a database study of 31,918 cases. J&#xa0;Am Acad Orthop Surg. 2022;30:949&#x2013;956. doi: 10.5435/JAAOS-D-22-00352.</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/JAAOS-D-22-00352</ArticleId><ArticleId IdType="pubmed">36135929</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22626760</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-6259</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Annals of thoracic surgery</Title><ISOAbbreviation>Ann Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>A systematic review of pulmonary embolism in patients with lung cancer.</ArticleTitle><Pagination><StartPage>311</StartPage><EndPage>316</EndPage><MedlinePgn>311-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.athoracsur.2012.03.025</ELocationID><Abstract><AbstractText>Pulmonary embolism (PE) is increasingly recognized as causing significant morbidity and mortality in modern societies; however, little is known about PE in patients with lung cancer. We systematically reviewed Medline, Web of Science, and the Cochrane Library databases and selected 26 studies, including 2 randomized controlled trials, and 4 prospective, 18 retrospective cohort, and 2 case-control studies. Overall incidence of PE was 3.6%. Pulmonary embolism abbreviated survival in 2 studies when the diagnosis was synchronous with lung cancer. Venous thromboembolism prophylaxis, treatment, and surveillance are inconsistently reported. Clinical outcome data pertaining to this topic are limited and of overall poor methodologic quality.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Malgor</LastName><ForeName>Rafael D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, Department of Surgery, Stony Brook University Medical Center, Stony Brook, New York 11794-8191, USA. rafael.malgor@sbumed.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilfinger</LastName><ForeName>Thomas V</ForeName><Initials>TV</Initials></Author><Author ValidYN="Y"><LastName>Labropoulos</LastName><ForeName>Nicos</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ann Thorac Surg</MedlineTA><NlmUniqueID>15030100R</NlmUniqueID><ISSNLinking>0003-4975</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22626760</ArticleId><ArticleId IdType="doi">10.1016/j.athoracsur.2012.03.025</ArticleId><ArticleId IdType="pii">S0003-4975(12)00639-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25069620</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2014</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>29</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty.</ArticleTitle><Pagination><StartPage>CD008207</StartPage><MedlinePgn>CD008207</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD008207</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD008207.pub3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Total knee arthroplasty (TKA) is a common form of orthopaedic surgery. Venous thromboembolism (VTE), which consists of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a major and potentially fatal complication after TKA. The incidence of DVT after TKA is 40% to 80% and the incidence of PE is approximately 2%. It is generally agreed that thromboprophylaxis should be used in patients who undergo TKA. Both pharmacological and mechanical methods are used in the prevention of DVT. Pharmacological methods alter the blood coagulation profile and may increase the risk of bleeding complications. When pharmacological methods cannot be used the mechanical methods become crucial for VTE prophylaxis. Continuous passive motion (CPM) is provided through an external motorised device which enables a joint to move passively throughout a preset arc of motion. Despite the theoretical effectiveness and widespread use of CPM, there are still differing views on the effectiveness of CPM as prophylaxis against thrombosis after TKA. This is an update of the review first published in 2012.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this review was to determine the effectiveness of continuous passive motion (CPM) therapy for preventing venous thromboembolism (VTE) in patients after total knee arthroplasty (TKA).</AbstractText><AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched February 2014), CENTRAL (2014, Issue 1), Ovid MEDLINE (to week 1 February 2014) and EMBASE (to Week 07 2014).</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised controlled trials (RCTs) comparing the use of CPM with control in preventing DVT or PE after TKA. People aged 18 years and older who had undergone TKA were included in this review. We excluded studies of patients who presented with DVT at baseline. The experimental and control groups received similar postoperative care and therapy other than the CPM.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two review authors independently assessed the citations retrieved by the search strategies for reports of relevant RCTs. They independently selected trials that satisfied the inclusion criteria, extracted data and undertook quality assessment. Effects were estimated as risk ratios (RRs), mean differences or standardised mean differences with 95% confidence intervals (CIs). Meta-analyses were performed using a fixed-effect model for continuous variables. Where heterogeneity existed (determined by the I(2) statistic) a random-effects model was used.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Eleven RCTs involving 808 participants met the inclusion criteria. The methodological quality of the included studies was variable and most of the predefined outcomes were reported by only one or two studies, therefore the quality of the evidence was low. Five studies with a total of 405 patients reported the incidence of DVT. In the CPM group (205 patients) 36 developed DVT (18%) compared to 29 (15%) in the control group (200 patients). The results of the meta-analysis showed no evidence that CPM had any effect on preventing VTE after TKA (RR 1.22, 95% CI 0.84 to 1.79). One trial (150 participants) did not find PE in any of the patients during hospitalisation or in the subsequent three months. PE was not reported in the other included studies. None of the trials reported deaths among the included participants.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">There is not enough evidence from the available RCTs to conclude that CPM reduces VTE after TKA. We cannot assess the effect of CPM on mortality because no such events occurred amongst the participants of these trials. The quality of the evidence was low. The results are supported by only a small number of studies, most of which are of low to moderate quality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Mao Lin</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Division of Spinal Surgery, 1st Affiliated Hospital of Guangxi Medical University, 22 Shuangyong Road, Nanning, Guangxi, China, 530021.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Zeng Ming</ForeName><Initials>ZM</Initials></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Ming</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ting Song</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hao</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CZB/4/788</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Cochrane Database Syst Rev. 2012 Jan 18;1:CD008207. doi: 10.1002/14651858.CD008207.pub2.</RefSource><PMID Version="1">22258981</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="N">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015915" MajorTopicYN="N">Motion Therapy, Continuous Passive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>None known</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25069620</ArticleId><ArticleId IdType="pmc">PMC10642625</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD008207.pub3</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Alkire 2010 {published data only}</Title><Reference><Citation>Alkire MR, Swank ML. Use of inpatient continuous passive motion versus no CPM in computer&#x2010;assisted total knee arthroplasty. Orthopaedic Nursing 2010;29(1):36&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">20142693</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bruun&#x2010;Olsen 2009 {published data only}</Title><Reference><Citation>Bruun&#x2010;Olsen V, Heiberg KE, Mengshoel AM. Continuous passive motion as an adjunct to active exercises in early rehabilitation following total knee arthroplasty &#x2010; a randomized controlled trial. Disability and Rehabilitation 2009;31(4):277&#x2010;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">18608367</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chen 2000 {published data only}</Title><Reference><Citation>Chen B, Zimmerman JR, Soulen L, DeLisa JA. Continuous passive motion after total knee arthroplasty: a prospective study. American Journal of Physical Medicine &amp; Rehabililation 2000;79(5):421&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10994883</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Denis 2006 {published data only}</Title><Reference><Citation>Denis M, Moffet H, Caron F, Ouellet D, Paquet J, Nolet L. Effectiveness of continuous passive motion and conventional physical therapy after total knee arthroplasty: a randomized clinical. Physical Therapy 2006;86(2):174&#x2010;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">16445331</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Harms 1991 {published data only}</Title><Reference><Citation>Harms M, Engstrom B. Continuous passive motion as an adjunct to treatment in the physiotherapy management of the total knee arthroplasty patient. Physiotherapy 1991;77(4):301&#x2010;7.</Citation></Reference></ReferenceList><ReferenceList><Title>Huang 2003 {published data only}</Title><Reference><Citation>Huang D, Peng Y, Su P, Ye W, Liang A. The effect of continuous passive motion after total knee arthroplasty on joint function. Chinese Journal of Clinical Rehabilitation 2003;7:1661&#x2010;2.</Citation></Reference></ReferenceList><ReferenceList><Title>Johnson 1992 {published data only}</Title><Reference><Citation>Johnson DP, Eastwood DM. Beneficial effects of continuous passive motion after total condylar knee arthroplasty. Annals of the Royal College of Surgeons of England 1992;74(6):412&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2497687</ArticleId><ArticleId IdType="pubmed">1471839</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lenssen 2008 {published data only}</Title><Reference><Citation>Lenssen TA, Steyn MJ, Crijns YH, Waltj&#xe9; EM, Roox GM, Geesink RJ, et al. Effectiveness of prolonged use of continuous passive motion (CPM), as an adjunct to physiotherapy, after total knee arthroplasty. BMC Musculoskeletal Disorders 2008;9:60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386789</ArticleId><ArticleId IdType="pubmed">18442423</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lynch 1988 {published data only}</Title><Reference><Citation>Lynch AF, Bourne RB, Rorabeck CH, Rankin RN, Donald A. Deep&#x2010;vein thrombosis and continuous passive motion after total knee arthroplasty. The Journal of Bone and Joint Surgery. American Volume 1988;70(1):11&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">3335558</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mclnnes 1992 {published data only}</Title><Reference><Citation>McInnes J, Larson MG, Daltroy LH, Brown T, Fossel AH, Eaton HM, et al. A controlled evaluation of continuous passive motion in patients undergoing total knee arthroplasty. JAMA 1992;268(11):1423&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1512910</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Montgomery 1996 {published data only}</Title><Reference><Citation>Montgomery F, Eliasson M. Continuous passive motion compared to active physical therapy after knee arthroplasty: similar hospitalization times in a randomized study of 68 patients. Acta Orthopaedica Scandinavica 1996;67(1):7&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8615108</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Beaupr&#xe9; 2001 {published data only}</Title><Reference><Citation>Beaupr&#xe9; LA, Davies DM, Jones CA, Cinats JG. Exercise combined with continuous passive motion or slider board therapy compared with exercise only: a randomized controlled trial of patients following total knee arthroplasty. Physical Therapy 2001;81(4):1029&#x2010;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">11296803</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Davies 2003 {published data only}</Title><Reference><Citation>Davies DM, Johnston DW, Beaupre LA, Lier DA. Effect of adjunctive range&#x2010;of&#x2010;motion therapy after primary total knee arthroplasty on the use of health services after hospital discharge. Canadian Journal of Surgery 2003;46(1):30&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3211656</ArticleId><ArticleId IdType="pubmed">12585791</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gose 1987 {published data only}</Title><Reference><Citation>Gose JC. Continuous passive motion in the postoperative treatment of patients with total knee replacement. A retrospective study. Physical Therapy 1987;67(1):39&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">3797475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kim 2009 {published data only}</Title><Reference><Citation>Kim TK, Park KK, Yoon SW, Kim SJ, Chang CB, Seong SC. Clinical value of regular passive ROM exercise by a physical therapist after total knee arthroplasty. Knee Surgery, Sports Traumatology, Arthroscopy 2009;17(10):1152&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19225758</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kusswetter 1991 {published data only}</Title><Reference><Citation>Kusswetter W, Sell S. Continuous passive motion in the after care of knee joint prostheses. Der Orthopade 1991;20(3):216&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">1876403</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lenssen 2003 {published data only}</Title><Reference><Citation>Lenssen AF, Bie RA, Bulstra SK, Steyn MJA. Continuous passive motion (CPM) in rehabilitation following total knee arthroplasty: a randomised controlled trial. Physical Therapy Reviews 2003;8:123&#x2010;9.</Citation></Reference></ReferenceList><ReferenceList><Title>London 1999 {published data only}</Title><Reference><Citation>London NJ, Brown M, Newman RJ. Continuous passive motion: Evaluation of a new portable low cost machine. Physiotherapy 1999;85(11):610&#x2010;2.</Citation></Reference></ReferenceList><ReferenceList><Title>Lotke 1991 {published data only}</Title><Reference><Citation>Lotke PA, Faralli VJ, Orenstein EM, Ecker ML. Blood loss after total knee replacement. Effects of tourniquet release and continuous passive motion. The Journal of Bone and Joint Surgery. American Volume 1991;73(7):1037&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">1874765</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Luo 2012 {published data only}</Title><Reference><Citation>Luo S, Liao Y, Chen L, Huang Y, Zhou L, Tang J. Effect of continuous passive motion on blood coagulation condition in patients with total knee joint replacement. Chinese Journal of Tissue Engineering Research 2012;16(44):8182&#x2010;5.</Citation></Reference></ReferenceList><ReferenceList><Title>Lynch 1990 {published data only}</Title><Reference><Citation>Lynch JA, Baker PL, Polly RE, Lepse PS, Wallace BE, Roudybush D, et al. Mechanical measures in the prophylaxis of postoperative thromboembolism in total knee arthroplasty. Clinical Orthopaedics and Related Research 1990;Nov(260):24&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2225629</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Maloney 1990 {published data only}</Title><Reference><Citation>Maloney WJ, Schurman DJ, Hangen D, Goodman SB, Edworthy S, Bloch DA. The influence of continuous passive motion on outcome in total knee arthroplasty. Clinical Orthopaedics and Related Research 1990;Jul(256):162&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2364605</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Pope 1997 {published data only}</Title><Reference><Citation>Pope RO, Corcoran S, McCaul K, Howie DW. Continuous passive motion after primary total knee arthroplasty. Does it offer any benefits?. The Journal of Bone Joint Surgery. British Volume 1997;79(6):914&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9393903</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rader 1998 {published data only}</Title><Reference><Citation>Rader CP, Kramer C, Hendrich C, K&#xf6;nig A, Gohlke F, Eulert J. Experiences with an ankle joint motion device in prevention of thrombosis in patients after total endoprosthesis knee replacement [Erfahrungen mit einer Sprunggelenksbewegungsschiene in der Thromboseprophylaxe bei Patienten nach totalendoprothetischem Kniegelenksersatz]. Zeitschrift f&#xfc;r Orthop&#xe4;die und ihre Grenzgebiete 1998;136(5):467&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9823645</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Scheidhauer 2003 {published data only}</Title><Reference><Citation>Scheidhauer H, Geistert A, Buhrlen B, Hildebrand S. Effectiveness of the active "Camoped&#x2010;active motion machine" with the continuous passive motion machine (CPM) following prosthetic knee implantation: a comparison. Zeitschrift fur Physiotherapeuten 2003;55(5):774&#x2010;87.</Citation></Reference></ReferenceList><ReferenceList><Title>Ververeli 1995 {published data only}</Title><Reference><Citation>Ververeli PA, Sutton DC, Hearn SL, Booth, RE Jr, Hozack WJ, Rothman RR. Continuous passive motion after total knee arthroplasty. Analysis of cost and benefits. Clinical Orthopaedics and Related Research 1995;321:208&#x2010;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">7497671</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Vince 1987 {published data only}</Title><Reference><Citation>Vince KG, Kelly MA, Beck J, Insall JN. Continuous passive motion after total knee arthroplasty. The Journal of Arthroplasty 1987;2(4):281&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">3430154</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Xu 2001 {published data only}</Title><Reference><Citation>Xu B, Shi Z, Jin D, Jing Z, Chen X, Feng Z. Effect of continuous passive motion after total knee replacement. Journal of First Military Medical University 2001;21(5):368&#x2010;9.</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies awaiting assessment</Title><ReferenceList><Title>Aubriot 1993 {published data only}</Title><Reference><Citation>Aubriot JH, Guincestre JY, Grandbastien B. Value of continuous passive motion in the early rehabilitation of total knee arthroplasty. Prospective study apropos of 120 medical records. Revue de Chirurgie Orthop&#xe9;dique et R&#xe9;paratrice de l'Appareil Moteur 1993;79(7):586&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8085040</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sosin 2000 {published data only}</Title><Reference><Citation>Sosin P, Dutka J, Stabach M. A comparison of kinesitherapy with and without continuous passive motion (CPM) after the entire allograft surgery of the knee. Chirurgia Narzadow Ruchu i Ortopedia Polska 2000;65(1):47&#x2010;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">10838768</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Brander 2006</Title><Reference><Citation>Brander V, Stulberg SD. Rehabilitation after hip&#x2010; and knee&#x2010;joint replacement. An experience&#x2010; and evidence&#x2010;based approach to care. American Journal of Physical Medicine and Rehabilitation 2006;85(11 Suppl):98&#x2013;118; quiz 119&#x2010;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079984</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Brosseau 2004</Title><Reference><Citation>Brosseau L, Milne S, Wells G, Tugwell P, Robinson V, Casimiro L, et al. Efficacy of continuous passive motion following total knee arthroplasty: a metaanalysis. Journal of Rheumatology 2004;31(11):2251&#x2010;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">15517640</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Chotanaphuti 2007</Title><Reference><Citation>Chotanaphuti T, Ongnamthip P, Songpatanasil T, Veerapan P, Deeprecha K. Risk factors of deep vein thrombosis (DVT) after total knee arthroplasty (TKA) at Phramongkutklao Hospital. Journal of the Medical Association of Thailand 2007;90(3):485&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17427525</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Clayton 2008</Title><Reference><Citation>Clayton RA, Gaston P, Watts AC, Howie CR. Thromboembolic disease after total knee replacement: experience of 5100 cases. Knee 2009;16(1):18&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">19008109</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Colwell 2006</Title><Reference><Citation>Colwell CW Jr, Hardwick ME. Rationale for low&#x2010;molecular&#x2010;weight heparin prophylaxis after total knee arthroplasty. Clinical Orthopaedics and Related Research 2006;Nov(452):181&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17016231</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fedi 1999</Title><Reference><Citation>Fedi S, Gori AM, Falciani M, Cellai AP, Aglietti P, Baldini A, et al. Procedure&#x2010;dependence and tissue factor&#x2010;independence of hypercoagulability during orthopaedic surgery. Thrombosis and Haemostasis 1999;81(6):874&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10404760</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fuji 2010</Title><Reference><Citation>Fuji T, Fujita S, Tachibana S, Kawai Y. A dose&#x2010;ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. Journal of Thrombosis and Haemostasis 2010;8(11):2458&#x2010;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">20723033</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Harvey 2010</Title><Reference><Citation>Harvey LA, Brosseau L, Herbert RD. Continuous passive motion following total knee arthroplasty in people with arthritis. Cochrane Database Systematic Reviews 2010;17(3):[DOI: 10.1002/14651858.CD004260].</Citation><ArticleIdList><ArticleId IdType="pubmed">20238330</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2011</Title><Reference><Citation>Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane&#x2010;handbook.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Huerta 2007</Title><Reference><Citation>Huerta C, Johansson S, Wallander MA, Garc&#xed;a Rodr&#xed;guez LA. Risk factors and short&#x2010;term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine 2007;167(9):935&#x2010;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502535</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>J&#xfc;ni 2001</Title><Reference><Citation>J&#xfc;ni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1120670</ArticleId><ArticleId IdType="pubmed">11440947</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Khaw 1993</Title><Reference><Citation>Khaw FM, Moran CG, Pinder IM, Smith SR. The incidence of fatal pulmonary embolism after knee replacement with no prophylactic anticoagulation. The Journal of Bone and Joint Surgery. British Volume 1993;75(6):940&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">8245087</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kurtz 2007</Title><Reference><Citation>Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. The Journal of Bone and Joint Surgery. American Volume 2007;89(4):780&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17403800</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Memtsoudis 2009</Title><Reference><Citation>Memtsoudis SG, Besculides MC, Gaber L, Liu S, Gonz&#xe1;lez Della Valle A. Risk factors for pulmonary embolism after hip and knee arthroplasty: a population&#x2010;based study. International Orthopaedics 2009;33(6):1739&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2899166</ArticleId><ArticleId IdType="pubmed">18925395</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>O&#x2019;Driscoll 2000</Title><Reference><Citation>O&#x2019;Driscoll SW, Giori NJ. Continuous passive motion (CPM): theory and principles of clinical application. Journal of Rehabilitation Research and Development 2000;37(2):179&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">10850824</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Peat 2001</Title><Reference><Citation>Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Annals of the Rheumatic Diseases 2001;60(2):91&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1753462</ArticleId><ArticleId IdType="pubmed">11156538</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>RevMan 5 [Computer program]</Title><Reference><Citation>The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration, 2012.</Citation></Reference></ReferenceList><ReferenceList><Title>Salter 1980</Title><Reference><Citation>Salter RB, Simmonds DF, Malcolm BW, Rumble EJ, MacMichael D, Clements ND. The biological effect of continuous passive motion on the healing of full&#x2010;thickness defects in articular cartilage. An experimental investigation in the rabbit. The Journal of Bone and Joint Surgery. American Volume 1980;62(8):1232&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">7440603</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Salter 2004</Title><Reference><Citation>Salter RB. Continuous passive motion: from origination to research to clinical application. The Journal of Rheumatology 2004;31(11):2104&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15517619</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stamatakis 1977</Title><Reference><Citation>Stamatakis JD, Kakkar VV, Sagar S, Lawrence D, Nairn D, Bentley PG. Femoral vein thrombosis and total hip replacement. British Medical Journal 1977;2(6081):223&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1631397</ArticleId><ArticleId IdType="pubmed">884445</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stringer 1989</Title><Reference><Citation>Stringer MD, Steadman CA, Hedges AR, Thomas EM, Morley TR, Kakkar VV. Deep vein thrombosis after elective knee surgery. An incidence study in 312 patients. The Journal of Bone and Joint Surgery. British Volume 1989;71(3):492&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2785998</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Stulberg 1984</Title><Reference><Citation>Stulberg BN, Insall JN, Willams GW, Ghelman B. Deep&#x2010;vein thrombosis following total knee replacement. An analysis of six hundred and thirty&#x2010;eight arthroplasties. The Journal of Bone and Joint Surgery. American Volume 1984;66(2):194&#x2010;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">6693445</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>von Schroeder 1991</Title><Reference><Citation>Schroeder HP, Coutts RD, Billings E Jr, Mai MT, Aratow M. The changes in intramuscular pressure and femoral vein flow with continuous passive motion, pneumatic compressive stockings, and leg manipulations. Clinical Orthopaedics and Related Research 1991;May(266):218&#x2010;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">2019055</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Yoo 2009</Title><Reference><Citation>Yoo MC, Cho YJ, Ghanem E, Ramteke A, Kim KI. Deep vein thrombosis after total hip arthroplasty in Korean patients and D&#x2010;dimer as a screening tool. Archives of Orthopaedic and Traumatic Surgery 2009;129(7):887&#x2010;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">18825397</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to other published versions of this review</Title><ReferenceList><Title>He 2012</Title><Reference><Citation>He ML, Xiao ZM, Lei M, Li TS, Wu H, Liao J. Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD008207.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD008207.pub2</ArticleId><ArticleId IdType="pubmed">22258981</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37156300</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-6143</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</Title><ISOAbbreviation>Am J Transplant</ISOAbbreviation></Journal><ArticleTitle>Intracardiac thrombosis and pulmonary thromboembolism during liver transplantation: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1227</StartPage><EndPage>1240</EndPage><MedlinePgn>1227-1240</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajt.2023.04.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1600-6135(23)00455-0</ELocationID><Abstract><AbstractText>Intracardiac thrombosis and/or pulmonary thromboembolism (ICT/PE) is a rare but devastating complication during liver transplantation. Its pathophysiology remains poorly understood, and successful treatment remains a challenge. This systematic review summarizes the available published clinical data regarding ICT/PE during liver transplantation. Databases were searched for all publications reporting on ICT/PE during liver transplantation. Data collected included its incidence, patient characteristics, the timing of diagnosis, treatment strategies, and patient outcomes. This review included 59 full-text citations. The point prevalence of ICT/PE was 1.42%. Thrombi were most often diagnosed during the neohepatic phase, particularly at allograft reperfusion. Intravenous heparin was effective in preventing early-stage thrombus from progressing further and restoring hemodynamics in 76.32% of patients it was utilized for; however, the addition of tissue plasminogen activator or sole use of tissue plasminogen activator offered diminishing returns. Despite all resuscitation efforts, the in-hospital mortality rate of an intraoperative ICT/PE was 40.42%, with nearly half of these patients dying intraoperatively. The results of our systematic review are an initial step for providing clinicians with data that can help identify higher-risk patients. The clinical implications of our results warrant the development of identification and management strategies for the timely and effective treatment of these tragic occurrences during liver transplantation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 American Society of Transplantation &amp; American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA; Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Antolin S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Ohio State University College of Medicine, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Nasir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Julia E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Ohio State University College of Medicine, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzsimons</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalia</LastName><ForeName>Adam A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Essandoh</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Sylvester M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Transplantation Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schenk</LastName><ForeName>Austin D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Division of Transplantation Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Katja</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawyer</LastName><ForeName>Tamara R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Central Michigan University College of Medicine, Mt. Pleasant, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iyer</LastName><ForeName>Manoj H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Electronic address: Manoj.Iyer@osumc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Transplant</MedlineTA><NlmUniqueID>100968638</NlmUniqueID><ISSNLinking>1600-6135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.68</RegistryNumber><NameOfSubstance UI="D010959">Tissue Plasminogen Activator</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010959" MajorTopicYN="N">Tissue Plasminogen Activator</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="Y">Heart Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">intracardiac thrombus</Keyword><Keyword MajorTopicYN="N">liver transplantation</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>9</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>19</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37156300</ArticleId><ArticleId IdType="doi">10.1016/j.ajt.2023.04.029</ArticleId><ArticleId IdType="pii">S1600-6135(23)00455-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28579397</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>Meta-analysis of heparin therapy for preventing venous thromboembolism in acute spinal cord injury.</ArticleTitle><Pagination><StartPage>94</StartPage><EndPage>100</EndPage><MedlinePgn>94-100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijsu.2017.05.066</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-9191(17)30451-X</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Venous thromboembolism (VTE) is a frequent complication in patients with acute spinal cord injury (SCI) and may have serious consequences. This study aimed to assess the efficacy and safety of heparin and low-molecular-weight heparin (LMWH) venous thromboprophylaxis in patients with acute SCI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, Web of Science, EMBASE and the Cochrane library were searched from January 1980 to August 2016. The primary outcome was the incidence of VTE. Secondary outcomes included the incidences of Deep-vein thrombosis (DVT), pulmonary embolism (PE) and major bleeding.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 11 studies including 1605 patients qualified for inclusion. Four studies evaluated the efficacy of heparin treatment compared with placebo or no treatment. There were significant differences between the two treatments, and the summary RR was 0.35 (95% confidence interval (CI) 0.15-0.87; P&#xa0;=&#xa0;0.02). Seven studies compared low dose unfractionated heparin (LDUH) with LMWH. The incidence of VTE was not significantly different between the two treatments (RR 1.09, 95% CI 0.63-1.89; P&#xa0;=&#xa0;0.76). There were no differences in the incidence of major bleeding with unfractionated heparin versus LMWH (summary RR 1.32, 95% CI 0.62-2.84; P&#xa0;=&#xa0;0.47).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this meta-analysis, heparin exhibited protective effects compared with placebo or no treatment with respect to the occurrence of VTE; there were no differences between LMWH and unfractionated heparin with ret to thromboembolism prophylaxis efficacy. LMWH did not reduce the risk of bleeding compared with LDUH.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, China. Electronic address: liuyang_orthopedics@foxmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, China. Electronic address: xiaoranxuhong@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feifei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, China. Electronic address: liufeif@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lv</LastName><ForeName>Zenghui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, China. Electronic address: lvzh1989@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kan</LastName><ForeName>Shunli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, China. Electronic address: kanshunli@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Guangzhi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, China. Electronic address: ninggz_tmu@foxmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Shiqing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, China. Electronic address: sqfeng@tmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bleeding</Keyword><Keyword MajorTopicYN="N">Heparin</Keyword><Keyword MajorTopicYN="N">Spinal cord injury</Keyword><Keyword MajorTopicYN="N">Thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28579397</ArticleId><ArticleId IdType="doi">10.1016/j.ijsu.2017.05.066</ArticleId><ArticleId IdType="pii">S1743-9191(17)30451-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31145362</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>22</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Bilateral total knee arthroplasty: Simultaneous or staged? A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e15931</StartPage><MedlinePgn>e15931</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e15931</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000015931</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Total knee arthroplasty (TKA) is one of the most successful orthopedic surgeries performed in recent decades. However, controversies still exist between conducting simultaneous or staged bilateral TKA. The objective of this study is to conduct a systematic review assessing the clinical outcome associated with simultaneous bilateral and staged bilateral total knee arthroplasty (BTKA).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A search was applied to CNKI, Embase, Medline, and Cochrane central database (January 2000-July 2018). All studies that compared simultaneous bilateral TKA (simBTKA) with staged bilateral TKA (staBTKA) without language restriction were reviewed, and qualities of included studies were assessed using the Newcastle-Ottawa Scale. Data were pooled and a meta-analysis completed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 18 studies were identified to be eligible. The 18 comparative studies published from 2001 to 2018, covered 73617 participants in the simBTKA group and 61838 in the staBTKA group, respectively. Results of meta-analyses indicated that simBTKA showed a lower risk of deep infection and respiratory complications, but increased mortality, pulmonary embolism (PE), and deep-vein thrombosis (DVT) compared with staBTKA. There were no significant differences in revision, superficial infection, arthrofibrosis, cardiac complications, neurological complications and urinary complications between procedures.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Since there are risks and benefits to both procedures, these potential complications must be interpreted in light of each individual patient's needs and concerns. Further research must be conducted, in the form of a randomized clinical trial, to evaluate the outcomes mentioned in this review.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Limin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, The North China Petroleum Administration Bureau General Hospital, Renqiu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongtian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Tuberculosis prevention and control center, Shijiazhuang Center for Disease Control and Prevention, Shijiazhuang, Hebei, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, The North China Petroleum Administration Bureau General Hospital, Renqiu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Jingtao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, The North China Petroleum Administration Bureau General Hospital, Renqiu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, The North China Petroleum Administration Bureau General Hospital, Renqiu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="N">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31145362</ArticleId><ArticleId IdType="pmc">PMC6708906</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000015931</ArticleId><ArticleId IdType="pii">00005792-201905310-00092</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferket BS, Feldman Z, Zhou J, et al. Impact of total knee replacement practice: cost effectiveness analysis of data from the osteoarthritis initiative. BMJ 2017;356:j1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6284324</ArticleId><ArticleId IdType="pubmed">28351833</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez JA, Bhende H, Ranawat CS. Total condylar knee replacement: a 20-year followup study. Clin Orthop Relat Res 2001;388:10&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11451106</ArticleId></ArticleIdList></Reference><Reference><Citation>Memtsoudis SG, Ma Y, Chiu YL, et al. Bilateral total knee arthroplasty: risk factors for major morbidity and mortality. Anesth Analg 2011;113:784&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183335</ArticleId><ArticleId IdType="pubmed">21752942</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard L, Williamson DM, Ivory JP, et al. An evaluation of the safety and efficacy of simultaneous bilateral total knee arthroplasty. J Arthrop 2003;18:972&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14658100</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheth DS, Cafri G, Paxton EW, et al. Bilateral simultaneous vs staged total knee arthroplasty: a comparison of complications and mortality. J Arthrop 2016;31:212&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27430183</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobh AH, Siljander MP, Mells AJ, et al. Cost analysis, complications, and discharge disposition associated with simultaneous vs staged bilateral total knee arthroplasty. J Arthrop 2018;33:320&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">28988612</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong F, Li G, Kai C, et al. Comparison of clinical outcome between simultaneous-bilateral and staged-bilateral total knee arthroplasty: a systematic review of retrospective studies. J Arthrop 2013;28:1141&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23518424</ArticleId></ArticleIdList></Reference><Reference><Citation>Memtsoudis S, Gaber L, Sculco T. In-hospital complications and mortality of unilateral, bilateral, and revision TKA: Based on an estimate of 4,159,661 discharges. Clin Orthop Relat Res 2008;466:2617&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2565056</ArticleId><ArticleId IdType="pubmed">18704616</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanley D, Stockley I, Getty CJ. Simultaneous or staged bilateral total knee replacements in rheumatoid arthritis. Prospect Study J Bone Joint Surg Br Vol 1990;72:772&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2211753</ArticleId></ArticleIdList></Reference><Reference><Citation>Adili A, Bhandari M, Petruccelli D, et al. Sequential bilateral total knee arthroplasty under 1 anesthetic in patients &#x2265;75 years old &#x2217; &#x2217;&#x2217;: complications and functional outcomes. J Arthroplasty 2001;16:271&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307122</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter MA, Meding JB. Bilateral simultaneous total knee arthroplasty. J Arthroplasty 1987;2:185&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3668546</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuben JD, Meyers SJ, Cox DD, et al. Cost comparison between bilateral simultaneous, staged, and unilateral total joint arthroplasty. J Arthroplasty 1998;13:172&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9526210</ArticleId></ArticleIdList></Reference><Reference><Citation>Binjie Zhu ZC, Feng Liu, Weimin Fan The safety and efficacy of simultaneous or staged bilateral total knee arthroplasty in treatment of both knee osteoarthritis. Chin J Orthop 2014;34:619&#x2013;23.</Citation></Reference><Reference><Citation>Chua HS, Whitehouse SL, Lorimer M, et al. Mortality and implant survival with simultaneous and staged bilateral total knee arthroplasty experience from the australian orthopaedic association national joint replacement registry. J Arthroplasty 2018;33:3167&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">29908796</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg-Larsen M, J&#xf8;rgensen CC, Husted H, et al. Early morbidity after simultaneous and staged bilateral total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc Off J Esska 2015;23:831&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24503963</ArticleId></ArticleIdList></Reference><Reference><Citation>Bini SA, Khatod M, Inacio MC, et al. Same-day versus staged bilateral total knee arthroplasty poses no increase in complications in 6672 primary procedures. J Arthroplasty 2014;29:694&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24360340</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2011;25:603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KV, Chen JD, Wu WT, et al. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis. J Formos Med Assoc 2019;118:833&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">30279030</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KV, Chen JD, Wu WT, et al. Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer 2018;7:90&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5892377</ArticleId><ArticleId IdType="pubmed">29662836</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Internal Med 1997;127:820&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9382404</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen IJ, Chang KV, Wu WT, et al. Ultrasound parameters other than the direct measurement of ulnar nerve size for diagnosing cubital tunnel syndrome: a systemic review and meta-analysis. Arch Phys Med Rehabil 2018;25:</Citation><ArticleIdList><ArticleId IdType="pubmed">30055161</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang KV, Wu WT, Han DS, et al. Ulnar nerve cross-sectional area for the diagnosis of cubital tunnel syndrome: a meta-analysis of ultrasonographic measurements. Arch Phys Med Rehabil 2018;99:743&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">28888384</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtney PM, Melnic CM, Alosh H, et al. Is bilateral total knee arthroplasty staged at a one-week interval safe? A matched case control study. J Arthroplasty 2014;29:1946&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24953946</ArticleId></ArticleIdList></Reference><Reference><Citation>Memtsoudis SG, Ma Y, Gonz&#xe1;lez DVA, et al. Perioperative outcomes after unilateral and bilateral total knee arthroplasty. Anesthesiology 2009;111:1206&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803038</ArticleId><ArticleId IdType="pubmed">19934863</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognesi MP, Tyler Steven W, Attarian DE, et al. Simultaneous vs staged bilateral total knee arthroplasty among Medicare beneficiaries, 2000-2009. J Arthroplasty 2013;28:87&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">23932073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchinson JR, Parish EN, Cross MJ. A comparison of bilateral uncemented total knee arthroplasty: simultaneous or staged. J Bone Joint Surg Br Vol 2006;88:40&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">16365118</ArticleId></ArticleIdList></Reference><Reference><Citation>Niki Y, Katsuyama E, Takeda Y, et al. Comparison of postoperative morbidity between simultaneous bilateral and staged bilateral total knee arthroplasties: serological perspective and clinical consequences. J Arthroplasty 2014;29:504&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23988436</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon H-S, Han C-D, Yang I-H. Comparison of simultaneous bilateral and staged bilateral total knee arthroplasty in terms of perioperative complications. J Arthroplasty 2010;25:179&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">19195827</ArticleId></ArticleIdList></Reference><Reference><Citation>Meehan JP, Danielsen B, Tancredi DJ, et al. A population-based comparison of the incidence of adverse outcomes after simultaneous-bilateral and staged-bilateral total knee arthroplasty. J Bone Joint Surg Am Vol 2011;93:2203&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">22159856</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubbs G, Pryke SE, Tewari S, et al. Safety and cost benefits of bilateral total knee replacement in an acute hospital. ANZ J Surg 2005;75:739&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16173984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter MA, Harty LD, Davis KE, et al. Simultaneous bilateral, staged bilateral, and unilateral total knee arthroplasty. A survival analysis. J Bone Joint Surg Am Vol 2003;85:1532&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925634</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangaleshkar SR, Prasad PSV, Chugh S, et al. Staged bilateral total knee replacement&#x2014;a safer approach in older patients. Knee 2001;8:207&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">11706728</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster MC, Bauze AJ, Bailie AG, et al. A retrospective comparative study of bilateral total knee replacement staged at a one-week interval. J Bone Joint Surg Br Vol 2006;88:1006&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16877597</ArticleId></ArticleIdList></Reference><Reference><Citation>Walmsley P, Murray A, Brenkel IJ. The practice of bilateral, simultaneous total knee replacement in Scotland over the last decade. Data from the Scottish Arthroplasty Project. Knee 2006;13:102&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481171</ArticleId></ArticleIdList></Reference><Reference><Citation>Agents AI, Effects NSA. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11014340</ArticleId></ArticleIdList></Reference><Reference><Citation>Picavet HSJ, Hazes JMW. Prevalence of self reported musculoskeletal diseases is high. Ann Rheum Dis 2003;62:644&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1754612</ArticleId><ArticleId IdType="pubmed">12810427</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002;14:573&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12192258</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun BH, Wu CW, Kalunian KC. New Developments in Osteoarthritis. Rheum Dis Clin North Am 2007;33:135&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">17367697</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr AJ, Robertsson O, Graves S, et al. Knee replacement. Lancet 2012;379:1331&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22398175</ArticleId></ArticleIdList></Reference><Reference><Citation>Sculco TP. Establishing a universal protocol for deep vein thrombosis following orthopedic surgery: total knee arthroplasty. Orthopedics 1996;19:6&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24826713</ArticleId></ArticleIdList></Reference><Reference><Citation>Mckenna R, Bachmann F, Kaushal SP, et al. Thromboembolic disease in patients undergoing total knee replacement. J Bone Joint Surg Am Vol 1976;58:928&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">977623</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson CM, Macmillan DP, Lachiewicz PF. Thromboembolism after total knee arthroplasty: intermittent pneumatic compression and aspirin prophylaxis. J South Orthop Assoc 2001;10:155&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">12132827</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelboom J, Karthikeyan GN, Hirsh J. American association of orthopedic surgeons and american college of chest physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients. Chest 2009;135:513&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">19201714</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy YD, Hardwick ME, Copp SN, et al. Thrombosis incidence in unilateral vs. simultaneous bilateral total knee arthroplasty with compression device prophylaxis. J Arthroplasty 2013;28:474&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23142435</ArticleId></ArticleIdList></Reference><Reference><Citation>Poultsides LA, Memtsoudis SG, Vasilakakos T, et al. Infection following simultaneous bilateral total knee arthroplasty. J Arthroplasty 2013;28:92&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23937920</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Zhang F, Chen W, et al. Risk factors for periprosthetic joint infection after total joint arthroplasty: a systematic review and meta-analysis. J Hospital Infect 2015;89:82&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25575769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock DP, Sporer SM, Jr, S.T Comparison of simultaneous bilateral with unilateral total knee arthroplasty in terms of perioperative complications. J Bone Joint Surg Am Vol 2003;85:1981&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">14563808</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavone V, Johnson T, Saulog PS, et al. Perioperative morbidity in bilateral one-stage total knee replacements. Clin Orthop Relat Res 2004;421:155&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123941</ArticleId></ArticleIdList></Reference><Reference><Citation>Ries MD, Rauscher LA, Hoskins S, et al. Intramedullary pressure and pulmonary function during total knee arthroplasty. Clin Orthop Relat Res 1998;356:154&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">9917680</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorr LD, Merkel C, Mellman MF, et al. Fat emboli in bilateral total knee arthroplasty. Predictive factors for neurologic manifestations. Clinorthoprelatres 1989;248:112&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2805467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane GJ, Hozack WJ, Shah S, et al. Simultaneous bilateral versus unilateral total knee arthroplasty. Outcomes analysis. Clin Orthop Relat Res 1997;345:106&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">9418627</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25910837</PMID><DateCompleted><Year>2016</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-111X</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Perfusion</Title><ISOAbbreviation>Perfusion</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal membrane oxygenation in acute massive pulmonary embolism: a systematic review.</ArticleTitle><Pagination><StartPage>611</StartPage><EndPage>616</EndPage><MedlinePgn>611-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0267659115583377</ELocationID><Abstract><AbstractText>Massive pulmonary embolism (PE) can present with extreme physiological dysfunction, characterised by acute right ventricular failure, hypoxaemia unresponsive to conventional therapy and cardiac arrest. Consensus regarding the management of patients with persistent shock following thrombolysis is lacking. Our primary objective was to describe the application of extracorporeal membrane oxygenation (ECMO) in the treatment of acute massive PE. We were unable to identify any randomised controlled trials (RCTs) comparing ECMO with other support systems in the setting of massive PE. We reviewed case reports and case series published in the past 20 years to evaluate the mortality rate and any poor prognostic factors. Overall survival was 70.1% and none of the definitive treatment modalities was associated with a higher mortality (thrombolysis - OR - 0.99, P - 0.9, catheter embolectomy - OR - 1.01, P - 0.99, surgical embolectomy - OR - 0.44, P - 0.20). Patients who had ECMO instituted whilst in cardiorespiratory arrest had a higher risk of death. (OR - 16.71, P - 0.0004). When compared with other causes of cardiac arrest, patients who survived a massive PE presented a good neurological outcome (cerebral performance category 1 or 2).</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2015.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yusuff</LastName><ForeName>H O</ForeName><Initials>HO</Initials><AffiliationInfo><Affiliation>Intensive Care Medicine, Health Education North West, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zochios</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cardiothoracic Intensive Care Medicine, Papworth Hospital, Papworth Everard, Cambridge, UK vasileioszochios@doctors.org.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vuylsteke</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiothoracic Anaesthesia and Intensive Care Medicine, Papworth Hospital, Papworth Everard, Cambridge, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Perfusion</MedlineTA><NlmUniqueID>8700166</NlmUniqueID><ISSNLinking>0267-6591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ECLS</Keyword><Keyword MajorTopicYN="N">ECMO</Keyword><Keyword MajorTopicYN="N">cardiac arrest</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">thrombolytic therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25910837</ArticleId><ArticleId IdType="doi">10.1177/0267659115583377</ArticleId><ArticleId IdType="pii">0267659115583377</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27776901</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8406</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of arthroplasty</Title><ISOAbbreviation>J Arthroplasty</ISOAbbreviation></Journal><ArticleTitle>Bilateral Total Hip Arthroplasty: 1-Stage or 2-Stage? A Meta-Analysis.</ArticleTitle><Pagination><StartPage>689</StartPage><EndPage>695</EndPage><MedlinePgn>689-695</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arth.2016.09.022</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-5403(16)30665-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Total hip arthroplasty (THA) is one of the most successful orthopedic surgeries performed in the last 50 years. However, controversies still exist between conducting 1- or 2-stage bilateral THA.</AbstractText><AbstractText Label="METHODS">Using PubMed, Ovid, Embase, and Cochrane library databases, we searched for papers written between January 1995 and October 2015 that contained the following search terms: "one-stage or two-stage" or "simultaneous or staged," and "hip" and "arthroplasty or replacement." A meta-analysis was conducted with the collected pooled data about major and minor systemic complications, surgical complications, and other perioperative data associated with 1- and 2-stage bilateral THA. Statistical analysis was performed by the Mantel-Haenszel method, and the fixed effect model was used to analyze data.</AbstractText><AbstractText Label="RESULTS">There were 13 studies with 17,762 patients who underwent 1-stage bilateral THA and 46,147 patients who underwent 2-stage bilateral THA. One-stage bilateral THA had a lower risk of major systemic complications, less deep venous thrombosis, and shorter operative time compared with 2-stage bilateral THA. There were no significant differences in death, pulmonary embolism, cardiovascular complication, infections, minor complications, and other surgical complications between procedures.</AbstractText><AbstractText Label="CONCLUSION">One-stage bilateral THA was superior to 2-stage bilateral THA in terms of major systemic complication, deep venous thrombosis, and surgical time compared with 2-stage bilateral THA. However, this study does not encourage performing 1-stage over 2-stage bilateral THA. Higher evidence level studies are necessary for further analysis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Hongyi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Orthopedics Department, Beijing Jishuitan Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chi-Lung</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Chiayi, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maltenfort</LastName><ForeName>Mitchell G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Restrepo</LastName><ForeName>Camilo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothman</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Antonia F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Rothman Institute at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Arthroplasty</MedlineTA><NlmUniqueID>8703515</NlmUniqueID><ISSNLinking>0883-5403</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Arthroplasty. 2017 Apr;32(4):1404-1405. doi: 10.1016/j.arth.2016.10.023.</RefSource><PMID Version="1">27889308</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Arthroplasty. 2017 Apr;32(4):1405-1406. doi: 10.1016/j.arth.2016.10.024.</RefSource><PMID Version="1">27889309</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">staged arthroplasty</Keyword><Keyword MajorTopicYN="N">total hip arthroplasty</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27776901</ArticleId><ArticleId IdType="doi">10.1016/j.arth.2016.09.022</ArticleId><ArticleId IdType="pii">S0883-5403(16)30665-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21881372</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2186-1005</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia</Title><ISOAbbreviation>Ann Thorac Cardiovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension : a systematic review.</ArticleTitle><Pagination><StartPage>435</StartPage><EndPage>445</EndPage><MedlinePgn>435-45</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Pulmonary thromboendarterectomy (PTE) is a treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH). The present systematic review was performed to assess the safety and efficacy of PTE for CTEPH.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review was performed, and six electronic databases were searched for published studies from January 1999 to February 2010. All articles that presented morbidity and mortality data, survival data or preoperative and postoperative pulmonary hemodynamic indices were included. The primary outcome measures extracted were early morbidity and mortality, pulmonary hemodynamic and functional outcome indices prior to and after the operation, and survival data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 654 publications retrieved, 19 relevant papers (total number of 2729 patients) representing the most recent and complete data set from each institute, were included for appraisal and data extraction. No randomized controlled trials or matched comparative studies were identified. Thirty-day mortality ranged from 1.3% to 24% (median 8%). Residual pulmonary hypertension was reported in 11%-35% of patients after PTE. Pulmonary artery pressure and pulmonary vascular resistance significantly decreased after PTE in all studies. Before PTE, 60%-100% of patients were in NYHA functional class III or IV. This percentage decreased to 0%-21% after PTE. Five-year survival ranged from 74% to 89%.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The current literature suggests that PTE for patients with CTEPH is associated with acceptable perioperative morbidity and mortality rates and improved hemodynamic indices and survival when viewed against the prognosis associated with historical controls using medical therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rahnavardi</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, The University of Sydney, Missenden Road, Camperdown, Sydney, Australia. rahnavardi@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Tristan D</ForeName><Initials>TD</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Vallely</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Bannon</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Michael K</ForeName><Initials>MK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Ann Thorac Cardiovasc Surg</MedlineTA><NlmUniqueID>9703158</NlmUniqueID><ISSNLinking>1341-1098</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004691" MajorTopicYN="Y">Endarterectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011651" MajorTopicYN="N">Pulmonary Artery</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21881372</ArticleId><ArticleId IdType="doi">10.5761/atcs.oa.10.01653</ArticleId><ArticleId IdType="pii">JST.JSTAGE/atcs/oa.10.01653</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34508872</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-3348</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of vascular surgery. Venous and lymphatic disorders</Title><ISOAbbreviation>J Vasc Surg Venous Lymphat Disord</ISOAbbreviation></Journal><ArticleTitle>Meta-analysis and systematic review of randomized controlled trials assessing the role of thromboprophylaxis after vascular surgery.</ArticleTitle><Pagination><StartPage>767</StartPage><EndPage>777.e3</EndPage><MedlinePgn>767-777.e3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvsv.2021.08.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-333X(21)00429-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Venous thromboembolism (VTE) is a well-known complication associated with surgical procedures. The implementation of thromboprophylaxis in this population has become a vital aspect of perioperative care to decrease VTE-associated morbidity and mortality risk. However, data assessing the role of thromboprophylaxis for patients undergoing vascular surgery are sparse. Assessing the role of thromboprophylaxis by low-molecular-weight heparin or unfractionated heparin in vascular surgery.</AbstractText><AbstractText Label="METHODS">We searched MEDLINE, Embase, and the Cochrane Collaboration Central Register of Controlled Trials from inception until December 2020, for randomized controlled trials assessing the role of thromboprophylaxis in vascular surgery.</AbstractText><AbstractText Label="RESULTS">Eight randomized controlled trials met inclusion criteria, including 3130 patients, with a mean age of 55.35&#xa0;years and 45% were females. Compared with placebo, anticoagulant use was associated with a decrease in deep venous thrombosis (DVT) (risk ratio [RR], 0.34; 95% confidence interval [CI], 0.11-1.05; P&#xa0;= .06; I<sup>2</sup>&#xa0;= 68%) and pulmonary embolism (PE) (RR, 0.17; 95% CI, 0.02-1.22; P&#xa0;= .08; I<sup>2</sup>&#xa0;= 41%), but this trend did not attain statistical significance. There was no difference for bleeding outcomes between anticoagulants and placebo (RR, 0.90; 95% CI, 0.05-15.01; P&#xa0;= .94; I<sup>2</sup>&#xa0;= 76%). There was no significant difference in outcomes when low-molecular-weight heparin was compared directly with unfractionated heparin. In a sensitivity analysis, anticoagulant use was associated with a significant decrease in DVT or PE in patients undergoing venous surgeries, but was not associated with a significant decrease in DVT or PE in patients undergoing arterial surgeries, although this analysis was limited by the small number of studies in each group.</AbstractText><AbstractText Label="CONCLUSIONS">Among patients undergoing vascular surgery, thromboprophylaxis with anticoagulants showed a trend toward a lesser incidence of VTE when compared with placebo, although this difference was not statistically significant. Bleeding outcomes were comparable between both treatment groups.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haykal</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine, Duke University, Durham, NC. Electronic address: tarek.haykal@duke.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zayed</LastName><ForeName>Yazan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, Fla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerbage</LastName><ForeName>Josiane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Lebanese University, Beirut, Lebanon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deliwala</LastName><ForeName>Smit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hurley Medical Center, Flint, Mich; College of Human Medicine, Michigan State University, East Lansing, Mich.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Chandler A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Division of Vascular and Endovascular Surgery, Department of Surgery, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortel</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Division of Hematology, Department of Medicine, Duke University, Durham, NC; Department of Pathology, Duke University, Durham, NC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Surg Venous Lymphat Disord</MedlineTA><NlmUniqueID>101607771</NlmUniqueID><ISSNLinking>2213-333X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014656" MajorTopicYN="Y">Vascular Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>11</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34508872</ArticleId><ArticleId IdType="doi">10.1016/j.jvsv.2021.08.019</ArticleId><ArticleId IdType="pii">S2213-333X(21)00429-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39111699</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-3348</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of vascular surgery. Venous and lymphatic disorders</Title><ISOAbbreviation>J Vasc Surg Venous Lymphat Disord</ISOAbbreviation></Journal><ArticleTitle>Perioperative and intermediate outcomes of patients with pulmonary embolism undergoing catheter-directed thrombolysis vs percutaneous mechanical thrombectomy.</ArticleTitle><Pagination><StartPage>101958</StartPage><MedlinePgn>101958</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101958</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvsv.2024.101958</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-333X(24)00353-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Thrombolytic therapy has been a mainstay of treatment for massive or submassive pulmonary embolism (PE), a common and highly morbid pathology. New percutaneous mechanical thrombectomy (PMT) devices have recently become widely available and have been used increasingly for the treatment of acute PE, but evidence demonstrating its efficacy over standard catheter-directed lytic protocol remains limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using TriNetX Data Network, a global federated database of &gt;250 million patients, we conducted a retrospective cohort study of patients from January 2017 to August 2023 with a diagnosis of PE, treated with either PMT or catheter-directed thrombolysis (CDT). Eligible patients were 1:1 propensity score-matched for preoperative covariates including demographics and comorbidities. We calculated and compared the 30-day outcomes of all-cause mortality, bleeding complications (blood transfusion, gastrointestinal bleed, and intracranial hemorrhage), diagnosis of acute respiratory failure (RF), myocardial infarction (MI), and pulmonary hypertension (PH) using odds ratios (OR) with 95% confidence intervals (CIs). Also, the 5-year outcomes of all-cause mortality, a composite outcome of chronic PH (chronic PE, chronic cor pulmonale, chronic thromboembolic PH), right heart failure (RHF), RF, and emergency department visits, were compared using hazard ratios (HRs) with 95% CIs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 2978 patients treated with PMT and 1137 patients treated with CDT. After matching, we compared 1102 patients in each cohort. For 30-day outcomes, all-cause mortality, acute RF, and blood transfusion were similar between the two groups. However, compared with CDT, PMT was associated with a better safety profile, including lower bleeding risk for both ICH (OR, 0.46; 95% CI, 0.24-0.890) and gastrointestinal bleed (OR, 0.42; 95% CI, 0.28-0.63). PMT also demonstrated better immediate functional outcomes, with less PH (OR, 0.53; 95% CI, 0.41-0.68) and MI (OR, 0.54; 95% CI, 0.41-0.76). At 5&#xa0;years, the all-cause mortality and RF for both procedures were similar, but PMT was associated with lower rates of chronic PH (HR, 0.70; 95% CI, 0.55-0.90), RHF (HR 0.49; 95% CI, 0.37-0.65), and emergency department visits (348 for PMT vs 426 for CDT; P&#xa0;&lt; .01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients undergoing catheter-based therapy for PE, PMT has an improved procedural safety profile vs CDT and results in significantly fewer 30-day postoperative complications, with fewer bleeding events, and is also associated with fewer periprocedural MIs and less acute PH. Perhaps, more important, PMT also demonstrated improved long-term outcomes with significantly fewer chronic PH and RHF diagnoses with fewer emergency department visits.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsukagoshi</LastName><ForeName>Junji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Texas Medical Branch, Galveston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wick</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karim</LastName><ForeName>Abbas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>John Sealy School of Medicine, University of Texas Medical Branch, Galveston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanipov</LastName><ForeName>Kamil</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Mitchell W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, Department of Surgery, University of Texas Medical Branch, Galveston, TX. Electronic address: mwcox@utmb.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Surg Venous Lymphat Disord</MedlineTA><NlmUniqueID>101607771</NlmUniqueID><ISSNLinking>2213-333X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="Y">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017131" MajorTopicYN="N">Thrombectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Catheter-directed thrombolysis</Keyword><Keyword MajorTopicYN="N">Percutaneous mechanical thrombectomy</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Pulmonary hypertension</Keyword></KeywordList><CoiStatement>Disclosures None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>8</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>7</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39111699</ArticleId><ArticleId IdType="pmc">PMC11774124</ArticleId><ArticleId IdType="doi">10.1016/j.jvsv.2024.101958</ArticleId><ArticleId IdType="pii">S2213-333X(24)00353-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Freund Y., Cohen-Aubart F., Bloom B. Acute pulmonary embolism: a Review. JAMA. 2022;328:1336&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">36194215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerrigan J., Morse M., Haddad E., Willers E., Ramaiah C. Advances in percutaneous management of pulmonary embolism. Int J Angiol Off Publ Int Coll Angiol Inc. 2022;31:203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9507563</ArticleId><ArticleId IdType="pubmed">36157096</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein P.D., Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med. 2012;125:465&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">22325236</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll B.J., Larnard E.A., Pinto D.S., Giri J., Secemsky E.A. Percutaneous management of high-risk pulmonary embolism. Circ Cardiovasc Interv. 2023;16</Citation><ArticleIdList><ArticleId IdType="pubmed">36744463</ArticleId></ArticleIdList></Reference><Reference><Citation>Inci E.K., Khandhar S., Toma C., et al. Mechanical thrombectomy versus catheter directed thrombolysis in patients with pulmonary embolism: a multicenter experience. Catheter Cardiovasc Interv. 2023;101:140&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">36448401</ArticleId></ArticleIdList></Reference><Reference><Citation>Graif A., Patel K.D., Wimmer N.J., et al. Large-bore aspiration thrombectomy versus catheter-directed thrombolysis for acute pulmonary embolism: a propensity score-matched comparison. J&#xa0;Vasc Interv Radiol JVIR. 2020;31:2052&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pubmed">33183975</ArticleId></ArticleIdList></Reference><Reference><Citation>Toma C. Impact of a blood return system on mechanical thrombectomy-associated blood loss and hemodynamic outcomes in a pulmonary embolism registry. Eur Heart J. 2022;43(Supplement_2)</Citation></Reference><Reference><Citation>Chung R., Weller A., Morgan R., Belli A.M., Ratnam L. Are complication rates lower with 4-Fr versus 6-Fr transfemoral arterial access &#x2013; prospective audit at a single interventional radiology centre. CVIR Endovasc. 2018;1:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6319516</ArticleId><ArticleId IdType="pubmed">30652147</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauder L., P&#xe9;rez Navarro P., G&#xf6;tzinger F., et al. Mechanical thrombectomy in intermediate- and high-risk acute pulmonary embolism: hemodynamic outcomes at three months. Respir Res. 2023;24:257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10601326</ArticleId><ArticleId IdType="pubmed">37880651</ArticleId></ArticleIdList></Reference><Reference><Citation>Delcroix M., Torbicki A., Gopalan D., et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021;57</Citation><ArticleIdList><ArticleId IdType="pubmed">33334946</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai K.R. Mechanical thrombectomy in pulmonary embolism. JACC Cardiovasc Interv. 2021;14:330&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">33454292</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31060732</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-6771</ISSN><JournalIssue CitedMedium="Internet"><Volume>123</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jul</Month></PubDate></JournalIssue><Title>British journal of anaesthesia</Title><ISOAbbreviation>Br J Anaesth</ISOAbbreviation></Journal><ArticleTitle>Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.</ArticleTitle><Pagination><StartPage>27</StartPage><EndPage>36</EndPage><MedlinePgn>27-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bja.2019.03.028</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0007-0912(19)30233-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Perioperative diabetic ketoacidosis (DKA) with near-normal blood glucose concentrations, termed euglycaemic ketoacidosis (EDKA), is an adverse effect associated with sodium-glucose co-transporter-2 inhibitors (SGLT2i). Guidelines are still evolving concerning the perioperative management of patients on SGLT2i. We performed a systematic review of published reports of DKA from SGLT2i in the surgical setting to understand better the clinical presentation and characteristics of SGLT2i-associated DKA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched PubMed, Embase, and ProQuest for reports of perioperative DKA involving SGLT2i up to January 2019.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-two reports of EDKA and five cases of hyperglycaemic diabetic ketoacidosis (HDKA) were identified from 33 publications. Canagliflozin was implicated in 26 cases. Presentation time varied from a few hours up to 6 weeks after operation. Precipitating factors may include diabetes medication changes, diet modifications, and intercurrent illnesses. There were 13 cases (12 EDKA and one HDKA) of bariatric surgery, 10 of them noted very-low-calorie diet regimes as a precipitating factor. No precise association between interruption of SGLT2i and the occurrence of DKA could be identified. Seven patients required mechanical ventilation, and acute kidney injury was noted in five. Five cases needed imaging to rule out anastomotic leak and pulmonary embolism, all of them revealed negative findings. Outcome data were available in 32 cases, all of them recovered completely.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">EDKA is likely to be under-recognised because of its atypical presentation and may delay the diagnosis. Understanding this clinical entity, vigilance towards monitoring plasma/capillary ketones helps in early identification and assists in the management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 British Journal of Anaesthesia. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thiruvenkatarajan</LastName><ForeName>Venkatesan</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, The Queen Elizabeth Hospital, Adelaide, Australia; Discipline of Acute Care Medicine, University of Adelaide, Adelaide, Australia. Electronic address: Venkatesan.Thiruvenkatarajan@sa.gov.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Emily Jane</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia; Department of Endocrinology and Diabetes, The Metabolic Unit, The Queen Elizabeth Hospital, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nanjappa</LastName><ForeName>Nagesh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, The Queen Elizabeth Hospital, Adelaide, Australia; Discipline of Acute Care Medicine, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Wijk</LastName><ForeName>Roelof M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, The Queen Elizabeth Hospital, Adelaide, Australia; Discipline of Acute Care Medicine, University of Adelaide, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jesudason</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia; Discipline of Medicine, University of Adelaide, Adelaide, Australia; Department of Endocrinology and Diabetes, The Metabolic Unit, The Queen Elizabeth Hospital, Adelaide, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Anaesth</MedlineTA><NlmUniqueID>0372541</NlmUniqueID><ISSNLinking>0007-0912</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016883" MajorTopicYN="N">Diabetic Ketoacidosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007431" MajorTopicYN="N">Intraoperative Complications</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="N">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">diabetic ketoacidosis</Keyword><Keyword MajorTopicYN="N">euglycaemic ketoacidosis</Keyword><Keyword MajorTopicYN="N">hyperglycaemic diabetic ketoacidosis</Keyword><Keyword MajorTopicYN="N">perioperative</Keyword><Keyword MajorTopicYN="N">sodium-glucose co-transporter-2 inhibitors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31060732</ArticleId><ArticleId IdType="doi">10.1016/j.bja.2019.03.028</ArticleId><ArticleId IdType="pii">S0007-0912(19)30233-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30005883</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-685X</ISSN><JournalIssue CitedMedium="Internet"><Volume>156</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of thoracic and cardiovascular surgery</Title><ISOAbbreviation>J Thorac Cardiovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Surgical pulmonary embolectomy and catheter-based therapies for acute pulmonary embolism: A contemporary systematic review.</ArticleTitle><Pagination><StartPage>2155</StartPage><EndPage>2167</EndPage><MedlinePgn>2155-2167</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtcvs.2018.05.085</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-5223(18)31520-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Mortality in acute pulmonary embolism (PE) is believed to be principally due to the subgroup of PEs that are massive. Systemic thrombolysis is the therapeutic mainstay for acute massive PE, despite evidence suggesting limited survival benefits. Both catheter-based therapies (CBT) and surgical pulmonary embolectomy (SE) are well-accepted alternatives to treat acute PE. However, the comparative effectiveness of these approaches is difficult to study. We conducted a systematic review of CBT and SE for acute PE.</AbstractText><AbstractText Label="METHODS">The PubMed database was queried for CBT- and SE-related publications between January 1998 and June 2017. A minimum of 10 patients undergoing intervention(s) was required for inclusion, and studies must not have excluded patients with massive PE. End points examined included hospital mortality, and additionally for CBT, procedural success rate.</AbstractText><AbstractText Label="RESULTS">A total of 75 studies (41 of CBT, 34 of SE) were identified, with 1650 patients undergoing CBT and 1101 undergoing SE. Patients undergoing SE were more critically ill than those undergoing CBT (massive PE, 545 out of 975 [55.9%] for SE vs 742 out of 1553 [47.8%] for CBT). Cardiopulmonary resuscitation (CPR) was required in 217 out of 1015 patients undergoing SE (21.4%) versus 38 out of 983 patients undergoing CBT (4.0%). The hospital mortality of SE was 14.0%, versus 5.6% for CBT, in the entire patient group. However, the hospital mortality of SE in patients with pre-SE CPR was 46.3%, whereas it was 6.8% in those patients without pre-SE CPR. Although CPR was associated with an increased risk of mortality both for CBT and SE, it accounted for all of the mortality effect on SE (the adjusted odds ratio for CPR in a random effects model with treatment considered was 9.79 (95% confidence interval, 4.98-19.17; P&#xa0;&lt;&#xa0;.0001). The adjusted odds ratio for mortality for SE relative to CBT was 1.36 (95% confidence interval, 0.80-2.32; P&#xa0;=&#xa0;.84). Moreover, CBT was associated with a procedural failure rate of 8.3%.</AbstractText><AbstractText Label="CONCLUSIONS">Both CBT and SE were associated with satisfactory published outcomes. SE is associated with greater absolute postprocedure mortality than CBT, but has been undertaken in more critically ill populations. The markedly higher incidence of CPR in SE accounts for the differential mortality between the patients undergoing SE and those undergoing CBT. Decision making with respect to best therapy must take into account potential needs for periprocedure artificial mechanical right ventricle and lung support, institutional experience and outcomes, anticipated therapeutic efficacy and benefit, and approach-specific risks.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loyalka</LastName><ForeName>Pranav</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, University of Texas-Houston McGovern Medical School and Memorial Hermann-Texas Medical Center, Houston, Tex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansari</LastName><ForeName>Muhammad Z</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Thoracic Surgery, University of Texas-Houston McGovern Medical School and Memorial Hermann-Texas Medical Center, Houston, Tex; Department of Advanced Cardiopulmonary Therapies and Transplantation, University of Texas-Houston McGovern Medical School and Memorial Hermann-Texas Medical Center, Houston, Tex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheema</LastName><ForeName>Faisal H</ForeName><Initials>FH</Initials><AffiliationInfo><Affiliation>Division of Cardiothoracic Transplantation and Circulatory Support, Texas Heart Institute at Baylor College of Medicine, Houston, Tex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Charles C</ForeName><Initials>CC</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Cardiovascular and Thoracic Surgery, University of Texas-Houston McGovern Medical School and Memorial Hermann-Texas Medical Center, Houston, Tex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajagopal</LastName><ForeName>Sudarshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, Duke University School of Medicine and Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajagopal</LastName><ForeName>Keshava</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular and Thoracic Surgery, University of Texas-Houston McGovern Medical School and Memorial Hermann-Texas Medical Center, Houston, Tex; Department of Advanced Cardiopulmonary Therapies and Transplantation, University of Texas-Houston McGovern Medical School and Memorial Hermann-Texas Medical Center, Houston, Tex. Electronic address: keshava.rajagopal@uth.tmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Thorac Cardiovasc Surg</MedlineTA><NlmUniqueID>0376343</NlmUniqueID><ISSNLinking>0022-5223</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Thorac Cardiovasc Surg. 2018 Dec;156(6):2168-2169. doi: 10.1016/j.jtcvs.2018.06.032.</RefSource><PMID Version="1">30098803</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002404" MajorTopicYN="N">Catheterization</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017128" MajorTopicYN="N">Embolectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011651" MajorTopicYN="N">Pulmonary Artery</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011652" MajorTopicYN="N">Pulmonary Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">catheter</Keyword><Keyword MajorTopicYN="N">embolectomy</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">surgery</Keyword><Keyword MajorTopicYN="N">thrombolysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30005883</ArticleId><ArticleId IdType="doi">10.1016/j.jtcvs.2018.05.085</ArticleId><ArticleId IdType="pii">S0022-5223(18)31520-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18005235</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7836</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of thrombosis and haemostasis : JTH</Title><ISOAbbreviation>J Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Intraoperative pulmonary embolism and intracardiac thrombosis complicating liver transplantation: a systematic review.</ArticleTitle><Pagination><StartPage>297</StartPage><EndPage>302</EndPage><MedlinePgn>297-302</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1538-7836.2008.02831.x</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1538-7836(22)12939-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Pulmonary embolism (PE) and intracardiac thrombosis (ICT) are rare but potentially lethal complications during orthotopic liver transplantation (OLT).</AbstractText><AbstractText Label="METHODS">We aimed to review clinical and pathological correlates of PE and ICT in patients undergoing OLT. A systematic review of the literature was conducted using MEDLINE and ISI Web of Science.</AbstractText><AbstractText Label="RESULTS">Seventy-four cases of intraoperative PE and/or ICT were identified; PE alone in 32 patients (43%) and a combination of PE and ICT in 42 patients (57%). Most frequent clinical symptoms included systemic hypotension and concomitant rising pulmonary artery pressure, often leading to complete circulatory collapse. PE and ICT occurred in every stage of the operation and were reported equally in patients with or without the use of venovenous bypass or antifibrinolytics. A large variety of putative risk factors have been suggested in the literature, including the use of pulmonary artery catheters or certain blood products. Nineteen patients underwent urgent thrombectomy or thrombolysis. Overall mortality was 68% (50/74) and 41 patients (82%) died intraoperatively.</AbstractText><AbstractText Label="CONCLUSION">Mortality was significantly higher in patients with an isolated PE, compared to patients with a combination of PE and ICT (91% and 50%, respectively; P &lt; 0.001). Intraoperative PE and ICT during OLT appear to have multiple etiologies and may occur unexpectedly at any time during the procedure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Warnaar</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Section Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molenaar</LastName><ForeName>I Q</ForeName><Initials>IQ</Initials></Author><Author ValidYN="Y"><LastName>Colquhoun</LastName><ForeName>S D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Slooff</LastName><ForeName>M J H</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Sherwani</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>de Wolf</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Porte</LastName><ForeName>R J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Thromb Haemost</MedlineTA><NlmUniqueID>101170508</NlmUniqueID><ISSNLinking>1538-7836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Liver Transpl. 2008 Apr;14(4):575.</RefSource><PMID Version="1">18396486</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="N">Heart Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007022" MajorTopicYN="N">Hypotension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007431" MajorTopicYN="N">Intraoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012769" MajorTopicYN="N">Shock</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013916" MajorTopicYN="N">Thrombelastography</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>58</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18005235</ArticleId><ArticleId IdType="doi">10.1111/j.1538-7836.2008.02831.x</ArticleId><ArticleId IdType="pii">S1538-7836(22)12939-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33309903</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-3348</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of vascular surgery. Venous and lymphatic disorders</Title><ISOAbbreviation>J Vasc Surg Venous Lymphat Disord</ISOAbbreviation></Journal><ArticleTitle>Systematic review and meta-analysis of the prevalence of venous thromboembolic events in novel coronavirus disease-2019 patients.</ArticleTitle><Pagination><StartPage>289</StartPage><EndPage>298.e5</EndPage><MedlinePgn>289-298.e5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvsv.2020.11.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-333X(20)30654-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">Emerging clinical evidence has shown that patients with the novel coronavirus disease-2019 (COVID-19) have complications that include venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE). The prevalence of VTE in patients hospitalized with COVID-19 is unclear.</AbstractText><AbstractText Label="METHODS">Eligible studies on COVID-19 were collected from PubMed, Web of Science, and Embase. Patient characteristics and information were extracted for three categories of patients: consecutive, ICU, and non-ICU group. All PEs and DVTs were diagnosed by computed tomographic pulmonary arteriography and duplex ultrasound examination, respectively. A subgroup analysis of testing strategies in ICU and non-ICU patients for PE and DVT was also performed.</AbstractText><AbstractText Label="RESULTS">Forty clinical studies involving 7966 patients hospitalized with COVID-19 were included. Pooled VTE prevalence was 13% in consecutive patients (95% confidence interval [CI], 0.05-0.24; I<sup>2</sup>&#xa0;= 97%), 7% in non-ICU patients (95% CI, 0.01-0.18; I<sup>2</sup>&#xa0;= 93%), and 31% in ICU patients (95% CI, 0.22-0.42; I<sup>2</sup>&#xa0;= 91%). ICU patients had the highest prevalence of PE among the three groups (17% [95% CI, 0.12-0.23] vs 8% in consecutive patients [95% CI, 0.04-0.13], 4% in non-ICU patients [95% CI, 0.01-0.08]). ICU patients also had the highest DVT prevalence (25% [95% CI, 0.14-0.37] vs 7% in consecutive patients [95% CI, 0.03-0.14], and 7% in non-ICU [95% CI, 0.02-0.14]). The subgroup analysis showed a three-fold improvement in the PE and DVT detection rates in both ICU and non-ICU patients with COVID-19 when the screening test for VTE was applied. In the settings of screening tests for VTE, ICU patients have a significantly higher prevalence of PE (37% vs 10%; P&#xa0;&lt; .0001) and DVT (40% vs 12%; P&#xa0;= .0065) compared with non-ICU patients.</AbstractText><AbstractText Label="CONCLUSIONS">VTE is common in patients hospitalized with COVID-19, especially among ICU patients. Screening tests for PE and DVT may significantly improve detection rates in both ICU and non-ICU patients with COVID-19 than tests based on clinical suspicion.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Leng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xuebin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Baitao</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Shuai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Changwei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: liucw@vip.sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Surg Venous Lymphat Disord</MedlineTA><NlmUniqueID>101607771</NlmUniqueID><ISSNLinking>2213-333X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>14</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>12</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33309903</ArticleId><ArticleId IdType="pmc">PMC7725061</ArticleId><ArticleId IdType="doi">10.1016/j.jvsv.2020.11.023</ArticleId><ArticleId IdType="pii">S2213-333X(20)30654-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Coronavirus disease (COVID-19) pandemic. www.who.int/emergencies/diseases/novel-coronavirus-2019 Available at:</Citation></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D., Kant K.M. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192101</ArticleId><ArticleId IdType="pubmed">32381264</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos A.C., Levy J.H., Ageno W., Connors J.M., Hunt B.J., Iba T. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19. J&#xa0;Thromb Haemost. 2020;18:1859&#x2013;1865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283841</ArticleId><ArticleId IdType="pubmed">32459046</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B., Salanti G., Caldwell D.M., Chaimani A., Schmid C.H., Cameron C. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman D.G., PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med. 2009;6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>JBI  The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews 2017. https://joannabriggs.org/ebp Available at:</Citation></Reference><Reference><Citation>Artifoni M., Danic G., Gautier G., Gicquel P., Boutoille D., Raffi F. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J&#xa0;Thromb Thrombolysis. 2020;50:211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7246965</ArticleId><ArticleId IdType="pubmed">32451823</ArticleId></ArticleIdList></Reference><Reference><Citation>Bavaro D.F., Poliseno M., Scardapane A., Belati A., De Gennaro N., Stabile Ianora A.A. Occurrence of acute pulmonary embolism in COVID-19-a case series. Int J Infect Dis. 2020;98:225&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308752</ArticleId><ArticleId IdType="pubmed">32585286</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T.J., Lee A., Xia Y., Lin L.H., Black M., Cotzia P. Biomarkers of platelet activity and vascular health associate with thrombosis and mortality in patients with COVID-19. Circ Res. 2020;127:945&#x2013;947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478197</ArticleId><ArticleId IdType="pubmed">32757722</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillet F., Behr J., Calame P., Aubry S., Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography. Radiology. 2020;296:E186&#x2013;E188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233384</ArticleId><ArticleId IdType="pubmed">32324103</ArticleId></ArticleIdList></Reference><Reference><Citation>Koleilat I., Galen B., Choinski K., Hatch A.N., Jones D.B., Billett H. Clinical characteristics of acute lower extremity deep venous thrombosis diagnosed by duplex in patients hospitalized for coronavirus disease 2019. J&#xa0;Vasc Surg Venous Lymphat Disord. 2020 Jun 25 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315975</ArticleId><ArticleId IdType="pubmed">32593770</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodigiani C., Iapichino G., Carenzo L., Cecconi M., Ferrazzi P., Sebastian T. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177070</ArticleId><ArticleId IdType="pubmed">32353746</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei F., Fan J., Yuan J., Liang Z., Wang K., Sun J. Comparison of venous thromboembolism risks between COVID-19 pneumonia and community-acquired pneumonia patients. Arterioscler Thromb Vasc Biol. 2020;40:2332&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7446987</ArticleId><ArticleId IdType="pubmed">32628040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre-G&#xf3;mez B., Lorente-Ramos R.M., Rogado J., Franco-Moreno A., Obispo B., Salazar-Chiriboga D. Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis. J&#xa0;Thromb Thrombolysis. 2020 June 29 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7327193</ArticleId><ArticleId IdType="pubmed">32613385</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp S., Coppens M., van Haaps T.F., Foppen M., Vlaar A.P., M&#xfc;ller M.C.A. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J&#xa0;Thromb Haemost. 2020;18:1995&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497052</ArticleId><ArticleId IdType="pubmed">32369666</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll M., Zon R.L., Sylvester K.W., Chen E.C., Cheng V., Connell N.T. VTE in ICU patients with COVID-19. Chest. 2020;158:2130&#x2013;2135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674987</ArticleId><ArticleId IdType="pubmed">32710891</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyiadji N., Cormier P., Patel P.Y., Hadied M.O., Bhargava P., Khanna K. Acute pulmonary embolism and COVID-19. Radiology. 2020;297:E335&#x2013;E338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7706099</ArticleId><ArticleId IdType="pubmed">32407256</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoneham S.M., Milne K.M., Nuttal E., Frew G.H., Sturrock B.R., Sivaloganathan H. Thrombotic risk in COVID-19: a case series and case-control study. Clin Med (Lond) 2020;20:e76&#x2013;e81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385762</ArticleId><ArticleId IdType="pubmed">32423903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Feng X., Zhang D., Jiang C., Mei H., Wang J. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: prevalence, risk factors, and outcome. Circulation. 2020;142:114&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">32421381</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo M., Bertinato E.M., Birocchi S., Brizio C., Malavolta D., Manzoni M. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020;120:1230&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7516356</ArticleId><ArticleId IdType="pubmed">32349132</ArticleId></ArticleIdList></Reference><Reference><Citation>Demelo-Rodr&#xed;guez P., Cervilla-Mu&#xf1;oz E., Ordieres-Ortega L., Parra-Virto A., Toledano-Mac&#xed;as M., Toledo-Samaniego N. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020;192:23&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219400</ArticleId><ArticleId IdType="pubmed">32405101</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgi-Pierfranceschi M., Paoletti O., Pan A., De Gennaro F., Nardecchia A.L., Morandini R. Prevalence of asymptomatic deep vein thrombosis in patients hospitalized with SARS-CoV-2 pneumonia: a cross-sectional study. Intern Emerg Med. 2020;15:1425&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445816</ArticleId><ArticleId IdType="pubmed">32840805</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Jeune S., Suhl J., Benainous R., Minvielle F., Purser C., Foudi F. High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards. J&#xa0;Thromb Thrombolysis. 2020 Aug 18 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7433772</ArticleId><ArticleId IdType="pubmed">32812199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzolo F., Rigoni A.M., De Marchi S., Friso S., Tinazzi E., Sartori G. Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: exploring a submerged portion of the iceberg. Thromb Res. 2020;194:216&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409796</ArticleId><ArticleId IdType="pubmed">33074107</ArticleId></ArticleIdList></Reference><Reference><Citation>Porfidia A., Santoliquido A., Camm&#xe1; G., Porceddu E., Pola R. Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. J&#xa0;Thromb Haemost. 2020;18:31110&#x2013;31111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361278</ArticleId><ArticleId IdType="pubmed">32633068</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharthy A., Faqihi F., Abuhamdah M., Noor A., Naseem N., Balhamar A. Prospective longitudinal evaluation of point-of-care lung ultrasound in critically ill patients with severe COVID-19 pneumonia. J&#xa0;Ultrasound Med. 2020 Aug 14 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436430</ArticleId><ArticleId IdType="pubmed">32797661</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Zhang D., Zheng T., Yu Y., Jiang J. DVT incidence and risk factors in critically ill patients with COVID-19. J&#xa0;Thromb Thrombolysis. 2020 Jun 30 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324310</ArticleId><ArticleId IdType="pubmed">32607652</ArticleId></ArticleIdList></Reference><Reference><Citation>Desborough M.J.R., Doyle A.J., Griffiths A., Retter A., Breen K.A., Hunt B.J. Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom. Thromb Res. 2020;193:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256551</ArticleId><ArticleId IdType="pubmed">32485437</ArticleId></ArticleIdList></Reference><Reference><Citation>Devreese K.M.J., Linskens E.A., Benoit D., Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J&#xa0;Thromb Haemost. 2020;18:2191&#x2013;2201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361253</ArticleId><ArticleId IdType="pubmed">32619328</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandmaison G., Andrey A., P&#xe9;riard D., Engelberger R.P., Carrel G., Doll S. Systematic screening for venous thromboembolic events in COVID-19 pneumonia. TH Open. 2020;4:e113&#x2013;e115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280022</ArticleId><ArticleId IdType="pubmed">32529170</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., Tacquard C., Severac F., Leonard-Lorant I., Ohana M., Delabranche X. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippensteel J.A., Burnham E.L., Jolley S.E. Prevalence of venous thromboembolism in critically ill patients with COVID-19. Br J Haematol. 2020;190:e134&#x2013;e137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300700</ArticleId><ArticleId IdType="pubmed">32484907</ArticleId></ArticleIdList></Reference><Reference><Citation>Ierardi A.M., Coppola A., Fusco S., Stellato E., Aliberti S., Andrisani M.C. Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound? J&#xa0;Ultrasound. 2020 Aug 18 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431752</ArticleId><ArticleId IdType="pubmed">32809207</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D.A.M.P.J., Kant K.M. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Llitjos J.-F., Leclerc M., Chochois C., Monsallier J.-M., Ramakers M., Auvray M. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J&#xa0;Thromb Haemost. 2020;18:1743&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264774</ArticleId><ArticleId IdType="pubmed">32320517</ArticleId></ArticleIdList></Reference><Reference><Citation>Longchamp A., Longchamp J., Manzocchi-Besson S., Whiting L., Haller C., Jeanneret S. Venous thromboembolism in critically ill patients with COVID-19: results of a screening study for deep vein thrombosis. Res Pract Thromb Haemost. 2020;4:842&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272794</ArticleId><ArticleId IdType="pubmed">32685893</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahum J., Morichau-Beauchant T., Daviaud F., Echegut P., Fichet J., Maillet J.M. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19) JAMA Netw Open. 2020;1:e2010478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260620</ArticleId><ArticleId IdType="pubmed">32469410</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel B.V., Arachchillage D.J., Ridge C.A., Bianchi P., Doyle J.F., Garfield B. Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations. Am J Respir Crit Care Med. 2020;202:690&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462405</ArticleId><ArticleId IdType="pubmed">32667207</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavoni V., Gianesello L., Pazzi M., Stera C., Meconi T., Frigieri F.C. Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia. J&#xa0;Thromb Thrombolysis. 2020;50:281&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211560</ArticleId><ArticleId IdType="pubmed">32394236</ArticleId></ArticleIdList></Reference><Reference><Citation>Poissy J., Goutay J., Caplan M., Parmentier E., Duburcq T., Lassalle F. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020;142:184&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">32330083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren B., Yan F., Deng Z., Zhang S., Xiao L., Wu M. Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan. Circulation. 2020;142:181&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">32412320</ArticleId></ArticleIdList></Reference><Reference><Citation>Stessel B., Vanvuchelen C., Bruckers L., Geebelen L., Callebaut I., Vandenbrande J. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: a longitudinal controlled before-after study. Thromb Res. 2020;194:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375318</ArticleId><ArticleId IdType="pubmed">32788120</ArticleId></ArticleIdList></Reference><Reference><Citation>Taccone F.S., Gevenois P.A., Peluso L., Pletchette Z., Lheureux O., Brasseur A. Higher intensity thromboprophylaxis regimens and pulmonary embolism in critically ill coronavirus disease 2019 patients. Crit Care Med. 2020;48:e1087&#x2013;e1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437413</ArticleId><ArticleId IdType="pubmed">32769623</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas W., Varley J., Johnston A., Symington E., Robinson M., Sheares K. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res. 2020;191:76&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182517</ArticleId><ArticleId IdType="pubmed">32402996</ArticleId></ArticleIdList></Reference><Reference><Citation>Voicu S., Bonnin P., Stepanian A., Chousterman B.G., Le Gall A., Malissin I. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients. J&#xa0;Am Coll Cardiol. 2020;76:480&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260513</ArticleId><ArticleId IdType="pubmed">32479784</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Qu Y., Tu J., Cao W., Hai N., Li S. Applicability of bedside ultrasonography for the diagnosis of deep venous thrombosis in patients with COVID-19 and treatment with low molecular weight heparin. J&#xa0;Clin Ultrasound. 2020;48:522&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436732</ArticleId><ArticleId IdType="pubmed">32757278</ArticleId></ArticleIdList></Reference><Reference><Citation>Marone E.M., Rinaldi L.F. Upsurge of deep venous thrombosis in patients affected by COVID-19: Preliminary data and possible explanations. J&#xa0;Vasc Surg Venous Lymphat Disord. 2020;8:694&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7162769</ArticleId><ArticleId IdType="pubmed">32305586</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J&#xa0;Thromb Haemost. 2020;18:844&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J&#xa0;Thromb Haemost. 2020;18:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906401</ArticleId><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J&#xa0;Am Coll Cardiol. 2020;75:2950&#x2013;2973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan S.S., Radford S., Kow C.S., Zaidi S.T.R. Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J&#xa0;Thromb Thrombolysis. 2020;50:814&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7396456</ArticleId><ArticleId IdType="pubmed">32748122</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi G., Lee J.J., Jamil A., Gunnam V., Najafi H., Memar Montazerin S. Venous thromboembolism among hospitalized patients with COVID-19 undergoing thromboprophylaxis: a systematic review and meta-analysis. J&#xa0;Clin Med. 2020;9:2489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7463975</ArticleId><ArticleId IdType="pubmed">32756383</ArticleId></ArticleIdList></Reference><Reference><Citation>Porfidia A., Valeriani E., Pola R., Porreca E., Rutjes A.W.S., Di Nisio M. Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb Res. 2020;196:67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7420982</ArticleId><ArticleId IdType="pubmed">32853978</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagadaki O., Birbas K., Mariolis T., Baltopoulos G., Myrianthefs P. Necessity of the periodical ultrasound assessment of the peripheral venous system in intensive care unit patients. Ultrasound Med Biol. 2019;45:367&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">30583820</ArticleId></ArticleIdList></Reference><Reference><Citation>Costanzo L., Palumbo F.P., Ardita G., Antignani P.L., Arosio E., Failla G. Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia. J&#xa0;Vasc Surg Venous Lymphat Disord. 2020;8:711&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7297687</ArticleId><ArticleId IdType="pubmed">32561465</ArticleId></ArticleIdList></Reference><Reference><Citation>Palareti G., Antonucci E., Dentali F., Mastroiacovo D., Mumoli N., Pengo V. Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution. Eur J Intern Med. 2019;69:64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">31500936</ArticleId></ArticleIdList></Reference><Reference><Citation>Criel M., Falter M., Jaeken J., Van Kerrebroeck M., Lefere I., Meylaerts L. Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? Eur Respir J. 2020;56:2001201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236825</ArticleId><ArticleId IdType="pubmed">32398294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichmann D., Sperhake J.-P., L&#xfc;tgehetmann M., Steurer S., Edler C., Heinemann A. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173:268&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240772</ArticleId><ArticleId IdType="pubmed">32374815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28159170</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-6259</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Annals of thoracic surgery</Title><ISOAbbreviation>Ann Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Surgical Embolectomy for Acute Pulmonary Embolism: Systematic Review and Comprehensive Meta-Analyses.</ArticleTitle><Pagination><StartPage>982</StartPage><EndPage>990</EndPage><MedlinePgn>982-990</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.athoracsur.2016.11.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0003-4975(16)31618-6</ELocationID><Abstract><AbstractText>Surgical pulmonary embolectomy (SPE) is a viable treatment approach for subsets of patients with acute pulmonary embolism. However, outcomes data are limited. We sought to characterize mortality and safety outcomes for this population. Studies reporting inhospital mortality for patients undergoing SPE for acute pulmonary embolism were included. In 56 eligible studies, we found 1,579 patients who underwent 1,590 SPE operations. The pooled inhospital all-cause mortality rate was 26.3% (95% confidence interval: 22.5% to 30.5%). Surgical site complications occurred in 7.0% of operations (95% confidence interval: 4.9% to 9.8%). More investigation is required to define the patient population that would benefit the most from SPE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Rajat</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, and Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajaj</LastName><ForeName>Navkaranbir S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama; Division of Cardiovascular Medicine and Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Pankaj</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Garima</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crosland</LastName><ForeName>William A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGiffin</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Alfred Hospital and Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Mustafa I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Baptist Princeton, Birmingham, Alabama. Electronic address: musiahm@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ann Thorac Surg</MedlineTA><NlmUniqueID>15030100R</NlmUniqueID><ISSNLinking>0003-4975</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017128" MajorTopicYN="N">Embolectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28159170</ArticleId><ArticleId IdType="doi">10.1016/j.athoracsur.2016.11.016</ArticleId><ArticleId IdType="pii">S0003-4975(16)31618-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36416696</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1536-3708</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Annals of plastic surgery</Title><ISOAbbreviation>Ann Plast Surg</ISOAbbreviation></Journal><ArticleTitle>Pulmonary Embolism Risk After Cosmetic Abdominoplasty and Functional Panniculectomy.</ArticleTitle><Pagination><StartPage>664</StartPage><EndPage>669</EndPage><MedlinePgn>664-669</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SAP.0000000000003281</ELocationID><Abstract><AbstractText Label="BACKGROUND">Tighter abdominal wall reconstruction may increase intra-abdominal pressure, which can decrease lower extremity venous return. Decreased venous return through the inferior vena cava has been demonstrated to increase risk of deep vein thrombosis.</AbstractText><AbstractText Label="OBJECTIVES">Tighter abdominal wall plication during cosmetic abdominoplasty compared with functional panniculectomy may increase these risks. The purpose of this study was to determine whether cosmetic abdominoplasty increases risk for thromboembolic events compared with functional panniculectomy.</AbstractText><AbstractText Label="METHODS">Retrospective cohort study was conducted using the National Surgical Quality Improvement Program database for excision of excessive subcutaneous infraumbilical skin and soft tissue at participating hospitals between 2015 and 2019. Procedures performed for cosmetic abdominoplasty versus functional panniculectomy were compared for occurrences of postoperative pulmonary embolism (PE).</AbstractText><AbstractText Label="RESULTS">During the study interval, 11,137 patients underwent excision of excessive infraumbilical abdominal skin, including 57.4% (n = 6397) patients undergoing functional panniculectomy and 42.6% (n = 4740) patients undergoing cosmetic abdominoplasty. Patients undergoing functional panniculectomy were significantly more likely to have comorbidities than those undergoing cosmetic abdominoplasty ( P &lt; 0.001). The risk for postoperative PE was independently associated with cosmetic abdominoplasty ( P &lt; 0.001), elevated body mass index ( P = 0.001), preoperative recent weight loss ( P = 0.006), and concurrent hernia repair ( P = 0.049). Most PE events occurred outpatient after discharge (87.2%), and the average postoperative time from surgery until PE was 10.5 &#xb1; 6.7 days.</AbstractText><AbstractText Label="CONCLUSIONS">Cosmetic abdominoplasty has greater than 4 times the risk of postoperative PE than functional panniculectomy. Risk of PE is further increased by concurrent hernia repair, elevated body mass index, and rapid weight loss in the immediate preoperative period. It may be advisable to caution patients to delay abdominal excisional body contouring procedures until their weight has plateaued.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kalmar</LastName><ForeName>Christopher L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>From the Department of Plastic Surgery, Vanderbilt University Medical Center, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thayer</LastName><ForeName>Wesley P</ForeName><Initials>WP</Initials></Author><Author ValidYN="Y"><LastName>Kassis</LastName><ForeName>Salam</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Higdon</LastName><ForeName>Kent K</ForeName><Initials>KK</Initials></Author><Author ValidYN="Y"><LastName>Perdikis</LastName><ForeName>Galen</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Plast Surg</MedlineTA><NlmUniqueID>7805336</NlmUniqueID><ISSNLinking>0148-7043</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061645" MajorTopicYN="Y">Abdominoplasty</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015187" MajorTopicYN="Y">Lipectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015431" MajorTopicYN="N">Weight Loss</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of interest and sources of funding: none declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36416696</ArticleId><ArticleId IdType="doi">10.1097/SAP.0000000000003281</ArticleId><ArticleId IdType="pii">00000637-202212000-00019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talisman R, Kaplan B, Haik J, et al. Measuring alterations in intra-abdominal pressure during abdominoplasty as a predictive value for possible postoperative complications. Aesthetic Plast Surg . 2002;26:189&#x2013;192.</Citation></Reference><Reference><Citation>Al-Basti HB, El-Khatib HA, Taha A, et al. Intraabdominal pressure after full abdominoplasty in obese multiparous patients. Plast Reconstr Surg . 2004;113:2145&#x2013;2150; discussion 2151&#x2013;2155.</Citation></Reference><Reference><Citation>Meldrum DR, Moore FA, Moore EE, et al. Prospective characterization and selective management of the abdominal compartment syndrome. Am J Surg . 1997;174:667&#x2013;672; discussion 672&#x2013;673.</Citation></Reference><Reference><Citation>Kashtan J, Green JF, Parsons EQ, et al. Hemodynamic effect of increased abdominal pressure. J Surg Res . 1981;30:249&#x2013;255.</Citation></Reference><Reference><Citation>Pereira N, Sciaraffia C, Danilla S, et al. Effects of abdominoplasty on intra-abdominal pressure and pulmonary function. Aesthet Surg J . 2016;36:697&#x2013;702.</Citation></Reference><Reference><Citation>Preventing Hospital-Acquired Venous Thromboembolism: A Guide for Effective Quality Improvement. November 3, 2021. Available at: https://www.mnhospitals.org/Portals/0/Documents/ptsafety/vte/vtguide.pdf . Accessed November 3, 2021.</Citation></Reference><Reference><Citation>Allman-Farinelli MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost . 2011;37:903&#x2013;907.</Citation></Reference><Reference><Citation>Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: a bench to bedside review. Thromb Res . 2020;192:40&#x2013;51.</Citation></Reference><Reference><Citation>Hotoleanu C. Association between obesity and venous thromboembolism. Med Pharm Rep . 2020;93:162&#x2013;168.</Citation></Reference><Reference><Citation>Blokhin IO, Lentz SR. Mechanisms of thrombosis in obesity. Curr Opin Hematol . 2013;20:437&#x2013;444.</Citation></Reference><Reference><Citation>Yang G, De Staercke C, Hooper WC. The effects of obesity on venous thromboembolism: a review. Open J Prev Med . 2012;2:499&#x2013;509.</Citation></Reference><Reference><Citation>Borch KH, Braekkan SK, Mathiesen EB, et al. Anthropometric measures of obesity and risk of venous thromboembolism: the Tromso study. Arterioscler Thromb Vasc Biol . 2010;30:121&#x2013;127.</Citation></Reference><Reference><Citation>Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis . 2016;41:3&#x2013;14.</Citation></Reference><Reference><Citation>ESHRE Capri Workshop Group. Venous thromboembolism in women: a specific reproductive health risk. Hum Reprod Update . 2013;19:471&#x2013;482.</Citation></Reference><Reference><Citation>Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med . 1999;159:445&#x2013;453.</Citation></Reference><Reference><Citation>Winocour J, Gupta V, Ramirez JR, et al. Abdominoplasty: risk factors, complication rates, and safety of combined procedures. Plast Reconstr Surg . 2015;136:597e&#x2013;606e.</Citation></Reference><Reference><Citation>Winocour J, Gupta V, Kaoutzanis C, et al. Venous thromboembolism in the cosmetic patient: analysis of 129,007 patients. Aesthet Surg J . 2017;37:337&#x2013;349.</Citation></Reference><Reference><Citation>Blaser AR, Bjorck M, De Keulenaer B, et al. Abdominal compliance: a bench-to-bedside review. J Trauma Acute Care Surg . 2015;78:1044&#x2013;1053.</Citation></Reference><Reference><Citation>Malbrain ML, Cheatham ML, Kirkpatrick A, et al. Results from the international conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. Intensive Care Med . 2006;32:1722&#x2013;1732.</Citation></Reference><Reference><Citation>Mabud TS, Sailer AM, Swee JKY, et al. Inferior vena cava atresia: characterisation of risk factors, treatment, and outcomes. Cardiovasc Intervent Radiol . 2020;43:37&#x2013;45.</Citation></Reference><Reference><Citation>Tufano A, Lopez-Jimenez L, Bikdeli B, et al., RIETE Investigators. Inferior vena cava agenesis in patients with lower limb deep vein thrombosis in the RIETE registry. When and why to suspect. Int J Cardiol . 2020;305:115&#x2013;119.</Citation></Reference><Reference><Citation>Angelici AM, Perotti B, Dezzi C, et al. Measurement of intra-abdominal pressure in large incisional hernia repair to prevent abdominal compartmental syndrome. G Chir . 2016;37:31&#x2013;36.</Citation></Reference><Reference><Citation>Mavrodin CI, Pariza G, Ion D, et al. Abdominal compartment syndrome&#x2014;a major complication of large incisional hernia surgery. Chirurgia (Bucur) . 2013;108:414&#x2013;417.</Citation></Reference><Reference><Citation>Petro CC, Raigani S, Fayezizadeh M, et al. Permissible intraabdominal hypertension following complex abdominal wall reconstruction. Plast Reconstr Surg . 2015;136:868&#x2013;881.</Citation></Reference><Reference><Citation>Kirkpatrick AW, Roberts DJ, De Waele J, et al; Executive Committee of the WSACS&#x2013;Abdominal Compartment Society. Permissive intraabdominal hypertension following complex abdominal wall reconstruction. Plast Reconstr Surg . 2016;137:762e&#x2013;764e.</Citation></Reference><Reference><Citation>Chandra R, Jacobson RA, Poirier J, et al. Successful non-operative management of intraabdominal hypertension and abdominal compartment syndrome after complex ventral hernia repair: a case series. Am J Surg . 2018;216:819&#x2013;823.</Citation></Reference><Reference><Citation>Mantilla CB, Horlocker TT, Schroeder DR, et al. Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty. Anesthesiology . 2003;99:552&#x2013;560; discussion 5A.</Citation></Reference><Reference><Citation>Lee KC, Chung KC, Chen HH, et al. The impact of obesity on postoperative outcomes in colorectal cancer patients: a retrospective database study. Support Care Cancer . 2022;30:2151&#x2013;2161.</Citation></Reference><Reference><Citation>Aasheim ET, Bjorkman S, Sovik TT, et al. Vitamin status after bariatric surgery: a randomized study of gastric bypass and duodenal switch. Am J Clin Nutr . 2009;90:15&#x2013;22.</Citation></Reference><Reference><Citation>Gowanlock Z, Lezhanska A, Conroy M, et al. Iron deficiency following bariatric surgery: a retrospective cohort study. Blood Adv . 2020;4:3639&#x2013;3647.</Citation></Reference><Reference><Citation>Lewis CA, de Jersey S, Seymour M, et al. Iron, vitamin B12, folate and copper deficiency after bariatric surgery and the impact on anaemia: a systematic review. Obes Surg . 2020;30:4542&#x2013;4591.</Citation></Reference><Reference><Citation>Majumder S, Soriano J, Louie Cruz A, et al. Vitamin B12 deficiency in patients undergoing bariatric surgery: preventive strategies and key recommendations. Surg Obes Relat Dis . 2013;9:1013&#x2013;1019.</Citation></Reference><Reference><Citation>Poitou Bernert C, Ciangura C, Coupaye M, et al. Nutritional deficiency after gastric bypass: diagnosis, prevention and treatment. Diabetes Metab . 2007;33:13&#x2013;24.</Citation></Reference><Reference><Citation>Sloan M, Sheth N, Lee GC. Is obesity associated with increased risk of deep vein thrombosis or pulmonary embolism after hip and knee arthroplasty? A large database study. Clin Orthop Relat Res . 2019;477:523&#x2013;532.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37796296</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">0942-0940</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Acta neurochirurgica</Title><ISOAbbreviation>Acta Neurochir (Wien)</ISOAbbreviation></Journal><ArticleTitle>Thromboembolic prophylaxis in neurosurgical practice: a systematic review.</ArticleTitle><Pagination><StartPage>3119</StartPage><EndPage>3135</EndPage><MedlinePgn>3119-3135</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00701-023-05792-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">In neurosurgical patients, the risk of developing venous thromboembolism (VTE) is high due to the relatively long duration of surgical interventions, usually long immobilization time after surgery, and possible neurological deficits which can negatively influence mobility. In neurosurgical clinical practice, there is lack of consensus on optimal prophylaxis against VTE, mechanical or pharmacological.</AbstractText><AbstractText Label="OBJECTIVE">To systematically review available literature on the incidence of VTE in neurosurgical interventions and to establish an optimum prevention strategy.</AbstractText><AbstractText Label="METHODS">A literature search was performed in PubMed, Embase, Web of Science, Cochrane Library, and EmCare, based on a sensitive search string combination. Studies were selected by predefined selection criteria, and risk of bias was assessed by Newcastle-Ottawa Quality Assessment Scale and Cochrane risk of bias.</AbstractText><AbstractText Label="RESULTS">Twenty-five studies were included, half of which had low risk of bias (21 case series, 3 comparative studies, 1 RCT). VTE was substantially higher if the evaluation was done by duplex ultrasound (DUS), or another systematic screening method, in comparison to clinical evaluation (clin). Without prophylaxis DVT, incidence varied from 4 (clin) to 10% (DUS), studies providing low molecular weight heparin (LMWH) reported an incidence of 2 (clin) to 31% (DUS), providing LMWH and compression stockings (CS) reported an incidence of 6.4% (clin) to 29.8% (DUS), and providing LMWH and intermittent pneumatic compression devices (IPC) reported an incidence of 3 (clin) to 22.3% (DUS). Due to a lack of data, VTE incidence could not meaningfully be compared between patients with intracranial and spine surgery. The reported incidence of pulmonary embolism (PE) was 0 to 7.9%.</AbstractText><AbstractText Label="CONCLUSION">Low molecular weight heparin, compression stockings, and intermittent pneumatic compression devices were all evaluated to give reduction in VTE, but data were too widely varying to establish an optimum prevention strategy. Systematic screening for DVT reveals much higher incidence percentages in comparison to screening solely on clinical grounds and is recommended in follow-up of neurosurgical procedures with an increased risk for DVT development in order to prevent occurrence of PE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhaoyuan</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-7986-5685</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. z.zhang@lumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Husule</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vleggeert-Lankamp</LastName><ForeName>Carmen L A</ForeName><Initials>CLA</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Leiden University Medical Centre, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spaarne Hospital, Hoofddorp, Haarlem, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Acta Neurochir (Wien)</MedlineTA><NlmUniqueID>0151000</NlmUniqueID><ISSNLinking>0001-6268</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neurosurgery</Keyword><Keyword MajorTopicYN="N">Postoperative complications</Keyword><Keyword MajorTopicYN="N">Prevention and control</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>5</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37796296</ArticleId><ArticleId IdType="pmc">PMC10624710</ArticleId><ArticleId IdType="doi">10.1007/s00701-023-05792-3</ArticleId><ArticleId IdType="pii">10.1007/s00701-023-05792-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Agarwal N, Zenonos GA, Agarwal P, Walch FJ, Roach E, Stokes SJ, Friedlander RM, Gerszten PC. Risk-to-benefit ratio of venous thromboembolism prophylaxis for neurosurgical procedures at a quaternary referral center. Neurosurgery. 2019;84:355&#x2013;361. doi: 10.1093/neuros/nyy035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuros/nyy035</ArticleId><ArticleId IdType="pubmed">29538700</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Dujaili TM, Majer CN, Madhoun TE, Kassis SZ, Saleh AA. Deep venous thrombosis in spine surgery patients: incidence and hematoma formation. Int Surg. 2012;97(2):150&#x2013;154. doi: 10.9738/CC71.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.9738/CC71.1</ArticleId><ArticleId IdType="pmc">PMC3723201</ArticleId><ArticleId IdType="pubmed">23102081</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali NES, Alyono JC, Song Y, Kouhi A, Blevins NH. Postoperative venous thromboembolism after neurotologic surgery. J Neurol Surg Part B: Skull Base. 2021;82(3):378&#x2013;382. doi: 10.1055/s-0039-3400223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-3400223</ArticleId><ArticleId IdType="pmc">PMC8133807</ArticleId><ArticleId IdType="pubmed">34026416</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002;4:465&#x2013;473. doi: 10.1038/sj.neo.7900263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.neo.7900263</ArticleId><ArticleId IdType="pmc">PMC1550339</ArticleId><ArticleId IdType="pubmed">12407439</ArticleId></ArticleIdList></Reference><Reference><Citation>Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51:70&#x2013;78. doi: 10.1016/j.disamonth.2005.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.disamonth.2005.02.003</ArticleId><ArticleId IdType="pubmed">15900257</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrabba G, Riva M, Conte V, Di Cristofori A, Caroli M, Locatelli M, Castellani M, Bucciarelli P, Artoni A, Stocchetti N, Martinelli I, Rampini P. Risk of post-operative venous thromboembolism in patients with meningioma. J Neurooncol. 2018;138:401&#x2013;406. doi: 10.1007/s11060-018-2810-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11060-018-2810-z</ArticleId><ArticleId IdType="pubmed">29500662</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaichana KL, Pendleton C, Jackson C, Martinez-Gutierrez JC, Diaz-Stransky A, Aguayo J, Olivi A, Weingart J, Gallia G, Lim M, Brem H, Quinones-Hinojosa A. Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. Neurol Res. 2013;35:206&#x2013;211. doi: 10.1179/1743132812y.0000000126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1743132812y.0000000126</ArticleId><ArticleId IdType="pmc">PMC3991124</ArticleId><ArticleId IdType="pubmed">23336127</ArticleId></ArticleIdList></Reference><Reference><Citation>Chibbaro S, Cebula H, Todeschi J, Fricia M, Vigouroux D, Abid H, Kourbanhoussen H, Pop R, Nannavecchia B, Gubian A, Prisco L, Ligarotti GKI, Proust F, Ganau M. Evolution of prophylaxis protocols for venous thromboembolism in neurosurgery: results from a prospective comparative study on low-molecular-weight heparin, elastic stockings, and intermittent pneumatic compression devices. World Neurosurg. 2018;109:e510&#x2013;e516. doi: 10.1016/j.wneu.2017.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2017.10.012</ArticleId><ArticleId IdType="pubmed">29033376</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloney MB, Goergen J, Hopkins BS, Dhillon ES, Dahdaleh NS. Factors associated with venous thromboembolic events following ICU admission in patients undergoing spinal surgery: an analysis of 1269 consecutive patients. J Neurosurg Spine. 2018;30:99&#x2013;105. doi: 10.3171/2018.5.Spine171027.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2018.5.Spine171027</ArticleId><ArticleId IdType="pubmed">30485211</ArticleId></ArticleIdList></Reference><Reference><Citation>Daley MJ, Ali S, Brown CV. Late venous thromboembolism prophylaxis after craniotomy in acute traumatic brain injury. Am Surg. 2015;81:207&#x2013;211. doi: 10.1177/000313481508100236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000313481508100236</ArticleId><ArticleId IdType="pubmed">25642886</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermody M, Alessi-Chinetti J, Iafrati MD, Estes JM. The utility of screening for deep venous thrombosis in asymptomatic, non-ambulatory neurosurgical patients. J Vasc Surg. 2011;53:1309&#x2013;1315. doi: 10.1016/j.jvs.2010.10.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvs.2010.10.115</ArticleId><ArticleId IdType="pubmed">21215569</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon ES, Khanna R, Cloney M, Roberts H, Cybulski GR, Koski TR, Smith ZA, Dahdaleh NS. Timing and risks of chemoprophylaxis after spinal surgery: a single-center experience with 6869 consecutive patients. J Neurosurg Spine. 2017;27:681&#x2013;693. doi: 10.3171/2017.3.Spine161076.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2017.3.Spine161076</ArticleId><ArticleId IdType="pubmed">28885127</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebeling M, L&#xfc;demann W, Frisius J, Karst M, Schedel I, Gerganov V, Samii A, Fahlbusch R. Venous thromboembolic complications with and without intermittent intraoperative and postoperative pneumatic compression in patients with glioblastoma multiforme using intraoperative magnetic resonance imaging. A retrospective study Neurochirurgie. 2018;64:161&#x2013;165. doi: 10.1016/j.neuchi.2018.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuchi.2018.04.007</ArticleId><ArticleId IdType="pubmed">29859696</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenring CV, Neidert MC, Saban&#xe9;sBov&#xe9; D, Held L, Sarnthein J, Krayenb&#xfc;hl N. Reduction of thromboembolic events in meningioma surgery: a cohort study of 724 consecutive patients. PLoS One. 2013;8:e79170. doi: 10.1371/journal.pone.0079170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0079170</ArticleId><ArticleId IdType="pmc">PMC3828295</ArticleId><ArticleId IdType="pubmed">24244441</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:381s-453s. 10.1378/chest.08-0656</Citation><ArticleIdList><ArticleId IdType="pubmed">18574271</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo F, Shashikiran T, Chen X, Yang L, Liu X, Song L. Clinical features and risk factor analysis for lower extremity deep venous thrombosis in Chinese neurosurgical patients. J Neurosci Rural Pract. 2015;6:471&#x2013;476. doi: 10.4103/0976-3147.169801.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0976-3147.169801</ArticleId><ArticleId IdType="pmc">PMC4692000</ArticleId><ArticleId IdType="pubmed">26752303</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton MG, Hull RD, Pineo GF (1994) Venous thromboembolism in neurosurgery and neurology patients: a review. Neurosurgery 34:280&#x2013;296; discussion 296. 10.1227/00006123-199402000-00012</Citation><ArticleIdList><ArticleId IdType="pubmed">8177390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoefnagel D, Kwee LE, Van Putten EHP, Kros JM, Dirven CMF, Dammers R. The incidence of postoperative thromboembolic complications following surgical resection of intracranial meningioma. A retrospective study of a large single center patient cohort. Clin Neurol Neurosurg. 2014;123:150&#x2013;154. doi: 10.1016/j.clineuro.2014.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2014.06.001</ArticleId><ArticleId IdType="pubmed">24956544</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda T, Miyamoto H, Hashimoto K, Akagi M. Predictable factors of deep venous thrombosis in patients undergoing spine surgery. J Orthop Sci. 2017;22:197&#x2013;200. doi: 10.1016/j.jos.2016.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jos.2016.11.014</ArticleId><ArticleId IdType="pubmed">28190568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaewborisutsakul A, Tunthanathip T, Yuwakosol P, Inkate S, Pattharachayakul S. Incidence and risk factors for venous thromboembolism following craniotomy for intracranial tumors: a cohort study. Asian J Neurosurg. 2020;15:31&#x2013;38. doi: 10.4103/ajns.AJNS_351_19.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ajns.AJNS_351_19</ArticleId><ArticleId IdType="pmc">PMC7057881</ArticleId><ArticleId IdType="pubmed">32181170</ArticleId></ArticleIdList></Reference><Reference><Citation>Karsy M, Azab MA, Harper J, Abou-Al-Shaar H, Guan J, Eli I, Brock AA, Ormond RD, Hosokawa PW, Gouripeddi R, Butcher R, Cole CD, Menacho ST, Couldwell WT. Evaluation of a D-dimer protocol for detection of venous thromboembolism. World Neurosurgery. 2020;133:E774&#x2013;E783. doi: 10.1016/j.wneu.2019.09.160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2019.09.160</ArticleId><ArticleId IdType="pubmed">31605841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107:I22&#x2013;30. doi: 10.1161/01.Cir.0000078464.82671.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.Cir.0000078464.82671.78</ArticleId><ArticleId IdType="pubmed">12814982</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S&#x2013;e496S. doi: 10.1378/chest.11-2301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2301</ArticleId><ArticleId IdType="pmc">PMC3278049</ArticleId><ArticleId IdType="pubmed">22315268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimmell KT, Jahromi BS. Clinical factors associated with venous thromboembolism risk in patients undergoing craniotomy. J Neurosurg. 2015;122:1004&#x2013;1011. doi: 10.3171/2014.10.Jns14632.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2014.10.Jns14632</ArticleId><ArticleId IdType="pubmed">25495743</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Ren X, Zhu X, Chen H, Lin Z, Huang M, Gu Z. Clinical predictive factors of lower extremity deep vein thrombosis in relative high-risk patients after neurosurgery: a retrospective study. Dis Markers. 2020;2020:5820749. doi: 10.1155/2020/5820749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5820749</ArticleId><ArticleId IdType="pmc">PMC7294362</ArticleId><ArticleId IdType="pubmed">32587639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukassen J, Groen J, Jacobs W, Vleggeert-Lankamp C. Thromboembolic prophylaxis in neurosurgical practice: a review. J Spine. 2015;4:2. doi: 10.4172/2165-7939.1000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2165-7939.1000199</ArticleId></ArticleIdList></Reference><Reference><Citation>Mammen EF. Pathogenesis of venous thrombosis. Chest. 1992;102:640s&#x2013;644s. doi: 10.1378/chest.102.6_supplement.640s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.102.6_supplement.640s</ArticleId><ArticleId IdType="pubmed">1451539</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda EM, Kistner RL. The case for managing calf vein thrombi with duplex surveillance and selective anticoagulation. Dis Mon. 2010;56:601&#x2013;613. doi: 10.1016/j.disamonth.2010.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.disamonth.2010.06.011</ArticleId><ArticleId IdType="pubmed">20971331</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med. 1981;94:439&#x2013;444. doi: 10.7326/0003-4819-94-4-439.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-94-4-439</ArticleId><ArticleId IdType="pubmed">7212500</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano F, Matsubara T, Ishigaki T, Hatazaki S, Mouri G, Nakatsuka Y, Suzuki H. Incidence and risk factor of deep venous thrombosis in patients undergoing craniotomy for brain tumors: a Japanese single-center, retrospective study. Thromb Res. 2018;165:95&#x2013;100. doi: 10.1016/j.thromres.2018.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2018.03.016</ArticleId><ArticleId IdType="pubmed">29605752</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr&#xf3;bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Palareti G, Cosmi B, Lessiani G, Rodorigo G, Guazzaloca G, Brusi C, Valdr&#xe9; L, Conti E, Sartori M, Legnani C. Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. Thromb Haemost. 2010;104:1063&#x2013;1070. doi: 10.1160/th10-06-0351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/th10-06-0351</ArticleId><ArticleId IdType="pubmed">20694281</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Lee KE, Yu YM, Park YH, Choi SA. Incidence and risk factors for venous thromboembolism after spine surgery in Korean patients. World Neurosurg. 2019;128:e289&#x2013;e307. doi: 10.1016/j.wneu.2019.04.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2019.04.140</ArticleId><ArticleId IdType="pubmed">31028984</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AP, Koltz MT, Sansur CA, Gulati M, Hamilton DK. An analysis of deep vein thrombosis in 1277 consecutive neurosurgical patients undergoing routine weekly ultrasonography. J Neurosurg. 2013;118:505&#x2013;509. doi: 10.3171/2012.11.Jns121243.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2012.11.Jns121243</ArticleId><ArticleId IdType="pubmed">23240698</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell J, Schenk G, Taute BM, Scheller C, Marquart C, Strauss C, Rampp S (2018) Reduced risk of venous thromboembolism with the use of intermittent pneumatic compression after craniotomy: a randomized controlled prospective study. J Neurosurg:1&#x2013;7. 10.3171/2017.9.Jns17533</Citation><ArticleIdList><ArticleId IdType="pubmed">29600912</ArticleId></ArticleIdList></Reference><Reference><Citation>Rethinasamy R, Alias A, Kandasamy R, Raffiq A, Looi MC, Hillda T. Deep vein thrombosis and the neurosurgical patient. Malaysian J Med Sci. 2019;26(5):139&#x2013;147. doi: 10.21315/mjms2019.26.5.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.21315/mjms2019.26.5.13</ArticleId><ArticleId IdType="pmc">PMC6839661</ArticleId><ArticleId IdType="pubmed">31728126</ArticleId></ArticleIdList></Reference><Reference><Citation>Righini M, Paris S, Le Gal G, Laroche JP, Perrier A, Bounameaux H. Clinical relevance of distal deep vein thrombosis. Rev Lit Data Thromb Haemost. 2006;95:56&#x2013;64. doi: 10.1160/TH05-08-0588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH05-08-0588</ArticleId><ArticleId IdType="pubmed">16543962</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldo L, Brown DA, Bhargav AG, Rusheen AE, Naylor RM, Gilder HE, Monie DD, Youssef SJ, Parney IF. Venous thromboembolic events in patients undergoing craniotomy for tumor resection: incidence, predictors, and review of literature. J Neurosurg. 2019;132:10&#x2013;21. doi: 10.3171/2018.7.Jns181175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2018.7.Jns181175</ArticleId><ArticleId IdType="pmc">PMC6609511</ArticleId><ArticleId IdType="pubmed">30611138</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolston JD, Han SJ, Bloch O, Parsa AT. What clinical factors predict the incidence of deep venous thrombosis and pulmonary embolism in neurosurgical patients? J Neurosurg. 2014;121:908&#x2013;918. doi: 10.3171/2014.6.Jns131419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2014.6.Jns131419</ArticleId><ArticleId IdType="pubmed">25084467</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel S, Patel N, McGuire MF, Salazar M, Nguyen T. Analysis of venous thromboembolism in neurosurgical patients undergoing standard versus routine ultrasonography. J Thromb Thrombolysis. 2019;47:209&#x2013;215. doi: 10.1007/s11239-018-1761-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-018-1761-8</ArticleId><ArticleId IdType="pubmed">30392138</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S, Cheng J, Chen H, Zhang Y, Zhao Y, Wang B. Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: a Chinese single-center, retrospective study. Thromb Res. 2020;196:245&#x2013;250. doi: 10.1016/j.thromres.2020.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.09.005</ArticleId><ArticleId IdType="pubmed">32919179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sj&#xe5;vik K, Bartek J, Jr, Solheim O, Ingebrigtsen T, Gulati S, Sagberg LM, F&#xf6;rander P, Jakola AS. Venous thromboembolism prophylaxis in meningioma surgery: a population-based comparative effectiveness study of routine mechanical prophylaxis with or without preoperative low-molecular-weight heparin. World Neurosurg. 2016;88:320&#x2013;326. doi: 10.1016/j.wneu.2015.12.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2015.12.077</ArticleId><ArticleId IdType="pubmed">26746334</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith TR, Lall RR, Graham RB, McClendon J, Jr, Lall RR, Nanney AD, Adel JG, Zakarija A, Chandler JP. Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period. J Neurooncol. 2014;120:347&#x2013;352. doi: 10.1007/s11060-014-1557-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11060-014-1557-4</ArticleId><ArticleId IdType="pubmed">25062669</ArticleId></ArticleIdList></Reference><Reference><Citation>Stecker M, Michel K, Antaky K, Cherian S, Koyfmann F. Risk factors for DVT/PE in patients with stroke and intracranial hemorrhage. Open Neurol J. 2014;8:1&#x2013;6. doi: 10.2174/1874205x01408010001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874205x01408010001</ArticleId><ArticleId IdType="pmc">PMC4021206</ArticleId><ArticleId IdType="pubmed">24847389</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK. Antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160:e545&#x2013;e608. doi: 10.1016/j.chest.2021.07.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.07.055</ArticleId><ArticleId IdType="pubmed">34352278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells G SB, O&#x2019;Connell D, Peterson J, Welch V, Losos M, Tugwell P (2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.</Citation></Reference><Reference><Citation>Yun R, Sciubba DM, Lewin JJ, 3rd, Streiff MB, Haut ER, Lau BD, Shermock KM, Kraus PS, Popoola VO, Dalpoas SE. Defects in processes of care for pharmacologic prophylaxis are common among neurosurgery patients who develop in-hospital postoperative venous thromboembolism. World Neurosurg. 2020;134:e664&#x2013;e671. doi: 10.1016/j.wneu.2019.10.163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2019.10.163</ArticleId><ArticleId IdType="pubmed">31698120</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40522505</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1438-8359</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jun</Month><Day>16</Day></PubDate></JournalIssue><Title>Journal of anesthesia</Title><ISOAbbreviation>J Anesth</ISOAbbreviation></Journal><ArticleTitle>Norepinephrine vs. phenylephrine for spinal hypotension in cesarean section: a network meta-analysis.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00540-025-03528-4</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Postspinal hypotension (PSH) during cesarean section (CS) often causes maternal intraoperative nausea and vomiting (IONV) and fetal acidosis. Phenylephrine (PE) and norepinephrine (NE) are commonly used for management; however, the optimal agent and method (bolus vs. infusion) remains uncertain. This review assessed bolus and infusion of PE and NE for IONV and PSH during CS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Systematic searches of MEDLINE, Embase, CENTRAL, and unpublished studies identified randomized controlled trials (RCTs) on PE and NE administration during CS under spinal anesthesia. Primary outcomes included IONV and PSH, whereas secondary outcomes encompassed Apgar scores, umbilical artery pH, rescue vasopressor bolus requirements, and adverse events. A random-effects meta-analysis and the Confidence in Network Meta-Analysis tool were utilized.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 74 RCTs (7798 patients), NE and PE infusion reduced IONV compared with PE bolus (risk ratio [RR]: 0.47; 95% confidence interval [CI] 0.34-0.66; RR: 0.54; 95% CI 0.42-0.69, high confidence). Similarly, these approaches reduced PSH (NE infusion: RR: 0.25; 95% CI 0.21-0.31, high confidence; PE infusion: RR: 0.29; 95% CI 0.24-0.34, moderate confidence). Rescue vasopressor bolus requirements showed a similar trend. Apgar scores and umbilical artery pH were comparable across all groups. Adverse event varied, with bradycardia more common with PE, tachycardia with boluses, and dizziness with PE bolus. Hypertension was more frequent with infusions. In prophylactic studies, hypotension trends persisted, but no differences were observed in IONV.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Prophylactic continuous infusion appears to be a favorable strategy for managing PSH and IONV during CS. No significant difference was observed between PE and NE infusions in preventing PSH and IONV.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s) under exclusive licence to Japanese Society of Anesthesiologists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Imai</LastName><ForeName>Eriya</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-4511-4672</Identifier><AffiliationInfo><Affiliation>Department of Social Medical Sciences, Graduate School of Medicine, International University of Health and Welfare, Minato City, Tokyo, Japan. eriyaimai74@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Anesthesia, Mitsui Memorial Hospital, Chiyoda City, Tokyo, Japan. eriyaimai74@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan. eriyaimai74@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Clinical Epidemiology, Department of Community Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Healthcare Epidemiology, Graduate School of Medicine/School of Public Health, Kyoto University, Kyoto, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of International and Community Oral Health, Graduate School of Dentistry, Tohoku University, Miyagi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Division of Gastroenterological, General and Transplant Surgery, Jichi Medical University, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okano</LastName><ForeName>Hiromu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Social Medical Sciences, Graduate School of Medicine, International University of Health and Welfare, Minato City, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Critical Care Medicine, St. Luke's International Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamimura</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Okazaki City Hospital, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogura</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodaira</LastName><ForeName>Ami</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Anesthesia, Mitsui Memorial Hospital, Chiyoda City, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamazaki</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Social Medical Sciences, Graduate School of Medicine, International University of Health and Welfare, Minato City, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Anesth</MedlineTA><NlmUniqueID>8905667</NlmUniqueID><ISSNLinking>0913-8668</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Anesth. 2025 Sep 15. doi: 10.1007/s00540-025-03579-7.</RefSource><PMID Version="1">40952513</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cesarean section</Keyword><Keyword MajorTopicYN="N">Norephinephrine</Keyword><Keyword MajorTopicYN="N">Phenylephrine</Keyword><Keyword MajorTopicYN="N">Spinal anesthesia</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList><CoiStatement>Declarations. Conflict of interest: The authors declare no competing interests or funding. The English editing costs were supported by the research fund from the Scholarly Works Peer Support Group (SRWS-PSG). Declaration of generative AI and AI-assisted technologies in the writing process: During the preparation of this work, the authors used GPT-4 (specifically the GPT-4o-05-13 model) in order to assist in the screening process. After using this tool/service, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>16</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>16</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>16</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40522505</ArticleId><ArticleId IdType="doi">10.1007/s00540-025-03528-4</ArticleId><ArticleId IdType="pii">10.1007/s00540-025-03528-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen Y, Guo L, Shi Y, Ma G, Xue W, He L, Ma S, Ni X. Norepinephrine prophylaxis for postspinal anesthesia hypotension in parturient undergoing cesarean section: a randomized, controlled trial. Arch Gynecol Obstet. 2020;302:829&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">32588134</ArticleId><ArticleId IdType="doi">10.1007/s00404-020-05663-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Chooi C, Cox JJ, Lumb RS, Middleton P, Chemali M, Emmett RS, Simmons SW, Cyna AM. Techniques for preventing hypotension during spinal anaesthesia for caesarean section. Cochrane Database Syst Rev. 2017;CD002251.</Citation></Reference><Reference><Citation>Li Y, Shuai B, Huang H. Prophylactic intravenous norepinephrine for the prevention of hypotension during spinal anesthesia for elective cesarean section: a systematic review and dose&#x2013;response meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1247214.</Citation><ArticleIdList><ArticleId IdType="pubmed">37795034</ArticleId><ArticleId IdType="pmc">10546307</ArticleId><ArticleId IdType="doi">10.3389/fphar.2023.1247214</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald JP, Fedoruk KA, Jadin SM, Carvalho B, Halpern SH. Prevention of hypotension after spinal anaesthesia for caesarean section: a systematic review and network meta-analysis of randomised controlled trials. Anaesthesia. 2020;75:109&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">31531852</ArticleId><ArticleId IdType="doi">10.1111/anae.14841</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh PM, Singh NP, Reschke M, Ngan Kee WD, Palanisamy A, Monks DT. Vasopressor drugs for the prevention and treatment of hypotension during neuraxial anaesthesia for caesarean delivery: a Bayesian network meta-analysis of fetal and maternal outcomes. Br J Anaesth. 2020;124:e95-107.</Citation><ArticleIdList><ArticleId IdType="pubmed">31810562</ArticleId><ArticleId IdType="doi">10.1016/j.bja.2019.09.045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinsella SM, Carvalho B, Dyer RA, Fernando R, McDonnell N, Mercier FJ, Palanisamy A, Sia ATH, Van De Velde M, Vercueil A. International consensus statement on the management of hypotension with vasopressors during caesarean section under spinal anaesthesia. Anaesthesia. 2018;73:71&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">29090733</ArticleId><ArticleId IdType="doi">10.1111/anae.14080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollag L, Lim G, Sultan P, Habib AS, Landau R, Zakowski M, Tiouririne M, Bhambhani S, Carvalho B. Society for Obstetric Anesthesia and Perinatology: consensus statement and recommendations for enhanced recovery after cesarean. Anesth Analg. 2021;132:1362&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">33177330</ArticleId><ArticleId IdType="doi">10.1213/ANE.0000000000005257</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty A, Ohashi Y, Downey K, Carvalho JCA. Phenylephrine infusion versus bolus regimens during cesarean delivery under spinal anesthesia: a double-blind randomized clinical trial to assess hemodynamic changes. Anesth Analg. 2012;115:1343&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">23011562</ArticleId><ArticleId IdType="doi">10.1213/ANE.0b013e31826ac3db</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngan Kee WD, Lee SWY, Ng FF, Tan PE, Khaw KS. Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery. Anesthesiology. 2015;122:736&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">25635593</ArticleId><ArticleId IdType="doi">10.1097/ALN.0000000000000601</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A, Jain K, Goel N, Arora A, Kumar P. Neonatal outcomes following prophylactic administration of phenylephrine or noradrenaline in women undergoing scheduled caesarean delivery: a randomised clinical trial. Eur J Anaesthesiol. 2022;39:269&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">34817421</ArticleId><ArticleId IdType="doi">10.1097/EJA.0000000000001634</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Xu X, Qin R, Xiong X, Chen Y. Prophylactic norepinephrine and phenylephrine boluses to prevent postspinal anesthesia hypotension during cesarean section: a randomized sequential allocation dose-finding study. Drug Des Devel Ther. 2023;17:1547&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">37249928</ArticleId><ArticleId IdType="pmc">10224683</ArticleId><ArticleId IdType="doi">10.2147/DDDT.S406671</ArticleId></ArticleIdList></Reference><Reference><Citation>de Queiroz DV, Velarde LGC, Alves RL, Ver&#xe7;osa N, Cavalcanti IL. Incidence of bradycardia during noradrenaline or phenylephrine bolus treatment of postspinal hypotension in cesarean delivery: a randomized double-blinded controlled trial. Acta Anaesthesiol Scand. 2023;67:797&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">36866963</ArticleId><ArticleId IdType="doi">10.1111/aas.14225</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr&#xf3;bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.</Citation><ArticleIdList><ArticleId IdType="pubmed">33782057</ArticleId><ArticleId IdType="pmc">8005924</ArticleId><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catal&#xe1;-L&#xf3;pez F, G&#xf8;tzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">26030634</ArticleId><ArticleId IdType="doi">10.7326/M14-2385</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai D, Kalarthi B. Norepinephrine versus phenylephrine for maintenance of blood pressure during spinal anaesthesia for caesarean delivery: a randomized double-blind controlled study. Indian J Clin Anaesth. 2021;8:460&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.18231/j.ijca.2021.087</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Guo L, Qin R, Xiong X, Li Z. Dose-response study of norepinephrine infusion for maternal hypotension in preeclamptic patients undergoing cesarean delivery under spinal anesthesia. Clin Pharmacokinet. 2024;63:847&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">38869701</ArticleId><ArticleId IdType="doi">10.1007/s40262-024-01381-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen TK, George RB, White WD, Muir HA, Habib AS. A double-blind, placebo-controlled trial of four fixed rate infusion regimens of phenylephrine for hemodynamic support during spinal anesthesia for cesarean delivery. Anesth Analg. 2010;111:1221&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20495139</ArticleId><ArticleId IdType="doi">10.1213/ANE.0b013e3181e1db21</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D, Qi X, Huang X, Wang X, Zhang Y. Efficacy and safety of different norepinephrine regimens for prevention of spinal hypotension in cesarean section: a randomized trial. Biomed Res Int. 2018;2018:2708175.</Citation><ArticleIdList><ArticleId IdType="pubmed">29951531</ArticleId><ArticleId IdType="pmc">5989297</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Xiong X, Qin R, Li Z, Chen Y. Prophylactic norepinephrine combined with 6% hydroxyethyl starch (130/0.4) co-load infusion for preventing postspinal anesthesia hypotension during cesarean section: a randomized, controlled, dose-finding trial. DARU J Pharm Sci. 2024;32:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40199-023-00479-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zou L, Li Z, Guo L, Xiong X. Prophylactic norepinephrine infusion for postspinal anesthesia hypotension in patients undergoing cesarean section: a randomized, controlled, dose-finding trial. Pharmacotherapy. 2021;41:370&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33583066</ArticleId><ArticleId IdType="doi">10.1002/phar.2514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohta M, Dubey M, Malhotra RK, Tyagi A. Comparison of the potency of phenylephrine and norepinephrine bolus doses used to treat post-spinal hypotension during elective caesarean section. Int J Obstet Anesth. 2019;38:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30685301</ArticleId><ArticleId IdType="doi">10.1016/j.ijoa.2018.12.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H, Chen Y, Jiang Y, Sun X, Ye W, Zhu X, Xiong X. Determination of ED90s of phenylephrine and norepinephrine infusion for prevention of spinal anesthesia-induced hypotension in patients with preeclampsia during cesarean delivery. Drug Des Devel Ther. 2024;18:2813&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">38984209</ArticleId><ArticleId IdType="pmc">11232882</ArticleId><ArticleId IdType="doi">10.2147/DDDT.S467072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojili GP, Vijayalakshmi V, Prasad SAV, Madhu N. A comparative study of two different prophylactic doses of phenylephrine infusion to prevent hypotension in elective cesarean delivery. Int J Med Public Health. 2024;14:194&#x2013;9.</Citation></Reference><Reference><Citation>Siddik-Sayyid SM, Taha SK, Kanazi GE, Aouad MT. A randomized controlled trial of variable rate phenylephrine infusion with rescue phenylephrine boluses versus rescue boluses alone on physician interventions during spinal anesthesia for elective cesarean delivery. Anesth Analg. 2014;118:611&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24299932</ArticleId><ArticleId IdType="doi">10.1213/01.ane.0000437731.60260.ce</ArticleId></ArticleIdList></Reference><Reference><Citation>George RB, McKeen DM, Dominguez JE, Allen TK, Doyle PA, Habib AS. A randomized trial of phenylephrine infusion versus bolus dosing for nausea and vomiting during cesarean delivery in obese women. Can J Anaesth. 2018;65:254&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">29209926</ArticleId><ArticleId IdType="doi">10.1007/s12630-017-1034-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel K, Luthra N, Goyal N, Grewal A, Taneja A. Comparison of norepinephrine and phenylephrine infusions for maintenance of haemodynamics following subarachnoid block in lower segment cesarean section. Indian J Anaesth. 2021;65:600&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34584283</ArticleId><ArticleId IdType="pmc">8445212</ArticleId><ArticleId IdType="doi">10.4103/ija.IJA_185_21</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W, Zheng Q, Zhou J, Li X, Zhou H. Norepinephrine versus phenylephrine on cerebral tissue oxygen saturation during prophylactic infusion to prevent spinal hypotension for cesarean birth. Medicine (Baltimore). 2024;103: e37454.</Citation><ArticleIdList><ArticleId IdType="pubmed">38457564</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000037454</ArticleId></ArticleIdList></Reference><Reference><Citation>Surendra J, Chanda K, Bhati FS, Abhilasha T. Comparison of prophylactic infusion of phenylephrine and norepinephrine for prevention of hypotension in elective cesarean section under spinal anaesthesia: a randomized controlled study. Int J Health Clin Res. 2021;4:76&#x2013;82.</Citation></Reference><Reference><Citation>Biricik E, Karacaer F, &#xdc;nal &#x130;, Sucu M, &#xdc;nl&#xfc;gen&#xe7; H. O efeito de epinefrina, norepinefrina e fenilefrina no tratamento da hipotens&#xe3;o p&#xf3;s-raquianestesia: estudo cl&#xed;nico comparativo. Braz J Anesthesiol. 2020;70:500&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32980142</ArticleId><ArticleId IdType="pmc">9373668</ArticleId><ArticleId IdType="doi">10.1016/j.bjan.2020.04.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Senapati LK. Comparison of infusions of phenylephrine, norepinephrine, and mephentermine on maternal hemodynamics and neonatal outcomes in cesarean section under spinal anaesthesia. J Med Pharm Allied Sci. 2024;13:6392&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="doi">10.55522/jmpas.V13I1.5919</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Obstetricians and Gynecologists&#x2019; Committee on Practice Bulletins&#x2014;Obstetrics. ACOG Practice Bulletin No. 209: Obstetric analgesia and anesthesia. Obstet Gynecol. 2019;133:e208&#x2013;25.</Citation></Reference><Reference><Citation>Apfelbaum JL, Hawkins JL, Agarkar M, Bucklin BA, Connis RT, Gambling DR, Mhyre J, Nickinovich DG, Sherman H, Tsen LC, Yaghmour ET. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia and the Society for Obstetric Anesthesia and Perinatology. Anesthesiology. 2016;124:270&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000000935</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngan Kee WD, Lee SWY, Ng FF, Lee A. Norepinephrine or phenylephrine during spinal anaesthesia for caesarean delivery: a randomised double-blind pragmatic non-inferiority study of neonatal outcome. Br J Anaesth. 2020;125:588&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">32682556</ArticleId><ArticleId IdType="doi">10.1016/j.bja.2020.05.057</ArticleId></ArticleIdList></Reference><Reference><Citation>Du W, Song Y, Li J, Zhou X, Xu Z, Liu Z. Comparison of prophylactic norepinephrine and phenylephrine infusions during spinal anaesthesia for primary caesarean delivery in twin pregnancies: a randomized double-blinded clinical study. Drug Des Devel Ther. 2022;16:789&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">35355656</ArticleId><ArticleId IdType="pmc">8959871</ArticleId><ArticleId IdType="doi">10.2147/DDDT.S357507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Zhou J, Wan L, Huang H. Norepinephrine versus phenylephrine infusion for preventing postspinal hypotension during cesarean section for twin pregnancy: a double-blinded randomized controlled clinical trial. BMC Anesthesiol. 2022;22:17.</Citation><ArticleIdList><ArticleId IdType="pubmed">34998371</ArticleId><ArticleId IdType="pmc">8742356</ArticleId><ArticleId IdType="doi">10.1186/s12871-022-01562-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. Version 6.5. 2024.</Citation></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hern&#xe1;n MA, Hopewell S, Hr&#xf3;bjartsson A, Junqueira DR, J&#xfc;ni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolakopoulou A, Higgins JPT, Papakonstantinou T, Chaimani A, Del Giovane C, Egger M, Salanti G. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17: e1003082.</Citation><ArticleIdList><ArticleId IdType="pubmed">32243458</ArticleId><ArticleId IdType="pmc">7122720</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1003082</ArticleId></ArticleIdList></Reference><Reference><Citation>Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G. CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis. Campbell Syst Rev. 2020;16: e1080.</Citation><ArticleIdList><ArticleId IdType="pubmed">37131978</ArticleId><ArticleId IdType="pmc">8356302</ArticleId><ArticleId IdType="doi">10.1002/cl2.1080</ArticleId></ArticleIdList></Reference><Reference><Citation>Massoth C, T&#xf6;pel L, Wenk M. Hypotension after spinal anesthesia for cesarean section: how to approach the iatrogenic sympathectomy. Curr Opin Anaesthesiol. 2020;33:291&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32371631</ArticleId><ArticleId IdType="doi">10.1097/ACO.0000000000000848</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C, Liao AH-W, Chen C-Y, Lin Y-C, Kang Y-N. A systematic review with network meta-analysis on mono strategy of anaesthesia for preeclampsia in caesarean section. Sci Rep. 2021;11:5630.</Citation></Reference><Reference><Citation>Ngan Kee WD, Khaw KS, Tan PE, Ng FF, Karmakar MK. Placental transfer and fetal metabolic effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. Anesthesiology. 2009;111:506&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19672175</ArticleId><ArticleId IdType="doi">10.1097/ALN.0b013e3181b160a3</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma P, Ekka S, Panda BK, Choudhury S, Padhi N, Dash A. Comparison of norepinephrine and phenylephrine boluses for the treatment of hypotension during spinal anaesthesia for caesarean section. Int J Pharm Clin Res. 2023;15:178&#x2013;83.</Citation></Reference><Reference><Citation>Jain N, Chatterjee B, Patodi V, Kumar P, Garg DK. Effectiveness of norepinephrine versus phenylephrine intravenous boluses for the treatment of hypotension in elective lower-segment cesarean section under spinal anesthesia: a randomized controlled, double-blind study. Indian Anaesth Forum. 2023;24:109&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/TheIAForum.TheIAForum_35_23</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelman A, Rubin DB. Markov chain Monte Carlo methods in biostatistics. Stat Methods Med Res. 1996;5:339&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">9004377</ArticleId><ArticleId IdType="doi">10.1177/096228029600500402</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS ONE. 2013;8: e76654.</Citation><ArticleIdList><ArticleId IdType="pubmed">24098547</ArticleId><ArticleId IdType="pmc">3789683</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0076654</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohta M, Bambode N, Chilkoti GT, Agarwal R, Malhotra RK, Batra P. Neonatal outcomes following phenylephrine or norepinephrine for treatment of spinal anaesthesia-induced hypotension at emergency caesarean section in women with fetal compromise: a randomised controlled study. Int J Obstet Anesth. 2022;49: 103247.</Citation><ArticleIdList><ArticleId IdType="pubmed">35012812</ArticleId><ArticleId IdType="doi">10.1016/j.ijoa.2021.103247</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikooseresht M, Seifrabiei MA, Hajian P, Khamooshi S. A clinical trial on the effects of different regimens of phenylephrine on maternal hemodynamics after spinal anesthesia for cesarean section. Anesth Pain Med. 2020;10: e58048.</Citation><ArticleIdList><ArticleId IdType="pubmed">33134140</ArticleId><ArticleId IdType="pmc">7539049</ArticleId><ArticleId IdType="doi">10.5812/aapm.58048</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Mao M, Liu S, Xu S, Yang J. A comparative study of bolus norepinephrine, phenylephrine, and ephedrine for the treatment of maternal hypotension in parturients with preeclampsia during cesarean delivery under spinal anesthesia. Med Sci Monit. 2019;25:1093&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">30738019</ArticleId><ArticleId IdType="pmc">6377586</ArticleId><ArticleId IdType="doi">10.12659/MSM.914143</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander G, Balakrishnan R, George T. A comparison of bolus doses of norepinephrine and phenylephrine in the treatment of hypotension during spinal anaesthesia for caesarean section. Curr Trends Biotechnol Pharm. 2023;17:1030&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="doi">10.5530/ctbp.2023.3.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari JP, Verma SJ, Singh AK. A prospective randomized study comparing the bolus doses of norepinephrine and phenylephrine for the treatment of spinal-induced hypotension in cesarean section. Cureus. 2022;14: e27166.</Citation><ArticleIdList><ArticleId IdType="pubmed">36017271</ArticleId><ArticleId IdType="pmc">9393321</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngan Kee WD. A random-allocation graded dose&#x2013;response study of norepinephrine and phenylephrine for treating hypotension during spinal anesthesia for cesarean delivery. Anesthesiology. 2017;127:934&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">28872480</ArticleId><ArticleId IdType="doi">10.1097/ALN.0000000000001880</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohta M, Garg A, Chilkoti GT, Malhotra RK. A randomized controlled trial of phenylephrine and noradrenaline boluses for treatment of postspinal hypotension during elective caesarean section. Anaesthesia. 2019;74:850&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">31044424</ArticleId><ArticleId IdType="doi">10.1111/anae.14675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohta M, Chilkoti GT, Agarwal R, Malhotra RK. A randomized double-blind comparison of phenylephrine and norepinephrine for the management of postspinal hypotension in pre-eclamptic patients undergoing caesarean section. Eur J Anaesthesiol. 2021;38:1077&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">34524157</ArticleId><ArticleId IdType="doi">10.1097/EJA.0000000000001461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari M, Sathyanarayana V. A study of phenylephrine administration for the prevention and treatment of hypotension in cesarean section during spinal anaesthesia. J Cell Mol Anesth. 2021;6:240&#x2013;8.</Citation></Reference><Reference><Citation>Wang X, Mao M, Zhang SS, Wang ZH, Xu SQ, Shen XF. Bolus norepinephrine and phenylephrine for maternal hypotension during elective cesarean section with spinal anesthesia: a randomized, double-blinded study. Chin Med J (Engl). 2020;133:509&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">31996543</ArticleId><ArticleId IdType="doi">10.1097/CM9.0000000000000621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngan Kee WD, Tam YH, Khaw KS, Ng FF, Lee SWY. Closed-loop feedback computer-controlled phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery: a randomized trial comparing automated boluses versus infusion. Anesth Analg. 2017;125:117&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">28368936</ArticleId><ArticleId IdType="doi">10.1213/ANE.0000000000001974</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen I, Hirachan R, Bhardwaj N, Jain K, Suri V, Kumar P. Colloid cohydration and variable rate phenylephrine infusion effectively prevents postspinal hypotension in elective cesarean deliveries. J Anaesthesiol Clin Pharmacol. 2013;29:348.</Citation><ArticleIdList><ArticleId IdType="pubmed">24106360</ArticleId><ArticleId IdType="pmc">3788234</ArticleId><ArticleId IdType="doi">10.4103/0970-9185.117106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehdi MI, Arya S, Verma P, Singh S. Comparative assessment of the use of norepinephrine with phenylephrine during spinal anaesthesia for caesarean birth. Int J Pharm Clin Res. 2021;13:389&#x2013;95.</Citation></Reference><Reference><Citation>Eskandr AM, Ahmed AM, Bahgat NME. Comparative study among ephedrine, norepinephrine and phenylephrine infusions to prevent spinal hypotension during cesarean section: a randomized controlled double-blind study. Egypt J Anaesth. 2021;37:295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/11101849.2021.1936841</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, Yadav JBS, Singh AK, Rai MK. Comparing the effect of phenylephrine bolus and phenylephrine infusion for maintaining arterial blood pressure during cesarean delivery under spinal anesthesia: a randomized prospective study. Cureus. 2023;15: e42713.</Citation><ArticleIdList><ArticleId IdType="pubmed">37654965</ArticleId><ArticleId IdType="pmc">10466076</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TT, Nguyen HC, Nguyen ATH, Doan TH, Ngo QS. Comparison of intermittent boluses of noradrenaline vs. phenylephrine for spinal anesthesia-induced hypotension during cesarean delivery. Anaesth Pain Intensive Care. 2023;27:562&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.35975/apic.v27i5.2312</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Yu Y, Chu M, Zhang Y, Yu X, Chen G. Comparison of metaraminol, phenylephrine, and norepinephrine infusion for prevention of hypotension during combined spinal-epidural anaesthesia for elective caesarean section: a three-arm, randomized, double-blind, non-inferiority trial. Drug Des Devel Ther. 2022;16:117&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027821</ArticleId><ArticleId IdType="pmc">8752065</ArticleId><ArticleId IdType="doi">10.2147/DDDT.S331177</ArticleId></ArticleIdList></Reference><Reference><Citation>Puthenveettil N, Sivachalam S, Rajan S, Paul J, Kumar L. Comparison of norepinephrine and phenylephrine boluses for the treatment of hypotension during spinal anaesthesia for caesarean section: a randomised controlled trial. Indian J Anaesth. 2019;63:995.</Citation><ArticleIdList><ArticleId IdType="pubmed">31879423</ArticleId><ArticleId IdType="pmc">6921314</ArticleId><ArticleId IdType="doi">10.4103/ija.IJA_481_19</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai AV, Prakash S, Chellani H, Mullick P, Wason R. Comparison of phenylephrine and norepinephrine for treatment of spinal hypotension during elective cesarean delivery: a randomised, double-blind study. J Anaesthesiol Clin Pharmacol. 2022;38:445&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">36505203</ArticleId><ArticleId IdType="pmc">9728423</ArticleId><ArticleId IdType="doi">10.4103/joacp.JOACP_499_20</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong L, Dong Q, Song X, Liu Y, Wang Y. Comparison of prophylactic bolus norepinephrine and phenylephrine on hypotension during spinal anesthesia for cesarean section. Int J Clin Exp Med. 2017;10:12315&#x2013;21.</Citation></Reference><Reference><Citation>Ravichandrane B, Subramaniam R, Muthiah T, Talawar P, Ramadurai R. Comparison of prophylactic infusion of phenylephrine versus norepinephrine for the prevention of postspinal hypotension in parturients undergoing elective caesarean section: a randomized, double-blinded, non-inferiority trial. Turk J Anaesthesiol Reanim. 2023;51:213&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">37455439</ArticleId><ArticleId IdType="pmc">10339757</ArticleId><ArticleId IdType="doi">10.4274/TJAR.2022.22909</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J, Singh J, Mitra S, Anand LK, Goel B, Kaur M. Comparison of prophylactic phenylephrine and norepinephrine infusion on umbilical arterial pH and maternal blood pressure during spinal anaesthesia for caesarean delivery. Indian J Anaesth. 2022;66:S115&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">35601041</ArticleId><ArticleId IdType="pmc">9116634</ArticleId><ArticleId IdType="doi">10.4103/ija.ija_345_21</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha P, Konwar C, Pandey A, Bharali P. Comparison of the effect of intravenous phenylephrine and norepinephrine boluses for postspinal hypotension on neonatal outcome in elective caesarean section: a randomised controlled trial. Indian J Anaesth. 2024;68:348&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">38586272</ArticleId><ArticleId IdType="pmc">10993945</ArticleId><ArticleId IdType="doi">10.4103/ija.ija_920_23</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravulapalli H, Laxman N, Anga R, Prithviraj B. Comparison of two methods of administration of phenylephrine for the prevention and treatment of hypotension in caesarean section under spinal anaesthesia. Eur J Mol Clin Med. 2020;7:4823&#x2013;33.</Citation></Reference><Reference><Citation>Tyagi A, Kakkar A, Niwal N, Mohta M, Sethi A. Effect of intravenous phenylephrine infusion on dose requirement of intrathecal plain levobupivacaine for cesarean section: a placebo-controlled preliminary study. Saudi J Anaesth. 2017;11:421.</Citation><ArticleIdList><ArticleId IdType="pubmed">29033722</ArticleId><ArticleId IdType="pmc">5637418</ArticleId><ArticleId IdType="doi">10.4103/sja.SJA_269_17</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Chen J, Liu M, Wang T, Sun W, Li L, Mao D. Effect of prophylactic phenylephrine in parturients prone to develop spinal hypotension. J Shanghai Jiao Tong Univ Med Sci. 2017;37:1143&#x2013;6.</Citation></Reference><Reference><Citation>Feng K, Wang X, Feng X, Zhang J, Xiao W, Wang F, Zhou Q, Wang T. Effects of continuous infusion of phenylephrine vs. norepinephrine on parturients and fetuses under LiDCOrapid monitoring: a randomized, double-blind, placebo-controlled study. BMC Anesthesiol. 2020;20:229.</Citation><ArticleIdList><ArticleId IdType="pubmed">32894044</ArticleId><ArticleId IdType="pmc">7487484</ArticleId><ArticleId IdType="doi">10.1186/s12871-020-01145-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahzad A, Nikoubakht N, Farahmandrad R, Ghozat R. Evaluation of the effect of norepinephrine, ephedrine and phenylephrine on prophylaxis and treatment of hemodynamic changes associated with spinal anesthesia in elective cesarean section surgeries. Pak Natl Res. 2022;13:1310&#x2013;7.</Citation></Reference><Reference><Citation>Liu L, Xiao F. Influence of prophylactic phenylephrine infusion on dose requirements of intrathecal hyperbaric bupivacaine during spinal anesthesia in cesarean sections: a pilot study. Int J Clin Exp Med. 2018;11:12500&#x2013;4.</Citation></Reference><Reference><Citation>Wu W, Zheng Q, Zhou J, Li X, Zhou H. Norepinephrine versus phenylephrine on cerebral tissue oxygen saturation during prophylactic infusion to prevent spinal hypotension for caesarean birth. Medicine (Baltimore). 2024;103: e37454.</Citation><ArticleIdList><ArticleId IdType="pubmed">38457564</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000037454</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal A, Javed HM, Ahmad K, Ashfaq MA, Butt MR, Khalid M. Phenylephrine boluses vs. noradrenaline boluses for hypotension after spinal anesthesia in LSCS. Pak J Med Health Sci. 2022;16:775&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.53350/pjmhs22167775</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YF, Xiao F, Xu WP, Liu L. Prophylactic infusion of phenylephrine increases the median effective dose of intrathecal hyperbaric bupivacaine in cesarean section: a prospective randomized study. Medicine (Baltimore). 2018;97: e11833.</Citation><ArticleIdList><ArticleId IdType="pubmed">30095659</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000011833</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundararajan M, Ravindran C, Ponnusamy R, Murugesan R. Prophylactic norepinephrine infusion or leg wrapping for postspinal hypotension in elective caesarean delivery: a randomised, double-blind, placebo-controlled trial. Eur J Anaesthesiol. 2020;37:803&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32398581</ArticleId><ArticleId IdType="doi">10.1097/EJA.0000000000001231</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Qin R, Ren X, Han C, Xue W, He L, Ma L, Pan H, Ma S, Chen Y, Ni X. Prophylactic norepinephrine or phenylephrine infusion for bradycardia and postspinal anaesthesia hypotension in patients with preeclampsia during caesarean delivery: a randomised controlled trial. Br J Anaesth. 2022;128:e305&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35190176</ArticleId><ArticleId IdType="doi">10.1016/j.bja.2022.01.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngan Kee WD, Khaw KS, Ng FF, Lee BB. Prophylactic phenylephrine infusion for preventing hypotension during spinal anesthesia for cesarean delivery. Anesth Analg. 2004;98:815&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">14980943</ArticleId><ArticleId IdType="doi">10.1213/01.ANE.0000099782.78002.30</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary M, Bajaj J. Study comparing phenylephrine bolus and infusion for maternal hypotension and neonatal outcome during cesarean section under spinal anesthesia. Anesth Essays Res. 2018;12:446.</Citation><ArticleIdList><ArticleId IdType="pubmed">29962614</ArticleId><ArticleId IdType="pmc">6020566</ArticleId><ArticleId IdType="doi">10.4103/aer.AER_23_18</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdanpanah S, Alinaghimaddah S, Tatari M, Ghorchaei A, Karamelahi Z. The effect of bolus injection of phenylephrine and norepinephrine in preventing hypotension in spinal anesthesia in patients undergoing elective cesarean section: a single-blind clinical trial study. Iran J Obstet Gynecol Infertil. 2023;26:31&#x2013;40.</Citation></Reference><Reference><Citation>Shafeinia A, Ghaed MA, Nikoubakht N. The effect of phenylephrine infusion on maternal hemodynamic changes during spinal anesthesia for cesarean delivery. Anesth Pain Med. 2020;10: e99094.</Citation><ArticleIdList><ArticleId IdType="pubmed">32309198</ArticleId><ArticleId IdType="pmc">7144416</ArticleId><ArticleId IdType="doi">10.5812/aapm.99094</ArticleId></ArticleIdList></Reference><Reference><Citation>Berawala PK, Mehta SH, Chaudhari MS, Shinde MK. A randomized, double-blinded comparative study of phenylephrine infusion and norepinephrine infusion for the prevention and treatment of spinal anesthesia-induced hypotension in elective and emergency cesarean deliveries. Indian Anaesth Forum. 2021;22:136&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/TheIAForum.TheIAForum_9_21</ArticleId></ArticleIdList></Reference><Reference><Citation>Das Neves JFNP, Monteiro GA, De Almeida JR, Sant&#x2019;Anna RS, Bonin HB, Macedo CF. Phenylephrine for blood pressure control in elective cesarean section: therapeutic versus prophylactic doses. Braz J Anesthesiol. 2010;60:391&#x2013;98.</Citation></Reference><Reference><Citation>Tyagi A, Mathur M, Salhotra R, Rautela RS. Minimum effective dose of intrathecal hyperbaric bupivacaine for cesarean section with and without prophylactic norepinephrine infusion: a randomized triple-blinded trial. J Anaesthesiol Clin Pharmacol. 2024;40:491&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">39391636</ArticleId><ArticleId IdType="pmc">11463919</ArticleId><ArticleId IdType="doi">10.4103/joacp.joacp_189_23</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Tang Y, Guo F, Liu J, Xu L, Zhu G, Wang Y, Ma N, Chen X, Qian X. Norepinephrine or phenylephrine for the prevention of postspinal hypotension after caesarean section: a double-blinded, randomized, controlled study of fetal heart rate and fetal cardiac output. J Clin Anesth. 2024;97: 111533.</Citation><ArticleIdList><ArticleId IdType="pubmed">38880002</ArticleId><ArticleId IdType="doi">10.1016/j.jclinane.2024.111533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanath Kumar J, Manjula B, Hemalatha S. Comparison of norepinephrine and phenylephrine boluses for the treatment of hypotension during spinal anaesthesia for elective caesarean section: a prospective interventional study. Int J Anesth Res. 2023;13:82&#x2013;4.</Citation></Reference><Reference><Citation>Patil A, Chavan R, Mudalagirigowda SK, Adda S. A comparative study to evaluate the effect of norepinephrine and phenylephrine in the treatment of postspinal hypotension for caesarean section. Adv Anesth Crit Care. 2022;8:1.</Citation></Reference><Reference><Citation>Gupta AK, Sinha S, Gera A, Marwaha A, Sood J. Effects of prophylactic bolus of norepinephrine versus phenylephrine on maternal and fetal outcome during caesarean section under subarachnoid block: a randomized study. J Indian Coll Anaesthesiol. 2023;2:37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jica.jica_4_23</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali CS, Bajaj JK. A randomised comparative study to compare the prophylactic use of phenylephrine and norepinephrine in caesarean delivery under spinal anaesthesia. J Obstet Anaesth Crit Care. 2023;13:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/JOACC.JOACC_12_22</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakshmikanthan C, Gayathri B, Ramani S, Balasubramanian N. A randomized controlled trial comparing the effect of phenylephrine by intramuscular route with intravenous infusion in maintaining haemodynamic stability during elective lower segment caesarean section under spinal anaesthesia. Cureus. 2023;15: e34118.</Citation><ArticleIdList><ArticleId IdType="pubmed">36843684</ArticleId><ArticleId IdType="pmc">9949751</ArticleId></ArticleIdList></Reference><Reference><Citation>Priya P, Devaraj I, Shetty NS, Srinivasalu DS, Kiranchand N, Bhaskar SB. Efficacy of prophylactic norepinephrine and phenylephrine infusions against spinal hypotension during lower segment caesarean section: a randomised clinical study. J Clin Diagn Res. 2023;17:1&#x2013;8.</Citation></Reference><Reference><Citation>Anusorntanawat R. A comparison of phenylephrine administration between intravenous bolus and slow injection in treatment of spinal anesthesia-induced hypotension on bradycardia and other side effects in patients undergoing cesarean section: a randomized, single-blind study. Thai J Anesthesiol. 2020;46:80&#x2013;7.</Citation></Reference><Reference><Citation>Sen T, Saha P, Kalita P, Saikia P, Mahanta B. Effect on neonatal acid&#x2013;base status of phenylephrine and norepinephrine boluses for management of spinal anesthesia-induced hypotension in patients with preeclampsia undergoing cesarean delivery: a randomized, double-blinded trial. J Obstet Anaesth Crit Care. 2025;15:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/JOACC.JOACC_77_23</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JE, George RB, Habib AS. Spinal-induced hypotension: incidence, mechanisms, prophylaxis, and management: summarizing 20 years of research. Best Pract Res Clin Anaesthesiol. 2017;31:57&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">28625306</ArticleId><ArticleId IdType="doi">10.1016/j.bpa.2017.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Onwochei DN, Ngan Kee WD, Fung L, Downey K, Ye XY, Carvalho JCA. Norepinephrine intermittent intravenous boluses to prevent hypotension during spinal anesthesia for cesarean delivery: a sequential allocation dose-finding study. Anesth Analg. 2017;125:212&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28248702</ArticleId><ArticleId IdType="doi">10.1213/ANE.0000000000001846</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu T, Zheng J, An XH, Xu ZF, Wang F. Norepinephrine intravenous prophylactic bolus versus rescue bolus to prevent and treat maternal hypotension after combined spinal and epidural anesthesia during cesarean delivery: a sequential dose-finding study. Ann Transl Med. 2019;7:451.</Citation><ArticleIdList><ArticleId IdType="pubmed">31700887</ArticleId><ArticleId IdType="pmc">6803215</ArticleId><ArticleId IdType="doi">10.21037/atm.2019.08.50</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33092804</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-6771</ISSN><JournalIssue CitedMedium="Internet"><Volume>126</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>British journal of anaesthesia</Title><ISOAbbreviation>Br J Anaesth</ISOAbbreviation></Journal><ArticleTitle>Systematic review and consensus definitions for the Standardized Endpoints in Perioperative Medicine (StEP) initiative: cardiovascular outcomes.</ArticleTitle><Pagination><StartPage>56</StartPage><EndPage>66</EndPage><MedlinePgn>56-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bja.2020.09.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0007-0912(20)30780-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Adverse cardiovascular events are a leading cause of perioperative morbidity and mortality. The definitions of perioperative cardiovascular adverse events are heterogeneous. As part of the international Standardized Endpoints in Perioperative Medicine initiative, this study aimed to find consensus amongst clinical trialists on a set of standardised and valid cardiovascular outcomes for use in future perioperative clinical trials.</AbstractText><AbstractText Label="METHODS">We identified currently used perioperative cardiovascular outcomes by a systematic review of the anaesthesia and perioperative medicine literature (PubMed/Ovid, Embase, and Cochrane Library). We performed a three-stage Delphi consensus-gaining process that involved 55 clinician researchers worldwide. Cardiovascular outcomes were first shortlisted and the most suitable definitions determined. These cardiovascular outcomes were then assessed for validity, reliability, feasibility, and clarity.</AbstractText><AbstractText Label="RESULTS">We identified 18 cardiovascular outcomes. Participation in the three Delphi rounds was 100% (n=19), 71% (n=55), and 89% (n=17), respectively. A final list of nine cardiovascular outcomes was elicited from the consensus: myocardial infarction, myocardial injury, cardiovascular death, non-fatal cardiac arrest, coronary revascularisation, major adverse cardiac events, pulmonary embolism, deep vein thrombosis, and atrial fibrillation. These nine cardiovascular outcomes were rated by the majority of experts as valid, reliable, feasible, and clearly defined.</AbstractText><AbstractText Label="CONCLUSIONS">These nine consensus cardiovascular outcomes can be confidently used as endpoints in clinical trials designed to evaluate perioperative interventions with the goal of improving perioperative outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beattie</LastName><ForeName>W Scott</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Cardiovascular Anesthesia, University Health Network, University of Toronto, Toronto, ON, Canada. Electronic address: scott.beattie@uhn.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalu</LastName><ForeName>Manoj</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bocock</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijeysundera</LastName><ForeName>Duminda N</ForeName><Initials>DN</Initials><AffiliationInfo><Affiliation>Li Ka Shing Knowledge Institute, St Michaels Hospital, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagele</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Lee A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, University of Pennsylvania Health System, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Outcomes Research, Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biccard</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Medicine, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leslie</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Melbourne, Vic., Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howell</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Leeds School of Medicine, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landoni</LastName><ForeName>Giovani</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Intensive Care and Anesthesiology, IRCCS San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grocott</LastName><ForeName>Hilary</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Medicine, University of Manitoba, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lamy</LastName><ForeName>Andre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richards</LastName><ForeName>Toby</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Western Australia, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myles</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alfred Health and Monash University Department of Anaesthesia and Perioperative Medicine, Melbourne, Vic., Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>StEP COMPAC Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Patient Comfort</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Clinical Indicators</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Delirium Postoperative Cognitive Dysfunction Stroke</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Cardiovascular</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Data Extractors</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Respiratory</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Inflammation Sepsis</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Acute Kidney Injury</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Bleeding Complications Patient Blood Management</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Healthcare Resource Utilisation</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Patient-Centred Outcomes</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Organ Failure and Survival</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Cancer Surgery</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>10/104/06</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Anaesth</MedlineTA><NlmUniqueID>0372541</NlmUniqueID><ISSNLinking>0007-0912</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003697" MajorTopicYN="N">Delphi Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023381" MajorTopicYN="N">Endpoint Determination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019990" MajorTopicYN="N">Perioperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079645" MajorTopicYN="N">Perioperative Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MACE</Keyword><Keyword MajorTopicYN="N">cardiovascular events</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">myocardial infarction</Keyword><Keyword MajorTopicYN="N">outcome measures</Keyword><Keyword MajorTopicYN="N">perioperative medicine</Keyword><Keyword MajorTopicYN="N">standardised endpoint</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>D Jamie</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myles</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gan</LastName><ForeName>T J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurz</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peyton</LastName><ForeName>Phil</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sessler</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tram&#xe8;r</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cyna</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Oliveira</LastName><ForeName>Gildasio S</ForeName><Initials>GS</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jensen</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kehlet</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Botti</LastName><ForeName>Mari</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boney</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haller</LastName><ForeName>Guy</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grocott</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neuman</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Story</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gruen</LastName><ForeName>Russell</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bampoe</LastName><ForeName>Sam</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evered</LastName><ForeName>Lis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silbert</LastName><ForeName>Brendan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Diederik</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalkman</LastName><ForeName>Cor</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grocott</LastName><ForeName>Hilary</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haller</LastName><ForeName>Guy</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eckenhoff</LastName><ForeName>Rod</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Lars</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beattie</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wijeysundera</LastName><ForeName>Duminda</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leslie</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biccard</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howell</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grocott</LastName><ForeName>Hilary</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagele</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richards</LastName><ForeName>Toby</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lamy</LastName><ForeName>Andre</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lalu</LastName><ForeName>Manoj</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartlett</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMonnies</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerstl</LastName><ForeName>Jakob V.E.</ForeName><Initials>JV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jay</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kishlyansky</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Machina</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bobcock</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feng</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearse</LastName><ForeName>Rupert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mythen</LastName><ForeName>Monty</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canet</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moller</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gin</LastName><ForeName>Tony</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>Marcus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelosi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabreu</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Futier</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Creagh-Brown</LastName><ForeName>Ben</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abbott</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mythen</LastName><ForeName>Monty</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalkman</LastName><ForeName>Cor</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Andy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corcoran</LastName><ForeName>Tomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>D Jamie</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dieleman</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diouf</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McIlroy</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellomo</LastName><ForeName>Rinaldo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prowle</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karkouti</LastName><ForeName>Keyvan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Billings</LastName><ForeName>Josh</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wijeysundera</LastName><ForeName>Duminda</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Andy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richards</LastName><ForeName>Toby</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazer</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myles</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayarajah</LastName><ForeName>Mohindas</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karkouti</LastName><ForeName>Keyvan</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lamy</LastName><ForeName>Andre</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartoszko</LastName><ForeName>Justyna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sneyd</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beattie</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grocott</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sessler</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>George</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moonesinghe</LastName><ForeName>Ramani</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myles</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shulman</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neuman</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalkman</LastName><ForeName>Cor</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lane-Fall</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Ulrica</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevenson</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grocott</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myles</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearse</LastName><ForeName>Rupert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurz</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moonesinghe</LastName><ForeName>Ramani</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>Jamie Dj</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Klei</LastName><ForeName>Wilton</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabrini</LastName><ForeName>Luca</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pace</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>Sandy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buggy</LastName><ForeName>Donal</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sessler</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leslie</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Short</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurz</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riedel</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottumukkala</LastName><ForeName>Vijay</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pace</LastName><ForeName>Nathan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alkhaffaf</LastName><ForeName>Bilal</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>23</Day><Hour>5</Hour><Minute>36</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33092804</ArticleId><ArticleId IdType="doi">10.1016/j.bja.2020.09.023</ArticleId><ArticleId IdType="pii">S0007-0912(20)30780-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39267429</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1932-8737</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical cardiology</Title><ISOAbbreviation>Clin Cardiol</ISOAbbreviation></Journal><ArticleTitle>Anticoagulant Impact on Clinical Outcomes of Pulmonary Embolism Compared With Thrombolytic Therapy; Meta-Analysis.</ArticleTitle><Pagination><StartPage>e70016</StartPage><MedlinePgn>e70016</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70016</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/clc.70016</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pulmonary embolism (PE) is a critical condition requiring effective management strategies. Several options are available, including thrombolytic therapy and anticoagulants.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the impact of thrombolytic therapy either combined with anticoagulant (AC) or alone versus AC alone on mortality, recurrence, clinical deterioration, bleeding, and hospital stay.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">This study included 25 previously published studies from 1990 to 2023, with a total of 12&#x2009;836 participants. Dichotomous and continuous analysis models were used to evaluate outcomes, with heterogeneity and publication bias tests applied. A random model was used for data analysis. Several databases were searched for the identification and inclusion of studies, such as Ovid, PubMed, Cochrane Library, Google Scholar, and Embase.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For sub-massive PE, CDT plus AC significantly reduced in-hospital, 30-day, and 12-month mortality compared to AC alone, odds ratio (OR) of -0.99 (95% CI [-1.32 to -0.66]), with increased major bleeding risk but no difference in minor bleeding or hospital stay, OR&#x2009;=&#x2009;0.46, 95% CI [-0.03 to 0.96]). For acute intermediate PE, systemic thrombolytic therapy did not affect all-cause or in-hospital mortality but increased minor bleeding, reduced recurrent PE, and prevented clinical deterioration. The heterogeneity of different models in the current study varied from 0% to 37.9%.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The addition of CDT to AC improves mortality outcomes for sub-massive PE but raises the risk of major bleeding. Systemic thrombolytic therapy reduces recurrence and clinical decline in acute intermediate PE despite increasing minor bleeding. Individualized patient assessment is essential for optimizing PE management strategies.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Clinical Cardiology published by Wiley Periodicals, LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular surgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Dongmei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular surgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular surgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Chaoqun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular surgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xialing</ForeName><Initials>X</Initials><Identifier Source="ORCID">0009-0003-3274-205X</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular surgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>The authors received no specific funding for this work.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cardiol</MedlineTA><NlmUniqueID>7903272</NlmUniqueID><ISSNLinking>0160-9289</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="Y">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CDT</Keyword><Keyword MajorTopicYN="N">anticoagulant</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">thrombolytic therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>15</Day><Hour>21</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>15</Day><Hour>21</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>13</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39267429</ArticleId><ArticleId IdType="pmc">PMC11393431</ArticleId><ArticleId IdType="doi">10.1002/clc.70016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corsi F., Lebreton G., Br&#xe9;chot N., et al., &#x201c;Life&#x2010;Threatening Massive Pulmonary Embolism Rescued by Venoarterial&#x2010;Extracorporeal Membrane Oxygenation,&#x201d; Critical Care 21, no. 1 (March 2017): 76, 10.1186/s13054-017-1655-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-017-1655-8</ArticleId><ArticleId IdType="pmc">PMC5369216</ArticleId><ArticleId IdType="pubmed">28347320</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller K., Hobohm L., Ebner M., et al., &#x201c;Trends in Thrombolytic Treatment and Outcomes of Acute Pulmonary Embolism in Germany,&#x201d; European Heart Journal 41, no. 4 (January 2020): 522&#x2013;529, 10.1093/eurheartj/ehz236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz236</ArticleId><ArticleId IdType="pubmed">31102407</ArticleId></ArticleIdList></Reference><Reference><Citation>Teleb M., Porres&#x2010;Aguilar M., Anaya&#x2010;Ayala J. E., Rodriguez&#x2010;Castro C., Porres&#x2010;Mu&#xf1;oz M., and Mukherjee D., &#x201c;Potential Role of Systemic Thrombolysis in Acute Submassive Intermediate Risk Pulmonary Embolism: Review and Future Perspectives,&#x201d; Therapeutic Advances in Cardiovascular Disease 10, no. 2 (April 2016): 103&#x2013;110, 10.1177/1753944716630694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753944716630694</ArticleId><ArticleId IdType="pmc">PMC5933630</ArticleId><ArticleId IdType="pubmed">26864121</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaff M. R., McMurtry M. S., Archer S. L., et al., &#x201c;Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association,&#x201d; Circulation 123, no. 16 (April 2011): 1788&#x2013;1830, 10.1161/CIR.0b013e318214914f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0b013e318214914f</ArticleId><ArticleId IdType="pubmed">21422387</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer F. J. and Opitz C., &#x201c;Post&#x2010;Pulmonary Embolism Syndrome: An Update Based on the Revised AWMF&#x2010;S2k Guideline,&#x201d; H&#xe4;mostaseologie 44, no. 2 (April 2024): 128&#x2013;134, 10.1055/a-2229-4190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-2229-4190</ArticleId><ArticleId IdType="pubmed">38531395</ArticleId></ArticleIdList></Reference><Reference><Citation>Vedantham S., Piazza G., Sista A. K., and Goldenberg N. A., &#x201c;Guidance for the Use of Thrombolytic Therapy for the Treatment of Venous Thromboembolism,&#x201d; Journal of Thrombosis and Thrombolysis 41, no. 1 (January 2016): 68&#x2013;80, 10.1007/s11239-015-1318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-015-1318-z</ArticleId><ArticleId IdType="pmc">PMC4715849</ArticleId><ArticleId IdType="pubmed">26780739</ArticleId></ArticleIdList></Reference><Reference><Citation>And&#xf2; G., Pelliccia F., Saia F., et al., &#x201c;Management of High and Intermediate&#x2010;High Risk Pulmonary Embolism: A Position Paper of the Interventional Cardiology Working Group of the Italian Society of Cardiology,&#x201d; International Journal of Cardiology 400 (April 2024): 131694, 10.1016/j.ijcard.2023.131694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2023.131694</ArticleId><ArticleId IdType="pubmed">38160911</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnelli G., Prandoni P., Becattini C., et al., &#x201c;Extended Oral Anticoagulant Therapy After a First Episode of Pulmonary Embolism,&#x201d; Annals of Internal Medicine 139, no. 1 (July 2003): 19&#x2013;25, 10.7326/0003-4819-139-1-200307010-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-139-1-200307010-00008</ArticleId><ArticleId IdType="pubmed">12834314</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu T., Toma C., Tapson V. F., et al., &#x201c;A Prospective, Single&#x2010;Arm, Multicenter Trial of Catheter&#x2010;Directed Mechanical Thrombectomy for Intermediate&#x2010;Risk Acute Pulmonary Embolism,&#x201d; JACC: Cardiovascular Interventions 12, no. 9 (May 2019): 859&#x2013;869, 10.1016/j.jcin.2018.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2018.12.022</ArticleId><ArticleId IdType="pubmed">31072507</ArticleId></ArticleIdList></Reference><Reference><Citation>Knox M. F., Langholz D. E., Berjaoui W. K., and Eberhart L., &#x201c;Preservation of Cardiopulmonary Function in Patients Treated With Ultrasound&#x2010;Accelerated Thrombolysis in the Setting of Submassive Pulmonary Embolism,&#x201d; Journal of Vascular and Interventional Radiology 30, no. 5 (May 2019): 734&#x2013;741, 10.1016/j.jvir.2018.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvir.2018.08.027</ArticleId><ArticleId IdType="pubmed">30857985</ArticleId></ArticleIdList></Reference><Reference><Citation>Makary M. S., Fogler B. D., Dube P. P., et al., &#x201c;Ultrasound&#x2010;Accelerated, Catheter&#x2010;Directed Thrombolysis for Submassive Pulmonary Embolism: Single&#x2010;Center Retrospective Review With Intermediate&#x2010;Term Outcomes,&#x201d; Journal of Vascular and Interventional Radiology 31, no. 3 (March 2020): 438&#x2013;443, 10.1016/j.jvir.2019.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvir.2019.11.008</ArticleId><ArticleId IdType="pubmed">31982316</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan P. P., Manov J. J., Contreras F., Langston M. E., Doshi M. H., and Narayanan G., &#x201c;Ultrasound&#x2010;Assisted Catheter&#x2010;Directed Thrombolysis for Submassive Pulmonary Embolism,&#x201d; Vascular and Endovascular Surgery 52, no. 3 (April 2018): 195&#x2013;201, 10.1177/1538574418757400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1538574418757400</ArticleId><ArticleId IdType="pubmed">29436310</ArticleId></ArticleIdList></Reference><Reference><Citation>Virk H. U. H., Chatterjee S., Sardar P., Bavishi C., Giri J., and Chatterjee S., &#x201c;Systemic Thrombolysis for Pulmonary Embolism: Evidence, Patient Selection, and Protocols for Management,&#x201d; Interventional Cardiology Clinics 7, no. 1 (January 2018): 71&#x2013;80, 10.1016/j.iccl.2017.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.iccl.2017.08.001</ArticleId><ArticleId IdType="pubmed">29157526</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza G., &#x201c;Advanced Management of Intermediate&#x2010; and High&#x2010;Risk Pulmonary Embolism,&#x201d; Journal of the American College of Cardiology 76, no. 18 (November 2020): 2117&#x2013;2127, 10.1016/j.jacc.2020.05.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.05.028</ArticleId><ArticleId IdType="pubmed">33121720</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudzinski D. M., Giri J., and Rosenfield K., &#x201c;Interventional Treatment of Pulmonary Embolism,&#x201d; Circulation: Cardiovascular Interventions 10, no. 2 (February 2017): e004345, 10.1161/circinterventions.116.004345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circinterventions.116.004345</ArticleId><ArticleId IdType="pubmed">28213377</ArticleId></ArticleIdList></Reference><Reference><Citation>Siordia J. A. and Kaur A., &#x201c;Catheter&#x2010;Directed Thrombolysis Versus Systemic Anticoagulation for Submassive Pulmonary Embolism: A Meta&#x2010;Analysis,&#x201d; Current Cardiology Reviews 18, no. 1 (2022): 112&#x2013;117, 10.2174/1573403x17666210603114116.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573403x17666210603114116</ArticleId><ArticleId IdType="pmc">PMC9241122</ArticleId><ArticleId IdType="pubmed">34082686</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson K., VandenHull A., Remund T., et al., &#x201c;Short&#x2010;Term Cost Comparison of Systemic Heparin Therapy vs. Catheter Directed Thrombolysis for the Treatment of Massive and Submassive Pulmonary Embolism With Long&#x2010;Term Chronic Pulmonary Hypertension Cost Model,&#x201d; South Dakota Medicine: Journal of the South Dakota State Medical Association 74, no. 2 (February 2021): 70&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8232014</ArticleId><ArticleId IdType="pubmed">34161687</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaresan A., &#x201c;Wound Complications Frequency in Minor Technique Gastrectomy Compared to Open Gastrectomy for Gastric Cancer: A Meta&#x2010;Analysis,&#x201d; International Journal of Clinical Medical Research 1, no. 3 (2023): 12, 10.61466/ijcmr1030012.</Citation><ArticleIdList><ArticleId IdType="doi">10.61466/ijcmr1030012</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R. K., &#x201c;A Meta&#x2010;Analysis of the Impact on Gastrectomy Versus Endoscopic Submucosal Dissection for Early Stomach Cancer,&#x201d; International Journal of Clinical Medical Research 1, no. 3 (2023): 11, 10.61466/ijcmr1030011.</Citation><ArticleIdList><ArticleId IdType="doi">10.61466/ijcmr1030011</ArticleId></ArticleIdList></Reference><Reference><Citation>Semaan D. B., Phillips A. R., Reitz K., et al., &#x201c;Improved Long&#x2010;Term Outcomes With Catheter&#x2010;Directed Therapies Over Medical Management in Patients With Submassive Pulmonary Embolism: A Retrospective Matched Cohort Study,&#x201d; Journal of Vascular Surgery: Venous and Lymphatic Disorders 11, no. 1 (January 2023): 70&#x2013;81, 10.1016/j.jvsv.2022.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2022.09.007</ArticleId><ArticleId IdType="pmc">PMC10024252</ArticleId><ArticleId IdType="pubmed">36210021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroupa J., Buk M., Weichet J., et al., &#x201c;A Pilot Randomised Trial of Catheter&#x2010;Directed Thrombolysis or Standard Anticoagulation for Patients With Intermediate&#x2010;High Risk Acute Pulmonary Embolism,&#x201d; EuroIntervention 18, no. 8 (October 2022): e639&#x2013;e646, 10.4244/eij-d-21-01080.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/eij-d-21-01080</ArticleId><ArticleId IdType="pubmed">35620984</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorgis S., Mawri S., Dabbagh M. F., et al., &#x201c;Ultrasound&#x2010;Assisted Catheter&#x2010;Directed Thrombolysis Versus Anticoagulation Alone for Management of Submassive Pulmonary Embolism,&#x201d; Journal of Cardiology 80, no. 5 (November 2022): 441&#x2013;448, 10.1016/j.jjcc.2022.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2022.04.008</ArticleId><ArticleId IdType="pubmed">35643741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley M., Bull T., Hountras P., and MacLaren R., &#x201c;Pragmatic Use of Catheter&#x2010;Directed Thrombolysis in Venous Thromboembolism and a Comparative Evaluation With Traditional Therapies in Submassive Pulmonary Embolism,&#x201d; Journal of Pharmacy Practice 35, no. 5 (October 2022): 738&#x2013;746, 10.1177/08971900211004833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08971900211004833</ArticleId><ArticleId IdType="pubmed">33823705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zulty M., Saleh N., Hernandez J., Kalaria A., Camire L., and Weisman D. S., &#x201c;Catheter&#x2010;Directed Therapy: Outcomes Versus Standard of Care and Evaluation of Current Practice,&#x201d; American Journal of Medicine 134, no. 3 (March 2021): 400&#x2013;404, 10.1016/j.amjmed.2020.09.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2020.09.045</ArticleId><ArticleId IdType="pubmed">33144134</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zden Omaygen&#xe7; D. and Omaygenc M. O., &#x201c;Comparison of Catheter&#x2010;Directed Thrombolysis and Anticoagulation in Intermediate&#x2010;Risk Pulmonary Embolism: A Retrospective Analysis,&#x201d; Eurasian Journal of Pulmonology 23, no. 1 (2021): 50&#x2013;58.</Citation></Reference><Reference><Citation>Kline T. M., Rodino A. M., Dorszynski A., Murray B., Cicci J., and Iyer P., &#x201c;Ultrasound&#x2010;Assisted Catheter&#x2010;Directed Thrombolysis Versus Systemic Anticoagulation Alone for Submassive Pulmonary Embolism,&#x201d; Journal of Thrombosis and Thrombolysis 52, no. 1 (July 2021): 130&#x2013;137, 10.1007/s11239-020-02278-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02278-2</ArticleId><ArticleId IdType="pubmed">32996083</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C. and Xie M., &#x201c;Clinical Outcomes of Intermediate&#x2010;Risk Pulmonary Embolism Across a Northeastern Health System: A Multi&#x2010;Center Retrospective Cohort Study,&#x201d; Cureus 13, no. 6 (June 2021): e15888, 10.7759/cureus.15888.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.15888</ArticleId><ArticleId IdType="pmc">PMC8312800</ArticleId><ArticleId IdType="pubmed">34336410</ArticleId></ArticleIdList></Reference><Reference><Citation>Haywood H. B., Pauley E., Orgel R., et al., &#x201c;Fibrinogen Levels and Bleeding Risk in Patients Undergoing Ultrasound&#x2010;Assisted Catheter&#x2010;Directed Thrombolysis for Submassive Pulmonary Embolism,&#x201d; Journal of Invasive Cardiology 33, no. 9 (September 2021): 702.</Citation><ArticleIdList><ArticleId IdType="pubmed">34148867</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein P. D., Matta F., and Hughes M. J., &#x201c;Catheter&#x2010;Directed Thrombolysis in Submassive Pulmonary Embolism and Acute Cor Pulmonale,&#x201d; American Journal of Cardiology 131 (September 2020): 109&#x2013;114, 10.1016/j.amjcard.2020.06.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2020.06.048</ArticleId><ArticleId IdType="pubmed">32718549</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekulic I., Dzudovic B., Matijasevic J., et al., &#x201c;Ultrasound Assisted Thrombolysis in Intermediate&#x2010;Risk Patients With Pulmonary Thromboembolism,&#x201d; Acta Cardiologica 75, no. 7 (November 2020): 623&#x2013;630, 10.1080/00015385.2019.1646850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00015385.2019.1646850</ArticleId><ArticleId IdType="pubmed">31368848</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Auria S., Sezer A., Thoma F., et al., &#x201c;Outcomes of Catheter&#x2010;Directed Thrombolysis vs. Standard Medical Therapy in Patients With Acute Submassive Pulmonary Embolism,&#x201d; Pulmonary Circulation 10, no. 1 (January/March 2020): 1&#x2013;8, 10.1177/2045894019898368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2045894019898368</ArticleId><ArticleId IdType="pmc">PMC7144676</ArticleId><ArticleId IdType="pubmed">32292583</ArticleId></ArticleIdList></Reference><Reference><Citation>Schissler A. J., Gylnn R. J., Sobieszczyk P. S., and Waxman A. B., &#x201c;Ultrasound&#x2010;Assisted Catheter&#x2010;Directed Thrombolysis Compared With Anticoagulation Alone for Treatment of Intermediate&#x2010;Risk Pulmonary Embolism,&#x201d; Pulmonary Circulation 8, no. 4 (October/December 2018): 1&#x2013;7, 10.1177/2045894018800265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2045894018800265</ArticleId><ArticleId IdType="pmc">PMC6134495</ArticleId><ArticleId IdType="pubmed">30142025</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S. K., Sachan M., Goel A., et al., &#x201c;Efficacy and Safety of Thrombolytic Therapy in Acute Submassive Pulmonary Embolism: Follow&#x2010;Up Study,&#x201d; Journal of Clinical Medicine Research 9, no. 2 (February 2017): 163&#x2013;169, 10.14740/jocmr2829w.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr2829w</ArticleId><ArticleId IdType="pmc">PMC5215020</ArticleId><ArticleId IdType="pubmed">28090232</ArticleId></ArticleIdList></Reference><Reference><Citation>Avgerinos E. D., Liang N. L., El&#x2010;Shazly O. M., et al., &#x201c;Improved Early Right Ventricular Function Recovery But Increased Complications With Catheter&#x2010;Directed Interventions Compared With Anticoagulation Alone for Submassive Pulmonary Embolism,&#x201d; Journal of Vascular Surgery: Venous and Lymphatic Disorders 4, no. 3 (July 2016): 268&#x2013;275, 10.1016/j.jvsv.2015.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2015.11.003</ArticleId><ArticleId IdType="pmc">PMC7151648</ArticleId><ArticleId IdType="pubmed">27318043</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer G., Vicaut E., Danays T., et al., &#x201c;Fibrinolysis for Patients With Intermediate&#x2010;Risk Pulmonary Embolism,&#x201d; New England Journal of Medicine 370, no. 15 (April 2014): 1402&#x2013;1411, 10.1056/NEJMoa1302097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1302097</ArticleId><ArticleId IdType="pubmed">24716681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucher N., Boekstegers P., M&#xfc;ller O. J., et al., &#x201c;Randomized, Controlled Trial of Ultrasound&#x2010;Assisted Catheter&#x2010;Directed Thrombolysis for Acute Intermediate&#x2010;Risk Pulmonary Embolism,&#x201d; Circulation 129, no. 4 (January 2014): 479&#x2013;486, 10.1161/circulationaha.113.005544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.113.005544</ArticleId><ArticleId IdType="pubmed">24226805</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline J. A., Nordenholz K. E., Courtney D. M., et al., &#x201c;Treatment of Submassive Pulmonary Embolism With Tenecteplase or Placebo: Cardiopulmonary Outcomes at 3 Months: Multicenter Double&#x2010;Blind, Placebo&#x2010;Controlled Randomized Trial,&#x201d; Journal of Thrombosis and Haemostasis 12, no. 4 (April 2014): 459&#x2013;468, 10.1111/jth.12521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12521</ArticleId><ArticleId IdType="pubmed">24484241</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifi M., Bay C., Skrocki L., Rahimi F., and Mehdipour M., &#x201c;Moderate Pulmonary Embolism Treated With Thrombolysis (From the &#x201c;MOPETT&#x201d; Trial),&#x201d; American Journal of Cardiology 111, no. 2 (January 2013): 273&#x2013;277, 10.1016/j.amjcard.2012.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2012.09.027</ArticleId><ArticleId IdType="pubmed">23102885</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasullo S., Scalzo S., Maringhini G., et al., &#x201c;Six&#x2010;Month Echocardiographic Study in Patients With Submassive Pulmonary Embolism and Right Ventricle Dysfunction: Comparison of Thrombolysis With Heparin,&#x201d; American Journal of the Medical Sciences 341, no. 1 (January 2011): 33&#x2013;39, 10.1097/MAJ.0b013e3181f1fc3e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAJ.0b013e3181f1fc3e</ArticleId><ArticleId IdType="pubmed">20890176</ArticleId></ArticleIdList></Reference><Reference><Citation>Becattini C., Agnelli G., Salvi A., et al., &#x201c;Bolus Tenecteplase for Right Ventricle Dysfunction in Hemodynamically Stable Patients With Pulmonary Embolism,&#x201d; Thrombosis Research 125, no. 3 (March 2010): e82&#x2013;e86, 10.1016/j.thromres.2009.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2009.09.017</ArticleId><ArticleId IdType="pubmed">19833379</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides S., Geibel A., Heusel G., Heinrich F., and Kasper W., &#x201c;Heparin Plus Alteplase Compared With Heparin Alone in Patients With Submassive Pulmonary Embolism,&#x201d; New England Journal of Medicine 347, no. 15 (October 2002): 1143&#x2013;1150, 10.1056/NEJMoa021274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa021274</ArticleId><ArticleId IdType="pubmed">12374874</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber S. Z., Come P. C., Lee R. T., et al., &#x201c;Alteplase Versus Heparin in Acute Pulmonary Embolism: Randomised Trial Assessing Right&#x2010;Ventricular Function and Pulmonary Perfusion,&#x201d; Lancet 341, no. 8844 (February 1993): 507&#x2013;511, 10.1016/0140-6736(93)90274-k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(93)90274-k</ArticleId><ArticleId IdType="pubmed">8094768</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalla&#x2010;Volta S., Palla A., Santolicandro A., et al., &#x201c;PAIMS 2: Alteplase Combined With Heparin Versus Heparin in the Treatment of Acute Pulmonary Embolism. Plasminogen Activator Italian Multicenter Study 2,&#x201d; Journal of the American College of Cardiology 20, no. 3 (September 1992): 520&#x2013;526, 10.1016/0735-1097(92)90002-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-1097(92)90002-5</ArticleId><ArticleId IdType="pubmed">1512328</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine M., Hirsh J., Weitz J., et al., &#x201c;A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients With Acute Pulmonary Embolism,&#x201d; Chest 98, no. 6 (December 1990): 1473&#x2013;1479, 10.1378/chest.98.6.1473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.98.6.1473</ArticleId><ArticleId IdType="pubmed">2123152</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei D. T., Liu J., Yaqoob M., et al., &#x201c;Meta&#x2010;Analysis of Catheter Directed Ultrasound&#x2010;Assisted Thrombolysis in Pulmonary Embolism,&#x201d; American Journal of Cardiology 124, no. 9 (November 2019): 1470&#x2013;1477, 10.1016/j.amjcard.2019.07.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.07.040</ArticleId><ArticleId IdType="pubmed">31492420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaymaz C., Akbal O. Y., Tanboga I. H., et al., &#x201c;Ultrasound&#x2010;Assisted Catheter&#x2010;Directed Thrombolysis in High&#x2010;Risk and Intermediate&#x2010;High&#x2010;Risk Pulmonary Embolism: A Meta&#x2010;Analysis,&#x201d; Current Vascular Pharmacology 16, no. 2 (January 2018): 179&#x2013;189, 10.2174/1570161115666170404122535.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570161115666170404122535</ArticleId><ArticleId IdType="pubmed">28393706</ArticleId></ArticleIdList></Reference><Reference><Citation>Daley M. J., Murthy M. S., and Peterson E. J., &#x201c;Bleeding Risk With Systemic Thrombolytic Therapy for Pulmonary Embolism: Scope of the Problem,&#x201d; Therapeutic Advances in Drug Safety 6, no. 2 (April 2015): 57&#x2013;66, 10.1177/2042098615572333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2042098615572333</ArticleId><ArticleId IdType="pmc">PMC4406921</ArticleId><ArticleId IdType="pubmed">25922654</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis G. M., Lam S. W., Reddy A. J., and Bauer S. R., &#x201c;Risk Factors Associated With Bleeding After Alteplase Administration for Pulmonary Embolism: A Case&#x2010;Control Study,&#x201d; Pharmacotherapy: Journal of Human Pharmacology and Drug Therapy 34, no. 8 (August 2014): 818&#x2013;825, 10.1002/phar.1440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/phar.1440</ArticleId><ArticleId IdType="pubmed">24854996</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J., Cao Y., Chen H., Gao W., and Wang Y., &#x201c;Systematic Review and Meta&#x2010;Analysis for Thrombolysis Treatment in Patients With Acute Submassive Pulmonary Embolism,&#x201d; Patient Preference and Adherence 8 (2014): 275&#x2013;282, 10.2147/ppa.S56280.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ppa.S56280</ArticleId><ArticleId IdType="pmc">PMC3945048</ArticleId><ArticleId IdType="pubmed">24611003</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S., Chakraborty A., Weinberg I., et al., &#x201c;Thrombolysis for Pulmonary Embolism and Risk of All&#x2010;Cause Mortality, Major Bleeding, and Intracranial Hemorrhage: A Meta&#x2010;Analysis,&#x201d; JAMA 311, no. 23 (June 2014): 2414&#x2013;2421, 10.1001/jama.2014.5990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.5990</ArticleId><ArticleId IdType="pubmed">24938564</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39064116</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>14</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>The Outcomes of Surgical Pulmonary Embolectomy for Pulmonary Embolism: A Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4076</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13144076</ELocationID><Abstract><AbstractText><b>Objectives:</b> The purpose of this study is to assess the efficacy, short- and long-term cardiovascular and non-cardiovascular mortalities and postoperative morbidities of surgical pulmonary embolectomy (SPE) for patients with massive or submassive pulmonary embolism. Methods: A comprehensive literature review was performed to identify articles reporting SPE for pulmonary embolism. The outcomes included in-hospital and long-term mortality in addition to postoperative morbidities. The random effect inverse variance method was used. Cumulative meta-analysis, leave-one-out sensitivity analysis, subgroup analysis and meta-regression were performed. <b>Results:</b> Among the 1949 searched studies in our systematic literature search, 78 studies met our inclusion criteria, including 6859 cases. The mean age ranged from 42 to 65 years. The percentage of males ranged from 25.6% to 86.7%. The median rate of preoperative cardiac arrest was 27.6%. The percentage of contraindications to preoperative systemic thrombolysis was 30.4%. The preoperative systemic thrombolysis use was 11.5%. The in-hospital mortality was estimated to be 21.96% (95% CI: 19.21-24.98); in-hospital mortality from direct cardiovascular causes was estimated to be 16.05% (95% CI: 12.95-19.73). With a weighted median follow-up of 3.05 years, the late cardiovascular and non-cardiovascular mortality incidence rates were 0.39 and 0.90 per person-year, respectively. The incidence of pulmonary bleeding, gastrointestinal bleeding, surgical site bleeding, non-surgical site bleeding and wound complications was 0.62%, 4.70%, 4.84%, 5.80% and 7.2%, respectively. Cumulative meta-analysis showed a decline in hospital mortality for SPE from 42.86% in 1965 to 20.56% in 2024. Meta-regression revealed that the publication year and male sex were associated with lower in-hospital mortality, while preoperative cardiac arrest, the need for inotropes or vasopressors and preoperative mechanical ventilation were associated with higher in-hospital mortality. <b>Conclusions</b>: This study demonstrates acceptable perioperative mortality rates and late cardiovascular and non-cardiovascular mortality in patients who undergo SPE for massive or submassive pulmonary embolism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rahouma</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8678-2060</Identifier><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, Weill Cornell Medicine, New York, NY 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Thani</LastName><ForeName>Shaikha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, Weill Cornell Medicine, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salem</LastName><ForeName>Haitham</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Ain Shams University Hospital, Ain Shams University, Cairo 11517, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahmoud</LastName><ForeName>Alzahraa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Beni Suef University, Beni Suef 2721562, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khairallah</LastName><ForeName>Sherif</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, Weill Cornell Medicine, New York, NY 10065, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgical Oncology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shenouda</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>New York Institute of Technology, New York, NY 10023, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultan</LastName><ForeName>Batool</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Rak Medical and Health Sciences University, Ras al Khaimah 11172, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalil</LastName><ForeName>Laila</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2772-9814</Identifier><AffiliationInfo><Affiliation>Weill Cornell Medicine, Doha 24144, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alomari</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3330-7239</Identifier><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Mostafa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makey</LastName><ForeName>Ian A</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haney</LastName><ForeName>John C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0009-0001-4002-0909</Identifier><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mick</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, Weill Cornell Medicine, New York, NY 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Sayed Ahmed</LastName><ForeName>Magdy M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Department, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Surgery Department, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">hospital mortality</Keyword><Keyword MajorTopicYN="N">pulmonary bleeding</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">surgical pulmonary embolectomy</Keyword><Keyword MajorTopicYN="N">thrombolysis</Keyword></KeywordList><CoiStatement>All authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>27</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39064116</ArticleId><ArticleId IdType="pmc">PMC11278425</ArticleId><ArticleId IdType="doi">10.3390/jcm13144076</ArticleId><ArticleId IdType="pii">jcm13144076</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldhaber S.Z. Surgical Pulmonary Embolectomy: The Resurrection of an Almost Discarded Operation. Tex. Heart Inst. J. 2013;40:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568292</ArticleId><ArticleId IdType="pubmed">23468580</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.-J., Harjola V.-P., Huisman M.V., Humbert M., Jennings C.S., Jim&#xe9;nez D., et al. 2019 ESC Guidelines for the Diagnosis and Management of Acute Pulmonary Embolism Developed in Collaboration with the European Respiratory Society (ERS) Eur. Heart J. 2020;41:543&#x2013;603. doi: 10.1093/eurheartj/ehz405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz405</ArticleId><ArticleId IdType="pubmed">31504429</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffett L., Castellucci L.A., Forgie M.A. Pulmonary Embolism: Update on Management and Controversies. BMJ. 2020;370:m2177. doi: 10.1136/bmj.m2177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2177</ArticleId><ArticleId IdType="pubmed">32759284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalra R., Bajaj N.S., Arora P., Arora G., Crosland W.A., McGiffin D.C., Ahmed M.I. Surgical Embolectomy for Acute Pulmonary Embolism: Systematic Review and Comprehensive Meta-Analyses. Ann. Thorac. Surg. 2017;103:982&#x2013;990. doi: 10.1016/j.athoracsur.2016.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.11.016</ArticleId><ArticleId IdType="pubmed">28159170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells G.A., Shea B., O&#x2019;Connell D., Peterson J., Welch V., Losos M., Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses.  [(accessed on 5 July 2024)].  Available online:  https://web.archive.org/web/20210716121605id_/http://www3.med.unipmn.it/dispense_ebm/2009-2010/Corso%20Perfezionamento%20EBM_Faggiano/NOS_oxford.pdf.</Citation></Reference><Reference><Citation>Hartman A.R., Manetta F., Lessen R., Pekmezaris R., Kozikowski A., Jahn L., Akerman M., Lesser M.L., Glassman L.R., Graver M., et al. Acute Surgical Pulmonary Embolectomy: A 9-Year Retrospective Analysis. Tex. Heart Inst. J. 2015;42:25&#x2013;29. doi: 10.14503/THIJ-13-3877.</Citation><ArticleIdList><ArticleId IdType="doi">10.14503/THIJ-13-3877</ArticleId><ArticleId IdType="pmc">PMC4378038</ArticleId><ArticleId IdType="pubmed">25873794</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed P., Khan A.A., Smith A., Pagala M., Abrol S., Cunningham J.N., Vaynblat M. Expedient Pulmonary Embolectomy for Acute Pulmonary Embolism: Improved Outcomes. Interact. Cardiovasc. Thorac. Surg. 2008;7:591&#x2013;594. doi: 10.1510/icvts.2008.176735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1510/icvts.2008.176735</ArticleId><ArticleId IdType="pubmed">18469011</ArticleId></ArticleIdList></Reference><Reference><Citation>Alqahtani F., Munir M.B., Aljohani S., Tarabishy A., Almustafa A., Alkhouli M. Surgical Thrombectomy for Pulmonary Embolism: Updated Performance Rates and Outcomes. Tex. Heart Inst. J. 2019;46:172&#x2013;174. doi: 10.14503/THIJ-18-6751.</Citation><ArticleIdList><ArticleId IdType="doi">10.14503/THIJ-18-6751</ArticleId><ArticleId IdType="pmc">PMC6827469</ArticleId><ArticleId IdType="pubmed">31708697</ArticleId></ArticleIdList></Reference><Reference><Citation>Amirghofran A.A., Emami Nia A., Javan R. Surgical Embolectomy in Acute Massive Pulmonary Embolism. Asian Cardiovasc. Thorac. Ann. 2007;15:149&#x2013;153. doi: 10.1177/021849230701500214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/021849230701500214</ArticleId><ArticleId IdType="pubmed">17387199</ArticleId></ArticleIdList></Reference><Reference><Citation>Argyriou A., Vohra H., Chan J., Ahmed E.M., Rajakaruna C., Angelini G.D., Fudulu D.P. Incidence and Outcomes of Surgical Pulmonary Embolectomy in the UK. Br. J. Surg. 2024;111:znae003. doi: 10.1093/bjs/znae003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bjs/znae003</ArticleId><ArticleId IdType="pmc">PMC11167207</ArticleId><ArticleId IdType="pubmed">38230762</ArticleId></ArticleIdList></Reference><Reference><Citation>Azari A., Bigdelu L., Moravvej Z. Surgical Embolectomy in the Management of Massive and Sub-Massive Pulmonary Embolism: The Results of 30 Consecutive Ill Patients. ARYA Atheroscler. 2015;11:208&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4568195</ArticleId><ArticleId IdType="pubmed">26405455</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett N.A., Byrne A., Delaney A., Hibbert M., Ramakrishnan N. Management of Massive Pulmonary Embolism: A Retrospective Single-Centre Cohort Study. Crit. Care Resusc. 2010;12:242&#x2013;247. doi: 10.1016/S1441-2772(23)01343-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1441-2772(23)01343-1</ArticleId><ArticleId IdType="pubmed">21143084</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer E., Laske A., Segesser L., Carrel T., Turina M. Early and Late Results after Surgery for Massive Pulmonary Embolism. Thorac. Cardiovasc. Surg. 1991;39:353&#x2013;356. doi: 10.1055/s-2007-1019998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-1019998</ArticleId><ArticleId IdType="pubmed">1788840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett J.M., Pretorius M., Ahmad R.M., Eagle S.S. Hemodynamic Instability in Patients Undergoing Pulmonary Embolectomy: Institutional Experience. J. Clin. Anesth. 2015;27:207&#x2013;213. doi: 10.1016/j.jclinane.2014.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinane.2014.10.007</ArticleId><ArticleId IdType="pubmed">25544262</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger R.L. Pulmonary Embolectomy with Preoperative Circulatory Support. Ann. Thorac. Surg. 1973;16:217&#x2013;227. doi: 10.1016/S0003-4975(10)64989-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(10)64989-2</ArticleId><ArticleId IdType="pubmed">4728607</ArticleId></ArticleIdList></Reference><Reference><Citation>Biglioli P., Alamanni F., Spirito R., Arena V. From deep venous thrombosis to pulmonary embolism. Cardiologia. 1991;36:195&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">1841770</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf8;ttzauw J., Vejlsted H., Albrechtsen O. Pulmonary Embolectomy Using Extracorporeal Circulation. Thorac. Cardiovasc. Surg. 1981;29:320&#x2013;322. doi: 10.1055/s-2007-1023507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-1023507</ArticleId><ArticleId IdType="pubmed">6179211</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulafendis D., Bastounis E., Panayiotopoulos Y.P., Papalambros E.L. Pulmonary Embolectomy (Answered and Unanswered Questions) Int. Angiol. J. Int. Union Angiol. 1991;10:187&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">1765724</ArticleId></ArticleIdList></Reference><Reference><Citation>Caleb M.G. Massive Pulmonary Embolism with Haemodynamic Collapse. Singap. Med. J. 2002;43:25&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12008772</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke D.B., Abrams L.D. Pulmonary Embolectomy: A 25 Year Experience. J. Thorac. Cardiovasc. Surg. 1986;92:442&#x2013;445. doi: 10.1016/S0022-5223(19)35798-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5223(19)35798-8</ArticleId><ArticleId IdType="pubmed">3747572</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauphine C., Omari B. Pulmonary Embolectomy for Acute Massive Pulmonary Embolism. Ann. Thorac. Surg. 2005;79:1240&#x2013;1244. doi: 10.1016/j.athoracsur.2004.08.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2004.08.081</ArticleId><ArticleId IdType="pubmed">15797055</ArticleId></ArticleIdList></Reference><Reference><Citation>De Weese J.A. The Role of Pulmonary Embolectomy in Venous Thromboembolism. J. Cardiovasc. Surg. 1976;17:348&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">939777</ArticleId></ArticleIdList></Reference><Reference><Citation>DiChiacchio L., Pasrija C., Boulos F.M., Ramani G., Jeudy J., Deatrick K.B., Griffith B.P., Kon Z.N. Occult Chronic Thromboembolic Disease in Patients Presenting for Surgical Pulmonary Embolectomy. Ann. Thorac. Surg. 2019;108:1183&#x2013;1188. doi: 10.1016/j.athoracsur.2019.03.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2019.03.088</ArticleId><ArticleId IdType="pubmed">31055039</ArticleId></ArticleIdList></Reference><Reference><Citation>Digonnet A., Moya-Plana A., Aubert S., Flecher E., Bonnet N., Leprince P., Pavie A., Gandjbakhch I. Acute Pulmonary Embolism: A Current Surgical Approach. Interdiscip. CardioVascular Thorac. Surg. 2007;6:27&#x2013;29. doi: 10.1510/icvts.2006.141366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1510/icvts.2006.141366</ArticleId><ArticleId IdType="pubmed">17669761</ArticleId></ArticleIdList></Reference><Reference><Citation>Doerge H., Schoendube F., Vo&#xdf; M., Seipelt R., Messmer B. Surgical Therapy of Fulminant Pulmonary Embolism: Early and Late Results. Thorac. Cardiovasc. Surg. 1999;47:9&#x2013;13. doi: 10.1055/s-2007-1013100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-1013100</ArticleId><ArticleId IdType="pubmed">10218613</ArticleId></ArticleIdList></Reference><Reference><Citation>Dohle K., Dohle D.-S., El Beyrouti H., Buschmann K., Emrich A.L., Brendel L., Vahl C.-F. Short- and Long-Term Outcomes for the Surgical Treatment of Acute Pulmonary Embolism. Innov. Surg. Sci. 2018;3:271&#x2013;276. doi: 10.1515/iss-2018-0024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/iss-2018-0024</ArticleId><ArticleId IdType="pmc">PMC6604590</ArticleId><ArticleId IdType="pubmed">31579791</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelman J.J., Okiwelu N., Anvardeen K., Joshi P., Murphy B., Sanders L.H., Newman M.A., Passage J. Surgical Pulmonary Embolectomy: Experience in a Series of 37 Consecutive Cases. Heart Lung Circ. 2016;25:1240&#x2013;1244. doi: 10.1016/j.hlc.2016.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2016.03.010</ArticleId><ArticleId IdType="pubmed">27423976</ArticleId></ArticleIdList></Reference><Reference><Citation>Estrera A.S., Platt M.R., Mills L.J. Pulmonary Embolectomy for Massive Pulmonary Embolism. Tex. Med. 1981;77:46&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">7209806</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedorov S.A., Pichugin V.V., Chiginev V.A., Brichkin Y.D., Kulkarni S.V., Tselousova L.M., Kalinina M.L., Taranov E.V., Domnin S.E. Domnin Possibilities and Perspectives of Retrograde Pulmonary Artery Perfusion as a Component of Surgical Treatment of Pulmonary Embolism. Opera Med. Physiol. 2022;9:95&#x2013;102. doi: 10.24412/2500-2295-2022-2-95-102.</Citation><ArticleIdList><ArticleId IdType="doi">10.24412/2500-2295-2022-2-95-102</ArticleId></ArticleIdList></Reference><Reference><Citation>Glassford D.M., Alford W.C., Burrus G.R., Stoney W.S., Thomas C.S. Pulmonary Embolectomy. Ann. Thorac. Surg. 1981;32:28&#x2013;32. doi: 10.1016/S0003-4975(10)61369-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(10)61369-0</ArticleId><ArticleId IdType="pubmed">7247558</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray H.H., Morgan J.M., Paneth M., Miller G.A. Pulmonary Embolectomy for Acute Massive Pulmonary Embolism: An Analysis of 71 Cases. Heart. 1988;60:196&#x2013;200. doi: 10.1136/hrt.60.3.196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.60.3.196</ArticleId><ArticleId IdType="pmc">PMC1216553</ArticleId><ArticleId IdType="pubmed">3179135</ArticleId></ArticleIdList></Reference><Reference><Citation>Greelish J.P., Leacche M., Solenkova N.S., Ahmad R.M., Byrne J.G. Improved Midterm Outcomes for Type A (Central) Pulmonary Emboli Treated Surgically. J. Thorac. Cardiovasc. Surg. 2011;142:1423&#x2013;1429. doi: 10.1016/j.jtcvs.2010.12.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2010.12.030</ArticleId><ArticleId IdType="pubmed">21481423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajizadeh R., Ghaffari S., Habibzadeh A., Safaei N., Mohammadi K., Ranjbar A., Ghodratizadeh S. Outcome of Surgical Embolectomy in Patients with Massive Pulmonary Embolism with and without Cardiopulmonary Resuscitation. Pol. J. Thorac. Cardiovasc. Surg. 2017;4:241&#x2013;244. doi: 10.5114/kitp.2017.72228.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/kitp.2017.72228</ArticleId><ArticleId IdType="pmc">PMC5767774</ArticleId><ArticleId IdType="pubmed">29354176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig K., Franke D., Fenn K. Pulmonary embolectomy (report on 3 personal cases) VASA Z. Gefasskrankh. 1974;3:342&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">4422163</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakob H., Vahl C., Lange R., Micek M., Tanzeem A., Hagl S. Modified Surgical Concept for Fulminant Pulmonary Embolism. Eur. J. Cardio-Thorac. Surg. 1995;9:557&#x2013;561. doi: 10.1016/S1010-7940(05)80005-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1010-7940(05)80005-3</ArticleId><ArticleId IdType="pubmed">8562100</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaumin P., Moriau M., el Gariani A., Rubay J., Baele P., Dautrebande J., Goenen M., Servaye-Kestens Y., Ponlot R. Pulmonary embolectomy. Clinical experience. Acta Chir. Belg. 1986;86:123&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">3716721</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeling W.B., Sundt T., Leacche M., Okita Y., Binongo J., Lasajanak Y., Aklog L., Lattouf O.M. Outcomes After Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus: A Multi-Institutional Study. Ann. Thorac. Surg. 2016;102:1498&#x2013;1502. doi: 10.1016/j.athoracsur.2016.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.05.004</ArticleId><ArticleId IdType="pubmed">27373187</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeling W.B., Leshnower B.G., Lasajanak Y., Binongo J., Guyton R.A., Halkos M.E., Thourani V.H., Lattouf O.M. Midterm Benefits of Surgical Pulmonary Embolectomy for Acute Pulmonary Embolus on Right Ventricular Function. J. Thorac. Cardiovasc. Surg. 2016;152:872&#x2013;878. doi: 10.1016/j.jtcvs.2015.11.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2015.11.042</ArticleId><ArticleId IdType="pubmed">26992603</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury E., Rabinov M., Davis B.B., Stirling G.R. Pulmonary Embolectomy in the Management of Massive Pulmonary Embolism. Australas. J. Card. Thorac. Surg. 1992;1:25&#x2013;26. doi: 10.1016/1037-2091(92)90008-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/1037-2091(92)90008-E</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieny R., Charpentier A., Kieny M.T. What Is the Place of Pulmonary Embolectomy Today? J. Cardiovasc. Surg. 1991;32:549&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">1939313</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinov I.E., Saxena P., Koniuszko M.D., Alvarez J., Newman M.A.J. Acute Massive Pulmonary Embolism with Cardiopulmonary Resuscitation: Management and Results. Tex. Heart Inst. J. 2007;34:41&#x2013;45; discussion 45&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847913</ArticleId><ArticleId IdType="pubmed">17420792</ArticleId></ArticleIdList></Reference><Reference><Citation>Laas J., Schmid C., Albes J.M., Borst H.G. Surgical aspects of fulminant pulmonary embolism. Z. Kardiol. 1993;82((Suppl. S2)):25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">8328205</ArticleId></ArticleIdList></Reference><Reference><Citation>Leacche M., Unic D., Goldhaber S.Z., Rawn J.D., Aranki S.F., Couper G.S., Mihaljevic T., Rizzo R.J., Cohn L.H., Aklog L., et al. Modern Surgical Treatment of Massive Pulmonary Embolism: Results in 47 Consecutive Patients after Rapid Diagnosis and Aggressive Surgical Approach. J. Thorac. Cardiovasc. Surg. 2005;129:1018&#x2013;1023. doi: 10.1016/j.jtcvs.2004.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2004.10.023</ArticleId><ArticleId IdType="pubmed">15867775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehnert P., M&#xf8;ller C.H., Carlsen J., Grande P., Steinbr&#xfc;chel D.A. Surgical Treatment of Acute Pulmonary Embolism&#x2014;A 12-Year Retrospective Analysis. Scand. Cardiovasc. J. 2012;46:172&#x2013;176. doi: 10.3109/14017431.2011.642811.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14017431.2011.642811</ArticleId><ArticleId IdType="pubmed">22369435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund O., Nielsen T., Schifter S., Roenne K. Treatment of Pulmonary Embolism with Full-Dose Heparin, Streptokinase or Embolectomy&#x2014;Results and Indications. Thorac. Cardiovasc. Surg. 1986;34:240&#x2013;246. doi: 10.1055/s-2007-1020420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-1020420</ArticleId><ArticleId IdType="pubmed">2429392</ArticleId></ArticleIdList></Reference><Reference><Citation>Malekan R., Saunders P.C., Yu C.J., Brown K.A., Gass A.L., Spielvogel D., Lansman S.L. Peripheral Extracorporeal Membrane Oxygenation: Comprehensive Therapy for High-Risk Massive Pulmonary Embolism. Ann. Thorac. Surg. 2012;94:104&#x2013;108. doi: 10.1016/j.athoracsur.2012.03.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2012.03.052</ArticleId><ArticleId IdType="pubmed">22542068</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall L., Mundy J., Garrahy P., Christopher S., Wood A., Griffin R., Shah P. Surgical Pulmonary Embolectomy: Mid-term Outcomes. ANZ J. Surg. 2012;82:822&#x2013;826. doi: 10.1111/j.1445-2197.2012.06190.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1445-2197.2012.06190.x</ArticleId><ArticleId IdType="pubmed">22943165</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattox K.L., Feldtman R.W., Beall A.C., DeBAKEY M.E. Pulmonary Embolectomy for Acute Massive Pulmonary Embolism. Ann. Surg. 1982;195:726&#x2013;731. doi: 10.1097/00000658-198206000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-198206000-00008</ArticleId><ArticleId IdType="pmc">PMC1352667</ArticleId><ArticleId IdType="pubmed">7082065</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer G., Tamisier D., Sors H., Stern M., Vouh&#xe9; P., Makowski S., Neveux J.-Y., Leca F., Even P. Pulmonary Embolectomy: A 20-Year Experience at One Center. Ann. Thorac. Surg. 1991;51:232&#x2013;236. doi: 10.1016/0003-4975(91)90792-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-4975(91)90792-O</ArticleId><ArticleId IdType="pubmed">1989537</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyns B., Sergeant P., Flameng W., Daenen W. Surgery for Massive Pulmonary Embolism. Acta Cardiol. 1992;47:487&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">1441856</ArticleId></ArticleIdList></Reference><Reference><Citation>Minakawa M., Fukuda I., Miyata H., Motomura N., Takamoto S., Taniguchi S., Daitoku K., Kondo N., Japan Cardiovascular Surgery Database Organization Outcomes of Pulmonary Embolectomy for Acute Pulmonary Embolism. Circ. J. 2018;82:2184&#x2013;2190. doi: 10.1253/circj.CJ-18-0371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1253/circj.CJ-18-0371</ArticleId><ArticleId IdType="pubmed">29952349</ArticleId></ArticleIdList></Reference><Reference><Citation>Mkalaluh S., Szczechowicz M., Karck M., Szabo G. Twenty-Year Results of Surgical Pulmonary Thromboembolectomy in Acute Pulmonary Embolism. Scand. Cardiovasc. J. 2019;53:98&#x2013;103. doi: 10.1080/14017431.2019.1600013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14017431.2019.1600013</ArticleId><ArticleId IdType="pubmed">30919668</ArticleId></ArticleIdList></Reference><Reference><Citation>Neely R.C., Byrne J.G., Gosev I., Cohn L.H., Javed Q., Rawn J.D., Goldhaber S.Z., Piazza G., Aranki S.F., Shekar P.S., et al. Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series of 115 Patients. Ann. Thorac. Surg. 2015;100:1245&#x2013;1252. doi: 10.1016/j.athoracsur.2015.03.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2015.03.111</ArticleId><ArticleId IdType="pubmed">26165484</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcomb G., Wilson B.L., White R.J., Goldman B., Lachant N.A., Lachant D.J. An Untapped Resource: Characteristics of Thrombus Recovered from Intermediate or High Risk Pulmonary Embolus Patients. Cardiovasc. Pathol. 2022;57:107392. doi: 10.1016/j.carpath.2021.107392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carpath.2021.107392</ArticleId><ArticleId IdType="pubmed">34718141</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne Z.J., Rossi P., Aucar J., Dharamsy S., Cook S., Wheatley B. Surgical Pulmonary Embolectomy in a Community Hospital. Am. J. Surg. 2014;207:337&#x2013;341. doi: 10.1016/j.amjsurg.2013.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2013.10.011</ArticleId><ArticleId IdType="pubmed">24418179</ArticleId></ArticleIdList></Reference><Reference><Citation>Panholzer B., Gravert H., Borzikowsky C., Huenges K., Schoettler J., Schoeneich F., Attmann T., Haneya A., Frank D., Cremer J., et al. Outcome after Surgical Embolectomy for Acute Pulmonary Embolism. J. Cardiovasc. Med. 2022;23:519&#x2013;523. doi: 10.2459/JCM.0000000000001349.</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000001349</ArticleId><ArticleId IdType="pubmed">35905002</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J., Lim S.-H., Hong Y.S., Park S., Lee C.J., Lee S.O. Acute Pulmonary Thromboembolism: 14 Years of Surgical Experience. Korean J. Thorac. Cardiovasc. Surg. 2019;52:78&#x2013;84. doi: 10.5090/kjtcs.2019.52.2.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.5090/kjtcs.2019.52.2.78</ArticleId><ArticleId IdType="pmc">PMC6493267</ArticleId><ArticleId IdType="pubmed">31089444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasrija C., Shah A., Sultanik E., Rouse M., Ghoreishi M., Bittle G.J., Boulos F., Griffith B.P., Kon Z.N. Minimally Invasive Surgical Pulmonary Embolectomy: A Potential Alternative to Conventional Sternotomy. Innov. Technol. Tech. Cardiothorac. Vasc. Surg. 2017;12:406&#x2013;410. doi: 10.1097/imi.0000000000000439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/imi.0000000000000439</ArticleId><ArticleId IdType="pubmed">29219944</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasrija C., Kronfli A., Rouse M., Raithel M., Bittle G.J., Pousatis S., Ghoreishi M., Gammie J.S., Griffith B.P., Sanchez P.G., et al. Outcomes after Surgical Pulmonary Embolectomy for Acute Submassive and Massive Pulmonary Embolism: A Single-Center Experience. J. Thorac. Cardiovasc. Surg. 2018;155:1095&#x2013;1106.e2. doi: 10.1016/j.jtcvs.2017.10.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2017.10.139</ArticleId><ArticleId IdType="pubmed">29452460</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Chen L., Chen D., Qiu H., Huang Z., Dai X., Huang X., Lin F., Chen H. Clinical Outcomes of Acute Pulmonary Embolectomy as the First-Line Treatment for Massive and Submassive Pulmonary Embolism: A Single-Centre Study in China. J. Cardiothorac. Surg. 2020;15:321. doi: 10.1186/s13019-020-01364-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-020-01364-z</ArticleId><ArticleId IdType="pmc">PMC7576708</ArticleId><ArticleId IdType="pubmed">33087152</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore K.S., Weightman W., Passage J., Joshi P., Sanders L., Newman M. Risk Stratification Using Serum Lactate in Patients Undergoing Surgical Pulmonary Embolectomy. J. Cardiothorac. Surg. 2020;35:1531&#x2013;1538. doi: 10.1111/jocs.14652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocs.14652</ArticleId><ArticleId IdType="pubmed">32598529</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas J., Bircks W., Nier H., Schneider E., Tarbiat S. Lungenembolie. DMW&#x2014;Dtsch. Med. Wochenschr. 1975;100:1239&#x2013;1243. doi: 10.1055/s-0028-1106363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0028-1106363</ArticleId><ArticleId IdType="pubmed">1132337</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa Y., Choi S., Lee J., Kwon J., Moon S., Jo K., Wang Y., Kim S., Kim P., Jung H. Off-Pump Open Pulmonary Embolectomy for Patients with Major Pulmonary Embolism. Heart Surg. Forum. 2007;10:E304&#x2013;E308. doi: 10.1532/HSF98.20071043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1532/HSF98.20071043</ArticleId><ArticleId IdType="pubmed">17599880</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi R., Ansarin K. Surgical Embolectomy in Treating Acute Massive Pulmonary Embolism. J. Pak. Med. Assoc. 2013;63:969&#x2013;972.</Citation></Reference><Reference><Citation>Sareyyupoglu B., Greason K.L., Suri R.M., Keegan M.T., Dearani J.A., Sundt T.M. A More Aggressive Approach to Emergency Embolectomy for Acute Pulmonary Embolism. Mayo Clin. Proc. 2010;85:785&#x2013;790. doi: 10.4065/mcp.2010.0250.</Citation><ArticleIdList><ArticleId IdType="doi">10.4065/mcp.2010.0250</ArticleId><ArticleId IdType="pmc">PMC2931613</ArticleId><ArticleId IdType="pubmed">20810792</ArticleId></ArticleIdList></Reference><Reference><Citation>Satter P. Pulmonary Embolectomy. Indication and Results. Ann. Radiol. 1980;23:321&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">7387088</ArticleId></ArticleIdList></Reference><Reference><Citation>Saylam A., Melo J.Q., Ahmad A., Chapman R.D., Wood J.A., Starr A. Pulmonary Embolectomy. West. J. Med. 1978;128:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1238147</ArticleId><ArticleId IdType="pubmed">664640</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiomi D., Kiyama H., Shimizu M., Yamada M., Shimada N., Takahashi A., Kaki N. Surgical Embolectomy for High-Risk Acute Pulmonary Embolism Is Standard Therapy. Interdiscip. CardioVascular Thorac. Surg. 2017;25:297&#x2013;301. doi: 10.1093/icvts/ivx091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivx091</ArticleId><ArticleId IdType="pubmed">28472317</ArticleId></ArticleIdList></Reference><Reference><Citation>Spagnolo S., Grasso M.A., Tesler U.F. Retrograde Pulmonary Perfusion Improves Results in Pulmonary Embolectomy for Massive Pulmonary Embolism. Tex. Heart Inst. J. 2006;33:473&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1764971</ArticleId><ArticleId IdType="pubmed">17215973</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalpaert G., Suy R., Daenen W., Flameng W., Sergeant P., Nevelsteen A., Lauwers P., De Geest H., Van Elst F. Surgical Treatment of Acute, Massive Lung Embolism. Results and Follow-Up. Acta Chir. Belg. 1986;86:118&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">3716720</ArticleId></ArticleIdList></Reference><Reference><Citation>Stulz P., Schlapfer R., Feer R., Habicht J., Gradel E. Decision Making in the Surgical Treatment of Massive Pulmonary Embolism. Eur. J. Cardio-Thorac. Surg. 1994;8:188&#x2013;193. doi: 10.1016/1010-7940(94)90113-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/1010-7940(94)90113-9</ArticleId><ArticleId IdType="pubmed">8031561</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H., Okada K., Matsumori M., Kano H., Kitagawa A., Okita Y. Aggressive Surgical Treatment of Acute Pulmonary Embolism with Circulatory Collapse. Ann. Thorac. Surg. 2012;94:785&#x2013;791. doi: 10.1016/j.athoracsur.2012.03.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2012.03.101</ArticleId><ArticleId IdType="pubmed">22698769</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi S., Fukuda W., Fukuda I., Watanabe K.-I., Saito Y., Nakamura M., Sakuma M. Outcome of Pulmonary Embolectomy for Acute Pulmonary Thromboembolism: Analysis of 32 Patients from a Multicentre Registry in Japan. Interact. Cardiovasc. Thorac. Surg. 2012;14:64&#x2013;67. doi: 10.1093/icvts/ivr018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivr018</ArticleId><ArticleId IdType="pmc">PMC3420282</ArticleId><ArticleId IdType="pubmed">22108928</ArticleId></ArticleIdList></Reference><Reference><Citation>Thielmann M., Pasa S., Wendt D., Price V., Marggraf G., Neuhauser M., Piotrowski A., Jakob H. Prognostic Significance of Cardiac Troponin I on Admission for Surgical Treatment of Acute Pulmonary Embolism: A Single-Centre Experience over More than 10 Years. Eur. J. Cardiothorac. Surg. 2012;42:951&#x2013;957. doi: 10.1093/ejcts/ezs122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezs122</ArticleId><ArticleId IdType="pubmed">22491666</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnier E., Hill J.D., Kerth W.J., Gerbode F. Massive Pulmonary Embolism. Am. J. Surg. 1973;125:611&#x2013;622. doi: 10.1016/0002-9610(73)90148-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9610(73)90148-7</ArticleId><ArticleId IdType="pubmed">4699205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullmann M., Hemmer W., Hannekum A. The Urgent Pulmonary Embolectomy: Mechanical Resuscitation in the Operating Theatre Determines the Outcome. Thorac. Cardiovasc. Surg. 1999;47:5&#x2013;8. doi: 10.1055/s-2007-1013099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-1013099</ArticleId><ArticleId IdType="pubmed">10218612</ArticleId></ArticleIdList></Reference><Reference><Citation>Vohra H.A., Whistance R.N., Mattam K., Kaarne M., Haw M.P., Barlow C.W., Tsang G.M.K., Livesey S.A., Ohri S.K. Early and Late Clinical Outcomes of Pulmonary Embolectomy for Acute Massive Pulmonary Embolism. Ann. Thorac. Surg. 2010;90:1747&#x2013;1752. doi: 10.1016/j.athoracsur.2010.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2010.08.002</ArticleId><ArticleId IdType="pubmed">21095299</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossschulte K., Stiller H., Eisenreich F. Emergency Embolectomy by the Transsternal Approach in Acute Pulmonary Embolism. Surgery. 1965;58:317&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">14316491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M.-Y., Liu Y.-C., Tseng Y.-H., Chang Y.-S., Lin P.-J., Wu T.-I. Pulmonary Embolectomy in High-Risk Acute Pulmonary Embolism: The Effectiveness of a Comprehensive Therapeutic Algorithm Including Extracorporeal Life Support. Resuscitation. 2013;84:1365&#x2013;1370. doi: 10.1016/j.resuscitation.2013.03.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2013.03.032</ArticleId><ArticleId IdType="pubmed">23583612</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalamanchili K., Fleisher A.G., Lehrman S.G., Axelrod H.I., Lafaro R.J., Sarabu M.R., Zias E.A., Moggio R.A. Open Pulmonary Embolectomy for Treatment of Major Pulmonary Embolism. Ann. Thorac. Surg. 2004;77:819&#x2013;823. doi: 10.1016/j.athoracsur.2003.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2003.08.008</ArticleId><ArticleId IdType="pubmed">14992879</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavuz S., Toktas F., Goncu T., Eris C., Gucu A., Ay D., Erdolu B., Tenekecioglu E., Karaagac K., Vural H., et al. Surgical Embolectomy for Acute Massive Pulmonary Embolism. Int. J. Clin. Exp. Med. 2014;7:5362&#x2013;5375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4307492</ArticleId><ArticleId IdType="pubmed">25664045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarrabi K., Zolghadrasli A., Ostovan M.A., Azimifar A., Malekmakan L. Residual Pulmonary Hypertension after Retrograde Pulmonary Embolectomy: Long-Term Follow-up of 30 Patients with Massive and Submassive Pulmonary Embolism. Interact. Cardiovasc. Thorac. Surg. 2013;17:242&#x2013;246. doi: 10.1093/icvts/ivt210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivt210</ArticleId><ArticleId IdType="pmc">PMC3715199</ArticleId><ArticleId IdType="pubmed">23677779</ArticleId></ArticleIdList></Reference><Reference><Citation>Zieli&#x144;ski D., Zygier M., Dyk W., Wojdyga R., Wr&#xf3;bel K., Pirsztuk E., Szostakiewicz K., Szatkowski P., Darocha S., Kurzyna M., et al. Acute Pulmonary Embolism with Coexisting Right Heart Thrombi in Transit-Surgical Treatment of 20 Consecutive Patients. Eur. J. Cardio-Thorac. Surg. Off. J. Eur. Assoc. Cardio-Thorac. Surg. 2023;63:ezad022. doi: 10.1093/ejcts/ezad022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezad022</ArticleId><ArticleId IdType="pubmed">36661312</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilic A., Shah A.S., Conte J.V., Yuh D.D. Nationwide Outcomes of Surgical Embolectomy for Acute Pulmonary Embolism. J. Thorac. Cardiovasc. Surg. 2013;145:373&#x2013;377. doi: 10.1016/j.jtcvs.2012.01.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2012.01.066</ArticleId><ArticleId IdType="pubmed">22341655</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein P.D., Alnas M., Beemath A., Patel N.R. Outcome of Pulmonary Embolectomy. Am. J. Cardiol. 2007;99:421&#x2013;423. doi: 10.1016/j.amjcard.2006.08.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2006.08.050</ArticleId><ArticleId IdType="pubmed">17261411</ArticleId></ArticleIdList></Reference><Reference><Citation>Poterucha T.J., Bergmark B., Aranki S., Kaneko T., Piazza G. Surgical Pulmonary Embolectomy. Circulation. 2015;132:1146&#x2013;1151. doi: 10.1161/CIRCULATIONAHA.115.015916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.015916</ArticleId><ArticleId IdType="pubmed">26391295</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33707559</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A systematic review with network meta-analysis on mono strategy of anaesthesia for preeclampsia in caesarean section.</ArticleTitle><Pagination><StartPage>5630</StartPage><MedlinePgn>5630</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5630</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-85179-5</ELocationID><Abstract><AbstractText>The aim of this study was to reveal the effects of anaesthesia strategies on maternal mean arterial pressure (MAP), heart rate, vasopressor consumption, adverse events, and neonatal resuscitation when women with preeclampsia (PE) undergo caesarean section (CS). Three major databases were searched for randomized controlled trials (RCTs) and prospective controlled studies (PCSs). Two authors independently screened, extracted, and checked eligibility and outcome data. Outcomes involved MAP, vasopressor use, maternal adverse events, APGAR scores, and neonatal resuscitation. Pooled estimates were carried out by contrast-based network meta-analysis, and pooled effect sizes were presented with 95% confidence interval (CI). Eleven RCTs and one PCS (n&#x2009;=&#x2009;782) formed three-node network meta-analysis, and non-significant differences were observed in MAP, 5-min APGAR score, and neonatal intubation rate among the three anaesthesia strategies. General anaesthesia had significantly lower vasopressor consumption than spinal anaesthesia did (standardised mean difference&#x2009;=&#x2009;&#x2009;-&#x2009;1.19, 95% confidence interval [CI]:&#x2009;-&#x2009;1.76 to&#x2009;-&#x2009;0.63), but it had higher maternal adverse event rate (risk ratio&#x2009;=&#x2009;2.00, 95% CI 1.16-3.47). Because no optimal anaesthesia strategy has been shown to achieve a balanced maternal and neonatal outcome, therefore a shared decision-making process may be required regarding the most suitable choice of anaesthetic strategy for individual preeclamptic mother undergoing CS. Future larger studies may need to focus on evaluating the role of vasopressors on maternal hemodynamic as well as factors affecting maternal outcomes for different anaesthetic techniques in preeclamptic women undergoing CS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cheng</LastName><ForeName>Chu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liao</LastName><ForeName>Alan Hsi-Wen</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Taipei Medical University Hospital, No. 252, Wuxing Street, Taipei, 11031, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chien-Yu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Taipei Medical University Hospital, No. 252, Wuxing Street, Taipei, 11031, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Cih</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Taipei Medical University Hospital, No. 252, Wuxing Street, Taipei, 11031, Taiwan. y.c.lin.tracy@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan. y.c.lin.tracy@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Yi-No</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. academicnono@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. academicnono@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan. academicnono@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan. academicnono@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000758" MajorTopicYN="Y">Anesthesia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062186" MajorTopicYN="N">Arterial Pressure</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="Y">Cesarean Section</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011225" MajorTopicYN="N">Pre-Eclampsia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011256" MajorTopicYN="N">Pregnancy Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33707559</ArticleId><ArticleId IdType="pmc">PMC7970950</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-85179-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-85179-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ramanathan J. Pathophysiology and anesthetic implications in preeclampsia. Clin. Obstet. Gynecol. 1992;35:414&#x2013;425. doi: 10.1097/00003081-199235020-00022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003081-199235020-00022</ArticleId><ArticleId IdType="pubmed">1638832</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariharan N, Shoemaker A, Wagner S. Pathophysiology of hypertension in preeclampsia. Microvasc. Res. 2017;109:34&#x2013;37. doi: 10.1016/j.mvr.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2016.10.002</ArticleId><ArticleId IdType="pubmed">27793558</ArticleId></ArticleIdList></Reference><Reference><Citation>Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: A systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013;170:1&#x2013;7. doi: 10.1016/j.ejogrb.2013.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2013.05.005</ArticleId><ArticleId IdType="pubmed">23746796</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WH, et al. Comparison between general, spinal, epidural, and combined spinal-epidural anesthesia for cesarean delivery: A network meta-analysis. Int. J. Obstet. Anesth. 2019;37:5&#x2013;15. doi: 10.1016/j.ijoa.2018.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijoa.2018.09.012</ArticleId><ArticleId IdType="pubmed">30415797</ArticleId></ArticleIdList></Reference><Reference><Citation>Izci B, et al. The upper airway in pregnancy and pre-eclampsia. Am. J. Respir. Crit. Care Med. 2003;167:137&#x2013;140. doi: 10.1164/rccm.200206-590OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200206-590OC</ArticleId><ArticleId IdType="pubmed">12411285</ArticleId></ArticleIdList></Reference><Reference><Citation>Roopa S, et al. Anesthetic management of combined emergency cesarean section and craniotomy for intracerebral hemorrhage in a patient with severe pre-eclampsia. Curr. Anaesth. Crit. Care. 2010;21:292&#x2013;295. doi: 10.1016/j.cacc.2010.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cacc.2010.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Aya AGM, et al. Patients with severe preeclampsia experience less hypotension during spinal anesthesia for elective cesarean delivery than healthy parturients: A prospective cohort comparison. Anesth. Analg. 2003;97:867&#x2013;872. doi: 10.1213/01.ane.0000073610.23885.f2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ane.0000073610.23885.f2</ArticleId><ArticleId IdType="pubmed">12933418</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer RA, Piercy JL, Reed AR. The role of the anaesthetist in the management of the pre-eclamptic patient. Curr. Opin. Anaesthesiol. 2007;20:168&#x2013;174. doi: 10.1097/ACO.0b013e328136c1ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0b013e328136c1ac</ArticleId><ArticleId IdType="pubmed">17479015</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones L, et al. Pain management for women in labour: An overview of systematic reviews. Cochrane Database Syst. Rev. 2012 doi: 10.1002/14651858.CD009234.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009234.pub2</ArticleId><ArticleId IdType="pmc">PMC7132546</ArticleId><ArticleId IdType="pubmed">22419342</ArticleId></ArticleIdList></Reference><Reference><Citation>Shnider SM, et al. Maternal catecholamines decrease during labor after lumbar epidural anesthesia. Am. J. Obstet. Gynecol. 1983;147:13&#x2013;15. doi: 10.1016/0002-9378(83)90076-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9378(83)90076-5</ArticleId><ArticleId IdType="pubmed">6614080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederman RP, Lederman E, Work B, Jr, McCann DS. Anxiety and epinephrine in multiparous women in labor: Relationship to duration of labor and fetal heart rate pattern. Am. J. Obstet. Gynecol. 1985;153:870&#x2013;877. doi: 10.1016/0002-9378(85)90692-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9378(85)90692-1</ArticleId><ArticleId IdType="pubmed">4073158</ArticleId></ArticleIdList></Reference><Reference><Citation>Jouppila R, Jouppila P, Hollm&#xe9;n A, Kuikka J. Effect of segmental extradural analgesia on placental blood flow during normal labour. Br. J. Anaesth. 1978;50:563&#x2013;567. doi: 10.1093/bja/50.6.563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/50.6.563</ArticleId><ArticleId IdType="pubmed">666930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanathan J, Coleman P, Sibai B. Anesthetic modification of hemodynamic and neuroendocrine stress responses to cesarean delivery in women with severe preeclampsia. Anesth. Analg. 1991;73:772&#x2013;779. doi: 10.1213/00000539-199112000-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/00000539-199112000-00016</ArticleId><ArticleId IdType="pubmed">1659254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hood DD, Curry R. Spinal versus epidural anesthesia for cesarean section in severely preeclamptic patients: A retrospective survey. Anesthesiology. 1999;90:1276&#x2013;1282. doi: 10.1097/00000542-199905000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-199905000-00009</ArticleId><ArticleId IdType="pubmed">10319773</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark VA, Sharwood-Smith GH, Stewart AVG. Ephedrine requirements are reduced during spinal anaesthesia for caesarean section in preeclampsia. Int. J. Obstet. Anesth. 2005;14:9&#x2013;13. doi: 10.1016/j.ijoa.2004.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijoa.2004.08.002</ArticleId><ArticleId IdType="pubmed">15627532</ArticleId></ArticleIdList></Reference><Reference><Citation>Visalyaputra S, et al. Spinal versus epidural anesthesia for cesarean delivery in severe preeclampsia: A prospective randomized, multicenter study. Anesth. Analg. 2005;101:862. doi: 10.1213/01.ANE.0000160535.95678.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ANE.0000160535.95678.34</ArticleId><ArticleId IdType="pubmed">16116005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CL, Mansor M, Ng KP, Chan YK. Retrospective review of spinal versus epidural anaesthesia for caesarean section in preeclamptic patients. Int. J. Obstet. Anesth. 2003;12:23&#x2013;27. doi: 10.1016/s0959-289x(02)00137-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0959-289x(02)00137-1</ArticleId><ArticleId IdType="pubmed">15676316</ArticleId></ArticleIdList></Reference><Reference><Citation>Izak M, Bussel JB. Management of thrombocytopenia. F1000Prime Rep. 2014;6:45&#x2013;45. doi: 10.12703/P6-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.12703/P6-45</ArticleId><ArticleId IdType="pmc">PMC4047949</ArticleId><ArticleId IdType="pubmed">24991422</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos AC, Birnbach DJ. Spinal anesthesia in the parturient with severe preeclampsia: Time for reconsideration. Anesth. Analg. 2003;97:621&#x2013;622. doi: 10.1213/01.ane.0000085017.03397.59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ane.0000085017.03397.59</ArticleId><ArticleId IdType="pubmed">12933372</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos AC. Spinal anesthesia in severely preeclamptic women: When is it safe? Anesthesiology. 1999;90:1252&#x2013;1254. doi: 10.1097/00000542-199905000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-199905000-00005</ArticleId><ArticleId IdType="pubmed">10319769</ArticleId></ArticleIdList></Reference><Reference><Citation>Chattopadhyay S, Das A, Pahari S. Fetomaternal outcome in severe preeclamptic women undergoing emergency cesarean section under either general or spinal anesthesia. J. Pregnan. 2014;325098&#x2013;325098:2014. doi: 10.1155/2014/325098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/325098</ArticleId><ArticleId IdType="pmc">PMC4016895</ArticleId><ArticleId IdType="pubmed">24864211</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta S, Chakraborty B, Saha D, Ghosh D. Comparison of neonatal outcome in women with severe pre-eclampsia undergoing caesarean section under spinal or general anaesthesia. J. Indian Med. Assoc. 2011;109:166&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">22010585</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinzhalova S, Makarov R, Davidova N. Comparison of general and spinal anaesthesia on haemodynamic parameters in severe preeclamptic pregnancy undergoing caesarean section. Eur. J. Anaesthesiol. 2013;30:178. doi: 10.1097/00003643-201306001-00555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003643-201306001-00555</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinzhalova SD, Makarov R. Haemodynamic parameters of pregnant women with chronic arterial hypertension during Caesarean section: Comparison of general and spinal anaesthesia: 11AP3&#x2013;6. Eur. J. Anaesthesiol. 2012;29:167&#x2013;168.</Citation></Reference><Reference><Citation>Kinzhalova SV, Makarov RA, Davydova NS. Central haemodynamics parameters during different anaesthesia methods of surgical delivery in preeclampsia women. Anesteziol. Reanimatol. 2012;5:52&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">23662522</ArticleId></ArticleIdList></Reference><Reference><Citation>Moslemi F, Rasooli S. Comparison of spinal versus general anesthesia for cesarean delivery in patients with severe preeclampsia. J. Med. Sci. 2007;7:1044&#x2013;1048. doi: 10.3923/jms.2007.1044.1048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3923/jms.2007.1044.1048</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharwood-Smith G, Clark V, Watson E. Regional anaesthesia for caesarean section in severe preeclampsia: Spinal anaesthesia is the preferred choice. Int. J. Obstet. Anesth. 1999;8:85&#x2013;89. doi: 10.1016/S0959-289X(99)80003-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-289X(99)80003-X</ArticleId><ArticleId IdType="pubmed">15321150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivevski AG, Sholjakova MV, Kartalov AB, Kuzmanovska BK, Durnev VM. Comparison of low dose spinal anesthesia with general anesthesia in pre-eclamptic parturients undergoing emergency cesarean section. Anaesth. Pain Intens. Care. 2015;19:37&#x2013;43.</Citation></Reference><Reference><Citation>Hodgkinson R, Husain FJ, Hayashi RH. Systemic and pulmonary blood pressure during caesarean section in parturients with gestational hypertension. Can. Anaesth. Soc. J. 1980;27:389&#x2013;394. doi: 10.1007/BF03007461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03007461</ArticleId><ArticleId IdType="pubmed">7407669</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DH, et al. Randomized comparison of general and regional anesthesia for cesarean delivery in pregnancies complicated by severe preeclampsia. Obstet. Gynecol. 1995;86:193&#x2013;199. doi: 10.1016/0029-7844(95)00139-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0029-7844(95)00139-I</ArticleId><ArticleId IdType="pubmed">7617349</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DH, et al. Randomized study of general anesthesia vs epidural or spinal-epidural analgesia for Cesarean section in pregnancies complicated by severe preeclampsia. Am. J. Obstet. Gynecol. 1992;166:302.</Citation></Reference><Reference><Citation>Mathur V, Nagrath A, Saxena S, Maheshwari M. Study of the maternal and neonatal outcome in caesarean deliveries in pregnancies complicated by pre-eclampsia conducted under general anaesthesia and regional anaesthesia. J. Obstet. Gynaecol. India. 2002;52:28&#x2013;32.</Citation></Reference><Reference><Citation>Sayg&#x131; A&#x130;, et al. Comparison of maternal and fetal outcomes among patients undergoing cesarean section under general and spinal anesthesia: A randomized clinical trial. Sao Paulo Med. J. 2015;133:227&#x2013;234. doi: 10.1590/1516-3180.2014.8901012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1516-3180.2014.8901012</ArticleId><ArticleId IdType="pmc">PMC10876380</ArticleId><ArticleId IdType="pubmed">26176927</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumpathong S, et al. Maternal and neonatal outcomes in women with severe pre-eclampsia undergoing cesarean section: A 10-year retrospective study from a single tertiary care center: Anesthetic point of view. J. Matern. Fetal Neona. 2016;29:4096&#x2013;4100. doi: 10.3109/14767058.2016.1159674.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14767058.2016.1159674</ArticleId><ArticleId IdType="pubmed">26952582</ArticleId></ArticleIdList></Reference><Reference><Citation>Algert CS, et al. Regional block versus general anaesthesia for caesarean section and neonatal outcomes: A population-based study. BMC Med. 2009;7:20&#x2013;20. doi: 10.1186/1741-7015-7-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-7-20</ArticleId><ArticleId IdType="pmc">PMC2683867</ArticleId><ArticleId IdType="pubmed">19402884</ArticleId></ArticleIdList></Reference><Reference><Citation>ACOG Practice Bulletin No 202: Gestational hypertension and preeclampsia. Obstet. Gynecol. 2019;133:e1&#x2013;e25. doi: 10.1097/AOG.0000000000003018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000003018</ArticleId><ArticleId IdType="pubmed">30575675</ArticleId></ArticleIdList></Reference><Reference><Citation>Butalia S, et al. Hypertension Canada's 2018 guidelines for the management of hypertension in pregnancy. Can. J. Cardiol. 2018;34:526&#x2013;531. doi: 10.1016/j.cjca.2018.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2018.02.021</ArticleId><ArticleId IdType="pubmed">29731014</ArticleId></ArticleIdList></Reference><Reference><Citation>Regitz-Zagrosek V, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur. Heart J. 2018;39:3165&#x2013;3241. doi: 10.1093/eurheartj/ehy340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy340</ArticleId><ArticleId IdType="pubmed">30165544</ArticleId></ArticleIdList></Reference><Reference><Citation>Magee LA, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: Executive summary. J. Obstet. Gynaecol. Can. 2014;36:416&#x2013;441. doi: 10.1016/s1701-2163(15)30588-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1701-2163(15)30588-0</ArticleId><ArticleId IdType="pubmed">24927294</ArticleId></ArticleIdList></Reference><Reference><Citation>Tranquilli AL, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnan. Hypertens. 2014;4:97&#x2013;104. doi: 10.1016/j.preghy.2014.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.preghy.2014.02.001</ArticleId><ArticleId IdType="pubmed">26104417</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MA, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72:24&#x2013;43. doi: 10.1161/HYPERTENSIONAHA.117.10803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.117.10803</ArticleId><ArticleId IdType="pubmed">29899139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe SA, et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust. N. Z. J. Obstet. Gynaecol. 2015;55:e1&#x2013;e29. doi: 10.1111/ajo.12399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajo.12399</ArticleId><ArticleId IdType="pubmed">26412014</ArticleId></ArticleIdList></Reference><Reference><Citation>Redman CWG. Hypertension in pregnancy: The NICE guidelines. Heart. 2011;97:1967&#x2013;1969. doi: 10.1136/heartjnl-2011-300949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2011-300949</ArticleId><ArticleId IdType="pubmed">21990386</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner JA. Severe preeclampsia: Anesthetic implications of the disease and its management. Am. J .Ther. 2009;16:284&#x2013;288. doi: 10.1097/MJT.0b013e31816f6fd8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MJT.0b013e31816f6fd8</ArticleId><ArticleId IdType="pubmed">19546805</ArticleId></ArticleIdList></Reference><Reference><Citation>Aya AGM, et al. Spinal anesthesia-induced hypotension: A risk comparison between patients with severe preeclampsia and healthy women undergoing preterm cesarean delivery. Anesth. Analg. 2005;101:869. doi: 10.1213/01.ANE.0000175229.98493.2B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ANE.0000175229.98493.2B</ArticleId><ArticleId IdType="pubmed">16116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Soma-Pillay P, Nelson-Piercy C, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc. J. Afr. 2016;27:89&#x2013;94. doi: 10.5830/CVJA-2016-021.</Citation><ArticleIdList><ArticleId IdType="doi">10.5830/CVJA-2016-021</ArticleId><ArticleId IdType="pmc">PMC4928162</ArticleId><ArticleId IdType="pubmed">27213856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindheimer MD, Katz AI. Preeclampsia: Pathophysiology, diagnosis, and management. Annu. Rev. Med. 1989;40:233&#x2013;250. doi: 10.1146/annurev.me.40.020189.001313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.me.40.020189.001313</ArticleId><ArticleId IdType="pubmed">2658750</ArticleId></ArticleIdList></Reference><Reference><Citation>Kee VR. Hemodynamic pharmacology of intravenous vasopressors. Crit. Care Nurse. 2003;23:79&#x2013;82. doi: 10.4037/ccn2003.23.4.79.</Citation><ArticleIdList><ArticleId IdType="doi">10.4037/ccn2003.23.4.79</ArticleId><ArticleId IdType="pubmed">12961786</ArticleId></ArticleIdList></Reference><Reference><Citation>Overgaard Christopher B, D&#x17e;av&#xed;k V. Inotropes and vasopressors. Circulation. 2008;118:1047&#x2013;1056. doi: 10.1161/CIRCULATIONAHA.107.728840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.728840</ArticleId><ArticleId IdType="pubmed">18765387</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations. Ann. Intern. Med. 2015;162:777&#x2013;784. doi: 10.7326/m14-2385.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m14-2385</ArticleId><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, et al. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley &amp; Sons; 2019.</Citation></Reference><Reference><Citation>Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann. Intern. Med. 2013;159:130&#x2013;137. doi: 10.7326/0003-4819-159-2-201307160-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-159-2-201307160-00008</ArticleId><ArticleId IdType="pubmed">23856683</ArticleId></ArticleIdList></Reference><Reference><Citation>Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: Many names, many benefits, many concerns for the next generation evidence synthesis tool. Res. Synth. Methods. 2012;3:80&#x2013;97. doi: 10.1002/jrsm.1037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1037</ArticleId><ArticleId IdType="pubmed">26062083</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: A technique to gather evidence from direct and indirect comparisons. Pharmacy Pract. 2017;15:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5386629</ArticleId><ArticleId IdType="pubmed">28503228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G, Ades A. Assessing evidence inconsistency in mixed treatment comparisons. J. Am. Stat. Assoc. 2006;101:447&#x2013;459. doi: 10.1198/016214505000001302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/016214505000001302</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J, et al. Consistency and inconsistency in network meta-analysis: Concepts and models for multi-arm studies. Res. Synth. Methods. 2012;3:98&#x2013;110. doi: 10.1002/jrsm.1044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1044</ArticleId><ArticleId IdType="pmc">PMC4433772</ArticleId><ArticleId IdType="pubmed">26062084</ArticleId></ArticleIdList></Reference><Reference><Citation>White IR. Network meta-analysis. Stata J. 2015;15:951&#x2013;985. doi: 10.1177/1536867X1501500403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1536867X1501500403</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RJ, et al. Metan: Fixed-and random-effects meta-analysis. Stata J. 2008;8:3&#x2013;28. doi: 10.1177/1536867X0800800102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1536867X0800800102</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolakopoulou A, et al. CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17:e1003082. doi: 10.1371/journal.pmed.1003082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003082</ArticleId><ArticleId IdType="pmc">PMC7122720</ArticleId><ArticleId IdType="pubmed">32243458</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33657926</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1938-9116</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Vascular and endovascular surgery</Title><ISOAbbreviation>Vasc Endovascular Surg</ISOAbbreviation></Journal><ArticleTitle>The Impact of COVID-19 on Vascular Surgery Practice: A Systematic Review.</ArticleTitle><Pagination><StartPage>601</StartPage><EndPage>611</EndPage><MedlinePgn>601-611</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1538574421998212</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 is characterized by a pulmonary interstitial compromise which can require intensive care unit (ICU) and mechanical ventilation. Covid patients develop a wide range of pathologies. This study aims to identify the impact of COVID-19 in diseases commonly treated by vascular surgeons.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Four conditions were selected: venous thromboembolism (VTE), pulmonary embolism (PE), peripheral arterial disease (PAD), and microangiopathy. A systematic review of the literature using PRISMA guidelines was.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Out of 1195 papers reviewed for conditions in COVID-19 patients relevant to routine vascular surgery practice, 43 papers were included and analyzed. Venous thrombosis was found to be the most common COVID-19 associated pathology with a cumulative incidence of 25% at 7 days and 48% at 14 days. Additionally, D-dimer levels proved to be a good predictor, even in the early stages of the disease with a sensitivity of 85%, specificity of 88.5% and a negative predictive value of 94.7%. Patients in the ICU demonstrated a significantly higher risk of developing VTE, even when receiving pharmacologic thromboprophylaxis. Although evidence of arterial thrombosis was less common (1% to 16.3%), its consequences were typically more serious, including limb loss and death even in young individuals (OR = 25, 95% CI). Finally, microangiopathy has a wide spectrum of clinical presentations from retinal microangiopathy to other more severe manifestations such as myocardial injury, pulmonary compromise and potential multiple organ dysfunction syndrome.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although the pathophysiological pathway by which COVID-19 produces thrombosis is not completely clear, the incidence of both arterial and venous thrombosis is increased. D-dimer screening should be done in all COVID-19 patients, as a predictor of thrombotic complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ulloa</LastName><ForeName>Jorge H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>27991Universidad de los Andes, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Valentin</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-6410-8430</Identifier><AffiliationInfo><Affiliation>173061Hospital Universitario de la Fundacion Santa Fe de Bogota, Bogot&#xe1;, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cifuentes</LastName><ForeName>Juan Sebastian</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-6180-7455</Identifier><AffiliationInfo><Affiliation>27991Universidad de los Andes, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>27991Universidad de los Andes, Bogota, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lurie</LastName><ForeName>Fedor</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0644-0560</Identifier><AffiliationInfo><Affiliation>92661Jobst Vascular Institute, Toledo, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Vasc Endovascular Surg</MedlineTA><NlmUniqueID>101136421</NlmUniqueID><ISSNLinking>1538-5744</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058729" MajorTopicYN="N">Peripheral Arterial Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057049" MajorTopicYN="N">Thrombotic Microangiopathies</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014656" MajorTopicYN="N">Vascular Surgical Procedures</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">microangiopathy</Keyword><Keyword MajorTopicYN="N">peripheral arterial disease</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>5</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33657926</ArticleId><ArticleId IdType="doi">10.1177/1538574421998212</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39768546</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>24</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Pulmonary Embolism Response Teams-Evidence of Benefits? A Systematic Review and Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7623</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13247623</ELocationID><Abstract><AbstractText><b>Background:</b> Venous thromboembolisms constitute a major cause of morbidity and mortality with 60,000 to 100,000 deaths attributed to pulmonary embolism in the US annually. Both clinical presentations and treatment strategies can vary greatly, and the selection of an appropriate therapeutic strategy is often provider specific. A pulmonary embolism response team (PERT) offers a multidisciplinary approach to clinical decision making and the management of high-risk pulmonary emboli. There is insufficient data on the effect of PERT programs on clinical outcomes. <b>Methods:</b> We searched PubMed, Scopus, Web of Science, and Cochrane to identify PERT studies through March 2024. The primary outcome was all-cause mortality, and the secondary outcomes included the rates of surgical thrombectomy, catheter directed thrombolysis, hospital length of stay (HLOS), and ICU length of stay (ICULOS). We used the Newcastle-Ottawa Scale tool to assess studies' quality. We used random-effects models to compare outcomes between the pooled populations and moderator analysis to identify sources of heterogeneity and perform subgroup analysis. <b>Results:</b> We included 13 observational studies, which comprised a total of 12,586 patients, 7512 (60%) patients were from the pre-PERT period and 5065 (40%) patients were from the PERT period. Twelve studies reported the rate of all-cause mortality for their patient population. Patients in the PERT period were associated with similar odds of all-cause mortality as patients in the pre-PERT period (OR: 1.52; 95% CI: 0.80-2.89; <i>p</i> = 0.20). In the random-effects meta-analysis, there was no significant difference in ICULOS between PERT and pre-PERT patients (difference in means: 0.08; 95% CI: -0.32 to 0.49; <i>p</i> = 0.68). There was no statistically significant difference in HLOS between the two groups (difference in means: -0.82; 95% CI: -2.86 to 1.23; <i>p</i> = 0.43). <b>Conclusions:</b> This meta-analysis demonstrates no significant difference in all studied measures in the pre- and post-PERT time periods, which notably included patient mortality and length of stay. Further study into the details of the PERT system at institutions reporting mortality benefits may reveal practice differences that explain the outcome discrepancy and could help optimize PERT implementation at other institutions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bryan</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-5757-2333</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tran</LastName><ForeName>Quincy K</ForeName><Initials>QK</Initials><Identifier Source="ORCID">0000-0002-7774-154X</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Program in Trauma, The R Adam Cowley Shock Trauma Center, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahari</LastName><ForeName>Jalil</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2794-3773</Identifier><AffiliationInfo><Affiliation>Pulmonary and Critical Care Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mclaughlin</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boone</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-6150-4323</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourmand</LastName><ForeName>Ali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8440-8454</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PERT</Keyword><Keyword MajorTopicYN="N">catheter-directed therapy</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">thrombolysis PE</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>1</Month><Day>8</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39768546</ArticleId><ArticleId IdType="pmc">PMC11728172</ArticleId><ArticleId IdType="doi">10.3390/jcm13247623</ArticleId><ArticleId IdType="pii">jcm13247623</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC  CDC Data and Statistics on Venous Thromboembolism.  [(accessed on 7 February 2024)]; Available online:  https://www.cdc.gov/blood-clots/index.html.</Citation></Reference><Reference><Citation>Freund Y., Cohen-Aubart F., Bloom B. Acute Pulmonary Embolism: A Review. JAMA. 2022;328:1336&#x2013;1345. doi: 10.1001/jama.2022.16815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.16815</ArticleId><ArticleId IdType="pubmed">36194215</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuomo J.R., Arora V., Wilkins T. Management of Acute Pulmonary Embolism with a Pulmonary Embolism Response Team. J. Am. Board Fam. Med. 2021;34:402&#x2013;408. doi: 10.3122/jabfm.2021.02.200308.</Citation><ArticleIdList><ArticleId IdType="doi">10.3122/jabfm.2021.02.200308</ArticleId><ArticleId IdType="pubmed">33833010</ArticleId></ArticleIdList></Reference><Reference><Citation>Licha C.R.M., McCurdy C.M., Maldonado S.M., Lee L.S. Current Management of Acute Pulmonary Embolism. Ann. Thorac. Cardiovasc. Surg. 2020;26:65&#x2013;71. doi: 10.5761/atcs.ra.19-00158.</Citation><ArticleIdList><ArticleId IdType="doi">10.5761/atcs.ra.19-00158</ArticleId><ArticleId IdType="pmc">PMC7184035</ArticleId><ArticleId IdType="pubmed">31588070</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortel T.L., Neumann I., Ageno W., Beyth R., Clark N.P., Cuker A., Hutten B.A., Jaff M.R., Manja V., Schulman S., et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693&#x2013;4738. doi: 10.1182/bloodadvances.2020001830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001830</ArticleId><ArticleId IdType="pmc">PMC7556153</ArticleId><ArticleId IdType="pubmed">33007077</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaff M.R., McMurtry M.S., Archer S.L., Cushman M., Goldenberg N., Goldhaber S.Z., Jenkins J.S., Kline J.A., Michaels A.D., Thistlethwaite P., et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: A scientific statement from the American Heart Association. Circulation. 2011;123:1788&#x2013;1830. doi: 10.1161/CIR.0b013e318214914f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0b013e318214914f</ArticleId><ArticleId IdType="pubmed">21422387</ArticleId></ArticleIdList></Reference><Reference><Citation>Vedantham S., Piazza G., Sista A.K., Goldenberg N.A. Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. J. Thromb. Thrombolysis. 2016;41:68&#x2013;80. doi: 10.1007/s11239-015-1318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-015-1318-z</ArticleId><ArticleId IdType="pmc">PMC4715849</ArticleId><ArticleId IdType="pubmed">26780739</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Lebron B.N., Rali P.M., Tapson V.F. The PERT Concept: A Step-by-Step Approach to Managing Pulmonary Embolism. Chest. 2021;159:347&#x2013;355. doi: 10.1016/j.chest.2020.07.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.07.065</ArticleId><ArticleId IdType="pubmed">32758561</ArticleId></ArticleIdList></Reference><Reference><Citation>Provias T., Dudzinski D.M., Jaff M.R., Rosenfield K., Channick R., Baker J., Weinberg I., Donaldson C., Narayan R., Rassi A.N., et al. The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): Creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism. Hosp. Pract. 2014;42:31&#x2013;37. doi: 10.3810/hp.2014.02.1089.</Citation><ArticleIdList><ArticleId IdType="doi">10.3810/hp.2014.02.1089</ArticleId><ArticleId IdType="pubmed">24566594</ArticleId></ArticleIdList></Reference><Reference><Citation>Todoran T.M., Giri J., Barnes G.D., Rosovsky R.P., Chang Y., Jaff M.R., Rosenfield K., Kabrhel C. PERT Consortium Treatment of submassive and massive pulmonary embolism: A clinical practice survey from the second annual meeting of the Pulmonary Embolism Response Team Consortium. J. Thromb. Thrombolysis. 2018;46:39&#x2013;49. doi: 10.1007/s11239-018-1659-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-018-1659-5</ArticleId><ArticleId IdType="pubmed">29667126</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosovsky R., Zhao K., Sista A., Rivera-Lebron B., Kabrhel C. Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. Res. Pract. Thromb. Haemost. 2019;3:315&#x2013;330. doi: 10.1002/rth2.12216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12216</ArticleId><ArticleId IdType="pmc">PMC6611377</ArticleId><ArticleId IdType="pubmed">31294318</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells G.A., Shea B., O&#x2019;Connell D., Pereson J., Welch V., Losos M., Tugwell P. Ottawa Hospital Research Institute.  [(accessed on 8 February 2024)].  Available online:  https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.</Citation></Reference><Reference><Citation>Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol. 2005;5:13. doi: 10.1186/1471-2288-5-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-5-13</ArticleId><ArticleId IdType="pmc">PMC1097734</ArticleId><ArticleId IdType="pubmed">15840177</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh M., Chahine N.M., Hammad T.A., Tefera L., Li J., Carman T., Schilz R., Shishehbor M.H. Predictors and potential advantages of PERT and advanced therapy use in acute pulmonary embolism. Catheter. Cardiovasc. Interv. 2021;97:1430&#x2013;1437. doi: 10.1002/ccd.29697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.29697</ArticleId><ArticleId IdType="pubmed">33844438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagoschen I., Scibior B., Farmakis I.T., Keller K., Graafen D., Griemert E.-V., Vosseler M., Treede H., M&#xfc;nzel T., Knorr M., et al. A multidisciplinary pulmonary embolism response team (PERT): First experience from a single center in Germany. Clin. Res. Cardiol. 2024;113:581&#x2013;590. doi: 10.1007/s00392-023-02364-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-023-02364-4</ArticleId><ArticleId IdType="pmc">PMC10954947</ArticleId><ArticleId IdType="pubmed">38112742</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhury P., Gadre S.K., Schneider E., Renapurkar R.D., Gomes M., Haddadin I., Heresi G.A., Tong M.Z., Bartholomew J.R. Impact of Multidisciplinary Pulmonary Embolism Response Team Availability on Management and Outcomes. Am. J. Cardiol. 2019;124:1465&#x2013;1469. doi: 10.1016/j.amjcard.2019.07.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.07.043</ArticleId><ArticleId IdType="pubmed">31495443</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll B.J., Beyer S.E., Mehegan T., Dicks A., Pribish A., Locke A., Godishala A., Soriano K., Kanduri J., Sack K., et al. Changes in Care for Acute Pulmonary Embolism Through a Multidisciplinary Pulmonary Embolism Response Team. Am. J. Med. 2020;133:1313&#x2013;1321.e6. doi: 10.1016/j.amjmed.2020.03.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2020.03.058</ArticleId><ArticleId IdType="pmc">PMC8076889</ArticleId><ArticleId IdType="pubmed">32416175</ArticleId></ArticleIdList></Reference><Reference><Citation>Jen W.-Y., Kristanto W., Teo L., Phua J., Yip H.S., MacLaren G., Teoh K., Sim T.B., Loh J., Ong C.C., et al. Assessing the Impact of a Pulmonary Embolism Response Team and Treatment Protocol on Patients Presenting with Acute Pulmonary Embolism. Heart Lung Circ. 2020;29:345&#x2013;353. doi: 10.1016/j.hlc.2019.02.190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2019.02.190</ArticleId><ArticleId IdType="pubmed">30910512</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed R., St Hill, C.A.; Engstrom, B.I.; Tierney, D.M.; Smith, C.S.; Agboto, V.K.; Weise, B.E.; Eckman, P.M.; Skeik, N. Effects of a Consensus-Based Pulmonary Embolism Treatment Algorithm and Response Team on Treatment Modality Choices, Outcomes, and Complications. Clin. Appl. Thromb. 2020;26:1076029620928420. doi: 10.1177/1076029620928420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029620928420</ArticleId><ArticleId IdType="pmc">PMC7427027</ArticleId><ArticleId IdType="pubmed">32539524</ArticleId></ArticleIdList></Reference><Reference><Citation>Myc L.A., Solanki J.N., Barros A.J., Nuradin N., Nevulis M.G., Earasi K., Richardson E.D., Tsutsui S.C., Enfield K.B., Teman N.R., et al. Adoption of a dedicated multidisciplinary team is associated with improved survival in acute pulmonary embolism. Respir. Res. 2020;21:159. doi: 10.1186/s12931-020-01422-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01422-z</ArticleId><ArticleId IdType="pmc">PMC7310489</ArticleId><ArticleId IdType="pubmed">32571318</ArticleId></ArticleIdList></Reference><Reference><Citation>Annabathula R., Dugan A., Bhalla V., Davis G.A., Smyth S.S., Gupta V.A. Value-based assessment of implementing a Pulmonary Embolism Response Team (PERT) J. Thromb. Thrombolysis. 2021;51:217&#x2013;225. doi: 10.1007/s11239-020-02188-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02188-3</ArticleId><ArticleId IdType="pmc">PMC8325945</ArticleId><ArticleId IdType="pubmed">32542527</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright C., Goldenberg I., Schleede S., McNitt S., Gosev I., Elbadawi A., Pietropaoli A., Barrus B., Chen Y.L., Mazzillo J., et al. Effect of a Multidisciplinary Pulmonary Embolism Response Team on Patient Mortality. Am. J. Cardiol. 2021;161:102&#x2013;107. doi: 10.1016/j.amjcard.2021.08.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2021.08.066</ArticleId><ArticleId IdType="pmc">PMC8761489</ArticleId><ArticleId IdType="pubmed">34794606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardeshna N.S., Song M., Hyder S.N., Grace K.A., O&#x2019;Hare C., Schaeffer W.J., Stover M., Greineder C.F., Barnes G.D. Effect of pulmonary embolism response team on advanced therapies administered: The University of Michigan experience. Thromb. Res. 2023;221:73&#x2013;78. doi: 10.1016/j.thromres.2022.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.11.017</ArticleId><ArticleId IdType="pmc">PMC10353850</ArticleId><ArticleId IdType="pubmed">36493540</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussein E.A., Semaan D.B., Phillips A.R., Andraska E.A., Rivera-Lebron B.N., Chaer R.A., Eslami M.H., Sridharan N. Pulmonary embolism response team for hospitalized patients with submassive and massive pulmonary embolism: A single-center experience. J. Vasc. Surg. Venous Lymphat. Disord. 2023;11:741&#x2013;747.e2. doi: 10.1016/j.jvsv.2023.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2023.03.002</ArticleId><ArticleId IdType="pubmed">36906104</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell N., Sayfo S., George T., Gable D. Effect of a pulmonary embolism response team on the management and outcomes of patients with acute pulmonary embolism. J. Vasc. Surg. 2024;80:A17. doi: 10.1016/j.jvs.2024.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvs.2024.05.024</ArticleId><ArticleId IdType="pubmed">37271478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosovsky R., Chang Y., Rosenfield K., Channick R., Jaff M.R., Weinberg I., Sundt T., Witkin A., Rodriguez-Lopez J., Parry B.A., et al. Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. J. Thromb. Thrombolysis. 2019;47:31&#x2013;40. doi: 10.1007/s11239-018-1737-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-018-1737-8</ArticleId><ArticleId IdType="pubmed">30242551</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33009716</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-7563</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Asia-Pacific journal of clinical oncology</Title><ISOAbbreviation>Asia Pac J Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>The venous thromboembolism prophylaxis in patients receiving thoracic surgery: A systematic review.</ArticleTitle><Pagination><StartPage>e142</StartPage><EndPage>e152</EndPage><MedlinePgn>e142-e152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ajco.13386</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Venous thromboembolism (VTE) is a significant and preventable cause of mortality and morbidity in thoracic surgery. It usually deep venous thromboembolism (DVT) and pulmonary thromboembolism (PE). We conducted this article to perform a systematic review on prophylaxis of perioperative VTE in patients undergoing thoracic surgery especially lung surgery and esophageal surgery and to identify potential areas for future research.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The systematic review we conducted included studies of patients undergoing thoracic surgery especially lung surgery and esophageal surgery RESULTS: The study identified 2621 references. Finally, 22 trials with a total of 9072 patients were included. Only six studies declared that they continued a follow-up after the discharge of the patients. (range: 1-3 months); three studies reported on major bleeding events as an outcome measure, and the incidence varied from 0.8% to 1.6%. Total 346 VTEs occurred, and the overall mean risk of VTE was estimated at 3.8% (range: 0.77-27%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The evidence for using thromboprophylaxis in thoracic surgery is limited and controversial, predominantly based on clinical consensus. Future research is needed to focus on identifying risk of VTE and providing sufficient evidence with high quality to support clinical strategies concerning the prophylaxis for VTE.</AbstractText><CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-1899-9444</Identifier><AffiliationInfo><Affiliation>Department of Thoracic Surgery, The Affiliated Brain Hospital of Nanjing Medical University (South Branch, Nanjing Chest Hospital), Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Jiefang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, The Affiliated Brain Hospital of Nanjing Medical University (South Branch, Nanjing Chest Hospital), Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Rusong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, The Affiliated Brain Hospital of Nanjing Medical University (South Branch, Nanjing Chest Hospital), Nanjing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Asia Pac J Clin Oncol</MedlineTA><NlmUniqueID>101241430</NlmUniqueID><ISSNLinking>1743-7555</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013903" MajorTopicYN="Y">Thoracic Surgery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">thoracic surgery</Keyword><Keyword MajorTopicYN="N">thromboprophylaxis</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>3</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33009716</ArticleId><ArticleId IdType="doi">10.1111/ajco.13386</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Cohen AT, Tapson VF, Bergmann JF, et&#xa0;al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394.</Citation></Reference><Reference><Citation>Goldhaber SZ, Tapson VF. A prospective registry of 5451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93(2):259-262.</Citation></Reference><Reference><Citation>Kahn SR, Panju A, Geerts W, et&#xa0;al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res. 2007;119(2):145-155.</Citation></Reference><Reference><Citation>Tapson VF, Decousus H, Pini M, et&#xa0;al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132(3):936-945.</Citation></Reference><Reference><Citation>Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722.</Citation></Reference><Reference><Citation>Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-815.</Citation></Reference><Reference><Citation>Geerts WH, Bergqvist D, Pineo GF, et&#xa0;al. Prevention of venous thromboembolism; American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(Suppl. 6):381-453.</Citation></Reference><Reference><Citation>Leonardi MJ, McGory ML, Ko CY. A systematic review of deep venous thrombosis prophylaxis in cancer patients: implications for improving quality. Ann Surg Oncol. 2007;14:929-936.</Citation></Reference><Reference><Citation>Fagarasanu A, Alotaibi GS, Hrimiuc R, Lee AY, Wu C. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:1422-1430.</Citation></Reference><Reference><Citation>Behranwala KA, Williamson RC. Cancer-associated venous thrombosis in the surgical setting. Ann Surg. 2009;249:366-375.</Citation></Reference><Reference><Citation>Gould MK, Garcia DA, Wren SM, et&#xa0;al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis. Chest. 2012;141:e227S-e277S.</Citation></Reference><Reference><Citation>Merkow RP, Bilimoria KY, McCarter MD, et&#xa0;al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011;254(1):131-137.</Citation></Reference><Reference><Citation>Agnelli G, Bolis G, Capussotti L, et&#xa0;al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery. The @RISTOS Project. Ann Surg. 2006;243(1):89-95.</Citation></Reference><Reference><Citation>Gangireddy C, Rectenwald JR, Upchurch GR, et&#xa0;al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg. 2007;45(2):335-342.</Citation></Reference><Reference><Citation>Jackaman FR, Perry BJ, Siddons H. Deep vein thrombosis after thoracotomy. Thorax. 1978;33:761-763.</Citation></Reference><Reference><Citation>Ljungstrom KG. Deep-vein thrombosis after major noncardiovascular thoracic surgery. Scand J Thorac Cardiovasc Surg. 1985;19:161-164.</Citation></Reference><Reference><Citation>Nagahiro I, Andou A, Aoe M, Sano Y, Date H, Shimizu N. Intermittent pneumatic compression is effective in preventing symptomatic pulmonary embolism after thoracic surgery. Surg Today. 2004;34(1):6-10.</Citation></Reference><Reference><Citation>Sugarbaker DJ, Jaklitsch MT, Bueno R, et&#xa0;al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138-146.</Citation></Reference><Reference><Citation>White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Thromb Haemost. 2003;90(3):446-455.</Citation></Reference><Reference><Citation>Song C, Shargall Y, Li H, et&#xa0;al. Prevalence of venous thromboembolism after lung surgery in China: a single-centre, prospective cohort study involving patients undergoing lung resections without perioperative venous thromboembolism prophylaxis. Eur J Cardiothorac Surg. 2019;55(3):455-460.</Citation></Reference><Reference><Citation>Bani-Hani M, Titi MA, Jaradat I, Al-KhaLaf H. Interventions for preventing venous thromboembolism following abdominal aortic surgery. Cochrane Database Syst Rev. 2008;(1):CD005509. https://doi.org/10.1002/14651858.CD005509.pub2</Citation></Reference><Reference><Citation>Ramos J, Perrotta C, Badariotti G, Berenstein G. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database Syst Rev. 2008;(4):CD005259.</Citation></Reference><Reference><Citation>Lyman GH, Bohlke K, Khorana AA, et&#xa0;al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol. 2015;33:654-656.</Citation></Reference><Reference><Citation>Farge D, Debourdeau P, Beckers M, et&#xa0;al. International Clinical Practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56-70.</Citation></Reference><Reference><Citation>Linkins LA, Dans AL, Moores LK, et&#xa0;al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S.</Citation></Reference><Reference><Citation>Cade JF, Clegg EA, Westlake GW. Prophylaxis of venous thrombosis after major thoracic surgery. Aust N Z J Surg. 1983;53(4):301-304.</Citation></Reference><Reference><Citation>Richardson RB, Dufresnet C, Staddontt GE, Chudry FA, Whitehead P, Jeyasinghamt K. A predictive index for postoperative deep vein thrombosis in thoracic surgery patients. Bristol Med Chir J. 1987;102(4):97-100.</Citation></Reference><Reference><Citation>Kalweit G, Huwer H, Volkmer I, Petzold T, Gams E. Pulmonary embolism: a frequent cause of acute fatality after lung resection. Eur J Cardiothorac Surg. 1996;10(4):242-246.</Citation></Reference><Reference><Citation>Tsutsumi K, Udagawa H, Kajiyama Y, et&#xa0;al. Pulmonary thromboembolism after surgery for esophageal cancer: its features and prophylaxis. Surg Today. 2000;30(5):416-420.</Citation></Reference><Reference><Citation>Daddi G, Milillo G, Lupattelli L, et&#xa0;al. Postoperative pulmonary embolism detected with multislice computed tomography in lung surgery for cancer. J Thorac Cardiovasc Surg. 2006;132(1):197-198.</Citation></Reference><Reference><Citation>Mason DP, Quader MA, Blackstone EH, et&#xa0;al. Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg. 2006;131(3):711-718.</Citation></Reference><Reference><Citation>Dentali F, Malato A, Ageno W, et&#xa0;al. Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. J Thorac Cardiovasc Surg. 2008;135(3):705-706.</Citation></Reference><Reference><Citation>Attaran S, Somov P, Awad WI. Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography. Eur J Cardiothorac Surg. 2010;37(6):1384-1390.</Citation></Reference><Reference><Citation>Rollins KE, Peters CJ, Safranek PM, Ford H, Baglin TP, Hardwick RH. Venous thromboembolism in oesophago-gastric carcinoma: incidence of symptomatic and asymptomatic events following chemotherapy and surgery. Eur J Surg Oncol. 2011;37(12):1072-1077.</Citation></Reference><Reference><Citation>Song JQ, Xuan LZ, Wu W, Huang JF, Zhong M. Low molecular weight heparin once versus twice for thromboprophylaxis following esophagectomy: a randomised, double-blind and placebo-controlled trial. J Thorac Dis. 2015;7(7):1158-1164.</Citation></Reference><Reference><Citation>Mantziari S, Gronnier C, Pasquer A, et&#xa0;al. Incidence and risk factors related to symptomatic venous thromboembolic events after esophagectomy for cancer. Ann Thorac Surg. 2016;102(3):979-984.</Citation></Reference><Reference><Citation>Agzarian J, Hanna WC, Schneider L, et&#xa0;al. Postdischarge venous thromboembolic complications following pulmonary oncologic resection: an underdetected problem. J Thorac Cardiovasc Surg. 2016;151(4):992-999.</Citation></Reference><Reference><Citation>Deng HY, Shi CL, Li G, et&#xa0;al. The safety profile of preoperative administration of heparin for thromboprophylaxis in Chinese patients intended for thoracoscopic major thoracic surgery: a pilot randomized controlled study. J Thorac Dis. 2017;9(4):1065-1072.</Citation></Reference><Reference><Citation>Parry K, Sadeghi AH, van der Horst S, Westerink J, Ruurda JP, van Hillegersberg R. Intermittent pneumatic compression in combination with low-molecular weight heparin in the prevention of venous thromboembolic events in esophageal cancer surgery. J Surg Oncol. 2017;115(2):181-185.</Citation></Reference><Reference><Citation>Christensen TD, Vad H, Pedersen S, et&#xa0;al. Coagulation profile in patients undergoing video-assisted thoracoscopic lobectomy: a randomized, controlled trial. PLoS One. 2017;12(2):e0171809.</Citation></Reference><Reference><Citation>Song J, Xuan L, Wu W, Shen Y, Tan L, Zhong M. Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: a randomized controlled trial. Thromb Res. 2018;166:22-27.</Citation></Reference><Reference><Citation>Pannucci CJ, Fleming KI, Holoyda K, Moulton L, Prazak AM, Varghese TK Jr. Enoxaparin 40 mg per day is inadequate for venous thromboembolism prophylaxis after thoracic surgical procedure. Ann Thorac Surg. 2018;106(2):404-411.</Citation></Reference><Reference><Citation>Alai GH, Deng HY, Li G, Luo J, Liu LX, Lin YD. The influence of heparin on coagulation function of patients undergoing video-assisted major thoracic surgery. J Thorac Dis. 2018;10(4):2288-2294.</Citation></Reference><Reference><Citation>Esme H, Can A, &#x15e;ehitogullari A. Does the use of postoperative low-molecular-weight heparin in patients with lung cancer increase tube drainage? Asian J Surg. 2020;43(1):278-281.</Citation></Reference><Reference><Citation>Wang X, Song S, Ni R, Lu M, Mao Y. Effectiveness of intraoperative administration of intermittent pneumatic compression in preventing deep vein thrombosis in lung cancer patients undergoing video-assisted thoracoscopic surgery lobectomy. J Thorac Dis. 2019;11(7):2832-2838.</Citation></Reference><Reference><Citation>Tanaka Y, Yamada A, Hirata S, et&#xa0;al. Efficacy and safety of enoxaparin for prophylaxis of postoperative venous thromboembolism after esophagectomy: a single-center prospective randomized controlled phase II study. Anticancer Res. 2019;39(5):2615-2625.</Citation></Reference><Reference><Citation>A-Lai GH, Zhu YK, Li G, et&#xa0;al. Preoperative thromboprophylactic administration of low-molecular-weight-heparin significantly decreased the risk of intraoperative bleeding compared with heparin in patients undergoing video-assisted lobectomy for lung cancer. Ann Transl Med. 2019;7(5):90.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29909859</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2213-3348</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of vascular surgery. Venous and lymphatic disorders</Title><ISOAbbreviation>J Vasc Surg Venous Lymphat Disord</ISOAbbreviation></Journal><ArticleTitle>A meta-analysis of outcomes of catheter-directed thrombolysis for high- and intermediate-risk pulmonary embolism.</ArticleTitle><Pagination><StartPage>530</StartPage><EndPage>540</EndPage><MedlinePgn>530-540</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvsv.2018.03.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-333X(18)30141-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE">During the past few years, there has been a surge in the use of catheter-directed thrombolysis (CDT) for acute pulmonary embolism (PE), in the form of either standard CDT or ultrasound-assisted CDT (usCDT). This is a systematic review and meta-analysis of all published series on contemporary CDT for acute PE seeking to determine their clinical efficacy, stratifying by PE severity and CDT modality.</AbstractText><AbstractText Label="METHODS">A comprehensive MEDLINE and Embase search was performed to identify studies that reported outcomes of CDT for acute PE published from 2009 to July 2017. Outcomes included clinical success (in-hospital survival with stabilization of hemodynamics, without decompensation or any major complication), in-hospital mortality, major bleeding, right ventricular/left ventricular ratio, and Miller score changes after CDT. Meta-analyses assumed random effects.</AbstractText><AbstractText Label="RESULTS">Twenty studies with 1168 patients were included in the meta-analysis. Available for subgroup analysis were 210&#xa0;patients with high-risk PE and 945 patients with intermediate-risk PE; 181 patients received CDT using a standard multiside hole catheter, and 850 received usCDT. The pooled average right ventricular/left ventricular improvement and Miller score drop after CDT were 0.30 (95% confidence interval [CI], 0.22-0.39) and 8.8 (95% CI, 7.1-10.5). For high-risk PE, the pooled estimate for clinical success was 81.3% (95% CI, 72.5%-89.1%), the 30-day mortality estimate was 8.0% (95% CI, 3.2%-14.0%), and major bleeding was 6.7% (95% CI, 1.0%-15.3%). For intermediate-risk PE, the pooled estimate for clinical success was 97.5% (95% CI, 95.3%-99.1%), the 30-day mortality was 0% (95% CI, 0%-0.5%), and major bleeding was 1.4% (95% CI, 0.3%-2.8%). In high-risk PE, clinical success for CDT and usCDT was 70.8% (95% CI, 53.4%-85.8%) and 83.1% (95%&#xa0;CI, 68.5%-94.5%), respectively. In intermediate-risk PE, clinical success for CDT and usCDT was 95.0% (95% CI, 88.5%-99.2%) and 97.5% (95% CI, 95.0%-99.4%), respectively.</AbstractText><AbstractText Label="CONCLUSIONS">Catheter thrombolysis has high clinical success rates in both high- and intermediate-risk PE, but higher mortality and bleeding rates should be anticipated in high-risk PE. Ultrasound-assisted thrombolysis may be more effective than standard CDT in the higher risk population.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Avgerinos</LastName><ForeName>Efthymios D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saadeddin</LastName><ForeName>Zein</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abou Ali</LastName><ForeName>Adham N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fish</LastName><ForeName>Larry</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toma</LastName><ForeName>Catalin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaer</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera-Lebron</LastName><ForeName>Belinda N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaer</LastName><ForeName>Rabih A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa. Electronic address: chaerra@upmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Surg Venous Lymphat Disord</MedlineTA><NlmUniqueID>101607771</NlmUniqueID><ISSNLinking>2213-333X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002406" MajorTopicYN="Y">Catheterization, Peripheral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018084" MajorTopicYN="N">Ultrasonography, Interventional</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Catheter-directed thrombolysis</Keyword><Keyword MajorTopicYN="N">Ultrasound-assisted thrombolysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29909859</ArticleId><ArticleId IdType="doi">10.1016/j.jvsv.2018.03.010</ArticleId><ArticleId IdType="pii">S2213-333X(18)30141-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39192283</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-799X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of orthopaedic surgery and research</Title><ISOAbbreviation>J Orthop Surg Res</ISOAbbreviation></Journal><ArticleTitle>Intravenous versus topical tranexamic acid in spinal surgery: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>512</StartPage><MedlinePgn>512</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">512</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13018-024-04989-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The administration of tranexamic acid (TXA) during spinal surgery has been shown to reduce blood loss. However, the efficacy and safety of intravenous TXA (ivTXA) and topical TXA (tTXA) are poorly documented. The present meta-analysis aimed to compare the efficacy and safety of ivTXA and tTXA administration in spinal surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Potentially relevant academic articles were identified from PubMed, Ovid, Cochrane Library, CNKI database, and Wanfang Data from the date of inception until March 1, 2024. Randomized controlled trials (RCTs) and nonrandomized controlled trials (non-RCTs) were included in our meta-analysis if they compared the efficacy and safety of ivTXA versus tTXA administration during spinal surgery. Secondary sources were identified from the references of the included literature. The meta-analysis was performed in accordance with the guidelines of the Cochrane Reviewer's Handbook and the PRISMA statement. Data were summarized using RevMan 5.3 software from Denmark.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four RCTs and one non-RCT met our inclusion criteria. The pooled outcomes demonstrated that ivTXA groups compared with tTXA groups had significantly less amount of total blood loss [weighted mean difference (WMD)=-159.55, 95% CI (-181.91,-137.19), P&#x2009;&lt;&#x2009;0.00001], hidden blood loss [WMD=-132.27, 95% CI (-159.81, -104.72), P&#x2009;&lt;&#x2009;0.00001], intraoperative blood loss [WMD=-86.22, 95% CI (-99.13, -73.31), P&#x2009;&lt;&#x2009;0.00001, I<sup>2</sup>&#x2009;=&#x2009;96%], and more high postoperative hemoglobin level [WMD&#x2009;=&#x2009;8.96, 95% CI (5.18, 12.75), P&#x2009;&lt;&#x2009;0.00001, I<sup>2</sup>&#x2009;=&#x2009;29%], and less transfusion rate [risk ratio (RR)&#x2009;=&#x2009;1.11, 95% CI (0.81,1.52), P&#x2009;=&#x2009;0.50, I<sup>2</sup>&#x2009;=&#x2009;94%]. The pooled results showed no significant difference in thromboembolic events (deep venous thrombosis and pulmonary embolism) between the two groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our meta-analysis demonstrated that ivTXA was more effective than tTXA in inducing hemostatic effect during spinal surgery. However, the risk of a thrombotic event was not different between the two administration methods of TXA. More high quality RCTs are needed to further confirm our conclusions.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Orthopedics Department, The Seven Affiliated Hospital of South China University, Changsha, 410000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xudong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Orthopedics Department, The Seven Affiliated Hospital of South China University, Changsha, 410000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Orthopedics Department, The Seven Affiliated Hospital of South China University, Changsha, 410000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Xiaozhong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Orthopedics Department, The Seven Affiliated Hospital of South China University, Changsha, 410000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xueliang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Spine Surgery, The Second Affiliated Hospital of South China University, Hengyang, 421000, China. 63754628@qq.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Life Science, Central South University, Changsha, 410000, China. 63754628@qq.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NO</GrantID><Agency>No</Agency><Country/></Grant><Grant><GrantID>NO</GrantID><Agency>No</Agency><Country/></Grant><Grant><GrantID>NO</GrantID><Agency>No</Agency><Country/></Grant><Grant><GrantID>NO</GrantID><Agency>No</Agency><Country/></Grant><Grant><GrantID>NO</GrantID><Agency>No</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Orthop Surg Res</MedlineTA><NlmUniqueID>101265112</NlmUniqueID><ISSNLinking>1749-799X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="Y">Administration, Intravenous</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000287" MajorTopicYN="Y">Administration, Topical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="Y">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="Y">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013131" MajorTopicYN="N">Spine</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="Y">Tranexamic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Intravenous</Keyword><Keyword MajorTopicYN="N">Spinal surgery</Keyword><Keyword MajorTopicYN="N">Topical</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>2</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>27</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39192283</ArticleId><ArticleId IdType="pmc">PMC11348596</ArticleId><ArticleId IdType="doi">10.1186/s13018-024-04989-1</ArticleId><ArticleId IdType="pii">10.1186/s13018-024-04989-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nuttall GA, Horlocker TT, Santrach PJ, Oliver WC Jr, Dekutoski MB, Bryant S. Predictors of blood transfusions in spinal instrumentation and fusion surgery. Spine (Philadelphia Pa 1976). 2000;25(5):596&#x2013;601.10.1097/00007632-200003010-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007632-200003010-00010</ArticleId><ArticleId IdType="pubmed">10749636</ArticleId></ArticleIdList></Reference><Reference><Citation>Theusinger OM, Spahn DR. Perioperative blood conservation strategies for major spine surgery. Best Pract Res Clin Anaesthesiol. 2016;30:41&#x2013;52. 10.1016/j.bpa.2015.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpa.2015.11.007</ArticleId><ArticleId IdType="pubmed">27036602</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen SJ, Braun Y, Wood KB, Cha TD, Schwab JH. Allogeneic blood transfusions and postoperative infections after lumbar spine surgery. Spine J. 2015;15:901&#x2013;9. 10.1016/j.spinee.2015.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spinee.2015.02.010</ArticleId><ArticleId IdType="pubmed">25681582</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardone D, Klein AA. Perioperative blood conservation. Eur J Anaesthesiol. 2009;26:722&#x2013;9. 10.1097/EJA.0b013e32832c5280</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0b013e32832c5280</ArticleId><ArticleId IdType="pubmed">19448549</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu SS. Blood loss in adult spinal surgery. Eur Spine J. 2004;13(Suppl 1):53&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592187</ArticleId><ArticleId IdType="pubmed">15197630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui S, Xu D, Ren Z, et al. Can txanexamic acid conserve blood and save operative time in spinal surgeries? A meta-analysis. Spine J. 2018;18:1325&#x2013;37. 10.1016/j.spinee.2017.11.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spinee.2017.11.017</ArticleId><ArticleId IdType="pubmed">29246849</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J, Beheiry EI, Rampersaud H, Lewis YR, Ahn S, De Silva H, Abrishami Y, Baig A, McBroom N. Chung F:tranexamic acid reduces perioperative blood loss in adult patients having spinal fusion surgery. Anesth Analg. 2008;107:1479&#x2013;86. 10.1213/ane.0b013e3181831e44</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0b013e3181831e44</ArticleId><ArticleId IdType="pubmed">18931202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt BJ. The current place of tranexamic acid in the management of bleeding. Anaesthesia. 2015;70:50&#x2013;e18. 10.1111/anae.12910</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.12910</ArticleId><ArticleId IdType="pubmed">25440395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Liang Y, Chen P, Fang Y, He J, Wang J. Combined application versus topical and intravenous application of tranexamic acid following primary total hip arthroplasty: a meta-analysis. BMC Musculoskelet Disord. 2017;18(1):90. 10.1186/s12891-017-1429-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-017-1429-0</ArticleId><ArticleId IdType="pmc">PMC5320770</ArticleId><ArticleId IdType="pubmed">28222709</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngichabe S, Obura T, Stones W. Intravenous tranexamic acid as an adjunct haemostat to ornipressin during open myomectomy. A randomized double blind placebo controlled trial. Ann Surg Innov Res. 2015;9:1&#x2013;6. 10.1186/s13022-015-0017-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13022-015-0017-y</ArticleId><ArticleId IdType="pmc">PMC4644022</ArticleId><ArticleId IdType="pubmed">26568770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonis MD, Cavaliere F, Alessandrini F, et al. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000;119:575&#x2013;80. 10.1016/S0022-5223(00)70139-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5223(00)70139-5</ArticleId><ArticleId IdType="pubmed">10694619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Luo Ru-xin, Han Jiangand Xin-long Ma. The efficacy and safety of topical administration of tranexamic acid in spine surgery: a meta-analysis. J Orthop Surg Res. 2018;13(1):96. 10.1186/s13018-018-0815-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-018-0815-0</ArticleId><ArticleId IdType="pmc">PMC5937828</ArticleId><ArticleId IdType="pubmed">29690892</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima N, Barra ME, Roberts RJ, Massaad E, Hadzipasic M, Shankar GM, Shin JH. Advances in surgical hemostasis: a comprehensive review and meta-analysis on topical tranexamic acid in spinal deformity surgery. Neurosurg Rev. 2020;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31938967</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerneni K, Burke JF, Tuchman A, Li XJ, Metz LN, Lehman RA Jr, Lenke LG, Tan LA. Topical tranexamic acid in spinal surgery: a systematic review and meta-analysis. J Clin Neurosci. 2019;61:114&#x2013;9. 10.1016/j.jocn.2018.10.121</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2018.10.121</ArticleId><ArticleId IdType="pubmed">30401569</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui S, Tao L, Mahmood F, Xu D, Ren Z, Chen X, Sheng L, Zhuang Q, Li S, Huang Y. Tranexamic acid in reducing gross hemorrhage and transfusions of spine surgeries (TARGETS): Study protocol for a prospective, randomized, double-blind, non-inferiority trial. Trials. 2019,12;20(1):125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6373130</ArticleId><ArticleId IdType="pubmed">30755256</ArticleId></ArticleIdList></Reference><Reference><Citation>ZhangP, Liang Y, Chen P, Fang Y, He J, Wang J. Intravenous versus topical tranexamic acid in primary total hip replacement: a meta-analysis. Medicine(Baltimore). 2016;95(50):e5573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5268036</ArticleId><ArticleId IdType="pubmed">27977590</ArticleId></ArticleIdList></Reference><Reference><Citation>MENG, Xian-yong H, Changbo. Yang Xin-ming. Effects of tranexamic acid on lumbar surgery by different ways of administration. J Hebei Med Univ. 2017;38(1):29&#x2013;37.</Citation></Reference><Reference><Citation>Mu X, Wei J, Wang C, Ou Y, Yin D, Liang B, Qiu D, Li Z. Intravenous administration of tranexamic acid significantly reduces visible and hidden blood loss compared with its topical administration for double-segment posterior lumbar Interbody Fusion: a single-center, placebo-controlled, randomized trial. World Neurosurg. 2019;122:e821&#x2013;7. 10.1016/j.wneu.2018.10.154</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2018.10.154</ArticleId><ArticleId IdType="pubmed">30391759</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou Y, Wei J, Li R, Liang B, Qiu D, Wei M, Mu X, Li Z. Clinical research of combined intravenous administration and topical application of tranexamic acid to a surgical wound during posterior lumbar fusion. Surg Innov. 2018;25(2):128&#x2013;35. 10.1177/1553350617751449</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1553350617751449</ArticleId><ArticleId IdType="pubmed">29303065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Yang R, Sun H, Zhang Y. Different effects of intravenous, topical, and combined application of tranexamic acid on patients with thoracolumbar fracture. World Neurosurg. 2019;127:e1185&#x2013;9. 10.1016/j.wneu.2019.04.095</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2019.04.095</ArticleId><ArticleId IdType="pubmed">31004853</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Z, Ji P, Yun-qin R, Peng Z, Hong Y. Effect of local application of tranexamic acid on coagulation and fibrinolysis in patients undergoing spinal surgery. Med J Chin PLA. 2019;44(5):405&#x2013;11.</Citation></Reference><Reference><Citation>Elgafy H, Bransford RJ, McGuire RA, Dettori JR, Fischer D. Blood loss in major spine surgery: are there effective measures to decrease massive hemorrhage in major spine fusion surgery? Spine (Philadelphia Pa 1976). 2010;35(9 Suppl):547&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20407351</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Expert Committee on the Selection and Use of Essential Medicines, Summary of the report of the 18th meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines. 2011. http://www.who.int/selection_medicines/committees/TRS_web_summary.pdf. Accessed 20 Mar 2015.</Citation></Reference><Reference><Citation>Alshryda S, Mason J, Vaghela M, et al. Topical (intraarticular) tranexamic acid reduces blood loss and transfusion rates following total knee replacement: a randomized controlled trial (TRANX-K). J Bone Joint Surg Am. 2013;95:1961&#x2013;8. 10.2106/JBJS.L.00907</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.L.00907</ArticleId><ArticleId IdType="pubmed">24196466</ArticleId></ArticleIdList></Reference><Reference><Citation>Endress S, Heinz M, Wilke A. Efficacy of tranexamic acid in reducing blood loss in posterior lumbar spine surgery for degenerative spinal stenosis with instability: a retrospective case control study. BMC Surg. 2011;11:29. 10.1186/1471-2482-11-29</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2482-11-29</ArticleId><ArticleId IdType="pmc">PMC3234174</ArticleId><ArticleId IdType="pubmed">22047046</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera X, Martinez-Zapata MJ, Hinarejos P, et al. Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial. Arch Orthop Trauma Surg. 2015;135:1017&#x2013;25. 10.1007/s00402-015-2232-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-015-2232-8</ArticleId><ArticleId IdType="pubmed">25944156</ArticleId></ArticleIdList></Reference><Reference><Citation>Zufferey Y, Merquiol, Laporte S. (2006) Do anti-fibrinolytics reduce allogenic blood transfusion in orthopedic surgery&#xff1f;Anesthesiology. 2006,105: 1034&#x2013;1046.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065899</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z, Li S, Sheng L, Zhuang Q, Li Z, Xu D, Chen X, Jiang P, Zhang X. Topical use of tranexamic acid can effectively decrease hidden blood loss during posterior lumbar spinal fusion surgery: a retrospective study. Med (Baltim). 2017;96(42):e8233.10.1097/MD.0000000000008233</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000008233</ArticleId><ArticleId IdType="pmc">PMC5662376</ArticleId><ArticleId IdType="pubmed">29049210</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W, Sun RX, Jiang H, Ma XL. The efficacy and safety of topical administration of tranexamic acid in spine surgery: a meta-analysis. J Orthop Surg Res. 2018;24(1):96.10.1186/s13018-018-0815-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-018-0815-0</ArticleId><ArticleId IdType="pmc">PMC5937828</ArticleId><ArticleId IdType="pubmed">29690892</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Li H, Wang D, He X, Zhang C, Yang P. Systematic review and meta-analysis of perioperative intravenous tranexamic acid use in spinal surgery. PLoS ONE. 2013;8(2):e55436. 10.1371/journal.pone.0055436</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0055436</ArticleId><ArticleId IdType="pmc">PMC3570541</ArticleId><ArticleId IdType="pubmed">23424632</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaszczyk M, Kozerawski D, Kazimierczak A, et al. Effect of single preoperative dose of tranexamic acid on blood loss and transfusion in hip arthroplasty. Ortop Traumatol Rehabil. 2015;17:265&#x2013;73. 10.5604/15093492.1162426</Citation><ArticleIdList><ArticleId IdType="doi">10.5604/15093492.1162426</ArticleId><ArticleId IdType="pubmed">26248628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wind TC, Bareld WR, Moskal JT. The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty. J Arthroplasty. 2014;29:387&#x2013;9. 10.1016/j.arth.2013.05.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2013.05.026</ArticleId><ArticleId IdType="pubmed">23790499</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32040553</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2473-9537</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>Blood advances</Title><ISOAbbreviation>Blood Adv</ISOAbbreviation></Journal><ArticleTitle>Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>500</StartPage><EndPage>513</EndPage><MedlinePgn>500-513</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1182/bloodadvances.2019001223</ELocationID><Abstract><AbstractText>Increasing evidence supports the safety and effectiveness of managing low-risk deep vein thrombosis (DVT) or pulmonary embolism (PE) in outpatient settings. We performed a systematic review to assess safety and effectiveness of managing patients with DVT or PE at home compared with the hospital. Medline, Embase, and Cochrane databases were searched up to July 2019 for relevant randomized clinical trials (RCTs), and prospective cohort studies. Two investigators independently screened titles and abstracts of identified citations and extracted data from relevant full-text papers. Risk ratios (RRs) were calculated, and certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Seven RCTs (1922 patients) were included in meta-analyses on managing patients with DVT. Pooled estimates indicated decreased risk of PE (RR = 0.64; 95% confidence interval [CI], 0.44-0.93) and recurrent DVT (RR = 0.61; 95% CI, 0.42-0.90) for home management, both with moderate certainty of the evidence. Reductions in mortality and major bleeding were not significant, both with low certainty of the evidence. Two RCTs (445 patients) were included in meta-analyses on home management of low-risk patients with PE. Pooled estimates indicated no significant difference in all-cause mortality, recurrent PE, and major bleeding, all with low certainty of the evidence. Results of pooled estimates from 3 prospective cohort studies (234 patients) on home management of PE showed similar results. Our findings indicate that low-risk DVT patients had similar or lower risk of patient-important outcomes with home treatment compared with hospital treatment. In patients with low-risk PE, there was important uncertainty about a difference between home and hospital treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khatib</LastName><ForeName>Rasha</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Advocate Research Institute, Advocate Health Care, Downers Grove, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Sean Alexander</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florez</LastName><ForeName>Ivan D</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Antioquia, Medellin, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortel</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Division of Hematology, Medicine and Pathology, Duke University Medical Center, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieuwlaat</LastName><ForeName>Robby</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Witt</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulman</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, The First I. M. Sechenov Moscow State Medical University, Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manja</LastName><ForeName>Veena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of California Davis, Sacramento, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beyth</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Medicine, University of Florida, Gainesville, FL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Malcom Randall Veterans Affairs Medical Center, Gainesville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Nathan P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Clinical Pharmacy Anticoagulation Service, Kaiser Permanente Colorado, Aurora, CO; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiercioch</LastName><ForeName>Wojtek</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;nemann</LastName><ForeName>Holger J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guang' anmen Hospital, China Academy of Chinese Medical Science, Xicheng District, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Blood Adv</MedlineTA><NlmUniqueID>101698425</NlmUniqueID><ISSNLinking>2473-9529</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict-of-interest disclosure: R.K. received research support from Bristol-Myers Squibb and Takeda. D.M.W received research support and consulting fees from Roche Diagnostics. H.J.S. was the principal investigator for the McMaster GRADE Centre and received funding from ASH that supported this systematic review. The remaining authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32040553</ArticleId><ArticleId IdType="pmc">PMC7013254</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2019001223</ArticleId><ArticleId IdType="pii">S2473-9529(20)31497-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. Am J Med. 2013;126(9):832.e13-832.e21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23830539</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA, Silverstein MD, Mohr DN, Petterson TM, O&#x2019;Fallon WM, Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159(5):445-453.</Citation><ArticleIdList><ArticleId IdType="pubmed">10074952</ArticleId></ArticleIdList></Reference><Reference><Citation>McRae SJ, Ginsberg JS. Initial treatment of venous thromboembolism [published corrections appear in Circulation. 2004;110(24 suppl 1):IV33 and Circulation. 2005;111(3):378]. Circulation. 2004;110(9 suppl 1):I3-I9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15339875</ArticleId></ArticleIdList></Reference><Reference><Citation>Koopman MM, Prandoni P, Piovella F, et al. ; The Tasman Study Group . Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334(11):682-687.</Citation><ArticleIdList><ArticleId IdType="pubmed">8594426</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine M, Gent M, Hirsh J, et al. . A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334(11):677-681.</Citation><ArticleIdList><ArticleId IdType="pubmed">8594425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C, Akl EA, Comerota AJ, et al. . Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest. 2012;141(suppl 2):e419S-e496S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278049</ArticleId><ArticleId IdType="pubmed">22315268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C, Akl EA, Ornelas J, et al. . Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [published correction appears in Chest. 2016;150(4):988]. Chest. 2016;149(2):315-352.</Citation><ArticleIdList><ArticleId IdType="pubmed">26867832</ArticleId></ArticleIdList></Reference><Reference><Citation>Almutairi AR, Zhou L, Gellad WF, et al. . Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther. 2017;39(7):1456-1478.e36.</Citation><ArticleIdList><ArticleId IdType="pubmed">28668628</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinson DR, Ballard DW, Huang J, et al. ; MAPLE Investigators of the KP CREST Network . Outpatient management of emergency department patients with acute pulmonary embolism: variation, patient characteristics, and outcomes. Ann Emerg Med. 2018;72(1):62-72.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">29248335</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer AJ, Thode HC Jr., Peacock WF IV. Admission rates for emergency department patients with venous thromboembolism and estimation of the proportion of low risk pulmonary embolism patients: a US perspective. Clin Exp Emerg Med. 2016;3(3):126-131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5065336</ArticleId><ArticleId IdType="pubmed">27752630</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.  Available at: www.handbook.cochrane.org. Accessed 10 October 2019.</Citation></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-e34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19631507</ArticleId></ArticleIdList></Reference><Reference><Citation>Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 2018;1:CD003076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491318</ArticleId><ArticleId IdType="pubmed">29315455</ArticleId></ArticleIdList></Reference><Reference><Citation>MDCalc. Pulmonary Embolism Severity Index (PESI). Available at: https://www.mdcalc.com/pulmonary-embolism-severity-index-pesi. Accessed 15 November 2019.</Citation></Reference><Reference><Citation>Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis . Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.</Citation><ArticleIdList><ArticleId IdType="pubmed">15842354</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, et al. ; GRADE Working Group . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2335261</ArticleId><ArticleId IdType="pubmed">18436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Boccalon H, Elias A, Chal&#xe9; JJ, Cad&#xe8;ne A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Arch Intern Med. 2000;160(12):1769-1773.</Citation><ArticleIdList><ArticleId IdType="pubmed">10871969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramacciotti E, Ara&#xfa;jo GR, Lastoria S, et al. ; CLETRAT Investigators . An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thromb Res. 2004;114(3):149-153.</Citation><ArticleIdList><ArticleId IdType="pubmed">15342210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong BH, Brighton TA, Baker RI, Thurlow P, Lee CH; ASTH DVT Study Group . Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis. 2005;19(3):173-181.</Citation><ArticleIdList><ArticleId IdType="pubmed">16082604</ArticleId></ArticleIdList></Reference><Reference><Citation>Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, et al. . Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg. 2005;29(6):638-650.</Citation><ArticleIdList><ArticleId IdType="pubmed">15878544</ArticleId></ArticleIdList></Reference><Reference><Citation>Romera-Villegas A, Cairols-Castellote MA, Vila-Coll R, et al. . Early mobilisation in patients with acute deep vein thrombosis does not increase the risk of a symptomatic pulmonary embolism. Int Angiol. 2008;27(6):494-499.</Citation><ArticleIdList><ArticleId IdType="pubmed">19078912</ArticleId></ArticleIdList></Reference><Reference><Citation>Aujesky D, Roy PM, Verschuren F, et al. . Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011;378(9785):41-48.</Citation><ArticleIdList><ArticleId IdType="pubmed">21703676</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank Peacock W, Coleman CI, Diercks DB, et al. . Emergency department discharge of pulmonary embolus patients. Acad Emerg Med. 2018;25(9):995-1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175358</ArticleId><ArticleId IdType="pubmed">29757489</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer JH, Burger M, Gretener S, Bernard-Bagattini S, Bounameaux H. Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients. J Thromb Haemost. 2003;1(1):186-187.</Citation><ArticleIdList><ArticleId IdType="pubmed">12871557</ArticleId></ArticleIdList></Reference><Reference><Citation>Siragusa S, Arcara C, Malato A, et al. . Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol. 2005;16(suppl 4):iv136-iv139.</Citation><ArticleIdList><ArticleId IdType="pubmed">15923414</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Cerrillo M, Alvarez-Arcaya A, Fern&#xe1;ndez-D&#xed;az E, Fern&#xe1;ndez-Cruz A. A prospective study of the management of non-massive pulmonary embolism in the home. Eur J Intern Med. 2009;20(6):598-600.</Citation><ArticleIdList><ArticleId IdType="pubmed">19782920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs MJ, Hawel JD, Rekman JF, Lazo-Langner A. Ambulatory management of pulmonary embolism: a pragmatic evaluation. J Thromb Haemost. 2010;8(11):2406-2411.</Citation><ArticleIdList><ArticleId IdType="pubmed">20626624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahler ZP, Beam DM, Kline JA. Cost of treating venous thromboembolism with heparin and warfarin versus home treatment with rivaroxaban. Acad Emerg Med. 2015;22(7):796-802.</Citation><ArticleIdList><ArticleId IdType="pubmed">26111453</ArticleId></ArticleIdList></Reference><Reference><Citation>Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019;173:158-163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119655</ArticleId><ArticleId IdType="pubmed">29506866</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco S, Schmidtmann I, Ageno W, et al. ; HoT-PE Investigators . 
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial [published online ahead of print 23 May 2019]. Eur Heart J. doi:10.1093/eurheartj/ehz367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz367</ArticleId><ArticleId IdType="pubmed">31120118</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo HH, Nunes-Nogueira VS, Fortes Villas Boas PJ, Broderick C. Outpatient versus inpatient treatment for acute pulmonary embolism. Cochrane Database Syst Rev. 2019;3:CD010019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402388</ArticleId><ArticleId IdType="pubmed">30839095</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondag W, Kooiman J, Klok FA, Dekkers OM, Huisman MV. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J. 2013;42(1):134-144.</Citation><ArticleIdList><ArticleId IdType="pubmed">23100493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano F, Trujillo-Santos J, Barron M, et al. . Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. J Vasc Surg. 2014;59(5):1362-1367.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">24439322</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34845516</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-5241</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Aesthetic plastic surgery</Title><ISOAbbreviation>Aesthetic Plast Surg</ISOAbbreviation></Journal><ArticleTitle>Autologous Versus Alloplastic Reconstruction for Patients with Obesity: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>597</StartPage><EndPage>609</EndPage><MedlinePgn>597-609</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00266-021-02664-y</ELocationID><Abstract><AbstractText Label="BACKGROUND">Autologous flaps may have superior outcomes when compared to implant breast reconstruction in patients with obesity. To date, no published review has illustrated the superiority of autologous to implant-based reconstruction in this study group in terms of aesthetics outcomes and surgical complications.</AbstractText><AbstractText Label="METHODS">A systematic search was conducted on PubMed, Cochrane, Google Scholar, and Embase from inception to December 31, 2020. Studies comparing the outcomes (patient satisfaction and complications) of autologous versus implant-based reconstruction in patients with BMI &gt; 30 were selected.</AbstractText><AbstractText Label="RESULTS">The search yielded 1633 articles, of which 76 were assessed in full text. A total of 12 articles fit inclusion for qualitative review; of them, 7 were meta-analyzed. Autologous reconstruction had a lower incidence of infection (OR 0.74 [95% CI 0.59, 0.92]), hematoma/seroma formation (OR 0.34 [95% CI 0.23, 0.49]), and reconstructive failure (OR 0.47 [95% CI 0.36, 0.62]), but not skin necrosis (OR 0.95 [95% CI 0.73, 1.25]) or wound dehiscence (OR 1.03 [95% CI 0.72, 1.49]) when compared to implant-based reconstruction. Deep vein thrombosis (DVT) and pulmonary embolism occurred more frequently with autologous versus alloplastic reconstruction (OR 2.21 [95% CI 1.09, 4.49] for DVT and OR 2.49 [95% CI 1.13, 5.48] for PE). BREASTQ scores were higher for the autologous breast reconstruction when compared to implant-based group, but failed to reach significance (p value &gt;0.05).</AbstractText><AbstractText Label="CONCLUSION">The current evidence in the literature suggests that autologous breast reconstruction has lower surgical complication rate when compared to implant-based reconstruction at the expense of higher risk of thrombotic complications for patients with BMI &gt; 30.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE III">This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .</AbstractText><CopyrightInformation>&#xa9; 2021. Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>ElAbd</LastName><ForeName>Rawan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgery, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prabhu</LastName><ForeName>Neetin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Plastic Surgery, Faculty of Medicine, Dalhousie University, Halifax, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alibrahim</LastName><ForeName>Alaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Plastic Surgery, Faculty of Medicine, Dalhousie University, Halifax, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Plastic Surgery, Faculty of Medicine, Dalhousie University, Halifax, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Plastic Surgery, Faculty of Medicine, Dalhousie University, Halifax, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samargandi</LastName><ForeName>Osama</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-5681-9769</Identifier><AffiliationInfo><Affiliation>Okanagan Plastic Surgery Center &amp;, Kelowna General Hospital, University of British Columbia, Okanagan Campus, Kelowna, British Columbia, Canada. Osamargandi@dal.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, King Abdulaziz University, Jeddah, Saudi Arabia. Osamargandi@dal.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Aesthetic Plast Surg</MedlineTA><NlmUniqueID>7701756</NlmUniqueID><ISSNLinking>0364-216X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Aesthetic Plast Surg. 2022 Apr;46(Suppl 1):229. doi: 10.1007/s00266-022-02767-0.</RefSource><PMID Version="1">35201379</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004954" MajorTopicYN="N">Esthetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016462" MajorTopicYN="Y">Mammaplasty</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013524" MajorTopicYN="N">Surgical Flaps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alloplastic Reconstruction</Keyword><Keyword MajorTopicYN="N">Autogenous</Keyword><Keyword MajorTopicYN="N">Autologous</Keyword><Keyword MajorTopicYN="N">Breast reconstruction</Keyword><Keyword MajorTopicYN="N">Free flap</Keyword><Keyword MajorTopicYN="N">Implantbased reconstruction</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34845516</ArticleId><ArticleId IdType="doi">10.1007/s00266-021-02664-y</ArticleId><ArticleId IdType="pii">10.1007/s00266-021-02664-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999&#x2013;2008. JAMA 303(3):235&#x2013;241</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.2014</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999&#x2013;2004. JAMA 295(13):1549&#x2013;1555</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.295.13.1549</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KB, Smith MS (2016) Obesity statistics. Prim Care 43(1):121-35, ix</Citation></Reference><Reference><Citation>Morgen CS, S&#xf8;rensen TI (2014) Obesity: global trends in the prevalence of overweight and obesity. Nat Rev Endocrinol 10(9):513&#x2013;514</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2014.124</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvey PB, Buchel EW, Pockaj BA, Gray RJ, Samson TD (2005) The deep inferior epigastric perforator flap for breast reconstruction in overweight and obese patients. Plast Reconstr Surg 115(2):447&#x2013;457</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PRS.0000149588.09148.53</ArticleId></ArticleIdList></Reference><Reference><Citation>Spear SL, Ducic I, Cuoco F, Taylor N (2007) Effect of obesity on flap and donor-site complications in pedicled TRAM flap breast reconstruction. Plast Reconstr Surg 119(3):788&#x2013;795</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.prs.0000252003.14537.d2</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy CM, Mehrara BJ, Riedel E, Davidge K, Hinson A, Disa JJ et al (2008) Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk. Plast Reconstr Surg 121(6):1886&#x2013;1892</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e31817151c4</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CL, Shore AD, Johns R, Clark JM, Manahan M, Makary MA (2011) The impact of obesity on breast surgery complications. Plast Reconstr Surg 128(5):395e&#x2013;402e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e3182284c05</ArticleId></ArticleIdList></Reference><Reference><Citation>Atisha DM, Alderman AK, Kuhn LE, Wilkins EG (2008) The impact of obesity on patient satisfaction with breast reconstruction. Plast Reconstr Surg 121(6):1893&#x2013;1899</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e3181715198</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamel GN, Mehta K, Nash D, Jacobson J, Berk R, Rizzo AM et al (2019) Patient-reported satisfaction and quality of life in obese patients: a comparison between microsurgical and prosthetic implant recipients. Plast Reconstr Surg 144(6):960e-e966</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0000000000006201</ArticleId></ArticleIdList></Reference><Reference><Citation>Klement KA, Hijjawi JB, LoGiudice JA, Alghoul M, Omesiete-Adejare P (2019) Microsurgical breast reconstruction in the obese: a better option than tissue expander/implant reconstruction? Plast Reconstr Surg 144(3):539&#x2013;546</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0000000000005897</ArticleId></ArticleIdList></Reference><Reference><Citation>Panayi AC, Agha RA, Sieber BA, Orgill DP (2018) Impact of obesity on outcomes in breast reconstruction: a systematic review and meta-analysis. J Reconstr Microsurg 34(5):363&#x2013;375</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1627449</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, Mulrow C, G&#xf8;tzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100</Citation></Reference><Reference><Citation>Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712&#x2013;716</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1445-2197.2003.02748.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, J&#xfc;ni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928</Citation></Reference><Reference><Citation>Nguyen A, Mahabir RC (2016) An update on the level of evidence for plastic surgery research published in plastic and reconstructive surgery. Plast Reconstr Surg Glob Open 4(7):e798</Citation></Reference><Reference><Citation>Garvey PB, Villa MT, Rozanski AT, Liu J, Robb GL, Beahm EK (2012) The advantages of free abdominal-based flaps over implants for breast reconstruction in obese patients. Plast Reconstr Surg 130(5):991&#x2013;1000</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e318267efc5</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanwright PJ, Davila AA, Hirsch EM, Khan SA, Fine NA, Bilimoria KY et al (2013) The differential effect of BMI on prosthetic versus autogenous breast reconstruction: a multivariate analysis of 12,986 patients. Breast 22(5):938&#x2013;945</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.breast.2013.05.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasa DR, Clemens MW, Qi J, Hamill JB, Kim HM, Pusic AL et al (2020) Obesity and Breast Reconstruction: Complications and patient-reported outcomes in a multicenter, prospective study. Plast Reconstr Surg 145(3):481e-e490</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0000000000006543</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong WMY, Baumann DP, Villa MT, Mittendorf EA, Liu J, Robb GL et al (2016) Obese women experience fewer complications after oncoplastic breast repair following partial mastectomy than after immediate total breast reconstruction. Plast Reconstr Surg 137(3):777&#x2013;791</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.prs.0000479939.69211.19</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J, Smith BD, Giordano SH, Reece GP, Tina Shih YC (2016) A comparison of patient-centered economic and clinical outcomes of post-mastectomy breast reconstruction between obese and non-obese patients. Breast 30:118&#x2013;124</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.breast.2016.09.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Koltz PF, Sbitany H (2014) Lessons learned from the American College of Surgeons National Surgical Quality Improvement Program Database: Has centralized data collection improved immediate breast reconstruction outcomes and safety? Plast Reconstr Surg 134(5):859&#x2013;868</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0000000000000615</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer JP, Wes AM, Kanchwala S, Kovach SJ (2014) Effect of BMI on modality-specific outcomes in immediate breast reconstruction (IBR)&#x2014;a propensity-matched analysis using the 2005&#x2013;2011 ACS-NSQIP datasets. J Plast Surg Hand Surg 48(5):297&#x2013;304</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/2000656X.2013.877915</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer JP, Cleveland EC, Nelson JA, Kovach SJ, Serletti JM, Wu LC et al (2013) Breast reconstruction in the morbidly obese patient: assessment of 30-day complications using the 2005 to 2010 National Surgical Quality Improvement Program data sets. Plast Reconstr Surg 132(4):750&#x2013;761</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e31829fe33c</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer JP, Wes AM, Tuggle CT, Wu LC (2014) Venous thromboembolism risk in mastectomy and immediate breast reconstruction: analysis of the 2005 to 2011 American College of Surgeons National Surgical Quality Improvement Program data sets. Plast Reconstr Surg 133(3):263e-e273</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.prs.0000438062.53914.22</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87&#x2013;108</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21262</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagsi R, Jiang J, Momoh AO, Alderman A, Giordano SH, Buchholz TA et al (2014) Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. J Clin Oncol 32(9):919&#x2013;926</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2013.52.2284</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick AM, Gao LL, Smith BL, Cetrulo CL Jr, Colwell AS, Winograd JM et al (2014) Cost and outcome analysis of breast reconstruction paradigm shift. Ann Plast Surg 73(2):141&#x2013;149</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SAP.0b013e318276d979</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J, Smith BD, Giordano SH, Reece GP, Shih YT (2016) Post-mastectomy breast reconstruction and its subsequent complications: a comparison between obese and non-obese women with breast cancer. Breast Cancer Res Treat 157(2):373&#x2013;383</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-016-3832-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen KT, Hanwright PJ, Smetona JT, Hirsch EM, Seth AK, Kim JY (2014) Body mass index as a continuous predictor of outcomes after expander-implant breast reconstruction. Ann Plast Surg 73(1):19&#x2013;24</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SAP.0b013e318276d91d</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer JP, Nelson JA, Cleveland E, Sieber B, Rohrbach JI, Serletti JM et al (2013) Breast reconstruction modality outcome study: a comparison of expander/implants and free flaps in select patients. Plast Reconstr Surg 131(5):928&#x2013;934</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e3182865977</ArticleId></ArticleIdList></Reference><Reference><Citation>Razdan SN, Cordeiro PG, Albornoz CR, Disa JJ, Panchal HJ, Ho AY et al (2017) National breast reconstruction utilization in the setting of postmastectomy radiotherapy. J Reconstr Microsurg 33(5):312&#x2013;317</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1598201</ArticleId></ArticleIdList></Reference><Reference><Citation>Negenborn VL, Dikmans REG, Bouman MB, Wilschut JA, Mullender MG, Salzberg CA (2018) Patient-reported Outcomes after ADM-assisted Implant-based Breast Reconstruction: a Cross-sectional Study. Plast Reconstr Surg Glob Open 6(2):e1654</Citation></Reference><Reference><Citation>Saulis AS, Mustoe TA, Fine NA (2007) A retrospective analysis of patient satisfaction with immediate postmastectomy breast reconstruction: comparison of three common procedures. Plast Reconstr Surg 119(6):1669&#x2013;1676</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.prs.0000258827.21635.84</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, Zhuang Y, Momeni A, Luan J, Chung MT, Wright E et al (2014) Quality of life and patient satisfaction after microsurgical abdominal flap versus staged expander/implant breast reconstruction: a critical study of unilateral immediate breast reconstruction using patient-reported outcomes instrument BREAST-Q. Breast Cancer Res Treat 146(1):117&#x2013;126</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-014-2981-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu ES, Pusic AL, Waljee JF, Kuhn L, Hawley ST, Wilkins E et al (2009) Patient-reported aesthetic satisfaction with breast reconstruction during the long-term survivorship Period. Plast Reconstr Surg 124(1):1&#x2013;8</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e3181ab10b2</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoma A, Ignacy TA, Ziolkowski N, Voineskos S (2012) The performance and publication of cost-utility analyses in plastic surgery: making our specialty relevant. Can J Plast Surg 20(3):187&#x2013;193</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/229255031202000319</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35761099</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-5195</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International orthopaedics</Title><ISOAbbreviation>Int Orthop</ISOAbbreviation></Journal><ArticleTitle>Incidence, characteristics, and risk factors of venous thromboembolism in shoulder arthroplasty-a systematic review.</ArticleTitle><Pagination><StartPage>2081</StartPage><EndPage>2088</EndPage><MedlinePgn>2081-2088</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00264-022-05496-w</ELocationID><Abstract><AbstractText Label="PURPOSE">The purpose of this study was to investigate the incidence, characteristics, and risk factors for venous thromboembolism (VTE) in patients who underwent shoulder arthroplasty (SA) through systematic review.</AbstractText><AbstractText Label="METHODS">A search of studies was conducted using the databases for PubMed, EMBASE, Scopus, Ovid, MEDLINE, and Cochrane Library according to the guidelines for PRISMA (Preferred Reporting Items for Systematic Meta-Analyses). Quality assessment was performed using the Methodological Index for Nonrandomized Studies (MINORS).</AbstractText><AbstractText Label="RESULTS">Nine studies (12,566 shoulders) were finally eligible and the mean MINORS score was 13.2 (ranges, 9-18). The overall incidence of VTE was 0.81% (78/9681) including 0.54% (52/9681) for deep vein thrombosis (DVT) and 0.33% (42/12,566) for pulmonary embolism (PE). There were no significant differences in the incidences according to the type of arthroplasty. DVT was detected at an average of 18.8&#xa0;days after index surgery, and PE was detected at an average of 12.7&#xa0;days after index surgery. The risk factors for VTE included age older than 70&#xa0;years, higher BMI, raised Charlson Comorbidity Index, history of DVT, asthma, cardiac arrhythmia, diabetes, lower haemoglobin level, use of general endotracheal anaesthesia without interscalene nerve block, traumatic indication, longer operative time, and revision SA. The mortality rate was 4.1% (2/49) for VTE and 8.3% (2/24) for PE.</AbstractText><AbstractText Label="CONCLUSION">Despite the fact that the overall incidence of VTE following SA was as low as 0.81%, shoulder surgeons should consider the potential for this serious complication in high-risk patients. Further well-designed large-scale studies are necessary to clarify the consensus for VTE after SA including risk factors, treatment, and prophylaxis.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s) under exclusive licence to SICOT aisbl.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Sang-Soo</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, 1035 Dalgubeol-daero, Dalseo-gu, Daegu, 42601, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Du-Han</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, 1035 Dalgubeol-daero, Dalseo-gu, Daegu, 42601, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Byung-Chan</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, 1035 Dalgubeol-daero, Dalseo-gu, Daegu, 42601, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Chul-Hyun</ForeName><Initials>CH</Initials><Identifier Source="ORCID">0000-0003-0252-8741</Identifier><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, 1035 Dalgubeol-daero, Dalseo-gu, Daegu, 42601, South Korea. oscho5362@dsmc.or.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021R1F1A1047546</GrantID><Agency>the National Research Foundation of Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Int Orthop</MedlineTA><NlmUniqueID>7705431</NlmUniqueID><ISSNLinking>0341-2695</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001178" MajorTopicYN="N">Arthroplasty</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072228" MajorTopicYN="Y">Arthroplasty, Replacement, Shoulder</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Arthroplasty</Keyword><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Shoulder</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>27</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35761099</ArticleId><ArticleId IdType="doi">10.1007/s00264-022-05496-w</ArticleId><ArticleId IdType="pii">10.1007/s00264-022-05496-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Navarro RP, Barr JE, Faubus K, Sabharwal AD, Stern E, Unger K (2011) Improving outcomes in patients at risk for venous thromboembolism following total knee and total hip replacement: implications for managed care. Am J Manag Care 17(Suppl 9):S251-258</Citation><ArticleIdList><ArticleId IdType="pubmed">21819165</ArticleId></ArticleIdList></Reference><Reference><Citation>Baser O (2011) Prevalence and economic burden of venous thromboembolism after total hip arthroplasty or total knee arthroplasty. Am J Manag Care 17:S6-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21517654</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunutsor SK, Barrett MC, Whitehouse MR, Blom AW (2020) Venous thromboembolism following 672,495 primary total shoulder and elbow replacements: meta-analyses of incidence, temporal trends and potential risk factors. Thromb Res 189:13&#x2013;23. https://doi.org/10.1016/j.thromres.2020.02.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.02.018</ArticleId><ArticleId IdType="pubmed">32135385</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp CM, Shields EJ, Wiater BP, Wiater JM (2019) Venous thromboembolism after shoulder arthoplasty and arthroscopy. J Am Acad Orthop Surg 27:265&#x2013;274. https://doi.org/10.5435/jaaos-d-17-00763</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/jaaos-d-17-00763</ArticleId><ArticleId IdType="pubmed">30480588</ArticleId></ArticleIdList></Reference><Reference><Citation>Anakwe RE, Middleton SD, Beresford-Cleary N, McEachan JE, Talwalkar SC (2013) Preventing venous thromboembolism in elective upper limb surgery. J Shoulder Elbow Surg 22:432&#x2013;438. https://doi.org/10.1016/j.jse.2012.10.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2012.10.033</ArticleId><ArticleId IdType="pubmed">23333169</ArticleId></ArticleIdList></Reference><Reference><Citation>Day JS, Ramsey ML, Lau E, Williams GR (2015) Risk of venous thromboembolism after shoulder arthroplasty in the Medicare population. J Shoulder Elbow Surg 24:98&#x2013;105. https://doi.org/10.1016/j.jse.2014.09.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2014.09.025</ArticleId><ArticleId IdType="pubmed">25467306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman S, Sherman S, Carter TI, Bach PB, Mandl LA, Marx RG (2006) Prevalence and risk factors for symptomatic thromboembolic events after shoulder arthroplasty. Clin Orthop Relat Res 448:152&#x2013;156. https://doi.org/10.1097/01.blo.0000194679.87258.6e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.blo.0000194679.87258.6e</ArticleId><ArticleId IdType="pubmed">16826110</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho SH, Jeong J (2020) Radiologic results of three-dimensional templating for total shoulder arthroplasty. Clin Orthop Surg 12:232&#x2013;237. https://doi.org/10.4055/cios19100</Citation><ArticleIdList><ArticleId IdType="doi">10.4055/cios19100</ArticleId><ArticleId IdType="pubmed">32489546</ArticleId><ArticleId IdType="pmc">7237245</ArticleId></ArticleIdList></Reference><Reference><Citation>Collotte P, Bercik M, Vieira TD, Walch G (2021) Long-term reverse total shoulder arthroplasty outcomes: the effect of the inferior shifting of glenoid component fixation. Clin Orthop Surg 13:505&#x2013;512. https://doi.org/10.4055/cios20245</Citation><ArticleIdList><ArticleId IdType="doi">10.4055/cios20245</ArticleId><ArticleId IdType="pubmed">34868500</ArticleId><ArticleId IdType="pmc">8609210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Wise BL, Zhang Y, Szabo RM (2011) Increasing incidence of shoulder arthroplasty in the United States. J Bone Joint Surg Am 93:2249&#x2013;2254. https://doi.org/10.2106/jbjs.J.01994</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/jbjs.J.01994</ArticleId><ArticleId IdType="pubmed">22258770</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh HE, Pennings AL, ElMaraghy AW (2013) Venous thromboembolism after shoulder arthroplasty: a systematic review. J Shoulder Elbow Surg 22:1440&#x2013;1448. https://doi.org/10.1016/j.jse.2013.05.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2013.05.013</ArticleId><ArticleId IdType="pubmed">23973166</ArticleId></ArticleIdList></Reference><Reference><Citation>Aibinder WR, Sanchez-Sotelo J (2018) Venous thromboembolism prophylaxis in shoulder surgery. Orthop Clin North Am 49:257&#x2013;263. https://doi.org/10.1016/j.ocl.2017.11.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ocl.2017.11.012</ArticleId><ArticleId IdType="pubmed">29499826</ArticleId></ArticleIdList></Reference><Reference><Citation>Dattani R, Smith CD, Patel VR (2013) The venous thromboembolic complications of shoulder and elbow surgery a systematic review. Bone Joint J 95-b:70&#x2013;74. https://doi.org/10.1302/0301-620x.95b1.29854</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620x.95b1.29854</ArticleId><ArticleId IdType="pubmed">23307676</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojike NI, Bhadra AK, Giannoudis PV, Roberts CS (2011) Venous thromboembolism in shoulder surgery: a systematic review. Acta Orthop Belg 77:281&#x2013;289</Citation><ArticleIdList><ArticleId IdType="pubmed">21845993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolz JM, Aibinder WR, Adams RA, Cofield RH, Sperling JW (2019) Symptomatic thromboembolic complications after shoulder arthroplasty: an update. J Bone Joint Surg Am 101:1845&#x2013;1851. https://doi.org/10.2106/jbjs.18.01200</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/jbjs.18.01200</ArticleId><ArticleId IdType="pubmed">31626009</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis AA, Warren RF, Craig EV, Adler RS, Cordasco FA, Lyman S, Fealy S (2009) Deep vein thrombosis after reconstructive shoulder arthroplasty: a prospective observational study. J Shoulder Elbow Surg 18:100&#x2013;106. https://doi.org/10.1016/j.jse.2008.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2008.07.011</ArticleId><ArticleId IdType="pubmed">19095183</ArticleId></ArticleIdList></Reference><Reference><Citation>Lung BE, Kanjiya S, Bisogno M, Komatsu DE, Wang ED (2019) Risk factors for venous thromboembolism in total shoulder arthroplasty. JSES Open Access 3:183&#x2013;188. https://doi.org/10.1016/j.jses.2019.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jses.2019.07.003</ArticleId><ArticleId IdType="pubmed">31709360</ArticleId><ArticleId IdType="pmc">6834973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho CH, Jang HG, Park UJ, Kim HT (2017) The incidence of venous thromboembolism following shoulder surgery: a pilot study. Clin Shoulder Elbow 20:18&#x2013;23. https://doi.org/10.5397/cise.2017.20.1.18</Citation><ArticleIdList><ArticleId IdType="doi">10.5397/cise.2017.20.1.18</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyer JH, Parker RL, Lynch T, Parry T, Neviaser AS (2021) Rate of venous thromboembolism after surgical treatment of proximal humerus fractures. Arch Orthop Trauma Surg 141:403&#x2013;409. https://doi.org/10.1007/s00402-020-03505-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-020-03505-4</ArticleId><ArticleId IdType="pubmed">32504179</ArticleId></ArticleIdList></Reference><Reference><Citation>Imberti D, Ivaldo N, Murena L, Paladini P, Castagna A, Barillari G, Guerra E, Fama G, Castoldi F, Marelli B, Pierfranceschi MG, Camporese G, Dentali F, Porcellini G (2014) Venous thromboembolism in patients undergoing shoulder surgery: findings from the RECOS registry. Thromb Res 134:273&#x2013;277. https://doi.org/10.1016/j.thromres.2014.05.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2014.05.014</ArticleId><ArticleId IdType="pubmed">24916548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsch JM, Gutman M, Patel M, Rondon A, Ramsey ML, Abboud JA, Williams GR, Namdari S (2021) Low-dose aspirin and the rate of symptomatic venous thromboembolic complications following primary shoulder arthroplasty. J Shoulder Elbow Surg 30:1613&#x2013;1618. https://doi.org/10.1016/j.jse.2020.09.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2020.09.030</ArticleId><ArticleId IdType="pubmed">33536125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling JW, Cofield RH (2002) Pulmonary embolism following shoulder arthroplasty. J Bone Joint Surg Am 84:1939&#x2013;1941. https://doi.org/10.2106/00004623-200211000-00005</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-200211000-00005</ArticleId><ArticleId IdType="pubmed">12429752</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashjian RZ, Lilly DT, Isaacson AM, Georgopoulos CE, Bettwieser SP, Burks RT, Greis PE, Presson AP, Granger EK, Zhang Y (2016) Incidence of and risk factors for symptomatic venous thromboembolism after shoulder arthroplasty. Am J Orthop (Belle Mead NJ) 45:E379-e385</Citation></Reference><Reference><Citation>Wronka KS, Pritchard M, Sinha A (2014) Incidence of symptomatic venous thrombo-embolism following shoulder surgery. Int Orthop 38:1415&#x2013;1418. https://doi.org/10.1007/s00264-014-2329-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00264-014-2329-7</ArticleId><ArticleId IdType="pubmed">24691988</ArticleId><ArticleId IdType="pmc">4071505</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro RA, Inacio MC, Burke MF, Costouros JG, Yian EH (2013) Risk of thromboembolism in shoulder arthroplasty: effect of implant type and traumatic indication. Clin Orthop Relat Res 471:1576&#x2013;1581. https://doi.org/10.1007/s11999-013-2829-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-013-2829-6</ArticleId><ArticleId IdType="pubmed">23392993</ArticleId><ArticleId IdType="pmc">3613522</ArticleId></ArticleIdList></Reference><Reference><Citation>Young BL, Menendez ME, Baker DK, Ponce BA (2015) Factors associated with in-hospital pulmonary embolism after shoulder arthroplasty. J Shoulder Elbow Surg 24:e271-278. https://doi.org/10.1016/j.jse.2015.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2015.04.002</ArticleId><ArticleId IdType="pubmed">25976989</ArticleId><ArticleId IdType="pmc">4575830</ArticleId></ArticleIdList></Reference><Reference><Citation>Jameson SS, James P, Howcroft DW, Serrano-Pedraza I, Rangan A, Reed MR, Candal-Couto J (2011) Venous thromboembolic events are rare after shoulder surgery: analysis of a national database. J Shoulder Elbow Surg 20:764&#x2013;770. https://doi.org/10.1016/j.jse.2010.11.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2010.11.034</ArticleId><ArticleId IdType="pubmed">21420324</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35831010</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1600-0617</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>165</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>European respiratory review : an official journal of the European Respiratory Society</Title><ISOAbbreviation>Eur Respir Rev</ISOAbbreviation></Journal><ArticleTitle>Impact of pulmonary embolism response teams on acute pulmonary embolism: a systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">220023</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1183/16000617.0023-2022</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The impact of pulmonary embolism response teams (PERTs) on treatment choice and outcomes of patients with acute pulmonary embolism (PE) is still uncertain.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the effect of PERTs in the management and outcomes of patients with PE.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, Embase, Web of Science, CINAHL, WorldWideScience and MedRxiv were searched for original articles reporting PERT patient outcomes from 2009. Data were analysed using a random effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">16 studies comprising 3827 PERT patients and 3967 controls met inclusion criteria. The PERT group had more patients with intermediate and high-risk PE (66.2%) compared to the control group (48.5%). Meta-analysis demonstrated an increased risk of catheter-directed interventions, systemic thrombolysis and surgical embolectomy (odds ratio (OR) 2.10, 95% confidence interval (CI) 1.74-2.53; p&lt;0.01), similar bleeding complications (OR 1.10, 95% CI 0.88-1.37) and decreased utilisation of inferior vena cava (IVC) filters (OR 0.71, 95% CI 0.58-0.88; p&lt;0.01) in the PERT group. Furthermore, there was a nonsignificant trend towards decreased mortality (OR 0.87, 95% CI 0.71-1.07; p=0.19) with PERTs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The PERT group showed an increased use of advanced therapies and a decreased utilisation of IVC filters. This was not associated with increased bleeding. Despite comprising more severe PE patients, there was a trend towards lower mortality in the PERT group.</AbstractText><CopyrightInformation>Copyright &#xa9;The authors 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleitas Sosa</LastName><ForeName>Derlis</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7648-5276</Identifier><AffiliationInfo><Affiliation>Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA christianderlis@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Both authors contributed equally.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehr</LastName><ForeName>Andrew L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care and Sleep Medicine, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Both authors contributed equally.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Huaqing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dept of Clinical Sciences, Temple University School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5415-1718</Identifier><AffiliationInfo><Affiliation>Biomedical and Research Services Librarian, Simmy and Harry Ginsburg Library, Temple University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakhther</LastName><ForeName>Vlad</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Dept of Cardiovascular Diseases, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bashir</LastName><ForeName>Riyaz</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dept of Cardiovascular Diseases, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dept of Radiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panaro</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dept of Radiology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado</LastName><ForeName>Thomas S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horowitz</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cardiology, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amoroso</LastName><ForeName>Nancy E</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care and Sleep Medicine, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Criner</LastName><ForeName>Gerard J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brosnahan</LastName><ForeName>Shari B</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0000-0002-2092-3633</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Critical Care and Sleep Medicine, New York University Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rali</LastName><ForeName>Parth</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2432-8137</Identifier><AffiliationInfo><Affiliation>Dept of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Respir Rev</MedlineTA><NlmUniqueID>9111391</NlmUniqueID><ISSNLinking>0905-9180</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017128" MajorTopicYN="N">Embolectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016306" MajorTopicYN="Y">Vena Cava Filters</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest: R. Bashir has patents planned, issued or pending with Thrombolex Inc., and stock or stock options in Thrombolex Inc., outside the submitted work. J. Horowitz has received consulting fees from Inari Medical and Penumbra, outside the submitted work. P. Rali has an unpaid leadership or fiduciary role in other board, society, committee or advocacy group: Chair, Protocol Committee National PERT consortium, outside the submitted work. All other authors have no conflicts to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>13</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35831010</ArticleId><ArticleId IdType="pmc">PMC9724819</ArticleId><ArticleId IdType="doi">10.1183/16000617.0023-2022</ArticleId><ArticleId IdType="pii">31/165/220023</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bikdeli B, Wang Y, Jimenez D, et al. . Pulmonary embolism hospitalization, readmission, and mortality rates in US older adults, 1999&#x2013;2015. JAMA 2019; 322: 574&#x2013;576. doi:10.1001/jama.2019.8594</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.8594</ArticleId><ArticleId IdType="pmc">PMC6692667</ArticleId><ArticleId IdType="pubmed">31408124</ArticleId></ArticleIdList></Reference><Reference><Citation>Furfaro D, Stephens RS, Streiff MB, et al. . Catheter-directed thrombolysis for intermediate-risk pulmonary embolism . Ann Am Thorac Soc 2018; 15: 134&#x2013;144. doi:10.1513/AnnalsATS.201706-467FR</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.201706-467FR</ArticleId><ArticleId IdType="pubmed">29073366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Itagaki S, Chiang YP, et al. . Survival and recurrence after acute pulmonary embolism treated with pulmonary embolectomy or thrombolysis in New York State, 1999 to 2013. J Thorac Cardiovasc Surg 2018; 155: 1084&#x2013;1090.e12. doi:10.1016/j.jtcvs.2017.07.074</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2017.07.074</ArticleId><ArticleId IdType="pubmed">28942971</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides SV, Meyer G, Becattini C, et al. . 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41: 543&#x2013;603. doi:10.1093/eurheartj/ehz405</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz405</ArticleId><ArticleId IdType="pubmed">31504429</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhury P, Gadre SK, Schneider E, et al. . Impact of multidisciplinary pulmonary embolism response team availability on management and outcomes. Am J Cardiol 2019; 124: 1465&#x2013;1469. doi:10.1016/j.amjcard.2019.07.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.07.043</ArticleId><ArticleId IdType="pubmed">31495443</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll BJ, Beyer SE, Mehegan T, et al. . Changes in care for acute pulmonary embolism through a multidisciplinary pulmonary embolism response team. Am J Med 2020; 133: 1313&#x2013;1321.e6. doi:10.1016/j.amjmed.2020.03.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2020.03.058</ArticleId><ArticleId IdType="pmc">PMC8076889</ArticleId><ArticleId IdType="pubmed">32416175</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. doi:10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosovsky R, Zhao K, Sista A, et al. . Pulmonary embolism response teams: purpose, evidence for efficacy, and future research directions. Res Pract Thromb Haemost 2019; 3: 315&#x2013;330. doi:10.1002/rth2.12216</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12216</ArticleId><ArticleId IdType="pmc">PMC6611377</ArticleId><ArticleId IdType="pubmed">31294318</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth S, Parth R, Brosnahan S, et al. . Search strategies for a systematic review of PERT based outcomes for patients with pulmonary embolism. Temple University Health Sciences Libraries, Systematic Review Service, 2020. 10.34944/dspace/4472doi:10.34944/dspace/4472</Citation><ArticleIdList><ArticleId IdType="doi">10.34944/dspace/4472</ArticleId><ArticleId IdType="doi">10.34944/dspace/4472</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Heath Economics . IHE quality appraisal checklist for case series studies. Date last updated: 3 March 2016. www.ihe.ca/advanced-search/ihe-quality-appraisal-checklist-for-case-series-studies</Citation></Reference><Reference><Citation>Luchini C, Stubbs B, Solmi M, et al. . Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa scale. World J Meta-Analysis 2017; 5: 80&#x2013;84. doi:10.13105/wjma.v5.i4.80</Citation><ArticleIdList><ArticleId IdType="doi">10.13105/wjma.v5.i4.80</ArticleId></ArticleIdList></Reference><Reference><Citation>Annabathula R, Dugan A, Bhalla V, et al. . Value-based assessment of implementing a Pulmonary Embolism Response Team (PERT). J Thromb Thrombolysis 2021; 51: 217&#x2013;225. doi:10.1007/s11239-020-02188-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02188-3</ArticleId><ArticleId IdType="pmc">PMC8325945</ArticleId><ArticleId IdType="pubmed">32542527</ArticleId></ArticleIdList></Reference><Reference><Citation>Jen WY, Kristanto W, Teo L, et al. . Assessing the impact of a pulmonary embolism response team and treatment protocol on patients presenting with acute pulmonary embolism . Heart Lung Circ 2019; 29: 345&#x2013;353. doi:10.1016/j.hlc.2019.02.190</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2019.02.190</ArticleId><ArticleId IdType="pubmed">30910512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabrhel C, Rosovsky R, Channick R, et al. . A multidisciplinary pulmonary embolism response team (PERT): initial 30-month experience with a novel approach to delivery of care to patients with sub-massive and massive PE. Acad Emerg Med 2016; 23: S244.</Citation><ArticleIdList><ArticleId IdType="pubmed">27006156</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaing P, Paruchuri A, Eisenbrey JR, et al. . First year experience of a pulmonary embolism response team with comparisons of outcomes between catheter directed therapy versus standard anticoagulation. Hosp Pract 2020; 48: 23&#x2013;28. doi:10.1080/21548331.2020.1706315</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21548331.2020.1706315</ArticleId><ArticleId IdType="pubmed">31847615</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok B, Brosnahan SB, Amoroso NE, et al. . Pulmonary embolism response team activation during the COVID-19 pandemic in a New York City academic hospital: a retrospective cohort analysis. J Thromb Thrombolysis 2021; 51: 330&#x2013;338. doi:10.1007/s11239-020-02264-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02264-8</ArticleId><ArticleId IdType="pmc">PMC7482370</ArticleId><ArticleId IdType="pubmed">32910409</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahar JH, Haddadin I, Sadana D,et al. . A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland Clinic. J Thromb Thrombolysis 2018; 46: 186&#x2013;192. doi:10.1007/s11239-018-1686-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-018-1686-2</ArticleId><ArticleId IdType="pubmed">29855780</ArticleId></ArticleIdList></Reference><Reference><Citation>Myc LA, Solanki JN, Barros AJ, et al. . Adoption of a dedicated multidisciplinary team is associated with improved survival in acute pulmonary embolism. Respir Res 2020; 21: 159. doi:10.1186/s12931-020-01422-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01422-z</ArticleId><ArticleId IdType="pmc">PMC7310489</ArticleId><ArticleId IdType="pubmed">32571318</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano KR, Cory JM, Ronco JJ, et al. . Vancouver General Hospital Pulmonary Embolism Response Team (VGH PERT): initial three-year experience. Can J Anaesth 2020; 67: 1806&#x2013;1813. doi:10.1007/s12630-020-01790-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-020-01790-6</ArticleId><ArticleId IdType="pubmed">32808096</ArticleId></ArticleIdList></Reference><Reference><Citation>Sista AK, Friedman OA, Dou E, et al. . A pulmonary embolism response team's initial 20&#x2005;month experience treating 87 patients with submassive and massive pulmonary embolism. Vasc Med 2018; 23: 65&#x2013;71. doi:10.1177/1358863X17730430</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1358863X17730430</ArticleId><ArticleId IdType="pubmed">28920554</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed R, St. Hill CA, Engstrom BI,et al. . Effects of a consensus-based pulmonary embolism treatment algorithm and response team on treatment modality choices, outcomes, and complications. Clin Appl Thrombosis/Hemostasis 2020; 26: 1076029620928420. doi:10.1177/1076029620928420</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029620928420</ArticleId><ArticleId IdType="pmc">PMC7427027</ArticleId><ArticleId IdType="pubmed">32539524</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#x142;awek-Szmyt S, Jankiewicz S, Smukowska-Gorynia A, et al. . Implementation of a regional multidisciplinary pulmonary embolism response team: PERT -POZ initial 1-year experience. Polish Heart J 2020; 78: 300&#x2013;310. doi:10.33963/KP.15230</Citation><ArticleIdList><ArticleId IdType="doi">10.33963/KP.15230</ArticleId><ArticleId IdType="pubmed">32165606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiske CP, Shen C, Amoroso N, et al. . Evaluating time to treatment and in-hospital outcomes of pulmonary embolism response teams. J Vasc Surg Venous Lymphat Disord 2020; 8: 717&#x2013;724. doi:10.1016/j.jvsv.2019.12.077</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2019.12.077</ArticleId><ArticleId IdType="pubmed">32179041</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright C, Elbadawi A, Chen YL, et al. . The impact of a pulmonary embolism response team on the efficiency of patient care in the emergency department. J Thromb Thrombolysis 2019; 48: 331&#x2013;335. doi:10.1007/s11239-019-01875-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-019-01875-0</ArticleId><ArticleId IdType="pmc">PMC6599732</ArticleId><ArticleId IdType="pubmed">31102160</ArticleId></ArticleIdList></Reference><Reference><Citation>Xenos ES, Davis GA, He Q, et al. . The implementation of a pulmonary embolism response team in the management of intermediate- or high-risk pulmonary embolism. J Vasc Surg Venous Lymphat Disord 2019; 7: 493&#x2013;500. doi:10.1016/j.jvsv.2018.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2018.11.014</ArticleId><ArticleId IdType="pubmed">30930079</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll BJ, Pemberton H, Bauer KA, et al. . Initiation of a multidisciplinary, rapid response team to massive and submassive pulmonary embolism. Am J Cardiol 2017; 120: 1393&#x2013;1398. doi:10.1016/j.amjcard.2017.07.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2017.07.033</ArticleId><ArticleId IdType="pubmed">28807405</ArticleId></ArticleIdList></Reference><Reference><Citation>Deadmon EK, Giordano NJ, Rosenfield K, et al. . Comparison of emergency department patients to inpatients receiving a pulmonary embolism response team (PERT) activation. Acad Emerg Med 2017; 24: 814&#x2013;821. doi:10.1111/acem.13199</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acem.13199</ArticleId><ArticleId IdType="pubmed">28419620</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Nie SP, Wang X, et al. . Role of pulmonary embolism response team in patients with intermediate- and high-risk pulmonary embolism: a concise review and preliminary experience from China. J Geriatr Cardiol 2020; 17: 510&#x2013;518. doi:10.11909/j.issn.1671-5411.2020.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.11909/j.issn.1671-5411.2020.08.005</ArticleId><ArticleId IdType="pmc">PMC7475222</ArticleId><ArticleId IdType="pubmed">32952526</ArticleId></ArticleIdList></Reference><Reference><Citation>Roik M, Wretowski D, &#x141;abyk A, et al. . Initial experience of pulmonary embolism response team with percutaneous embolectomy in intermediate-high- and high-risk acute pulmonary embolism. Kardiol Pol 2018; 77: 228&#x2013;231. doi:10.5603/KP.a2018.0239</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/KP.a2018.0239</ArticleId><ArticleId IdType="pubmed">30566224</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosovsky R, Chang Y, Rosenfield K, et al. . Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. J Thromb Thrombolysis 2019; 47: 31&#x2013;40. doi:10.1007/s11239-018-1737-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-018-1737-8</ArticleId><ArticleId IdType="pubmed">30242551</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz J, Giordano N, Zheng H, et al. . EXPRESS: a multidisciplinary pulmonary embolism response team (PERT) &#x2013; experience from a national multicenter consortium. Pulm Circ 2019; 9: 2045894018824563. doi:10.1177/2045894018824563</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2045894018824563</ArticleId><ArticleId IdType="pmc">PMC6690111</ArticleId><ArticleId IdType="pubmed">30632901</ArticleId></ArticleIdList></Reference><Reference><Citation>Provias T, Dudzinski DM, Jaff MR, et al. . The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism. Hosp Pract 2014; 42: 31&#x2013;37. doi:10.3810/hp.2014.02.1089</Citation><ArticleIdList><ArticleId IdType="doi">10.3810/hp.2014.02.1089</ArticleId><ArticleId IdType="pubmed">24566594</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera-Lebron B, McDaniel M, Ahrar K, et al. . Diagnosis, treatment and follow up of acute pulmonary embolism: consensus practice from the PERT consortium. Clin Appl Thromb Hemost 2019; 25: 1076029619853037. doi:10.1177/1076029619853037</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029619853037</ArticleId><ArticleId IdType="pmc">PMC6714903</ArticleId><ArticleId IdType="pubmed">31185730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucher N, Boekstegers P, M&#xfc;ller OJ, et al. . Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129: 479&#x2013;486. doi:10.1161/CIRCULATIONAHA.113.005544</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.005544</ArticleId><ArticleId IdType="pubmed">24226805</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei DT, Liu J, Yaqoob M, et al. . Meta-analysis of catheter directed ultrasound-assisted thrombolysis in pulmonary embolism. Am J Cardiol 2019; 124: 1470&#x2013;1477. doi:10.1016/j.amjcard.2019.07.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2019.07.040</ArticleId><ArticleId IdType="pubmed">31492420</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza G, Hohlfelder B, Jaff MR, et al. . A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. JACC Cardiovasc Interv 2015; 8: 1382&#x2013;1392. doi:10.1016/j.jcin.2015.04.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2015.04.020</ArticleId><ArticleId IdType="pubmed">26315743</ArticleId></ArticleIdList></Reference><Reference><Citation>Marron RM, Rali P, Hountras P, et al. . Inferior vena cava filters: past, present, and future . Chest 2020; 158: 2579&#x2013;2589. doi:10.1016/j.chest.2020.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.08.002</ArticleId><ArticleId IdType="pubmed">32795479</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer SE, Shanafelt C, Pinto DS, et al. . Utilization and outcomes of thrombolytic therapy for acute pulmonary embolism: a nationwide cohort study. Chest 2020; 157: 645&#x2013;653. doi:10.1016/j.chest.2019.10.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2019.10.049</ArticleId><ArticleId IdType="pubmed">31783016</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes GD, Kabrhel C, Courtney DM, et al. . Diversity in the pulmonary embolism response team model: an organizational survey of the national PERT consortium members. Chest 2016; 150: 1414&#x2013;1417. doi:10.1016/j.chest.2016.09.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2016.09.034</ArticleId><ArticleId IdType="pubmed">27938758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright C, Goldenberg I, Schleede S, et al. . Effect of a multidisciplinary pulmonary embolism response team on patient mortality. Am J Cardiol 2021; 161: 102&#x2013;107. doi:10.1016/j.amjcard.2021.08.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2021.08.066</ArticleId><ArticleId IdType="pmc">PMC8761489</ArticleId><ArticleId IdType="pubmed">34794606</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40645596</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1632</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>09</Day></PubDate></JournalIssue><Title>The spine journal : official journal of the North American Spine Society</Title><ISOAbbreviation>Spine J</ISOAbbreviation></Journal><ArticleTitle>Does cognition status affect spinal surgery outcomes: a systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1529-9430(25)00326-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.spinee.2025.07.020</ELocationID><Abstract><AbstractText Label="BACKGROUND CONTEXT" NlmCategory="BACKGROUND">Mild cognitive impairment (MCI) and Dementia have been shown to be independent risk factors for complications after spine surgery. To date, no systematic review has been conducted on the effect of cognitive impairment (CI) on spine surgery outcomes.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This study aims to perform a systematic review and meta-analysis of previous studies on perioperative outcomes and facility-based measures in cognitively impaired patients undergoing spine surgery.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Systematic review and meta-analysis.</AbstractText><AbstractText Label="PATIENT SAMPLE" NlmCategory="METHODS">Eleven articles encompassing approximately 16,070 patients with cognitive impairment were included in this study.</AbstractText><AbstractText Label="OUTCOMES MEASURED" NlmCategory="METHODS">Data on postoperative outcomes including delirium, urinary tract infection (UTI), myocardial infarction, pulmonary embolism (PE), deep vein thrombosis (DVT), pneumonia, surgical site infection (SSI), wound dehiscence, sepsis, acute kidney injury, reoperation, readmission, intensive care unit (ICU) admission, length of stay, and cost were collected and assessed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search of PubMed, Embase, Cochrane Library, and Web of Science was conducted on July 8th, 2024. This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies directly comparing spine surgery outcomes in cognitively impaired populations versus normal cognition were included for meta-analysis. A Random-effect model was used to estimate the pooled odds ratios of relevant outcomes. Lumbar and cervical subgroup analyses were also conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1,074 articles were screened as titles and abstracts. 54 studies were included for full-text review, yielding 11 articles to be included in this study. These 11 studies (6 retrospective cohort studies, 5 prospective observational studies) directly analyzed the effect of CI on spine surgery outcomes. Random-effect model demonstrated patients with CI were found to have significantly higher odds of developing UTI (OR 4.32[2.24-8.33]), delirium (OR 2.33[1.68-3.22]), DVT (OR 2.49[1.23-5.03]) pneumonia (OR 3.24[1.94-5.43]), wound dehiscence (OR 1.50[1.08-2.08]), and sepsis (OR 2.18[1.04-4.56]). The presence of cognitive impairment was associated with a 2-fold higher odds of ICU admission after surgery (OR 2.05[1.22-3.44]), and 20% increase likelihood of 30-day readmission (OR 1.20[1.03-1.40]) after spine surgery.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study suggests that preoperative CI is associated with worse postoperative health outcomes and inferior facility-based measures in patients undergoing spine surgery. These findings highlight the importance of early recognition and management of cognitive impairment prior to spine surgery, as doing so may mitigate postoperative risks and improve both clinical and facility-based outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ashraf</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karnati</LastName><ForeName>Janesh</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashraf</LastName><ForeName>Mir</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaghazchi</LastName><ForeName>Aydin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>Harry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shankar</LastName><ForeName>Sachin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranganathan</LastName><ForeName>Sruthi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Mikayla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adogwa</LastName><ForeName>Owoicho</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, University of Cincinnati College of Medicine, Cincinnati OH, USA; Spine Translational and Aging Laboratory, University of Cincinnati College of Medicine, Cincinnati OH, USA. Electronic address: owoicho.adogwa@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Spine J</MedlineTA><NlmUniqueID>101130732</NlmUniqueID><ISSNLinking>1529-9430</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">Lumbar</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Mild cognitive impairment</Keyword><Keyword MajorTopicYN="N">Spine surgery</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>12</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>12</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>19</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40645596</ArticleId><ArticleId IdType="doi">10.1016/j.spinee.2025.07.020</ArticleId><ArticleId IdType="pii">S1529-9430(25)00326-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29192859</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1933-0693</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurosurgery</Title><ISOAbbreviation>J Neurosurg</ISOAbbreviation></Journal><ArticleTitle>Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>906</StartPage><EndPage>915</EndPage><MedlinePgn>906-915</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2017.2.JNS162040</ELocationID><ELocationID EIdType="pii" ValidYN="Y">2017.2.JNS162040</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Venous thromboembolism (VTE) is a common and potentially life-threatening complication. The risk of serious hemorrhagic complications when starting chemical prophylaxis for VTE prevention is a substantial concern for neurosurgeons. The objective of this study was to perform an updated systematic review and meta-analysis to determine if the rates of VTE and bleeding complications are different in patients undergoing chemoprophylaxis compared with placebo or mechanical prophylaxis alone following cranial or spinal procedures.</AbstractText><AbstractText Label="METHODS">In February 2016 a systematic literature review was performed identifying 3944 articles from 4 different databases. A random-effects meta-analysis was performed after identifying the articles that met inclusion criteria.</AbstractText><AbstractText Label="RESULTS">Nine articles that met the inclusion criteria were included. The quality of the studies was good, with all of them being classified as Level 2 evidence, with moderate Jadad scores. A meta-analysis comparing chemoprophylaxis with placebo in the prevention of deep venous thrombosis showed a significant benefit to chemical prophylaxis (OR 0.51, 95% CI 0.37-0.71; p &lt; 0.0001). No significant increase in major intracranial hemorrhage (p = 0.60), major extracranial hemorrhage (p = 0.98), or minor bleeding complications (p = 0.60) was found.</AbstractText><AbstractText Label="CONCLUSIONS">Based on moderate-to-good quality of evidence, chemoprophylaxis is beneficial in preventing VTE, with no significant increase in either major or minor bleeding complications in patients undergoing cranial and spinal procedures. Further research is needed to determine whether this conclusion holds true for more specific subpopulations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Nickalus R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Departments of1Neurosurgery and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Prayash G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Departments of1Neurosurgery and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharpe</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>2Surgery-Critical Care, University of Tennessee Health Science Center, Memphis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Siang Liao</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>3Department of Neurosurgery, Louisiana State University Health Sciences Center-Shreveport, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorenson</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of1Neurosurgery and.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>4Semmes Murphey Neurologic &amp; Spine Institute, Memphis, Tennessee; and.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosurg</MedlineTA><NlmUniqueID>0253357</NlmUniqueID><ISSNLinking>0022-3085</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020300" MajorTopicYN="N">Intracranial Hemorrhages</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007431" MajorTopicYN="N">Intraoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019635" MajorTopicYN="Y">Neurosurgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DVT = deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">ECH = extracranial hemorrhage</Keyword><Keyword MajorTopicYN="N">ICH = intracranial hemorrhage</Keyword><Keyword MajorTopicYN="N">LMWH = low-molecular-weight heparin</Keyword><Keyword MajorTopicYN="N">OCEBM = Oxford Centre for Evidence-Based Medicine</Keyword><Keyword MajorTopicYN="N">PE = pulmonary embolism</Keyword><Keyword MajorTopicYN="N">RCT = randomized controlled trial</Keyword><Keyword MajorTopicYN="N">VTE = venous thromboembolism</Keyword><Keyword MajorTopicYN="N">deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">enoxaparin</Keyword><Keyword MajorTopicYN="N">heparin</Keyword><Keyword MajorTopicYN="N">intracranial hemorrhage</Keyword><Keyword MajorTopicYN="N">neurosurgery</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">review</Keyword><Keyword MajorTopicYN="N">vascular disorders</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29192859</ArticleId><ArticleId IdType="doi">10.3171/2017.2.JNS162040</ArticleId><ArticleId IdType="pii">2017.2.JNS162040</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30824975</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1262</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of colorectal disease</Title><ISOAbbreviation>Int J Colorectal Dis</ISOAbbreviation></Journal><ArticleTitle>The prevalence of venous thromboembolism in rectal surgery: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>849</StartPage><EndPage>860</EndPage><MedlinePgn>849-860</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00384-019-03244-y</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Venous thromboembolism (VTE) following rectal surgery is a significant and preventable cause of morbidity and mortality, yet the true prevalence is not well established. This systematic review and meta-analysis assessed the available literature and determined its prevalence following rectal surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review assessed the prevalence of VTE following rectal surgery. In addition, we evaluated whether subgroups (open vs. minimally invasive or benign vs. malignant resections) impacted on its prevalence or rate of deep venous thrombosis (DVT) or pulmonary embolism (PE).</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Thirty-eight studies met the predefined inclusion criteria. The aggregate prevalence of VTE following rectal surgery was 1.25% (95% CI 0.86-1.63), with DVT and PE occurring in 0.68% (95% CI 0.48-0.89) and 0.57% (95% CI 0.47-0.68) of patients. VTE following cancer and benign resection was 1.59% (95% CI 0.60-1.23 and 1.5% (95% CI 0.89-2.12) respectively. The prevalence of VTE in patients having minimally invasive resection was lower than those having open surgery [0.58% (16/2770) vs. 2.22% (250/11278); RR 0.54, 95% CI 0.33-0.86].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This review observed that there is sparse evidence on prevalence of VTE following rectal surgery. It provides aggregated data and analysis of available literature, showing overall prevalence is low, especially in those having minimally invasive procedures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Joshua W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Surgery, James Connolly Memorial Hospital, Blanchardstown, Dublin, Ireland. joshuawphayes@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>&#xc9;anna J</ForeName><Initials>&#xc9;J</Initials><AffiliationInfo><Affiliation>Department of Surgery, James Connolly Memorial Hospital, Blanchardstown, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Patrick A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Surgery, James Connolly Memorial Hospital, Blanchardstown, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Creavin</LastName><ForeName>Ben</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Surgery, James Connolly Memorial Hospital, Blanchardstown, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Surgery, James Connolly Memorial Hospital, Blanchardstown, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beddy</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, James Connolly Memorial Hospital, Blanchardstown, Dublin, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Int J Colorectal Dis</MedlineTA><NlmUniqueID>8607899</NlmUniqueID><ISSNLinking>0179-1958</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D013505" MajorTopicYN="N">Digestive System Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="N">Laparoscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019060" MajorTopicYN="N">Minimally Invasive Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017594" MajorTopicYN="N">Publication Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012007" MajorTopicYN="N">Rectum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012371" MajorTopicYN="N">Robotics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Rectal surgery</Keyword><Keyword MajorTopicYN="N">Surgical outcomes</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30824975</ArticleId><ArticleId IdType="doi">10.1007/s00384-019-03244-y</ArticleId><ArticleId IdType="pii">10.1007/s00384-019-03244-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Intern Med. 1999 Mar 8;159(5):445-53</Citation><ArticleIdList><ArticleId IdType="pubmed">10074952</ArticleId></ArticleIdList></Reference><Reference><Citation>Colorectal Dis. 2002 Jan;4(1):61-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12780658</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromb Haemost. 2003 Sep;90(3):446-55</Citation><ArticleIdList><ArticleId IdType="pubmed">12958614</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2004 Feb;18(2):281-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14691716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2004 Sep;126(3 Suppl):338S-400S</Citation><ArticleIdList><ArticleId IdType="pubmed">15383478</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 1992 Mar;127(3):310-3</Citation><ArticleIdList><ArticleId IdType="pubmed">1550477</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2005 May 14-20;365(9472):1718-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15894098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 2006 Jan;243(1):89-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16371741</ArticleId></ArticleIdList></Reference><Reference><Citation>Colorectal Dis. 2006 Mar;8(3):177-85</Citation><ArticleIdList><ArticleId IdType="pubmed">16466556</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 2006 Aug;141(8):790-7; discussion 797-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16924087</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Colon Rectum. 2006 Oct;49(10):1620-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17019655</ArticleId></ArticleIdList></Reference><Reference><Citation>Colorectal Dis. 2008 May;10(4):373-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17714533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg Oncol. 2008 Sep;15(9):2418-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18392659</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromb Haemost. 2008 Jun;99(6):1104-11</Citation><ArticleIdList><ArticleId IdType="pubmed">18521515</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg Oncol. 2008 Oct;15(10):2847-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18649105</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Colorectal Dis. 2009 Jul;24(7):761-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19221764</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Jul 21;339:b2700</Citation><ArticleIdList><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromb Res. 2010 Mar;125(3):e65-70</Citation><ArticleIdList><ArticleId IdType="pubmed">19919878</ArticleId></ArticleIdList></Reference><Reference><Citation>Tech Coloproctol. 2010 Jun;14(2):125-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20405303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg Oncol. 2010 Dec;17(12):3195-202</Citation><ArticleIdList><ArticleId IdType="pubmed">20589436</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Surg. 2011 May;212(5):844-54</Citation><ArticleIdList><ArticleId IdType="pubmed">21414814</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 2011 Jun;146(6):739-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21690452</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromb Res. 2012 May;129(5):568-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21872295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Oncol. 2011 Sep;22 Suppl 6:vi85-92</Citation><ArticleIdList><ArticleId IdType="pubmed">21908511</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Surg. 2012 Feb;147(2):120-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22006853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 2011 Dec;254(6):941-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22076066</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Methods Med Res. 2013 Apr;22(2):117-32</Citation><ArticleIdList><ArticleId IdType="pubmed">22218366</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Res Notes. 2012 Jan 20;5:52</Citation><ArticleIdList><ArticleId IdType="pubmed">22264277</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2012 Feb;141(2 Suppl):e227S-e277S</Citation><ArticleIdList><ArticleId IdType="pubmed">22315263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 2013 Apr;257(4):737-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22968079</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Surg. 2013 Jan;148(1):65-71</Citation><ArticleIdList><ArticleId IdType="pubmed">22986932</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Colon Rectum. 2012 Nov;55(11):1138-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23044674</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Surg. 2013 Mar;216(3):395-401.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">23312467</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2013 Sep;27(9):3452-64</Citation><ArticleIdList><ArticleId IdType="pubmed">23508815</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2014 Apr;207(4):520-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24239525</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Angiol. 2013 Apr;32(2):111-260</Citation><ArticleIdList><ArticleId IdType="pubmed">24402349</ArticleId></ArticleIdList></Reference><Reference><Citation>Tech Coloproctol. 2014 Aug;18(8):719-24</Citation><ArticleIdList><ArticleId IdType="pubmed">24562596</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Colon Rectum. 2014 Apr;57(4):415-22</Citation><ArticleIdList><ArticleId IdType="pubmed">24608296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg Oncol. 2015 Mar;22(3):931-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25201505</ArticleId></ArticleIdList></Reference><Reference><Citation>Colorectal Dis. 2015 Jan;17(1):57-65</Citation><ArticleIdList><ArticleId IdType="pubmed">25204543</ArticleId></ArticleIdList></Reference><Reference><Citation>J Surg Res. 2015 Feb;193(2):613-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25214259</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Surg Oncol. 2015 Feb;41(2):201-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25572974</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Surg Oncol. 2015 Feb 12;13:39</Citation><ArticleIdList><ArticleId IdType="pubmed">25889121</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res Treat. 2016 Jul;48(3):978-89</Citation><ArticleIdList><ArticleId IdType="pubmed">26582397</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastrointest Endosc. 2016 Aug;84(2):296-303.e1</Citation><ArticleIdList><ArticleId IdType="pubmed">26828760</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg Oncol. 2016 May;23(5):1422-30</Citation><ArticleIdList><ArticleId IdType="pubmed">26887853</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Surg. 2016 Aug;223(2):291-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27112126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 2016 Oct;264(4):632-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27455158</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2017 Jul;31(7):2798-2807</Citation><ArticleIdList><ArticleId IdType="pubmed">27785627</ArticleId></ArticleIdList></Reference><Reference><Citation>J Surg Oncol. 2017 Jun;115(8):1033-1044</Citation><ArticleIdList><ArticleId IdType="pubmed">28334436</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 2017 Sep;214(3):416-420</Citation><ArticleIdList><ArticleId IdType="pubmed">28622838</ArticleId></ArticleIdList></Reference><Reference><Citation>J Surg Oncol. 2017 Dec;116(8):989-995</Citation><ArticleIdList><ArticleId IdType="pubmed">28743178</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2018 May;32(5):2517-2524</Citation><ArticleIdList><ArticleId IdType="pubmed">29101566</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgery. 2018 Dec;164(6):1234-1240</Citation><ArticleIdList><ArticleId IdType="pubmed">30190110</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Colon Rectum. 1982 Sep;25(6):563-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7117060</ArticleId></ArticleIdList></Reference><Reference><Citation>Control Clin Trials. 1996 Feb;17(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Surg. 1997 Jul;174(1):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9240942</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34282541</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1937-5395</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of cardiovascular translational research</Title><ISOAbbreviation>J Cardiovasc Transl Res</ISOAbbreviation></Journal><ArticleTitle>Venoarterial Extracorporeal Membrane Oxygenation for Acute Massive Pulmonary Embolism: a Meta-Analysis and Call to Action.</ArticleTitle><Pagination><StartPage>258</StartPage><EndPage>267</EndPage><MedlinePgn>258-267</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12265-021-10158-0</ELocationID><Abstract><AbstractText>Venoarterial extracorporeal membrane oxygenation (ECMO) has been used to treat acute massive pulmonary embolism (PE) patients. However, the incremental benefit of ECMO to standard therapy remains unclear. Our meta-analysis objective is to compare in-hospital mortality in patients treated for acute massive PE with and without ECMO. The National Library of Medicine MEDLINE (USA), Web of Science, and PubMed databases from inception through October 2020 were searched. Screening identified 1002 published articles. Eleven eligible studies were identified, and 791 patients with acute massive PE were included, of whom 270 received ECMO and 521 did not. In-hospital mortality was not significantly different between patients treated with vs. without ECMO (OR = 1.24 [95% CI, 0.63-2.44], p = 0.54). However, these findings were limited by significant study heterogeneity. Additional research will be needed to clarify the role of ECMO in massive PE treatment. In-hospital mortality for patients with acute massive pulmonary embolism was not significantly different (OR of 1.24, p = 0.54) between those treated with and without venoarterial ECMO.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaso</LastName><ForeName>Elona Rrapo</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Medicine, Cardiovascular Division, University of Virginia, 1215 Lee Street, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Jonathan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Cardiovascular Division, University of Virginia, 1215 Lee Street, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salerno</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Cardiovascular Division, University of Virginia, 1215 Lee Street, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadl</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary and Critical Care, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aldridge</LastName><ForeName>Chad</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Therapy Services, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haskal</LastName><ForeName>Ziv J</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Jamie L W</ForeName><Initials>JLW</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Inova Heart and Vascular Institute, Falls Church, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazimba</LastName><ForeName>Sula</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Cardiovascular Division, University of Virginia, 1215 Lee Street, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihalek</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary and Critical Care, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teman</LastName><ForeName>Nicholas R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giri</LastName><ForeName>Jay</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronow</LastName><ForeName>Herbert D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Aditya M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-1756-2504</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Cardiovascular Division, University of Virginia, 1215 Lee Street, Charlottesville, VA, USA. asharma@virginia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Cardiovasc Transl Res</MedlineTA><NlmUniqueID>101468585</NlmUniqueID><ISSNLinking>1937-5387</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Massive or high-risk pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Venoarterial extracorporeal membrane oxygenation</Keyword></KeywordList><CoiStatement>Dr. Sharma receives research grants from Vascular Medcure Inc, DalCor Pharma UK Ltd, and Portola. Dr. Giri is on the advisory board for Inari Medical and Astra Zeneca and has research grants from Boston Scientific. All other authors have no conflict of interest related to the work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>7</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34282541</ArticleId><ArticleId IdType="pmc">PMC8288068</ArticleId><ArticleId IdType="doi">10.1007/s12265-021-10158-0</ArticleId><ArticleId IdType="pii">10.1007/s12265-021-10158-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease C, Prevention Venous thromboembolism in adult hospitalizations - United States, 2007-2009. MMWR. Morbidity and Mortality Weekly Report. 2012;61(22):401&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">22672974</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathbun S. Cardiology patient pages. The Surgeon General&#x2019;s call to action to prevent deep vein thrombosis and pulmonary embolism. Circulation. 2009;119(15):e480&#x2013;e482. doi: 10.1161/CIRCULATIONAHA.108.841403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.841403</ArticleId><ArticleId IdType="pubmed">19380627</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 2016;41(1):3&#x2013;14. doi: 10.1007/s11239-015-1311-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-015-1311-6</ArticleId><ArticleId IdType="pmc">PMC4715842</ArticleId><ArticleId IdType="pubmed">26780736</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakr Y, Giovini M, Leone M, Pizzilli G, Kortgen A, Bauer M, et al. Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: A narrative review. Annals of Intensive Care. 2020;10(1):124. doi: 10.1186/s13613-020-00741-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-020-00741-0</ArticleId><ArticleId IdType="pmc">PMC7492788</ArticleId><ArticleId IdType="pubmed">32953201</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Visani L, De Rosa M. Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) Lancet; 1999. Acute pulmonary embolism; pp. 1386&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227218</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, et al. Systemic thrombolytic therapy for acute pulmonary embolism: A systematic review and meta-analysis. European Heart Journal. 2015;36(10):605&#x2013;614. doi: 10.1093/eurheartj/ehu218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu218</ArticleId><ArticleId IdType="pmc">PMC4352209</ArticleId><ArticleId IdType="pubmed">24917641</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. The American Journal of Medicine. 2012;125(5):465&#x2013;470. doi: 10.1016/j.amjmed.2011.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2011.10.015</ArticleId><ArticleId IdType="pubmed">22325236</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinberg A, Tapson VF, Ramzy D. Massive pulmonary embolism: Extracorporeal membrane oxygenation and surgical pulmonary embolectomy. Seminars in Respiratory and Critical Care Medicine. 2017;38(1):66&#x2013;72. doi: 10.1055/s-0036-1597559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0036-1597559</ArticleId><ArticleId IdType="pubmed">28208200</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasrija C, Kronfli A, George P, Raithel M, Boulos F, Herr DL, et al. Utilization of veno-arterial extracorporeal membrane oxygenation for massive pulmonary embolism. The Annals of Thoracic Surgery. 2018;105(2):498&#x2013;504. doi: 10.1016/j.athoracsur.2017.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.08.033</ArticleId><ArticleId IdType="pubmed">29174781</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant C, Jr, Richards JB, Frakes M, Cohen J, Wilcox SR. ECMO and Right Ventricular Failure: Review of the Literature. Journal of Intensive Care Medicine. 2021;36(3):352&#x2013;360. doi: 10.1177/0885066619900503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066619900503</ArticleId><ArticleId IdType="pubmed">31964208</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuff HO, Zochios V, Vuylsteke A. Extracorporeal membrane oxygenation in acute massive pulmonary embolism: A systematic review. Perfusion. 2015;30(8):611&#x2013;616. doi: 10.1177/0267659115583377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659115583377</ArticleId><ArticleId IdType="pubmed">25910837</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008&#x2013;2012. doi: 10.1001/jama.283.15.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.15.2008</ArticleId><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG, Group P Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao G, Lopez-Jimenez F, Boyd J, D'Amico F, Durant NH, Hlatky MA, et al. Methodological standards for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies: A scientific statement from the American Heart Association. Circulation. 2017;136(10):e172&#x2013;ee94. doi: 10.1161/CIR.0000000000000523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000523</ArticleId><ArticleId IdType="pubmed">28784624</ArticleId></ArticleIdList></Reference><Reference><Citation>Giri J, Sista AK, Weinberg I, Kearon C, Kumbhani DJ, Desai ND, et al. Interventional therapies for acute pulmonary embolism: Current status and principles for the development of novel evidence: a scientific statement from the American Heart Association. Circulation. 2019;140(20):e774&#x2013;e801. doi: 10.1161/CIR.0000000000000707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000707</ArticleId><ArticleId IdType="pubmed">31585051</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database of Systematic Reviews. 2019;10:ED000142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10284251</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. Jama. 2006;295(6):676&#x2013;680. doi: 10.1001/jama.295.6.676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.295.6.676</ArticleId><ArticleId IdType="pubmed">16467236</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629&#x2013;634. doi: 10.1136/bmj.315.7109.629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId><ArticleId IdType="pmc">PMC2127453</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandigers L, Scholten E, Rietdijk WJR, den Uil CA, van Thiel RJ, Rigter S, et al. Survival and neurological outcome with extracorporeal cardiopulmonary resuscitation for refractory cardiac arrest caused by massive pulmonary embolism: A two center observational study. Resuscitation. 2019;136:8&#x2013;13. doi: 10.1016/j.resuscitation.2018.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2018.12.008</ArticleId><ArticleId IdType="pubmed">30572065</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggio P, Hemmila M, Haft J, Bartlett R. Extracorporeal life support for massive pulmonary embolism. The Journal of Trauma. 2007;62(3):570&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">17414330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MY, Liu YC, Tseng YH, Chang YS, Lin PJ, Wu TI. Pulmonary embolectomy in high-risk acute pulmonary embolism: The effectiveness of a comprehensive therapeutic algorithm including extracorporeal life support. Resuscitation. 2013;84(10):1365&#x2013;1370. doi: 10.1016/j.resuscitation.2013.03.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resuscitation.2013.03.032</ArticleId><ArticleId IdType="pubmed">23583612</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbon JH, Jr, Hill JD. Part I. The development of the first successful heart-lung machine. The Annals of Thoracic Surgery. 1982;34(3):337&#x2013;341. doi: 10.1016/S0003-4975(10)62507-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-4975(10)62507-6</ArticleId><ArticleId IdType="pubmed">7052001</ArticleId></ArticleIdList></Reference><Reference><Citation>Noah MA, Peek GJ, Finney SJ, Griffiths MJ, Harrison DA, Grieve R, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1) Jama. 2011;306(15):1659&#x2013;1668. doi: 10.1001/jama.2011.1471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2011.1471</ArticleId><ArticleId IdType="pubmed">21976615</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbadawi, A., Mentias, A., Elgendy, I. Y., Mohamed, A. H., Syed, M. H., Ogunbayo, G. O., et al. National trends and outcomes for extra-corporeal membrane oxygenation use in high-risk pulmonary embolism. Vascular Medicine (London, England), 2019, 24(3), 230&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6527463</ArticleId><ArticleId IdType="pubmed">30834824</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides SV, Meyer G. The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. European Heart Journal. 2019;40(42):3453&#x2013;3455. doi: 10.1093/eurheartj/ehz726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz726</ArticleId><ArticleId IdType="pubmed">31697840</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi M, Metge A, Martelin A, Giroudon C, Lanier Demma J, Koffel C, et al. Efficacy and safety of extracorporeal membrane oxygenation for high-risk pulmonary embolism: A systematic review and meta-analysis. Vascular Medicine. 2020;25(5):460&#x2013;467. doi: 10.1177/1358863X20944469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1358863X20944469</ArticleId><ArticleId IdType="pubmed">32790536</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon D, Lee SN, Yoo KD, Jo MS. Extracorporeal membrane oxygenation improved survival in patients with massive pulmonary embolism. Annals of Saudi Medicine. 2018;38(3):174&#x2013;180. doi: 10.5144/0256-4947.2018.174.</Citation><ArticleIdList><ArticleId IdType="doi">10.5144/0256-4947.2018.174</ArticleId><ArticleId IdType="pmc">PMC6074311</ArticleId><ArticleId IdType="pubmed">29848934</ArticleId></ArticleIdList></Reference><Reference><Citation>Meneveau N, Guillon B, Planquette B, Piton G, Kimmoun A, Gaide-Chevronnay L, et al. Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: A multicentre series of 52 cases. European Heart Journal. 2018;39(47):4196&#x2013;4204. doi: 10.1093/eurheartj/ehy464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehy464</ArticleId><ArticleId IdType="pubmed">30137303</ArticleId></ArticleIdList></Reference><Reference><Citation>Basir MB, Kapur NK, Patel K, Salam MA, Schreiber T, Kaki A, et al. Improved outcomes associated with the use of shock protocols: Updates from the National Cardiogenic Shock Initiative. Catheterization and Cardiovascular Interventions. 2019;93(7):1173&#x2013;1183.</Citation><ArticleIdList><ArticleId IdType="pubmed">31025538</ArticleId></ArticleIdList></Reference><Reference><Citation>Samsky MD, Krucoff MW, Morrow DA, Abraham WT, Aguel F, Althouse AD, et al. Cardiac safety research consortium &#x201c;shock II&#x201d; think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. American Heart Journal. 2020;230:93&#x2013;97. doi: 10.1016/j.ahj.2020.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2020.09.015</ArticleId><ArticleId IdType="pmc">PMC7704747</ArticleId><ArticleId IdType="pubmed">33011148</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz J, Giordano N, Zheng H, Parry BA, Barnes GD, Heresi GA, Jaber W, Wood T, Todoran T, Courtney DM, Naydenov S, Khandhar S, Green P, Kabrhel C. EXPRESS: A Multidisciplinary Pulmonary Embolism Response Team (PERT) - Experience from a national multicenter consortium. Pulmonary Circulation. 2019;9(3):2045894018824563. doi: 10.1177/2045894018824563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2045894018824563</ArticleId><ArticleId IdType="pmc">PMC6690111</ArticleId><ArticleId IdType="pubmed">30632901</ArticleId></ArticleIdList></Reference><Reference><Citation>Myc LA, Solanki JN, Barros AJ, Nuradin N, Nevulis MG, Earasi K, et al. Adoption of a dedicated multidisciplinary team is associated with improved survival in acute pulmonary embolism. Respiratory Research. 2020;21(1):159. doi: 10.1186/s12931-020-01422-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-020-01422-z</ArticleId><ArticleId IdType="pmc">PMC7310489</ArticleId><ArticleId IdType="pubmed">32571318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. The Annals of Thoracic Surgery. 2014;97(2):610&#x2013;616. doi: 10.1016/j.athoracsur.2013.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2013.09.008</ArticleId><ArticleId IdType="pubmed">24210621</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R, Tisljar K, Marsch S. Acute neurologic complications during extracorporeal membrane oxygenation: A systematic review. Critical Care Medicine. 2018;46(9):1506&#x2013;1513. doi: 10.1097/CCM.0000000000003223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000003223</ArticleId><ArticleId IdType="pubmed">29782356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37663232</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2391-5463</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Open medicine (Warsaw, Poland)</Title><ISOAbbreviation>Open Med (Wars)</ISOAbbreviation></Journal><ArticleTitle>Aspirin versus LMWH for VTE prophylaxis after orthopedic surgery.</ArticleTitle><Pagination><StartPage>20230760</StartPage><MedlinePgn>20230760</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">20230760</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1515/med-2023-0760</ELocationID><Abstract><AbstractText>Low molecular weight heparin (LMWH) is often used to prevent perioperative venous thrombosis after surgery, but aspirin is also recommended by academics. Studies were searched in electronic databases until February 24, 2023. We performed a meta-analysis to evaluate the safety and efficacy of aspirin and LMWH for venous thromboembolism (VTE) prophylaxis in patients after orthopedic surgery. The outcomes were death from any causes, deep vein thrombosis (DVT), pulmonary embolism (PE), etc. This study was registered with INPLASY, number 202320117. Six randomized controlled trials enrolled 13,851 patients with postoperative joint surgery. The risk of DVT was comparable between the two groups when aspirin was combined with mechanical devices (RR 0.61 [95% CI 0.27-1.39], <i>I</i>&#xb2; = 62%, <i>P</i> = 0.24). No significant differences in all cause death, PE, wound infection, and wound complication were found between the aspirin and LMWH groups. In this meta-analysis, the mortality rate was comparable between the aspirin and LMWH groups. However, aspirin alone had a higher risk of DVT than LMWH. Based on the results of this meta-analysis, we suggest aspirin combined with mechanical devices for VTE prophylaxis in patients after orthopedic surgery.</AbstractText><CopyrightInformation>&#xa9; 2023 the author(s), published by De Gruyter.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Qingqing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Emergency General Hospital, Beijing, 100028, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Emergency General Hospital, Beijing, 100028, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yusuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Chuiyangliu Hospital Affiliated to Tsinghua University, Beijing, 100022, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Chang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Emergency, Emergency General Hospital, Beijing, 100028, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miao</LastName><ForeName>Guobin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Emergency, Emergency General Hospital, XiBaHe South Road 29, Chaoyang District, Beijing, 100028, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Ordos Central Hospital, Ordos School of Clinical Medicine, Inner Mongolia Medical University, 23 Yijinhuoluo West Street, Dongsheng District, Inner Mongolia, 017000, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haijun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Ordos Central Hospital, Ordos School of Clinical Medicine, Inner Mongolia Medical University, 23 Yijinhuoluo West Street, Dongsheng District, Inner Mongolia, 017000, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Open Med (Wars)</MedlineTA><NlmUniqueID>101672167</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">aspirin</Keyword><Keyword MajorTopicYN="N">joint surgery</Keyword><Keyword MajorTopicYN="N">low-molecular-weight heparin</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList><CoiStatement>Conflict of interest: Authors state no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>4</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37663232</ArticleId><ArticleId IdType="pmc">PMC10473459</ArticleId><ArticleId IdType="doi">10.1515/med-2023-0760</ArticleId><ArticleId IdType="pii">med-2023-0760</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Knudson MM, Ikossi DG, Khaw L, Morabito D, Speetzen LS. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg. 2004;240:490&#x2013;8. 10.1097/01.sla.0000137138.40116.6c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.sla.0000137138.40116.6c</ArticleId><ArticleId IdType="pmc">PMC1356439</ArticleId><ArticleId IdType="pubmed">15319720</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagi HC, Ahn J, Ciesla D, Collinge C, Molina C, Obremskey WT. Venous thromboembolism prophylaxis in orthopedic trauma patients: a survey of OTAmember practice patterns and OTA expert panel recommendations. J Orthop Trauma. 2015;29(10):e355&#x2013;62. 10.1097/BOT.0000000000000387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOT.0000000000000387</ArticleId><ArticleId IdType="pubmed">26402304</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schu&#xfc;nemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence based clinical practice guidelines. Chest. 2012;141(Suppl):7S&#x2013;47S. 10.1378/chest.1412S3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.1412S3</ArticleId><ArticleId IdType="pmc">PMC3278060</ArticleId><ArticleId IdType="pubmed">22315257</ArticleId></ArticleIdList></Reference><Reference><Citation>Drescher FS, Sirovich BE, Lee A, Morrison DH, Chiang WH, Larson RJ. Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. J Hosp Med. 2014;9:579&#x2013;85. 10.1002/jhm.2224. Epub 2014 Jul 17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jhm.2224</ArticleId><ArticleId IdType="pubmed">25045166</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole RV, Stein DM, O&#x2019;Hara NN, Frey KP, Taylor TJ, Scharfstein DO, et al. Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture. N Engl J Med. 2023;388(3):203&#x2013;13. 10.1056/NEJMoa2205973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2205973</ArticleId><ArticleId IdType="pubmed">36652352</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158(11):800&#x2013;7. 10.7326/0003-4819-158-11-201306040-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-158-11-201306040-00004</ArticleId><ArticleId IdType="pubmed">23732713</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Z, Shaoqi T, Yuanhe W, Kang S. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagul Fibrinolysis. 2014;25:660&#x2013;4. 10.1097/MBC.0000000000000121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBC.0000000000000121</ArticleId><ArticleId IdType="pubmed">24695091</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi J, Hui D, Jian L, Yixin Z. Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Chin Med J. 2014;127(12):2201&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24931228</ArticleId></ArticleIdList></Reference><Reference><Citation>Colwell CW, Froimson MI, Mont MA, Ritter MA, Trousdale RT, Buehler KC, et al. Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin. J Bone Jt Surg Am. 2010;92(3):527&#x2013;35. 10.2106/JBJS.I.00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.I.00047</ArticleId><ArticleId IdType="pubmed">20194309</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfer Y, Tavor H, Oron A, Peer A, Halperin N, Robinson D. Deep vein thrombosis prevention in joint arthroplasties: deep vein thrombosis prevention in joint arthroplasties. J Arthroplasty. 2006;21(2):206&#x2013;14. 10.1016/j.arth.2005.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2005.04.031</ArticleId><ArticleId IdType="pubmed">16520208</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018;378(8):699&#x2013;707. 10.1056/NEJMoa1712746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1712746</ArticleId><ArticleId IdType="pubmed">29466159</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman D, Tetzlaff J, Mulrow C, G&#xf8;tzsche P, Ioannidis J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clin Res ed). 2009;339:b2700. 10.1136/bmj.b2700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochlane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]; 2011. http://handbook-5-1.cochrane.org/.</Citation></Reference><Reference><Citation>Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ (Clin Res ed). 2003;327(7414):557&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the US, 2014 to 2030. J Bone Jt Surg Am. 2018;100(17):1455&#x2013;60. 10.2106/JBJS.17.01617.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.17.01617</ArticleId><ArticleId IdType="pubmed">30180053</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Jt Surg Am. 2007;89(4):780&#x2013;5. 10.2106/00004623-200704000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-200704000-00012</ArticleId><ArticleId IdType="pubmed">17403800</ArticleId></ArticleIdList></Reference><Reference><Citation>An VV, Phan K, Levy YD, Bruce WJ. Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty. 2016;31(11):2608&#x2013;16. 10.1016/j.arth.2016.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2016.04.004</ArticleId><ArticleId IdType="pubmed">27178011</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel MP, Meneghini RM, Berry DJ. Current practice trends in primary hip and knee arthroplasties among members of the American Association of Hip and Knee Surgeons: an update during the COVID-19 pandemic. J Arthroplasty. 2021;36(7S):S40&#x2013;4. 10.1016/j.arth.2021.01.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2021.01.080</ArticleId><ArticleId IdType="pubmed">33640185</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirkazemi C, Bereznicki LR, Peterson GM. Comparing Australian orthopaedic surgeons&#x2019; reported use of thromboprophylaxis following arthroplasty in 2012 and 2017. BMC Musculoskelet Disord. 2019;20(1):57. 10.1186/s12891-019-2409-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-019-2409-3</ArticleId><ArticleId IdType="pmc">PMC6368726</ArticleId><ArticleId IdType="pubmed">30736774</ArticleId></ArticleIdList></Reference><Reference><Citation>Farey JE, An VVG, Sidhu V, Karunaratne S, Harris IA. Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: a systematic review and meta-analysis. Orthop Traumatol Surg Res. 2021;107(1):102606. 10.1016/j.otsr.2020.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2020.04.002</ArticleId><ArticleId IdType="pubmed">32631716</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold&#x161;tajn MS, Miku&#x161; M, Ferrari FA, Bosco M, Uccella S, Noventa M, et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Arch Gynecol Obstet. 2023;307:1727&#x2013;45. 10.1007/s00404-022-06647-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00404-022-06647-5</ArticleId><ArticleId IdType="pmc">PMC10147786</ArticleId><ArticleId IdType="pubmed">35713694</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturlese E, Triolo O, Grasso R, Lagan&#xe0; AS, Retto A, Rossetti D, et al. Thromboembolism prophylaxis in laparoscopic surgery for gynecologic benign diseases. Results of a single center experience in 922 procedures. Ann Ital Chir. 2017;88:342&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28590256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Li H, Weng H, Zhou G, Chen H, Yang G, et al. Genome-wide association analyses identified novel susceptibility loci for pulmonary embolism among Han Chinese population. BMC Med. 2023;21(1):153. 10.1186/s12916-023-02844-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-02844-4</ArticleId><ArticleId IdType="pmc">PMC10116678</ArticleId><ArticleId IdType="pubmed">37076872</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37053508</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-7598</ISSN><JournalIssue CitedMedium="Internet"><Volume>137</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Anesthesia and analgesia</Title><ISOAbbreviation>Anesth Analg</ISOAbbreviation></Journal><ArticleTitle>Complications of Factor V Leiden in Adults Undergoing Noncardiac Surgical Procedures: A Systematic Review.</ArticleTitle><Pagination><StartPage>601</StartPage><EndPage>617</EndPage><MedlinePgn>601-617</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1213/ANE.0000000000006483</ELocationID><Abstract><AbstractText>Factor V Leiden is the commonest hereditary prothrombotic allele, affecting 1% to 5% of the world's population. The objective of this study was to characterize the perioperative and postoperative outcomes of patients with Factor V Leiden compared to patients without a diagnosis of hereditary thrombophilia. This was a focused systematic review of studies including adult (&gt;18 years) patients with Factor V Leiden (heterozygous or homozygous) undergoing noncardiac surgery. Included studies were either randomized controlled trials or observational. The primary clinical outcomes of interest were thromboembolic events occurring from the perioperative period up to 1 year postoperatively, defined as deep venous thrombosis, pulmonary embolism, or other clinically significant thrombosis occurring during or after a surgical procedure. Secondary outcomes included cerebrovascular events, cardiac events, death, transplant-related outcomes, and surgery-specific morbidity. Pediatric and obstetrical patients were excluded, as were case reports and case series. Databases searched included MEDLINE and EMBASE from inception until August 2021. Study bias was assessed through the CLARITY (Collaboration of McMaster University researchers) Risk of Bias tools, and heterogeneity through analysis of study design and end points, as well as the I 2 statistic with its confidence interval and the Q statistic. A total of 5275 potentially relevant studies were identified, with 115 having full text assessed for eligibility and 32 included in the systematic review. On the whole, the literature suggests that patients with Factor V Leiden have an increased risk of perioperative and postoperative thromboembolic events compared to patients without the diagnosis. Increased risk was also seen in relation to surgery-specific morbidity and transplant-related outcomes, particularly arterial thrombotic events. The literature did not support an increased risk for mortality, cerebrovascular, or cardiac complications. Limitations of the data include predisposition toward bias due in many study designs and small sample sizes across the majority of published studies. Variable outcome definitions and durations of patient follow-up across different surgical procedures resulted in high study heterogeneity precluding the effective use of meta-analysis. Factor V Leiden status may confer additional risk for surgery-related adverse outcomes. Large, adequately powered studies are required to accurately estimate the degree of this risk by zygosity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 International Anesthesia Research Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Au</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elias</LastName><ForeName>Zeyad</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koivu</LastName><ForeName>Annabel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Edinburgh Medical School, University of Edinburgh, Edinburgh, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zabida</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Pain Management, Sinai Health System, Women's College Hospital, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Andrew W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Blood Research, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cserti-Gazdewich</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Klei</LastName><ForeName>Wilton A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Pain Management, Sinai Health System, Women's College Hospital, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anaesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartoszko</LastName><ForeName>Justyna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Pain Management, Sinai Health System, Women's College Hospital, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anaesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anesth Analg</MedlineTA><NlmUniqueID>1310650</NlmUniqueID><ISSNLinking>0003-2999</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C095381">factor V Leiden</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-24-5</RegistryNumber><NameOfSubstance UI="D005165">Factor V</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C540694">Thrombophilia, hereditary</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005165" MajorTopicYN="N">Factor V</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="Y">Thrombophilia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="Y">Heart Diseases</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflicts of Interest: See Disclosures at the end of the article. Conflicts of Interest: J. Bartoszko supported by a merit award from the Department of Anesthesiology and Pain Medicine, University of Toronto. J. Bartoszko has received honoraria from Octapharma.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>15</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37053508</ArticleId><ArticleId IdType="doi">10.1213/ANE.0000000000006483</ArticleId><ArticleId IdType="pii">00000539-202309000-00018</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mullen MG, Michaels AD, Mehaffey JH, et al. Risk associated with complications and mortality after urgent surgery vs elective and emergency surgery: implications for defining &#x201c;quality&#x201d; and reporting outcomes for urgent surgery. JAMA Surg. 2017;152:768&#x2013;774.</Citation></Reference><Reference><Citation>Smilowitz NR, Gupta N, Guo Y, et al. Trends in perioperative venous thromboembolism associated with major noncardiac surgery. TH Open. 2017;1:e82&#x2013;e91.</Citation></Reference><Reference><Citation>Smilowitz NR, Gupta N, Guo Y, Beckman JA, Bangalore S, Berger JS. Trends in cardiovascular risk factor and disease prevalence in patients undergoing non-cardiac surgery. Heart. 2018;104:1180&#x2013;1186.</Citation></Reference><Reference><Citation>Wolters U, Wolf T, St&#xfc;tzer H, Schr&#xf6;der T. ASA classification and perioperative variables as predictors of postoperative outcome. Br J Anaesth. 1996;77:217&#x2013;222.</Citation></Reference><Reference><Citation>Partridge JS, Harari D, Dhesi JK. Frailty in the older surgical patient: a review. Age Ageing. 2012;41:142&#x2013;147.</Citation></Reference><Reference><Citation>Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13:1&#x2013;16.</Citation></Reference><Reference><Citation>De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: clinical implications. Semin Thromb Hemost. 1998;24:367&#x2013;379.</Citation></Reference><Reference><Citation>Donahue BS. Factor V Leiden and perioperative risk. Anesth Analg. 2004;98:1623&#x2013;1634.</Citation></Reference><Reference><Citation>Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44:62&#x2013;69.</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation></Reference><Reference><Citation>Benford D, Halldorsson T, Jeger MJ, et al.; EFSA Scientific Committee. The principles and methods behind EFSA&#x2019;s guidance on uncertainty analysis in scientific assessment. EFSA J. 2018;16:e05122.</Citation></Reference><Reference><Citation>Foley PW, Irvine CD, Standen GR, et al. Activated protein C resistance, factor V Leiden and peripheral vascular disease. Cardiovasc Surg. 1997;5:157&#x2013;160.</Citation></Reference><Reference><Citation>Kreienberg PB, Chang BB, Darling RC III, et al. Long-term results in patients treated with thrombolysis, thoracic inlet decompression, and subclavian vein stenting for Paget-Schroetter syndrome. J Vasc Surg. 2001;33(2 suppl):S100&#x2013;S105.</Citation></Reference><Reference><Citation>Fijnheer R, Paijmans B, Verdonck LF, Nieuwenhuis HK, Roest M, Dekker AW. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol. 2002;118:267&#x2013;270.</Citation></Reference><Reference><Citation>van Adrichem RA, Nelissen RG, Schipper IB, Rosendaal FR, Cannegieter SC. Risk of venous thrombosis after arthroscopy of the knee: results from a large population-based case-control study. J Thromb Haemost. 2015;13:1441&#x2013;1448.</Citation></Reference><Reference><Citation>Nemeth B, Lijfering WM, Nelissen R, et al. Risk and risk factors associated with recurrent venous thromboembolism following surgery in patients with history of venous thromboembolism. JAMA Netw Open. 2019;2:e193690.</Citation></Reference><Reference><Citation>Zambelli R, Nemeth B, Touw CE, Rosendaal FR, Rezende SM, Cannegieter SC. High risk of venous thromboembolism after orthopedic surgery in patients with thrombophilia. J Thromb Haemost. 2021;19:444&#x2013;451.</Citation></Reference><Reference><Citation>Ryan DH, Crowther MA, Ginsberg JS, Francis CW. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med. 1998;128:270&#x2013;276.</Citation></Reference><Reference><Citation>Kibbe MR, Hassett AL, McSherry F, et al. Can screening for genetic markers improve peripheral artery bypass patency? J Vasc Surg. 2002;36:1198&#x2013;1206.</Citation></Reference><Reference><Citation>W&#xe5;hlander K, Larson G, Lindahl TL, et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb Haemost. 2002;87:580&#x2013;585.</Citation></Reference><Reference><Citation>Douville NJ, Kheterpal S, Engoren M, et al. Genetic mutations associated with susceptibility to perioperative complications in a longitudinal biorepository with integrated genomic and electronic health records. Br J Anaesth. 2020;125:986&#x2013;994.</Citation></Reference><Reference><Citation>Ulrych J, Kvasni&#x10d;ka T, Fr&#xfd;ba V, et al. The impact of hereditary thrombophilia on the incidence of postoperative venous thromboembolism in colorectal cancer patients: a prospective cohort study. Eur Surg. 2018;51:5&#x2013;12.</Citation></Reference><Reference><Citation>Hirshfield G, Collier JD, Brown K, et al. Donor factor V Leiden mutation and vascular thrombosis following liver transplantation. Liver Transpl Surg. 1998;4:58&#x2013;61.</Citation></Reference><Reference><Citation>Ekberg H, Svensson PJ, Simanaitis M, Dahlb&#xe4;ck B. Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. Transplantation. 2000;69:1577&#x2013;1581.</Citation></Reference><Reference><Citation>Fan J, Nishida S, Selvaggi G, et al. Factor V Leiden mutation is a risk factor for hepatic artery thrombosis in liver transplantation. Transplant Proc. 2013;45:1990&#x2013;1993.</Citation></Reference><Reference><Citation>Loew A, Jacob D, Neuhaus P, Riess H. Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation. Transplantation. 2005;79:1422&#x2013;1427.</Citation></Reference><Reference><Citation>Sampram ES, Lindblad B. The impact of factor V mutation on the risk for occlusion in patients undergoing peripheral vascular reconstructions. Eur J Vasc Endovasc Surg. 2001;22:134&#x2013;138.</Citation></Reference><Reference><Citation>Adrogu&#xe9; HE, Matas AJ, McGlennon RC, et al. Do inherited hypercoagulable states play a role in thrombotic events affecting kidney/pancreas transplant recipients? Clin Transplant. 2007;21:32&#x2013;37.</Citation></Reference><Reference><Citation>Heidenreich S, Dercken C, August C, Koch HG, Nowak-G&#xf6;ttl U. High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol. 1998;9:1309&#x2013;1313.</Citation></Reference><Reference><Citation>Irish AB, Green FR, Gray DW, Morris PJ. The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation. 1997;64:604&#x2013;607.</Citation></Reference><Reference><Citation>Meyer M, Laux G, Scherer S, Tran TH, Opelz G, Mytilineos J. No association of factor V Leiden, prothrombin G20210A, and MTHFR C677T gene polymorphisms with kidney allograft survival: a multicenter study. Transplantation. 2007;83:1055&#x2013;1058.</Citation></Reference><Reference><Citation>Pereboom IT, Adelmeijer J, van der Steege G, van den Berg AP, Lisman T, Porte RJ. Prothrombotic gene polymorphisms: possible contributors to hepatic artery thrombosis after orthotopic liver transplantation. Transplantation. 2011;92:587&#x2013;593.</Citation></Reference><Reference><Citation>Blaszyk H, Bj&#xf6;rnsson J. Factor V Leiden and morbid obesity in fatal postoperative pulmonary embolism. Arch Surg. 2000;135:1410&#x2013;1413.</Citation></Reference><Reference><Citation>Sampram ES, Lindblad B, Dahlb&#xe4;ck B. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg. 1998;28:624&#x2013;629.</Citation></Reference><Reference><Citation>W&#xfc;thrich RP, Cicvara-Muzar S, Booy C, Maly FE. Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss. Transplantation. 2001;72:549&#x2013;550.</Citation></Reference><Reference><Citation>Baba-Ahmed M, Le Gal G, Couturaud F, Lacut K, Oger E, Leroyer C. High frequency of factor V Leiden in surgical patients with symptomatic venous thromboembolism despite prophylaxis. Thromb Haemost. 2007;97:171&#x2013;175.</Citation></Reference><Reference><Citation>Painter TW, McIlroy D, Myles PS, Leslie K. A survey of anaesthetists&#x2019; use of tranexamic acid in noncardiac surgery. Anaesth Intensive Care. 2019;47:76&#x2013;84.</Citation></Reference><Reference><Citation>Levent A, Kose O, Linke P, Gehrke T, Citak M. Tranexamic acid is safe and effective in patients with heterozygous factor V Leiden mutation during total joint arthroplasty. Arch Orthop Trauma Surg. 2023;143:613&#x2013;620.</Citation></Reference><Reference><Citation>Bowler DJ, Bale E, O'Byrne J. Factor V Leiden: prevalence and thromboembolic complications after total hip replacement in Ireland. Ir J Med Sci. 2007;176(4):273&#x2013;277. doi:10.1007/s11845-007-0095-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-007-0095-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Charen DA, Qian ET, Hutzler LH, Bosco JA. Risk factors for postoperative venous thromboembolism in orthopaedic spine surgery, hip arthroplasty, and knee arthroplasty patients. Bull Hosp Jt Dis (2013). 2015;73(3):198&#x2013;203.</Citation></Reference><Reference><Citation>Della Valle CJ, Issack PS, Baitner A, Steiger DJ, Fang C, Di Cesare PE. The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. BMC Musculoskelet Disord. 2001;2:1. doi:10.1186/1471-2474-2-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2474-2-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson MC, Belkin M, Whittemore AD, Mannick JA, Longtine JA, Dorfman DM. Impact of activated protein C resistance on general vascular surgical patients. J Vasc Surg. 1997;25(6):1054&#x2013;1060. doi:10.1016/s0741-5214(97)70129-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0741-5214(97)70129-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe GD, Haverkate F, Thompson SG, et al. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost. 1999;81(6):879&#x2013;886.</Citation></Reference><Reference><Citation>Joseph JE, Low J, Courtenay B, Neil MJ, McGrath M, Ma D. A single-centre prospective study of clinical and haemostatic risk factors for venous thromboembolism following lower limb arthroplasty. Br J Haematol. 2005;129(1):87&#x2013;92. doi:10.1111/j.1365-2141.2005.05419.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2005.05419.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringwald J, Berger A, Adler W, Kraus C, Pitto RP. Genetic polymorphisms in venous thrombosis and pulmonary embolism after total hip arthroplasty: a pilot study. Clin Orthop Relat Res. 2009;467(6):1507&#x2013;1515. doi:10.1007/s11999-008-0498-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-008-0498-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartori M, Conti E, Favaretto E, Frascaro M, Legnani C, Palareti G. Thrombotic risk factors and cardiovascular events after endovascular intervention for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2011;42(6):817&#x2013;823. doi:10.1016/j.ejvs.2011.08.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejvs.2011.08.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sz&#xfc;cs G, Ajzner E, Muszbek L, Simon T, Szepesi K, F&#xfc;lesdi B. Assessment of thrombotic risk factors predisposing to thromboembolic complications in prosthetic orthopedic surgery. J Orthop Sci. 2009;14(5):484&#x2013;490. doi:10.1007/s00776-009-1368-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00776-009-1368-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolson ST, Zehnder JL, Maloney WJ. Factor V Leiden and the risk of proximal venous thrombosis after total hip arthroplasty. J Arthroplasty. 1998;13(2):207&#x2013;210.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31476570</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-3064</ISSN><JournalIssue CitedMedium="Internet"><Volume>157</Volume><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Respiratory medicine</Title><ISOAbbreviation>Respir Med</ISOAbbreviation></Journal><ArticleTitle>Elevated serum cardiac troponin and mortality in acute pulmonary embolism: Systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>26</StartPage><EndPage>35</EndPage><MedlinePgn>26-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rmed.2019.08.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0954-6111(19)30268-9</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To evaluate whether elevated levels of cardiac troponin increases the risk of mortality in patients with acute PE.</AbstractText><AbstractText Label="METHODS">We conducted a systematic review and meta-analysis with rigorous statistical evaluation using publications (2000-2018) from Cochrane Library, MEDLINE, PubMed, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), WHO International Clinical Trials Registry Platform, and Google Scholar databases. We searched for retrospective, prospective, and randomized controlled trials (RCT) or quasi-RCT studies that assessed the effect of elevated troponin versus normal levels on the outcomes of PE. The main outcome of interest was all-cause mortality. Extracted data included authors, the origin of studies, source population, study settings and duration, inclusion/exclusion criteria, data sources and measurement, sample size, and mortality. Data heterogeneity was assessed using the Cochrane Q homogeneity test with a significance set at p&#x202f;&lt;&#x202f;0.10. If the studies were statistically homogeneous, a fixed effect model was selected.</AbstractText><AbstractText Label="RESULTS">Out of 1825 references, 46 analytical studies were included with a total of 10842 patients with PE. The effect of elevated troponin on mortality had a pooled odd ratio (OR) of 4.33 for all studies, 3.7for HsTnT, 14.81 for HsTnI, 7.85 for cTnT, 2.81 for cTnI, 9.02 for low-risk PE and 4.80 for 90-day mortality. The pooled negative likelihood ratios for all-cause mortality using HsTnI, cTnI and cTnT assay were 0.21, 0.33 and 0.65, respectively.</AbstractText><AbstractText Label="CONCLUSION">Regardless of the troponin assay, pooled analysis indicates that elevated troponin is significantly associated with higher mortality in patients with PE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El-Menyar</LastName><ForeName>Ayman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Clinical Research, Trauma &amp; Vascular Surgery, Hamad Medical Corporation (HMC), Doha, Qatar; Clinical Medicine, Weill Cornell Medical College, Doha, Qatar. Electronic address: aelmenyar@hamad.qa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sathian</LastName><ForeName>Brijesh</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Surgery, Clinical Research, Trauma &amp; Vascular Surgery, Hamad Medical Corporation (HMC), Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Thani</LastName><ForeName>Hassan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Surgery, Trauma &amp; Vascular Surgery, HMC, Doha, Qatar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Respir Med</MedlineTA><NlmUniqueID>8908438</NlmUniqueID><ISSNLinking>0954-6111</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014336">Troponin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019210">Troponin I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020107">Troponin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014336" MajorTopicYN="N">Troponin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019210" MajorTopicYN="N">Troponin I</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020107" MajorTopicYN="N">Troponin T</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">All-cause mortality</Keyword><Keyword MajorTopicYN="N">Conventional assay</Keyword><Keyword MajorTopicYN="N">High-sensitive</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Serum cardiac troponin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31476570</ArticleId><ArticleId IdType="doi">10.1016/j.rmed.2019.08.011</ArticleId><ArticleId IdType="pii">S0954-6111(19)30268-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34768445</PMID><DateRevised><Year>2021</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>21</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Venous Thromboembolism in COVID-19 Compared to Non-COVID-19 Cohorts: A Systematic Review with Meta-Analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4925</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm10214925</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A high incidence of venous thromboembolism (VTE) is reported in hospitalized COVID-19 patients, in particular in patients admitted to the intensive care unit (ICU). In patients with respiratory tract infections, including influenza A (H1N1), many studies have demonstrated an increased incidence of thromboses, but evidence is lacking regarding the risk difference (RD) of the occurrence of VTE between COVID-19 and non-COVID-19 patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this systematic review with meta-analysis, we evaluated the RD of the occurrence of VTE, pulmonary embolism (PE), and deep venous thrombosis (DVT) between COVID-19 and other pulmonary infection cohorts, in particular H1N1, and in an ICU setting. We searched for all studies comparing COVID-19 vs. non-COVID-19 regarding VTE, PE, and DVT.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The systematic review included 12 studies and 1,013,495 patients. The RD for VTE in COVID-19 compared to non-COVID-19 patients was 0.06 (95% CI 0.11-0.25, <i>p</i> = 0.011, I<sup>2</sup> = 97%), and 0.16 in ICU (95% CI 0.045-0.27, <i>p</i> = 0.006, I<sup>2</sup> = 80%). The RD for PE between COVID-19 and non-COVID-19 patients was 0.03 (95% CI, 0.006-0.045, <i>p</i> = 0.01, I<sup>2</sup> = 89%). The RD for PE between COVID-19 and non-COVID-19 patients was 0.021 in retrospective studies (95% CI 0.00-0.04, <i>p</i> = 0.048, I<sup>2</sup> = 92%) and 0.11 in ICU studies (95% CI 0.06-0.16, <i>p</i> &lt; 0.001, I<sup>2</sup> = 0%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The growing awareness and understanding of a massive inflammatory response combined with a hypercoagulable state that predisposes patients to thrombosis in COVID-19, in particular in the ICU, may contribute to a more appropriate strategy of prevention and earlier detection of the thrombotic events.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tufano</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2398-6135</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rendina</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0331-0392</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abate</LastName><ForeName>Veronica</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casoria</LastName><ForeName>Aniello</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Annachiara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buonanno</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galletti</LastName><ForeName>Ferruccio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Minno</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Servillo</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7652-970X</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">risk difference</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>13</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34768445</ArticleId><ArticleId IdType="pmc">PMC8584903</ArticleId><ArticleId IdType="doi">10.3390/jcm10214925</ArticleId><ArticleId IdType="pii">jcm10214925</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Middeldorp S., Coppens M., Van Haaps T.F., Foppen M., Vlaar A.P., M&#xfc;ller M.C.A., Bouman C.C.S., Beenen L.F.M., Kootte R.S., Heijmans J., et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J. Thromb. Haemost. 2020;18:1995&#x2013;2002. doi: 10.1111/jth.14888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14888</ArticleId><ArticleId IdType="pmc">PMC7497052</ArticleId><ArticleId IdType="pubmed">32369666</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez D., Garc&#xed;a-Sanchez A., Rali P., Muriel A., Bikdeli B., Ruiz-Artacho P., Le Mao R., Rodr&#xed;guez C., Hunt B.J., Monreal M. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: A systematic review and meta-analysis. Chest. 2021;159:1182&#x2013;1196. doi: 10.1016/j.chest.2020.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.11.005</ArticleId><ArticleId IdType="pmc">PMC7670889</ArticleId><ArticleId IdType="pubmed">33217420</ArticleId></ArticleIdList></Reference><Reference><Citation>Abate V., Casoria A., Rendina D., Muscariello R., Nuzzo V., Vargas M., Servillo G., Venetucci P., Conca P., Tufano A., et al. Spontaneous muscle hematoma in patients with COVID-19: A systematic literature review with description of an additional case series. Semin. Thromb. Hemost. 2021:1&#x2013;9. doi: 10.1055/s-0041-1732370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1732370</ArticleId><ArticleId IdType="pubmed">34388842</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P., Di Minno A., Maniscalco M., Di Minno M.N.D. COVID-19 and venous thromboembolism: Current insights and prophylactic strategies. Ann. Med. 2020;52:239&#x2013;242. doi: 10.1080/07853890.2020.1791355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2020.1791355</ArticleId><ArticleId IdType="pmc">PMC7877920</ArticleId><ArticleId IdType="pubmed">32619360</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:844&#x2013;847. doi: 10.1111/jth.14768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannis D., Ziogas I.A., Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J. Clin. Virol. 2020;127:104362. doi: 10.1016/j.jcv.2020.104362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104362</ArticleId><ArticleId IdType="pmc">PMC7195278</ArticleId><ArticleId IdType="pubmed">32305883</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Minno A., Ambrosino P., Calcaterra I., Di Minno M.N. COVID-19 and venous thromboembolism: A meta-analysis of literature studies. Semin. Thromb. Hemost. 2020;46:763&#x2013;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645842</ArticleId><ArticleId IdType="pubmed">32882719</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Minno M.N., Calcaterra I., Lupoli R., Storino A., Spedicato G.A., Maniscalco M., Di Minno A., Ambrosino P. Hemostatic changes in patients with COVID-19: A meta-analysis with meta-regressions. J. Clin. Med. 2020;9:2244. doi: 10.3390/jcm9072244.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9072244</ArticleId><ArticleId IdType="pmc">PMC7408674</ArticleId><ArticleId IdType="pubmed">32679766</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Cao W., Jiang W., Xiao M., Li Y., Tang N., Liu Z., Yan X., Zhao Y., Li T., et al. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J. Thromb. Thrombolysis. 2020;50:580&#x2013;586. doi: 10.1007/s11239-020-02182-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02182-9</ArticleId><ArticleId IdType="pmc">PMC7346854</ArticleId><ArticleId IdType="pubmed">32648093</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D.A.M.P.J., Kant K.M., Kaptein F.H.J., van Paassen J., Stals M.A.M., Huisman M.V., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020;191:145&#x2013;147. doi: 10.1016/j.thromres.2020.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.04.013</ArticleId><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai V., Tan B.K., Mainbourg S., Potus F., Cucherat M., Lega J.-C., Provencher S. Venous thromboembolism in COVID-19 compared to non-COVID-19 cohorts: A systematic review with meta-analysis. Vasc. Pharmacol. 2021;139:106882. doi: 10.1016/j.vph.2021.106882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2021.106882</ArticleId><ArticleId IdType="pmc">PMC8169236</ArticleId><ArticleId IdType="pubmed">34087481</ArticleId></ArticleIdList></Reference><Reference><Citation>Stals M.A.M., Grootenboers M.J.J.H., van Guldener C., Kaptein F.H.J., Braken S.J.E., Chen Q., Chu G., Driel E.M., del Sol A.I., Jonge E., et al. Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients. Res. Pr. Thromb. Haemost. 2021;5:412&#x2013;420. doi: 10.1002/rth2.12496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12496</ArticleId><ArticleId IdType="pmc">PMC8014477</ArticleId><ArticleId IdType="pubmed">33821230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluin-Nelemans J.C., Meijer K., Tichelaar Y.I.G.V. Infections and inflammatory diseases as risk factors for venous thrombosis. Thromb. Haemost. 2012;107:827&#x2013;837. doi: 10.1160/TH11-09-0611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH11-09-0611</ArticleId><ArticleId IdType="pubmed">22437808</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Altman D.G., G&#xf8;tzsche P.C., J&#xfc;ni P., Moher D., Oxman A.D., Savovic J., Schulz K.F., Weeks L., Sterne J.A., et al. The cochrane collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., Thacker S.B., et al. Meta-analysis of observational studies in epidemiology a proposal for reporting. JAMA. 2000;283:2008&#x2013;2012. doi: 10.1001/jama.283.15.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.15.2008</ArticleId><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman D.G., Prisma Group Preferred reporting items for systematic reviews and meta-analyses: The Prisma statement. J. Clin. Epidemiol. 2009;62:1006&#x2013;1012. doi: 10.1016/j.jclinepi.2009.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2009.06.005</ArticleId><ArticleId IdType="pubmed">19631508</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalager-Pedersen M., Lund L.C., Mariager T., Winther R., Hellfritzsch M., Larsen T.B., Thomsen R.W., Johansen N.B., S&#xf8;gaard O.S., Nielsen S.L., et al. Venous thromboembolism and major bleeding in patients with COVID-19: A nationwide population-based cohort study. Clin. Infect. Dis. 2021:ciab003. doi: 10.1093/cid/ciab003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab003</ArticleId><ArticleId IdType="pmc">PMC7929126</ArticleId><ArticleId IdType="pubmed">33400771</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund Y., Drogrey M., Mir&#xf3; &#xd2;., Marra A., F&#xe9;ral-Pierssens A.L., Penaloza A., Hernandez B.A.L., Beaune S., Gorlicki J., Vaittinada Ayar P., et al. Improving emergency care fhu collaborators. Association between pulmonary embolism and COVID-19 in emergency department patients undergoing computed tomography pulmonary angiogram: The PEPCOV international retrospective study. Acad. Emerg. Med. 2020;27:811&#x2013;820. doi: 10.1111/acem.14096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acem.14096</ArticleId><ArticleId IdType="pubmed">32734624</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., Tacquard C., Severac F., Leonard-Lorant I., Ohana M., Delabranche X., Merdji H., Clere-Jehl R., Schenck M., Fagot Gandet F., et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med. 2020;46:1089&#x2013;1098. doi: 10.1007/s00134-020-06062-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06062-x</ArticleId><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei F., Fan J., Yuan J., Liang Z., Wang K., Sun J., Guan W., Huang M., Li Y., Zhang W.W. Comparison of venous thromboembolism risks between COVID-19 pneumonia and community-acquired pneumonia patients. Arter. Thromb. Vasc. Biol. 2020;40:2332&#x2013;2337. doi: 10.1161/ATVBAHA.120.314779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.314779</ArticleId><ArticleId IdType="pmc">PMC7446987</ArticleId><ArticleId IdType="pubmed">32628040</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini J.A.S., Rech T.H., Schwarz P., de Oliveira A.C.T., Vieceli T., Moraes R.B., Sekine L., Viana M.V. Incidence of venous thromboembolism among patients with severe COVID-19 requiring mechanical ventilation compared to other causes of respiratory failure: A prospective cohort study. J. Thromb. Thrombolysis. 2021;52:1&#x2013;11. doi: 10.2139/ssrn.3696842.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3696842</ArticleId><ArticleId IdType="pmc">PMC7890785</ArticleId><ArticleId IdType="pubmed">33599858</ArticleId></ArticleIdList></Reference><Reference><Citation>Poissy J., Goutay J., Caplan M., Parmentier E., Duburcq T., Lassalle F., Jeanpierre E., Rauch A., Labreuche J., Susen S., et al. Pulmonary embolism in patients with COVID-19: Awareness of an increased prevalence. Circulation. 2020;142:184&#x2013;186. doi: 10.1161/CIRCULATIONAHA.120.047430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047430</ArticleId><ArticleId IdType="pubmed">32330083</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieder M., Goller I., Jeserich M., Baldus N., Pollmeier L., Wirth L., Supady A., Bode C., Busch H.-J., Schmid B., et al. Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19. J. Thromb. Thrombolysis. 2020;50:558&#x2013;566. doi: 10.1007/s11239-020-02202-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02202-8</ArticleId><ArticleId IdType="pmc">PMC7331913</ArticleId><ArticleId IdType="pubmed">32617807</ArticleId></ArticleIdList></Reference><Reference><Citation>Doyle A.J., Hunt B.J., Sanderson B., Zhang J., Mak S.M., Benedetti G., Breen K.A., Camporota L., Barrett N.A., Retter A. A comparison of thrombosis and hemorrhage rates in patients with severe respiratory failure due to coronavirus disease 2019 and influenza requiring extracorporeal membrane oxygenation. Crit. Care Med. 2021;49:663. doi: 10.1097/ccm.0000000000004971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ccm.0000000000004971</ArticleId><ArticleId IdType="pubmed">33861545</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd S., Martin-Loeches I. The incidence of venous thromboembolism in critically ill patients with COVID-19 compared with critically ill non-COVID patients. Ir. J. Med. Sci. 2021;190:1&#x2013;4. doi: 10.1007/s11845-020-02503-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11845-020-02503-0</ArticleId><ArticleId IdType="pmc">PMC7790472</ArticleId><ArticleId IdType="pubmed">33415688</ArticleId></ArticleIdList></Reference><Reference><Citation>Smilowitz N.R., Subashchandran V., Yuriditsky E., Horowitz J.M., Reynolds H.R., Hochman J.S., Berger J.S. Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19. Am. Hearth J. 2021;231:93&#x2013;95. doi: 10.1016/j.ahj.2020.10.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2020.10.075</ArticleId><ArticleId IdType="pmc">PMC7654304</ArticleId><ArticleId IdType="pubmed">33181067</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhard-Koren N.M., Haberecker M., Maccio U., Ruschitzka F., Schuepbach R.A., Zinkernagel A.S., Hardmeier T., Varga Z., Moch H. Higher prevalence of pulmonary macrothrombi in SARS-CoV-2 than in influenza A: Autopsy results from &#x2018;Spanish flu&#x2019; 1918/1919 in Switzerland to Coronavirus disease 2019. J. Pathol. Clin. Res. 2021;7:135&#x2013;143. doi: 10.1002/cjp2.189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cjp2.189</ArticleId><ArticleId IdType="pmc">PMC7869934</ArticleId><ArticleId IdType="pubmed">33185036</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll M., Zon R.L., Sylvester K.W., Chen E.C., Cheng V., Connell N., Fredenburgh L.E., Baron R.M., Cho M.H., Woolley A.E., et al. VTE in ICU patients with COVID-19. Chest. 2020;158:2130&#x2013;2135. doi: 10.1016/j.chest.2020.07.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.07.031</ArticleId><ArticleId IdType="pmc">PMC7674987</ArticleId><ArticleId IdType="pubmed">32710891</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed M.F.H., Al-Shokri S.D., Shunnar K.M., Mohamed S.F., Najim M.S., Ibrahim S.I., Elewa H., Abdalla L.O., El-Bardissy A., Elshafei M.N., et al. Prevalence of venous thromboembolism in critically ill COVID-19 patients: Systematic review and meta-analysis. Front. Cardiovasc. Med. 2021;7:598846. doi: 10.3389/fcvm.2020.598846.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2020.598846</ArticleId><ArticleId IdType="pmc">PMC7874113</ArticleId><ArticleId IdType="pubmed">33585578</ArticleId></ArticleIdList></Reference><Reference><Citation>McFadyen J.D., Stevens H., Peter K. The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications. Circ. Res. 2020;127:571&#x2013;587. doi: 10.1161/CIRCRESAHA.120.317447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317447</ArticleId><ArticleId IdType="pmc">PMC7386875</ArticleId><ArticleId IdType="pubmed">32586214</ArticleId></ArticleIdList></Reference><Reference><Citation>Attia J., Ray J.G., Cook D.J., Douketis J., Ginsberg J.S., Geerts W.H. Deep vein thrombosis and its prevention in critically ill adults. Arch. Intern. Med. 2001;161:1268&#x2013;1279. doi: 10.1001/archinte.161.10.1268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.161.10.1268</ArticleId><ArticleId IdType="pubmed">11371254</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook D., Crowther M., Meade M., Rabbat C., Griffith L., Schiff D., Geerts W., Guyatt G. Deep venous thrombosis in medical-surgical critically ill patients: Prevalence, incidence, and risk factors. Crit. Care Med. 2005;33:1565&#x2013;1571. doi: 10.1097/01.CCM.0000171207.95319.B2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000171207.95319.B2</ArticleId><ArticleId IdType="pubmed">16003063</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan D., Casper T.C., Elliott C.G., Men S., Pendleton R.C., Kraiss L.W., Weyrich A., Grissom C.K., Zimmerman G.A., Rondina M.T. VTE incidence and risk factors in patients with severe sepsis and septic shock. Chest. 2015;148:1224&#x2013;1230. doi: 10.1378/chest.15-0287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.15-0287</ArticleId><ArticleId IdType="pmc">PMC4631038</ArticleId><ArticleId IdType="pubmed">26111103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Zhang Z., Mi J., Wang X., Zou Y., Chen X., Nie Z., Luo X., Gan R. The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxis. Medicine. 2019;98:e15833. doi: 10.1097/MD.0000000000015833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000015833</ArticleId><ArticleId IdType="pmc">PMC6571428</ArticleId><ArticleId IdType="pubmed">31169685</ArticleId></ArticleIdList></Reference><Reference><Citation>Potus F., Mai V., Lebret M., Malenfant S., Breton-Gagnon E., Lajoie A.C., Boucherat O., Bonnet S., Provencher S. Novel insights on the pulmonary vascular consequences of COVID-19. Am. J. Physiol. Cell. Mol. Physiol. 2020;319:L277&#x2013;L288. doi: 10.1152/ajplung.00195.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00195.2020</ArticleId><ArticleId IdType="pmc">PMC7414237</ArticleId><ArticleId IdType="pubmed">32551862</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 2020;383:120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Goeijenbier M., van Wissen M., van de Weg C., Jong E., Gerdes V., Meijers J., Brandjes D., van Gorp E. Review: Viral infections and mechanisms of thrombosis and bleeding. J. Med. Virol. 2012;84:1680&#x2013;1696. doi: 10.1002/jmv.23354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23354</ArticleId><ArticleId IdType="pmc">PMC7166625</ArticleId><ArticleId IdType="pubmed">22930518</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris G., Bortolasci C.C., Puri B.K., Marx W., O&#x2019;Neil A., Athan E., Walder K., Berk M., Olive L., Carvalho A.F., et al. The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all? Cytokine. 2021;144:155593. doi: 10.1016/j.cyto.2021.155593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2021.155593</ArticleId><ArticleId IdType="pmc">PMC8149193</ArticleId><ArticleId IdType="pubmed">34074585</ArticleId></ArticleIdList></Reference><Reference><Citation>Wool G.D., Miller J.L. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88:15&#x2013;27. doi: 10.1159/000512007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000512007</ArticleId><ArticleId IdType="pmc">PMC7649697</ArticleId><ArticleId IdType="pubmed">33049751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M., Ballotta A., Di Dedda U., Baryshnikova E., Poli M.D., Resta M., Falco M., Albano G., Menicanti L. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J. Thromb. Haemost. 2020;18:1747&#x2013;1751. doi: 10.1111/jth.14854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14854</ArticleId><ArticleId IdType="pmc">PMC9906332</ArticleId><ArticleId IdType="pubmed">32302448</ArticleId></ArticleIdList></Reference><Reference><Citation>Manne B.K., Denorme F., Middleton E.A., Portier I., Rowley J.W., Stubben C., Petrey A.C., Tolley N.D., Guo L., Cody M., et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020;136:1317&#x2013;1329. doi: 10.1182/blood.2020007214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007214</ArticleId><ArticleId IdType="pmc">PMC7483430</ArticleId><ArticleId IdType="pubmed">32573711</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu S.X., Tyagi T., Jain K., Gu V.W., Lee S.H., Hwa J.M., Kwan J.M., Krause D.S., Lee A.I., Halene S., et al. Thrombocytopathy and endotheliopathy: Crucial contributors to COVID-19 thromboinflammation. Nat. Rev. Cardiol. 2021;18:194&#x2013;209. doi: 10.1038/s41569-020-00469-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-00469-1</ArticleId><ArticleId IdType="pmc">PMC7675396</ArticleId><ArticleId IdType="pubmed">33214651</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37789268</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>Risk of venous thromboembolism in patients undergoing gastric cancer surgery: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>933</StartPage><MedlinePgn>933</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">933</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-023-11424-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Venous thromboembolism (VTE) is a common postoperative complication in patients undergoing surgery for gastric cancer (GC). Although VTE incidence may vary among cancers, guidelines rarely stratify preventive methods for postoperative VTE by cancer type. The risk of VTE in patients undergoing surgery for GC remains unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review and meta-analysis was undertaken to determine the risk of VTE after GC surgery and discuss the clinical value of pharmacological thromboprophylaxis in these cases. Medline, Embase, Web of Science, and Cochrane Library databases were searched for articles published from their inception to September 2022.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 13 studies (111,936 patients) were included. The overall 1-month incidence of VTE, deep vein thrombosis (DVT), and pulmonary embolism (PE) after GC surgery was 1.8% (95% CI, 0.8-3.1%; I&#xb2;=98.5%), 1.2% (95% CI, 0.5-2.1%; I&#xb2;=96.1%), and 0.4% (95% CI, 0.1-1.1%; I&#xb2;=96.3%), respectively. The prevalence of postoperative VTE was comparable between Asian and Western populations (1.8% vs. 1.8%; P&#x2009;&gt;&#x2009;0.05). Compared with mechanical prophylaxis alone, mechanical plus pharmacological prophylaxis was associated with a significantly lower 1-month rate of postoperative VTE and DVT (0.6% vs. 2.9% and 0.6% vs. 2.8%, respectively; all P&#x2009;&lt;&#x2009;0.05), but not PE (P&#x2009;&gt;&#x2009;0.05). The 1-month postoperative incidence of VTE was not significantly different between laparoscopic and open surgery (1.8% vs. 4.3%, P&#x2009;&gt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients undergoing GC surgery do not have a high risk of VTE. The incidence of VTE after GC surgery is not significantly different between Eastern and Western patients. Mechanical plus pharmacological prophylaxis is more effective than mechanical prophylaxis alone in postoperative VTE prevention. The VTE risk is comparable between open and laparoscopic surgery for GC.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Lanzhou University, Lanzhou, China. xiangl18@lzu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Lanzhou University Second Hospital, 82 Cuiying Gate, Lanzhou, 730030, China. xiangl18@lzu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Shuai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Qiaokou Hususu Clinic, Wuhan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Tumour Surgery, Lanzhou University Second Hospital, 82 Cuiying Gate, Lanzhou, 730030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dengfeng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Second Clinical Medical College, Lanzhou University, Lanzhou, China. ery_chenh@lzu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Tumour Surgery, Lanzhou University Second Hospital, 82 Cuiying Gate, Lanzhou, 730030, China. ery_chenh@lzu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Key Laboratory of the Digestive System Tumours of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China. ery_chenh@lzu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No. 2019RCXM020</GrantID><Agency>Key Talents Project of Gansu Province</Agency><Country/></Grant><Grant><GrantID>22ZD6FA054</GrantID><Agency>Key Project of Science and Technology in Gansu province</Agency><Country/></Grant><Grant><GrantID>lzuyxcx-2022-45</GrantID><Agency>Medical Innovation and Development Project of Lanzhou University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013274" MajorTopicYN="Y">Stomach Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Gastric cancer surgery</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>1</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>3</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37789268</ArticleId><ArticleId IdType="pmc">PMC10546706</ArticleId><ArticleId IdType="doi">10.1186/s12885-023-11424-x</ArticleId><ArticleId IdType="pii">10.1186/s12885-023-11424-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3(1):27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11908507</ArticleId></ArticleIdList></Reference><Reference><Citation>De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004;50(3):187&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">15182825</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntupalli SR, Spinosa D, Wethington S, Eskander R, Khorana AA. Prevention of venous thromboembolism in patients with cancer. BMJ (Clinical Research ed) 2023;381:e072715.</Citation><ArticleIdList><ArticleId IdType="pubmed">37263632</ArticleId></ArticleIdList></Reference><Reference><Citation>Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15701913</ArticleId></ArticleIdList></Reference><Reference><Citation>Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6(6):401&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15925818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AY. Cancer and venous thromboembolism: prevention, treatment and survival. J Thromb Thrombolysis. 2008;25(1):33&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17906917</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet (London England) 2021;398(10294):64&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">33984268</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243(1):89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449979</ArticleId><ArticleId IdType="pubmed">16371741</ArticleId></ArticleIdList></Reference><Reference><Citation>Merkow RP, Bilimoria KY, McCarter MD, Cohen ME, Barnett CC, Raval MV, Caprini JA, Gordon HS, Ko CY, Bentrem DJ. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011;254(1):131&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527843</ArticleId></ArticleIdList></Reference><Reference><Citation>Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, et al. Venous thromboembolism prophylaxis and treatment in patients with Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncology: Official J Am Soc Clin Oncol. 2020;38(5):496&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">31381464</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7903232</ArticleId><ArticleId IdType="pubmed">33570602</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo DX, Junnarkar S, Balasubramaniam S, Tan YP, Low JK, Woon W, Pang TC. Incidence of venous thromboembolism and its pharmacological prophylaxis in asian general surgery patients: a systematic review. World J Surg. 2015;39(1):150&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25189450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KL, Yap ES, Goto S, Zhang S, Siu CW, Chiang CE. The diagnosis and treatment of venous thromboembolism in asian patients. Thromb J. 2018;16:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5774147</ArticleId><ArticleId IdType="pubmed">29375274</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew NC, Alemany GV, Angchaisuksiri P, Bang SM, Choi G, DA DES, Hong JM, Lee L, Li YJ, Rajamoney GN, et al. Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. Int Angiol. 2017;36(1):1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606807</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakai NA, McClure LA, Judd SE, Safford MM, Folsom AR, Lutsey PL, Cushman M. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation. 2014;129(14):1502&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098668</ArticleId><ArticleId IdType="pubmed">24508826</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Yu Y, Tao P, Wang D, Chen Y, Chen H. Risk of venous thromboembolism in patients undergoing gastric cancer surgery: protocol for a systematic review and meta-analysis. BMJ open. 2020;10(1):e033267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6955495</ArticleId><ArticleId IdType="pubmed">31919125</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg (London England) 2021;88:105906.</Citation><ArticleIdList><ArticleId IdType="pubmed">33789826</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Clinical Research ed) 2017;358:j4008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833365</ArticleId><ArticleId IdType="pubmed">28935701</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22742910</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogire RM, Mutua A, Kimita W, Kamau A, Bejon P, Pettifor JM, Adeyemo A, Williams TN, Atkinson SH. Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis. The Lancet Global Health. 2020;8(1):e134&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7024961</ArticleId><ArticleId IdType="pubmed">31786117</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, J&#xfc;ni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ (Clinical Research ed) 2011;343:d5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Archives of Public Health = Archives belges de sante Publique. 2014;72(1):39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4373114</ArticleId><ArticleId IdType="pubmed">25810908</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiamah A, Ban L, West J, Humes DJ. The risk of venous thromboembolism after surgery for esophagogastric malignancy and the impact of chemotherapy: a population-based cohort study. Dis Esophagus: Official J Int Soc Dis Esophagus 2020, 33(6).</Citation><ArticleIdList><ArticleId IdType="pubmed">31617892</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellini G, Teng A, Kotecha N, Sutton E, Yang CK, Passeri M, Lee DY, Rose K. The identification of risk factors for venous thromboembolism in gastrointestinal oncologic surgery. J Surg Res. 2016;205(2):279&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">27664873</ArticleId></ArticleIdList></Reference><Reference><Citation>Colapkulu-Akgul N, Ozemir IA, Beyazadam D, Alimoglu O. Perioperative Short Term Prophylaxis against Deep Vein thrombosis after major abdominal Cancer surgery: Retrospective Cohort Study. Vascular Specialist International. 2021;37:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8752334</ArticleId><ArticleId IdType="pubmed">35008064</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna NM, Williams E, Kong W, Fundytus A, Booth CM, Patel SV, Caycedo-Marulanda A, Chung W, Nanji S, Merchant SJ. Incidence, timing, and outcomes of venous thromboembolism in patients undergoing surgery for Esophagogastric Cancer: a Population-Based Cohort Study. Annals of surgical oncology 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">35279774</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung YJ, Seo HS, Park CH, Jeon HM, Kim JI, Yim HW, Song KY. Venous thromboembolism incidence and Prophylaxis Use after Gastrectomy among korean patients with gastric adenocarcinoma: the PROTECTOR Randomized Clinical Trial. JAMA Surg. 2018;153(10):939&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6233790</ArticleId><ArticleId IdType="pubmed">30027281</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaida S, Miyake T, Murata S, Yamaguchi T, Tatsuta T, Murakami K, Okauchi H, Nishimura S, Ohta H, Tsuchihashi H, et al. A prospective Multicenter Observational study of venous thromboembolism after gastric Cancer surgery (SHISA-1601) Eur Surg Res Europaische Chirurgische Forschung Recherches Chirurgicales Europeennes. 2021;62(1):10&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33657552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JW, Chun EJ, Choi SI, Park DJ, Kim HH, Bang SM, Kim MJ, Lee JH, Lee MS, Lee JO, et al. A prospective study on the incidence of postoperative venous thromboembolism in korean gastric cancer patients: an inquiry into the application of western guidelines to asian cancer patients. PLoS ONE. 2013;8(4):e61968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629116</ArticleId><ArticleId IdType="pubmed">23613988</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura Y, Oki E, Ando K, Saeki H, Kusumoto T, Maehara Y. Incidence of venous thromboembolism following laparoscopic surgery for gastrointestinal Cancer: a Single-Center, prospective cohort study. World J Surg. 2016;40(2):309&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">26316113</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KW, Bang SM, Kim S, Lee HJ, Shin DY, Koh Y, Lee YG, Cha Y, Kim YJ, Kim JH, et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemostasis: JTH. 2010;8(3):540&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20040044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallick S, Aiken T, Varley P, Abbott D, Tzeng CW, Weber S, Wasif N, Zafar SN. Readmissions from venous thromboembolism after Complex Cancer surgery. JAMA Surg. 2022;157(4):312&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8792793</ArticleId><ArticleId IdType="pubmed">35080619</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaki T, Saito H, Fukumoto Y, Kono Y, Murakami Y, Shishido Y, Kuroda H, Matsunaga T, Sato K, Hirooka Y, et al. Risk and incidence of perioperative deep vein thrombosis in patients undergoing gastric cancer surgery. Surg Today. 2018;48(5):525&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">29234961</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruff SM, Weber KT, Khader A, Conte C, Kadison A, Sullivan J, Wang J, Zaidi R, Deutsch GB. Venous thromboembolism in patients with cancer undergoing surgical exploration. J Thromb Thrombolysis. 2019;47(2):316&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">30560488</ArticleId></ArticleIdList></Reference><Reference><Citation>Yhim HY, Jang MJ, Bang SM, Kim KH, Kim YK, Nam SH, Bae SH, Kim SH, Mun YC, Kim I, et al. Incidence of venous thromboembolism following major surgery in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemostasis: JTH. 2014;12(7):1035&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">24837640</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll W, Fergusson N, Ivankovic V, Wang TF, Caiano L, Auer R, Carrier M. Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: a systematic review and meta-analysis of the literature. Thromb Res. 2021;204:114&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">34175749</ArticleId></ArticleIdList></Reference><Reference><Citation>Afshari A, Ageno W, Ahmed A, Duranteau J, Faraoni D, Kozek-Langenecker S, Llau J, Nizard J, Solca M, Stensballe J, et al. European guidelines on perioperative venous thromboembolism prophylaxis: executive summary. Eur J Anaesthesiol. 2018;35(2):77&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">29112553</ArticleId></ArticleIdList></Reference><Reference><Citation>Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">31492632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis-Lloyd CA, Pettitt EM, Adiamah A, Crooks CJ, Humes DJ. Risk of postoperative venous thromboembolism after surgery for colorectal malignancy: a systematic review and Meta-analysis. Dis Colon Rectum. 2021;64(4):484&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">33496485</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Jia Y, Zhang Q, Du Y, He Y, Zheng A. Incidence and risk factors for postoperative venous thromboembolism in patients with ovarian cancer: systematic review and meta-analysis. Gynecol Oncol. 2021;160(2):610&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">33221022</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F, Lee AYY. Cancer-associated venous thromboembolism. Nat Reviews Disease Primers. 2022;8(1):11.</Citation><ArticleIdList><ArticleId IdType="pubmed">35177631</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol. 2007;189(1):162&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">17579167</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidrich H, Konau E, Hesse P. Asymptomatic venous thrombosis in cancer patients&#x2013;a problem often overlooked. Results of a retrospective and prospective study. VASA Z fur Gefasskrankheiten. 2009;38(2):160&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19588304</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi S, Sidana S, Elson P, Khorana AA, McCrae KR. Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS ONE. 2014;9(8):e94048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134135</ArticleId><ArticleId IdType="pubmed">25126949</ArticleId></ArticleIdList></Reference><Reference><Citation>Palareti G, Antonucci E, Dentali F, Mastroiacovo D, Mumoli N, Pengo V, Poli D, Testa S, Pujatti PL, Menditto VG, et al. Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution. Eur J Intern Med. 2019;69:64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">31500936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505267</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncology: Official J Am Soc Clin Oncol. 2006;24(7):1112&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505431</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncology: Official J Am Soc Clin Oncol. 2007;25(1):70&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17194906</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee D, Lidor AO, Chu KM, Gearhart SL, Haut ER, Chang DC. Postoperative venous thromboembolism rates vary significantly after different types of major abdominal operations. J Gastrointest Surgery: Official J Soc Surg Aliment Tract. 2008;12(11):2015&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18668299</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang MJ, Bang SM, Oh D. Incidence of venous thromboembolism in Korea: from the Health Insurance Review and Assessment Service database. J Thromb Haemostasis: JTH. 2011;9(1):85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">20942850</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S, Lee KW, Bang SM, Kim S, Lee JO, Kim YJ, Kim JH, Park YS, Kim DW, Kang SB, et al. Different characteristics and prognostic impact of deep-vein thrombosis / pulmonary embolism and intraabdominal venous thrombosis in colorectal cancer patients. Thromb Haemost. 2011;106(6):1084&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">22072215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakon M, Kakkar AK, Ikeda M, Sekimoto M, Nakamori S, Yano M, Monden M. Current status of pulmonary embolism in general surgery in Japan. Surg Today. 2004;34(10):805&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15449147</ArticleId></ArticleIdList></Reference><Reference><Citation>Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Mu&#xf1;oz A, Brenner B, Prata PH, Brilhante D, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9236567</ArticleId><ArticleId IdType="pubmed">35772465</ArticleId></ArticleIdList></Reference><Reference><Citation>Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(5):452&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">36638869</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines for the Diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009) Circ J. 2011;75(5):1258&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">21441695</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang SM, Jang MJ, Kim KH, Yhim HY, Kim YK, Nam SH, Hwang HG, Bae SH, Kim SH, Mun YC, et al. Prevention of venous thromboembolism, 2nd edition: korean society of thrombosis and hemostasis evidence-based Clinical Practice Guidelines. J Korean Med Sci. 2014;29(2):164&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3923992</ArticleId><ArticleId IdType="pubmed">24550640</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemostasis: JTH. 2007;5(9):1854&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">17723125</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano PE, Parpia S, Linkins LA, Elit L, Simunovic M, Ruo L, Bhandari M, Levine M. Venous thromboembolic events following major pelvic and abdominal surgeries for Cancer: a prospective cohort study. Ann Surg Oncol. 2018;25(11):3214&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">30051364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong O, Ryu SY, Park YK, Kim YJ. The effect of low molecular weight heparin thromboprophylaxis on bleeding complications after gastric cancer surgery. Ann Surg Oncol. 2010;17(9):2363&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20358302</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweetland S, Green J, Liu B, Berrington de Gonz&#xe1;lez A, Canonico M, Reeves G, Beral V. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ (Clinical Research ed. 2009;339:b4583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788913</ArticleId><ArticleId IdType="pubmed">19959589</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvis CA, Bonney PA, Ding L, Tang AM, Giannotta SL, Kim AW, Mack WJ, Attenello FJ. Readmission with venous thromboembolism after surgical treatment by primary cancer site. Surg Oncol. 2020;35:268&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">32942082</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg PK, Teckchandani N, Hadke NS, Chander J, Nigam S, Puri SK. Alteration in coagulation profile and incidence of DVT in laparoscopic cholecystectomy. Int J Surg (London England) 2009;7(2):130&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19144583</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen NT, Hinojosa MW, Fayad C, Varela E, Konyalian V, Stamos MJ, Wilson SE. Laparoscopic surgery is associated with a lower incidence of venous thromboembolism compared with open surgery. Ann Surg. 2007;246(6):1021&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18043105</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro R, Vogel JD, Kiran RP. Risk of postoperative venous thromboembolism after laparoscopic and open colorectal surgery: an additional benefit of the minimally invasive approach? Dis Colon Rectum. 2011;54(12):1496&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">22067177</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, Coit DG, Brennan MF. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251(4):640&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">20224369</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet (London England) 2016;388(10060):2654&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">27156933</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Reviews Disease Primers. 2017;3:17036.</Citation><ArticleIdList><ArticleId IdType="pubmed">28569272</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AJ, West J, Card TR, Crooks C, Kirwan CC, Grainge MJ. When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. Blood. 2016;127(7):849&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4778298</ArticleId><ArticleId IdType="pubmed">26574606</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Guo Q, Hu W. Incidence, risk factors, and outcomes of venous thromboembolism after oncologic surgery: a systematic review and meta-analysis. Thromb Res. 2019;173:48&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30471508</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27866948</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8406</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The Journal of arthroplasty</Title><ISOAbbreviation>J Arthroplasty</ISOAbbreviation></Journal><ArticleTitle>Pulmonary Embolism Rates Following Total Hip Arthroplasty With Prophylactic Anticoagulation: Some Pulmonary Emboli Cannot Be Avoided.</ArticleTitle><Pagination><StartPage>980</StartPage><EndPage>986</EndPage><MedlinePgn>980-986</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arth.2016.09.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-5403(16)30646-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">A symptomatic pulmonary embolism (PE) after total joint arthroplasty has been described as a "never event." Despite potent anticoagulants and improvements in patient care, PE continues to occur following total hip arthroplasty (THA). This study evaluates symptomatic PE rates over time in THA patients enrolled in multicenter randomized clinical trials (RCTs) assessing the efficacy of venous thromboembolism prophylaxis regimens.</AbstractText><AbstractText Label="METHODS">The MEDLINE and Cochrane Central Register of Controlled Trials were searched to identify clinical trials assessing prophylactic anticoagulation in patients undergoing THA between January 1995 and December 2015. Inclusion criteria consisted of RCTs evaluating prophylactic anticoagulation in patients undergoing THA. A random effect model was used to combine PE rates across studies.</AbstractText><AbstractText Label="RESULTS">A total of 21 studies (34,764 patients) were included. Patients were administered low molecular weight heparin (13,590 patients), oral factor Xa inhibitors (6609 patients), oral direct thrombin inhibitors (5965 patients), indirect factors Xa/IIa inhibitors (3444 patients), aspirin (2427 patients), and warfarin (489 patients). Mobile compression was used in 199 patients, and placebo was used in 2041 patients. Across all included studies, the estimated PE rate was 0.21% (95% confidence interval: 0.13%, 0.32%). Between 1997 and 2013, the proportion of PEs did not change in regression analysis.</AbstractText><AbstractText Label="CONCLUSION">Although the PE rate was low, it was consistent throughout the 17 years spanning these RCTs, which excluded patients with significant morbidity. These results suggest that even healthy THA patients receiving aggressive anticoagulation still have a risk for PE, and the "never event" designation requires reassessment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Jay R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Keck School of Medicine of USC, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Keck School of Medicine of USC, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cote</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington, Connecticut.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Arthroplasty</MedlineTA><NlmUniqueID>8703515</NlmUniqueID><ISSNLinking>0883-5403</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000991">Antithrombins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065427">Factor Xa Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber><NameOfSubstance UI="D014859">Warfarin</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000991" MajorTopicYN="N">Antithrombins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065427" MajorTopicYN="N">Factor Xa Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006296" MajorTopicYN="N">Health Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anticoagulation</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">randomized trials</Keyword><Keyword MajorTopicYN="N">total joint arthroplasty</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27866948</ArticleId><ArticleId IdType="doi">10.1016/j.arth.2016.09.006</ArticleId><ArticleId IdType="pii">S0883-5403(16)30646-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24074702</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2472</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Thrombosis research</Title><ISOAbbreviation>Thromb Res</ISOAbbreviation></Journal><ArticleTitle>Who are at risk for thromboembolism after arthroplasty? A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>531</StartPage><EndPage>536</EndPage><MedlinePgn>531-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.thromres.2013.09.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-3848(13)00405-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Thromboembolism, including deep venous thrombosis and pulmonary embolism, is a grave threat to patients undergoing total joint replacement. Using a systematic review and meta-analysis we asked whether gene mutations or polymorphisms could be risk factors for thrombosis after arthroplasty.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a comprehensive search of Medline, PubMed, Embase, Cochrane databases, China National Knowledge Infrastructure (CNKI), and Google Scholar, and identified 19 studies detailing genetic investigations of patients with thromboembolism following joint replacement.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our meta-analyses included 5149 patients who underwent arthroplasty surgery. Significant associations with venous thromboembolism were identified for factor G1691A (odds ratio (OR) 1.41, 95% confidence interval (CI) 1.03 - 1.94, p=0.03), prothrombin G20210A (OR 2.16, 95% CI, 1.27- 3.69, p=0.005), and MTHFR/C677T/TT (OR 2.36, 95% CI 1.03 - 5.42, p=0.04) in Caucasian populations. No significant gene mutation was identified in Asian populations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study suggests a way to identify patients scheduled for arthroplasty who are at higher risk of thrombosis, enabling individualized treatment.</AbstractText><CopyrightInformation>&#xa9; 2013.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xindie</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Orthopedics Surgery, The Second Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Wenkang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Pengli</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhigao</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weiping</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lidong</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Thromb Res</MedlineTA><NlmUniqueID>0326377</NlmUniqueID><ISSNLinking>0049-3848</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C095381">factor V Leiden</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-24-5</RegistryNumber><NameOfSubstance UI="D005165">Factor V</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-26-7</RegistryNumber><NameOfSubstance UI="D011516">Prothrombin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.5.1.20</RegistryNumber><NameOfSubstance UI="C573423">MTHFR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.5.1.20</RegistryNumber><NameOfSubstance UI="D042965">Methylenetetrahydrofolate Reductase (NADPH2)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019643" MajorTopicYN="N">Arthroplasty, Replacement</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005165" MajorTopicYN="N">Factor V</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042965" MajorTopicYN="N">Methylenetetrahydrofolate Reductase (NADPH2)</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011516" MajorTopicYN="N">Prothrombin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE</Keyword><Keyword MajorTopicYN="N">APC</Keyword><Keyword MajorTopicYN="N">Arthroplasty</Keyword><Keyword MajorTopicYN="N">CI</Keyword><Keyword MajorTopicYN="N">DVT</Keyword><Keyword MajorTopicYN="N">FLV</Keyword><Keyword MajorTopicYN="N">Gene</Keyword><Keyword MajorTopicYN="N">Genetic Susceptibility</Keyword><Keyword MajorTopicYN="N">I/D</Keyword><Keyword MajorTopicYN="N">MTHFR</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">OR</Keyword><Keyword MajorTopicYN="N">PAI-1</Keyword><Keyword MajorTopicYN="N">PE</Keyword><Keyword MajorTopicYN="N">Polymorphism</Keyword><Keyword MajorTopicYN="N">STREGA</Keyword><Keyword MajorTopicYN="N">STROBE</Keyword><Keyword MajorTopicYN="N">THA</Keyword><Keyword MajorTopicYN="N">TKA</Keyword><Keyword MajorTopicYN="N">Thromboembolism</Keyword><Keyword MajorTopicYN="N">VTE</Keyword><Keyword MajorTopicYN="N">activated protein C</Keyword><Keyword MajorTopicYN="N">confidence interval</Keyword><Keyword MajorTopicYN="N">deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">encoding angiotensin-converting enzyme</Keyword><Keyword MajorTopicYN="N">factor V Leiden</Keyword><Keyword MajorTopicYN="N">insertion/deletion</Keyword><Keyword MajorTopicYN="N">methylenetetrahydrofolate Reductase</Keyword><Keyword MajorTopicYN="N">odds ratio</Keyword><Keyword MajorTopicYN="N">plasminogen-activator inhibitor 1</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">strengthening the Reporting of Genetic Association Studies</Keyword><Keyword MajorTopicYN="N">strengthening the Reporting of Observational Studies in Epidemiology</Keyword><Keyword MajorTopicYN="N">total hip arthroplasty</Keyword><Keyword MajorTopicYN="N">total knee arthroplasty</Keyword><Keyword MajorTopicYN="N">venous thrombus embolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24074702</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2013.09.005</ArticleId><ArticleId IdType="pii">S0049-3848(13)00405-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34148191</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1863-2491</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of robotic surgery</Title><ISOAbbreviation>J Robot Surg</ISOAbbreviation></Journal><ArticleTitle>Robotic-assisted hiatal hernia repair and pulmonary embolism: an institution-based retrospective cohort study.</ArticleTitle><Pagination><StartPage>501</StartPage><EndPage>505</EndPage><MedlinePgn>501-505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11701-021-01264-x</ELocationID><Abstract><AbstractText>Hiatal hernia (HH) is an abnormal protrusion of components of the abdominal viscera through the esophageal hiatus. The laparoscopic approach is the gold standard for repair with the robotic technique now gaining wide acceptance. Pulmonary embolism (PE) is a well-known post-operative complication but its incidence following robotically assisted HH repairs is not well known. This study provides a descriptive analysis of three patients who developed PE after robotic repairs of their HHs. The incidence of PE in the studied cohort was 2.7% (3 of 112) with a male preponderance (66.7%). The mean age of the patients was 55.3&#xa0;years with a mean BMI of 32.2&#xa0;kg/m<sup>2</sup>. The average duration of surgery was 4.2&#xa0;h with sizes of the diaphragmatic defects ranging from 3 to 6&#xa0;cm. Confirmatory PE diagnosis was made with a chest CT angiogram and the mean length of hospital stay was 4&#xa0;days. PE although rare, is a preventable cause of in-patient mortality and morbidity with implications on healthcare costs and hospital resource use. The Caprini model provides a guide to pre-operative patient risk stratification and PE prevention, and the patients in this study were in the moderate to high-risk groups. Risk factors common to all patients were: age&#x2009;&gt;&#x2009;40&#xa0;years, BMI&#x2009;&gt;&#x2009;30&#xa0;kg/m<sup>2</sup> and duration of surgery&#x2009;&gt;&#x2009;2&#xa0;h with one of the patients having a previous history of PE. There are no established PE chemoprophylaxis guidelines for robotic HH repairs and in this cohort, heparin was commenced 6-8&#xa0;h post-operatively. Thus, there is a need for a consensus chemoprophylaxis guideline in this subset of surgical patients. PE following robotic HH repair is associated with prolonged hospital stay and increased healthcare costs. Guidelines for effective pre-operative chemoprophylaxis for these repairs are needed to optimize patient outcomes.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Aanuoluwapo</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5864-1407</Identifier><AffiliationInfo><Affiliation>Department of Surgery, St. Luke's University Health Network, Bethlehem, PA, USA. aanuoluwapo.obisesan@sluhn.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singhal</LastName><ForeName>Vinay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Surgery, St. Luke's University Health Network, Bethlehem, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satoskar</LastName><ForeName>Savni</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, St. Luke's University Health Network, Bethlehem, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Robot Surg</MedlineTA><NlmUniqueID>101300401</NlmUniqueID><ISSNLinking>1863-2483</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006551" MajorTopicYN="Y">Hernia, Hiatal</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059685" MajorTopicYN="N">Herniorrhaphy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="Y">Laparoscopy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065287" MajorTopicYN="Y">Robotic Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Elective hiatal hernia repair</Keyword><Keyword MajorTopicYN="N">Hiatal hernia</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Robotic-assisted hiatal hernia repair</Keyword><Keyword MajorTopicYN="N">VTE chemoprophylaxis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>20</Day><Hour>21</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34148191</ArticleId><ArticleId IdType="doi">10.1007/s11701-021-01264-x</ArticleId><ArticleId IdType="pii">10.1007/s11701-021-01264-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cameron AM (2017) Current surgical therapy. Ann Surg. https://doi.org/10.1097/sla.0000000000002518</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/sla.0000000000002518</ArticleId><ArticleId IdType="pubmed">28657938</ArticleId></ArticleIdList></Reference><Reference><Citation>Klinginsmith M, Jolley J, Lomelin D, Krause C, Heiden J, Oleynikov D (2016) Paraesophageal hernia repair in the emergency setting: is laparoscopy with the addition of a fundoplication the new gold standard? Surg Endosc. https://doi.org/10.1007/s00464-015-4447-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-015-4447-8</ArticleId><ArticleId IdType="pubmed">26194263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkaria IS, Latif MJ, Bianco VJ et al (2017) Early operative outcomes and learning curve of robotic-assisted giant paraesophageal hernia repair. Int J Med Robot Comput Assist Surg. https://doi.org/10.1002/rcs.1730</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rcs.1730</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian W, Fei Y (2018) Application of Da Vinci robotic surgery to hernia repair. Zhonghua Wei Chang Wai Ke Za Zhi 21:740&#x2013;743</Citation><ArticleIdList><ArticleId IdType="pubmed">30051439</ArticleId></ArticleIdList></Reference><Reference><Citation>Seetharamaiah R, Romero RJ, Kosanovic R et al (2013) Robotic repair of giant paraesophageal hernias. J Soc Laparoendosc Surg. https://doi.org/10.4293/108680813X13654754534594</Citation><ArticleIdList><ArticleId IdType="doi">10.4293/108680813X13654754534594</ArticleId></ArticleIdList></Reference><Reference><Citation>Luca M, Simone G, Maria DM et al (2015) Robotic giant hiatal hernia repair: 3 year prospective evaluation and review of the literature. Int J Med Robot Comput Assist Surg. https://doi.org/10.1002/rcs.1595</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rcs.1595</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolboom RC, Broeders IAMJ, Draaisma WA (2015) Robot-assisted laparoscopic hiatal hernia and antireflux surgery. J Surg Oncol. https://doi.org/10.1002/jso.23912</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.23912</ArticleId><ArticleId IdType="pubmed">25997926</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolboom RC, Draaisma WA, Broeders IAMJ (2016) Evaluation of conventional laparoscopic versus robot-assisted laparoscopic redo hiatal hernia and antireflux surgery: a cohort study. J Robot Surg. https://doi.org/10.1007/s11701-016-0558-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11701-016-0558-z</ArticleId><ArticleId IdType="pubmed">26809755</ArticleId><ArticleId IdType="pmc">4766202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohn GP, Price RR, Demeester SR et al (2013) Guidelines for the management of hiatal hernia. Surg Endosc. https://doi.org/10.1007/s00464-013-3173-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-013-3173-3</ArticleId><ArticleId IdType="pubmed">24018762</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-015-1311-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-015-1311-6</ArticleId><ArticleId IdType="pubmed">26780736</ArticleId><ArticleId IdType="pmc">4715842</ArticleId></ArticleIdList></Reference><Reference><Citation>Charles M, Alexander CS (2010) Venous thromboembolism prevention: a systematic review of methods to improve prophylaxis and decrease events in the hospitalized patient. Hosp Pract (1995) 38:97&#x2013;108</Citation><ArticleIdList><ArticleId IdType="doi">10.3810/hp.2010.02.284</ArticleId></ArticleIdList></Reference><Reference><Citation>LaMori JC, Shoheiber O, Mody SH, Bookhart BK (2015) Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States. Clin Ther. https://doi.org/10.1016/j.clinthera.2014.10.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2014.10.024</ArticleId><ArticleId IdType="pubmed">25524389</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez MM, Hogue S, Preblick R, Kwong WJ (2015) Review of the cost of venous thromboembolism. Clin Outcomes Res. https://doi.org/10.2147/CEOR.S85635</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CEOR.S85635</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmon CT (2009) Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev. https://doi.org/10.1016/j.blre.2009.07.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2009.07.002</ArticleId><ArticleId IdType="pubmed">19683659</ArticleId><ArticleId IdType="pmc">2762278</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould MK, Garcia DA, Wren SM et al (2012) Prevention of VTE in nonorthopedic surgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. https://doi.org/10.1378/chest.11-2297</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2297</ArticleId><ArticleId IdType="pubmed">22315268</ArticleId><ArticleId IdType="pmc">3590883</ArticleId></ArticleIdList></Reference><Reference><Citation>Inderbitzin DT, Opitz I, Giger U, Kocher T, Kr&#xe4;henb&#xfc;hl L (2007) Incidence of clinical pulmonary embolism after laparoscopic surgery. Br J Surg. https://doi.org/10.1002/bjs.5666</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.5666</ArticleId><ArticleId IdType="pubmed">17330858</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DR, Morgano GP, Bennett C et al (2019) American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. https://doi.org/10.1182/bloodadvances.2019000975</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019000975</ArticleId><ArticleId IdType="pubmed">31794602</ArticleId><ArticleId IdType="pmc">6963238</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. https://doi.org/10.1378/chest.11-2301</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2301</ArticleId><ArticleId IdType="pubmed">22315268</ArticleId><ArticleId IdType="pmc">3278049</ArticleId></ArticleIdList></Reference><Reference><Citation>Felder S, Rasmussen MS, King R et al (2019) Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004318.pub4</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD004318.pub4</ArticleId><ArticleId IdType="pubmed">31449321</ArticleId><ArticleId IdType="pmc">6709764</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang SJ, Tran T, Memmesheimer C et al (2002) Paraesophageal hernia repair and deep vein thrombosis [1]. J Clin Gastroenterol. https://doi.org/10.1097/00004836-200202000-00017</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004836-200202000-00017</ArticleId><ArticleId IdType="pubmed">11782617</ArticleId><ArticleId IdType="pmc">6736583</ArticleId></ArticleIdList></Reference><Reference><Citation>Davila DG, Stetler JL, Lin E, Davis SS, Yheulon CG (2019) Laparoscopic paraesophageal hernia repair and pulmonary embolism. Surg Laparosc Endosc Percutaneous Tech. https://doi.org/10.1097/SLE.0000000000000708</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLE.0000000000000708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahl V, Hu HM, Henke PK, Wakefield TW, Campbell DA, Caprini JA (2010) A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. https://doi.org/10.1097/SLA.0b013e3181b7fca6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181b7fca6</ArticleId><ArticleId IdType="pubmed">19779324</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28805341</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7836</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of thrombosis and haemostasis : JTH</Title><ISOAbbreviation>J Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Treatment options for severe pulmonary embolism during pregnancy and the postpartum period: a systematic review.</ArticleTitle><Pagination><StartPage>1942</StartPage><EndPage>1950</EndPage><MedlinePgn>1942-1950</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jth.13802</ELocationID><Abstract><AbstractText Label="UNLABELLED">Essentials The evidence on how to manage life-threatening pregnancy-related pulmonary embolism (PE) is scarce. We systematically reviewed all available cases of (sub)massive PE until December 2016. Thrombolysis in such severe PE was associated with a high maternal survival (94%). The major bleeding risk was much greater in the postpartum (58%) than antepartum period (18%).</AbstractText><AbstractText Label="SUMMARY">Background Massive pulmonary embolism (PE) during pregnancy or the postpartum period is a rare but dramatic event. Our aim was to systematically review the evidence to guide its management. Methods We searched Pubmed, Embase, conference proceedings and the RIETE registry for published cases of severe (submassive/massive) PE treated with thrombolysis, percutaneous or surgical thrombectomy and/or extracorporeal membrane oxygenation (ECMO), occurring during pregnancy or within 6 weeks of delivery. Main outcomes were maternal survival and major bleeding, premature delivery, and fetal survival and bleeding. Results We found 127 cases of severe PE (at least 83% massive; 23% with cardiac arrest) treated with at least one modality. Among 83 women with thrombolysis, survival was 94% (95% CI, 86-98). The risk of major bleeding was 17.5% during pregnancy and 58.3% in the postpartum period, mainly because of severe postpartum hemorrhages. Fetal deaths possibly related to PE or its treatment occurred in 12.0% of cases treated during pregnancy. Among 36 women with surgical thrombectomy, maternal survival and risk of major bleeding were 86.1% (95% CI, 71-95) and 20.0%, with fetal deaths possibly related to surgery in 20.0%. About half of severe postpartum PEs occurred within 24 h of delivery. Conclusions Published cases of thrombolysis for massive PE during pregnancy and the postpartum period suggest a high maternal and fetal survival (94% and 88%). In the postpartum period, given the high risk of major bleeding with thrombolysis, other therapeutic options (catheter [or surgical] thrombectomy, ECMO) may be considered if available.</AbstractText><CopyrightInformation>&#xa9; 2017 International Society on Thrombosis and Haemostasis.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martillotti</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boehlen</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Angiology and Hemostasis, Department of Specialties of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robert-Ebadi</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Angiology and Hemostasis, Department of Specialties of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jastrow</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Righini</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Angiology and Hemostasis, Department of Specialties of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blondon</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Angiology and Hemostasis, Department of Specialties of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Thromb Haemost</MedlineTA><NlmUniqueID>101170508</NlmUniqueID><ISSNLinking>1538-7836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017128" MajorTopicYN="Y">Embolectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005313" MajorTopicYN="N">Fetal Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006473" MajorTopicYN="N">Postpartum Hemorrhage</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049590" MajorTopicYN="Y">Postpartum Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011249" MajorTopicYN="N">Pregnancy Complications, Cardiovascular</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017131" MajorTopicYN="Y">Thrombectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="Y">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">fibrinolysis</Keyword><Keyword MajorTopicYN="N">postpartum period</Keyword><Keyword MajorTopicYN="N">pregnancy</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">thrombectomy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28805341</ArticleId><ArticleId IdType="doi">10.1111/jth.13802</ArticleId><ArticleId IdType="pii">S1538-7836(22)04372-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35926347</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2472</ISSN><JournalIssue CitedMedium="Internet"><Volume>217</Volume><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Thrombosis research</Title><ISOAbbreviation>Thromb Res</ISOAbbreviation></Journal><ArticleTitle>Optimal management, prevalence, and clinical behavior of saddle pulmonary embolism: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>86</StartPage><EndPage>95</EndPage><MedlinePgn>86-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.thromres.2022.07.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-3848(22)00330-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The central location, size, and instability of saddle pulmonary embolism (SPE) have raised significant concerns regarding its clinical, hemodynamic effects as well as optimal management. Pulmonary embolism (PE) guidelines barely address such concerns. We aimed to pool the available data on the clinical behavior and outcomes of SPE and study the effects of various treatment modalities on mortality outcomes.</AbstractText><AbstractText Label="METHODS">PubMed, Scopus, and Google Scholar were searched for articles (any date up to February 28, 2022) reporting patients with SPE. Data on SPE demographics, clinical characteristics, management, and outcomes were extracted and analyzed.</AbstractText><AbstractText Label="RESULTS">Results from all SPE cases: A total of 5251 patients from 194 studies were included in the review. Dyspnea (57&#xa0;%) was the most prevalent symptom. Massive and submassive PE comprised 9.7&#xa0;% and 45.8% of cases, respectively. Thrombolytic therapy (TT) was administered in 18.1&#xa0;%, and thrombectomy was performed in 16&#xa0;% of cases. SPE-related mortality was observed in 4.6&#xa0;%, late decompensation in 9.5&#xa0;%, and PE recurrence in 4.5&#xa0;% of cases. Female sex (61.5&#xa0;% vs. 41.3&#xa0;%, p&#xa0;=&#xa0;0.019), hypoxemia (90&#xa0;% vs. 59.2&#xa0;%, p&#xa0;&lt;&#xa0;0.001), massive PE features (89.7&#xa0;% vs. 30.1&#xa0;%, p&#xa0;&lt;&#xa0;0.001), associated chronic kidney disease (CKD) (10.3&#xa0;% vs. 1.4&#xa0;%, p&#xa0;=&#xa0;0.002), and the need for mechanical ventilation (28.2&#xa0;% vs. 13.1&#xa0;%, p&#xa0;=&#xa0;0.02) were significantly associated with increased mortality. The use of TT was significantly associated with increased survival (27.1&#xa0;% vs. 12.5&#xa0;%, p&#xa0;&lt;&#xa0;0.001). In a multivariate logistic regression model, massive PE features significantly increased the odds of death (OR: 29.3, CI: 4.86-181.81, p&#xa0;&lt;&#xa0;0.001), whereas, treatment with anticoagulation (AC) alone (OR: 0.1, CI: 0.027-0.356, p&#xa0;&lt;&#xa0;0.001), TT (OR: 0.065, CI: 0.019-0.26, p&#xa0;&lt;&#xa0;0.001), surgical thrombectomy (ST) (OR: 0.047, CI: (0.010-0.23), p&#xa0;&lt;&#xa0;0.001), or percutaneous thrombectomy (PT) (OR: 0.12, CI: 0.020-0.84, p&#xa0;=&#xa0;0.032) significantly decreased odds of death. Results from a meta-analysis of observational studies: Meta-analysis of the included 17 observational studies revealed an overall 10&#xa0;% (95&#xa0;% CI: 4.56-16.89) SPE prevalence among all PE cases. The overall SPE-related mortality rate was 8&#xa0;% (95&#xa0;% CI: 5.26-10.96). Massive PE was observed in 13.3&#xa0;% (95&#xa0;% CI: 5.56-23.70), PE recurrence in 5.1&#xa0;% (95&#xa0;% CI: 2.22-9.05), and late decompensation in 11&#xa0;% (95&#xa0;% CI: 3.43-22.34) of patients.</AbstractText><AbstractText Label="CONCLUSIONS">SPE comprises 10&#xa0;% of all PE cases. Despite its ominous radiologic appearance, the clinical, hemodynamic, and mortality outcomes of SPE seem comparable to that of other PE types in general. The presence of massive PE features is the main predictor of mortality in SPE patients. AC, TT, ST, and PT are all associated with decreased odds of death from SPE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ata</LastName><ForeName>Fateen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hamad General Hospital, Doha, Qatar. Electronic address: docfateenata@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Wanis H</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Pulmonology and Internal Medicine, Weill-Cornell Medicine &amp; Hamad General Hospital, Doha, Qatar. Electronic address: Wanisian@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudry</LastName><ForeName>Hassan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University Hospital of Leicester, UK. Electronic address: h4hach@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shams</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hamad General Hospital, Doha, Qatar. Electronic address: AShams1@hamad.qa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arshad</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hamad General Hospital, Doha, Qatar. Electronic address: AArshad1@hamad.qa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younas</LastName><ForeName>Hafiz Waqas</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Emergency Department, Forth Valley Royal Hospital, Larbert, Scotland, UK. Electronic address: waqasyounas70@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilal</LastName><ForeName>Ammara Bint I</ForeName><Initials>ABI</Initials><AffiliationInfo><Affiliation>Department of Radiology, Hamad General Hospital, Doha, Qatar. Electronic address: ABilal@hamad.qa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikram</LastName><ForeName>Muhammad Qaiser</ForeName><Initials>MQ</Initials><AffiliationInfo><Affiliation>Department of Acute Medicine, Aintree University Hospital, Liverpool, UK. Electronic address: mqi205@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahir</LastName><ForeName>Shuja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Faisalabad Institute of Cardiology, Faisalabad, Pakistan. Electronic address: drshuja192@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mogassabi</LastName><ForeName>Waqar W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Medicine, College of Medicine, Qatar University, Doha, Qatar. Electronic address: wm2005615@qu.edu.qa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Errayes</LastName><ForeName>Nada Mehdi</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Department of Medical Education, University of Lincoln, UK. Electronic address: nerrayes@lincoln.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Thromb Res</MedlineTA><NlmUniqueID>0326377</NlmUniqueID><ISSNLinking>0049-3848</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017131" MajorTopicYN="N">Thrombectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Saddle pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Thrombolysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>4</Day><Hour>18</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35926347</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2022.07.013</ArticleId><ArticleId IdType="pii">S0049-3848(22)00330-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32282377</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1140</ISSN><JournalIssue CitedMedium="Internet"><Volume>273</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Annals of surgery</Title><ISOAbbreviation>Ann Surg</ISOAbbreviation></Journal><ArticleTitle>Prophylactic Topical Tranexamic Acid Versus Placebo in Surgical Patients: A Systematic Review and Meta-analysis&#x2217;.</ArticleTitle><Pagination><StartPage>676</StartPage><EndPage>683</EndPage><MedlinePgn>676-683</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SLA.0000000000003896</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Perioperative bleeding remains a major concern to all clinicians caring for perioperative patients. Due to the theoretical risk of thromboembolic events associated with tranexamic acid (TXA) when administered intravenously, topical route of TXA has been extensively studied, but its safety and efficacy profile remain unclear in the literature. The primary aim of this review was to assess the effect of topical TXA on incidence of blood transfusion and mortality in adults undergoing surgery.</AbstractText><AbstractText Label="DATA SOURCES">EMBASE, MEDLINE, CENTRAL, and ISI Web of Science were systematically searched from their inception until May 31, 2019.</AbstractText><AbstractText Label="REVIEW METHODS">Parallel-arm randomized controlled trials were included.</AbstractText><AbstractText Label="RESULTS">Seventy-one trials (7539 participants: orthopedics 5450 vs nonorthopedics 1909) were included for quantitative meta-analysis. In comparison to placebo, topical TXA significantly reduced intraoperative blood loss [mean difference (MD) -36.83 mL, 95% confidence interval (CI) -54.77 to -18.88, P &lt; 0.001], total blood loss (MD -319.55 mL, 95% CI -387.42 to -251.69, P &lt; 0.001), and incidence of blood transfusion [odds ratio (OR) 0.30, 95% CI 0.26-0.34, P &lt; 0.001]. Patients who received topical TXA were associated with a shorter length of hospital stay (MD -0.28 days, 95% CI -0.47 to -0.08, P = 0.006). No adverse events associated with the use of topical TXA were observed, namely mortality (OR 0.78, 95% CI 0.45-1.36, P = 0.39), pulmonary embolism (OR 0.73, 95% CI 0.27-1.93, P = 0.52), deep vein thrombosis (OR 1.07, 95% CI 0.65-1.77, P = 0.79), myocardial infarction (OR 0.79, 95% CI 0.21-2.99, P = 0.73), and stroke (OR 0.85, 95% CI 0.28-2.57, P = 0.77). Of all included studies, the risk of bias assessment was "low" for 20 studies, "unclear" for 26 studies and "high" for 25 studies.</AbstractText><AbstractText Label="CONCLUSIONS">In the meta-analysis of 71 trials (7539 patients), topical TXA reduced the incidence of blood transfusion without any notable adverse events associated with TXA in adults undergoing surgery.</AbstractText><AbstractText Label="PROSPERO">CRD 42018111762.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teoh</LastName><ForeName>Wan Yi</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>University of Liverpool, School of Medicine, Cedar House, Liverpool, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Tun Giap</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Basingstoke and North Hampshire Hospital, Hampshire, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Ka Ting</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Faculty of Medicine, University of Malaya, Jalan University, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Ke Xin</ForeName><Initials>KX</Initials><AffiliationInfo><Affiliation>University of Warwick, Gibbet Hill Road, Coventry, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Xue Lin</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Faculty of Medicine, University of Malaya, Jalan University, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung Tsan</LastName><ForeName>Samuel Ern</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Sciences, University of Malaysia Sarawak, Sarawak, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chew Yin</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Faculty of Medicine, University of Malaya, Jalan University, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg</MedlineTA><NlmUniqueID>0372354</NlmUniqueID><ISSNLinking>0003-4932</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000287" MajorTopicYN="N">Administration, Topical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="N">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="N">Tranexamic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32282377</ArticleId><ArticleId IdType="doi">10.1097/SLA.0000000000003896</ArticleId><ArticleId IdType="pii">00000658-202104000-00010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rasouli MR, Maltenfort MG, Erkocak OF, et al. Blood management after total joint arthroplasty in the United States: 19-year trend analysis. Transfusion 2016; 56:1112&#x2013;1120.</Citation></Reference><Reference><Citation>Levine B, Haughom B, Strong B, et al. Blood management strategies for total knee arthroplasty. J Am Acad Orthop Surg 2014; 22:361&#x2013;371.</Citation></Reference><Reference><Citation>Paparella D, Brister S, Buchanan M. Coagulation disorder of cardiopulmonary bypass. A review. Intensive Care Med 2004; 30:1873&#x2013;1881.</Citation></Reference><Reference><Citation>Tse E, Cheung W, Ng K, et al. Reducing perioperative blood loss and allogeneic blood transfusion in patients undergoing major spine surgery. J Bone Joint Surg Am 2011; 93:1268&#x2013;1277.</Citation></Reference><Reference><Citation>Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. Br J Anaesth 2005; 95:33&#x2013;42.</Citation></Reference><Reference><Citation>Alter H, Klein H. The hazards of blood transfusion in historical perspective. Blood 2008; 112:2617&#x2013;2626.</Citation></Reference><Reference><Citation>Spahn D. Anemia and patient blood management in hip and knee surgery: a systematic review of the literature. Anesthesiology 2010; 113:482&#x2013;495.</Citation></Reference><Reference><Citation>Na Y, Bamme A, Won H, et al. After early release of tourniquet in total knee arthroplasty, should it be reinflated or kept deflated? A randomized trial. Knee Surg Sports Traumatol Arthrosc 2017; 25:2769&#x2013;2777.</Citation></Reference><Reference><Citation>Juelsgaard P, Larsen U, S&#xf8;rensen J, et al. Hypotensive epidural anesthesia (HEA) in total knee replacement without Tourniquet reduced blood loss and transfusion. Reg Anesth Pain Med 2001; 26:105&#x2013;110.</Citation></Reference><Reference><Citation>Li Z, Fu X, Tian P, et al. Fibrin sealant before wound closure in total knee arthroplasty reduced blood loss: a meta-analysis. Knee Surg Sports Traumatol Arthrosc 2015; 23:2019&#x2013;2025.</Citation></Reference><Reference><Citation>Kagoma Y, Crowther M, Douketis J, et al. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res 2009; 123:687&#x2013;696.</Citation></Reference><Reference><Citation>Dunn C, Goa K. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57:1005&#x2013;1032.</Citation></Reference><Reference><Citation>Royston D. Blood-sparing drugs: aprotinin, tranexamic acid, and epsilon-aminocaproic acid. Int Anesthesiol Clin 1995; 33:155&#x2013;179.</Citation></Reference><Reference><Citation>Lopez-Picado A, Barrachina B, Rem&#xf3;n M, et al. Cost-benefit analysis of the use of tranexamic acid in total replacement hip surgery. J Clin Anesth 2019; 57:124&#x2013;128.</Citation></Reference><Reference><Citation>Raveendran R, Wong J. Tranexamic acid reduces blood transfusion in surgical patients while its effects on thromboembolic events and mortality are uncertain. Evid Based Med 2013; 18:65&#x2013;66.</Citation></Reference><Reference><Citation>McCormack P. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012; 72:585&#x2013;617.</Citation></Reference><Reference><Citation>Wong J, Abrishami A, El Beheiry H, et al. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am 2010; 92:2503&#x2013;2513.</Citation></Reference><Reference><Citation>Mu X, Wei J, Wang C, et al. Intravenous administration of tranexamic acid significantly reduces visible and hidden blood loss compared with its topical administration for double-segment posterior lumbar interbody fusion: a single-center, placebo-controlled, randomized trial. World Neurosurg 2019; 122:e821&#x2013;e827.</Citation></Reference><Reference><Citation>Sallam H, Shady N. Reducing blood loss during abdominal hysterectomy with intravenous versus topical tranexamic acid: a double-blind randomized controlled trial. J Obstet Gynecol India 2019; 69:173&#x2013;179.</Citation></Reference><Reference><Citation>L&#xf3;pez-Hualda &#xc1;, Dauder-Gallego C, Ferre&#xf1;o-M&#xe1;rquez D, et al. Efficacy and safety of topical tranexamic acid in knee arthroplasty. Med Clin (Barc) 2018; 151:431&#x2013;434.</Citation></Reference><Reference><Citation>Rani R, Mittal S, Choubey S, et al. Use of tranexamic acid as a topical agent to reduce bleeding during TURP: a novel technique!. Int J Sci Res 2018; 7:291&#x2013;293.</Citation></Reference><Reference><Citation>Mirmohammadsadeghi A, Mirmohammadsadeghi M, Kheiri M, et al. Does topical tranexamic acid reduce postcoronary artery bypass graft bleeding? J Res Med 2018; 23:6.</Citation></Reference><Reference><Citation>Perez-Jimeno N, Munoz M, Mateo J, et al. Efficacy of topical tranexamic acid within a blood-saving programme for primary total hip arthroplasty: a pragmatic, open-label randomised study. Blood Transfusion 2018; 16:490&#x2013;497.</Citation></Reference><Reference><Citation>Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Br Med J 2015; 349:g7647.</Citation></Reference><Reference><Citation>Higgins J, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Upadated March 2011]. The Cochraine Collaboration . Available from: https://training.cochrane.org/handbook . 2011.</Citation></Reference><Reference><Citation>Perry D, Noakes T, Helliwell P. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J 2007; 203:389&#x2013;393.</Citation></Reference><Reference><Citation>McMaster University and Evidence Prime Icn. GRADEpro|GDT. Available from: https://gradepro.org/ . 2015.</Citation></Reference><Reference><Citation>Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group . Available from: http://cccrg.cochrane.org/author-resources .</Citation></Reference><Reference><Citation>Collaboration T. Review Manager (RevMan) [Computer Program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre.</Citation></Reference><Reference><Citation>Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. bMC Med Res Methodol 2014; 14:135.</Citation></Reference><Reference><Citation>Yuan X, Li B, Wang Q, et al. Comparison of 3 routes of administration of tranexamic acid on primary unilateral total knee arthroplasty: a prospective, randomized, controlled study. J Arthroplasty 2017; 32:2738&#x2013;4273.</Citation></Reference><Reference><Citation>Drosos GI, Ververidis A, Valkanis C, et al. A randomized comparative study of topical versus intravenous tranexamic acid administration in enhanced recovery after surgery (ERAS) total knee replacement. J Orthop 2016; 13:127&#x2013;131.</Citation></Reference><Reference><Citation>Drakos A, Raoulis V, Karatzios K, et al. Efficacy of local administration of tranexamic acid for blood salvage in patients undergoing intertrochanteric fracture surgery. J Orthop Trauma 2016; 30:409&#x2013;414.</Citation></Reference><Reference><Citation>Zekcer A, Priori R, Del, et al. Comparative study of topical vs. intravenous tranexamic acid regarding blood loss in total knee arthroplasty. Rev Bras Ortop 2017; 52:589&#x2013;595.</Citation></Reference><Reference><Citation>De Bonis M, Cavaliere F, Alessandrini F, et al. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg 2000; 119:575&#x2013;580.</Citation></Reference><Reference><Citation>Abul-Azm A, Abdullah K. Effect of topical tranexamic acid in open heart surgery. Eur J Anaesthesiol 2006; 23:380&#x2013;384.</Citation></Reference><Reference><Citation>Baric D, Biocina B, Unic D, et al. Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study. Eur J Cardiothorcic Surg 2007; 31:366&#x2013;371.</Citation></Reference><Reference><Citation>Fawzy H, Elmistekawy E, Bonneau D, et al. Can local application of Tranexamic acid reduce post-coronary bypass surgery blood loss? J Cardiothorac Surg 2009; 4:25.</Citation></Reference><Reference><Citation>Nouraei M, Gholipour Baradari A, Ghafari R, et al. Decreasing blood loss and the need for transfusion after CABG surgery: a double-blind randomized clinical trial of topical tranexamic acid. Turkish J Med Sci 2013; 43:273&#x2013;278.</Citation></Reference><Reference><Citation>Hosseini H, Rahimianfar A, Abdollahi A, et al. Evaluations of topical application of tranexamic acid on post-operative blood loss in off-pump coronary artery bypass surgery. Saudi J Anaesth 2014; 8:224&#x2013;228.</Citation></Reference><Reference><Citation>Ali Shah M, Asghar M, Siddiqi R, et al. Topical application of tranexamic acid reduces postoperative bleeding in open-heart surgery: myth or fact? J Coll Physicians Surg Pakistan 2015; 25:161&#x2013;165.</Citation></Reference><Reference><Citation>Chaudhary F, Pervaz Z, Ilyas S, et al. Topical use of tranexamic acid in open heart surgery. J Pak Med Assoc 2018; 68:538&#x2013;542.</Citation></Reference><Reference><Citation>Ausen K, Fossmark R, Spigset O, et al. Randomized clinical trial of topical tranexamic acid after reduction mammoplasty. Br J Soc 2015; 102:1248&#x2013;1253.</Citation></Reference><Reference><Citation>Shady NW, Sallam HF, Fahmy H. Reducing blood loss during open myomectomy with intravenous versus topical tranexamic acid: A double-blinded randomized placebo-controlled trial. Middle East Fertil Soc J 2018; 23:225&#x2013;231.</Citation></Reference><Reference><Citation>Jabalameli M, Zakeri K. Evaluation of topical tranexamic acid on intraoperative bleeding in endoscopic sinus surgery. Iran J Med Sci 2006; 31:221&#x2013;223.</Citation></Reference><Reference><Citation>Dell&#x2019;Amore A, Caroli G, Nizar A, et al. Can topical application of tranexamic acid reduce blood loss in thoracic surgery? a prospective randomised double blind investigation. Hear Lung Circ 2012; 21:706&#x2013;710.</Citation></Reference><Reference><Citation>Pourfakhr P, Gatavi E, Gooran S, et al. Local administration of tranexamic acid during prostatectomy surgery: effects on reducing the amount of bleeding. Nephrourol Mon 2016; 8:e40409.</Citation></Reference><Reference><Citation>Bansal A, Arora A. A double-blind, placebo-controlled randomized clinical trial to evaluate the efficacy of tranexamic acid in irrigant solution on blood loss during percutaneous nephrolithotomy: a pilot study from tertiary care center of North India. World J Urol 2017; 35:1233&#x2013;1240.</Citation></Reference><Reference><Citation>Sabry MM, Sallam AA, Elgebaly AS, et al. Evaluation of local intra-pleural application of tranexamic acid on postoperative blood loss in lung decortication surgery, a prospective, randomized, double-blind, placebo-controlled study. Ann Card Anaesth 2018; 21:409&#x2013;412.</Citation></Reference><Reference><Citation>Baradaranfar M, Dadgarnia M, Mahmoudi H, et al. The effect of topical tranexamic acid on bleeding reduction during functional endoscopic sinus surgery. Iran J Otorhinolaryngol 2017; 29:69&#x2013;74.</Citation></Reference><Reference><Citation>Ishida K, Tsumura N, Kitagawa A, et al. Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty. Int Orthop 2011; 35:1639&#x2013;1645.</Citation></Reference><Reference><Citation>Zhang Y, Zhang L, Ma X, et al. What is the optimal approach for tranexamic acid application in patients with unilateral total hip arthroplasty? Orthopade 2016; 45:616&#x2013;621.</Citation></Reference><Reference><Citation>Stowers M, Aoina J, Vane A, et al. Tranexamic acid in knee surgery studyda multicentered, randomized, controlled trial. J Arthroplasty 2017; 32:3379&#x2013;3384.</Citation></Reference><Reference><Citation>Lin S, Chen C, Fu Y, et al. The efficacy of combined use of intraarticular and intravenous tranexamic acid on reducing blood loss and transfusion rate in total knee arthroplasty. J Arthroplasty 2015; 30:776&#x2013;780.</Citation></Reference><Reference><Citation>Li Q, Xiao J, Zhu H, et al. Effects of tranexamic acid administration on recovery after unilateral total knee arthroplasty. Farmacia 2018; 66:718&#x2013;724.</Citation></Reference><Reference><Citation>Laoruengthana A, Rattanaprichavej P, Rasamimongkol S, et al. Intra-articular tranexamic acid mitigates blood loss and morphine use after total knee arthroplasty. a randomized controlled trial. J Arthroplasty 2019; 34:877&#x2013;881.</Citation></Reference><Reference><Citation>Aguilera X, Mart&#xed;nez-Zapata M, Hinarejos P, et al. Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial. Arch Orthop Trauma Surg 2015; 135:1017&#x2013;1025.</Citation></Reference><Reference><Citation>Krohn C, S&#xf8;rensen R, Lange J, et al. Tranexamic acid given into the wound reduces postoperative blood loss by half in major orthopaedic surgery. Eur J Surg 2003; 168:57&#x2013;61.</Citation></Reference><Reference><Citation>Triyudanto A, Lubis A. The effects of intra-articular tranexamic acid given intraoperatively and intravenous tranexamic acid given preoperatively on post surgical bleeding and transfusion rate post total knee arthroplasty. Med J Indones 2016; 25:234&#x2013;239.</Citation></Reference><Reference><Citation>Ker K, Beecher D, Roberts I. Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev 2013; 23:CD010562.</Citation></Reference><Reference><Citation>Montroy J, Hutton B, Moodley P, et al. The efficacy and safety of topical tranexamic acid: a systematic review and meta-analysis. Transfus Med Rev 2018; 32:165&#x2013;178.</Citation></Reference><Reference><Citation>Belayneh T, Messele G, Abdissa Z, et al. Blood requisition and utilization practice in surgical patients at University of Gondar Hospital, Northwest Ethiopia. Transfus Med Rev 2018; 32:165&#x2013;178.</Citation></Reference><Reference><Citation>Practice Guidelines for Perioperative Blood Management: An Updated Report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management&#x2217;. Anesthesiology 2015; 122:241&#x2013;275.</Citation></Reference><Reference><Citation>Mullen M, Michaels A, Mehaffey J, et al. Risk associated with complications and mortality after urgent surgery vs elective and emergency surgery implications for defining &#x201c;quality&#x201d; and reporting outcomes for urgent surgery. JAMA Surg 2017; 152:768&#x2013;774.</Citation></Reference><Reference><Citation>Wang Y, Deng L, Xu H, et al. Laparoscopy versus laparotomy for the management of early stage cervical cancer. BMC Cancer 2015; 15:928.</Citation></Reference><Reference><Citation>Gill I, Kavoussi L, Lane B, et al. Comparison of 1800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007; 178:41&#x2013;46.</Citation></Reference><Reference><Citation>van der Pas M, Haglind E, Cuesta M, et al. COlorectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol 2013; 14:210&#x2013;218.</Citation></Reference><Reference><Citation>Guo J, Gao X, Ma Y, et al. Different dose regimes and administration methods of tranexamic acid in cardiac surgery: a meta-analysis of randomized trials. BMC Anesthesiol 2010; 19:129.</Citation></Reference><Reference><Citation>Murkin JM, Granton J, Falter F, et al. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010; 110:350&#x2013;353.</Citation></Reference><Reference><Citation>Baharoglu M, Germans M, Rinkel G, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database of Syst Rev 2013; CD001245.</Citation></Reference><Reference><Citation>Myles PS, Smith JA, Forbes A, et al. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2016; 376:136&#x2013;148.</Citation></Reference><Reference><Citation>Keyl C, Uhl R, Beyersdorf F, et al. High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorcic Surg 2011; 39:e1114&#x2013;e1121.</Citation></Reference><Reference><Citation>Lee J, Singletary R, Schmader K, et al. Surgical site infection in the elderly following orthopaedic surgery: risk factors and outcomes. J Bone Jt Surg 2006; 88:1705&#x2013;1712.</Citation></Reference><Reference><Citation>Fencl J. Guideline implementation: prevention of retained surgical items. Assoc Perioper Regist Nurse J 2016; 104:37&#x2013;48.</Citation></Reference><Reference><Citation>Brown J, Singh K, Dumitru R, et al. The benefits of enhanced recovery after surgery programs and their application in cardiothoracic surgery. Methodist Debakey Cardiovasc J 2018; 14:77&#x2013;88.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24559222</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1933-0693</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of neurosurgery</Title><ISOAbbreviation>J Neurosurg</ISOAbbreviation></Journal><ArticleTitle>Evolution of cranial epilepsy surgery complication rates: a 32-year systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1415</StartPage><EndPage>1427</EndPage><MedlinePgn>1415-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3171/2014.1.JNS131694</ELocationID><Abstract><AbstractText Label="OBJECT" NlmCategory="OBJECTIVE">Surgical interventions for medically refractory epilepsy are effective in selected patients, but they are underutilized. There remains a lack of pooled data on complication rates and their changes over a period of multiple decades. The authors performed a systematic review and meta-analysis of reported complications from intracranial epilepsy surgery from 1980 to 2012.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A literature search was performed to find articles published between 1980 and 2012 that contained at least 2 patients. Patients were divided into 3 groups depending on the procedure they underwent: A) temporal lobectomy with or without amygdalohippocampectomy, B) extratemporal lobar or multilobar resections, or C) invasive electrode placement. Articles were divided into 2 time periods, 1980-1995 and 1996-2012.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-one articles with a total of 5623 patients met the study's eligibility criteria. Based on the 2 time periods, neurological deficits decreased dramatically from 41.8% to 5.2% in Group A and from 30.2% to 19.5% in Group B. Persistent neurological deficits in these 2 groups decreased from 9.7% to 0.8% and from 9.0% to 3.2%, respectively. Wound infections/meningitis decreased from 2.5% to 1.1% in Group A and from 5.3% to 1.9% in Group B. Persistent neurological deficits were uncommon in Group C, although wound infections/meningitis and hemorrhage/hematoma increased over time from 2.3% to 4.3% and from 1.9% to 4.2%, respectively. These complication rates are additive in patients undergoing implantation followed by resection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Complication rates have decreased dramatically over the last 30 years, particularly for temporal lobectomy, but they remain an unavoidable consequence of epilepsy surgery. Permanent neurological deficits are rare following epilepsy surgery compared with the long-term risks of intractable epilepsy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tebo</LastName><ForeName>Collin C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Neurological Surgery, Weill Cornell Medical College, Cornell University, NewYork-Presbyterian Hospital; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evins</LastName><ForeName>Alexander I</ForeName><Initials>AI</Initials></Author><Author ValidYN="Y"><LastName>Christos</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Theodore H</ForeName><Initials>TH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2UL1TR000457-06</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosurg</MedlineTA><NlmUniqueID>0253357</NlmUniqueID><ISSNLinking>0022-3085</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurosurg. 2015 Feb;122(2):475-7. doi: 10.3171/2014.7.JNS141680.</RefSource><PMID Version="1">25526269</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Neurosurg. 2015 Feb;122(2):477-8.</RefSource><PMID Version="1">25763433</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038481" MajorTopicYN="N">Anterior Temporal Lobectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003399" MajorTopicYN="Y">Craniotomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004567" MajorTopicYN="N">Electrodes, Implanted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019635" MajorTopicYN="Y">Neurosurgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AED = antiepileptic drug</Keyword><Keyword MajorTopicYN="N">CVA = cerebral vascular accident</Keyword><Keyword MajorTopicYN="N">DVT = deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">PE = pulmonary embolism</Keyword><Keyword MajorTopicYN="N">complication</Keyword><Keyword MajorTopicYN="N">epilepsy surgery</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">morbidity</Keyword><Keyword MajorTopicYN="N">neurological deficits</Keyword><Keyword MajorTopicYN="N">review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24559222</ArticleId><ArticleId IdType="doi">10.3171/2014.1.JNS131694</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28807470</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>07</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8406</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>12</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of arthroplasty</Title><ISOAbbreviation>J Arthroplasty</ISOAbbreviation></Journal><ArticleTitle>Persistent Pulmonary Embolism Rates Following Total Knee Arthroplasty Even With Prophylactic Anticoagulants.</ArticleTitle><Pagination><StartPage>3833</StartPage><EndPage>3839</EndPage><MedlinePgn>3833-3839</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arth.2017.06.041</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-5403(17)30570-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Symptomatic pulmonary embolism (PE), a significant and life-threatening complication following total knee arthroplasty (TKA), has been described as a "never event." Despite a number of advancements in care, PE continues to occur following TKA. This study evaluates symptomatic PE rates over time in TKA patients enrolled in multicenter randomized clinical trials assessing the efficacy of venous thromboembolism prophylaxis regimens.</AbstractText><AbstractText Label="METHODS">The MEDLINE and Cochrane Central Register of Controlled Trials were searched to identify clinical trials assessing prophylactic anticoagulation in patients undergoing TKA between January 1995 and December 2016. A random effect model was used to combine PE rates across studies. The pooled proportion of symptomatic PEs was calculated and heterogeneity was quantified with the I<sup>2</sup> statistic. A 95% prediction interval was constructed to examine what the expected range in the proportion of symptomatic PEs would be in future studies. Meta-regression was used to explore the effect of time on the rate of symptomatic PEs.</AbstractText><AbstractText Label="RESULTS">A total of 18 studies representing 27,073 patients were included in the meta-analysis. The symptomatic PE rate was 0.37% (95% confidence interval, 0.24%-0.52%). There was significant heterogeneity across studies, I<sup>2</sup>&#xa0;= 66%. Between 1996 and 2010, the proportion of PEs did not change in the regression analysis. The 95% prediction interval was 0.0002 to 0.0106, indicating that in similar future studies, the true proportion of symptomatic PEs would range from 0.02% to 1.06%.</AbstractText><AbstractText Label="CONCLUSION">Over a 14-year period, the symptomatic PE rate after TKA was relatively constant even when patients received potent anticoagulation. These results suggest that some patients may have a genetic predisposition to develop a PE and more effective risk stratification protocols need to be developed to make sure patients receive appropriate anticoagulation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cote</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Orthopaedic Surgery, UConn Health, Farmington, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Keck School of Medicine of USC, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Keck School of Medicine of USC, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Keck School of Medicine of USC, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Jay R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Keck School of Medicine of USC, Los Angeles, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Arthroplasty</MedlineTA><NlmUniqueID>8703515</NlmUniqueID><ISSNLinking>0883-5403</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="N">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009985" MajorTopicYN="N">Orthopedics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anticoagulation</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">randomized trials</Keyword><Keyword MajorTopicYN="N">total knee arthroplasty</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28807470</ArticleId><ArticleId IdType="doi">10.1016/j.arth.2017.06.041</ArticleId><ArticleId IdType="pii">S0883-5403(17)30570-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">27790330</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1976-1902</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Asian spine journal</Title><ISOAbbreviation>Asian Spine J</ISOAbbreviation></Journal><ArticleTitle>Thromboembolism in the Sub-Acute Phase of Spinal Cord Injury: A Systematic Review of the Literature.</ArticleTitle><Pagination><StartPage>972</StartPage><EndPage>981</EndPage><MedlinePgn>972-981</MedlinePgn></Pagination><Abstract><AbstractText>To review the evidence of thromboembolism incidence and prophylaxis in the sub-acute phase of spinal cord injury (SCI) 3-6 months post injury. All observational and experimental studies with any length of follow-up and no limitations on language or publication status published up to March 2015 were included. Two review authors independently selected trials for inclusion and extracted data. Outcomes studied were incidence of pulmonary embolism (PE) and deep vein thrombosis (DVT) in the sub-acute phase of SCI. The secondary outcome was type of thromboprophylaxis. Our search identified 4305 references and seven articles that met the inclusion criteria. Five papers reported PE events and three papers reported DVT events in the sub-acute phase of SCI. Studies were heterogeneous in populations, design and outcome reporting, therefore a meta-analysis was not performed. The included studies report a PE incidence of 0.5%-6.0% and DVT incidence of 2.0%-8.0% in the sub-acute phase of SCI. Thromboprophylaxis was poorly reported. Spinal patients continue to have a significant risk of PE and DVT after the acute period of their injury. Clinicians are advised to have a low threshold for suspecting venous thromboembolism in the sub-acute phase of SCI and to continue prophylactic anticoagulation therapy for a longer period of time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alabed</LastName><ForeName>Samer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Spinal Injuries Centre, Stoke Mandeville Hospital, Aylesbury, UK.; Academic Unit of Radiology, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belci</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>National Spinal Injuries Centre, Stoke Mandeville Hospital, Aylesbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Middendorp</LastName><ForeName>Joost J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>National Spinal Injuries Centre, Stoke Mandeville Hospital, Aylesbury, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Halabi</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, General Hospital of Celle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meagher</LastName><ForeName>Tom M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Radiology Department, Stoke Mandeville Hospital, Aylesbury, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Asian Spine J</MedlineTA><NlmUniqueID>101314177</NlmUniqueID><ISSNLinking>1976-1902</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Rehabilitation</Keyword><Keyword MajorTopicYN="N">Spinal cord injury</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">Thromboembolism</Keyword></KeywordList><CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27790330</ArticleId><ArticleId IdType="pmc">PMC5081337</ArticleId><ArticleId IdType="doi">10.4184/asj.2016.10.5.972</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Saraf SK, Rana RJ, Sharma OP. Venous thromboembolism in acute spinal cord injury patients. Indian J Orthop. 2007;41:194&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989117</ArticleId><ArticleId IdType="pubmed">21139743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Kim YT. Value of the D-dimer test in diagnosing venous thromboembolism in acute rehabilitation inpatients in Korea. PM R. 2010;2(9 Suppl):S155.</Citation></Reference><Reference><Citation>Riklin C, Baumberger M, Wick L, Michel D, Sauter B, Knecht H. Deep vein thrombosis and heterotopic ossification in spinal cord injury: a 3 year experience at the Swiss Paraplegic Centre Nottwil. Spinal Cord. 2003;41:192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">12612623</ArticleId></ArticleIdList></Reference><Reference><Citation>Teasell RW, Hsieh JT, Aubut JA, et al. Venous thromboembolism after spinal cord injury. Arch Phys Med Rehabil. 2009;90:232&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3104991</ArticleId><ArticleId IdType="pubmed">19236977</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Mos IC, Nijkeuter M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med. 2008;168:2131&#x2013;2136.</Citation><ArticleIdList><ArticleId IdType="pubmed">18955643</ArticleId></ArticleIdList></Reference><Reference><Citation>Douma RA, Gibson NS, Gerdes VE, et al. Validity and clinical utility of the simplified Wells rule for assessing clinical probability for the exclusion of pulmonary embolism. Thromb Haemost. 2009;101:197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">19132208</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein PD, Fowler SE, Goodman LR, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med. 2006;354:2317&#x2013;2327.</Citation><ArticleIdList><ArticleId IdType="pubmed">16738268</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd JW, Frisbie JH, Rossier AB, et al. Deep venous thrombosis in acute spinal cord injury: a comparison of 125I fibrinogen leg scanning, impedance plethysmography and venography. Paraplegia. 1976;14:50&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">934690</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi EC, Green D, Rosen JS, Spies SM, Jao JS. Sequential changes in factor VIII and platelets preceding deep vein thrombosis in patients with spinal cord injury. Br J Haematol. 1980;45:143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">6769466</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver JR, Noori Z. Pulmonary embolism following anticoagulation therapy. Int Disabil Stud. 1991;13:16&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">1917798</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts WH. Prevention of venous thromboembolism in high-risk patients. Hematology Am Soc Hematol Educ Program. 2006:462&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">17124100</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisbie JH, Sharma GV. The prevalence of pulmonary embolism in chronically paralyzed subjects: a review of available evidence. Spinal Cord. 2012;50:400&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">22158255</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh JJ, Tribe C. Phlebo-thrombosis and pulmonary embolism in paraplegia. Paraplegia. 1965;3:209&#x2013;213.</Citation></Reference><Reference><Citation>Kim SW, Charallel JT, Park KW, et al. Prevalence of deep venous thrombosis in patients with chronic spinal cord injury. Arch Phys Med Rehabil. 1994;75:965&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pubmed">8085931</ArticleId></ArticleIdList></Reference><Reference><Citation>Alabed S, Al Halabi A, Belci M, Van Middendorp J, Meagher T.  Systematic review of thromboembolism in sub-acute phase of spinal cord injury [Internet] York, UK: PROSPERO Int.; 2015.  [cited 2016 Sep 20].  Available from:  http://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42014013471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081337</ArticleId><ArticleId IdType="pubmed">27790330</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J, Higgins J, Reeves B. A Cochrane risk of bias assessment tool: for non-randomized studies of interventions (ACROBAT-NRSI) [Internet]  [cited 2015 Jul 1].  Available from:  http://www.riskofbias.info.</Citation></Reference><Reference><Citation>Perkash A, Prakash V, Perkash I. Experience with the management of thromboembolism in patients with spinal cord injury: Part I. Incidence, diagnosis and role of some risk factors. Paraplegia. 1978;16:322&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">733316</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinley WO, Jackson AB, Cardenas DD, DeVivo MJ. Long-term medical complications after traumatic spinal cord injury: a regional model systems analysis. Arch Phys Med Rehabil. 1999;80:1402&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569434</ArticleId></ArticleIdList></Reference><Reference><Citation>El Masri WS, Silver JR. Prophylactic anticoagulant therapy in patients with spinal cord injury. Paraplegia. 1981;19:334&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">7312386</ArticleId></ArticleIdList></Reference><Reference><Citation>Alabed S, de Heredia LL, Naidoo A, Belci M, Hughes RJ, Meagher TM. Incidence of pulmonary embolism after the first 3 months of spinal cord injury. Spinal Cord. 2015;53:835&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">26099210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung WS, Lin CL, Chang SN, Chung HA, Sung FC, Kao CH. Increased risk of deep vein thrombosis and pulmonary thromboembolism in patients with spinal cord injury: a nationwide cohort prospective study. Thromb Res. 2014;133:579&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">24457145</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackiewicz-Milewska M, Jung S, Kroszczynski AC, et al. Deep venous thrombosis in patients with chronic spinal cord injury. J Spinal Cord Med. 2016;39:400&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5102284</ArticleId><ArticleId IdType="pubmed">26132450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb GC, Tomski MA, Kaufman J, Maiman DJ. Is chronic spinal cord injury associated with increased risk of venous thromboembolism? J Am Paraplegia Soc. 1993;16:153&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">8366336</ArticleId></ArticleIdList></Reference><Reference><Citation>Haisma JA, van der Woude LH, Stam HJ, et al. Complications following spinal cord injury: occurrence and risk factors in a longitudinal study during and after inpatient rehabilitation. J Rehabil Med. 2007;39:393&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">17549331</ArticleId></ArticleIdList></Reference><Reference><Citation>Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">10823257</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21:722&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1924694</ArticleId><ArticleId IdType="pubmed">16808773</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28214497</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-3348</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of vascular surgery. Venous and lymphatic disorders</Title><ISOAbbreviation>J Vasc Surg Venous Lymphat Disord</ISOAbbreviation></Journal><ArticleTitle>Incidence of pulmonary embolism in patients with isolated calf deep vein thrombosis.</ArticleTitle><Pagination><StartPage>274</StartPage><EndPage>279</EndPage><MedlinePgn>274-279</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvsv.2016.09.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-333X(16)30179-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">The severity of pulmonary embolism (PE) after isolated calf deep vein thrombosis (C-DVT) is controversial, which leads to inconsistent clinical decision making when treating C-DVT. This systematic review assessed PE frequency and severity in patients with C-DVT.</AbstractText><AbstractText Label="METHODS">Database searches were completed using MEDLINE and Scopus along with cross-referencing. Two independent reviewers used using rigorous inclusion and exclusion criteria to screen the papers. Data concerning PE and C-DVT characteristics as well as methods of detection were abstracted. Studies reporting combined outcomes for patients with proximal and C-DVT, those with concurrent PE at diagnosis, and retrospective studies not allowing the determination of C-DVT and PE as separate events were excluded.</AbstractText><AbstractText Label="RESULTS">Of 586 papers that were screened, 21 met inclusion criteria, which included eight randomized clinical trials and 13 prospective cohort studies. There was data heterogeneity among patients, methods of diagnosis, and follow-up. PE diagnosis was often based on ventilation/perfusion scanning, where more recent studies used computed tomography angiography. The PE is usually overestimated because it includes concurrent events. The incidence of PE from isolated C-DVT in our review was 0% to 6.2%. No fatal PEs were reported. No data were found on PE severity and patient outcomes regarding this complication.</AbstractText><AbstractText Label="CONCLUSIONS">Reported adverse outcomes of PE from C-DVT are infrequent, and clinical severity is unclear. Further studies are necessary to determine the actual risk associated with PE after C-DVT to establish proper treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Alvin R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, Stony Brook School of Medicine, Stony Brook, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garry</LastName><ForeName>Jonah</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, Stony Brook School of Medicine, Stony Brook, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Labropoulos</LastName><ForeName>Nicos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Vascular Surgery, Stony Brook School of Medicine, Stony Brook, NY. Electronic address: nlabrop@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Surg Venous Lymphat Disord</MedlineTA><NlmUniqueID>101607771</NlmUniqueID><ISSNLinking>2213-333X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000792" MajorTopicYN="N">Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072226" MajorTopicYN="N">Computed Tomography Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004812" MajorTopicYN="N">Epidemiologic Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28214497</ArticleId><ArticleId IdType="doi">10.1016/j.jvsv.2016.09.005</ArticleId><ArticleId IdType="pii">S2213-333X(16)30179-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24619042</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1435-1269</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Zeitschrift fur Gerontologie und Geriatrie</Title><ISOAbbreviation>Z Gerontol Geriatr</ISOAbbreviation></Journal><ArticleTitle>Mode of anesthesia, mortality and outcome in geriatric patients.</ArticleTitle><Pagination><StartPage>110</StartPage><EndPage>124</EndPage><MedlinePgn>110-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00391-014-0611-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In older non-cardiac surgery patients, the influence of the mode of anesthesia on late-term outcome (rehabilitation, mobility, independence) is a controversial issue in the medical literature. In light of an aging society, this review assessed the association between regional (RA), local (LA) and general anesthesia (GA) and mortality and morbidity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A literature search within the PubMed and Cochrane databases yielded 47 clinical trials and 35 reviews/meta-analyses published between 1965 and 2013. Potential outcome-influencing factors such as mortality, risk factors, early complications (e.g. postoperative confusion, aspiration, vomiting), adverse events (e.g. deep vein thrombosis, pulmonary embolism), discharge, rehabilitation and mobilization were evaluated in relation to the mode of anesthesia (RA, LA or GA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The current literature contains 82 references covering 74,476 non-cardiac surgery patients. Analysis shows that the particular mode of anesthesia influences mortality and morbidity. RA is associated with reduced early mortality and morbidity, e.g. fewer incidents of deep vein thrombosis and less acute postoperative confusion, as well as a tendency toward fewer myocardial infarctions and fatal pulmonary embolisms. GA has the advantages of a lower incidence of hypotension and reduced surgery time.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Strictly speaking, true anesthesia-related complications appear to be rare and many adverse outcomes may be multifactorial. Postoperative complications are largely related to the perioperative procedure and not to the anesthesia itself. GA and RA are both useful for older non-cardiac patients, but for some procedures, e.g. hip fracture surgery, RA seems to be the technique of choice. The mode of anesthesia may only play a secondary role in mobility, rehabilitation and discharge destination. In general, due to the many different possible outcomes--which are often very difficult or impossible to compare--no other specific recommendations can be made with regard to the type of anesthesia to be preferred for older non-cardiac patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luger</LastName><ForeName>T J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Anichstr. 25, 6020, Innsbruck, Austria, thomas.luger@i-med.ac.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kammerlander</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Luger</LastName><ForeName>M F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Kammerlander-Knauer</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Gosch</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Z Gerontol Geriatr</MedlineTA><NlmUniqueID>9506215</NlmUniqueID><ISSNLinking>0948-6704</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000765" MajorTopicYN="N">Anesthesia, Conduction</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000768" MajorTopicYN="N">Anesthesia, General</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051346" MajorTopicYN="N">Mobility Limitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24619042</ArticleId><ArticleId IdType="doi">10.1007/s00391-014-0611-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Bone Joint Surg Am. 2008 Jan;90(1):34-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18171955</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 2006 Mar;35(2):154-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16414964</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirurg. 2000 May;71(5):564-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10875015</ArticleId></ArticleIdList></Reference><Reference><Citation>Minerva Anestesiol. 2011 Apr;77(4):394-400</Citation><ArticleIdList><ArticleId IdType="pubmed">21483383</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonsei Med J. 2011 Jan;52(1):145-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21155047</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Anaesth. 2006 Jul;53(7):669-77</Citation><ArticleIdList><ArticleId IdType="pubmed">16803914</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Assoc Thai. 2009 Feb;92(2):198-207</Citation><ArticleIdList><ArticleId IdType="pubmed">19253795</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2008 Oct 08;(4):CD000126</Citation><ArticleIdList><ArticleId IdType="pubmed">18843606</ArticleId></ArticleIdList></Reference><Reference><Citation>Pain Med. 2012 Jul;13(7):948-56</Citation><ArticleIdList><ArticleId IdType="pubmed">22758782</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Sci Law. 2012 Apr;52(2):112-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22422787</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Orthop. 2010 Jun;81(3):296-302</Citation><ArticleIdList><ArticleId IdType="pubmed">20450426</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Obstet Gynecol. 2003 Dec;189(6):1584-7; discussion 1587-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14710073</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 2007 Mar;106(3):572-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17325517</ArticleId></ArticleIdList></Reference><Reference><Citation>Z Gerontol Geriatr. 2011 Jun;44(3):187-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21607796</ArticleId></ArticleIdList></Reference><Reference><Citation>Control Clin Trials. 1996 Feb;17(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Orthop Trauma Surg. 2011 Oct;131(10):1435-44</Citation><ArticleIdList><ArticleId IdType="pubmed">21523326</ArticleId></ArticleIdList></Reference><Reference><Citation>AANA J. 2007 Aug;75(4):267-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17711157</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bone Joint Surg Am. 2013 Apr 17;95(8):729-35</Citation><ArticleIdList><ArticleId IdType="pubmed">23595072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2000 Apr;48(4):405-12</Citation><ArticleIdList><ArticleId IdType="pubmed">10798467</ArticleId></ArticleIdList></Reference><Reference><Citation>Foot Ankle Spec. 2010 Aug;3(4):205-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20664009</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2005 Jul;95(1):95-109</Citation><ArticleIdList><ArticleId IdType="pubmed">15908453</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1992 Jan;40(1):8-11</Citation><ArticleIdList><ArticleId IdType="pubmed">1727853</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2001 Aug;49(8):1080-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11555070</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Biomed. 2005;76 Suppl 1:64-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16450515</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfusion. 2009 Feb;49(2):227-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19389209</ArticleId></ArticleIdList></Reference><Reference><Citation>Dent Traumatol. 2010 Dec;26(6):459-65</Citation><ArticleIdList><ArticleId IdType="pubmed">21078071</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gerontol Geriatr. 2013 May-Jun;56(3):507-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23246499</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 2010 Nov;113(5):1144-62</Citation><ArticleIdList><ArticleId IdType="pubmed">20966667</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2009 Sep;103(3):335-45</Citation><ArticleIdList><ArticleId IdType="pubmed">19628483</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 2003 Feb;96(2):590-4, table of contents</Citation><ArticleIdList><ArticleId IdType="pubmed">12538217</ArticleId></ArticleIdList></Reference><Reference><Citation>J Orthop Surg Res. 2011 Feb 07;6:7</Citation><ArticleIdList><ArticleId IdType="pubmed">21294923</ArticleId></ArticleIdList></Reference><Reference><Citation>Z Gerontol Geriatr. 2011 Dec;44(6):363-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22159829</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Colon Rectum. 2009 Jan;52(1):59-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19273957</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005563</Citation><ArticleIdList><ArticleId IdType="pubmed">17443600</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vasc Surg. 2009 Sep;50(3):518-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19576719</ArticleId></ArticleIdList></Reference><Reference><Citation>Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Mar;87(3):272-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10102585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2008 Dec 20;372(9656):2132-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19041130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2002;(1):CD001159</Citation><ArticleIdList><ArticleId IdType="pubmed">11869594</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Orthop Relat Res. 2012 Jul;470(7):1958-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22270468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 2001 May;233(5):612-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11360891</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Surg. 2012;12 Suppl 1:S12</Citation><ArticleIdList><ArticleId IdType="pubmed">23173755</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Endosc. 2008 Jan;22(1):61-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17943385</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Med Sci. 2002 Aug;56(8):385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12645164</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2004 Oct 18;(4):CD000521</Citation><ArticleIdList><ArticleId IdType="pubmed">15494999</ArticleId></ArticleIdList></Reference><Reference><Citation>Geriatr Orthop Surg Rehabil. 2012 Sep;3(3):121-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23569705</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Orthop Relat Res. 2011 May;469(5):1391-400</Citation><ArticleIdList><ArticleId IdType="pubmed">21347818</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 2013 Mar;118(3):729-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23291626</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1996 Jun 6;334(23):1519-25</Citation><ArticleIdList><ArticleId IdType="pubmed">8618608</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2011 Jul;59(7):1313-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21718258</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2000 Dec 16;321(7275):1493</Citation><ArticleIdList><ArticleId IdType="pubmed">11118174</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 2003 Feb;96(2):583-9, table of contents</Citation><ArticleIdList><ArticleId IdType="pubmed">12538216</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2010 Oct;58(10):1843-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20831727</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Chir Orthop Traumatol Cech. 2009 Feb;76(1):41-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19268048</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 2008 Mar;37(2):173-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18349013</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Anaesth. 1989 May;36(3 Pt 1):311-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2655951</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2000 Apr;84(4):450-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10823094</ArticleId></ArticleIdList></Reference><Reference><Citation>Z Gerontol Geriatr. 2008 Dec;41(6):447-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19190867</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 2002 Dec;97(6):1609-17</Citation><ArticleIdList><ArticleId IdType="pubmed">12459692</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 1999 Mar;28(2):135-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10350409</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Orthop Belg. 2001 Dec;67(5):468-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11822077</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 1995 Jun;80(6):1223-32</Citation><ArticleIdList><ArticleId IdType="pubmed">7762856</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesia. 2001 Dec;56(12):1141-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11736769</ArticleId></ArticleIdList></Reference><Reference><Citation>Osteoporos Int. 2010 Dec;21(Suppl 4):S555-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21057995</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 2013 Aug;117(2):471-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23757476</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Surg. 2012;12 Suppl 1:S2</Citation><ArticleIdList><ArticleId IdType="pubmed">23174028</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 2001 Aug;93(2):301-8, 2nd contents page</Citation><ArticleIdList><ArticleId IdType="pubmed">11473849</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesiol Intensive Ther. 2012 Aug 08;44(2):104-11</Citation><ArticleIdList><ArticleId IdType="pubmed">22992971</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2009 Jan;102(1):111-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19059921</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2008 Jul 16;(3):CD000337</Citation><ArticleIdList><ArticleId IdType="pubmed">18646065</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Phys Med Rehabil. 2007 Jul;88(7):916-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17601474</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20216979</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2567-689X</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Thrombosis and haemostasis</Title><ISOAbbreviation>Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Thrombolysis for pulmonary embolism: Past, present and future.</ArticleTitle><Pagination><StartPage>877</StartPage><EndPage>883</EndPage><MedlinePgn>877-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1160/TH10-01-0005</ELocationID><Abstract><AbstractText>Patients with high-risk pulmonary embolism (PE), i.e. those with shock or hypotension at presentation, are at high risk of in-hospital death, particularly during the first hours after admission. A meta-analysis of trials which included haemodynamically compromised patients indicated that thrombolytic treatment significantly reduces the rate of in-hospital death or PE recurrence. Therefore, thrombolysis should be administered to patients with high-risk PE unless there are absolute contraindications to its use. Uncontrolled data further suggest that thrombolysis may be a safe and effective alternative to surgery in patients with PE and free-floating thrombi in the right heart. On the other hand, normotensive patients generally have a favourable short-term prognosis if heparin anticoagulation is instituted promptly, and they are thus considered to have non-high-risk PE. Generally, the bleeding risk of thrombolysis appears to outweigh the clinical benefits of this treatment in patients without haemodynamic compromise. However, within the group of normotensive patients with PE, some may have evidence of right ventricular dysfunction on echocardiography or computed tomography, or of myocardial injury based on elevated cardiac biomarkers (troponin I or T, heart-type fatty acid-binding protein). These patients have an intermediate risk of an adverse outcome in the acute phase of PE. Existing data suggest that selected patients with intermediate-risk PE may benefit from early thrombolytic treatment, particularly if they have a low bleeding risk. However, controversy will continue to surround the optimal treatment for this group until the results of a large ongoing thrombolysis trial are available in a few years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lankeit</LastName><ForeName>Mareike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Pulmonology, Georg August University of G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstantinides</LastName><ForeName>Stavros</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Thromb Haemost</MedlineTA><NlmUniqueID>7608063</NlmUniqueID><ISSNLinking>0340-6245</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007022" MajorTopicYN="N">Hypotension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>91</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20216979</ArticleId><ArticleId IdType="doi">10.1160/TH10-01-0005</ArticleId><ArticleId IdType="pii">10-01-0005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32481281</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>21</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>22</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Thromboprophylaxis in elective spinal surgery: A protocol for systematic review.</ArticleTitle><Pagination><StartPage>e20127</StartPage><MedlinePgn>e20127</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e20127</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000020127</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Venous thromboembolism (VTE) is a serious, sometimes life-threatening complication that can occur following spine surgery. The incidence of VTE, and the optimal type and timing of thromboprophylaxis for this complication in elective spine surgery is a matter of debate.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To perform a systematic review with the aim of clarifying the efficacy and adverse effects of mechanical and chemical prophylaxis for preventing thromboembolic complications in elective spine surgery for conditions other than trauma and malignant disease.</AbstractText><AbstractText Label="METHODS/DESIGN" NlmCategory="METHODS">A search strategy of related articles up to March 2018 was designed and executed in Medline and Embase.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">adolescents (&gt;10 years) and adults undergoing elective surgery for spinal deformity or degenerative disease (from C1 to S1).</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Perioperative mechanical and chemical thromboprophylaxis. Studies could be randomized controlled trials or observational studies that reported data on any relevant clinical outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 2451 uniquecitations were identified and 35 studies were ultimately included in the systematic review. The overall mean incidence of complications was 3.7% for deep venous thrombosis, 0.0% for pulmonary embolism, and 3.7% for bleeding in chemoprophylaxis group; 2.9% for deep venous thrombosis, 0.4% for pulmonary embolism and 0.0% for bleeding in mechanoprophylaxis; and 0.7% for deep venous thrombosis, 0.1% for pulmonary embolism and 0.2% for bleeding in mixed prophylaxis group with no specific data on these rates for the type of patient and type and location of surgery. None of the articles retrieved provided information on the adolescent population.</AbstractText><AbstractText Label="DISCUSSION AND CONCLUSIONS" NlmCategory="CONCLUSIONS">The poor design and high variability among the studies regarding characteristics of study population, details of interventions, and definitions of outcomes, determines a low quality of the available evidence and limits the interpretation of the results. We were unable to identify a clear advantage of one type of thromboprophylaxis over the other, although there was an increased risk of bleeding with chemoprophylaxis, which could favor the use of mechanoprophylaxis in this scenario.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colomina</LastName><ForeName>Mar&#xed;a J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">00000003-0106-0956</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, Hospital Universitari Bellvitge, L'Hospitalet de LLobregat, Barcelona, Universitat de Barcelona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bag&#xf3;</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Spine Surgery Unit, Department of Orthopedic and Trauma Surgery, Hospital Universitari Vall d'Hebron, Barcelona, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Bracchiglione</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Centre for Health Studies (CIESAL), Universidad de Valpara&#xed;so, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishishinya Aquino</LastName><ForeName>Maria Betina</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Iberoamerican Cochrane Centre, Sant Pau Biomedical Research Institute (IIB Sant Pau).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salas</LastName><ForeName>Karla R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Iberoamerican Cochrane Centre, Sant Pau Biomedical Research Institute (IIB Sant Pau).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Requeijo</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Iberoamerican Cochrane Centre, Sant Pau Biomedical Research Institute (IIB Sant Pau).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urr&#xfa;tia</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Iberoamerican Cochrane Centre, Sant Pau Biomedical Research Institute (IIB Sant Pau), CIBERESP, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019635" MajorTopicYN="N">Neurosurgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013131" MajorTopicYN="N">Spine</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32481281</ArticleId><ArticleId IdType="pmc">PMC7249943</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000020127</ArticleId><ArticleId IdType="pii">00005792-202005220-00036</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eskildsen SM, Moll S, Lim MR. An algorithmic approach to venous thromboembolism prophylaxis in Spine Surgery. J Spinal Disord Tech 2015;28:275&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">26327600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryson DJ, Uzoigwe CE, Braybrooke J. Thromboprophylaxis in spinal surgery: a survey. J Orthop Surg Res 2012;7:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3349591</ArticleId><ArticleId IdType="pubmed">22458927</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayer A, Mohebali N, Razmkon A. Incidence of deep vein thrombosis in patients undergoing degenerative spine surgery on prophylactic dalteparin; a single center report. Bull Emerg Trauma 2016;4:38&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779468</ArticleId><ArticleId IdType="pubmed">27162925</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J, Li W, Pei Y, et al. Clinical analysis of preoperative risk factors for the incidence of deep venous thromboembolism in patients undergoing posterior lumbar interbody fusion. J Orthop Surg Res 2016;11:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4907081</ArticleId><ArticleId IdType="pubmed">27297081</ArticleId></ArticleIdList></Reference><Reference><Citation>Glotzbecker MP, Bono CM, Wood KB, et al. Thromboembolic disease in spinal surgery. Spine 2009;34:291&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">19179925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferree BA. Deep venous thrombosis following lumbar laminotomy and laminectomy. Orthopedics 1994;17:35&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8121832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferree BA, Stern PJ, Jolson RS, et al. Deep venous thrombosis after spinal surgery. Spine 1993;18:315&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8475429</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferree BA, Wright AM. Deep venous thrombosis following posterior lumbar spinal surgery. Spine 1993;18:1079&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">8367776</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda T, Fuji T, Kato Y, et al. Deep venous thrombosis after posterior spinal surgery. Spine 2000;25:2962&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11074685</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon L, Rodriguez H, Tawk RG, et al. The prophylactic use of inferior vena cava filters in patients undergoing high-risk spinal surgery. Ann Vasc Surg 2005;19:442&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15864473</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokito SE, Schwartz MC, Neuwirth MG. Deep vein thrombosis after major reconstructive spinal surgery. Spine 1996;21:853&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8779018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng JS, Arnold PM, Anderson PA, et al. Anticoagulation risk in spine surgery. Spine 2010;35:S117&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">20407343</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira L, Marchi L, Pimenta L. Up-to-date thromboprophylaxis in elective spinal surgery. A systematic review. Coluna/Columna 2014;13:143&#x2013;6.</Citation></Reference><Reference><Citation>Mosenthal WP, Landy DC, Boyajian HH, et al. Thromboprophylaxis in spinal surgery. Spine 2018;43:E474&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">28820759</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi S, Yoon DH, Kim KN, et al. Postoperative spinal epidural hematoma: risk factor and clinical outcome. Yonsei Med J 2006;47:326&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688151</ArticleId><ArticleId IdType="pubmed">16807981</ArticleId></ArticleIdList></Reference><Reference><Citation>Kou J, Fischgrund J, Biddinger A, et al. Risk factors for spinal epidural hematoma after spinal surgery. Spine 2002;27:1670&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12163731</ArticleId></ArticleIdList></Reference><Reference><Citation>Bono CM, Watters WC, 3rd, Heggeness MH, et al. An evidence-based clinical guideline for the use of antithrombotic therapies in spine surgery. Spine J 2009;9:1046&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">19931184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e419S&#x2013;96S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278049</ArticleId><ArticleId IdType="pubmed">22315268</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: John Wiley &amp; Sons; 2011.</Citation></Reference><Reference><Citation>Du W, Zhao C, Wang J, et al. Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. J Orthop Surg Res 2015;10:78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4455337</ArticleId><ArticleId IdType="pubmed">25998624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidi S, Riazi M. Incidence of venous thromboembolic complications in instrumental spinal surgeries with preoperative chemoprophylaxis. J Korean Neurosurg Soc 2015;57:114&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4345188</ArticleId><ArticleId IdType="pubmed">25733992</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson LD, Jr, Montgomery SP, Dameron TB, Jr, et al. Deep vein thrombosis in lumbar spinal fusion: a prospective study of antiembolic and pneumatic compression stockings. J South Orthop Assoc 1996;5:181&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8884705</ArticleId></ArticleIdList></Reference><Reference><Citation>Voth D, Schwarz M, Hahn K, et al. Prevention of deep vein thrombosis in neurosurgical patients: a prospective double-blind comparison of two prophylactic regimen. Neurosurg Rev 1992;15:289&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">1336131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood KB, Kos PB, Abnet JK, et al. Prevention of deep-vein thrombosis after major spinal surgery: a comparison study of external devices. J Spinal Disord 1997;10:209&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9213276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber UF, Rem J, Meisner C, et al. Prevention of thromboembolic complications with miniheparin-dihydroergotamine in patients undergoing lumbar disc operations. Eur Arch Psychiatry Neurol Sci 1984;234:157&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">6386481</ArticleId></ArticleIdList></Reference><Reference><Citation>Akeda K, Matsunaga H, Imanishi T, et al. Prevalence and countermeasures for venous thromboembolic diseases associated with spinal surgery: a follow-up study of an institutional protocol in 209 patients. Spine 2014;39:791&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24583727</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Dujaili TM, Majer CN, Madhoun TE, et al. Deep venous thrombosis in spine surgery patients: incidence and hematoma formation. Int Surg 2012;97:150&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723201</ArticleId><ArticleId IdType="pubmed">23102081</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox JB, Bridger Cox J, Weaver KJ, et al. Decreased incidence of venous thromboembolism after spine surgery with early multimodal prophylaxis. J Neurosurg Spine 2014;4:677&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25105337</ArticleId></ArticleIdList></Reference><Reference><Citation>Dearborn JT, Hu SS, Tribus CB, et al. Thromboembolic complications after major thoracolumbar spine surgery. Spine 1999;24:1471&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10423793</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein NE. A review of the risks and benefits of differing prophylaxis regimens for the treatment of deep venous thrombosis and pulmonary embolism in neurosurgery. Surg Neurol 2005;64:295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">16181995</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein NE. Efficacy of pneumatic compression stocking prophylaxis in the prevention of deep venous thrombosis and pulmonary embolism following 139 lumbar laminectomies with instrumented fusions. J Spinal Disord Tech 2006;19:28&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16462215</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohl JB, Lee JY, Rayappa SP, et al. Prevalence of venous thromboembolic events after elective major thoracolumbar degenerative spine surgery. J Spinal Disord Tech 2015;28:E310&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23511649</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicol M, Sun Y, Craig N, et al. Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients. Eur Spine J 2009;18:1548&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2899370</ArticleId><ArticleId IdType="pubmed">19484271</ArticleId></ArticleIdList></Reference><Reference><Citation>Pateder DB, Gonzales RA, Kebaish KM, et al. Pulmonary embolism after adult spinal deformity surgery. Spine 2008;33:301&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">18303463</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizas C, Neumayer F, Kosmopoulos V. Incidence and management of pulmonary embolism following spinal surgery occurring while under chemical thromboprophylaxis. Eur Spine J 2008;17:970&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443263</ArticleId><ArticleId IdType="pubmed">18421483</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MD, Bressler EL, Lonstein JE, et al. Deep venous thrombosis and pulmonary embolism after major reconstructive operations on the spine. A prospective analysis of three hundred and seventeen patients. J Bone Joint Surg Am 1994;76:980&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8027126</ArticleId></ArticleIdList></Reference><Reference><Citation>Strom RG, Frempong-Boadu AK. Low-molecular-weight heparin prophylaxis 24 to 36&#x200a;hours after degenerative spine surgery: risk of hemorrhage and venous thromboembolism. Spine 2013;38:E1498&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">23873245</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Yokoyama Y, Iida Y, et al. Incidence of venous thromboembolism after spine surgery. J Orthop Sci 2012;17:114&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22222443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tominaga H, Setoguchi T, Tanabe F, et al. Risk factors for venous thromboembolism after spine surgery. Medicine 2015;94:e466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4602703</ArticleId><ArticleId IdType="pubmed">25654385</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshioka K, Murakami H, Demura S, et al. Prevalence and risk factors for development of venous thromboembolism after degenerative spinal surgery. Spine 2015;40:E301&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25494320</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhi-jian S, Yu Z, Giu-xing Q, et al. Efficacy and safety of low molecular weight heparin prophylaxis for venous thromboembolism following lumbar decompression surgery. Chin Med Sci J 2011;26:221&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22218049</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerlach R, Raabe A, Beck J, et al. Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery. Eur Spine J 2004;13:9&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468029</ArticleId><ArticleId IdType="pubmed">14615928</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S-D, Liu H, Sun Y-P, et al. Prevalence and risk factors of deep vein thrombosis in patients after spine surgery: a retrospective case-cohort study. Sci Rep 2015. 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4488742</ArticleId><ArticleId IdType="pubmed">26135271</ArticleId></ArticleIdList></Reference><Reference><Citation>Piasecki DP, Poynton AR, Mintz DN, et al. Thromboembolic disease after combined anterior/posterior reconstruction for adult spinal deformity: a prospective cohort study using magnetic resonance venography. Spine 2008;33:668&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">18344861</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki K, Hoshino M, Omori K, et al. Prevalence and risk factors of deep vein thrombosis in patients undergoing lumbar spine surgery. J Orthop Sci 2017;22:1021&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28818570</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber B, Seal A, McGirr J, et al. Case series of elective instrumented posterior lumbar spinal fusions demonstrating a low incidence of venous thromboembolism. ANZ J Surg 2016;86:796&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">24897952</ArticleId></ArticleIdList></Reference><Reference><Citation>McLynn RP, Diaz-Collado PJ, Ottesen TD, et al. Risk factors and pharmacologic prophylaxis for venous thromboembolism in elective spine surgery. Spine J 2018;8:970&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29056565</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawi HMT, Saba K, Cunningham A, et al. Venous thromboembolism in adult elective spinal surgery: a tertiary centre review of 2181 patients. Bone Joint J 2017;99-B:1204&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28860401</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S-D, Ding W-Y, Yang D-L, et al. Prevalence and risk factors of deep vein thrombosis in patients undergoing lumbar interbody fusion surgery: a single-center cross-sectional study. Medicine 2015;94:e2205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4674212</ArticleId><ArticleId IdType="pubmed">26632909</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Zou Z, Jia L, et al. Safety and effectiveness of argatroban versus heparin for preventing venous thromboembolism after lumbar decompressive surgery. Int J Surg 2017;44:324&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28694001</ArticleId></ArticleIdList></Reference><Reference><Citation>Catre MG. Anticoagulation in spinal surgery. A critical review of the literature. Can J Surg 1997;40:413&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3950029</ArticleId><ArticleId IdType="pubmed">9416250</ArticleId></ArticleIdList></Reference><Reference><Citation>Glotzbecker MP, Bono CM, Wood KB, et al. Postoperative spinal epidural hematoma: a systematic review. Spine 2010;35:E413&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">20431474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sansone JM, del Rio AM, Anderson PA. The prevalence of and specific risk factors for venous thromboembolic disease following elective spine surgery. J Bone Joint Surg Am 2010;92:304&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">20124056</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster JM, Fischer D, Dettori JR. Is chemical antithrombotic prophylaxis effective in elective thoracolumbar spine surgery? Results of a systematic review. Evid Based Spine Care J 2010;1:40&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623098</ArticleId><ArticleId IdType="pubmed">23637666</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S&#x2013;453S.</Citation><ArticleIdList><ArticleId IdType="pubmed">18574271</ArticleId></ArticleIdList></Reference><Reference><Citation>Venous thromboembolism: reducing the risk: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital [CG92]. NICE; n.d. https://www.nice.org.uk/guidance/CG92/uptake [access December 31, 2018].</Citation><ArticleIdList><ArticleId IdType="pubmed">23346611</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19588357</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Issue>3</Issue><PubDate><Year>2009</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Thrombolytic therapy for pulmonary embolism.</ArticleTitle><Pagination><StartPage>CD004437</StartPage><MedlinePgn>CD004437</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD004437.pub3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and might reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages. This is an update of a Cochrane review first published in 2006.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the effectiveness and safety of thrombolytic therapy in patients with acute PE.</AbstractText><AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">For this update the Cochrane Peripheral Vascular Diseases Review Group searched their Specialised Register (last searched April 2009) and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (last searched Issue 2, 2009). We also searched individual trial collections and private databases, along with bibliographies of relevant articles. Relevant medical journals were handsearched.</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised controlled trials (RCTs) that compared thrombolytic therapy with placebo or heparin or surgical intervention in patients with acute PE. We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two authors (DB and WQ) assessed the eligibility and quality of trials and extracted data.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">We included eight trials, with a total of 679 patients, in this review. Results between thrombolytics compared with heparin alone or placebo and heparin were similar in terms of: a) death rate: odds ratio (OR) 0.89; 95% confidence interval (CI) 0.45 to 1.78; b) recurrence of pulmonary embolism: OR 0.63; 95% CI 0.33 to 1.20; c) major haemorrhagic events: OR 1.61; 95% CI 0.91 to 2.86; d) minor haemorrhagic events: OR 1.98; 95% CI 0.68 to 5.75.We found no trials comparing thrombolytic therapy to surgical intervention.Using recombinant tissue-type plasminogen activator (rt-PA) and heparin together compared to heparin alone appeared to reduce the need for further treatment for in-hospital events (OR 0.35; 95% CI 0.17 to 0.71).Thrombolytics improved haemodynamic outcomes, perfusion lung scanning, pulmonary angiogram assessment and echocardiograms to a greater extent than heparin alone.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">Based on the limited evidence found we cannot conclude whether thrombolytic therapy is better than heparin for pulmonary embolism. More double-blind RCTs, with subgroup analysis of patients presenting with haemodynamically stable acute pulmonary embolism compared to those patients with a haemodynamic unstable condition, are required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Bi Rong</ForeName><Initials>BR</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Qiukui</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Jirong</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Taixiang</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guan Jian</ForeName><Initials>GJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CZB/4/609</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004437. doi: 10.1002/14651858.CD004437.pub2.</RefSource><PMID Version="1">16625603</PMID></CommentsCorrections><CommentsCorrections RefType="UpdateIn"><RefSource>Cochrane Database Syst Rev. 2015 Sep 30;(9):CD004437. doi: 10.1002/14651858.CD004437.pub4.</RefSource><PMID Version="1">26419832</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="Y">Thrombolytic Therapy</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>67</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>10</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19588357</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD004437.pub3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22158255</PMID><DateCompleted><Year>2012</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5624</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Spinal cord</Title><ISOAbbreviation>Spinal Cord</ISOAbbreviation></Journal><ArticleTitle>The prevalence of pulmonary embolism in chronically paralyzed subjects: a review of available evidence.</ArticleTitle><Pagination><StartPage>400</StartPage><EndPage>403</EndPage><MedlinePgn>400-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/sc.2011.154</ELocationID><Abstract><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Qualitative systematic review.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To examine the validity of the prevailing notion that pulmonary embolism (PE) is rare in the chronic spinal cord injury (SCI) population.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">USA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Review surveys of adult SCI subjects &gt;2 months after injury in which PE has been looked for and its prevalence estimated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 16 surveys of chronic SCI subjects published between 1956 and 2009 offered data on PE prevalence. Two autopsy surveys, 178 subjects paralyzed &gt;2 months, revealed no PE. Eleven surveys of the cause of death, 3193 subjects paralyzed 1-25 years, revealed PE in 2.1%. Two surveys of survivors of SCI, 5761 subjects paralyzed 1-25 years, revealed PE in 0.4%. Our survey of 112 subjects paralyzed 1-50 years before death, revealed PE in 21 (18.7%), based on autopsy, imaging, clinical and electrocardiographic evidence. In 7 (33%) of the 21 subjects with PE, pulmonary hypertension by transthoracic echocardiography was detected, indicating recurrent and/or unresolved PE.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">PE is not infrequent in the chronic SCI subject; but its presentation may be subclinical; and its apparent recurrence may lead to pulmonary hypertension.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frisbie</LastName><ForeName>J H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Medical Service, Boston Veterans Affairs Healthcare System, St Paul, MN 55115, USA. jfrisbie@comcast.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>G V R K</ForeName><Initials>GV</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Spinal Cord</MedlineTA><NlmUniqueID>9609749</NlmUniqueID><ISSNLinking>1362-4393</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Spinal Cord. 2012 Dec;50(12):931; author reply 932. doi: 10.1038/sc.2012.114.</RefSource><PMID Version="1">23045297</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010243" MajorTopicYN="N">Paralysis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013119" MajorTopicYN="N">Spinal Cord Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22158255</ArticleId><ArticleId IdType="doi">10.1038/sc.2011.154</ArticleId><ArticleId IdType="pii">sc2011154</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32627124</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1573-742X</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of thrombosis and thrombolysis</Title><ISOAbbreviation>J Thromb Thrombolysis</ISOAbbreviation></Journal><ArticleTitle>Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>502</StartPage><EndPage>512</EndPage><MedlinePgn>502-512</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11239-020-02211-7</ELocationID><Abstract><AbstractText>Despite the wide range of studies supporting an association between exposure to active tuberculosis and risk of venous thromboembolism (VTE), the current systematic review and meta-analysis is the first study assessing the global epidemiology of VTE in patients having active tuberculosis. In this systematic review and meta-analysis, EMBASE, Medline, and Web of Science were searched to identify observational studies, published until December 15, 2019, and reporting on venous thromboembolism in patients with active tuberculosis. No language restriction was applied. Studies were synthetized using a random-effect model. This review is registered with PROSPERO, CRD42019130347. We included 9 studies with an overall total of 16,190 patients with active tuberculosis. The prevalence of VTE was 3.5% (95% CI 2.2-5.2) in patients with active tuberculosis. Furthermore, we found a prevalence of pulmonary embolism (PE) at 5.8% (95% CI 2.2-10.7) and for deep vein thrombosis (DVT) at 1.3% (95% CI 0.8-2.0) in patients with active tuberculosis. Patients with active tuberculosis had a higher risk for VTE (OR 2.90; 95% CI 2.30-3.67), DVT (OR 1.56; 95% CI 1.14-2.14), and PE (OR 3.58; 95% CI 2.54-5.05). This study suggests that VTE is not rare among patients with active TB. Cost-effective preventive strategies and interventions to curb this dreadful burden of VTE among people with active TB are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Danwang</LastName><ForeName>Celestin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-7976-4331</Identifier><AffiliationInfo><Affiliation>Epidemiology and Biostatistics Unit, Institut de Recherche Exp&#xe9;rimentale et Clinique, Universit&#xe9; Catholique de Louvain, Brussels, Belgium. danram07@yahoo.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaound&#xe9; I, Yaound&#xe9;, Cameroon. danram07@yahoo.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigna</LastName><ForeName>Jean Joel</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaound&#xe9;, Cameroon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Faculty of Medicine, University of Paris Sud XI, Le Kremlin-Bic&#xea;tre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awana</LastName><ForeName>Armel Philippe</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Department of Radiology, Jamot Hospital, Yaound&#xe9;, Cameroon.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of Ngaoundere, Ngaoundere, Cameroon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nzalie</LastName><ForeName>Rolf Nyah-Tuku</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>School of Public Health, University of Buea, Buea, Cameroon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Annie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Epidemiology and Biostatistics Unit, Institut de Recherche Exp&#xe9;rimentale et Clinique, Universit&#xe9; Catholique de Louvain, Brussels, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Thromb Thrombolysis</MedlineTA><NlmUniqueID>9502018</NlmUniqueID><ISSNLinking>0929-5305</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="N">Tuberculosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Review</Keyword><Keyword MajorTopicYN="N">Tuberculosis</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32627124</ArticleId><ArticleId IdType="doi">10.1007/s11239-020-02211-7</ArticleId><ArticleId IdType="pii">10.1007/s11239-020-02211-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corbett EL, Marston B, Churchyard GJ, Cock KMD (2006) Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. The Lancet 367(9514):926&#x2013;937</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)68383-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Dheda K, Barry CE, Maartens G (2016) Tuberculosis. The Lancet 387(10024):1211&#x2013;1226</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00151-8</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO|Global tuberculosis report 2019. WHO. https://www.who.int/tb/publications/global_report/en/ . Accessed 2 Nov 2019</Citation></Reference><Reference><Citation>WHO|10 facts on tuberculosis. WHO. https://www.who.int/features/factfiles/tuberculosis/en/ . Accessed 2 Sept 2019</Citation></Reference><Reference><Citation>Khan PY, Yates TA, Osman M, Warren RM, van der Heijden Y, Padayatchi N et al (2019) Transmission of drug-resistant tuberculosis in HIV-endemic settings. Lancet Infect Dis 19(3):e77&#x2013;88</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(18)30537-1</ArticleId><ArticleId IdType="pubmed">30554996</ArticleId></ArticleIdList></Reference><Reference><Citation>Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M et al (2017) The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 5(4):291&#x2013;360</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(17)30079-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson SC, White NW, Aronson I, Woollgar R, Goodman H, Jacobs P (1996) Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br J Haematol 93(4):943&#x2013;949</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.1996.d01-1722.x</ArticleId><ArticleId IdType="pubmed">8703831</ArticleId></ArticleIdList></Reference><Reference><Citation>Turken O, Kunter E, Sezer M, Solmazgul E, Cerrahoglu K, Bozkanat E et al (2002) Hemostatic changes in active pulmonary tuberculosis. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis 6(10):927&#x2013;932</Citation></Reference><Reference><Citation>Lang IM, Mackman N, Kriett JM, Moser KM, Schleef RR (1996) Prothrombotic activation of pulmonary arterial endothelial cells in a patient with tuberculosis. Hum Pathol 27(4):423&#x2013;427</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0046-8177(96)90118-5</ArticleId><ArticleId IdType="pubmed">8617488</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben Amar J, Dahri B, Aouina H, Bouacha H (2015) Venous thromboembolism in patients with acute tuberculosis. Rev Pneumol Clin 71(6):327&#x2013;334</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneumo.2015.04.004</ArticleId><ArticleId IdType="pubmed">26190336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouismi H, Laine M, Bourkadi J-E, Iraqi G (2013) Association of deep venous thrombosis with pulmonary tuberculosis. Egypt J Chest Dis Tuberc 62(3):541&#x2013;543</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejcdt.2013.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008&#x2013;2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.283.15.2008</ArticleId><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Awana PA, Danwang C, Tochie JN, Bigna JJ (2019) Epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis protocol. BMJ Open 9(11):e031402</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-031402</ArticleId><ArticleId IdType="pubmed">31722945</ArticleId><ArticleId IdType="pmc">6858194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C et al (2012) Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 65(9):934&#x2013;939</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2011.11.014</ArticleId><ArticleId IdType="pubmed">22742910</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N (2015) Meta-analysis in clinical trials revisited. Contemp Clin Trials 45(Pt A):139&#x2013;145</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2015.09.002</ArticleId><ArticleId IdType="pubmed">26343745</ArticleId><ArticleId IdType="pmc">4639420</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller JJ (1978) The inverse of the Freeman&#x2013;Tukey double arcsine transformation. Am Stat 32(4):138&#x2013;138</Citation></Reference><Reference><Citation>Cochran: The combination of estimates from different&#x2014;google scholar. https://scholar.google.com/scholar_lookup?hl=en&amp;volume=10&amp;publication_year=1954&amp;pages=101-129&amp;journal=Biometrics&amp;author=GW+Cochran.&amp;title=The+combination+of+estimates+from+different+experiments . Accessed 24 Aug 2018</Citation></Reference><Reference><Citation>Huedo-Medina TB, S&#xe1;nchez-Meca J, Mar&#xed;n-Mart&#xed;nez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11(2):193&#x2013;206</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/1082-989X.11.2.193</ArticleId><ArticleId IdType="pubmed">16784338</ArticleId></ArticleIdList></Reference><Reference><Citation>Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37(5):360&#x2013;363</Citation><ArticleIdList><ArticleId IdType="pubmed">15883903</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629&#x2013;634</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId><ArticleId IdType="pmc">2127453</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromboses in tuberculosis are linked to antiphosphatidylethanolamine antibodies levels: a cross-sectional study&#x2014;ScienceDirect. https://www.sciencedirect.com/science/article/pii/S2405579418300913 . Accessed 3 Oct 2019</Citation></Reference><Reference><Citation>Borjas-Howard JF, Bierman WFW, Meijer K, van der Werf TS, Tichelaar YIGV (2017) Venous thrombotic events in patients admitted to a tuberculosis centre. QJM Mon J Assoc Physicians 110(4):215&#x2013;218</Citation></Reference><Reference><Citation>Dentan C, Epaulard O, Seynaeve D, Genty C, Bosson J-L (2014) Active tuberculosis and venous thromboembolism: association according to international classification of diseases, ninth revision hospital discharge diagnosis codes. Clin Infect Dis Off Publ Infect Dis Soc Am 58(4):495&#x2013;501</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cit780</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjani M, Tabarsi P, Baghaei P, Shamaei M, Biani PG, Mansouri D et al (2012) Incidence of thromboembolism in hospitalized patients with tuberculosis and associated risk factors. Arch Clin Infect Dis 7:56</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/archcid.13950</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SY, Lee SM, Shin JW, Choi BW, Kim H, Lee JS et al (2016) Epidemiology of chronic thromboembolic pulmonary hypertension in Korea: results from the Korean registry. Korean J Intern Med 31(2):305&#x2013;312</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2014.122</ArticleId><ArticleId IdType="pubmed">26689916</ArticleId><ArticleId IdType="pmc">4773708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramlakhan R, Andronikou S, Rajkumar A (2017) The prevalence and radiological findings of pulmonary embolism in HIV-positive patients referred for computed tomography pulmonary angiography in the Western Cape of South Africa. Cardiovasc J Afr 28(4):221&#x2013;228</Citation><ArticleIdList><ArticleId IdType="doi">10.5830/CVJA-2016-083</ArticleId><ArticleId IdType="pubmed">28218770</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaarawy H, Mohamed EE-S (2018) Assessment of the prevalence of pulmonary embolism in patients with severe pulmonary tuberculosis. Egypt J Chest Dis Tuberc 67(1):62</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ejcdt.ejcdt_12_17</ArticleId></ArticleIdList></Reference><Reference><Citation>Shitrit D, Fox L, Preiss R, Raz M, Mtvitzuk A (2012) Incidence of venous thromboembolism in 700 patients with acute tuberculosis. Harefuah 151(4):208&#x2013;210</Citation><ArticleIdList><ArticleId IdType="pubmed">22616147</ArticleId></ArticleIdList></Reference><Reference><Citation>White N (1989) Venous thrombosis and rifampicin. The Lancet 334(8660):434&#x2013;435</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(89)90603-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendelboe AM, Raskob GE (2016) Global burden of thrombosis. Circ Res 118(9):1340&#x2013;1347</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.115.306841</ArticleId><ArticleId IdType="pubmed">27126645</ArticleId></ArticleIdList></Reference><Reference><Citation>ISCfWT D (2014) Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 12(10):1580&#x2013;1590</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12698</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev Cardiol 12(8):464&#x2013;474</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2015.83</ArticleId><ArticleId IdType="pubmed">26076949</ArticleId><ArticleId IdType="pmc">4624298</ArticleId></ArticleIdList></Reference><Reference><Citation>Danwang C, Temgoua MN, Agbor VN, Tankeu AT, Noubiap JJ (2017) Epidemiology of venous thromboembolism in Africa: a systematic review. J Thromb Haemost JTH 15(9):1770&#x2013;1781</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13769</ArticleId><ArticleId IdType="pubmed">28796427</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyrle PA, Eichinger S (2005) Deep vein thrombosis. Lancet Lond Engl 365(9465):1163&#x2013;1174</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(05)71880-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagot CN, Arya R (2008) Virchow and his triad: a question of attribution. Br J Haematol 143(2):180&#x2013;190</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2008.07323.x</ArticleId><ArticleId IdType="pubmed">18783400</ArticleId></ArticleIdList></Reference><Reference><Citation>CV Physiology|Factors Promoting Venous Return. https://www.cvphysiology.com/Cardiac%2520Function/CF018 . Accessed 6 Nov 2019</Citation></Reference><Reference><Citation>Silverstein MD, Heit JA, Mohr DN, Petterson TM, O&#x2019;Fallon WM, Melton LJ (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158(6):585&#x2013;593</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.158.6.585</ArticleId><ArticleId IdType="pubmed">9521222</ArticleId></ArticleIdList></Reference><Reference><Citation>Oger E (2000) Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study. Group Groupe d&#x2019;Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 83(5):657&#x2013;660</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1613887</ArticleId><ArticleId IdType="pubmed">10823257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarolo L, Milan M, Turatti G, Bilora F, Prandoni P (2016) Inter-observer variability of compression ultrasound for the assessment of residual vein thrombosis. Thromb Res 145:1&#x2013;2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2016.07.004</ArticleId><ArticleId IdType="pubmed">27421090</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamm M, Zavodni A, Mitchell L, Bonanni JR, Noga M (2014) Evaluation of the interpretation of serial ultrasound examinations in the diagnosis of deep venous thrombosis in children: a retrospective cohort study. Can Assoc Radiol J J Assoc Can Radiol 65(3):218&#x2013;224</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carj.2013.09.002</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37152363</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>Clinical profile and outcome of isolated pulmonary embolism: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>101973</StartPage><MedlinePgn>101973</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101973</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2023.101973</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Isolated pulmonary embolism (PE) appears to be associated with a specific clinical profile and sequelae compared to deep vein thrombosis (DVT)-associated PE. The objective of this study was to identify clinical characteristics that discriminate both phenotypes, and to characterize their differences in clinical outcome.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed a systematic review and meta-analysis of studies comparing PE phenotypes. A systematic search of the electronic databases PubMed and CENTRAL was conducted, from inception until January 27, 2023. Exclusion criteria were irrelevant content, inability to retrieve the article, language other than English or German, the article comprising a review or case study/series, and inappropriate study design. Data on risk factors, clinical characteristics and clinical endpoints were pooled using random-effects meta-analyses.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Fifty studies with 435,768&#xa0;PE patients were included. In low risk of bias studies, 30% [95% CI 19-42%, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;97%] of PE were isolated. The Factor V Leiden [OR: 0.47, 95% CI 0.37-0.58, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;0%] and prothrombin G20210A mutations [OR: 0.55, 95% CI 0.41-0.75, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;0%] were significantly less prevalent among patients with isolated PE. Female sex [OR: 1.30, 95% CI 1.17-1.45, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;79%], recent invasive surgery [OR: 1.31, 95% CI 1.23-1.41, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;65%], a history of myocardial infarction [OR: 2.07, 95% CI 1.85-2.32, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;0%], left-sided heart failure [OR: 1.70, 95% CI 1.37-2.10, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;76%], peripheral artery disease [OR: 1.36, 95% CI 1.31-1.42, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;0%] and diabetes mellitus [OR: 1.23, 95% CI 1.21-1.25, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;0%] were significantly more frequently represented among isolated PE patients. In a synthesis of clinical outcome data, the risk of recurrent VTE in isolated PE was half that of DVT-associated PE [RR: 0.55, 95% CI 0.44-0.69, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;0%], while the risk of arterial thrombosis was nearly 3-fold higher [RR: 2.93, 95% CI 1.43-6.02, <i>I</i> <sup>2</sup>&#xa0;=&#xa0;0%].</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Our findings suggest that isolated PE appears to be a specific entity that may signal a long-term risk of arterial thrombosis. Randomised controlled trials are necessary to establish whether alternative treatment regimens are beneficial for this patient subgroup.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">None.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ten Cate</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prochaska</LastName><ForeName>J&#xfc;rgen H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagler</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robles</LastName><ForeName>Alejandro Pallares</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jurk</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koeck</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rapp</LastName><ForeName>Steffen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;ber</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;nzel</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology - Cardiology I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konstantinides</LastName><ForeName>Stavros V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Democritus University of Thrace, University General Hospital, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wild</LastName><ForeName>Philipp S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site Rhine Main, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular Biology (IMB), Mainz, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>None of the authors declare competing interests relevant to the subject matter of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37152363</ArticleId><ArticleId IdType="pmc">PMC10154961</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2023.101973</ArticleId><ArticleId IdType="pii">S2589-5370(23)00150-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bounameaux H., Rosendaal F.R. Venous thromboembolism: why does ethnicity matter? Circulation. 2011;123(20):2189&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pubmed">21555708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet (London, England) 2000;356(9225):182&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">10963193</ArticleId></ArticleIdList></Reference><Reference><Citation>Prandoni P., Pesavento R., Sorensen H.T., et al. Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey. Eur J Intern Med. 2009;20(5):470&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">19712846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen H.T., Horvath-Puho E., Lash T.L., et al. Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation. 2011;124(13):1435&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900083</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller K., Hobohm L., Munzel T., Ostad M.A. Impact of concomitant deep or superficial venous thrombosis of the legs on survival of patients with pulmonary embolism. Int J Cardiol. 2020;315:92&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">32445886</ArticleId></ArticleIdList></Reference><Reference><Citation>Palareti G., Antonucci E., Dentali F., et al. Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution. Eur J Intern Med. 2019;69:64&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">31500936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten Cate V., Eggebrecht L., Schulz A., et al. Isolated pulmonary embolism is associated with a high risk of arterial thrombotic disease: results from the VTEval study. Chest. 2020;158(1):341&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">32217063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ten Cate V., Prochaska J.H., Schulz A., et al. Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism. Blood. 2021;137(19):2681&#x2013;2693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9635523</ArticleId><ArticleId IdType="pubmed">33529319</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F., Rahman A., Carrier M., et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019;366:l4363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6651066</ArticleId><ArticleId IdType="pubmed">31340984</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace B.C., Small K., Brodley C.E., Lau J., Trikalinos T.A. Proceedings of the 2nd ACM SIGHIT international health informatics symposium; 2012. 2012. Deploying an interactive machine learning system in an evidence-based practice center: abstrackr; pp. 819&#x2013;824.</Citation></Reference><Reference><Citation>Program N.T. OHAT risk of bias rating tool for human animal studies. 2014. https://ntp.niehs.nih.gov/ntp/ohat/pubs/riskofbiastool_508.pdf Accessed March 2021.</Citation></Reference><Reference><Citation>Whiting P.F., Rutjes A.W., Westwood M.E., et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">22007046</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath S., Zhao X., Steele R., Thombs B.D., Benedetti A. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Stat Methods Med Res. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390706</ArticleId><ArticleId IdType="pubmed">32292115</ArticleId></ArticleIdList></Reference><Reference><Citation>IntHout J., Ioannidis J.P., Borm G.F. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14(1):1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4015721</ArticleId><ArticleId IdType="pubmed">24548571</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting meta-analyses in R with the metafor package. J&#xa0;Stat Software. 2010;36(3):1&#x2013;48.</Citation></Reference><Reference><Citation>Al Sayegh F., Almahmeed W., Al Humood S., et al. Global risk profile verification in patients with venous thromboembolism (GRIP VTE) in 5 Gulf countries. Clin Appl Thromb Hemost. 2008;15(3):289&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400764</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambron J.C., Saba E.S., McBane R.D., et al. Adverse events and mortality in anticoagulated patients with different categories of pulmonary embolism. Mayo Clin Proc Innov Qual Outcomes. 2020;4(3):249&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283932</ArticleId><ArticleId IdType="pubmed">32542216</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordeanu E.M., Lambach H., Heitz M., et al. Pulmonary embolism and coexisting deep vein thrombosis: a detrimental association? J&#xa0;Clin Med. 2019;8(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6617259</ArticleId><ArticleId IdType="pubmed">31234594</ArticleId></ArticleIdList></Reference><Reference><Citation>De Moerloose P., Reber G., Perrier A., Perneger T., Bounameaux H. Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism. Br J Haematol. 2000;110(1):125&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">10930988</ArticleId></ArticleIdList></Reference><Reference><Citation>Douek P., Rotzinger D.C., Meuli R.A., Dunet V., Schmidt S. Impact of CT venography added to CT pulmonary angiography for the detection of deep venous thrombosis and relevant incidental CT findings. Eur J Radiol. 2020;133</Citation><ArticleIdList><ArticleId IdType="pubmed">33197747</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkekol F., Ulu A., Numanoglu N., Akar N. High plasma levels of factor VIII: an important risk factor for isolated pulmonary embolism. Respirology. 2006;11(1):70&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16423204</ArticleId></ArticleIdList></Reference><Reference><Citation>Girard P., Musset D., Parent F., Maitre S., Phlippoteau C., Simonneau G. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest. 1999;116(4):903&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531151</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni E., Marcucci R., Ciuti G., et al. The thrombophilic pattern of different clinical manifestations of venous thromboembolism: a survey of 443 cases of venous thromboembolism. Semin Thromb Hemost. 2012;38(2):230&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">22422337</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirmerova J., Seidlerova J., Subrt I. The association of factor V Leiden with various clinical patterns of venous thromboembolism-the factor V Leiden paradox. QJM. 2014;107(9):715&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pubmed">24633260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirmerova J., Seidlerova J., Chudacek Z. The prevalence of concomitant deep vein thrombosis, symptomatic or asymptomatic, proximal or distal, in patients with symptomatic pulmonary embolism. Clin Appl Thromb Hemost. 2018;24(8):1352&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6714772</ArticleId><ArticleId IdType="pubmed">29848045</ArticleId></ArticleIdList></Reference><Reference><Citation>Imberti D., Barillari G., eXperience V.T.E.I.G. Real-life management of venous thromboembolism with rivaroxaban: results from EXperience VTE, an Italian epidemiological survey. Clin Appl Thromb Hemost. 2018;24(2):241&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6714675</ArticleId><ArticleId IdType="pubmed">28718296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov P., Komsa-Penkova R., Kovacheva K., et al. Impact of thrombophilic genetic factors on pulmonary embolism: early onset and recurrent incidences. Lung. 2008;186(1):27&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097719</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez D., Aujesky D., Diaz G., et al. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med. 2010;181(9):983&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">20110556</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.C., Brown M.D., McCullough N., Smith S. CT lower extremity venography in suspected pulmonary embolism in the ED. Emerg Radiol. 2006;12(4):160&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">16528492</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun Z.J., Ping T., Lei Y., Li L., Ming S.Y., Jing W. Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism. Clin Lab Haematol. 2006;28(2):111&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">16630215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalva S.P., Jagannathan J.P., Hahn P.F., Wicky S.T. Venous thromboembolism: indirect CT venography during CT pulmonary angiography -- should the pelvis be imaged? Radiology. 2008;246(2):605&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">18227548</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamerkar D.R., John M.J., Desai S.C., Dsilva L.C., Joglekar S.J. Arrive: a retrospective registry of Indian patients with venous thromboembolism. Indian J Crit Care Med. 2016;20(3):150&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810892</ArticleId><ArticleId IdType="pubmed">27076726</ArticleId></ArticleIdList></Reference><Reference><Citation>Karimi A., Abolhasani M., Hashemzadeh-Chaleshtori M., Pourgheysari B. A&#xa0;preliminary study of inherited thrombophilic risk factors in different clinical manifestations of venous thromboembolism in central Iran. Indian J Med Res. 2015;142(1):46&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4557250</ArticleId><ArticleId IdType="pubmed">26261166</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller K., Prochaska J.H., Coldewey M., et al. History of deep vein thrombosis is a discriminator for concomitant atrial fibrillation in pulmonary embolism. Thromb Res. 2015;136(5):899&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">26376038</ArticleId></ArticleIdList></Reference><Reference><Citation>Kluge A., Mueller C., Strunk J., Lange U., Bachmann G. Experience in 207 combined MRI examinations for acute pulmonary embolism and deep vein thrombosis. AJR Am J Roentgenol. 2006;186(6):1686&#x2013;1696.</Citation><ArticleIdList><ArticleId IdType="pubmed">16714660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroger K., Moerchel C., Bus C., Serban M. Venous thromboembolism in Germany: results of the German VTE registry (GATE-registry) Int J Clin Pract. 2014;68(12):1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">25333964</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.S., Moon T., Kim T.H., et al. Deep vein thrombosis in patients with pulmonary embolism: prevalance, clinical significance and outcome. Vasc Specialist Int. 2016;32(4):166&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5198763</ArticleId><ArticleId IdType="pubmed">28042556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucena J., Rico A., Vazquez R., et al. Pulmonary embolism and sudden-unexpected death: prospective study on 2477 forensic autopsies performed at the Institute of Legal Medicine in Seville. J&#xa0;Forensic Leg Med. 2009;16(4):196&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">19329075</ArticleId></ArticleIdList></Reference><Reference><Citation>Margaglione M., Brancaccio V., De Lucia D., et al. Inherited thrombophilic risk factors and venous thromboembolism: distinct role in peripheral deep venous thrombosis and pulmonary embolism. Chest. 2000;118(5):1405&#x2013;1411.</Citation><ArticleIdList><ArticleId IdType="pubmed">11083693</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer G., Emmerich J., Helley D., et al. Factors V Leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis. Am J Med. 2001;110(1):12&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11152859</ArticleId></ArticleIdList></Reference><Reference><Citation>Monreal M., Barba R., Tolosa C., Tiberio G., Todol&#xed; J., Samperiz A.L. Deep vein thrombosis and pulmonary embolism: the same disease? Pathophysiol Haemostasis Thrombosis. 2006;35(1&#x2013;2):133&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">16855358</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiwaki S., Morita Y., Yamashita Y., et al. Impact of no, distal, and proximal deep vein thrombosis on clinical outcomes in patients with acute pulmonary embolism: from the COMMAND VTE registry. J&#xa0;Cardiol. 2021;77(4):395&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">33218901</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumus G., Kiyan E., Arseven O., et al. Hereditary thrombophilic risk factors and venous thromboembolism in Istanbul, Turkey: the role in different clinical manifestations of venous thromboembolism. Clin Appl Thromb Hemost. 2008;14(2):168&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">17895505</ArticleId></ArticleIdList></Reference><Reference><Citation>Ord&#xf3;&#xf1;ez A.G., Carreira J.F., Alvarez C.F., Rodriguez J.M., Alvarez M.V., Coto E. Comparison of the risk of pulmonary embolism and deep vein thrombosis in the presence of factor V Leiden or prothrombin G20210A. Thromb Haemost. 2000;83(2):352&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">10739402</ArticleId></ArticleIdList></Reference><Reference><Citation>Pribish A.M., Beyer S.E., Krawisz A.K., Weinberg I., Carroll B.J., Secemsky E.A. Sex differences in presentation, management, and outcomes among patients hospitalized with acute pulmonary embolism. Vasc Med. 2020;25(6):541&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8076890</ArticleId><ArticleId IdType="pubmed">33203347</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuma M., Nakamura M., Yamada N., et al. Venous thromboembolism, deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J. 2009;73:305&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">19096193</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheres L.J.J., Brekelmans M.P.A., Beenen L.F.M., Buller H.R., Cannegieter S.C., Middeldorp S. Sex-specific differences in the presenting location of a first venous thromboembolism. J&#xa0;Thromb Haemost. 2017;15(7):1344&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">28440013</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz T., Hingorani A., Ascher E., et al. Pulmonary embolism without deep venous thrombosis. Ann Vasc Surg. 2012;26(7):973&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749324</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevestre M.A., Quashie C., Genty C., et al. Clinical presentation and mortality in pulmonary embolism: the Optimev study. J&#xa0;Mal Vasc. 2010;35(4):242&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">20598461</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivananthan G., Halin N.J., Estes J.M., Alessi-Chinetti J.M., Polak J.F. Value of complete full-length lower extremity sonography in patients undergoing computed tomographic pulmonary angiography. J&#xa0;Ultrasound Med. 2014;33(12):2137&#x2013;2143.</Citation><ArticleIdList><ArticleId IdType="pubmed">25425370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadlock M.D., Chouliaras K., Kennedy M., et al. The origin of fatal pulmonary emboli: a postmortem analysis of 500 deaths from pulmonary embolism in trauma, surgical, and medical patients. Am J Surg. 2015;209(6):959&#x2013;968.</Citation><ArticleIdList><ArticleId IdType="pubmed">25669120</ArticleId></ArticleIdList></Reference><Reference><Citation>van Stralen K.J., Doggen C.J., Bezemer I.D., Pomp E.R., Lisman T., Rosendaal F.R. Mechanisms of the factor V leiden paradox. Arterioscler Thromb Vasc Biol. 2008;28(10):1872&#x2013;1877.</Citation><ArticleIdList><ArticleId IdType="pubmed">18617648</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X.H., Cui L.B., Liu Y., et al. Association between risk stratification for pulmonary embolism and deep vein thrombosis of lower extremities. Clin Res J. 2020;14(7):631&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">32125778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wildberger J.E., Mahnken A.H., Stargardt A., et al. A&#xa0;differentiated approach to the diagnosis of pulmonary embolism and deep venous thrombosis using multi-slice CT; Abklaerung von Lungenembolie und venoeser Thromboembolie mittels Mehrschicht-Spiral CT. RoeFo-Fortschritte auf dem Gebiete der Roentgenstrahlen und der Neuen Bildgebenden Verfahren. 2002;174:301&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">11885007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasui T., Tanabe N., Terada J., et al. Multidetector-row computed tomography management of acute pulmonary embolism. Circ J. 2007;71(12):1948&#x2013;1954.</Citation><ArticleIdList><ArticleId IdType="pubmed">18037752</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber S.Z., Ageno W., Casella I.B., et al. Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. J&#xa0;Thromb Thrombolysis. 2022;53(2):399&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">34453675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders A., El-Bouri W.K., Lip G.Y.H. The Birmingham and Black Country cohort of venous thromboembolism (BBC-VTE) registry: rationale, design and preliminary results. Eur J Intern Med. 2022;97:50&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">35078696</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Kapoor S., Singh B., et al. Real world data on clinical profile, management and outcomes of venous thromboembolism from a tertiary care centre in India. Indian Heart J. 2021;73(3):336&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8322750</ArticleId><ArticleId IdType="pubmed">34154752</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.H., Cha S.I., Shin K.M., et al. Clinical characteristics and outcomes of patients with isolated pulmonary embolism. Blood Coagul Fibrinolysis. 2021;32(6):387&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010169</ArticleId></ArticleIdList></Reference><Reference><Citation>Klarin D., Busenkell E., Judy R., et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet. 2019;51(11):1574&#x2013;1579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858581</ArticleId><ArticleId IdType="pubmed">31676865</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A., Vecchi&#xe9; A., Dagna L., et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021;21(5):319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023349</ArticleId><ArticleId IdType="pubmed">33824483</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosovsky R., Zhao K., Sista A., Rivera-Lebron B., Kabrhel C. Pulmonary embolism response teams: purpose, evidence for efficacy, and future research directions. Res Pract Thromb Haemost. 2019;3(3):315&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6611377</ArticleId><ArticleId IdType="pubmed">31294318</ArticleId></ArticleIdList></Reference><Reference><Citation>Porres-Aguilar M., Jim&#xe9;nez D., Porres-Mu&#xf1;oz M., Mukherjee D. Pulmonary embolism response teams: purpose, evidence for efficacy, and future research directions. Res Pract Thromb Haemost. 2019;3(4):769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6781912</ArticleId><ArticleId IdType="pubmed">31624797</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes G.D. Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematol Am Soc Hematol Edu Prog. 2020;2020(1):642&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727581</ArticleId><ArticleId IdType="pubmed">33275740</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes K.M., Turner R.M., Higgins J.P. Empirical evidence about inconsistency among studies in a pair-wise meta-analysis. Res Synth Methods. 2016;7(4):346&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5217093</ArticleId><ArticleId IdType="pubmed">26679486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37226426</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-1489</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of intensive care medicine</Title><ISOAbbreviation>J Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Use of Perioperative Extracorporeal Membranous Oxygenation in Pulmonary Endarterectomy Cases: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>785</StartPage><EndPage>796</EndPage><MedlinePgn>785-796</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/08850666231178262</ELocationID><Abstract><AbstractText><b>Introduction:</b> Pulmonary endarterectomy (PEA) is known to be a curative intervention for chronic thromboembolic pulmonary hypertension (CTEPH). Its complications include endobronchial bleeding, persistent pulmonary arterial hypertension, right ventricular failure, and reperfusion lung injury. Extracorporeal membranous oxygenation (ECMO) is a perioperative salvage method for PEA. Although risk factors and outcomes have been reported in several studies, overall trends remain unknown. We performed a systematic review and study-level meta-analysis to understand the outcomes of ECMO utilization in the perioperative period of PEA. <b>Methods:</b> We performed a literature search with PubMed and EMBASE on 11/18/2022. We included studies including patients who underwent perioperative ECMO in PEA. We collected data including baseline demographics, hemodynamic measurements, and outcomes such as mortality and weaning of ECMO and performed a study-level meta-analysis. <b>Results:</b> Eleven studies with 2632 patients were included in our review. ECMO insertion rate was 8.7% (225/2,625, 95% CI 5.9-12.5) in total, VV-ECMO was performed as the initial intervention in 1.1% (41/2,625, 95% CI 0.4-1.7) (Figure 3), and VA-ECMO was performed as an initial intervention in 7.1% (184/2,625, 95% CI 4.7-9.9). Preoperative hemodynamic measurements showed higher pulmonary vascular resistance, mean pulmonary arterial pressure, and lower cardiac output in the ECMO group. Mortality rates were 2.8% (32/1238, 95% CI: 1.7-4.5) in the non-ECMO group and 43.5% (115/225, 95% CI: 30.8-56.2) in the ECMO group. The proportion of patients with successful weaning of ECMO was 72.6% (111/188, 95% CI: 53.4-91.7). Regarding complications of ECMO, the incidence of bleeding and multi-organ failure were 12.2% (16/79, 95% CI: 13.0-34.8) and 16.5% (15/99, 95% CI: 9.1-28.1), respectively. <b>Conclusion:</b> Our systematic review showed a higher baseline cardiopulmonary risk in patients with perioperative ECMO in PEA, and its insertion rate was 8.7%. Further studies that compare the use of ECMO in high-risk patients who undergo PEA are anticipated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishisaka</LastName><ForeName>Yoshiko</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4937-5260</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth, Israel.</Affiliation><Identifier Source="RINGGOLD">22524</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Atsuyuki</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8781-0329</Identifier><AffiliationInfo><Affiliation>Division of Hospital Medicine, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan.</Affiliation><Identifier Source="RINGGOLD">68320</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Hisato</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.</Affiliation><Identifier Source="RINGGOLD">26357</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takayama</LastName><ForeName>Hiroo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation><Identifier Source="RINGGOLD">21611</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiley</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Section of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA.</Affiliation><Identifier Source="RINGGOLD">12255</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuno</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-2487-8366</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.</Affiliation><Identifier Source="RINGGOLD">2013</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Intensive Care Med</MedlineTA><NlmUniqueID>8610344</NlmUniqueID><ISSNLinking>0885-0666</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004691" MajorTopicYN="N">Endarterectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic thromboembolic pulmonary hypertension</Keyword><Keyword MajorTopicYN="N">extracorporeal membranous oxygenation</Keyword><Keyword MajorTopicYN="N">pulmonary endarterectomy</Keyword><Keyword MajorTopicYN="N">pulmonary hypertension</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>25</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37226426</ArticleId><ArticleId IdType="doi">10.1177/08850666231178262</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30699447</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2567-689X</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Thrombosis and haemostasis</Title><ISOAbbreviation>Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>668</StartPage><EndPage>674</EndPage><MedlinePgn>668-674</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0039-1677732</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">&#x2003;Systematic reviews reporting time trends in mortality following major orthopaedic surgery are few and have limitations. They reported on only a fraction (&lt; 15%) of the available data and did not investigate potential causes of the reduction in mortality.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">&#x2003;We searched PubMed for randomized trials and observational studies, published between 1950 and 2016, reporting on mortality within 3 months of elective total hip and knee replacement (THR/TKR). Mortality risks were estimated for each 5-year interval using a Poisson regression model and presented by study design and mode of prophylaxis. To estimate the mortality reduction unrelated to anti-thrombotic use, we performed a pooled analysis of four thromboprophylaxis strategies for which data spanned five decades.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">&#x2003;We identified 255 eligible studies, which documented 31,604 deaths among 6,293,954 patients, and found a consistent decline in mortality irrespective of study design and mode of prophylaxis. Mortality declined from 1.15% pre-1980 to 0.24% post-2000, a 78.7% relative risk reduction (95% confidence interval [CI]: 74.7-82.1%) in randomized and cohort studies. Furthermore, our data showed a 74.4% (95% CI: 68.7-79.0%) relative reduction in mortality independent of the methods of prophylaxis, thereby indicating that improvements in peri-operative care unrelated to anti-thrombotic prophylaxis played a major role in such reduction.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">&#x2003;Mortality following elective THR/TKR has markedly declined over the past 50 years and is now low irrespective of which prophylactic agent is being used. Although anti-thrombotic prophylaxis may have contributed, other improvements in peri-operative care played a major role in the mortality reduction.</AbstractText><CopyrightInformation>Georg Thieme Verlag KG Stuttgart &#xb7; New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Noel C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Quazi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kruger</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Smita</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhagirath</LastName><ForeName>Vinai</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bangdiwala</LastName><ForeName>Shrikant</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guyatt</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eikelboom</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirsh</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Thromb Haemost</MedlineTA><NlmUniqueID>7608063</NlmUniqueID><ISSNLinking>0340-6245</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="N">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019637" MajorTopicYN="N">Orthopedic Procedures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059035" MajorTopicYN="N">Perioperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016012" MajorTopicYN="N">Poisson Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30699447</ArticleId><ArticleId IdType="doi">10.1055/s-0039-1677732</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25010753</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1541-2563</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>COPD</Title><ISOAbbreviation>COPD</ISOAbbreviation></Journal><ArticleTitle>Pulmonary embolism in chronic obstructive pulmonary disease: a population-based cohort study.</ArticleTitle><Pagination><StartPage>438</StartPage><EndPage>443</EndPage><MedlinePgn>438-43</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/15412555.2013.813927</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To evaluate the incidence of pulmonary embolism (PE) in patients with chronic obstructive pulmonary disease (COPD) in Taiwan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a retrospective population-based cohort study using data retrieved from Taiwan's National Health Insurance Research Database (2000 to 2008), which contains 99% of Taiwanese healthcare data. The evaluations included 355,878 COPD patients and 355,878 non-COPD patients for comparison.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence of PE in the COPD cohort was 12.31 per 10,000 person-years (1.37/10,000 persons/y), which was approximately 4-times higher than in the comparison cohort (0.35/10,000 persons/y). In the COPD cohort, risk of PE was higher in the young age group (20-59 y, HR 4.64, 95% CI 3.06-7.03) than in other age groups. Risk of PE was higher in patients with COPD combined with hypertension, coronary artery disease, and cancer, or those with previous operation (HR 4.16, 4.75, 4.56, and 4.50 respectively) than in those with COPD and no comorbidity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The overall incidence of PE is lower in Taiwan than in western countries. However, the prevalence of PE in COPD patients is higher than in non-COPD patients and increases with age. It is crucial to incorporate PE into the differential diagnosis of COPD exacerbation for clinical physicians.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei-Ji</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>1From the Chest Division, Department of Internal Medicine, Mackay Memorial Hospital , Taipei , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Che-Chen</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chang-Yi</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yen-Jung</ForeName><Initials>YJ</Initials></Author><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Fung-Chang</ForeName><Initials>FC</Initials></Author><Author ValidYN="Y"><LastName>Kao</LastName><ForeName>Chia-Hung</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Jun-Jun</ForeName><Initials>JJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>COPD</MedlineTA><NlmUniqueID>101211769</NlmUniqueID><ISSNLinking>1541-2563</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="N">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029424" MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013514" MajorTopicYN="N">Surgical Procedures, Operative</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic obstructive pulmonary disease</Keyword><Keyword MajorTopicYN="N">cohort study</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25010753</ArticleId><ArticleId IdType="doi">10.3109/15412555.2013.813927</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31097186</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-2165</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</Title><ISOAbbreviation>Eur J Vasc Endovasc Surg</ISOAbbreviation></Journal><ArticleTitle>Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.</ArticleTitle><Pagination><StartPage>685</StartPage><EndPage>701</EndPage><MedlinePgn>685-701</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejvs.2018.11.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1078-5884(18)30850-5</ELocationID><Abstract><AbstractText Label="OBJECTIVE/BACKGROUND" NlmCategory="OBJECTIVE">The aim was to review the relative efficacy and safety of anticoagulation for managing venous thromboembolism (VTE) in patients with cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review and meta-analysis was carried out. On 17 May 2018 the MEDLINE and Scopus databases were searched for randomised controlled trials (RCTs). Eligible RCTs had to be performed in patients with cancer exclusively or to report results on a subset of patients with cancer. The main study outcomes (efficacy/recurrent VTE and safety/bleeding events) were expressed as risk ratios (RR) with a 95% confidence interval (CI). The quality of evidence was assessed following the GRADE method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-three RCTs with 6980 patients were identified. Low molecular weight heparins (LMWHs) were more effective than vitamin K antagonists (VKAs) in preventing recurrent VTE (RR 0.58, 95% CI 0.45-0.75) and deep vein thrombosis (RR 0.44, 95% CI 0.29-0.69) but not pulmonary embolism (PE), bleeding, or overall mortality. Direct oral anticoagulants (DOACs) were more effective than VKAs in preventing recurrent VTE (RR 0.65, 95% CI 0.45-0.95) but not DVT, PE, overall mortality, or bleeding. However, anti-Xa DOACs were more effective (RR for VTE 0.64, 95% CI 0.42-0.97) and caused less bleeding than VKAs, although major bleeding was reduced only with DOACs not requiring initial parenteral anticoagulation (RR 0.45, 95% CI 0.21-0.97). In a direct comparison, DOACs were more effective than LMWHs in preventing VTE recurrence (RR 0.64, 95% CI 0.45-0.90) but caused more major bleeding (RR 1.75, 95% CI 1.10-2.77), with no difference in fatal bleeding and overall mortality. Quality of evidence, where sufficient, was mostly moderate or high.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Compared with VKAs, LMWHs and DOACs are more effective in treating VTE, but the former caused less bleeding. DOACs are more effective than LMWHs in preventing VTE recurrence but may carry a higher risk of major bleeding, pending additional information by ongoing trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kirkilesis</LastName><ForeName>George I</ForeName><Initials>GI</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakkos</LastName><ForeName>Stavros K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital of Patras, Patras, Greece. Electronic address: kakkos@upatras.gr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsolakis</LastName><ForeName>Ioannis A</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital of Patras, Patras, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Vasc Endovasc Surg</MedlineTA><NlmUniqueID>9512728</NlmUniqueID><ISSNLinking>1078-5884</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>J177FOW5JL</RegistryNumber><NameOfSubstance UI="D000077425">Fondaparinux</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>6ADD3H8MFZ</RegistryNumber><NameOfSubstance UI="C479958">idraparinux</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009844">Oligosaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>12001-79-5</RegistryNumber><NameOfSubstance UI="D014812">Vitamin K</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Eur J Vasc Endovasc Surg. 2019 Dec;58(6):943. doi: 10.1016/j.ejvs.2019.09.505.</RefSource><PMID Version="1">31594697</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077425" MajorTopicYN="N">Fondaparinux</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009844" MajorTopicYN="N">Oligosaccharides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014812" MajorTopicYN="N">Vitamin K</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anticoagulation</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31097186</ArticleId><ArticleId IdType="doi">10.1016/j.ejvs.2018.11.004</ArticleId><ArticleId IdType="pii">S1078-5884(18)30850-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34916036</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Injury</Title><ISOAbbreviation>Injury</ISOAbbreviation></Journal><ArticleTitle>Equivalence of DOACS and LMWH for thromboprophylaxis after hip fracture surgery: Systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1169</StartPage><EndPage>1176</EndPage><MedlinePgn>1169-1176</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.injury.2021.11.052</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0020-1383(21)00973-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with hip fractures (HF) have an increased risk of venous thromboembolism (VTE). In elective orthopedic surgery direct oral anticoagulants (DOACs) have proven to be similarly or more effective compared to low molecular weight heparin (LMWH), but DOACs are not yet approved for thromboprophylaxis in trauma patients with HF. The aim of this study was to systematically review the literature comparing the effectiveness of DOACs and LMWH for thromboprophylaxis in trauma patients with surgically treated HF.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We searched PubMed, the Cochrane Library, Web of Science, and Embase. The primary outcome was the incidence of VTE (symptomatic and asymptomatic combined). Secondary outcomes were symptomatic VTE; a symptomatic VTE, symptomatic deep venous thrombosis (DVT); symptomatic pulmonary embolism (PE); major, clinically relevant non-major (CRNM), and minor bleeding. Meta-analysis was performed to compare the odds of VTE and secondary outcomes between DOACs and LMWH.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The search resulted in 738 titles. Five studies matched inclusion criteria. In total, 4748 hip fracture patients were analyzed (DOACs: 2276 patients, LMWH: 2472 patients). The pooled odds ratio for the risk of VTE for DOAC use was 0.52 (95% confidence interval 0.25-1.11, p&#xa0;=&#xa0;0.09) compared to LMWH. No statistically significant differences between DOAC and LMWH were found for asymptomatic VTE, symptomatic DVT, PE, major or CRNM bleeding, and minor bleeding.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Meta-analysis of the literature suggests that DOACs are associated with equivalent effectiveness and safety compared to LMWH.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nederpelt</LastName><ForeName>Charlie J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Leiden University Medical Center, Leiden, the Netherlands; Division of Trauma, Emergency Surgery and Surgical Critical Care, Massachusetts General Hospital, Boston, MA, United States. Electronic address: c.j.nederpelt@lumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bijman</LastName><ForeName>Quinten</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krijnen</LastName><ForeName>Pieta</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schipper</LastName><ForeName>Inger B</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Leiden University Medical Center, Leiden, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Injury</MedlineTA><NlmUniqueID>0226040</NlmUniqueID><ISSNLinking>0020-1383</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Direct oral anticoagulant</Keyword><Keyword MajorTopicYN="N">Hip fracture surgery</Keyword><Keyword MajorTopicYN="N">Low molecular weight heparin</Keyword><Keyword MajorTopicYN="N">Thromboprophylaxis</Keyword><Keyword MajorTopicYN="N">Trauma</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>17</Day><Hour>5</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34916036</ArticleId><ArticleId IdType="doi">10.1016/j.injury.2021.11.052</ArticleId><ArticleId IdType="pii">S0020-1383(21)00973-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38290623</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-6280</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Current problems in cardiology</Title><ISOAbbreviation>Curr Probl Cardiol</ISOAbbreviation></Journal><ArticleTitle>A meta-analysis of outcomes of aspiration thrombectomy for high and intermediate-risk pulmonary embolism.</ArticleTitle><Pagination><StartPage>102420</StartPage><MedlinePgn>102420</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cpcardiol.2024.102420</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0146-2806(24)00059-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Aspiration thrombectomy has gained popularity in patients with massive and sub-massive pulmonary embolism (PE) and having contraindications to thrombolysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A meta-analysis was conducted including studies on aspiration thrombectomy in patients with high-risk and intermediate-risk PE. The pooled odds ratio for efficacy parameters, including change in heart rate, blood pressure and right ventricle/left ventricle (RV/LV) ratio, and safety parameters including major bleeding and stroke, was calculated using a random effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The meta-analysis of 24 selected studies revealed that intermediate and high-risk pulmonary embolism (PE) patients demonstrated significant improvements: modified Miller score odds ratio of 10.60, mean pulmonary artery pressure reduction by 0.04 mm Hg, and an overall all-cause mortality odds ratio of 0.10. Considerable heterogeneity was observed in various outcomes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Aspiration thrombectomy has success rates in both high-risk and intermediate-risk PE, however, procedural risks, including bleeding, must be anticipated.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khandait</LastName><ForeName>Harshwardhan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Trinitas Regional Medical Center/RWJ Barnabas Health, NJ, USA. Electronic address: harshkhandait1@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanif</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramadan</LastName><ForeName>Alaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, South Valley University, Qena, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attia</LastName><ForeName>Abdelrahman M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Cairo University, Cairo, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Endurance</LastName><ForeName>Evbayekha</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>St. Luke's Hospital, Chesterfield, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siddiq</LastName><ForeName>Abdelmonem</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Unzela</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Trinitas Regional Medical Center/RWJ Barnabas Health, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Icahn School of Medicine at Mount Sinai Elmhurst Hospital Center, Queens NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaudhuri</LastName><ForeName>Debanik</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Probl Cardiol</MedlineTA><NlmUniqueID>7701802</NlmUniqueID><ISSNLinking>0146-2806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017131" MajorTopicYN="N">Thrombectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006352" MajorTopicYN="N">Heart Ventricles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Aspiration thrombectomy</Keyword><Keyword MajorTopicYN="N">Thrombolysis</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>31</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>30</Day><Hour>19</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38290623</ArticleId><ArticleId IdType="doi">10.1016/j.cpcardiol.2024.102420</ArticleId><ArticleId IdType="pii">S0146-2806(24)00059-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35589498</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1479-666X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland</Title><ISOAbbreviation>Surgeon</ISOAbbreviation></Journal><ArticleTitle>Peri-procedural thromboprophylaxis in the prevention of DVT in varicose vein interventions: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e392</StartPage><EndPage>e404</EndPage><MedlinePgn>e392-e404</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.surge.2022.04.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1479-666X(22)00059-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">A systematic review and meta-analysis was performed to determine the role of thromboprophylaxis in the prevention of venous thromboembolism in patients undergoing varicose vein interventions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PUBMED, EMBASE and Web of Science were searched for comparative studies of patients undergoing varicose vein interventions and received either thromboprophylaxis or no thromboprophylaxis. Data were collected on the number of thrombotic events including deep vein thrombosis (DVT), pulmonary embolism (PE) and endothermal heat-induced thrombosis (EHIT) as well as bleeding events. The primary outcomes for the meta-analysis were the risk of all thrombotic events, risk of DVT and risk of bleeding. Pooled risk ratios were calculated using random effects modelling.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight studies (6479 participants) were included. The use of thromboprophylaxis reduces the risk of all thrombotic events (Pooled risk ratio&#xa0;=&#xa0;0.63, 95% Confidence interval [CI], 0.04-10.43) and the risk of DVT (Pooled risk ratio&#xa0;=&#xa0;0.59, 95% CI, 0.08-4.60) with no increased risk of bleeding (Pooled risk ratio&#xa0;=&#xa0;0.66, 95% CI, 0.06-7.21]. Rivaroxaban has similar efficacy in the prevention of DVT compared to Fondaparinux in patients undergoing endovenous ablation of varicose veins (Pooled risk ratio&#xa0;=&#xa0;0.68, 95% CI, 0.06-7.41). An extended course of thromboprophylaxis reduces the risk of developing DVT compared to a short course (Pooled risk ratio&#xa0;=&#xa0;1.40, 95% CI, 0.44-4.46). However, the two studies reporting on the duration of thromboprophylaxis did not stratify patients according to their risk of developing venous thromboembolism.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of thromboprophylaxis in patients undergoing varicose vein interventions reduces the risk of venous thromboembolism with no significant increase in the risk of bleeding. However, the included studies were underpowered with high to moderate risk of bias. Therefore, more randomised controlled trials with a large sample size are needed in order to provide high quality evidence for clinical practice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alameer</LastName><ForeName>Aqeel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Radiology, Ninewells Hospital and Medical School, Dundee, United Kingdom. Electronic address: aqeelalameer@rcsi.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aherne</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naughton</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aly</LastName><ForeName>Sayed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHugh</LastName><ForeName>Seamus</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moneley</LastName><ForeName>Daragh</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kheirelseid</LastName><ForeName>Elrasheid A H</ForeName><Initials>EAH</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Royal College of Surgeons in Ireland and Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>Surgeon</MedlineTA><NlmUniqueID>101168329</NlmUniqueID><ISSNLinking>1479-666X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9NDF7JZ4M3</RegistryNumber><NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014648" MajorTopicYN="Y">Varicose Veins</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DVT prevention</Keyword><Keyword MajorTopicYN="N">Endovenous ablation</Keyword><Keyword MajorTopicYN="N">Thromboprophylaxis</Keyword><Keyword MajorTopicYN="N">Varicose veins</Keyword><Keyword MajorTopicYN="N">Vascular surgery</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>19</Day><Hour>22</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35589498</ArticleId><ArticleId IdType="doi">10.1016/j.surge.2022.04.002</ArticleId><ArticleId IdType="pii">S1479-666X(22)00059-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26864215</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2318</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2016</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>BMC geriatrics</Title><ISOAbbreviation>BMC Geriatr</ISOAbbreviation></Journal><ArticleTitle>The effects of advanced age on primary total knee arthroplasty: a meta-analysis and systematic review.</ArticleTitle><Pagination><StartPage>41</StartPage><MedlinePgn>41</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">41</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12877-016-0215-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Total knee arthroplasty is an effective treatment when nonsurgical treatments fail, but it is associated with risk of complications which may be increased in advanced age. The purpose of this study was to quantify age-related differences in perioperative morbidity and mortality after total knee arthroplasty through systematic review of existing literature.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, the Cochrane database of systematic reviews, Scopus, and clinicaltrials.gov, were queried for relevant studies that compared primary total knee arthroplasty outcomes of mortality, myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE) and functional status, of geriatric patients (&gt;75&#xa0;years old) with a younger control group (&lt;65&#xa0;years old). Pertinent journals and reference lists were hand searched. Eligibility criteria included all articles except case reports, meta-analyses, and systematic reviews. Two authors independently extracted data from each paper. Article quality was assessed using the Newcastle-Ottawa Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-two studies were included. Geriatric patients had higher rates of mortality, MI, DVT, and length of stay in older compared to younger patients, however the absolute magnitude of these increases were small. The increase in mortality may have reflected decreased life expectancy in the geriatric populations as opposed to mortality specifically due perioperative risk. There were no differences in PE incidence and improvement in pain and functional status was equal in older and younger patients. Existing studies were limited by non-randomized patient selection, as well as variation in definitions and methodology.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Existing data supports offering primary total knee arthroplasty to select geriatric patients, although the risk of complications may be increased. Much of the data was of poor quality. Future prospective studies are needed to better identify risks and benefits of total knee arthroplasty so that patients and surgeons can make informed decisions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuperman</LastName><ForeName>Ethan F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa, Carver College of Medicine, SE 622 GH 200 Hawkins Drive, Iowa City, IA, 52242, USA. ethan-kuperman@uiowa.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schweizer</LastName><ForeName>Marin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa, Carver College of Medicine, SE 622 GH 200 Hawkins Drive, Iowa City, IA, 52242, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Comprehensive Access and Delivery Research and Evaluation, Iowa City VA Health System, Iowa City, IA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joy</LastName><ForeName>Parijat</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa, Carver College of Medicine, SE 622 GH 200 Hawkins Drive, Iowa City, IA, 52242, USA. Parijat-joy@uiowa.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Xiaomei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Health Sciences Clinical Education Librarian, Hardin Library of the Health Sciences, University of Iowa, Iowa City, IA, USA. Xiaomei-gu@uiowa.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Michele M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa, Carver College of Medicine, SE 622 GH 200 Hawkins Drive, Iowa City, IA, 52242, USA. Michele-fang@uiowa.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Geriatr</MedlineTA><NlmUniqueID>100968548</NlmUniqueID><ISSNLinking>1471-2318</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="N">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26864215</ArticleId><ArticleId IdType="pmc">PMC4750247</ArticleId><ArticleId IdType="doi">10.1186/s12877-016-0215-4</ArticleId><ArticleId IdType="pii">10.1186/s12877-016-0215-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Katz BPFD, Heck DA, Dittus RS, Paul JE, Wright J, Coyte P, et al. Demographic variation in the rate of knee replacement: a multi-year analysis. Health Serv Res. 1996;31(2):125&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1070109</ArticleId><ArticleId IdType="pubmed">8675435</ArticleId></ArticleIdList></Reference><Reference><Citation>Cram P, Lu X, Kates SL, Singh JA, Li Y, Wolf BR. Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991&#x2013;2010. JAMA. 2012;308(12):1227&#x2013;36. doi: 10.1001/2012.jama.11153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2012.jama.11153</ArticleId><ArticleId IdType="pmc">PMC4169369</ArticleId><ArticleId IdType="pubmed">23011713</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane RL, Saleh KJ, Wilt TJ, Bershadsky B. The functional outcomes of total knee arthroplasty. J Bone Joint Surg Am. 2005;87(8):1719&#x2013;24. doi: 10.2106/JBJS.D.02714.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.D.02714</ArticleId><ArticleId IdType="pubmed">16085610</ArticleId></ArticleIdList></Reference><Reference><Citation>Skou ST, Roos EM, Laursen MB, Rathleff MS, Arendt-Nielsen L, Simonsen O, et al. A randomized, controlled trial of total knee replacement. N Engl J Med. 2015;373(17):1597&#x2013;606. doi: 10.1056/NEJMoa1505467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1505467</ArticleId><ArticleId IdType="pubmed">26488691</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker PN, van der Meulen JH, Lewsey J, Gregg PJ, National Joint Registry for England and Wales The role of pain and function in determining patient satisfaction after total knee replacement. Data from the National Joint Registry for England and Wales. J Bone Joint Surg (Br) 2007;89(7):893&#x2013;900. doi: 10.1302/0301-620X.89B7.19091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.89B7.19091</ArticleId><ArticleId IdType="pubmed">17673581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamel MB, Toth M, Legedza A, Rosen MP. Joint replacement surgery in elderly patients with severe osteoarthritis of the hip or knee: decision making, postoperative recovery, and clinical outcomes. Arch Intern Med. 2008;168(13):1430&#x2013;40. doi: 10.1001/archinte.168.13.1430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.168.13.1430</ArticleId><ArticleId IdType="pubmed">18625924</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson M, Baig MK, Ashraf H. Quality of life in octagenarians after coronary artery bypass grafting. Am J Cardiol. 2005;95(6):761&#x2013;4. doi: 10.1016/j.amjcard.2004.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2004.11.031</ArticleId><ArticleId IdType="pubmed">15757606</ArticleId></ArticleIdList></Reference><Reference><Citation>Finlayson EFZ, Birkmeyer JD. Outcomes in Octogenarians undergoing high-risk caner operation: a national study. J Am Coll Surg. 2007;205(6):729&#x2013;34. doi: 10.1016/j.jamcollsurg.2007.06.307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2007.06.307</ArticleId><ArticleId IdType="pubmed">18035254</ArticleId></ArticleIdList></Reference><Reference><Citation>Alibakhshi A, Aminian A, Mirsharifi R, Jahangriri Y, Dashti H, Karimian F. The effect of age on the outcome of esophageal cancer surgery. Ann Thorac Med. 2009;4(2):71&#x2013;4. doi: 10.4103/1817-1737.49415.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1817-1737.49415</ArticleId><ArticleId IdType="pmc">PMC2700490</ArticleId><ArticleId IdType="pubmed">19561928</ArticleId></ArticleIdList></Reference><Reference><Citation>Oghalai J, Buxbaum JL, Pitts LH, Jackler RK. The effect of age on acoustic neuroma surgery outcomes. Otol Neurotol. 2003;24(3):473&#x2013;7. doi: 10.1097/00129492-200305000-00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00129492-200305000-00020</ArticleId><ArticleId IdType="pubmed">12806302</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida GKT, Ishikawa Y, Matsumoto A, Ito Z, Tauchi R, Muramoto A, et al. The effects of surgery on locomotion in elderly patients with cervical spondylotic myelopathy. Eur Spine J. 2013;22(11):2545&#x2013;51. doi: 10.1007/s00586-013-2961-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00586-013-2961-8</ArticleId><ArticleId IdType="pmc">PMC3886528</ArticleId><ArticleId IdType="pubmed">23955371</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264&#x2013;9. doi: 10.7326/0003-4819-151-4-200908180-00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-4-200908180-00135</ArticleId><ArticleId IdType="pubmed">19622511</ArticleId></ArticleIdList></Reference><Reference><Citation>Odum SM, Springer BD. In-hospital complication rates and associated factors after simultaneous bilateral versus unilateral total knee arthroplasty. J Bone Joint Surg Am. 2014;96(13):1058&#x2013;65. doi: 10.2106/JBJS.M.00065.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.M.00065</ArticleId><ArticleId IdType="pubmed">24990970</ArticleId></ArticleIdList></Reference><Reference><Citation>The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [http://www.ohri.ca/programs/clinical_epidemiology/oxford_web.ppt].</Citation></Reference><Reference><Citation>Review Manager (RevMan) VeTNCC, The Cochrane Collaboration, Copenhagen. 2014.</Citation></Reference><Reference><Citation>Zicat B, Rorabeck C, Bourne R, Devane P, Nott L. Total knee arthroplasty in the octogenarian. J Arthroplasty. 1993;8(4):395&#x2013;400. doi: 10.1016/S0883-5403(06)80038-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0883-5403(06)80038-0</ArticleId><ArticleId IdType="pubmed">8409991</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam R, Noble J. Primary total knee arthroplasty in the elderly. J Arthroplasty. 1994;9(5):495&#x2013;7. doi: 10.1016/0883-5403(94)90095-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0883-5403(94)90095-7</ArticleId><ArticleId IdType="pubmed">7807106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohzawa S, Takahara Y, Furumatsu T, Inoue H. Patient survival after total knee arthroplasty. Acta Med Okayama. 2001;55(5):295&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">11688953</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J, Sullivan TA, Trousdale RT, Lewallen DG. Thirty-day mortality after total knee arthroplasty. J Bone Joint Surg Am. 2001;83(8):1157&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11507123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill GS, Mills D, Joshi AB. Mortality following primary total knee arthroplasty. J Bone Joint Surg Am. 2003;85(3):432&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12637427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton AI, Back DL, Espag MP, Briggs TW, Cannon SR. The octogenarian total knee arthroplasty. Orthopedics. 2004;27(1):37&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">14763527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamel MB, Henderson WG, Khuri SF, Daley J. Surgical outcomes for patients aged 80 and older: morbidity and mortality from major noncardiac surgery. J Am Geriatr Soc. 2005;53(3):424&#x2013;9. doi: 10.1111/j.1532-5415.2005.53159.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53159.x</ArticleId><ArticleId IdType="pubmed">15743284</ArticleId></ArticleIdList></Reference><Reference><Citation>Biau D, Mullins M, Judet T, Piriou P. Is anyone too old for a total knee replacement? Clin Orthop Relat Res. 2006;448:180&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16826114</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement N, MacDonald D, Howie C, Biant L. The outcome of primary total hip and knee arthroplasty in patients aged 80 years or more. J Bone Joint Surg Br. 2011;93(9):1265&#x2013;70. doi: 10.1302/0301-620X.93B9.25962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.93B9.25962</ArticleId><ArticleId IdType="pubmed">21911540</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement N, Jenkins P, Brenkel I, Walmsley P. Predictors of mortality after total knee replacement A ten-year survivorship analysis. J Bone Joint Surg Br. 2012;94(2):200&#x2013;4. doi: 10.1302/0301-620X.94B2.28114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.94B2.28114</ArticleId><ArticleId IdType="pubmed">22323686</ArticleId></ArticleIdList></Reference><Reference><Citation>Chikuda H, Yasunaga H, Horiguchi H, Takeshita K, Sugita S, Taketomi S, et al. Impact of age and comorbidity burden on mortality and major complications in older adults undergoing orthopaedic surgery: an analysis using the Japanese diagnosis procedure combination database. BMC Musculoskelet Disord. 2013;14(1):173. doi: 10.1186/1471-2474-14-173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2474-14-173</ArticleId><ArticleId IdType="pmc">PMC3669039</ArticleId><ArticleId IdType="pubmed">23711221</ArticleId></ArticleIdList></Reference><Reference><Citation>Maempel JF, Riddoch F, Calleja N, Brenkel IJ. Longer hospital stay, more complications, and increased mortality but substantially improved function after knee replacement in older patients: A study of 3,144 primary unilateral total knee replacements. Acta Orthop. 2015;86(5):1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513600</ArticleId><ArticleId IdType="pubmed">25885004</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy JW, Johnston L, Cochrane L, Boscainos PJ. Total knee arthroplasty in the elderly: does age affect pain, function or complications? Clin Orthop Relat Res. 2013;471(6):1964&#x2013;9. doi: 10.1007/s11999-013-2803-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-013-2803-3</ArticleId><ArticleId IdType="pmc">PMC3706666</ArticleId><ArticleId IdType="pubmed">23354464</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo F-C, Hsu C-H, Chen W-S, Wang J-W. Total knee arthroplasty in carefully selected patients aged 80 years or older. J Orthop Surg Res. 2014;9:61&#x2013;6. doi: 10.1186/s13018-014-0061-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-014-0061-z</ArticleId><ArticleId IdType="pmc">PMC4131159</ArticleId><ArticleId IdType="pubmed">25017667</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CA, Voaklander DC, Johnston DWC, Suarez-Almazor ME. The effect of age on pain, function, and quality of life after total hip and knee arthroplasty. Arch Intern Med. 2001;161(3):454&#x2013;60. doi: 10.1001/archinte.161.3.454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.161.3.454</ArticleId><ArticleId IdType="pubmed">11176772</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood M, Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL. Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology. 2002;96(5):1140&#x2013;6. doi: 10.1097/00000542-200205000-00017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200205000-00017</ArticleId><ArticleId IdType="pubmed">11981154</ArticleId></ArticleIdList></Reference><Reference><Citation>Baser O, Supina D, Sengupta N, Wang L, Kwong L. Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery. Am J Health Syst Pharm. 2010;67(17):1438&#x2013;45. doi: 10.2146/ajhp090572.</Citation><ArticleIdList><ArticleId IdType="doi">10.2146/ajhp090572</ArticleId><ArticleId IdType="pubmed">20720243</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent KR, Vincent HK, Lee LW, Alfano AP. Outcomes in total knee arthroplasty patients after inpatient rehabilitation: influence of age and gender. Am J Phys Med Rehabil. 2006;85(6):482&#x2013;9. doi: 10.1097/01.phm.0000219151.18749.50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.phm.0000219151.18749.50</ArticleId><ArticleId IdType="pubmed">16715017</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith I, Elton R, Ballantyne J, Brenkel I. Pre-operative predictors of the length of hospital stay in total knee replacement. J Bone Joint Surg Br. 2008;90(11):1435&#x2013;40. doi: 10.1302/0301-620X.90B11.20687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.90B11.20687</ArticleId><ArticleId IdType="pubmed">18978261</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskin RS. Total knee replacement in patients older than 85 years. Clin Orthop Relat Res. 1999;367:43&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10546597</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Vaquero D, Fern&#xe1;ndez-Carreira JM, P&#xe9;rez-Hern&#xe1;ndez D, Fern&#xe1;ndez-Lombard&#xed;a J, Garc&#xed;a-Sandoval MA. Total knee arthroplasty in the elderly. Is there an age limit? J Arthroplasty. 2006;21(3):358&#x2013;61. doi: 10.1016/j.arth.2005.05.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2005.05.030</ArticleId><ArticleId IdType="pubmed">16627143</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams D, Price A, Beard D, Hadfield S, Arden N, Murray D, et al. The effects of age on patient-reported outcome measures in total knee replacements. Bone Joint J. 2013;95(1):38&#x2013;44. doi: 10.1302/0301-620X.95B1.28061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.95B1.28061</ArticleId><ArticleId IdType="pubmed">23307671</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharrock NE, Cazan MG, Hargett MJL, Williams-Russo P, Wilson PD. Changes in mortality after total hip and knee arthroplasty over a ten-year period. Anesth Analg. 1995;80(2):242&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7818108</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahomed NN, Barrett J, Katz JN, Baron JA, Wright J, Losina E. Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am. 2005;87(6):1222&#x2013;8. doi: 10.2106/JBJS.D.02546.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.D.02546</ArticleId><ArticleId IdType="pubmed">15930530</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie SA, Pratt N, Ryan P, Enges&#xe6;ter LB, Havelin LI, Furnes O, et al. Duration of the increase in early postoperative mortality after elective hip and knee replacement. J Bone Joint Surg Am. 2010;92(1):58&#x2013;63. doi: 10.2106/JBJS.H.01882.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.H.01882</ArticleId><ArticleId IdType="pubmed">20048096</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep. 2013;61(4):1&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">24979972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalmohamed A, Vestergaard P, Klop C, Grove EL, de Boer A, Leufkens HG, et al. Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. Arch Intern Med. 2012;172(16):1229&#x2013;35. doi: 10.1001/archinternmed.2012.2713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2012.2713</ArticleId><ArticleId IdType="pubmed">22826107</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza G, Seddighzadeh A, Goldhaber SZ. Deep-vein thrombosis in the elderly. Clin Appl Thromb Hemost. 2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">18593747</ArticleId></ArticleIdList></Reference><Reference><Citation>March LM, Cross MJ, Lapsley H, Brnabic A, Tribe KL, Bachmeier C, et al. Outcomes after hip or knee replacement surgery for osteoarthritis. A prospective cohort study comparing patients' quality of life before and after surgery with age-related population norms. Med J Aust. 1999;171(5):235&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10495753</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40382433</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Aspirin for the extended prevention of venous thromboembolism: a meta-analysis and trial sequential analysis.</ArticleTitle><Pagination><StartPage>17213</StartPage><MedlinePgn>17213</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17213</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-02171-z</ELocationID><Abstract><AbstractText>Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major complication following surgery and in high-risk scenarios. Aspirin may provide an alternative for extended VTE prophylaxis, but its risk-benefit profile remains unclear. We conducted a systematic review and meta-analysis of randomized controlled trials, following PRISMA guidelines, to evaluate aspirin's efficacy and safety for extended VTE prevention. Subgroup analyses included primary and secondary prevention, provoked and unprovoked VTE, and low-dose aspirin. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using a random-effects model, and trial sequential analysis was used to assess the robustness of the evidence. Five trials including 68,554 patients were analyzed. Aspirin (100-160&#xa0;mg) significantly reduced the risk of VTE, DVT, PE, and VTE-related mortality compared to placebo, particularly in primary prevention and provoked VTE cases. No benefit was observed in secondary prevention, while some benefit emerged for unprovoked VTE, limited to overall VTE risk. Low-dose aspirin (100&#xa0;mg) did not significantly reduce the incidence of VTE, DVT, or PE. Aspirin increased the risks of overall and major bleeding but did not elevate blood transfusion requirements or major cardiovascular events. These findings suggest that prolonged aspirin therapy may have a role in extended VTE prevention, particularly in patients at risk for provoked VTE. However, careful patient selection remains crucial, and further studies are needed to refine its indications and optimal dosing strategy.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carron</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine-DIMED, Section of Anaesthesiology and Intensive Care, University of Padua, Gallucci V. St. 13, Padua, 35121, Italy. michele.carron@unipd.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Anaesthesia and Intensive Care, Padua University Hospital, Padua, Italy. michele.carron@unipd.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamburini</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Anaesthesia and Intensive Care, Padua University Hospital, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pettenuzzo</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Anaesthesia and Intensive Care, Padua University Hospital, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarantonello</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Anaesthesia and Intensive Care, Padua University Hospital, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campello</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine-DIMED, Thrombotic and Haemorrhagic Diseases Unit, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navalesi</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine-DIMED, Section of Anaesthesiology and Intensive Care, University of Padua, Gallucci V. St. 13, Padua, 35121, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Anaesthesia and Intensive Care, Padua University Hospital, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simioni</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine-DIMED, Thrombotic and Haemorrhagic Diseases Unit, University of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="Y">Aspirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aspirin</Keyword><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword><Keyword MajorTopicYN="N">Venous thrombosis</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests. Institutional review board statement: The network meta-analysis protocol was registered prospectively under the PROSPERO identification number CRD42024557218, and strict adherence PRISMA checklist was ensured in the preparation of this manuscript. Declaration of Generative AI and AI-assisted technologies in the writing process: The authors declare that no generative AI tools or AI-assisted technologies were used in the preparation of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>18</Day><Hour>17</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>18</Day><Hour>17</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40382433</ArticleId><ArticleId IdType="pmc">PMC12085591</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-02171-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-02171-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kearon, C. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest149, 315&#x2013;352. 10.1016/j.chest.2015.11.026 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26867832</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson, D. R. et al. American society of hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv.3, 3898&#x2013;3944. 10.1182/bloodadvances.2019000975 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6963238</ArticleId><ArticleId IdType="pubmed">31794602</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355: 1295&#x2009;&#x2013;&#x2009;302. (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10776741</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn, R. J., Ridker, P. M., Goldhaber, S. Z. &amp; Buring, J. E. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann. Intern. Med.147, 525&#x2013;533. 10.7326/0003-4819-147-8-200710160-00004 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17938390</ArticleId></ArticleIdList></Reference><Reference><Citation>Becattini, C. et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl. J. Med.366, 1959&#x2013;1967. 10.1056/NEJMoa1114238 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22621626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brighton, T. A. et al. ASPIRE investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl. J. Med.367, 1979&#x2013;1987. 10.1056/NEJMoa1210384 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23121403</ArticleId></ArticleIdList></Reference><Reference><Citation>Devereaux, P. J. et al. POISE-2 investigators. Aspirin in patients undergoing noncardiac surgery. N Engl. J. Med.370, 1494&#x2013;1503. 10.1056/NEJMoa1401105 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24679062</ArticleId></ArticleIdList></Reference><Reference><Citation>Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ372, n71. 10.1136/bmj.n71 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Simes, J. et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation130, 1062&#x2013;1071. 10.1161/CIRCULATIONAHA.114.008828 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25156992</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman, S., Kearon, C. &amp; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3, 692&#x2013;694. 10.1111/j.1538-7836.2005.01204.x (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15842354</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne, J. A. C. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ366, l4898. 10.1136/bmj.l4898 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhan, M. A. et al. A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ349, g5630. 10.1136/bmj.g5630 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25252733</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins, J. P., Thompson, S. G., Deeks, J. J. &amp; Altman, D. G. Measuring inconsistency in meta-analyses. BMJ327, 557&#x2013;560. 10.1136/bmj.327.7414.557 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne, J. A. et al. Recommendations for examining and interpreting funnel plot asymmetry in Meta-Analyses of randomised controlled trials. BMJ343, d4002. 10.1136/bmj.d4002 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21784880</ArticleId></ArticleIdList></Reference><Reference><Citation>De Cassai, A. et al. Explanation of trial sequential analysis: using a post-hoc analysis of meta-analyses published in Korean journal of anesthesiology. Korean J. Anesthesiol. 74, 383&#x2013;393. 10.4097/kja.21218 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497914</ArticleId><ArticleId IdType="pubmed">34283909</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelboom, J. W. et al. Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials. Anesthesiology125, 1121&#x2013;1129. 10.1097/ALN.0000000000001352 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27627817</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh, T. et al. Timing of symptomatic venous thromboembolism after surgery: meta-analysis. Br. J. Surg.110, 553&#x2013;561. 10.1093/bjs/znad035 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10364527</ArticleId><ArticleId IdType="pubmed">36912116</ArticleId></ArticleIdList></Reference><Reference><Citation>Froehling, D. A. et al. Incidence of venous thromboembolism after bariatric surgery: a population-based cohort study. Obes. Surg.23, 1874&#x2013;1879. 10.1007/s11695-013-1073-1 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924592</ArticleId><ArticleId IdType="pubmed">24022324</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinari, G. et al. Enhanced recovery after bariatric surgery: an Italian consensus statement. Surg. Endosc. 36, 7171&#x2013;7186. 10.1007/s00464-022-09498-y (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9485178</ArticleId><ArticleId IdType="pubmed">35953683</ArticleId></ArticleIdList></Reference><Reference><Citation>Major Extremity Trauma Research Consortium (METRC) et al. Aspirin or Low-Molecular-Weight heparin for thromboprophylaxis after a fracture. N Engl. J. Med.388, 203&#x2013;213. 10.1056/NEJMoa2205973 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36652352</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides, S. V. &amp; ESC Scientific Document Group. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 41, 543&#x2013;603. 10.1093/eurheartj/ehz405 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31504429</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, B. et al. Pros and cons of aspirin for the primary prevention of cardiovascular events: A secondary study of trial sequential analysis. Front. Pharmacol.11, 592116. 10.3389/fphar.2020.592116 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845480</ArticleId><ArticleId IdType="pubmed">33519452</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud, A. N., Gad, M. M., Elgendy, A. Y., Elgendy, I. Y. &amp; Bavry, A. A. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur. Heart J.40, 607&#x2013;617. 10.1093/eurheartj/ehy813 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30561620</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, S. L. &amp; Roddick, A. J. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: A systematic review and Meta-analysis. JAMA321, 277&#x2013;287. 10.1001/jama.2018.20578 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439678</ArticleId><ArticleId IdType="pubmed">30667501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaatz, S., Ahmad, D., Spyropoulos, A. C., Schulman, S. &amp; Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J. Thromb. Haemost. 13 (11), 2119&#x2013;2126. 10.1111/jth.13140 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26764429</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25950688</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>18</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Anesthetic influence on occurrence and treatment of the trigemino-cardiac reflex: a systematic literature review.</ArticleTitle><Pagination><StartPage>e807</StartPage><MedlinePgn>e807</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e807</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000000807</ELocationID><Abstract><AbstractText>Trigeminocardiac reflex (TCR) is defined as sudden onset of parasympathetic dysrhythmia including hypotension, apnea, and gastric hypermotility during stimulation of any branches of the trigeminal nerve. Previous publications imply a relation between TCR and depth of anesthesia. To gain more detailed insights into this hypothesis, we performed a systematic literature review.Literature about occurrence of TCR was systematically identified through searching in Cochrane Central Register of Controlled Trials (CENTRAL), PubMed (MEDLINE), EMBASE (Ovid SP), and the Institute for Scientific Information (ISI Web of Sciences) databases until June 2013, as well as reference lists of articles for risk calculation. In this study, TCR was defined as drop in mean arterial blood pressure and heart rate, both &gt;20% to baseline. We calculated intraoperative cerebral state index (CSI) of each TCR-case using a newly developed method. These data were further divided into 3 subgroups: CSI &lt;40 (deep anesthesia), CSI 40-60 (regular anesthesia), and CSI &gt;60 (slight anesthesia).Including 45 studies with 910 patients, 140 (15%) presented with TCR, and 770 (85%) without TCR during operation. TCR occurrence showed a 1.2-fold higher pooled risk slighter anesthesia (CSI &lt;40: 13%, at CSI 40-60: 21%, and at CSI &gt;60: 27%) compared with deeper anesthesia. In addition, we could discover a 1.3-fold higher pooled risk of higher MABP drop with a strong negative correlation (r&#x200a;=&#x200a;-0.935; r&#x200a;=&#x200a;0.89) and a 4.5-fold higher pooled risk of asystole during TCR under slight anesthesia compared with deeper anesthesia.Our work is the first systematic review about TCR and demonstrates clear evidence for TCR occurrence and a more severe course of the TCR in slight anesthesia underlying the importance of skills in anesthesia management during skull base surgery. Furthermore, we have introduced a new standard method to calculate the depth of anesthesia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meuwly</LastName><ForeName>Cyrill</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the University Hospital, 4031 Basel, Switzerland (CM, MR); Cardiology Luzerner Kantonsspital, 6000 Luzern, Switzerland (PE); Present address: Cardiology, St Anna Clinic, St Anna Strasse 32, 6006 Luzern, Switzerland (PE); Departments of Anesthesia and Perioperative Medicine, University of Manitoba, Winnipeg, Canada (TC); and Department of Research, University of Southampton, Southampton, UK (NS, BS).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Tumul</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sandu</LastName><ForeName>Nora</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Reck</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Erne</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Schaller</LastName><ForeName>Bernhard</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000777">Anesthetics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000758" MajorTopicYN="N">Anesthesia</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000777" MajorTopicYN="N">Anesthetics</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007431" MajorTopicYN="Y">Intraoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059230" MajorTopicYN="Y">Reflex, Trigeminocardiac</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019291" MajorTopicYN="N">Skull Base</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25950688</ArticleId><ArticleId IdType="pmc">PMC4602521</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000000807</ArticleId><ArticleId IdType="pii">00005792-201505020-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schaller B, Prost R, Strebel S, et al. Trigeminocardiac reflex during surgery in the cerebellopontine angle. J Neurosurg 1999; 90:215&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">9950491</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller B. Trigeminocardiac reflex: a clinical phenomenon or a new physiological entity? J Neurol 2004; 251:658&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311339</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller B, Cornelius JF, Prabhakar H, et al. The trigemino-cardiac reflex: an update of the current knowledge. J Neurosurg Anesthesiol 2009; 21:187&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">19542994</ArticleId></ArticleIdList></Reference><Reference><Citation>Arasho B, Sandu N, Spiriev T, et al. Management of the trigeminocardiac reflex. Facts and own experience. Neurol India 2009; 57:375&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">19770535</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury T, Sandu N, Meuwly C, et al. Peripheral trigeminocardiac reflex. Am J Otolaryngol 2013; 34:616.</Citation><ArticleIdList><ArticleId IdType="pubmed">23886805</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiriev T, Sandu N, Kondoff S, et al. Tic and autonomic symptoms. J Neurosurg 2012; 116:1397&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pubmed">22462510</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller BJ. Trigeminocardiac reflex. J Neurosurg 2007; 107:243.</Citation><ArticleIdList><ArticleId IdType="pubmed">17639902</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiriev T, Tzekov C, Laleva L, et al. Central trigeminocardiac reflex in pediatric neurosurgery: a case report and review of the literature. J Med Case Rep 2012; 30:372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3514120</ArticleId><ArticleId IdType="pubmed">23110862</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiriev T, Kondoff S, Schaller B. Cardiovascular changes after subarachnoid hemorrhage initiated by the trigeminocardiac reflex: first description of a case series. J Neurosurg Anesthesiol 2011; 23:379&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">21908992</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiriev T, Kondoff S, Schaller B. Trigeminocardiac reflex during temporary clipping in aneurismal surgery: first description. J Neurosurg Anesthesiol 2011; 23:271&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">21654337</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiriev T, Tzekov C, Kondoff S, et al. Trigemino-cardiac reflex during chronic subdural haematoma removal: report of chemical initiation of dorsal sensitization. JRSM Short Rep 2011; 2:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085972</ArticleId><ArticleId IdType="pubmed">21541075</ArticleId></ArticleIdList></Reference><Reference><Citation>Filis A, Schaller B, Buchfelder M. Trigeminocardiac reflex in pituitary surgery: a prospective pilot study. Nervenarzt 2008; 79:669&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">18060379</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller B. Trigemino-cardiac reflex during transsphenoidal surgery for pituitary adenomas. Clin Neurol Neurosurg 2005; 106:468&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">16202819</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller B. Trigemino-cardiac reflex during microvascular trigeminal decompression in cases of trigeminal neuralgia. J Neurosurg Anesthesiol 2005; 17:45&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">15632542</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller BJ, Filis A, Buchfelder M. Trigemino-cardiac reflex in humans initiated by peripheral stimulation during neurosurgical skull-base operations. Its first description. Acta Neurochir (Wien) 2008; 150:715&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">18536994</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury T, Sandu N, Meuwly C, et al. Trigeminal cardiac reflex: differential behavior and risk factors around the course of the trigeminal nerve. Future Neurol 2014; 9:41&#x2013;47.</Citation></Reference><Reference><Citation>InTech, Rijeka, Croatia, Abdulazim A, Stienen MN, Sadr-Eshkevari P. Signorelli F, et al. Trigeminocardiac reflex in neurosurgery &#x2013; current knowledge and prospects. Explicative cases of controversial issues in neurosurgery 2013; 3&#x2013;18.</Citation></Reference><Reference><Citation>Schaller BJ, Rasper J, Filis A, et al. Difference in functional outcome of ipsilateral tinnitus after intraoperatve occurence of the trigemino-cardiac reflex in surgery for vestibular schwannomas. Acta Neurochir (Wien) 2008; 150:157&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">18080085</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xf6;then C, Sandu N, Prabhakar H, et al. Trigemino-cardiac reflex and antecedent transient ischemic attacks. Expert Rev Cardiovasc Ther 2010; 8:509&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">20397825</ArticleId></ArticleIdList></Reference><Reference><Citation>Meuwly C, Chowdhury T, Schaller B. Topical lidocaine to suppress trigemino-cardiac reflex. Br J Anaesth 2013; 111:302.</Citation><ArticleIdList><ArticleId IdType="pubmed">23858078</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller B, Sandu N, Filis A, et al. Peribulbar block or topical application of local anaesthesia combined for paediatric strabismus surgery. Anaesthesia 2008; 63:1142&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pubmed">18821892</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison CE, De Lange JJ, Koole FD, et al. A comparison of the incidence of the oculocardiac and oculorespiratory reflexes during sevoflurane or halothane anesthesia for strabismus surgery in children. Anesth Analg 2000; 90:306&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648311</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahnenkamp K, Honemann CW, Fischer LG, et al. Effect of different anaesthetic regimes on the oculocardiac reflex during paediatric strabismus surgery. Paediatr Anaesth 2000; 10:601&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">11119192</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Lee SJ, Kim SH, et al. Single bolus of intravenous ketamine for anesthetic induction decreases oculocardiac reflex in children undergoing strabismus surgery. Acta Anaesthesiol Scand 2007; 51:759&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">17488312</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold RW, Jensen PA, Kovtoun TA, et al. The profound augmentation of the oculocardiac reflex by fast acting opioids. Binocul Vis Strabismus Q 2004; 19:215&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">15530138</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CJ, Lee JM, Choi SR, et al. Effect of remifentanil on oculocardiac reflex in paediatric strabismus surgery. Acta Anaesthesiol Scand 2008; 52:1273&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pubmed">18823468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghai B, Ram J, Makkar JK, et al. Subtenon block compared to intravenous fentanyl for perioperative analgesia in pediatric cataract surgery. Anesth Analg 2009; 108:1132&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">19299775</ArticleId></ArticleIdList></Reference><Reference><Citation>Etzedai F, Orandi AA, Orandi AH, et al. Trigeminocardiac reflex in neurosurgical practice: an observational prospective study. Surg Neurol Int 2013; 4:116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3784954</ArticleId><ArticleId IdType="pubmed">24083052</ArticleId></ArticleIdList></Reference><Reference><Citation>The Cochrane Collaboration, Higgins JPT, Altman DG, Sterne JAC.
Higgins JPT, Green S.
Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions Version 5.1.0 (updated March 2011)
2011; Available from www.cochrane-handbook.org.</Citation></Reference><Reference><Citation>Nishiyama T, Komatsu K. Cerebral state index versus bispectral index during propofol-fentanyl&#x2013;nitrous oxide anesthesia. J Anesth 2010; 24:380&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">20339885</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekimoto K, Nishikawa K, Ishizeki J, et al. The effects of volatile anesthetics on intraoperative monitoring of myogenic motor-evoked potentials to transcranial electrical stimulation and on partial neuromuscular blockade during propofol/fentanyl/nitrous oxide anesthesia in humans. J Neurosurg Anesthesiol 2006; 18:106&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16628063</ArticleId></ArticleIdList></Reference><Reference><Citation>Olofsen E, Dahan A. The dynamic relationship between end-tidal sevoflurane and isoflurane concentrations and bispectral index and spectral edge frequency of the electroencephalogram. Anesthesiology 1999; 90:1345&#x2013;1353.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandu N, Cornelius J, Filis A, et al. Cerebral hemodynamic changes during the trigeminocardiac reflex: description of a new animal model protocol. ScientificWorldJournal 2010; 10:1416&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5763697</ArticleId><ArticleId IdType="pubmed">20661534</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang S, Lanigan DT, van der Wal M. Trigeminocardiac reflexes: maxillary and mandibular variants of the oculocardiac reflex. Can J Anaesth 1991; 38:757&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">1914059</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Gorini C, Sharp D, et al. Anaesthetics differentially modulate the trigeminocardiac reflex excitatory synaptic pathway in the brainstem. J Physiol 2011; 589 (Pt 22):5431&#x2013;5442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240882</ArticleId><ArticleId IdType="pubmed">21930602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chigurupati K, Vemuri NN, Velivela SR, et al. Topical lidocaine to suppress trigemino-cardiac reflex. Br J Anaesth 2013; 110:144&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">23236116</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhakar H, Ali Z, Rath GP. Trigemino-cardiac reflex may be refractory to conventional management in adults. Acta Neurochir 2008; 150:509&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">18465091</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirakhur RK, Jones CJ, Dundee JW, et al. I.m. or i.v. atropine or glycopyrrolate for the prevention of oculocardiac reflex in children undergoing squint surgery. Br J Anaesth 1982; 54:1059&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pubmed">7126399</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulazim A, Filis A, Sadr-Eshkevari P, et al. Postcraniotomy function of the temporal muscle in skull base surgery: technical note based on a preliminary study. ScientificWorldJournal 2012; 427081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317610</ArticleId><ArticleId IdType="pubmed">22536141</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy KR, Chandramouli BA, Rao GS. Cardiac asystole during radiofrequency lesioning of the trigeminal ganglion. J Neurosurg Anesthesiol 2006; 18:163.</Citation><ArticleIdList><ArticleId IdType="pubmed">16628076</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;bbers HT, Zweifel D, Gr&#xe4;tz KW, et al. Classification of potential risk factors for trigeminocardiac reflex in craniomaxillofacial surgery. J Oral Maxillofac Surg 2010; 68:1317&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">20347202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmer LB, Afifi S, Koht A. Trigeminocardiac reflex in the postanesthesia care unit. J Clin Anesth 2010; 22:9205&#x2013;9208.</Citation><ArticleIdList><ArticleId IdType="pubmed">20400008</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha ST, Eby J, Katzen JT, et al. Trigeminocardiac reflex: a unique case of recurrent asystole during bilateral trigeminal sensory root rhizotomy. J Craniomaxillofac Surg 2002; 30:108&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">12069514</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiriev T, Sandu N, Arasho B, et al. A new predisposing factor for trigemino-cardiac reflex during subdural empyema drainage: a case report. J Med Case Rep 2010; 4:391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3002900</ArticleId><ArticleId IdType="pubmed">21118536</ArticleId></ArticleIdList></Reference><Reference><Citation>Wartak S, Mehendale R, Lotfi A. A unique case of asystole secondary to facial injury. Case Rep Med 2012; 382605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3297481</ArticleId><ArticleId IdType="pubmed">22454645</ArticleId></ArticleIdList></Reference><Reference><Citation>Seker A, Toktas ZO, Peker S, et al. Asystole due to trigemino-cardiac reflex: a rare complication of trans-sphenoidal surgery for pituitary adenoma. J Clin Neurosci 2009; 16:338&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056276</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhu VC, Bamber NI, Shea JF, et al. Avoidance and management of trigeminocardiac reflex complicating awake-craniotomy. Clin Neurol Neurosurg 2008; 110:1064&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">18845385</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana H, Dewan P, Ali Z, et al. Electrocardiographic changes due to vagosympathetic coactivation during the trigeminocardiac reflex. J Neurosurgical Anesthesiol 2009; 21:270.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543008</ArticleId></ArticleIdList></Reference><Reference><Citation>Amiridze N, Zoarski G, Darwish R, et al. Embolization of a cavernous sinus dural arteriovenous fistula with onyx via direct puncture of the cavernous sinus through the superior orbital fissure: asystole resulting from the trigeminocardiac reflex. A case report. Interv Neuroradiol 2009; 15:179&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3299019</ArticleId><ArticleId IdType="pubmed">20465896</ArticleId></ArticleIdList></Reference><Reference><Citation>Arasho B, Sandu N, Spiriev T, et al. Management of the trigeminocardiac reflex: facts and own experience. Neurol India 1999; 57:375&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">19770535</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho JM, Min KT, Kim EH, et al. Sudden asystole due to trigeminocardiac reflex during transsphenoidal surgery for pituitary tumor. World Neurosurg 2011; 76:477.e11-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">22152579</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhakar H, Anand N, Chouhan RS, et al. Sudden asystole during surgery in the cerebellopontine angle. Acta Neurochir 2006; 148:699&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">16374562</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhakar H, Rath GP, Arora R. Sudden cardiac standstill during skin flap elevation in a patient undergoing craniotomy. J Neurosurg Anesthesiol 2007; 19:203&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17592354</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer DF, Youkilis A, Schenck C, et al. The falcine trigeminocardiac reflex: case report and review of the literature. Surg Neurol 2005; 63:143&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">15680656</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Zeid AH, Davis JR, Kearney T, et al. Transient asystole during endoscopic transsphenoidal surgery for acromegaly: an example of trigeminocardiac reflex. Pituitary 2009; 12:373&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">18404383</ArticleId></ArticleIdList></Reference><Reference><Citation>Rath GP, Chaturvedi A, Chouhan RS, et al. Transient cardiac asystole in transsphenoidal pituitary surgery: a case report. J Neurosurg Anesthesiol 2004; 16:299&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">15557836</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiriev T, Tzekov C, Kondoff S, et al. Trigemino-cardiac reflex during chronic subdural haematoma removal: report of chemical initiation of dural sensitization. JRSM Short Rep 2011; 2:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085972</ArticleId><ArticleId IdType="pubmed">21541075</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller BJ, Filis A, Buchfelder M. Trigemino-cardiac reflex in humans initiated by peripheral stimulation during neurosurgical skull-base operations. Its first description. Acta Neurochir 2008; 150:715&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">18536994</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiriev T, Kondoff S, Schaller B. Trigeminocardiac reflex during temporary clipping in aneurismal surgery: first description. J Neurosurg Anesthesiol 2011; 23:271&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">21654337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv X, Li Y, Lv M, et al. Trigeminocardiac reflex in embolization of intracranial dural arteriovenous fistula. AJNR Am J Neuroradiol 2007; 28:1769&#x2013;1770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8134204</ArticleId><ArticleId IdType="pubmed">17885228</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal AK, Gupta D, Verma N, et al. Trigeminocardiac reflex: a cause of sudden asystole during cerebellopontine angle surgery. J Clin Neurosci 2010; 17:644&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">20188568</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiriev T, Prabhakar H, Sandu N, et al. Use of hydrogen peroxide in neurosurgery: case series of cardiovascular complications. JRSM Short Rep 2012; 3:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3269103</ArticleId><ArticleId IdType="pubmed">22299072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury T, West M. Intraoperative asystole in a patient undergoing craniotomy under monitored anesthesia care: is it TCR? J Neurosurg Anesthesiol 2013; 25:92&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">23147445</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborn TM, Ueeck BA, Ham LB, et al. A case of asystole from periorbital laceration manipulation and oculocardiac reflex in an acute trauma setting. J Trauma 2008; 65:228&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">17429330</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung MY, Viney M. A Unique case of recurrent asystole secondary to paroxysmal pain of acute herpetic ophthalmicus. Anesth Analg 2007; 105:1127&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898398</ArticleId></ArticleIdList></Reference><Reference><Citation>Min SW, Hwang JM. Adjustment in patients with asystole during strabismus surgery. Graefes Arch Clin Exp Ophthalmol 2011; 249:1889&#x2013;1892.</Citation><ArticleIdList><ArticleId IdType="pubmed">21301860</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimura T, Amano S, Funatsu H, et al. Oculocardiac reflex caused by contact lenses. Ophthalmic Physiol Opt 2003; 23:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">12753482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroll HR, Arora V, Vangura D. Coronary artery spasm occurring in the setting of the oculocardiac reflex. J Anesth 2010; 24:757&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">20526723</ArticleId></ArticleIdList></Reference><Reference><Citation>Rippmann V, Scholz T, Hellmann S, et al. The oculocardiac reflex in blepharoplasties. Handchir Mikrochir Plast Chir 2008; 40:267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">18716987</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek HI, Park BC, Kim WH, et al. Oculocardiac reflex during the endoscopic sinus surgery. Am J Otolaryngol 2010; 31:136&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">20015721</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandu N, Sadr-Eshkevari P, Schaller BJ. Usefulness of case reports to improve medical knowledge regarding trigemino-cardiac reflex in skull base surgery. J Med Case Rep 2011; 5:1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3089793</ArticleId><ArticleId IdType="pubmed">21496216</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuura T, Oda Y, Tanaka K, et al. Advance of age decreases the minimum alveolar concentrations of isoflurane and sevoflurane for maintaining bispectral index below 50. Br J Anaesth 2009; 102:331&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">19168857</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama T. Cerebral state index vs. bispectral index during sevoflurane-nitrous oxide anaesthesia. Eur J Anaesthesiol 2009; 26:638&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">19300270</ArticleId></ArticleIdList></Reference><Reference><Citation>Meuwly C, Golanov E, Chowdhury T, et al. Trigeminal cardiac reflex: new thinking model about the definition based on a literature review. Medicine (Baltimore) 2015; 94:e484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4602726</ArticleId><ArticleId IdType="pubmed">25654391</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury T, Mendelowith D, Golanov E, et al. Trigeminocardiac reflex: the current clinical and physiological knowledge. J Neurosurg Anesthesiol 2015; 27:136&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">25602626</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandu N, Chowdhury T, Sadr-Eshkevari P, et al. Trigeminocardiac reflex during cerebellopontine angle surgery: anatomical location as a new risk factor. Future Neurol 2015; 10:7&#x2013;13.</Citation></Reference><Reference><Citation>Chowdhury T, Sandu N, Meuwly C, et al. Trigeminocardiac reflex: differential behavior and risk factors in the course of the trigeminal nerve. Future Neurol 2014; 9:41&#x2013;47.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">28662956</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8406</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of arthroplasty</Title><ISOAbbreviation>J Arthroplasty</ISOAbbreviation></Journal><ArticleTitle>Tranexamic Acid in Knee Surgery Study-A Multicentered, Randomized, Controlled Trial.</ArticleTitle><Pagination><StartPage>3379</StartPage><EndPage>3384</EndPage><MedlinePgn>3379-3384</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arth.2017.05.058</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-5403(17)30498-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Postoperative anemia following elective arthroplasty can lead to prolonged hospital stay and delays in rehabilitation and is often poorly tolerated in patients with cardiovascular disease. Tranexamic acid (TXA) has been shown to reduce perioperative blood loss in total knee arthroplasty (TKA). However, questions over its optimal route of administration remain.</AbstractText><AbstractText Label="METHODS">A double-blinded, placebo, multicentered, randomized, controlled trial investigating the efficacy of topical and systemic routes of a single intraoperative dose (1.5 g) of TXA was conducted. Patients undergoing primary, unilateral TKA were screened for eligibility. Eligible patients were consecutively enrolled from 5 New Zealand centers between July 2014 and November 2015. Three prospective groups running in parallel (topical TXA [tTXA], systemic TXA [sTXA], and placebo) were investigated for a primary outcome of estimated perioperative blood loss. An intention-to-treat analysis was used to compare outcomes between the study groups (P value &lt;.05).</AbstractText><AbstractText Label="RESULTS">One hundred and thirty-four patients across the 5 hospitals were recruited into the study. Estimated blood loss was equivalent in the 2 treatment groups, sTXA (749 mL [95% confidence interval, 637-860]) and tTXA (723 mL [620-826]). Compared to the placebo group (1090 mL [923-1257]), blood loss was significantly lower in both treatment groups (P&#xa0;= .001 and P&#xa0;= .0003, respectively). There were no significant differences in secondary outcomes, including rates of symptomatic deep vein thrombosis and pulmonary embolism (P&#xa0;= .759).</AbstractText><AbstractText Label="CONCLUSION">In the setting of elective TKA, a single 1.5-g dose of tTXA given intraoperatively either systemically or topically effectively reduces blood loss without an increase in complications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stowers</LastName><ForeName>Marinus D J</ForeName><Initials>MDJ</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Middlemore Hospital, Counties Manukau District Health Board (DHB), Auckland, New Zealand; Ko Awatea, Middlemore Hospital, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoina</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tauranga Hospital, Bay of Plenty DHB, Tauranga, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vane</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tauranga Hospital, Bay of Plenty DHB, Tauranga, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poutawera</LastName><ForeName>Vaughan</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tauranga Hospital, Bay of Plenty DHB, Tauranga, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Andrew G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>South Auckland Clinical Campus, University of Auckland, Middlemore Hospital, Auckland, New Zealand; Department of Surgery, Middlemore Hospital, Counties Manukau DHB, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munro</LastName><ForeName>Jacob T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Surgery, School of Medicine, University of Auckland, Auckland Clinical School, Auckland, New Zealand; Department of Orthopaedics, Auckland City Hospital, Auckland DHB, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02278263</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Arthroplasty</MedlineTA><NlmUniqueID>8703515</NlmUniqueID><ISSNLinking>0883-5403</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000777">Anesthetics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000777" MajorTopicYN="N">Anesthetics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="N">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="Y">Arthroplasty, Replacement, Knee</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007432" MajorTopicYN="N">Intraoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007717" MajorTopicYN="N">Knee</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009520" MajorTopicYN="N">New Zealand</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059035" MajorTopicYN="N">Perioperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="N">Tranexamic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TRACKS</Keyword><Keyword MajorTopicYN="N">blood transfusion</Keyword><Keyword MajorTopicYN="N">estimated blood loss</Keyword><Keyword MajorTopicYN="N">perioperative care</Keyword><Keyword MajorTopicYN="N">total knee arthroplasty</Keyword><Keyword MajorTopicYN="N">tranexamic acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28662956</ArticleId><ArticleId IdType="doi">10.1016/j.arth.2017.05.058</ArticleId><ArticleId IdType="pii">S0883-5403(17)30498-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36776649</PMID><DateRevised><Year>2023</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2631-827X</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Crohn's &amp; colitis 360</Title><ISOAbbreviation>Crohns Colitis 360</ISOAbbreviation></Journal><ArticleTitle>Perioperative Venous Thromboembolism in Ulcerative Colitis: A Multicenter Prospective Study in Japan.</ArticleTitle><Pagination><StartPage>otab024</StartPage><MedlinePgn>otab024</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">otab024</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/crocol/otab024</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Recently, the prevalence of venous thromboembolism (VTE) in Asian patients with inflammatory bowel disease (IBD) is gradually increasing. IBD surgery is a well-recognized risk factor for VTE. However, there are no prospective studies about VTE after surgery for ulcerative colitis (UC) in Asia. This multicenter prospective study aimed to clarify the prevalence and risk factors for perioperative VTE in UC surgery in Japan.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A total of 134 patients with UC were included from January 1, 2013 to December 31, 2014. Preoperative screening was performed in all patients. In the perioperative period, standard VTE prophylaxis based on risk assessment was administered. The prevalence of pre- and postoperative VTE, its risk factors, and mortality rates were investigated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Perioperative deep vein thrombosis and pulmonary embolism were diagnosed in 15 (11.1%) and 1 patient (0.7%), respectively. All patients were asymptomatic. No surgery-related deaths were found (mortality rate 0%). Seven patients (5.2%) were diagnosed, and 8 (6.4%) during postoperative follow-up by ultrasonography or computed tomography. Forty-seven percent of VTE cases was developed preoperatively. A preoperative hospital length stay of over 5 days was a significant risk factor [<i>P</i> = 0.04; odds ratio: 8.26 (1.06-64.60)] for preoperative VTE. Postoperative deep vein thrombosis occurred in 8 of the 127 patients (6.4%). Six out of these 8 (75.0%) occurred after postoperative day 14. Perioperative blood transfusion was a significant risk factor [<i>P</i> = 0.04; odds ratio: 8.26 (1.06-64.60)] for postoperative VTE.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">A VTE-conscious perioperative management is as necessary in Asia as in Western countries.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press on behalf of Crohn's &amp; Colitis Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Itabashi</LastName><ForeName>Michio</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2664-1984</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Inflammatory Bowel Disease Surgery, Hyogo College of Medicine, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Hideaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Inflammatory Bowel Disease Center, Yokohama City University Medical Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukushima</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Surgical and Molecular Pathophysiology, Tohoku University School of Medicine, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Hisao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Surgery, Nara Medical University, Nara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nezu</LastName><ForeName>Riichiro</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nishinomiya Municipal Center Hospital, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Futami</LastName><ForeName>Kitaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, Fukuoka University Chikushi Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugita</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inflammatory Bowel Disease Center, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Sakura Medical Center, Toho University, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hisamatsu</LastName><ForeName>Tadakazu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Kyorin University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crohns Colitis 360</MedlineTA><NlmUniqueID>101752188</NlmUniqueID><ISSNLinking>2631-827X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">inflammatory bowel disease</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">ulcerative colitis</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>13</Day><Hour>3</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>23</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>23</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>5</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36776649</ArticleId><ArticleId IdType="pmc">PMC9802445</ArticleId><ArticleId IdType="doi">10.1093/crocol/otab024</ArticleId><ArticleId IdType="pii">otab024</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kappelman MD, Horvath-Puho E, Sandler RS, et al. . Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011;60:937&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pubmed">21339206</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307809</ArticleId></ArticleIdList></Reference><Reference><Citation>Miehsler W, Reinisch W, Valic E, et al. . Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004;53:542&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1773996</ArticleId><ArticleId IdType="pubmed">15016749</ArticleId></ArticleIdList></Reference><Reference><Citation>Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol. 2011;106:713&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">21407182</ArticleId></ArticleIdList></Reference><Reference><Citation>Solem CA, Loftus EV, Tremaine WJ, et al. . Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99:97&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687149</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen GC, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:2272&#x2013;2280.</Citation><ArticleIdList><ArticleId IdType="pubmed">18684186</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson MZ, Connelly TM, Tinsley A, et al. . Ulcerative colitis is associated with an increased risk of venous thromboembolism in the postoperative period: the results of a matched cohort analysis. Ann Surg. 2015;261:1160&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pubmed">24983992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan GG, Lim A, Seow CH, et al. . Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. World J Gastroenterol. 2015;21:1251&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306170</ArticleId><ArticleId IdType="pubmed">25632199</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna NP, Behm KT, Ubl DS, et al. . Analysis of postoperative venous thromboembolism in patients with chronic ulcerative colitis: is it the disease or the operation? Dis Colon Rectum. 2017;60:714&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">28594721</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JY, Terdiman JP, Vittinghoff E, et al. . Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events. World J Gastroenterol. 2009;15:927&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2653404</ArticleId><ArticleId IdType="pubmed">19248191</ArticleId></ArticleIdList></Reference><Reference><Citation>Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">20149425</ArticleId></ArticleIdList></Reference><Reference><Citation>Papay P, Miehsler W, Tilg H, et al. . Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis. 2013;7:723&#x2013;729.</Citation><ArticleIdList><ArticleId IdType="pubmed">23127785</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady MT, Patts GJ, Rosen A, et al. . Postoperative venous thromboembolism in patients undergoing abdominal surgery for IBD: a common but rarely addressed problem. Dis Colon Rectum. 2017;60:61&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">27926558</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonoda K, Ikeda S, Mizuta Y, et al. . Evaluation of venous thromboembolism and coagulation-fibrinolysis markers in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2004;39:948&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">15549447</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcalay A, Wun T, Khatri V, et al. . Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 2006;24:1112&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505431</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatta K, Ogawa S, Itabashi M, et al. . d-dimer measurement for prediction of pre- and post-operative venous thromboembolism in general and abdominal surgical case. J Tokyo Wom Med Univ. 2014;84:E397&#x2013;E405.</Citation></Reference><Reference><Citation>Sakon M, Maehara Y, Yoshikawa H, Akaza H. Incidence of venous thromboembolism following major abdominal surgery: a multi-center, prospective epidemiological study in Japan. J Thromb Haemost. 2006;4:581&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pubmed">16460440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K, Fujiya M, Nomura Y, et al. . The incidence and risk factors of venous thromboembolism in Japanese inpatients with inflammatory bowel disease: a retrospective cohort study. Intest Res. 2018;16:416&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077312</ArticleId><ArticleId IdType="pubmed">30090041</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng MT, Park SH, Matsuoka K, et al. . Incidence and risk factor analysis of thromboembolic events in East Asian patients with inflammatory bowel disease, a multinational collaborative study. Inflamm Bowel Dis. 2018;24:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">29726897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando K, Fujiya M, Nomura Y, et al. . The incidence and risk factors of venous thromboembolism in patients with inflammatory bowel disease: a prospective multicenter cohort study. Digestion. 2019;100:229&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">30554225</ArticleId></ArticleIdList></Reference><Reference><Citation>Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51:70&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">15900257</ArticleId></ArticleIdList></Reference><Reference><Citation>JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011;75:1258&#x2013;1281.</Citation><ArticleIdList><ArticleId IdType="pubmed">21441695</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka K, Kobayashi T, Ueno F, et al. . Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5847182</ArticleId><ArticleId IdType="pubmed">29429045</ArticleId></ArticleIdList></Reference><Reference><Citation>Metcalf RL, Al-Hadithi E, Hopley N, et al. . Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers. World J Gastrointest Oncol. 2017;9:363&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5605336</ArticleId><ArticleId IdType="pubmed">28979718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalpit D, Nirav P, Simons-Linares CR, et al. . Trends in hospitalization and mortality of venous thromboembolism in hospitalized patients with colon cancer and their outcomes: US perspective. Clin Colorectal Cancer. 2017;16:E199&#x2013;E204.</Citation><ArticleIdList><ArticleId IdType="pubmed">27777043</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna NP, Habermann EB, Glasgow AE, et al. . Risk factors for readmission following ileal pouch-anal anastomosis: an American College of Surgeons National Surgical Quality Improvement Program analysis. J Surg Res. 2018;229:324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">29937009</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross ME, Vogler SA, Mone MC, et al. . The importance of extended postoperative venous thromboembolism prophylaxis in IBD: a National Surgical Quality Improvement Program analysis. Dis Colon Rectum. 2014;57:482&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">24608305</ArticleId></ArticleIdList></Reference><Reference><Citation>Vedovati MC, Becattini C, Rondelli F, et al. . A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014;259:665&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pubmed">24253138</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasue K, Eiji O, Koji A, et al. . Incidence of venous thromboembolism following laparoscopic surgery for gastrointestinal cancer: a single-center, prospective cohort study. World J Surg. 2016;40:309&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">26316113</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39126462</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1068</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of orthopaedic surgery &amp; traumatology : orthopedie traumatologie</Title><ISOAbbreviation>Eur J Orthop Surg Traumatol</ISOAbbreviation></Journal><ArticleTitle>Antithrombotic prophylaxis following total knee arthroplasty: a level I Bayesian network meta-analysis.</ArticleTitle><Pagination><StartPage>2881</StartPage><EndPage>2890</EndPage><MedlinePgn>2881-2890</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00590-024-04071-w</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Venous thromboembolism (VTE) is a major concern following total knee arthroplasty (TKA). The optimal pharmacological prophylaxis remains, however, controversial. The present investigation compared several non-vitamin K antagonist oral anticoagulants commonly employed as VTE prophylaxis following TKA. A Bayesian network meta-analysis was conducted to compare apixaban, aspirin, dabigatran, edoxaban, enoxaparin, fondaparinux, and rivaroxaban. The outcomes of interest were to compare the rate of deep venous thrombosis (DVT), pulmonary embolism (PE), and major and minor haemorrhages.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study was conducted according to the PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions. In March 2024, PubMed, Web of Science, and Google Scholar were accessed with no time constraints. All randomised controlled trials (RCTs) comparing two or more drugs for the prevention of VTE following TKA were considered for inclusion.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Data from 29,678 patients were collected. Of them, 67% (19,884 of 29,678 patients) were women. The mean age of the patients was 66.8&#x2009;&#xb1;&#x2009;2.8&#xa0;years, and the mean BMI was 29.2&#x2009;&#xb1;&#x2009;1.5&#xa0;kg/m<sup>2</sup>. There was comparability in age, sex, and BMI at baseline. Apixaban 5&#xa0;mg, dabigatran 220&#xa0;mg, and rivaroxaban 10&#xa0;mg were the most effective in reducing the rate of DVT. Apixaban 5&#xa0;mg, enoxaparin 60&#xa0;mg, and rivaroxaban 40&#xa0;mg were the most effective in reducing the rate of PE. Apixaban 5&#xa0;mg, rivaroxaban 10&#xa0;mg, and apixaban 10&#xa0;mg were associated with the lowest rate of major haemorrhages. Apixaban 5&#xa0;mg and 20&#xa0;mg, and dabigatran 220&#xa0;mg were associated with the lowest rate of minor haemorrhages.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Administration of apixaban 5&#xa0;mg demonstrated the best balance between VTE prevention and haemorrhage control following TKA.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Level I, network meta-analysis of RCTs.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Migliorini</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH University Medical Centre, 52074, Aachen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopedics and Trauma Surgery, Academic Hospital of Bolzano (SABES-ASDAA), 39100, Bolzano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic and Trauma Surgery, Eifelklinik St.Brigida, 52152, Simmerath, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Life Sciences, Health, and Health Professions, Link Campus University of Rome, Italy, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maffulli</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5327-3702</Identifier><AffiliationInfo><Affiliation>School of Pharmacy and Bioengineering, Faculty of Medicine, Keele University, Stoke On Trent, ST4 7QB, UK. n.maffulli@qmul.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Sports and Exercise Medicine, Barts and the London School of Medicine and Dentistry, Mile End Hospital, Queen Mary University of London, London, E1 4DG, UK. n.maffulli@qmul.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Trauma and Orthopaedic Surgery, Faculty of Medicine and Psychology, University La Sapienza, 00185, Rome, Italy. n.maffulli@qmul.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velaj</LastName><ForeName>Erlis</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH University Medical Centre, 52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic and Trauma Surgery, Eifelklinik St.Brigida, 52152, Simmerath, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xe4;mmer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic and Trauma Surgery, Eifelklinik St.Brigida, 52152, Simmerath, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Eschweiler</LastName><ForeName>J&#xf6;rg</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Trauma and Reconstructive Surgery, BG Hospital Bergmannstrost, Halle (Saale), Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hofmann</LastName><ForeName>Ulf Krister</ForeName><Initials>UK</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic, Trauma, and Reconstructive Surgery, RWTH University Medical Centre, 52074, Aachen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Orthop Surg Traumatol</MedlineTA><NlmUniqueID>9518037</NlmUniqueID><ISSNLinking>1633-8065</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>3Z9Y7UWC1J</RegistryNumber><NameOfSubstance UI="C522181">apixaban</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NDF7JZ4M3</RegistryNumber><NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011728">Pyridones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>I0VM4M70GC</RegistryNumber><NameOfSubstance UI="D000069604">Dabigatran</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>NDU3J18APO</RegistryNumber><NameOfSubstance UI="C552171">edoxaban</NameOfSubstance></Chemical><Chemical><RegistryNumber>J177FOW5JL</RegistryNumber><NameOfSubstance UI="D000077425">Fondaparinux</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="Y">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="Y">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069604" MajorTopicYN="N">Dabigatran</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077425" MajorTopicYN="N">Fondaparinux</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antithrombotic prophylaxis</Keyword><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Haemorrhages</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Total knee arthroplasty</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>10</Day><Hour>15</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>10</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39126462</ArticleId><ArticleId IdType="doi">10.1007/s00590-024-04071-w</ArticleId><ArticleId IdType="pii">10.1007/s00590-024-04071-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Salaffi F, Di Carlo M, Carotti M, Farah S, Giovagnoni A (2021) Frailty prevalence according to the survey of health, ageing and retirement in Europe-frailty instrument (SHARE-FI) definition, and its variables associated, in patients with symptomatic knee osteoarthritis: findings from a cross-sectional study. Aging Clin Exp Res 33:1519&#x2013;1527. https://doi.org/10.1007/s40520-020-01667-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-020-01667-0</ArticleId><ArticleId IdType="pubmed">32734577</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H et al (2019) The effects of a home-based exercise intervention on elderly patients with knee osteoarthritis: a quasi-experimental study. BMC Musculoskelet Disord 20:160. https://doi.org/10.1186/s12891-019-2521-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-019-2521-4</ArticleId><ArticleId IdType="pubmed">30967131</ArticleId><ArticleId IdType="pmc">6456993</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Jordan JM (2010) Epidemiology of osteoarthritis. Clin Geriatr Med 26:355&#x2013;369. https://doi.org/10.1016/j.cger.2010.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cger.2010.03.001</ArticleId><ArticleId IdType="pubmed">20699159</ArticleId><ArticleId IdType="pmc">2920533</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari B (2011) Knee osteoarthritis prevalence, risk factors, pathogenesis and features: part I. Casp J Intern Med 2:205&#x2013;212</Citation></Reference><Reference><Citation>Allen KD, Golightly YM (2015) State of the evidence. Curr Opin Rheumatol 27:276&#x2013;283. https://doi.org/10.1097/bor.0000000000000161</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/bor.0000000000000161</ArticleId><ArticleId IdType="pubmed">25775186</ArticleId><ArticleId IdType="pmc">4405030</ArticleId></ArticleIdList></Reference><Reference><Citation>Feeley BT, Gallo RA, Sherman S, Williams RJ (2010) Management of osteoarthritis of the knee in the active patient. J Am Acad Orthop Surg 18:406&#x2013;416. https://doi.org/10.5435/00124635-201007000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/00124635-201007000-00003</ArticleId><ArticleId IdType="pubmed">20595133</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild L et al (2022) Surgical outcomes and analysis of quality of life following knee arthroplasty in very elderly patients. J Knee Surg. https://doi.org/10.1055/s-0042-1747946</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0042-1747946</ArticleId><ArticleId IdType="pubmed">35901799</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean C (2017) Value-based purchasing for osteoarthritis and total knee arthroplasty: what role for patient-reported outcomes? J Am Acad Orthop Surg 25(Suppl 1):S55-s59. https://doi.org/10.5435/jaaos-d-16-00638</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/jaaos-d-16-00638</ArticleId><ArticleId IdType="pubmed">27984343</ArticleId></ArticleIdList></Reference><Reference><Citation>Dakin H, Gray A, Fitzpatrick R, Maclennan G, Murray D (2012) Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set. BMJ Open 2:e000332. https://doi.org/10.1136/bmjopen-2011-000332</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2011-000332</ArticleId><ArticleId IdType="pubmed">22290396</ArticleId><ArticleId IdType="pmc">3269047</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai WL, Lin ZM, Shi ZJ, Wang J (2020) Venous thromboembolic events after total knee arthroplasty: which patients are at a high risk? J Knee Surg 33:947&#x2013;957. https://doi.org/10.1055/s-0039-1688962</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1688962</ArticleId><ArticleId IdType="pubmed">31127600</ArticleId></ArticleIdList></Reference><Reference><Citation>White RH, Henderson MC (2002) Risk factors for venous thromboembolism after total hip and knee replacement surgery. Curr Opin Pulm Med 8:365&#x2013;371. https://doi.org/10.1097/00063198-200209000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00063198-200209000-00004</ArticleId><ArticleId IdType="pubmed">12172437</ArticleId></ArticleIdList></Reference><Reference><Citation>An VV, Phan K, Levy YD, Bruce WJ (2016) Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systematic review and meta-analysis. J Arthroplast 31:2608&#x2013;2616. https://doi.org/10.1016/j.arth.2016.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2016.04.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DR et al (2018) Aspirin or rivaroxaban for VTE Prophylaxis after hip or knee arthroplasty. N Engl J Med 378:699&#x2013;707. https://doi.org/10.1056/NEJMoa1712746</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1712746</ArticleId><ArticleId IdType="pubmed">29466159</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA (2015) Epidemiology of venous thromboembolism. Nat Rev Cardiol 12:464&#x2013;474. https://doi.org/10.1038/nrcardio.2015.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2015.83</ArticleId><ArticleId IdType="pubmed">26076949</ArticleId><ArticleId IdType="pmc">4624298</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly RF, Burgess IA, Zicat B (2005) The prevalence of venous thromboembolism after hip and knee replacement surgery. Med J Aust 182:154&#x2013;159. https://doi.org/10.5694/j.1326-5377.2005.tb06643.x</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/j.1326-5377.2005.tb06643.x</ArticleId><ArticleId IdType="pubmed">15720169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SY et al (2015) Incidence of deep vein thrombosis after major lower limb orthopedic surgery: analysis of a nationwide claim registry. Yonsei Med J 56:139&#x2013;145. https://doi.org/10.3349/ymj.2015.56.1.139</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2015.56.1.139</ArticleId><ArticleId IdType="pubmed">25510757</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA et al (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86:452&#x2013;463</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1616243</ArticleId><ArticleId IdType="pubmed">11487036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan M, Sheth N, Lee GC (2019) Is obesity associated with increased risk of deep vein thrombosis or pulmonary embolism after hip and knee arthroplasty? A large database study. Clin Orthop Relat Res 477:523&#x2013;532. https://doi.org/10.1097/corr.0000000000000615</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/corr.0000000000000615</ArticleId><ArticleId IdType="pubmed">30624321</ArticleId><ArticleId IdType="pmc">6382191</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaffer AK et al (2005) Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty. Mayo Clin Proc 80:732&#x2013;738. https://doi.org/10.1016/s0025-6196(11)61526-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0025-6196(11)61526-7</ArticleId><ArticleId IdType="pubmed">15945526</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Chen Z, Zheng J, Breusch SJ, Tian J (2015) Risk factors for venous thromboembolism after total hip and total knee arthroplasty: a meta-analysis. Arch Orthop Trauma Surg 135:759&#x2013;772. https://doi.org/10.1007/s00402-015-2208-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-015-2208-8</ArticleId><ArticleId IdType="pubmed">25854654</ArticleId></ArticleIdList></Reference><Reference><Citation>Gathof BS, Picker SM, Rojo J (2004) Epidemiology, etiology and diagnosis of venous thrombosis. Eur J Med Res 9:95&#x2013;103</Citation><ArticleIdList><ArticleId IdType="pubmed">15096318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C (2001) Epidemiology of venous thromboembolism. Semin Vasc Med 1:7&#x2013;26. https://doi.org/10.1055/s-2001-14668</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2001-14668</ArticleId><ArticleId IdType="pubmed">15199510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ (2019) Deep vein thrombosis: update on diagnosis and management. Med J Aust 210:516&#x2013;524. https://doi.org/10.5694/mja2.50201</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja2.50201</ArticleId><ArticleId IdType="pubmed">31155730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim W et al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv 2:3226&#x2013;3256. https://doi.org/10.1182/bloodadvances.2018024828</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2018024828</ArticleId><ArticleId IdType="pubmed">30482764</ArticleId><ArticleId IdType="pmc">6258916</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahi A et al (2018) What are the incidence and risk factors of in-hospital mortality after venous thromboembolism events in total hip and knee arthroplasty patients? Arthroplast Today 4:343&#x2013;347. https://doi.org/10.1016/j.artd.2018.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.artd.2018.02.014</ArticleId><ArticleId IdType="pubmed">30186919</ArticleId><ArticleId IdType="pmc">6123180</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller K et al (2020) Venous thromboembolism in patients hospitalized for knee joint replacement surgery. Sci Rep 10:22440. https://doi.org/10.1038/s41598-020-79490-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-79490-w</ArticleId><ArticleId IdType="pubmed">33384429</ArticleId><ArticleId IdType="pmc">7775461</ArticleId></ArticleIdList></Reference><Reference><Citation>Quah C, Bayley E, Bhamber N, Howard P (2017) Fatal pulmonary embolism following elective total knee replacement using aspirin in multi-modal prophylaxis&#x2014;a 12&#xa0;year study. Knee 24:1187&#x2013;1190. https://doi.org/10.1016/j.knee.2017.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.knee.2017.05.021</ArticleId><ArticleId IdType="pubmed">28622843</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudipati S et al (2014) A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patients. BMC Med 12:39. https://doi.org/10.1186/1741-7015-12-39</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-12-39</ArticleId><ArticleId IdType="pubmed">24589368</ArticleId><ArticleId IdType="pmc">3996019</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts WH et al (2001) Prevention of venous thromboembolism. Chest 119:132s&#x2013;175s. https://doi.org/10.1378/chest.119.1_suppl.132s</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.119.1_suppl.132s</ArticleId><ArticleId IdType="pubmed">11157647</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM (1993) Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment. Arch Intern Med 153:2221&#x2013;2228</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1993.00410190057007</ArticleId><ArticleId IdType="pubmed">8215725</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson BI et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765&#x2013;2775. https://doi.org/10.1056/NEJMoa0800374</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0800374</ArticleId><ArticleId IdType="pubmed">18579811</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenny JY et al (2020) Bleeding and thromboembolism risk of standard antithrombotic prophylaxis after hip or knee replacement within an enhanced recovery program. Orthop Traumatol Surg Res 106:1533&#x2013;1538. https://doi.org/10.1016/j.otsr.2020.02.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2020.02.026</ArticleId><ArticleId IdType="pubmed">33127330</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, Zhang T, Yang Z, Nie L (2018) Effect of different types of anticoagulants in the prevention of venous thrombosis in the operation of knee joint bone operation. Pak J Pharm Sci 31:1093&#x2013;1097</Citation><ArticleIdList><ArticleId IdType="pubmed">29735456</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Ma J, Huang Q, Yue C, Pei F (2017) Comparison of enoxaparin and rivaroxaban in balance of anti-fibrinolysis and anticoagulation following primary total knee replacement: a pilot study. Med Sci Monit 23:704&#x2013;711. https://doi.org/10.12659/msm.900059</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/msm.900059</ArticleId><ArticleId IdType="pubmed">28174415</ArticleId><ArticleId IdType="pmc">5312245</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie AG et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673&#x2013;1680. https://doi.org/10.1016/s0140-6736(09)60734-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(09)60734-0</ArticleId><ArticleId IdType="pubmed">19411100</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuenyongviwat V et al (2019) Aspirin versus rivaroxaban in postoperative bleeding after total knee arthroplasty: a retrospective case-matched study. Eur J Orthop Surg Traumatol 29:877&#x2013;881. https://doi.org/10.1007/s00590-019-02365-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-019-02365-y</ArticleId><ArticleId IdType="pubmed">30627921</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Y, Tian S, Wang Y, Sun K (2014) Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagul Fibrinolysis 25:660&#x2013;664. https://doi.org/10.1097/MBC.0000000000000121</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBC.0000000000000121</ArticleId><ArticleId IdType="pubmed">24695091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji T et al (2014) Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial. Thromb Res 134:1198&#x2013;1204. https://doi.org/10.1016/j.thromres.2014.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2014.09.011</ArticleId><ArticleId IdType="pubmed">25294589</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson BI et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE&#x2010;MODEL randomized trial. J Thromb Haemost 5(11):2178&#x2013;2185. https://doi.org/10.1111/j.1538-7836.2007.02748.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2007.02748.x</ArticleId><ArticleId IdType="pubmed">17764540</ArticleId></ArticleIdList></Reference><Reference><Citation>Colleoni JL et al (2018) Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban. Rev Bras de Ortop 53(1):22&#x2013;27. https://doi.org/10.1016/j.rboe.2017.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rboe.2017.11.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer KA, Eriksson BI, Lassen MR, Turpie AG (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. New Engl J Med 345(18):1305&#x2013;1310. https://doi.org/10.1056/NEJMoa011099</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa011099</ArticleId><ArticleId IdType="pubmed">11794149</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Du H, Liu J, Zhou Y (2014) Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Chin Med J (Engl) 127:2201&#x2013;2205</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0366-6999.20132175</ArticleId><ArticleId IdType="pubmed">24931228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen MR et al (2007) The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 5:2368&#x2013;2375. https://doi.org/10.1111/j.1538-7836.2007.02764.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2007.02764.x</ArticleId><ArticleId IdType="pubmed">17868430</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen MR et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776&#x2013;2786. https://doi.org/10.1056/NEJMoa076016</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa076016</ArticleId><ArticleId IdType="pubmed">18579812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen MR et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594&#x2013;604. https://doi.org/10.1056/NEJMoa0810773</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0810773</ArticleId><ArticleId IdType="pubmed">19657123</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen MR et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807&#x2013;815. https://doi.org/10.1016/s0140-6736(09)62125-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(09)62125-5</ArticleId><ArticleId IdType="pubmed">20206776</ArticleId></ArticleIdList></Reference><Reference><Citation>Leclerc JR et al (1996) Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 124(7):619&#x2013;626. https://doi.org/10.7326/0003-4819-124-7-199604010-00001</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-124-7-199604010-00001</ArticleId><ArticleId IdType="pubmed">8607589</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineo GF et al (2013) Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost 11:444&#x2013;451. https://doi.org/10.1111/jth.12109</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12109</ArticleId><ArticleId IdType="pubmed">23279103</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie AG et al (2005) BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3(11):2479&#x2013;2486. https://doi.org/10.1111/j.1538-7836.2005.01602.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01602.x</ArticleId><ArticleId IdType="pubmed">16241946</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg JS et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplast 24:1&#x2013;9. https://doi.org/10.1016/j.arth.2008.01.132</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2008.01.132</ArticleId></ArticleIdList></Reference><Reference><Citation>Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, Moschetti I, Phillips B, Thornton H, Goddard O, Hodgkinson M (2011) The 2011 Oxford CEBM Levels of evidence. Oxford Centre for evidence-based medicine. Available at https://www.cebm.net/index.aspx?o=5653</Citation></Reference><Reference><Citation>Hutton B et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777&#x2013;784. https://doi.org/10.7326/M14-2385</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-2385</ArticleId><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M et al (2019) Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:ED000142. https://doi.org/10.1002/14651858.ED000142</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.ED000142</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2021) Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane 2021. Available from www.training.cochrane.org/handbook . Accessed on February 2022</Citation></Reference><Reference><Citation>Junqueira DR, Zorzela LM, Perini E (2017) Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 4:CD007557. https://doi.org/10.1002/14651858.CD007557.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD007557.pub3</ArticleId><ArticleId IdType="pubmed">28431186</ArticleId></ArticleIdList></Reference><Reference><Citation>Falck-Ytter Y et al (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest 141:e278S-e325S. https://doi.org/10.1378/chest.11-2404</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2404</ArticleId><ArticleId IdType="pubmed">22315265</ArticleId><ArticleId IdType="pmc">3278063</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CW (2013) Prevention of VTE in patients having major orthopedic surgery. J Thromb Thromb 35:359&#x2013;367. https://doi.org/10.1007/s11239-013-0889-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-013-0889-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson BI, Bauer KA, Lassen MR, Turpie AG (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. New Engl J Med 345(18):1298&#x2013;1304. https://doi.org/10.1056/NEJMoa011100</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa011100</ArticleId><ArticleId IdType="pubmed">11794148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen MR, Bauer KA, Eriksson BI, Turpie AG (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359:1715&#x2013;1720. https://doi.org/10.1016/s0140-6736(02)08652-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(02)08652-x</ArticleId><ArticleId IdType="pubmed">12049858</ArticleId></ArticleIdList></Reference><Reference><Citation>Trudelle-Jackson E, Emerson R, Smith S (2002) Outcomes of total hip arthroplasty: a study of patients one year postsurgery. J Orthop Sports Phys Ther 32:260&#x2013;267. https://doi.org/10.2519/jospt.2002.32.6.260</Citation><ArticleIdList><ArticleId IdType="doi">10.2519/jospt.2002.32.6.260</ArticleId><ArticleId IdType="pubmed">12061707</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson BI et al (2003) The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 1:2490&#x2013;2496. https://doi.org/10.1111/j.1538-7836.2003.00494.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2003.00494.x</ArticleId><ArticleId IdType="pubmed">14675083</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson BI et al (2006) Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4:121&#x2013;128. https://doi.org/10.1111/j.1538-7836.2005.01657.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2005.01657.x</ArticleId><ArticleId IdType="pubmed">16409461</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson BI et al (2006) A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 114:2374&#x2013;2381. https://doi.org/10.1161/CIRCULATIONAHA.106.642074</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.642074</ArticleId><ArticleId IdType="pubmed">17116766</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson BI et al (2007) Dose-escalation study of rivaroxaban (BAY 59-7939)&#x2014;an oral, direct Factor Xa inhibitor&#x2014;for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120:685&#x2013;693. https://doi.org/10.1016/j.thromres.2006.12.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2006.12.025</ArticleId><ArticleId IdType="pubmed">17292948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkar AK et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31&#x2013;39. https://doi.org/10.1016/S0140-6736(08)60880-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(08)60880-6</ArticleId><ArticleId IdType="pubmed">18582928</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao YB, Zhang JD, Shen H, Jiang YY (2010) Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 66:1099&#x2013;1108. https://doi.org/10.1007/s00228-010-0889-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-010-0889-z</ArticleId><ArticleId IdType="pubmed">20812009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassen MR et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363:2487&#x2013;2498. https://doi.org/10.1056/NEJMoa1006885</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1006885</ArticleId><ArticleId IdType="pubmed">21175312</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson BI et al (2011) Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 105:721&#x2013;729. https://doi.org/10.1160/TH10-10-0679</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH10-10-0679</ArticleId><ArticleId IdType="pubmed">21225098</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskob GE et al (2012) Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 94:257&#x2013;264. https://doi.org/10.1302/0301-620X.94B2.27850</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.94B2.27850</ArticleId><ArticleId IdType="pubmed">22323697</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji T et al (2014) Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty 29:2439&#x2013;2446. https://doi.org/10.1016/j.arth.2014.05.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2014.05.029</ArticleId><ArticleId IdType="pubmed">25047458</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuji T et al (2015) Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thromb J 13:27. https://doi.org/10.1186/s12959-015-0057-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-015-0057-x</ArticleId><ArticleId IdType="pubmed">26269694</ArticleId><ArticleId IdType="pmc">4534125</ArticleId></ArticleIdList></Reference><Reference><Citation>Jupalli A, Iqbal AM (2022) In StatPearls (StatPearls Publishing Copyright&#xa9; 2022, StatPearls Publishing LLC., 2022)</Citation></Reference><Reference><Citation>Fareed J et al (2003) Pharmacodynamic and pharmacokinetic properties of enoxaparin&#x202f;: implications for clinical practice. Clin Pharmacokinet 42:1043&#x2013;1057. https://doi.org/10.2165/00003088-200342120-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200342120-00003</ArticleId><ArticleId IdType="pubmed">12959635</ArticleId></ArticleIdList></Reference><Reference><Citation>Byon W, Garonzik S, Boyd RA, Frost CE (2019) Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 58:1265&#x2013;1279. https://doi.org/10.1007/s40262-019-00775-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-019-00775-z</ArticleId><ArticleId IdType="pubmed">31089975</ArticleId><ArticleId IdType="pmc">6769096</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvasnicka T et al (2017) Rivaroxaban&#x2014;metabolism, pharmacologic properties and drug interactions. Curr Drug Metab 18:636&#x2013;642. https://doi.org/10.2174/1389200218666170518165443</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389200218666170518165443</ArticleId><ArticleId IdType="pubmed">28524005</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S, Singh R, Preuss CV, Patel N (2022) In StatPearls (StatPearls Publishing Copyright&#xa9; 2022, StatPearls Publishing LLC., 2022).</Citation></Reference><Reference><Citation>Comin J, Kallmes DF (2012) Dabigatran (Pradaxa). AJNR Am J Neuroradiol 33:426&#x2013;428. https://doi.org/10.3174/ajnr.A3000</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A3000</ArticleId><ArticleId IdType="pubmed">22345499</ArticleId><ArticleId IdType="pmc">7966436</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman R, Luciardi HL, Muntaner J, Herrera RN (2004) The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J 2:1. https://doi.org/10.1186/1477-9560-2-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-9560-2-1</ArticleId><ArticleId IdType="pubmed">14723795</ArticleId><ArticleId IdType="pmc">331420</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowther MA, Berry LR, Monagle PT, Chan AK (2002) Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116:178&#x2013;186. https://doi.org/10.1046/j.1365-2141.2002.03233.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.2002.03233.x</ArticleId><ArticleId IdType="pubmed">11841415</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36397431</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>45</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>11</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Pulmonary embolism risk in hospitalized patients with nonalcoholic fatty liver disease: A case-control study.</ArticleTitle><Pagination><StartPage>e31710</StartPage><MedlinePgn>e31710</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e31710</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000031710</ELocationID><Abstract><AbstractText>Abundant research has associated nonalcoholic fatty liver disease (NAFLD) with atherosclerosis, but very few reports have evaluated the association between NAFLD and venous thromboembolism. We aimed to investigate the association between NAFLD and pulmonary embolism (PE) in hospitalized patients. In this retrospective case-control study, we included consecutive patients from 2 university-affiliated hospitals who were referred for CT pulmonary angiograms for a suspected PE. Patients with a history of excessive alcohol consumption, chronic liver diseases or cirrhosis were excluded. The imaging studies of the entire cohort were reviewed by 2 expert radiologists who confirmed the diagnosis of PE and examined the liver to detect and grade hepatic steatosis. Accordingly, patients were categorized into NAFLD patients and non-NAFLD controls. Patient demographics, medical history, hospitalization details as well as patients' outcomes were documented. Multivariate analysis was performed to identify predictors for developing PE and hazard ratios with corresponding 95% confidence intervals were estimated. A total of 377 patients (101 with NAFLD and 276 controls) were included. NAFLD patients had significantly higher BMI values (33.16&#x2005;&#xb1;&#x2005;6.78 vs 26.81&#x2005;&#xb1;&#x2005;5.6; P&#x2005;&lt;&#x2005;.001) and prevalence of diabetes (41 (40%) vs 85 (30.8%); P&#x2005;=&#x2005;.03). The prevalence of PE was significantly higher in the NAFLD group (80 (79.2%) vs 147 (53.3%), P&#x2005;&lt;&#x2005;.001). In a multivariate analysis, older age, recent surgery or trauma, active malignancy, smoking, and NAFLD (HR ratio&#x2005;=&#x2005;4.339, P&#x2005;&lt;&#x2005;.0001 and 95% CI&#x2005;=&#x2005;2.196-8.572) were independently associated with PE development. Patients with NAFLD were associated with an increased risk of developing PE independent of other classical risk factors for PE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeina</LastName><ForeName>Abdel-Rauf</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Radiology, Hillel Yaffe Medical Center, Hadera, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopelman</LastName><ForeName>Yael</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Hadera, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mari</LastName><ForeName>Amir</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Nazareth EMMS Hospital, Nazareth, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Helal Said</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Nazareth EMMS Hospital, Nazareth, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Artul</LastName><ForeName>Suheil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiology, Nazareth EMMS Hospital, Nazareth, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalaila</LastName><ForeName>Ali Sleman</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nazareth EMMS Hospital, Nazareth, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taher</LastName><ForeName>Randa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hillel Yaffe Medical Center, Hadera, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villannueva</LastName><ForeName>Fernando Zertuche</ForeName><Initials>FZ</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Hadera, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Safadi</LastName><ForeName>Rabea</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiology, Hillel Yaffe Medical Center, Hadera, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu Mouch</LastName><ForeName>Saif</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hillel Yaffe Medical Center, Hadera, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu Baker</LastName><ForeName>Fadi</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-5428-7180</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Hadera, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065626" MajorTopicYN="Y">Non-alcoholic Fatty Liver Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36397431</ArticleId><ArticleId IdType="pmc">PMC9666162</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000031710</ArticleId><ArticleId IdType="pii">00005792-202211110-00115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matteoni CA, Younossi ZM, Gramlich T, et al. . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10348825</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastro Hepatol. 2012;10:837&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">22446927</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchesini G, Brizi M, Morselli-Labate AM, et al. . Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569299</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong RJ, Aguilar M, Cheung R, et al. . Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">25461851</ArticleId></ArticleIdList></Reference><Reference><Citation>Flegal KM, Carroll MD, Ogden CL, et al. . Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">20071471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28:339&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18956290</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:501&#x2013;19, vii.</Citation><ArticleIdList><ArticleId IdType="pubmed">15331060</ArticleId></ArticleIdList></Reference><Reference><Citation>Browning JD, Szczepaniak LS, Dobbins R, et al. . Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15565570</ArticleId></ArticleIdList></Reference><Reference><Citation>Falck-Ytter Y, Younossi ZM, Marchesini G, et al. . Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001;21:17&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">11296693</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortez-Pinto H, Camilo ME, Baptista A, et al. . Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634920</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong MJ, Adams LA, Canbay A, et al. . Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">24002776</ArticleId></ArticleIdList></Reference><Reference><Citation>Musso G, Gambino R, Tabibian JH, et al. . Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106719</ArticleId><ArticleId IdType="pubmed">25050550</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijay LM, Mouen K, Naga C. Non-alcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep. 2009;11:50&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732016</ArticleId><ArticleId IdType="pubmed">19166659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong VW, Wong GL, Tsang SW, et al. . High prevalence of colorectal neoplasm in patients with nonalcoholic steatohepatitis. Gut. 2011;60:829&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">21339204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008;49:600&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18672311</ArticleId></ArticleIdList></Reference><Reference><Citation>Oni ET, Agatston AS, Blaha MJ, et al. . A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230:258&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">24075754</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander M, Loomis AK, van der Lei J, et al. . Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019;367:l5367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6780322</ArticleId><ArticleId IdType="pubmed">31594780</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotronen A, Joutsi-Korhonen L, Sevastianova K, et al. . Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int. 2011;31:176&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">21134109</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripodi A, Fracanzani AL, Primignani M, et al. . Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;61:148&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">24657400</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25920090</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Scorletti E, Mosca A, et al. . Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154170.</Citation><ArticleIdList><ArticleId IdType="pubmed">32006558</ArticleId></ArticleIdList></Reference><Reference><Citation>Darze ES, Latado AL, Guimar&#xe3;es AG, et al. . Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest. 2005;128:2576&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">16236926</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA, O&#x2019;Fallon WM, Petterson TM, et al. . Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12038942</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Grodstein F, Stampfer MJ, et al. . A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277:642&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9039882</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Minno MND, Tufano A, Rusolillo A, et al. . High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol. 2010;16:6119&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012581</ArticleId><ArticleId IdType="pubmed">21182227</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Razik A, Mousa N, Shabana W, et al. . De novo portal vein thrombosis in non-cirrhotic non-alcoholic fatty liver disease: a 9-year prospective cohort study. Front Med (Lausanne). 2021;8:650818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117420</ArticleId><ArticleId IdType="pubmed">33996858</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine JG, Niccum BA, Zimmet AN, et al. . Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis. Clin Transl Gastroenterol. 2018;9:140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5862151</ArticleId><ArticleId IdType="pubmed">29511162</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine JG, Argo CK, Pelletier SJ, et al. . Advanced non-alcoholic steatohepatitis cirrhosis: a high-risk population for pre-liver transplant portal vein thrombosis. World J Hepatol. 2017;9:139&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5295147</ArticleId><ArticleId IdType="pubmed">28217250</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinosa M, Stine JG. Nonalcoholic fatty liver disease-evidence for a thrombophilic state? Curr Pharm Des. 2020;26:1036&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7226677</ArticleId><ArticleId IdType="pubmed">32003679</ArticleId></ArticleIdList></Reference><Reference><Citation>Potze W, Siddiqui MS, Sanyal AJ. Vascular disease in patients with nonalcoholic fatty liver disease. Semin Thromb Hemost. 2015;41:488&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">26049073</ArticleId></ArticleIdList></Reference><Reference><Citation>Targher G, Zoppini G, Moghetti P, et al. . Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin Thromb Hemost. 2010;36:41&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20391295</ArticleId></ArticleIdList></Reference><Reference><Citation>Targher G, Bertolini L, Rodella S, et al. . NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring). 2008;16:1394&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18369343</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37274017</PMID><DateRevised><Year>2023</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2731-3786</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Journal of anesthesia, analgesia and critical care</Title><ISOAbbreviation>J Anesth Analg Crit Care</ISOAbbreviation></Journal><ArticleTitle>Does COVID-19 vaccination protect against pulmonary embolism?</ArticleTitle><Pagination><StartPage>14</StartPage><MedlinePgn>14</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s44158-023-00097-4</ELocationID><Abstract><AbstractText>The prevalence of venous thromboembolism (VTE) in COVID-19 patients is highly variable, depending on methodological and clinical factors, among which vaccination (1). The hypothesis of a possible protective role of vaccination in preventing pulmonary embolism (PE) in hospitalized COVID-19 patients has not been explored. The aim of the study was to evaluate PE prevalence in vaccinated versus unvaccinated hospitalized COVID-19 patients. We conducted a retrospective case-control study from 2021/11/01 to 2022/01/15; we reviewed all the chest computed topographies (chest-CT) performed because of a clinical suspicion for PE at our Institution. Sixty-two patients were included in the study: 27/62 (43.5%) were vaccinated and 35/62 (56.4%) were not. Vaccinated patients were older and with more comorbidities than unvaccinated people. Overall, PE was diagnosed in 19/62 patients (30.1% prevalence). CT Severity Score (CT-SS) differs between the two groups; not vaccinated patients had a more severe CT imaging than the vaccinated (&lt;&#x2009;0.00005). PE prevalence in ICU was 43.2% (16/37 patients), while in the Internal Medicine ward, it was 12% (3/25 cases). PE was significantly higher among unvaccinated people: 16/35 (45.7%) vs 3/27 (11.1%), OR <i>p</i>&#x2009;=&#x2009;0.04. We observed a strong association between vaccination and protection from PE in hospitalized COVID-19 patients: morbidity was significantly lower in vaccinated versus not vaccinated patients. The issue of the protective role of vaccination in COVID-19-associated VTE should be addressed in adequately designed and powered future prospective studies.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tantillo</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bologna, Italy Department of Anaesthesia, Intensive Care and EMS, Ospedale Maggiore "Carlo Alberto Pizzardi".</Affiliation><Identifier Source="GRID">grid.416290.8</Identifier><Identifier Source="ISNI">0000 0004 1759 7093</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cilloni</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Bologna, Italy Department of Anaesthesia, Intensive Care and EMS, Ospedale Maggiore "Carlo Alberto Pizzardi".</Affiliation><Identifier Source="GRID">grid.416290.8</Identifier><Identifier Source="ISNI">0000 0004 1759 7093</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarnera</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8266-0595</Identifier><AffiliationInfo><Affiliation>Bologna, Italy Department of Anaesthesia, Intensive Care and EMS, Ospedale Maggiore "Carlo Alberto Pizzardi".</Affiliation><Identifier Source="GRID">grid.416290.8</Identifier><Identifier Source="ISNI">0000 0004 1759 7093</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talarico</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Bologna, Italy Department of Anaesthesia, Intensive Care and EMS, Ospedale Maggiore "Carlo Alberto Pizzardi".</Affiliation><Identifier Source="GRID">grid.416290.8</Identifier><Identifier Source="ISNI">0000 0004 1759 7093</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Citino</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bologna, Italy Department of Anaesthesia, Intensive Care and EMS, Ospedale Maggiore "Carlo Alberto Pizzardi".</Affiliation><Identifier Source="GRID">grid.416290.8</Identifier><Identifier Source="ISNI">0000 0004 1759 7093</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silingardi</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bologna, Italy Department of Internal Medicine, Ospedale Maggiore "Carlo Alberto Pizzardi".</Affiliation><Identifier Source="GRID">grid.416290.8</Identifier><Identifier Source="ISNI">0000 0004 1759 7093</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catalano</LastName><ForeName>Leonardo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Radiology Unit, Ospedle Maggiore "Carlo Alberto Pizzardi", Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imbriani</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Radiology Unit, Ospedle Maggiore "Carlo Alberto Pizzardi", Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Anesth Analg Crit Care</MedlineTA><NlmUniqueID>9918591885906676</NlmUniqueID><ISSNLinking>2731-3786</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Unvaccinated patients</Keyword><Keyword MajorTopicYN="N">Vaccinated patients</Keyword></KeywordList><CoiStatement>Competing interestsThe authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>13</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>11</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37274017</ArticleId><ArticleId IdType="pmc">PMC10227776</ArticleId><ArticleId IdType="doi">10.1186/s44158-023-00097-4</ArticleId><ArticleId IdType="pii">97</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nab L, Groenwold RHH, Klok FA, Bhoelan S, Kruip MJHA, Cannegieter SC. Estimating incidence of venous thromboembolism in COVID-19: Methodological considerations. Res Pract Thromb Haemost. 2022;6(6):e12776. doi: 10.1002/rth2.12776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12776</ArticleId><ArticleId IdType="pmc">PMC9376932</ArticleId><ArticleId IdType="pubmed">35992195</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Prats-Uribe A, Feng Q, et al. Clinical and genetic risk factors for acute incident venous thromboembolism in ambulatory patients with COVID-19. JAMA Intern Med. 2022;182(10):1063&#x2013;1070. doi: 10.1001/jamainternmed.2022.3858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2022.3858</ArticleId><ArticleId IdType="pmc">PMC9389434</ArticleId><ArticleId IdType="pubmed">35980616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieveld AWE, Azijli K, Teunissen BP, et al. Chest CT in COVID-19 at the ED: Validation of the COVID-19 Reporting and Data System (CO-RADS) and CT Severity Score: a Prospective, Multicenter Observational Study. Chest. 2021;159(3):1126&#x2013;1135. doi: 10.1016/j.chest.2020.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.11.026</ArticleId><ArticleId IdType="pmc">PMC7704067</ArticleId><ArticleId IdType="pubmed">33271157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuswardhani RAT, Henrina J, Pranata R, Lim MA, Lawrensia S, Suastika K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr Nov-Dec. 2020;14(6):2103&#x2013;2109. doi: 10.1016/j.dsx.2020.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.10.022</ArticleId><ArticleId IdType="pmc">PMC7598371</ArticleId><ArticleId IdType="pubmed">33161221</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway EM, Mackman N, Warren RQ, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 2022;22(10):639&#x2013;649. doi: 10.1038/s41577-022-00762-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00762-9</ArticleId><ArticleId IdType="pmc">PMC9362465</ArticleId><ArticleId IdType="pubmed">35931818</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrati C, Carsetti R, Bordoni V, et al. The immune response as a double-edged sword: the lesson learnt during the COVID-19 pandemic. Immunology. 2022;167(3):287&#x2013;302. doi: 10.1111/imm.13564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13564</ArticleId><ArticleId IdType="pmc">PMC9538066</ArticleId><ArticleId IdType="pubmed">35971810</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzani A, Cutti S, Arici V, Ragni F, Sterpetti AV, Arbustini E. Venous thromboembolism in hospitalized coronavirus disease 2019 patients stratified by vaccination status. J Vasc Surg Venous Lymphat Disord. 2023;11(2):473&#x2013;474. doi: 10.1016/j.jvsv.2022.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvsv.2022.10.011</ArticleId><ArticleId IdType="pmc">PMC9943527</ArticleId><ArticleId IdType="pubmed">36822798</ArticleId></ArticleIdList></Reference><Reference><Citation>Houghton DE, Wysokinski W, Casanegra AI, et al. Risk of venous thromboembolism after COVID-19 vaccination. J Thromb Haemost. 2022;20(7):1638&#x2013;1644. doi: 10.1111/jth.15725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15725</ArticleId><ArticleId IdType="pmc">PMC9115120</ArticleId><ArticleId IdType="pubmed">35398975</ArticleId></ArticleIdList></Reference><Reference><Citation>Law N, Chan J, Kelly C, Auffermann WF, Dunn DP. Incidence of pulmonary embolism in COVID-19 infection in the ED: ancestral, Delta Omicron variants and vaccines. Emerg Radiol. 2022;29(4):625&#x2013;629. doi: 10.1007/s10140-022-02039-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10140-022-02039-z</ArticleId><ArticleId IdType="pmc">PMC9022402</ArticleId><ArticleId IdType="pubmed">35446000</ArticleId></ArticleIdList></Reference><Reference><Citation>Gra&#xf1;a C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022;7(12):CD015477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726273</ArticleId><ArticleId IdType="pubmed">36473651</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhikari B, YeongCheah P, von Seidlein L. Trust is the common denominator for COVID-19 vaccine acceptance: a literature review. Vaccine X. 2022;12:100213. doi: 10.1016/j.jvacx.2022.100213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvacx.2022.100213</ArticleId><ArticleId IdType="pmc">PMC9536059</ArticleId><ArticleId IdType="pubmed">36217424</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35307608</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-3348</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of vascular surgery. Venous and lymphatic disorders</Title><ISOAbbreviation>J Vasc Surg Venous Lymphat Disord</ISOAbbreviation></Journal><ArticleTitle>A systematic review and meta-analysis of racial disparities in deep vein thrombosis and pulmonary embolism events in patients hospitalized with coronavirus disease 2019.</ArticleTitle><Pagination><StartPage>939</StartPage><EndPage>944.e3</EndPage><MedlinePgn>939-944.e3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvsv.2022.03.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-333X(22)00100-7</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Coronavirus disease 2019 (COVID-19) is associated with an increased risk of venous thromboembolism (VTE). Recent studies have characterized racial disparities in the incidence of VTE. The aim of our study was to present a systematic review and meta-analysis to assess the association between race and VTE in patients hospitalized with COVID-19.</AbstractText><AbstractText Label="METHODS">We performed a systematic literature review to evaluate the number of deep vein thrombosis (DVT) and pulmonary embolism (PE) events reported by racial groups in patients hospitalized with COVID-19. For the qualitative analysis, independent reviewers extracted the data from eligible studies, and we used the Newcastle-Ottawa scale to assess the quality of design and content for accurate interpretation. For the quantitative analysis, we pooled the odds ratios with Der Simonian and Laird random effects models.</AbstractText><AbstractText Label="RESULTS">The qualitative analysis included 11 studies, with 6 included in the meta-analysis. All studies were observational, retrospective cohort studies, except for one retrospective case-control study. Six studies were eligible for the meta-analysis owing to the high interstudy heterogeneity; thus, the variable reports of racial groups reduced the cohort to Black/African American and White patients (n&#xa0;= 9723) in the analysis. The estimated proportion for DVT and PE events for Black/African American and White patients was 0.07 (95% confidence interval, 0.00-0.10) and 0.04 (95% confidence interval, 0.00-0.07), respectively. The P value of .13 suggested nonsignificant differences in the VTE rates between Black/African American and White patients.</AbstractText><AbstractText Label="CONCLUSIONS">In our study, the proportion of DVT and PE events between Black/African American and White patients with COVID-19 were comparable. Future COVID-19 studies should include systematic racial group reporting to identify any disparities in the setting of VTE events.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhakta</LastName><ForeName>Shivang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Critical Care, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erben</LastName><ForeName>Young</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Vascular and Endovascular Surgery, Mayo Clinic, Jacksonville, FL. Electronic address: erben.young@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanghavi</LastName><ForeName>Devang</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Critical Care, Mayo Clinic, Jacksonville, FL; Department of Transplant, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortich</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Vascular and Endovascular Surgery, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yupeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Political Science and Economics, Rowan University, Glassboro, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasan</LastName><ForeName>Mohammed M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Critical Care, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brigham</LastName><ForeName>Tara J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Mayo Clinic Libraries, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meschia</LastName><ForeName>James F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>Pablo Moreno</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Critical Care, Mayo Clinic, Jacksonville, FL; Department of Transplant, Mayo Clinic, Jacksonville, FL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Surg Venous Lymphat Disord</MedlineTA><NlmUniqueID>101607771</NlmUniqueID><ISSNLinking>2213-333X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Racial disparities</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>21</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35307608</ArticleId><ArticleId IdType="pmc">PMC8928725</ArticleId><ArticleId IdType="doi">10.1016/j.jvsv.2022.03.003</ArticleId><ArticleId IdType="pii">S2213-333X(22)00100-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Iba T., Levy J.H., Levi M., Thachil J. Coagulopathy in COVID-19. J&#xa0;Thromb Haemost. 2020;18:2103&#x2013;2109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323352</ArticleId><ArticleId IdType="pubmed">32558075</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamadian M., Chiti H., Shoghli A., Biglari S., Parsamanesh N., Esmaeilzadeh A. COVID-19: virology, biology and novel laboratory diagnosis. J&#xa0;Gene Med. 2021;23:e3303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7883242</ArticleId><ArticleId IdType="pubmed">33305456</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf O., Young M., Malik K.J., Cheema T. Systemic complications of COVID-19. Crit Care Nurs Q. 2020;43:390&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">32833775</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Yang L., Liu R., Liu F., Wu K., Li J., et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58:1116&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">32172226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Porfidia A., Valeriani E., Pola R., Porreca E., Rutjes A.W.S., Di Nisio M. Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb Res. 2020;196:67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7420982</ArticleId><ArticleId IdType="pubmed">32853978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Shen L., Le K.J., Pan M.M., Kong L.C., Gu Z.C., et al. Incidence of venous thromboembolism in hospitalized coronavirus disease 2019 patients: a systematic review and meta-analysis. Front Cardiovasc Med. 2020;7:151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7423832</ArticleId><ArticleId IdType="pubmed">32850990</ArticleId></ArticleIdList></Reference><Reference><Citation>Erben Y., Franco-Mesa C., Gloviczki P., Stone W., Quinones-Hinojoas A., Meltzer A.J., et al. Deep vein thrombosis and pulmonary embolism among hospitalized coronavirus disease 2019-positive patients predicted for higher mortality and prolonged intensive care unit and hospital stays in a multisite healthcare system. J&#xa0;Vasc Surg Venous Lymphat Disord. 2021;9:1361&#x2013;13670.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023789</ArticleId><ArticleId IdType="pubmed">33836287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakai N.A., McClure L.A. Racial differences in venous thromboembolism. J&#xa0;Thromb Haemost. 2011;9:1877&#x2013;1882.</Citation><ArticleIdList><ArticleId IdType="pubmed">21797965</ArticleId></ArticleIdList></Reference><Reference><Citation>White R.H., Keenan C.R. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res. 2009;123:S11&#x2013;S17.</Citation><ArticleIdList><ArticleId IdType="pubmed">19303496</ArticleId></ArticleIdList></Reference><Reference><Citation>Folsom A.R., Basu S., Hong C.P., Heckbert S.R., Lutsey P.L., Rosamond W.D., et al. Reasons for differences in the incidence of venous thromboembolism in black versus white Americans. Am J Med. 2019;132:970&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6744355</ArticleId><ArticleId IdType="pubmed">30953632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramer W, Holland L, Mollema J, Hannon T, Bekhuis T. Removing duplicates in retrieval sets from electronic databases 2015. Available at: http://www.iss.it/ibnary/eahi/cont/57_Bramer_Wichor_slides_EAHIL_2014.pdf. Accessed April 2, 2022.</Citation></Reference><Reference><Citation>Peterson J., Welch V., Losos M., Tugwell P. 2011. The Newcastle-Ottawa scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute.</Citation></Reference><Reference><Citation>Charoenngam N., Ilori T.O., Holick M.F., Hochberg N.S., Apovian C.M. Self-identified race and COVID-19-associated acute kidney injury and inflammation: a retrospective cohort study of hospitalized inner-city COVID-19 patients. J&#xa0;Gen Intern Med. 2021;36:3487&#x2013;3496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183592</ArticleId><ArticleId IdType="pubmed">34100227</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho E.S., McClelland P.H., Cheng O., Kim Y., Hu J., Zenilman M.E., et al. Utility of D-dimer for diagnosis of deep vein thrombosis in coronavirus disease-19 infection. J&#xa0;Vasc Surg Venous Lymphat Disord. 2021;9:47&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390766</ArticleId><ArticleId IdType="pubmed">32738407</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S.L., Gianos E., Barish M.A., Chatterjee S., Kohn N., Lesser M., et al. Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients. Thromb Haemost. 2021;121:1043&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044533</ArticleId><ArticleId IdType="pubmed">33472255</ArticleId></ArticleIdList></Reference><Reference><Citation>Esenwa C., Unda S.R., Altschul D.J., Patel N.K., Malaviya A., Seiden J., et al. The effect of race on composite thrombotic events in patients with COVID-19. Thromb Res. 2021;199:10&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833453</ArticleId><ArticleId IdType="pubmed">33385794</ArticleId></ArticleIdList></Reference><Reference><Citation>Koleilat I., Galen B., Choinski K., Hatch A.N., Jones D.B., Billett H., et al. Clinical characteristics of acute lower extremity deep venous thrombosis diagnosed by duplex in patients hospitalized for coronavirus disease 2019. J&#xa0;Vasc Surg Venous Lymphat Disord. 2021;9:36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315975</ArticleId><ArticleId IdType="pubmed">32593770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilaloglu S., Aphinyanaphongs Y., Jones S., Iturrate E., Hochman J., Berger J.S. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020;324:799&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7372509</ArticleId><ArticleId IdType="pubmed">32702090</ArticleId></ArticleIdList></Reference><Reference><Citation>Creel-Bulos C., Liu M., Auld S.C., Gaddh M., Kempton C.L., Sharifpour M., et al. Trends and diagnostic value of D-dimer levels in patients hospitalized with coronavirus disease 2019. Medicine (Baltimore) 2020;99:e23186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668476</ArticleId><ArticleId IdType="pubmed">33181697</ArticleId></ArticleIdList></Reference><Reference><Citation>Maatman T.K., Jalali F., Feizpour C., Douglas A., II, McGuire S.P., Kinnaman G., et al. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019. Crit Care Med. 2020;48:e783&#x2013;e790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302085</ArticleId><ArticleId IdType="pubmed">32459672</ArticleId></ArticleIdList></Reference><Reference><Citation>Papageorgiou N., Providencia R., Saberwal B., Sohrabi C., Tyrlis A., Atieh A.E., et al. Ethnicity and COVID-19 cardiovascular complications: a multi-center UK cohort. Am J Cardiovasc Dis. 2020;10:455&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675148</ArticleId><ArticleId IdType="pubmed">33224596</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyiadji N., Cormier P., Patel P.Y., Hadied M.O., Bhargava P., Khanna K., et al. Acute pulmonary embolism and COVID-19. Radiology. 2020;297:E335&#x2013;E338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7706099</ArticleId><ArticleId IdType="pubmed">32407256</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H., Martin A., Singh A., Narasimhan M., Lau J., Weinberg M., et al. Pulmonary embolism in patients hospitalized with COVID-19 (from a New York health system) Am J Cardiol. 2020;133:148&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378502</ArticleId><ArticleId IdType="pubmed">32800295</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R., Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">16807131</ArticleId></ArticleIdList></Reference><Reference><Citation>Thondapu V., Montes D., Rosovsky R., Dua A., McDermott S., Lu M.T., et al. Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019. J&#xa0;Vasc Surg Venous Lymphat Disord. 2021;9:835&#x2013;844. e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7657877</ArticleId><ArticleId IdType="pubmed">33188961</ArticleId></ArticleIdList></Reference><Reference><Citation>Malas M.B., Naazie I.N., Elsayed N., Mathlouthi A., Marmor R., Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7679115</ArticleId><ArticleId IdType="pubmed">33251499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan S.S., Radford S., Kow C.S., Zaidi S.T.R. Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J&#xa0;Thromb Thrombolysis. 2020;50:814&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7396456</ArticleId><ArticleId IdType="pubmed">32748122</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y.F., Pan L.Y., Zhang W.W., Cheng F., Hu S.S., Zhang X., et al. A&#xa0;meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int J Infect Dis. 2020;100:34&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7425668</ArticleId><ArticleId IdType="pubmed">32798659</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Zakai N.A., McClure L.A., Judd S.E., Safford M.M., Folsom A.R., Lutsey P.L., et al. Racial and regional differences in venous thromboembolism in the United States in 3 cohorts. Circulation. 2014;129:1502&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098668</ArticleId><ArticleId IdType="pubmed">24508826</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichmann D., Sperhake J.P., L&#xfc;tgehetmann M., Steurer S., Edler C., Heinemann A., et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173:268&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7240772</ArticleId><ArticleId IdType="pubmed">32374815</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzek A., Sch&#xe4;dler J., Dietz E., Ron A., Gerling M., Kammal A.L., et al. Prospective postmortem evaluation of 735 consecutive SARS-CoV-2-associated death cases. Sci Rep. 2021;11:19342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8481286</ArticleId><ArticleId IdType="pubmed">34588486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37424485</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1878-6448</ISSN><JournalIssue CitedMedium="Internet"><Volume>53</Volume><Issue>1</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>NeuroRehabilitation</Title><ISOAbbreviation>NeuroRehabilitation</ISOAbbreviation></Journal><ArticleTitle>Venous thromboembolism and anticoagulation in spinal cord lesion rehabilitation inpatients: A 10-year retrospective study.</ArticleTitle><Pagination><StartPage>143</StartPage><EndPage>153</EndPage><MedlinePgn>143-153</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/NRE-230063</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Venous thromboembolism (VTE) is a concern following the onset of spinal cord lesions (SCL).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the current efficacy and risks of anticoagulation after SCL and consider changes in thromboprophylaxis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective cohort study included individuals admitted to inpatient rehabilitation within 3 months of SCL onset. Main outcome measures were the incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), bleeding, thrombocytopenia, or death, which occurred within 1 year of the SCL onset.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">VTE occurred in 37 of the 685 patients included in the study (5.4%, 95% CI 3.7-7.1%, 2.8% PE), and in 16 of 526 patients who received prophylactic anticoagulation at rehabilitation (3%, 95% CI 1.6-4.5%, 1.1% PE, with at least 1 fatality). Of these 526, 1.3% developed clinically significant bleeding and 0.8% thrombocytopenia. Prophylactic anticoagulation, most commonly 40&#x200a;mg/day, continued until a median period of 6.4 weeks after SCL onset (25% -75% percentiles 5.8-9.7), but in 29.7%, VTE occurred more than 3 months after SCL onset.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The VTE prophylaxis used for the present cohort contributed to a considerable but limited reduction of VTE incidence. The authors recommend conducting a prospective study to assess the efficacy and safety of an updated preventive anticoagulation regimen.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bluvshtein</LastName><ForeName>Vadim</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catz</LastName><ForeName>Amiram</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahamid</LastName><ForeName>Ala</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkayam</LastName><ForeName>Keren</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michaeli</LastName><ForeName>Dianne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Front</LastName><ForeName>Lilach</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kfir</LastName><ForeName>Adi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Spinal Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelernter</LastName><ForeName>Ilana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>School of Mathematical Sciences, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aidinoff</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care for Consciousness Rehabilitation, Loewenstein Rehabilitation Medical Center, Raanana, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>NeuroRehabilitation</MedlineTA><NlmUniqueID>9113791</NlmUniqueID><ISSNLinking>1053-8135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">anticoagulation</Keyword><Keyword MajorTopicYN="N">prophylaxis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">spinal cord lesions</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>10</Day><Hour>4</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37424485</ArticleId><ArticleId IdType="pmc">PMC10473086</ArticleId><ArticleId IdType="doi">10.3233/NRE-230063</ArticleId><ArticleId IdType="pii">NRE230063</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aito, S., Pieri, A., D&#x2019;Andrea, M., Marcelli, F., &amp; Cominelli, E. (2002). Primary prevention of deep venous thrombosis and pulmonary embolism in acute spinal cord injured patients. Spinal Cord 40(6), 300&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">12037712</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida, R. L., Rodrigues, C. C., Melo e Silva, C. A., Beraldo, P. S. S., &amp; Amado, V. M. (2019). Comparison of two pharmacological prophylaxis strategies for venous thromboembolism in spinal cord injury patients: a retrospective study. Spinal Cord 57(10), 890&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">31101899</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson F. A. Jr,, &amp; Spencer, F. A. (2003). Risk factors for venous thromboembolism. Circulation 107(23_suppl_1), I-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12814980</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold, P. M., Harrop, J. S., Merli, G., Tetreault, L. G., Kwon, B. K., Casha, S., &amp; Norvell, D. C. (2017). Efficacy, safety, and timing of anticoagulant thromboprophylaxis for the prevention of venous thromboembolism in patients with acute spinal cord injury: a systematic review. Global Spine Journal 7(3_suppl), 138S&#x2013;150S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684847</ArticleId><ArticleId IdType="pubmed">29164021</ArticleId></ArticleIdList></Reference><Reference><Citation>Belohl&#xe1;vek, J., Dytrych, V., &amp; Linhart, A. (2013). Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Experimental and Clinical Cardiology, 18(2), 129&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3718593</ArticleId><ArticleId IdType="pubmed">23940438</ArticleId></ArticleIdList></Reference><Reference><Citation>Clements, R., Churilov, L., Wahab, A. L. A., &amp; Ng, L. C. (2017). Exploratory analysis of factors associated with venous thromboembolism in Victorian acute traumatic spinal cord-injured patients 2010&#x2013;2013. Spinal Cord 55(1), 74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">27296857</ArticleId></ArticleIdList></Reference><Reference><Citation>Coull, A. F., Kyle, R. G., Hanson, C. L., &amp; Watterson, A. E. (2021). Risk factors for leg ulceration in people who inject drugs: A cross-sectional study. Journal of Clinical Nursing 30(11-12), 1623&#x2013;1632.</Citation><ArticleIdList><ArticleId IdType="pubmed">33590564</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin, B. J., Godat, L. N., Berndtson, A. E., Pham, A., Kolan, S., Box, K., &amp; Costantini, T. W. (2019). Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients. Burns 45(4), 818&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">30827851</ArticleId></ArticleIdList></Reference><Reference><Citation>Crous-Bou, M., Harrington, L. B., &amp; Kabrhel, C. (2016). Environmental and genetic risk factors associated with venous thromboembolism. In Seminars in Thrombosis and Hemostasis (Vol. 42, No. 08, pp. 808&#x2013;820). Thieme Medical Publishers.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5146955</ArticleId><ArticleId IdType="pubmed">27764878</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, S. B., Lee, S. H., Kim, E. S., &amp; Eoh, W. (2011). Incidence of deep vein thrombosis after spinal cord injury: a prospective study in 37 consecutive patients with traumatic or nontraumatic spinal cord injury treated by mechanical prophylaxis. Journal of Trauma and Acute Care Surgery 71(4), 867&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">21986735</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhall, S. S., Hadley, M. N., Aarabi, B., Gelb, D. E., Hurlbert, R. J., Rozzelle, C. J., &amp; Walters, B. C. (2013). Deep venous thrombosis and thromboembolism in patients with cervical spinal cord injuries. Neurosurgery 72(suppl 3), 244&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">23417195</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichinger, S., Eischer, L., Sinkovec, H., Wittgruber, G., Traby, L., Kammer, M., &amp; Wildburger, R. (2018). Risk of venous thromboembolism during rehabilitation of patients with spinal cord injury. PLoS One 13(3), e0193735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5873993</ArticleId><ArticleId IdType="pubmed">29590126</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehlings, M. G., Tetreault, L. A., Wilson, J. R., Kwon, B. K., Burns, A. S., Martin, A. R., &amp; Harrop, J. S. (2017). A clinical practice guideline for the management of acute spinal cord injury: introduction, rationale, and scope. Global Spine Journal 7(suppl 3), 84S&#x2013;94S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5684846</ArticleId><ArticleId IdType="pubmed">29164036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii, Y., Mammen, E. F., Farag, A., Muz, J., Salciccioli, G. G., &amp; Weingarden, S. T. (1992). Thrombosis in spinal cord injury. Thrombosis Research 68(4-5), 357&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">1290164</ArticleId></ArticleIdList></Reference><Reference><Citation>Galson S. K. (2008). Prevention of deep vein thrombosis and pulmonary embolism. Public Health Reports 123(4), 420&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430635</ArticleId><ArticleId IdType="pubmed">18763402</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgi Pierfranceschi, M., Donadini, M. P., Dentali, F., Ageno, W., Marazzi, M., Bocchi, R., &amp; Imberti, D. (2013). The short- and long-term risk of venous thromboembolism in patients with acute spinal cord injury: a prospective cohort study. Thrombosis and Haemostasis 109(1), 34&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">23223906</ArticleId></ArticleIdList></Reference><Reference><Citation>Halim, T. A., Chhabra, H. S., Arora, M., &amp; Kumar, S. (2014). Pharmacological prophylaxis for deep vein thrombosis in acute spinal cord injury: an Indian perspective. Spinal Cord 52(7), 547&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">24819510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidi, M., Zeeshan, M., Kulvatunyou, N., Mitra, H. S., Hanna, K., Tang, A., &amp; Joseph, B. (2019). Operative spinal trauma: thromboprophylaxis with low molecular weight heparin or a direct oral anticoagulant. Journal of Thrombosis and Haemostasis 17(6), 925&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">30924300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassouna H. I. (2000). Blood stasis, thrombosis and fibrinolysis. Hematology/oncology clinics of North America 14(2), xvii&#x2013;xxii.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806556</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebbeler, S. L., Marciniak, C. M., Crandall, S., Chen, D., Nussbaum, S., &amp; Mendelewski, S. (2004). Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury. The Journal of Spinal Cord Medicine 27(3), 236&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">15478526</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira, D. R., Zorzela, L. M., &amp; Perini, E. (2017). Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database of Systematic Reviews, (4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6478064</ArticleId><ArticleId IdType="pubmed">28431186</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemen, N. D., Feingold, P. L., Hashimoto, B., Wang, M., Kleyman, S., Brackett, A., &amp; Pei, K. Y. (2020). Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis. The Lancet Haematology 7(8), e583&#x2013;e593.</Citation><ArticleIdList><ArticleId IdType="pubmed">32735837</ArticleId></ArticleIdList></Reference><Reference><Citation>Line, B. R. (2001). Pathophysiology and diagnosis of deep venous thrombosis. In Seminars in nuclear medicine (Vol. 31, No. 2, pp. 90-101). WB Saunders.</Citation><ArticleIdList><ArticleId IdType="pubmed">11330789</ArticleId></ArticleIdList></Reference><Reference><Citation>Markel, A., Weich, Y., &amp; Gaitini, D. (1995). Doppler ultrasound in the diagnosis of venous thrombosis. Angiology 46(1), 65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">7818159</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin, A. M., Polistena, P., Mahmud, A., Bettridge, B., Morling, A., Chuah, H., &amp; Leahy, M. F. (2021). Optimal enoxaparin dosing strategies for venous thromboembolism prophylaxis and treatment of high body weight patients. Thrombosis Research 207, 116&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">34619448</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda, A. R., &amp; Hassouna, H. I. (2000). Mechanisms of thrombosis in spinal cord injury. Hematology/Oncology Clinics of North America 14(2), 401&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806563</ArticleId></ArticleIdList></Reference><Reference><Citation>Piran, S., &amp; Schulman, S. (2016). Incidence and risk factors for venous thromboembolism in patients with acute spinal cord injury: a retrospective study. Thrombosis Research, 147, 97&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">27721141</ArticleId></ArticleIdList></Reference><Reference><Citation>Smythe, M. A., Priziola, J., Dobesh, P. P., Wirth, D., Cuker, A., &amp; Wittkowsky, A. K. (2016). Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis 41, 165&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4715846</ArticleId><ArticleId IdType="pubmed">26780745</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;gaard, K. K., Schmidt, M., Pedersen, L., Horv&#xe1;th&#x2013;Puh&#xf3;, E., &amp; S&#xf8;rensen, H. T. (2014). 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation 130(10), 829&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pubmed">24970783</ArticleId></ArticleIdList></Reference><Reference><Citation>Tator, C. H., Duncan, E. G., Edmonds, V. E., Lapczak, L. I., &amp; Andrews, D. F. (1987). Comparison of surgical and conservative management in 208 patients with acute spinal cord injury. Canadian Journal of Neurological Sciences 14(S1), 60&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">3815167</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, O., Lybeck, E., Strandberg, K., Tynng&#xe5;rd, N., &amp; Sch&#xf6;tt, U. (2015). Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays. PLoS One 10(1), e0116835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4308107</ArticleId><ArticleId IdType="pubmed">25625201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, T. F., Milligan, P. E., Wong, C. A., Deal, E. N., Thoelke, M. S., &amp; Gage, B. F. (2014). Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thrombosis and Haemostasis 111(01), 88&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505726</ArticleId><ArticleId IdType="pubmed">24136071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wattanakit, K., &amp; Cushman, M. (2009). Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Current Opinion in Pulmonary Medicine 15(5), 408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811494</ArticleId><ArticleId IdType="pubmed">19561505</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei, B., Zhou, H., Liu, G., Zheng, Y., Zhang, Y., Hao, C., Wang, Y., Kang, H., Lu, X., Yuan, Y., &amp; Meng, Q. (2023). Risk factors for venous thromboembolism in patients with spinal cord injury: A systematic review and meta-analysis. The Journal of Spinal Cord Medicine 46(2), 181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9987783</ArticleId><ArticleId IdType="pubmed">33890837</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidner, N., M&#xfc;ller, O. J., Hach-Wunderle, V., Schwerdtfeger, K., Krauspe, R., Pauschert, R., Waydhas, C., Baumberger, M., G&#xf6;ggelmann, C., Wittgruber, G., Wildburger, R., &amp; Marcus, O. (2020). Prevention of thromboembolism in spinal cord injury -S1 guideline. Neurological Research and Practice 2, 43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727164</ArticleId><ArticleId IdType="pubmed">33324943</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada, K., Suda, K., Matsumoto Harmon, S., Komatsu, M., Ushiku, C., Takahata, M., Minami, A., &amp; Iwasaki, N. (2019). Rapidly progressive cervical myelopathy had a high risk of developing deep venous thrombosis: a prospective observational study in 289 cases with degenerative cervical spine disease. Spinal Cord 57(1), 58&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30374063</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue, J. K., Winkler, E. A., Rick, J. W., Deng, H., Partow, C. P., Upadhyayula, P. S., Birk, H. S., Chan, A. K., &amp; Dhall, S. S. (2017). Update on critical care for acute spinal cord injury in the setting of polytrauma. Neurosurgical Focus 43(5), E19.</Citation><ArticleIdList><ArticleId IdType="pubmed">29088951</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25224168</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7533</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery</Title><ISOAbbreviation>Surg Obes Relat Dis</ISOAbbreviation></Journal><ArticleTitle>Inferior vena cava filters and postoperative outcomes in patients undergoing bariatric surgery: a meta-analysis.</ArticleTitle><Pagination><StartPage>725</StartPage><EndPage>733</EndPage><MedlinePgn>725-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.soard.2014.04.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1550-7289(14)00157-9</ELocationID><Abstract><AbstractText>Background: Pulmonary embolism(PE)accounts for almost 40% of perioperative deaths after bariatric surgery.Placement of prophylactic inferior vena cava(IVC) filter before bariatric surgery to improve outcomes has shown varied results. We performed a meta-analysis to evaluate post- operative outcomes associated with the preoperative placement of IVC filters in these patients. Methods: A systematic review was conducted by three investigators independently in PubMed, EMBASE, the Web of Science and Scopus until February 28,2013.Our search was restricted to studies in adult patients undergoing bariatric surgery with and without IVC filters. Primary outcomes were postoperative deep vein thrombosis(DVT),pulmonary embolism (PE),and postoperative mortality. Meta-analysis used random effects models to account for heterogeneity,and Sidik- Jonkman method to account for scarcity of outcomes and studies. Associations are shown as Relative Risks(RR) and 95% Confidence Intervals(CI). Results: Seven observational studies were identified (n=102,767), with weighted average inci- dences of DVT(0.9%),PE(1.6%),and mortality(1.0%)for a follow-up ranging from 3 weeks to 3 months. Use of IVC filters was associated with an approximately 3-fold higher risk of DVT and death that was nominally significant for the former outcome, but not the latter (RR2.81,95%CI 1.33-5.97, p=0.007; and RR 3.27,95%CI0.78-13.64, p=0.1, respectively);there was no difference in the risk of PE(RR1.02,95%CI0.31-3.77,p=0.9). Moderate to high heterogeneity of effects was noted across studies. Conclusions: Placement of IVC filter before bariatric surgery Is associated with higher risk of postoperative DVT and mortality. A similar risk of PE inpatients with and without IVC filter placement cannot exclude a benefit, given the potential large imbalance in risk at baseline.Ran- domized trials are needed before IVC placement can be recommended. (SurgObesRelatDis 2015;11:268-269.) r 2015 American Society for Metabolic and Bariatric Surgery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaw</LastName><ForeName>Roop</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Hospital Medicine, Medicine Institute, Cleveland Clinic, Cleveland, Ohio; Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: kawr@ccf.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasupuleti</LastName><ForeName>Vinay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wayne Overby</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Gastrointestinal Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deshpande</LastName><ForeName>Abhishek</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medicine Institute Center for Value Based Care Research, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Craig I</ForeName><Initials>CI</Initials><AffiliationInfo><Affiliation>Evidence-Based Practice Center, UCONN/Hartford Hospital, and University of Connecticut School of Pharmacy, Hartford, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ioannidis</LastName><ForeName>John P A</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Stanford Prevention Research Center, Department of Medicine and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Adrian V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; Postgraduate and Medical Schools, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru; Unidad de An&#xe1;lisis y Generaci&#xf3;n de Evidencias en Salud P&#xfa;blica (UNAGESP), Instituto Nacional de Salud, Lima, Peru.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Cardiovascular Meta-analysis Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Obes Relat Dis</MedlineTA><NlmUniqueID>101233161</NlmUniqueID><ISSNLinking>1550-7289</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Surg Obes Relat Dis. 2014 Jan-Feb;11(1):268-9</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D050110" MajorTopicYN="N">Bariatric Surgery</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009767" MajorTopicYN="N">Obesity, Morbid</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016306" MajorTopicYN="Y">Vena Cava Filters</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bariatric surgery</Keyword><Keyword MajorTopicYN="N">Inferior vena cava filters</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25224168</ArticleId><ArticleId IdType="doi">10.1016/j.soard.2014.04.008</ArticleId><ArticleId IdType="pii">S1550-7289(14)00157-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37169670</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-2574</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>HPB : the official journal of the International Hepato Pancreato Biliary Association</Title><ISOAbbreviation>HPB (Oxford)</ISOAbbreviation></Journal><ArticleTitle>Venous thromboembolism (VTE) after open hepatectomy compared to minimally invasive liver resection: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>872</StartPage><EndPage>880</EndPage><MedlinePgn>872-880</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hpb.2023.04.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1365-182X(23)00129-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Even though the risk of postoperative venous thromboembolism (VTE) after liver resection is well recognized, the association between surgical approach and VTE risk is unknown. This study aims to compare VTE rates following open liver resection (OLR) and minimally invasive liver resection (MILR).</AbstractText><AbstractText Label="METHODS">MEDLINE, Web Of Sciences and EMBASE databases were interrogated to identify eligible studies published between February 2016 and August 2022. Studies were considered suitable if they reported a comparison between OLR and MILR (including laparoscopic liver resection [LLR] or robotic liver resection [RLR]).</AbstractText><AbstractText Label="RESULTS">Fourteen studies including 11&#xa0;356 patients met the inclusion criteria. 5622 patients underwent OLR and 5734 patients underwent MILR. The VTE rate was higher among patients who underwent OLR compared to MILR (2.8% vs 1.4%, OR (95% CI)&#xa0;=&#xa0;1.84, p=&lt;00001). Similarly, the subgroup analysis showed a higher rate of deep venous thrombosis (DVT) (1.4% vs 0.7%, OR (95% CI)&#xa0;=&#xa0;1.98, p&#xa0;=&#xa0;0.02) and pulmonary embolism (PE) (1.3% vs 0.7%, OR (95% CI)&#xa0;=&#xa0;1.88, p&#xa0;=&#xa0;0.002) in patients who underwent OLR compared to MILR.</AbstractText><AbstractText Label="DISCUSSION">Patients who undergo open hepatectomy have a higher incidence of postoperative VTE when compared to those undergoing minimally invasive liver resection. This finding was consistent for both DVT and PE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lancellotti</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Pancreatic Surgery Unit, Manchester University NHS FT, Manchester, M13 9WL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coletta</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Ospedali Riuniti Marche Nord, Pesaro, Italy; Department of Surgical Sciences, Umberto I University Hospital, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de'Liguori Carino</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Pancreatic Surgery Unit, Manchester University NHS FT, Manchester, M13 9WL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satyadas</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Pancreatic Surgery Unit, Manchester University NHS FT, Manchester, M13 9WL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jegatheeswaran</LastName><ForeName>Santhalingam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Pancreatic Surgery Unit, Manchester University NHS FT, Manchester, M13 9WL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruccio</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheen</LastName><ForeName>Aali J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Pancreatic Surgery Unit, Manchester University NHS FT, Manchester, M13 9WL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siriwardena</LastName><ForeName>Ajith K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Pancreatic Surgery Unit, Manchester University NHS FT, Manchester, M13 9WL, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jamdar</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Pancreatic Surgery Unit, Manchester University NHS FT, Manchester, M13 9WL, UK. Electronic address: Saurabh.jamdar@mft.nhs.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>HPB (Oxford)</MedlineTA><NlmUniqueID>100900921</NlmUniqueID><ISSNLinking>1365-182X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006498" MajorTopicYN="N">Hepatectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010535" MajorTopicYN="Y">Laparoscopy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>22</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37169670</ArticleId><ArticleId IdType="doi">10.1016/j.hpb.2023.04.012</ArticleId><ArticleId IdType="pii">S1365-182X(23)00129-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">27262881</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>Intravenous versus topical tranexamic acid in primary total hip replacement: A systemic review and meta-analysis.</ArticleTitle><Pagination><StartPage>10</StartPage><EndPage>18</EndPage><MedlinePgn>10-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijsu.2016.05.064</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-9191(16)30150-9</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Total hip arthroplasty (THA) is associated with substantial blood loss. Tranexamic acid (TXA) could reduce perioperative blood loss. The optimal administration routine of TXA remains controversial. The objective of the present systemic review and meta-analysis was to compare the effectiveness and safety of various application methods of tranexamic acid in primary THA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Potential relevant literature was identified from electronic databases including Medline, PubMed, Embase, ScienceDirect, web of science and Cochrane Library. Grey academic studies were also identified from the references of the included literature. There was no language restriction. The pooling of data was carried out by using RevMan 5.1.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three randomized controlled trials (RCTs) and two non-RCTs involving 1614 patients met the inclusion criteria. Current meta-analysis indicated that there were no significant differences in terms of total blood loss (MD&#xa0;=&#xa0;-30.04, 95% CI:&#xa0;-114.67 to 54.59, P&#xa0;=&#xa0;0.49), postoperative hemoglobin level (MD&#xa0;=&#xa0;-0.29, 95% CI:&#xa0;-0.68 to 0.10, P&#xa0;=&#xa0;0.14), transfusion rate (RD&#xa0;=&#xa0;-0.02, 95% CI:&#xa0;-0.5 to&#xa0;-0.00, P&#xa0;=&#xa0;0.09), length of stay ((MD&#xa0;=&#xa0;-0.14, 95% CI:&#xa0;-0.30 to 0.01, P&#xa0;=&#xa0;0.07) or operation time ((MD&#xa0;=&#xa0;1.00, 95% CI:&#xa0;-0.31 to 2.31, P&#xa0;=&#xa0;0.14) between treatment groups. No significant differences were found regarding the incidence of adverse effects such as wound infection (RD&#xa0;=&#xa0;-0.01, 95% CI:&#xa0;-0.06 to 0.04, P&#xa0;=&#xa0;0.66), myocardial infarction (MI) (RD&#xa0;=&#xa0;-0.01, 95% CI:&#xa0;-0.04 to 0.02, P&#xa0;=&#xa0;0.61), deep venous thrombosis (DVT) (RD&#xa0;=&#xa0;0.00, 95% CI:&#xa0;-0.01 to 0.01, P&#xa0;=&#xa0;0.51) or pulmonary embolism (PE) (RD&#xa0;=&#xa0;RD&#xa0;=&#xa0;0.00, 95% CI:&#xa0;-0.01 to 0.01, P&#xa0;=&#xa0;0.63) between groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The topical administration of TXA in THA carried similar hemostasis effects compared with intravenous use without an increased risk of thrombotic complications. No other adverse effect was identified. Topical TXA application was a simple, safe, effective and cost-effective adjunct for blood management following primary THA. For patients with a high risk of thromboembolic events, there may be benefits with topical administration.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Traumatology Department, Tianjin Hospital, Tianjin, 300211, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Traumatology Department, Tianjin Hospital, Tianjin, 300211, PR China. Electronic address: 3244213427@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yin-Guang</ForeName><Initials>YG</Initials><AffiliationInfo><Affiliation>Traumatology Department, Tianjin Hospital, Tianjin, 300211, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000287" MajorTopicYN="N">Administration, Topical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="N">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006488" MajorTopicYN="N">Hemostasis, Surgical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="N">Tranexamic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Blood loss</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Total hip arthroplasty</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27262881</ArticleId><ArticleId IdType="doi">10.1016/j.ijsu.2016.05.064</ArticleId><ArticleId IdType="pii">S1743-9191(16)30150-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21057995</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1433-2965</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>Suppl 4</Issue><PubDate><Year>2010</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA</Title><ISOAbbreviation>Osteoporos Int</ISOAbbreviation></Journal><ArticleTitle>Neuroaxial versus general anaesthesia in geriatric patients for hip fracture surgery: does it matter?</ArticleTitle><Pagination><StartPage>S555</StartPage><EndPage>S572</EndPage><MedlinePgn>S555-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00198-010-1399-7</ELocationID><Abstract><AbstractText>The influence of the mode of anaesthesia on outcome of geriatric patients with hip fractures is a controversial issue in the medical literature. In the light of an ageing society, a conclusive answer to this question is of growing importance. The purpose of this review was to assess the effect of neuroaxial and general anaesthesia on mortality and morbidity in geriatric patients sustaining a hip fracture. Following a current literature search within the Pubmed and Cochrane database (1967-2010), 34 randomised controlled trials, 14 observational studies and eight reviews/meta-analysis publications were included. Potentially outcome-influencing factors such as mortality, deep vein thrombosis, pulmonary embolism, postoperative confusion and other anaesthesia-related outcomes were evaluated. After analysing the current literature with 56 references, covering 18,715 patients with hip fracture, it can be concluded that spinal anaesthesia is associated with significantly reduced early mortality, fewer incidents of deep vein thrombosis, less acute postoperative confusion, a tendency to fewer myocardial infarctions, fewer cases of pneumonia, fatal pulmonary embolism and postoperative hypoxia. General anaesthesia has the advantages of having a lower incidence of hypotension and a tendency towards fewer cerebrovascular accidents compared to neuroaxial anaesthesia. Otherwise, general anaesthesia and respiratory diseases were significant predictors of morbidity in hip fracture patients. These data suggest that regional anaesthesia is the preferred technique, but the limited evidence available does not permit a definitive conclusion to be drawn for mortality or other outcomes. For hip fracture surgery, the choice of anaesthesia (general or neuroaxial) is made by the anaesthesiologist and is based on the patient's preference, comorbidities, potential general postoperative complications and the clinical experience of the anaesthesiologist. The overall therapeutic approach in hip fracture care should be determined jointly by the orthopaedic surgeon, the geriatrician and the anaesthesiologist (multidisciplinary approach).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luger</LastName><ForeName>T J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Innsbruck, Austria. thomas.luger@i-med.ac.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kammerlander</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gosch</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Luger</LastName><ForeName>M F</ForeName><Initials>MF</Initials></Author><Author ValidYN="Y"><LastName>Kammerlander-Knauer</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kreutziger</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Osteoporos Int</MedlineTA><NlmUniqueID>9100105</NlmUniqueID><ISSNLinking>0937-941X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000765" MajorTopicYN="N">Anesthesia, Conduction</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000768" MajorTopicYN="N">Anesthesia, General</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005592" MajorTopicYN="N">Fracture Fixation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="N">Hip Fractures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058866" MajorTopicYN="N">Osteoporotic Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21057995</ArticleId><ArticleId IdType="doi">10.1007/s00198-010-1399-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reg Anesth Pain Med. 2010 Jan-Feb;35(1):64-101</Citation><ArticleIdList><ArticleId IdType="pubmed">20052816</ArticleId></ArticleIdList></Reference><Reference><Citation>Orthopedics. 1997 Feb;20(2):109-15</Citation><ArticleIdList><ArticleId IdType="pubmed">9048387</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1988 Jun;36(6):525-30</Citation><ArticleIdList><ArticleId IdType="pubmed">2897391</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesia. 1980 Nov;35(11):1107-10</Citation><ArticleIdList><ArticleId IdType="pubmed">7446914</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Anesth. 2005 Sep;17(6):431-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16171663</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 2006 May;102(5):1559-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16632842</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 1999 Apr;88(4):822-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10195531</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesia. 2010 Mar;65(3):243-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20039864</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Anaesthesiol Scand. 1991 Aug;35(6):548-52</Citation><ArticleIdList><ArticleId IdType="pubmed">1897353</ArticleId></ArticleIdList></Reference><Reference><Citation>Masui. 1995 Nov;44(11):1489-97</Citation><ArticleIdList><ArticleId IdType="pubmed">8544286</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2005 Oct;53(10):1658-66</Citation><ArticleIdList><ArticleId IdType="pubmed">16181163</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Orthop Relat Res. 1998 Mar;(348):37-41</Citation><ArticleIdList><ArticleId IdType="pubmed">9553531</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 1985 Sep;57(9):853-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4027101</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesia. 1985 Jul;40(7):672-6</Citation><ArticleIdList><ArticleId IdType="pubmed">4025772</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesth Intensive Care. 1994 Apr;22(2):150-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8210017</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Anesth. 2006 Mar;18(2):124-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16563330</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2004 Apr 14;291(14):1738-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15082701</ArticleId></ArticleIdList></Reference><Reference><Citation>Reg Anesth Pain Med. 2005 Sep-Oct;30(5):452-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16135349</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasth Intensivther Notfallmed. 1990 Aug;25(4):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">2171375</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Anaesth. 2008 Mar;55(3):146-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18310624</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Esp Anestesiol Reanim. 2001 Mar;48(3):113-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11333794</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott Med J. 1999 Oct;44(5):152-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10629913</ArticleId></ArticleIdList></Reference><Reference><Citation>Orthopade. 1994 Feb;23(1):16-20</Citation><ArticleIdList><ArticleId IdType="pubmed">8134092</ArticleId></ArticleIdList></Reference><Reference><Citation>Masui. 2003 Sep;52(9):972-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14531256</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesist. 1990 Feb;39(2):83-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2310007</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 2000 Apr;92(4):947-57</Citation><ArticleIdList><ArticleId IdType="pubmed">10754613</ArticleId></ArticleIdList></Reference><Reference><Citation>Control Clin Trials. 1996 Feb;17(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1999 Mar 4;340(9):669-76</Citation><ArticleIdList><ArticleId IdType="pubmed">10053175</ArticleId></ArticleIdList></Reference><Reference><Citation>J Orthop Trauma. 2009 Jul;23(6):386-94</Citation><ArticleIdList><ArticleId IdType="pubmed">19550223</ArticleId></ArticleIdList></Reference><Reference><Citation>Minerva Anestesiol. 1998 Jan-Feb;64(1-2):13-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9658786</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Orthop (Belle Mead NJ). 2000 Jan;29(1):25-35</Citation><ArticleIdList><ArticleId IdType="pubmed">10647516</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 1987 Sep;59(9):1080-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3311100</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 1999 Jul;89(1):111-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10389787</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1992 Jan;40(1):8-11</Citation><ArticleIdList><ArticleId IdType="pubmed">1727853</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesth Intensive Care. 1981 Nov;9(4):352-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6797318</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 2002 Jan;94(1):215-20, table of contents</Citation><ArticleIdList><ArticleId IdType="pubmed">11772832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Fr Anesth Reanim. 1986;5(1):24-30</Citation><ArticleIdList><ArticleId IdType="pubmed">3706840</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2006 Jul 1;333(7557):27-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16809710</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2002 Oct 1;167(7):753-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12389836</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 1992 Dec;77(6):1095-104</Citation><ArticleIdList><ArticleId IdType="pubmed">1466461</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2009 Sep;103(3):335-45</Citation><ArticleIdList><ArticleId IdType="pubmed">19628483</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Anaesthesiol Scand. 1986 Apr;30(3):247-52</Citation><ArticleIdList><ArticleId IdType="pubmed">3739582</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bone Joint Surg Br. 2006 Aug;88(8):1060-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16877606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 2008 Jul;56(7):1349-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18503520</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesist. 1999 Jun;48(6):379-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10421921</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2004 Oct 18;(4):CD000521</Citation><ArticleIdList><ArticleId IdType="pubmed">15494999</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Assoc Thai. 2002 Sep;85 Suppl 3:S875-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12452224</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesthesiology. 1990 Dec;73(6):1103-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2248389</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesist. 2003 Jul;52(7):596-605</Citation><ArticleIdList><ArticleId IdType="pubmed">12898044</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Anaesthesiol. 1998 Nov;15(6):656-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9884850</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1990 Jun 30;300(6741):1683-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2390547</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1996 Jun 6;334(23):1519-25</Citation><ArticleIdList><ArticleId IdType="pubmed">8618608</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2000 Dec 16;321(7275):1493</Citation><ArticleIdList><ArticleId IdType="pubmed">11118174</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med J. 1980 Dec 6;281(6254):1528-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7437865</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesia. 2001 Dec;56(12):1189-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11736778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Fr Anesth Reanim. 1988;7(4):305-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3202339</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Anaesth. 2006 Jul;53(7):669-77</Citation><ArticleIdList><ArticleId IdType="pubmed">16803914</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 1980 Jan;52(1):49-54</Citation><ArticleIdList><ArticleId IdType="pubmed">6769450</ArticleId></ArticleIdList></Reference><Reference><Citation>Unfallchirurgie. 1981;7(3):138-41</Citation><ArticleIdList><ArticleId IdType="pubmed">7256979</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Anaesthesiol Scand. 2003 Mar;47(3):260-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12648190</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 1984 Jun;56(6):581-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6721969</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg (Paris). 1977 Sep-Oct;34(5):987-97</Citation><ArticleIdList><ArticleId IdType="pubmed">613869</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Anesthesiol Clin. 2002 Winter;40(1):61-71</Citation><ArticleIdList><ArticleId IdType="pubmed">11910250</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Anaesthesiol. 2008 Dec;21(6):729-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19009689</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Anaesth. 1989 May;36(3 Pt 1):311-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2655951</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2005 Jan;94(1):24-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15516350</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 2004 Jun;98(6):1798-1802</Citation><ArticleIdList><ArticleId IdType="pubmed">15155351</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2000 Apr;84(4):450-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10823094</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 1987 Jun;66(6):497-504</Citation><ArticleIdList><ArticleId IdType="pubmed">3578861</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Anaesthesiol. 2008 May;25(5):418-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18028577</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesia. 1994 Mar;49(3):237-40</Citation><ArticleIdList><ArticleId IdType="pubmed">8147519</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Anaesthesiol Scand. 1980 Aug;24(4):279-87</Citation><ArticleIdList><ArticleId IdType="pubmed">7468115</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 2002 Jul;89(1):3-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12173238</ArticleId></ArticleIdList></Reference><Reference><Citation>Best Pract Res Clin Anaesthesiol. 2006 Jun;20(2):249-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16850776</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaesthesia. 1978 Jan;33(1):10-14</Citation><ArticleIdList><ArticleId IdType="pubmed">626331</ArticleId></ArticleIdList></Reference><Reference><Citation>Age Ageing. 1999 Mar;28(2):135-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10350409</ArticleId></ArticleIdList></Reference><Reference><Citation>Orthop Clin North Am. 1974 Jul;5(3):493-508</Citation><ArticleIdList><ArticleId IdType="pubmed">4600223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Anesth. 2003 Sep;15(6):433-40</Citation><ArticleIdList><ArticleId IdType="pubmed">14652120</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Anaesthesiol. 2005 Jul;22(7):492-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16045136</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Anaesth. 1986 Mar;58(3):284-91</Citation><ArticleIdList><ArticleId IdType="pubmed">3947489</ArticleId></ArticleIdList></Reference><Reference><Citation>Orthopedics. 2009 Apr;32(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">19388614</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2007 Dec 15;335(7632):1251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18056740</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesth Analg. 1994 Apr;78(4):706-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8135390</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2008 Jun;133(6 Suppl):381S-453S</Citation><ArticleIdList><ArticleId IdType="pubmed">18574271</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Anaesthesiol. 2000 Oct;13(5):539-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17016354</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bone Joint Surg Am. 2008 Sep;90(9):1899-905</Citation><ArticleIdList><ArticleId IdType="pubmed">18762650</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Anaesthesiol. 2003 Aug;20(8):640-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12932066</ArticleId></ArticleIdList></Reference><Reference><Citation>Orthopedics. 1999 Jan;22(1):31-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9925195</ArticleId></ArticleIdList></Reference><Reference><Citation>Injury. 2005 Nov;36(11):1355-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16214478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39496064</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>44</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Application of dexmedetomidine combined with propofol-etomidate mixture in radical gastrectomy under general anesthesia.</ArticleTitle><Pagination><StartPage>e39669</StartPage><MedlinePgn>e39669</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e39669</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000039669</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Gastric cancer is the third most common malignant tumor with the second highest mortality rate in the world, and radical gastrectomy is the main treatment method, but the operation needs a long period of time to carry out and has strong surgical trauma stimulation, which is likely to cause sympathetic nerve excitement and stress reaction in the body. Therefore, the selection of appropriate anesthetic medication regimen and anesthesia method has an important impact on the intraoperative management and postoperative recovery of patients. This study aims to compare the clinical effects of dexmedetomidine alone in combination with propofol, etomidate and propofol-etomidate mixture in the treatment of radical gastrectomy for gastric cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 90 patients undergoing elective radical gastrectomy were randomly divided into the propofol group (group P), the etomidate group (group E), and the etomidate-propofol mixture group (group PE). Anesthesia induction was performed under the monitoring of bispectral index anesthesia depth. The same pumping drugs were used in 3 groups: 0.1 to 0.3 &#x3bc;g/kg&#xb7;min remifentanil, 0.5 &#x3bc;g/kg&#xb7;h dexmedetomidine, and 5 to 10 &#x3bc;g/kg&#xb7;min rocuronium. The primary outcome indicator was the hemodynamic conditions. The secondary outcome indicators included awakening time and time to accurately answer questions after operation, the prevalence of postoperative respiratory depression and adverse events, the incidence of postoperative cognitive dysfunction, and preoperative and postoperative Montreal Cognitive Assessment and Mini-Mental State Examination scores.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 3 groups of patients, the use rate of vasoactive drugs in group P was higher (P&#x2005;&lt;&#x2005;.05); the systolic blood pressure, diastolic blood pressure, and heart rate of group P at T1 to T4 were significantly lower than those of groups E and PE (P&#x2005;&lt;&#x2005;.05); the systolic blood pressure, diastolic blood pressure, and heart rate of group E in T2, T4, and T6 were significantly higher than those of groups P and PE (P&#x2005;&lt;&#x2005;.05). The wake-up time after operation and the time to accurately answer the questions were longer in group E than in groups P and PE (P&#x2005;&lt;&#x2005;.05). The incidence of postoperative respiratory depression in group P was higher than that in groups E and PE (P&#x2005;&lt;&#x2005;.05). The Montreal Cognitive Assessment score of group P was lower than that of groups E and PE 7 days after operation (P&#x2005;&lt;&#x2005;.05).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Dexmedetomidine combined with propofol-etomidate mixture is a better anesthesia drug combination.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Yongchuan Hospital Affiliated to Chongqing Medical University, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jinqiu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Chongqing University Three Gorges Hospital, Chongqing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiyang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Guangfen</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4852-0158</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, The First Affiliated Hospital of Dali University, Dali, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, No.1 People's Hospital of Dali City, Dali, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruoyu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Clinical Medicine, Dali University, Dali, Yunnan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ai</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Clinical Medicine, Dali University, Dali, Yunnan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>67VB76HONO</RegistryNumber><NameOfSubstance UI="D020927">Dexmedetomidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YI7VU623SF</RegistryNumber><NameOfSubstance UI="D015742">Propofol</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z22628B598</RegistryNumber><NameOfSubstance UI="D005045">Etomidate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018686">Anesthetics, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020927" MajorTopicYN="Y">Dexmedetomidine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015742" MajorTopicYN="Y">Propofol</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005743" MajorTopicYN="Y">Gastrectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005045" MajorTopicYN="Y">Etomidate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000768" MajorTopicYN="Y">Anesthesia, General</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013274" MajorTopicYN="Y">Stomach Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018686" MajorTopicYN="N">Anesthetics, Intravenous</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006993" MajorTopicYN="N">Hypnotics and Sedatives</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>22</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>22</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>4</Day><Hour>15</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39496064</ArticleId><ArticleId IdType="pmc">PMC11537582</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000039669</ArticleId><ArticleId IdType="pii">00005792-202411010-00097</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">25559415</ArticleId></ArticleIdList></Reference><Reference><Citation>Akira Y, Tai O, Tetsuji Y. Changing trends in cancer incidence of upper aerodigestive tract and stomach in Japanese alcohol-dependent men (1993&#x2013;2018). Cancer Med. 2020;9:837&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6970038</ArticleId><ArticleId IdType="pubmed">31957322</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai HX. Advances in the incidence and mortality of gastric cancer in China. Electronic J Clin Med Literature. 2019;6:192.</Citation></Reference><Reference><Citation>Han C, Wu Q, Ni Z, et al. . Correlation analysis between incidence of gastric cancer and statistical yearbook indicators in China from 1989 to 2014. J Canc Control Treat. 2019;32:434&#x2013;40.</Citation></Reference><Reference><Citation>Sahinovic MM, Struys MMRF, Absalom AR. Clinical pharmacokinetics and pharmacodynamics of propofol. Clin Pharmacokinet. 2018;57:1539&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6267518</ArticleId><ArticleId IdType="pubmed">30019172</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Duan J, Xie C, Yu Y, Lu Y. Comparison between intravenous nalbuphine and lidocaine in reducing propofol-induced injection pain during gastroscopy: a randomized controlled trial. Pain Ther. 2020;9:563&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648831</ArticleId><ArticleId IdType="pubmed">32748184</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao-Chun S, Xing A, Yan C, et al. . Etomidate-remifentanil is more suitable for monitored anesthesia care during gastroscopy in older patients than propofol-remifentanil. Med Sci Monitor. 2015;21:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4288392</ArticleId><ArticleId IdType="pubmed">25553506</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, et al. ., &#x201c;The Component Analysis of Propofol and Etomidate Mixture and Its Clinical Efficacy,&#x201d; 2015 Seventh International Conference on Measuring Technology and Mechatronics Automation, Nanchang, 2015:1152&#x2013;1155.</Citation></Reference><Reference><Citation>Zhou X, Li B-X, Chen L-M, et al. . Etomidate plus propofol versus propofol alone for sedation during gastroscopy: a randomized prospective clinical trial. Surg Endosc. 2016;30:5108&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">27005294</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu YE, Tong CC, Zhang YB, Jin H-X, Gao Y, Hou M-X. Effect of dexmedetomidine on rats with renal ischemia-reperfusion injury and the expression of tight junction protein in kidney. Int J Clin Exp Med. 2015;8:18751&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4694391</ArticleId><ArticleId IdType="pubmed">26770491</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Wang Y, Wang Y, et al. . Dexmedetomidine attenuates inflammatory reaction in the lung tissues of septic mice by activating cholinergic anti-inflammatory pathway. Int Immunopharmacol. 2016;35:210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27074053</ArticleId></ArticleIdList></Reference><Reference><Citation>McMorrow SP, Abramo TJ. Dexmedetomidine sedation: uses in pediatric procedural sedation outside the operating room. Pediatr Emerg Care. 2012;28:292&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22391930</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa RH, Ibrahim IM, Ayoub AH. Effect of perioperative dexmedetomidine infusion on blood glucose levels in non-diabetic morbid obese patients undergoing laparoscopic bariatric surgery. Egyptian J Anaesth. 2018;34:75&#x2013;81.</Citation></Reference><Reference><Citation>Kim SH, Kim DH, Shin S, Kim SJ, Kim TL, Choi YS. Effects of dexmedetomidine on inflammatory mediators after tourniquet-induced ischemia-reperfusion injury: a randomized, double-blinded, controlled study. Minerva Anestesiol. 2018;85:279&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207136</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis SR, Nicholson A, Smith AF, et al. . Alpha-2 adrenergic agonists for the prevention of shivering following general anaesthesia. Cochrane Database Syst Rev. 2015;8:68&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9221859</ArticleId><ArticleId IdType="pubmed">26256531</ArticleId></ArticleIdList></Reference><Reference><Citation>Funai Y, Pickering AE, Uta D, et al. . Systemic dexmedetomidine augments inhibitory synaptic transmission in the superficial dorsal horn through activation of descending noradrenergic control: an in vivo patch-clamp analysis of analgesic mechanisms. Pain. 2014;155:617&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237836</ArticleId><ArticleId IdType="pubmed">24355412</ArticleId></ArticleIdList></Reference><Reference><Citation>Guneli E, Yavasoglu NUK, Apaydin S, et al. . Analysis of the antinociceptive effect of systemic administration of tramadol and dexmedetomidine combination on rat models of acute and neuropathic pain. Pharmacol Biochem Behav. 2007;88:9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">17651791</ArticleId></ArticleIdList></Reference><Reference><Citation>Li WB, Cai YL, Li AX, Zhu H. Application of dexmedetomidine combined with etomidate in interventional anesthesia for stroke. Modern Diagnosis Treat. 2016;27:1040&#x2013;1.</Citation></Reference><Reference><Citation>Liu Y, Huang Y, Wang R, Zhai Y, Huang K, Ren Z. Sedation with a 1:1 mixture of etomidate and propofol for gastroscopy in hypertensive elderly patients. J Clin Hypertens (Greenwich). 2023;25:778&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10423762</ArticleId><ArticleId IdType="pubmed">37436589</ArticleId></ArticleIdList></Reference><Reference><Citation>Du J, Bie X, Zhu D. Application of etomidate and propofol mixture in hematoma removal in patients with intracranial epidural hematoma. Am J Transl Res. 2021;13:8403&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340204</ArticleId><ArticleId IdType="pubmed">34377335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal V, Sisodia RS, Tiwari D, et al. . A comparative study of effect of propofol, etomidate lipuro and propofol&#x2013;etomidate lipuro admixture on haemodyanamic response and on BIS values at induction of general anaesthesia&#x2014;A RCT. Int J Health Clin Res. 2020;3:61&#x2013;7.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31530593</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Tranexamic acid in cardiac surgery: a systematic review and meta-analysis (protocol).</ArticleTitle><Pagination><StartPage>e028585</StartPage><MedlinePgn>e028585</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e028585</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2018-028585</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Bleeding during cardiac surgery is associated with increased morbidity and mortality. Tranexamic acid is an antifibrinolytic with proven efficacy in major surgeries. Current clinical practice guidelines recommend intraoperative use in cardiac procedures. However, several complications have been reported with tranexamic acid including seizures. This review intends to summarise the evidence examining the efficacy and safety of tranexamic acid in patients undergoing cardiac surgery.</AbstractText><AbstractText Label="METHODS/DESIGN">We will search MEDLINE, Embase, PubMED, ACPJC, CINAHL and the Cochrane trial registry for eligible randomised controlled trials, the search dates for all databases will be from inception until 1 January 2019, investigating the perioperative use of topical and/or intravenous tranexamic acid as a stand-alone antifibrinolytic agent compared with placebo in patients undergoing open cardiac surgery. We categorised outcomes as patient critical or patient important. Selected patient-critical outcomes are: mortality (intensive care unit, hospital and 30-day endpoints), reoperation within 24&#x2009;hours, postoperative bleeding requiring transfusion of packed red blood cells, myocardial infarction, stroke, pulmonary embolism, bowel infarction, upper or lower limb deep vein thrombosis and seizures. Those outcomes, we perceived as clinical experts to be most patient valued and patients were not involved in outcomes selection process. We will not apply publication date, language, journal or methodological quality restrictions. Two reviewers will independently screen and identify eligible studies using predefined eligibility criteria and then review full reports of all potentially relevant citations. A third reviewer will resolve disagreements if consensus cannot be achieved. We will present the results as relative risk with 95% CIs for dichotomous outcomes and as mean difference or standardised mean difference for continuous outcomes with 95% CIs. We will assess the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation approach.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">Formal ethical approval is not required as primary data will not be collected. The results will be disseminated through a peer-reviewed publication TRIAL REGISTRATION NUMBER: CRD42018105904.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alaifan</LastName><ForeName>Thamer</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9547-9186</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Critical Care, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alenazy</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Critical Care, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiang Wang</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Schulich School of Medicine and Dentistry, University of Western, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernando</LastName><ForeName>Shannon M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0003-4549-4289</Identifier><AffiliationInfo><Affiliation>Division of Critical Care, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spence</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1267-9455</Identifier><AffiliationInfo><Affiliation>Departments of Anesthesia and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belley-Cote</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Critical Care, Cardiology, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence &amp; Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox-Robichaud</LastName><ForeName>Alison</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9912-3606</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Critical Care, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ainswoth</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Critical Care, Cardiology, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karachi</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine, Critical Care, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyeremanteng</LastName><ForeName>Kwadwo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Critical Care, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarychanski</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Sections of Critical Care Medicine and of Hematology/Medical Oncology, University of Manitoba, Winnipeg, MB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitlock</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Population Health Research Institute, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence &amp; Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, Division of Cardiac Surgery, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rochwerg</LastName><ForeName>Bram</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-8293-7061</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Critical Care, McMaster University, Hamilton, Ontario, Canada rochwerg@mcmaster.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="N">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="N">Tranexamic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bleeding</Keyword><Keyword MajorTopicYN="N">cardiac surgery</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">seizure</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword><Keyword MajorTopicYN="N">tranexamic acid</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31530593</ArticleId><ArticleId IdType="pmc">PMC6756438</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2018-028585</ArticleId><ArticleId IdType="pii">bmjopen-2018-028585</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sullivan MT, Cotten R, Read EJ, et al. . Blood collection and transfusion in the United States in 2001. Transfusion 2007;47:385&#x2013;94. 10.1111/j.1537-2995.2007.01128.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2007.01128.x</ArticleId><ArticleId IdType="pubmed">17319817</ArticleId></ArticleIdList></Reference><Reference><Citation>Colson PH, Gaudard P, Fellahi J-L, et al. . Active bleeding after cardiac surgery: a prospective observational multicenter study. PLoS One 2016;11:e0162396 10.1371/journal.pone.0162396</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0162396</ArticleId><ArticleId IdType="pmc">PMC5010224</ArticleId><ArticleId IdType="pubmed">27588817</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen KL, Rauer LJ, Mortensen PE, et al. . Reoperation for bleeding in cardiac surgery. Interact Cardiovasc Thorac Surg 2012;14:709&#x2013;13. 10.1093/icvts/ivs050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/icvts/ivs050</ArticleId><ArticleId IdType="pmc">PMC3352720</ArticleId><ArticleId IdType="pubmed">22368106</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivacqua A, Koch CG, Yousuf AM, et al. . Morbidity of bleeding after cardiac surgery: is it blood transfusion, reoperation for bleeding, or both? Ann Thorac Surg 2011;91:1780&#x2013;90. 10.1016/j.athoracsur.2011.03.105</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2011.03.105</ArticleId><ArticleId IdType="pubmed">21619974</ArticleId></ArticleIdList></Reference><Reference><Citation>Paparella D, Galeone A, Venneri MT, et al. . Activation of the coagulation system during coronary artery bypass grafting: comparison between on-pump and off-pump techniques. J Thorac Cardiovasc Surg 2006;131:290&#x2013;7. 10.1016/j.jtcvs.2005.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2005.10.018</ArticleId><ArticleId IdType="pubmed">16434256</ArticleId></ArticleIdList></Reference><Reference><Citation>Ickx BE, Faraoni D. Management of the clotting system: a European perspective. Curr Opin Anaesthesiol 2012;25:80&#x2013;5. 10.1097/ACO.0b013e32834ef3d1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ACO.0b013e32834ef3d1</ArticleId><ArticleId IdType="pubmed">22157197</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess PJ. Systemic inflammatory response to coronary artery bypass graft surgery. Am J Health Syst Pharm 2005;62(18 Suppl 4):S6&#x2013;9. 10.2146/ajhp050302</Citation><ArticleIdList><ArticleId IdType="doi">10.2146/ajhp050302</ArticleId><ArticleId IdType="pubmed">16227195</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano D, Milojevic M, Meesters MI, et al. . 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg 2018;53:79&#x2013;111. 10.1093/ejcts/ezx325</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezx325</ArticleId><ArticleId IdType="pubmed">29029100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ker K, Edwards P, Perel P, et al. . Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012;344:e3054 10.1136/bmj.e3054</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e3054</ArticleId><ArticleId IdType="pmc">PMC3356857</ArticleId><ArticleId IdType="pubmed">22611164</ArticleId></ArticleIdList></Reference><Reference><Citation>CRASH-2 trial collaborators Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23&#x2013;32. 10.1016/S0140-6736(10)60835-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)60835-5</ArticleId><ArticleId IdType="pubmed">20554319</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraris VA, Brown JR, Despotis GJ, et al. . 2011 Update to the Society of thoracic surgeons and the Society of cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011;91:944&#x2013;82. 10.1016/j.athoracsur.2010.11.078</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2010.11.078</ArticleId><ArticleId IdType="pubmed">21353044</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57:1005&#x2013;32. 10.2165/00003495-199957060-00017</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-199957060-00017</ArticleId><ArticleId IdType="pubmed">10400410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukes AS, Moore KA, Muse KN, et al. . Tranexamic acid treatment for heavy menstrual bleeding. Obstet Gynecol 2010;116:865&#x2013;75. 10.1097/AOG.0b013e3181f20177</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0b013e3181f20177</ArticleId><ArticleId IdType="pubmed">20859150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukeik M, Alshryda S, Haddad FS, et al. . Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011;93-B:39&#x2013;46. 10.1302/0301-620X.93B1.24984</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.93B1.24984</ArticleId><ArticleId IdType="pubmed">21196541</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison JJ, Dubose JJ, Rasmussen TE, et al. . Military application of tranexamic acid in trauma emergency resuscitation (MATTERS) study. Arch Surg 2012;147:113&#x2013;9. 10.1001/archsurg.2011.287</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.2011.287</ArticleId><ArticleId IdType="pubmed">22006852</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JR, Birkmeyer NJO, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115:2801&#x2013;13. 10.1161/CIRCULATIONAHA.106.671222</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.671222</ArticleId><ArticleId IdType="pubmed">17533182</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma V, Katznelson R, Jerath A, et al. . The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. Anaesthesia 2014;69:124&#x2013;30. 10.1111/anae.12516</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.12516</ArticleId><ArticleId IdType="pubmed">24588023</ArticleId></ArticleIdList></Reference><Reference><Citation>Koster A, B&#xf6;rgermann J, Zittermann A, et al. . Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome. Br J Anaesth 2013;110:34&#x2013;40. 10.1093/bja/aes310</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aes310</ArticleId><ArticleId IdType="pubmed">22986419</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z-F, Zhang F-J, Huo Y-F, et al. . Intraoperative tranexamic acid is associated with postoperative stroke in patients undergoing cardiac surgery. PLoS One 2017;12:e0177011 10.1371/journal.pone.0177011</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177011</ArticleId><ArticleId IdType="pmc">PMC5446127</ArticleId><ArticleId IdType="pubmed">28552944</ArticleId></ArticleIdList></Reference><Reference><Citation>Myles PS, Smith JA, Forbes A, et al. . Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2017;376:136&#x2013;48. 10.1056/NEJMoa1606424</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1606424</ArticleId><ArticleId IdType="pubmed">27774838</ArticleId></ArticleIdList></Reference><Reference><Citation>Borger MA, Ivanov J, Weisel RD, et al. . Stroke during coronary bypass surgery: principal role of cerebral macroemboli. Eur J Cardiothorac Surg 2001;19:627&#x2013;32. 10.1016/S1010-7940(01)00649-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1010-7940(01)00649-2</ArticleId><ArticleId IdType="pubmed">11343943</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander M, Spies CD, Martiny V, et al. . Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Critical Care 2010;14 10.1186/cc9216</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9216</ArticleId><ArticleId IdType="pmc">PMC2945131</ArticleId><ArticleId IdType="pubmed">20682059</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigaut S, Tremey B, Ouattara A, et al. . Comparison of two doses of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Anesthesiology 2014;120:590&#x2013;600. 10.1097/ALN.0b013e3182a443e8</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e3182a443e8</ArticleId><ArticleId IdType="pubmed">23903022</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldow T, Szlapka M, Haferkorn M, et al. . Prospective clinical trial on dosage optimizing of tranexamic acid in non-emergency cardiac surgery procedures. Clin Hemorheol Microcirc 2013;55:457&#x2013;68. 10.3233/CH-131782</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/CH-131782</ArticleId><ArticleId IdType="pubmed">24113504</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012;72:585&#x2013;617. 10.2165/11209070-000000000-00000</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11209070-000000000-00000</ArticleId><ArticleId IdType="pubmed">22397329</ArticleId></ArticleIdList></Reference><Reference><Citation>Cilia La Corte AL, Philippou H, Ari&#xeb;ns RAS, et al. . Role of fibrin structure in thrombosis and vascular disease. Adv Protein Chem Struct Biol 2011;83:75&#x2013;127. 10.1016/B978-0-12-381262-9.00003-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-381262-9.00003-3</ArticleId><ArticleId IdType="pubmed">21570666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sniecinski RM, Chandler WL. Activation of the hemostatic system during cardiopulmonary bypass. Anesth Analg 2011;113:1319&#x2013;33. 10.1213/ANE.0b013e3182354b7e</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e3182354b7e</ArticleId><ArticleId IdType="pubmed">22003219</ArticleId></ArticleIdList></Reference><Reference><Citation>McIlroy DR, Myles PS, Phillips LE, et al. . Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis. Br J Anaesth 2009;102:168&#x2013;78. 10.1093/bja/aen377</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aen377</ArticleId><ArticleId IdType="pubmed">19151047</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai Z, Chu H, Wang S, et al. . The effect of tranexamic acid to reduce blood loss and transfusion on off-pump coronary artery bypass surgery: a systematic review and cumulative meta-analysis. J Clin Anesth 2018;44:23&#x2013;31. 10.1016/j.jclinane.2017.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinane.2017.10.004</ArticleId><ArticleId IdType="pubmed">29107853</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Altman DG, G&#xf8;tzsche PC, et al. . The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928 10.1136/bmj.d5928</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>
Higgins JPT, Green S, eds
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.  Available: www.cochrane-handbook.org
</Citation></Reference><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, et al. . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924&#x2013;6. 10.1136/bmj.39489.470347.AD</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39489.470347.AD</ArticleId><ArticleId IdType="pmc">PMC2335261</ArticleId><ArticleId IdType="pubmed">18436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsaros D, Petricevic M, Snow NJ, et al. . Tranexamic acid reduces postbypass blood use. Ann Thorac Surg 1996;61:1131&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8607670</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26514983</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1496-8975</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Canadian journal of anaesthesia = Journal canadien d'anesthesie</Title><ISOAbbreviation>Can J Anaesth</ISOAbbreviation></Journal><ArticleTitle>A systematic review of transthoracic and transesophageal echocardiography in non-cardiac surgery: implications for point-of-care ultrasound education in the operating room.</ArticleTitle><Pagination><StartPage>480</StartPage><EndPage>487</EndPage><MedlinePgn>480-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12630-015-0524-7</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Point-of-care ultrasound (POCU) is an evolving field in anesthesia. Therefore a systematic review of common diagnoses made by POCU during non-cardiac surgery was conducted. The information obtained from the review may be used to develop POCU curricula for the perioperative setting during non-cardiac surgery.</AbstractText><AbstractText Label="SOURCE" NlmCategory="METHODS">A systematic review was conducted for perioperative use of transthoracic /transesophageal echocardiography (TTE/TEE) in high-risk patients or in other patients experiencing periods of hemodynamic instability. The diagnoses included segmental wall motion abnormalities (SWMAs), low left ventricular ejection fraction (LVEF), hypovolemia, air embolism, cardiac/aortic thrombus, pulmonary embolus (PE), aortic valve disease, mitral valve disease, tricuspid valve disease, right ventricular (RV) failure, pericardial disease, and patent foramen ovale.</AbstractText><AbstractText Label="PRINCIPAL FINDINGS" NlmCategory="RESULTS">Three hundred twenty-one studies were found using our search terms, and thirteen studies were retained that met our inclusion criteria for review. The studies included 968 patients analyzed as either preoperative exams in high-risk patients (n = 568) or intraoperative exams during times of hemodynamic compromise/cardiac arrest (n = 400). The most common diagnoses in the preoperative exam group were low ejection fraction (25.4%), aortic valve disease (24.4%), mitral valve disease (20.0%), RV failure (6.6%), and hypovolemia (6.3%). In the intraoperative exam group, the most common diagnoses were hypovolemia (33.2%), low ejection fraction (20.5%), RV failure (13.1%), SWMAs (10.1%), and PE (5.8%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this systematic review examining the use of TTE or TEE in non-cardiac surgery, the most frequent diagnoses were valvulopathy, low LVEF, hypovolemia, PE, SWMAs, and RV failure. This information should be used to inform evidence-based curricula for POCU in anesthesiology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jasudavisius</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Schulich School of Medicine and Dentistry, London Health Sciences Centre, Western University, London, ON, Canada. Amandajasudavisius@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arellano</LastName><ForeName>Ramiro</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Schulich School of Medicine and Dentistry, London Health Sciences Centre, Western University, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Schulich School of Medicine and Dentistry, London Health Sciences Centre, Western University, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McConnell</LastName><ForeName>Brie</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Western University, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bainbridge</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Schulich School of Medicine and Dentistry, London Health Sciences Centre, Western University, London, ON, Canada. Daniel.bainbridge@lhsc.on.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Western University, London, ON, Canada. Daniel.bainbridge@lhsc.on.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Anaesth</MedlineTA><NlmUniqueID>8701709</NlmUniqueID><ISSNLinking>0832-610X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000776" MajorTopicYN="N">Anesthesiology</DescriptorName><QualifierName UI="Q000193" MajorTopicYN="Y">education</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003479" MajorTopicYN="N">Curriculum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004452" MajorTopicYN="Y">Echocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017548" MajorTopicYN="Y">Echocardiography, Transesophageal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009873" MajorTopicYN="N">Operating Rooms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019095" MajorTopicYN="Y">Point-of-Care Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013514" MajorTopicYN="Y">Surgical Procedures, Operative</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26514983</ArticleId><ArticleId IdType="doi">10.1007/s12630-015-0524-7</ArticleId><ArticleId IdType="pii">10.1007/s12630-015-0524-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25576011</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>Topical application of tranexamic acid in primary total hip arthroplasty: a systemic review and meta-analysis.</ArticleTitle><Pagination><StartPage>134</StartPage><EndPage>139</EndPage><MedlinePgn>134-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijsu.2014.12.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1743-9191(15)00007-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">A systematic review of randomized controlled trials (RCTs) and non-RCTs was performed to evaluate efficacy for the reduction of postoperative blood loss and transfusion requirements of topical use of tranexamic acid in patients undergoing primary total hip arthroplasty.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Potential articles were identified from Medline (1966 - September 2014), Embase (1980 - September 2014), Pubmed (1980 - September 2014) and The Cochrane Central Register of Controlled Trials. Other internet databases are also searched to find trials according to the Cochrane Collaboration guidelines. Moreover, gray literatures are also selected from the reference list of the included studies. High quality randomized controlled trials (RCTs) and non-RCTs were selected. The software RevMan 5.1 was used for the mate-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four RCTs and four non-RCT meet the inclusion criteria. There were significant differences in hemoglobin, total blood loss, transfusion requirements and postoperative drainage volume between TXA groups and control groups. There were no significant differences in length of stay, incidence of wound infection, deep vein thrombosis (DVT) and pulmonary embolism (PE) between treatment and control groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Present meta-analysis indicates that the antifibrinolytic agent, also known as tranexamic acid, could reduce hemoglobin decline, volume of drainage, total blood loss and transfusion requirements after THA, and is not related to adverse reactions or complications such as wound infection, DVT and PE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin 300050, People's Republic of China; Tianjin Medical University, Tianjin 300070, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Gui-jun</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Tianjin Hospital, Tianjin 300211, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Tianjin Hospital, Tianjin 300211, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jian-xiong</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin 300050, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xin-long</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, Tianjin Hospital, Tianjin 300211, People's Republic of China. Electronic address: orthodoc969@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin 300050, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biomechanics Labs of Orthopaedics Institute, Tianjin Hospital, Tianjin 300050, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000287" MajorTopicYN="N">Administration, Topical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="N">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="N">Tranexamic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Topical</Keyword><Keyword MajorTopicYN="N">Total hip arthroplasty</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25576011</ArticleId><ArticleId IdType="doi">10.1016/j.ijsu.2014.12.023</ArticleId><ArticleId IdType="pii">S1743-9191(15)00007-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30780008</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2472</ISSN><JournalIssue CitedMedium="Internet"><Volume>176</Volume><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Thrombosis research</Title><ISOAbbreviation>Thromb Res</ISOAbbreviation></Journal><ArticleTitle>Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis.</ArticleTitle><Pagination><StartPage>79</StartPage><EndPage>84</EndPage><MedlinePgn>79-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.thromres.2019.02.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-3848(19)30056-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Unprovoked venous thromboembolism (VTE) may be the first manifestation of an underlying cancer. We aimed to assess the period prevalence of occult cancer detection stratified by VTE location (deep vein thrombosis [DVT], pulmonary embolism [PE] or both) and the anatomical relationship between occult cancer and VTE.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Post-hoc analysis of a systematic review and individual patient data meta-analysis of adults with unprovoked VTE with at least 12&#x202f;months of follow-up. Cancer types were grouped according to thoracic, abdomino-pelvic, or other locations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 2300 patients were eligible including 1218 with DVT only (53%), 719 with PE only (31%), and 363 with both PE and DVT (16%). The pooled 12-month period prevalence of cancer in DVT only, PE only, and DVT&#x202f;+&#x202f;PE was 5.6% (95% CI, 4.4 to 7.2), 4.3% (95% CI, 2.7 to 6.9), and 5.6% (95% CI, 1.7 to 15.5), respectively. Most occult cancers were located in the abdomen (68.4%). The proportion of patients with an abdomino-pelvic cancer was not different in patients with DVT&#x202f;+&#x202f;PE (81%; 95% CI, 54 to 96) than in those with DVT (68%; 95% CI, 57 to 78) or PE alone (65%; 95% CI, 48 to 79).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The 12-month prevalence of occult cancer was similar in patients with DVT only, PE only, or both. Most cancers were located in the abdomen, and there was no relationship between VTE type and cancer location.</AbstractText><CopyrightInformation>Crown Copyright &#xa9; 2019. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jara-Palomares</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Surgical Unit of Respiratory Diseases, Instituto de Biomedicina de Sevilla (IBiS), Virgen del Rocio Hospital, Sevilla, Spain; Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: luisoneumo@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Praena-Fernandez</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Statistics, Methodology and Research Evaluation Unit, Andalusian Public Foundation for Health Research Management, Hospital Virgen del Roc&#xed;o, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Gal</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada; D&#xe9;partement de M&#xe9;decine Interne et Pneumologie, Centre Hospitalo-Universitaire de Brest, Universit&#xe9; de Bretagne Occidentale, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otten</LastName><ForeName>H M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, MC Slotervaart, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robin</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Nucl&#xe9;aire, Centre Hospitalo-Universitaire de Brest, Universit&#xe9; de Bretagne Occidentale, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccioli</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Cardiovascular Sciences and Medicine, University Hospital of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lecumberri</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hematology Service, Clinica Universidad de Navarra, Pamplona, Spain; CIBER-CV, Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Religa</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Karolinska Institutet, Stockholm, Sweden; Department of Medicine, Warsaw Medical University, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rieu</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Centre Hospitalo-Universitaire Estaing, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rondina</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and the Molecular Medicine Program, University of Utah, Salt Lake City, UT, USA; George E. Wahlen VAMC GRECC, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckers</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prandoni</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departments of Cardiovascular Sciences and Medicine, University Hospital of Padua, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salaun</LastName><ForeName>P Y</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Service de M&#xe9;decine Nucl&#xe9;aire, Centre Hospitalo-Universitaire de Brest, Universit&#xe9; de Bretagne Occidentale, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Nisio</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands; Dipartimento di Medicina e Scienze dell'Invecchiamento, Universit&#xe0; "Gabriele d'Annunzio", Chieti, Pescara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bossuyt</LastName><ForeName>P M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraaijpoel</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfc;ller</LastName><ForeName>H R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrier</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Thromb Res</MedlineTA><NlmUniqueID>0326377</NlmUniqueID><ISSNLinking>0049-3848</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">(MeSH terms): Meta-analysis [publication type]</Keyword><Keyword MajorTopicYN="N">Neoplasms</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword><Keyword MajorTopicYN="N">Venous thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30780008</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2019.02.011</ArticleId><ArticleId IdType="pii">S0049-3848(19)30056-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33618065</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-3348</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of vascular surgery. Venous and lymphatic disorders</Title><ISOAbbreviation>J Vasc Surg Venous Lymphat Disord</ISOAbbreviation></Journal><ArticleTitle>Systematic review on the incidence and management of endovenous heat-induced thrombosis following endovenous thermal ablation of the great saphenous vein.</ArticleTitle><Pagination><StartPage>1312</StartPage><EndPage>1320.e10</EndPage><MedlinePgn>1312-1320.e10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvsv.2021.02.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-333X(21)00090-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE">A systematic review and meta-analysis was performed to determine the incidence of endovenous heat-induced thrombosis (EHIT) and evaluate its management after endovenous thermal ablation of the great saphenous vein (GSV).</AbstractText><AbstractText Label="METHODS">MEDLINE and Embase were searched for studies with at least 100 patients who underwent great saphenous vein endovenous thermal ablation and had duplex ultrasound follow-up within 30 days. Data were gathered on the incidence of thrombotic complications and on the management of cases of EHIT. The primary outcome for the meta-analysis was EHIT types 2 to 4 and secondary outcomes were deep venous thrombotic events (which we defined as types 2-4 EHIT plus deep vein thrombosis [DVT]), DVT, and pulmonary embolism (PE). Pooled proportions were calculated using random effects modelling.</AbstractText><AbstractText Label="RESULTS">We included 75 studies (23,265 patients). EHIT types 2 to 4 occurred in 1.27% of cases (95% confidence interval [CI], 0.74%-1.93%). Deep venous thrombotic events occurred in 1.59% (95% CI, 0.95%-2.4%). DVT occurred in 0.28% (95% CI, 0.18%-0.4%). Pulmonary embolism occurred in 0.11% (95% CI, 0.06%-0.18%). Of the 75 studies, 24 gave a description of the management strategy and outcomes for EHIT and there was inconsistency regarding its management. Asymmetrical funnel plots of studies that reported incidence of EHIT 2 to 4 and DVT suggest publication bias.</AbstractText><AbstractText Label="CONCLUSIONS">The recently published guidelines on EHIT from the Society for Vascular Surgery/American Venous Forum provide a framework to direct clinical decision-making. EHIT and other thrombotic complications occur infrequently and have a benign course.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Society for Vascular Surgery. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Healy</LastName><ForeName>Donagh A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Twyford</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital Limerick, University of Limerick School of Medicine, Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moloney</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital Limerick, University of Limerick School of Medicine, Limerick, Ireland. Electronic address: m.tony.moloney@hse.ie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kavanagh</LastName><ForeName>Eamon G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University Hospital Limerick, University of Limerick School of Medicine, Limerick, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Vasc Surg Venous Lymphat Disord</MedlineTA><NlmUniqueID>101607771</NlmUniqueID><ISSNLinking>2213-333X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055011" MajorTopicYN="N">Ablation Techniques</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012501" MajorTopicYN="N">Saphenous Vein</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Endovenous heat-induced thrombosis</Keyword><Keyword MajorTopicYN="N">Great saphenous vein</Keyword><Keyword MajorTopicYN="N">Laser ablation</Keyword><Keyword MajorTopicYN="N">Radiofrequency ablation</Keyword><Keyword MajorTopicYN="N">Varicose veins</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>22</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33618065</ArticleId><ArticleId IdType="doi">10.1016/j.jvsv.2021.02.006</ArticleId><ArticleId IdType="pii">S2213-333X(21)00090-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39735018</PMID><DateRevised><Year>2025</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Risk Factors and Outcomes of Acute Pulmonary Embolism in African Patients: A Systematic Review.</ArticleTitle><Pagination><StartPage>e74673</StartPage><MedlinePgn>e74673</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e74673</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.74673</ELocationID><Abstract><AbstractText>Pulmonary embolism is a common cause of morbidity and mortality. Numerous risk factors have been identified that predispose patients to this disease. This study aims to identify these risk factors and the possible outcomes (recovery or mortality) after receiving treatment from any hospital. Healthcare is expensive in Africa, hence hindering its easy accessibility.&#xa0; PubMed, Scopus, and African Journals Online were searched from the database inception to October 2024 to identify relevant studies. A total of 719 articles were identified, for which 172 duplicate articles were removed. After screening 592 articles by title and abstract, 508 were excluded. Eighty-four articles were screened by full text to determine their eligibility. Finally, 13 articles were used in the final qualitative analysis. We included original research published in English in peer-reviewed journals from January 2000 to September 2024 that reported the risk factors and outcomes of pulmonary embolism, and studies that used computed tomography pulmonary angiography as a diagnosis of acute pulmonary embolism in patients more than 18 years old, irrespective of gender and medical or surgical condition, managed in any African hospital, were included. In total, 7650 patients were included in 13 articles, from 10 countries (Nigeria, Togo, Angola, Kenya, Cameroon, South Africa, Sierra Leone, Egypt, DR Congo, and Ethiopia), and 861 patients had pulmonary embolism. The mean age of the reported patients ranged from 40.8 to 64.4 years across the studies. There were 309 male and 552 female patients diagnosed with pulmonary embolism. The study types included in this review are retrospective studies,&#xa0;cross-sectional studies, and case-control studies. Deep vein thrombosis (DVT), heart disease, immobilization, obesity, smoking, recent surgery, and malignancy were the most commonly identified risk factors across the included articles. Pulmonary embolism contributes significantly to morbidity and mortality among African patients, with key risk factors including DVT, immobilization, heart disease, obesity, smoking, recent surgery, malignancy, pregnancy, and contraceptive use. Limited diagnostic resources in low-resource settings pose a major challenge, but adopting affordable diagnostic alternatives and clinical algorithms could improve outcomes by enabling earlier diagnosis and timely treatment. The availability and implementation of a standardized PE treatment protocol will ensure quality care, decrease mortality, and increase recovery rates.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024, Okeke et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okeke</LastName><ForeName>Collins C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amadi</LastName><ForeName>Emmanuel S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hallel Hospital and Maternity, Port Harcourt, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebiliekwe</LastName><ForeName>Onyinye E</ForeName><Initials>OE</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ekeocha</LastName><ForeName>Ifunanya R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nnanna Okoro</LastName><ForeName>Emeka</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Imo State University College of Medicine, Owerri, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nduji</LastName><ForeName>Oluchi J</ForeName><Initials>OJ</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Abia State University, Uturu, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Undie</LastName><ForeName>Malipeh-Unim</ForeName><Initials>MU</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Surgery Interest Group of Africa, Lagos, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngige</LastName><ForeName>Onyinye</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eze-Odurukwe</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Salford Royal NHS Foundation Trust, Manchester, GBR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezema</LastName><ForeName>Chinecherem</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Onyeogulu</LastName><ForeName>Afamefuna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ojo</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Afe Babalola University, Ado Ekiti, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obuseh</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Delta State University Teaching Hospital, Oghara, NGA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okonta</LastName><ForeName>Kelechi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cardiothoracic Surgery Unit, Department of Surgery, University of Port Harcourt Teaching Hospital, Port Harcourt, NGA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">outcome</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList><CoiStatement>Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>30</Day><Hour>5</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39735018</ArticleId><ArticleId IdType="pmc">PMC11681974</ArticleId><ArticleId IdType="doi">10.7759/cureus.74673</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pulmonary embolism. Tarbox AK, Swaroop M. Int J Crit Illn Inj Sci. 2013;3:69&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3665123</ArticleId><ArticleId IdType="pubmed">23724389</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiology, pathophysiology, and natural history of pulmonary embolism. Turetz M, Sideris AT, Friedman OA, Triphathi N, Horowitz JM. Semin Intervent Radiol. 2018;35:92&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5986574</ArticleId><ArticleId IdType="pubmed">29872243</ArticleId></ArticleIdList></Reference><Reference><Citation>Global incidence and case fatality rate of pulmonary embolism following major surgery: a protocol for a systematic review and meta-analysis of cohort studies. Temgoua MN, Tochie JN, Noubiap JJ, Agbor VN, Danwang C, Endomba FT, Nkemngu NJ. Syst Rev. 2017;6:240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5716368</ArticleId><ArticleId IdType="pubmed">29202836</ArticleId></ArticleIdList></Reference><Reference><Citation>Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: vital registration data from 123&#xa0;countries. Barco S, Valerio L, Gallo A, et al. Res Pract Thromb Haemost. 2021;5:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8268665</ArticleId><ArticleId IdType="pubmed">34263098</ArticleId></ArticleIdList></Reference><Reference><Citation>Association AL. Pulmonary embolism symptoms and diagnosis.  [
Oct;
2024 
]. 2024. https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-embolism/symptoms-diagnosis https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-embolism/symptoms-diagnosis</Citation></Reference><Reference><Citation>Pulmonary embolism. Essien EO, Rali P, Mathai SC. Med Clin North Am. 2019;103:549&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">30955521</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary embolism (PE) clinical presentation. 2024. https://emedicine.medscape.com/article/300901-clinical https://emedicine.medscape.com/article/300901-clinical</Citation></Reference><Reference><Citation>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Page MJ, McKenzie JE, Bossuyt PM, et al. BMJ. 2021;372:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8008539</ArticleId><ArticleId IdType="pubmed">33781348</ArticleId></ArticleIdList></Reference><Reference><Citation>Critical appraisal tools.  [
Oct;
2024 
]. 2024. https://jbi.global/critical-appraisal-tools https://jbi.global/critical-appraisal-tools</Citation></Reference><Reference><Citation>Acute pulmonary thromboembolism: a retrospective study in a Nigerian private tertiary hospital. Ogunkoya J, Oluwole A, Adefuye B, Adebola-Yusuf AO, Ehioghae O. https://www.ajol.info/index.php/ahr/article/view/226821 Ann Health Res. 2021;7:107&#x2013;117.</Citation></Reference><Reference><Citation>Pulmonary embolism at the University Hospital Campus of Lome (Togo): a retrospective study about 51 cases [Article in French] Pessinaba S, Atti YD, Baragou S, et al. Pan Afr Med J. 2017;27:129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567959</ArticleId><ArticleId IdType="pubmed">28904659</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical profile, management and outcomes of patients with pulmonary embolism: a retrospective tertiary centre study in Angola. Manuel A, Aufico A, Africano R, et al.  https://pubmed.ncbi.nlm.nih.gov/28556850/ Cardiovasc J Afr. 2017;28:356&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885046</ArticleId><ArticleId IdType="pubmed">28556850</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary thromboembolism in an East African tertiary referral hospital. Ogeng'o JA, Obimbo MM, Olabu BO, Gatonga PM, Ong'era D. J Thromb Thrombolysis. 2011;32:386&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pubmed">21674133</ArticleId></ArticleIdList></Reference><Reference><Citation>Acute pulmonary embolism in the era of multi-detector CT: a reality in sub-Saharan Africa. Tambe J, Moifo B, Fongang E, Guegang E, Juimo AG. BMC Med Imaging. 2012;12:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3485620</ArticleId><ArticleId IdType="pubmed">23072500</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical presentation and diagnostic work up of suspected pulmonary embolism in a district hospital emergency centre serving a high HIV/TB burden population. Bulajic B, Welzel T, Vallabh K. Afr J Emerg Med. 2019;9:134&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742596</ArticleId><ArticleId IdType="pubmed">31528531</ArticleId></ArticleIdList></Reference><Reference><Citation>The clinical features and management of pulmonary embolism at Chris Hani Baragwanath Academic Hospital. Meel S, Peter A, Menezes C. https://pmc.ncbi.nlm.nih.gov/articles/PMC8424778/ Afr J Thorac Crit Care Med. 2018;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8424778</ArticleId><ArticleId IdType="pubmed">34541509</ArticleId></ArticleIdList></Reference><Reference><Citation>Acute pulmonary embolism in an intensive care unit setting in Sierra Leone. Russell JB, Baio S, Koroma TR, et al.  https://pubmed.ncbi.nlm.nih.gov/36260002/ West Afr J Med. 2022;39:997&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">36260002</ArticleId></ArticleIdList></Reference><Reference><Citation>Patient characteristics and predictors of pulmonary embolism in patients infected with COVID - 19 in Upper Egypt. Hussein A, Khalaf AM, Alsharawy LA, Abdelrazek G, Shafiq Awad M. Vasc Health Risk Manag. 2023;19:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10084826</ArticleId><ArticleId IdType="pubmed">37050930</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary embolism: epidemiological data and diagnosis in Kinshasa hospitals. Bakebe A, Kashongwe I, Mulenga C, et al. Int J Tuberc Lung Dis. 2017;21:875&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">28786795</ArticleId></ArticleIdList></Reference><Reference><Citation>The value of electrocardiography in predicting inpatient mortality in patients with acute pulmonary embolism: a cross sectional analysis. Raghubeer N, Lahri S, Hendrikse C. Afr J Emerg Med. 2024;14:65&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10899042</ArticleId><ArticleId IdType="pubmed">38425642</ArticleId></ArticleIdList></Reference><Reference><Citation>Hospital survival of patients with pulmonary embolism in a country with limited resources case of the city of Kinshasa. Marc TB, Michel TP, Florence M, et al. BMC Cardiovasc Disord. 2023;23:439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10476371</ArticleId><ArticleId IdType="pubmed">37667172</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence and factors associated with pulmonary embolism among RT-PCR confirmed Covid-19 patients with upfront CT pulmonary angiography in Ethiopia: a nested casecontrol study. Belayneh EK, Leulseged TW, Tarekegn TK, et al.  https://www.ajol.info/index.php/emj/article/view/249901 Ethiop Med J. 2023;61:1.</Citation></Reference><Reference><Citation>Prevalence and risk factors of pulmonary embolism in COPD patients complicated with secondary polycythemia. Li J, Xiong Y, Li S, et al. Int J Chron Obstruct Pulmon Dis. 2024;19:2371&#x2013;2385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11542496</ArticleId><ArticleId IdType="pubmed">39512997</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Arch Intern Med. 2000;160:809&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737280</ArticleId></ArticleIdList></Reference><Reference><Citation>A prospective study of risk factors for pulmonary embolism in women. Goldhaber SZ, Grodstein F, Stampfer MJ, et al.  https://pubmed.ncbi.nlm.nih.gov/9039882/ JAMA. 1997;277:642&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">9039882</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence and risk factors for pulmonary embolism in the postpartum period. Morris JM, Algert CS, Roberts CL. J Thromb Haemost. 2010;8:998&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">20128859</ArticleId></ArticleIdList></Reference><Reference><Citation>Antenatal pulmonary embolism: risk factors, management and outcomes. Knight M. BJOG. 2008;115:453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">18201281</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk factors for pulmonary embolism. The Framingham study. Goldhaber SZ, Savage DD, Garrison RJ, et al. Am J Med. 1983;74:1023&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">6859053</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk factor and mortality in patients with pulmonary embolism combined with infectious disease. Lee GD, Ju S, Kim JY, et al. Tuberc Respir Dis (Seoul) 2020;83:157&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105430</ArticleId><ArticleId IdType="pubmed">32185917</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics, risk factors, and outcomes of acute pulmonary embolism in Asian population. Bumroongkit C, Deesomchok A, Liwsrisakun C, et al. J Clin Med. 2022;11:6954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9741370</ArticleId><ArticleId IdType="pubmed">36498530</ArticleId></ArticleIdList></Reference><Reference><Citation>Outpatient treatment of pulmonary embolism with dalteparin. Kovacs MJ, Anderson D, Morrow B, Gray L, Touchie D, Wells PS. https://pubmed.ncbi.nlm.nih.gov/10739374/ Thromb Haemost. 2000;83:209&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">10739374</ArticleId></ArticleIdList></Reference><Reference><Citation>Catheter-directed thrombolysis compared with systemic thrombolysis and anticoagulation in patients with intermediate- or high-risk pulmonary embolism: systematic review and network meta-analysis. Planer D, Yanko S, Matok I, et al. CMAJ. 2023;195:0&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10281204</ArticleId><ArticleId IdType="pubmed">37336568</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparison of interventions for intermediate to high-risk pulmonary embolism: a network meta-analysis. Ishisaka Y, Watanabe A, Fujisaki T, et al. Catheter Cardiovasc Interv. 2023;102:249&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">37269229</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy and safety of anticoagulation,&#xa0;catheter-directed thrombolysis, or systemic thrombolysis in acute&#xa0;pulmonary embolism. Zhang RS, Maqsood MH, Sharp AS, et al. JACC Cardiovasc Interv. 2023;16:2644&#x2013;2651.</Citation><ArticleIdList><ArticleId IdType="pubmed">37855802</ArticleId></ArticleIdList></Reference><Reference><Citation>Long-term mortality in patients with pulmonary embolism: results in a single-center registry. Eckelt J, Hobohm L, Merten MC, et al. Res Pract Thromb Haemost. 2023;7:100280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10439384</ArticleId><ArticleId IdType="pubmed">37601025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuberculosis and venous thromboembolism: a case series. Goncalves IM, Alves DC, Carvalho A, do Ceu Brito M, Calvario F, Duarte R. Cases J. 2009;2:9333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804722</ArticleId><ArticleId IdType="pubmed">20066058</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence of venous thromboembolism in tuberculosis patients. Ambrosetti M, Ferrarese M, Codecasa LR, Besozzi G, Sarassi A, Viggiani P, Migliori GB. Respiration. 2006;73:396.</Citation><ArticleIdList><ArticleId IdType="pubmed">16439829</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuberculose (TB)  [
Nov;
2024 
]. 2024. https://www.afro.who.int/health-topics/tuberculosis-tb https://www.afro.who.int/health-topics/tuberculosis-tb</Citation></Reference><Reference><Citation>HIV/AIDS.  [
Nov;
2024 
]. 2024. https://www.afro.who.int/health-topics/hivaids https://www.afro.who.int/health-topics/hivaids</Citation></Reference><Reference><Citation>Acute pulmonary embolism in patients with HIV disease. Howling SJ, Shaw PJ, Miller RF. Sex Transm Infect. 1999;75:25&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1758180</ArticleId><ArticleId IdType="pubmed">10448338</ArticleId></ArticleIdList></Reference><Reference><Citation>Venous thromboembolic disease in the HIV-infected patient. Malek J, Rogers R, Kufera J, Hirshon JM. Am J Emerg Med. 2011;29:278&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">20825798</ArticleId></ArticleIdList></Reference><Reference><Citation>AIDS and thrombosis: retrospective study of 131 HIV-infected patients. Saif MW, Bona R, Greenberg B. AIDS Patient Care STDS. 2001;15:311&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">11445013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37646876</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1068</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>European journal of orthopaedic surgery &amp; traumatology : orthopedie traumatologie</Title><ISOAbbreviation>Eur J Orthop Surg Traumatol</ISOAbbreviation></Journal><ArticleTitle>A systemic review and meta-analysis of pararectus versus ilioinguinal approach for the management of acetabular fractures.</ArticleTitle><Pagination><StartPage>549</StartPage><EndPage>560</EndPage><MedlinePgn>549-560</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00590-023-03700-0</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The complex anatomy of acetabular fracture needs a surgical approach that can achieve anatomical reduction with fewer complications for the fixation of these fractures. Current literature suggests that both Pararectus (PR) approach and Ilioinguinal (IL) approach can be used for the fixation of these fractures safely. However, superiority of the PR approach over the IL approach is not established. Hence, this meta-analysis aimed to compare the PR versus IL approach.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">A literature search was performed on five databases Medline/PubMed, Scopus Embase, Cinhal, and Cochrane Library, from the inception to January 14, 2023. A qualitative and quantitative analysis was done for the five eligible studies from the literature search. Individual study characteristics data and outcomes were extracted, and Software version 5.4.1 of Review Manager was used for statistical analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Five articles, one Randomized trial (RCT), and four retrospective articles were included and analyzed in this meta-analysis. PR approach has a shorter surgical time [mean difference (MD) -48.4 with 95% CI -74.49, -22.30; p&#x2009;=&#x2009;0.0003], less intraoperative blood loss (MD -123.22 with 95% CI -212.28, -34.15; p&#x2009;=&#x2009;0.007), and smaller surgical incision (MD -9.87 with 95% CI -15.21, -4.52; p&#x2009;=&#x2009;0.0003) than the IL approach. However, the meta-analysis failed to show a difference between the two surgical approaches concerning the quality of reduction, overall complications, nerve injury, vascular injury, heterotopic ossification, deep vein thrombosis, and pulmonary embolism.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The PR approach has a shorter surgical duration, less blood loss, and a smaller surgical incision than the IL approach. However, both surgical approaches have equivocal results regarding fracture reduction quality, complication rates, and functional outcomes for acetabular fracture fixation. Hence, for acetabular fractures fixation, PR approach can be considered a safe and feasible alternative to the IL approach.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajnish</LastName><ForeName>Rajesh Kumar</ForeName><Initials>RK</Initials><Identifier Source="ORCID">0000-0002-2080-2612</Identifier><AffiliationInfo><Affiliation>Department of Orthopaedics, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, University College of Medical Sciences and GTB Hospital, Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elhence</LastName><ForeName>Abhay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Sandeep Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, All India Institute of Medical Sciences, Jodhpur, India. drsandeepkyadav@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rathor</LastName><ForeName>Kuldeep</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, All India Institute of Medical Sciences, Jodhpur, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Orthop Surg Traumatol</MedlineTA><NlmUniqueID>9518037</NlmUniqueID><ISSNLinking>1633-8065</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005593" MajorTopicYN="N">Fracture Fixation, Internal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072836" MajorTopicYN="Y">Surgical Wound</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077" MajorTopicYN="N">Acetabulum</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050723" MajorTopicYN="Y">Fractures, Bone</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016103" MajorTopicYN="Y">Spinal Fractures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acetabular fractures</Keyword><Keyword MajorTopicYN="N">Fracture acetabulum</Keyword><Keyword MajorTopicYN="N">Ilioinguinal approach</Keyword><Keyword MajorTopicYN="N">Pararectus approach</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>30</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>30</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37646876</ArticleId><ArticleId IdType="doi">10.1007/s00590-023-03700-0</ArticleId><ArticleId IdType="pii">10.1007/s00590-023-03700-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zou R, Wu M, Guan J, Xiao Y, Chen X (2021) Clinical Results of Acetabular Fracture via the Pararectus versus Ilioinguinal Approach. Orthop Surg 13(4):1191&#x2013;1195. https://doi.org/10.1111/os.12970</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/os.12970</ArticleId><ArticleId IdType="pubmed">33945221</ArticleId><ArticleId IdType="pmc">8274146</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe4;rdian S, Schaser KD, Hinz P, Wittenberg S, Haas NP, Schwabe P (2015) Fixation of acetabular fractures via the ilioinguinal versus pararectus approach: a direct comparison. Bone Joint J 97(9):1271&#x2013;1278. https://doi.org/10.1302/0301-620X.97B9.35403</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.97B9.35403</ArticleId><ArticleId IdType="pubmed">26330596</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava A, Rajnish RK, Kumar P, Haq RU, Dhammi IK (2023) Ilioinguinal versus modified Stoppa approach for open reduction and internal fixation of displaced acetabular fractures: a systematic review and meta-analysis of 717 patients across ten studies. Arch Orthop Trauma Surg 143(2):895&#x2013;907. https://doi.org/10.1007/s00402-022-04369-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-022-04369-6</ArticleId><ArticleId IdType="pubmed">35138428</ArticleId></ArticleIdList></Reference><Reference><Citation>Letournel E (1993) (1993): The treatment of acetabular fractures through the ilioinguinal approach. Clin Orthop Relat Res 292:62&#x2013;76</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003086-199307000-00009</ArticleId></ArticleIdList></Reference><Reference><Citation>Letournel E (1994) Fractures of the acetabulum. A study of a series of 75 cases. 1961. Clin Orthop Relat Res 305:5&#x2013;9</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003086-199408000-00002</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta JM (2006) Operative treatment of acetabular fractures through the ilioinguinal approach: a 10&#xa0;year perspective. J Orthop Trauma 20(1 Suppl):S20&#x2013;S29</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.bot.0000202389.40246.c0</ArticleId><ArticleId IdType="pubmed">16385203</ArticleId></ArticleIdList></Reference><Reference><Citation>Masse A, Aprato A, Rollero L, Bersano A, Ganz R (2013) Surgical dislocation technique for the treatment of acetabular fractures. Clin Orthop Relat Res 471(12):4056&#x2013;4064. https://doi.org/10.1007/s11999-013-3228-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-013-3228-8</ArticleId><ArticleId IdType="pubmed">24002867</ArticleId><ArticleId IdType="pmc">3825905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma K, Luan F, Wang X, Ao Y, Liang Y, Fang Y et al (2013) Randomized, controlled trial of the modified Stoppa versus the ilioinguinal approach for acetabular fractures. Orthopedics 36(10):e1307&#x2013;e1315. https://doi.org/10.3928/01477447-20130920-25</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/01477447-20130920-25</ArticleId><ArticleId IdType="pubmed">24093709</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel MJ, Ecker TM, Cullmann JL, Bergmann M, Bonel HM, B&#xfc;chler L et al (2012) The Pararectus approach for anterior intrapelvic management of acetabular fractures: an anatomical study and clinical evaluation. J Bone Joint Surg Br 94(3):405&#x2013;411. https://doi.org/10.1302/0301-620X.94B3.27801</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.94B3.27801</ArticleId><ArticleId IdType="pubmed">22371551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastian JD, Savic M, Cullmann JL, Zech WD, Djonov V, Keel MJ (2016) Surgical exposures and options for instrumentation in acetabular fracture fixation: pararectus approach versus the modified Stoppa. Injury 47(3):695&#x2013;701. https://doi.org/10.1016/j.injury.2016.01.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2016.01.025</ArticleId><ArticleId IdType="pubmed">26861799</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigemura T, Yamamoto Y, Maruyama J, Kitamura T, Nakane R, Kawaguchi H et al (2022) Efficacy and safety of pararectus approach for the treatment of acetabular fractures: a systematic review and meta-analysis. Orthop Traumatol Surg Res. https://doi.org/10.1016/j.otsr.2022.103498</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2022.103498</ArticleId><ArticleId IdType="pubmed">36460292</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372:n71. https://doi.org/10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId><ArticleId IdType="pmc">8005924</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajnish RK, Srivastava A, Yadav SK, Elhence A, Rathor K, Gupta S (2023) Pararectus versus ilioinguinal approach for the management of acetabular fractures: a protocol for systemic review and meta-analysis. MedRxiv. https://doi.org/10.1101/2023.04.14.23288547</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.04.14.23288547</ArticleId></ArticleIdList></Reference><Reference><Citation>Review Manager (RevMan) [Computer program] (2020) Version 5.4, The Cochrane Collaboration</Citation></Reference><Reference><Citation>Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) (2003): Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712&#x2013;716. https://doi.org/10.1046/j.1445-2197.2003.02748.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1445-2197.2003.02748.x</ArticleId><ArticleId IdType="pubmed">12956787</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, J&#xfc;ni P, Moher D, Oxman AD et al (2011) The cochrane collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. 343:d5928. https://doi.org/10.1136/bmj.d5928</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId><ArticleId IdType="pmc">3196245</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev 18(2):e1230. https://doi.org/10.1002/cl2.1230</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cl2.1230</ArticleId><ArticleId IdType="pubmed">36911350</ArticleId><ArticleId IdType="pmc">8958186</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Qiyong Wu, Honghua Sun Xu, Chunpeng Zhao, Zhu Shiwen Wu, Xinbao. (2021) Comparison of perioperative data between the pararectus and ilioinguinal approaches in the internal fixation of acetabular fractures: a prospective randomized control trial. Chin J Orthop Trauma. 23(6):513&#x2013;518</Citation></Reference><Reference><Citation>Wenzel L, von R&#xfc;den C, Thannheimer A, Becker J, Brand A, Augat P et al (2020) The pararectus approach in acetabular surgery: radiological and clinical outcome. J Orthop Trauma 34(2):82&#x2013;88. https://doi.org/10.1097/BOT.0000000000001636</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOT.0000000000001636</ArticleId><ArticleId IdType="pubmed">31714471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Sheng XL, Sha WP, Zhang XX, Wang J, Xw Zhu et al (2021) Comparison of the efficacy and biocompatibility of two anterior acetabular approaches with low-profile reconstruction plate fixation in the treatment of acetabular fractures involving quadrilateral area. Zhongguo Zuzhi Gongcheng Yanjiu 25(27):4348&#x2013;4353. https://doi.org/10.12307/2021.195</Citation><ArticleIdList><ArticleId IdType="doi">10.12307/2021.195</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel MJ, Ecker TM, Siebenrock KA, Bastian JD (2012) Rationales for the Bernese approaches in acetabular surgery. Eur J Trauma Emerg Surg 38(5):489&#x2013;498. https://doi.org/10.1007/s00068-012-0229-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-012-0229-3</ArticleId><ArticleId IdType="pubmed">23162669</ArticleId><ArticleId IdType="pmc">3495274</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolopoulos FV, Tzoras NT (2019) The advantages of stoppa approach-ilioinguinal modification, for surgical treatment of the acetabulum fractures with the traditional plate and the new anatomical suprapectineal plate system. J Orthop CaseRep 10(1):78&#x2013;81. https://doi.org/10.13107/jocr.2019.v10.i01.1646</Citation><ArticleIdList><ArticleId IdType="doi">10.13107/jocr.2019.v10.i01.1646</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel MJ, Tomagra S, Bonel HM, Siebenrock KA, Bastian JD (2014) Clinical results of acetabular fracture management with the Pararectus approach. Injury 45(12):1900&#x2013;1907. https://doi.org/10.1016/j.injury.2014.10.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2014.10.040</ArticleId><ArticleId IdType="pubmed">25457342</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Yang H, Yu Z, Zhao Y, Hu J, Li B, Zhu Y (2022) Comparison of therapeutic outcomes of transabdominal pararectus approach and modified stoppa approach in treating pelvic and acetabular fractures. Indian J Orthop 56(5):829&#x2013;836. https://doi.org/10.1007/s43465-021-00585-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43465-021-00585-1</ArticleId><ArticleId IdType="pubmed">35542317</ArticleId><ArticleId IdType="pmc">9043044</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastian JD, Tannast M, Siebenrock KA, Keel MJ (2013) Mid-term results in relation to age and analysis of predictive factors after fixation of acetabular fractures using the modified Stoppa approach. Injury 44(12):1793&#x2013;1798. https://doi.org/10.1016/j.injury.2013.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2013.08.009</ArticleId><ArticleId IdType="pubmed">24008225</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury A, Weill Y, Mosheiff R (2012) The Stoppa approach for acetabular fracture. Oper Orthop Traumatol 24(4&#x2013;5):439&#x2013;448. https://doi.org/10.1007/s00064-011-0093-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00064-011-0093-z</ArticleId><ArticleId IdType="pubmed">22971850</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21674473</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2168</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>10</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The British journal of surgery</Title><ISOAbbreviation>Br J Surg</ISOAbbreviation></Journal><ArticleTitle>Systematic review and meta-analysis on the rate of postoperative venous thromboembolism in orthopaedic surgery in Asian patients without thromboprophylaxis.</ArticleTitle><Pagination><StartPage>1356</StartPage><EndPage>1364</EndPage><MedlinePgn>1356-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/bjs.7589</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Postoperative venous thromboembolism (VTE) is a common life-threatening complication after surgery. This review analysed the rate and mortality of VTE after orthopaedic surgery in Asia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Inclusion criteria were: prospective study; deep vein thrombosis (DVT) diagnosed by venography or ultrasonography; hip fracture surgery (HFS), total hip arthroplasty (THA) or total knee arthroplasty (TKA); and no thromboprophylaxis. The pooled proportion was back-calculated by Freeman-Tukey variant transformation, using a random-effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-two studies (total population 2454) published from 1979 to 2009 were included. Using venography, the pooled rates of all-site, proximal, distal and isolated distal DVT were 31&#xb7;7, 8&#xb7;9, 22&#xb7;5 and 18&#xb7;8 per cent respectively. With duplex ultrasonography, the respective rates were 9&#xb7;4, 5&#xb7;9, 5&#xb7;9 and 5&#xb7;8 per cent. After THA or HFS, using venography, the pooled rates of all-site and proximal DVT were 25&#xb7;8 and 9&#xb7;6 per cent; with ultrasonography, the respective rates were 10&#xb7;8 and 7&#xb7;2 per cent. In TKA groups, using venography, the pooled rates of all-site and proximal DVT were 42&#xb7;5 and 8&#xb7;7 per cent; with ultrasonography, the respective rates were 9&#xb7;5 and 5&#xb7;2 per cent. The overall pooled rates of symptomatic DVT and symptomatic pulmonary embolism (PE) were 4&#xb7;5 and 0&#xb7;6 per cent. No patient died from PE (pooled rate 0&#xb7;2 per cent).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">None of these Asian patients undergoing orthopaedic surgery died from VTE. Pooled rates of proximal and symptomatic DVT were lower than in Western reports.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 British Journal of Surgery Society Ltd. Published by John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kanchanabat</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Vascular Unit, Department of Surgery, Faculty of Medicine, Vajira Hospital, University of Bangkok Metropolitan, Bangkok, Thailand. burapa@vajira.ac.th</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stapanavatr</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Meknavin</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Soorapanth</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sumanasrethakul</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kanchanasuttirak</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Surg</MedlineTA><NlmUniqueID>0372553</NlmUniqueID><ISSNLinking>0007-1323</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="N">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001208" MajorTopicYN="N">Asia</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010690" MajorTopicYN="N">Phlebography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000208" MajorTopicYN="Y">ethnology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21674473</ArticleId><ArticleId IdType="doi">10.1002/bjs.7589</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37314744</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2044</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Anaesthesia</Title><ISOAbbreviation>Anaesthesia</ISOAbbreviation></Journal><ArticleTitle>Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis.</ArticleTitle><Pagination><StartPage>1153</StartPage><EndPage>1161</EndPage><MedlinePgn>1153-1161</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/anae.16058</ELocationID><Abstract><AbstractText>Tranexamic acid is an antifibrinolytic drug that is widely used during surgery, but there are concerns about its thromboembolic effects. We aimed to investigate the effect of prophylactic intravenous tranexamic acid on thromboembolic outcomes in patients undergoing non-cardiac surgery. The MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials were searched. Randomised controlled trials comparing intravenous tranexamic acid with placebo or no treatment in patients undergoing non-cardiac surgery were included. The primary outcome was a composite of peri-operative cardiovascular thromboembolic events, defined as any deep vein thrombosis, pulmonary embolism, myocardial ischaemia/infarction or cerebral ischaemia/infarction. A total of 191 randomised controlled trials (40,621 patients) were included in the review. The primary outcome occurred in 4.5% of patients receiving intravenous tranexamic acid compared with 4.9% of patients in the control group. Our analysis showed that there was no difference between groups for composite cardiovascular thromboembolic events (risk ratio 1.02, 95%CI 0.94-1.11, p&#x2009;=&#x2009;0.65, I<sup>2</sup> 0%, n&#x2009;=&#x2009;37,512). This finding remained robust when sensitivity analysis was performed with continuity correction and in studies with a low risk of bias. However, in trial sequential analysis, our meta-analysis only achieved 64.6% of the required information size. There was no association between intravenous tranexamic acid and seizure rate or mortality rate within 30&#x2009;days. Intravenous tranexamic acid was associated with a reduced blood transfusion rate compared with control (9.9% vs. 19.4%, risk ratio 0.46, 95%CI 0.41-0.51, p&#x2009;&lt;&#x2009;0.0001). It was encouraging to see the evidence that the administration of intravenous tranexamic in patients undergoing non-cardiac surgery was not associated with an increased risk of thromboembolic outcomes. However, our trial sequential analysis demonstrated that currently available evidence is not yet sufficient to reach a firm conclusion.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Anaesthesia published by John Wiley &amp; Sons Ltd on behalf of Association of Anaesthetists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsan</LastName><ForeName>S E H</ForeName><Initials>SEH</Initials><Identifier Source="ORCID">0000-0002-2092-5305</Identifier><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, Faculty of Medicine and Health Sciences, University of Malaysia Sarawak, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viknaswaran</LastName><ForeName>N L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Department of Medicine, Victoria Hospital, Kirkcaldy, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheong</LastName><ForeName>C C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Faculty of Medicine, University of Malaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheah</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, Hospital Sultanah Nora Ismail, Batu Pahat, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>K T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Faculty of Medicine, University of Malaya, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mong</LastName><ForeName>S X Y</ForeName><Initials>SXY</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Intensive Care, Hospital Raja Permaisuri Bainun, Ipoh, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>C Y</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Faculty of Medicine, University of Malaya, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Anaesthesia</MedlineTA><NlmUniqueID>0370524</NlmUniqueID><ISSNLinking>0003-2409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="Y">Tranexamic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="Y">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="Y">Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="Y">Myocardial Infarction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">non-cardiac surgery</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">thromboembolism</Keyword><Keyword MajorTopicYN="N">tranexamic acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37314744</ArticleId><ArticleId IdType="doi">10.1111/anae.16058</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Wong J, George RB, Hanley CM, Saliba C, Yee DA, Jerath A. Tranexamic acid: current use in obstetrics, major orthopedic, and trauma surgery. Canadian Journal of Anesthesia 2021; 68: 894-917.</Citation></Reference><Reference><Citation>Dunn CJ, Goa KL. Tranexamic acid. Drugs 1999; 57: 1005-32.</Citation></Reference><Reference><Citation>Taeuber I, Weibel S, Herrmann E, et&#xa0;al. Association of intravenous tranexamic acid with thromboembolic events and mortality: a systematic review, meta-analysis, and meta-regression. Journal of the American Medical Association Surgery 2021; 156: e210884.</Citation></Reference><Reference><Citation>Murao S, Nakata H, Roberts I, Yamakawa K. Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a&#xa0;systematic review and meta-analysis. Critical Care 2021; 25: 380.</Citation></Reference><Reference><Citation>Devereaux PJ, Marcucci M, Painter TW, et&#xa0;al. Tranexamic acid in patients undergoing noncardiac surgery. New England Journal of Medicine 2022; 386: 1986-97.</Citation></Reference><Reference><Citation>Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]. The Cochraine Collaboration, 2011.</Citation></Reference><Reference><Citation>Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. British Medical Journal 2012; 344: e3054.</Citation></Reference><Reference><Citation>Franchini M, Marano G, Veropalumbo E, et&#xa0;al. Patient blood management: a revolutionary approach to transfusion medicine. Blood Transfusion 2019; 17: 191-5.</Citation></Reference><Reference><Citation>Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwischenberger JB. Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. Journal of the American College of Surgeons 2009; 208: 931-7.e2.</Citation></Reference><Reference><Citation>Jakobsen CJ, Ryhammer PK, Tang M, Andreasen JJ, Mortensen PE. Transfusion of blood during cardiac surgery is associated with higher long-term mortality in low-risk patients. European Journal of Cardiothoracic Surgery 2012; 42: 114-20.</Citation></Reference><Reference><Citation>Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Annals of Thoracic Surgery 2012; 93: 148-54.</Citation></Reference><Reference><Citation>Lecker I, Wang DS, Whissell PD, Avramescu S, Mazer CD, Orser BA. Tranexamic acid-associated seizures: causes and treatment. Annals of Neurology 2016; 79: 18-26.</Citation></Reference><Reference><Citation>Sentilhes L, S&#xe9;nat MV, Le Lous M, et&#xa0;al. Tranexamic acid for the prevention of blood loss after cesarean delivery. New England Journal of Medicine 2021; 384: 1623-34.</Citation></Reference><Reference><Citation>Morrison A, Polisena J, Husereau D, et&#xa0;al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. International Journal of Technology Assessment in Health Care 2012; 28: 138-44.</Citation></Reference><Reference><Citation>Nussbaumer-Streit B, Klerings I, Dobrescu AI, et&#xa0;al. Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study. Journal of Clinical Epidemiology 2020; 118: 42-54.</Citation></Reference><Reference><Citation>Pilbrant &#xc5;, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. European Journal of Clinical Pharmacology 1981; 20: 65-72.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19628483</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-6771</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>British journal of anaesthesia</Title><ISOAbbreviation>Br J Anaesth</ISOAbbreviation></Journal><ArticleTitle>Does regional anaesthesia improve outcome after total hip arthroplasty? A systematic review.</ArticleTitle><Pagination><StartPage>335</StartPage><EndPage>345</EndPage><MedlinePgn>335-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/bja/aep208</ELocationID><Abstract><AbstractText>Total hip arthroplasty (THA) is amenable to a variety of regional anaesthesia (RA) techniques that may improve patient outcome. We sought to answer whether RA decreased mortality, cardiovascular morbidity, deep venous thrombosis (DVT) and pulmonary embolism (PE), blood loss, duration of surgery, pain, opioid-related adverse effects, cognitive defects, and length of stay. We also questioned whether RA improved rehabilitation. To do so, we performed a systematic review of the contemporary literature to compare general anaesthesia (GA) and RA and also systemic and regional analgesia for THA. To reflect contemporary surgical and anaesthetic practice, only randomized controlled trials (RCTs) from 1990 onward were included. We identified 18 studies involving 1239 patients. Only two of the 18 trials were of Level I quality. There is insufficient evidence from RCTs alone to conclude if anaesthetic technique influenced mortality, cardiovascular morbidity, or the incidence of DVT and PE when using thromboprophylaxis. Blood loss may be reduced in patients receiving RA rather than GA for THA. Our review suggests that there is no difference in duration of surgery in patients who receive GA or RA. Compared with systemic analgesia, regional analgesia can reduce postoperative pain, morphine consumption, and nausea and vomiting. Length of stay is not reduced and rehabilitation does not appear to be facilitated by RA or analgesia for THA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Macfarlane</LastName><ForeName>A J R</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia and Pain Management, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON M5T 2S8, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasad</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>V W S</ForeName><Initials>VW</Initials></Author><Author ValidYN="Y"><LastName>Brull</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Anaesth</MedlineTA><NlmUniqueID>0372541</NlmUniqueID><ISSNLinking>0007-0912</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000698" MajorTopicYN="N">Analgesia</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000765" MajorTopicYN="Y">Anesthesia, Conduction</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>78</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19628483</ArticleId><ArticleId IdType="doi">10.1093/bja/aep208</ArticleId><ArticleId IdType="pii">S0007-0912(17)33968-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">24987238</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0972-5229</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine</Title><ISOAbbreviation>Indian J Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Thrombo-prophylaxis in acutely ill medical and critically ill patients.</ArticleTitle><Pagination><StartPage>382</StartPage><EndPage>391</EndPage><MedlinePgn>382-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/0972-5229.133902</ELocationID><Abstract><AbstractText>Thrombo-prophylaxis has been shown to reduce the incidence of pulmonary embolism (PE) and mortality in surgical patients. The purpose of this review is to find out the evidence-based clinical practice criteria of deep vein thrombosis (DVT) prophylaxis in acutely ill medical and critically ill patients. English-language randomized controlled trials, systematic reviews, and meta-analysis were included if they provided clinical outcomes and evaluated therapy with low-dose heparin or related agents compared with placebo, no treatment, or other active prophylaxis in the critically ill and medically ill population. For the same, we searched MEDLINE, PUBMED, Cochrane Library, and Google Scholar. In acutely ill medical patients on the basis of meta-analysis by Lederle et al. (40 trials) and LIFENOX study, heparin prophylaxis had no significant effect on mortality. The prophylaxis may have reduced PE in acutely ill medical patients, but led to more bleeding events, thus resulting in no net benefit. In critically ill patients, results of meta-analysis by Alhazzani et al. and PROTECT Trial indicate that any heparin prophylaxis compared with placebo reduces the rate of DVT and PE, but not symptomatic DVT. Major bleeding risk and mortality rates were similar. On the basis of MAGELLAN trial and EINSTEIN program, rivaroxaban offers a single-drug approach to the short-term and continued treatment of venous thrombosis. Aspirin has been used as antiplatelet agent, but when the data from two trials the ASPIRE and WARFASA study were pooled, there was a 32% reduction in the rate of recurrence of venous thrombo-embolism and a 34% reduction in the rate of major vascular events.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saigal</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Trauma and Emergency Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Jai Prakash</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Rajnish</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Dinesh Kumar</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Trauma and Emergency Medicine, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Crit Care Med</MedlineTA><NlmUniqueID>101208863</NlmUniqueID><ISSNLinking>0972-5229</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Critically ill</Keyword><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">heparin</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">thrombo-prophylaxis</Keyword></KeywordList><CoiStatement><b>Conflict of Interest:</b> None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24987238</ArticleId><ArticleId IdType="pmc">PMC4071683</ArticleId><ArticleId IdType="doi">10.4103/0972-5229.133902</ArticleId><ArticleId IdType="pii">IJCCM-18-382</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med. 2012;367:2039&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23121404</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts W, Cook D, Selby R, Etchells E. Venous thromboembolism and its prevention in critical care. J Crit Care. 2002;17:95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">12096372</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribic C, Lim W, Cook D, Crowther M. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review. J Crit Care. 2009;24:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">19327323</ArticleId></ArticleIdList></Reference><Reference><Citation>Warwick D, Samama MM. The contrast between venographic and clinical endpoints in trials of thromboprophylaxis in hip replacement. J Bone Joint Surg Br. 2000;82:480&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">10855865</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Jr, et al. Prevention of venous thromboembolism. Chest. 2001;119:132S&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">11157647</ArticleId></ArticleIdList></Reference><Reference><Citation>Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med. 1982;10:448&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">7044682</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review and meta-analysis of randomized trials. Crit Care Med. 2013;41:2088&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">23782973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, et al. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364:1305&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">21417952</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorr AF, Williams MD. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost. 2009;101:139&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">19132200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor M, Kupfer YY, Tessler S. Subcutaneous heparin prophylaxis significantly reduces the incidence of venous thromboembolic events in the critically ill. Abstr. Crit Care Med. 1999;27(Suppl):A69.</Citation></Reference><Reference><Citation>Goldhaber SZ, Kett DH, Cusumano CJ. Low molecular weight heparin versus mini-dose unfractionated heparin for prophylaxis against venous thromboembolism in medical intensive care unit patients: A randomized controlled trial. Abstr. J Am Coll Cardiol. 2000;35(Suppl):325A.</Citation></Reference><Reference><Citation>Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med. 2000;161:1109&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10764298</ArticleId></ArticleIdList></Reference><Reference><Citation>De A, Roy P, Garg VK, Pandey NK. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. Blood Coagul Fibrinolysis. 2010;21:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">19844176</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis. 1986;16:159&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">3710294</ArticleId></ArticleIdList></Reference><Reference><Citation>Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">10477777</ArticleId></ArticleIdList></Reference><Reference><Citation>Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15289368</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe4;rdlund B. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. Lancet. 1996;347:1357&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8637340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe GD, Sandercock PA, Rosendaal FR. Prevention of venous thromboembolism after major orthopaedic surgery: Is fondaparinux an advance? Lancet. 2003;362:504&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12932379</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederle FA, Sacks JM, Fiore L, Landefeld CS, Steinberg N, Peters RW, et al. The prophylaxis of medical patients for thromboembolism pilot study. Am J Med. 2006;119:54&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16431185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: A background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2011;155:602&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">22041949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011;365:2463&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">22204723</ArticleId></ArticleIdList></Reference><Reference><Citation>Mah&#xe9; I, Bergmann JF, d&#x2019;Az&#xe9;mar P, Vaissie JJ, Caulin C. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: A prospective randomised double-blind study. Eur J Clin Pharmacol. 2005;61:347&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15981008</ArticleId></ArticleIdList></Reference><Reference><Citation>Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J. 1981;26:115&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7291971</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ. 2006;332:325&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1363908</ArticleId><ArticleId IdType="pubmed">16439370</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber C, Merminod T, Herrmann FR, Zulian GB. Prophylactic anti-coagulation in cancer palliative care: A prospective randomised study. Support Care Cancer. 2008;16:847&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">17940809</ArticleId></ArticleIdList></Reference><Reference><Citation>Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, K&#xfc;bler W, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res. 1990;59:639&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">2173168</ArticleId></ArticleIdList></Reference><Reference><Citation>Aquino JP, Gambier A, Ducros JJ. Prophylaxis of thromboembolic disorders in elderly patients with fraxiparine. In: Bounameaux H, Samama M, ten Cate JW, editors. Fraxiparine: Second International Symposium Recent Pharmacological and Clinical Data. Monte Carlo: Schattauer; 1990.</Citation></Reference><Reference><Citation>Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis. 1996;26:127&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8738587</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost. 1996;76:529&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">8902991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis. 1996;26(Suppl 2):49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">8707167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003;145:614&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12679756</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellong SM, Haas S, Greinacher A, Schwanebeck U, Sieder C, Abletshauser C, et al. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opin Pharmacother. 2010;11:2953&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">20950224</ArticleId></ArticleIdList></Reference><Reference><Citation>Riess H, Haas S, Tebbe U, Gerlach HE, Abletshauser C, Sieder C, et al. A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study. J Thromb Haemost. 2010;8:1209&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">20218984</ArticleId></ArticleIdList></Reference><Reference><Citation>Luba M, Firek A, Kochanowski Z. Two models of thromboprophylaxis in acutely ill medical inpatients. Pol Arch Med Wewn. 2007;117:31&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17722473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: A randomized trial. Ann Intern Med. 2010;153:8&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">20621900</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy ST, Turner JJ, Robertson D, Hawkey CJ, Macey DJ. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet. 1977;2:800&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">71605</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing. 1986;15:84&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">3962762</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie AG, Levine MN, Hirsh J, Carter CJ, Jay RM, Powers PJ, et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet. 1987;1:523&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2434815</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickmann U, Voth E, Schicha H, Henze T, Prange H, Emrich D. Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage. Klin Wochenschr. 1988;66:1182&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">3062268</ArticleId></ArticleIdList></Reference><Reference><Citation>Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJ. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis. 1989;19:245&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">2550335</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Hemost. 1990;16(Suppl):25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">1962901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay R, Wong KS, Yu YL, Chan YW, Tsoi TH, Ahuja AT, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med. 1995;333:1588&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">7477193</ArticleId></ArticleIdList></Reference><Reference><Citation>The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349:1569&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9174558</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumas R, Woitinas F, Kutnowski M, Nikolic I, Berberich R, Abedinpour F, et al. A multicentre, double-blind, randomized study to compare the safety and efficacy of once-daily ORG 10172 and twice-daily low-dose heparin in preventing deep-vein thrombosis in patients with acute ischaemic stroke. Age Ageing. 1994;23:512&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9231947</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpie AG, Gent M, C&#xf4;te R, Levine MN, Ginsberg JS, Powers PJ, et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Ann Intern Med. 1992;117:353&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1503326</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillbom M, Eril&#xe4; T, Sotaniemi K, Tatlisumak T, Sarna S, Kaste M. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: A randomized, double-blind study. Acta Neurol Scand. 2002;106:84&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12100367</ArticleId></ArticleIdList></Reference><Reference><Citation>Diener HC, Ringelstein EB, von Kummer R, Landgraf H, Koppenhagen K, Harenberg J, et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: Results of the PROTECT Trial. Stroke. 2006;37:139&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">16306456</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): An open-label randomised comparison. Lancet. 2007;369:1347&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448820</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad BK, Banerjee AK, Howard H. Incidence of deep vein thrombosis and the effect of pneumatic compression of the calf in elderly hemiplegics. Age Ageing. 1982;11:42&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7072559</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir KW, Watt A, Baxter G, Grosset DG, Lees KR. Randomized trial of graded compression stockings for prevention of deep-vein thrombosis after acute stroke. QJM. 2000;93:359&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">10873185</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis M, Sandercock PA, Reid J, Graham C, Murray G, et al. CLOTS Trials Collaboration. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): A multicentre, randomised controlled trial. Lancet. 2009;373:1958&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692021</ArticleId><ArticleId IdType="pubmed">19477503</ArticleId></ArticleIdList></Reference><Reference><Citation>Green D, Akuhota V, Eiken M, Feinglass J, Fuller S, Hwang C, et al. Prevention of thromboembolism in stroke rehabilitation patients. Top Stroke Rehabil. 1998;5:68&#x2013;74.</Citation></Reference><Reference><Citation>Lacut K, Bressollette L, Le Gal G, Etienne E, De Tinteniac A, Renault A, et al. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology. 2005;65:865&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16186525</ArticleId></ArticleIdList></Reference><Reference><Citation>CLOTS (Clots in Legs or Stockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: A randomized trial. Ann Intern Med. 2010;153:553&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">20855784</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schu&#xfc;nemann HJ American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl):7S&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278060</ArticleId><ArticleId IdType="pubmed">22315257</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: The Padua Prediction Score. J Thromb Haemost. 2010;8:2450&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20738765</ArticleId></ArticleIdList></Reference><Reference><Citation>Oger E. Incidence of venous thromboembolism: A community-based study in Western France. EPI-GETBP Study Group. Groupe d&#x2019;Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">10823257</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer FA, Emery C, Lessard D, Anderson F, Emani S, Aragam J, et al. The Worcester Venous Thromboembolism study: A population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21:722&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1924694</ArticleId><ArticleId IdType="pubmed">16808773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2006;25:CD001367.</Citation><ArticleIdList><ArticleId IdType="pubmed">16437432</ArticleId></ArticleIdList></Reference><Reference><Citation>Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8644983</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179:417&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2518177</ArticleId><ArticleId IdType="pubmed">18725614</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AT, Spiro TE, B&#xfc;ller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">23388003</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">22077144</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">21128814</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xfc;ller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">22449293</ArticleId></ArticleIdList></Reference><Reference><Citation>Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">22621626</ArticleId></ArticleIdList></Reference><Reference><Citation>Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">23121403</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24012101</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2472</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Thrombosis research</Title><ISOAbbreviation>Thromb Res</ISOAbbreviation></Journal><ArticleTitle>The role of soluble P selectin in the diagnosis of venous thromboembolism.</ArticleTitle><Pagination><StartPage>17</StartPage><EndPage>24</EndPage><MedlinePgn>17-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.thromres.2013.08.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-3848(13)00344-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Soluble P selectin (sPsel), a member of the selectin family of cell adhesion receptors, has been proposed as a key molecule in hemostasis and thrombosis mediating platelet rolling, generating procoagulant microparticles and enhancing fibrin deposition. The aim of this study was to examine the role of sPsel in the diagnosis of venous thromboembolism (VTE).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We performed a systematic review and we used meta-analysis to synthesize data from published studies reporting sPsel levels in patients with i) VTE (deep venous thrombosis; DVT or DVT and pulmonary embolism; PE) and ii) DVT only. Pooled Odds Ratios (ORs) with 95% Confidence Intervals (CIs) were appropriately calculated among patients and controls. Diagnostic performance of sPsel was tested with pooled sensitivity, specificity, Diagnostic Odds Ratio (DOR) and summary receiver operator characteristic (SROC) curve.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eleven studies, comprising of 586 VTE patients and 1,843 controls were deemed eligible. The sPsel was significantly increased after VTE (OR=2.89, 95%CI=2.31-3.61, p&lt;0.001), or DVT only (OR=2.64, 95%CI=1.95-3.56, p&lt;0.001). Subgroup analysis evidenced that sPsel was also increased after VTE when evaluating only studies with patients that had no prior medical history (OR=2.88, 95%CI=1.98-4.19, p&lt;0.001). Exclusion of studies including patients with solid organ tumor, HIV or lupus anticoagulants positive patients did not alter findings. Pooled sensitivity and specificity of sPsel was 0.57 (95%CI=0.30-082, p&lt;0.001) and 0.73 (95%CI=0.51-0.90, p&lt;0.001), respectively and DOR was 4.31 (95%CI=2.22-8.37, p&lt;0.01). SROC curve yielded in significant accuracy of sPsel performance (AUC=0.74, p=0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The sPsel was significantly elevated in patients with DVT, both uncomplicated and complicated with PE and presented with high levels of diagnostic performance. sPsel is a plasma biomarker that may help in the diagnosis of VTE.</AbstractText><CopyrightInformation>&#xa9; 2013.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Antonopoulos</LastName><ForeName>Constantine N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Athens Medical School, "Attikon" University Hospital, Athens, Greece. Electronic address: kostas.antonopoulos@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sfyroeras</LastName><ForeName>George S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Athens Medical School, "Attikon" University Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakisis</LastName><ForeName>John D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Athens Medical School, "Attikon" University Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moulakakis</LastName><ForeName>Konstantinos G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Athens Medical School, "Attikon" University Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liapis</LastName><ForeName>Christos D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Vascular Surgery, University of Athens Medical School, "Attikon" University Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Thromb Res</MedlineTA><NlmUniqueID>0326377</NlmUniqueID><ISSNLinking>0049-3848</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019007">P-Selectin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019007" MajorTopicYN="N">P-Selectin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Soluble P selectin</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword><Keyword MajorTopicYN="N">sPsel</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24012101</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2013.08.014</ArticleId><ArticleId IdType="pii">S0049-3848(13)00344-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22412039</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1539-3704</ISSN><JournalIssue CitedMedium="Internet"><Volume>156</Volume><Issue>10</Issue><PubDate><Year>2012</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Annals of internal medicine</Title><ISOAbbreviation>Ann Intern Med</ISOAbbreviation></Journal><ArticleTitle>Prolonged versus standard-duration venous thromboprophylaxis in major orthopedic surgery: a systematic review.</ArticleTitle><Pagination><StartPage>720</StartPage><EndPage>727</EndPage><MedlinePgn>720-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7326/0003-4819-156-10-201205150-00423</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal duration of thromboprophylaxis after major orthopedic surgery is unclear.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To compare the benefits and harms of prolonged versus standard-duration thromboprophylaxis after major orthopedic surgery in adults.</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">Cochrane Central Register of Controlled Trials and Scopus from 1980 to July 2011 and MEDLINE from 1980 through November 2011, without language restrictions.</AbstractText><AbstractText Label="STUDY SELECTION" NlmCategory="METHODS">Randomized trials reporting thromboembolic or bleeding outcomes that compared prolonged (&#x2265;21 days) with standard-duration (7 to 10 days) thromboprophylaxis.</AbstractText><AbstractText Label="DATA ABSTRACTION" NlmCategory="METHODS">Two independent reviewers abstracted data and rated study quality and strength of evidence.</AbstractText><AbstractText Label="DATA SYNTHESIS" NlmCategory="RESULTS">Eight randomized, controlled trials (3 good-quality and 5 fair-quality) met the inclusion criteria. High-strength evidence showed that compared with standard-duration therapy, prolonged prophylaxis resulted in fewer cases of pulmonary embolism (PE) (5 trials; odds ratio [OR], 0.14 [95% CI, 0.04 to 0.47]; absolute risk reduction [ARR], 0.8%), asymptomatic deep venous thrombosis (DVT) (4 trials; relative risk [RR], 0.48 [CI, 0.31 to 0.75]; ARR, 5.8%), symptomatic DVT (4 trials; OR, 0.36 [CI, 0.16 to 0.81]; ARR, 1.5%), and proximal DVT (6 trials; RR, 0.29 [CI, 0.16 to 0.52]; ARR, 7.1%). Moderate-strength evidence showed fewer symptomatic objectively confirmed episodes of venous thromboembolism (4 trials; RR, 0.38 [CI, 0.19 to 0.77]; ARR, 5.7%), nonfatal PE (4 trials; OR, 0.13 [CI, 0.03 to 0.54]; ARR, 0.7%), and DVT (7 trials; RR, 0.37 [CI, 0.21 to 0.64]; ARR, 12.1%) with prolonged prophylaxis. High-strength evidence showed more minor bleeding events with prolonged prophylaxis (OR, 2.44 [CI, 1.41 to 4.20]; absolute risk increase, 6.3%), and insufficient evidence from 1 trial on hip fracture surgery suggested more surgical-site bleeding events (OR, 7.55 [CI, 1.51 to 37.64]) with prolonged prophylaxis.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Data relevant to knee replacement or hip fracture surgery were scant and insufficient. Most trials had few events; the strength of evidence ratings that were used may not adequately capture uncertainty in such situations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Prolonged prophylaxis decreases the risk for venous thromboembolism, PE, and DVT while increasing the risk for minor bleeding in patients undergoing total hip replacement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sobieraj</LastName><ForeName>Diana M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Soyon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Craig I</ForeName><Initials>CI</Initials></Author><Author ValidYN="Y"><LastName>Tongbram</LastName><ForeName>Vanita</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Colby</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kluger</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Makanji</LastName><ForeName>Sagar</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ashaye</LastName><ForeName>Ajibade O</ForeName><Initials>AO</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>C Michael</ForeName><Initials>CM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Intern Med</MedlineTA><NlmUniqueID>0372351</NlmUniqueID><ISSNLinking>0003-4819</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019637" MajorTopicYN="N">Orthopedic Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22412039</ArticleId><ArticleId IdType="doi">10.7326/0003-4819-156-10-201205150-00423</ArticleId><ArticleId IdType="pii">0003-4819-156-10-201205150-00423</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31718992</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0539</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of plastic, reconstructive &amp; aesthetic surgery : JPRAS</Title><ISOAbbreviation>J Plast Reconstr Aesthet Surg</ISOAbbreviation></Journal><ArticleTitle>Pre-, intra-, and/or postoperative arterial and venous thromboembolism prophylaxis for breast surgery: Systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>18</EndPage><MedlinePgn>1-18</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bjps.2019.09.038</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1748-6815(19)30441-3</ELocationID><Abstract><AbstractText>Both thromboembolism and excessive bleeding following breast surgery could result in multiple surgical procedures, breast reconstruction failure, or even mortality. This systematic review and meta-analysis of 5617 female breast surgery patients compared pharmacological prophylaxis to nonpharmacological prophylaxis interventions during the pre-, intra-, and/or postoperative time points and evaluated associated outcomes and complications. The PubMed, EMBASE, Cochrane Library, Web of Science, and Google Scholar databases were systematically and independently searched. Patient and clinical characteristics, surgical and medical interventions, outcomes, and complications were recorded. Eleven of the 344 studies queried were eligible for systematic review and meta-analysis, with results from 26 of the possible 117 outcomes and complications using strict PRISMA and Cochrane guidelines. Patients receiving intraoperative pharmacological prophylaxis for breast surgery were found to have more reoperations and more occurrences of any bleeding, while patients receiving postoperative pharmacological prophylaxis were found to have more occurrences of any bleeding than patients receiving nonpharmacological prophylaxis. Patients were more likely to receive preoperative pharmacological prophylaxis if they had diabetes mellitus and postoperative chemoprophylaxis if they had higher BMIs. Patients administered pharmacological prophylaxis during the pre-, intra-, and/or postoperative time periods did not show a significant decrease in deep vein thrombosis and/or pulmonary embolism or increase in hematomas compared to those administered nonpharmacological prophylaxis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klifto</LastName><ForeName>Kevin M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States of America. Electronic address: kklifto@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurno</LastName><ForeName>Caresse F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>The Johns Hopkins University School of Nursing, Baltimore, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Major</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seal</LastName><ForeName>Stella M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Welch Medical Library, The Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacks</LastName><ForeName>Justin M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosson</LastName><ForeName>Gedge D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manahan</LastName><ForeName>Michele A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States of America. Electronic address: mmanahan@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Plast Reconstr Aesthet Surg</MedlineTA><NlmUniqueID>101264239</NlmUniqueID><ISSNLinking>1748-6815</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001940" MajorTopicYN="N">Breast</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016462" MajorTopicYN="N">Mammaplasty</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019990" MajorTopicYN="N">Perioperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="N">Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast</Keyword><Keyword MajorTopicYN="N">Chemoprevention</Keyword><Keyword MajorTopicYN="N">Hematoma</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword><Keyword MajorTopicYN="N">Thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31718992</ArticleId><ArticleId IdType="doi">10.1016/j.bjps.2019.09.038</ArticleId><ArticleId IdType="pii">S1748-6815(19)30441-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31556080</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1864-6743</ISSN><JournalIssue CitedMedium="Internet"><Volume>158</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Zeitschrift fur Orthopadie und Unfallchirurgie</Title><ISOAbbreviation>Z Orthop Unfall</ISOAbbreviation></Journal><ArticleTitle>Influence of the Tourniquet on Pain and Function in Total Knee Arthroplasty: a Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>630</StartPage><EndPage>640</EndPage><MedlinePgn>630-640</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/a-0983-3808</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The use of the tourniquet in total knee arthroplasty is still a subject of controversial discussion. Previous studies mainly focus on parameters like blood loss and operation time. The aim of this systematic review is to evaluate the postoperative outcome involving parameters such as pain intensity, analgesic consumption, knee function and complication rate with and without tourniquet use, to find a recommendation for future application in total knee arthroplasty.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">This review is based on the PRISMA Checklists. A systematic research was performed in PubMed using the key words "tourniquet", "total knee arthroplasty", "TKA" and "knee endoprosthesis" up to and including January 2018. The initial search revealed 686 Papers which were extracted by the parameters intensity of pain, analgesic consumption, function (range of motion, Hospital for Special Surgery Score, Knee Society Score) and complications (deep vein thrombosis, surgical side infection, pulmonary embolism). The program Review Manager Version 5.3 was used for statistical analysis. A significance level of p&#x2009;&lt;&#x2009;0,05 was defined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">18 studies were included in this review with 1279 total knee arthroplasties overall (646 with the use of tourniquet and 633 without). The analysis shows a significant lower pain intensity until the fifth postoperative day (p&#x2009;=&#x2009;0,03) and also after one to three months (p&#x2009;=&#x2009;0,04) without using the tourniquet. Range of motion is significantly higher in two to three days postoperatively (p&#x2009;&lt;&#x2009;0,00&#x200a;001) when the surgery was performed without tourniquet. Knee Society Score shows no difference between the two groups. A deep vein thrombosis appears significantly more often when using a tourniquet (p&#x2009;=&#x2009;0,04). There was no higher occurrence in pulmonary embolism and surgical side infections.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of a pneumatic tourniquet in total knee arthroplasty affects especially the early postoperative pain and functional recovery.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jawhar</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Orthopaedic-Trauma Surgery Centre, University Medicine Mannheim; Medical Faculty Mannheim of the University of Heidelberg, Mannheim.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skeirek</LastName><ForeName>Dania</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Orthopaedic-Trauma Surgery Centre, University Medicine Mannheim; Medical Faculty Mannheim of the University of Heidelberg, Mannheim.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stetzelberger</LastName><ForeName>Vera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Orthopaedic-Trauma Surgery Centre, University Medicine Mannheim; Medical Faculty Mannheim of the University of Heidelberg, Mannheim.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obertacke</LastName><ForeName>Udo</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Orthopaedic-Trauma Surgery Centre, University Medicine Mannheim; Medical Faculty Mannheim of the University of Heidelberg, Mannheim.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><VernacularTitle>Einfluss der Blutsperre auf die postoperative Schmerzintensit&#xe4;t und Funktion nach der Implantation von Knietotalendoprothesen: eine systematische &#xdc;bersichtsarbeit und Metaanalyse.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Z Orthop Unfall</MedlineTA><NlmUniqueID>101308227</NlmUniqueID><ISSNLinking>1864-6697</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="Y">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007719" MajorTopicYN="N">Knee Joint</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016059" MajorTopicYN="N">Range of Motion, Articular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014111" MajorTopicYN="N">Tourniquets</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText Label="HINTERGRUND" NlmCategory="UNASSIGNED">Der Einsatz einer Blutsperre bei der Implantation von Knietotalendoprothesen wird in der Literatur kontrovers diskutiert. Bisherige &#xdc;bersichtsarbeiten konzentrieren sich vor allem auf die Parameter Blutverlust und Operationszeit. Ziel der vorliegenden Metaanalyse hingegen ist es, das postoperative Ergebnis anhand der Parameter Schmerzintensit&#xe4;t, Analgetikabedarf sowie Funktion des Kniegelenks und Komplikationsrate nach der Implantation einer Knietotalendoprothese mit und ohne Anwendung der Blutsperre zu analysieren.</AbstractText><AbstractText Label="METHODEN" NlmCategory="METHODS">Zur Erstellung dieser Arbeit wurden die PRISMA-Checklisten angewandt. Es erfolgte eine systematische Literaturrecherche mithilfe der PubMed-Datenbank anhand der Suchbegriffe &#x201e;tourniquet&#x201c;, &#x201e;total knee arthroplasty&#x201c;, &#x201e;TKA&#x201c; und &#x201e;knee endoprosthesis&#x201c; bis einschlie&#xdf;lich Januar 2018. Analysiert wurden insgesamt 686 Manuskripte hinsichtlich der Parameter Schmerzintensit&#xe4;t, Analgetikabedarf, Funktion (Bewegungsausma&#xdf;, Hospital for Special Surgery Score und Knee Society Score). Bei den Komplikationen wurden das Auftreten tiefer Beinvenenthrombosen, Wundinfektionen und Lungenembolien untersucht. Zur statistischen Analyse diente das Programm Review Manager Version 5.3. Ein p-Wert von &lt;&#x2009;0,05 wurde als Signifikanzniveau festgelegt.</AbstractText><AbstractText Label="ERGEBNISSE" NlmCategory="UNASSIGNED">Es konnten 18 Studien mit insgesamt 1279 Knietotalendoprothesen eingeschlossen werden, davon 646 mit und 633 ohne Anwendung einer Blutsperre. Die Analyse ergab bis zum 5.&#xa0;postoperativen Tag eine signifikant niedrigere Schmerzintensit&#xe4;t (p&#x2009;=&#x2009;0,03) und ebenfalls nach 1&#x200a;&#x2013;&#x200a;3 Monaten (p&#x2009;=&#x2009;0,04) bei der Implantation ohne Blutsperre. Beim Bewegungsausma&#xdf; war in den ersten 2&#x200a;&#x2013;&#x200a;3 Tagen postoperativ ein signifikanter Unterschied (p&#x2009;&lt;&#x2009;0,00001) zugunsten der Operation ohne Blutsperre nachzuweisen; bei dem Knee Society Score ergab sich zu keinem Zeitpunkt eine Differenz zwischen den beiden Gruppen. Eine tiefe Beinvenenthrombose trat signifikant h&#xe4;ufiger auf, wenn mit Blutsperre operiert wurde (p&#x2009;=&#x2009;0,04). Bei der H&#xe4;ufigkeit einer Lungenembolie oder einer oberfl&#xe4;chlichen Wundinfektion gab es keinen Unterschied.</AbstractText><AbstractText Label="SCHLUSSFOLGERUNG" NlmCategory="UNASSIGNED">Eine Blutsperre bei einer Implantation von Knietotalendoprothesen zu verwenden, beeinflusst vor allem die fr&#xfc;hen postoperativen Schmerzen und die funktionelle Rehabilitation negativ.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></OtherAbstract><CoiStatement>The authors declare that they have no conflict of interest./Die Autoren geben an, dass kein Interessenkonflikt besteht.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31556080</ArticleId><ArticleId IdType="doi">10.1055/a-0983-3808</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25635593</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1175</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Anesthesiology</Title><ISOAbbreviation>Anesthesiology</ISOAbbreviation></Journal><ArticleTitle>Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery.</ArticleTitle><Pagination><StartPage>736</StartPage><EndPage>745</EndPage><MedlinePgn>736-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/ALN.0000000000000601</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">During spinal anesthesia for cesarean delivery, phenylephrine can cause reflexive decreases in maternal heart rate and cardiac output. Norepinephrine has weak &#x3b2;-adrenergic receptor agonist activity in addition to potent &#x3b1;-adrenergic receptor activity and therefore may be suitable for maintaining blood pressure with less negative effects on heart rate and cardiac output compared with phenylephrine.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a randomized, double-blinded study, 104 healthy patients having cesarean delivery under spinal anesthesia were randomized to have systolic blood pressure maintained with a computer-controlled infusion of norepinephrine 5 &#x3bc;g/ml or phenylephrine 100 &#x3bc;g/ml. The primary outcome compared was cardiac output. Blood pressure heart rate and neonatal outcome were also compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Normalized cardiac output 5 min after induction was greater in the norepinephrine group versus the phenylephrine group (median 102.7% [interquartile range, 94.3 to 116.7%] versus 93.8% [85.0 to 103.1%], P = 0.004, median difference 9.8%, 95% CI of difference between medians 2.8 to 16.1%). From induction until uterine incision, for norepinephrine versus phenylephrine, systolic blood pressure and stroke volume were similar, heart rate and cardiac output were greater, systemic vascular resistance was lower, and the incidence of bradycardia was smaller. Neonatal outcome was similar between groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">When given by computer-controlled infusion during spinal anesthesia for cesarean delivery, norepinephrine was effective for maintaining blood pressure and was associated with greater heart rate and cardiac output compared with phenylephrine. Further work would be of interest to confirm the safety and efficacy of norepinephrine as a vasopressor in obstetric patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ngan Kee</LastName><ForeName>Warwick D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>From the Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China (W.D.N.K., F.F.N., P.E.T., K.S.K.); and Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong, China (S.W.Y.L.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Shara W Y</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>Floria F</ForeName><Initials>FF</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Perpetua E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Khaw</LastName><ForeName>Kim S</ForeName><Initials>KS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anesthesiology</MedlineTA><NlmUniqueID>1300217</NlmUniqueID><ISSNLinking>0003-3022</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1WS297W6MV</RegistryNumber><NameOfSubstance UI="D010656">Phenylephrine</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W3ENH1CV</RegistryNumber><NameOfSubstance UI="D009638">Norepinephrine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Anesthesiology. 2015 Apr;122(4):728-30. doi: 10.1097/ALN.0000000000000602.</RefSource><PMID Version="1">25654435</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000775" MajorTopicYN="Y">Anesthesia, Spinal</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001795" MajorTopicYN="N">Blood Pressure Determination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="Y">Cesarean Section</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016343" MajorTopicYN="N">Monitoring, Intraoperative</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009638" MajorTopicYN="N">Norepinephrine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010656" MajorTopicYN="N">Phenylephrine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25635593</ArticleId><ArticleId IdType="doi">10.1097/ALN.0000000000000601</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37255216</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-8737</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical cardiology</Title><ISOAbbreviation>Clin Cardiol</ISOAbbreviation></Journal><ArticleTitle>Association of race and in-hospital outcomes following acute pulmonary embolism: A retrospective cohort study.</ArticleTitle><Pagination><StartPage>768</StartPage><EndPage>776</EndPage><MedlinePgn>768-776</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/clc.24055</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Racial disparities in health care are well established, with Black patients frequently experiencing the most significant consequences of this inequality. Acute pulmonary embolism (PE) is increasing in incidence and an important cause of morbidity and mortality in the United States, but little is known about racial disparities in the inpatient setting.</AbstractText><AbstractText Label="HYPOTHESIS" NlmCategory="OBJECTIVE">Black and White patients admitted with acute PE will have different in-hospital outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">All PE patients from January 1, 2016 to June 30, 2017 were retrospectively identified using ICD-10 codes. Data were abstracted by manual chart review for all image-confirmed PEs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 782 patients with acute PE were identified, of which 319 (40.8%) were Black and 463 (59.2%) were White. Black patients had higher BMI (median [Q1-Q3]: 30.3 [25.4-36.6] vs. 29.3 [24.5-33.8]&#x2009;kg/m<sup>2</sup> , p&#x2009;=&#x2009;.017), were younger (61 [48-74] vs. 67 [54-75] years, p&#x2009;=&#x2009;.001), and were more likely to have a history of heart failure (16.0 vs. 7.1%, p&#x2009;&lt;&#x2009;.001), while White patients had higher rates of malignancy (46.9 vs. 34.5%, p&#x2009;=&#x2009;.001) and recent surgery (29.6 vs. 18.2%, p&#x2009;&lt;&#x2009;.001). Black patients were more likely to receive systemic thrombolysis (3.1% vs. 1.1%, p&#x2009;=&#x2009;.040), while White patients had numerically higher rates of surgical embolectomy (0.3% vs. 1.1%, p&#x2009;=&#x2009;.41). No difference in inpatient mortality was observed; however, Black patients had longer hospital length of stay (5.0 [3-9] vs. 4.0 [2-9] days, p&#x2009;=&#x2009;.007) and were more likely to receive warfarin (23.5 vs. 12.1%, p&#x2009;&lt;&#x2009;.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Similar in-hospital mortality rates were observed in Black and White patients following acute PE. However, Black patients had longer hospital stays, higher warfarin prescription, and fewer traditional PE-related risk factors.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Alexander E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0002-1755-0055</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbery</LastName><ForeName>Carlos E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holder</LastName><ForeName>Tara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Cynthia L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Manesh R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Kevin L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>W Schuyler</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM007569</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007569</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cardiol</MedlineTA><NlmUniqueID>7903272</NlmUniqueID><ISSNLinking>0160-9289</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5Q7ZVV76EI</RegistryNumber><NameOfSubstance UI="D014859">Warfarin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014859" MajorTopicYN="Y">Warfarin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">racial disparities</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList><CoiStatement>Manesh R. Patel: Advisory Board/Consultant: Bayer, Janssen, Novartis, Medscape, Research Grants: Bayer, Janssen, Novartis, NHBLI. All the remaining authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>13</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37255216</ArticleId><ArticleId IdType="pmc">PMC10352978</ArticleId><ArticleId IdType="doi">10.1002/clc.24055</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thomas KL, Honeycutt E, Shaw LK, Peterson ED. Racial differences in long&#x2010;term survival among patients with coronary artery disease. Am Heart J. 2010;160(4):744&#x2010;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">20934570</ArticleId></ArticleIdList></Reference><Reference><Citation>Laiteerapong N, Fairchild PC, Chou CH, Chin MH, Huang ES. Revisiting disparities in quality of care among US adults with diabetes in the era of individualized care, NHANES 2007&#x2010;2010. Med Care. 2015;53(1):25&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394649</ArticleId><ArticleId IdType="pubmed">25373405</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunniyi MO, Commodore&#x2010;Mensah Y, Ferdinand KC. Race, ethnicity, hypertension, and heart disease. JACC. 2021;78(24):2460&#x2010;2470.</Citation><ArticleIdList><ArticleId IdType="pubmed">34886968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong MH, Peterson ED, Fonarow GC, et al. Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. Am Heart J. 2010;160(4):605&#x2010;618.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956019</ArticleId><ArticleId IdType="pubmed">20934553</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugowe FE, Jackson LR 2nd, Thomas KL. Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: a systematic review. Heart Rhythm. 2018;15(9):1337&#x2010;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">29803022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson JB, Jackson LR 2nd, Ugowe FE, et al. Racial and ethnic differences in treatment and outcomes of severe aortic stenosis. JACC: Cardiovasc Interv. 2020;13(2):149&#x2010;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">31973792</ArticleId></ArticleIdList></Reference><Reference><Citation>Galea S, Blaney S, Nandi A, et al. Explaining racial disparities in incidence of and survival from out&#x2010;of&#x2010;hospital cardiac arrest. Am J Epidemiol. 2007;166(5):534&#x2010;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">17584756</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism. Am J Prev Med. 2010;38(4 suppl):S495&#x2010;S501.</Citation><ArticleIdList><ArticleId IdType="pubmed">20331949</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). The Lancet. 1999;353(9162):1386&#x2010;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227218</ArticleId></ArticleIdList></Reference><Reference><Citation>Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke Statistics&#x2010;2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139&#x2010;e596.</Citation><ArticleIdList><ArticleId IdType="pubmed">31992061</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider D, Lilienfeld DE, Im W. The epidemiology of pulmonary embolism: racial contrasts in incidence and in&#x2010;hospital case fatality. J Natl Med Assoc. 2006;98(12):1967&#x2010;1972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569672</ArticleId><ArticleId IdType="pubmed">17225843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim SA, Stone RA, Obrosky DS, Sartorius J, Fine MJ, Aujesky D. Racial differences in 30&#x2010;day mortality for pulmonary embolism. Am J Public Health. 2006;96(12):2161&#x2010;2164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698166</ArticleId><ArticleId IdType="pubmed">17077409</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco S, Valerio L, Ageno W, et al. Age&#x2010;sex specific pulmonary embolism&#x2010;related mortality in the USA and Canada, 2000&#x2010;18: an analysis of the WHO mortality database and of the CDC multiple cause of death database. Lancet Respir Med. 2021;9(1):33&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7550106</ArticleId><ArticleId IdType="pubmed">33058771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganz DA, Glynn RJ, Mogun H, Knight EL, Bohn RL, Avorn J. Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism. J Gen Intern Med. 2000;15(11):776&#x2010;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1495613</ArticleId><ArticleId IdType="pubmed">11119169</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner TW, Key NS. Venous thrombosis in blacks. Circulation. 2012;125(6):837&#x2010;839.</Citation><ArticleIdList><ArticleId IdType="pubmed">22331921</ArticleId></ArticleIdList></Reference><Reference><Citation>White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep&#x2010;venous thrombosis. Am J Med. 1999;107(5):414&#x2010;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">10569295</ArticleId></ArticleIdList></Reference><Reference><Citation>Holder T, Sullivan AE, Truong T, et al. Identification, diagnosis, treatment, and in&#x2010;hospital outcomes of acute pulmonary embolism: results from a single integrated health system. Am Heart J. 2019;216:136&#x2010;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">31434031</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population&#x2010;based case&#x2010;control study. Arch Intern Med. 2000;160(6):809&#x2010;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">10737280</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson FA Jr., Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med. 1991;115(8):591&#x2010;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">1892330</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep&#x2010;vein thrombosis in symptomatic outpatients. Arch Intern Med. 1994;154(2):164&#x2010;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8285811</ArticleId></ArticleIdList></Reference><Reference><Citation>Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160(22):3415&#x2010;3420.</Citation><ArticleIdList><ArticleId IdType="pubmed">11112234</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson FA Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl 1):I9&#x2010;I16.</Citation><ArticleIdList><ArticleId IdType="pubmed">12814980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hargraves JL, Hadley J. The contribution of insurance coverage and community resources to reducing racial/ethnic disparities in access to care. Health Serv Res. 2003;38(3):809&#x2010;829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360918</ArticleId><ArticleId IdType="pubmed">12822914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y, Wang C, Civan JM, et al. Effects of cancer stage and treatment differences on racial disparities in survival from colon cancer: a United States population&#x2010;based study. Gastroenterology. 2016;150(5):1135&#x2010;1146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842115</ArticleId><ArticleId IdType="pubmed">26836586</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn H. Racial and ethnic disparities in health insurance coverage: dynamics of gaining and losing coverage over the life&#x2010;course. Popul Res Policy Rev. 2017;36(2):181&#x2010;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5370590</ArticleId><ArticleId IdType="pubmed">28366968</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller&#x2010;Kleinhenz JM, Collin LJ, Seidel R, et al. Racial disparities in diagnostic delay among women with breast cancer. J Am Coll Radiol. 2021;18(10):1384&#x2010;1393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8492512</ArticleId><ArticleId IdType="pubmed">34280379</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA, Beckman MG, Bockenstedt PL, et al. Comparison of characteristics from White&#x2010; and Black&#x2010;Americans with venous thromboembolism: a cross&#x2010;sectional study. Am J Hematol. 2010;85(7):467&#x2010;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">20575037</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips AR, Reitz KM, Myers S, et al. Association between black race, clinical severity, and management of acute pulmonary embolism: a retrospective cohort study. J Am Heart Assoc. 2021;10(17):e021818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8649302</ArticleId><ArticleId IdType="pubmed">34431356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilienfeld DE, Lilienfeld DE. Decreasing mortality from pulmonary embolism in the United States, 1979&#x2010;1996. Int J Epidemiol. 2000;29(3):465&#x2010;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">10869318</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin KA, Molsberry R, Cuttica MJ, Desai KR, Schimmel DR, Khan SS. Time trends in pulmonary embolism mortality rates in the United States, 1999 to 2018. J Am Heart Assoc. 2020;9(17):e016784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7660782</ArticleId><ArticleId IdType="pubmed">32809909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline JA, Garrett JS, Sarmiento EJ, Strachan CC, Courtney DM. Over&#x2010;Testing for suspected pulmonary embolism in American emergency departments: the continuing epidemic. Circ: Cardiovasc Qual Outcomes. 2020;13(1):e005753.</Citation><ArticleIdList><ArticleId IdType="pubmed">31957477</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med. 2010;363(3):266&#x2010;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">20592294</ArticleId></ArticleIdList></Reference><Reference><Citation>Than M, Aldous S, Lord SJ, et al. A 2&#x2010;hour diagnostic protocol for possible cardiac chest pain in the emergency department: a randomized clinical trial. JAMA Intern Med. 2014;174(1):51&#x2010;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">24100783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule&#x2010;out criteria. J Thromb Haemostasis. 2008;6(5):772&#x2010;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">18318689</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d&#x2010;dimer. Ann Intern Med. 2001;135(2):98&#x2010;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">11453709</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965&#x2010;1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">29791822</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate&#x2010;risk pulmonary embolism. N Engl J Med. 2014;370(15):1402&#x2010;1411.</Citation><ArticleIdList><ArticleId IdType="pubmed">24716681</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucher N, Boekstegers P, M&#xfc;ller OJ, et al. Randomized, controlled trial of ultrasound&#x2010;assisted catheter&#x2010;directed thrombolysis for acute intermediate&#x2010;risk pulmonary embolism. Circulation. 2014;129(4):479&#x2010;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">24226805</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapson VF, Sterling K, Jones N, et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate&#x2010;risk pulmonary embolism. JACC: Cardiovasc Interven. 2018;11(14):1401&#x2010;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">30025734</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza G, Hohlfelder B, Jaff MR, et al. A prospective, single&#x2010;arm, multicenter trial of ultrasound&#x2010;facilitated, catheter&#x2010;directed, low&#x2010;dose fibrinolysis for acute massive and submassive pulmonary embolism. JACC: Cardiovasc Interv. 2015;8(10):1382&#x2010;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">26315743</ArticleId></ArticleIdList></Reference><Reference><Citation>Paczy&#x144;ska M, Kurnicka K, Lichodziejewska B, et al. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience. Kardiol Pol. 2016;74(7):650&#x2010;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">26779849</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36259216</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1445-2197</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>ANZ journal of surgery</Title><ISOAbbreviation>ANZ J Surg</ISOAbbreviation></Journal><ArticleTitle>Efficacy of intermittent compression devices for thromboembolic prophylaxis in major abdominal surgery: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>2926</StartPage><EndPage>2934</EndPage><MedlinePgn>2926-2934</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ans.18101</ELocationID><Abstract><AbstractText Label="BACKGROUND">The benefits of mechanical prophylaxis for the prevention of venous thromboembolism (VTE) in abdominal and pelvic surgery are uncertain, with different guidelines stating that graduated compression stockings (GCS) and intermittent pneumatic compression devices (IPCDs) can be used either alone or in combination. To review the efficacy of IPCDs in preventing VTE following abdominal and pelvic surgery.</AbstractText><AbstractText Label="METHODS">A systematic review was conducted, identifying relevant literature reporting clinical trials conducted in abdominopelvic surgery, comparing the effect of IPCDs alone or in combination with no prophylaxis, GCS and chemical prophylaxis. The review identified studies reported from 1966 to 2022 in Medline, Embase, PubMed and Cochrane databases for randomized controlled trials.</AbstractText><AbstractText Label="RESULTS">Thirteen RCTs involving 1914 participants were identified. IPCDs were superior to placebo (OR VTE 0.39; 95% CI 0.20-0.76) but not superior to other forms of prophylaxis (OR 0.83; 95% CI 0.30-2.27) or to GCS alone (OR 0.9; 95% CI 0.24-3.36). The addition of IPCDs to GCS compared with GCS alone was beneficial (OR 0.45; 95% CI 0.23-0.91) as was the addition of IPCDs to standard perioperative chemoprophylaxis (OR 0.25; 95% CI 0.09-0.74). The overall quality and reliability of trials were low, with high risk of bias.</AbstractText><AbstractText Label="CONCLUSIONS">IPCDs are more effective than placebo in reducing VTE rates but are not more effective than other forms of thrombo-prophylaxis (chemical or mechanical) following abdominal and pelvic surgery. There is poor quality evidence to suggest that they might have a role as additional prophylaxis when combined with GCS and chemical prophylaxis.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. ANZ Journal of Surgery published by John Wiley &amp; Sons Australia, Ltd on behalf of Royal Australasian College of Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lott</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5905-6357</Identifier><AffiliationInfo><Affiliation>Surgical Services, John Hunter Hospital, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Surgical Clinical Research Unit, John Hunter Hospital, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robb</LastName><ForeName>Felicity</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, Kookaburra Circuit, New Lambton Heights, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>Erin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, Kookaburra Circuit, New Lambton Heights, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attia</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, Kookaburra Circuit, New Lambton Heights, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reeves</LastName><ForeName>Penny</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunter Medical Research Institute, Kookaburra Circuit, New Lambton Heights, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gani</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hunter Surgical Clinical Research Unit, John Hunter Hospital, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hunter Surgical Clinical Research Unit, John Hunter Hospital, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>ANZ J Surg</MedlineTA><NlmUniqueID>101086634</NlmUniqueID><ISSNLinking>1445-1433</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000005" MajorTopicYN="N">Abdomen</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010388" MajorTopicYN="N">Pelvis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053828" MajorTopicYN="N">Stockings, Compression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048228" MajorTopicYN="N">Intermittent Pneumatic Compression Devices</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">intermittent pnuematic compression devices</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">surgery</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>3</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36259216</ArticleId><ArticleId IdType="pmc">PMC9828528</ArticleId><ArticleId IdType="doi">10.1111/ans.18101</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nepogodiev D, Martin J, Biccard B, Makupe A. Global burden of postoperative death. Lancet 2019; 393: 401.</Citation><ArticleIdList><ArticleId IdType="pubmed">30722955</ArticleId></ArticleIdList></Reference><Reference><Citation>Laryea J, Champagne B. Venous thromboembolism prophylaxis. Clin. Colon Rectal Surg. 2013; 26: 153&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747284</ArticleId><ArticleId IdType="pubmed">24436666</ArticleId></ArticleIdList></Reference><Reference><Citation>
The Australian and New Zealand Working Party and The Royal Australasian College of Surgeons: Prevention of Venous Thromboembolism&#x2010;Best Practice Guidelines for Australia and New Zealand 4th Edition. 

 https://www.surgeons.org/media/19372/VTE_Guidelines.pdf</Citation></Reference><Reference><Citation>
NSW Health Policy Directive
. Prevention of Venous Thromboembolism. PD2014_032 22_09_2014
https://www.health.nsw.gov.au/pds/ActivePDSDocuments/PD2014_032.pdf
</Citation></Reference><Reference><Citation>National Health and Medical Research Council . Clinical Practice Guidelines for the Prevention of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Patients Admitted to Australian Hospitals. Melbourne: National Health ND Medical Research Council, 2009. (Rescinded).</Citation></Reference><Reference><Citation>Venous thromboembolism in over 16s: reducing the risk of hospital&#x2010;acquired deep vein thrombosis or pulmonary embolism VTE: Reducing the Risk for Patients in Hospital, NICE guideline [NG89], Mar 2018.</Citation></Reference><Reference><Citation>
NICE
. Venous thromboembolism in over 16s: reducing the risk of hospital&#x2010;acquired deep vein thrombosis or pulmonary embolism. NICE guidance 89. 2018. https://www.nice.org.uk/guidance/ng89
</Citation><ArticleIdList><ArticleId IdType="pubmed">29697228</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt G, Akl E, Crowther M, Gutterman D, Schu&#xfc;nemann H. American College of Chest Physicians Antithrombotic Therapy and Prevention of thrombosis panel. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed. Chest 2012; 141: 7S&#x2013;47S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278060</ArticleId><ArticleId IdType="pubmed">22315257</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele R, Kinzl L, Koelsch T. Rapid&#x2010;inflation intermittent pneumatic compression for prevention of deep venous thrombosis. J. Bone Joint Surg. Am. 2007; 89: 1050&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17473143</ArticleId></ArticleIdList></Reference><Reference><Citation>Comerota A, Chouhan V, Harada R et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann. Surg. 1997; 226: 306&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1191029</ArticleId><ArticleId IdType="pubmed">9339937</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R, Woodcock J. Evidence&#x2010;based compression: prevention of stasis and deep vein thrombosis. Ann. Surg. 2004; 239: 162&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1356208</ArticleId><ArticleId IdType="pubmed">14745323</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho K, Tan J. Stratified meta&#x2010;analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation 2013; 128: 1003&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">23852609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkos S, Caprini J, Geroulakos G et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst. Rev. 2016; 9: CD005258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6457599</ArticleId><ArticleId IdType="pubmed">27600864</ArticleId></ArticleIdList></Reference><Reference><Citation>
Farlex Partner Medical Dictionary. S.V. "major surgery." [Cited 10 Jan 2022.] Available from URL: https://medical-dictionary.thefreedictionary.com/major+surgery
</Citation></Reference><Reference><Citation>Duval S, Tweedie R. Trim and fill: a simple funnel&#x2010;plot&#x2010;based method of testing and adjusting for publication bias in meta&#x2010;analysis. Biometrics 2000; 56: 455&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">10877304</ArticleId></ArticleIdList></Reference><Reference><Citation>Duval S, Tweedie R. A nonparametric "trim and fill" method of accounting for publication bias in meta&#x2010;analysis. J. Am. Stat. Assoc. 2000; 95: 89&#x2013;98.</Citation></Reference><Reference><Citation>Duval S. The trim and fill method. In: Rothstein HR, Sutton AJ, Borenstein M (eds). Publication Bias in Meta&#x2010;Analysis: Prevention, Assessment, and Adjustments. Chichester, England: Wiley, 2005; 127&#x2013;44.</Citation></Reference><Reference><Citation>Viechtbauer W. Conducting meta&#x2010;analyses in R with the metafor package. J. Stat. Softw. 2010; 36: 1&#x2013;48.</Citation></Reference><Reference><Citation>Hills H, Pflug J, Jeyasingh K, Boardman L, Calnan J. Prevention of deep vein thrombosis by intermittent pneumatic compression of calf. Br. Med. J. 1972; 1: 131&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1787116</ArticleId><ArticleId IdType="pubmed">5007837</ArticleId></ArticleIdList></Reference><Reference><Citation>Butson A. Intermittent pneumatic calf compression for prevention of deep venous thrombosis in general abdominal surgery. Am. J. Surg. 1981; 142: 525&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7025675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellbring G, Palm&#xe9;r K. Prophylaxis of deep vein thrombosis after major abdominal surgery. Comparison between dihydroergotamine&#x2010;heparin and intermittent pneumatic calf compression and evaluation of added graduated static compression. Acta Chir. Scand. 1986; 152: 597&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">3544626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosir M, Kozol R, Perales A et al. Is DVT prophylaxis overemphasized? A randomized prospective study. J. Surg. Res. 1996; 60: 289&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8598656</ArticleId></ArticleIdList></Reference><Reference><Citation>Lobastov K, Sautina E, Alencheva E et al. Intermittent pneumatic compression in addition to standard prophylaxis of postoperative venous thromboembolism in extremely high&#x2010;risk patients (IPC SUPER): a randomized controlled trial. Ann. Surg. 2021; 274: 63&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33201130</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke&#x2010;Pearson D, Synan I, Hinshaw W, Coleman R, Creasman W. Prevention of postoperative venous thromboembolism by external pneumatic calf compression in patients with gynaecologic malignancy. Obstet. Gynecol. 1984; 63: 92&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">6691021</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke&#x2010;Pearson D, Synan I, Dodge R, Soper J, Berchuck A, Coleman R. A randomized trial of low&#x2010;dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynaecologic oncology surgery. Am. J. Obstet. Gynecol. 1993; 168: 1146&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8475960</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata C, Tanabe H, Takakura S et al. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. J. Obstet. Gynaecol. Res. 2015; 41: 1440&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26111609</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Zhang Z, Li Z et al. Two mechanical methods for thromboembolism prophylaxis after gynaecological pelvic surgery: a prospective, randomised study. Chin. Med. J. 2012; 125: 4259&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">23217397</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell GL, Synan I, Dodge R, Carroll B, Clarke&#x2010;Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet. Gynecol. 2001; 98: 989&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755543</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Arsdalen K, Smith J, Barnes R, Koontz W, Clarke G. Deep vein thrombosis and prostatectomy. Urology 1983; 21: 461&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">6857882</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansberry K, Thompson I, Bauman J, Deppe S, Rodriguez S, Francisco R. A prospective comparison of thromboembolic stockings, external sequential pneumatic compression stockings and heparin sodium/Dihydroergotamine Mesylate for the prevention of thromboembolic complications in urological surgery. J. Urol. 1991; 145: 1205&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2033693</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang C, Zhao N, Zhang J et al. Different combination strategies for prophylaxis of venous thromboembolism in patients: a prospective multicentre randomized controlled study. Sci. Rep. 2018; 8: 8277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5974317</ArticleId><ArticleId IdType="pubmed">29844423</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J, Sterne J, Savovi&#x107; J et al. A revised tool for assessing risk of bias in randomized trials In: Chandler J, McKenzie J, Boutron I, Welch V (eds). Cochrane methods . Cochrane Database Syst. Rev. 2016; 10: CD201601.</Citation></Reference><Reference><Citation>
NSW Health Policy Directive. Prevention of Venous Thromboembolism.PD2014_032. 

 https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2014_032.pdf</Citation></Reference><Reference><Citation>
Venous Thromboembolism Prevention Clinical Care Standard, Australian Commission on Safety and Quality in Health Care, Oct 2018. https://www.safetyandquality.gov.au/our&#x2010;work/clinical&#x2010;care&#x2010;standards/venousthromboembolism&#x2010;prevention&#x2010;clinical&#x2010;care&#x2010;standard/
</Citation></Reference><Reference><Citation>VTE Prophylaxis, BMJ Best Practice, July 2018.</Citation></Reference><Reference><Citation>Guyatt GH, Akl EA, Crowther M et al. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians (ACCP) evidence&#x2010;based clinical practice guidelines. Chest 2012; 141: 7S&#x2013;47S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278060</ArticleId><ArticleId IdType="pubmed">22315257</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolaides A, Fareed J, Kakkar A et al. Prevention and treatment of venous thromboembolism. International consensus statement (guidelines according to scientific evidence) . Int. Angiol. 2013; 32: 111&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">24402349</ArticleId></ArticleIdList></Reference><Reference><Citation>Comerota A, Katz M, White J. Why does prophylaxis with external pneumatic compression for deep vein thrombosis fail? Am. J. Surg. 1992; 164: 265&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1415927</ArticleId></ArticleIdList></Reference><Reference><Citation>Felder S, Rasmussen M, King R et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst. Rev. 2019; 8: CD004318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6709764</ArticleId><ArticleId IdType="pubmed">31449321</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett M, Mauck K, Stephenson C, Ganesh R, Daniels P. Perioperative venous thromboembolism prophylaxis. Mayo Clin. Proc. 2020; 95: 2775&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">33276846</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkidou K, Appleby J. Eliminating waste in healthcare spending. BMJ 2017; 7: j570.</Citation><ArticleIdList><ArticleId IdType="pubmed">28174162</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27058801</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0301-1526</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>2</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>VASA. Zeitschrift fur Gefasskrankheiten</Title><ISOAbbreviation>Vasa</ISOAbbreviation></Journal><ArticleTitle>Diagnostic accuracy of magnetic resonance angiography for acute pulmonary embolism - a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>149</StartPage><EndPage>154</EndPage><MedlinePgn>149-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1024/0301-1526/a000509</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this meta-analysis was to evaluate the diagnostic accuracy of magnetic resonance angiography (MRA) for acute pulmonary embolism (PE).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature search was conducted that included studies from January 2000 to August 2015 using the electronic databases PubMed, Embase and Springer link. The summary receiver operating characteristic (SROC) curve, sensitivity, specificity, positive likelihood ratios (PLR), negative likelihood ratios (NLR), and diagnostic odds ratio (DOR) as well as the 95 % confidence intervals (CIs) were calculated to evaluate the diagnostic accuracy of MRA for acute PE. Meta-disc software version 1.4 was used to analyze the data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Five studies were included in this meta-analysis. The pooled sensitivity (86 %, 95 % CI: 81 % to 90 %) and specificity (99 %, 95 % CI: 98 % to 100 %) demonstrated that MRA diagnosis had limited sensitivity and high specificity in the detection of acute PE. The pooled estimate of PLR (41.64, 95 % CI: 17.97 to 96.48) and NLR (0.17, 95 % CI: 0.11 to 0.27) provided evidence for the low missed diagnosis and misdiagnosis rates of MRA for acute PE. The high diagnostic accuracy of MRA for acute PE was demonstrated by the overall DOR (456.51, 95 % CI: 178.38 - 1168.31) and SROC curves (AUC = 0.9902 &#xb1; 0.0061).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MRA can be used for the diagnosis of acute PE. However, due to limited sensitivity, MRA cannot be used as a stand-alone test to exclude acute PE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1 Department of thoracic Surgery, Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>2 Department of Gynecology and Obstetrics, People's Hospital of Pingyi County, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jiangbo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>3 Department of Cardio-thoracic Surgery, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>3 Department of Cardio-thoracic Surgery, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vasa</MedlineTA><NlmUniqueID>0317051</NlmUniqueID><ISSNLinking>0301-1526</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018810" MajorTopicYN="Y">Magnetic Resonance Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011651" MajorTopicYN="N">Pulmonary Artery</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Magnetic resonance angiography</Keyword><Keyword MajorTopicYN="N">acute pulmonary embolism</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27058801</ArticleId><ArticleId IdType="doi">10.1024/0301-1526/a000509</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35837438</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0974-8237</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Journal of craniovertebral junction &amp; spine</Title><ISOAbbreviation>J Craniovertebr Junction Spine</ISOAbbreviation></Journal><ArticleTitle>Cigarette smoking and complications in elective thoracolumbar fusions surgery: An analysis of 58,304 procedures.</ArticleTitle><Pagination><StartPage>169</StartPage><EndPage>174</EndPage><MedlinePgn>169-174</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/jcvjs.jcvjs_15_22</ELocationID><Abstract><AbstractText Label="STUDY DESIGN" NlmCategory="UNASSIGNED">This was retrospective cohort study.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">The current investigation uses a large, multi-institutional dataset to compare short-term morbidity and mortality rates between current smokers and nonsmokers undergoing thoracolumbar fusion surgery.</AbstractText><AbstractText Label="OVERVIEW OF LITERATURE" NlmCategory="UNASSIGNED">The few studies that have addressed perioperative complications following thoracolumbar fusion surgeries are each derived from small cohorts from single institutions.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">A retrospective study was conducted on thoracolumbar fusion patients in the American College of Surgeons National Surgical Quality Improvement Program database (2006-2016). The primary outcome compared the rates of overall morbidity, severe postoperative morbidity, infections, pneumonia, deep venous thrombosis (DVT), pulmonary embolism (PE), transfusions, and mortality in smokers and nonsmokers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 57,677 patients were identified. 45,952 (78.8%) were nonsmokers and 12,352 (21.2%) smoked within 1 year of surgery. Smokers had fewer severe complications (1.6% vs. 2.0%, <i>P</i> = 0.014) and decreased discharge to skilled nursing facilities (6.3% vs. 11.5%, <i>P</i> &lt; 0.001) compared to nonsmokers. They had lower incidences of transfusions (odds ratio [OR] = 0.9, confidence interval [CI] = 0.8-1.0, <i>P</i> = 0.009) and DVT (OR = 0.7, CI = 0.5-0.9, <i>P</i> = 0.039) as well as shorter length of stay (LOS) (OR = 0.9, CI = 0.9-0.99, <i>P</i> &lt; 0.001). They had a higher incidence of postoperative pneumonia (OR = 1.4, CI = 1.1-1.8, <i>P</i> = 0.002). There was no difference in the remaining primary outcomes between smoking and nonsmoking cohorts.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">There is a positive correlation between smoking and postoperative pneumonia after thoracolumbar fusion. The incidence of blood transfusions, DVT, and LOS was decreased in smokers. Early postoperative mortality, severe complications, discharge to subacute rehabilitation facilities, extubation failure, PE, SSI, and return to OR were not associated with smoking.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2022 Journal of Craniovertebral Junction and Spine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharfman</LastName><ForeName>Zachary T</ForeName><Initials>ZT</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelfand</LastName><ForeName>Yaroslav</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoang</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Rafael De La Garza</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Jaime A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krystal</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yassari</LastName><ForeName>Reza</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>J Craniovertebr Junction Spine</MedlineTA><NlmUniqueID>101536746</NlmUniqueID><ISSNLinking>0974-8237</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">National surgical quality improvement program</Keyword><Keyword MajorTopicYN="N">postoperative period</Keyword><Keyword MajorTopicYN="N">smokers</Keyword><Keyword MajorTopicYN="N">smoking</Keyword><Keyword MajorTopicYN="N">thoracolumbar fusion</Keyword></KeywordList><CoiStatement>There are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>15</Day><Hour>2</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35837438</ArticleId><ArticleId IdType="pmc">PMC9274679</ArticleId><ArticleId IdType="doi">10.4103/jcvjs.jcvjs_15_22</ArticleId><ArticleId IdType="pii">JCVJS-13-169</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bilano V, Gilmour S, Moffiet T. Global Trends and Projections for Tobacco Use, 1990-2025: An Analysis of Smoking Indicators From the WHO Comprehensive Information Systems for Tobacco Control. Journal of Vascular Surgery. 2015;62:1370.</Citation><ArticleIdList><ArticleId IdType="pubmed">25784347</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. State tobacco activities tracking &amp; evaluation (STATE) System. Map of Current cigarette use among adults (Behavior Risk Factor Surveillance System) 2018</Citation></Reference><Reference><Citation>Elsamadicy AA, Adogwa O, Sergesketter A, Vuong VD, Lydon E, Behrens S, et al. Reduced impact of smoking status on 30-day complication and readmission rates after elective spinal fusion (&#x2265;3 Levels) for adult spine deformity: A single institutional study of 839 patients. World Neurosurg. 2017;107:233&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28790002</ArticleId></ArticleIdList></Reference><Reference><Citation>De la Garza Ramos R, Goodwin CR, Qadi M, Abu-Bonsrah N, Passias PG, Lafage V, et al. Impact of smoking on 30-day morbidity and mortality in adult spinal deformity surgery. Spine (Phila Pa 1976) 2017;42:465&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">27434180</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin CT, Gao Y, Duchman KR, Pugely AJ. The impact of current smoking and smoking cessation on short-term morbidity risk after lumbar spine surgery. Spine (Phila Pa 1976) 2016;41:577&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">27018898</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeravagu A, Patil CG, Lad SP, Boakye M. Risk factors for postoperative spinal wound infections after spinal decompression and fusion surgeries. Spine (Phila Pa 1976) 2009;34:1869&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">19644339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang A, Hu SS, Endres N, Bradford DS. Risk factors for infection after spinal surgery. Spine (Phila Pa 1976) 2005;30:1460&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15959380</ArticleId></ArticleIdList></Reference><Reference><Citation>McCunniff PT, Young ES, Ahmadinia K, Ahn UM, Ahn NU. Smoking is associated with increased blood loss and transfusion use after lumbar spinal surgery. Clin Orthop Relat Res. 2016;474:1019&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4773328</ArticleId><ArticleId IdType="pubmed">26642788</ArticleId></ArticleIdList></Reference><Reference><Citation>Murgai R, D&#x2019;Oro A, Heindel P, Schoell K, Barkoh K, Buser Z, et al. Incidence of respiratory complications following lumbar spine surgery. Int J Spine Surg. 2018;12:718&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6314350</ArticleId><ArticleId IdType="pubmed">30619676</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Yang SD, Huang WZ, Liu FY, Wang H, Ding WY. Factors predicting venous thromboembolism after spine surgery. Medicine (Baltimore) 2016;95:e5776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5207595</ArticleId><ArticleId IdType="pubmed">28033299</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H, Zhu J, Ji F, Wang S, Xie Y, Fei H. Risk factors for postoperative complication after spinal fusion and instrumentation in degenerative lumbar scoliosis patients. J Orthop Surg Res. 2014;9:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995926</ArticleId><ArticleId IdType="pubmed">24606963</ArticleId></ArticleIdList></Reference><Reference><Citation>Appaduray SP, Lo P. Effects of diabetes and smoking on lumbar spinal surgery outcomes. J Clin Neurosci. 2013;20:1713&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23993899</ArticleId></ArticleIdList></Reference><Reference><Citation>Echt M, De la Garza Ramos R, Nakhla J, Gelfand Y, Cezayirli P, Holland R, et al. The effect of cigarette smoking on wound complications after single-level posterolateral and interbody fusion for spondylolisthesis. World Neurosurg. 2018;116:e824&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29803058</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens RK, 2nd, Crawford CH, 3rd, Djurasovic M, Canan CE, Burke LO, Bratcher KR, et al. Predictive factors for the use of autologous cell saver transfusion in lumbar spinal surgery. Spine (Phila Pa 1976) 2013;38:217&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">23197016</ArticleId></ArticleIdList></Reference><Reference><Citation>Jules-Elysee K, Urban MK, Urquhart BL, Susman MH, Brown AC, Kelsey WT. Pulmonary complications in anterior-posterior thoracic lumbar fusions. Spine J. 2004;4:312&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15125855</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson PA, Savage JW, Vaccaro AR, Radcliff K, Arnold PM, Lawrence BD, et al. Prevention of surgical site infection in spine surgery. Neurosurgery. 2017;80:S114&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">28350942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong L, Liu Z, Meng F, Shen Y. Smoking and risk of surgical site infection after spinal surgery: A systematic review and meta-analysis. Surg Infect (Larchmt) 2017;18:206&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">28004986</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng F, Cao J, Meng X. Risk factors for surgical site infections following spinal surgery. J Clin Neurosci. 2015;22:1862&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26282155</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen MA, Mayfield J, Lauryssen C, Polish LB, Jones M, Vest J, et al. Risk factors for surgical site infection in spinal surgery. J Neurosurg. 2003;98:149&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">12650399</ArticleId></ArticleIdList></Reference><Reference><Citation>Maragakis LL, Cosgrove SE, Martinez EA, Tucker MG, Cohen DB, Perl TM. Intraoperative fraction of inspired oxygen is a modifiable risk factor for surgical site infection after spinal surgery. Anesthesiology. 2009;110:556&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">19225396</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsoumbelis S, Hughes AP, Girardi FP, Cammisa FP, Jr, Finerty EA, Nguyen JT, et al. Risk factors for postoperative infection following posterior lumbar instrumented arthrodesis. J Bone Joint Surg Am. 2011;93:1627&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">21915578</ArticleId></ArticleIdList></Reference><Reference><Citation>Cizik AM, Lee MJ, Martin BI, Bransford RJ, Bellabarba C, Chapman JR, et al. Using the spine surgical invasiveness index to identify risk of surgical site infection: A multivariate analysis. J Bone Joint Surg Am. 2012;94:335&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3273877</ArticleId><ArticleId IdType="pubmed">22336972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonjon G, Dauzac C, Fourniols E, Guigui P, Bonnomet F, Bonnevialle P, et al. Early surgical site infections in adult spinal trauma: A prospective, multicentre study of infection rates and risk factors. Orthop Traumatol Surg Res. 2012;98:788&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">23044465</ArticleId></ArticleIdList></Reference><Reference><Citation>Platzer P, Thalhammer G, Jaindl M, Obradovic A, Benesch T, Vecsei V, et al. Thromboembolic complications after spinal surgery in trauma patients. Acta Orthop. 2006;77:755&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">17068706</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmonds MJ, Crichton TJ, Runciman WB, Pradhan M. Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J Surg. 2004;74:1082&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15574153</ArticleId></ArticleIdList></Reference><Reference><Citation>Puvanesarajah V, Rao SS, Hassanzadeh H, Kebaish KM. Determinants of perioperative transfusion risk in patients with adult spinal deformity. J Neurosurg Spine. 2018;28:429&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">29350594</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng F, Cammisa FP, Jr, Sandhu HS, Girardi FP, Khan SN. Factors predicting hospital stay, operative time, blood loss, and transfusion in patients undergoing revision posterior lumbar spine decompression, fusion, and segmental instrumentation. Spine (Phila Pa 1976) 2002;27:818&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">11935103</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenga MF, Kieneker LM, Touw DJ, Nolte IM, van der Meer P, Huls G, et al. Active smoking and hematocrit and fasting circulating erythropoietin concentrations in the general population. Mayo Clin Proc. 2018;93:337&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">29502563</ArticleId></ArticleIdList></Reference><Reference><Citation>McAloon EJ, Streiff RR, Kitchens CS. Erythrocytosis associated with carboxyhemoglobinemia in smokers. South Med J. 1980;73:137&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7355308</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen KM, &#xc7;olak Y, Ellervik C, Hasselbalch HC, Bojesen SE, Nordestgaard BG. Smoking and increased white and red blood cells. Arterioscler Thromb Vasc Biol. 2019;39:965&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30866659</ArticleId></ArticleIdList></Reference><Reference><Citation>Blache D, Bouthillier D, Davignon J. Acute influence of smoking on platelet behaviour, endothelium and plasma lipids and normalization by aspirin. Atherosclerosis. 1992;93:179&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">1534226</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald R, Pirmohamed M. Aspirin resistance: Effect of clinical, biochemical and genetic factors. Pharmacol Ther. 2011;130:213&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">21295071</ArticleId></ArticleIdList></Reference><Reference><Citation>Li WJ, Zhang HY, Miao CL, Tang RB, DU X, Shi JH, et al. Cigarette smoking inhibits the anti-platelet activity of aspirin in patients with coronary heart disease. Chin Med J (Engl) 2011;124:1569&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21740818</ArticleId></ArticleIdList></Reference><Reference><Citation>Soroceanu A, Burton DC, Oren JH, Smith JS, Hostin R, Shaffrey CI, et al. Medical complications after adult spinal deformity surgery: Incidence, risk factors, and clinical impact. Spine (Phila Pa 1976) 2016;41:1718&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">27105460</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohl DD, Mayo BC, Massel DH, Iantorno SE, Ahn J, Basques BA, et al. Incidence and risk factors for pneumonia after posterior lumbar fusion procedures: An ACS-NSQIP study. Spine (Phila Pa 1976) 2016;41:1058&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">26679873</ArticleId></ArticleIdList></Reference><Reference><Citation>Raval MV, Pawlik TM. Practical guide to surgical data sets: National Surgical Quality Improvement Program (NSQIP) and pediatric NSQIP. JAMA Surg. 2018;153:764&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">29617521</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiloach M, Frencher SK, Jr, Steeger JE, Rowell KS, Bartzokis K, Tomeh MG, et al. Toward robust information: Data quality and inter-rater reliability in the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg. 2010;210:6&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">20123325</ArticleId></ArticleIdList></Reference><Reference><Citation>Alluri RK, Leland H, Heckmann N. Surgical research using national databases. Ann Transl Med. 2016;4:393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5107400</ArticleId><ArticleId IdType="pubmed">27867945</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman D, Oren JH, Bendo J, Spivak J. The effect of smoking on spinal fusion. Int J Spine Surg. 2017;11:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5779238</ArticleId><ArticleId IdType="pubmed">29372133</ArticleId></ArticleIdList></Reference><Reference><Citation>Glassman SD, Anagnost SC, Parker A, Burke D, Johnson JR, Dimar JR. The effect of cigarette smoking and smoking cessation on spinal fusion. Spine (Phila Pa 1976) 2000;25:2608&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">11034645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32790536</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0377</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Vascular medicine (London, England)</Title><ISOAbbreviation>Vasc Med</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of extracorporeal membrane oxygenation for high-risk pulmonary embolism: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>460</StartPage><EndPage>467</EndPage><MedlinePgn>460-467</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1358863X20944469</ELocationID><Abstract><AbstractText>High-risk pulmonary embolism (PE) requires hemodynamic and respiratory support along with reperfusion strategies. Recently updated European guidelines assign a low class of recommendation to extracorporeal membrane oxygenation (ECMO) for high-risk PE. This systematic review assessed clinical outcomes after ECMO in high-risk PE. We searched electronic databases including PubMed, Embase and Web of Science from January 2000 to April 2020. Efficacy outcomes included in-hospital survival with good neurological outcome and survival at follow-up. Safety outcomes included lower limb ischemia and hemorrhagic and ischemic stroke. Where possible (absence of high heterogeneity), meta-analyses of outcomes were undertaken using a random-effects model. We included 16 uncontrolled case-series (533 participants). In-hospital survival with good neurological outcome ranged between 50% and 95% while overall survival at follow-up ranged from 35% to 95%, both with a major degree of heterogeneity (I<sup>2</sup> &gt; 70%). The prevalence of lower limb ischemia was 8% (95% CI 3% to 15%). The prevalence of stroke (either hemorrhagic or ischemic) was 11% (95% CI 3% to 23%), with notable heterogeneity (I&#xb2; = 63.35%). Based on currently available literature, it is not possible to draw definite conclusions on the usefulness of ECMO for high-risk PE. Prospective, multicenter, large-scale studies or nationwide registries are needed to best define the role of ECMO for high-risk PE. <b>PROSPERO registration ID: CRD42019136282</b>.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pozzi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6550-0872</Identifier><AffiliationInfo><Affiliation>Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metge</LastName><ForeName>Augustin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martelin</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Devices Unit - Pharmacy Department, "Edouard Herriot" Hospital, - Lyon University Hospitals, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giroudon</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7947-9437</Identifier><AffiliationInfo><Affiliation>Central Documentation Department, Hospices Civils de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanier Demma</LastName><ForeName>Justine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koffel</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and ICU, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornier</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and ICU, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiari</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and ICU, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fellahi</LastName><ForeName>Jean Luc</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and ICU, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obadia</LastName><ForeName>Jean Francois</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, "Louis Pradel" Cardiologic Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armoiry</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>University of Lyon, School of Pharmacy - Pharmacy Department (ISPB)/UMR CNRS 5510 MATEIS/"Edouard Herriot" Hospital - Lyon University Hospitals, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vasc Med</MedlineTA><NlmUniqueID>9610930</NlmUniqueID><ISSNLinking>1358-863X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiac arrest</Keyword><Keyword MajorTopicYN="N">cardiogenic shock</Keyword><Keyword MajorTopicYN="N">cardiovascular disease</Keyword><Keyword MajorTopicYN="N">extracorporeal membrane oxygenation (ECMO)</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism (PE)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32790536</ArticleId><ArticleId IdType="doi">10.1177/1358863X20944469</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38939492</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Venous Thromboembolism in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis of 4,170,027 Patients.</ArticleTitle><Pagination><StartPage>100555</StartPage><MedlinePgn>100555</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100555</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2023.100555</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Data on the association between atrial fibrillation (AF) and venous thromboembolism (VTE) are controversial.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The purpose of this study was to investigate the risk of VTE in patients with AF according to the time from AF diagnosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Systematic review of MEDLINE (PubMed), Embase, Cumulative Index to Nursing and Allied Health Literature (EBSCO host), Cochrane Central Register of Controlled Trials (2020) in the Cochrane Library, and World Health Organization Global Index Medicus databases and meta-analysis of observational studies. The risk of VTE, deep vein thrombosis (DVT) and pulmonary embolism (PE) was analyzed according to the time of AF onset: 1) short (&#x2264;3&#xa0;months); 2)&#xa0;medium (&#x2264;6&#xa0;months); and 3) long (&gt;6&#xa0;months) time groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Eight studies were included with 4,170,027 patients, of whom 650,828 with AF. In the short-term group, AF was associated with the highest risk of either PE (HR: 9.62; 95%&#xa0;CI: 7.07-13.09; I<sup>2</sup> = 0%) or DVT (HR: 6.18; 95%&#xa0;CI: 4.51-8.49, I<sup>2</sup> = 0%). Even if to a lesser extent, AF was associated with a higher risk of VTE (HR: 3.69; 95%&#xa0;CI: 1.65-8.27; I<sup>2</sup> = 79%), DVT (HR: 1.75; 95%&#xa0;CI: 1.43-2.14; I<sup>2</sup> = 0%), and PE (HR: 4.3; 95%&#xa0;CI: 1.61-11.47; I<sup>2</sup> = 68%) in the up to 6&#xa0;months and&#xa0;long-term risk group &gt;6&#xa0;months groups (HR: 1.39; 95%&#xa0;CI: 1.00-1.92; I<sup>2</sup> = 72%) and PE (HR: 1.08; 95%&#xa0;CI: 1.00-1.16; I<sup>2</sup> = 0%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The risk of VTE is highest in the first 3 to 6&#xa0;months after AF diagnosis and decreases over time. The early initiation of anticoagulation in patients with AF may reduce the risk of VTE.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pastori</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart &amp; Chest Hospital, Liverpool, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazzaniga</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Oncology and Hemato-Oncology Department, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farcomeni</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Economics and Finance, University of Rome "Tor Vergata", Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bucci</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart &amp; Chest Hospital, Liverpool, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Surgical Specialties and Organ Transplantation "Paride Stefanini", Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menichelli</LastName><ForeName>Danilo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Surgery, Surgical Specialties and Organ Transplantation "Paride Stefanini", Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franchino</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pani</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oncology and Hemato-Oncology Department, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Violi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mediterranea Cardiocentro, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pignatelli</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mediterranea Cardiocentro, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fauchier</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service de Cardiologie, Centre Hospitalier Universitaire Trousseau, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lip</LastName><ForeName>Gregory Y H</ForeName><Initials>GYH</Initials><AffiliationInfo><Affiliation>Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart &amp; Chest Hospital, Liverpool, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList><CoiStatement>The authors have reported that they have no relationships relevant to the contents of this paper to disclose.PERSPECTIVESCOMPETENCY IN MEDICAL KNOWLEDGE: AF is associated with an increased risk of arterial thromboembolic events, which may represent serious life threating complications but data about VTE are lacking. COMPETENCY IN PATIENT CARE: The risk of VTE is highest in the first 3 to 6&#xa0;months after AF diagnosis and decreases over time. TRANSLATIONAL OUTLOOK: The early initiation of anticoagulation and a narrow follow-up in patients with AF may reduce the risk of VTE.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>28</Day><Hour>4</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38939492</ArticleId><ArticleId IdType="pmc">PMC11198539</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2023.100555</ArticleId><ArticleId IdType="pii">S2772-963X(23)00484-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldin M., Koulas I., Weitz J.I., Spyropoulos A.C. State-of-the-art mini review: dual-pathway inhibition to reduce arterial and venous thromboembolism. Thromb Haemost. 2022;122:1279&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pubmed">35189662</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J., 3rd Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521222</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell M.D., Geraci J.M., Knowlton A.A. Congestive heart failure and outpatient risk of venous thromboembolism: a retrospective, case-control study. J&#xa0;Clin Epidemiol. 2001;54:810&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470390</ArticleId></ArticleIdList></Reference><Reference><Citation>Beemath A., Stein P.D., Skaf E., Al Sibae M.R., Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol. 2006;98:793&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">16950187</ArticleId></ArticleIdList></Reference><Reference><Citation>Bembenek J., Karlinski M., Kobayashi A., Czlonkowska A. Early stroke-related deep venous thrombosis: risk factors and influence on outcome. J&#xa0;Thromb Thrombolysis. 2011;32:96&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111553</ArticleId><ArticleId IdType="pubmed">21359647</ArticleId></ArticleIdList></Reference><Reference><Citation>Warlow C., Ogston D., Douglas A.S. Deep venous thrombosis of the legs after strokes. Part I--incidence and predisposing factors. Br Med J. 1976;1:1178&#x2013;1181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1639761</ArticleId><ArticleId IdType="pubmed">1268614</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly J., Rudd A., Lewis R.R., Coshall C., Moody A., Hunt B.J. Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. Stroke. 2004;35:2320&#x2013;2325.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J.A., Hernan M.A., Reeves B.C., et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Thompson S.G., Spiegelhalter D.J. A&#xa0;re-evaluation of random-effects meta-analysis. J&#xa0;R Stat Soc Ser A Stat Soc. 2009;172:137&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667312</ArticleId><ArticleId IdType="pubmed">19381330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.C., Lin C.L., Wang G.J., Chang C.T., Sung F.C., Kao C.H. Atrial fibrillation associated with increased risk of venous thromboembolism. A population-based cohort study. Thromb Haemost. 2015;113:185&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">25318828</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundboll J., Hovath-Puho E., Adelborg K., et al. Risk of arterial and venous thromboembolism in patients with atrial fibrillation or flutter: a nationwide population-based cohort study. Int J Cardiol. 2017;241:182&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">28473169</ArticleId></ArticleIdList></Reference><Reference><Citation>Noel P., Gregoire F., Capon A., Lehert P. Atrial fibrillation as a risk factor for deep venous thrombosis and pulmonary emboli in stroke patients. Stroke. 1991;22:760&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">2057976</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutsey P.L., Norby F.L., Alonso A., et al. Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the Atherosclerosis Risk in Communities Study. J&#xa0;Thromb Haemost. 2018;16:670&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893387</ArticleId><ArticleId IdType="pubmed">29431904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen H.T., Horvath-Puho E., Lash T.L., et al. Heart disease may be a risk factor for pulmonary embolism without peripheral deep venous thrombosis. Circulation. 2011;124:1435&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900083</ArticleId></ArticleIdList></Reference><Reference><Citation>Enga K.F., Rye-Holmboe I., Hald E.M., et al. Atrial fibrillation and future risk of venous thromboembolism: the Tromso study. J&#xa0;Thromb Haemost. 2015;13:10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">25330989</ArticleId></ArticleIdList></Reference><Reference><Citation>Friberg L., Svennberg E. A&#xa0;diagnosis of atrial fibrillation is not a predictor for pulmonary embolism. Thromb Res. 2020;195:238&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32799131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornestam B., Adiels M., Wai Giang K., Hansson P.O., Bjorck L., Rosengren A. Atrial fibrillation and risk of venous thromboembolism: a Swedish Nationwide Registry Study. Europace. 2021;23:1913&#x2013;1921.</Citation><ArticleIdList><ArticleId IdType="pubmed">34279622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassand J.P., Virdone S., Goldhaber S.Z., et al. Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation. Circulation. 2019;139:787&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">30586740</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose A.J., Hylek E.M., Ozonoff A., Ash A.S., Reisman J.I., Berlowitz D.R. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA) J&#xa0;Thromb Haemost. 2010;8:2182&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pubmed">20653840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutsey P.L., Norby F.L., Zakai N.A., et al. Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients. Curr Med Res Opin. 2019;35:837&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6449182</ArticleId><ArticleId IdType="pubmed">30362847</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobsen C.B., Lamberts M., Carlson N., et al. Incidence of atrial fibrillation in different major cancer subtypes: a nationwide population-based 12 year follow up study. BMC Cancer. 2019;19:1105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6854796</ArticleId><ArticleId IdType="pubmed">31726997</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Tong Y., Deng Y., Zou L., Li S., Chen H. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis. J&#xa0;Am Heart Assoc. 2019;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6662149</ArticleId><ArticleId IdType="pubmed">31310583</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg B.A., Kim S., Fonarow G.C., et al. Drivers of hospitalization for patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) Am Heart J. 2014;167:735&#x2013;742 e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4006943</ArticleId><ArticleId IdType="pubmed">24766985</ArticleId></ArticleIdList></Reference><Reference><Citation>Saliba W., Rennert G. CHA2DS2-VASc score is directly associated with the risk of pulmonary embolism in patients with atrial fibrillation. Am J Med. 2014;127:45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">24384101</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Nunez N., Ruano-Ravina A., Lama A., et al. Impact of cardiovascular risk factors on the clinical presentation and survival of pulmonary embolism without identifiable risk factor. J&#xa0;Thorac Dis. 2020;12:5411&#x2013;5419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7656446</ArticleId><ArticleId IdType="pubmed">33209374</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai A.W., Cushman M., Rosamond W.D., Heckbert S.R., Polak J.F., Folsom A.R. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162:1182&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020191</ArticleId></ArticleIdList></Reference><Reference><Citation>Ageno W., Becattini C., Brighton T., Selby R., Kamphuisen P.W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117:93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">18086925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding W.Y., Gupta D., Lip G.Y.H. Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020. Heart. 2020;106:1463&#x2013;1468.</Citation><ArticleIdList><ArticleId IdType="pubmed">32675218</ArticleId></ArticleIdList></Reference><Reference><Citation>Li-Saw-Hee F.L., Blann A.D., Gurney D., Lip G.Y. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J. 2001;22:1741&#x2013;1747.</Citation><ArticleIdList><ArticleId IdType="pubmed">11511124</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastori D., Pignatelli P., Farcomeni A., et al. Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. Am Heart J. 2015;170:490&#x2013;497.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">26385032</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuchi M., Watanabe J., Kumagai K., et al. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J&#xa0;Am Coll Cardiol. 2001;37:1436&#x2013;1442.</Citation><ArticleIdList><ArticleId IdType="pubmed">11300458</ArticleId></ArticleIdList></Reference><Reference><Citation>Akar J.G., Jeske W., Wilber D.J. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J&#xa0;Am Coll Cardiol. 2008;51:1790&#x2013;1793.</Citation><ArticleIdList><ArticleId IdType="pubmed">18452786</ArticleId></ArticleIdList></Reference><Reference><Citation>Romiti G.F., Pastori D., Rivera-Caravaca J.M., et al. Adherence to the 'atrial fibrillation better care' pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost. 2021;122(3):406&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">34020488</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao T.F., Joung B., Takahashi Y., et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary. Thromb Haemost. 2022;122:20&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8763451</ArticleId><ArticleId IdType="pubmed">34773920</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34349191</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>04</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Deep learning for pulmonary embolism detection on computed tomography pulmonary angiogram: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>15814</StartPage><MedlinePgn>15814</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15814</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-95249-3</ELocationID><Abstract><AbstractText>Computed tomographic pulmonary angiography (CTPA) is the gold standard for pulmonary embolism (PE) diagnosis. However, this diagnosis is susceptible to misdiagnosis. In this study, we aimed to perform a systematic review of current literature applying deep learning for the diagnosis of PE on CTPA. MEDLINE/PUBMED were searched for studies that reported on the accuracy of deep learning algorithms for PE on CTPA. The risk of bias was evaluated using the QUADAS-2 tool. Pooled sensitivity and specificity were calculated. Summary receiver operating characteristic curves were plotted. Seven studies met our inclusion criteria. A total of 36,847 CTPA studies were analyzed. All studies were retrospective. Five studies provided enough data to calculate summary estimates. The pooled sensitivity and specificity for PE detection were 0.88 (95% CI 0.803-0.927) and 0.86 (95% CI 0.756-0.924), respectively. Most studies had a high risk of bias. Our study suggests that deep learning models can detect PE on CTPA with satisfactory sensitivity and an acceptable number of false positive cases. Yet, these are only preliminary retrospective works, indicating the need for future research to determine the clinical impact of automated PE detection on patient care. Deep learning models are gradually being implemented in hospital systems, and it is important to understand the strengths and limitations of these algorithms.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soffer</LastName><ForeName>Shelly</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Internal Medicine B, Assuta Medical Center, Samson Assuta Ashdod University Hospital, Ashdod, Israel. soffer.shelly@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ben-Gurion University of the Negev, Be'er Sheva, Israel. soffer.shelly@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deep Vision Lab, The Chaim Sheba Medical Center, Ramat Gan, Israel. soffer.shelly@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klang</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Deep Vision Lab, The Chaim Sheba Medical Center, Ramat Gan, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Science and Policy, Institute for Healthcare Delivery Science, Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sheba Talpiot Medical Leadership Program, Tel Hashomer, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimon</LastName><ForeName>Orit</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barash</LastName><ForeName>Yiftach</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Deep Vision Lab, The Chaim Sheba Medical Center, Ramat Gan, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahan</LastName><ForeName>Noa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Faculty of Engineering, Tel-Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenspana</LastName><ForeName>Hayit</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Faculty of Engineering, Tel-Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Konen</LastName><ForeName>Eli</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000072226" MajorTopicYN="N">Computed Tomography Angiography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077321" MajorTopicYN="Y">Deep Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>8</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34349191</ArticleId><ArticleId IdType="pmc">PMC8338977</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-95249-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-95249-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Becattini C, Vedovati MC, Agnelli G. Diagnosis and prognosis of acute pulmonary embolism: Focus on serum troponins. Expert Rev. Mol. Diagn. 2008;8:339&#x2013;349. doi: 10.1586/14737159.8.3.339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737159.8.3.339</ArticleId><ArticleId IdType="pubmed">18598112</ArticleId></ArticleIdList></Reference><Reference><Citation>Javed QA, Sista AK. Endovascular therapy for acute severe pulmonary embolism. Int. J. Cardiovasc. Imaging. 2019;35:1443&#x2013;1452. doi: 10.1007/s10554-019-01567-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-019-01567-z</ArticleId><ArticleId IdType="pubmed">30877411</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnelli G, Becattini C. Acute pulmonary embolism. N. Engl. J. Med. 2010;363:266&#x2013;274. doi: 10.1056/NEJMra0907731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra0907731</ArticleId><ArticleId IdType="pubmed">20592294</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DR, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: A randomized controlled trial. JAMA. 2007;298:2743&#x2013;2753. doi: 10.1001/jama.298.23.2743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.298.23.2743</ArticleId><ArticleId IdType="pubmed">18165667</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoepf U, Costello P. Spiral computed tomography is the first-line chest imaging test for acute pulmonary embolism: Yes. J. Thromb. Haemost. 2005;3:7&#x2013;10. doi: 10.1111/j.1538-7836.2004.01142.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2004.01142.x</ArticleId><ArticleId IdType="pubmed">15634258</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoepf UJ. Diagnosing pulmonary embolism: Time to rewrite the textbooks. Int. J. Cardiovasc. Imaging. 2005;21:155&#x2013;163. doi: 10.1007/s10554-004-5345-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10554-004-5345-7</ArticleId><ArticleId IdType="pubmed">15915948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittram C, et al. CT angiography of pulmonary embolism: Diagnostic criteria and causes of misdiagnosis. Radiographics. 2004;24:1219&#x2013;1238. doi: 10.1148/rg.245045008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/rg.245045008</ArticleId><ArticleId IdType="pubmed">15371604</ArticleId></ArticleIdList></Reference><Reference><Citation>Rufener SL, Patel S, Kazerooni EA, Schipper M, Kelly AM. Comparison of on-call radiology resident and faculty interpretation of 4-and 16-row multidetector CT pulmonary angiography with indirect CT venography. Acad. Radiol. 2008;15:71&#x2013;76. doi: 10.1016/j.acra.2007.06.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acra.2007.06.030</ArticleId><ArticleId IdType="pubmed">18078909</ArticleId></ArticleIdList></Reference><Reference><Citation>Soffer S, et al. Convolutional neural networks for radiologic images: A radiologist&#x2019;s guide. Radiology. 2019;290:590&#x2013;606. doi: 10.1148/radiol.2018180547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2018180547</ArticleId><ArticleId IdType="pubmed">30694159</ArticleId></ArticleIdList></Reference><Reference><Citation>Klang E. Deep learning and medical imaging. J. Thorac. Dis. 2018;10:1325&#x2013;1328. doi: 10.21037/jtd.2018.02.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2018.02.76</ArticleId><ArticleId IdType="pmc">PMC5906243</ArticleId><ArticleId IdType="pubmed">29708147</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan MI, Mitchell TM. Machine learning: Trends, perspectives, and prospects. Science. 2015;349:255&#x2013;260. doi: 10.1126/science.aaa8415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa8415</ArticleId><ArticleId IdType="pubmed">26185243</ArticleId></ArticleIdList></Reference><Reference><Citation>Arel I, Rose DC, Karnowski TP. Deep machine learning-a new frontier in artificial intelligence research. IEEE Comput. Intell. Mag. 2010;5:13&#x2013;18. doi: 10.1109/MCI.2010.938364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/MCI.2010.938364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinton GE, Salakhutdinov RR. Reducing the dimensionality of data with neural networks. Science. 2006;313:504&#x2013;507. doi: 10.1126/science.1127647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1127647</ArticleId><ArticleId IdType="pubmed">16873662</ArticleId></ArticleIdList></Reference><Reference><Citation>Russakovsky O, et al. Imagenet large scale visual recognition challenge. Int. J. Comput. Vision. 2015;115:211&#x2013;252. doi: 10.1007/s11263-015-0816-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11263-015-0816-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Krizhevsky A, Sutskever I, Hinton GE. Imagenet classification with deep convolutional neural networks. Adv. Neural Inf. Process Syst. 2012;25:1097&#x2013;1105.</Citation></Reference><Reference><Citation>Ma J, et al. Survey on deep learning for pulmonary medical imaging. Front. Med. 2019 doi: 10.1007/s11684-019-0726-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-019-0726-4</ArticleId><ArticleId IdType="pubmed">31840200</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann. Intern. Med. 2009;151:264&#x2013;269. doi: 10.7326/0003-4819-151-4-200908180-00135.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-151-4-200908180-00135</ArticleId><ArticleId IdType="pubmed">19622511</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting PF, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 2011;155:529&#x2013;536. doi: 10.7326/0003-4819-155-8-201110180-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-155-8-201110180-00009</ArticleId><ArticleId IdType="pubmed">22007046</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong MT, Colopy GW, Weber AM, Ercole A, Bergmann JH. The efficacy and effectiveness of machine learning for weaning in mechanically ventilated patients at the intensive care unit: A systematic review. Bio-Design Manuf. 2019;2:31&#x2013;40. doi: 10.1007/s42242-018-0030-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42242-018-0030-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Soffer S, et al. Deep learning for wireless capsule endoscopy: A systematic review and meta-analysis. Gastrointest. Endosc. 2020;92(4):831&#x2013;839. doi: 10.1016/j.gie.2020.04.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2020.04.039</ArticleId><ArticleId IdType="pubmed">32334015</ArticleId></ArticleIdList></Reference><Reference><Citation>Doebler P, Holling H. Meta-analysis of diagnostic accuracy with mada. R Packag. 2015;1:15.</Citation><ArticleIdList><ArticleId IdType="pubmed">25361619</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyaga, V., Arbyn, M. &amp; Aerts, M. METAPROP: Stata Module to Perform Fixed and Random Effects Meta-analysis of Proportions (2017).</Citation></Reference><Reference><Citation>Reitsma JB, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J. Clin. Epidemiol. 2005;58:982&#x2013;990. doi: 10.1016/j.jclinepi.2005.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2005.02.022</ArticleId><ArticleId IdType="pubmed">16168343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JP, Patsopoulos NA, Evangelou E. Uncertainty in heterogeneity estimates in meta-analyses. BMJ. 2007;335:914&#x2013;916. doi: 10.1136/bmj.39343.408449.80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39343.408449.80</ArticleId><ArticleId IdType="pmc">PMC2048840</ArticleId><ArticleId IdType="pubmed">17974687</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajbakhsh, N., Gotway, M. B. &amp; Liang, J. Computer-aided pulmonary embolism detection using a novel vessel-aligned multi-planar image representation and convolutional neural networks. In International Conference on Medical Image Computing and Computer-Assisted Intervention 62&#x2013;69 (Springer, 2015).</Citation></Reference><Reference><Citation>Tajbakhsh N, Shin JY, Gotway MB, Liang J. Computer-aided detection and visualization of pulmonary embolism using a novel, compact, and discriminative image representation. Med. Image Anal. 2019 doi: 10.1016/j.media.2019.101541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.media.2019.101541</ArticleId><ArticleId IdType="pmc">PMC6815717</ArticleId><ArticleId IdType="pubmed">31416007</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang SC, et al. PENet&#x2014;A scalable deep-learning model for automated diagnosis of pulmonary embolism using volumetric CT imaging. npj Digit. Med. 2020 doi: 10.1038/s41746-020-0266-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-0266-y</ArticleId><ArticleId IdType="pmc">PMC7181770</ArticleId><ArticleId IdType="pubmed">32352039</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S-C, Pareek A, Zamanian R, Banerjee I, Lungren MP. Multimodal fusion with deep neural networks for leveraging CT imaging and electronic health record: A case-study in pulmonary embolism detection. Sci. Rep. 2020;10:1&#x2013;9. doi: 10.1038/s41598-019-56847-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-56847-4</ArticleId><ArticleId IdType="pmc">PMC7746687</ArticleId><ArticleId IdType="pubmed">33335111</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, et al. Evaluation of acute pulmonary embolism and clot burden on CTPA with deep learning. Eur. Radiol. 2020;30:3567&#x2013;3575. doi: 10.1007/s00330-020-06699-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-020-06699-8</ArticleId><ArticleId IdType="pubmed">32064559</ArticleId></ArticleIdList></Reference><Reference><Citation>Weikert T, et al. Automated detection of pulmonary embolism in CT pulmonary angiograms using an AI-powered algorithm. Eur. Radiol. 2020;30:6545&#x2013;6553. doi: 10.1007/s00330-020-06998-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-020-06998-0</ArticleId><ArticleId IdType="pubmed">32621243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kligerman SJ, et al. Radiologist performance in the detection of pulmonary embolism. J. Thorac. Imaging. 2018;33:350&#x2013;357. doi: 10.1097/RTI.0000000000000361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RTI.0000000000000361</ArticleId><ArticleId IdType="pubmed">30142136</ArticleId></ArticleIdList></Reference><Reference><Citation>Das M, et al. Computer-aided detection of pulmonary embolism: Influence on radiologists&#x2019; detection performance with respect to vessel segments. Eur. Radiol. 2008;18:1350&#x2013;1355. doi: 10.1007/s00330-008-0889-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-008-0889-x</ArticleId><ArticleId IdType="pubmed">18292998</ArticleId></ArticleIdList></Reference><Reference><Citation>Eng J, et al. Accuracy of CT in the diagnosis of pulmonary embolism: A systematic literature review. Am. J. Roentgenol. 2004;183:1819&#x2013;1827. doi: 10.2214/ajr.183.6.01831819.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/ajr.183.6.01831819</ArticleId><ArticleId IdType="pubmed">15547236</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitka M. Joint commission warns of alarm fatigue: Multitude of alarms from monitoring devices problematic. JAMA. 2013;309:2315&#x2013;2316. doi: 10.1001/jama.2013.6032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.6032</ArticleId><ArticleId IdType="pubmed">23757063</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;zkan H, Osman O, &#x15e;ahin S, Boz AF. A novel method for pulmonary embolism detection in CTA images. Comput. Methods Programs Biomed. 2014;113:757&#x2013;766. doi: 10.1016/j.cmpb.2013.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2013.12.014</ArticleId><ArticleId IdType="pubmed">24440133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiji K, Kligerman S, Jeudy J, White C. Improved accuracy of pulmonary embolism computer-aided detection using iterative reconstruction compared with filtered back projection. Am. J. Roentgenol. 2014;203:763&#x2013;771. doi: 10.2214/AJR.13.11838.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.13.11838</ArticleId><ArticleId IdType="pubmed">25247942</ArticleId></ArticleIdList></Reference><Reference><Citation>Kligerman SJ, Lahiji K, Galvin JR, Stokum C, White CS. Missed pulmonary emboli on CT angiography: Assessment with pulmonary embolism&#x2013;computer-aided detection. Am. J. Roentgenol. 2014;202:65&#x2013;73. doi: 10.2214/AJR.13.11049.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/AJR.13.11049</ArticleId><ArticleId IdType="pubmed">24370130</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittenberg R, et al. Acute pulmonary embolism: Effect of a computer-assisted detection prototype on diagnosis&#x2014;An observer study. Radiology. 2012;262:305&#x2013;313. doi: 10.1148/radiol.11110372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.11110372</ArticleId><ArticleId IdType="pubmed">22190659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, et al. Evaluation of computer-aided detection and dual energy software in detection of peripheral pulmonary embolism on dual-energy pulmonary CT angiography. Eur. Radiol. 2011;21:54&#x2013;62. doi: 10.1007/s00330-010-1903-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-010-1903-7</ArticleId><ArticleId IdType="pubmed">20680290</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittenberg R, et al. Stand-alone performance of a computer-assisted detection prototype for detection of acute pulmonary embolism: A multi-institutional comparison. Br. J. Radiol. 2012;85:758&#x2013;764. doi: 10.1259/bjr/26769569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1259/bjr/26769569</ArticleId><ArticleId IdType="pmc">PMC3474087</ArticleId><ArticleId IdType="pubmed">22167514</ArticleId></ArticleIdList></Reference><Reference><Citation>Colak, E. et al. The RSNA pulmonary embolism CT (RSPECT) dataset. Radiol. Artif. Intell. e200254 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043364</ArticleId><ArticleId IdType="pubmed">33937862</ArticleId></ArticleIdList></Reference><Reference><Citation>aidoc. Pulmonary Embolism Guidelines and the Intersection with AI, https://www.aidoc.com/blog/pulmonary-embolism-guidelines-and-the-intersection-with-ai/ (2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36939472</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-1489</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of intensive care medicine</Title><ISOAbbreviation>J Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Prophylactic Inferior Vena Cava Filters for Venous Thromboembolism in Adults With Trauma: An Updated Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>491</StartPage><EndPage>510</EndPage><MedlinePgn>491-510</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/08850666231163141</ELocationID><Abstract><AbstractText><b>Background:</b> Trauma is an independent risk factor for venous thromboembolism (VTE). Due to contraindications or delay in starting pharmacological prophylaxis among trauma patients with a high risk of bleeding, the inferior vena cava (IVC) filter has been utilized as alternative prevention for pulmonary embolism (PE). Albeit, its clinical efficacy has remained uncertain. Therefore, we performed an updated systematic review and meta-analysis on the effectiveness and safety of prophylactic IVC filters in severely injured patients. <b>Methods:</b> Three databases (MEDLINE, EMBASE, and Cochrane) were searched from August 1, 2012, to October 27, 2021. Independent reviewers performed data extraction and quality assessment. Relative risk (RR) at 95% confidence interval (CI) pooled in a randomized meta-analysis. A parallel clinical practice guideline committee assessed the certainty of evidence using the GRADE approach. The outcomes of interest included VTE, PE, deep venous thrombosis, mortality, and IVC filter complications. <b>Results:</b> We included 10 controlled studies (47&#x2005;140 patients), of which 3 studies (310 patients) were randomized controlled trials (RCTs) and 7 were observational studies (46&#x2005;830 patients). IVC filters demonstrated no significant reduction in PE and fatal PE (RR, 0.27; 95% CI, 0.06-1.28 and RR, 0.32; 95% CI, 0.01-7.84, respectively) by pooling RCTs with low certainty. However, it demonstrated a significant reduction in the risk of PE and fatal PE (RR, 0.25; 95% CI, 0.12-0.55 and RR, 0.09; 95% CI, 0.011-0.81, respectively) by pooling observational studies with very low certainty. IVC filter did not improve mortality in both RCTs and observational studies (RR, 1.44; 95% CI, 0.86-2.43 and RR, 0.63; 95% CI, 0.3-1.31, respectively). <b>Conclusion:</b> In trauma patients, moderate risk reduction of PE and fatal PE was demonstrated among observational data but not RCTs. The desirable effect is not robust to outweigh the undesirable effects associated with IVC filter complications. Current evidence suggests against routinely using prophylactic IVC filters.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alshaqaq</LastName><ForeName>Hassan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Emergency Medicine Department, King Saud Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Sharydah</LastName><ForeName>Abdulaziz M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-6590-5850</Identifier><AffiliationInfo><Affiliation>Diagnostic and Interventional Radiology Department, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation><Identifier Source="RINGGOLD">48023</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshahrani</LastName><ForeName>Mohammed S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation><Identifier Source="RINGGOLD">48023</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alqahtani</LastName><ForeName>Saad M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Orthopedics surgery, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation><Identifier Source="RINGGOLD">48102</Identifier><Identifier Source="RINGGOLD">48023</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amer</LastName><ForeName>Marwa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9497-1451</Identifier><AffiliationInfo><Affiliation>Medical/Critical Pharmacy Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</Affiliation><Identifier Source="RINGGOLD">37852</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation><Identifier Source="RINGGOLD">101686</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Intensive Care Med</MedlineTA><NlmUniqueID>8610344</NlmUniqueID><ISSNLinking>0885-0666</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016306" MajorTopicYN="Y">Vena Cava Filters</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">inferior vena cava filters</Keyword><Keyword MajorTopicYN="N">prophylaxis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">trauma</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>20</Day><Hour>10</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36939472</ArticleId><ArticleId IdType="doi">10.1177/08850666231163141</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38213352</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Risk Factors for Pulmonary Complications After Major Oral and Maxillofacial Surgery With Free Flap Reconstruction.</ArticleTitle><Pagination><StartPage>e50408</StartPage><MedlinePgn>e50408</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e50408</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.50408</ELocationID><Abstract><AbstractText>Background Postoperative pulmonary complications (PPCs) are common and result in increased morbidity and mortality. A variable incidence of PPCs has been reported in patients who have undergone major oral and maxillofacial surgery with free flap reconstruction, which is one of the most extensive forms of head and neck cancer surgery, and perioperative risk factors for PPCs in these patients have not been fully elucidated. Furthermore, the ARISCAT (Assess Respiratory Risk in Surgical Patients in Catalonia) score and Gupta risk index have not been investigated in patients undergoing head and neck cancer surgery. This study aimed to identify perioperative risk factors for PPCs after major oral and maxillofacial surgery with free flap reconstruction. Methodology This was a single-center, retrospective cohort study of 118 patients who had undergone major oral and maxillofacial surgery with free flap reconstruction between 2009 and 2020. PPCs were defined as pneumonia, hypoxemia caused by atelectasis, pleural effusion, pulmonary embolism, pulmonary edema, bronchospasm, pneumothorax, and acute respiratory failure. Predictors of PPCs were identified in univariate and multiple Poisson regression analyses. Results The incidence of PPCs was 18.6% (22/118 patients). The most frequent PPC was pneumonia. No preoperative patient-related parameter was identified to predict PPCs. In univariate analysis, the only predictor was anesthesia time &#x2265;1,140 minutes (odds ratio = 3.0, p = 0.036). Multivariable Poisson regression identified two independent predictors of PPCs, namely, anesthesia time &#x2265;1,140 minutes (incidence rate ratio (IRR) = 2.18, 95% confidence interval (CI) = 1.1-4.3, p = 0.024) and a large amount of intraoperative fluid (IRR = 1.00018, 95% CI = 1.000018-1.000587, p = 0.037). Conclusions Patients undergoing major oral and maxillofacial surgery with free flap reconstruction are at high risk of PPCs. Longer anesthesia time and administering a large amount of fluid during surgery were significantly correlated with the risk of PPCs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023, NItta et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>NItta</LastName><ForeName>Yukie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Dental Anesthesiology, Department of Oral Pathological Science, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Sapporo, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Preventive Dentistry, Department of Oral Health Science, Graduate School of Dental Medicine, Hokkaido University, Sapporo, JPN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kido</LastName><ForeName>Kanta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Dental Anesthesiology, Department of Oral Pathological Science, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Sapporo, JPN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anesthesia time</Keyword><Keyword MajorTopicYN="N">free flap reconstruction</Keyword><Keyword MajorTopicYN="N">oral and maxillofacial surgery</Keyword><Keyword MajorTopicYN="N">postoperative pulmonary complications</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>12</Day><Hour>3</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38213352</ArticleId><ArticleId IdType="pmc">PMC10783958</ArticleId><ArticleId IdType="doi">10.7759/cureus.50408</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Perioperative risk factors for postoperative pulmonary complications after major oral and maxillofacial surgery with microvascular reconstruction: a retrospective analysis of 648 cases. Loeffelbein DJ, Julinek A, Wolff KD, Kochs E, Haller B, Haseneder R. J Craniomaxillofac Surg. 2016;44:952&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">27259678</ArticleId></ArticleIdList></Reference><Reference><Citation>Prospective external validation of a predictive score for postoperative pulmonary complications. Mazo V, Sabat&#xe9; S, Canet J, et al. Anesthesiology. 2014;121:219&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">24901240</ArticleId></ArticleIdList></Reference><Reference><Citation>Perioperative interventions for prevention of postoperative pulmonary complications: systematic review and meta-analysis. Odor PM, Bampoe S, Gilhooly D, Creagh-Brown B, Moonesinghe SR. BMJ. 2020;368:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190038</ArticleId><ArticleId IdType="pubmed">32161042</ArticleId></ArticleIdList></Reference><Reference><Citation>An improved predictive model for postoperative pulmonary complications after free flap reconstructions in the head and neck. Smith DK, Freundlich RE, Shinn JR, Wood CB, Rohde SL, McEvoy MD. Head Neck. 2021;43:2178&#x2013;2184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8197740</ArticleId><ArticleId IdType="pubmed">33783905</ArticleId></ArticleIdList></Reference><Reference><Citation>Preoperative pulmonary evaluation. Costescu F, Slinger P. Curr Anesthesiol Rep. 2018;8:52&#x2013;58.</Citation></Reference><Reference><Citation>Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. The National Veterans Administration Surgical Quality Improvement Program. Arozullah AM, Daley J, Henderson WG, Khuri SF. Ann Surg. 2000;232:242&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1421137</ArticleId><ArticleId IdType="pubmed">10903604</ArticleId></ArticleIdList></Reference><Reference><Citation>Adult respiratory distress syndrome after microvascular free tissue reconstruction in head and neck malignancy. Logan SW, Rogers SN, Richardson D, Vaughan ED, Brown JS. Br J Oral Maxillofac Surg. 1998;36:371&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">9831058</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary complications after major head and neck surgery: a retrospective cohort study. Petrar S, Bartlett C, Hart RD, MacDougall P. Laryngoscope. 2012;122:1057&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">22447296</ArticleId></ArticleIdList></Reference><Reference><Citation>Postoperative pulmonary complications following major head and neck cancer surgery. Shaw LM, Iseli TA, Wiesenfeld D, Ramakrishnan A, Granger CL. Int J Oral Maxillofac Surg. 2021;50:302&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">32682644</ArticleId></ArticleIdList></Reference><Reference><Citation>Development and validation of a risk calculator predicting postoperative respiratory failure. Gupta H, Gupta PK, Fang X, Miller WJ, Cemaj S, Forse RA, Morrow LE. Chest. 2011;140:1207&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">21757571</ArticleId></ArticleIdList></Reference><Reference><Citation>Existing predictive models for postoperative pulmonary complications perform poorly in a head and neck surgery population. Wood CB, Shinn JR, Rees AB, et al. J Med Syst. 2019;43:312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800103</ArticleId><ArticleId IdType="pubmed">31451999</ArticleId></ArticleIdList></Reference><Reference><Citation>Incidence, outcome, and risk factors for postoperative pulmonary complications in head and neck cancer surgery patients with free flap reconstructions. Damian D, Esquenazi J, Duvvuri U, Johnson JT, Sakai T. J Clin Anesth. 2016;28:12&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">26796608</ArticleId></ArticleIdList></Reference><Reference><Citation>What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. Zhang J, Yu KF. JAMA. 1998;280:1690&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pubmed">9832001</ArticleId></ArticleIdList></Reference><Reference><Citation>APACHE II, POSSUM, and ASA scores and the risk of perioperative complications in patients with oral or oropharyngeal cancer. de C&#xe1;ssia Braga Ribeiro K, Kowalski LP. Arch Otolaryngol Head Neck Surg. 2003;129:739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">12874075</ArticleId></ArticleIdList></Reference><Reference><Citation>Identifying risk factors for postoperative cardiovascular and respiratory complications after major oral cancer surgery. Dillon JK, Liu SY, Patel CM, Schmidt BL. Head Neck. 2011;33:112&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">20578073</ArticleId></ArticleIdList></Reference><Reference><Citation>Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. Smetana GW, Lawrence VA, Cornell JE. Ann Intern Med. 2006;144:581&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">16618956</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonwound infections following head and neck oncologic surgery. Weber RS, Hankins P, Rosenbaum B, Raad I. Laryngoscope. 1993;103:22&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">8421415</ArticleId></ArticleIdList></Reference><Reference><Citation>Pneumonia in patients who require prolonged mechanical ventilation. Rumbak MJ. Microbes Infect. 2005;7:275&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">15715988</ArticleId></ArticleIdList></Reference><Reference><Citation>Atelectasis and perioperative pulmonary complications in high-risk patients. Tusman G, B&#xf6;hm SH, Warner DO, Sprung J. Curr Opin Anaesthesiol. 2012;25:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">22113182</ArticleId></ArticleIdList></Reference><Reference><Citation>Immediate postoperative extubation in patients undergoing free tissue transfer. Allak A, Nguyen TN, Shonka DC Jr, Reibel JF, Levine PA, Jameson MJ. Laryngoscope. 2011;121:763&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">21433018</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35691358</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1026</ISSN><JournalIssue CitedMedium="Internet"><Volume>838</Volume><Issue>Pt 4</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>The Science of the total environment</Title><ISOAbbreviation>Sci Total Environ</ISOAbbreviation></Journal><ArticleTitle>Impact of high altitude on the incidence of postoperative venous thromboembolism and its genetic susceptibility: A meta-analysis and systematic review.</ArticleTitle><Pagination><StartPage>156632</StartPage><MedlinePgn>156632</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.scitotenv.2022.156632</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0048-9697(22)03729-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The effect of high-altitude (HA) on venous thromboembolism (VTE) and its mechanism remains ambiguous. To clarify this, we aimed to conduct a meta-analysis and systematic review to evaluate the incidence of VTE at HA and comparatively low altitude (LA) and figure out the intrinsic risk factors such as susceptibility genes of patients with VTE at HA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We selected studies that explored the risk factors for HA and VTE by searching PubMed, Embase, and Web of Science to analyze the impact of HA on VTE. All relevant studies before August 2021 were screened using the terms ([high altitude] OR [plateau] OR [mountain]) AND ([venous thromboembolism] OR [deep vein thrombosis] OR [pulmonary embolism]). Latest studies on the gene of HA-VTE patients were also summarized and analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifteen studies were eventually assessed, and the overall numbers of subjects with and without VTE were 1475 and 286,926 respectively. The overall incidence of VTE, deep vein thrombosis (DVT) and pulmonary embolism (PE) in the HA group was significantly higher than that in the LA group (P &lt; 0.01). The overall incidence of VTE, DVT and PE in the HA group was significantly higher than that in the LA group at 30 days post operation (P &lt; 0.05, P &lt; 0.05 and P &lt; 0.01, respectively). At 90 days post operation, incidence of VTE and PE in the HA group was higher than that in the LA group (P &lt; 0.01and P &lt; 0.01, respectively), but there was no difference in the incidence of DVT (P = 0.07). Regarding endogenous factors, the analysis of genes in patients with HA-VTE revealed numerous targeted genes such as ANG, ACE, lncRNA-LINC00 659/UXT-AS1 and GP4.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We observed a significant association between HA and the overall incidence of VTE and that at 30/90 days post operation, indicating that HA may be a risk factor for VTE.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Haihong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, The General Hospital of Western Theater Command, Chengdu 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Guan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pain, The General Hospital of Western Theater Command, Chengdu 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Meiling</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, The General Hospital of Western Theater Command, Chengdu 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The General Hospital of Western Theater Command, Chengdu 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Shengdong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The General Hospital of Western Theater Command, Chengdu 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qiwu</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The General Hospital of Western Theater Command, Chengdu 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The General Hospital of Western Theater Command, Chengdu 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The General Hospital of Western Theater Command, Chengdu 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jianping</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, The General Hospital of Western Theater Command, Chengdu 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The General Hospital of Western Theater Command, Chengdu 610083, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yongxiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, The General Hospital of Western Theater Command, Chengdu 610083, China. Electronic address: yangyongxiang2014@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Siyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, The General Hospital of Western Theater Command, Chengdu 610083, China. Electronic address: hesiyi@vip.163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Sci Total Environ</MedlineTA><NlmUniqueID>0330500</NlmUniqueID><ISSNLinking>0048-9697</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C118920">UXT protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000531" MajorTopicYN="N">Altitude</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">High altitude</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Low altitude</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>12</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35691358</ArticleId><ArticleId IdType="doi">10.1016/j.scitotenv.2022.156632</ArticleId><ArticleId IdType="pii">S0048-9697(22)03729-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38582200</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1615-5947</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of vascular surgery</Title><ISOAbbreviation>Ann Vasc Surg</ISOAbbreviation></Journal><ArticleTitle>Prognostic Value of Neutrophil/Lymphocyte Ratio for Pulmonary Embolism: A Meta-Analysis and External Validation.</ArticleTitle><Pagination><StartPage>48</StartPage><EndPage>59</EndPage><MedlinePgn>48-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.avsg.2024.01.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0890-5096(24)00134-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prognostic value of neutrophil/lymphocyte ratio (NLR) for pulmonary embolism (PE) has been reported in several retrospective studies. The purpose of this investigation was to perform a pooled analysis and external validation of predictive value of NLR.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, Embase, and Cochrane databases were searched from inception to November 5, 2022. A random effects model was used. Grade was used to evaluate the certainty of evidence. External validation was conducted in clinical cohorts before and after a propensity scoring matching (PSM). Covariates include basic clinical characteristics, such as age, gender, etc. The value of NLR in prediction model was also evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 15 studies comprising 5,874 patients were included. Pooled risk ratio of NLR was 2.33 (95% confidence interval [CI]: 1.97-2.75), with an area under the curve of 0.78 (95% CI: 0.74-0.81), a sensitivity of 0.75 (95% CI: 0.71-0.79), a specificity of 0.67 (95% CI: 0.61-0.73), and a median cut-off value of 5.7. Grade of Recommendations Assessment Development and Evaluation (GRADE) certainty analysis showed the quality of the evidence was moderate. Before (n&#xa0;=&#xa0;336) and after (n&#xa0;=&#xa0;152) propensity scoring matching, risk ratio of NLR was 2.69 (95% CI: 1.04-6.97) and 6.58 (95% CI: 1.99-17.75). A prediction model consisting of NLR, age, D-dimer, and simplified PE severity index had an area under the curve of 0.809 (95% CI: 0.738-0.88), a sensitivity of 0.638 (95% CI: 0.511-0.745), and a specificity of 0.851 (95% CI: 0.709-0.917). Net reclassification index (12%, P&#xa0;=&#xa0;0.035) and integrated discrimination improvement (17%, P&#xa0;=&#xa0;0.022) indicated an improvement caused by NLR.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prognostic value of NLR for PE was confirmed by meta-analysis and validated in an independent cohort, deserving further clinical application.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruihua</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Vascular Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Shuohao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Vascular Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jianjun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Vascular Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China. Electronic address: jiangjianjun1995@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Vascular Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China. Electronic address: liuyang_sdu@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Ann Vasc Surg</MedlineTA><NlmUniqueID>8703941</NlmUniqueID><ISSNLinking>0890-5096</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="Y">Neutrophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="Y">Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="Y">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>21</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>7</Day><Hour>3</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>6</Day><Hour>19</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38582200</ArticleId><ArticleId IdType="doi">10.1016/j.avsg.2024.01.019</ArticleId><ArticleId IdType="pii">S0890-5096(24)00134-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25980400</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-3231</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>9</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Arthroscopy : the journal of arthroscopic &amp; related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association</Title><ISOAbbreviation>Arthroscopy</ISOAbbreviation></Journal><ArticleTitle>The Incidence of Complications of Tibial Tubercle Osteotomy: A Systematic Review.</ArticleTitle><Pagination><StartPage>1819</StartPage><EndPage>1825</EndPage><MedlinePgn>1819-25</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arthro.2015.03.028</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0749-8063(15)00255-8</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The goal of this review was to quantify the risk of perioperative and early postoperative complications of tibial tubercle osteotomy (TTO) with different techniques.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review of multiple databases was performed to identify studies that reported complications of TTO. Complications were defined as any adverse outcome, including osteotomy site nonunion, fracture, infection, wound complications, neurovascular complications, deep vein thrombosis (DVT), and pulmonary embolism (PE). Major complications were defined as nonunion, fracture, infections/wound complications requiring return to the operating room, and DVT or PE. The risk of subsequent hardware removal was also quantified.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 19 identified studies included a total of 787 TTOs: 472 direct medialization procedures (Elmslie-Trillat technique), 193 anteromedialization procedures (Fulkerson technique), and 102 procedures in which the tibial tubercle was completely detached for medialization or distalization, or a combination. The overall complication risk was 4.6%. The risk of complications was higher when the tibial tubercle was completely detached (10.7%) than with Elmslie-Trillat (3.3%) or Fulkerson (3.7%) procedures (P = .004). The overall risk of major complications was 3.0%. Hardware removal was performed in 36.7% of osteotomies and was less frequent with the Elmslie-Trillat technique (26.8%) than with the Fulkerson technique (49.0%) or complete tubercle detachment (48.3%) (P &lt; .001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Tibial tubercle osteotomy is a complex surgical procedure with a significant risk of complications. Osteotomies that involve complete detachment of the tubercle have an increased risk of complications compared with those in which a distal cortical hinge is maintained.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Level IV, systematic review of Level IV studies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Payne</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, The Ohio State University, Columbus, Ohio, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rimmke</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, The Ohio State University, Columbus, Ohio, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>School of Health and Rehabilitation Sciences, The Ohio State University, Columbus, Ohio, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanigan</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, The Ohio State University, Columbus, Ohio, U.S.A.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magnussen</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, The Ohio State University, Columbus, Ohio, U.S.A.. Electronic address: robert.magnussen@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arthroscopy</MedlineTA><NlmUniqueID>8506498</NlmUniqueID><ISSNLinking>0749-8063</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arthroscopy. 2015 Sep;31(9):1826. doi: 10.1016/j.arthro.2015.06.045.</RefSource><PMID Version="1">26354200</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007719" MajorTopicYN="N">Knee Joint</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010027" MajorTopicYN="N">Osteotomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013977" MajorTopicYN="N">Tibia</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25980400</ArticleId><ArticleId IdType="doi">10.1016/j.arthro.2015.03.028</ArticleId><ArticleId IdType="pii">S0749-8063(15)00255-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31790756</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-1570</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><PubDate><Year>2020</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Resuscitation</Title><ISOAbbreviation>Resuscitation</ISOAbbreviation></Journal><ArticleTitle>Outcomes of extracorporeal life support for the treatment of acute massive pulmonary embolism: A systematic review.</ArticleTitle><Pagination><StartPage>132</StartPage><EndPage>137</EndPage><MedlinePgn>132-137</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.resuscitation.2019.11.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0300-9572(19)30709-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Massive pulmonary embolism (PE) can cause hemodynamic instability leading to high mortality. Extracorporeal life support (ECLS) has been increasingly used as a bridge to definitive therapy. This systematic review investigates the outcomes of ECLS for the treatment of massive PE.</AbstractText><AbstractText Label="METHODS">Electronic search was performed to identify all relevant studies published on ECLS use in patients with PE. 50 case series or reports were selected comprising 128 patients with acute massive PE who required ECLS. Patient-level data were extracted for statistical analysis.</AbstractText><AbstractText Label="RESULTS">Median patient age was 50 [36, 63]&#x202f;years and 41.3% (50/121) were male. 67.2% (86/128) of patients presented with cardiac arrest. Median heart rate was 126 [118, 135] and median systolic pulmonary artery pressure (sPAP) was 55 [48, 69]&#x202f;mmHg. The majority of ECLS included veno-arterial ECLS [97.1% (99/102)]. Median ECLS time was 3 [2, 6]&#x202f;days. 43.0% (55/128) patients received systemic thrombolysis, 22.7% (29/128), received catheter-guided thrombolysis, and 37.5% (48/128) underwent surgical embolectomy. 85.1% (97/114) were weaned off ECLS. Post-ECLS complications included bleeding in 23.4% (30/128), acute renal failure in 8.6% (11/128), dialysis in 6.3% (8/128), heparin-induced thrombocytopenia in 3.1 (4/128), and extremity hypoperfusion in 2.3% (3/128). The most common cause of death was shock at 30.3% (10/33). The median length of hospital stay was 22 [11, 39]&#x202f;days including 8 [5, 13] intensive care unit (ICU) days. The 30-day mortality rate was 22% (20/91).</AbstractText><AbstractText Label="CONCLUSIONS">ECLS is safe and effective therapy in unstable patients with acute massive pulmonary embolism and offers acceptable outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jae Hwan</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maynes</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Chelsey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Antonio</LastName><ForeName>Nicholas D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellado</LastName><ForeName>Mart&#xed;n</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Facultad de Medicina de la Universidad de Chile, Av. Independencia 1027, Independencia, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Frances M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Division of Critical Care/Pulmonary/Allergy/Immunology, Thomas Jefferson University, 834 Walnut Street Suite 650, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galanis</LastName><ForeName>Taki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, Thomas Jefferson Vascular Center, Thomas Jefferson University, 111 S 11th Street, Gibbon Building Suite 6210, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonsalves</LastName><ForeName>Carin F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Division of Vascular and Interventional Radiology, Thomas Jefferson University, 111 S 11th St, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marhefka</LastName><ForeName>Gregary D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Thomas Jefferson University, 925 Chestnut St, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awsare</LastName><ForeName>Bharat K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Division of Critical Care/Pulmonary/Allergy/Immunology, Thomas Jefferson University, 834 Walnut Street Suite 650, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merli</LastName><ForeName>Geno J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Thomas Jefferson Vascular Center, Thomas Jefferson University, 111 S 11th Street, Gibbon Building Suite 6210, Philadelphia, PA 19107, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tchantchaleishvili</LastName><ForeName>Vakhtang</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA 19107, USA. Electronic address: Vakhtang.Tchantchaleishvili@jefferson.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Resuscitation</MedlineTA><NlmUniqueID>0332173</NlmUniqueID><ISSNLinking>0300-9572</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008020" MajorTopicYN="N">Life Support Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31790756</ArticleId><ArticleId IdType="doi">10.1016/j.resuscitation.2019.11.018</ArticleId><ArticleId IdType="pii">S0300-9572(19)30709-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25189450</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1432-2323</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>World journal of surgery</Title><ISOAbbreviation>World J Surg</ISOAbbreviation></Journal><ArticleTitle>Incidence of venous thromboembolism and its pharmacological prophylaxis in Asian general surgery patients: a systematic review.</ArticleTitle><Pagination><StartPage>150</StartPage><EndPage>157</EndPage><MedlinePgn>150-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00268-014-2763-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Venous thromboembolism (VTE) is a condition that has always been perceived to be rare in Asia. The aim of this systematic review was to gather the current available evidence on the incidence of VTE in this population. A secondary aim was to assess the efficacy of pharmacological prophylaxis, and hence determine its role, in the Asian population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive literature search was performed using MEDLINE, Embase, and the Cochrane Database of Systematic Reviews in June 2014. Articles found using search terms related to venous thromboembolism (VTE), Asian countries and general surgery procedures and pathologies were screened using the following inclusion criteria: (1) either the population studied was primarily Asian or the study was conducted in an Asian country, (2) the subjects studied underwent a major gastrointestinal or other general surgery procedure, (3) the primary outcome was the incidence of deep vein thrombosis (DVT) or pulmonary embolus (PE), and (4) secondary outcomes assessed included mortality and complications due to the VTE or prophylaxis against VTE.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fourteen publications with a total of 11,218 patients were analyzed. Nine of the fourteen were observational studies, with half being prospective in nature. There were five interventional studies of which two were randomized controlled trials. Among the observational studies, the median (range) incidence of above-knee DVT was 0.08 % (0-2.9 %), while the median (range) incidence of PE was 0.18 % (0-0.58 %). The rates of DVT in the control groups were reported to be between 0 and 7.4 %, while the incidence of PE in the control groups ranged from 0 to 1.9 %. Analysis of the comparative studies revealed that the incidence of bleeding-related complications varied from 0 to 18.1 % in the low-molecular-weight heparin (LMWH) group compared to 0-7.5 % in the control group. The difference in minor bleeding complications between the LMWH group and the control group was found to be statistically significant.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Data from this systematic review suggest that the risk of VTE in Asian general surgery patients is low, even in the context of risk factors typically regarded as high risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yeo</LastName><ForeName>Danson X W</ForeName><Initials>DX</Initials><AffiliationInfo><Affiliation>Hepatic, Pancreatic and Biliary (HPB) Surgery Unit, Department of General Surgery, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore, dansonis@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junnarkar</LastName><ForeName>Sameer</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Balasubramaniam</LastName><ForeName>Sunder</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Yen Pin</ForeName><Initials>YP</Initials></Author><Author ValidYN="Y"><LastName>Low</LastName><ForeName>Jee Keem</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Woon</LastName><ForeName>Winston</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Tony Chun Yeung</ForeName><Initials>TC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Surg</MedlineTA><NlmUniqueID>7704052</NlmUniqueID><ISSNLinking>0364-2313</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>World J Surg. 2016 Jul;40(7):1788-9. doi: 10.1007/s00268-015-3273-4.</RefSource><PMID Version="1">26464151</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001208" MajorTopicYN="N" Type="Geographic">Asia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013514" MajorTopicYN="N">Surgical Procedures, Operative</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25189450</ArticleId><ArticleId IdType="doi">10.1007/s00268-014-2763-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ann Surg Treat Res. 2014 Jan;86(1):22-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24761403</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2001 Jan;119(1 Suppl):132S-175S</Citation><ArticleIdList><ArticleId IdType="pubmed">11157647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg. 2010 Feb;251(2):344-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19779324</ArticleId></ArticleIdList></Reference><Reference><Citation>Dis Colon Rectum. 1999 Feb;42(2):196-202; discussion 202-3</Citation><ArticleIdList><ArticleId IdType="pubmed">10211496</ArticleId></ArticleIdList></Reference><Reference><Citation>ANZ J Surg. 2001 Nov;71(11):637-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11736821</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Angiol. 2012 Dec;31(6):501-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23222928</ArticleId></ArticleIdList></Reference><Reference><Citation>Singapore Med J. 1968 Dec;9(4):276-9</Citation><ArticleIdList><ArticleId IdType="pubmed">5728867</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2010 Mar;8(3):540-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20040044</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Angiol. 2001 Mar;20(1):1-37</Citation><ArticleIdList><ArticleId IdType="pubmed">11342993</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2005 Jan;3(1):28-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15634263</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Crit Care Med. 2012 Apr;16(2):71-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22988360</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Jul 21;339:b2535</Citation><ArticleIdList><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Gastroenterol. 2008 Mar-Apr;27(2):71-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18695308</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Surg. 2011 Apr;35(4):881-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21264469</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Apr 17;8(4):e61968</Citation><ArticleIdList><ArticleId IdType="pubmed">23613988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Surg Oncol. 2010 Sep;17(9):2363-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20358302</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Angiol. 2012 Dec;31(6):526-33</Citation><ArticleIdList><ArticleId IdType="pubmed">23222930</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2012 Feb;141(2 Suppl):e227S-e277S</Citation><ArticleIdList><ArticleId IdType="pubmed">22315263</ArticleId></ArticleIdList></Reference><Reference><Citation>Malays J Med Sci. 2004 Jan;11(1):75-80</Citation><ArticleIdList><ArticleId IdType="pubmed">22977363</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Thromb Hemost. 1991;17 Suppl 3:304-12</Citation><ArticleIdList><ArticleId IdType="pubmed">1754886</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Surg. 2008 Apr;31(2):63-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18490217</ArticleId></ArticleIdList></Reference><Reference><Citation>Surg Today. 2004;34(10):805-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15449147</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Surg. 2001 Jul;88(7):913-30</Citation><ArticleIdList><ArticleId IdType="pubmed">11442521</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2006 Mar;4(3):581-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16460440</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin Med J (Engl). 2010 Aug 5;123(15):1973-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20819527</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromb Haemost. 2011 Dec;106(6):1084-94</Citation><ArticleIdList><ArticleId IdType="pubmed">22072215</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2003 Jan;24(2):151-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12573272</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39662114</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2653</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</Title><ISOAbbreviation>J Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>A systematic review and meta-analysis on the impact of early vs. delayed pharmacological thromboprophylaxis in patients with traumatic brain injury.</ArticleTitle><Pagination><StartPage>110936</StartPage><MedlinePgn>110936</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jocn.2024.110936</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0967-5868(24)00475-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Traumatic brain injury (TBI) poses significant health challenges, often leading to complications such as venous thromboembolism (VTE) and increased mortality rates. The administration of early post-traumatic prophylaxis (PTP) is intended to mitigate these risks and enhance overall patient recovery. This study aims to perform a systematic review and meta-analysis assessing clinical outcomes associated with early versus late pharmacologic thromboprophylaxis in TBI patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a literature search across PubMed and Scopus databases from their inception to March 2024. Data from eligible studies were aggregated using the generic inverse variance method, with outcomes reported as odds ratios (OR).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The review encompassed 20 studies involving 87,726 patients. Early PTP was categorized based on the timing of administration: 1) within 24&#xa0;h, 2) within 48&#xa0;h, and 3) within 72&#xa0;h of hospital admission. Our findings indicated that early prophylaxis significantly reduced the incidence of VTE, deep vein thrombosis (DVT), pulmonary embolism (PE), and overall mortality when compared to late administration. Specifically, early PTP was associated with a markedly lower risk of VTE (OR: 0.38; 95&#xa0;% CI: 0.30 to 0.48; P&#xa0;&lt;&#xa0;0.00001), DVT (OR: 0.32; 95&#xa0;% CI: 0.25 to 0.41; P&#xa0;&lt;&#xa0;0.00001), and PE (OR: 0.39; 95&#xa0;% CI: 0.31 to 0.49; P&#xa0;&lt;&#xa0;0.00001). Furthermore, the analysis revealed a significant reduction in all-cause mortality within the early PTP group (OR: 0.71; 95&#xa0;% CI: 0.53 to 0.97; P&#xa0;=&#xa0;0.03). However, while statistically significant improvements were observed in the &lt;48-hour subgroup, neither the &lt;24-hour nor &lt;72-hour groups achieved statistical significance.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These robust findings highlight the potential of early pharmacologic thromboprophylaxis as a crucial intervention to enhance patient outcomes following traumatic brain injuries.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shuja</LastName><ForeName>Muhammad Hamza</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasir</LastName><ForeName>Muhammad Moiz</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mushahid</LastName><ForeName>Hasan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Adam Bilal</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Javed</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nursing Department Communicable Diseases Center Hamad Medical Corporation, Doha, Qatar. Electronic address: jiqbal3@hamad.qa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jawaid</LastName><ForeName>Afia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhan</LastName><ForeName>Syed Husain</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latif</LastName><ForeName>Fakhar</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayyan</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Mayo Hospital, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farooq</LastName><ForeName>Minaam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Jawad</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haq Ansari</LastName><ForeName>Huzaifa Ul</ForeName><Initials>HU</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Unzela</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>RWJBH/Trinitas Regional Medical Center, Elizabeth, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansoor</LastName><ForeName>Sobia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, NYMC Landmark Medical Center, Rhode Island, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhan</LastName><ForeName>Syed Ali</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Surgery, Ohio State University, Columbus, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mubariz</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Akhtar Saeed Medical College, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Clin Neurosci</MedlineTA><NlmUniqueID>9433352</NlmUniqueID><ISSNLinking>0967-5868</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="Y">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Early prophylaxis</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Pharmacologic thromboprophylaxis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Traumatic brain injury</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>27</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>12</Month><Day>12</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>12</Month><Day>11</Day><Hour>18</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39662114</ArticleId><ArticleId IdType="doi">10.1016/j.jocn.2024.110936</ArticleId><ArticleId IdType="pii">S0967-5868(24)00475-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35487534</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1399-3003</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The European respiratory journal</Title><ISOAbbreviation>Eur Respir J</ISOAbbreviation></Journal><ArticleTitle>Optimal reperfusion strategy in acute high-risk pulmonary embolism requiring extracorporeal membrane oxygenation support: a systematic review and meta-analysis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2102977</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1183/13993003.02977-2021</ELocationID><Abstract><AbstractText Label="BACKGROUND">The optimal pulmonary revascularisation strategy in high-risk pulmonary embolism (PE) requiring implantation of extracorporeal membrane oxygenation (ECMO) remains controversial.</AbstractText><AbstractText Label="METHODS">We conducted a systematic review and meta-analysis of evidence comparing mechanical embolectomy and other strategies, including systemic thrombolysis, catheter-directed thrombolysis or ECMO as stand-alone therapy, with regard to mortality and bleeding outcomes.</AbstractText><AbstractText Label="RESULTS">We identified 835 studies, 17 of which were included, comprising 327 PE patients. Overall, 32.4% were treated with mechanical pulmonary reperfusion (of whom 85.9% had surgical embolectomy), while 67.6% received other strategies. The mortality rate was 22.6% in the mechanical reperfusion group and 42.8% in the "other strategies" group. The pooled odds ratio for mortality with mechanical reperfusion was 0.439 (95% CI 0.237-0.816) (p=0.009; I<sup>2</sup>=35.2%) <i>versus</i> other reperfusion strategies and 0.368 (95% CI 0.185-0.733) (p=0.004; I<sup>2</sup>=32.9%) for surgical embolectomy <i>versus</i> thrombolysis. The rate of bleeding in patients under ECMO was 22.2% in the mechanical reperfusion group and 19.1% in the "other strategies" group (OR 1.27, 95% CI 0.54-2.96; I<sup>2</sup>=7.7%). The meta-regression model did not identify any relationship between the covariates "more than one pulmonary reperfusion therapy", "ECMO implantation before pulmonary reperfusion therapy", "clinical presentation of PE" or "cancer-associated PE" and the associated outcomes.</AbstractText><AbstractText Label="CONCLUSIONS">The results of the present meta-analysis and meta-regression suggest that mechanical reperfusion, notably by surgical embolectomy, may yield favourable results regardless of the timing of ECMO implantation in the reperfusion timeline, independent of thrombolysis administration or cardiac arrest presentation.</AbstractText><CopyrightInformation>Copyright &#xa9;The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chopard</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dept of Cardiology, University Hospital Jean Minjoz, Besan&#xe7;on, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EA3920, University of Burgundy Franche-Comt&#xe9;, Besan&#xe7;on, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>F-CRIN, INNOVTE Network, Saint Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dept of Cardiology, Aalborg University Hospital, Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>These two authors contributed equally.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ius</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dept of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>These two authors contributed equally.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cebotari</LastName><ForeName>Serghei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dept of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ecarnot</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dept of Cardiology, University Hospital Jean Minjoz, Besan&#xe7;on, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EA3920, University of Burgundy Franche-Comt&#xe9;, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilichowski</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dept of Cardiology, University Hospital Jean Minjoz, Besan&#xe7;on, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM, UMRS_1166-ICAN, Institute of Cardiometabolism and Nutrition, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de M&#xe9;decine Intensive-R&#xe9;animation, Institut de Cardiologie, AP-HP Sorbonne Universit&#xe9; H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kjaergaard</LastName><ForeName>Benedict</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Dept of Cardiothoracic Surgery, Aalborg University Hospital, Hobrovej, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sousa-Casasnovas</LastName><ForeName>Iago</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Dept of Cardiology, General University Hospital Gregorio Maranon, Complutense University, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghoreishi</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narayan</LastName><ForeName>Rajeev L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Nuvance Health - Vassar Brothers Medical Center, Poughkeepsie, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Hackensack University Medical Center, Rutgers New Jersey Medical School, Newark, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Su Nam</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Dept of Internal Medicine, St Vincent's Hospital, The Catholic University of Korea, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piazza</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Dept of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meneveau</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Dept of Cardiology, University Hospital Jean Minjoz, Besan&#xe7;on, France nicolas.meneveau@univ-fcomte.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EA3920, University of Burgundy Franche-Comt&#xe9;, Besan&#xe7;on, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>F-CRIN, INNOVTE Network, Saint Etienne, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Respir J</MedlineTA><NlmUniqueID>8803460</NlmUniqueID><ISSNLinking>0903-1936</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017128" MajorTopicYN="N">Embolectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015424" MajorTopicYN="N">Reperfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest: G. Piazza has received research grant support from Bristol Myers Squibb/Pfizer Alliance, Janssen, Boston Scientific Corporation, Amgen and Bayer, and consulting fees from Amgen, Agile, Pfizer, and the Prairie Education and Research Cooperative. No other author has any conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>20</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35487534</ArticleId><ArticleId IdType="doi">10.1183/13993003.02977-2021</ArticleId><ArticleId IdType="pii">13993003.02977-2021</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38204918</PMID><DateRevised><Year>2024</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-5484</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><PubDate><Year>2024</Year><Month>Mar</Month></PubDate></JournalIssue><Title>North American Spine Society journal</Title><ISOAbbreviation>N Am Spine Soc J</ISOAbbreviation></Journal><ArticleTitle>Chemical prophylaxis and venous thromboembolism following elective spinal surgery: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>100295</StartPage><MedlinePgn>100295</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100295</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xnsj.2023.100295</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially devastating complication after surgery. Spine surgery is associated with an increased risk of postoperative bleeding, such as spinal epidural hematomas (SEH), which complicates the use of anticoagulation. Despite this dilemma, there is a lack of consensus around perioperative VTE prophylaxis. This systematic review investigates the relationship between chemoprophylaxis and the incidence rates of VTE and SEH in the elective spine surgical population.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A comprehensive literature search was performed using PubMed, Embase, and Cochrane databases to identify studies published after 2,000 that compared VTE chemoprophylaxis use in elective spine surgery. Studies involving patients aged &lt; 18 years or with known trauma, cancer, or spinal cord injuries were excluded. Pooled incidence rates of VTE and SEH were calculated for all eligible studies, and meta-analyses were performed to assess the relationship between chemoprophylaxis and the incidences of VTE and SEH.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Nineteen studies met our eligibility criteria, comprising a total of 220,932 patients. The overall pooled incidence of VTE was 3.2%, including 3.3% for DVT and 0.4% for PE. A comparison of VTE incidence between patients that did and did not receive chemoprophylaxis was not statistically significant (OR 0.97, p=.95, 95% CI 0.43-2.19). The overall pooled incidence of SEH was 0.4%, and there was also no significant difference between patients that did and did not receive chemoprophylaxis (OR 1.57, p=.06, 95% CI 0.99-2.50).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">The use of perioperative chemoprophylaxis may not significantly alter rates of VTE or SEH in the elective spine surgery population. This review highlights the need for additional randomized controlled trials to better define the risks and benefits of specific chemoprophylactic protocols in various subpopulations of elective spine surgery.</AbstractText><CopyrightInformation>&#xa9; 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rahmani</LastName><ForeName>Roman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Mercy Health St. Vincent Medical Center, Department of Orthopedics, 2409 Cherry St, Suite #10, Toledo, OH 43608, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eaddy</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mercy Health St. Vincent Medical Center, Department of Orthopedics, 2409 Cherry St, Suite #10, Toledo, OH 43608, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stegelmann</LastName><ForeName>Samuel D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>HCA Medical City Healthcare UNT-TCU GME (Denton), 3535 S Interstate 35, Denton, TX 76210, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skrobot</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Mercy Health St. Vincent Medical Center, Department of Orthopedics, 2409 Cherry St, Suite #10, Toledo, OH 43608, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreshak</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mercy Health St. Vincent Medical Center, Department of Orthopedics, 2409 Cherry St, Suite #10, Toledo, OH 43608, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Am Spine Soc J</MedlineTA><NlmUniqueID>9918335076906676</NlmUniqueID><ISSNLinking>2666-5484</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anticoagulation</Keyword><Keyword MajorTopicYN="N">Chemoprophylaxis</Keyword><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Elective</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Spinal epidural hematoma</Keyword><Keyword MajorTopicYN="N">Spine surgery</Keyword><Keyword MajorTopicYN="N">Thromboprophylaxis</Keyword><Keyword MajorTopicYN="N">Thrombosis</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>7</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>11</Day><Hour>4</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38204918</ArticleId><ArticleId IdType="pmc">PMC10777073</ArticleId><ArticleId IdType="doi">10.1016/j.xnsj.2023.100295</ArticleId><ArticleId IdType="pii">S2666-5484(23)00097-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mosenthal WP, Landy DC, Boyajian HH, et al. Thromboprophylaxis in spinal surgery. Spine (Phila Pa 1976) 2018;43(8):E474&#x2013;E481. doi: 10.1097/BRS.0000000000002379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0000000000002379</ArticleId><ArticleId IdType="pubmed">28820759</ArticleId></ArticleIdList></Reference><Reference><Citation>Senders ZJ, Zussman BM, Maltenfort MG, Sharan AD, Ratliff JK, Harrop JS. The incidence of pulmonary embolism (PE) after spinal fusions. Clin Neurol Neurosurg. 2012;114(7):897&#x2013;901. doi: 10.1016/j.clineuro.2012.01.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2012.01.044</ArticleId><ArticleId IdType="pubmed">22386262</ArticleId></ArticleIdList></Reference><Reference><Citation>Glotzbecker MP, Bono CM, Wood KB, Harris MB. Thromboembolic disease in spinal surgery: a systematic review. Spine (Phila Pa 1976) 2009;34(3):291&#x2013;303. doi: 10.1097/BRS.0b013e318195601d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0b013e318195601d</ArticleId><ArticleId IdType="pubmed">19179925</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon L, Rodriguez H, Tawk RG, Ondra SL, Labropoulos N, Morasch MD. The prophylactic use of inferior vena cava filters in patients undergoing high-risk spinal surgery. Ann Vasc Surg. 2005;19(3):442&#x2013;447. doi: 10.1007/s10016-005-0025-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10016-005-0025-1</ArticleId><ArticleId IdType="pubmed">15864473</ArticleId></ArticleIdList></Reference><Reference><Citation>Sansone JM, del Rio AM, Anderson PA. The prevalence of and specific risk factors for venous thromboembolic disease following elective spine surgery. J Bone Joint Surg Am. 2010;92(2):304&#x2013;313. doi: 10.2106/JBJS.H.01815.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.H.01815</ArticleId><ArticleId IdType="pubmed">20124056</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S&#x2013;e277S. doi: 10.1378/chest.11-2297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2297</ArticleId><ArticleId IdType="pmc">PMC3278061</ArticleId><ArticleId IdType="pubmed">22315263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellenbogen Y, Power RG, Martyniuk A, Engels PT, Sharma SV, Kasper EM. Pharmacoprophylaxis for venous thromboembolism in spinal surgery: a systematic review and meta-analysis. World Neurosurg. 2021;150:e144&#x2013;e154. doi: 10.1016/j.wneu.2021.02.120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2021.02.120</ArticleId><ArticleId IdType="pubmed">33684581</ArticleId></ArticleIdList></Reference><Reference><Citation>Glotzbecker MP, Bono CM, Wood KB, Harris MB. Postoperative spinal epidural hematoma: a systematic review. Spine (Phila Pa 1976) 2010;35(10):E413&#x2013;E420. doi: 10.1097/BRS.0b013e3181d9bb77.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0b013e3181d9bb77</ArticleId><ArticleId IdType="pubmed">20431474</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimenti P, Molinari R. Postoperative spinal epidural hematoma causing American Spinal Injury Association B spinal cord injury in patients with suction wound drains. J Spinal Cord Med. 2013;36(3):213&#x2013;219. doi: 10.1179/2045772312Y.0000000070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/2045772312Y.0000000070</ArticleId><ArticleId IdType="pmc">PMC3654447</ArticleId><ArticleId IdType="pubmed">23809591</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeeb N, Hattab T, Savardekar A, et al. Venous thromboembolism prophylaxis in elective neurosurgery: a survey of board-certified neurosurgeons in the United States and updated literature review. World Neurosurg. 2021;150:e631&#x2013;e638. doi: 10.1016/j.wneu.2021.03.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2021.03.072</ArticleId><ArticleId IdType="pubmed">33757886</ArticleId></ArticleIdList></Reference><Reference><Citation>Bono CM, Watters WC, 3rd, Heggeness MH, et al. An evidence-based clinical guideline for the use of antithrombotic therapies in spine surgery. Spine J. 2009;9(12):1046&#x2013;1051. doi: 10.1016/j.spinee.2009.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spinee.2009.09.005</ArticleId><ArticleId IdType="pubmed">19931184</ArticleId></ArticleIdList></Reference><Reference><Citation>Colomina MJ, Bago J, Perez-Bracchiglione J, et al. Thromboprophylaxis in elective spinal surgery: a protocol for systematic review. Medicine (Baltimore) 2020;99(21):e20127. doi: 10.1097/MD.0000000000020127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000020127</ArticleId><ArticleId IdType="pmc">PMC7249943</ArticleId><ArticleId IdType="pubmed">32481281</ArticleId></ArticleIdList></Reference><Reference><Citation>Du W, Zhao C, Wang J, Liu J, Shen B, Zheng Y. Comparison of rivaroxaban and parnaparin for preventing venous thromboembolism after lumbar spine surgery. J Orthop Surg Res. 2015;10:78. doi: 10.1186/s13018-015-0223-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-015-0223-7</ArticleId><ArticleId IdType="pmc">PMC4455337</ArticleId><ArticleId IdType="pubmed">25998624</ArticleId></ArticleIdList></Reference><Reference><Citation>McLynn RP, Diaz-Collado PJ, Ottesen TD, et al. Risk factors and pharmacologic prophylaxis for venous thromboembolism in elective spine surgery. Spine J. 2018;18(6):970&#x2013;978. doi: 10.1016/j.spinee.2017.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spinee.2017.10.013</ArticleId><ArticleId IdType="pubmed">29056565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox JB, Weaver KJ, Neal DW, Jacob RP, Hoh DJ. Decreased incidence of venous thromboembolism after spine surgery with early multimodal prophylaxis: clinical article. J Neurosurg Spine. 2014;21(4):677&#x2013;684. doi: 10.3171/2014.6.SPINE13447.</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2014.6.SPINE13447</ArticleId><ArticleId IdType="pubmed">25105337</ArticleId></ArticleIdList></Reference><Reference><Citation>Pateder DB, Gonzales RA, Kebaish KM, et al. Pulmonary embolism after adult spinal deformity surgery. Spine (Phila Pa 1976) 2008;33(3):301&#x2013;305. doi: 10.1097/BRS.0b013e31816245e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0b013e31816245e1</ArticleId><ArticleId IdType="pubmed">18303463</ArticleId></ArticleIdList></Reference><Reference><Citation>Karande GY, Hedgire SS, Sanchez Y, et al. Advanced imaging in acute and chronic deep vein thrombosis. Cardiovasc Diagn Ther. 2016;6(6):493&#x2013;507. doi: 10.21037/cdt.2016.12.06.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/cdt.2016.12.06</ArticleId><ArticleId IdType="pmc">PMC5220209</ArticleId><ArticleId IdType="pubmed">28123971</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19&#x2013;25. doi: 10.1016/j.amjmed.2004.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2004.01.018</ArticleId><ArticleId IdType="pubmed">15210384</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GA, Shea B, O'Connell D, et&#xa0;al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed February 15, 2023, https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.</Citation></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022;18(2):e1230. doi: 10.1002/cl2.1230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cl2.1230</ArticleId><ArticleId IdType="pmc">PMC8958186</ArticleId><ArticleId IdType="pubmed">36911350</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicol M, Sun Y, Craig N, Wardlaw D. Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients. Eur Spine J. 2009;18(10):1548&#x2013;1552. doi: 10.1007/s00586-009-1035-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00586-009-1035-4</ArticleId><ArticleId IdType="pmc">PMC2899370</ArticleId><ArticleId IdType="pubmed">19484271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham JE, Swamy G, Thomas KC. Does preoperative DVT chemoprophylaxis in spinal surgery affect the incidence of thromboembolic complications and spinal epidural hematomas? J Spinal Disord Tech. 2011;24(4):E31&#x2013;E34. doi: 10.1097/BSD.0b013e3181f605ea.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BSD.0b013e3181f605ea</ArticleId><ArticleId IdType="pubmed">20975599</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SD, Liu H, Sun YP, et al. Prevalence and risk factors of deep vein thrombosis in patients after spine surgery: a retrospective case-cohort study. Sci Rep. 2015;5:11834. doi: 10.1038/srep11834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep11834</ArticleId><ArticleId IdType="pmc">PMC4488742</ArticleId><ArticleId IdType="pubmed">26135271</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamidi S, Riazi M. Incidence of venous thromboembolic complications in instrumental spinal surgeries with preoperative chemoprophylaxis. J Korean Neurosurg Soc. 2015;57(2):114&#x2013;118. doi: 10.3340/jkns.2015.57.2.114.</Citation><ArticleIdList><ArticleId IdType="doi">10.3340/jkns.2015.57.2.114</ArticleId><ArticleId IdType="pmc">PMC4345188</ArticleId><ArticleId IdType="pubmed">25733992</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber B, Seal A, McGirr J, Fielding K. Case series of elective instrumented posterior lumbar spinal fusions demonstrating a low incidence of venous thromboembolism. ANZ J Surg. 2016;86(10):796&#x2013;800. doi: 10.1111/ans.12702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.12702</ArticleId><ArticleId IdType="pubmed">24897952</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawi HMT, Saba K, Cunningham A, et al. Venous thromboembolism in adult elective spinal surgery: a tertiary centre review of 2181 patients. Bone Joint J. 2017;99-B(9):1204&#x2013;1209. doi: 10.1302/0301-620X.99B9.BJJ-2016-1193.R2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.99B9.BJJ-2016-1193.R2</ArticleId><ArticleId IdType="pubmed">28860401</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro JA, Stillwagon MR, Padovano AG, Moll S, Lim MR. An evidence-based algorithm for determining venous thromboembolism prophylaxis after degenerative spinal surgery. Int J Spine Surg. 2020;14(4):599&#x2013;606. doi: 10.14444/7080.</Citation><ArticleIdList><ArticleId IdType="doi">10.14444/7080</ArticleId><ArticleId IdType="pmc">PMC7478019</ArticleId><ArticleId IdType="pubmed">32986584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiguchi MM, Schobel H, TenEyck E, et al. The risks and benefits of early venous thromboembolism prophylaxis after elective spinal surgery: a single-centre experience. J Perioper Pract. 2022;32(11):286&#x2013;294. doi: 10.1177/17504589211002070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17504589211002070</ArticleId><ArticleId IdType="pubmed">34301162</ArticleId></ArticleIdList></Reference><Reference><Citation>Thota DR, Bagley CA, Tamimi MA, Nakonezny PA, Van Hal M. Anticoagulation in elective spine cases: rates of hematomas versus thromboembolic disease. Spine (Phila Pa 1976) 2021;46(13):901&#x2013;906. doi: 10.1097/BRS.0000000000003935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0000000000003935</ArticleId><ArticleId IdType="pubmed">34100843</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Jiao G, Li J, et al. Combined use of tranexamic acid and rivaroxaban in posterior/transforaminal lumbar interbody fusion surgeries safely reduces blood loss and incidence of thrombosis: evidence from a prospective, randomized, double-blind, placebo-controlled study. Global Spine J. 2023;13(5):1229&#x2013;1237. doi: 10.1177/21925682211024556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21925682211024556</ArticleId><ArticleId IdType="pmc">PMC10416579</ArticleId><ArticleId IdType="pubmed">34569334</ArticleId></ArticleIdList></Reference><Reference><Citation>Macki M, Haddad Y, Suryadevara R, et al. Prophylactic low-molecular-weight heparin versus unfractionated heparin in spine surgery (PLUSS): a pilot matched cohort study. Neurosurgery. 2021;89(6):1097&#x2013;1103. doi: 10.1093/neuros/nyab363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuros/nyab363</ArticleId><ArticleId IdType="pubmed">34634115</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikouei F, Chehrassan M, Shakeri M, et al. Effect of aspirin in preventing deep vein thrombosis (DVT) after lumbar canal spinal stenosis surgeries: a double-blind parallel randomized clinical trial. Curr Orthop Pract. 2022;33(6):543&#x2013;547. doi: 10.1097/BCO.0000000000001169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCO.0000000000001169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloney MB, Hopkins B, Dhillon E, El Tecle N, Koski TR, Dahdaleh NS. Chemoprophylactic anticoagulation following lumbar surgery significantly reduces thromboembolic events after instrumented fusions, not decompressions. Spine (Phila Pa 1976) 2023;48(3):172&#x2013;179. doi: 10.1097/BRS.0000000000004489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0000000000004489</ArticleId><ArticleId IdType="pubmed">36191060</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiasconaro M, Poeran J, Liu J, Wilson LA, Memtsoudis SG. Venous thromboembolism and prophylaxis therapy after elective spine surgery: a population-based study. Can J Anaesth. 2021;68(3):345&#x2013;357. doi: 10.1007/s12630-020-01859-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12630-020-01859-2</ArticleId><ArticleId IdType="pubmed">33210220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirkle S, Cook DJ, Kaskovich S, et al. Comparing Bleeding and thrombotic rates in spine surgery: an analysis of 119,888 patients. Global Spine J. 2021;11(2):161&#x2013;166. doi: 10.1177/2192568219896295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2192568219896295</ArticleId><ArticleId IdType="pmc">PMC7882830</ArticleId><ArticleId IdType="pubmed">32875853</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Li Y, Liu D, et al. Combined use of tranexamic acid and rivaroxaban in posterior lumbar interbody fusion safely reduces blood loss and transfusion rates without increasing the risk of thrombosis-a prospective, stratified, randomized, controlled trial. Int Orthop. 2020;44(10):2079&#x2013;2087. doi: 10.1007/s00264-020-04699-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00264-020-04699-3</ArticleId><ArticleId IdType="pubmed">32676780</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourman MS, Shaw JD, Nwasike CO, et al. Use of fondaparinux following elective lumbar spine surgery is associated with a reduction in symptomatic venous thromboembolism. Global Spine J. 2020;10(7):844&#x2013;850. doi: 10.1177/2192568219878418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2192568219878418</ArticleId><ArticleId IdType="pmc">PMC7485070</ArticleId><ArticleId IdType="pubmed">32905722</ArticleId></ArticleIdList></Reference><Reference><Citation>Zervos TM, Bazydlo M, Tundo K, Macki M, Rock J. Risk factors associated with symptomatic deep vein thrombosis following elective spine surgery: a case-control study. World Neurosurg. 2020;144:e460&#x2013;e465. doi: 10.1016/j.wneu.2020.08.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2020.08.182</ArticleId><ArticleId IdType="pubmed">32889183</ArticleId></ArticleIdList></Reference><Reference><Citation>Glotzbecker MP, Bono CM, Harris MB, Brick G, Heary RF, Wood KB. Surgeon practices regarding postoperative thromboembolic prophylaxis after high-risk spinal surgery. Spine (Phila Pa 1976) 2008;33(26):2915&#x2013;2921. doi: 10.1097/BRS.0b013e318190702a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BRS.0b013e318190702a</ArticleId><ArticleId IdType="pubmed">19092624</ArticleId></ArticleIdList></Reference><Reference><Citation>Louie P, Harada G, Harrop J, et al. Perioperative anticoagulation management in spine surgery: initial findings from the AO spine anticoagulation global survey. Global Spine J. 2020;10(5):512&#x2013;527. doi: 10.1177/2192568219897598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2192568219897598</ArticleId><ArticleId IdType="pmc">PMC7359688</ArticleId><ArticleId IdType="pubmed">32677576</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster JM, Fischer D, Dettori JR. Is chemical antithrombotic prophylaxis effective in elective thoracolumbar spine surgery? results of a systematic review. Evid Based Spine Care J. 2010;1(2):40&#x2013;45. doi: 10.1055/s-0028-1100913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0028-1100913</ArticleId><ArticleId IdType="pmc">PMC3623098</ArticleId><ArticleId IdType="pubmed">23637666</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayer A, Mohebali N, Razmkon A. Incidence of deep vein thrombosis in patients undergoing degenerative spine surgery on prophylactic dalteparin; a single center report. Bull Emerg Trauma. 2016;4(1):38&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4779468</ArticleId><ArticleId IdType="pubmed">27162925</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36156738</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1068</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European journal of orthopaedic surgery &amp; traumatology : orthopedie traumatologie</Title><ISOAbbreviation>Eur J Orthop Surg Traumatol</ISOAbbreviation></Journal><ArticleTitle>Update on the efficacy and safety of intravenous tranexamic acid in hip fracture surgery: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>2179</StartPage><EndPage>2190</EndPage><MedlinePgn>2179-2190</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00590-022-03387-9</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim of this meta-analysis was to assess the safety and efficacy of tranexamic acid (TXA) in the management of hip fracture surgeries in comparison with placebo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic search was conducted from August 6, 2021. Eligible studies included randomized clinical trials and prospective studies comparing the use of intravenous TXA in patients treated for hip fractures, in comparison with placebo. Review Manager was used for the meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighteen prospective studies including 14 RCTs met the eligibility criteria. The results favored the TXA group in the quantity of total blood loss (MD&#x2009;=&#x2009;&#x2009;-&#x2009;196.91&#xa0;mL, 95% CI&#x2009;-&#x2009;247.59,&#x2009;-&#x2009;146.23, I<sup>2</sup>&#x2009;=&#x2009;92%), intraoperative blood loss (MD&#x2009;= -&#xa0;26.86&#xa0;mL, 95% CI -&#xa0;36.96, -&#xa0;16.78, I<sup>2</sup>&#x2009;=&#x2009;62%), and rate of blood transfusion (OR 0.35, 95% CI 0.28, 0.42, I<sup>2</sup>&#x2009;=&#x2009;0%). TXA also exhibited higher hemoglobin level at day 1 (MD&#x2009;=&#x2009;6.77&#xa0;g/L, 95% CI 4.30, 9.24, I<sup>2</sup>&#x2009;=&#x2009;83%) and day 3 (MD&#x2009;=&#x2009;7.02&#xa0;g/L, 95% CI 3.30, 10.74, I<sup>2</sup>&#x2009;=&#x2009;82%) postoperatively. There was no significant difference found in the incidence of thromboembolic events from occurring between the two groups, such as deep vein thrombosis (OR 1.22, 95% CI 0.73, 2.02, I<sup>2</sup>&#x2009;=&#x2009;0%) and pulmonary embolism (OR 0.82, 95% CI 0.33, 2.05, I<sup>2</sup>&#x2009;=&#x2009;0%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Administration of intravenous TXA appears to reduce blood loss, rate of blood transfusions and pose no increased risk of thromboembolic events. Therefore, TXA should be considered by physicians when managing hip fracture patients.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miangul</LastName><ForeName>Shahid</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8236-4902</Identifier><AffiliationInfo><Affiliation>St George's University of London, London, SW17 0RE, UK. shahster96@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Nicosia Medical School, University of Nicosia, 2417, Nicosia, Cyprus. shahster96@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oluwaremi</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>St George's University of London, London, SW17 0RE, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Nicosia Medical School, University of Nicosia, 2417, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Haddad</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>St George's University of London, London, SW17 0RE, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Nicosia Medical School, University of Nicosia, 2417, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adra</LastName><ForeName>Maamoun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>St George's University of London, London, SW17 0RE, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Nicosia Medical School, University of Nicosia, 2417, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinnawala</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>St George's University of London, London, SW17 0RE, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Nicosia Medical School, University of Nicosia, 2417, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakanishi</LastName><ForeName>Hayato</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>St George's University of London, London, SW17 0RE, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Nicosia Medical School, University of Nicosia, 2417, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matar</LastName><ForeName>Reem H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>St George's University of London, London, SW17 0RE, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Nicosia Medical School, University of Nicosia, 2417, Nicosia, Cyprus.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Than</LastName><ForeName>Christian A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>St George's University of London, London, SW17 0RE, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Nicosia Medical School, University of Nicosia, 2417, Nicosia, Cyprus.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Biomedical Sciences, The University of Queensland, St Lucia, Brisbane, 4072, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Orthop Surg Traumatol</MedlineTA><NlmUniqueID>9518037</NlmUniqueID><ISSNLinking>1633-8065</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Eur J Orthop Surg Traumatol. 2023 Dec;33(8):3735-3736. doi: 10.1007/s00590-023-03709-5.</RefSource><PMID Version="1">37679423</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="Y">Tranexamic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="Y">Antifibrinolytic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013923" MajorTopicYN="Y">Thromboembolism</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Blood loss</Keyword><Keyword MajorTopicYN="N">Hip fracture surgery</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">TXA</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword></KeywordList><CoiStatement>The authors have no non-financial or competing interests to declare that are relevant to the content of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>26</Day><Hour>16</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36156738</ArticleId><ArticleId IdType="pmc">PMC10275812</ArticleId><ArticleId IdType="doi">10.1007/s00590-022-03387-9</ArticleId><ArticleId IdType="pii">10.1007/s00590-022-03387-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Landefeld CS. Goals of care for hip fracture: promoting independence and reducing mortality. Arch Intern Med. 2011;171:1837&#x2013;1838. doi: 10.1001/archinternmed.2011.534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2011.534</ArticleId><ArticleId IdType="pubmed">22083570</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA, Epidemiology ICWGoF Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011;22:1277&#x2013;1288. doi: 10.1007/s00198-011-1601-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-011-1601-6</ArticleId><ArticleId IdType="pmc">PMC3546313</ArticleId><ArticleId IdType="pubmed">21461721</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell S, Friedman SM, Mendelson DA, Bingham KW, Kates SL. The 1-year mortality of patients treated in a hip fracture program for elders. Geriatr Orthop Surg Rehabil. 2010;1:6&#x2013;14. doi: 10.1177/2151458510378105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2151458510378105</ArticleId><ArticleId IdType="pmc">PMC3597289</ArticleId><ArticleId IdType="pubmed">23569656</ArticleId></ArticleIdList></Reference><Reference><Citation>Simunovic N, Devereaux PJ, Bhandari M. Surgery for hip fractures: Does surgical delay affect outcomes? Indian J Orthop. 2011;45:27&#x2013;32. doi: 10.4103/0019-5413.73660.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0019-5413.73660</ArticleId><ArticleId IdType="pmc">PMC3004074</ArticleId><ArticleId IdType="pubmed">21221220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Park SS, Davey JR. Tranexamic acid for the prevention and management of orthopedic surgical hemorrhage: current evidence. J Blood Med. 2015;6:239&#x2013;244. doi: 10.2147/JBM.S61915.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JBM.S61915</ArticleId><ArticleId IdType="pmc">PMC4556304</ArticleId><ArticleId IdType="pubmed">26345147</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Wei B. Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty. J Arthroplasty. 2014;29:2113&#x2013;2116. doi: 10.1016/j.arth.2014.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2014.07.019</ArticleId><ArticleId IdType="pubmed">25155138</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanie A, Bellamy L, Rhayem Y, Flaujac C, Samama CM, Fontenay M, Rosencher N. Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res. 2013;131:e6&#x2013;e11. doi: 10.1016/j.thromres.2012.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2012.11.006</ArticleId><ArticleId IdType="pubmed">23195143</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel MP, Chalmers BP, Taunton MJ, Pagnano MW, Trousdale RT, Sierra RJ, Lee YY, Boettner F, Su EP, Haas SB, Figgie MP, Mayman DJ. Intravenous versus topical tranexamic acid in total knee arthroplasty: both effective in a randomized clinical trial of 640 patients. J Bone Joint Surg Am. 2018;100:1023&#x2013;1029. doi: 10.2106/JBJS.17.00908.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.17.00908</ArticleId><ArticleId IdType="pubmed">29916929</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy SP, Tanki UF, Dutta A, Jain SK, Nagi ON. Efficacy of intra-articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2012;20:2494&#x2013;2501. doi: 10.1007/s00167-012-1942-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00167-012-1942-5</ArticleId><ArticleId IdType="pubmed">22419263</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuff DJ, Simon P, Gorman RA., 2nd Randomized prospective evaluation of the use of tranexamic acid and effects on blood loss for proximal humeral fracture surgery. J Shoulder Elbow Surg. 2020;29:1627&#x2013;1632. doi: 10.1016/j.jse.2020.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jse.2020.04.016</ArticleId><ArticleId IdType="pubmed">32713466</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitler CA, Row ER, Gardner WE, 2nd, Swafford RE, Hankins MJ, Nowotarski PJ, Kiner DW. Tranexamic acid use in open reduction and internal fixation of fractures of the pelvis, acetabulum, and proximal femur: a randomized controlled trial. J Orthop Trauma. 2019;33:371&#x2013;376. doi: 10.1097/BOT.0000000000001480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOT.0000000000001480</ArticleId><ArticleId IdType="pubmed">30939507</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumustas SA, Celen ZE, Onay T, Abul MS, Cevik HB. The efficiency and safety of intravenous tranexamic acid administration in open reduction and internal fixation of pelvic and acetabular fractures. Eur J Trauma Emerg Surg. 2021 doi: 10.1007/s00068-021-01624-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-021-01624-0</ArticleId><ArticleId IdType="pubmed">33641043</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao C, Zhang S, Long N, Yu W, Jiang Y. Is intravenous tranexamic acid effective and safe during hip fracture surgery? An updated meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg. 2019;139:893&#x2013;902. doi: 10.1007/s00402-019-03118-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-019-03118-6</ArticleId><ArticleId IdType="pubmed">30637503</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi YM, Wang HP, Li YJ, Ma BB, Xie T, Wang C, Chen H, Rui YF. The efficacy and safety of intravenous tranexamic acid in hip fracture surgery: a systematic review and meta-analysis. J Orthop Translat. 2019;19:1&#x2013;11. doi: 10.1016/j.jot.2019.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jot.2019.03.007</ArticleId><ArticleId IdType="pmc">PMC6896672</ArticleId><ArticleId IdType="pubmed">31844608</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, He J, Fang Y, Chen P, Liang Y, Wang J. Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis: a meta-analysis. Medicine (Baltimore) 2017;96:e6940. doi: 10.1097/MD.0000000000006940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000006940</ArticleId><ArticleId IdType="pmc">PMC5457864</ArticleId><ArticleId IdType="pubmed">28538384</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers SP, Kutcher ME, Rosengart MR, Sperry JL, Peitzman AB, Brown JB, Neal MD. Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. J Trauma Acute Care Surg. 2019;86:20&#x2013;27. doi: 10.1097/TA.0000000000002061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000002061</ArticleId><ArticleId IdType="pubmed">30239375</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557&#x2013;560. doi: 10.1136/bmj.327.7414.557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142. doi: 10.1002/14651858.ED000142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.ED000142</ArticleId><ArticleId IdType="pmc">PMC10284251</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51:224&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">21936146</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J, Mui A, Purtill JJ, Sharkey PF, Hozack WJ, Rothman RH. Total joint arthroplasty: When do fatal or near-fatal complications occur? J Bone Joint Surg Am. 2007;89:27&#x2013;32. doi: 10.2106/JBJS.E.01443.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.E.01443</ArticleId><ArticleId IdType="pubmed">17200306</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross JB. Estimating allowable blood loss: corrected for dilution. Anesthesiology. 1983;58:277&#x2013;280. doi: 10.1097/00000542-198303000-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-198303000-00016</ArticleId><ArticleId IdType="pubmed">6829965</ArticleId></ArticleIdList></Reference><Reference><Citation>Camarasa MA, Olle G, Serra-Prat M, Martin A, Sanchez M, Ricos P, Perez A, Opisso L. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth. 2006;96:576&#x2013;582. doi: 10.1093/bja/ael057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/ael057</ArticleId><ArticleId IdType="pubmed">16531440</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei J, Zhang B, Cong Y, Zhuang Y, Wei X, Fu Y, Wei W, Wang P, Wen S, Huang H, Wang H, Han S, Liu S, Zhang K. Tranexamic acid reduces hidden blood loss in the treatment of intertrochanteric fractures with PFNA: a single-center randomized controlled trial. J Orthop Surg Res. 2017;12:124. doi: 10.1186/s13018-017-0625-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-017-0625-9</ArticleId><ArticleId IdType="pmc">PMC5558747</ArticleId><ArticleId IdType="pubmed">28810918</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaou VS, Masouros P, Floros T, Chronopoulos E, Skertsou M, Babis GC. Single dose of tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients undergoing surgery for hip fracture: a randomized controlled trial. Bone Joint J. 2021;103-B:442&#x2013;448. doi: 10.1302/0301-620X.103B3.BJJ-2020-1288.R1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.103B3.BJJ-2020-1288.R1</ArticleId><ArticleId IdType="pubmed">33641430</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss NB, Kehlet H. Hidden blood loss after surgery for hip fracture. J Bone Joint Surg Br. 2006;88:1053&#x2013;1059. doi: 10.1302/0301-620X.88B8.17534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.88B8.17534</ArticleId><ArticleId IdType="pubmed">16877605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Picado A, Albinarrate A, Barrachina B. Determination of perioperative blood loss: Accuracy or approximation? Anesth Analg. 2017;125:280&#x2013;286. doi: 10.1213/ANE.0000000000001992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000001992</ArticleId><ArticleId IdType="pubmed">28368940</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian S, Shen Z, Liu Y, Zhang Y, Peng A. The effect of tranexamic acid on hidden bleeding in older intertrochanteric fracture patients treated with PFNA. Injury. 2018;49:680&#x2013;684. doi: 10.1016/j.injury.2018.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2018.01.026</ArticleId><ArticleId IdType="pubmed">29426608</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S, Hu W, Shen Z, Wang M. Application of tranexamic acid intravenous drip before internal fixation in the treatment of elderly patients with unstable intertrochanteric fracture. Acta Medica Mediterranea. 2021;37:1183&#x2013;1187.</Citation></Reference><Reference><Citation>Zhang S, Xiao C, Yu W, Long N, He F, Cai P, Luo K, Jiang Y. Tranexamic acid safely reduces hidden blood loss in patients undergoing intertrochanteric fracture surgery: a randomized controlled trial. Eur J Trauma Emerg Surg. 2020 doi: 10.1007/s00068-020-01387-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-020-01387-0</ArticleId><ArticleId IdType="pubmed">32415365</ArticleId></ArticleIdList></Reference><Reference><Citation>Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, Boettner F, Memtsoudis SG. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014;349:g4829. doi: 10.1136/bmj.g4829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g4829</ArticleId><ArticleId IdType="pmc">PMC4130961</ArticleId><ArticleId IdType="pubmed">25116268</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao JM, He ML, Xiao ZM, Li TS, Wu H, Jiang H. Different types of intermittent pneumatic compression devices for preventing venous thromboembolism in patients after total hip replacement. Cochrane Database Syst Rev. 2014 doi: 10.1002/14651858.CD009543.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009543.pub3</ArticleId><ArticleId IdType="pmc">PMC7100582</ArticleId><ArticleId IdType="pubmed">25528992</ArticleId></ArticleIdList></Reference><Reference><Citation>Haj-Younes B, Sivakumar BS, Wang M, An VV, Lorentzos P, Adie S. Tranexamic acid in hip fracture surgery: a systematic review and meta-analysis. J Orthop Surg (Hong Kong) 2020;28:2309499019887995. doi: 10.1177/2309499019887995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2309499019887995</ArticleId><ArticleId IdType="pubmed">31835969</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy P, Heal JM, Blumberg N. Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions. Transfusion. 1991;31:212&#x2013;217. doi: 10.1046/j.1537-2995.1991.31391165169.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1537-2995.1991.31391165169.x</ArticleId><ArticleId IdType="pubmed">2003322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdi H, Klement MR, Hammad M, Inoue D, Xu C, Goswami K, Parvizi J. Tranexamic acid is associated with reduced periprosthetic joint infection after primary total joint arthroplasty. J Arthroplasty. 2020;35:840&#x2013;844. doi: 10.1016/j.arth.2019.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2019.10.029</ArticleId><ArticleId IdType="pubmed">31722855</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera-Roig X, Jordan-Sales M, Natera-Cisneros L, Monllau-Garcia JC, Martinez-Zapata MJ. Tranexamic acid in orthopedic surgery. Rev Esp Cir Ortop Traumatol. 2014;58:52&#x2013;56. doi: 10.1016/j.recot.2013.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.recot.2013.08.005</ArticleId><ArticleId IdType="pubmed">24126146</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine BR, Haughom BD, Belkin MN, Goldstein ZH. Weighted versus uniform dose of tranexamic acid in patients undergoing primary, elective knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty. 2014;29:186&#x2013;188. doi: 10.1016/j.arth.2014.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2014.01.038</ArticleId><ArticleId IdType="pubmed">24997651</ArticleId></ArticleIdList></Reference><Reference><Citation>Zufferey PJ, Lanoiselee J, Chapelle C, Borisov DB, Bien JY, Lambert P, Philippot R, Molliex S, Delavenne X, investigators of the PeriOpeRative Tranexamic acid in hip arthrOplasty S Intravenous tranexamic acid bolus plus infusion is not more effective than a single bolus in primary hip arthroplasty: a randomized controlled trial. Anesthesiology. 2017;127:413&#x2013;422. doi: 10.1097/ALN.0000000000001787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000001787</ArticleId><ArticleId IdType="pubmed">28692467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano M, Basora M, Peidro L, Merino I, Segur JM, Pereira A, Salazar F, Cid J, Lozano L, Mazzara R, Macule F. Effectiveness and safety of tranexamic acid administration during total knee arthroplasty. Vox Sang. 2008;95:39&#x2013;44. doi: 10.1111/j.1423-0410.2008.01045.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1423-0410.2008.01045.x</ArticleId><ArticleId IdType="pubmed">18363576</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshryda S, Sukeik M, Sarda P, Blenkinsopp J, Haddad FS, Mason JM. A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement. Bone Joint J. 2014;96-B:1005&#x2013;1015. doi: 10.1302/0301-620X.96B8.33745.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.96B8.33745</ArticleId><ArticleId IdType="pubmed">25086114</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X, Wang J, Wang X, Xie L, Chen C, Zheng W. The efficacy and safety of tranexamic acid in the treatment of intertrochanteric fracture: an updated meta-analysis of 11 randomized controlled trials. J Thromb Thrombolysis. 2020;50:243&#x2013;257. doi: 10.1007/s11239-019-02034-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-019-02034-1</ArticleId><ArticleId IdType="pubmed">31902124</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31426937</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1524-4733</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>8</Issue><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</Title><ISOAbbreviation>Value Health</ISOAbbreviation></Journal><ArticleTitle>Venous Thromboembolism Prophylaxis Strategies for People Undergoing Elective Total Hip Replacement: A Systematic Review and Network Meta-Analysis.</ArticleTitle><Pagination><StartPage>953</StartPage><EndPage>969</EndPage><MedlinePgn>953-969</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jval.2019.02.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1098-3015(19)30151-2</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To assess the efficacy and safety of venous thromboembolism prophylaxis in people undergoing elective total hip replacement.</AbstractText><AbstractText Label="METHODS">Systematic review and Bayesian network meta-analyses of randomized controlled trials were conducted for 3 outcomes: deep vein thrombosis (DVT), pulmonary embolism (PE), and major bleeding (MB). MEDLINE, EMBASE, and Cochrane Library (CENTRAL) databases were searched. Study quality was assessed using the Cochrane risk-of-bias checklist. Fixed- and random-effects models were fitted and compared. The median relative risk (RR) and odds ratio (OR) compared with no prophylaxis, with their 95% credible intervals (CrIs), rank, and probability of being the best, were calculated.</AbstractText><AbstractText Label="RESULTS">Forty-two (n&#xa0;= 24&#x2009;374, 26 interventions), 30 (n&#xa0;= 28&#x2009;842, 23 interventions), and 24 (n&#xa0;= 31&#x2009;792, 15 interventions) randomized controlled trials were included in the DVT, PE, and MB networks, respectively. Rivaroxaban had the highest probability of being the most effective intervention for DVT (RR 0.06 [95% CrI 0.01-0.29]). Strategy of low-molecular-weight heparin followed by aspirin had the highest probability of reducing the risk of PE and MB (RR 0.0011 [95% CrI 0.00-0.096] and OR 0.37 [95% CrI 0.00-26.96], respectively). The ranking of efficacy estimates across the 3 networks, particularly PE and MB, had very wide CrIs, indicating high degree of uncertainty.</AbstractText><AbstractText Label="CONCLUSIONS">A strategy of low-molecular-weight heparin given for 10 days followed by aspirin for 28 days had the best benefit-risk balance, with the highest probability of being the best on the basis of the results of the PE and MB network meta-analyses. Nevertheless, there is considerable uncertainty around the median ranks of the interventions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 ISPOR&#x2013;The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Sedina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Guideline Centre, Royal College of Physicians, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glen</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Guideline Centre, Royal College of Physicians, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawoud</LastName><ForeName>Dalia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK. Electronic address: ddawoud@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dias</LastName><ForeName>Sofia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of York, York, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobb</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>National Guideline Centre, Royal College of Physicians, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Northumbria Healthcare NHS Foundation Trust, Northumbria, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharpin</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Guideline Centre, Royal College of Physicians, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stansby</LastName><ForeName>Gerard</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Newcastle University and Freeman Hospital, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barry</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>16/114/15</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M005232/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Value Health</MedlineTA><NlmUniqueID>100883818</NlmUniqueID><ISSNLinking>1098-3015</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NDF7JZ4M3</RegistryNumber><NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017558" MajorTopicYN="N">Elective Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057240" MajorTopicYN="N">Patient Preference</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">direct-acting oral anticoagulants</Keyword><Keyword MajorTopicYN="N">hospital-acquired thrombosis</Keyword><Keyword MajorTopicYN="N">network meta-analysis</Keyword><Keyword MajorTopicYN="N">orthopedics</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword><Keyword MajorTopicYN="N">total hip replacement</Keyword><Keyword MajorTopicYN="N">venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31426937</ArticleId><ArticleId IdType="doi">10.1016/j.jval.2019.02.013</ArticleId><ArticleId IdType="pii">S1098-3015(19)30151-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37707745</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1720-8319</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Aging clinical and experimental research</Title><ISOAbbreviation>Aging Clin Exp Res</ISOAbbreviation></Journal><ArticleTitle>The impact of frailty evaluation on the risk of venous thromboembolism in patients with hip fracture following surgery: a meta-analysis.</ArticleTitle><Pagination><StartPage>2413</StartPage><EndPage>2423</EndPage><MedlinePgn>2413-2423</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40520-023-02529-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Frailty has been associated with a higher incidence of overall postoperative complications and mortality. However, the influence of frailty on the risk of venous thromboembolism (VTE) in patients with hip fracture following surgery remains unclear. We performed a meta-analysis to systematically evaluate the above association.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, Embase, Cochrane Library, Wanfang and CNKI were searched for relevant observational studies comparing the incidence of postoperative VTE in patients of hip fracture with and without frailty. Data collection, literature searching, and statistical analysis were conducted independently by two authors. Using a heterogeneity-incorporating random-effects model, the results were pooled.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In this meta-analysis, 9509 patients from nine cohort studies were included. Pooled results showed that compared to those without frailty, patients with frailty at admission had a higher incidence of postoperative VTE (odds ratio [OR]: 2.59, 95% confidence interval [CI]: 1.25-5.39, p&#x2009;=&#x2009;0.01; I<sup>2</sup>&#x2009;=&#x2009;66%). Subgroup analysis suggested the association between frailty and postoperative VTE was more remarkable in studies of patients with frailty prevalence&#x2009;&lt;&#x2009;50% (OR 6.28, 95% CI 3.31-11.90, p&#x2009;&lt;&#x2009;0.001; I<sup>2</sup>&#x2009;=&#x2009;8%) as compared to those&#x2009;&#x2265;&#x2009;50% (OR 1.30, 95% CI 0.80-2.11, p&#x2009;=&#x2009;0.28; I<sup>2</sup>&#x2009;=&#x2009;0%; p for subgroup difference&#x2009;&lt;&#x2009;0.001). Further meta-analyses showed that frailty at baseline was associated with a higher incidence of deep venous thrombosis (OR 3.15, 95% CI 1.33-7.47, p&#x2009;=&#x2009;0.009; I<sup>2</sup>&#x2009;=&#x2009;59%), but not pulmonary embolism (OR 1.13, 95% CI 0.59-2.16, p&#x2009;=&#x2009;0.72; I<sup>2</sup>&#x2009;=&#x2009;0%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Frailty is associated with a higher incidence of postoperative VTE in patients with hip fracture.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Haixia</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Medicine, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wu</LastName><ForeName>Fang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Medicine, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jianbin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hand, Foot and Ankle Surgery, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yongchao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Medicine, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Zifu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Burn and Plastic Surgery Department, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xuejun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Burn and Plastic Surgery Department, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0009-0003-2975-2361</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, People's Hospital of Ningxia Hui Autonomous Region, No. 301, Zhengyuan Beijie, Jinfeng District, Yinchuan, 750004, China. lbnxan_2399@21cn.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Aging Clin Exp Res</MedlineTA><NlmUniqueID>101132995</NlmUniqueID><ISSNLinking>1594-0667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073496" MajorTopicYN="Y">Frailty</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Frailty</Keyword><Keyword MajorTopicYN="N">Hip fracture</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>14</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>14</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37707745</ArticleId><ArticleId IdType="doi">10.1007/s40520-023-02529-1</ArticleId><ArticleId IdType="pii">10.1007/s40520-023-02529-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Williamson S, Landeiro F, McConnell T et al (2017) Costs of fragility hip fractures globally: a systematic review and meta-regression analysis. Osteoporos Int 28:2791&#x2013;2800. https://doi.org/10.1007/s00198-017-4153-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-017-4153-6</ArticleId><ArticleId IdType="pubmed">28748387</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths R, Babu S, Dixon P et al (2021) Guideline for the management of hip fractures 2020: guideline by the Association of Anaesthetists. Anaesthesia 76:225&#x2013;237. https://doi.org/10.1111/anae.15291</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.15291</ArticleId><ArticleId IdType="pubmed">33289066</ArticleId></ArticleIdList></Reference><Reference><Citation>Veronese N, Maggi S (2018) Epidemiology and social costs of hip fracture. Injury 49:1458&#x2013;1460</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2018.04.015</ArticleId><ArticleId IdType="pubmed">29699731</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari M, Swiontkowski M (2017) Management of acute hip fracture. N Engl J Med 377:2053&#x2013;2062. https://doi.org/10.1056/NEJMcp1611090</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp1611090</ArticleId><ArticleId IdType="pubmed">29166235</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan KJ, Guerrero EM, Tainter D et al (2019) Prognostic factors of in-hospital complications after hip fracture surgery: a scoping review. Osteoporos Int 30:1339&#x2013;1351. https://doi.org/10.1007/s00198-019-04976-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-019-04976-x</ArticleId><ArticleId IdType="pubmed">31037362</ArticleId></ArticleIdList></Reference><Reference><Citation>Segon YS, Summey RD, Slawski B et al (2020) Surgical venous thromboembolism prophylaxis: clinical practice update. Hosp Pract (1995) 48:248&#x2013;257. https://doi.org/10.1080/21548331.2020.1788893</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21548331.2020.1788893</ArticleId><ArticleId IdType="pubmed">32589468</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald DRW, Neilly D, Schneider PS et al (2020) Venous thromboembolism in hip fracture patients: a subanalysis of the FAITH and HEALTH Trials. J Orthop Trauma 34:S70&#x2013;S75. https://doi.org/10.1097/BOT.0000000000001939</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOT.0000000000001939</ArticleId><ArticleId IdType="pubmed">33027169</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauchamp-Chalifour P, Belzile EL, Michael R et al (2022) The risk of venous thromboembolism in surgically treated hip fracture: a retrospective cohort study of 5184 patients. Orthop Traumatol Surg Res 108:103142</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.otsr.2021.103142</ArticleId><ArticleId IdType="pubmed">34775033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngarmukos S, Kim KI, Wongsak S et al (2021) Asia-Pacific venous thromboembolism consensus in knee and hip arthroplasty and hip fracture surgery: Part 1. Diagnosis and risk factors. Knee Surg Relat Res 33:18. https://doi.org/10.1186/s43019-021-00099-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43019-021-00099-y</ArticleId><ArticleId IdType="pubmed">34147134</ArticleId><ArticleId IdType="pmc">8214263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamtora PH, Fortier MA, Barnett SR et al (2020) Peri-operative management of frailty in the orthopedic patient. J Orthop 22:304&#x2013;307. https://doi.org/10.1016/j.jor.2020.05.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jor.2020.05.024</ArticleId><ArticleId IdType="pubmed">32616993</ArticleId><ArticleId IdType="pmc">7322091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoogendijk EO, Afilalo J, Ensrud KE et al (2019) Frailty: implications for clinical practice and public health. Lancet 394:1365&#x2013;1375. https://doi.org/10.1016/S0140-6736(19)31786-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31786-6</ArticleId><ArticleId IdType="pubmed">31609228</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue T, Maeda K, Nagano A et al (2020) Undernutrition, sarcopenia, and frailty in fragility hip fracture: advanced strategies for improving clinical outcomes. Nutrients. https://doi.org/10.3390/nu12123743</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12123743</ArticleId><ArticleId IdType="pubmed">33383715</ArticleId><ArticleId IdType="pmc">7823945</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan B, Sun W, Wang W et al (2022) Prognostic significance of frailty in older patients with hip fracture: a systematic review and meta-analysis. Int Orthop 46:2939&#x2013;2952. https://doi.org/10.1007/s00264-022-05605-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00264-022-05605-9</ArticleId><ArticleId IdType="pubmed">36227383</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Wang A, Lou Y et al (2022) Effects of frailty on outcomes following surgery among patients with hip fractures: a systematic review and meta-analysis. Front Med (Lausanne) 9:829762. https://doi.org/10.3389/fmed.2022.829762</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.829762</ArticleId><ArticleId IdType="pubmed">35402430</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, Moher D, Bossuyt PM et al (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160. https://doi.org/10.1136/bmj.n160</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n160</ArticleId><ArticleId IdType="pubmed">33781993</ArticleId><ArticleId IdType="pmc">8005925</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId><ArticleId IdType="pmc">8005924</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J, Thomas J, Chandler J et al (2021) Cochrane Handbook for Systematic Reviews of Interventions version 6.2. The Cochrane Collaboration. www.training.cochrane.org/handbook</Citation></Reference><Reference><Citation>Wells GA, Shea B, O'Connell D et al (2010) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</Citation></Reference><Reference><Citation>Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539&#x2013;1558. https://doi.org/10.1002/sim.1186</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.1186</ArticleId><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Patsopoulos NA, Evangelou E, Ioannidis JP (2008) Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 37:1148&#x2013;1157. https://doi.org/10.1093/ije/dyn065</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyn065</ArticleId><ArticleId IdType="pubmed">18424475</ArticleId><ArticleId IdType="pmc">6281381</ArticleId></ArticleIdList></Reference><Reference><Citation>Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629&#x2013;634</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.315.7109.629</ArticleId><ArticleId IdType="pubmed">9310563</ArticleId><ArticleId IdType="pmc">2127453</ArticleId></ArticleIdList></Reference><Reference><Citation>Kua J, Ramason R, Rajamoney G et al (2016) Which frailty measure is a good predictor of early post-operative complications in elderly hip fracture patients? Arch Orthop Trauma Surg 136:639&#x2013;647. https://doi.org/10.1007/s00402-016-2435-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00402-016-2435-7</ArticleId><ArticleId IdType="pubmed">26980097</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan S, Wong EKC, Ward SE et al (2019) The predictive value of the clinical frailty scale on discharge destination and complications in older hip fracture patients. J Orthop Trauma 33:497&#x2013;502. https://doi.org/10.1097/BOT.0000000000001518</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOT.0000000000001518</ArticleId><ArticleId IdType="pubmed">31188261</ArticleId></ArticleIdList></Reference><Reference><Citation>You L, Wu KQ (2020) Effect of Frality on perioperative risk and prognosis in elderly patients with hip fracture. J Nanchang Univ 8:95</Citation></Reference><Reference><Citation>Zhu SQ, Xing YH, Zhang L et al (2020) Predictive value of Frail Scale and CHS index on postoperative outcomes in elderly patients with hip fracture. J Clin Anesthesiol 36:962&#x2013;965. https://doi.org/10.12089/jca.2020.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.12089/jca.2020.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang WA, Durrani H, Liu H et al (2021) Frailty score as a predictor of outcomes in geriatric patients with isolated hip fractures. Am Surg. https://doi.org/10.1177/00031348211058629</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00031348211058629</ArticleId><ArticleId IdType="pubmed">34905976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ZF, Yu XH, Zhao B (2022) Risk factor of postoperative lower exemity deep venous thrombosis in geriatric hip fracture patients. J Clin Emerg 23:237&#x2013;241. https://doi.org/10.13201/j.issn.1009-5918.2022.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.13201/j.issn.1009-5918.2022.04.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao XY, Ouyang CL, Xu ZY et al (2022) Clinical application of modified frailty index in predicting complications after hip fracture in the elderly. Chin J Mult Organ Dis Elderly 21:481. https://doi.org/10.11915/j.issn.1671-5403.2022.07.104</Citation><ArticleIdList><ArticleId IdType="doi">10.11915/j.issn.1671-5403.2022.07.104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tram MK, O&#x2019;Connor CM, Qian AS et al (2022) Frailty is associated with increased 30-day adverse events and hospitalization costs after primary total hip arthroplasty. J Arthroplasty 37:S925&#x2013;S930.e4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2022.01.047</ArticleId><ArticleId IdType="pubmed">35091035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Wang L, Cao A et al (2022) Modified frailty index combined with a prognostic nutritional index for predicting postoperative complications of hip fracture surgery in elderly. J Invest Surg 35:1739&#x2013;1746. https://doi.org/10.1080/08941939.2022.2101166</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08941939.2022.2101166</ArticleId><ArticleId IdType="pubmed">35906737</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Wu Z, Huo H et al (2022) The impact of frailty on adverse outcomes in geriatric hip fracture patients: a systematic review and meta-analysis. Front Public Health 10:890652. https://doi.org/10.3389/fpubh.2022.890652</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.890652</ArticleId><ArticleId IdType="pubmed">35844855</ArticleId><ArticleId IdType="pmc">9280195</ArticleId></ArticleIdList></Reference><Reference><Citation>Folsom AR, Boland LL, Cushman M et al (2007) Frailty and risk of venous thromboembolism in older adults. J Gerontol A Biol Sci Med Sci 62:79&#x2013;82</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/62.1.79</ArticleId><ArticleId IdType="pubmed">17301042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutsey PL, Windham BG, Misialek JR et al (2020) Long-term association of venous thromboembolism with frailty, physical functioning, and quality of life: the atherosclerosis risk in communities study. J Am Heart Assoc 9:e015656. https://doi.org/10.1161/JAHA.119.015656</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.015656</ArticleId><ArticleId IdType="pubmed">32476561</ArticleId><ArticleId IdType="pmc">7429054</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimian S, Lee C, Tran Z et al (2022) Association of frailty with outcomes of resection for colonic volvulus: a national analysis. PLoS ONE 17:e0276917. https://doi.org/10.1371/journal.pone.0276917</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0276917</ArticleId><ArticleId IdType="pubmed">36346811</ArticleId><ArticleId IdType="pmc">9642887</ArticleId></ArticleIdList></Reference><Reference><Citation>Phan K, Kim JS, Lee NJ et al (2017) Frailty is associated with morbidity in adults undergoing elective anterior lumbar interbody fusion (ALIF) surgery. Spine J 17:538&#x2013;544&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spinee.2016.10.023</ArticleId><ArticleId IdType="pubmed">27989724</ArticleId></ArticleIdList></Reference><Reference><Citation>Putthapiban P, Vutthikraivit W, Rattanawong P et al (2020) Association of frailty with all-cause mortality and bleeding among elderly patients with acute myocardial infarction: a systematic review and meta-analysis. J Geriatr Cardiol 17:270&#x2013;278. https://doi.org/10.11909/j.issn.1671-5411.2020.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.11909/j.issn.1671-5411.2020.05.006</ArticleId><ArticleId IdType="pubmed">32547610</ArticleId><ArticleId IdType="pmc">7276305</ArticleId></ArticleIdList></Reference><Reference><Citation>Proietti M, Romiti GF, Raparelli V et al (2022) Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients. Ageing Res Rev 79:101652</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2022.101652</ArticleId><ArticleId IdType="pubmed">35659945</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon JY, Kim S, Chang JS et al (2020) Venous thromboembolism after delayed surgery for a hip fracture: a retrospective cohort study. Geriatr Gerontol Int 20:1151&#x2013;1156. https://doi.org/10.1111/ggi.14055</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ggi.14055</ArticleId><ArticleId IdType="pubmed">33058481</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, Yamamoto S, Suzuki Y et al (2023) Comparison of the association between six different frailty scales and clinical events in patients on hemodialysis. Nephrol Dial Transplant 38:455&#x2013;462. https://doi.org/10.1093/ndt/gfac047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfac047</ArticleId><ArticleId IdType="pubmed">35212731</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukkriang N, Punsawad C (2020) Comparison of geriatric assessment tools for frailty among community elderly. Heliyon 6:e04797. https://doi.org/10.1016/j.heliyon.2020.e04797</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2020.e04797</ArticleId><ArticleId IdType="pubmed">32964152</ArticleId><ArticleId IdType="pmc">7490815</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldawi M, Awad ME, McKelvey G et al (2023) Neuraxial anesthesia significantly reduces 30-day venous thromboembolism rate and length of hospital stay in primary total hip arthroplasty: a stratified propensity score-matched cohort analysis. J Arthroplasty 38:108&#x2013;116</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2022.07.003</ArticleId><ArticleId IdType="pubmed">35843379</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Jiang Z, Li Y et al (2022) Prevalence of preoperative Deep Venous Thrombosis (DVT) following elderly intertrochanteric fractures and development of a risk prediction model. BMC Musculoskelet Disord 23:417. https://doi.org/10.1186/s12891-022-05381-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-022-05381-y</ArticleId><ArticleId IdType="pubmed">35509097</ArticleId><ArticleId IdType="pmc">9065244</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39396001</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-8090</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of cardiothoracic surgery</Title><ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Perioperative outcomes of thoracoscopic versus non-thoracoscopic minimally invasive repair of pectus excavatum: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>603</StartPage><MedlinePgn>603</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">603</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13019-024-03016-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pectus excavatum is the most common chest wall deformity, with the Nuss procedure being the preferred surgical approach for correction. However, the decision to use thoracoscopic assistance remains challenging. This study aimed to evaluate the perioperative outcomes of thoracoscopic-assisted versus non-thoracoscopic-assisted minimally invasive repair of pectus excavatum (TA-MIRPE vs. NTA-MIRPE).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive search was conducted across PubMed, Medline, Embase, WOS, and CBM databases for studies published from 2010 to the present related to this topic. Meta-analysis was performed using RevMan 5.0 and STATA 15.0, with primary comparisons focusing on postoperative complications and the incidence of poor incision healing.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eighteen studies involving a total of 5933 patients were included in the analysis, with 1670 undergoing non-thoracoscopic surgery and 4263 receiving thoracoscopic surgery. The meta-analysis revealed that, compared to the NTA-MIRPE group, the TA-MIRPE group had longer operation times [SMD = 1.71, 95% CI (1.14, 2.28), P &lt; 0.001] and extended postoperative hospital stays [SMD = 0.12, 95% CI (0.04, 0.20), P = 0.004]. However, the TA-MIRPE group showed a lower incidence of postoperative complications [OR = 0.48, 95% CI (0.35, 0.65), z = 4.63, P &lt; 0.001] and higher patient satisfaction [OR = 1.88, 95% CI (1.32, 2.67), z = 3.51, P &lt; 0.001].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While TA-MIRPE is associated with longer operation times and hospital stays, it offers greater patient satisfaction, reduces postoperative complications, and enhances surgical safety.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Haipeng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>West China School of Medicine, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yunyan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>West China School of Medicine, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China. linfeng0220@aliyun.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Cardiothorac Surg</MedlineTA><NlmUniqueID>101265113</NlmUniqueID><ISSNLinking>1749-8090</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005660" MajorTopicYN="Y">Funnel Chest</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019060" MajorTopicYN="Y">Minimally Invasive Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013906" MajorTopicYN="Y">Thoracoscopy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Minimally invasive repair of pectus excavatum (MIRPE)</Keyword><Keyword MajorTopicYN="N">Nuss procedure</Keyword><Keyword MajorTopicYN="N">Pectus exavatum (PE)</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword><Keyword MajorTopicYN="N">Thoracoscopy</Keyword></KeywordList><CoiStatement>All authors have no competing interest or financial ties to disclose, and all data in this study come from published literature. At the same time, this study is secondary literature research and does not involve ethical disputes. The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>23</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39396001</ArticleId><ArticleId IdType="pmc">PMC11470680</ArticleId><ArticleId IdType="doi">10.1186/s13019-024-03016-y</ArticleId><ArticleId IdType="pii">10.1186/s13019-024-03016-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cui Y, Zhai B, Wang P. Analysis of orthopedic effect of thoracoscopic assisted in patients with congenital excavatum chest[J]. Anhui Med J. 2018;39(1).</Citation></Reference><Reference><Citation>Xie K, Wang Y, Li Y. Application of thoracoscopically assisted NUSS correction in 350 cases of infundination-chest correction[J]. J Clin Med. 2018;38(12).</Citation></Reference><Reference><Citation>Schmidt J, Redwan B, Koesek V, et al. Pectus Excavatum and cardiac surgery: simultaneous correction advocated [J]. Thorac Cardiovasc Surg. 2014;62(3):238&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">24510432</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Liu D, Liu W. Efficacy evaluation of nonthoracoscopically assisted minimally invasive Nuss surgery in the treatment of congenital funnel chest[J]. Chin J Med Sci. 2014;4(19).</Citation></Reference><Reference><Citation>Nuss D, Kelly RE, JR, Croitoru DP, et al. A 10-year review of a minimally invasive technique for the correction of pectus excavatum [J]. J Pediatr Surg. 1998;33(4):545&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9574749</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetteh O, Rhee DS, Boss E, et al. Minimally invasive repair of pectus excavatum: analysis of the NSQIP database and the use of thoracoscopy [J]. J Pediatr Surg. 2018;53(6):1230&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">29602550</ArticleId></ArticleIdList></Reference><Reference><Citation>Mennie N, Frawley G, Crameri J, et al. The effect of thoracoscopy upon the repair of pectus excavatum [J]. J Pediatr Surg. 2018;53(4):740&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">28827049</ArticleId></ArticleIdList></Reference><Reference><Citation>Du J, Hu antimony, Zhao Q et al. Clinical efficacy of Modified Nuss technique assisted by Thoracoscopic to treat adult will funnel chest [J]. J Med Res.2012;41(6).</Citation></Reference><Reference><Citation>Sterne JA, Hern&#xe1;n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in nonrandomized studies of interventions [J]. BMJ. 2016;355:i4919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcgrath S, Zhao X, Steele R, et al. Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis [J]. Stat Methods Med Res. 2020;29(9):2520&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390706</ArticleId><ArticleId IdType="pubmed">32292115</ArticleId></ArticleIdList></Reference><Reference><Citation>Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis [J]. Biometrics. 2000;56(2):455&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">10877304</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen T, Lu Z, Duan C et al. Comparative study of non thoracoscopic subaxiphoid small incision and thoracoscopic assisted Nuss surgery in the treatment of pectus excavatum [J]. Lingnan Mod Clin Surg. 2020;20(6).</Citation></Reference><Reference><Citation>Kang C, Teng Y. Comparison of efficacy of thoracoscopic assisted excavatum orthopedics and traditional Nuss in the treatment of pediatric congenital pectus excavatum [J]. China J Pract Med. 2020;6.</Citation></Reference><Reference><Citation>Li X, Han Y, Wang J et al. Nonthoracoscopic Nuss correction for pectus excavatum [J]. Chinese J Thorac Cardiovasc Surg. 2010;3.</Citation></Reference><Reference><Citation>Liu W, Kong D, Yu F. Clinical comparison between thoracoscopic and nonthoracoscopic modified Nuss surgical correction of excavatum chest[J]. J Cent South Univ Med Sci. 2013;38(8).</Citation><ArticleIdList><ArticleId IdType="pubmed">23982000</ArticleId></ArticleIdList></Reference><Reference><Citation>Like inheritance, Huang B, Liu H. Clinical application of nonthoracoscopic Nuss surgery[J]. J Clin Pulmonol. 2017;22(7).</Citation></Reference><Reference><Citation>Wang Y, Zaicheng YU, Xu HU et al. Clinical observation of thoracoscopic assisted Nuss surgery in the treatment of pectus excavatum [J]. J Anhui Med Univ. 2011;46(11).</Citation></Reference><Reference><Citation>Minhua W, Wenliang L. Clinical observation of minimally invasive pecthorax excavatum orthopedics in the treatment of congenital pecthorax excavatum [J]. World J Traditional Chin Med. 2016;B03.</Citation></Reference><Reference><Citation>Yang J, Li W. Comparison of efficacy of nonthoracoscopically assisted modified Nuss surgery with thoracoscopic surgery for the correction of excavatus chest[J]. J Math Med. 2016;6.</Citation></Reference><Reference><Citation>C G F A D T, et al. Minimally invasive repair of pectus excavatum in children: results of a modified Nuss procedure [J]. Annales de chirurgie plastique et esthetique. 2017;62:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">27823841</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Y, Wang J, Li W, et al. Nonthoracoscopic extrapleural Nuss procedure for the correction of pectus excavatum in children [J]. Eur J Cardiothorac Surg. 2010;37(2):312&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19781953</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauffman JD, Benzie AL, Snyder CW, et al. Short-term outcomes after Pectus Excavatum repair in adults and children [J]. J Surg Res. 2019;244:231&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">31301479</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco-Casamassima MG, Goldstein SD, Gause CD, et al. Minimally invasive repair of pectus excavatum: analyzing contemporary practice in 50 ACS NSQIP-pediatric institutions [J]. Pediatr Surg Int. 2015;31(5):493&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25814003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y, Liu W, Xu B, Qin D. [Non-thoracoscopic minimally invasive Nuss procedure for correction of recurrent pectus excavatum]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi Zhongguo Xiufu Chongjian Waike Zazhi Chin. J Reparative Reconstr Surg. 2008;22:1213&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18979881</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19373223</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1930-7381</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>11</Issue><PubDate><Year>2009</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Obesity (Silver Spring, Md.)</Title><ISOAbbreviation>Obesity (Silver Spring)</ISOAbbreviation></Journal><ArticleTitle>Prospective study of BMI and the risk of pulmonary embolism in women.</ArticleTitle><Pagination><StartPage>2040</StartPage><EndPage>2046</EndPage><MedlinePgn>2040-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/oby.2009.92</ELocationID><Abstract><AbstractText>Pulmonary embolism (PE) is common and associated with significant morbidity and mortality. An association between obesity and PE has been suggested, but the nature of the association has not been well defined. We performed a prospective cohort study of 87,226 women in the Nurses' Health Study (1984-2002) to define the association between BMI and the risk of incident PE. Primary exposure was BMI (&lt;22.5, 22.5-24.9, 25.0-27.4, 27.5-29.9, 30.0-34.9, and &gt;or=35.0 kg/m(2)). Primary outcome was idiopathic PE (medical record confirmed cases of PE not associated with prior surgery, trauma, or malignancy). Secondary analysis of nonidiopathic PE was also performed. Multivariable Cox proportional hazards models were controlled for age, physical activity, caloric intake, smoking, pack-years, race, spouse's educational attainment, parity, menopause, nonaspirin nonsteroidal anti-inflammatory drugs, warfarin, multivitamin supplements, hypertension, coronary heart disease, and rheumatological disease. There were 157 incident idiopathic PE and 338 nonidiopathic PE. There was a strong positive association between BMI, the risk of idiopathic PE (relative risk (RR) = 1.08 (95% confidence interval (CI), 1.06-1.10) per 1 kg/m(2) increase in BMI, P &lt; 0.001) and nonidiopathic PE (RR = 1.08 (95% CI, 1.07-1.10), P &lt; 0.001). The association was linear, and apparent even with modest increases in BMI (22.5-25 kg/m(2)). The risk increased nearly sixfold among subjects with BMI &gt;or=35 kg/m(2), and was present in multiple subgroups. Increasing BMI has a strong, linear association with the development of PE in women. Clinicians should consider BMI when assessing the risk of PE in their patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kabrhel</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA. ckabrhel@partners.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varraso</LastName><ForeName>Rapha&#xeb;lle</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Goldhaber</LastName><ForeName>Samuel Z</ForeName><Initials>SZ</Initials></Author><Author ValidYN="Y"><LastName>Rimm</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Camargo</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 AG031079</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21AG031079</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Obesity (Silver Spring)</MedlineTA><NlmUniqueID>101264860</NlmUniqueID><ISSNLinking>1930-7381</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="Y">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19373223</ArticleId><ArticleId IdType="mid">NIHMS515365</ArticleId><ArticleId IdType="pmc">PMC3769947</ArticleId><ArticleId IdType="doi">10.1038/oby.2009.92</ArticleId><ArticleId IdType="pii">oby200992</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521222</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) Lancet. 1999;353:1386&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurkciyan I, Meron G, Sterz F, et al. Pulmonary embolism as a cause of cardiac arrest: presentation and outcome. Arch Intern Med. 2000;160:1529&#x2013;1535.</Citation><ArticleIdList><ArticleId IdType="pubmed">10826469</ArticleId></ArticleIdList></Reference><Reference><Citation>Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest. 2006;130:172&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">16840398</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pubmed">15163775</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc. 2006;3:564&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pubmed">16963534</ArticleId></ArticleIdList></Reference><Reference><Citation>Acting Surgeon General Issues &#x2018;Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism&#x2019;. Office of the Surgeon General, U.S. Department of Health and Human Sciences;  &lt; http://www.surgeongeneral.gov/news/pressreleases/pr20080915.html&gt;.</Citation><ArticleIdList><ArticleId IdType="pubmed">20669525</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Hemost. 2002;28(Suppl 2):3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">12073175</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487036</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med. 2005;118:978&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">16164883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucher N, Tapson VF, Goldhaber SZ. Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. Thromb Haemost. 2005;93:494&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">15735800</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnemann B, Zgouras D, Schindewolf M, et al. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry. Blood Coagul Fibrinolysis. 2008;19:159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">18277138</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277:642&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pubmed">9039882</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med. 1983;74:1023&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pubmed">6859053</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimm EB, Stampfer MJ, Colditz GA, et al. Validity of self-reported waist and hip circumferences in men and women. Epidemiology. 1990;1:466&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">2090285</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett W, Stampfer MJ, Bain C, et al. Cigarette smoking, relative weight, and menopause. Am J Epidemiol. 1983;117:651&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">6859020</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy LM, Hunter DJ, Manson JE, et al. The validity of recalled weight among younger women. Int J Obes Relat Metab Disord. 1995;19:570&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7489028</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon T, Beau Yon de Jonage-Canonico M, Oger E, et al. Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost. 2006;4:71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">16409454</ArticleId></ArticleIdList></Reference><Reference><Citation>Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost. 2006;4:1259&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pubmed">16706969</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002;162:1182&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pubmed">12020191</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: &#x201c;the study of men born in 1913. Arch Intern Med. 1999;159:1886&#x2013;1890.</Citation><ArticleIdList><ArticleId IdType="pubmed">10493318</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol. 2005;162:975&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207808</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides S, Schafer K, Neels JG, Dellas C, Loskutoff DJ. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:2196&#x2013;2201.</Citation><ArticleIdList><ArticleId IdType="pubmed">15458978</ArticleId></ArticleIdList></Reference><Reference><Citation>Napoleone E, ADIS, Amore C, et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J Thromb Haemost. 2007;5:1462&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17425664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">15467059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">8022039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogden CL, Carroll MD, McDowell MA, Flegal KM. NCHS data brief no 1. Hyattsville, MD: National Center for Health Statistics; 2007. Obesity among adults in the United States&#x2014;no statistically significant change since 2003&#x2013;2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">19389313</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Minno G, Mannucci PM, Tufano A, et al. The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. J Thromb Haemost. 2005;3:1459&#x2013;1466.</Citation><ArticleIdList><ArticleId IdType="pubmed">15978103</ArticleId></ArticleIdList></Reference><Reference><Citation>Arterburn DE, Crane PK, Sullivan SD. The coming epidemic of obesity in elderly Americans. J Am Geriatr Soc. 2004;52:1907&#x2013;1912.</Citation><ArticleIdList><ArticleId IdType="pubmed">15507070</ArticleId></ArticleIdList></Reference><Reference><Citation>Villareal DT, Apovian CM, Kushner RF, Klein S. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Obes Res. 2005;13:1849&#x2013;1863.</Citation><ArticleIdList><ArticleId IdType="pubmed">16339115</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan MS, Huguet N, Newsom JT, McFarland BH, Lindsay J. Prevalence and correlates of overweight and obesity among older adults: findings from the Canadian National Population Health Survey. J Gerontol A Biol Sci Med Sci. 2003;58:1018&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630884</ArticleId></ArticleIdList></Reference><Reference><Citation>Gostic CL. The crucial role of exercise and physical activity in weight management and functional improvement for seniors. Clin Geriatr Med. 2005;21:747&#x2013;756. vii.</Citation><ArticleIdList><ArticleId IdType="pubmed">16182087</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38847680</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>23</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Effect of different anesthetic modalities on postoperative delirium in elderly hip fractures: A meta-analysis.</ArticleTitle><Pagination><StartPage>e38418</StartPage><MedlinePgn>e38418</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e38418</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000038418</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous findings on the effect of general versus spinal anesthesia on postoperative delirium in elderly people with hip fractures are somewhat controversial. This article included the latest randomized controlled study for meta-analysis to evaluate the effect of general anesthesia (GA) and spinal anesthesia (SA) on delirium after hip fracture surgery in the elderly, so as to guide the clinical.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cochrane Library, PubMed, Web Of Science, and Embase were searched from inception up to January 16, 2024. Randomized controlled trial (RCT) was included to evaluate the postoperative results of GA and SA in elderly patients (&#x2265;50 years old) undergoing hip fracture surgery. Two researchers independently screened for inclusion in the study and extracted data. Heterogeneity was assessed by the I&#xb2;and Chi-square tests, and P&#x2005;&lt;&#x2005;.1 or I&#xb2; &#x2265; 50% indicated marked heterogeneity among studies. The Mantel-Haenszel method was used to estimate the combined relative risk ratio (RR) and the corresponding 95% confidence interval (CI) for the binary variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine randomized controlled trials were included. There was no significant difference (RR&#x2005;=&#x2005;0.93, 95% CI&#x2005;=&#x2005;0.774-1.111, P&#x2005;&gt;&#x2005;.05) in the incidence of postoperative delirium between the GA group and the SA group. In intraoperative blood transfusion (RR&#x2005;=&#x2005;1.0, 95% CI&#x2005;=&#x2005;0.77-1.28, Z&#x2005;=&#x2005;0.04, P&#x2005;=&#x2005;.971), pulmonary embolism (RR&#x2005;=&#x2005;0.795, 95% CI&#x2005;=&#x2005;0.332-1.904, Z&#x2005;=&#x2005;0.59, P&#x2005;=&#x2005;.606), pneumonia (RR&#x2005;=&#x2005;1.47, 95% CI&#x2005;=&#x2005;0.75-2.87, P&#x2005;=&#x2005;.675), myocardial infarction (RR&#x2005;=&#x2005;0.97, 95% CI&#x2005;=&#x2005;0.24-3.86, Z&#x2005;=&#x2005;0.05, P&#x2005;=&#x2005;.961), heart failure (RR&#x2005;=&#x2005;0.80, 95% CI&#x2005;=&#x2005;0.26-2.42, Z&#x2005;=&#x2005;0.40, P&#x2005;=&#x2005;.961), urinary retention (RR&#x2005;=&#x2005;1.42, 95% CI&#x2005;=&#x2005;0.77-2.61, Z&#x2005;=&#x2005;1.11, P&#x2005;=&#x2005;.267) were similar between the 2 anesthetic techniques.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is no significant difference in the effect of GA and SA on postoperative delirium in elderly patients with hip fracture, and their effects on postoperative complications are similar.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Guangya</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Orthopedics,The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Musen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Orthopedics,The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Wenshuo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Orthopedics,The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Zhongcheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Orthopedics,The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopedics,The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopedics,The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Liqiang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Orthopedics,The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lianguo</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0008-0382-2065</Identifier><AffiliationInfo><Affiliation>Department of Orthopedics,The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-4842-8060</Identifier><AffiliationInfo><Affiliation>Department of Geriatrics, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000768" MajorTopicYN="Y">Anesthesia, General</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000775" MajorTopicYN="Y">Anesthesia, Spinal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="Y">Delirium</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071257" MajorTopicYN="N">Emergence Delirium</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>7</Day><Hour>12</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>7</Day><Hour>12</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>7</Day><Hour>10</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38847680</ArticleId><ArticleId IdType="pmc">PMC11155603</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000038418</ArticleId><ArticleId IdType="pii">00005792-202406070-00024</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Curtis EM, van der Velde R, Moon RJ, et al. . Epidemiology of fractures in the United Kingdom 1988-2012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone. 2016;87:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4890652</ArticleId><ArticleId IdType="pubmed">26968752</ArticleId></ArticleIdList></Reference><Reference><Citation>Loggers SAI, Van Lieshout EMM, Joosse P, Verhofstad MHJ, Willems HC. Prognosis of nonoperative treatment in elderly patients with a hip fracture: a systematic review and meta-analysis. Injury. 2020;51:2407&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">32907702</ArticleId></ArticleIdList></Reference><Reference><Citation>Jay RH, Hipps D. Hip fracture-great steps forward but we still need better evidence. A commentary on NICE CG124 and QS16 on fractured neck of femur. Age Ageing. 2018;47:630&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">29982272</ArticleId></ArticleIdList></Reference><Reference><Citation>Veronese N, Maggi S. Epidemiology and social costs of hip fracture. Injury. 2018;49:1458&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">29699731</ArticleId></ArticleIdList></Reference><Reference><Citation>Str&#xf8;m C, Rasmussen LS, Sieber FE. Should general anaesthesia be avoided in the elderly? Anaesthesia. 2014;69(Suppl 1):35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5207212</ArticleId><ArticleId IdType="pubmed">24303859</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths R, Alper J, Beckingsale A, et al. . Membership of the Working Party. Management of proximal femoral fractures 2011: association of anaesthetists of Great Britain and Ireland. Anaesthesia. 2012;67:85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">22150501</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman MD, Feng R, Carson JL, et al. . REGAIN Investigators. Spinal anesthesia or general anesthesia for hip surgery in older adults. N Engl J Med. 2021;385:2025&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">34623788</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Tan Y, Gao Y, Liu Z. Comparative efficacy of neuraxial and general anesthesia for hip fracture surgery: a meta-analysis of randomized clinical trials. BMC Anesthesiol. 2020;20:162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7325684</ArticleId><ArticleId IdType="pubmed">32605591</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Li J, Yuan L, et al. . RAGA Study Investigators. Effect of regional vs general anesthesia on incidence of postoperative delirium in older patients undergoing hip fracture surgery: the RAGA randomized trial. JAMA. 2022;327:50&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689436</ArticleId><ArticleId IdType="pubmed">34928310</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Altman DG, G&#xf8;tzsche PC, et al. . Cochrane Statistical Methods Group. The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928&#x2013;d5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari SM, Soltani H, Hashemi SJ, Talakoub R, Soleimani B. Comparative study of two anesthesia methods according to postoperative complications and one month mortality rate in the candidates of hip surgery. J Res Med Sci. 2011;16:323&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3214341</ArticleId><ArticleId IdType="pubmed">22091252</ArticleId></ArticleIdList></Reference><Reference><Citation>Hole A, Terjesen T, Breivik H. Epidural versus general anaesthesia for total hip arthroplasty in elderly patients. Acta Anaesthesiol Scand. 1980;24:279&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">7468115</ArticleId></ArticleIdList></Reference><Reference><Citation>Berggren D, Gustafson Y, Eriksson B, et al. . Postoperative confusion after anesthesia in elderly patients with femoral neck fractures. Anesth Analg. 1987;66:497&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">3578861</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker MJ, Griffiths R. General versus regional anaesthesia for hip fractures. A pilot randomised controlled trial of 322 patients. Injury. 2015;46:1562&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26049662</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzimas P, Samara E, Petrou A, Korompilias A, Chalkias A, Papadopoulos G. The influence of anesthetic techniques on postoperative cognitive function in elderly patients undergoing hip fracture surgery: general vs spinal anesthesia. Injury. 2018;49:2221&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30526923</ArticleId></ArticleIdList></Reference><Reference><Citation>Casati A, Aldegheri G, Vinciguerra E, Marsan A, Fraschini G, Torri G. Randomized comparison between sevoflurane anaesthesia and unilateral spinal anaesthesia in elderly patients undergoing orthopaedic surgery. Eur J Anaesthesiol. 2003;20:640&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12932066</ArticleId></ArticleIdList></Reference><Reference><Citation>Meuret P, Bouvet L, Villet B, Hafez M, Allaouchiche B, Boselli E. Hypobaric unilateral spinal anaesthesia versus general anaesthesia in elderly patients undergoing hip fracture surgical repair: a prospective randomised open trial. Turk J Anaesthesiol Reanim. 2018;46:121&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5937458</ArticleId><ArticleId IdType="pubmed">29744247</ArticleId></ArticleIdList></Reference><Reference><Citation>Saied NN, Helwani MA, Weavind LM, Shi Y, Shotwell MS, Pandharipande PP. Effect of anaesthesia type on postoperative mortality and morbidities: a matched analysis of the NSQIP database. Br J Anaesth. 2017;118:105&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">28039248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Yin Y, Jin M, Li B. The risk factors for postoperative delirium in adult patients after hip fracture surgery: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2021;36:3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">32833302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka P, Goodman S, Sommer BR, Maloney W, Huddleston J, Lemmens HJ. The effect of desflurane versus propofol anesthesia on postoperative delirium in elderly obese patients undergoing total knee replacement: a randomized, controlled, double-blinded clinical trial. J Clin Anesth. 2017;39:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">28494898</ArticleId></ArticleIdList></Reference><Reference><Citation>Evered LA, Chan MTV, Han R, et al. . Anaesthetic depth and delirium after major surgery: a randomised clinical trial. Br J Anaesth. 2021;127:704&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579421</ArticleId><ArticleId IdType="pubmed">34465469</ArticleId></ArticleIdList></Reference><Reference><Citation>Short TG, Campbell D, Frampton C, et al. . Australian and New Zealand College of Anaesthetists Clinical Trials Network. Anaesthetic depth and complications after major surgery: an international, randomised controlled trial. Lancet. 2019;394:1907&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31645286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedford PD. Adverse cerebral effects of anaesthesia on old people. Lancet. 1955;269:259&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">13243706</ArticleId></ArticleIdList></Reference><Reference><Citation>Vutskits L, Xie Z. Lasting impact of general anaesthesia on the brain: mechanisms and relevance. Nat Rev Neurosci. 2016;17:705&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">27752068</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell BG, Spitz W, Porter J. Association of increasing use of spinal anesthesia in hip fracture repair with treating an aging patient population. JAMA Surg. 2020;155:167&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902104</ArticleId><ArticleId IdType="pubmed">31746959</ArticleId></ArticleIdList></Reference><Reference><Citation>Urwin SC, Parker MJ, Griffiths R. General versus regional anaesthesia for hip fracture surgery: a meta-analysis of randomized trials. Br J Anaesth. 2000;84:450&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10823094</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwer HMF, Swelem SE, el-Sheshai A, et al. . Postoperative cognitive dysfunction in adult and elderly patients&#x2014;general anesthesia vs subarachnoid or epidural analgesia. Middle East J Anaesthesiol. 2006;18:1123&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">17263267</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Swain CA, Ward SAP, et al. . Preoperative cerebrospinal fluid &#x3b2;-Amyloid/Tau ratio and postoperative delirium. Ann Clin Transl Neurol. 2014;1:319&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4029597</ArticleId><ArticleId IdType="pubmed">24860840</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnussen RA, Tressler MA, Obremskey WT, Kregor PJ. Predicting blood loss in isolated pelvic and acetabular high-energy trauma. J Orthop Trauma. 2007;21:603&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17921834</ArticleId></ArticleIdList></Reference><Reference><Citation>Scannell BP, Loeffler BJ, Bosse MJ, Kellam JF, Sims SH. Efficacy of intraoperative red blood cell salvage and autotransfusion in the treatment of acetabular fractures. J Orthop Trauma. 2009;23:340&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19390361</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Chen F, Zhao W, et al. . Pulmonary artery pressure and variations in arterial blood pressure during the induction period of general anesthesia in elderly patients. J Coll Physicians Surg Pak. 2021;31:8&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">33546526</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Y-X, Wang J-C, Lu X-Y, et al. . Intention to control low central venous pressure reduced blood loss during laparoscopic hepatectomy: a double-blind randomized clinical trial. Surgery. 2020;167:933&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">32216964</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou M-Y, Wang Y-C, Peng L-N, et al. . Intraoperative blood transfusion predicts postoperative delirium among older patients undergoing elective orthopedic surgery: a prospective cohort study. Int J Geriatr Psychiatry. 2019;34:881&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30761615</ArticleId></ArticleIdList></Reference><Reference><Citation>van Munster BC, Korevaar JC, Zwinderman AH, Levi M, Wiersinga WJ, De Rooij SE. Time-course of cytokines during delirium in elderly patients with hip fractures. J Am Geriatr Soc. 2008;56:1704&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18691278</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensler T, Heinemann B, Sauerland S, et al. . Immunologic alterations associated with high blood transfusion volume after multiple injury: effects on plasmatic cytokine and cytokine receptor concentrations. Shock. 2003;20:497&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">14625472</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodale V, Tripodi VF, Penna O, et al. . An update on anesthetics and impact on the brain. Expert Opin Drug Saf. 2017;16:997&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">28697315</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei X, Zheng H-L, Li C, et al. . The effects of propofol and sevoflurane on postoperative delirium in older patients: a randomized clinical trial study. J Alzheimers Dis. 2020;76:1627&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7844419</ArticleId><ArticleId IdType="pubmed">32651322</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldecoa C, Bettelli G, Bilotta F, et al. . European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. Eur J Anaesthesiol. 2017;34:192&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">28187050</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, Miao S, Gu T, Wang D, Zhang H, Liu J. Dexmedetomidine for the prevention of emergence delirium and postoperative behavioral changes in pediatric patients with sevoflurane anesthesia: a double-blind, randomized trial. Drug Des Devel Ther. 2019;13:897&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6421876</ArticleId><ArticleId IdType="pubmed">30936683</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H-Y, Chen T-Y, Li D-J, et al. . Association of pharmacological prophylaxis with the risk of pediatric emergence delirium after sevoflurane anesthesia: an updated network meta-analysis. J Clin Anesth. 2021;75:110488.</Citation><ArticleIdList><ArticleId IdType="pubmed">34481361</ArticleId></ArticleIdList></Reference><Reference><Citation>Momeni M, Khalifa C, Lemaire G, et al. . Propofol plus low-dose dexmedetomidine infusion and postoperative delirium in older patients undergoing cardiac surgery. Br J Anaesth. 2021;126:665&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">33358336</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarour S, Weiss Y, Kiselevich Y, et al. . The association between midazolam premedication and postoperative delirium&#x2014;a retrospective cohort study. J Clin Anesth. 2024;92:111113.</Citation><ArticleIdList><ArticleId IdType="pubmed">37280146</ArticleId></ArticleIdList></Reference><Reference><Citation>Greengrass RA. Midazolam and delirium: can you have it both ways? Reg Anesth Pain Med. 2022;47:449&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">35296540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37563702</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-799X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of orthopaedic surgery and research</Title><ISOAbbreviation>J Orthop Surg Res</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of single- and double-dose intravenous tranexamic acid in hip and knee arthroplasty: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>593</StartPage><MedlinePgn>593</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">593</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13018-023-03929-9</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">With the increasing prevalence of osteoarthritis of the hip and knee, total joint replacement, the end-stage treatment, provides pain relief and restoration of function, but is often associated with massive blood loss. Tranexamic acid (TXA) has been reported to reduce perioperative blood loss in hip or knee arthroplasty. However, the optimal dose of TXA administration remains controversial. Therefore, we performed a meta-analysis combining data from 5 trials comparing the efficacy and safety of one fixed dose of 1&#xa0;g intravenously administered TXA with two doses of 1&#xa0;g each administered intravenously for hip or knee arthroplasty.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, Medline, Embase, Web of Science, and The Cochrane Library were searched from January 2000 to February 2023. Our meta-analysis included randomized controlled trials and cohort studies comparing the efficacy and safety of different doses of intravenous TXA (IV-TXA) for THA or TKA. The observation endpoints included total blood loss, postoperative hemoglobin drop, blood transfusion rate, length of hospital stay, incidence of deep venous thrombosis (DVT), and incidence of pulmonary embolism (PE). Meta-analysis was performed according to Cochrane's guidelines and PRISMA statement. The Danish RevMan5.3 software was used for data merging.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Five cohort studies involving 5542 patients met the inclusion criteria. Our meta-analysis showed that the two groups were significantly higher in total blood loss (mean difference (MD)&#x2009;=&#x2009;-&#x2009;65.60, 95% confidence interval (CI) [-&#x2009;131.46, 0.26], P&#x2009;=&#x2009;0.05); blood transfusion rate (risk difference (RD)&#x2009;=&#x2009;0.00, 95% CI [-&#x2009;0.01, 0.02], P&#x2009;=&#x2009;0.55); postoperative hemoglobin (MD&#x2009;=&#x2009;0.02, 95% CI [-&#x2009;0.09, 0.13], P&#x2009;=&#x2009;0.31); postoperative hospital stay days (MD&#x2009;=&#x2009;-&#x2009;0.13), 95% CI [-&#x2009;0.35, 0.09], P&#x2009;=&#x2009;0.25); DVT (RD&#x2009;=&#x2009;0.00, 95% CI [-&#x2009;0.00, 0.01], P&#x2009;=&#x2009;0.67); PE (RD&#x2009;=&#x2009;0.00, 95% CI [-&#x2009;0.01, 0.00], P&#x2009;=&#x2009;0.79). There was some inherent heterogeneity due to variance in sample size across each major study.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">1 dose of 1&#xa0;g and 2 doses of 1&#xa0;g IV-TXA each time have similar effects on reducing blood loss, blood transfusion rate, postoperative hemoglobin level, and postoperative hospital stay after TKA or THA, without increasing the risk of postoperative complications risk. For patients at high risk of thromboembolic events, one dose of 1&#xa0;g TXA throughout surgery may be preferred. However, higher-quality RCT is needed to explore the optimal protocol dose to recommend the widespread use of TXA in total joint arthroplasty. Trial registration We conducted literature selection, eligibility criteria evaluation, data extraction and analysis on the research program registered in Prospero (CRD42023405387) on March 16, 2023.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yong-Ze</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>First Clinical Medical College of Gansu, University of Traditional Chinese Medicine, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>People's Hospital of Gansu Province, 204 Donggang West Road, Chengguan District, Lanzhou, 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Qing-Hao</ForeName><Initials>QH</Initials><AffiliationInfo><Affiliation>People's Hospital of Gansu Province, 204 Donggang West Road, Chengguan District, Lanzhou, 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>An-Ren</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>First Clinical Medical College of Gansu, University of Traditional Chinese Medicine, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>People's Hospital of Gansu Province, 204 Donggang West Road, Chengguan District, Lanzhou, 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>First Clinical Medical College of Gansu, University of Traditional Chinese Medicine, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>People's Hospital of Gansu Province, 204 Donggang West Road, Chengguan District, Lanzhou, 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhuang-Zhuang</ForeName><Initials>ZZ</Initials><AffiliationInfo><Affiliation>First Clinical Medical College of Gansu, University of Traditional Chinese Medicine, Lanzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>People's Hospital of Gansu Province, 204 Donggang West Road, Chengguan District, Lanzhou, 730000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Hong-Zhang</ForeName><Initials>HZ</Initials><AffiliationInfo><Affiliation>People's Hospital of Gansu Province, 204 Donggang West Road, Chengguan District, Lanzhou, 730000, China. g_hz@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20JR10RA358</GrantID><Agency>Gansu Provincial Natural Science Foundation of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Orthop Surg Res</MedlineTA><NlmUniqueID>101265112</NlmUniqueID><ISSNLinking>1749-799X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="Y">Tranexamic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="Y">Antifibrinolytic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="Y">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="Y">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Arthroplasty, replacement, hip</Keyword><Keyword MajorTopicYN="N">Arthroplasty, replacement, knee</Keyword><Keyword MajorTopicYN="N">Double dose</Keyword><Keyword MajorTopicYN="N">Single dose</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>10</Day><Hour>23</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37563702</ArticleId><ArticleId IdType="pmc">PMC10413625</ArticleId><ArticleId IdType="doi">10.1186/s13018-023-03929-9</ArticleId><ArticleId IdType="pii">10.1186/s13018-023-03929-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kurtz SM, Ong KL, Lau E, Bozic KJ. Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021. J Bone Joint Surg Am. 2014;96(8):624&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">24740658</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace IJ, Worthington S, Felson DT, Jurmain RD, Wren KT, Maijanen H, et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc Natl Acad Sci USA. 2017;114(35):9332&#x2013;9336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584421</ArticleId><ArticleId IdType="pubmed">28808025</ArticleId></ArticleIdList></Reference><Reference><Citation>James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, Abdollahpour I. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990&#x2013;2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789&#x2013;1858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6227754</ArticleId><ArticleId IdType="pubmed">30496104</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley A, Gregson CL, Paternoster L, Tobias JH. Osteoarthritis: insights offered by the study of bone mass genetics. Curr Osteoporos Rep. 2021;19(2):115&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016765</ArticleId><ArticleId IdType="pubmed">33538965</ArticleId></ArticleIdList></Reference><Reference><Citation>Quicke JG, Conaghan PG, Corp N, Peat G. Osteoarthritis year in review 2021: epidemiology and therapy. Osteoarthr Cartil. 2022;30(2):196&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">34695571</ArticleId></ArticleIdList></Reference><Reference><Citation>Moonen AF, Knoors NT, van Os JJ, Verburg AD, Pilot P. Retransfusion of filtered shed blood in primary total hip and knee arthroplasty: a prospective randomized clinical trial. Transfusion. 2007;47(3):379&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">17319816</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsamadicy AA, Adogwa O, Vuong VD, Mehta AI, Vasquez RA, Cheng J, et al. Association of intraoperative blood transfusions on postoperative complications, 30-day readmission rates, and 1-year patient-reported outcomes. Spine (Phila Pa 1976) 2017;42(8):610&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">28399073</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMik DE, Carender CN, Glass NA, Brown TS, Callaghan JJ, Bedard NA. Who is still receiving blood transfusions after primary and revision total joint arthroplasty? J Arthroplasty. 2022;37(6s):S63&#x2013;S69.</Citation><ArticleIdList><ArticleId IdType="pubmed">34511282</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayupov E, Fillingham YA, Okroj K, Plummer DR, Moric M, Gerlinger TL, et al. Oral and intravenous tranexamic acid are equivalent at reducing blood loss following total hip arthroplasty: a randomized controlled trial. J Bone Joint Surg Am. 2017;99(5):373&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">28244907</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Zhang MM, Jifeng Li MM, Xiao Wang MM. Combined versus single application of tranexamic acid in total knee and hip arthroplasty: a meta-analysis of randomized controlled trials. Int J Surg. 2017;43:171&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602763</ArticleId></ArticleIdList></Reference><Reference><Citation>Banach L, Janczewski L, Kajdanek J, Milowska K, Kolodziejczyk-Czepas J, Galita G, et al. Synthesis and hemostatic activity of new amide derivatives. Molecules. 2022;27(7):2271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9000710</ArticleId><ArticleId IdType="pubmed">35408669</ArticleId></ArticleIdList></Reference><Reference><Citation>Draxler DF, Medcalf RL. Fibrinolysis and tranexamic acid: mechanistic principles. ANZ J Surg. 2020;90(4):410&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">32339417</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanyam KN, Khanchandani P, Tulajaprasad PV, Jaipuria J, Mundargi AV. Efficacy and safety of intra-articular versus intravenous tranexamic acid in reducing perioperative blood loss in total knee arthroplasty: a prospective randomized double-blind equivalence trial. Bone Joint J. 2018;100(2):152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">29437056</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, et al. The efficacy of tranexamic acid in total knee arthroplasty: a network meta-analysis. J Arthroplasty. 2018;33(10):3090&#x2013;8.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">29805106</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling T, Zhang L, Huang L. The efficacy and safety of combined administration of intravenous and intra-articular tranexamic acid in total knee arthroplasty: an update meta-analysis. J Clin Pharm Ther. 2022;47(9):1312&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">35790455</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X, Ma XL, Ma JX. Efficiency and safety of intravenous tranexamic acid in simultaneous bilateral total knee arthroplasty: a systematic review and meta-analysis. Orthop Surg. 2016;8(3):285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6584435</ArticleId><ArticleId IdType="pubmed">27627710</ArticleId></ArticleIdList></Reference><Reference><Citation>Hines JT, Petis SM, Amundson AW, Pagnano MW, Sierra RJ, Abdel MP. Intravenous tranexamic acid safely and effectively reduces transfusion rates in revision total knee arthroplasties. J Bone Joint Surg Am. 2020;102(5):381&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">31977819</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain NP, Nisthane PP, Shah NA. Combined administration of systemic and topical tranexamic acid for total knee arthroplasty: can it be a better regimen and yet safe? A randomized controlled trial. J Arthroplasty. 2016;31(2):542&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">26507526</ArticleId></ArticleIdList></Reference><Reference><Citation>Blani&#xe9; A, Bellamy L, Rhayem Y, Flaujac C, Samama CM, Fontenay M, et al. Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res. 2013;131(1):e6&#x2013;e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">23195143</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 1980;14:41&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1347104</ArticleId><ArticleId IdType="pubmed">7000846</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JY, Chin PL, Moo IH, Pang HN, Tay DK, Chia SL, et al. Intravenous versus intra-articular tranexamic acid in total knee arthroplasty: a double-blinded randomised controlled noninferiority trial. Knee. 2016;23(1):152&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">26746044</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LK, Ma JX, Kuang MJ, Zhao J, Wang Y, Lu B, et al. Comparison of oral versus intravenous application of tranexamic acid in total knee and hip arthroplasty: a systematic review and meta-analysis. Int J Surg. 2017;45:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">28755884</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X, Gong G, Han N, Liu M. Efficacy and safety of oral compared with intravenous tranexamic acid in reducing blood loss after primary total knee and hip arthroplasty: a meta-analysis. BMC Musculoskelet Disord. 2018;19(1):430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6278110</ArticleId><ArticleId IdType="pubmed">30509227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Li J, Chen J, Zheng C, Liu C, Jia Y. Comparison of intravenous, topical or combined routes of tranexamic acid administration in patients undergoing total knee and hip arthroplasty: a meta-analysis of randomised controlled trials. BMJ Open. 2019;9(1):e024350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6352808</ArticleId><ArticleId IdType="pubmed">30696680</ArticleId></ArticleIdList></Reference><Reference><Citation>Hmidan Simsam M, Delorme L, Grimm D, Priestap F, Bohnert S, Descoteaux M, et al. Efficacy of high dose tranexamic acid (TXA) for hemorrhage: a systematic review and meta-analysis. Injury. 2023;54(3):857&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">36746710</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xed;gar A, Mc Loughlin S, Slullitel PA, Scordo W, Buttaro MA. Influence of single-dose intravenous tranexamic acid on total hip replacement: a study on transfusions, collateral complications, and readmissions. Orthopade. 2017;46(4):359&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">27832317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Yu X, Wu J, Ge W, Cai M, Li S. Efficacy of a single dose and an additional dose of tranexamic acid in reduction of blood loss in total knee arthroplasty. J Arthroplasty. 2017;32(7):2108&#x2013;2112.</Citation><ArticleIdList><ArticleId IdType="pubmed">27889307</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde JM, Copp SN, McCauley JC, Bugbee WD. One dose of intravenous tranexamic acid is equivalent to two doses in total hip and knee arthroplasty. J Bone Joint Surg Am. 2018;100(13):1104&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">29975264</ArticleId></ArticleIdList></Reference><Reference><Citation>George DA, Sarraf KM, Nwaboku H. Single perioperative dose of tranexamic acid in primary hip and knee arthroplasty. Eur J Orthop Surg Traumatol. 2015;25(1):129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">24756178</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai T, Tsuji S, Tomita T, Sugamoto K, Hideki Y, Hamada M. Repeat-dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty. Int Orthop. 2013;37(3):441&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580084</ArticleId><ArticleId IdType="pubmed">23371424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hourlier H, Fennema P. Single tranexamic acid dose to reduce perioperative morbidity in primary total hip replacement: a randomised clinical trial. Hip Int. 2014;24(1):63&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6159839</ArticleId><ArticleId IdType="pubmed">24062227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hourlier H, Reina N, Fennema P. Single dose intravenous tranexamic acid as effective as continuous infusion in primary total knee arthroplasty: a randomised clinical trial. Arch Orthop Trauma Surg. 2015;135(4):465&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pubmed">25666288</ArticleId></ArticleIdList></Reference><Reference><Citation>Sershon RA, Fillingham YA, Abdel MP, Malkani AL, Schwarzkopf R, Padgett DE, et al. The optimal dosing regimen for tranexamic acid in revision total hip arthroplasty: a multicenter randomized clinical trial. J Bone Joint Surg Am. 2020;102(21):1883&#x2013;1890.</Citation><ArticleIdList><ArticleId IdType="pubmed">33148955</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang BX, Li YL, Xu H, Gao CX, Zhong S, Zhang J, et al. Effect of multiple doses of intravenous tranexamic acid on perioperative blood loss in total knee arthroplasty: a randomized controlled study. Orthop Surg. 2021;13(1):126&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7862185</ArticleId><ArticleId IdType="pubmed">33295133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zhao C, Luo Y, Wang Q, Li Q, Kang P. Different doses of intravenous tranexamic acid in revision total knee arthroplasty: a retrospective study. J Knee Surg. 2021;36:652&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">34952545</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilde JM, Copp SN, Ezzet KA, Rosen AS, Walker RH, McCauley JC, et al. No difference in blood loss and risk of transfusion between patients treated with one or two doses of intravenous tranexamic acid after simultaneous bilateral TKA. Clin Orthop Relat Res. 2022;480(4):702&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8923576</ArticleId><ArticleId IdType="pubmed">35302971</ArticleId></ArticleIdList></Reference><Reference><Citation>Charette RS, Bernstein JA, Sloan M, Nchako CM, Kamath AF, Nelson CL. One versus two doses of intravenous tranexamic acid in total knee arthroplasty. J Knee Surg. 2021;34(7):749&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">31731323</ArticleId></ArticleIdList></Reference><Reference><Citation>Golz AG, Yee HK, Davis BJ, Adams WH, Brown NM. One dose versus two doses of intravenous tranexamic acid in total joint arthroplasty. J Am Acad Orthop Surg. 2021;29(11):e555&#x2013;e562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8166358</ArticleId><ArticleId IdType="pubmed">32826662</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanoisel&#xe9;e J, Zufferey PJ, Ollier E, Hodin S, Delavenne X. Is tranexamic acid exposure related to blood loss in hip arthroplasty? A pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol. 2018;84(2):310&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5777664</ArticleId><ArticleId IdType="pubmed">29193211</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Li B, Wang Q, Zhang X. Comparison of 3 routes of administration of tranexamic acid on primary unilateral total knee arthroplasty: a prospective, randomized, controlled study. J Arthroplasty. 2017;32(9):2738&#x2013;2743.</Citation><ArticleIdList><ArticleId IdType="pubmed">28455182</ArticleId></ArticleIdList></Reference><Reference><Citation>Konarski W, Pobo&#x17c;y T, Hordowicz M. Tranexamic acid in total knee replacement and total hip replacement&#x2014;a single-center retrospective, observational study. Orthop Rev (Pavia) 2022;14(3):33875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9239398</ArticleId><ArticleId IdType="pubmed">35775036</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KL, Chen IH, Wen SH. Low dose tranexamic acid reduces blood transfusion rate after total knee arthroplasty: a population-based study in Taiwan. J Formos Med Assoc. 2017;116(1):24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">26852084</ArticleId></ArticleIdList></Reference><Reference><Citation>Frassanito L, Vergari A, Nestorini R, Cerulli G, Placella G, Pace V, et al. Enhanced recovery after surgery (ERAS) in hip and knee replacement surgery: description of a multidisciplinary program to improve management of the patients undergoing major orthopedic surgery. Musculoskelet Surg. 2020;104(1):87&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">31054080</ArticleId></ArticleIdList></Reference><Reference><Citation>Auyong DB, Allen CJ, Pahang JA, Clabeaux JJ, MacDonald KM, Hanson NA. Reduced length of hospitalization in primary total knee arthroplasty patients using an updated enhanced recovery after orthopedic surgery (ERAS) pathway. J Arthroplasty. 2015;30(10):1705&#x2013;1709.</Citation><ArticleIdList><ArticleId IdType="pubmed">26024988</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrachina B, Lopez-Picado A, Remon M, Fondarella A, Iriarte I, Bastida R, et al. Tranexamic acid compared with placebo for reducing total blood loss in hip replacement surgery: a randomized clinical trial. Anesth Analg. 2016;122(4):986&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pubmed">26991616</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskal JT, Harris RN, Capps SG. Transfusion cost savings with tranexamic acid in primary total knee arthroplasty from 2009 to 2012. J Arthroplasty. 2015;30(3):365&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">25458093</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28145042</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-726X</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>4</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &amp; Interventions</Title><ISOAbbreviation>Catheter Cardiovasc Interv</ISOAbbreviation></Journal><ArticleTitle>Safety of catheter-directed thrombolysis for massive and submassive pulmonary embolism: Results of a multicenter registry and meta-analysis.</ArticleTitle><Pagination><StartPage>754</StartPage><EndPage>760</EndPage><MedlinePgn>754-760</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ccd.26900</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the safety and efficacy of catheter-directed thrombolysis (CDT) in the treatment of acute pulmonary embolism (PE).</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The use of CDT for the treatment of acute submassive and massive PE is increasing in frequency. However, its safety and efficacy have not been well elucidated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study is made of two parts: one is a two-center registry of acute PE patients treated with CDT. The safety outcome evaluated was any major complication including fatal, intracranial (ICH), intraocular, or retroperitoneal hemorrhage or any overt bleeding requiring transfusion or surgical repair. The efficacy outcome was acute change in invasive pulmonary artery systolic pressure (PASP). The second part is a meta-analysis of all contemporary studies that used CDT for PE. Reported outcomes are the same as in the registry, with the addition of right ventricular to left ventricular (RV/LV) ratio change.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the registry, 137 patients were included (age 59&#x2009;&#xb1;&#x2009;15, 50% male, 88% submassive PE). ICH occurred in two patients and major complications in 13 (9.4%). PASP decreased post procedure by 19&#x2009;&#xb1;&#x2009;15 mm Hg (95% CI 16-23). In the meta-analysis, 16 studies were included with 860 patients. Rate of ICH was 0.35% and the major complication rate was 4.65%, most requiring transfusion only. In-hospital mortality was 12.9% in the massive and 0.74% in the submassive group. All studies showed improvement in PASP and/or RV/LV ratio post CDT.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CDT is associated with a low major complication rate. Randomized studies are needed to evaluate its efficacy relative to anticoagulation alone. &#xa9; 2017 Wiley Periodicals, Inc.</AbstractText><CopyrightInformation>&#xa9; 2017 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bloomer</LastName><ForeName>Tyler L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Hayek</LastName><ForeName>Georges E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDaniel</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandvall</LastName><ForeName>Breck C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liberman</LastName><ForeName>Henry A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devireddy</LastName><ForeName>Chandan M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Gautam</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Pete P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaber</LastName><ForeName>Wissam A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Catheter Cardiovasc Interv</MedlineTA><NlmUniqueID>100884139</NlmUniqueID><ISSNLinking>1522-1946</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Catheter Cardiovasc Interv. 2017 Mar 1;89(4):761-762. doi: 10.1002/ccd.27014.</RefSource><PMID Version="1">28342248</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000792" MajorTopicYN="N">Angiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002405" MajorTopicYN="N">Catheterization, Central Venous</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062905" MajorTopicYN="Y">Central Venous Catheters</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">catheter-directed thrombolysis</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28145042</ArticleId><ArticleId IdType="doi">10.1002/ccd.26900</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36912758</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-9159</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of surgery (London, England)</Title><ISOAbbreviation>Int J Surg</ISOAbbreviation></Journal><ArticleTitle>Comparison of risk of complication between neuraxial anaesthesia and general anaesthesia for hip fracture surgery: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>458</StartPage><EndPage>468</EndPage><MedlinePgn>458-468</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JS9.0000000000000291</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Controversy remains over the choice of anaesthetic technique for patients undergoing surgery for hip fracture.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The aim was to compare the risk of complication of neuraxial anaesthesia with that of general anaesthesia in patients undergoing hip fracture surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines and was registered at PROSPERO (CRD42022337384). The study included eligible randomised controlled trials published before February 2022. Data synthesis was performed to compare the differences between general and neuraxial anaesthesia. Meta-regression analysis was performed to investigate the influence of the publication year. A subgroup analysis was performed based on patient age and the anaesthetic technique used. A grading of recommendations, assessment, development and evaluations assessment was performed to assess the quality of each outcome.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty randomised controlled trials and 4802 patients were included. Data synthesis revealed significant higher risk of acute kidney injury in the general anaesthesia group ( P =0.01). There were no significant differences between the two techniques in postoperative short-term mortality ( P =0.34), delirium ( P =0.40), postoperative nausea and vomiting ( P =0.40), cardiac infarction ( P =0.31), acute heart failure ( P =0.34), pulmonary embolism ( P =0.24) and pneumonia ( P =0.15). Subgroup analysis based on patient age and use of sedative medication did not reveal any significant differences. Meta-regression analysis of the publication year versus each adverse event revealed no statistically significant differences.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A significantly higher risk of postoperative acute kidney injury was found in patients receiving general anaesthesia. This study revealed no significant differences in terms of postoperative mortality and other complications between general and neuraxial anaesthesia. The results were consistent across the age groups.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xi</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Departments of Orthopedics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hairui</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5188-3435</Identifier><AffiliationInfo><Affiliation>Plastic Surgery, West China Hospital, West China School of Medicine, Sichuan University, Chengdu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Songlin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yiou</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Ruichen</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Medicine, Tsinghua University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Wenwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departments of Orthopedics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Departments of Orthopedics.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Surg</MedlineTA><NlmUniqueID>101228232</NlmUniqueID><ISSNLinking>1743-9159</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000768" MajorTopicYN="N">Anesthesia, General</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="Y">Hip Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020250" MajorTopicYN="N">Postoperative Nausea and Vomiting</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000776" MajorTopicYN="Y">Anesthesiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>13</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36912758</ArticleId><ArticleId IdType="pmc">PMC10389547</ArticleId><ArticleId IdType="doi">10.1097/JS9.0000000000000291</ArticleId><ArticleId IdType="pii">01279778-202303000-00031</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Curtis EM, Moon RJ, Harvey NC, et al. . The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide. Bone 2017;104:29&#x2013;38. 10.1016/j.bone.2017.01.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bone.2017.01.024</ArticleId><ArticleId IdType="pmc">PMC5420448</ArticleId><ArticleId IdType="pubmed">28119181</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell CM, McLoughlin L, Patterson CC, et al. . Perioperative outcomes in the context of mode of anaesthesia for patients undergoing hip fracture surgery: systematic review and meta-analysis. Br J Anaesth 2018;1:37&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">29397135</ArticleId></ArticleIdList></Reference><Reference><Citation>Werner M, Macke C, Gogol M, et al. . Differences in hip fracture care in Europe: a systematic review of recent annual reports of hip fracture registries. Eur J Trauma Emerg Surg 2022;3:1625&#x2013;1638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9192454</ArticleId><ArticleId IdType="pubmed">34623474</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoulis M, Benetou V, Karapetyan T, et al. . Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J Intern Med 2017;3:300&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">28093824</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik AT, Panni UY, Masri BA, et al. . The impact of surgeon volume and hospital volume on postoperative mortality and morbidity after hip fractures: a systematic review. Int J Surg 2018;54:316&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">29102691</ArticleId></ArticleIdList></Reference><Reference><Citation>He R, Wang G, Li T, et al. . Factors associated with 90-day acute ischemic stroke in patients &#x2265;70&#x2009;years old with total hip arthroplasty for hip fracture. BMC Geriatr 2022;1:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8733812</ArticleId><ArticleId IdType="pubmed">34991502</ArticleId></ArticleIdList></Reference><Reference><Citation>Guay J, Parker MJ, Gajendragadkar PR, et al. . Anaesthesia for hip fracture surgery in adults. Cochrane Database Syst Rev 2016;2:Cd000521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464323</ArticleId><ArticleId IdType="pubmed">26899415</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Tan Y, Gao Y, et al. . Comparative efficacy of neuraxial and general anesthesia for hip fracture surgery: a meta-analysis of randomized clinical trials. BMC Anesthesiol 2020;1:162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7325684</ArticleId><ArticleId IdType="pubmed">32605591</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman MD, Feng R, Carson JL, et al. . Spinal anesthesia or general anesthesia for hip surgery in older adults. N Engl J Med 2021;22:2025&#x2013;2035.</Citation><ArticleIdList><ArticleId IdType="pubmed">34623788</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman MD, Silber JH, Elkassabany NM, et al. . Comparative effectiveness of regional versus general anesthesia for hip fracture surgery in adults. Anesthesiology 2012;1:72&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">22713634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn EJ, Kim HJ, Kim KW, et al. . Comparison of general anaesthesia and regional anaesthesia in terms of mortality and complications in elderly patients with hip fracture: a nationwide population-based study. BMJ Open 2019;9:e029245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6738684</ArticleId><ArticleId IdType="pubmed">31501111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravi B, Pincus D, Choi S, et al. . Association of duration of surgery with postoperative delirium among patients receiving hip fracture repair. JAMA Netw Open 2019;2:e190111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6484601</ArticleId><ArticleId IdType="pubmed">30794305</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu CC, Weng SF, Chen KT, et al. . Propensity score-matched comparison of postoperative adverse outcomes between geriatric patients given a general or a neuraxial anesthetic for hip surgery: a population-based study. Anesthesiol 2015;1:136&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">25955981</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Li J, Yuan L, et al. . Effect of regional vs general anesthesia on incidence of postoperative delirium in older patients undergoing hip fracture surgery: the raga randomized trial. Jama 2022;1:50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689436</ArticleId><ArticleId IdType="pubmed">34928310</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell CM, Black N, McCourt KC, et al. . Development of a Core Outcome Set for studies evaluating the effects of anaesthesia on perioperative morbidity and mortality following hip fracture surgery. Br J Anaesth 2019;1:120&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">30579390</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzimas P, Samara E, Petrou A, et al. . The influence of anesthetic techniques on postoperative cognitive function in elderly patients undergoing hip fracture surgery: general vs spinal anesthesia. Injury 2018;12:2221&#x2013;2226.</Citation><ArticleIdList><ArticleId IdType="pubmed">30526923</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Fang P, Fang Y, et al. . Comparison of effects between combined lumbar-sacral plexus block plus general anesthesia and unilateral spinal anesthesia in elderly patients undergoing hip fracture surgery: a pilot randomized controlled trial. Evid Based Complement Alternat Med 2021;&#x25a0;:6685497. 10.1155/2021/6685497</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6685497</ArticleId><ArticleId IdType="pmc">PMC8105098</ArticleId><ArticleId IdType="pubmed">34012474</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S, Kim SH, Park KK, et al. . Effects of anesthesia techniques on outcomes after hip fracture surgery in elderly patients: a prospective, randomized, controlled trial. J Clin Med 2020;6:1605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7355551</ArticleId><ArticleId IdType="pubmed">32466360</ArticleId></ArticleIdList></Reference><Reference><Citation>Meuret P, Bouvet L, Villet B, et al. . Hypobaric unilateral spinal anaesthesia versus general anaesthesia in elderly patients undergoing hip fracture surgical repair: a prospective randomised open trial. Turk J Anaesthesiol Reanim 2018;2:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5937458</ArticleId><ArticleId IdType="pubmed">29744247</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonin M, Delsuc C, Meuret P, et al. . Hypobaric unilateral spinal anesthesia versus general anesthesia for hip fracture surgery in the elderly: a randomized controlled trial. Anesth Analg 2022;6:1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">36135347</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel V, Champaneria R, Dretzke J, et al. . Effect of regional versus general anaesthesia on postoperative delirium in elderly patients undergoing surgery for hip fracture: a systematic review. BMJ Open 2018;12:e020757.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6286489</ArticleId><ArticleId IdType="pubmed">30518580</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Waesberghe J, Stevanovic A, Rossaint R, et al. . General vs. neuraxial anaesthesia in hip fracture patients: a systematic review and meta-analysis. BMC Anesthesiol 2017;1:87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5490182</ArticleId><ArticleId IdType="pubmed">28659127</ArticleId></ArticleIdList></Reference><Reference><Citation>Urwin SC, Parker MJ, Griffiths R. General versus regional anaesthesia for hip fracture surgery: a meta-analysis of randomized trials. Br J Anaesth 2000;4:450&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">10823094</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenson RM, Pace NL. Anesthetic techniques during surgical repair of femoral neck fractures. A meta-analysis, Anesthesiol 1992;6:1095&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">1466461</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021;88:105906. 10.1016/j.ijsu.2021.105906</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2021.105906</ArticleId><ArticleId IdType="pubmed">33789826</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea BJ, Reeves BC, Wells G, et al. . AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj 2017;358:j4008. 10.1136/bmj.j4008</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j4008</ArticleId><ArticleId IdType="pmc">PMC5833365</ArticleId><ArticleId IdType="pubmed">28935701</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Kunz R, et al. . What is &#x2018;quality of evidence&#x2019; and why is it important to clinicians? Bmj 2008;7651:995&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2364804</ArticleId><ArticleId IdType="pubmed">18456631</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt G, Oxman AD, Akl EA, et al. . GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;4:383&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pubmed">21195583</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, et al. . The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. 10.1136/bmj.d5928</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Soft 2010;3:1&#x2013;48.</Citation></Reference><Reference><Citation>Higgins JP, Thomas J, Chandler J, et al. . Cochrane Handbook for Systematic Reviews of Interventions. John Wiley &amp; Sons; 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D, Wan X, Liu J, et al. . Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 2018;6:1785&#x2013;1805.</Citation><ArticleIdList><ArticleId IdType="pubmed">27683581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Wang W, Liu J, et al. . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135. 10.1186/1471-2288-14-135</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-135</ArticleId><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Biboulet P, Jourdan A, Van Haevre V, et al. . Hemodynamic profile of target-controlled spinal anesthesia compared with 2 target-controlled general anesthesia techniques in elderly patients with cardiac comorbidities. Reg Anesth Pain Med 2012;4:433&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">22609644</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigler D, Adelh&#xf8;j B, Petring OU, et al. . Mental function and morbidity after acute hip surgery during spinal and general anaesthesia. Anaesthesia 1985;40:672&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">4025772</ArticleId></ArticleIdList></Reference><Reference><Citation>Casati A, Aldegheri G, Vinciguerra E, et al. . Randomized comparison between sevoflurane anaesthesia and unilateral spinal anaesthesia in elderly patients undergoing orthopaedic surgery. Eur J Anaesthesiol 2003;20:640&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">12932066</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis FM, Laurenson VG. Spinal anaesthesia or general anaesthesia for emergency hip surgery in elderly patients. Anaesth Intensive Care 1981;9:352&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">6797318</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis FM, Woolner DF, Frampton C, et al. . Prospective, multi-centre trial of mortality following general or spinal anaesthesia for hip fracture surgery in the elderly. Br J Anaesth 1987;59:1080&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">3311100</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghighi M, Sedighinejad A, Nabi BN, et al. . Is Spinal Anesthesia with Low Dose Lidocaine Better than Sevoflorane Anesthesia in Patients Undergoing Hip Fracture Surgery. Arch Bone Jt Surg 2017;5:226&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5592363</ArticleId><ArticleId IdType="pubmed">28913379</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Li J, Yuan L, et al. . Effect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery: The RAGA Randomized Trial. Jama 2022;327:50&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689436</ArticleId><ArticleId IdType="pubmed">34928310</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie PJ, Wishart HY, Dewar KM, et al. . Comparison of the effects of spinal anaesthesia and general anaesthesia on postoperative oxygenation and perioperative mortality. Br J Anaesth 1980;52:49&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">6769450</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie PJ, Wishart HY, Smith G. Long-term outcome after repair of fractured neck of femur. Comparison of subarachnoid and general anaesthesia. Br J Anaesth 1984;56:581&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">6721969</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie PJ, Wishart HY, Gray I, et al. . Effects of anaesthetic technique on deep vein thrombosis. A comparison of subarachnoid and general anaesthesia. Br J Anaesth 1985;57:853&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">4027101</ArticleId></ArticleIdList></Reference><Reference><Citation>Messina A, Frassanito L, Colombo D, et al. . Hemodynamic changes associated with spinal and general anesthesia for hip fracture surgery in severe ASA III elderly population: a pilot trial. Minerva Anestesiol 2013;79:1021&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23635998</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman MD, Mehta S, Bannister ER, et al. . Pilot Randomized Controlled Trial of Spinal Versus General Anesthesia for Hip Fracture Surgery. J Am Geriatr Soc 2016;64:2604&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5180205</ArticleId><ArticleId IdType="pubmed">27996117</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker MJ, Griffiths R. General versus regional anaesthesia for hip fractures. A pilot randomised controlled trial of 322 patients. Injury 2015;46:1562&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26049662</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L, Fang P, Fang Y, et al. . Comparison of Effects between Combined Lumbar-Sacral Plexus Block plus General Anesthesia and Unilateral Spinal Anesthesia in Elderly Patients Undergoing Hip Fracture Surgery: A Pilot Randomized Controlled Trial. Evid Based Complement Alternat Med 2021;2021:6685497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8105098</ArticleId><ArticleId IdType="pubmed">34012474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickstr&#xf6;m I, Holmberg I, Stef&#xe1;nsson T. Survival of female geriatric patients after hip fracture surgery. A comparison of 5 anesthetic methods. Acta Anaesthesiol Scand 1982;26:607&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">7158270</ArticleId></ArticleIdList></Reference><Reference><Citation>Mufarrih SH, Qureshi NQ, Schaefer MS, et al. . Regional anaesthesia for lower extremity amputation is associated with reduced postoperative complications compared with general anaesthesia. Eur J Vasc Endovasc Surg 2021;3:476&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">34303598</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa AS, Ferrito C, Paiva JA. Intubation-associated pneumonia: an integrative review. Intensive Crit Care Nurs 2018;44:45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">28869146</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, Hu J, Ma D. Postoperative delirium: perioperative assessment, risk reduction, and management. Br J Anaesth 2020;4:492&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">32798069</ArticleId></ArticleIdList></Reference><Reference><Citation>Palanne R, Rantasalo M, Vakkuri A, et al. . Effects of anaesthesia method and tourniquet use on recovery following total knee arthroplasty: a randomised controlled study. Br J Anaesth 2020;5:762&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">32620260</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu SY, Li C, Zhang PX. Enhanced recovery after surgery for hip fractures: a systematic review and meta-analysis. Perioper Med (Lond) 2021;1:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8436561</ArticleId><ArticleId IdType="pubmed">34511117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W, Yan Y, Sun Y, et al. . Implementation of Enhanced Recovery After Surgery (ERAS) protocol for elderly patients receiving surgery for intertrochanteric fracture: a propensity score-matched analysis. J Orthop Surg Res 2021;1:469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8317361</ArticleId><ArticleId IdType="pubmed">34315507</ArticleId></ArticleIdList></Reference><Reference><Citation>Morcos MW, Nowak L, Schemitsch E. Prolonged surgical time increases the odds of complications following total knee arthroplasty. Can J Surg 2021;3:E273&#x2013;E279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8327989</ArticleId><ArticleId IdType="pubmed">33908732</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornell&#xe0; N, Sancho J, Sitges-Serra A. Short and long-term outcomes after surgical procedures lasting for more than six hours. Sci Rep 2017;1:9221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5569056</ArticleId><ArticleId IdType="pubmed">28835620</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhang J, Yang L, et al. . Isoflurane and sevoflurane increase interleukin-6 levels through the nuclear factor-kappa B pathway in neuroglioma cells. Br J Anaesth 2013;Suppl 1:i82&#x2013;i91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3667345</ArticleId><ArticleId IdType="pubmed">23604542</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu X, Sun JM. General anesthesia vs spinal anesthesia for patients undergoing total-hip arthroplasty: a meta-analysis. Med (Baltimore) 2019;16:e14925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494405</ArticleId><ArticleId IdType="pubmed">31008923</ArticleId></ArticleIdList></Reference><Reference><Citation>Maradit Kremers H, Larson DR, Crowson CS, et al. . Prevalence of total hip and knee replacement in the United States. J Bone Joint Surg Am 2015;17:1386&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551172</ArticleId><ArticleId IdType="pubmed">26333733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Zhi X, Zhang H. Investigation on the etiology of patients undergoing nontraumatic total hip arthroplasty in China. J Orthop Surg (Hong Kong) 2022;1:10225536221092114.</Citation><ArticleIdList><ArticleId IdType="pubmed">35400228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari M, Swiontkowski M. Management of acute hip fracture. N Engl J Med 2017;21:2053&#x2013;2062.</Citation><ArticleIdList><ArticleId IdType="pubmed">29166235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MD, Parry M, Whitehouse MR, et al. . Early death following revision total hip arthroplasty. Hip Int 2018;4:400&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">29218686</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosk CA, Mus M, Vroemen JP, et al. . Dementia and delirium, the outcomes in elderly hip fracture patients. Clin Interv Aging 2017;12:421&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5354532</ArticleId><ArticleId IdType="pubmed">28331300</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang W, Lv H, Feng C, et al. . Preventable risk factors of mortality after hip fracture surgery: systematic review and meta-analysis. Int J Surg 2018;52:320&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">29530826</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandharipande P, Ely EW. Sedative and analgesic medications: risk factors for delirium and sleep disturbances in the critically ill. Crit Care Clin 2006;2:313&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">16678002</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EHZ, Sunderland S, Edwards NY, et al. . A single prophylactic dose of ondansetron given at cessation of postoperative propofol sedation decreases postoperative nausea and vomiting in cardiac surgery patients: a randomized controlled trial. Anesth Analg 2020;4:1164&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">32925337</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng H, Chen BP, Soleas IM, et al. . Prolonged operative duration increases risk of surgical site infections: a systematic review. Surg Infect (Larchmt) 2017;6:722&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5685201</ArticleId><ArticleId IdType="pubmed">28832271</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak LL, Schemitsch EH. Duration of surgery affects the risk of complications following total hip arthroplasty. Bone Joint J 2019;6_Supple_B:51&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">31146572</ArticleId></ArticleIdList></Reference><Reference><Citation>Said CM, Delahunt M, Ciavarella V, et al. . Factors impacting early mobilization following hip fracture: an observational study. J Geriatr Phys Ther 2021;2:88&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">33534334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenyon-Smith T, Nguyen E, Oberai T, et al. . Early mobilization post-hip fracture surgery. Geriatr Orthop Surg Rehabil 2019;10:2151459319826431. 10.1177/2151459319826431</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2151459319826431</ArticleId><ArticleId IdType="pmc">PMC6454638</ArticleId><ArticleId IdType="pubmed">31001454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37904393</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><Issue>43</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>27</Day></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Ultrasound surveillance for deep venous thrombosis and subsequent venous thromboembolism in adults with trauma: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e35625</StartPage><MedlinePgn>e35625</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e35625</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000035625</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Studies have shown routine ultrasound surveillance (RUSS) will facilitate deep vein thrombosis (DVT) detection in patients with trauma and reduce the subsequent incidence of pulmonary embolism (PE); however, the findings were inconsistent. In adults with trauma at a high risk of venous thromboembolism, this systematic review and meta-analysis compared RUSS outcomes with those of "no RUSS."</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three databases were screened for relevant articles from inception to October 18, 2021. Randomized controlled trials (RCTs) and observational studies comparing RUSS with no RUSS were included. We used relative risks (RRs), odds ratios (ORs), and mean differences to pool effect estimates for dichotomous and continuous outcomes. The cochrane risk of bias or the risk of bias in non-randomized studies of interventions were used to assess bias risk. The grading of recommendations, assessment, development, and evaluation framework assessed the certainty of the evidence.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Out of 1685 articles, 5 met the inclusion criteria (RCT: 1; observational studies: 4). Observational studies suggested RUSS is associated with higher odds of DVT detection (OR, 4.87; 95% confidence interval [CI], 3.13-7.57; very low certainty). Whereas higher risks of DVT were associated with RUSS in the RCT (distal DVT: RR, 15.48; 95% CI, 7.62-31.48; low certainty, and proximal DVT: RR, 2.37; 95% CI, 1.04-5.39; very low certainty). Reduced odds of PE risk were observed with the RUSS (OR, 0.47; 95% CI, 0.24-0.91; very low certainty). Observational studies indicated that RUSS had an uncertain effect on mortality (OR, 0.46; 95% CI, 0.06-3.49). In the RCT, times to proximal and distal DVT diagnoses were shorter with RUSS (proximal DVT, mean difference 2.25 days shorter [95% CI, 5.74-1.24]; distal DVT, mean differences 1.56 days shorter [95% CI, 4.22-1.12]; very low certainty for both). Increasing bleeding risk was not linked to the RUSS group (RR, 1.24; 95% CI, 0.31-4.92).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The RUSS efficacy in adults with trauma at high risk for venous thromboembolism showed that it increases DVT detection, decreases PE incidence, and shortens the time to DVT diagnosis, with an uncertain impact on mortality. The evidence is low or very low in certainty because of bias, inconsistency, imprecision, and indirectness.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 the Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Sharydah</LastName><ForeName>Abdulaziz M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-6590-5850</Identifier><AffiliationInfo><Affiliation>Diagnostic and Interventional Radiology Department, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshahrani</LastName><ForeName>Mohammed S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maghrabi</LastName><ForeName>Khalid</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tashkandi</LastName><ForeName>Wail</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Surgery, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Critical Care, Fakeeh Care Group, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amer</LastName><ForeName>Marwa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical/Critical Pharmacy Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Medicine and Pharmacy, Alfaisal University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>2</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>31</Day><Hour>1</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37904393</ArticleId><ArticleId IdType="pmc">PMC10615543</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000035625</ArticleId><ArticleId IdType="pii">00005792-202310270-00049</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haut ER, Schneider EB, Patel A, et al. . Duplex ultrasound screening for deep vein thrombosis in asymptomatic trauma patients: a survey of individual trauma surgeon opinions and current trauma center practices. J Trauma. 2011;70:27&#x2013;33; discussion 33.</Citation><ArticleIdList><ArticleId IdType="pubmed">21217477</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipolle MD, Wojcik R, Seislove E, et al. . The role of surveillance duplex scanning in preventing venous thromboembolism in trauma patients. J Trauma. 2002;52:453&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11901319</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen CJ, Murray CR, Meizoso JP, et al. . Surveillance and early management of deep vein thrombosis decreases rate of pulmonary embolism in high-risk trauma patients. J Am Coll Surg. 2016;222:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">26616034</ArticleId></ArticleIdList></Reference><Reference><Citation>Haut ER, Noll K, Efron DT, et al. . Can increased incidence of deep vein thrombosis (DVT) be used as a marker of quality of care in the absence of standardized screening? The potential effect of surveillance bias on reported DVT rates after trauma. J Trauma. 2007;63:1132&#x2013;5; discussion 1135.</Citation><ArticleIdList><ArticleId IdType="pubmed">17993962</ArticleId></ArticleIdList></Reference><Reference><Citation>Shackford SR, Cipolle MD, Badiee J, et al. . Determining the magnitude of surveillance bias in the assessment of lower extremity deep venous thrombosis: a prospective observational study of two centers. J Trauma Acute Care Surg. 2016;80:734&#x2013;9; discussion 740.</Citation><ArticleIdList><ArticleId IdType="pubmed">26891155</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel S, Patel N, McGuire MF, et al. . Analysis of venous thromboembolism in neurosurgical patients undergoing standard versus routine ultrasonography. J Thromb Thrombolysis. 2019;47:209&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">30392138</ArticleId></ArticleIdList></Reference><Reference><Citation>Satiani B, Falcone R, Shook L, et al. . Screening for major deep vein thrombosis in seriously injured patients: a prospective study. Ann Vasc Surg. 1997;11:626&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363309</ArticleId></ArticleIdList></Reference><Reference><Citation>Spain DA, Richardson JD, Polk HC, Jr, et al. . Venous thromboembolism in the high-risk trauma patient: do risks justify aggressive screening and prophylaxis? J Trauma. 1997;42:463&#x2013;7; discussion 467.</Citation><ArticleIdList><ArticleId IdType="pubmed">9095114</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano LM, Garlapati VS, Heard SO, et al. . Asymptomatic deep venous thrombosis in the trauma patient: is an aggressive screening protocol justified? J Trauma. 1995;39:651&#x2013;7; discussion 657.</Citation><ArticleIdList><ArticleId IdType="pubmed">7473949</ArticleId></ArticleIdList></Reference><Reference><Citation>Piotrowski JJ, Alexander JJ, Brandt CP, et al. . Is deep vein thrombosis surveillance warranted in high-risk trauma patients? Am J Surg. 1996;172:210&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8795534</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarcz TH, Quick RC, Minion DJ, et al. . Enoxaparin treatment in high-risk trauma patients limits the utility of surveillance venous duplex scanning. J Vasc Surg. 2001;34:447&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">11533596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandle J, Shackford SR, Kahl JE, et al. . The value of lower-extremity duplex surveillance to detect deep vein thrombosis in trauma patients. J Trauma Acute Care Surg. 2013;74:575&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">23354253</ArticleId></ArticleIdList></Reference><Reference><Citation>De Martino RR, Beck AW, Edwards MS, et al. . Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry. J Vasc Surg. 2012;56:1045&#x2013;51.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3767393</ArticleId><ArticleId IdType="pubmed">22832263</ArticleId></ArticleIdList></Reference><Reference><Citation>Velmahos GC, Nigro J, Tatevossian R, et al. . Inability of an aggressive policy of thromboprophylaxis to prevent deep venous thrombosis (DVT) in critically injured patients: are current methods of DVT prophylaxis insufficient? J Am Coll Surg. 1998;187:529&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809571</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietch ZC, Edwards BL, Thames M, et al. . Rate of lower-extremity ultrasonography in trauma patients is associated with rate of deep venous thrombosis but not pulmonary embolism. Surgery. 2015;158:379&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492879</ArticleId><ArticleId IdType="pubmed">26032827</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietch ZC, Petroze RT, Thames M, et al. . The &#x201c;high-risk&#x201d; deep venous thrombosis screening protocol for trauma patients: is it practical? J Trauma Acute Care Surg. 2015;79:970&#x2013;5; discussion 975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684967</ArticleId><ArticleId IdType="pubmed">26488317</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker JE, Niziolek GM, Elson NC, et al. . Optimizing lower extremity duplex ultrasound screening after traumatic injury. J Surg Res. 2019;243:143&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">31176284</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GE, Pugh A, Williams SG, et al. . Lower extremity duplex ultrasound screening protocol for moderate- and high-risk trauma patients. J Surg Res. 2019;235:280&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">30691807</ArticleId></ArticleIdList></Reference><Reference><Citation>Azarbal A, Rowell S, Lewis J, et al. . Duplex ultrasound screening detects high rates of deep vein thromboses in critically ill trauma patients. J Vasc Surg. 2011;54:743&#x2013;7; discussion 747.</Citation><ArticleIdList><ArticleId IdType="pubmed">21620614</ArticleId></ArticleIdList></Reference><Reference><Citation>Amer M, Alshahrani MS, Arabi YM, et al. . Saudi Critical Care Society clinical practice guidelines on the prevention of venous thromboembolism in adults with trauma: reviewed for evidence-based integrity and endorsed by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Ann Intensive Care. 2023;13:1&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10172441</ArticleId><ArticleId IdType="pubmed">37165105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigur&#xf0;sson MI, Chew M, Olkkola KT, et al. . Saudi critical care society clinical practice guidelines on the prevention of venous thromboembolism in adults with trauma: endorsement by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. Acta Anaesthesiol Scand. 2023;67:1288&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">37280639</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, et al. . Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:e1&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19631507</ArticleId></ArticleIdList></Reference><Reference><Citation>Veritas Health Innovation Melbourne, Australia. Covidence. Covidence systematic review software.
Available at: http://www.covidence.org [access date September 16, 2022].</Citation></Reference><Reference><Citation>Guyatt G, Busse J. Methods commentary: risk of bias in randomized trials 1. 2019.</Citation></Reference><Reference><Citation>J&#xfc;ni P, Loke Y, Pigott T, et al. . Risk of bias in non-randomized studies of interventions (ROBINS-I): detailed guidance. Br Med J. 2016.</Citation></Reference><Reference><Citation>Sch&#xfc;nemann HJ, Vist GE, Higgins JP, et al. . Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, Cochrane Handbook for Systematic Reviews of Interventions Version 6.1. Cochrane; 2020: Available at: https://training.cochrane.org/handbook/current/chapter-15 [access date September 16, 2022].</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M, Li T, Page MJ, et al. . Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10:ED000142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10284251</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Zeng J, Tian J, et al. . Multiple uses of forest plots in presenting analysis results in health research. J Clin Epidemiol. 2020;117:89&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">31589955</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Wang W, Liu J, et al. . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi YM, Burns KEA, Alsolamy SJ, et al. . Surveillance or no surveillance ultrasonography for deep vein thrombosis and outcomes of critically ill patients: a pre-planned sub-study of the PREVENT trial. Intensive Care Med. 2020;46:737&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">32095845</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay AB, Morris DS, Woller SC, et al. . Trauma patients at risk for venous thromboembolism who undergo routine duplex ultrasound screening experience fewer pulmonary emboli: a prospective randomized trial. J Trauma Acute Care Surg. 2021;90:787&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">33560104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruen GS, McClain EJ, Gruen RJ. The diagnosis of deep vein thrombosis in the multiply injured patient with pelvic ring or acetabular fractures. Orthopedics. 1995;18:253&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7761315</ArticleId></ArticleIdList></Reference><Reference><Citation>White RH, Goulet JA, Bray TJ, et al. . Deep-vein thrombosis after fracture of the pelvis: assessment with serial duplex-ultrasound screening. J Bone Joint Surg Am. 1990;72:495&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">2182638</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams RC, Hamrick M, Berenguer C, et al. . Four years of an aggressive prophylaxis and screening protocol for venous thromboembolism in a large trauma population. J Trauma. 2008;65:300&#x2013;6; discussion 306.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695464</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadyan V, Clinchot DM, Colachis SC. Cost-effectiveness of duplex ultrasound surveillance in spinal cord injury. Am J Phys Med Rehabil. 2004;83:191&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15043353</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce CA, Haut ER, Kardooni S, et al. . Surveillance bias and deep vein thrombosis in the national trauma data bank: the more we look, the more we find. J Trauma. 2008;64:932&#x2013;6; discussion 936.</Citation><ArticleIdList><ArticleId IdType="pubmed">18404058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorkgitis BK, Berndtson AE, Cross A, et al. . American association for the surgery of trauma/American college of surgeons-committee on trauma clinical protocol for inpatient venous thromboembolism prophylaxis after trauma. J Trauma Acute Care Surg. 2022;92:597&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pubmed">34797813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ley EJ, Brown CVR, Moore EE, et al. . Updated guidelines to reduce venous thromboembolism in trauma patients: a Western trauma association critical decisions algorithm. J Trauma Acute Care Surg. 2020;89:971&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7587238</ArticleId><ArticleId IdType="pubmed">32590563</ArticleId></ArticleIdList></Reference><Reference><Citation>Meizoso JP, Karcutskie CA, 4th, Ray JJ, et al. . A simplified stratification system for venous thromboembolism risk in severely injured trauma patients. J Surg Res. 2017;207:138&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">27979470</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould MK, Garcia DA, Wren SM, et al. . Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e227S&#x2013;77S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278061</ArticleId><ArticleId IdType="pubmed">22315263</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiasson TC, Manns BJ, Stelfox HT. An economic evaluation of venous thromboembolism prophylaxis strategies in critically ill trauma patients at risk of bleeding. PLoS Med. 2009;6:e1000098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2695771</ArticleId><ArticleId IdType="pubmed">19554085</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser JD, Anderson DR. Deep venous thrombosis: recent advances and optimal investigation with US. Radiology. 1999;211:9&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">10189448</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Kunz R, et al. . GRADE Working Group GRADE guidelines: 8 Rating the quality of evidence--indirectness. J Clin Epidemiol. 2011;64:1303&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">21802903</ArticleId></ArticleIdList></Reference><Reference><Citation>Granholm A, Alhazzani W, Derde LPG, et al. . Randomised clinical trials in critical care: past, present and future. Intensive Care Med. 2022;48:164&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8636283</ArticleId><ArticleId IdType="pubmed">34853905</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36423623</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2567-689X</ISSN><JournalIssue CitedMedium="Internet"><Volume>123</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Thrombosis and haemostasis</Title><ISOAbbreviation>Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Diagnostic Accuracy of V/Q and Q SPECT/CT in Patients with Suspected Acute Pulmonary Embolism: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>700</StartPage><EndPage>713</EndPage><MedlinePgn>700-713</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/a-1986-8878</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">&#x2003;Computed tomography (CT) pulmonary angiography has simplified the diagnostic approach to patients with clinically suspected acute pulmonary embolism (PE), but alternative imaging tests are still advocated. We aimed to systematically assess the diagnostic accuracy of ventilation/perfusion (V/Q) and Q single-photon emission CT combined with low-dose CT (SPECT/CT) for PE diagnosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">&#x2003;Studies evaluating the diagnostic accuracy of SPECT/CT for the diagnosis of acute PE were systematically searched in MEDLINE and EMBASE databases (up to August 2022). The QUADAS-2 tool was used for risk-of-bias assessment of the primary studies. A bivariate random-effects regression approach was used for summary estimates of both sensitivity and specificity. The PROSPERO registration number is CRD42021276538.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">&#x2003;Eight studies, for a total of 1,086 patients, were included. The risk of bias of all included studies was high. The weighted mean prevalence of PE was 27.1% at the random-effects model. The SPECT/CT bivariate weighted mean sensitivity was 96% (95% confidence interval [CI]: 93-98%), with a bivariate weighted mean specificity of 95% (95% CI: 90-97%). At subgroup analysis, for V/Q SPECT/CT bivariate weighted mean sensitivity and specificity were 96% (95% CI: 89-98%) and 96% (95% CI: 91-99%), while for Q SPECT/CT they were 96% (95% CI: 92-98%) and 84% (95% CI: 66-93%), respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">&#x2003;V/Q SPECT/CT has high sensitivity and specificity for the diagnosis of acute PE, meanwhile Q SPECT/CT has high sensitivity but limited specificity for the diagnosis of PE. Management studies will conclusively ascertain the actual role of SPECT/CT in the diagnostic workup of patients with suspected acute PE.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Squizzato</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5705-2897</Identifier><AffiliationInfo><Affiliation>Research Center on Thromboembolic Disorders and Antithrombotic Therapies, ASST Lariana, University of Insubria, Como, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venturini</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine Residency Program, School of Medicine, University of Insubria, Varese and Como, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelitti</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Internal Medicine Residency Program, School of Medicine, University of Insubria, Varese and Como, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellini</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Internal Medicine Residency Program, School of Medicine, University of Insubria, Varese and Como, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernasconi</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Internal Medicine Unit, ASST Sette Laghi, Cittiglio, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Depalo</LastName><ForeName>Tommaso</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Unit, 'Sant'Anna' Hospital, ASST Lariana, Como, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corso</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Unit, 'Sant'Anna' Hospital, ASST Lariana, Como, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Nicoletta</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-8922-8823</Identifier><AffiliationInfo><Affiliation>Department of Pathology, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Thromb Haemost</MedlineTA><NlmUniqueID>7608063</NlmUniqueID><ISSNLinking>0340-6245</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015899" MajorTopicYN="Y">Tomography, Emission-Computed, Single-Photon</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>24</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36423623</ArticleId><ArticleId IdType="doi">10.1055/a-1986-8878</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38021015</PMID><DateRevised><Year>2023</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-5294</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Brain &amp; spine</Title><ISOAbbreviation>Brain Spine</ISOAbbreviation></Journal><ArticleTitle>Does the choice of chemoprophylaxis affect the prevention of deep vein thrombosis in lumbar fusion surgery? A systematic review of the literature.</ArticleTitle><Pagination><StartPage>102711</StartPage><MedlinePgn>102711</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102711</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bas.2023.102711</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">To date, the available guidance on venous thromboembolism (VTE) prevention in elective lumbar fusion surgery is largely open to surgeon interpretation and preference without any specific suggested chemoprophylactic regimen.</AbstractText><AbstractText Label="RESEARCH QUESTION" NlmCategory="UNASSIGNED">This study aimed to comparatively analyze the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) with the use of commonly employed chemoprophylactic agents such as unfractionated heparin (UH) and low molecular weight heparin (LMWH) in lumbar fusion surgery.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">An independent systematic review of four scientific databases (PubMed, Scopus, clinicaltrials.gov, Web of Science) was performed to identify relevant articles as per the preferred reporting in systematic reviews and meta-analysis (PRISMA) guidelines. Studies reporting on DVT/PE outcomes of lumbar fusion surgery in adult patients with UH or LMWH chemoprophylaxis were included for analysis. Analysis was performed using the Stata software.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Twelve studies with 8495 patients were included in the analysis. A single-arm meta-analysis of the included studies found a DVT incidence of 14% (95%CI [8%-20%]) and 1% (95%CI [-6% - 8%]) with LMWH and UH respectively. Both the chemoprophylaxis agents prevented PE with a noted incidence of 0% (95%CI [0%-0.1%]) and 0% (95%CI [0%-1%]) with LMWH and UH respectively. The risk of bleeding-related complications with the usage of LMWH and UH was 0% (95% CI [0.0%-0.30%]) and 3% (95% CI [0.3%-5%]) respectively.</AbstractText><AbstractText Label="DISCUSSION AND CONCLUSION" NlmCategory="UNASSIGNED">Both LMWH and UH reduces the overall incidence of DVT/PE, but there is a paucity of evidence analyzing the comparative effectiveness of the chemoprophylaxis regimens in lumbar fusion procedures. The heterogeneity in data prevents any conclusions, as there remains an evidence gap. We recommend future high-quality randomized controlled trials to investigate in this regard to help develop recommendations on thromboprophylaxis usage.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muthu</LastName><ForeName>Sathish</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Spine Surgery, Orthopaedic Research Group, Coimbatore, Tamil Nadu, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, Faculty of Engineering, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedics, Government Medical College, Karur, Tamil Nadu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mavrovounis</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Faculty of Medicine, University of Thessaly, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corluka</LastName><ForeName>Stipe</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Spinal surgery Division, Department of Traumatology, University Hospital Centre Sestre milosrdnice, Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anatomy and Physiology, University of Applied Health Sciences, Zagreb, Croatia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Catherine Specialty Hospital, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buser</LastName><ForeName>Zorica</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Gerling Institute, Brooklyn, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, NYU Grossman School of Medicine, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodano</LastName><ForeName>Giovanni Barbanti</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>IRCCS Istituto Ortopedico Rizzoli, Bologna, IT, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yabin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Research Department, AO Spine International, Davos, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meisel</LastName><ForeName>Hans-Jorg</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>BG Klinikum Bergmannstrost Halle, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Neurological Surgery, Keck School of Medicine, University of Southern California, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>S Tim</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demetriades</LastName><ForeName>Andreas K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Edinburgh Spinal Surgery Outcome Studies Group, Department of Neurosurgery, Royal Infirmary Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>AO Spine Knowledge Forum Degenerative</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Brain Spine</MedlineTA><NlmUniqueID>9918470888906676</NlmUniqueID><ISSNLinking>2772-5294</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemoprophylaxis</Keyword><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Heparin</Keyword><Keyword MajorTopicYN="N">LMWH</Keyword><Keyword MajorTopicYN="N">Low-molecular-weight heparin</Keyword><Keyword MajorTopicYN="N">Lumbar fusion</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword></KeywordList><CoiStatement>THE authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>14</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38021015</ArticleId><ArticleId IdType="pmc">PMC10668088</ArticleId><ArticleId IdType="doi">10.1016/j.bas.2023.102711</ArticleId><ArticleId IdType="pii">S2772-5294(23)00999-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adogwa O., Parker S.L., Bydon A., et al. Comparative effectiveness of minimally invasive versus open transforaminal lumbar interbody fusion: 2-year assessment of narcotic use, return to work, disability, and quality of life. J. Spinal Disord. Tech. 2011;24:479&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">21336176</ArticleId></ArticleIdList></Reference><Reference><Citation>Altshuler M., Mueller K., MacConnell A., et al. Does minimally invasive spine surgery reduce the rate of perioperative medical complications? A retrospective single-center experience of 1435 degenerative lumbar spine surgeries. Eur. Spine J. 2021;30:122&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">32700125</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarado A.M., Porto G.B.F., Wessell J., et al. Venous thromboprophylaxis in spine surgery. Global Spine J. 2020;10:65S&#x2013;70S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6947674</ArticleId><ArticleId IdType="pubmed">31934524</ArticleId></ArticleIdList></Reference><Reference><Citation>Badireddy M., Mudipalli V.R.  StatPearls. Treasure Island (FL. StatPearls Publishing; 2022. Deep venous thrombosis prophylaxis.http://www.ncbi.nlm.nih.gov/books/NBK534865/</Citation><ArticleIdList><ArticleId IdType="pubmed">30521286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai J., Zhang W., Liu X., et al. Percutaneous transforaminal endoscopic discectomy in the treatment of senior patients with lumbar degenerative disc disease. Exp. Ther. Med. 2019;17:874&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6307357</ArticleId><ArticleId IdType="pubmed">30651875</ArticleId></ArticleIdList></Reference><Reference><Citation>BOA Guidance documents. https://www.boa.ac.uk/standards-guidance/guidance-documents.html</Citation></Reference><Reference><Citation>Bono C., Watters W., Heggeness M., et al. An evidence-based clinical guideline for the use of antithrombotic therapies in spine surgery. Epub ahead of print. 2009 doi: 10.1016/j.spinee.2009.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spinee.2009.09.005</ArticleId><ArticleId IdType="pubmed">19931184</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla S., Ruosi C., La Maida G.A., et al. Prevention of venous thromboembolism in spinal surgery. Eur. Spine J. 2004;13:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468034</ArticleId><ArticleId IdType="pubmed">14610663</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloney M.B., Hopkins B., Dhillon E., et al. Anterior approach lumbar fusions cause a marked increase in thromboembolic events: causal inferences from a propensity-matched analysis of 1147 patients. Clin. Neurol. Neurosurg. 2022;223</Citation><ArticleIdList><ArticleId IdType="pubmed">36347180</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon E.S., Khanna R., Cloney M., et al. Timing and risks of chemoprophylaxis after spinal surgery: a single-center experience with 6869 consecutive patients. J. Neurosurg. Spine. 2017;27:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">28885127</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawi H.M.T., Saba K., Cunningham A., et al. Venous thromboembolism in adult elective spinal surgery: a tertiary centre review of 2181 patients. The Bone &amp; Joint Journal. 2017;99-B:1204&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pubmed">28860401</ArticleId></ArticleIdList></Reference><Reference><Citation>Finks S.W., Trujillo T.C., Dobesh P.P. Management of venous thromboembolism: recent advances in oral anticoagulation therapy. Ann. Pharmacother. 2016;50:486&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4871170</ArticleId><ArticleId IdType="pubmed">26917821</ArticleId></ArticleIdList></Reference><Reference><Citation>Glotzbecker M.P., Bono C.M., Wood K.B., et al. Postoperative spinal epidural hematoma: a systematic review. Spine (Phila Pa 1976. 2010;35:E413&#x2013;E420.</Citation><ArticleIdList><ArticleId IdType="pubmed">20431474</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould M.K., Garcia D.A., Wren S.M., et al. Prevention of VTE in nonorthopedic surgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e227S&#x2013;e277S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278061</ArticleId><ArticleId IdType="pubmed">22315263</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff M.W. Introduction: guideline update for the performance of fusion procedures for degenerative disease of the lumbar spine. J. Neurosurg. Spine. 2014;21:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">24980577</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Zou Z., Jia L., et al. Safety and effectiveness of argatroban versus heparin for preventing venous thromboembolism after lumbar decompressive surgery. Int. J. Surg. 2017;44:324&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">28694001</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiguchi M.M., Schobel H., TenEyck E., et al. The risks and benefits of early venous thromboembolism prophylaxis after elective spinal surgery: a single-centre experience. J. Perioperat. Pract. 2022;32:286&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">34301162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.M., Suk K.S., Moon S.H., et al. Deep vein thrombosis after major spinal surgery: incidence in an East Asian population. Spine (Phila Pa 1976. 2000;25:1827&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888952</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Li Z., Huo Y., et al. Time-to-event analyses of lower-limb venous thromboembolism in aged patients undergoing lumbar spine surgery: a retrospective study of 1620 patients. Aging-Us. 2019;11:8701&#x2013;8709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6814587</ArticleId><ArticleId IdType="pubmed">31613794</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Yang S.-D., Yang D.-L., et al. Risk assessment of lower-limb deep vein thrombosis in patients with lumbar spondylolisthesis: a retrospective study. Biomed. Res. 2017;28:6043&#x2013;6047.</Citation></Reference><Reference><Citation>Louie P., Harada G., Harrop J., et al. Perioperative anticoagulation management in spine surgery: initial findings from the AO spine anticoagulation global survey. Global Spine J. 2020;10:512&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359688</ArticleId><ArticleId IdType="pubmed">32677576</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin B.I., Mirza S.K., Spina N., et al. Trends in lumbar fusion procedure rates and associated hospital costs for degenerative spinal diseases in the United States, 2004 to 2015. Spine (Phila Pa 1976. 2019;44:369&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">30074971</ArticleId></ArticleIdList></Reference><Reference><Citation>Murad M.H., Sultan S., Haffar S., et al. Methodological quality and synthesis of case series and case reports. BMJ Evidence-Based Medicine. 2018;23:60&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234235</ArticleId><ArticleId IdType="pubmed">29420178</ArticleId></ArticleIdList></Reference><Reference><Citation>National Clinical Guideline Centre &#x2013; Acute and Chronic Conditions (UK). Venous Thromboembolism: Reducing The Risk Of Venous Thromboembolism (Deep Vein Thrombosis And Pulmonary Embolism) in Patients Admitted To Hospital. Royal College of Physicians (UK); London: 2010. http://www.ncbi.nlm.nih.gov/books/NBK116518/</Citation><ArticleIdList><ArticleId IdType="pubmed">23346611</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (Nice)  2018. Venous Thromboembolism in over 16s: Reducing the Risk of Hospital-Acquired Deep Vein Thrombosis or Pulmonary Embolism.https://www.nice.org.uk/guidance/ng89</Citation><ArticleIdList><ArticleId IdType="pubmed">29697228</ArticleId></ArticleIdList></Reference><Reference><Citation>Obi A.T., Pannucci C.J., Nackashi A., et al. Validation of the caprini venous thromboembolism risk assessment model in critically ill surgical patients. JAMA Surg. 2015;150:941&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pubmed">26288124</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M.J., McKenzie J.E., Bossuyt P.M., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb. Haemostasis. 2001;86:488&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487039</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson L., Jones L.E. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev. 2017;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464611</ArticleId><ArticleId IdType="pubmed">28182249</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokito S.E., Schwartz M.C., Neuwirth M.G. Deep vein thrombosis after major reconstructive spinal surgery. Spine (Phila Pa 1976. 1996;21:853&#x2013;858. discussion 859.</Citation><ArticleIdList><ArticleId IdType="pubmed">8779018</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;nemann H.J., Cushman M., Burnett A.E., et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Advances. 2018;2:3198&#x2013;3225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6258910</ArticleId><ArticleId IdType="pubmed">30482763</ArticleId></ArticleIdList></Reference><Reference><Citation>Vint H., Mawdsley M.J., Coe C., et al. The incidence of venous thromboembolism in patients undergoing anterior lumbar interbody fusion: a proposed thromboprophylactic regime. International Journal of Spine Surgery. 2021;15:348&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8059399</ArticleId><ArticleId IdType="pubmed">33900993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Wu L. Risk factors for venous thrombosis after spinal surgery: a systematic review and meta-analysis. Comput. Math. Methods Med. 2022;2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8977314</ArticleId><ArticleId IdType="pubmed">35387225</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber B., Seal A., McGirr J., et al. Case series of elective instrumented posterior lumbar spinal fusions demonstrating a low incidence of venous thromboembolism. ANZ J. Surg. 2016;86:796&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">24897952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei J., Li W., Pei Y., et al. Clinical analysis of preoperative risk factors for the incidence of deep venous thromboembolism in patients undergoing posterior lumbar interbody fusion. J. Orthop. Surg. Res. 2016;11 doi: 10.1186/s13018-016-0403-0. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-016-0403-0</ArticleId><ArticleId IdType="pmc">PMC4907081</ArticleId><ArticleId IdType="pubmed">27297081</ArticleId></ArticleIdList></Reference><Reference><Citation>West J.L., Anderson L.D. Incidence of deep vein thrombosis in major adult spinal surgery. Spine (Phila Pa 1976. 1992;17:S254&#x2013;S257.</Citation><ArticleIdList><ArticleId IdType="pubmed">1523508</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki K., Hoshino M., Omori K., et al. Prevalence and risk factors of deep vein thrombosis in patients undergoing lumbar spine surgery. J. Orthop. Sci. 2017;22:1021&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">28818570</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S.-D., Ding W.-Y., Yang D.-L., et al. Prevalence and risk factors of deep vein thrombosis in patients undergoing lumbar interbody fusion surgery. Medicine. 2015;94 doi: 10.1097/MD.0000000000002205. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000002205</ArticleId><ArticleId IdType="pmc">PMC4674212</ArticleId><ArticleId IdType="pubmed">26632909</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S.-D., Liu H., Sun Y.-P., et al. Prevalence and risk factors of deep vein thrombosis in patients after spine surgery: a retrospective case-cohort study. Sci. Rep. 2015;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4488742</ArticleId><ArticleId IdType="pubmed">26135271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C.-M., Zhang Y., Yang S.-D., et al. Risk factors for lower limb deep vein thrombosis in patients with single-level lumbar fusion: a prospective study of 710 cases. Clin. Appl. Thromb. Hemost. 2018;24:157S&#x2013;162S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6714819</ArticleId><ArticleId IdType="pubmed">30200770</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman S.L., Berven S., Streiff M.B., et al. Management of anticoagulation/antiplatelet medication and venous thromboembolism prophylaxis in elective spine surgery: concise clinical recommendations based on a modified delphi process. Spine. 2023;48:301.</Citation><ArticleIdList><ArticleId IdType="pubmed">36730667</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37873525</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2345-4644</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>The archives of bone and joint surgery</Title><ISOAbbreviation>Arch Bone Jt Surg</ISOAbbreviation></Journal><ArticleTitle>Cephalomedullary Nailing has a Higher Reoperation Rate Compared to Sliding Hip Screw Fixation in the Treatment of Intertrochanteric Femur Fractures: A Systematic Literature Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>595</StartPage><EndPage>604</EndPage><MedlinePgn>595-604</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.22038/ABJS.2023.64311.3088</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Intertrochanteric hip fractures are a common orthopaedic injury in the United States. Complications of surgical treatment include nonunion, lag screw cutout, implant failure, post-operative pain, risk of refracture or reoperation, and infection. The purpose of this study was to compare the rate of complications of sliding hip screw fixation (SHS) compared to cephalomedullary nailing (CMN) for the treatment of closed intertrochanteric femur fractures in adult patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">PubMed, CINAHL, and Cochrane Library databases were searched for studies comparing SHS to CMN in the treatment of closed intertrochanteric femur fractures in adults. Data were compiled to observe the rate of nonunion, cutout failure, infection, refracture, perioperative blood loss, reoperation, postoperative pain, pulmonary embolism/deep venous thrombosis (DVT), length of hospital stay, and mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Seventeen studies were included comprising 1,500 patients treated with SHS and 1,890 patients treated with CMN. Treatment of intertrochanteric femur fractures with SHS demonstrated significantly fewer refractures and reoperations. There was no significant difference in other variables between SHS and CMN treated groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This meta-analysis shows that the only notable difference in outcomes is patients treated with CMN have a higher rate of refracture and reoperation. With new advances in the development of both CMNs and SHS, further studies will be required to see if these differences persist in the coming years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amer</LastName><ForeName>Kamil M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Congiusta</LastName><ForeName>Dominick V</ForeName><Initials>DV</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Brendan</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Kunj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Shaath</LastName><ForeName>M Kareem</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Dalcortivo</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Irfan H</ForeName><Initials>IH</Initials></Author><Author ValidYN="Y"><LastName>Vosbikian</LastName><ForeName>Michael M</ForeName><Initials>MM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Arch Bone Jt Surg</MedlineTA><NlmUniqueID>101636743</NlmUniqueID><ISSNLinking>2345-461X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Fracture fixation</Keyword><Keyword MajorTopicYN="N">Hip fracture</Keyword><Keyword MajorTopicYN="N">Outcomes</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList><CoiStatement>Author Michael M. Vosbikian, M.D. receives honorarium for content authorship from the Journal of Bone and Joint Surgery and is an editorial board member for ePlasty. We otherwise have no other conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>24</Day><Hour>3</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37873525</ArticleId><ArticleId IdType="pmc">PMC10590488</ArticleId><ArticleId IdType="doi">10.22038/ABJS.2023.64311.3088</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA. 2009;302(14):1573&#x2013;1579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410861</ArticleId><ArticleId IdType="pubmed">19826027</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldacre MJ, Roberts SE, Yeates D. Mortality after admission to hospital with fractured neck of femur: database study. BMJ. 2002;325(7369):868&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129634</ArticleId><ArticleId IdType="pubmed">12386038</ArticleId></ArticleIdList></Reference><Reference><Citation>Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA. Cost-equivalence of different osteoporotic fractures. Osteoporos Int. 2003;14(5):383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730750</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosounidis TH, Castillo R, Kanakaris NK, Giannoudis PV. Common complications in hip fracture surgery: Tips/tricks and solutions to avoid them. Injury. 2015;46 Suppl 5:S3&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">26298022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang ST, Aitken SA, Golay SK, Silverwood RK, Biant LC. When does hip fracture surgery fail? Injury. 2014;45(7):1059&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">24794618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortman JM, Velkoff VA, Hogan H. An Aging Nation: The Older Population in the United States. ProQuest, Ann Arbor; 2014.</Citation></Reference><Reference><Citation>Kaplan K, Miyamoto R, Levine BR, Egol KA, Zuckerman JD. Surgical management of hip fractures: an evidence-based review of the literature II: intertrochanteric fractures. J Am Acad Orthop Surg. 2008;16(11):665&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">18978289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokoroghiannis C, Aktselis I, Deligeorgis A, Fragkomichalos E, Papadimas D, Pappadas I. Evolving concepts of stability and intramedullary fixation of intertrochanteric fractures--a review. Injury. 2012;43(6):686&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pubmed">21752370</ArticleId></ArticleIdList></Reference><Reference><Citation>Swart E, Makhni EC, Macaulay W, Rosenwasser MP, Bozic KJ. Cost-effectiveness analysis of fixation options for intertrochanteric hip fractures. J Bone Joint Surg Am. 2014;96(19):1612&#x2013;1620.</Citation><ArticleIdList><ArticleId IdType="pubmed">25274786</ArticleId></ArticleIdList></Reference><Reference><Citation>Asif N, Ahmad S, Qureshi OA, Jilani LZ, Hamesh T, Jameel T. Unstable Intertrochanteric Fracture Fixation - Is Proximal Femoral Locked Compression Plate Better Than Dynamic Hip Screw. J Clin Diagn Res. 2016;10(1):RC09&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4740662</ArticleId><ArticleId IdType="pubmed">26894134</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobe M, Drescher W, Heussen N, Sellei RM, Pape HC. Is helical blade nailing superior to locked minimally invasive plating in unstable pertrochanteric fractures? Clin Orthop Relat Res. 2012;470(8):2302&#x2013;2312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392400</ArticleId><ArticleId IdType="pubmed">22311725</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohl DD, Basques BA, Golinvaux NS, Miller CP, Baumgaertner MR, Grauer JN. Extramedullary compared with intramedullary implants for intertrochanteric hip fractures: thirty-day outcomes of 4432 procedures from the ACS NSQIP database. J Bone Joint Surg Am. 2014;96(22):1871&#x2013;1877.</Citation><ArticleIdList><ArticleId IdType="pubmed">25410504</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua IT, Rajamoney GN, Kwek EB. Cephalomedullary nail versus sliding hip screw for unstable intertrochanteric fractures in elderly patients. J Orthop Surg (Hong Kong). 2013;21(3):308&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">24366790</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams CI, Robinson CM, Court-Brown CM, McQueen MM. Prospective randomized controlled trial of an intramedullary nail versus dynamic screw and plate for intertrochanteric fractures of the femur. J Orthop Trauma. 2001;15(6):394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">11514765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahrengart L, T&#xf6;rnkvist H, Fornander P, et al. A randomized study of the compression hip screw and Gamma nail in 426 fractures. Clin Orthop Relat Res. 2002;(401):209&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">12151898</ArticleId></ArticleIdList></Reference><Reference><Citation>Aktselis I, Kokoroghiannis C, Fragkomichalos E, et al. Prospective randomised controlled trial of an intramedullary nail versus a sliding hip screw for intertrochanteric fractures of the femur. Int Orthop. 2014;38(1):155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3890147</ArticleId><ArticleId IdType="pubmed">24318319</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton TM, Gleeson R, Topliss C, Greenwood R, Harries WJ, Chesser TJ. A comparison of the long gamma nail with the sliding hip screw for the treatment of AO/OTA 31-A2 fractures of the proximal part of the femur: a prospective randomized trial. J Bone Joint Surg Am. 2010;92(4):792&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">20360500</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridle SH, Patel AD, Bircher M, Calvert PT. Fixation of intertrochanteric fractures of the femur A randomised prospective comparison of the gamma nail and the dynamic hip screw. J Bone Joint Surg Br. 1991;73(2):330&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">2005167</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford CH, Malkani AL, Cordray S, Roberts CS, Sligar W. The trochanteric nail versus the sliding hip screw for intertrochanteric hip fractures: a review of 93 cases. J Trauma. 2006;60(2):325&#x2013;328; discussion 328-329.</Citation><ArticleIdList><ArticleId IdType="pubmed">16508490</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulongne E, Gilleron M, Roussignol X, Lenoble E, Dujardin F. Mini-invasive nail versus DHS to fix pertrochanteric fractures: a case-control study. Orthop Traumatol Surg Res. 2009;95(8):592&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">19945367</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman CW, Lynskey TG. Intertrochanteric fractures of the femur: a randomized prospective comparison of the Gamma nail and the Ambi hip screw. Aust N Z J Surg. 1996;66(3):151&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pubmed">8639131</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung KS, So WS, Shen WY, Hui PW. Gamma nails and dynamic hip screws for peritrochanteric fractures A randomised prospective study in elderly patients. J Bone Joint Surg Br. 1992;74(3):345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">1587874</ArticleId></ArticleIdList></Reference><Reference><Citation>Morvan A, Boddaert J, Cohen-Bittan J, Picard H, Pascal-Mousselard H, Khiami F. Risk factors for cut-out after internal fixation of trochanteric fractures in elderly subjects. Orthop Traumatol Surg Res. 2018;104(8):1183&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">30342858</ArticleId></ArticleIdList></Reference><Reference><Citation>Ovesen O, Andersen M, Poulsen T, Nymark T, Overgaard S, Rock ND. The trochanteric gamma nail versus the dynamic hip screw: a prospective randomised study One-year follow-up of 146 intertrochanteric fractures. Hip Int. 2006;16(4):293&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">19219808</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SR, Kang JS, Kim HS, Lee WH, Kim YH. Treatment of intertrochanteric fracture with the Gamma AP locking nail or by a compression hip screw--a randomised prospective trial. Int Orthop. 1998;22(3):157&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619600</ArticleId><ArticleId IdType="pubmed">9728307</ArticleId></ArticleIdList></Reference><Reference><Citation>Radford PJ, Needoff M, Webb JK. A prospective randomised comparison of the dynamic hip screw and the gamma locking nail. J Bone Joint Surg Br. 1993;75(5):789&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pubmed">8376441</ArticleId></ArticleIdList></Reference><Reference><Citation>Reina N, Geiss L, Pailh&#xe9; R, Maubisson L, Laffosse JM, Chiron P. Traumax screw plate vs Gamma nail Blood loss in pertrochanteric fractures treated by minimally invasive osteosynthesis. Hip Int. 2014;24(2):200&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">24619872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronga M, Bonzini D, Valoroso M, et al. Blood loss in trochanteric fractures: multivariate analysis comparing dynamic hip screw and Gamma nail. Injury. 2017;48 Suppl 3:S44&#x2013;S47.</Citation><ArticleIdList><ArticleId IdType="pubmed">29025609</ArticleId></ArticleIdList></Reference><Reference><Citation>Saarenp&#xe4;&#xe4; I, Heikkinen T, Ristiniemi J, Hyv&#xf6;nen P, Leppilahti J, Jalovaara P. Functional comparison of the dynamic hip screw and the Gamma locking nail in trochanteric hip fractures: a matched-pair study of 268 patients. Int Orthop. 2009;33(1):255&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2899252</ArticleId><ArticleId IdType="pubmed">17943284</ArticleId></ArticleIdList></Reference><Reference><Citation>Verettas DA, Ifantidis P, Chatzipapas CN, et al. Systematic effects of surgical treatment of hip fractures: gliding screw-plating vs intramedullary nailing. Injury. 2010;41(3):279&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">20176167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung WW, Morrison RS. Hip fracture: a complex illness among complex patients. Ann Intern Med. 2011;155(4):267&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">21844553</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu E, Yang A, Harris AH, Bishop J. Which Fixation Device is Preferred for Surgical Treatment of Intertrochanteric Hip Fractures in the United States? A Survey of Orthopaedic Surgeons. Clin Orthop Relat Res. 2015;473(11):3647&#x2013;3655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586189</ArticleId><ArticleId IdType="pubmed">26208608</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones HW, Johnston P, Parker M. Are short femoral nails superior to the sliding hip screw? A meta-analysis of 24 studies involving 3,279 fractures. Int Orthop. 2006;30(2):69&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2532072</ArticleId><ArticleId IdType="pubmed">16496147</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Leung F, Xiang Z, et al. Proximal femoral nail versus dynamic hip screw fixation for trochanteric fractures: a meta-analysis of randomized controlled trials. ScientificWorldJournal. 2013;2013:805805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590640</ArticleId><ArticleId IdType="pubmed">23533361</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang SD, Jiang LS, Zhao CQ, Dai LY. No advantages of Gamma nail over sliding hip screw in the management of peritrochanteric hip fractures: a meta-analysis of randomized controlled trials. Disabil Rehabil. 2008;30(7):493&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">17852303</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton TM, Gleeson R, Topliss C, Greenwood R, Harries WJ, Chesser TJ. A comparison of the long gamma nail with the sliding hip screw for the treatment of AO/OTA 31-A2 fractures of the proximal part of the femur: a prospective randomized trial. J Bone Joint Surg Am. 2010;92(4):792&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">20360500</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung AS, Hustedt JW, Walker R, Jones C, Lowe J, Russell GV. Increasing Severity of Malnutrition Is Associated With Poorer 30-Day Outcomes in Patients Undergoing Hip Fracture Surgery. J Orthop Trauma. 2018;32(4):155&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">29558371</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiberi JV 3rd, Hansen V, El-Abbadi N, Bedair H. Increased complication rates after hip and knee arthroplasty in patients with cirrhosis of the liver. Clin Orthop Relat Res. 2014;472(9):2774&#x2013;2778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117879</ArticleId><ArticleId IdType="pubmed">24993141</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang W, Lv H, Feng C, et al. Preventable risk factors of mortality after hip fracture surgery: Systematic review and meta-analysis. Int J Surg. 2018;52:320&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">29530826</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann R, Schmidmaier G, Schulz R, Sch&#xfc;tz M, S&#xfc;dkamp NP. [Classic nail versus DHS A prospective randomised study of fixation of trochanteric femur fractures] Unfallchirurg. 1999;102(3):182&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">10232034</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Xu X, Yang X, et al. Intramedullary nails versus sliding hip screws for AO/OTA 31-A2 trochanteric fractures in adults: A meta-analysis. Int J Surg. 2017;43:67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">28549994</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36527742</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2472</ISSN><JournalIssue CitedMedium="Internet"><Volume>221</Volume><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Thrombosis research</Title><ISOAbbreviation>Thromb Res</ISOAbbreviation></Journal><ArticleTitle>The optimal regimen, efficacy and safety of tranexamic acid and aminocaproic acid to reduce bleeding for patients after total hip arthroplasty: A systematic review and Bayesian network meta-analysis.</ArticleTitle><Pagination><StartPage>120</StartPage><EndPage>129</EndPage><MedlinePgn>120-129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.thromres.2022.11.010</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-3848(22)00458-3</ELocationID><Abstract><AbstractText Label="OBJECTIVES">We aimed to evaluate the optimal regimen, efficacy and safety of tranexamic acid (TXA) and aminocaproic acid (EACA) for patients after total hip arthroplasty (THA).</AbstractText><AbstractText Label="METHODS">The network meta-analysis was guided by the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guideline. The outcomes were total blood loss, transfusion rates, hemoglobin (HB) drop, and risk for pulmonary embolism (PE) or deep vein thrombosis (DVT). Subgroup analyses were performed among most effective regimens to determine the influences of timing and number of doses.</AbstractText><AbstractText Label="RESULTS">A total of 56 eligible RCTs with different regimens were assessed. For reducing total blood loss, all high doses of TXA and EACA except high dose of intra-articular (IA) TXA, as well as medium dose of combination of intravenous and intra-articular (combined IV/IA) TXA were most effective. All high doses of TXA, as well as medium dose of combined IV/IA TXA did not show inferiority in reducing transfusion rates and HB drop compared with other regimens. No regimens showed higher risk for PE or DVT compared with placebo, and no statistical differences were seen among most effective regimens in subgroup analyses.</AbstractText><AbstractText Label="CONCLUSIONS">As effective as high doses of EACA and TXA, medium dose (20-40&#xa0;mg/kg or 1.5-3.0&#xa0;g) of combined IV/IA TXA was enough to control bleeding for patients after THA without increasing risk for PE/DVT. TXA was at least 5 times more potent than EACA. Timing and number of doses had few influences on blood conserving efficacy.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE">Level I.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Che</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jiawen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yuangang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. Electronic address: shenbin_1971@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Thromb Res</MedlineTA><NlmUniqueID>0326377</NlmUniqueID><ISSNLinking>0049-3848</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>U6F3787206</RegistryNumber><NameOfSubstance UI="D015119">Aminocaproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="Y">Tranexamic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015119" MajorTopicYN="N">Aminocaproic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="Y">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="Y">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aminocaproic acid</Keyword><Keyword MajorTopicYN="N">Bleeding</Keyword><Keyword MajorTopicYN="N">Total hip arthroplasty</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword><Keyword MajorTopicYN="N">Transfusion</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>18</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36527742</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2022.11.010</ArticleId><ArticleId IdType="pii">S0049-3848(22)00458-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23887247</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-6771</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>British journal of anaesthesia</Title><ISOAbbreviation>Br J Anaesth</ISOAbbreviation></Journal><ArticleTitle>Hypercapnia and surgical site infection: a randomized trial.</ArticleTitle><Pagination><StartPage>759</StartPage><EndPage>767</EndPage><MedlinePgn>759-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/bja/aet233</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Tissue oxygenation is a strong predictor of surgical site infection (SSI). Mild intraoperative hypercapnia increases peripheral, gastrointestinal, and splanchnic tissue oxygenation and perfusion. Hypercapnia also has anti-inflammatory effects. However, it is unknown whether hypercapnia reduces SSI risk. We tested the hypothesis that mild intraoperative hypercapnia reduces the risk of SSI in patients having colon resection surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">With institutional review board approval and subject consent, patients having elective colon resection (e.g. hemicolectomy and low-anterior resection) expected to last &gt;2 h were randomly assigned to intraoperative normocapnia (PE'CO2 &#x2248; 35 mm Hg; n=623) or hypercapnia ( PE'CO2 &#x2248; 50 mm Hg; n=592). Investigators blinded to group assignment evaluated perioperative SSI (Center for Disease Control criteria) for 30 postoperative days. SSI rates were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patient and surgical characteristics were comparable among the groups. The SSI rate for normocapnia was 13.3%, and for hypercapnia, it was 11.2% (P=0.29). The Executive Committee stopped the trial after the first a priori determined statistical assessment point because of much smaller actual effect compared with the projected. However, because the actual difference found in the SSI rates (15-16%) were within the 95% confidence intervals (CIs) of the projected relative difference of 33% (95% CI -43 to +24%), our results cannot be considered as 'no difference', and cannot exclude a Type II error. Time to first bowel movement was half-a-day shorter in the hypercapnia group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mild hypercapnia appears to have little or-possibly-no ability to prevent SSI after colon resection. Other strategies for reducing SSI risk should thus take priority.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ak&#xe7;a</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology and Perioperative Medicine, Neuroscience ICU, University of Louisville, Louisville, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fleischmann</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Buggy</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Herbst</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Stocchi</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Galandiuk</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Iscoe</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Apfel</LastName><ForeName>C C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Sessler</LastName><ForeName>D I</ForeName><Initials>DI</Initials></Author><Author ValidYN="Y"><CollectiveName>Hypercapnia Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00273377</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Anaesth</MedlineTA><NlmUniqueID>0372541</NlmUniqueID><ISSNLinking>0007-0912</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>142M471B3J</RegistryNumber><NameOfSubstance UI="D002245">Carbon Dioxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000768" MajorTopicYN="N">Anesthesia, General</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001784" MajorTopicYN="N">Blood Gas Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002245" MajorTopicYN="N">Carbon Dioxide</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003106" MajorTopicYN="N">Colon</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003672" MajorTopicYN="N">Defecation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013505" MajorTopicYN="N">Digestive System Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006935" MajorTopicYN="N">Hypercapnia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013530" MajorTopicYN="N">Surgical Wound Infection</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">carbon dioxide, hypercapnia</Keyword><Keyword MajorTopicYN="N">complications, infections</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">surgery, abdominal</Keyword><Keyword MajorTopicYN="N">surgery, gastrointestinal</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Erdik</LastName><ForeName>Klaus</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eredics</LastName><ForeName>Erol</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kabon</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kazerounian</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kimberger</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kugener</LastName><ForeName>Andre</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marschalek</LastName><ForeName>Corinna</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mikocki</LastName><ForeName>Pia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niedermayer</LastName><ForeName>Monika</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obewegeser</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ratzenbock</LastName><ForeName>Ina</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rozum</LastName><ForeName>Romana</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sindhuber</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlemitz</LastName><ForeName>Katja</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schebesta</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stift</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bala</LastName><ForeName>Endrit</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Samuel T</ForeName><Initials>ST</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devarajan</LastName><ForeName>Jagan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maheshwari</LastName><ForeName>Ankit</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahboobi</LastName><ForeName>Ramatia</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mascha</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagem</LastName><ForeName>Hassan</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajogopalan</LastName><ForeName>Suman</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Luke</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zirzow</LastName><ForeName>Erich</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hager</LastName><ForeName>Helmut</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Akiko</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleshman</LastName><ForeName>James W</ForeName><Initials>JW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Read</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeLong</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doufas</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Govinda</LastName><ForeName>Raghavendra</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasuya</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Komatsu</LastName><ForeName>Ryu</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lenhardt</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orhan-Sungur</LastName><ForeName>Mukadder</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sengupta</LastName><ForeName>Papiya</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wadhwa</LastName><ForeName>Anupama</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arain</LastName><ForeName>Mujeeb</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>Siun</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGuire</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ragheb</LastName><ForeName>Jackie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Podranski</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taguchi</LastName><ForeName>Akikio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kimberger</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23887247</ArticleId><ArticleId IdType="doi">10.1093/bja/aet233</ArticleId><ArticleId IdType="pii">S0007-0912(17)32019-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33217420</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1931-3543</ISSN><JournalIssue CitedMedium="Internet"><Volume>159</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Chest</Title><ISOAbbreviation>Chest</ISOAbbreviation></Journal><ArticleTitle>Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>1182</StartPage><EndPage>1196</EndPage><MedlinePgn>1182-1196</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chest.2020.11.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0012-3692(20)35146-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Individual studies have reported widely variable rates for VTE and bleeding among hospitalized patients with coronavirus disease 2019 (COVID-19).</AbstractText><AbstractText Label="RESEARCH QUESTION">What is the incidence of VTE and bleeding among hospitalized patients with COVID-19?</AbstractText><AbstractText Label="METHODS">In this systematic review and meta-analysis, 15 standard sources and COVID-19-specific sources were searched between January 1, 2020, and July 31, 2020, with no restriction according to language. Incidence estimates were pooled by using random effects meta-analyses. Heterogeneity was evaluated by using the I<sup>2</sup> statistic, and publication bias was assessed by using the Begg and Egger tests.</AbstractText><AbstractText Label="RESULTS">The pooled incidence was 17.0%&#xa0;(95%&#xa0;CI, 13.4-20.9) for VTE, 12.1%&#xa0;(95%&#xa0;CI, 8.4-16.4) for DVT, 7.1%&#xa0;(95%&#xa0;CI, 5.3-9.1) for pulmonary embolism (PE), 7.8%&#xa0;(95%&#xa0;CI, 2.6-15.3) for bleeding, and 3.9%&#xa0;(95%&#xa0;CI, 1.2-7.9) for major bleeding. In subgroup meta-analyses, the incidence of VTE was higher when assessed according to screening (33.1%&#xa0;vs&#xa0;9.8%&#xa0;by clinical diagnosis), among patients in the ICU (27.9%&#xa0;vs&#xa0;7.1%&#xa0;in the ward), in prospective studies (25.5%&#xa0;vs&#xa0;12.4%&#xa0;in retrospective studies), and with the inclusion of catheter-associated thrombosis/isolated distal DVTs and isolated subsegmental PEs. The highest pooled incidence estimate of bleeding was reported for patients receiving intermediate- or full-dose anticoagulation (21.4%) and the lowest in the only prospective study that assessed bleeding events (2.7%).</AbstractText><AbstractText Label="INTERPRETATION">Among hospitalized patients with COVID-19, the overall estimated pooled incidence of VTE was 17.0%, with higher rates with routine screening, inclusion of distal DVT, and subsegmental PE, in critically ill patients and in prospective studies. Bleeding events were observed in 7.8%&#xa0;of patients and were sensitive to use of escalated doses of anticoagulants and nature of data collection. Additional studies are required to ascertain the significance of various thrombotic events and to identify strategies to improve patient outcomes.</AbstractText><AbstractText Label="TRIAL REGISTRY">PROSPERO; No.: CRD42020198864; URL: https://www.crd.york.ac.uk/prospero/.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jim&#xe9;nez</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Respiratory Department, Hospital Ram&#xf3;n y Cajal (IRYCIS), Madrid, Spain; Medicine Department, Universidad de Alcal&#xe1; (IRYCIS), Madrid, Spain; CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain. Electronic address: djimenez.hrc@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Sanchez</LastName><ForeName>Aldara</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Respiratory Department, Hospital Ram&#xf3;n y Cajal (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rali</LastName><ForeName>Parth</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University Hospital, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muriel</LastName><ForeName>Alfonso</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biostatistics Clinic Unit, EA3878-Groupe d'Etude de la Thrombose de Bretagne Occidentale, Hospital Ram&#xf3;n y Cajal (IRYCIS), CIBERESP, Nursing Department Universidad de Alcal&#xe1;, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bikdeli</LastName><ForeName>Behnood</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, CT; Cardiovascular Research Foundation, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Artacho</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain; Department of Internal Medicine, Clinica Universidad de Navarra, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Mao</LastName><ForeName>Raphael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>EA3878-Groupe d'Etude de la Thrombose de Bretagne Occidentale, Universit&#xe9; Europ&#xe9;enne de Bretagne, Brest, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Respiratory Department, Hospital Ram&#xf3;n y Cajal (IRYCIS), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>Beverley J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Thrombosis &amp; Haemophilia Centre, Guys &amp; St Thomas' NHS Foundation Trust, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monreal</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain; Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Barcelona, Universidad Cat&#xf3;lica de Murcia, Murcia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Chest</MedlineTA><NlmUniqueID>0231335</NlmUniqueID><ISSNLinking>0012-3692</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Chest. 2021 Mar;159(3):908-909. doi: 10.1016/j.chest.2020.12.022.</RefSource><PMID Version="1">33678274</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Chest. 2021 Jun;159(6):2512-2513. doi: 10.1016/j.chest.2021.01.022.</RefSource><PMID Version="1">34099141</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Chest. 2021 Jun;159(6):2513. doi: 10.1016/j.chest.2021.01.024.</RefSource><PMID Version="1">34099142</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="Y">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">DVT</Keyword><Keyword MajorTopicYN="N">VTE</Keyword><Keyword MajorTopicYN="N">bleeding</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>20</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33217420</ArticleId><ArticleId IdType="pmc">PMC7670889</ArticleId><ArticleId IdType="doi">10.1016/j.chest.2020.11.005</ArticleId><ArticleId IdType="pii">S0012-3692(20)35146-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zaim S., Chong J.H., Sankaranarayanan V., Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187881</ArticleId><ArticleId IdType="pubmed">32439197</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Madhavan M.V., Sehgal K., et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11972613</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M.V., Jimenez D., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J&#xa0;Am Coll Cardiol. 2020;75(23):2950&#x2013;2973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Poissy J., Goutay J., Caplan M., et al. Lille ICU Haemostasis COVID-19 group Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020;142(2):184&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">32330083</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Capit&#xe1;n C, Barba R, D&#xed;az-Pedroche MDC, et&#xa0;al. Presenting characteristics, treatment patterns and outcomes among patients with Venous Thromboembolism during hospitalisation for COVID-19 [published online ahead of print October 21, 2020]. Semin Thromb Hemost. https://doi.org/10.1055/s-0040-1718402..</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1718402</ArticleId><ArticleId IdType="pubmed">33086403</ArticleId></ArticleIdList></Reference><Reference><Citation>Moores L.K., Tritschler T., Brosnahan S., et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report. Chest. 2020;158(3):1143&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265858</ArticleId><ArticleId IdType="pubmed">32502594</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Samkari H., Karp Leaf R.S., Dzik W.H., et al. COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection. Blood. 2020;136(4):489&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378457</ArticleId><ArticleId IdType="pubmed">32492712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren B., Yan F., Deng Z., et al. Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan. Circulation. 2020;142(2):181&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">32412320</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas W., Varley J., Johnston A., et al. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res. 2020;191:76&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182517</ArticleId><ArticleId IdType="pubmed">32402996</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp S., Coppens M., van Haaps T.F., et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J&#xa0;Thromb Haemost. 2020;18(8):1995&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497052</ArticleId><ArticleId IdType="pubmed">32369666</ArticleId></ArticleIdList></Reference><Reference><Citation>McFadyen J.D., Stevens H., Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127(4):571&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386875</ArticleId><ArticleId IdType="pubmed">32586214</ArticleId></ArticleIdList></Reference><Reference><Citation>Colling M.E., Kanthi Y. COVID-19-associated coagulopathy: an exploration of mechanisms. Vasc Med. 2020;25(5):471&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7306998</ArticleId><ArticleId IdType="pubmed">32558620</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J&#xa0;Thromb Haemost. 2020;18(4):844&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111919</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Moskalewicz A., Oremus M. No clear choice between Newcastle-Ottawa Scale and Appraisal Tool for Cross-Sectional Studies to assess methodological quality in cross-sectional studies of health-related quality of life and breast cancer. J&#xa0;Clin Epidemiol. 2020;120:94&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">31866469</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells G.A., Shea B., O&#x2019;Connell D., et al.  The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</Citation></Reference><Reference><Citation>Artifoni M., Danic G., Gautier G., et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J&#xa0;Thromb Thrombolysis. 2020;50(1):211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7246965</ArticleId><ArticleId IdType="pubmed">32451823</ArticleId></ArticleIdList></Reference><Reference><Citation>Beun R., Kusadasi N., Sikma M., Westerink J., Huisman A. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol. 2020;42(suppl 1):19&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264532</ArticleId><ArticleId IdType="pubmed">32311843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilaloglu S., Aphinyanaphongs Y., Jones S., Iturrate E., Hochman J., Berger J.S. Thrombosis in hospitalized patients with COVID-19 in a New York City Health System. JAMA. 2020;324(8):799&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7372509</ArticleId><ArticleId IdType="pubmed">32702090</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo M., Bertinato E.M., Birocchi S., et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020;120(8):1230&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7516356</ArticleId><ArticleId IdType="pubmed">32349132</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Wang X., Zhang S., et al. Characteristics of acute pulmonary embolism in patients with COVID-19 associated pneumonia from the city of Wuhan. Clin Appl Thromb Hemost. 2020;26 1076029620936772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7391435</ArticleId><ArticleId IdType="pubmed">32726134</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Zhang D, Zheng T, Yu Y, Jiang J. DVT incidence and risk factors in critically ill patients with COVID-19 [published online ahead of print June 30, 2020]. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-020-02181-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02181-w</ArticleId><ArticleId IdType="pmc">PMC7324310</ArticleId><ArticleId IdType="pubmed">32607652</ArticleId></ArticleIdList></Reference><Reference><Citation>Criel M., Falter M., Jaeken J., et al. Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? Eur Respir J. 2020;56(1):2001201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236825</ArticleId><ArticleId IdType="pubmed">32398294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J&#xa0;Thromb Haemost. 2020;18(6):1421&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262324</ArticleId><ArticleId IdType="pubmed">32271988</ArticleId></ArticleIdList></Reference><Reference><Citation>Demelo-Rodriguez P., Cervilla-Mu&#xf1;oz E., Ordieres-Ortega L., et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020;192:23&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7219400</ArticleId><ArticleId IdType="pubmed">32405101</ArticleId></ArticleIdList></Reference><Reference><Citation>Desborough M.J.R., Doyle A.J., Griffiths A., Retter A., Breen K.A., Hunt B.J. Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom. Thromb Res. 2020;193:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256551</ArticleId><ArticleId IdType="pubmed">32485437</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois-Silva &#xc1;., Barbagelata-L&#xf3;pez C., Mena &#xc1;., Pi&#xf1;eiro-Parga P., Llinares-Garc&#xed;a D., Freire-Castro S. Pulmonary embolism and screening for concomitant proximal deep vein thrombosis in noncritically ill hospitalized patients with coronavirus disease 2019. Intern Emerg Med. 2020;15(5):865&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7318906</ArticleId><ArticleId IdType="pubmed">32592114</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauvel C., Weizman O., Trimaille A., et al. Critical Covid-19 France Investigators Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. Eur Heart J. 2020;41(32):3058&#x2013;3068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7528952</ArticleId><ArticleId IdType="pubmed">32656565</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraiss&#xe9; M., Logre E., Pajot O., Mentec H., Plantef&#xe8;ve G., Contou D. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Crit Care. 2020;24(1):275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265664</ArticleId><ArticleId IdType="pubmed">32487122</ArticleId></ArticleIdList></Reference><Reference><Citation>Grandmaison G., Andrey A., P&#xe9;riard D., et al. Systematic screening for venous thromboembolic events in COVID-19 pneumonia. TH Open. 2020;4(2):e113&#x2013;e115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280022</ArticleId><ArticleId IdType="pubmed">32529170</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillet F., Behr J., Calame P., Aubry S., Delabrousse E. Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography. Radiology. 2020;296(3):E186&#x2013;E188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233384</ArticleId><ArticleId IdType="pubmed">32324103</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;kimian G., Lebreton G., Br&#xe9;chot N., Luyt C.E., Schmidt M., Combes A. Severe pulmonary embolism in COVID-19 patients: a call for increased awareness. Crit Care. 2020;24(1):274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264962</ArticleId><ArticleId IdType="pubmed">32487231</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., Tacquard C., Severac F., et al. CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippensteel J.A., Burnham E.L., Jolley S.E. Prevalence of venous thromboembolism in critically ill patients with COVID-19. Br J Haematol. 2020;190(3):e134&#x2013;e137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300700</ArticleId><ArticleId IdType="pubmed">32484907</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7192101</ArticleId><ArticleId IdType="pubmed">32381264</ArticleId></ArticleIdList></Reference><Reference><Citation>Koleilat I, Galen B, Choinski K, et&#xa0;al. Clinical characteristics of acute lower extremity deep venous thrombosis diagnosed by duplex in patients hospitalized for coronavirus disease 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7315975</ArticleId><ArticleId IdType="pubmed">32593770</ArticleId></ArticleIdList></Reference><Reference><Citation>Llitjos J.F., Leclerc M., Chochois C., et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J&#xa0;Thromb Haemost. 2020;18(7):1743&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264774</ArticleId><ArticleId IdType="pubmed">32320517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodigiani C., Iapichino G., Carenzo L., et al. Humanitas COVID-19 Task Force Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in&#xa0;Milan, Italy. Thromb Res. 2020;191:9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177070</ArticleId><ArticleId IdType="pubmed">32353746</ArticleId></ArticleIdList></Reference><Reference><Citation>Longchamp A., Longchamp J., Manzocchi-Besson S., et al. Venous thromboembolism in critically ill patients with COVID-19: results of a screening study for deep vein thrombosis. Res Pract Thromb Haemost. 2020;4(5):842&#x2013;847.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272794</ArticleId><ArticleId IdType="pubmed">32685893</ArticleId></ArticleIdList></Reference><Reference><Citation>Maatman T.K., Jalali F., Feizpour C., et al. Routine venous thromboembolism prophylaxis may be inadequate in the hypercoagulable state of severe coronavirus disease 2019. Crit Care Med. 2020;48(9):e783&#x2013;e790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302085</ArticleId><ArticleId IdType="pubmed">32459672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzaccaro D., Giacomazzi F., Giannetta M., et al. Non-overt coagulopathy in non-ICU patients with mild to moderate COVID-19 pneumonia. J&#xa0;Clin Med. 2020;9(6):1781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7355651</ArticleId><ArticleId IdType="pubmed">32521707</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei F., Fan J., Yuan J., et al. Comparison of venous thromboembolism risks between COVID-19 pneumonia and community-acquired pneumonia patients. Arterioscler Thromb Vasc Biol. 2020;40(9):2332&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7446987</ArticleId><ArticleId IdType="pubmed">32628040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mestre-G&#xf3;mez B., Lorente-Ramos R.M., Rogado J., et al. Infanta Leonor Thrombosis Research Group. Incidence of pulmonary embolism in non-critically ill COVID-19 patients. Predicting factors for a challenging diagnosis. J Thromb Thrombolysis. 2021;51(1):40&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7327193</ArticleId><ArticleId IdType="pubmed">32613385</ArticleId></ArticleIdList></Reference><Reference><Citation>Minuz P, Mansueto G, Mazzaferri F, et&#xa0;al. High rate of pulmonary thromboembolism in patients with SARS-CoV-2 pneumonia. Clin Microbiol Infect. 2020 Nov;26(11):1572-1573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301812</ArticleId><ArticleId IdType="pubmed">32565320</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll M., Zon R.L., Sylvester K.W., et al. VTE in ICU patients with COVID-19. Chest. 2020;158(5):2130&#x2013;2135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674987</ArticleId><ArticleId IdType="pubmed">32710891</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahum J., Morichau-Beauchant T., Daviaud F., Echegut P., Fichet J., Maillet J.M., Thierry S. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19) JAMA Netw Open. 2020;3(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260620</ArticleId><ArticleId IdType="pubmed">32469410</ArticleId></ArticleIdList></Reference><Reference><Citation>Patell R., Bogue T., Bindal P., et al. Incidence of thrombosis and hemorrhage in hospitalized cancer patients with COVID-19. J Thromb Haemost. 2020;18(9):2349&#x2013;2357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405046</ArticleId><ArticleId IdType="pubmed">32692862</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesavento R., Ceccato D., Pasquetto G., et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience. J Thromb Haemost. 2020;18(10):2629&#x2013;2635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7404507</ArticleId><ArticleId IdType="pubmed">32692874</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieder M., Goller I., Jeserich M., et al. Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19. J&#xa0;Thromb Thrombolysis. 2020;50(3):558&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7331913</ArticleId><ArticleId IdType="pubmed">32617807</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoliquido A., Porfidia A., Nesci A., et al. GEMELLI AGAINST COVID-19 Group. Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis. J Thromb Haemost. 2020;18(9):2358&#x2013;2363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361278</ArticleId><ArticleId IdType="pubmed">32633068</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoneham S.M., Milne K.M., Nuttall E., et al. Thrombotic risk in COVID-19: a case series and case-control study. Clin Med (Lond) 2020;20(4):e76&#x2013;e81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7385762</ArticleId><ArticleId IdType="pubmed">32423903</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavazzi G., Civardi L., Caneva L., Mongodi S., Mojoli F. Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening. Intensive Care Med. 2020;46(6):1121&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7175449</ArticleId><ArticleId IdType="pubmed">32322918</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimaille A., Curtiaud A., Marchandot B., et al. Venous thromboembolism in non-critically ill patients with COVID-19&#xa0;infection. Thromb Res. 2020;193:166&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7367026</ArticleId><ArticleId IdType="pubmed">32707275</ArticleId></ArticleIdList></Reference><Reference><Citation>Voicu S., Bonnin P., St&#xe9;panian A., et al. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients. J&#xa0;Am Coll Cardiol. 2020;76(4):480&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260513</ArticleId><ArticleId IdType="pubmed">32479784</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte M.B., Kelly P.A., Gonzalez E., Arya R., Roberts L.N. Pulmonary embolism in hospitalised patients with COVID-19. Thromb Res. 2020;195:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7351054</ArticleId><ArticleId IdType="pubmed">32682004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright F.L., Vogler T.O., Moore E.E., et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J&#xa0;Am Coll Surg. 2020;231(2):193&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227511</ArticleId><ArticleId IdType="pubmed">32422349</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Wang L, Zhao L, Li Q, Gu J, Liang S, Zhao Q, Liu J. Risk assessment of venous thromboembolism and bleeding in COVID-19 patients. Research Square. In press. https://www.researchsquare.com/article/rs-18340/v1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9060011</ArticleId><ArticleId IdType="pubmed">35060325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerwes S., Hernandez Cancino F., Liebetrau D., et al. Increased risk of deep vein thrombosis in intensive care unit patients with CoViD-19 infections? Preliminary data. Der Chirurg. 2020;91(7):588&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7274071</ArticleId><ArticleId IdType="pubmed">32504106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Feng X., Zhang D., et al. Deep&#xa0;vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China. Prevalence, risk factors, and outcome. Circulation. 2020;142(2):114&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">32421381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kodadek L.M., Haut E.R. Screening and diagnosis of VTE: the more you look, the more you find? Current Trauma Reports. 2016;2:29&#x2013;34.</Citation></Reference><Reference><Citation>Boonyawat K., Crowther M.A. Venous thromboembolism prophylaxis in critically ill patients. Semin Thromb Hemost. 2015;41(1):68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">25594495</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Talasaz A.H., Rashidi F., et al. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: rationale and design of the INSPIRATION/INSPIRATION-S studies. Thromb Res. 2020;196:382&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7513771</ArticleId><ArticleId IdType="pubmed">32992075</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors J.M., Levy J.H. Thromboinflammation and the hypercoagulability of COVID-19. J&#xa0;Thromb Haemost. 2020;18(7):1559&#x2013;1561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9770920</ArticleId><ArticleId IdType="pubmed">32302453</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M.V., Gupta A., et al. Global COVID-19 Thrombosis Collaborative Group Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost. 2020;120(7):1004&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7516364</ArticleId><ArticleId IdType="pubmed">32473596</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et&#xa0;al. Dexamethasone in hospitalized patients with Covid-19&#x2014;preliminary report [published online ahead of print July 17, 2020]. N Engl J Med. https://doi.org/10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId></ArticleIdList></Reference><Reference><Citation>Toniati P., Piva S., Cattalini M., et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia. Italy. Autoimmun Rev. 2020;19(7):102568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252115</ArticleId><ArticleId IdType="pubmed">32376398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemos A.C.B., do Esp&#xed;rito Santo D.A., Salvetti M.C., et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID) Thromb Res. 2020;196:359&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503069</ArticleId><ArticleId IdType="pubmed">32977137</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco T., Zangrillo A., Biondi-Zoccai G., Landoni G. Meta-analysis: pitfalls and hints. Heart Lung Vessel. 2013;5(4):219&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868184</ArticleId><ArticleId IdType="pubmed">24364016</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37559029</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2253</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>09</Day></PubDate></JournalIssue><Title>BMC anesthesiology</Title><ISOAbbreviation>BMC Anesthesiol</ISOAbbreviation></Journal><ArticleTitle>Continuous nerve block versus thoracic epidural analgesia for post-operative pain of pectus excavatum repair: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>266</StartPage><MedlinePgn>266</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">266</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12871-023-02221-x</ELocationID><Abstract><AbstractText>Surgery to repair pectus excavatum (PE) is often associated with severe postoperative pain, which can impact the length of hospital stay (LOS). While thoracic epidural analgesia (TEA) has traditionally been used for pain management in PE, its placement can sometimes result in severe neurological complications. Recently, paravertebral block (PVB) and erector spinae plane block (ESPB) have been recommended for many other chest and abdominal surgeries. However, due to the more severe and prolonged pain associated with PE repair, it is still unclear whether continuous administration of these blocks is as effective as TEA. Therefore, we conducted this systematic review and meta-analysis to demonstrate the equivalence of continuous PVB and ESPB to TEA.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li-Jung</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No.289, Jianguo Rd., Xindian Dist, 231405, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shih-Hong</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No.289, Jianguo Rd., Xindian Dist, 231405, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Yung-Lin</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No.289, Jianguo Rd., Xindian Dist, 231405, New Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Po-Chuan</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No.289, Jianguo Rd., Xindian Dist, 231405, New Taipei City, Taiwan. yu136917@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Anesthesiol</MedlineTA><NlmUniqueID>100968535</NlmUniqueID><ISSNLinking>1471-2253</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005660" MajorTopicYN="Y">Funnel Chest</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015360" MajorTopicYN="Y">Analgesia, Epidural</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000767" MajorTopicYN="Y">Anesthesia, Epidural</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009407" MajorTopicYN="Y">Nerve Block</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Erector spinae plane block</Keyword><Keyword MajorTopicYN="N">Paravertebral block</Keyword><Keyword MajorTopicYN="N">Pectus excavatum</Keyword><Keyword MajorTopicYN="N">Thoracic epidural analgesia</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>10</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>9</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37559029</ArticleId><ArticleId IdType="pmc">PMC10410789</ArticleId><ArticleId IdType="doi">10.1186/s12871-023-02221-x</ArticleId><ArticleId IdType="pii">10.1186/s12871-023-02221-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brochhausen C, et al. Pectus excavatum: history, hypotheses and treatment options. Interact Cardiovasc Thorac Surg. 2012;14(6):801&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3352718</ArticleId><ArticleId IdType="pubmed">22394989</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly RE, Jr, Obermeyer RJ, Nuss D. Diminished pulmonary function in pectus excavatum: from denying the problem to finding the mechanism. Ann Cardiothorac Surg. 2016;5(5):466&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056935</ArticleId><ArticleId IdType="pubmed">27747180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramadan S et al. Cardiopulmonary function in adolescent patients with pectus excavatum or carinatum. BMJ Open Respir Res, 2021. 8(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8323368</ArticleId><ArticleId IdType="pubmed">34326157</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugyte DC, et al. Systemic postoperative pain management following minimally invasive pectus excavatum repair in children and adolescents: a retrospective comparison of intravenous patient-controlled analgesia and continuous infusion with morphine. Pediatr Surg Int. 2010;26(7):665&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20490811</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao YZ, Tang S, Li S. Comparison of the Nuss versus Ravitch procedure for pectus excavatum repair: an updated meta-analysis. J Pediatr Surg. 2017;52(10):1545&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">28606386</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroud AM, et al. Epidural analgesia versus intravenous patient-controlled analgesia following minimally invasive pectus excavatum repair: a systematic review and meta-analysis. J Pediatr Surg. 2014;49(5):798&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5315444</ArticleId><ArticleId IdType="pubmed">24851774</ArticleId></ArticleIdList></Reference><Reference><Citation>Manion SC, Brennan TJ. Thoracic epidural analgesia and acute pain management. Anesthesiology. 2011;115(1):181&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21606825</ArticleId></ArticleIdList></Reference><Reference><Citation>Giebler RM, Scherer RU, Peters J. Incidence of neurologic complications related to thoracic epidural catheterization. Anesthesiology. 1997;86(1):55&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9009940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruppen W, et al. Incidence of epidural haematoma and neurological injury in cardiovascular patients with epidural analgesia/anaesthesia: systematic review and meta-analysis. BMC Anesthesiol. 2006;6:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1586186</ArticleId><ArticleId IdType="pubmed">16968537</ArticleId></ArticleIdList></Reference><Reference><Citation>Manassero A, et al. Postoperative thoracic epidural analgesia: adverse events from a Single-Center Series of 3126 patients. Local Reg Anesth. 2020;13:111&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7490049</ArticleId><ArticleId IdType="pubmed">32982397</ArticleId></ArticleIdList></Reference><Reference><Citation>Frawley G, Frawley J, Crameri J. A review of anesthetic techniques and outcomes following minimally invasive repair of pectus excavatum (Nuss procedure) Paediatr Anaesth. 2016;26(11):1082&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">27510834</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshizaki M, et al. Bilateral erector spinae plane block using a programmed intermittent bolus technique for pain management after Nuss procedure. J Clin Anesth. 2019;57:51&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">30852328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowery DR, et al. Continuous Erector Spinae Plane Blocks for adult Pectus Excavatum Repair. Ann Thorac Surg. 2019;108(1):e19&#x2013;e20.</Citation><ArticleIdList><ArticleId IdType="pubmed">30597141</ArticleId></ArticleIdList></Reference><Reference><Citation>Batra RK, Krishnan K, Agarwal A. Paravertebral block. J Anaesthesiol Clin Pharmacol. 2011;27(1):5&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146159</ArticleId><ArticleId IdType="pubmed">21804697</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmakar MK. Thoracic paravertebral block. Anesthesiology. 2001;95(3):771&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">11575553</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall Burton DM, Boretsky KR. A comparison of paravertebral nerve block catheters and thoracic epidural catheters for postoperative analgesia following the Nuss procedure for pectus excavatum repair. Paediatr Anaesth. 2014;24(5):516&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24612096</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltran R, et al. Postoperative pain management in patients undergoing thoracoscopic repair of pectus excavatum: a retrospective analysis of opioid consumption and adverse effects in adolescents. Saudi J Anaesth. 2017;11(4):427&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5637419</ArticleId><ArticleId IdType="pubmed">29033723</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhly WT, et al. Perioperative Management and In-Hospital outcomes after minimally invasive repair of Pectus Excavatum: a Multicenter Registry Report from the Society for Pediatric Anesthesia Improvement Network. Anesth Analg. 2019;128(2):315&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">30346358</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang XL, et al. The Analgesic Effects of thoracic paravertebral block versus thoracic epidural anesthesia after thoracoscopic surgery: a Meta-analysis. J Pain Res. 2021;14:815&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009548</ArticleId><ArticleId IdType="pubmed">33814927</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin KJ, El-Boghdadly K. Mechanisms of action of the erector spinae plane (ESP) block: a narrative review. Can J Anaesth. 2021;68(3):387&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">33403545</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain K, Jaiswal V, Puri A. Erector spinae plane block: relatively new block on horizon with a wide spectrum of application - a case series. Indian J Anaesth. 2018;62(10):809&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6190410</ArticleId><ArticleId IdType="pubmed">30443066</ArticleId></ArticleIdList></Reference><Reference><Citation>De Cassai A, et al. Injectate spread in ESP block: a review of anatomical investigations. J Clin Anesth. 2020;61:109669.</Citation><ArticleIdList><ArticleId IdType="pubmed">31784308</ArticleId></ArticleIdList></Reference><Reference><Citation>Santana L, Driggers J, Carvalho NF. Pain management for the Nuss procedure: comparison between erector spinae plane block, thoracic epidural, and control. World J Pediatr Surg. 2022;5(4):e000418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9717353</ArticleId><ArticleId IdType="pubmed">36474733</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter CM, et al. Retrospective study comparing outcomes of multimodal epidural and erector spinae catheter pain protocols after pectus surgery. J Pediatr Surg. 2023;58(3):397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">35907711</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss DP, Jr, et al. Ultrasound-guided erector spinae plane block versus thoracic epidural analgesia: postoperative pain management after Nuss repair for pectus excavatum. J Pediatr Surg. 2022;57(2):207&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">34949445</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartzmann A, et al. A magnetic resonance imaging study of local anesthetic spread in patients receiving an erector spinae plane block. Can J Anaesth. 2020;67(8):942&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32152885</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorenstua M, et al. Spread of local anesthetics after erector spinae plane block: an MRI study in healthy volunteers. Reg Anesth Pain Med. 2023;48(2):74&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">36351741</ArticleId></ArticleIdList></Reference><Reference><Citation>Macaire P, et al. Ultrasound-guided continuous thoracic erector Spinae Plane Block within an enhanced recovery program is Associated with decreased opioid consumption and Improved Patient Postoperative Rehabilitation after Open Cardiac Surgery-A Patient-Matched, controlled before-and-after study. J Cardiothorac Vasc Anesth. 2019;33(6):1659&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">30665850</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarci M, Joshi A, Attia R. Patients undergoing thoracic surgery is paravertebral block as effective as epidural analgesia for pain management? Interact Cardiovasc Thorac Surg. 2010;10(1):92&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19854794</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, et al. [The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsDeclaracion PRISMA 2020: una guia actualizada para la publicacion de revisiones sistematicas] Rev Panam Salud Publica. 2022;46:e112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9798848</ArticleId><ArticleId IdType="pubmed">36601438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>Loftus PD, et al. Paravertebral regional blocks decrease length of stay following surgery for pectus excavatum in children. J Pediatr Surg. 2016;51(1):149&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">26577910</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladak SS, et al. Incidence of urinary retention in patients with thoracic patient-controlled epidural analgesia (TPCEA) undergoing thoracotomy. Pain Manag Nurs. 2009;10(2):94&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19481048</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leon LE, et al. Risk of urinary recatheterization for thoracic Surgical patients with epidural anesthesia. J Surg Res (Houst) 2020;3(3):163&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409986</ArticleId><ArticleId IdType="pubmed">32776012</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuethrich PY, Kessler TM, Burkhard FC. The effects of thoracic epidurally administered drugs on urethral sphincter function in women: a pooled analysis. Pain Med. 2013;14(8):1248&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">23614971</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold PA, et al. The effect of bladder catheterization on ambulation and venous thromboembolism following total knee arthroplasty: an institutional analysis. J Arthroplasty. 2020;35(6S):S197&#x2013;S200.</Citation><ArticleIdList><ArticleId IdType="pubmed">32197962</ArticleId></ArticleIdList></Reference><Reference><Citation>Baidya DK, Khanna P, Maitra S. Analgesic efficacy and safety of thoracic paravertebral and epidural analgesia for thoracic surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2014;18(5):626&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">24488821</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber T, et al. Superior postoperative pain relief with thoracic epidural analgesia versus intravenous patient-controlled analgesia after minimally invasive pectus excavatum repair. J Thorac Cardiovasc Surg. 2007;134(4):865&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">17903498</ArticleId></ArticleIdList></Reference><Reference><Citation>Densmore JC, et al. Initial surgical and pain management outcomes after Nuss procedure. J Pediatr Surg. 2010;45(9):1767&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20850618</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves CE, et al. Intraoperative intercostal nerve cryoablation during the Nuss procedure reduces length of stay and opioid requirement: a randomized clinical trial. J Pediatr Surg. 2019;54(11):2250&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6920013</ArticleId><ArticleId IdType="pubmed">30935731</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant CRK, Checketts MR. Analgesia for primary hip and knee arthroplasty: the role of regional anaesthesia. Continuing Educ Anaesth Crit Care Pain. 2008;8(2):56&#x2013;61.</Citation></Reference><Reference><Citation>Gan TJ, et al. Fourth Consensus Guidelines for the management of postoperative nausea and vomiting. Volume 131. Anesthesia &amp; Analgesia; 2020. 2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32467512</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib AS et al. Amisulpride for the Rescue Treatment of Postoperative Nausea or Vomiting in Patients Failing Prophylaxis: A Randomized, Placebo-controlled Phase III Trial (1528 &#x2013; 1175 (Electronic)).</Citation><ArticleIdList><ArticleId IdType="pubmed">30475232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonnqvist PA, et al. Paravertebral blockade. Failure rate and complications. Anaesthesia. 1995;50(9):813&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7573876</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsui BCH, et al. The erector spinae plane (ESP) block: a pooled review of 242 cases. J Clin Anesth. 2019;53:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">30292068</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly RE, et al. Twenty-one years of experience with minimally invasive repair of pectus excavatum by the Nuss procedure in 1215 patients. Ann Surg. 2010;252(6):1072&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">21107118</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhly WT, Maxwell LG, Cravero JP. Pain management following the Nuss procedure: a survey of practice and review. Acta Anaesthesiol Scand. 2014;58(9):1134&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25087774</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D-X, Zhu Z-Q. Ultrasound-guided peripheral trunk block technique: a new approach gradually stepping onto the stage of clinical anesthesia. Ibrain. 2021;7(3):211&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10529195</ArticleId><ArticleId IdType="pubmed">37786802</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakanii M, Namba T, Uemura S. Pain caused by the Pectus Bar Implant after the Nuss Procedure for Pectus Excavatum among Junior High and High School Children. Kawasaki J Med Welf. 2011;17(1):15&#x2013;21.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31844608</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2214-031X</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of orthopaedic translation</Title><ISOAbbreviation>J Orthop Translat</ISOAbbreviation></Journal><ArticleTitle>The efficacy and safety of intravenous tranexamic acid in hip fracture surgery: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>11</EndPage><MedlinePgn>1-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jot.2019.03.007</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The present meta-analysis was conducted to compare the efficacy and safety of intravenous application of tranexamic acid (TXA) with placebo in patients with hip fracture undergoing hip surgeries.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, EMBASE&#xa0;and Cochrane Library were searched from inception until March 2018. A combined searching strategy of subject words and random words was adopted. Only randomized clinical trials were included. The comparisons regarding transfusion rate, total blood loss, intraoperative blood loss, postoperative blood loss, postoperative haemoglobin&#xa0;and postoperative thromboembolic complications were conducted. The meta-analysis was performed using Review Manager 5.3, and the bias evaluation was based on the Cochrane Handbook 5.1.0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ten randomized controlled trials published from 2007 to 2018 were included in the meta-analysis. The results showed that there were significant differences in the two groups concerning transfusion rate of allogeneic blood [risk ratio (RR)&#xa0;=&#xa0;0.66, 95% confidence interval (CI): 0.56 to 0.78, P&#xa0;=&#xa0;0.003], total blood loss [mean difference (MD)&#xa0;=&#xa0;-273.00, 95% CI: -353.15 to -192.84, P&#xa0;&lt;&#xa0;0.00001], intraoperative blood loss (MD&#xa0;=&#xa0;-76.63, 95% CI: -139.55 to -13.71, P&#xa0;=&#xa0;0.02), postoperative blood loss (MD&#xa0;=&#xa0;-125.29, 95% CI: -221.96 to -28.62, P&#xa0;=&#xa0;0.01) and postoperative haemoglobin (MD&#xa0;=&#xa0;0.80, 95% CI: 0.38 to 1.22, P&#xa0;=&#xa0;0.0002). Nonsignificant differences were found in the incidence of thromboembolic events (RR&#xa0;=&#xa0;1.38, 95% CI: 0.74 to 2.55, P&#xa0;=&#xa0;0.31).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This meta-analysis of the available evidence implies that the intravenous route of TXA shows an ability to reduce transfusion requirements and total blood loss, not increasing the incidence of thromboembolic events in patients undergoing hip surgeries.</AbstractText><AbstractText Label="THE TRANSLATIONAL POTENTIAL OF THIS ARTICLE" NlmCategory="UNASSIGNED">The result of this meta-analysis shows that the utilization of intravenous TXA in patients with hip fracture undergoing hip surgeries possesses great potential in reducing blood loss and allogeneic blood transfusion safely.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Yi-Ming</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Orthopaedic Trauma Institute of Southeast University, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Multidisciplinary Team (MDT) for Geriatric Hip Fracture Comprehensive Management, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hai-Peng</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>The Department of Orthopedics, Jing' An District Centre Hospital of Shanghai (Huashan Hospital Fudan University Jing' An Branch), 20040, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ying-Juan</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Multidisciplinary Team (MDT) for Geriatric Hip Fracture Comprehensive Management, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatrics, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Bin-Bin</ForeName><Initials>BB</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Orthopaedic Trauma Institute of Southeast University, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Multidisciplinary Team (MDT) for Geriatric Hip Fracture Comprehensive Management, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Orthopaedic Trauma Institute of Southeast University, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Multidisciplinary Team (MDT) for Geriatric Hip Fracture Comprehensive Management, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Orthopaedic Trauma Institute of Southeast University, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Multidisciplinary Team (MDT) for Geriatric Hip Fracture Comprehensive Management, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Orthopaedic Trauma Institute of Southeast University, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Multidisciplinary Team (MDT) for Geriatric Hip Fracture Comprehensive Management, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rui</LastName><ForeName>Yun-Feng</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Orthopaedic Trauma Institute of Southeast University, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Multidisciplinary Team (MDT) for Geriatric Hip Fracture Comprehensive Management, Zhongda Hospital, School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Southeast University, NO. 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>J Orthop Translat</MedlineTA><NlmUniqueID>101625127</NlmUniqueID><ISSNLinking>2214-031X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Allogeneic blood transfusion</Keyword><Keyword MajorTopicYN="N">Blood loss</Keyword><Keyword MajorTopicYN="N">Hip fracture</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial, RCT</Keyword><Keyword MajorTopicYN="N">Thromboembolic events</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword><Keyword MajorTopicYN="N">Tranexamic acid, TXA</Keyword><Keyword MajorTopicYN="N">cerebrovascular accident, CVA</Keyword><Keyword MajorTopicYN="N">confidence interval, CI</Keyword><Keyword MajorTopicYN="N">deep vein thrombolism, DVT</Keyword><Keyword MajorTopicYN="N">haemoglobin, Hb</Keyword><Keyword MajorTopicYN="N">mean difference, MD</Keyword><Keyword MajorTopicYN="N">pulmonary embolism, PE</Keyword><Keyword MajorTopicYN="N">risk ratio, RR</Keyword><Keyword MajorTopicYN="N">standard deviation, SD</Keyword><Keyword MajorTopicYN="N">total hip arthroplasty, THA</Keyword><Keyword MajorTopicYN="N">total knee arthroplasty, TKA</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31844608</ArticleId><ArticleId IdType="pmc">PMC6896672</ArticleId><ArticleId IdType="doi">10.1016/j.jot.2019.03.007</ArticleId><ArticleId IdType="pii">S2214-031X(18)30165-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>LeBlanc K.E., Muncie H.J., LeBlanc L.L. Hip fracture: diagnosis, treatment, and secondary prevention. Am Fam Physician. 2014;89(12):945&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pubmed">25162161</ArticleId></ArticleIdList></Reference><Reference><Citation>Gullberg B., Johnell O., Kanis J.A. World-wide projections for hip fracture. Osteoporos Int. 1997;7:407.</Citation><ArticleIdList><ArticleId IdType="pubmed">9425497</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss N.B., Kehlet H. Hidden blood loss after surgery for hip fracture. J Bone Joint Surg Br. 2006;88:1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">16877605</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A.M., Mushtaq N., Giannakas K., Sochart D.H., Andrews J.G. Cross-match protocols for femoral neck fractures--finding one that can work. Ann R Coll Surg Engl. 2004;86:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1964008</ArticleId><ArticleId IdType="pubmed">15005938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence V.A., Silverstein J.H., Cornell J.E., Pederson T., Noveck H., Carson J.L. Higher Hb level is associated with better early functional recovery after hip fracture repair. Transfusion. 2003;43:1717.</Citation><ArticleIdList><ArticleId IdType="pubmed">14641869</ArticleId></ArticleIdList></Reference><Reference><Citation>Halm E.A., Wang J.J., Boockvar K., Penrod J., Silberzweig S.B., Magaziner J. The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture. J Orthop Trauma. 2004;18:369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1454739</ArticleId><ArticleId IdType="pubmed">15213502</ArticleId></ArticleIdList></Reference><Reference><Citation>Maraldi C., Ble A., Zuliani G., Guralnik J.M., Mussi C., Fellin R. Association between anemia and physical disability in older patients: role of comorbidity. Aging Clin Exp Res. 2006;18:485.</Citation><ArticleIdList><ArticleId IdType="pubmed">17255637</ArticleId></ArticleIdList></Reference><Reference><Citation>Foss N.B., Kristensen M.T., Kehlet H. Anaemia impedes functional mobility after hip fracture surgery. Age Ageing. 2008;37:173.</Citation><ArticleIdList><ArticleId IdType="pubmed">18349013</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman B.A. An analysis of surgical blood use in United States hospitals with application to the maximum surgical blood order schedule. Transfusion. 1979;19:268.</Citation><ArticleIdList><ArticleId IdType="pubmed">452067</ArticleId></ArticleIdList></Reference><Reference><Citation>Conteduca F., Massai F., Iorio R., Zanzotto E., Luzon D., Ferretti A. Blood loss in computer-assisted mobile bearing total knee arthroplasty. A comparison of computer-assisted surgery with a conventional technique. Int Orthop. 2009;33:1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2899193</ArticleId><ArticleId IdType="pubmed">18762940</ArticleId></ArticleIdList></Reference><Reference><Citation>Tengberg P.T., Foss N.B., Palm H., Kallemose T., Troelsen A. Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial. Bone Joint Lett J. 2016;98-B:747.</Citation><ArticleIdList><ArticleId IdType="pubmed">27235515</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiarugi M., Buccianti P., Disarli M., Galatioto C., Cavina E. Effect of blood transfusions on disease-free interval after rectal cancer surgery. Hepato-Gastroenterology. 2000;47:1002.</Citation><ArticleIdList><ArticleId IdType="pubmed">11020864</ArticleId></ArticleIdList></Reference><Reference><Citation>Marik P.E., Corwin H.L. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008;36:2667.</Citation><ArticleIdList><ArticleId IdType="pubmed">18679112</ArticleId></ArticleIdList></Reference><Reference><Citation>Izuel R.M., Garcia E.J., Gomez-Barrera M., Cuenca E.J., Abad S.R., Rabanaque H.M. [Relationship between allogeneic blood transfusion, iron deficiency and nosocomial infection in patients with hip fracture] Med Clin. 2008;131:647.</Citation><ArticleIdList><ArticleId IdType="pubmed">19087790</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Chen J., Chen F., Que W. The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2012;20:1742.</Citation><ArticleIdList><ArticleId IdType="pubmed">22065294</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F., Wu D., Ma G., Yin Z., Wang Q. The use of tranexamic acid to reduce blood loss and transfusion in major orthopedic surgery: a meta-analysis. J Surg Res. 2014;186:318.</Citation><ArticleIdList><ArticleId IdType="pubmed">24075404</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgili M.G., Ercin E., Peker G., Kural C., Basaran S.H., Duramaz A. Efficiency and cost analysis of cell saver auto transfusion system in total knee arthroplasty. Balkan Med J. 2014;31:149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115923</ArticleId><ArticleId IdType="pubmed">25207187</ArticleId></ArticleIdList></Reference><Reference><Citation>Appassakij H., Promwong C., Rujirojindakul P., Wutthanarungsan R., Silpapojakul K. The risk of blood transfusion-associated Chikungunya fever during the 2009 epidemic in Songkhla Province, Thailand. Transfusion. 2014;54:1945.</Citation><ArticleIdList><ArticleId IdType="pubmed">24527811</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan M., Liu D., Martos S.M., Beller E. Intra-operative blood salvage in total hip and knee arthroplasty. J Orthop Surg (Hong Kong) 2016;24:204.</Citation><ArticleIdList><ArticleId IdType="pubmed">27574264</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera-Roig X., Jordan-Sales M., Natera-Cisneros L., Monllau-Garcia J.C., Martinez-Zapata M.J. [Tranexamic acid in orthopedic surgery] Rev Espa&#xf1;ola Cirug&#xed;a Ortop&#xe9;dica Traumatol. 2014;58:52.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126146</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson J.L., Stanworth S.J., Roubinian N., Fergusson D.A., Triulzi D., Doree C. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;10:D2042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6457993</ArticleId><ArticleId IdType="pubmed">27731885</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Q.J., Chang W.Y., Wong Y.C. Blood-sparing efficacy of oral tranexamic acid in primary total hip arthroplasty. J Arthroplast. 2017;32:139.</Citation><ArticleIdList><ArticleId IdType="pubmed">27498390</ArticleId></ArticleIdList></Reference><Reference><Citation>Wind T.C., Barfield W.R., Moskal J.T. The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty. J Arthroplast. 2014;29:387.</Citation><ArticleIdList><ArticleId IdType="pubmed">23790499</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajesparan K., Biant L.C., Ahmad M., Field R.E. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Joint Surg Br. 2009;91:776.</Citation><ArticleIdList><ArticleId IdType="pubmed">19483232</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Sun T.W., Luo G., Zhang C. Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: a meta-analysis. Eur Spine J. 2017;26:140.</Citation><ArticleIdList><ArticleId IdType="pubmed">27671279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Dong Q., Zhang Y.G. Intravenous versus topical tranexamic acid in primary total hip replacement: a systemic review and meta-analysis. Int J Surg. 2016;32:10.</Citation><ArticleIdList><ArticleId IdType="pubmed">27262881</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi H., Behdad S., Ayatollahi V., Nazemian N., Mirshamsi P. Comparison of two doses of tranexamic acid on bleeding and surgery site quality during sinus endoscopy surgery. Adv Clin Exp Med. 2012;21:773.</Citation><ArticleIdList><ArticleId IdType="pubmed">23457130</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn C.J., Goa K.L. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57:1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">10400410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemi S.M., Mosaffa F., Eajazi A., Kaffashi M., Daftari B.L., Bigdeli M.R. The effect of tranexamic acid on reducing blood loss in cementless total hip arthroplasty under epidural anesthesia. Orthopedics. 2010;33:17.</Citation><ArticleIdList><ArticleId IdType="pubmed">20055345</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts C.D., Houdek M.T., Sems S.A., Cross W.W., Pagnano M.W. Tranexamic acid safely reduced blood loss in hemi- and total hip arthroplasty for acute femoral neck fracture: a randomized clinical trial. J Orthop Trauma. 2017;31:345.</Citation><ArticleIdList><ArticleId IdType="pubmed">28633147</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohib Y., Rashid R.H., Ali M., Zubairi A.J., Umer M. Does tranexamic acid reduce blood transfusion following surgery for inter-trochanteric fracture? A randomized control trial. J Pak Med Assoc. 2015;65:S17.</Citation><ArticleIdList><ArticleId IdType="pubmed">26878513</ArticleId></ArticleIdList></Reference><Reference><Citation>Zufferey P.J., Miquet M., Quenet S., Martin P., Adam P., Albaladejo P. Tranexamic acid in hip fracture surgery: a randomized controlled trial. Br J Anaesth. 2010;104:23.</Citation><ArticleIdList><ArticleId IdType="pubmed">19926634</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian S., Shen Z., Liu Y., Zhang Y., Peng A. The effect of tranexamic acid on hidden bleeding in older intertrochanteric fracture patients treated with PFNA. Injury. 2018;49:680.</Citation><ArticleIdList><ArticleId IdType="pubmed">29426608</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijay B.S., Bedi V., Mitra S., Das B. Role of tranexamic acid in reducing postoperative blood loss and transfusion requirement in patients undergoing hip and femoral surgeries. Saudi J Anaesth. 2013;7:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3657919</ArticleId><ArticleId IdType="pubmed">23717228</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi . 2007. Does a single bolus dose of tranexamic acid reduce blood loss and transfusion requirements during hip fracture surgery? A prospective randomized double blind study in 67 patients.</Citation></Reference><Reference><Citation>Emara W.M., Moez K.K., Elkhouly A.H. Topical versus intravenous tranexamic acid as a blood conservation intervention for reduction of post-operative bleeding in hemiarthroplasty. Anesth Essays Res. 2014;8:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4173581</ArticleId><ArticleId IdType="pubmed">25886103</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei J., Zhang B., Cong Y., Zhuang Y., Wei X., Fu Y. Tranexamic acid reduces hidden blood loss in the treatment of intertrochanteric fractures with PFNA: a single-center randomized controlled trial. J Orthop Surg Res. 2017;12:124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558747</ArticleId><ArticleId IdType="pubmed">28810918</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruah R.K., Borah P.J., Haque R. Use of tranexamic acid in dynamic hip screw plate fixation for trochanteric fractures. J Orthop Surg (Hong Kong) 2016;24:379.</Citation><ArticleIdList><ArticleId IdType="pubmed">28031511</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO) WHO model list of essential medicines. 2017.  Available at:  http://www.who.int/medicines/publications/essentialmedicines/en/</Citation><ArticleIdList><ArticleId IdType="pubmed">29221540</ArticleId></ArticleIdList></Reference><Reference><Citation>Drakos A., Raoulis V., Karatzios K., Doxariotis N., Kontogeorgakos V., Malizos K. Efficacy of local administration of tranexamic acid for blood salvage in patients undergoing intertrochanteric fracture surgery. J Orthop Trauma. 2016;30:409.</Citation><ArticleIdList><ArticleId IdType="pubmed">26978136</ArticleId></ArticleIdList></Reference><Reference><Citation>Virani S.R., Dahapute A.A., Panda I., Bava S.S. Role of local infiltration of tranexamic acid in reducing blood loss in peritrochanteric fracture surgery in the elderly population. Malays Orthop J. 2016;10:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333680</ArticleId><ArticleId IdType="pubmed">28553444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., He J., Fang Y., Chen P., Liang Y., Wang J. Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis: a meta-analysis. Medicine (Baltim) 2017;96:e6940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5457864</ArticleId><ArticleId IdType="pubmed">28538384</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z., Liu M. The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases. Transfus Med. 2015;25:151.</Citation><ArticleIdList><ArticleId IdType="pubmed">26033447</ArticleId></ArticleIdList></Reference><Reference><Citation>Goobie S.M., Meier P.M., Sethna N.F., Soriano S.G., Zurakowski D., Samant S. Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniosynostosis surgery. Clin Pharmacokinet. 2013;52:267.</Citation><ArticleIdList><ArticleId IdType="pubmed">23371895</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Liang Y., Chen P., Fang Y., He J., Wang J. Intravenous versus topical tranexamic acid in primary total hip replacement: a meta-analysis. Medicine (Baltim) 2016;95:e5573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5268036</ArticleId><ArticleId IdType="pubmed">27977590</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Q.J., Chang W.Y., Wong Y.C. Blood-sparing efficacy of oral tranexamic acid in primary total hip arthroplasty. J Arthroplast. 2017;32:139.</Citation><ArticleIdList><ArticleId IdType="pubmed">27498390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi R., Evans H.M., Mahomed S.R., Mahomed N.N. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Res Notes. 2013;6:184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655041</ArticleId><ArticleId IdType="pubmed">23651507</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoni G., Lethagen S., Fredin H. The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res. 1997;85:195.</Citation><ArticleIdList><ArticleId IdType="pubmed">9058494</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbag O.D., Abdel M.P., Amundson A.W., Larson D.R., Pagnano M.W. Tranexamic acid was safe in arthroplasty patients with a history of venous thromboembolism: a matched outcome study. J Arthroplasty. 2017;32:S246.</Citation><ArticleIdList><ArticleId IdType="pubmed">28262452</ArticleId></ArticleIdList></Reference><Reference><Citation>Evangelista P.J., Aversano M.W., Koli E., Hutzler L., Inneh I., Bosco J. Effect of tranexamic acid on transfusion rates following total joint arthroplasty: a cost and comparative effectiveness analysis. Orthop Clin N Am. 2017;48:109.</Citation><ArticleIdList><ArticleId IdType="pubmed">28336035</ArticleId></ArticleIdList></Reference><Reference><Citation>Demos H.A., Lin Z.X., Barfield W.R., Wilson S.H., Robertson D.C., Pellegrini V.J. Process improvement Project using tranexamic acid is cost-effective in reducing blood loss and transfusions after total hip and total knee arthroplasty. J Arthroplasty. 2017;32:2375.</Citation><ArticleIdList><ArticleId IdType="pubmed">28343823</ArticleId></ArticleIdList></Reference><Reference><Citation>DiBlasi J.F., Smith R.P., Garavaglia J., Quedado J., Frye B.M., Dietz M.J. Comparing cost, efficacy, and safety of intravenous and topical tranexamic acid in total hip and knee arthroplasty. Am J Orthop (Belle Mead NJ) 2016;45:E439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5817988</ArticleId><ArticleId IdType="pubmed">28005108</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31096433</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>20</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Oral vs intravenous tranexamic acid in total-knee arthroplasty and total hip arthroplasty: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e15248</StartPage><MedlinePgn>e15248</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e15248</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000015248</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study aimed to compare the efficacy and safety of oral tranexamic acid (TXA) with intravenous (IV) TXA in reducing perioperative blood loss in total-knee arthroplasty (TKA) and total-hip arthroplasty (THA).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, Web of Science, Embase, and Cochrane Library were fully searched for relevant studies. Studies comparing the efficacy and safety of oral TXA with IV TXA in TKA and THA were included in this research. Odds ratio (OR) or risk difference (RD) was applied to compare dichotomous variables, while mean difference (MD) was used to compare continues variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 7 studies (5 randomized controlled trials and 2 retrospective studies) were included into this study. As for patients undergoing TKA or THA, there were no obvious differences between oral TXA group and IV TXA group in hemoglobin (Hb) drop (MD&#x200a;=&#x200a;0.06, 95% confidence interval [CI]&#x200a;=&#x200a;-0.01 to 0.13, P&#x200a;=&#x200a;.09), transfusion rate (OR&#x200a;=&#x200a;0.78, 95% CI&#x200a;=&#x200a;0.54-1.13, P&#x200a;=&#x200a;.19), total blood loss (MD&#x200a;=&#x200a;16.31, 95% CI&#x200a;=&#x200a;-69.85 to 102.46, P&#x200a;=&#x200a;.71), total Hb loss (MD&#x200a;=&#x200a;5.18, 95% CI&#x200a;=&#x200a;-12.65 to 23.02, P&#x200a;=&#x200a;.57), length of hospital stay (MD&#x200a;=&#x200a;-0.06, 95% CI&#x200a;=&#x200a;-0.30 to 0.18, P&#x200a;=&#x200a;.63), drain out (MD&#x200a;=&#x200a;21.04, 95% CI&#x200a;=&#x200a;-15.81 to 57.88, P&#x200a;=&#x200a;.26), incidence of deep vein deep vein thrombosis (RD&#x200a;=&#x200a;0.00, 95% CI&#x200a;=&#x200a;-0.01 to 0.01, P&#x200a;=&#x200a;.82) or pulmonary embolism (RD&#x200a;=&#x200a;0.00, 95% CI&#x200a;=&#x200a;-0.01 to 0.01, P&#x200a;=&#x200a;.91). The sample size of this study was small and several included studies were with relatively low quality.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Oral TXA is equivalent to IV TXA in reducing perioperative blood loss and should be recommended in TKA and THA. More high-quality studies are needed to elucidate this issue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xuanhuang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Orthopedics, The Affiliated Hospital of Putian University, Putian, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Zugao</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xianwei</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Changfu</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="N">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="N">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059035" MajorTopicYN="N">Perioperative Period</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="N">Tranexamic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31096433</ArticleId><ArticleId IdType="pmc">PMC6531257</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000015248</ArticleId><ArticleId IdType="pii">00005792-201905170-00004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Courpied JP, Caton JH. Total Hip Arthroplasty, state of the art for the 21st century. Int Orthop 2011;35:149&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032113</ArticleId><ArticleId IdType="pubmed">21243356</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschini R, et al. Joint replacement in osteoarthritis: state of the art. Semin Arthritis Rheum 2005;34Suppl 2:73&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16206963</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan D, Yang J, Pei F. Total knee arthroplasty treatment of rheumatoid arthritis with severe versus moderate flexion contracture. J Orthop Surg Res 2013;8:41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829704</ArticleId><ArticleId IdType="pubmed">24229435</ArticleId></ArticleIdList></Reference><Reference><Citation>Oladeji LO, Dreger TK, Pratte EL, et al. Total knee arthroplasty versus osteochondral allograft: prevalence and risk factors following tibial plateau fractures. J Knee Surg 2019;32:380&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29669383</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherubino P. Total hip arthroplasty. Orthopedics 2012;35:1039&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23218617</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YK, Kim KC, Ha YC, et al. Combined anterior and posterior approach in total hip arthroplasty for Crowe IV dysplasia or ankylosed hips. J Arthroplasty 2015;30:797&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">25682205</ArticleId></ArticleIdList></Reference><Reference><Citation>Albinarrate A, L&#xf3;pez-Picado A, Oiartzabal I, et al. Assessment of the introduction of a blood management program in orthopaedic surgery. Rev Esp Anestesiol Reanim 2015;62:443&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25315985</ArticleId></ArticleIdList></Reference><Reference><Citation>Jans &#xd8;, Bandholm T, Kurbegovic S, et al. Postoperative anemia and early functional outcomes after fast-track hip arthroplasty: a prospective cohort study. Transfusion 2016;56:917&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">26945552</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Porras JR, Colado E, Conde MP, et al. An individualized pre-operative blood saving protocol can increase pre-operative haemoglobin levels and reduce the need for transfusion in elective total hip or knee arthroplasty. Transfus Med 2009;19:35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">19302453</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Hu Q, Huang Q, et al. Comparison of intravenous versus topical tranexamic acid in primary total hip and knee arthroplasty: an updated meta-analysis. Thromb Res 2017;153:28&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">28319822</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara H, Yoneoka D. Predictors of allogeneic blood transfusion in total hip and knee arthroplasty in the United States, 2000&#x2013;2009. J Arthroplasty 2014;29:1736&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">24891002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin PC, Hsu CH, Chen WS, et al. Does tranexamic acid save blood in minimally invasive total knee arthroplasty? Clin Orthop Relat Res 2011;469:1995&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111781</ArticleId><ArticleId IdType="pubmed">21286886</ArticleId></ArticleIdList></Reference><Reference><Citation>MacGillivray RG, Tarabichi SB, Hawari MF, et al. Tranexamic acid to reduce blood loss after bilateral total knee arthroplasty: a prospective, randomized double blind study. J Arthroplasty 2011;26:24&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20171048</ArticleId></ArticleIdList></Reference><Reference><Citation>Wind TC, Barfield WR, Moskal JT. The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty. J Arthroplasty 2014;29:387&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23790499</ArticleId></ArticleIdList></Reference><Reference><Citation>Perreault RE, Fournier CA, Mattingly DA, et al. Oral tranexamic acid reduces transfusions in total knee arthroplasty. J Arthroplasty 2017;32:2990&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">28757131</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LK, Ma JX, Kuang MJ, et al. The efficacy of tranexamic acid using oral administration in total knee arthroplasty: a systematic review and meta-analysis. J Orthop Surg Res 2017;12:159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5658985</ArticleId><ArticleId IdType="pubmed">29078788</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Shen X. The efficacy of combined intra-articular and intravenous tranexamic acid for blood loss in primary total knee arthroplasty: a meta-analysis. Medicine (Baltimore) 2017;96:e8123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5662361</ArticleId><ArticleId IdType="pubmed">29049195</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiev GP, Tanchev PP, Zheleva Z, et al. Comparison of topical and intravenous administration of tranexamic acid for blood loss control during total joint replacement: Review of literature. J Orthop Translat 2018;13:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5892384</ArticleId><ArticleId IdType="pubmed">29662786</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillingham YA, Kayupov E, Plummer DR, et al. The James A. Rand Young Investigator's Award: a randomized controlled trial of oral and intravenous tranexamic acid in total knee arthroplasty: the same efficacy at lower cost? J Arthroplasty 2016;31Suppl:26&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">27113948</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayupov E, Fillingham YA, Okroj K, et al. Oral and intravenous tranexamic acid are equivalent at reducing blood loss following total hip arthroplasty: a randomized controlled trial. J Bone Joint Surg Am 2017;99:373&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28244907</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin A, Khan SK, Jameson SS, et al. Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures. Bone Joint J 2013;95-b:1556&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24151279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Li B, Wang Q, et al. Comparison of 3 routes of administration of tranexamic acid on primary unilateral total knee arthroplasty: a prospective, randomized, controlled study. J Arthroplasty 2017;32:2738&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">28455182</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohar E, Ellis M, Ifrach N, et al. The postoperative blood-sparing efficacy of oral versus intravenous tranexamic acid after total knee replacement. Anesth Analg 2004;99:1679&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">15562053</ArticleId></ArticleIdList></Reference><Reference><Citation>Gortemoller MA, Allen B, Forsyth R, et al. Comparison of oral and intravenous tranexamic acid for prevention of perioperative blood loss in total knee and total hip arthroplasty. Ann Pharmacother 2018;52:246&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980475</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo ZY, Wang HY, Wang D, et al. Oral vs intravenous vs topical tranexamic acid in primary hip arthroplasty: a prospective, randomized, double-blind, controlled study. J Arthroplasty 2018;33:786&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">29107495</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J, GS Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008</Citation></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee QJ, Chang WY, Wong YC. Blood-sparing efficacy of oral tranexamic acid in primary total hip arthroplasty. J Arthroplasty 2017;32:139&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">27498390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao LQ, Wang QW, Chen WQ, et al. Comparison of oral and intravenous tranexamic acid in total knee and hip arthroplasty: a systematic review and meta-analysis. Int J Surg 2017;47:52&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">28919096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LK, Ma JX, Kuang MJ, et al. Comparison of oral versus intravenous application of tranexamic acid in total knee and hip arthroplasty: a systematic review and meta-analysis. Int J Surg 2017;45:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">28755884</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37053117</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-2291</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of orthopaedic trauma</Title><ISOAbbreviation>J Orthop Trauma</ISOAbbreviation></Journal><ArticleTitle>Is There a Role for Anti-factor Xa Activity Assay in Venous Thromboembolism Prophylaxis Management Among Orthopaedic Trauma Patients? Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>e368</StartPage><EndPage>e376</EndPage><MedlinePgn>e368-e376</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/BOT.0000000000002611</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To determine the effect of anti-factor Xa assay dosing of low-molecular-weight heparin (LMWH) on rates of venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE), bleeding, and mortality among orthopaedic trauma patients.</AbstractText><AbstractText Label="DATA SOURCES">PubMed/MEDLINE, Embase, Ovid, Cochrane Central Register of Controlled Trials (CENTRAL), clinicaltrials.gov , and Scopus were systematically searched from inception of the database to 2021.</AbstractText><AbstractText Label="STUDY SELECTION">Prospective, retrospective, and randomized controlled trial studies were included if they compared rates of VTE, DVT, PE, bleeding, and/or mortality between orthopaedic trauma patients receiving anti-factor Xa-based LMWH dosing and those receiving standard dosing.</AbstractText><AbstractText Label="DATA EXTRACTION">Two independent reviewers screened titles and abstracts for eligibility. Study characteristics including study design, inclusion criteria, and intervention were extracted.</AbstractText><AbstractText Label="DATA SYNTHESIS">Meta-analysis was performed using pooled proportion of events (effect size) with 95% confidence intervals. A random-effects model was used. Heterogeneity was quantified by Higgins I 2 . Heterogeneity and variability between subgroups indicated differences in the pooled estimate represented by a P -value.</AbstractText><AbstractText Label="RESULTS">Six hundred eighty-five studies were identified, and 10 studies including 2870 patients were included. In total, 30.3% and 69.7% received an adjusted and nonadjusted dose of LMWH, respectively. The rate of VTE and DVT were significantly lower in the anti-factor Xa-adjusted cohort, whereas there was no statistically significant difference in rates of PE, bleeding, or mortality between the cohorts.</AbstractText><AbstractText Label="CONCLUSIONS">This systematic review and meta-analysis demonstrates that anti-factor Xa activity assay dosing of LMWH among orthopaedic trauma patients leads to a reduction in overall DVT rates, although not PE rates, without an increased risk of bleeding events.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE">Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tischler</LastName><ForeName>Eric H</ForeName><Initials>EH</Initials><Identifier Source="ORCID">0000-0003-2098-0440</Identifier><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Rehabilitation Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Sung Huang Laurent</ForeName><Initials>SHL</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Keelung Branch, Keelung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolfert</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-1704-5569</Identifier><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Rehabilitation Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Keudell</LastName><ForeName>Arvind</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roudnitsky</LastName><ForeName>Valery</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of General Surgery, The State University of New York Downstate Health Sciences University, Brooklyn, NY; and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gross</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Staten Island University Hospital, Northwell Health Staten Island, Staten Island, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suneja</LastName><ForeName>Nishant</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1608-159</Identifier><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery and Rehabilitation Medicine, The State University of New York Downstate Health Sciences University, Brooklyn, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Brigham and Women's Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Orthop Trauma</MedlineTA><NlmUniqueID>8807705</NlmUniqueID><ISSNLinking>0890-5339</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="Y">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009985" MajorTopicYN="Y">Orthopedics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>13</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37053117</ArticleId><ArticleId IdType="doi">10.1097/BOT.0000000000002611</ArticleId><ArticleId IdType="pii">00005131-202309000-00015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ludwig KP, Simons HJ, Mone M, et al. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ann Pharmacother. 2011;45:1356&#x2013;1362.</Citation></Reference><Reference><Citation>Jones DL, Jones WA, Fleming KI, et al. Underdosing of prophylactic enoxaparin is common in orthopaedic trauma and predicts 90-day venous thromboembolism. J Orthop Trauma. 2019;33:570&#x2013;576.</Citation></Reference><Reference><Citation>Geerts WH, Code KI, Jay RM, et al. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331:1601&#x2013;1606.</Citation></Reference><Reference><Citation>Starr AJ, Shirley Z, Sutphin PD, et al. Significant reduction of pulmonary embolism in orthopaedic trauma patients. J Orthop Trauma. 2019;33:78&#x2013;81.</Citation></Reference><Reference><Citation>Dalen JE. Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis. Chest. 2002;122:1440&#x2013;1456.</Citation></Reference><Reference><Citation>Rodier SG, Bukur M, Moore S, et al. Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting. Eur J Trauma Emerg Surg. 2021;47:145&#x2013;151.</Citation></Reference><Reference><Citation>Stannard JP, Lopez-Ben RR, Volgas DA, et al. Prophylaxis against deep-vein thrombosis following trauma: a prospective, randomized comparison of mechanical and pharmacologic prophylaxis. J Bone Joint Surg-Am. 2006;88:261&#x2013;266.</Citation></Reference><Reference><Citation>Connelly CR, Van PY, Hart KD, et al. Thrombelastography-based dosing of enoxaparin for thromboprophylaxis in trauma and surgical patients: a randomized clinical trial. JAMA Surg. 2016;151:e162069.</Citation></Reference><Reference><Citation>Egan G, Ensom MHH. Measuring anti-factor Xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hosp Pharm. 2015;68:33&#x2013;47.</Citation></Reference><Reference><Citation>J&#xf8;rgensen PS, Knudsen JB, Broeng L, et al. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study. Clin Orthop Relat Res. 1992;278:95&#x2013;100.</Citation></Reference><Reference><Citation>Cuschieri J, Freeman B, O'Keefe G, et al. Inflammation and the host response to injury a large-scale collaborative project: patient-oriented research core standard operating procedure for clinical care X. Guidelines for venous thromboembolism prophylaxis in the trauma patient. J Trauma Inj Infect Crit Care. 2008;65:944&#x2013;950.</Citation></Reference><Reference><Citation>Hakeam HA, Al Duhailib Z, Alsemari M, et al. Anti-factor Xa levels in low-weight surgical patients receiving enoxaparin for venous thromboembolism prophylaxis: a prospective cohort study. Clin Appl Thrombo Hemost. 2020;26:107602962093119.</Citation></Reference><Reference><Citation>Newall F. Anti-factor Xa (anti-Xa) assay. Methods Mol Biol. 2013;992:265&#x2013;272.</Citation></Reference><Reference><Citation>Vera-Aguilera J, Yousef H, Beltran-Melgarejo D, et al. Clinical scenarios for discordant anti-Xa. Adv Hematol. 2016;2016:1&#x2013;6.</Citation></Reference><Reference><Citation>Costantini TW, Min E, Box K, et al. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. J Trauma Acute Care Surg. 2013;74:128&#x2013;135.</Citation></Reference><Reference><Citation>Bickford A, Majercik S, Bledsoe J, et al. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. Am J Surg. 2013;206:847&#x2013;852; discussion 851&#x2013;852.</Citation></Reference><Reference><Citation>Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603&#x2013;605.</Citation></Reference><Reference><Citation>Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.</Citation></Reference><Reference><Citation>Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22:209&#x2013;212.</Citation></Reference><Reference><Citation>Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21:607&#x2013;611.</Citation></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177&#x2013;188.</Citation></Reference><Reference><Citation>Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557&#x2013;560.</Citation></Reference><Reference><Citation>Dhillon NK, Smith EJT, Gillette E, et al. Trauma patients with lower extremity and pelvic fractures: should anti-factor Xa trough level guide prophylactic enoxaparin dose? Int J Surg. 2018;51:128&#x2013;132.</Citation></Reference><Reference><Citation>Droege ME, Mueller EW, Besl KM, et al. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg. 2014;76:450&#x2013;456.</Citation></Reference><Reference><Citation>Imran JB, Madni TD, Clark AT, et al. Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin. J Trauma Acute Care Surg. 2018;85:867&#x2013;872.</Citation></Reference><Reference><Citation>Karcutskie CA, Dharmaraja A, Patel J, et al. Association of anti-factor Xa-guided dosing of enoxaparin with venous thromboembolism after trauma. JAMA Surg. 2018;153:144&#x2013;149.</Citation></Reference><Reference><Citation>Ko A, Harada MY, Barmparas G, et al. Association between enoxaparin dosage adjusted by anti-factor Xa trough level and clinically evident venous thromboembolism after trauma. JAMA Surg. 2016;151:1006&#x2013;1013.</Citation></Reference><Reference><Citation>Kopelman TR, Walters JW, Bogert JN, et al. Goal directed enoxaparin dosing provides superior chemoprophylaxis against deep vein thrombosis. Injury. 2017;48:1088&#x2013;1092.</Citation></Reference><Reference><Citation>Schulman S, Anger&#xe5;s U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8:202&#x2013;204.</Citation></Reference><Reference><Citation>Malinoski D, Jafari F, Ewing T, et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma Inj Infect Crit Care. 2010;68:874&#x2013;880.</Citation></Reference><Reference><Citation>Walker CK, Sandmann EA, Horyna TJ, et al. Increased enoxaparin dosing for venous thromboembolism prophylaxis in general trauma patients. Ann Pharmacother. 2017;51:323&#x2013;331.</Citation></Reference><Reference><Citation>Rondina MT, Wheeler M, Rodgers GM, et al. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thrombosis Res. 2010;125:220&#x2013;223.</Citation></Reference><Reference><Citation>Pannucci CJ, Hunt MM, Fleming KI, et al. Weight-based dosing for once-daily enoxaparin cannot provide adequate anticoagulation for venous thromboembolism prophylaxis. Plastic Reconstr Surg. 2017;140:815&#x2013;822.</Citation></Reference><Reference><Citation>Lin H, Faraklas I, Saffle J, et al. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients. J Trauma Inj Infect Crit Care. 2011;71:1557&#x2013;1561.</Citation></Reference><Reference><Citation>Singer GA, Riggi G, Karcutskie CA, et al. Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg. 2016;81:1101&#x2013;1108.</Citation></Reference><Reference><Citation>Shuster R, Mathew J, Olaussen A, et al. Variables associated with pulmonary thromboembolism in injured patients: a systematic review. Injury. 2018;49:1&#x2013;7.</Citation></Reference><Reference><Citation>Klemen ND, Feingold PL, Hashimoto B, et al. Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis. Lancet Haematol. 2020;7:e583&#x2013;e593.</Citation></Reference><Reference><Citation>Suen K, Westh RN, Churilov L, et al. Low-molecular-weight heparin and the relative risk of surgical site bleeding complications: results of a systematic review and meta-analysis of randomized controlled trials of venous thromboprophylaxis in patients after total joint arthroplasty. J Arthroplasty. 2017;32:2911&#x2013;2919.e6.</Citation></Reference><Reference><Citation>Levine MN, Planes A, Hirsh J, et al. The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemost. 1989;62:940&#x2013;944.</Citation></Reference><Reference><Citation>Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144:673&#x2013;684.</Citation></Reference><Reference><Citation>Gerlach AT, Pickworth KK, Seth SK, et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy. 2000;20:771&#x2013;775.</Citation></Reference><Reference><Citation>Wei MY, Ward SM. The anti-factor Xa range for low molecular weight heparin thromboprophylaxis. Hematol Rep. 2015;7:5844.</Citation></Reference><Reference><Citation>Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32:546&#x2013;558.</Citation></Reference><Reference><Citation>Trivedi NN, Abola MV, Kim CY, et al. The incremental cost of inpatient venous thromboembolism after hip fracture surgery. J Orthop Trauma. 2020;34:169&#x2013;173.</Citation></Reference><Reference><Citation>Shahi A, Chen AF, Tan TL, et al. The incidence and economic burden of in-hospital venous thromboembolism in the United States. J Arthroplasty. 2017;32:1063&#x2013;1066.</Citation></Reference><Reference><Citation>Stuart M, Johnson L, Hanigan S, et al. Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors. J Thromb Haemost. 2020;18:1653&#x2013;1660.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39042653</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>7</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Effects of intermittent pneumatic compression devices interventions to prevent deep vein thrombosis in surgical patients: A systematic review and meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>e0307602</StartPage><MedlinePgn>e0307602</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0307602</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0307602</ELocationID><Abstract><AbstractText>This review aimed to determine the effectiveness of Intermittent Pneumatic Compression (IPC) intervention on Deep Vein Thrombosis (DVT) in surgical patients. An electronic database search was conducted with PubMed, OVID-MEDLINE, EMBASE, and CENTRAL, from September 22 to 28, 2023. Three researchers independently selected the studies, assessed their methodological quality, and extracted relevant data. We conducted a meta-analysis of the effect of IPC versus the control group and summarized the intervention results from the included studies. Of the 2,696 articles identified 16 randomized control trials met the inclusion criteria for review. IPC interventions significantly affected DVT prevention (OR = 0.81, 95% CI: 0.59-1.11). In the subgroup analysis, there was a significant pooled effect (OR = 0.41, 95% CI: 0.26-0.65]), when the comparison group was no prophylaxis group. However, when the comparison groups were the pharmacologic prophylaxis group ([OR = 1.32, 95% CI 0.78-2.21]) and IPC combined with the pharmacologic prophylaxis group (OR = 2.43, 95% CI: 0.99-5.96) did not affect DVT prevention. The pooled effects of Pulmonary Embolism (PE) (OR = 5.81, 95% CI: 1.25-26.91) were significant. IPC intervention showed a significant effect on bleeding prevention (OR = 0.17, 95% CI: 0.08-0.36) when compared to IPC combined with the pharmacologic groups. IPC intervention effectively prevented DVT, PE, and bleeding in surgical patients. Therefore, we propose that IPC intervention be applied to surgical patients to avoid DVT, pulmonary embolism, and bleeding in the surgical nursing field as scientific evidence suggests.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Kim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Nam Young</ForeName><Initials>NY</Initials><AffiliationInfo><Affiliation>Department of Nursing, Jungwon University, Goesan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Seang</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4677-1658</Identifier><AffiliationInfo><Affiliation>Department of Nursing, Mokpo National University, Muan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yun-Hee</ForeName><Initials>YH</Initials><Identifier Source="ORCID">0000-0002-4024-9455</Identifier><AffiliationInfo><Affiliation>Department of Nursing, Mokpo National University, Muan, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048228" MajorTopicYN="Y">Intermittent Pneumatic Compression Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>23</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>23</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39042653</ArticleId><ArticleId IdType="pmc">PMC11265719</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0307602</ArticleId><ArticleId IdType="pii">PONE-D-24-18224</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cheng S, Gao H, Li Y, Shi X, Li X, Yang T, et al.. Analysis of risk factors of postoperative lower extremity deep venous thrombosis in patients with cervical cancer. Clin Appl Thromb Hemost. 2024;30:1&#x2013;8. doi: 10.1177/10760296241240747</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10760296241240747</ArticleId><ArticleId IdType="pmc">PMC10964453</ArticleId><ArticleId IdType="pubmed">38528746</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastori D, Cormaci VM, Marucci S, Franchino G, Del Sole F, Capozza A, et al.. A comprehensive review of risk factors for venous thromboembolism: From epidemiology to pathophysiology. Int J Mol Sci. 2023; 24(4):3169. doi: 10.3390/ijms24043169</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24043169</ArticleId><ArticleId IdType="pmc">PMC9964264</ArticleId><ArticleId IdType="pubmed">36834580</ArticleId></ArticleIdList></Reference><Reference><Citation>Elpern E, Killeen K, Patel G, Senecal PA. The application of intermittent pneumatic compression devices for thromboprophylaxis: An observational study found frequent errors in the application of these mechanical devices in ICUs. Am J Nur. 2013;113(4):30&#x2013;6. doi: 10.1097/01.NAJ.0000428736.48428.10</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.NAJ.0000428736.48428.10</ArticleId><ArticleId IdType="pubmed">23492806</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynard G.
Preventing hospital-associated venous thromboembolism: a guide for effective quality improvement.
2nd ed.
AHRQ Publication No. 16-0001-EF [Internet].
Rockville, MD: Agency for Healthcare Research and Quality. [updated August 2016; cited 2016 October 7]. Available from: https://www.ahrq.gov/sites/default/files/publications/files/vteguide.pdf</Citation></Reference><Reference><Citation>Nicolaides AN, Fareed J, Kakkar AK, Comerota AJ, Goldhaber SZ, Hull R, et al.. Prevention and treatment of venous thromboembolism&#x2013;International Consensus Statement. Int Angiol. 2013;32(2):111&#x2013;260</Citation><ArticleIdList><ArticleId IdType="pubmed">24402349</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Akl EA, Crowther M, Gutterman DG, Schu&#xfc;nemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):7S&#x2013;47S. doi: 10.1378/chest.1412S3</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.1412S3</ArticleId><ArticleId IdType="pmc">PMC3278060</ArticleId><ArticleId IdType="pubmed">22315257</ArticleId></ArticleIdList></Reference><Reference><Citation>Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism [Internet].
Edinburgh: Scottish Intercollegiate Guidelines Network; 2010. [cited 2023 September 22]. Available from: http://www.sign.ac.uk/guidelines/fulltext/122/index.html</Citation></Reference><Reference><Citation>Wang Y, Huang D, Wang M, Liang Z. Can intermittent pneumatic compression reduce the incidence of venous thrombosis in critically ill patients: A systematic review and meta-analysis. Clin Appl Thromb Hemost. 2020;26:1&#x2013;8. doi: 10.1177/1076029620913942</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029620913942</ArticleId><ArticleId IdType="pmc">PMC7592327</ArticleId><ArticleId IdType="pubmed">33074726</ArticleId></ArticleIdList></Reference><Reference><Citation>Iverson RE, Gomez JL. Deep venous thrombosis: Prevention and management. Clinics in Plastic Surgery. 2013;40(3):389&#x2013;398. doi: 10.1016/j.cps.2013.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cps.2013.04.002</ArticleId><ArticleId IdType="pubmed">23830747</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel AP, Koltz MT, Sansur CA, Gulati M, Hamilton DK. An analysis of deep vein thrombosis in 1277 consecutive neurosurgical patients undergoing routine weekly ultrasonography. Journal of Neurosurgery. 2013;118(3):505&#x2013;509. doi: 10.3171/2012.11.JNS121243</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/2012.11.JNS121243</ArticleId><ArticleId IdType="pubmed">23240698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM. Risk factors of lower extremity deep venous thrombosis in postoperative patients. M.Sc. Thesis, The Catholic University, 2014. Available from: https://www.dbpia.co.kr/journal/articleDetail?nodeId=NODE09340730</Citation></Reference><Reference><Citation>Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby G, Reddy DJ, et al.. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst Rev. 2016;9(9):CD005258. doi: 10.1002/14651858.CD005258.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005258.pub3</ArticleId><ArticleId IdType="pmc">PMC6457599</ArticleId><ArticleId IdType="pubmed">27600864</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing GJ, et al.. Executive summary: Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):2247&#x2013;59. doi: 10.1016/j.chest.2021.07.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.07.056</ArticleId><ArticleId IdType="pubmed">34352279</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical-surgical critically ill patients: A systematic review and meta-analysis of randomized trials. Crit Care Med. 2013;41(9):2088&#x2013;98. doi: 10.1097/CCM.0b013e31828cf104</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828cf104</ArticleId><ArticleId IdType="pubmed">23782973</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, Lee JM, Lee JS, Cho YJ. Pharmacological and mechanical thromboprophylaxis in critically ill patients: a network meta-analysis of 12 trials. J Korean Med Sci. 2016;31(11):1828&#x2013;37. doi: 10.3346/jkms.2016.31.11.1828</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2016.31.11.1828</ArticleId><ArticleId IdType="pmc">PMC5056218</ArticleId><ArticleId IdType="pubmed">27709864</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al.. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3. [Internet]. London: The Cochrane Collaboration; 2022.  [cited 2023 September 25]. Available from: https://www.training.cochrane.org/handbook</Citation></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidwell S, Jensen MF. Etext on health technology assessment (HTA) information resources. Chapter 3: Using a search protocol to identify sources of information: the COSI model [Internet]. Rockville Pike, MD: National Library of Medicine [cited 2023 September 22]. Available from https://www.nlm.nih.gov/archive/20060905/nichsr/ ehta/chapter3.html.</Citation></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l4898</ArticleId><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>Haykal T, Zayed Y, Dhillon H, Miran MS, Kerbage J, Bala A, et al.. Meta-analysis of the role of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in critically ill patients. Int J Low Extrem Wounds. 2022;21(1):31&#x2013;40. doi: 10.1177/1534734620925391</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1534734620925391</ArticleId><ArticleId IdType="pubmed">32527203</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng JP, Xiong YT, Fan ZQ, Yan LJ, Wang JY, Gu ZJ. Efficacy of intermittent pneumatic compression for venous thromboembolism prophylaxis in patients undergoing gynecologic surgery: A systematic review and meta-analysis. Oncotarget. 2017;8(12):20371&#x2013;379. doi: 10.18632/oncotarget.13620</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.13620</ArticleId><ArticleId IdType="pmc">PMC5386769</ArticleId><ArticleId IdType="pubmed">27901494</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;nemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, et al.. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198&#x2013;225. doi: 10.1182/bloodadvances.2018022954</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2018022954</ArticleId><ArticleId IdType="pmc">PMC6258910</ArticleId><ArticleId IdType="pubmed">30482763</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelboom JW, Quinlan DJ, O&#x2019;Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation. 2009;120(20):2006&#x2013;11. doi: 10.1161/CIRCULATIONAHA.109.872630</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.872630</ArticleId><ArticleId IdType="pubmed">19884469</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamontagne F, Mclntyre L, Dodek P, Heels-Ansdell D, Meade M, Pemberton J, et al.. Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study. JAMA Intern Med 2014; 174(5):689&#x2013;96. doi: 10.1001/jamainternmed.2014.169</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2014.169</ArticleId><ArticleId IdType="pubmed">24638843</ArticleId></ArticleIdList></Reference><Reference><Citation>Beitland S, Sandven I, Kj&#xe6;rvik LK, Sandset PM, Sunde K, Eken T. Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2015;41(7):1209&#x2013;19. doi: 10.1007/s00134-015-3840-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-3840-z</ArticleId><ArticleId IdType="pubmed">25971389</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RJ, Roberts CH. Haematological Effects of Intermittent Pneumatic Compression for Deep Vein Thrombosis Prophylaxis. Thrombosis and Haemostasis. 2020;120(6):912&#x2013;23. doi: 10.1055/s-0040-1710016</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1710016</ArticleId><ArticleId IdType="pubmed">32359225</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37661228</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0932</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society</Title><ISOAbbreviation>Eur Spine J</ISOAbbreviation></Journal><ArticleTitle>Comparison of intraoperative blood loss and perioperative complications between preoperative embolization and nonembolization combined with spinal tumor surgeries: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>4272</StartPage><EndPage>4296</EndPage><MedlinePgn>4272-4296</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00586-023-07898-9</ELocationID><Abstract><AbstractText Label="PURPOSE">The present study aimed to comparatively evaluate intraoperative blood loss (IBL) and perioperative complications between preoperative embolization (PE) and nonembolization (NE) combined with spinal tumor surgeries as well as to determine the subgroup of spinal tumor surgeries suitable for PE.</AbstractText><AbstractText Label="METHODS">A systematic search in PubMed and EMBASE and an additional search by reference lists of the retrieved studies were undertaken by two reviewers. The mean IBL and perioperative complication rate were employed as the effect size in the general quantitative synthesis through direct calculation. Meta-analysis was performed using standardized mean difference (SMD) and weighted mean difference (WMD) of IBL and the odds ratio (OR) of complications. Heterogeneity was assessed using the I2 statistic.</AbstractText><AbstractText Label="RESULTS">The reviewers selected 17 published studies for the general quantitative synthesis and meta-analyses. The mean IBL of spinal tumor surgeries was 1786.3&#xa0;mL in the NE group and 1716.4&#xa0;mL in the PE group. The mean IBL between the two groups was similar. The pooled WMD and SMD of IBL in spinal tumor surgeries was 324.15&#xa0;mL (95% CI 89.50-1640.9, p&#x2009;=&#x2009;0.007) and 0.398 (95% CI 0.114-0.682, p&#x2009;=&#x2009;0.006), respectively. The reduction of the PE group compared with the NE group for the rates of major complications and major hemorrhagic complications were 7.80% and 5.71%, respectively. The risk of PE-related complications in the PE group was only 1.53% more than in the PE group. The pooled OR of major complications in spinal tumor surgeries was 1.426 (95% CI 0.760-2.674; p&#x2009;=&#x2009;0.269).</AbstractText><AbstractText Label="CONCLUSIONS">PE may be suitable for spinal tumor surgeries and some subgroups. From the perspective of complications, PE may also be a feasible option for spinal tumor surgeries.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Ruiqi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Bone and Soft Tissue Oncology, Tianjin Hospital, 406 Jiefang Southern Road, Tianjin, 300000, MD, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Rongxing</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaozhao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Qinghai Renji Hospital, Xining, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lun</LastName><ForeName>Dengxing</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Bone Oncology, Weifang People's Hospital, Weifang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruifeng</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Graduate School, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yongcheng</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9846-6735</Identifier><AffiliationInfo><Affiliation>Department of Bone and Soft Tissue Oncology, Tianjin Hospital, 406 Jiefang Southern Road, Tianjin, 300000, MD, China. huycdoctor@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Spine J</MedlineTA><NlmUniqueID>9301980</NlmUniqueID><ISSNLinking>0940-6719</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013125" MajorTopicYN="Y">Spinal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019635" MajorTopicYN="N">Neurosurgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013120" MajorTopicYN="Y">Spinal Cord Neoplasms</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Intraoperative blood loss</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Perioperative complication</Keyword><Keyword MajorTopicYN="N">Preoperative embolization</Keyword><Keyword MajorTopicYN="N">Systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>3</Day><Hour>23</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37661228</ArticleId><ArticleId IdType="doi">10.1007/s00586-023-07898-9</ArticleId><ArticleId IdType="pii">10.1007/s00586-023-07898-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pauyo T, Verma N, Marwan Y, Aoude A, Khashan M, Weber MH (2017) Canadian consensus for the prevention of blood loss in spine surgery. Spine 42:E50-e55. https://doi.org/10.1097/brs.0000000000001686</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/brs.0000000000001686</ArticleId><ArticleId IdType="pubmed">27172287</ArticleId></ArticleIdList></Reference><Reference><Citation>Westbroek EM, Ahmed AK, Pennington Z, Goodwin ML, Xia Y, Boone C, Gailloud P, Sciubba DM (2019) Hypervascular Metastatic spine tumor angiographic relationships with the artery of adamkiewicz and other radiculomedullary arteries. World Neurosurg 126:e480&#x2013;e485. https://doi.org/10.1016/j.wneu.2019.02.075</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2019.02.075</ArticleId><ArticleId IdType="pubmed">30825630</ArticleId></ArticleIdList></Reference><Reference><Citation>Parshuram C, Doyle J, Lau W, Shemie SD (2002) Transfusion-associated graft versus host disease. Pediatr Crit Care Med J Soc Crit Care Med World Federation Pediatr Intensive Crit Care Soc 3:57&#x2013;62. https://doi.org/10.1097/00130478-200201000-00013</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00130478-200201000-00013</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP (1999) Transfusion medicine. first of two parts&#x2013;blood transfusion. N Engl J Med 340:438&#x2013;447. https://doi.org/10.1056/nejm199902113400606</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199902113400606</ArticleId><ArticleId IdType="pubmed">9971869</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu SS (2004) Blood loss in adult spinal surgery. Eur Spine J: Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc 13(Suppl 1):S3-5. https://doi.org/10.1007/s00586-004-0753-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00586-004-0753-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Tai BC, Nayak D, Kumar N, Chua KH, Lim JW, Goy RW, Wong HK (2013) Blood loss in spinal tumour surgery and surgery for metastatic spinal disease: a meta-analysis. Bone Jt J 95:683&#x2013;688. https://doi.org/10.1302/0301-620x.95b5.31270</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620x.95b5.31270</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YJ, Du XC, Deng XQ, Zhang H, Zhang HR, Qiao RQ, Zhang JY, Hu YC (2021) Resuscitative endovascular balloon occlusion of the aorta for blood control in lumbar spine tumor resection surgery: a technical note. Orthop Surg 13:1540&#x2013;1545. https://doi.org/10.1111/os.13048</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/os.13048</ArticleId><ArticleId IdType="pubmed">34086401</ArticleId><ArticleId IdType="pmc">8313148</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Guo W, Yang R, Tang S, Dong S (2010) Use of aortic balloon occlusion to decrease blood loss during sacral tumor resection. J Bone Jt Surg Am 92:1747&#x2013;1753. https://doi.org/10.2106/jbjs.I.01333</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/jbjs.I.01333</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Duan H, Liu W, Min L, Shi R, Zhang W, Zhou Y, Tu C (2013) Clinical evaluation for lower abdominal aorta balloon occluding in the pelvic and sacral tumor resection. J Surg Oncol 108:148&#x2013;151. https://doi.org/10.1002/jso.23376</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.23376</ArticleId><ArticleId IdType="pubmed">23846994</ArticleId></ArticleIdList></Reference><Reference><Citation>Voelker A, Osterhoff G, Einhorn S, Ebel S, Heyde CE, Pieroh P (2022) Does the anatomical region predict blood loss or neurological deficits in embolized renal cancer spine metastases? A single-center experience with 31 patients. World J Surg Oncol 20:208. https://doi.org/10.1186/s12957-022-02676-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12957-022-02676-1</ArticleId><ArticleId IdType="pubmed">35710422</ArticleId><ArticleId IdType="pmc">9202195</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahood W, Alexander AY, Yolcu YU, Brinjikji W, Kallmes DF, Lanzino G, Bydon M (2021) Trends in utilization of preoperative embolization for spinal metastases: a study of the national inpatient sample 2005&#x2013;2017. Neurointervention 16:52&#x2013;58. https://doi.org/10.5469/neuroint.2020.00381</Citation><ArticleIdList><ArticleId IdType="doi">10.5469/neuroint.2020.00381</ArticleId><ArticleId IdType="pubmed">33657312</ArticleId><ArticleId IdType="pmc">7946559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HZ, Dong L, Wang HM, Hu F, Shao Q, Chen X, Chen L (2020) Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study. Br J Neurosurg 34:313&#x2013;315. https://doi.org/10.1080/02688697.2020.1717442</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02688697.2020.1717442</ArticleId><ArticleId IdType="pubmed">31994911</ArticleId></ArticleIdList></Reference><Reference><Citation>Damade C, Tesson G, Gilard V, Vigny S, Foulongne E, Gauth&#xe9; R, Ould-Slimane M (2019) Blood loss and perioperative transfusions related to surgery for spinal tumors. Relevance of tranexamic acid. Neuro-Chirurgie 65:377&#x2013;381. https://doi.org/10.1016/j.neuchi.2019.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuchi.2019.05.003</ArticleId><ArticleId IdType="pubmed">31202780</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman AK, Thorne CJ, Gaston CL, Shellard R, Neal T, Parry MC, Grimer RJ, Jeys L (2017) Hypotensive epidural anesthesia reduces blood loss in pelvic and sacral bone tumor resections. Clin Orthop Relat Res 475:634&#x2013;640. https://doi.org/10.1007/s11999-016-4858-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-016-4858-4</ArticleId><ArticleId IdType="pubmed">27172818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma RX, Qiao RQ, Xu MY, Li RF, Hu YC (2022) Application of controlled hypotension during surgery for spinal metastasis. Technol Cancer Res Treat 21:15330338221105718. https://doi.org/10.1177/15330338221105718</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/15330338221105718</ArticleId><ArticleId IdType="pubmed">35668701</ArticleId><ArticleId IdType="pmc">9178972</ArticleId></ArticleIdList></Reference><Reference><Citation>Osei H, Munoz-Abraham AS, Bates KS, Kim JS, Saxena S, Greenspon J, Villalona GA (2019) Laparoscopic division of median sacral artery and dissection of types III and IV sacrococcygeal teratomas to decrease intraoperative hemorrhagic complications: case series and review of the literature. J Laparoendosc Adv Surg Tech A 29:272&#x2013;277. https://doi.org/10.1089/lap.2018.0189</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/lap.2018.0189</ArticleId><ArticleId IdType="pubmed">30351221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozkan E, Gupta S (2011) Embolization of spinal tumors: vascular anatomy, indications, and technique. Tech Vasc Interv Radiol 14:129&#x2013;140. https://doi.org/10.1053/j.tvir.2011.02.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.tvir.2011.02.005</ArticleId><ArticleId IdType="pubmed">21767780</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman R, Dubach-Schwizer S, Heini P, Lovblad KO, Kalbermatten D, Schroth G, Remonda L (2005) Preoperative transarterial embolization of vertebral metastases. Eur Spine J: Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc 14:263&#x2013;268. https://doi.org/10.1007/s00586-004-0757-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00586-004-0757-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HL, Chen KW, Wang GL, Lu J, Ji YM, Liu JY, Wu GZ, Gu Y, Sun ZY (2010) Pre-operative transarterial embolization for treatment of primary sacral tumors. J Clin Neurosci Off J Neurosurg Soc Australas 17:1280&#x2013;1285. https://doi.org/10.1016/j.jocn.2009.12.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2009.12.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Benati A, Dalle Ore G, Da Pian R, Bricolo A, Maschio A, Perini S (1974) Transfemoral selective embolisation in the treatment of some cranial and vertebro-spinal vascular malformations and tumours. Preliminary results. J Neurosurg Sci 18:233&#x2013;238</Citation><ArticleIdList><ArticleId IdType="pubmed">4377573</ArticleId></ArticleIdList></Reference><Reference><Citation>Olerud C, J&#xf3;nsson H Jr, L&#xf6;fberg AM, L&#xf6;relius LE, Sj&#xf6;str&#xf6;m L (1993) Embolization of spinal metastases reduces peroperative blood loss. 21 patients operated on for renal cell carcinoma. Acta Orthop Scand 64:9&#x2013;12. https://doi.org/10.3109/17453679308994517</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17453679308994517</ArticleId><ArticleId IdType="pubmed">8451959</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo SL, Kim YH, Park HY, Kim SI, Ha KY, Min HK, Seo JY, Oh IS, Chang DG, Ahn JH, Kim YW (2019) Clinical significance of preoperative embolization for non-hypervascular metastatic spine tumors. J Korean Neurosurg Soc 62:106&#x2013;113. https://doi.org/10.3340/jkns.2018.0073</Citation><ArticleIdList><ArticleId IdType="doi">10.3340/jkns.2018.0073</ArticleId><ArticleId IdType="pubmed">30630297</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirbel RJ, Roth R, Schulte M, Kramann B, Mutschler W (2005) Preoperative embolization in spinal and pelvic metastases. J Orthop Sci Off J Jpn Orthop Assoc 10:253&#x2013;257. https://doi.org/10.1007/s00776-005-0900-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00776-005-0900-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Onishi E, Hashimura T, Ota S, Fujita S, Tsukamoto Y, Matsunaga K, Yasuda T (2022) The efficacy and complications of preoperative embolization of metastatic spinal tumors: risk of paralysis after embolization. Spine Surg Relat Res 6:288&#x2013;293. https://doi.org/10.22603/ssrr.2021-0171</Citation><ArticleIdList><ArticleId IdType="doi">10.22603/ssrr.2021-0171</ArticleId><ArticleId IdType="pubmed">35800632</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan BWL, Zaw AS, Rajendran PC, Ruiz JN, Kumar N, Anil G (2017) Preoperative embolization in spinal tumour surgery: enhancing its effectiveness. J Clin Neurosci Off J Neurosurg Soc Australas 43:108&#x2013;114. https://doi.org/10.1016/j.jocn.2017.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2017.05.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Reh&#xe1;k S, Krajina A, Ungermann L, Ryska P, Cern&#xfd; V, Tal&#xe1;b R, Kanta M, Bartos M (2008) The role of embolization in radical surgery of renal cell carcinoma spinal metastases. Acta Neurochir 150:1177&#x2013;1181. https://doi.org/10.1007/s00701-008-0031-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00701-008-0031-5</ArticleId><ArticleId IdType="pubmed">18958386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K, Ozkan E, Tam A, Ensor J, Wallace MJ, Gupta S (2012) Preoperative embolization of spinal tumors: variables affecting intraoperative blood loss after embolization. Acta Radiol 53:935&#x2013;942. https://doi.org/10.1258/ar.2012.120314</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/ar.2012.120314</ArticleId><ArticleId IdType="pubmed">22927661</ArticleId></ArticleIdList></Reference><Reference><Citation>Finstein JL, Chin KR, Alvandi F, Lackman RD (2006) Postembolization paralysis in a man with a thoracolumbar giant cell tumor. Clin Orthop Relat Res 453:335&#x2013;340. https://doi.org/10.1097/01.blo.0000229304.59771.a3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.blo.0000229304.59771.a3</ArticleId><ArticleId IdType="pubmed">16936586</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkefeld J, Scale D, Kirchner J, Heinrich T, Kollath J (1999) Hypervascular spinal tumors: influence of the embolization technique on perioperative hemorrhage. AJNR Am J Neuroradiol 20:757&#x2013;763</Citation><ArticleIdList><ArticleId IdType="pubmed">10369341</ArticleId><ArticleId IdType="pmc">7056167</ArticleId></ArticleIdList></Reference><Reference><Citation>Thirunavu VM, Roumeliotis A, Shlobin NA, Kandula V, Shah P, Larkin C, Chan K, Hopkins BS, Cloney M, Karras CL, Dahdaleh NS (2022) The role of preoperative embolization in the treatment of spinal metastases from renal cell carcinoma. Clin Neurol Neurosurg 215:107181. https://doi.org/10.1016/j.clineuro.2022.107181</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2022.107181</ArticleId><ArticleId IdType="pubmed">35217392</ArticleId></ArticleIdList></Reference><Reference><Citation>Manke C, Bretschneider T, Lenhart M, Strotzer M, Neumann C, Gmeinwieser J, Feuerbach S (2001) Spinal metastases from renal cell carcinoma: effect of preoperative particle embolization on intraoperative blood loss. AJNR Am J Neuroradiol 22:997&#x2013;1003</Citation><ArticleIdList><ArticleId IdType="pubmed">11337348</ArticleId><ArticleId IdType="pmc">8174929</ArticleId></ArticleIdList></Reference><Reference><Citation>Luksanapruksa P, Buchowski JM, Tongsai S, Singhatanadgige W, Jennings JW (2018) Systematic review and meta-analysis of effectiveness of preoperative embolization in surgery for metastatic spine disease. J Neurointerv Surg 10:596&#x2013;601. https://doi.org/10.1136/neurintsurg-2017-013350</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/neurintsurg-2017-013350</ArticleId><ArticleId IdType="pubmed">28918384</ArticleId></ArticleIdList></Reference><Reference><Citation>Griessenauer CJ, Salem M, Hendrix P, Foreman PM, Ogilvy CS, Thomas AJ (2016) Preoperative embolization of spinal tumors: a systematic review and meta-analysis. World Neurosurg 87:362&#x2013;371. https://doi.org/10.1016/j.wneu.2015.11.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2015.11.064</ArticleId><ArticleId IdType="pubmed">26704206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao ZY, Zhang T, Zhang H, Pang CG, Xia Q (2021) Effectiveness of preoperative embolization in patients with spinal metastases: a systematic review and meta-analysis. World Neurosurg 152:e745&#x2013;e757. https://doi.org/10.1016/j.wneu.2021.06.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2021.06.062</ArticleId><ArticleId IdType="pubmed">34153484</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr&#xf3;bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clin Res Ed) 372:n71. https://doi.org/10.1136/bmj.n71</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:Ed000142. https://doi.org/10.1002/14651858.Ed000142</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.Ed000142</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603&#x2013;605. https://doi.org/10.1007/s10654-010-9491-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-010-9491-z</ArticleId><ArticleId IdType="pubmed">20652370</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1&#x2013;12. https://doi.org/10.1016/0197-2456(95)00134-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(95)00134-4</ArticleId><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen C, Dahl B, Frevert SC, Hansen LV, Nielsen MB, L&#xf6;nn L (2015) Preoperative embolization in surgical treatment of spinal metastases: single-blind, randomized controlled clinical trial of efficacy in decreasing intraoperative blood loss. J Vasc Interv Radiol JVIR 26:402-412.e401. https://doi.org/10.1016/j.jvir.2014.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jvir.2014.11.014</ArticleId><ArticleId IdType="pubmed">25636672</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S, Murakami H, Minami T, Demura S, Yoshioka K, Matsui O, Tsuchiya H (2012) Preoperative embolization significantly decreases intraoperative blood loss during palliative surgery for spinal metastasis. Orthopedics 35:e1389-1395. https://doi.org/10.3928/01477447-20120822-27</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/01477447-20120822-27</ArticleId><ArticleId IdType="pubmed">22955407</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D, Kong M, Zhu K, Han X, Zhang W, Zeng X, Zhou C, Ma X (2021) Clinical evaluation of preoperative embolization, vertebroplasty, and decompression in the treatment of aggressive vertebral hemangiomas. J Orthop Surg (Hong Kong) 29:2309499021993997. https://doi.org/10.1177/2309499021993997</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2309499021993997</ArticleId><ArticleId IdType="pubmed">33641539</ArticleId></ArticleIdList></Reference><Reference><Citation>Ptashnikov D, Zaborovskii N, Mikhaylov D, Masevnin S (2014) Preoperative embolization versus local hemostatic agents in surgery of hypervascular spinal tumors. Int J Spine Surg. https://doi.org/10.14444/1033</Citation><ArticleIdList><ArticleId IdType="doi">10.14444/1033</ArticleId><ArticleId IdType="pubmed">25694943</ArticleId><ArticleId IdType="pmc">4325511</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao Z, Jia N, He Q (2015) Does preoperative transarterial embolization decrease blood loss during spine tumor surgery? Interv Neuroradiol J Perith Neuroradiol Surg Proced Relat Neurosci 21:129&#x2013;135. https://doi.org/10.15274/inr-2014-10091</Citation><ArticleIdList><ArticleId IdType="doi">10.15274/inr-2014-10091</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaborovskii N, Ptashnikov D, Mikaylov D, Masevnin S, Smekalenkov O (2018) Preoperative embolization and local hemostatic agents in palliative decompression surgery for spinal metastases of renal cell carcinoma. Eur J Orthop Surg Traumatol Orthop Traumatol 28:1047&#x2013;1052. https://doi.org/10.1007/s00590-018-2162-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00590-018-2162-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess T, Kramann B, Schmidt E, Rupp S (1997) Use of preoperative vascular embolisation in spinal metastasis resection. Arch Orthop Trauma Surg 116:279&#x2013;282. https://doi.org/10.1007/bf00390053</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/bf00390053</ArticleId><ArticleId IdType="pubmed">9177804</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong CG, Cho JH, Suh DC, Hwang CJ, Lee DH, Lee CS (2017) Preoperative embolization in patients with metastatic spinal cord compression: mandatory or optional? World J Surg Oncol 15:45. https://doi.org/10.1186/s12957-017-1118-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12957-017-1118-3</ArticleId><ArticleId IdType="pubmed">28193282</ArticleId><ArticleId IdType="pmc">5307698</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks D, McClenny TE, Cardella JF, Lewis CA (2003) Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol JVIR 14:S199-202. https://doi.org/10.1097/01.rvi.0000094584.83406.3e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.rvi.0000094584.83406.3e</ArticleId><ArticleId IdType="pubmed">14514818</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastava RK, Epstein FJ, Perin NI, Post KD, Jallo GI (2005) Intramedullary spinal cord tumors in patients older than 50 years of age: management and outcome analysis. J Neurosurg Spine 2:249&#x2013;255. https://doi.org/10.3171/spi.2005.2.3.0249</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/spi.2005.2.3.0249</ArticleId><ArticleId IdType="pubmed">15796348</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi JH, Cachola K, Parsa AT (2006) Genetics and molecular biology of intramedullary spinal cord tumors. Neurosurg Clin N Am 17:1&#x2013;5. https://doi.org/10.1016/j.nec.2005.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nec.2005.10.002</ArticleId><ArticleId IdType="pubmed">16448901</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27627710</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1757-7861</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Orthopaedic surgery</Title><ISOAbbreviation>Orthop Surg</ISOAbbreviation></Journal><ArticleTitle>Efficiency and Safety of Intravenous Tranexamic Acid in Simultaneous Bilateral Total Knee Arthroplasty: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>285</StartPage><EndPage>293</EndPage><MedlinePgn>285-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/os.12256</ELocationID><Abstract><AbstractText>The objective of this systematic review and meta-analysis was to evaluate the efficacy and safety of i.v. tranexamic acid (TXA) in simultaneous bilateral total knee arthroplasty (TKA). Potentially relevant published reports were identified from the following electronic databases: Medline, PubMed, Embase, ScienceDirect and Cochrane Library. RevMan v5.3was used to pool data. Two randomized controlled trials and four case-control studies met the inclusion criteria. The current meta-analysis identified significant differences between TXA group and control groups in terms of postoperative hemoglobin concentration (P &lt; 0.01), drainage volume (P &lt; 0.01), transfusion rate (P &lt; 0.01) and units transfused (P = 0.006). There were no significant differences in length of stay (P = 0.66), operation time (P = 0.81) or and incidence of adverse effects such as infection (P = 0.42), deep venous thrombosis (DVT) (P = 0.88) and pulmonary embolism (PE) (P = 0.11). Our results show that i.v. administration of TXA in simultaneous bilateral TKA reduces postoperative drops in hemoglobin concentration, drainage volume, and transfusion requirements and does not prolong length of stay or operation time. Moreover, no adverse effects, such as infection, DVT or PE, were associated with TXA.</AbstractText><CopyrightInformation>&#xa9; 2016 Chinese Orthopaedic Association and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Graduate School of General Hospital, Tianjin Medical University, Tianjin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedics, Tianjin Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xin-Long</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>Graduate School of General Hospital, Tianjin Medical University, Tianjin, China. 15922028810@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedics, Tianjin Hospital, Tianjin, China. 15922028810@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jian-Xiong</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Tianjin Hospital, Tianjin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Orthop Surg</MedlineTA><NlmUniqueID>101501666</NlmUniqueID><ISSNLinking>1757-7853</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="N">Antifibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="Y">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="N">Tranexamic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Blood loss</Keyword><Keyword MajorTopicYN="N">Meta analysis</Keyword><Keyword MajorTopicYN="N">Total knee arthroplasty</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27627710</ArticleId><ArticleId IdType="pmc">PMC6584435</ArticleId><ArticleId IdType="doi">10.1111/os.12256</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sculco TP. Global blood management in orthopaedic surgery. Clin Orthop Relat Res, 1998, 357: 43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">9917699</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med, 2007, 356: 2301&#x2013;2311.</Citation><ArticleIdList><ArticleId IdType="pubmed">17538089</ArticleId></ArticleIdList></Reference><Reference><Citation>Conteduca F, Massai F, Iorio R, Zanzotto E, Luzon D, Ferretti A. Blood loss in computer&#x2010;assisted mobile bearing total knee arthroplasty. A comparison of computer&#x2010;assisted surgery with a conventional technique. Int Orthop, 2009, 33: 1609&#x2013;1613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2899193</ArticleId><ArticleId IdType="pubmed">18762940</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgili MG, Ercin E, Peker G, et al. Efficiency and cost analysis of cell saver auto transfusion system in total knee arthroplasty. Balkan Med J, 2014, 31: 149&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4115923</ArticleId><ArticleId IdType="pubmed">25207187</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoni G, Lethagen S, Fredin H. The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res, 1997, 85: 195&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">9058494</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J, Abrishami A, El Beheiry H, et al. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am, 2010, 92: 2503&#x2013;2513.</Citation><ArticleIdList><ArticleId IdType="pubmed">21048170</ArticleId></ArticleIdList></Reference><Reference><Citation>Cid J, Lozano M. Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta&#x2010;analysis of randomized controlled trials. Transfusion, 2005, 45: 1302&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">16078916</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu DJ, Chen C, Guo L, Yang L. Use of intravenous tranexamic acid in total knee arthroplasty: a meta&#x2010;analysis of randomized controlled trials. Chin J Traumatol, 2013, 16: 67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">23540893</ArticleId></ArticleIdList></Reference><Reference><Citation>Restrepo C, Parvizi J, Dietrich T, Einhorn TA. Safety of simultaneous bilateral total knee arthroplasty. A meta&#x2010;analysis. J Bone Joint Surg Am, 2007, 89: 1220&#x2013;1226.</Citation><ArticleIdList><ArticleId IdType="pubmed">17545424</ArticleId></ArticleIdList></Reference><Reference><Citation>Memtsoudis SG, Ma Y, Gonzalez Della Valle A, et al. Perioperative outcomes after unilateral and bilateral total knee arthroplasty. Anesthesiology, 2009, 111: 1206&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2803038</ArticleId><ArticleId IdType="pubmed">19934863</ArticleId></ArticleIdList></Reference><Reference><Citation>Walmsley P, Murray A, Brenkel IJ. The practice of bilateral, simultaneous total knee replacement in Scotland over the last decade. Data from the Scottish arthroplasty project. Knee, 2006, 13: 102&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481171</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock DP, Sporer SM, Shirreffs TG Jr. Comparison of simultaneous bilateral with unilateral total knee arthroplasty in terms of perioperative complications. J Bone Joint Surg Am, 2003, 85: 1981&#x2013;1986.</Citation><ArticleIdList><ArticleId IdType="pubmed">14563808</ArticleId></ArticleIdList></Reference><Reference><Citation>
Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. The Cochrane Collaboration, 2011.  Available from: www.handbook.cochrane.org (accessed 31 October 2015).</Citation></Reference><Reference><Citation>Slim K, Nini E, Forestier D, et al. Methodological index for non&#x2010;randomized studies (minors): development and validation of a new instrument. ANZ J Surg, 2003, 73: 712&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pubmed">12956787</ArticleId></ArticleIdList></Reference><Reference><Citation>Karaaslan F, Karaoglu S, Mermerkaya MU, Baktir A. Reducing blood loss in simultaneous bilateral total knee arthroplasty: combined intravenous&#x2010;intra&#x2010;articular tranexamic acid administration. A prospective randomized controlled trial. Knee, 2015, 22: 131&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">25659440</ArticleId></ArticleIdList></Reference><Reference><Citation>MacGillivray RG, Tarabichi SB, Hawari MF, Raoof NT. Tranexamic acid to reduce blood loss after bilateral total knee arthroplasty: a prospective, randomized double blind study. J Arthroplasty, 2011, 26: 24&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">20171048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagsby DT, Samujh CA, Vissing JL, Empson JA, Pomeroy DL, Malkani AL. Tranexamic acid decreases incidence of blood transfusion in simultaneous bilateral total knee arthroplasty. J Arthroplasty, 2015, 30: 2106&#x2013;2109.</Citation><ArticleIdList><ArticleId IdType="pubmed">26235522</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam JA, Bloomfield MR, DiIorio TM, Irizarry AM, Sharkey PF. Evaluation of the efficacy and safety of tranexamic acid for reducing blood loss in bilateral total knee arthroplasty. J Arthroplasty, 2014, 29: 501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">24051240</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley TC, Tucker KK, Adams MJ, Dalury DF. Use of tranexamic acid results in decreased blood loss and decreased transfusions in patients undergoing staged bilateral total knee arthroplasty. Transfusion, 2014, 54: 26&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">23521109</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon MS, Bali K, Prabhakar S. Tranexamic acid for control of blood loss in bilateral total knee replacement in a single stage. Indian J Orthop, 2011, 45: 148&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3051122</ArticleId><ArticleId IdType="pubmed">21430870</ArticleId></ArticleIdList></Reference><Reference><Citation>Brotherton SL, Roberson JR, de Andrade JR, Fleming LL. Staged versus simultaneous bilateral total knee replacement. J Arthroplasty, 1986, 1: 221&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">3559598</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinclair KC, Clarke HD, Noble BN. Blood management in total knee arthroplasty: a comparison of techniques. Orthopedics, 2009, 32: 19.</Citation><ArticleIdList><ArticleId IdType="pubmed">19226044</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Han Z, Zhang T, et al. The efficacy of a thrombin&#x2010;based hemostatic agent in primary total knee arthroplasty: a meta&#x2010;analysis. J Orthop Surg Res, 2014, 9: 90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4212119</ArticleId><ArticleId IdType="pubmed">25316253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res, 2009, 123: 687&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">19007970</ArticleId></ArticleIdList></Reference><Reference><Citation>Bidolegui F, Arce G, Lugones A, Pereira S, Vindver G. Tranexamic acid reduces blood loss and transfusion in patients undergoing total knee arthroplasty without tourniquet: a prospective randomized controlled trial. Open Orthop J, 2014, 8: 250&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4133924</ArticleId><ArticleId IdType="pubmed">25132872</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Ma J, Shen B, Pei F. Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty, 2014, 29: 2342&#x2013;2346.</Citation><ArticleIdList><ArticleId IdType="pubmed">25007725</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman RJ. Limit the bleeding, limit the pain in total hip and knee arthroplasty. Orthopedics, 2010, 33: 11&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">20839716</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiippala S, Strid L, Wennerstrand M, et al. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. Br J Anaesth, 1995, 74: 534&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">7772427</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double&#x2010;blind study of 86 patients. J Bone Joint Surg Br, 1996, 78: 434&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">8636182</ArticleId></ArticleIdList></Reference><Reference><Citation>Veien M, Sorensen JV, Madsen F, Juelsgaard P. Tranexamic acid given intraoperatively reduces blood loss after total knee replacement: a randomized, controlled study. Acta Anaesthesiol Scand, 2002, 46: 1206&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12421192</ArticleId></ArticleIdList></Reference><Reference><Citation>Camarasa MA, Olle G, Serra&#x2010;Prat M, et al. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth, 2006, 96: 576&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="pubmed">16531440</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisch NB, Wessell NM, Charters MA, Yu S, Jeffries JJ, Silverton CD. Predictors and complications of blood transfusion in total hip and knee arthroplasty. J Arthroplasty, 2014, 29: 189&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">25007727</ArticleId></ArticleIdList></Reference><Reference><Citation>Danninger T, Rasul R, Poeran J, et al. Blood transfusions in total hip and knee arthroplasty: an analysis of outcomes. Sci World J, 2014, 2014: 623460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918859</ArticleId><ArticleId IdType="pubmed">24587736</ArticleId></ArticleIdList></Reference><Reference><Citation>Klika AK, Small TJ, Saleh A, Szubski CR, Chandran Pillai AL, Barsoum WK. Primary total knee arthroplasty allogenic transfusion trends, length of stay, and complications: nationwide inpatient sample 2000&#x2013;2009. J Arthroplasty, 2014, 29: 2070&#x2013;2077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4254025</ArticleId><ArticleId IdType="pubmed">25073900</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara H, Yoneoka D. National trends in the utilization of blood transfusions in total hip and knee arthroplasty. J Arthroplasty, 2014, 29: 1932&#x2013;1937.</Citation><ArticleIdList><ArticleId IdType="pubmed">24890994</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano A, Bori G, Garcia&#x2010;Ramiro S, et al. Timing of antibiotic prophylaxis for primary total knee arthroplasty performed during ischemia. Clin Infect Dis, 2008, 46: 1009&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pubmed">18444817</ArticleId></ArticleIdList></Reference><Reference><Citation>Onodera T, Majima T, Sawaguchi N, et al. Risk of deep venous thrombosis in drain clamping with tranexamic acid and carbazochrome sodium sulfonate hydrate in total knee arthroplasty. J Arthroplasty, 2012, 27: 105&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">21435821</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33663813</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0210-5705</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Season>Jun-Jul</Season></PubDate></JournalIssue><Title>Gastroenterologia y hepatologia</Title><ISOAbbreviation>Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>The outcomes of interventional treatment for Budd-Chiari Syndrome complicated by inferior vena cava thrombosis: Systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>405</StartPage><EndPage>417</EndPage><MedlinePgn>405-417</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gastrohep.2020.06.028</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0210-5705(20)30307-1</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of this study was to perform a systematic review and meta-analysis to assess the safety and efficacy of interventional treatment for Budd-Chiari syndrome (BCS) complicated by Inferior Vena Cava thrombosis (IVCT) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated the published studies on interventional treatment for BCS complicated by IVCT. Meta-analysis was used to calculate the combined effect size and their 95% confidence intervals (CI) based on random effect. The publication bias was assessed by Begg's test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixteen studies on interventional treatment for BCS complicated by IVCT patient were selected for meta-analysis, a total of 767 BCS complicated by IVCT patients were included. The combined effect size (95% CI) were 99% (98-100%) for the total successful rate of IVC recanalization, 15% (11-21%) for the rate of IVC restenosis after initial operation, 92.0% (86-97%) for the rate of clinical improvement, 76% (68-84%) for the rate of thrombus clearance and 0.00% (0-1%) for the incidence of pulmonary embolism (PE). Through subgroup meta-analysis about the rate of thrombus clearance, we got the pooled results (95% CI) of individualized treatment strategy (ITS) group and non-individualized treatment strategy (non-ITS) group, were 81% (71-92%) and 73% (63-83%), respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The interventional treatment for BCS complicated by IVCT patients is safe and effective with low incidence of PE, high thrombus clearance rate, high technically successful rate, good patency, and high clinical improvement rate. Moreover, subgroup analysis indicated that management based on the type and extent of the thrombus is proposed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020. Publicado por Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xuedong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Medicine, Nankai University, No.94 Weijin Road, Nankai District, Tianjin, PR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Liaocheng People's Hospital, No.67 Dongchang Road, Dongchangfu District, Liaocheng, PR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jinlong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Interventional Radiology, Chinese PLA General Hospital, 28 Fu-xing Rd, Beijing 100853, PR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Maoqiang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine, Nankai University, No.94 Weijin Road, Nankai District, Tianjin, PR, China; Department of Interventional Radiology, Chinese PLA General Hospital, 28 Fu-xing Rd, Beijing 100853, PR, China. Electronic address: wangmq@vip.sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Gastroenterol Hepatol</MedlineTA><NlmUniqueID>8406671</NlmUniqueID><ISSNLinking>0210-5705</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006502" MajorTopicYN="N">Budd-Chiari Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017594" MajorTopicYN="N">Publication Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014682" MajorTopicYN="N">Vena Cava, Inferior</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Budd-Chiari syndrome</Keyword><Keyword MajorTopicYN="N">Inferior vena cava thrombosis</Keyword><Keyword MajorTopicYN="N">Interventional treatment</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Metaan&#xe1;lisis</Keyword><Keyword MajorTopicYN="N">S&#xed;ndrome de Budd-Chiari</Keyword><Keyword MajorTopicYN="N">Tratamiento intervencionista</Keyword><Keyword MajorTopicYN="N">Trombosis de la vena cava inferior</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>5</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33663813</ArticleId><ArticleId IdType="doi">10.1016/j.gastrohep.2020.06.028</ArticleId><ArticleId IdType="pii">S0210-5705(20)30307-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29993117</PMID><DateCompleted><Year>2018</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>Jul</Month><Day>11</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Anticoagulation for perioperative thromboprophylaxis in people with cancer.</ArticleTitle><Pagination><StartPage>CD009447</StartPage><MedlinePgn>CD009447</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CD009447</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD009447.pub3</ELocationID><Abstract><AbstractText Label="BACKGROUND">The choice of the appropriate perioperative thromboprophylaxis for people with cancer depends on the relative benefits and harms of different anticoagulants.</AbstractText><AbstractText Label="OBJECTIVES">To systematically review the evidence for the relative efficacy and safety of anticoagulants for perioperative thromboprophylaxis in people with cancer.</AbstractText><AbstractText Label="SEARCH METHODS">This update of the systematic review was based on the findings of a comprehensive literature search conducted on 14 June 2018 that included a major electronic search of Cochrane Central Register of Controlled Trials (CENTRAL, 2018, Issue 6), MEDLINE (Ovid), and Embase (Ovid); handsearching of conference proceedings; checking of references of included studies; searching for ongoing studies; and using the 'related citation' feature in PubMed.</AbstractText><AbstractText Label="SELECTION CRITERIA">Randomized controlled trials (RCTs) that enrolled people with cancer undergoing a surgical intervention and assessed the effects of low-molecular weight heparin (LMWH) to unfractionated heparin (UFH) or to fondaparinux on mortality, deep venous thrombosis (DVT), pulmonary embolism (PE), bleeding outcomes, and thrombocytopenia.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS">Using a standardized form, we extracted data in duplicate on study design, participants, interventions outcomes of interest, and risk of bias. Outcomes of interest included all-cause mortality, PE, symptomatic venous thromboembolism (VTE), asymptomatic DVT, major bleeding, minor bleeding, postphlebitic syndrome, health related quality of life, and thrombocytopenia. We assessed the certainty of evidence for each outcome using the GRADE approach (GRADE Handbook).</AbstractText><AbstractText Label="MAIN RESULTS">Of 7670 identified unique citations, we included 20 RCTs with 9771 randomized people with cancer receiving preoperative prophylactic anticoagulation. We identified seven reports for seven new RCTs for this update.The meta-analyses did not conclusively rule out either a beneficial or harmful effect of LMWH compared with UFH for the following outcomes: mortality (risk ratio (RR) 0.82, 95% confidence interval (CI) 0.63 to 1.07; risk difference (RD) 9 fewer per 1000, 95% CI 19 fewer to 4 more; moderate-certainty evidence), PE (RR 0.49, 95% CI 0.17 to 1.47; RD 3 fewer per 1000, 95% CI 5 fewer to 3 more; moderate-certainty evidence), symptomatic DVT (RR 0.67, 95% CI 0.27 to 1.69; RD 3 fewer per 1000, 95% CI 7 fewer to 7 more; moderate-certainty evidence), asymptomatic DVT (RR 0.86, 95% CI 0.71 to 1.05; RD 11 fewer per 1000, 95% CI 23 fewer to 4 more; low-certainty evidence), major bleeding (RR 1.01, 95% CI 0.69 to 1.48; RD 0 fewer per 1000, 95% CI 10 fewer to 15 more; moderate-certainty evidence), minor bleeding (RR 1.01, 95% CI 0.76 to 1.33; RD 1 more per 1000, 95% CI 34 fewer to 47 more; moderate-certainty evidence), reoperation for bleeding (RR 0.93, 95% CI 0.57 to 1.50; RD 4 fewer per 1000, 95% CI 22 fewer to 26 more; moderate-certainty evidence), intraoperative transfusion (mean difference (MD) -35.36 mL, 95% CI -253.19 to 182.47; low-certainty evidence), postoperative transfusion (MD 190.03 mL, 95% CI -23.65 to 403.72; low-certainty evidence), and thrombocytopenia (RR 3.07, 95% CI 0.32 to 29.33; RD 6 more per 1000, 95% CI 2 fewer to 82 more; moderate-certainty evidence). LMWH was associated with lower incidence of wound hematoma (RR 0.70, 95% CI 0.54 to 0.92; RD 26 fewer per 1000, 95% CI 39 fewer to 7 fewer; moderate-certainty evidence). The meta-analyses found the following additional results: outcomes intraoperative blood loss (MD -6.75 mL, 95% CI -85.49 to 71.99; moderate-certainty evidence); and postoperative drain volume (MD 30.18 mL, 95% CI -36.26 to 96.62; moderate-certainty evidence).In addition, the meta-analyses did not conclusively rule out either a beneficial or harmful effect of LMWH compared with Fondaparinux for the following outcomes: any VTE (DVT or PE, or both; RR 2.51, 95% CI 0.89 to 7.03; RD 57 more per 1000, 95% CI 4 fewer to 228 more; low-certainty evidence), major bleeding (RR 0.74, 95% CI 0.45 to 1.23; RD 8 fewer per 1000, 95% CI 16 fewer to 7 more; low-certainty evidence), minor bleeding (RR 0.83, 95% CI 0.34 to 2.05; RD 8fewer per 1000, 95% CI 33 fewer to 52 more; low-certainty evidence), thrombocytopenia (RR 0.35, 95% CI 0.04 to 3.30; RD 14 fewer per 1000, 95% CI 20 fewer to 48 more; low-certainty evidence), any PE (RR 3.13, 95% CI 0.13 to 74.64; RD 2 more per 1000, 95% CI 1 fewer to 78 more; low-certainty evidence) and postoperative drain volume (MD -20.00 mL, 95% CI -114.34 to 74.34; low-certainty evidence) AUTHORS' CONCLUSIONS: We found no difference between perioperative thromboprophylaxis with LMWH versus UFH and LMWH compared with fondaparinux in their effects on mortality, thromboembolic outcomes, major bleeding, or minor bleeding in people with cancer. There was a lower incidence of wound hematoma with LMWH compared to UFH.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matar</LastName><ForeName>Charbel F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon, 1107 2020.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahale</LastName><ForeName>Lara A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Hakoum</LastName><ForeName>Maram B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Tsolakian</LastName><ForeName>Ibrahim G</ForeName><Initials>IG</Initials></Author><Author ValidYN="Y"><LastName>Etxeandia-Ikobaltzeta</LastName><ForeName>Itziar</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Yosuico</LastName><ForeName>Victor Ed</ForeName><Initials>VE</Initials></Author><Author ValidYN="Y"><LastName>Terrenato</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Sperati</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Barba</LastName><ForeName>Maddalena</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sch&#xfc;nemann</LastName><ForeName>Holger</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Akl</LastName><ForeName>Elie A</ForeName><Initials>EA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Cochrane Database Syst Rev. 2014 Jun 26;(6):CD009447. doi: 10.1002/14651858.CD009447.pub2.</RefSource><PMID Version="1">24966161</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013921" MajorTopicYN="N">Thrombocytopenia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>CFM: declares no conflicts of interests&#x2028;
LAK: declares no conflicts of interests&#x2028;
MBH: declares no conflicts of interests.&#x2028;
IGT: declares no conflicts of interests.&#x2028;
IEI: declares no conflicts of interests&#x2028;
VY: declares no conflicts of interests.&#x2028;
IT: declares no conflicts of interests&#x2028;
FS: declares conflicts of interests&#x2028;
MB: declares conflicts of interests&#x2028;
HS: panel member of the ASH VTE in Cancer patients, Vice&#x2010;Chair of the ASH VTE guidelines and played various leadership roles from 1999 until 2014 with ACCP VTE guidelines.&#x2028;
EAA served on the executive committee the ACCP Antithrombotic Therapy Guidelines published in 2016.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29993117</ArticleId><ArticleId IdType="pmc">PMC6389341</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD009447.pub3</ArticleId></ArticleIdList><ReferenceList><Title>References to studies included in this review</Title><ReferenceList><Title>Agnelli 2005 {published data only}</Title><Reference><Citation>Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high&#x2010;risk abdominal surgery. British Journal of Surgery 2005;92(10):1212&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16175516</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Baykal 2001 {published data only}</Title><Reference><Citation>Baykal C, Al A, Demirtas E, Ayhan A. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double&#x2010;blind clinical study. European Journal of Gynaecological Oncology 2001;22(2):127&#x2010;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11446476</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bergqvist 1990 {published data only}</Title><Reference><Citation>Bergqvist D, Burmark US, Frisell J. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low&#x2010;dose heparin. Seminars in Thrombosis &amp; Hemostasis 1990;16:19&#x2010;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">1962900</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergqvist D, M&#xe4;tzsch T, Burmark US, Frisell J, Guilbaud O, Hallb&#xf6;&#xf6;k T, et al. Low molecular weight heparin given the evening before surgery compared with conventional low&#x2010;dose heparin in prevention of thrombosis. British Journal of Surgery 1988;75(9):888&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">2846113</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bergqvist 1997 (ENOXACAN) {published data only}</Title><Reference><Citation>Berqvist D, Eldor A, Thorlacius&#x2010;Ussing O, Combe S, Cossec&#x2010;Vion MJ, ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double&#x2010;blind randomized multicentre trial with venographic assessment. British Journal of Surgery 1997;84(8):1099&#x2010;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278651</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Boncinelli 2001 {published data only}</Title><Reference><Citation>Boncinelli S, Marsili M, Lorenzi P, Fabbri LP, Pittino S, Filoni M, et al. Haemostatic molecular markers in patients undergoing radical retropubic prostatectomy for prostate cancer and submitted to prophylaxis with unfractioned or low molecular weight heparin. Minerva Anestesiologica 2001;67(10):693&#x2010;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740417</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dahan 1990 {published data only}</Title><Reference><Citation>Dahan M, Boneu B, Renella J, Berjaud J, Bogaty J, Durand J, et al. Prevention of deep venous thromboses in cancer thoracic surgery with a low&#x2010;molecular&#x2010;weight heparin: fraxiparine. A comparative randomized trial. Fraxiparine: Second International Symposium Recent Pharmacological and Clinical Data. New York (NY): John Wiley &amp; Sons Inc, 1990:27&#x2010;31.</Citation></Reference><Reference><Citation>Dahan M, Levasseur, P, Bogaty, J, Boneu, B, &amp; Samama, M. Prevention of post&#x2010;operative deep vein thrombosis (DVT) in malignant patients by fraxiparine (a low molecular weight heparin). Thrombosis and Haemostasis 1989;62(1):519 Abstract no: 1636.</Citation></Reference></ReferenceList><ReferenceList><Title>Encke 1988 (EFS) {published data only}</Title><Reference><Citation>European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. British Journal of Surgery 1988;75(11):1058&#x2010;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">2905187</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Fricker 1988 {published data only}</Title><Reference><Citation>Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L, et al. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. European Journal of Clinical Investigation 1988;18(6):561&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2852111</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunebaum L, Fricker JP, Wiesel ML, Vergnes Y, Kapps J, Cazenave J. Preliminary results of a randomized trial comparing the efficacy of standard heparin with that of fragmine, a low molecular weight heparin, in the prevention of postoperative thrombosis in cancer surgery. Journal des Maladies Vasculaires 1987;12 Suppl B:102&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2834478</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gallus 1993 {published data only}</Title><Reference><Citation>Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, et al. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double&#x2010;blind, randomised, multicentre comparison. ANZ&#x2010;Organon Investigators' Group. Thrombosis and Hemostasis 1993;70(4):562&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7509509</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Godwin 1993 {published data only}</Title><Reference><Citation>Godwin JE, Comp P, Davidson B, Rossi M. Comparison of the efficacy and safety of subcutaneous Rd heparin vs subcutaneous unfractionated heparin for the prevention of deep&#x2010;vein thrombosis in patients undergoing abdominal or pelvic&#x2010;surgery for cancer. Thrombosis and Haemostasis 1993;69(6):647.</Citation></Reference></ReferenceList><ReferenceList><Title>Goldhaber 2002 {published data only}</Title><Reference><Citation>Goldhaber SZ, Dunn K, Gerhard&#x2010;Herman M, Park JK, Black PM. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002;122(6):1933&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12475829</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Hata 2016 {published data only}</Title><Reference><Citation>Hata K, Kimura T, Tsuzuki S, Ishii G, Kido M, Yamamoto T, et al. Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: a prospective randomized clinical trial. International Journal of Urology 2016;23(11):923&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27545448</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kakkar 1997 {published data only}</Title><Reference><Citation>Kakkar VV, Boekl O, Boneu B, Bordnave L, Brehm OA. Efficacy and safety of LMWH and standard UFH for prophylaxis of postoperative venous thromboembolism. European multicenter trial. World Journal of Surgery 1997;21:2&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943170</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kakkar 2005 {published data only}</Title><Reference><Citation>Haas S, Wolf H, Kakkar AK, Fareed J, Encke A. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double&#x2010;blind comparison of LMWH with unfractionated heparin. Thrombosis and Haemostasis 2005;94:814&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16270636</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas SK, Wolf H. Prevention of fatal pulmonary embolism and death in elective cancer surgery patients: a substudy comparison of certoparin with unfractionated heparin. Blood 2000;96(11):4039.</Citation></Reference><Reference><Citation>Haas SK, Wolf H, Kakkar A, Fareed J, Encke A. Prevention of fatal pulmonary embolism and death in elective cancer surgery patients. A substudy comparison of certoparin with unfractionated heparin. Blood 2000;96 (11 Part 2):83b.</Citation></Reference><Reference><Citation>Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC&#x2010;4 cancer substudy. Thrombosis and Haemostasis 2005;94(4):867&#x2010;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">16270644</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Koppenhagen 1992 {published data only}</Title><Reference><Citation>Koppenhagen K, Adolf J, Matthes M, Tr&#xf6;ster E, Roder JD, Hass S, et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thrombosis and Haemostasis 1992;67(6):627&#x2010;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">1324534</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Onarheim 1986 {published data only}</Title><Reference><Citation>Onarheim H, Lund T, Heimdal A, Arnesjo B. A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis. Acta Chirurgica Scandinavica 1986;152:593&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">3544625</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Song 2018 {published data only}</Title><Reference><Citation>Song J, Xuan L, Wu W, Shen Y, Tan L, Zhong M. Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: A randomized controlled trial. Thrombosis research 2018;166:22&#x2010;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">29653390</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Von Tempelhoff 1997 {published data only}</Title><Reference><Citation>Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thrombosis and Haemostasis 1997;77(3):456&#x2010;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065993</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Von Tempelhoff 2000 {published data only}</Title><Reference><Citation>Heilmann L, Schneider D, Herrie B, Vontempelhoff F, Manstein J, Wolf H. A prospective randomized trial of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) in patients with gynecologic cancer. Thrombosis and Haemostasis 1996;73(6):974.</Citation></Reference><Reference><Citation>Heilmann L, Schneider D, Herrie B, Vontempelhoff F, Manstein J, Wolf H. A prospective randomized trial of low&#x2010;molecular&#x2010;weight heparin (LMWH) versus unfractionated heparin (UFH) in patients with gynecologic cancer. Thrombosis and Haemostasis 1995;73(6):974.</Citation></Reference><Reference><Citation>Heilmann L, Tempelhoff GF, Kirkpatrick C, Schneider DM, Hommel G, Pollow K. Comparison of unfractionated versus low molecular weight heparin for deep vein thrombosis prophylaxis during breast and pelvic cancer surgery: efficacy, safety, and follow&#x2010;up. Clinical and Applied Thrombosis&#x2010;Hemostasis 1998;4(4):268&#x2010;73.</Citation></Reference><Reference><Citation>Heilmann L, Tempelhoff GF, Herrle B, Hojnacki B, Schneider D, Michaelis H, et al. Prevention of postoperative venous thrombosis. A randomized trial comparing low&#x2010;dose heparin and low molecular weight heparin in gynaecological oncology. Geburtshilfe und Frauenheilkunde 1997;57(1):1&#x2010;6.</Citation></Reference><Reference><Citation>Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double&#x2010;blind trial. International Journal of Oncology 2000;16(4):815&#x2010;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">10717252</ArticleId></ArticleIdList></Reference><Reference><Citation>Tempelhoff GF, Schneider D, Niemann F, Hommel G, Heilmann L. Long&#x2010;term mortality In 324 gynecological cancer patients after perioperative thrombosis prophylaxis with either low molecular weight heparin (Certoparin (R)) or unfractionated heparin &#x2010; a double blind randomized prospective trial. Thrombosis and Haemostasis 1999;76:54&#x2010;5.</Citation></Reference><Reference><Citation>Tempelhoff GF, Schneider D, Niemann F, Hommel G, Heilmann L. Long&#x2010;term mortality in 324 gynecological cancer patients after perioperative thrombosis prophylaxis with either low molecular weight heparin (Certoparin&#xae;) or unfractionated heparin &#x2010; a double blind randomized prospective trial. Annals of Hematology 1998;76(Suppl 1):A26.</Citation></Reference></ReferenceList><ReferenceList><Title>Ward 1998 {published data only}</Title><Reference><Citation>Ward B, Pradhan S. Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology 1998;38:91&#x2010;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521401</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to studies excluded from this review</Title><ReferenceList><Title>Agnelli 1998 {published data only}</Title><Reference><Citation>Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. New England Journal of Medicine 1998;339:80&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9654538</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Agnelli 2015 (AMPLIFY) {published data only}</Title><Reference><Citation>Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial. Canadian Journal of Cardiology 2014;30:S278.</Citation><ArticleIdList><ArticleId IdType="pubmed">26407753</ArticleId></ArticleIdList></Reference><Reference><Citation>Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. Journal of Thrombosis and Haemostasis 2015;13(12):2187&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">26407753</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Alikhan 2003 (MEDENOX) {published data only}</Title><Reference><Citation>Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation &amp; Fibrinolysis 2003;14(4):341&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12945875</ArticleId></ArticleIdList></Reference><Reference><Citation>Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. New England Journal of Medicine 1999;341(11):793&#x2010;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">10477777</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Arbeit 1981 {published data only}</Title><Reference><Citation>Arbeit JM, Lowry SF, Line BR, Jones DC, Brennan MF. Deep venous thromboembolism in patients undergoing inguinal lymph node dissection for melanoma. Annals of Surgery 1981;194(5):648&#x2010;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1345273</ArticleId><ArticleId IdType="pubmed">7294936</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Attaran 2010 {published data only}</Title><Reference><Citation>Attaran S, Somov P, Awad WI. Randomised high&#x2010; and low&#x2010;dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo&#x2010;elastography. European Journal of Cardio&#x2010;thoracic Surgery 2010;37:1384&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">20153216</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Auer 2011a {published data only}</Title><Reference><Citation>Auer R, Scheer A, Wells PS, Boushey R, Asmis T, Jonker D, et al. The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease&#x2010;free survival following surgical resection of colon cancer: a pilot randomized controlled trial. Blood Coagulation &amp; Fibrinolysis 2011;22:760&#x2010;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">22198365</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Auer 2011b {published data only}</Title><Reference><Citation>Auer R, Scheer A, Wells PS, Boushey R, Asmis T, Jonker D, et al. The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease&#x2010;free survival following surgical resection of colon cancer: a pilot randomized controlled trial. Blood Coagulation &amp; Fibrinolysis 2011;22(8):760&#x2010;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">22198365</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bergqvist 1986 {published data only}</Title><Reference><Citation>Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, et al. Prospective double&#x2010;blind comparison between Fragmin and conventional low&#x2010;dose heparin: thromboprophylactic effect and bleeding complications. Haemostasis 1986;16(Suppl 2):11&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">3744131</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bergqvist 1988 {published data only}</Title><Reference><Citation>Bergqvist D, Matzsch T, Burmark US, Frisell J, Guilbaud O, Hallbook T, et al. Low molecular weight heparin given the evening before surgery compared with conventional low&#x2010;dose heparin in prevention of thrombosis. British Journal of Surgery 1988;75:888&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">2846113</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bergqvist 2006 {published data only}</Title><Reference><Citation>Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Moigne&#x2010;Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. New England Journal of Medicine 2002;346(13):975&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">11919306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergqvist D, Agnelli G, Cohen AT, Nilsson PE, Moigne&#x2010;Amrani A, Dietrich&#x2010;Neto F. Prolonged prophylaxis against venous thromboembolism with enoxaparin in patients undergoing cancer surgery: long&#x2010;term survival analysis. Phlebology / Venous Forum of the Royal Society of Medicine 2006;21:195&#x2010;8.</Citation></Reference><Reference><Citation>Bergqvist, D, Agnelli, G, Cohen, A. T, Nilsson, P. E, Le Moigne&#x2010;Amrani, A, &amp; Dietrich&#x2010;Neto, F. Prolonged prophylaxis against venous thromboembolism with enoxaparin in patients undergoing surgery for malignancy: 1&#x2010;year survival study. Blood Abstract no: P1899 2002;100(11):502a.</Citation></Reference><Reference><Citation>Eldor A, Bergqvist D, Agnelli G, Cohen AT, Nilsson PE, Moigne&#x2010;Amrani A, et al. Prolonged thromboprophylaxis in patients undergoing abdominal cancer surgery with Enoxaparin: the Enoxacan II study. Blood 2001;98(11):706A.</Citation></Reference></ReferenceList><ReferenceList><Title>Bigg 1992 {published data only}</Title><Reference><Citation>Bigg SW, Catalona WJ. Prophylactic mini&#x2010;dose heparin in patients undergoing radical retropubic prostatectomy: a prospective trial. Urology 1992;39(4):309&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">1557840</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Boneu 1993 {published data only}</Title><Reference><Citation>Boneu B. An international multicentre study: Clivarin (R) in the prevention of venous thromboembolism in patients undergoing general surgery. Blood Coagulation &amp; Fibrinolysis 1993;4:S21&#x2010;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">8180325</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Borstad 1988 {published data only}</Title><Reference><Citation>Borstad E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin versus unfractionated heparin in gynaecological surgery. Acta Obstetricia et Gynecologica Scandinavica 1988;67:99&#x2010;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">2845707</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Borstad 1992 {published data only}</Title><Reference><Citation>Borstad E, Urdal K, Handeland G, Abildgaard. Comparison of low molecular weight heparin versus unfractionated heparin in gynecological surgery. Acta Obstetricia et Gynecologica Scandinavica 1992;71:471&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1326846</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Bricchi 1991 &#xa0; {published data only}</Title><Reference><Citation>Bricchi M, Gemma M, Fiacchino F, Cerrato D, Ariano C. Prevention of thromboembolic disease with heparin&#x2010;calcium in neurosurgery: evaluation of postoperative hemorrhagic complications. Minerva Anestesiologica 1991;57(10):1004&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961448</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cade 1983 {published data only}</Title><Reference><Citation>Cade JF, Clegg EA, Westlake GW. Prophylaxis of venous thrombosis after major thoracic surgery. New Zealand Journal of Surgery 1983;53(4):301&#x2010;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">6577843</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cahan 2000 {published data only}</Title><Reference><Citation>Cahan MA, Hanna DJ, Wileya LA, Cox DK, Killewich LA. External pneumatic compression and fibrinolysis in abdominal surgery. Journal of Vascular Surgery 2000;32(3):537&#x2010;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">10957661</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Caprini 2003 {published data only}</Title><Reference><Citation>Caprini JA, Arcelus JI, Bautista E, Reyna JJ. Relative risk of bleeding when starting enoxaparin 2 or 12 hours before surgery for colorectal cancer. Phlebology 2003;18(3):147.</Citation></Reference></ReferenceList><ReferenceList><Title>Chodri 2002 {published data only}</Title><Reference><Citation>Chodri T, Groth M. Duration of prophylaxis against thromboembolism after surgery for cancer. Clinical Pulmonary Medicine 2002;9(5):290&#x2010;2.</Citation></Reference></ReferenceList><ReferenceList><Title>Ciftci 2012 {published data only}</Title><Reference><Citation>Ciftci A, Altiay G. The effect of warfarin on survival in patients with lung cancer. Journal of Thoracic Oncology 2012;7(7):S122.</Citation></Reference></ReferenceList><ReferenceList><Title>Clarke&#x2010;Pearson 1983 {published data only}</Title><Reference><Citation>Clarke&#x2010;Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman W. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low&#x2010;dose heparin. American Journal of Obstetrics &amp; Gynecology 1983;145:606&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">6338722</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Clarke&#x2010;Pearson 1984 {published data only}</Title><Reference><Citation>Clarke&#x2010;Pearson DL, DeLong ER, Synan IS, Creasman WT. Complications of low&#x2010;dose heparin prophylaxis in gynecologic oncology surgery. Obstetrics and Gynecology 1984;64(5):689&#x2010;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">6493660</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Clarke&#x2010;Pearson 1993 {published data only}</Title><Reference><Citation>Clarke&#x2010;Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE. A randomized trial of low&#x2010;dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. American Journal of Obstetrics and Gynecology 1993;168(4):1146&#x2010;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">8475960</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Clark&#x2010;Pearson 1990a {published data only}</Title><Reference><Citation>Clark&#x2010;Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE. A controlled trial of two low&#x2010;dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstetrics &amp; Gynecology 1990;75(4):684&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2179782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Clark&#x2010;Pearson 1990b {published data only}</Title><Reference><Citation>Clark&#x2010;Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE. A controlled trial of two low&#x2010;dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstetrics &amp; Gynecology 1990;75(4):684&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2179782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cohen 2006 {published data only}</Title><Reference><Citation>Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MR, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332(7537):325&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1363908</ArticleId><ArticleId IdType="pubmed">16439370</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Cohen 2007 (PREVENT) {published data only}</Title><Reference><Citation>Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332(7537):325&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1363908</ArticleId><ArticleId IdType="pubmed">16439370</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AT, Turpie AG, Leizorovicz A, Olsson CG, Vaitkus PT, Goldhaber SZ. Thromboprophylaxis with dalteparin in medical patients: which patients benefit?. Vascular Medicine 2007;12(2):123&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17615800</ArticleId></ArticleIdList></Reference><Reference><Citation>Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo&#x2010;controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110(7):874&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15289368</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Couban 2005 {published data only}</Title><Reference><Citation>Anderson D, et al. A randomized double&#x2010;blind placebo controlled study of low dose warfarin for the prevention of symptomatic central venous catheter&#x2010;associated thrombosis in patients with cancer. Journal of Thrombosis &amp; Haemostasis: JTH 1, Abstract no: P198 2003;100(11):703A.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767639</ArticleId></ArticleIdList></Reference><Reference><Citation>Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al. A randomized double&#x2010;blind placebo&#x2010;controlled study of low dose warfarin for the prevention of symptomatic central venous catheter&#x2010;associated thrombosis in patients with cancer. Blood 2002;2769, 100(11):703A.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767639</ArticleId></ArticleIdList></Reference><Reference><Citation>Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al. Randomized placebo&#x2010;controlled study of low&#x2010;dose warfarin for the prevention of central venous catheter&#x2010;associated thrombosis in patients with cancer. Journal of Clinical Oncology 2005;23(18):4063&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767639</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dickinson 1998 {published data only}</Title><Reference><Citation>Dickinson LD, Miller LD, Patel CP, Gupta SK. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998;43(5):1074&#x2010;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9802851</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Dindelli 1990 {published data only}</Title><Reference><Citation>Dindelli M, Guarnerio P, Salari PC, Ferrari A. Defibrotide in the prevention of deep venous thrombosis in gynecologic surgery. A controlled study versus calcium heparin in 120 patients. Minerva Ginecologica 1990;42:79&#x2010;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">2187169</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Di Somma 1992 {published data only}</Title><Reference><Citation>Somma C, Canepa G, Gipponi M, Frascio M. The postoperative prevention of deep venous thrombosis and pulmonary embolism with defibrotide versus heparin&#x2010;calcium: a randomized clinical multicenter study of 1296 patients undergoing major abdominal surgery. Annali Italiani di Chirurgia 1992;63(1):83&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1605451</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gondret 1995 {published data only}</Title><Reference><Citation>Gondret R, Dominici L, Angelard B, Dubos S, Alrawi S, Huet Y, et al. Safety of preoperative enoxaparin in head and neck cancer surgery. Head and Neck 1995;1:1&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7883543</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Haas 2011 {published data only}</Title><Reference><Citation>Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach HE, Abletshauser, et al. CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis 2011;105(6):981&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21505722</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas S, Schellong SM, Tebbe U, Gerlach HE, Bauersachs R, Abletshauser C, et al. CERTIFY: certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer. H&#xe4;mostaseologie 2011;31(1):A10.</Citation><ArticleIdList><ArticleId IdType="pubmed">21658750</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas S, Schellong SM, Tebbe U, Gerlach HE, Bauersachs R, Melzer N, et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer&#x2010;a subgroup analysis of CERTIFY. BMC Cancer 2011;11(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3161035</ArticleId><ArticleId IdType="pubmed">21791091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Harenberg 1996 {published data only}</Title><Reference><Citation>Harenberg J, Roebruck P, Heene DL. Subcutaneous low&#x2010;molecular&#x2010;weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Pathophysiology of Haemostasis and Thrombosis 1996;26(3):127&#x2010;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8738587</ArticleId></ArticleIdList></Reference><Reference><Citation>Harenberg J, Roebruck P, Stehle G, Habscheid W, Biegholdt M, Heene DL. Heparin Study in Internal Medicine (HESIM): design and preliminary results. Thrombosis Research 1992;68(1):33&#x2010;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">1333105</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ho 1999 {published data only}</Title><Reference><Citation>Ho YH, Seow&#x2010;Choen F, Leong A, Eu KW, Nyam D, Teoh MK. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. Diseases of the Colon &amp; Rectum 1999;42(2):196&#x2010;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211496</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Jorgensen 2002 {published data only}</Title><Reference><Citation>Jorgensen LN, Lausen I, Rasmussen MS, Willie Jorgensen P, Bergqvist D. Prolonged thromboprophylaxis with low&#x2010;molecular weight heparin following major general surgery: an individual patient data meta&#x2010;analysis. Blood 2002;100:1952.</Citation></Reference></ReferenceList><ReferenceList><Title>Kakkar 1985 {published data only}</Title><Reference><Citation>Kakkar VV, Murray WJ. Efficacy and safety of low&#x2010;molecular&#x2010;weight heparin (CY216) in preventing postoperative venous thrombo&#x2010;embolism: a co&#x2010;operative study. British Journal of Surgery 1985;72:786&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">3899240</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kakkar 1989 {published data only}</Title><Reference><Citation>Kakkar VV, Stringer MD, Hedges AR, Parker CJ, Welzel D, Ward VP, et al. Fixed combinations of low&#x2010;molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis. American Journal of Surgery 1989;157:413&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2539025</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kakkar 2009 {published data only}</Title><Reference><Citation>Kakkar VV, Balibrea J, Martinez&#x2010;Gonzalez J, Prandoni P. Late breaking clinical trial: a randomised double blind trial to evaluate the efficacy and safety of prolonging the thromboprophylaxis with bemiparin in patients undergoing cancer abdominal or pelvic surgery (the CANBESURE study). International Society on Thrombosis and Haemostasis 2009;7(Suppl 2):1&#x2010;1204.</Citation></Reference></ReferenceList><ReferenceList><Title>Kakkar 2010 (CANBESURE) {published data only}</Title><Reference><Citation>Kakkar VV, Balibrea J, Martinez&#x2010;Gonzalez J, Prandoni P. Late breaking clinical trial: a randomised double blind trial to evaluate the efficacy and safety of prolonging the thromboprophylaxis with bemiparin in patients undergoing cancer abdominal or pelvic surgery (the CANBESURE study). International Society on Thrombosis and Haemostasis 2009;7(Suppl 2):1202, LB&#x2010;MO&#x2010;002.</Citation></Reference><Reference><Citation>Kakkar VV, Balibrea JL, Martinez&#x2010;Gonzalez J, Prandoni P. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. Journal of Thrombosis and Haemostasis 2010;8(6):1223&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20456751</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kakkar 2010a {published data only}</Title><Reference><Citation>Kakkar VV, Balibrea JL, Mart&#xed;nez&#x2010;Gonz&#xe1;lez J, Prandoni P, CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. Journal of Thrombosis and Haemostasis 2010;8:1223&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20456751</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kakkar 2010b {published data only}</Title><Reference><Citation>Kakkar AK, Agnelli G, Fisher WD, George D, Mouret P, Lassen MR, et al. The ultra&#x2010;low&#x2010;molecular&#x2010;weight heparin semuloparin for prevention of venous thromboembolism in patients undergoing major abdominal surgery. Blood 2010;116:188.</Citation></Reference></ReferenceList><ReferenceList><Title>Kakkar 2014 (SAVE&#x2010;ABDO) {published data only}</Title><Reference><Citation>Kakkar AK, Agnelli G, Fisher W, George D, Lassen MR, Mismetti P, et al. SAVE&#x2010;ABDO Investigators. Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial. Annals of Surgery 2014;259(6):1073&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24374549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkar AK, Agnelli G, Fisher WD, George D, Mouret P, Lassen MR, et al. The ultra&#x2010;low&#x2010;molecular&#x2010;weight heparin semuloparin for prevention of venous thromboembolism in patients undergoing major abdominal surgery. Blood 2010;116(21):188.</Citation></Reference></ReferenceList><ReferenceList><Title>Khorana 2017 (PHACS) {published data only}</Title><Reference><Citation>Khorana AA, Francis CW, Kuderer N, Carrier M, Ortel TL, Wun T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Blood 2015;126(23):427.</Citation><ArticleIdList><ArticleId IdType="pubmed">28139259</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorana AA, Francis CW, Kuderer N, Carrier M, Ortel TL, Wun T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thrombosis Research 2017. [DOI: ]</Citation><ArticleIdList><ArticleId IdType="pubmed">28139259</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Larocca 2012 {published data only}</Title><Reference><Citation>Larocca A, Cavallo F, Bringhen S, Raimondo FD, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012;119:933&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21835953</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lausen 1998 {published data only}</Title><Reference><Citation>Lausen I, Jensen R, Jorgensen LN, Rasmussen MS, Lyng KM, Andersen M, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. European Journal of Surgery 1998;164:657&#x2010;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">9728784</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Lee 2015 (CATCH) {published data only}</Title><Reference><Citation>Bauersachs R, Lee AY, et al. Catch&#x2010;a randomised clinical trial comparing long&#x2010;term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2011;13(1):284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691586</ArticleId><ArticleId IdType="pubmed">23764005</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauersachs R, Lee AY, Kamphuisen PW, Meyer G, Janas MS, Jarner MF, et al. Long&#x2010;term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients&#x2010;analysis of renal impairment (RI) in the catch study. Journal of Thrombosis and Haemostasis 2015;13:76.</Citation></Reference><Reference><Citation>Kamphuisen PW, Lee AYY, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Characteristics and risk factors of major and clinically relevant non&#x2010;major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism &#x2010; the CATCH study. Journal of Thrombosis and Haemostasis 2015;13:182&#x2010;3.</Citation></Reference><Reference><Citation>Khorana AA, Bauersachs R, Kamphuisen PW, Meyer G, Janas MS, Jarner MF, et al. Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long&#x2010;term tinzaparin versus warfarin for treatment: the CATCH study. Journal of Clinical Oncology Conference 2015;33(15 (Suppl 1)):9621.</Citation></Reference><Reference><Citation>Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, et al. CATCH: a randomised clinical trial comparing long&#x2010;term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer 2013;13(1):284. [NCT01130025]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691586</ArticleId><ArticleId IdType="pubmed">23764005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677.</Citation><ArticleIdList><ArticleId IdType="pubmed">26284719</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. A randomized trial of long&#x2010;term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients &#x2010; the CATCH study. Blood 2014;124:21.</Citation></Reference></ReferenceList><ReferenceList><Title>Liezorovicz 1991 {published data only}</Title><Reference><Citation>Liezorovicz A, Picolet H, Peyrieux JC, Boissel JP. Prevention of perioperative deep vein thrombosis in general surgery double blind study comparing two doses of logiparin and standard heparin. British Journal of Surgery 1991;78:412&#x2010;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1851649</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Limmer 1994 {published data only}</Title><Reference><Citation>Limmer J, Ellbruck D, Muller H, Eisele E, Rist J, Schutze F, et al. Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis. Clinical Investigator 1994;72:913&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7894222</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Macbeth 2016 (FRAGMATIC) {published data only}</Title><Reference><Citation>Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS. FRAGMATIC: a randomised phase III clinical trial investigating the effect of Fragmin&#xae; added to standard therapy in patients with lung cancer. BMC Cancer 2009;9(1):1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2761945</ArticleId><ArticleId IdType="pubmed">19807917</ArticleId></ArticleIdList></Reference><Reference><Citation>Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial. Journal of Clinical Oncology 2016;34(5):488&#x2010;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">26700124</ArticleId></ArticleIdList></Reference><Reference><Citation>Macbeth F, Noble S, Griffiths G, Chowdhury R, Rolfe C, Hood K, et al. Preliminary results from the FRAGMATIC trial: a randomised phase III clinical trial investigating the effect of Fragmin (R) added to standard therapy in patients with lung cancer. Journal of Thoracic Oncology 2013;8:S243.</Citation></Reference><Reference><Citation>Noble S, Robbins A, Alikhan R, Hood K, Macbeth F. Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy. Journal of Thrombosis and Haemostasis 2015;13:143.</Citation></Reference></ReferenceList><ReferenceList><Title>Macdonald 2003 {published data only}</Title><Reference><Citation>Macdonald RL, Amidei C, Baron J, Weir B, Brown F, Erickson RK, et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surgical Neurology 2003;59:363.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765806</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Marassi 1993 {published data only}</Title><Reference><Citation>Marassi A, Balzano G, Mari G, D'Angelo SV, Della Valle P, Carlo V, et al. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216). International Surgery 1993;78(2):166&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">8394842</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Maxwell 2001 {published data only}</Title><Reference><Citation>Maxwell GL, Synan I, Dodge R, Carroll B, Clarke&#x2010;Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. American College of Obstetricians and Gynecologists 2001;98(6):989&#x2010;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11755543</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mazilu 2014 (OVIDIUS) {published data only}</Title><Reference><Citation>Mazilu L, Parepa IR, Suceveanu AI, Suceveanu A, Baz R, Catrinoiu D. Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania. Cardiovascular Research 2014;103(Suppl 1):S39, P221.</Citation></Reference></ReferenceList><ReferenceList><Title>Murakami 2002 {published data only}</Title><Reference><Citation>Cahan MA, Hanna DJ, Wiley LA, Cox DK, Killewich LA. External pneumatic compression and fibrinolysis in abdominal surgery. Journal of Vascular Surgery 2000;32(3):537&#x2010;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">10957661</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami M, Wiley LA, Cindrick&#x2010;Pounds L, Hunter GC, Uchida T, Killewich LA. External pneumatic compression does not increase urokinase plasminogen activator after abdominal surgery. Journal of Vascular Surgery 2002;36(5):917&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12422101</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nagata 2015 {published data only}</Title><Reference><Citation>Nagata C, Tanabe H, Takakura S, Narui C, Saito M, Yanaihara N, et al. Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. Journal of Obstetrics and Gynaecology Research 2015;41(9):1440&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26111609</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nurmohamed 1995 {published data only}</Title><Reference><Citation>Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, Rij AM, et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. American Journal of Surgery 1995;169(6):567&#x2010;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">7771617</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Nurmohamed 1996 {published data only}</Title><Reference><Citation>Nurmohamed MT, Riel AM, Henkens CM, Koopman, Que GT, d'Azemar P, et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thrombosis Haemostasis 1996;75:233&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8815566</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Palumbo 2011 {published data only}</Title><Reference><Citation>Cavo M, Palumbo A, Bringhen S, Raimondo F, Patriarca F, Rossi D, et al. Phase III study of enoxaparin versus aspirin versus low&#x2010;dose warfarin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated upfront with thalidomide&#x2010;containing regimens. Haematologica 2010;95:391.</Citation></Reference><Reference><Citation>Cavo M, Palumbo A, Bringhen S, Falcone A, Musto P, Ciceri F, et al. A phase III study of enoxaparin versus low&#x2010;dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up&#x2010;front with thalidomide&#x2010;containing regimens. Blood 2008;112(11):3017.</Citation></Reference><Reference><Citation>Cavo M, Palumbo A, Bringhen S, Falcone A, Musto P, Ciceri F, et al. A phase III study of enoxaparin versus low&#x2010;dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up&#x2010;front with thalidomide&#x2010;containing regimens. Haematologica 2009;94:s4.</Citation></Reference><Reference><Citation>Magarotto V, Brioli A, Patriarca F, Rossi D, Petrucci MT, Nozzoli C, et al. Enoxaparin, aspirin, or warfarin for the thromboprophylaxis in newly diagnosed myeloma patients receiving thalidomide: a randomized controlled trial. XI Congress of the Italian Society of Experimental Hematology 2010;95:986&#x2010;993.</Citation></Reference><Reference><Citation>Palumbo A, Cavo M, Bringhen S, Zaccaria A, Spadano A, Palmieri S, et al. Enoxaparin versus aspirin versus low&#x2010;fixed&#x2010;dose of warfarin in newly diagnosed myeloma patients treated with thalidomide&#x2010;containing regimens: a randomized, controlled trial. Haematologica 2008;93:362.</Citation></Reference><Reference><Citation>Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open&#x2010;label, randomized trial. Journal of Clinical Oncology 2011;29:986&#x2010;993.</Citation><ArticleIdList><ArticleId IdType="pubmed">21282540</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Pelzer 2015 (CONKO&#x2010;004) {published data only}</Title><Reference><Citation>Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P, Hahnfeld S, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy &#x2010; first results of the CONKO 004 trial. Onkologie &#x2010; DGHO meeting October 2009; Vol. 580:Abstract.</Citation></Reference><Reference><Citation>Pelzer U, Hilbig A, Stieler J, Roll L, Riess H, Dorken B, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT &#x2010; CONKO 004). Onkologie 2005;28(Suppl 3):54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613915</ArticleId><ArticleId IdType="pubmed">19055847</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelzer U, Hilbig A, Stieler J, Roll L, Stauch M, Opitz B, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT&#x2010;CONKO 004). ASCO Annual Meeting Proceedings 2006;24(18):4110.</Citation></Reference><Reference><Citation>Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, et al. Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer &#x2010; the CONKO 004 pilot trial. BMC Cancer 2014;14:204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3994651</ArticleId><ArticleId IdType="pubmed">24641937</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelzer U, Oettle H, Stauch M, Opitz B, Stieler J, Scholten T, et al. Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first&#x2010;line chemotherapy. XXIst Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6&#x2010;12; Geneva. 2007:P&#x2010;T&#x2010;488.</Citation></Reference><Reference><Citation>Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, et al. Efficacy of prophylactic low&#x2010;molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO&#x2010;004 Trial. Journal of Clinical Oncology 2015;33(18):2028&#x2010;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">25987694</ArticleId></ArticleIdList></Reference><Reference><Citation>Riess H, Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P, et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): results of the CONKO 004 trial. ASCO Annual Meeting Proceedings 2009;27(18S):LBA4506.</Citation></Reference><Reference><Citation>Riess H, Pelzer U, Hilbig A, Stieler J, Opitz B, Scholten T, et al. Rationale and design of PROSPECT&#x2010;CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. BMC Cancer 2008;8:361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2613915</ArticleId><ArticleId IdType="pubmed">19055847</ArticleId></ArticleIdList></Reference><Reference><Citation>Riess H, Pelzer U, Opitz B, Stauch M, Reitzig P, Hahnfeld S, et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO&#x2010;004 trial. Journal of Clinical Oncology Conference 2010;28(15 Suppl):4033.</Citation></Reference><Reference><Citation>Riess HB, Pelzer U, Opitz B, Hilbig A, Strauch M, Hahnfeld S, et al. Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients. International Society on Thrombosis and Haemostasis 2009;7(Suppl 2):1203.</Citation></Reference></ReferenceList><ReferenceList><Title>Prins 2014 (EINSTEIN) {published data only}</Title><Reference><Citation>Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN&#x2010;DVT and EINSTEIN&#x2010;PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology 2014;1(1):e37&#x2010;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">27030066</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Raskob 2016 (HOKUSAI) {published data only}</Title><Reference><Citation>Raskob GE, Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non&#x2010;inferiority subgroup analysis of the Hokusai&#x2010;VTE randomised, double&#x2010;blind, double&#x2010;dummy trial. Lancet Haematology 2016;3(8):e379&#x2010;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">27476789</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Raskob 2018 (HOKUSAI) {published data only}</Title><Reference><Citation>Raskob GE, Es N, Verhamme P, Carrier M, Nisio M, Garcia DA, et al. A randomized, open&#x2010;label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE&#x2010;Cancer study (LBA&#x2010;6). Blood 2017;130:LBA&#x2010;6.</Citation></Reference><Reference><Citation>Raskob GE, Es N, Verhamme P, Carrier M, Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer&#x2010;associated venous thromboembolism. New England Journal of Medicine 2018;378(7):615&#x2010;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">29231094</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rasmussen 2006 {published data only}</Title><Reference><Citation>Rasmussen M, Wille&#x2010;Jorgensen P, Jorgensen LN, Nielsen JD, Horn A, et al. Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) following major abdominal surgery for malignancy. Blood 2003;102:186.</Citation></Reference><Reference><Citation>Rasmussen MS, Jorgensen L, Wille&#x2010;Jorgensen P, Nielsen J, Soemod L, Harvald T, et al. Prolonged thromboprophylaxis with dalteparin after major abdominal surgery for malignant diseases. ASCO Proceedings 2001;4:407a.</Citation></Reference><Reference><Citation>Rasmussen MS, Jorgensen LN, Wille&#x2010;Jorgensen P, Nielsen JD, Horn A, Mohn AC, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open&#x2010;label study. Journal of Thrombosis and Haemostasis 2006;4:2384&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16881934</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Sakon 2010 {published data only}</Title><Reference><Citation>Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open&#x2010;label study. Thrombosis Research 2010;125(3):e65&#x2010;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">19919878</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Samama 1988 {published data only}</Title><Reference><Citation>Samama M, Bernard P, Bonnardot JP, Combe&#x2010;Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. British Journal of Surgery 1988;75:128&#x2010;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">2832030</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schulman 2003 {published data only}</Title><Reference><Citation>Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, Investigators TI, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. New England Journal of Medicine 2003;349(18):1713&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">14585939</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schulman 2013 (RE&#x2010;MEDY) {published data only}</Title><Reference><Citation>Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. New England Journal of Medicine 2013;368(8):709&#x2010;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">23425163</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Schulman 2015 (RECOVER) {published data only}</Title><Reference><Citation>Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thrombosis and Haemostasis 2015;114(1):150&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25739680</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Shukla 2008 {published data only}</Title><Reference><Citation>Shukla PJ, Siddachari R, Ahire S, Arya S, Ramani S, Barreto SG, et al. Postoperative deep vein thrombosis in patients with colorectal cancer. Indian Journal of Gastroenterology 2008;27(2):71&#x2010;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695308</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Simonneau 2006 {published data only}</Title><Reference><Citation>Simonneau G, Laporte S, Mismetti P, Derlon A, Samii K, Samama CM, et al. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. Journal of Thrombosis and Haemostasis 2006;4:1693&#x2010;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">16796710</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Song 2014 {published data only}</Title><Reference><Citation>Song KY, Yoo HM, Kim EY, Kim JI, Yim HW, Jeon HM, et al. Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial. Annals of Surgical Oncology 2014;21(13):4232&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25012265</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Tang 2012 {published data only}</Title><Reference><Citation>Tang BQ, Guo W, Yang RL, Tang XD, Yan TQ, Tang S. Evaluation of efficacy and safety of rivaroxaban in the prevention of postoperative venous thromboembolism in adult patients with primary bone tumor undergoing knee operation. Zhonghua Yi Xue za Zhi 2012;92(39):2768&#x2010;771.</Citation><ArticleIdList><ArticleId IdType="pubmed">23290165</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Vadhan&#x2010;Raj 2013 {published data only}</Title><Reference><Citation>Vadhan&#x2010;Raj S, Zhou X, Varadhachary GR, Milind J, Fogelman D, Shroff R, et al. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): risk factors predictive of VTE. Blood 2013;122(21):580.</Citation></Reference></ReferenceList><ReferenceList><Title>Vedovati 2014a {published data only}</Title><Reference><Citation>Becattini C, Rondelli F, Vedovati MC, Camporese G, Giustozzi M, Boncompagni M, et al. Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. Haematologia 2014;100(1):e35&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4281334</ArticleId><ArticleId IdType="pubmed">25216684</ArticleId></ArticleIdList></Reference><Reference><Citation>Becattini C, Rondelli F, Vedovati MC, Camporese G, Giustozzi M, Boncompagni M, et al. Letter to the editor. Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. Haematologia 2015;100:e35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4281334</ArticleId><ArticleId IdType="pubmed">25216684</ArticleId></ArticleIdList></Reference><Reference><Citation>Becattini C, Vedovati MC, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. One week vs. four week heparin prophylaxis after laparoscopic surgery for colorectal cancer. The pro&#x2010;laps pilot feasibility study. Journal of Thrombosis and Haemostasis 2013;11:11.</Citation></Reference><Reference><Citation>Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. A randomized study on 1 vs. 4 weeks prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Journal of Thrombosis and Haemostasis 2013;11:214.</Citation></Reference><Reference><Citation>Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. A randomized study on 1&#x2010;week versus 4&#x2010;week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Annals of Surgery 2014;259(4):665&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24253138</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Vedovati 2014b {published data only}</Title><Reference><Citation>Becattini C, Rondelli F, Vedovati MC, Camporese G, Giustozzi M, Boncompagni M, et al. Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. Haematologica 2015;100(1):e35&#x2010;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4281334</ArticleId><ArticleId IdType="pubmed">25216684</ArticleId></ArticleIdList></Reference><Reference><Citation>Becattini C, Vedovati MC, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. One week vs. four week heparin prophylaxis after laparoscopic surgery for colorectal cancer. The pro&#x2010;laps pilot feasibility study. International Society on Thrombosis and Haemostasis 2013;11:ATT05, 1&#x2010;105.</Citation></Reference><Reference><Citation>Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. A randomized study on 1 vs. 4 weeks prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Journal of Thrombosis and Haemostasis 2013;11:214.</Citation></Reference><Reference><Citation>Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. A randomized study on 1&#x2010;week versus 4&#x2010;week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Annals of Surgery 2014;259(4):665&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24253138</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Verso 2008 {published data only}</Title><Reference><Citation>Agnelli G, Verso M, Bertoglio S, Ageno W, Bazzan M, Parise P, et al. A double&#x2010;blind placebo&#x2010;controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter. Journal of Clinical Oncology 2004;22:734S.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767643</ArticleId></ArticleIdList></Reference><Reference><Citation>Verso M, Agnelli G, Bertoglio S, Somma FC, Paoletti F, Ageno W, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double&#x2010;blind, placebo&#x2010;controlled, randomized study in cancer patients. Journal of Clinical Oncology 2005;23(18):4057&#x2010;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767643</ArticleId></ArticleIdList></Reference><Reference><Citation>Verso M, Agnelli G, Kamphuisen PW, Ageno W, Bazzan M, Lazzaro A, et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Internal and Emergency Medicine 2008;3(2):117&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18317868</ArticleId></ArticleIdList></Reference><Reference><Citation>Verso, M, et al. A double&#x2010;blind placebo&#x2010;controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter. Journal of Thrombosis and Haemostasis : JTH 2008:8021.</Citation><ArticleIdList><ArticleId IdType="pubmed">18612558</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Young 2017 (SELECT&#x2010;D) {published data only}</Title><Reference><Citation>Young A, Dunn J, Chapman O, Grumett J, Marshall A, Phillips J, et al. SELECT&#x2010;D: anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings 2014;32(15 Suppl):TPS9661.</Citation><ArticleIdList><ArticleId IdType="pubmed">27161683</ArticleId></ArticleIdList></Reference><Reference><Citation>Young A, Marshall A, Thirlwall J, Hill C, Hale D, Dunn J, et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select&#x2010;D&#x2122; pilot trial. Blood 2017;130:625.</Citation></Reference><Reference><Citation>Young A, Phillips J, Hancocks H, Hill C, Joshi N, Marshall A, et al. OC&#x2010;11&#x2010;Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research 2016;140:S172&#x2010;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">27161683</ArticleId></ArticleIdList></Reference><Reference><Citation>Young A, Phillips J, Hancocks H, Marshall A, Grumett J, Dunn J, et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. ASCO Annual Meeting Proceedings 2015;33(15 Suppl):TPS9642.</Citation><ArticleIdList><ArticleId IdType="pubmed">27161683</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zheng 2014 {published data only}</Title><Reference><Citation>Zheng H, Gao Y, Yan X, Gao M, Gao W. Prophylactic use of low molecular weight heparin in combination with graduated compression stockings in post&#x2010;operative patients with gynecologic cancer. Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology] 2014;36(1):39&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">24685085</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Zwicker 2013 (MICRO TEC) {published data only}</Title><Reference><Citation>Zwicker J, Liebman HA, Bauer KA, Caughey T, Rosovsky R, Mantha S, et al. A randomized&#x2010;controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the MICROTEC study). Journal of Thrombosis and Haemostasis : JTH 2013;11:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609903</ArticleId><ArticleId IdType="pubmed">23240761</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, et al. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor&#x2010;bearing microparticles: a randomized&#x2010;controlled phase II trial (the Microtec study). British Journal of Haematology 2013;160(4):530&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609903</ArticleId><ArticleId IdType="pubmed">23240761</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to ongoing studies</Title><ReferenceList><Title>Safi 2011 {published data only}</Title><Reference><Citation>A Randomized, Controlled, Open Label Study of the Efficacy and Safety of the Low Molecular Weight Heparin (LMWH), Lovenox<sup>TM</sup> (Enoxaparin) versus Heparin<sup>TM</sup> (Unfractionated Heparin) for Prevention of Venous Thromboembolism (VTE) in Gynecologic Oncology Patients. 
Ongoing study October 2009. 
</Citation></Reference></ReferenceList></ReferenceList><ReferenceList><Title>Additional references</Title><ReferenceList><Title>Akl 2013</Title><Reference><Citation>Akl EA, Johnston BC, Alonso&#x2010;Coello P, Neumann I, Ebrahim S, Briel M, et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PloS One 2013;8(2):e57132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581575</ArticleId><ArticleId IdType="pubmed">23451162</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Akl 2016</Title><Reference><Citation>Akl EA, Kahale LA, Ebrahim S, Alonso&#x2010;Coello P, Sch&#xfc;nemann HJ, Guyatt GH. Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewers. Journal of Clinical Epidemiology 2016;76:147&#x2010;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">26944294</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Alshurafa 2012</Title><Reference><Citation>Alshurafa M, Briel M, Akl EA, Haines T, Moayyedi P, Gentles SJ, et al. Inconsistent definitions for intention&#x2010;to&#x2010;treat in relation to missing outcome data: systematic review of the methods literature. PloS One 2012;7(11):e49163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3499557</ArticleId><ArticleId IdType="pubmed">23166608</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Barritt 1960</Title><Reference><Citation>Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960;1:1309&#x2010;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">13797091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Borly 2005</Title><Reference><Citation>Borly L, Wille&#x2010;Jorgensen P, Rasmussen MS. Systematic review of thromboprophylaxis in colorectal surgery. Colorectal Disease 2005;7:122&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15720347</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Changolkar 2014</Title><Reference><Citation>Changolkar A, Menditto L, Shah M, Puto K, Farrelly E. Comparison of injectable anticoagulants for thromboprophylaxis after cancer&#x2010;related surgery. American Journal of Health&#x2010;system Pharmacy 2014;7:562&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24644116</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Deeks 2001</Title><Reference><Citation>Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta&#x2010;analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta&#x2010;Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.</Citation></Reference></ReferenceList><ReferenceList><Title>DerSimonian 1986</Title><Reference><Citation>DerSimonian R, Laird N. Meta&#x2010;analysis in clinical trials. Controlled Clinical Trials 1986;7:177&#x2010;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Ebrahim 2013</Title><Reference><Citation>Ebrahim S, Akl EA, Mustafa RA, Sun X, Walter SD, Heels&#x2010;Ansdell D, et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. Journal of Clinical Epidemiology 2013;66(9):1014&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774111</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Edmonds 2004</Title><Reference><Citation>Edmonds MJ, Crichton TJ, Runciman WB, Pradhan M. Evidence&#x2010;based risk factors for postoperative deep vein thrombosis. ANZ Journal of Surgery 2004;74(12):1082&#x2010;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15574153</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Einstein 2007</Title><Reference><Citation>Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecologic Oncology 2007;105(3):813&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17449089</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Flordal 1996</Title><Reference><Citation>Flordal PA, Berggvist D, Burmark US, Ljungstrom KG, Torngren S. Risk factors for major thromboembolism and bleeding tendency after elective general surgical operations. European Journal of Surgery 1996;162:783&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8934107</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gallus 1997</Title><Reference><Citation>Gallus AS. Prevention of post&#x2010;operative deep leg vein thrombosis in patients with cancer. Thrombosis and Haemostasis 1997;78:126&#x2010;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9198141</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Gould 2012</Title><Reference><Citation>Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence&#x2010;Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e227S&#x2010;77S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278061</ArticleId><ArticleId IdType="pubmed">22315263</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>GRADE Handbook</Title><Reference><Citation>Sch&#xfc;nemann H, Bro&#x17c;ek J, Guyatt G, Oxman A. GRADE Handbook, Updated October 2013. gdt.guidelinedevelopment.org/app/handbook/handbook.html. GRADE working group, (accessed prior to 3 November 2017).</Citation></Reference></ReferenceList><ReferenceList><Title>Guyatt 2017</Title><Reference><Citation>Guyatt GH, Ebrahim S, Alonso&#x2010;Coello P, Johnston BC, Mathioudakis AG, Briel M, et al. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology 2017;87:14&#x2010;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">28529188</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2003</Title><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta&#x2010;analysis. BMJ 2003;327:557&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Higgins 2011</Title><Reference><Citation>Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. Available from handbook.cochrane.org.</Citation></Reference></ReferenceList><ReferenceList><Title>Hirsh 1993</Title><Reference><Citation>Hirsh J. Low molecular weight heparin. Thrombosis and Haemostasis 1993;70(1):204&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8236105</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Kakkar 1970</Title><Reference><Citation>Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg. Is there a "high risk" group?. American Journal of Surgery 1970;120:527&#x2010;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">4097038</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Leonardi 2007</Title><Reference><Citation>Leonardi MJ, McGory ML, Ko CY. A systematic review of deep venous thrombosis prophylaxis in cancer patients: implications for improving quality. Annals of Surgical Oncology 2007;14(2):929&#x2010;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17103259</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Levitan 1999</Title><Reference><Citation>Levitan N, Dowlati A, Remick SC. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Medicine 1999;78:285&#x2010;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">10499070</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Martel 2005</Title><Reference><Citation>Martel N, Lee J, Wells PS. Risk for heparin&#x2010;induced thrombocytopenia with unfractionated and low&#x2010;molecular&#x2010;weight heparin thromboprophylaxis. Blood 2005;106:2710&#x2010;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15985543</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Mismetti 2001</Title><Reference><Citation>Mismetti P, Laporte S, Darmon JY, Buchmuller A. Meta&#x2010;analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. British Journal of Surgery 2001;88:913&#x2010;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">11442521</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Morris 2007</Title><Reference><Citation>Morris TA, Castrejon S, Devendra G, Gamst AC. No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low&#x2010;molecular&#x2010;weight heparin or unfractionated heparin. Chest 2007;132:1131&#x2010;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17646239</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Rahr 1992</Title><Reference><Citation>Rahr HB, Sorensen JV. Venous thromboembolism and cancer. Blood Coagulation &amp; Fibrinolysis 1992;3:451&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">1420820</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>RevMan 2014 [Computer program]</Title><Reference><Citation>The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.</Citation></Reference></ReferenceList><ReferenceList><Title>Sorensen 2000</Title><Reference><Citation>Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. New England Journal of Medicine 2000;343:1846&#x2010;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">11117976</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList><ReferenceList><Title>References to other published versions of this review</Title><ReferenceList><Title>Akl 2011</Title><Reference><Citation>Akl EA, Labedi N, Terrenato I, Barba M, Sperati F, Sempos EV, et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD009447.pub2]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009447.pub2</ArticleId><ArticleId IdType="pubmed">22071865</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Title>Akl 2014</Title><Reference><Citation>Akl EA, Kahale LA, Sperati F, Neumann I, Labedi N, Terrenato I, et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD009447]</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009447</ArticleId><ArticleId IdType="pubmed">24966161</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31971231</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1569-9285</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Interactive cardiovascular and thoracic surgery</Title><ISOAbbreviation>Interact Cardiovasc Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Thrombotic risk following video-assisted thoracoscopic surgery versus open thoracotomy: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>573</StartPage><EndPage>581</EndPage><MedlinePgn>573-581</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/icvts/ivz321</ELocationID><Abstract><AbstractText Label="OBJECTIVES">There is no consensus on the risk of thrombotic events following video-assisted thoracoscopic surgery (VATS) versus open thoracotomy (OT), despite multiple studies. In fact, the estimates for the overall thrombotic risk for VATS versus OT are inconclusive. In this systematic review and meta-analysis, we endeavoured to ascertain the best estimate of thrombotic risk in VATS versus OT.</AbstractText><AbstractText Label="METHODS">Relevant studies were searched through PubMed and Cochrane Library database. Outcomes of interests were myocardial infarction (MI), pulmonary embolism (PE) and deep vein thrombosis (DVT). Data were pooled using random-effects model. The results were presented as odds ratio (OR) with the corresponding 95% confidence interval (CI).</AbstractText><AbstractText Label="RESULTS">Nineteen studies were meta-analysed: 17 observational studies and 2 randomized controlled trials. Using propensity-matched data, in comparison with OT, VATS was associated with a statistically significant, postoperative reduction in MI (OR 0.60, 95% CI 0.39-0.91; P&#x2009;=&#x2009;0.017), DVT/PE (OR 0.52, 95% CI 0.44-0.61; P&#x2009;&lt;&#x2009;0.001), PE (OR 0.59, 95% CI 0.43-0.82; P&#x2009;=&#x2009;0.001) and DVT (OR 0.47, 95% CI 0.35-0.64; P&#x2009;&lt;&#x2009;0.001). Unadjusted data showed no statistical differences for all outcomes. The risk of DVT/PE (OR 0.55, 95% CI 0.42-0.72; P&#x2009;&lt;&#x2009;0.001), but not the other outcomes, remained significantly lower following the exclusion of the sole large study. There is no significant statistical heterogeneity between the included studies.</AbstractText><AbstractText Label="CONCLUSIONS">Overall, the postoperative thrombotic risk following VATS is significantly lower than OT. Further prospective randomized controlled trials with large sample sizes are warranted to corroborate our findings.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spiezia</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine - DIMED, Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liew</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National University of Ireland, Galway (NUIG), Galway, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Portiuncula University Hospital, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campello</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine - DIMED, Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Gregorio</LastName><ForeName>Guido</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiac Anaesthesia Unit, Department of Medicine, Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuin</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Thoracic Surgery Division, Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simioni</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine - DIMED, Padova University Hospital, Padova, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Interact Cardiovasc Thorac Surg</MedlineTA><NlmUniqueID>101158399</NlmUniqueID><ISSNLinking>1569-9285</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020775" MajorTopicYN="N">Thoracic Surgery, Video-Assisted</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013908" MajorTopicYN="N">Thoracotomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Thoracotomy</Keyword><Keyword MajorTopicYN="N">Video-assisted thoracoscopic surgery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31971231</ArticleId><ArticleId IdType="doi">10.1093/icvts/ivz321</ArticleId><ArticleId IdType="pii">5714631</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36878889</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1757-7861</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Orthopaedic surgery</Title><ISOAbbreviation>Orthop Surg</ISOAbbreviation></Journal><ArticleTitle>The Optimal Dose, Efficacy and Safety of Tranexamic Acid and Epsilon-Aminocaproic Acid to Reduce Bleeding in TKA: A Systematic Review and Bayesian Network Meta-analysis.</ArticleTitle><Pagination><StartPage>930</StartPage><EndPage>946</EndPage><MedlinePgn>930-946</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/os.13678</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The optimal dose and efficacy of tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA) in total knee arthroplasty (TKA) were under controversial, and we aimed to make comparisons between different doses of TXA and EACA in intravenous (IV) or intra-articular (IA) applications in patients undergoing TKA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This network meta-analysis was guided by the Priority Reporting Initiative for Systematic Assessment and Meta-Analysis (PRISMA). According to the administrations of antifibrinolytic agents, patients in eligible studies were divided into three subgroups: (i) IA applications of TXA and EACA; (ii) IV applications (g) of TXA and EACA; (iii) IV applications (mg/kg) of TXA and EACA. Total blood loss (TBL), hemoglobin (HB) drops and transfusion rates were the primary outcomes, while drainage volume, pulmonary embolism (PE) or deep vein thrombosis (DVT) risk were the secondary outcomes. A multivariate Bayesian random-effects model was adopted in the network analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 38 eligible trials with different regimens were assessed. Overall inconsistency and heterogeneity were acceptable. Taking all primary outcomes into account, 1.0-3.0&#x2009;g TXA were most effective in IA applications, 1-6&#x2009;g TXA and 10-14&#x2009;g EACA were most effective in IV applications (g), while 30&#x2009;mg/kg TXA and 150&#x2009;mg/kg EACA were most effective in IV applications (mg/kg). None of the regimens showed increasing risk for pulmonary embolism (PE) or deep vein thrombosis (DVT) compared with placebo.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">0&#x2009;g IA TXA, 1.0&#x2009;g IV TXA or 10.0&#x2009;g IV EACA, as well as 30&#x2009;mg/kg IV TXA or 150&#x2009;mg/kg IV EACA were most effective and enough to control bleeding for patients after TKA. TXA was at least 5 times more potent than EACA.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Orthopaedic Surgery published by Tianjin Hospital and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Che</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jiawen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mingyang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yuangang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Bin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-9632-7221</Identifier><AffiliationInfo><Affiliation>Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2020YFS0139</GrantID><Agency>Department of Science and Technology of Sichuan Province</Agency><Country/></Grant><Grant><GrantID>Z2021JC002</GrantID><Agency>National Clinical Research Center for Geriatrics, West China Hospital Sichuan University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Orthop Surg</MedlineTA><NlmUniqueID>101501666</NlmUniqueID><ISSNLinking>1757-7853</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>U6F3787206</RegistryNumber><NameOfSubstance UI="D015119">Aminocaproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000933">Antifibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6T84R30KC1</RegistryNumber><NameOfSubstance UI="D014148">Tranexamic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015119" MajorTopicYN="Y">Aminocaproic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000933" MajorTopicYN="Y">Antifibrinolytic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="Y">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014148" MajorTopicYN="Y">Tranexamic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bleeding</Keyword><Keyword MajorTopicYN="N">Epsilon-Aminocaproic acid</Keyword><Keyword MajorTopicYN="N">Total knee arthroplasty</Keyword><Keyword MajorTopicYN="N">Tranexamic acid</Keyword><Keyword MajorTopicYN="N">Transfusion</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>6</Day><Hour>22</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36878889</ArticleId><ArticleId IdType="pmc">PMC10102320</ArticleId><ArticleId IdType="doi">10.1111/os.13678</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sultan AA, Cantrell WA, Rose E, Surace P, Samuel LT, Chughtai M, et al. Total knee arthroplasty in the face of a previous tuberculosis infection of the knee: what do we know in 2018? Expert Rev Med Devices. 2018;15(10):717&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">30203999</ArticleId></ArticleIdList></Reference><Reference><Citation>Worland RL, Johnson G, Alemparte J, Jessup DE, Keenan J, Norambuena N. Ten&#x2010;to&#x2010;fourteen&#x2010;year survival and functional analysis of the AGC total knee replacement system. Knee. 2002;9(2):133&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11950577</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the U.S., 2014 to 2030. J Bone Jt Surg Am. 2018;100(17):1455&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">30180053</ArticleId></ArticleIdList></Reference><Reference><Citation>Sculco TP. Global blood management in orthopaedic surgery. Clin Orthop Relat Res. 1998;357:43&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9917699</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardone D, Klein AA. Perioperative blood conservation. Eur J Anaesthesiol. 2009;26(9):722&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19448549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak J, Wilkey AL, Abdalla M, Joshi R, Roman PEF, Greilich PE. Perioperative blood conservation: guidelines to practice. Adv Anesth. 2019;37:1&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">31677651</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiker&#xe5;s O, Clementsen T. Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations. J Thromb Thrombolysis. 2009;28(4):425&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19067121</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassoon A, Nam D, Jackups R, Johnson SR, Nunley RM, Barrack RL. Tranexamic acid: optimal blood loss management in surface replacement arthroplasty. Bone Jt J. 2016;98&#x2010;b(2):173&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26850421</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Wu Y, Yin Z, Ma G, Chang J. A systematic review and meta&#x2010;analysis of the use of antifibrinolytic agents in total hip arthroplasty. Hip Int. 2015;25(6):502&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26620803</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi R, Evans HMK, Mahomed SR, Mahomed NN. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta&#x2010;analysis. BMC Res Notes. 2013;6:184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655041</ArticleId><ArticleId IdType="pubmed">23651507</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachauri A, Acharya KK, Tiwari AK. The effect of tranexamic acid on hemoglobin levels during total knee arthroplasty. Am J Ther. 2014;21(5):366&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">23917458</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniar RN, Kumar G, Singhi T, Nayak RM, Maniar PR. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res. 2012;470(9):2605&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830076</ArticleId><ArticleId IdType="pubmed">22419350</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray M et al. Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty &#x2013; a prospective randomized double&#x2010;blind placebo&#x2010;controlled study. J Thromb Haemost. 2005;3(7):1421&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15978098</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppenheimer AJ, Ranganathan K, Levi B, Strahle JM, Kapurch J, Muraszko KM, et al. Minimizing transfusions in primary cranial vault remodeling: the role of aminocaproic acid. J Craniofac Surg. 2014;25(1):82&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24240766</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin K, Knorr J, Breuer T, Gertler R, MacGuill M, Lange R, et al. Seizures after open heart surgery: comparison of &#x3b5;&#x2010;aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth. 2011;25(1):20&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21272777</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Chen JY, Zheng Q, Lo NN, Chia SL, Tay KJD, et al. The safest and most efficacious route of tranexamic acid administration in total joint arthroplasty: a systematic review and network meta&#x2010;analysis. Thromb Res. 2019;176:61&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">30776688</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C, Zhang X, Chen L, Deng J, Ma Q, Cai X, et al. Comparison of oral versus intravenous tranexamic acid in total knee and hip arthroplasty: a GRADE analysis and meta&#x2010;analysis. Medicine. 2020;99(44):e22999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7598783</ArticleId><ArticleId IdType="pubmed">33126380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye W, Liu Y, Liu WF, Li XL, Shao J. The optimal regimen of oral tranexamic acid administration for primary total knee/hip replacement: a meta&#x2010;analysis and narrative review of a randomized controlled trial. J Orthop Surg Res. 2020;15(1):457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539468</ArticleId><ArticleId IdType="pubmed">33023637</ArticleId></ArticleIdList></Reference><Reference><Citation>Riaz O, Aqil A, Asmar S, Vanker R, Hahnel J, Brew C, et al. Epsilon&#x2010;aminocaproic acid versus tranexamic acid in total knee arthroplasty: a meta&#x2010;analysis study. J Orthop Traumatol. 2019;20(1):28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6639518</ArticleId><ArticleId IdType="pubmed">31321578</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z et al. Tranexamic acid versus epsilon&#x2010;aminocaproic acid in total knee arthroplasty: a meta&#x2010;analysis. J Healthcare Eng. 2021;2021:1758066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8580677</ArticleId><ArticleId IdType="pubmed">34777729</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, et al. The efficacy of tranexamic acid in total knee arthroplasty: a network meta&#x2010;analysis. J Arthroplasty. 2018;33(10):3090&#x2013;3098.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">29805106</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.</Citation><ArticleIdList><ArticleId IdType="pubmed">33789826</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias S et al. NICE decision support unit technical support documents. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta&#x2010;Analysis of Randomised Controlled Trials. London: National Institute for Health and Care Excellence (NICE); 2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">27466657</ArticleId></ArticleIdList></Reference><Reference><Citation>Camarasa MA, Oll&#xe9; G, Serra&#x2010;Prat M, Mart&#xed;n A, S&#xe1;nchez M, Ric&#xf3;s P, et al. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth. 2006;96(5):576&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">16531440</ArticleId></ArticleIdList></Reference><Reference><Citation>Orpen NM, Little C, Walker G, Crawfurd EJP. Tranexamic acid reduces early post&#x2010;operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients. Knee. 2006;13(2):106&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16487712</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J, Abrishami A, el Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, et al. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Jt Surg Am. 2010;92(15):2503&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">21048170</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy SP, Tanki UF, Dutta A, Jain SK, Nagi ON. Efficacy of intra&#x2010;articular tranexamic acid in blood loss reduction following primary unilateral total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2012;20(12):2494&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">22419263</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgiadis AG, Muh SJ, Silverton CD, Weir RM, Laker MW. A prospective double&#x2010;blind placebo&#x2010;controlled trial of topical tranexamic acid in total knee arthroplasty. J Arthroplasty. 2013;28(8 Suppl):78&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">23906869</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai T, Tsuji S, Tomita T, Sugamoto K, Hideki Y, Hamada M. Repeat&#x2010;dose intravenous tranexamic acid further decreases blood loss in total knee arthroplasty. Int Orthop. 2013;37(3):441&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580084</ArticleId><ArticleId IdType="pubmed">23371424</ArticleId></ArticleIdList></Reference><Reference><Citation>Sa&#x2010;Ngasoongsong P et al. Efficacy of low&#x2010;dose intra&#x2010;articular tranexamic acid in total knee replacement; a prospective triple&#x2010;blinded randomized controlled trial. BMC Musculoskeletal Disord. 2013;14:340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4234192</ArticleId><ArticleId IdType="pubmed">24308672</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo JG, Moon YW, Park SH, Kim SM, Ko KR. The comparative efficacies of intra&#x2010;articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2013;21(8):1869&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">22729012</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera X, Mart&#xed;nez&#x2010;Zapata MJ, Hinarejos P, Jord&#xe1;n M, Leal J, Gonz&#xe1;lez JC, et al. Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial. Arch Orthop Trauma Surg. 2015;135(7):1017&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25944156</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SY, Chen CH, Fu YC, Huang PJ, Chang JK, Huang HT. The efficacy of combined use of intraarticular and intravenous tranexamic acid on reducing blood loss and transfusion rate in total knee arthroplasty. J Arthroplasty. 2015;30(5):776&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">25534864</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CG, Sun ZH, Liu J, Cao JG, Li ZJ. Safety and efficacy of intra&#x2010;articular tranexamic acid injection without drainage on blood loss in total knee arthroplasty: a randomized clinical trial. Int J Surg. 2015;20:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26048730</ArticleId></ArticleIdList></Reference><Reference><Citation>Akg&#xfc;l T, B&#xfc;get M, Salduz A, Edipo&#x11f;lu &#x130;S, Ekinci M, K&#xfc;&#xe7;&#xfc;kay S, et al. Efficacy of preoperative administration of single high dose intravenous tranexamic acid in reducing blood loss in total knee arthroplasty: a prospective clinical study. Acta Orthop Traumatol Turc. 2016;50(4):429&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197312</ArticleId><ArticleId IdType="pubmed">27435332</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzatzairis TK, Drosos GI, Kotsios SE, Ververidis AN, Vogiatzaki TD, Kazakos KI. Intravenous vs topical tranexamic acid in total knee arthroplasty without tourniquet application: a randomized controlled study. J Arthroplasty. 2016;31(11):2465&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">27267228</ArticleId></ArticleIdList></Reference><Reference><Citation>Boese CK, Centeno L, Walters RW. Blood conservation using tranexamic acid is not superior to epsilon&#x2010;aminocaproic acid after total knee arthroplasty. J Bone Jt Surg Am. 2017;99(19):1621&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28976426</ArticleId></ArticleIdList></Reference><Reference><Citation>Churchill JL et al. Comparing &#x3b5;&#x2010;aminocaproic acid and tranexamic acid in reducing postoperative transfusions in total knee arthroplasty. J Knee Surg. 2017;30(5):460&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27699724</ArticleId></ArticleIdList></Reference><Reference><Citation>Song EK, Seon JK, Prakash J, Seol YJ, Park YJ, Jin C. Combined administration of IV and topical tranexamic acid is not superior to either individually in primary navigated TKA. J Arthroplasty. 2017;32(1):37&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">27633946</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowers MDJ et al. Tranexamic acid in knee surgery study&#x2010;a multicentered, randomized, controlled trial. J Arthroplasty. 2017;32(11):3379&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">28662956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Yu X, Wu JZ, Ge W, Cai M, Li S. Efficacy of a single dose and an additional dose of tranexamic acid in reduction of blood loss in total knee arthroplasty. J Arthroplasty. 2017;32(7):2108&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">27889307</ArticleId></ArticleIdList></Reference><Reference><Citation>U&#x11f;urlu M, Aksekili M, &#xc7;a&#x11f;lar C, Y&#xfc;ksel K, &#x15e;ahin E, Akyol M. Effect of topical and intravenously applied tranexamic acid compared to control group on bleeding in primary unilateral total knee arthroplasty. J Knee Surg. 2017;30(2):152&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27135960</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wang Q, Zhang X, Wang Q. Intra&#x2010;articular application is more effective than intravenous application of tranexamic acid in total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty. 2017;32(11):3385&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28697863</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen SH et al. Topical tranexamic acid reduces blood loss in minimally invasive total knee arthroplasty receiving rivaroxaban. Biomed Res Int. 2017;2017:9105645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5749315</ArticleId><ArticleId IdType="pubmed">29410968</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X, Li B, Wang Q, Zhang X. Comparison of 3 routes of Administration of Tranexamic acid on primary unilateral total knee arthroplasty: a prospective, randomized, controlled study. J Arthroplasty. 2017;32(9):2738&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">28455182</ArticleId></ArticleIdList></Reference><Reference><Citation>Arslan A, G&#xf6;rmeli G. Using intra&#x2010;articular tranexamic acid in total knee replacement surgery with and without bleeding control: a prospective randomized double&#x2010;blind study. Eur Rev Med Pharmacol Sci. 2018;22(18):6127&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">30280800</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Yang C, Huang X, Liu R. Tranexamic acid reduces occult blood loss, blood transfusion, and improves recovery of knee function after total knee arthroplasty: a comparative study. J Knee Surg. 2018;31(3):239&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">28460409</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez&#x2010;Hualda &#xc1;, Dauder&#x2010;Gallego C, Ferre&#xf1;o&#x2010;M&#xe1;rquez D, Mart&#xed;nez&#x2010;Mart&#xed;n J. Efficacy and safety of topical tranexamic acid in knee arthroplasty. Med Clin. 2018;151(11):431&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29496242</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley KE, Ryan SP, Penrose CT, Grant SA, Wellman SS, Attarian DE, et al. Tranexamic acid or epsilon&#x2010;aminocaproic acid in total joint arthroplasty? A randomized controlled trial. Bone Jt J. 2019;101:1093&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31474134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tille E, Mysliwietz J, Beyer F, Postler A, L&#xfc;tzner J. Intraarticular use of tranexamic acid reduces blood loss and transfusion rate after primary total knee arthroplasty. BMC Musculoskeletal Disord. 2019;20(1):341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6661102</ArticleId><ArticleId IdType="pubmed">31351459</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Xie J, Cao G, Lei Y, Huang Q, Pei F. Six&#x2010;dose intravenous tranexamic acid regimen further inhibits postoperative fibrinolysis and reduces hidden blood loss following total knee arthroplasty. J Knee Surg. 2021;34(2):224&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">31434149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JK, Park JY, Lee DY, Ro DH, Han HS, Lee MC. Optimal dose of topical tranexamic acid considering efficacy and safety in total knee arthroplasty: a randomized controlled study. Knee Surg Sports Traumatol Arthrosc. 2021;29(10):3409&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">32869124</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue CX, Yao YF, Lv H, Cheng L, Jing JH. Efficacy and safety of postoperative intravenous tranexamic acid in total knee arthroplasty: a prospective randomized controlled study. Orthop Surg. 2021;13(8):2227&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8654654</ArticleId><ArticleId IdType="pubmed">34668331</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro JPF et al. Intraarticular epsilon aminocaproic acid versus tranexamic acid in total knee arthroplasty. Acta Ortop Bras. 2021;29(6):312&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8601385</ArticleId><ArticleId IdType="pubmed">34849096</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Y, Xie J, Huang Q, Huang W, Pei F. Is there a role of tranexamic acid in rheumatoid arthritis with total knee arthroplasty? Findings from a multicenter prospective cohort study in China. Arch Orthop Trauma Surg. 2021;141(3):489&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">33386441</ArticleId></ArticleIdList></Reference><Reference><Citation>Magill P, Hill JC, Bryce L, Martin U, Dorman A, Hogg R, et al. Oral tranexamic acid for an additional 24 hours postoperatively versus a single preoperative intravenous dose for reducing blood loss in total knee arthroplasty: results of a randomized controlled trial (TRAC&#x2010;24). Bone Jt J. 2021;103(10):1595&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">34587808</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper RA, Sucher MG, Giordani M, Nedopil AJ. Topically applied epsilon&#x2010;aminocaproic acid reduces blood loss and length of hospital stay after total knee arthroplasty. Orthopedics. 2017;40(6):e1044&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28968480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobbs JC, Welsby IJ, Green CL, Dhakal IB, Wellman SS. Epsilon aminocaproic acid to reduce blood loss and transfusion after total hip and total knee arthroplasty. J Arthroplasty. 2018;33(1):55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">28939033</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum ZC, Manoukian MAC, Pacheco CS, Nedopil AJ, Giordani M, Meehan JP. Intravenous tranexamic acid versus topical aminocaproic acid: which method has the least blood loss and transfusion rates? J Am Acad Orthop Surg Glob Res Rev. 2018;2(11):e072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324898</ArticleId><ArticleId IdType="pubmed">30656262</ArticleId></ArticleIdList></Reference><Reference><Citation>Churchill JL, Toney VA, Truchan S, Anderson MJ. Using aminocaproic acid to reduce blood loss after primary unilateral total knee arthroplasty. Am J Orthop. 2016;45(5):E245&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27552460</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51(2):224&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">21936146</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecher ME, Monk T, Goodnough LT. A standardized method for calculating blood loss. Transfusion. 1997;37(10):1070&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354828</ArticleId></ArticleIdList></Reference><Reference><Citation>Eubanks JD. Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010;18(3):132&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20190103</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JF, Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth. 1992;39(4):353&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">1373346</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57(6):1005&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10400410</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehat KR, Evans R, Newman JH. How much blood is really lost in total knee arthroplasty? Correct blood loss management should take hidden loss into account. Knee. 2000;7(3):151&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10927208</ArticleId></ArticleIdList></Reference><Reference><Citation>Turan S, Bing&#xf6;l O. Is tranexamic acid effective on hidden blood loss in patients during total knee arthroplasty? Jt Dis Relat Surg. 2020;31(3):488&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7607961</ArticleId><ArticleId IdType="pubmed">32962580</ArticleId></ArticleIdList></Reference><Reference><Citation>Sehat KR, Evans RL, Newman JH. Hidden blood loss following hip and knee arthroplasty. Correct management of blood loss should take hidden loss into account. J Bone Jt Surg Br. 2004;86(4):561&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15174554</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31804347</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>49</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Perioperative outcomes in geriatric patients undergoing hip fracture surgery with different anesthesia techniques: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e18220</StartPage><MedlinePgn>e18220</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e18220</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000018220</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous meta-analyses assessing anesthetic techniques in adult patients undergoing hip fractures surgery are available. However, whether the anesthetic technique is associated with risk of mortality and complications in geriatric patients with hip fractures remains unclear. This study was conducted to assess postoperative outcomes of anesthesia technique in geriatric patients undergoing hip fracture surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Cochrane Library, PubMed, EMBASE, MEDLINE, CNKI, and CBM were searched from inception up to May 25, 2018. Observational studies and randomized controlled trials (RCTs) that assessed the perioperative outcomes of technique of anesthesia (general or regional [epidural/spinal/neuraxial]) in geriatric patients (&#x2265;60 years old) undergoing hip fracture surgery were included. Two investigators independently screened studies for inclusion and performed data extraction. Heterogeneity was assessed by the I and Chi-square tests. The odds ratio (OR) of the dichotomous data, mean difference (MD) of continuous data, and 95% confidence intervals (CI) were calculated to assess the pooled data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eleven retrospective and 2 RCTs were included. There was no difference in 30-day mortality (OR&#x200a;=&#x200a;0.96; 95% CI 0.86-1.08; P&#x200a;=&#x200a;.51) between the general and regional anesthesia groups. In-hospital mortality (OR&#x200a;=&#x200a;1.26; 95% CI 1.17-1.36; P&#x200a;&lt;&#x200a;.001), acute respiratory failure (OR&#x200a;=&#x200a;2.66; 95% CI 2.34-3.02; P&#x200a;&lt;&#x200a;.001), length of hospital stay (MD&#x200a;=&#x200a;0.33; 95% CI 0.24-0.42; P&#x200a;&lt;&#x200a;.001), and readmission (OR&#x200a;=&#x200a;1.09; 95% CI 1.01-1.18; P&#x200a;=&#x200a;.03) were significantly reduced in the regional anesthesia group. Pneumonia (OR&#x200a;=&#x200a;0.99; 95% CI 0.91-1.07; P&#x200a;=&#x200a;.79), heart failure (OR&#x200a;=&#x200a;0.97; 95% CI 0.86-1.09; P&#x200a;=&#x200a;.62), acute myocardial infraction (OR&#x200a;=&#x200a;1.07; 95% CI 0.99-1.16; P&#x200a;=&#x200a;.10), acute renal failure (OR&#x200a;=&#x200a;1.32; 95% CI 0.97-1.79; P&#x200a;=&#x200a;.07), cerebrovascular accident (OR&#x200a;=&#x200a;1.08; 95% CI 0.82-1.42; P&#x200a;=&#x200a;.58), postoperative delirium (OR&#x200a;=&#x200a;1.51; 95% CI 0.16-13.97; P&#x200a;=&#x200a;.72), and deep vein thrombosis/pulmonary embolism (OR&#x200a;=&#x200a;1.42; 95% CI 0.84-2.38; P&#x200a;=&#x200a;.19) were similar between the two anesthetic techniques.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">General anesthesia is associated with increased risk of in-hospital mortality, acute respiratory failure, longer hospital stays, and higher readmission. There is evidence to suggest that regional anesthesia is associated with improved perioperative outcomes. Large RCTs are needed to explore the most optimal anesthetic techniques for geriatric patients with hip fractures before drawing final conclusions.</AbstractText><AbstractText Label="PROSPERO REGISTRATION NUMBER" NlmCategory="UNASSIGNED">CRD42018093582.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Dong Xu</ForeName><Initials>DX</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital, Sichuan University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital, Sichuan University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital, Sichuan University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shi Yue</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital, Sichuan University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Ya Na</ForeName><Initials>YN</Initials><AffiliationInfo><Affiliation>Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital, Sichuan University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000758" MajorTopicYN="N">Anesthesia</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006620" MajorTopicYN="N">Hip Fractures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>12</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31804347</ArticleId><ArticleId IdType="pmc">PMC6919429</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000018220</ArticleId><ArticleId IdType="pii">00005792-201912060-00046</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997;5:407&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9425497</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes WC, Myers ER, Robinovitch SN, et al. Etiology and prevention of age-related hip fractures. Bone 1996;18:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">8717551</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis EM, van der Velde R, Moon RJ, et al. Epidemiology of fractures in the United Kingdom 1988-2012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone 2016;87:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4890652</ArticleId><ArticleId IdType="pubmed">26968752</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Waesberghe J, Stevanovic A, Rossaint R, et al. General vs. neuraxial anaesthesia in hip fracture patients: a systematic review and meta-analysis. BMC Anesthesiol 2017;17:1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5490182</ArticleId><ArticleId IdType="pubmed">28659127</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell CM, McLoughlin L, Patterson CC, et al. Perioperative outcomes in the context of mode of anaesthesia for patients undergoing hip fracture surgery: systematic review and meta-analysis. Br J Anaesth 2018;120:37&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">29397135</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths R, Alper J, Beckingsale A, et al. Management of proximal femoral fractures 2011: association of anaesthetists of Great Britain and Ireland. Anaesthesia 2012;67:85&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">22150501</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansen A, Boulton C, Hertz K, et al. The National Hip Fracture Database (NHFD) &#x2013; using a national clinical audit to raise standards of nursing care. Int J Orthop Trauma Nurs 2017;26:3&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">28237620</ArticleId></ArticleIdList></Reference><Reference><Citation>Brauer CA, Coca-Perraillon M, Cutler DM, et al. Incidence and mortality of hip fractures in the United States. JAMA 2009;302:1573&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410861</ArticleId><ArticleId IdType="pubmed">19826027</ArticleId></ArticleIdList></Reference><Reference><Citation>Seitz DP, Gill SS, Bell CM, et al. Postoperative medical complications associated with anesthesia in older adults with dementia. J Am Geriatr Soc 2014;62:2102&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25370019</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai V, Chan PH, Prentice HA, et al. Is anesthesia technique associated with a higher risk of mortality or complications within 90 days of surgery for geriatric patients with hip fractures? Clin Orthop Relat Res 2018;476:1178&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6263607</ArticleId><ArticleId IdType="pubmed">29601378</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvani R, Martone AM, Marzetti E, et al. Pre-hospital dietary intake correlates with muscle mass at the time of fracture in older hip fractured patients. Front Aging Neurosci 2014;6:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4236534</ArticleId><ArticleId IdType="pubmed">25477815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman MD, Rosenbaum PR, Ludwig JM, et al. Anesthesia technique, mortality, and length of stay after hip fracture surgery. JAMA 2014;24:2508&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344128</ArticleId><ArticleId IdType="pubmed">25058085</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker MJ, Griffiths R. General versus regional anaesthesia for hip fractures. A pilot randomised controlled trial of 322 patients. Injury 2015;46:1562&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26049662</ArticleId></ArticleIdList></Reference><Reference><Citation>Luger TJ, Kammerlander C, Gosch M, et al. Neuroaxial versus general anaesthesia in geriatric patients for hip fracture surgery: does it matter? Osteoporos Int 2010;21:555&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21057995</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hara DA, Duff A, Berlin JA, et al. The effect of anesthetic technique on postoperative outcomes in hip fracture repair. Anesthesiology 2000;92:947&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">10754613</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson RL, Kopp SL, Burkle CM, et al. Neuraxial vs general anaesthesia for total hip and total knee arthroplasty: a systematic review of comparative-effectiveness research. Br J Anaesth 2016;116:163&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">26787787</ArticleId></ArticleIdList></Reference><Reference><Citation>White SM, Moppett IK, Griffiths R. Outcome by mode of anaesthesia for hip fracture surgery. An observational audit of 65 535 patients in a national dataset. Anaesthesia 2014;69:224&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">24428375</ArticleId></ArticleIdList></Reference><Reference><Citation>White SM, Altermatt F, Barry J, et al. International fragility fracture network delphi consensus statement on the principles of anaesthesia for patients with hip fracture. Anaesthesia 2018;73:863&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">29508382</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4320440</ArticleId><ArticleId IdType="pubmed">25554246</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ 2009;339:b2700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation> Wells GA, Shea B, O&#x2019;Connell D, et al. The Newcastle&#x2013;Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Available at:  http://wwwohrica/programs/clinicalepidemiology/oxfordasp. [Accessed May 5, 2012]</Citation></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hekimo&#x11f;lu &#x15e;S, Heybeli N, &#xc7;olak A, et al. Comparison of different anesthetic techniques on postoperative outcomes in elderly patients with hip fracture. Turkiye Klin J Med Sci 2012;32:623&#x2013;9.</Citation></Reference><Reference><Citation>Biboulet P, Jourdan A, Van Haevre V, et al. Hemodynamic profile of target-controlled spinal anesthesia compared with 2 target-controlled general anesthesia techniques in elderly patients with cardiac comorbidities. Reg Anesth Pain Med 2012;37:433&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22609644</ArticleId></ArticleIdList></Reference><Reference><Citation>Le-Wendling L, Bihorac A, Baslanti TO, et al. Regional anesthesia as compared with general anesthesia for surgery in geriatric patients with hip fracture: does it decrease morbidity, mortality, and health care costs? Results of a single-centered study. Pain Med 2012;13:948&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3730262</ArticleId><ArticleId IdType="pubmed">22758782</ArticleId></ArticleIdList></Reference><Reference><Citation>Basques BA, Bohl DD, Golinvaux NS, et al. General versus spinal anaesthesia for patients aged 70 years and older with a fracture of the hip. Bone Jt J 2015;97-B:689&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">25922465</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu CC, Weng SF, Chen KT, et al. Propensity score &#x2013; matched comparison of postoperative adverse outcomes between geriatric patients given a general or a neuraxial anesthetic for hip surgery: a population-based study. Anesthesiology 2015;123:136&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">25955981</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C, Chan PH, Zohman GL, et al. Impact of anesthesia on hospital mortality and morbidities in geriatric patients following emergency hip fracture surgery. J Orthop Trauma 2018;32:116&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">29461445</ArticleId></ArticleIdList></Reference><Reference><Citation>Casati A, Aldegheri G, Vinciguerra E, et al. Randomized comparison between sevoflurane anaesthesia and unilateral spinal anaesthesia in elderly patients undergoing orthopaedic surgery. Eur J Anaesthesiol 2003;20:640&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12932066</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda T, Imai S, Nakadera M, et al. Postoperative daily living activities of geriatric patients administered general or spinal anesthesia for hip fracture surgery: a retrospective cohort study. J Orthop Surg (Hong Kong) 2018;26:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29366390</ArticleId></ArticleIdList></Reference><Reference><Citation>Radcliff TA, Henderson WG, Stoner TJ, et al. Patient risk factors, operative care, and outcomes among older community-dwelling male veterans with hip fracture. J Bone Joint Surg Am 2008;90:34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">18171955</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih YJ, Hsieh CH, Kang TW, et al. General versus spinal anesthesia: which is a risk factor for octogenarian hip fracture repair patients? Int J Gerontol 2010;4:37&#x2013;42.</Citation></Reference><Reference><Citation>Guay J, Parker MJ, Gajendragadkar PR, et al. Anaesthesia for hip fracture surgery in adults. Cochrane Database Syst Rev 2016;2:CD000521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464323</ArticleId><ArticleId IdType="pubmed">26899415</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuman MD, Silber JH, Elkassabany NM, et al. Comparative effectiveness of regional versus general anesthesia for hip fracture surgery in adults. Anesthesiology 2012;117:72&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">22713634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieber FE, Gottshalk A, Zakriya KJ, et al. General anesthesia occurs frequently in elderly patients during propofol-based sedation and spinal anesthesia. J Clin Anesth 2010;22:179&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20400003</ArticleId></ArticleIdList></Reference><Reference><Citation>Memtsoudis SG, Poeran J, Zubizarreta N, et al. Do hospitals performing frequent neuraxial anesthesia for hip and knee replacements have better outcomes? Anesthesiology 2018;129:428&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">29878899</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak JC, Cameron ID, March LM. Evidence-based guidelines for the management of hip fractures in older persons: an update. Med J Aust 2010;192:37&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">20047547</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowark A, Adam C, Ahrens J, et al. Improve hip fracture outcome in the elderly patient (iHOPE): a study protocol for a pragmatic, multicentre randomised controlled trial to test the efficacy of spinal versus general anaesthesia. BMJ Open 2018;8:e023609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6196806</ArticleId><ArticleId IdType="pubmed">30341135</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32534329</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-2472</ISSN><JournalIssue CitedMedium="Internet"><Volume>193</Volume><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Thrombosis research</Title><ISOAbbreviation>Thromb Res</ISOAbbreviation></Journal><ArticleTitle>Assessment of the Bova score for risk stratification of acute normotensive pulmonary embolism: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>99</StartPage><EndPage>106</EndPage><MedlinePgn>99-106</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.thromres.2020.05.047</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0049-3848(20)30227-9</ELocationID><Abstract><AbstractText Label="BACKGROUND">Identification of normotensive pulmonary embolism (PE) at high risk of early adverse outcome is crucial for guiding treatment. Studies showed the Bova score had promising performance in stratifying normotensive PE.</AbstractText><AbstractText Label="METHODS">We conducted a systematic review and meta-analysis to evaluate the prognostic performance of the Bova score for normotensive PE.</AbstractText><AbstractText Label="RESULTS">Nine studies involving 8342 acute normotensive PE patients were enrolled. Overall, 71.4%, 20.2% and 8.4% patients were stratified as risk class I, II and III. Pooled incidence of short-term PE related composite adverse outcome of each group were 3.8%, 10.8% and 19.9%, respectively, exhibiting a significant rising trend. Increasing trends of 30-day and in-hospital composite adverse outcome rates, as well as PE related mortality, were also observed with upper risk classes. Compared with risk class I and II, high risk group (class III) was significantly associated with short-term PE related composite adverse outcome (OR: 5.45, 95% CI, 3.70-8.02) and PE related death (OR: 5.09, 95% CI, 3.54-7.30). Pooled sensitivity, specificity, positive likelihood ratio and negative likelihood ratio of the score for predicting short-term composite adverse outcome were 0.25 (95% CI, 0.22-0.29), 0.93 (95% CI, 0.92-0.93), 4.05 (95% CI, 2.90-5.67) and 0.81 (95% CI, 0.74-0.88), respectively. The weighted area under the summarized receiver characteristics operation curve for predicting composite adverse outcome was 0.73&#xa0;&#xb1;&#xa0;0.09.</AbstractText><AbstractText Label="CONCLUSION">The Bova score could effectively discriminate normotensive PE with different short-term prognosis and has good performance in identifying patients at higher risk of short-term adverse events.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xinwang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing, China; Beijing University of Chinese Medicine, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yunxia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing, China; Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Xincao</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing, China; Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhai</LastName><ForeName>Zhenguo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing, China. Electronic address: zhaizhenguo2011@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, National Clinical Research Center for Respiratory Diseases, Beijing, China; Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Thromb Res</MedlineTA><NlmUniqueID>0326377</NlmUniqueID><ISSNLinking>0049-3848</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bova score</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Risk assessment</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that there are no conflicts of interest involved in this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32534329</ArticleId><ArticleId IdType="doi">10.1016/j.thromres.2020.05.047</ArticleId><ArticleId IdType="pii">S0049-3848(20)30227-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">35264372</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>376</Volume><PubDate><Year>2022</Year><Month>Mar</Month><Day>09</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials.</ArticleTitle><Pagination><StartPage>e066785</StartPage><MedlinePgn>e066785</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e066785</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj-2021-066785</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To systematically compare the effect of direct oral anticoagulants and low molecular weight heparin for thromboprophylaxis on the benefits and harms to patients undergoing non-cardiac surgery.</AbstractText><AbstractText Label="DESIGN">Systematic review and network meta-analysis of randomised controlled trials.</AbstractText><AbstractText Label="DATA SOURCES">Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL), up to August 2021.</AbstractText><AbstractText Label="REVIEW METHODS">Randomised controlled trials in adults undergoing non-cardiac surgery were selected, comparing low molecular weight heparin (prophylactic (low) or higher dose) with direct oral anticoagulants or with no active treatment. Main outcomes were symptomatic venous thromboembolism, symptomatic pulmonary embolism, and major bleeding. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for network meta-analyses. Abstracts and full texts were screened independently in duplicate. Data were abstracted on study participants, interventions, and outcomes, and risk of bias was assessed independently in duplicate. Frequentist network meta-analysis with multivariate random effects models provided odds ratios with 95% confidence intervals, and GRADE (grading of recommendations, assessment, development, and evaluation) assessments indicated the certainty of the evidence.</AbstractText><AbstractText Label="RESULTS">68 randomised controlled trials were included (51 orthopaedic, 10 general, four gynaecological, two thoracic, and one urological surgery), involving 45&#x2009;445 patients. Low dose (odds ratio 0.33, 95% confidence interval 0.16 to 0.67) and high dose (0.19, 0.07 to 0.54) low molecular weight heparin, and direct oral anticoagulants (0.17, 0.07 to 0.41) reduced symptomatic venous thromboembolism compared with no active treatment, with absolute risk differences of 1-100 per 1000 patients, depending on baseline risks (certainty of evidence, moderate to high). None of the active agents reduced symptomatic pulmonary embolism (certainty of evidence, low to moderate). Direct oral anticoagulants and low molecular weight heparin were associated with a 2-3-fold increase in the odds of major bleeding compared with no active treatment (certainty of evidence, moderate to high), with absolute risk differences as high as 50 per 1000 in patients at high risk. Compared with low dose low molecular weight heparin, high dose low molecular weight heparin did not reduce symptomatic venous thromboembolism (0.57, 0.26 to 1.27) but increased major bleeding (1.87, 1.06 to 3.31); direct oral anticoagulants reduced symptomatic venous thromboembolism (0.53, 0.32 to 0.89) and did not increase major bleeding (1.23, 0.89 to 1.69).</AbstractText><AbstractText Label="CONCLUSIONS">Direct oral anticoagulants and low molecular weight heparin reduced venous thromboembolism compared with no active treatment but probably increased major bleeding to a similar extent. Direct oral anticoagulants probably prevent symptomatic venous thromboembolism to a greater extent than prophylactic low molecular weight heparin.</AbstractText><AbstractText Label="SYSTEMATIC REVIEW REGISTRATION">PROSPERO CRD42018106181.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marcucci</LastName><ForeName>Maura</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8468-7991</Identifier><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada marcum2@mcmaster.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Research Institute, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etxeandia-Ikobaltzeta</LastName><ForeName>Itziar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Jewish General Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Germini</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Shyla</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Kingston Health Sciences Centre, Queen's University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Arnav</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ventresca</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Shaowen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Nanjing Medical University, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgano</LastName><ForeName>Gian Paolo</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Mengxiao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Science, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mathematics, University of Waterloo, Waterloo, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Muhammad Muneeb</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago de Chile, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izcovich</LastName><ForeName>Ariel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Alem&#xe1;n, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Criniti</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Alem&#xe1;n, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popoff</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hospital Alem&#xe1;n, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devereaux</LastName><ForeName>P J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Research Institute, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahm</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Minneapolis Veterans Affair Health Care System, Urology Section, Minneapolis, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Minnesota, Department of Urology, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavikainen</LastName><ForeName>Lauri I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tikkinen</LastName><ForeName>Kari A O</ForeName><Initials>KAO</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, South Karelian Central Hospital, Lappeenranta, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guyatt</LastName><ForeName>Gordon H</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xfc;nemann</LastName><ForeName>Holger J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Michael DeGroote Cochrane Canada Centre-Department of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Violette</LastName><ForeName>Philippe D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013514" MajorTopicYN="N">Surgical Procedures, Operative</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: no specific support for the submitted work; PDV received support from the Canadian Urological Association Scholarship Foundation for his work relevant to this study; FG&#x2019;s institution received research funding from F Hoffmann-La Roche, Novo Nordisk, Takeda, Pfizer, and Bayer, all outside the submitted work; PJD reports grants from Abbott Diagnostics, Boehringer-Ingelheim, Roche Diagnostics, and Siemens and non-financial support from Philips Healthcare outside the submitted work; no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>10</Day><Hour>5</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35264372</ArticleId><ArticleId IdType="pmc">PMC8905353</ArticleId><ArticleId IdType="doi">10.1136/bmj-2021-066785</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weiser TG, Haynes AB, Molina G, et al. . Estimate of the global volume of surgery in 2012: an assessment supporting improved health outcomes. Lancet 2015;385(Suppl 2):S11. 10.1016/S0140-6736(15)60806-6.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)60806-6</ArticleId><ArticleId IdType="pubmed">26313057</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon RJ, Lombard FW. Perioperative venous thromboembolism: a review. Anesth Analg 2017;125:403-12. 10.1213/ANE.0000000000002183.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000002183</ArticleId><ArticleId IdType="pubmed">28640782</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapoor A, Ellis A, Shaffer N, et al. . Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost 2017;15:284-94. 10.1111/jth.13566.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13566</ArticleId><ArticleId IdType="pmc">PMC5305416</ArticleId><ArticleId IdType="pubmed">28102615</ArticleId></ArticleIdList></Reference><Reference><Citation>Mismetti P, Laporte S, Darmon JY, Buchm&#xfc;ller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913-30. 10.1046/j.0007-1323.2001.01800.x.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0007-1323.2001.01800.x</ArticleId><ArticleId IdType="pubmed">11442521</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahn DD, Mamik MM, Sanses TVD, et al. Society of Gynecologic Surgeons Systematic Review Group . Venous thromboembolism prophylaxis in gynecologic surgery: a systematic review. Obstet Gynecol 2011;118:1111-25. 10.1097/AOG.0b013e318232a394.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0b013e318232a394</ArticleId><ArticleId IdType="pubmed">22015880</ArticleId></ArticleIdList></Reference><Reference><Citation>Falck-Ytter Y, Francis CW, Johanson NA, et al. . Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl):e278S-325S. 10.1378/chest.11-2404&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2404</ArticleId><ArticleId IdType="pmc">PMC3278063</ArticleId><ArticleId IdType="pubmed">22315265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould MK, Garcia DA, Wren SM, et al. . Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl):e227S-77S. 10.1378/chest.11-2297&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-2297</ArticleId><ArticleId IdType="pmc">PMC3278061</ArticleId><ArticleId IdType="pubmed">22315263</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson DR, Morgano GP, Bennett C, et al. . American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 2019;3:3898-944. 10.1182/bloodadvances.2019000975.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2019000975</ArticleId><ArticleId IdType="pmc">PMC6963238</ArticleId><ArticleId IdType="pubmed">31794602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozek-Langenecker S, Fenger-Eriksen C, Thienpont E, Barauskas G, ESA VTE Guidelines Task Force . European guidelines on perioperative venous thromboembolism prophylaxis: surgery in the elderly. Eur J Anaesthesiol 2018;35:116-22. 10.1097/EJA.0000000000000705.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000705</ArticleId><ArticleId IdType="pubmed">28901992</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. Guidelines. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. 2019. https://www.nice.org.uk/guidance/ng89.</Citation><ArticleIdList><ArticleId IdType="pubmed">32924386</ArticleId></ArticleIdList></Reference><Reference><Citation>Mont MA, Jacobs JJ. AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg 2011;19:777-8. 10.5435/00124635-201112000-00008.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.5435/00124635-201112000-00008</ArticleId><ArticleId IdType="pubmed">22134210</ArticleId></ArticleIdList></Reference><Reference><Citation>Tikkinen KAO, Craigie S, Agarwal A, et al. . Procedure-specific risks of thrombosis and bleeding in urological cancer surgery: systematic review and meta-analysis. Eur Urol 2018;73:242-51. 10.1016/j.eururo.2017.03.008.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eururo.2017.03.008</ArticleId><ArticleId IdType="pubmed">28342641</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal&#xe0; M, Falanga A, Roila F, ESMO Guidelines Working Group . Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22(Suppl 6):vi85-92. 10.1093/annonc/mdr392.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdr392</ArticleId><ArticleId IdType="pubmed">21908511</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyman GH, Bohlke K, Khorana AA, et al. American Society of Clinical Oncology . Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol 2015;33:654-6. 10.1200/JCO.2014.59.7351.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.59.7351</ArticleId><ArticleId IdType="pmc">PMC4881372</ArticleId><ArticleId IdType="pubmed">25605844</ArticleId></ArticleIdList></Reference><Reference><Citation>Violette PD, Lavall&#xe9;e LT, Kassouf W, Gross PL, Shayegan B. Canadian Urological Association guideline: Perioperative thromboprophylaxis and management of anticoagulation. Can Urol Assoc J 2019;13:105-14. 10.5489/cuaj.5828.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.5489/cuaj.5828</ArticleId><ArticleId IdType="pmc">PMC6456347</ArticleId><ArticleId IdType="pubmed">30575517</ArticleId></ArticleIdList></Reference><Reference><Citation>Tikkinen KAO, Cartwright R, Gould MK, et al. Thromboprophylaxis in urological surgery. European Association of Urology Guidelines Office 2017. https://uroweb.org/guideline/thromboprophylaxis/
</Citation></Reference><Reference><Citation>Al Rawahi B, Le Gal G, Auer R, Carrier M. A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients post major abdominal surgery. Thromb J 2017;15:2. 10.1186/s12959-016-0126-9.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-016-0126-9</ArticleId><ArticleId IdType="pmc">PMC5237241</ArticleId><ArticleId IdType="pubmed">28100960</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson DW, Simianu VV, Bastawrous AL, et al. Colorectal Writing Group for Surgical Care and Outcomes Assessment Program-Comparative Effectiveness Research Translation Network (SCOAP-CERTAIN) Collaborative . Thromboembolic complications and prophylaxis patterns in colorectal surgery. JAMA Surg 2015;150:712-20. 10.1001/jamasurg.2015.1057.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2015.1057</ArticleId><ArticleId IdType="pmc">PMC4545402</ArticleId><ArticleId IdType="pubmed">26060977</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund L, Nisen H, J&#xe4;rvinen P, et al. . Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA-2 study). Res Rep Urol 2018;10:181-7. 10.2147/RRU.S177774.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/RRU.S177774</ArticleId><ArticleId IdType="pmc">PMC6209070</ArticleId><ArticleId IdType="pubmed">30464929</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A, Kraus PS, Lau BD, et al. . Patient preferences regarding pharmacologic venous thromboembolism prophylaxis. J Hosp Med 2015;10:108-11. 10.1002/jhm.2282.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jhm.2282</ArticleId><ArticleId IdType="pubmed">25418208</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimminiello C, Anderson FA, Jr. Physician and patient perceptions of the route of administration of venous thromboembolism prophylaxis: results from an international survey. Thromb Res 2012;129:139-45. 10.1016/j.thromres.2011.07.017.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2011.07.017</ArticleId><ArticleId IdType="pubmed">21816454</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan&#xe9;elle D, Le Brun C, Mauger C, et al. SFMV VTE Study Group . Patient characteristics and preferences regarding anticoagulant treatment in venous thromboembolic disease. Front Cardiovasc Med 2021;8:675969. 10.3389/fcvm.2021.675969.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.675969</ArticleId><ArticleId IdType="pmc">PMC8255622</ArticleId><ArticleId IdType="pubmed">34235186</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton B, Salanti G, Caldwell DM, et al. . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84. 10.7326/M14-2385.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-2385</ArticleId><ArticleId IdType="pubmed">26030634</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900. 10.1136/bmj.331.7521.897.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.331.7521.897</ArticleId><ArticleId IdType="pmc">PMC1255806</ArticleId><ArticleId IdType="pubmed">16223826</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thomas J, eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Updated February 2021. https://training.cochrane.org/handbook/current
</Citation></Reference><Reference><Citation>Lim W, Le Gal G, Bates SM, et al. . American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv 2018;2:3226-56. 10.1182/bloodadvances.2018024828.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2018024828</ArticleId><ArticleId IdType="pmc">PMC6258916</ArticleId><ArticleId IdType="pubmed">30482764</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;nemann HJ, Cushman M, Burnett AE, et al. . American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018;2:3198-225. 10.1182/bloodadvances.2018022954.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2018022954</ArticleId><ArticleId IdType="pmc">PMC6258910</ArticleId><ArticleId IdType="pubmed">30482763</ArticleId></ArticleIdList></Reference><Reference><Citation>Monagle P, Cuello CA, Augustine C, et al. . American Society of Hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018;2:3292-316. 10.1182/bloodadvances.2018024786.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2018024786</ArticleId><ArticleId IdType="pmc">PMC6258911</ArticleId><ArticleId IdType="pubmed">30482766</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiercioch W, Nieuwlaat R, Akl EA, et al. . Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. Blood Adv 2020;4:2351-65. 10.1182/bloodadvances.2020001768.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020001768</ArticleId><ArticleId IdType="pmc">PMC7252554</ArticleId><ArticleId IdType="pubmed">32453843</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JA, Bodalia PN, Bryden PA, et al. . Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess 2017;21:1-386. 10.3310/hta21090.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/hta21090</ArticleId><ArticleId IdType="pmc">PMC5366855</ArticleId><ArticleId IdType="pubmed">28279251</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, et al. Cochrane Bias Methods Group. Cochrane Statistical Methods Group . The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. 10.1136/bmj.d5928.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhan MA, Sch&#xfc;nemann HJ, Murad MH, et al. GRADE Working Group . A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. 10.1136/bmj.g5630.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g5630</ArticleId><ArticleId IdType="pubmed">25252733</ArticleId></ArticleIdList></Reference><Reference><Citation>Brignardello-Petersen R, Bonner A, Alexander PE, et al. GRADE Working Group . Advances in the GRADE approach to rate the certainty in estimates from&#xa0;a network meta-analysis. J Clin Epidemiol 2018;93:36-44. 10.1016/j.jclinepi.2017.10.005.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2017.10.005</ArticleId><ArticleId IdType="pubmed">29051107</ArticleId></ArticleIdList></Reference><Reference><Citation>Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE working group . GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 2020;371:m3900. 10.1136/bmj.m3900.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3900</ArticleId><ArticleId IdType="pubmed">33177059</ArticleId></ArticleIdList></Reference><Reference><Citation>White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 2012;3:111-25. 10.1002/jrsm.1045.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1045</ArticleId><ArticleId IdType="pmc">PMC4433771</ArticleId><ArticleId IdType="pubmed">26062085</ArticleId></ArticleIdList></Reference><Reference><Citation>White IR. Multivariate random-effects meta-regression: Updates to mvmeta. Stata J 2011;11:255-70. 10.1177/1536867X1101100206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1536867X1101100206</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8:e76654. 10.1371/journal.pone.0076654.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0076654</ArticleId><ArticleId IdType="pmc">PMC3789683</ArticleId><ArticleId IdType="pubmed">24098547</ArticleId></ArticleIdList></Reference><Reference><Citation>Seide SE, Jensen K, Kieser M. A comparison of bayesian and frequentist methods in random-effects network meta-analysis of binary data. Res Synth Methods 2020;11:363-78. 10.1002/jrsm.1397.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jrsm.1397</ArticleId><ArticleId IdType="pubmed">31955519</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghirad B, Brignardello-Petersen R, Johnston BC, Guyatt GH, Beyene J. Comparing bayesian and frequentist approaches for network meta-analysis: an empirical study. Abstracts of the Global Evidence Summit, Cape Town, South Africa. Cochrane Database Syst Rev 2017;(9 Suppl 1). 10.1002/14651858.CD201702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD201702</ArticleId></ArticleIdList></Reference><Reference><Citation>Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71. 10.1016/j.jclinepi.2010.03.016.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2010.03.016</ArticleId><ArticleId IdType="pubmed">20688472</ArticleId></ArticleIdList></Reference><Reference><Citation>Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol 2009;62:857-64. 10.1016/j.jclinepi.2008.10.001.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2008.10.001</ArticleId><ArticleId IdType="pubmed">19157778</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntupalli SR, Brennecke A, Behbakht K, et al. . Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial. JAMA Netw Open 2020;3:e207410. 10.1001/jamanetworkopen.2020.7410.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.7410</ArticleId><ArticleId IdType="pmc">PMC7320298</ArticleId><ArticleId IdType="pubmed">32589230</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley RD, Jackson D, Salanti G, et al. . Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples. BMJ 2017;358:j3932. 10.1136/bmj.j3932.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j3932</ArticleId><ArticleId IdType="pmc">PMC5596393</ArticleId><ArticleId IdType="pubmed">28903924</ArticleId></ArticleIdList></Reference><Reference><Citation>Dar TI, Wani KA, Ashraf M, et al. . Low molecular weight heparin in prophylaxis of deep vein thrombosis in Asian general surgical patients: A Kashmir experience. Indian J Crit Care Med 2012;16:71-4. 10.4103/0972-5229.99107.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-5229.99107</ArticleId><ArticleId IdType="pmc">PMC3439781</ArticleId><ArticleId IdType="pubmed">22988360</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YH, Qiu H, He XL, Sun XW. Prevention of venous thromboembolism after resection of primary liver cancer with low molecular weight heparin and its association with P-selectin, lysosomal granule glycoprotein, platelet activating factor and plasma D-dimer. Eur Rev Med Pharmacol Sci 2018;22:4657-62. 10.26355/eurrev_201807_15525.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_201807_15525</ArticleId><ArticleId IdType="pubmed">30058703</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainwright TW, Gill M, McDonald DA, et al. . Consensus statement for perioperative care in total hip replacement and total knee replacement surgery: Enhanced Recovery After Surgery (ERAS&#xae;) Society recommendations. Acta Orthop 2020;91:3-19. 10.1080/17453674.2019.1683790.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17453674.2019.1683790</ArticleId><ArticleId IdType="pmc">PMC7006728</ArticleId><ArticleId IdType="pubmed">31663402</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafsson UO, Scott MJ, Schwenk W, et al. Enhanced Recovery After Surgery (ERAS) Society, for Perioperative Care. European Society for Clinical Nutrition and Metabolism (ESPEN) International Association for Surgical Metabolism and Nutrition (IASMEN) . Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(&#xae;)) Society recommendations. World J Surg 2013;37:259-84. 10.1007/s00268-012-1772-0.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-012-1772-0</ArticleId><ArticleId IdType="pubmed">23052794</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen K, Nilsson M, Slim K, et al. Enhanced Recovery After Surgery (ERAS&#xae;) Group . Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS&#xae;) Society recommendations. Br J Surg 2014;101:1209-29. 10.1002/bjs.9582.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9582</ArticleId><ArticleId IdType="pubmed">25047143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis S, Glen J, Dawoud D, et al. . Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. Lancet Haematol 2019;6:e530-9. 10.1016/S2352-3026(19)30155-3.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(19)30155-3</ArticleId><ArticleId IdType="pubmed">31444124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen A, Drost P, Marchant N, et al. . The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. Clin Appl Thromb Hemost 2012;18:611-27. 10.1177/1076029612437579.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029612437579</ArticleId><ArticleId IdType="pubmed">22387582</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann I, Rada G, Claro JC, et al. . Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med 2012;156:710-9. 10.7326/0003-4819-156-10-201205150-00421.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-156-10-201205150-00421</ArticleId><ArticleId IdType="pubmed">22412038</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobieraj DM, Coleman CI, Tongbram V, et al. . Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis. Pharmacotherapy 2012;32:799-808. 10.1002/j.1875-9114.2012.01106.x.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1875-9114.2012.01106.x</ArticleId><ArticleId IdType="pubmed">22744711</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X, Lin J. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis. BMC Musculoskelet Disord 2018;19:322. 10.1186/s12891-018-2215-3.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12891-018-2215-3</ArticleId><ArticleId IdType="pmc">PMC6129001</ArticleId><ArticleId IdType="pubmed">30193575</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun G, Wu J, Wang Q, et al. . Factor Xa inhibitors and direct thrombin inhibitors versus low-molecular-weight heparin for thromboprophylaxis after total hip or total knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty 2019;34:789-800.e6. 10.1016/j.arth.2018.11.029.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2018.11.029</ArticleId><ArticleId IdType="pubmed">30685261</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng W, Wang X, Huang D, Lu A. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis. Pharmacol Res 2021;166:105438. 10.1016/j.phrs.2021.105438.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105438</ArticleId><ArticleId IdType="pubmed">33540046</ArticleId></ArticleIdList></Reference><Reference><Citation>Violette PD, Cartwright R, Devereaux PJ, et al. . ARTS: A Large, International Trial of Thromboprophylaxis in Intra-abdominal, Gynecologic, and Urologic Surgery. Eur Urol Focus 2021;7:1222-5. 10.1016/j.euf.2021.08.010.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euf.2021.08.010</ArticleId><ArticleId IdType="pubmed">34556452</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavikainen LI, Guyatt GH, Lee Y, et al. . Systematic reviews of observational studies of Risk of Thrombosis and Bleeding in General and Gynecologic Surgery (ROTBIGGS): introduction and methodology. Syst Rev 2021;10:264. 10.1186/s13643-021-01814-2.&#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-021-01814-2</ArticleId><ArticleId IdType="pmc">PMC8499502</ArticleId><ArticleId IdType="pubmed">34625092</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32006929</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-6968</ISSN><JournalIssue CitedMedium="Internet"><Volume>191</Volume><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Clinical neurology and neurosurgery</Title><ISOAbbreviation>Clin Neurol Neurosurg</ISOAbbreviation></Journal><ArticleTitle>The use of intermittent pneumatic compression to prevent venous thromboembolism in neurosurgical patients-A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>105694</StartPage><MedlinePgn>105694</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clineuro.2020.105694</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0303-8467(20)30037-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The incidence of venous thromboembolism (VTE) remains high despite the use of low-molecular weight heparin (LMWH) and compression stocking (CS). We aimed to evaluate the use of IPC as VTE prophylaxis in neurosurgical patients.</AbstractText><AbstractText Label="PATIENTS AND METHODS">We conducted meta-analysis to assess the use of IPC as VTE prophylaxis in neurosurgical patients from several databases.</AbstractText><AbstractText Label="RESULTS">There was a total of 7.515 subjects from 5 studies. Reduction in VTE incidence was demonstrated by the IPC group (OR 0.40 [0.31, 0.52], p&#x202f;&lt;&#x202f;0.001; I<sup>2</sup>: 44 %). IPC was shown to reduce the incidence of deep venous thrombosis (DVT) (OR 0.43 [0.32, 0.57], p&#x202f;&lt;&#x202f;0.001; I<sup>2</sup>: 0 %) compared to the control group. Incidence of pulmonary embolism (PE) was lower (OR 0.42 [0.25, 0.70], p&#x202f;&lt;&#x202f;0.001; I<sup>2</sup>: 80 %) in IPC. Upon sensitivity analysis, PE was significantly lower in IPC (OR 0.24 [0.13, 0.45], p&#x202f;&lt;&#x202f;0.001; I<sup>2</sup>: 0 %). Subgroup analysis on patients undergoing neurosurgical intervention (operation) and receiving LMWH&#x202f;+&#x202f;CS shows a markedly reduced incidence of VTE (OR 0.37 [0.28, 0.50], p&#x202f;&lt;&#x202f;0.001; I<sup>2</sup>: 3 %), DVT (OR 0.39 [0.28, 0.54], p&#x202f;&lt;&#x202f;0.001; I<sup>2</sup>: 0 %), and PE (OR 0.22 [0.11, 0.43], p&#x202f;&lt;&#x202f;0.001; I<sup>2</sup>: 0 %) in IPC.</AbstractText><AbstractText Label="CONCLUSION">Intermittent pneumatic compression was associated with less VTE in neurosurgical patients, especially in those who received neurosurgical interventions, however, the certainty of evidence remained inadequate for creating a strong recommendation and further randomized controlled trials are needed before drawing a definite conclusion.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pranata</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia. Electronic address: raymond_pranata@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deka</LastName><ForeName>Hadrian</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Universitas Gadjah Mada, Jogjakarta, Indonesia. Electronic address: Hadrian.deka@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yonas</LastName><ForeName>Emir</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Universitas YARSI, Jakarta, Indonesia. Electronic address: E_yonas@windowslive.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vania</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia. Electronic address: Rachel.vania@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tondas</LastName><ForeName>Alexander Edo</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Cardiology and Vascular Medicine, Mohammad Hoesin General Hospital, Palembang, Sumatera Selatan, Indonesia; Biomedicine Doctoral Program, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia. Electronic address: edotondas@fk.unsri.ac.id.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lukito</LastName><ForeName>Antonia Anna</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia; Department of Cardiology and Vascular Medicine, Siloam Hospitals Lippo Village, Tangerang, Indonesia. Electronic address: Antonia.lukito@uph.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>July</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, Medical Faculty of Pelita Harapan University, Lippo Village Tangerang, Neuroscience Centre Siloam Hospital, Lippo Village Tangerang, Indonesia. Electronic address: juliusjuly@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Neurol Neurosurg</MedlineTA><NlmUniqueID>7502039</NlmUniqueID><ISSNLinking>0303-8467</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048228" MajorTopicYN="Y">Intermittent Pneumatic Compression Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019635" MajorTopicYN="Y">Neurosurgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019990" MajorTopicYN="N">Perioperative Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053828" MajorTopicYN="N">Stockings, Compression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Craniotomy</Keyword><Keyword MajorTopicYN="N">Deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">Intermittent pneumatic compression</Keyword><Keyword MajorTopicYN="N">Neurosurgery</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword><Keyword MajorTopicYN="N">Thromboprophylaxis</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32006929</ArticleId><ArticleId IdType="doi">10.1016/j.clineuro.2020.105694</ArticleId><ArticleId IdType="pii">S0303-8467(20)30037-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40957972</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-2218</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>16</Day></PubDate></JournalIssue><Title>Surgical endoscopy</Title><ISOAbbreviation>Surg Endosc</ISOAbbreviation></Journal><ArticleTitle>Surgical synergy or complication catalyst? Evaluating a meta-analysis of concomitant bariatric surgery and ventral hernia repair.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00464-025-12207-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Obesity has become a global comorbidity with increasing prevalence over the last decade. It is associated with an elevated risk for the development of ventral hernias. Bariatric surgery aims to address obesity through surgical intervention, which has become increasingly safe over time. However, a comparative meta-analysis with a double-arm evaluation of concomitant ventral hernia repair (VHR) and weight loss surgery is not yet available in the literature. Hence, we performed a systematic review and meta-analysis of simultaneous VHR and bariatric surgery.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Cochrane, Embase, Scopus, Scielo, and PubMed were systematically searched for studies comparing concomitant bariatric surgery and VHR with bariatric surgery alone or staged repair. Outcomes assessed for comparative meta-analysis were surgical site infection (SSI), dehiscence, readmission and reoperation, deep venous thrombosis (DVT) and pulmonary embolism (PE), overall mortality, operative time, and length of hospital stay (LOS). SSI was also analyzed separately as a superficial or deep infection. We also performed a single-arm meta-analysis of incarceration within the staged repair groups with a bariatric surgery as the first procedure and a single-arm meta-analysis of recurrence following concomitant bariatric surgery and VHR. Statistical analysis was performed with R Studio.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">805 studies were screened and 26 were thoroughly reviewed. Six studies were included, comprising a total of 131,323 patients, of whom 3002 (2.3%) underwent simultaneous bariatric and VHR procedures. Simultaneous repair was associated with an increase of 39.4&#xa0;min (95% CI 26.17 to 52.63; p&#x2009;&lt;&#x2009;0.01) in the operative time. We found an increased readmission rate for the concomitant procedures (OR 1.48; 95% CI 1.1 to 1.99; p&#x2009;&lt;&#x2009;0.01), but no differences were found in reoperation rates (OR 2.97; 95% CI 1.0 to 8.84; p&#x2009;=&#x2009;0.05). Concomitant procedures were also associated with higher DVT (OR 2.54; 95% CI 1.36 to 4.72; p&#x2009;&lt;&#x2009;0.01) and PE rates compared to separated procedures (OR 3.08; 95% CI 1.57 to 6.05; p&#x2009;&lt;&#x2009;0.01). No differences were found in overall SSI (OR 1.1; 95% CI 0.59 to 2.12; p&#x2009;=&#x2009;0.74) and superficial (OR 0.94; 95% CI 0.48 to 1.84; p&#x2009;=&#x2009;0.86) or deep (OR 7.02; 95% CI 0.36 to 136.1; p&#x2009;=&#x2009;0.2) SSI. No statistically significant differences were found in dehiscence rates between the groups (OR 0.2; 95% CI 0.01 to 4.16; p&#x2009;=&#x2009;0.3). Concomitant procedures were associated with an increase of 0.35&#xa0;days in LOS (95% CI 0.1 to 0.59; p&#x2009;=&#x2009;0.004) and with increased mortality odds (OR 3.99; 95% CI 1.92 to 8.3; p&#x2009;&lt;&#x2009;0.01). The proportional meta-analysis found an incarceration rate of 22.95 (95% CI 10.9 to 42) for the patients who delayed the VHR and a recurrence rate of 7.61 per 100 patients (95% CI 1.6 to 29.6) for the patients who underwent concomitant surgery.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our systematic review and meta-analysis found an increase in DVT, PE, readmission, operative time, LOS, and mortality for concomitant procedures. Incarceration rates of 22.95 were found for delayed VHR. Further research is needed to analyze individual bariatric surgery and VHR techniques and draw a more precise conclusion on this subject.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Balthazar da Silveira</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Dignity Health St. Joseph's Hospital, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasador</LastName><ForeName>Ana C D</ForeName><Initials>ACD</Initials><AffiliationInfo><Affiliation>Dignity Health St. Joseph's Hospital, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidotto</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Anhembi Morumbi University, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nogueira</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgery, Montefiore Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott Melvin</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Surgery, Montefiore Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camacho</LastName><ForeName>Diego</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, Montefiore Medical Center, Bronx, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lima</LastName><ForeName>Diego L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0001-7383-1284</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Montefiore Medical Center, Bronx, NY, USA. dilaurentino@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Surg Endosc</MedlineTA><NlmUniqueID>8806653</NlmUniqueID><ISSNLinking>0930-2794</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bariatric surgery</Keyword><Keyword MajorTopicYN="N">Incisional hernia</Keyword><Keyword MajorTopicYN="N">Ventral hernia</Keyword></KeywordList><CoiStatement>Declarations. Disclosures: Carlos A. B. Silveira, Ana C. D. Rasador, Laura Vidotto, Raquel Nogueira, W. Scott Melvin, Diego Camacho, and Diego L. Lima have no conflicts of interest or financial ties to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40957972</ArticleId><ArticleId IdType="doi">10.1007/s00464-025-12207-0</ArticleId><ArticleId IdType="pii">10.1007/s00464-025-12207-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Boutari C, Mantzoros CS (2022) A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism 133:155217</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2022.155217</ArticleId><ArticleId IdType="pubmed">35584732</ArticleId><ArticleId IdType="pmc">9107388</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock DJ, Wu N, Grimsby JS, Calle RA, Donahue S, Glass DJ et al (2022) The prevalence of low muscle mass associated with obesity in the USA. Skelet Muscle 12(1):26</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13395-022-00309-5</ArticleId><ArticleId IdType="pubmed">36539856</ArticleId><ArticleId IdType="pmc">9769063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazurro S, Ball L, Pelosi P (2018) Perioperative management of obese patient. Curr Opin Crit Care 24(6):560&#x2013;567</Citation><ArticleIdList><ArticleId IdType="pubmed">30299311</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S, Dai Y, Huang M (2024) Association between obesity and risk of delayed discharge and unplanned readmission for day surgery: a systematic review and meta-analysis. Int J Nurs Pract 30(3):113203</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijn.13203</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouwels S, Buise MP, Twardowski P, Stepaniak PS, Proczko M (2019) Obesity surgery and anesthesiology risks: a review of key concepts and related physiology. Obes Surg 29(8):2670&#x2013;2677</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11695-019-03952-y</ArticleId><ArticleId IdType="pubmed">31127496</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirapinyo P, Thompson CC (2022) Primary bariatric procedures. Dig Dis Sci 67(5):1674&#x2013;1687</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-022-07393-z</ArticleId><ArticleId IdType="pubmed">35348970</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien PE (2015) Controversies in bariatric surgery. Br J Surg 102(6):611&#x2013;618</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9760</ArticleId><ArticleId IdType="pubmed">25690271</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Wu Q, Guo N, Liu L, Widjaja J, Yang J et al (2024) Causal relationship of obesity and adiposity distribution on risk of ventral hernia. World J Surg 48(5):1141&#x2013;1148</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wjs.12137</ArticleId><ArticleId IdType="pubmed">38520680</ArticleId></ArticleIdList></Reference><Reference><Citation>Moszkowicz D, Jacota M, Nkam L, Giovinazzo D, Grimaldi L, Lazzati A (2021) Ventral hernia repair and obesity: results from a nationwide register study in France according to the timeframes of hernia repair and bariatric surgery. Obes Surg 31(12):5251&#x2013;5259</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11695-021-05720-3</ArticleId><ArticleId IdType="pubmed">34606046</ArticleId></ArticleIdList></Reference><Reference><Citation>Julliard O, Hauters P, Possoz J, Malvaux P, Landenne J, Gherardi D (2016) Incisional hernia after single-incision laparoscopic cholecystectomy: incidence and predictive factors. Surg Endosc 30(10):4539&#x2013;4543</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-016-4790-4</ArticleId><ArticleId IdType="pubmed">26895902</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds.) (2023) Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). Cochrane</Citation></Reference><Reference><Citation>Sterne JA, Hern&#xe1;n MA, Reeves BC, Savovi&#x107; J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 12:i4919</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudsi OY, Kaoukabani G, Bou-Ayash N, Gokcal F (2023) Robotic ventral hernia repair and concomitant procedures: mid-term outcomes and risk factors associated with postoperative complications. Surg Laparosc Endosc Percutan Tech 33(1):27&#x2013;30. https://doi.org/10.1097/SLE.0000000000001140</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLE.0000000000001140</ArticleId><ArticleId IdType="pubmed">36728686</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J, Cornejo J, Zevallos A, Sarmiento J, Powell J, Shojaeian F, Mokhtari-Esbuie F, Adrales G, Li C, Sebastian R (2024) Concurrent minimally invasive bariatric surgery and ventral hernia repair with mesh; is it safe? Propensity score matching analysis using the 2015&#x2013;2022 MBSAQIP database. Surg Endosc 38(12):7544&#x2013;7551. https://doi.org/10.1007/s00464-024-11260-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-024-11260-5</ArticleId><ArticleId IdType="pubmed">39289227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma G, Boules M, Punchai S, Strong A, Froylich D, Zubaidah NH, O&#x2019;Rourke C, Brethauer SA, Rodriguez J, El-Hayek K, Kroh M (2017) Outcomes of concomitant ventral hernia repair performed during bariatric surgery. Surg Endosc 31(4):1573&#x2013;1582. https://doi.org/10.1007/s00464-016-5143-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-016-5143-z</ArticleId><ArticleId IdType="pubmed">27495345</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xf6;hler I, R&#xf6;der D, Schlesinger T, Nassen CA, Germer CT, Wiegering A, Lock JF (2023) Risk-adjusted perioperative bridging anticoagulation reduces bleeding complications without increasing thromboembolic events in general and visceral surgery. BMC Anesthesiol 23(1):56. https://doi.org/10.1186/s12871-023-02017-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12871-023-02017-z</ArticleId><ArticleId IdType="pubmed">36797688</ArticleId><ArticleId IdType="pmc">9933373</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavikainen LI, Guyatt GH, Sallinen VJ, Karanicolas PJ, Couban RJ, Singh T, Lee Y, Elberkennou J, Aaltonen R, Ahopelto K, Beilmann-Lehtonen I, Blanker MH, C&#xe1;rdenas JL, Cartwright R, Craigie S, Devereaux PJ, Garcia-Perdomo HA, Ge FZ, Gomaa HA, Halme ALE, Haukka J, Karjalainen PK, Kilpel&#xe4;inen TP, Kivel&#xe4; AJ, Lampela H, Mattila AK, Najafabadi BT, Nyk&#xe4;nen TP, Pandanaboyana S, Pourjamal N, Ratnayake CBB, Raudasoja A, Vernooij RWM, Violette PD, Wang Y, Xiao Y, Yao L, Tikkinen KAO, ROTBIGGS Investigators (2024) Systematic reviews and meta-analyses of the procedure-specific risks of thrombosis and bleeding in general abdominal, colorectal, upper gastrointestinal, and hepatopancreatobiliary surgery. Ann Surg 279(2):213&#x2013;225. https://doi.org/10.1097/SLA.0000000000006059</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000006059</ArticleId><ArticleId IdType="pubmed">37551583</ArticleId></ArticleIdList></Reference><Reference><Citation>Veilleux E, Lutfi R (2020) Obesity and ventral hernia repair: is there success in staging? J Laparoendosc Adv Surg Tech A 30(8):896&#x2013;899. https://doi.org/10.1089/lap.2020.0265</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/lap.2020.0265</ArticleId><ArticleId IdType="pubmed">32453617</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassir R, Debs T, Blanc P, Gugenheim J, Ben Amor I, Boutet C, Tiffet O (2016) Complications of bariatric surgery: presentation and emergency management. Int J Surg 27:77&#x2013;81. https://doi.org/10.1016/j.ijsu.2016.01.067</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2016.01.067</ArticleId><ArticleId IdType="pubmed">26808323</ArticleId></ArticleIdList></Reference><Reference><Citation>Narouze S, Souzdalnitski D (2015) Obesity and chronic pain: opportunities for better patient care. Pain Manag 5(4):217&#x2013;219. https://doi.org/10.2217/pmt.15.16</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/pmt.15.16</ArticleId><ArticleId IdType="pubmed">26072666</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis RC, Maskal SM, Messer N, Miller BT, Petro CC, Prabhu AS, Rosen MJ, Zheng X, Beffa LRA (2024) Short-term outcomes of heavyweight versus mediumweight synthetic mesh in a retrospective cohort of clean-contaminated and contaminated retromuscular ventral hernia repairs. Surg Endosc 38(7):4006&#x2013;4013. https://doi.org/10.1007/s00464-024-10946-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-024-10946-0</ArticleId><ArticleId IdType="pubmed">38862822</ArticleId><ArticleId IdType="pmc">11219365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueno-Lled&#xf3; J, Torregrosa-Gallud A, Sala-Hernandez A, Carbonell-Tatay F, Pastor PG, Diana SB, Hern&#xe1;ndez JI (2017) Predictors of mesh infection and explantation after abdominal wall hernia repair. Am J Surg 213(1):50&#x2013;57. https://doi.org/10.1016/j.amjsurg.2016.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2016.03.007</ArticleId><ArticleId IdType="pubmed">27421189</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroga-Centeno AC, Quiroga-Centeno CA, Guerrero-Mac&#xed;as S, Navas-Quintero O, G&#xf3;mez-Ochoa SA (2022) Systematic review and meta-analysis of risk factors for mesh infection following abdominal wall hernia repair surgery. Am J Surg 224(1 Pt A):239&#x2013;246. https://doi.org/10.1016/j.amjsurg.2021.12.024 . (2021 Dec 24)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2021.12.024</ArticleId><ArticleId IdType="pubmed">34969506</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadashzadeh ER, Huckaby LV, Handzel R, Hossain MS, Sanin GD, Anto VP, Bou-Samra P, Moses JB, Cai S, Phelos HM, Simmons RL, Rosengart MR, van der Windt DJ (2022) The risk of incarceration during nonoperative management of incisional hernias: a population-based analysis of 30,998 patients. Ann Surg 275(2):e488&#x2013;e495. https://doi.org/10.1097/SLA.0000000000003916</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000003916</ArticleId><ArticleId IdType="pubmed">32773624</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillies M, Anthony L, Al-Roubaie A, Rockliff A, Phong J (2023) Trends in incisional and ventral hernia repair: a population analysis from 2001 to 2021. Cureus 15(3):e35744. https://doi.org/10.7759/cureus.35744</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.35744</ArticleId><ArticleId IdType="pubmed">36879583</ArticleId><ArticleId IdType="pmc">9984720</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;zen AS, Tokas T, Akin Y, Atis G, Hruza M, Rassweiler J (2014) Pain after hernia repair with simultaneous extraperitoneal laparoscopic radical prostatectomy. J Endourol 28(9):1143&#x2013;1148. https://doi.org/10.1089/end.2014.0223</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/end.2014.0223</ArticleId><ArticleId IdType="pubmed">24813061</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikami DJ, Melvin WS, Murayama MJ, Murayama KM (2017) Impact of minimally invasive surgery on healthcare utilization, cost, and workplace absenteeism in patients with incisional/ventral hernia (IVH). Surg Endosc 31(11):4412&#x2013;4418. https://doi.org/10.1007/s00464-017-5488-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00464-017-5488-y</ArticleId><ArticleId IdType="pubmed">28364155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindmark M, L&#xf6;wenmark T, Strig&#xe5;rd K, Gunnarsson U (2022) Major complications and mortality after ventral hernia repair: an eleven-year Swedish nationwide cohort study. BMC Surg 22(1):426. https://doi.org/10.1186/s12893-022-01873-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12893-022-01873-9</ArticleId><ArticleId IdType="pubmed">36514042</ArticleId><ArticleId IdType="pmc">9749316</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardoso L, Rodrigues D, Gomes L, Carrilho F (2017) Short- and long-term mortality after bariatric surgery: a systematic review and meta-analysis. Diabetes Obes Metab 19(9):1223&#x2013;1232. https://doi.org/10.1111/dom.12922</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12922</ArticleId><ArticleId IdType="pubmed">28244626</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcolin P, Poli M, de Figueiredo S, Walmir de Ara&#xfa;jo S, MotaConstante M, F&#xe9; M, de Melo V, Ginar da Silva S, Mao RD, DeJesus J, Lu R (2023) Preoperative optimization before ventral hernia repair: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech 33(2):211&#x2013;218. https://doi.org/10.1097/SLE.0000000000001160</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLE.0000000000001160</ArticleId><ArticleId IdType="pubmed">36971526</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19567860</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2044-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>7</Issue><PubDate><Year>2009</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of bone and joint surgery. British volume</Title><ISOAbbreviation>J Bone Joint Surg Br</ISOAbbreviation></Journal><ArticleTitle>A comparison of regional and general anaesthesia for total replacement of the hip or knee: a meta-analysis.</ArticleTitle><Pagination><StartPage>935</StartPage><EndPage>942</EndPage><MedlinePgn>935-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1302/0301-620X.91B7.21538</ELocationID><Abstract><AbstractText>We performed a meta-analysis to evaluate the relative efficacy of regional and general anaesthesia in patients undergoing total hip or knee replacement. A comprehensive search for relevant studies was performed in PubMed (1966 to April 2008), EMBASE (1969 to April 2008) and the Cochrane Library. Only randomised studies comparing regional and general anaesthesia for total hip or knee replacement were included. We identified 21 independent, randomised clinical trials. A random-effects model was used to calculate all effect sizes. Pooled results from these trials showed that regional anaesthesia reduces the operating time (odds ratio (OR) -0.19; 95% confidence interval (CI) -0.33 to -0.05), the need for transfusion (OR 0.45; 95% CI 0.22 to 0.94) and the incidence of thromboembolic disease (deep-vein thrombosis OR 0.45, 95% CI 0.24 to 0.84; pulmonary embolism OR 0.46, 95% CI 0.29 to 0.80). Regional anaesthesia therefore seems to improve the outcome of patients undergoing total hip or knee replacement.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Changhai Hospital, Second Military Medical University, 168, Changhai Road, Shanghai, 200433, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Z-Y</ForeName><Initials>ZY</Initials></Author><Author ValidYN="Y"><LastName>Hua</LastName><ForeName>Y-Q</ForeName><Initials>YQ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Z-D</ForeName><Initials>ZD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Bone Joint Surg Br</MedlineTA><NlmUniqueID>0375355</NlmUniqueID><ISSNLinking>0301-620X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Bone Joint Surg Am. 2010 May;92(5):1264. doi: 10.2106/JBJS.9205.ebo879.</RefSource><PMID Version="1">20439678</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000765" MajorTopicYN="N">Anesthesia, Conduction</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000768" MajorTopicYN="N">Anesthesia, General</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="N">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>43</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19567860</ArticleId><ArticleId IdType="doi">10.1302/0301-620X.91B7.21538</ArticleId><ArticleId IdType="pii">91-B/7/935</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34049258</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8615</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of critical care</Title><ISOAbbreviation>J Crit Care</ISOAbbreviation></Journal><ArticleTitle>Survival of patients with acute pulmonary embolism treated with venoarterial extracorporeal membrane oxygenation: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>245</StartPage><EndPage>254</EndPage><MedlinePgn>245-254</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcrc.2021.03.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0883-9441(21)00053-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">To examine whether venoarterial extracorporeal membrane oxygenation (VA-ECMO) improves survival of patients with acute pulmonary embolism (PE).</AbstractText><AbstractText Label="METHODS">Following the PRISMA guidelines, a systematic search was conducted up to August 2019 of the databases: PubMed/MEDLINE, EMBASE and Cochrane. All studies reporting the survival of adult patients with acute PE treated with VA-ECMO and including four patients or more were included. Exclusion criteria were: correspondences, reviews and studies in absence of a full text, written in other languages than English or Dutch, or dating before 1980. Short-term (hospital or 30-day) survival data were pooled and presented with relative risks (RR) and 95% confidence intervals (95% CI). Also, the following pre-defined factors were evaluated for their association with survival in VA-ECMO treated patients: age &gt; 60 years, male sex, pre-ECMO cardiac arrest, surgical embolectomy, catheter directed therapy, systemic thrombolysis, and VA-ECMO as single therapy.</AbstractText><AbstractText Label="RESULTS">A total of 29 observational studies were included (N = 1947 patients: VA-ECMO N = 1138 and control N = 809). There was no difference in short-term survival between VA-ECMO treated patients and control patients (RR 0.91, 95% CI 0.71-1.16). In acute PE patients undergoing VA-ECMO, age &gt; 60 years was associated with lower survival (RR 0.72, 95% CI 0.52-0.99), surgical embolectomy was associated with higher survival (RR 1.96, 95% CI 1.39-2.76) and pre-ECMO cardiac arrest showed a trend toward lower survival (RR 0.88, 95% CI 0.77-1.01). The other evaluated factors were not associated with a difference in survival.</AbstractText><AbstractText Label="CONCLUSIONS">At present, there is insufficient evidence that VA-ECMO treatment improves short-term survival of acute PE patients. Low quality evidence suggest that VA-ECMO patients aged &#x2264;60 years or who received SE have higher survival rates. Considering the limited evidence derived from the present data, this study emphasizes the need for prospective studies.</AbstractText><AbstractText Label="PROTOCOL REGISTRATION">PROSPERO CRD42019120370.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karami</LastName><ForeName>Mina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Heart Center; Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandigers</LastName><ForeName>Loes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Dinis Dos Reis</ForeName><Initials>DDR</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rietdijk</LastName><ForeName>Wim J R</ForeName><Initials>WJR</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binnekade</LastName><ForeName>Jan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knijn</LastName><ForeName>Dani&#xeb;lle C M</ForeName><Initials>DCM</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagrand</LastName><ForeName>Wim K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>den Uil</LastName><ForeName>Corstiaan A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Cardiology, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Jos&#xe9; P S</ForeName><Initials>JPS</Initials><AffiliationInfo><Affiliation>Heart Center; Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlaar</LastName><ForeName>Alexander P J</ForeName><Initials>APJ</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: a.p.vlaar@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>DUTCH ECLS Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Crit Care</MedlineTA><NlmUniqueID>8610642</NlmUniqueID><ISSNLinking>0883-9441</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Crit Care. 2022 Feb;67:223-224. doi: 10.1016/j.jcrc.2021.11.002.</RefSource><PMID Version="1">34782186</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Crit Care. 2022 Feb;67:225-226. doi: 10.1016/j.jcrc.2021.11.003.</RefSource><PMID Version="1">34794835</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="Y">Extracorporeal Membrane Oxygenation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="Y">Heart Arrest</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac arrest</Keyword><Keyword MajorTopicYN="N">ECPR</Keyword><Keyword MajorTopicYN="N">Extracorporeal life support</Keyword><Keyword MajorTopicYN="N">Extracorporeal membrane oxygenation</Keyword><Keyword MajorTopicYN="N">Hemodynamic instability</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>20</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34049258</ArticleId><ArticleId IdType="doi">10.1016/j.jcrc.2021.03.006</ArticleId><ArticleId IdType="pii">S0883-9441(21)00053-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39423670</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Injury</Title><ISOAbbreviation>Injury</ISOAbbreviation></Journal><ArticleTitle>Incidence of deep vein thrombosis and pulmonary embolism in closed foot and ankle fractures treated with conservative versus surgical management: A nationwide analysis.</ArticleTitle><Pagination><StartPage>111859</StartPage><MedlinePgn>111859</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.injury.2024.111859</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0020-1383(24)00588-6</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Though there is extensive research on recovery and outcomes of proximal joint fractures, such as hip and knee, there is a paucity of such research in foot and ankle fractures and a lack of uniform data on the incidence of venous thromboembolism (VTE). This is a retrospective cohort study that seeks to investigate the incidence of VTE following surgically versus conservatively treated foot and ankle fractures METHODS: This study included all adult-patient hospitalizations with International Classification of Disease 10th Revision diagnosis codes related to closed foot and ankle fractures as a primary diagnosis in the National Inpatient Sample, an administrative database part of the Healthcare Cost and Utilization Project, for a total of 209,595 cases. Multivariate binary logistic regression was performed to determine the effect of age, gender, past medical history of venous thromboembolism (PMHVTE), Charlson Comorbidity Index, race, surgery, and transfusion of red cell products on the incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our study found an overall incidence of DVT and PE to be 0.4 % and 0.3 %, respectively, following foot or ankle fracture. Conservative management was found to have an increased relative risk of DVT and PE of 2.02 and 1.15, respectively. This difference persisted on performing inverse probability treatment weighting (IPTW) analysis to account for confounders. PMHVTE and requirement of blood transfusion was associated with an increased odds ratio (OR) of 3.41 and 3.217, respectively. Cases identified as Black and Asian/Pacific Islander also had an increased OR of DVT.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results of this study demonstrate that surgical management of foot and ankle fractures is associated with a lower relative risk of VTE compared to medical management. PMHVTE and transfusion of red cell products increase the odds of VTE following either form of intervention.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kohli</LastName><ForeName>Meera</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Thomas Jefferson University Hospital - Philadelphia, PA, USA. Electronic address: mxk430@jefferson.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atodaria</LastName><ForeName>Kuldeepsinh P</ForeName><Initials>KP</Initials><AffiliationInfo><Affiliation>Internal Medicine, Jefferson Health - Abington, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Rajeshkumar</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, Jefferson Health - Abington, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brahmabhatt</LastName><ForeName>Shyam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rothman Orthopaedics - Willow Grove, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goyal</LastName><ForeName>Aakash R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Internal Medicine, Crozer Medical Center - Chester, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raval</LastName><ForeName>Neha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Vanita Vishram Women's University - Gujurat, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Injury</MedlineTA><NlmUniqueID>0226040</NlmUniqueID><ISSNLinking>0020-1383</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064386" MajorTopicYN="Y">Ankle Fractures</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072700" MajorTopicYN="Y">Conservative Treatment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005596" MajorTopicYN="N">Fractures, Closed</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018409" MajorTopicYN="N">Foot Injuries</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deep venous thrombosis</Keyword><Keyword MajorTopicYN="N">Foot and ankle fracture</Keyword><Keyword MajorTopicYN="N">Orthopaedics</Keyword><Keyword MajorTopicYN="N">Pulmonary embolism</Keyword><Keyword MajorTopicYN="N">Trauma</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList><CoiStatement>Declaration of competing interest None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>1</Day><Hour>15</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39423670</ArticleId><ArticleId IdType="doi">10.1016/j.injury.2024.111859</ArticleId><ArticleId IdType="pii">S0020-1383(24)00588-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28121338</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>03</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2284-0729</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>European review for medical and pharmacological sciences</Title><ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation></Journal><ArticleTitle>A meta-analysis of efficacy and safety of catheter-directed interventions in submassive pulmonary embolism.</ArticleTitle><Pagination><StartPage>184</StartPage><EndPage>198</EndPage><MedlinePgn>184-198</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">12046</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Catheter-directed interventions, such as catheter-directed thrombolysis (CDT), are becoming a popular therapeutic option for patients with hemodynamically stable pulmonary embolism (PE) and right ventricle (RV) dysfunction (submassive PE). We wished to quantitatively assess therapeutic efficacy and safety of catheter-directed interventions in submassive PE.</AbstractText><AbstractText Label="MATERIALS AND METHODS">PubMed, Embase, Cochrane and Scopus were searched for studies on catheter-directed interventions and submassive PE. Studies reporting data on therapeutic efficacy (RV to left ventricle [RV/LV] ratio, systolic pulmonary artery pressure) and safety outcomes (in-hospital and 30-day mortality rates, major and minor bleeding rates) were retained and assessed.</AbstractText><AbstractText Label="RESULTS">The final reference sample included 13 publications (11 papers and 2 conference abstracts), collectively enrolling 422 patients with submassive PE. The majority (8/13) studies were retrospective studies. One study was a randomized controlled study. Nine of 13 studies utilized CDT with or without ultrasound-assisted thrombolysis. The post-therapy pooled mean change of RV/LV ratio was -0.3 (95% confidence interval [CI]: -0.42, -0.18), and the pooled mean decrease of pulmonary artery pressure was -19.41 (95% CI: -27.65, -11.17) mm Hg. Safety outcome analysis demonstrated low pooled rates of adverse events (in-hospital mortality: 0.00 [95% CI: 0.00, 0.01]; 30-day mortality: 0.00 [95% CI: 0.00, 0.03]; major bleeding: 0.00 [95% CI: 0.00, 0.02]; minor bleeding: 0.05 [95% CI: 0.01, 0.12]).</AbstractText><AbstractText Label="CONCLUSIONS">This meta-analysis demonstrates evidence of therapeutic efficacy and low rates of adverse events of catheter-directed interventions in submassive PE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>B-H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Emergency Department, Vascular Surgery Department, Quzhou People's Hospital, Quzhou, Zhejiang Province, China. 568192219@qq.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>L-H</ForeName><Initials>LH</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA><NlmUniqueID>9717360</NlmUniqueID><ISSNLinking>1128-3602</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="Y">Thrombolytic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28121338</ArticleId><ArticleId IdType="pii">12046</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31574793</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>39</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Comparison of mortality and complications between bilateral simultaneous and staged total hip arthroplasty: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e16774</StartPage><MedlinePgn>e16774</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e16774</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000016774</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Total hip arthroplasty (THA) relieves pain and restores function in patients with severe rheumatoid arthritis and osteoarthritis. Over the past few decades, several authors have attempted to assess the efficacy and safety of simultaneous bilateral THA compared with staged bilateral THA. The purpose of this meta-analysis is to compare the mortalities and complications between simultaneous bilateral THA and staged bilateral THA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A literature search to identify eligible studies was undertaken to identify all relevant articles published until August 2018. We included studies that compared simultaneous bilateral THA and staged bilateral THA and their effects on mortality and complications. The outcomes included mortality, the occurrence of deep venous thrombosis (DVT), the occurrence of pulmonary embolism (PE), respiratory complications, cardiovascular complications, digestive system complications and the occurrence of dislocation. Stata 12.0 was used for the meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nineteen studies involving 59,257 patients were identified; among them, 16,758 patients were selected for treatment with simultaneous bilateral THA, and 42,499 patients were chosen for the purpose of staged bilateral THA. The meta-analysis results demonstrated that there was no significant difference between simultaneous bilateral THA and staged bilateral THA in terms of mortality (risk ratio [RR]&#x200a;=&#x200a;1.15, 95% CI&#x200a;=&#x200a;0.76, 1.74; P&#x200a;=&#x200a;.520). Compared with staged bilateral THA, simultaneous bilateral THA was associated with a reduction in the occurrence of DVT, PE and respiratory complications (P&#x200a;&lt;&#x200a;.05). There were no significant differences in the cardiovascular complications, digestive system complications or the occurrence of dislocation and infection (P&#x200a;=&#x200a;.057).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We observed that the prevalence of DVT, PE and respiratory complications was considerably lower with the use of simultaneous bilateral THA than with the use of staged bilateral THA. Thus, simultaneous bilateral THA is a considerably safer procedure than staged bilateral THA in selected THA patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Liangku</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Xi'an Honghui Hospital, Xi'an Jiaotong University Health Science Center, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yuben</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zandong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019644" MajorTopicYN="N">Arthroplasty, Replacement, Hip</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004066" MajorTopicYN="N">Digestive System Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006331" MajorTopicYN="N">Heart Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004204" MajorTopicYN="N">Joint Dislocations</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015207" MajorTopicYN="N">Osteoarthritis, Hip</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012120" MajorTopicYN="N">Respiration Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no funding and conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31574793</ArticleId><ArticleId IdType="pmc">PMC6775426</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000016774</ArticleId><ArticleId IdType="pii">00005792-201909270-00002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jaffe WL, Charnley J. Bilateral Charnley low-friction arthroplasty as a single operative procedure. A report of fifty cases. Bull Hosp Joint Dis 1971;32:198&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">5128234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu XT, Chen L, Lin JH. Selective COX-2 inhibitor versus non-selective COX-2 inhibitor for the prevention of heterotopic ossification after total hip arthroplasty: A meta-analysis. Medicine (Baltimore) 2018;97:e11649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6081155</ArticleId><ArticleId IdType="pubmed">30075549</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao H, et al. Bilateral total hip arthroplasty: 1-Stage or 2-Stage? A meta-analysis. J Arthroplasty 2017;32:689&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">27776901</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuben JD, et al. Cost comparison between bilateral simultaneous, staged, and unilateral total joint arthroplasty. J Arthroplasty 1998;13:172&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9526210</ArticleId></ArticleIdList></Reference><Reference><Citation>Odum SM, et al. A cost-utility analysis comparing the cost-effectiveness of simultaneous and staged bilateral total knee arthroplasty. J Bone Joint Surg Am 2013;95:1441&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23965693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter MA, Stringer EA. Bilateral total hip arthroplasty: a single procedure. Clin Orthop Relat Res 1980;185&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">7408301</ArticleId></ArticleIdList></Reference><Reference><Citation>Wykman A, Olsson E. Walking ability after total hip replacement. A comparison of gait analysis in unilateral and bilateral cases. J Bone Joint Surg Br 1992;74:53&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1732266</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhan S, Pankaj A, Malhotra R. One- or two-stage bilateral total hip arthroplasty: a prospective, randomised, controlled study in an Asian population. J Bone Joint Surg Br Vol 2006;88:298&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">16498000</ArticleId></ArticleIdList></Reference><Reference><Citation>GS, H.J., Cochrane handbook for systematic reviews of interventions version 5.1.0. [http://handbook.cochrane.org/]
2011.</Citation></Reference><Reference><Citation>Shih CH, Ho WB. One-stage versus two-stage bilateral autophor ceramic total hip arthroplasty. Clin Orthop Relat Res 1985;141&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">3971613</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvati EA, Hughes P, Lachiewicz P. Bilateral total hip-replacement arthroplasty in one stage. J Bone Joint Surg Am 1978;60:640&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">681382</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggli S, Huckell CB, Ganz R. Bilateral total hip arthroplasty: one stage versus two stage procedure. Clin Orthop Relat Res 1996;108&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">8653943</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenze M, et al. A comparison of the cost effectiveness of one-stage versus two-stage bilateral total hip replacement. Orthopedics 1998;21:1249&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9867298</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaro-Adrian J, et al. One- or two-stage bilateral total hip replacement. J Arthroplasty 1999;14:439&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">10428224</ArticleId></ArticleIdList></Reference><Reference><Citation>Berend KR, Lombardi AV, Jr, Adams JB. Simultaneous vs staged cementless bilateral total hip arthroplasty: perioperative risk comparison. J Arthroplasty 2007;226 Suppl 2:111&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17823028</ArticleId></ArticleIdList></Reference><Reference><Citation>McBryde CW, et al. One- or two-stage bilateral metal-on-metal hip resurfacing arthroplasty. J Bone Joint Surg Br 2007;89:1144&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17905948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper GJ, et al. Bilateral total joint arthroplasty: the early results from the New Zealand National Joint Registry. J Arthroplasty 2009;24:1174&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056233</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih LY, Wong YC, Shih HN. One-stage hip arthroplasty and bone grafting for bilateral femoral head osteonecrosis. Clin Orthop Relat Res 2009;467:1522&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674150</ArticleId><ArticleId IdType="pubmed">18648898</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghayev E, et al. Simultaneous bilateral hip replacement reveals superior outcome and fewer complications than two-stage procedures: a prospective study including 1819 patients and 5801 follow-ups from a total joint replacement registry. BMC Musculoskelet Disord 2010;11:245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987971</ArticleId><ArticleId IdType="pubmed">20973941</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston LR, Clift BA, Abboud RJ. Bilateral simultaneous hip replacement versus bilateral sequential hip replacement. A 7-year data review. Orthop Nurs 2011;30:119&#x2013;23. quiz 124-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">21422893</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg-Larsen M, et al. Simultaneous and staged bilateral total hip arthroplasty: a Danish nationwide study. Arch Orthop Trauma Surg 2013;133:1601&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23912419</ArticleId></ArticleIdList></Reference><Reference><Citation>Taheriazam A, et al. Bilateral total hip arthroplasty: one-stage versus two-stage procedure. Hip Int 2018;1120700018773427.</Citation><ArticleIdList><ArticleId IdType="pubmed">29756496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasouli MR, et al. Perioperative morbidity and mortality following bilateral total hip arthroplasty. J Arthroplasty 2014;29:142&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23664280</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito S, et al. One- versus two-stage bilateral total hip arthroplasty. Orthopedics 2010;33:</Citation><ArticleIdList><ArticleId IdType="pubmed">20704112</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J, et al. Bilateral total hip arthroplasty: one-stage versus two-stage procedures. Clin Orthop Relat Res 2006;453:137&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">17312590</ArticleId></ArticleIdList></Reference><Reference><Citation>Garland A, et al. Early postoperative mortality after simultaneous or staged bilateral primary total hip arthroplasty: an observational register study from the Swedish Hip Arthroplasty Register. BMC Musculoskelet Disord 2015;16:77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393879</ArticleId><ArticleId IdType="pubmed">25887667</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp D, et al. One stage bilateral total hip arthroplasty, is it safe? A meta-analysis. Hip Int 2010;20:440&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21157747</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiridis E, et al. The safety and efficacy of bilateral simultaneous total hip replacement: an analysis of 2063 cases. J Bone Joint Surg Br 2008;90:1005&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">18669954</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29049073</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1526-7598</ISSN><JournalIssue CitedMedium="Internet"><Volume>125</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Anesthesia and analgesia</Title><ISOAbbreviation>Anesth Analg</ISOAbbreviation></Journal><ArticleTitle>Postoperative Outcomes in Obstructive Sleep Apnea Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis of Comparative Studies.</ArticleTitle><Pagination><StartPage>2030</StartPage><EndPage>2037</EndPage><MedlinePgn>2030-2037</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1213/ANE.0000000000002558</ELocationID><Abstract><AbstractText Label="BACKGROUND">Obstructive sleep apnea (OSA) is a common comorbidity in patients undergoing cardiac surgery and may predispose patients to postoperative complications. The purpose of this meta-analysis is to determine the evidence of postoperative complications associated with OSA patients undergoing cardiac surgery.</AbstractText><AbstractText Label="METHODS">A literature search of Cochrane Database of Systematic Reviews, Medline, Medline In-process, Web of Science, Scopus, EMBASE, Cochrane Central Register of Controlled Trials, and CINAHL until October 2016 was performed. The search was constrained to studies in adult cardiac surgical patients with diagnosed or suspected OSA. All included studies must report at least 1 postoperative complication. The primary outcome is major adverse cardiac or cerebrovascular events (MACCEs) up to 30 days after surgery, which includes death from all-cause mortality, myocardial infarction, myocardial injury, nonfatal cardiac arrest, revascularization process, pulmonary embolism, deep venous thrombosis, newly documented postoperative atrial fibrillation (POAF), stroke, and congestive heart failure. Secondary outcome is newly documented POAF. The other exploratory outcomes include the following: (1) postoperative tracheal intubation and mechanical ventilation; (2) infection and/or sepsis; (3) unplanned intensive care unit (ICU) admission; and (4) duration of stay in hospital and ICU. Meta-analysis and meta- regression were conducted using Cochrane Review Manager 5.3 (Cochrane, London, UK) and OpenBUGS v3.0, respectively.</AbstractText><AbstractText Label="RESULTS">Eleven comparative studies were included (n = 1801 patients; OSA versus non-OSA: 688 vs 1113, respectively). MACCEs were 33.3% higher odds in OSA versus non-OSA patients (OSA versus non-OSA: 31% vs 10.6%; odds ratio [OR], 2.4; 95% confidence interval [CI], 1.38-4.2; P = .002). The odds of newly documented POAF (OSA versus non-OSA: 31% vs 21%; OR, 1.94; 95% CI, 1.13-3.33; P = .02) was higher in OSA compared to non-OSA. Even though the postoperative tracheal intubation and mechanical ventilation (OSA versus non-OSA: 13% vs 5.4%; OR, 2.67; 95% CI, 1.03-6.89; P = .04) were significantly higher in OSA patients, the length of ICU stay and hospital stay were not significantly prolonged in patients with OSA compared to non-OSA. The majority of OSA patients were not treated with continuous positive airway pressure therapy. Meta-regression and sensitivity analysis of the subgroups did not impact the OR of postoperative complications for OSA versus non-OSA groups.</AbstractText><AbstractText Label="CONCLUSIONS">Our meta-analysis demonstrates that after cardiac surgery, MACCEs and newly documented POAF were 33.3% and 18.1% higher odds in OSA versus non-OSA patients, respectively.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nagappa</LastName><ForeName>Mahesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Anesthesia and Perioperative Medicine, London Health Sciences Centre and St Joseph Health Care, Western University, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patra</LastName><ForeName>Jayadeep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Mandeep</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaw</LastName><ForeName>Roop</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departments of Hospital Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Outcomes Research (Anesthesiology), Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Davy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Medical Evidence, Decision Integrity and Clinical Impact (MEDICI), Western University, London, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia &amp; Perioperative Medicine, Western University, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Frances</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Anesth Analg</MedlineTA><NlmUniqueID>1310650</NlmUniqueID><ISSNLinking>0003-2999</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Anesth Analg. 2018 Jul;127(1):315-317. doi: 10.1213/ANE.0000000000003383.</RefSource><PMID Version="1">29677056</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Anesth Analg. 2018 Jul;127(1):314-315. doi: 10.1213/ANE.0000000000003382.</RefSource><PMID Version="1">29677064</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020181" MajorTopicYN="N">Sleep Apnea, Obstructive</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29049073</ArticleId><ArticleId IdType="doi">10.1213/ANE.0000000000002558</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35468241</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Clinical transplantation</Title><ISOAbbreviation>Clin Transplant</ISOAbbreviation></Journal><ArticleTitle>What is the optimal prophylaxis against postoperative deep vein thrombosis in the living donor to avoid complications and enhance recovery? - A systematic review of the literature and expert panel recommendations.</ArticleTitle><Pagination><StartPage>e14688</StartPage><MedlinePgn>e14688</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ctr.14688</ELocationID><Abstract><AbstractText Label="BACKGROUND">Deep venous thrombosis (DVT) prophylaxis is often employed to prevent the potentially serious complication of pulmonary embolism (PE). However, little data exist regarding the optimal DVT prophylaxis strategy for living donors undergoing hepatectomy for living donor liver transplantation. Here we present our consensus statement on DVT prophylaxis for living donors undergoing hepatectomy.</AbstractText><AbstractText Label="OBJECTIVES">To identify the optimal DVT prophylaxis strategy, which reduces, risk of complications in living liver donors, and enhances recovery.</AbstractText><AbstractText Label="METHODS">Systematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel. Of interest was the impact of DVT prophylaxis or lack of prophylaxis on living donors undergoing hepatectomy and subsequent rates of DVT, PE, and hemorrhagic complications.</AbstractText><AbstractText Label="PROSPERO ID">CRD42021260720 RESULTS: The review of the literature identified three studies, which directly addressed thrombogenesis following living donor hepatectomy. All studies were observational in nature without randomization into treatments. The rate of DVT-PE in unscreened living donors with chemoprophylaxis was 5%. Furthermore, thromboelastography of living donors demonstrated sustained hypercoagulability for 50% of donors 10 days postoperatively. In line with CHEST (The American College of Chest Physicians) guidelines of chemoprophylaxis for surgical procedures with 3% or greater risk of DVT-PE, we conclude that a minimum of 10 days of postoperative chemoprophylaxis with unfractionated heparin or low-molecular weight heparin is recommended for patients undergoing living donor hepatectomy. The quality of evidence (QOE) for these recommendations based on the GRADE criteria is low, with a Grade of Recommendation of Strong.</AbstractText><AbstractText Label="CONCLUSIONS">Chemoprophylaxis for DVT following living donor hepatectomy is associated with reduced adverse thrombotic events, (Quality of Evidence; Low | Grade of Recommendation; Strong).</AbstractText><CopyrightInformation>&#xa9; 2022 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruffolo</LastName><ForeName>Luis I</ForeName><Initials>LI</Initials><Identifier Source="ORCID">0000-0001-6002-9559</Identifier><AffiliationInfo><Affiliation>Division of Abdominal Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levstik</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Abdominal Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boehly</LastName><ForeName>Jen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Abdominal Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spiro</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Intensive Care Medicine, Royal Free Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Surgery and Interventional Science, University College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raptis</LastName><ForeName>Dimitri A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Clinical Service of HPB Surgery and Liver Transplantation, Royal Free Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Surgery and Interventional Science, University College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Perioperative Care, University of California, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernandez-Alejandro</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Abdominal Transplantation and Hepatobiliary Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ERAS4OLT.org Working Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Clin Transplant</MedlineTA><NlmUniqueID>8710240</NlmUniqueID><ISSNLinking>0902-0063</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="Y">Liver Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019520" MajorTopicYN="N">Living Donors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="Y">Venous Thrombosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">embolism</Keyword><Keyword MajorTopicYN="N">living donor liver transplantation</Keyword><Keyword MajorTopicYN="N">prophylaxis</Keyword><Keyword MajorTopicYN="N">thromboembolism</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Niemann</LastName><ForeName>Claus</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollok</LastName><ForeName>Joerg-Matthias</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berenguer</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinguely</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frola</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potts</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borakati</LastName><ForeName>Aditya</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tung</LastName><ForeName>Lam Sze</ForeName><Initials>LS</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>25</Day><Hour>17</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35468241</ArticleId><ArticleId IdType="doi">10.1111/ctr.14688</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Gould MK, Garcia DA, Wren SM, et&#xa0;al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e227S-e277S.</Citation></Reference><Reference><Citation>Melloul E, Dond&#xe9;ro F, Vilgrain V, Raptis DA, Paugam-Burtz C, Belghiti J. Pulmonary embolism after elective liver resection: a prospective analysis of risk factors. J Hepatol. 2012;57(6):1268-1275.</Citation></Reference><Reference><Citation>Barton JS, Riha GM, Differding JA, et&#xa0;al. Coagulopathy after a liver resection: is it over diagnosed and over treated? HPB. 2013;15(11):865-871.</Citation></Reference><Reference><Citation>Guyatt G, Oxman AD, Akl EA, et&#xa0;al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394.</Citation></Reference><Reference><Citation>Murad MH, Mustafa RA, Sch&#xfc;nemann HJ, Sultan S, Santesso N. Rating the certainty in evidence in the absence of a single estimate of effect. Evid Based Med. 2017;22(3):85-87.</Citation></Reference><Reference><Citation>Andrews J, Guyatt G, Oxman AD, et&#xa0;al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-725.</Citation></Reference><Reference><Citation>Andrews JC, Sch&#xfc;nemann HJ, Oxman AD, et&#xa0;al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66(7):726-735.</Citation></Reference><Reference><Citation>Din MMBE, El Din MMB, Kamal KM, Mohamed MI. Risk factors and management of venous thromboembolic diseases in donor of living donor liver transplant. Egypt J Hosp Med. 2017;69(5):2516-2524. https://doi.org/10.12816/0041704</Citation></Reference><Reference><Citation>Kamei H, Onishi Y, Kurata N, Ishigami M, Ogura Y. Donor selection and prophylactic strategy for venous thromboembolic events in living donors of liver transplantation based on results of thrombophilia screening tests. Ann Transpl. 2017;22:409-416. https://doi.org/10.12659/aot.902791</Citation></Reference><Reference><Citation>Cerutti E, Stratta C, Romagnoli R, et&#xa0;al. Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation. Liver Transpl. 2004;10(2):289-294.</Citation></Reference><Reference><Citation>Garg S, Sindwani G, Garg N, Arora MK, Pamecha V, Tempe D. Hypercoagulabilityon thromboelastography after living donor hepatectomy&#xa0;- the true side of the coin. Indian J Anaesth. 2021;65(4):295-301.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30190110</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-7361</ISSN><JournalIssue CitedMedium="Internet"><Volume>164</Volume><Issue>6</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Surgery</Title><ISOAbbreviation>Surgery</ISOAbbreviation></Journal><ArticleTitle>Extended versus conventional thromboprophylaxis after major abdominal and pelvic surgery: Systematic review and meta-analysis of randomized clinical trials.</ArticleTitle><Pagination><StartPage>1234</StartPage><EndPage>1240</EndPage><MedlinePgn>1234-1240</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.surg.2018.05.028</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0039-6060(18)30277-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">Venous thromboembolism, presenting as deep vein thrombosis or pulmonary embolism, can be associated with considerable morbidity after major abdominal and pelvic surgery. Perioperative thromboprophylaxis with low-molecular-weight heparin is well established, but the duration of treatment remains debated. We aimed to assess the efficacy and safety of extended (4-week) versus conventional (1-week) thromboprophylaxis with low-molecular-weight heparin in patients undergoing abdominopelvic surgery.</AbstractText><AbstractText Label="METHODS">Using MEDLINE databases (PubMed, EMBASE, and Web of Science), we conducted an electronic, systematic search of randomized controlled trials comparing post-operative extended versus conventional low-molecular-weight heparin on venous thromboembolism, deep vein thrombosis, and pulmonary embolism rates.</AbstractText><AbstractText Label="RESULTS">Four randomized controlled trials met the predefined criteria. Extended prophylaxis with low-molecular-weight heparin after major abdominal and pelvic surgery decreased rates of postoperative venous thromboembolism, deep vein thrombosis, and proximal deep vein thrombosis without increased postoperative bleeding. Numbers needed to treat to prevent venous thromboembolism, overall deep vein thrombosis, and proximal deep vein thrombosis were 14, 14, and 44, respectively. Rates of postoperative symptomatic PE were rare, and the incidence was similar in both groups.</AbstractText><AbstractText Label="CONCLUSION">Extended prophylaxis with low-molecular-weight heparin is associated with a decrease in asymptomatic venous thromboembolism. There remains sparse evidence regarding its impact on pulmonary embolism because of the overall low incidence. Extended prophylaxis should be considered in high-risk patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rausa</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of General Surgery, IRCCS Policlinico San Donato, Department of Biomedical Sciences of Health, University of Milan Medical School, San Donato Milanese, Milan, Italy. Electronic address: emarausa@yahoo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asti</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of General Surgery, IRCCS Policlinico San Donato, Department of Biomedical Sciences of Health, University of Milan Medical School, San Donato Milanese, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aiolfi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of General Surgery, IRCCS Policlinico San Donato, Department of Biomedical Sciences of Health, University of Milan Medical School, San Donato Milanese, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonitta</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of General Surgery, IRCCS Policlinico San Donato, Department of Biomedical Sciences of Health, University of Milan Medical School, San Donato Milanese, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winter</LastName><ForeName>Desmond C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, St Vincent's University Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonavina</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of General Surgery, IRCCS Policlinico San Donato, Department of Biomedical Sciences of Health, University of Milan Medical School, San Donato Milanese, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surgery</MedlineTA><NlmUniqueID>0417347</NlmUniqueID><ISSNLinking>0039-6060</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013514" MajorTopicYN="N">Surgical Procedures, Operative</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30190110</ArticleId><ArticleId IdType="doi">10.1016/j.surg.2018.05.028</ArticleId><ArticleId IdType="pii">S0039-6060(18)30277-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37120426</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1435-2451</ISSN><JournalIssue CitedMedium="Internet"><Volume>408</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>Langenbeck's archives of surgery</Title><ISOAbbreviation>Langenbecks Arch Surg</ISOAbbreviation></Journal><ArticleTitle>Effect of thoracic epidural anesthesia on postoperative outcome in major liver surgery: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>168</StartPage><MedlinePgn>168</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">168</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00423-023-02900-w</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Postoperative complications after major liver surgery are common. Thoracic epidural anesthesia may provide beneficial effects on postoperative outcome. We strove to compare postoperative outcomes in major liver surgery patients with and without thoracic epidural anesthesia.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a retrospective cohort study in a single university medical center. Patients undergoing elective major liver surgery between April 2012 and December 2016 were eligible for inclusion. We divided patients into two groups according to whether or not they had thoracic epidural anesthesia for major liver surgery. The primary outcome was postoperative hospital length of stay, i.e., from day of surgery until hospital discharge. Secondary outcomes included 30-day postoperative mortality and major postoperative complications. Additionally, we investigated the effect of thoracic epidural anesthesia on perioperative analgesia doses and the safety of thoracic epidural anesthesia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 328 patients included in this study, 177 (54.3%) received thoracic epidural anesthesia. There were no clinically important differences in postoperative hospital length of stay (11.0 [7.00-17.0] vs. 9.00 [7.00-14.0] days, p = 0.316, primary outcome), death (0.0 vs. 2.7%, p = 0.995), or the incidence of postoperative renal failure (0.6 vs. 0.0%, p = 0.99), sepsis (0.0 vs. 1.3%, p = 0.21), or pulmonary embolism (0.6 vs. 1.4%, p = 0.59) between patients with or without thoracic epidural anesthesia. Perioperative analgesia doses - including the intraoperative sufentanil dose (0.228 [0.170-0.332] vs. 0.405 [0.315-0.565] &#x3bc;g&#xb7;kg<sup>-1</sup>&#xb7;h<sup>-1</sup>, p &lt; 0.0001) - were lower in patients with thoracic epidural anesthesia. No major thoracic epidural anesthesia-associated infections or bleedings occurred.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This retrospective analysis suggests that thoracic epidural anesthesia does not reduce postoperative hospital length of stay in patients undergoing major liver surgery - but it may reduce perioperative analgesia doses. Thoracic epidural anesthesia was safe in this cohort of patients undergoing major liver surgery. These findings need to be confirmed in robust clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Behem</LastName><ForeName>Christoph R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistra&#xdf;e 52, 20246, Hamburg, Germany. c.behem@uke.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wegner</LastName><ForeName>Juliane C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistra&#xdf;e 52, 20246, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinnschmidt</LastName><ForeName>Hans O</ForeName><Initials>HO</Initials><AffiliationInfo><Affiliation>Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greiwe</LastName><ForeName>Gillis</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistra&#xdf;e 52, 20246, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graessler</LastName><ForeName>Michael F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistra&#xdf;e 52, 20246, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funcke</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistra&#xdf;e 52, 20246, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitzschke</LastName><ForeName>Rainer</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistra&#xdf;e 52, 20246, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trepte</LastName><ForeName>Constantin J C</ForeName><Initials>CJC</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistra&#xdf;e 52, 20246, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haas</LastName><ForeName>Sebastian A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Intensive Care Medicine, Rostock University Medical Center, Rostock, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Langenbecks Arch Surg</MedlineTA><NlmUniqueID>9808285</NlmUniqueID><ISSNLinking>1435-2443</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010149" MajorTopicYN="N">Pain, Postoperative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000767" MajorTopicYN="Y">Anesthesia, Epidural</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015360" MajorTopicYN="Y">Analgesia, Epidural</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epidural anesthesia</Keyword><Keyword MajorTopicYN="N">Hepatectomy</Keyword><Keyword MajorTopicYN="N">Liver neoplasms</Keyword><Keyword MajorTopicYN="N">Pain management</Keyword><Keyword MajorTopicYN="N">Perioperative care</Keyword></KeywordList><CoiStatement>Constantin J. C. Trepte has received honorary for lectures by Maquet. All other authors declare no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>29</Day><Hour>23</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37120426</ArticleId><ArticleId IdType="pmc">PMC10148777</ArticleId><ArticleId IdType="doi">10.1007/s00423-023-02900-w</ArticleId><ArticleId IdType="pii">10.1007/s00423-023-02900-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hughes MJ, Ventham NT, Harrison EM, Wigmore SJ. Central venous pressure and liver resection: a systematic review and meta-analysis. HPB (Oxford) 2015;17(10):863&#x2013;871. doi: 10.1111/hpb.12462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hpb.12462</ArticleId><ArticleId IdType="pmc">PMC4571753</ArticleId><ArticleId IdType="pubmed">26292655</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosero EB, Cheng GS, Khatri KP, Joshi GP. Evaluation of epidural analgesia for open major liver resection surgery from a US inpatient sample. Proc (Bayl Univ Med Cent) 2014;27(4):305&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255849</ArticleId><ArticleId IdType="pubmed">25484494</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones C, Kelliher L, Dickinson M, Riga A, Worthington T, Scott MJ, et al. Randomized clinical trial on enhanced recovery versus standard care following open liver resection. Br J Surg. 2013;100(8):1015&#x2013;1024. doi: 10.1002/bjs.9165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9165</ArticleId><ArticleId IdType="pubmed">23696477</ArticleId></ArticleIdList></Reference><Reference><Citation>Melloul E, Hubner M, Scott M, Snowden C, Prentis J, Dejong CH, et al. Guidelines for perioperative care for liver surgery: enhanced recovery after surgery (ERAS) society recommendations. World J Surg. 2016;40(10):2425&#x2013;2440. doi: 10.1007/s00268-016-3700-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-016-3700-1</ArticleId><ArticleId IdType="pubmed">27549599</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathi S, Roberts G, Mogford S, Bahlmann B, Ateleanu B, Kumar N. Epidural analgesia provides effective pain relief in patients undergoing open liver surgery. Br J Pain. 2015;9(2):78&#x2013;85. doi: 10.1177/2049463714525140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2049463714525140</ArticleId><ArticleId IdType="pmc">PMC4616967</ArticleId><ArticleId IdType="pubmed">26516562</ArticleId></ArticleIdList></Reference><Reference><Citation>Freise H, Van Aken HK. Risks and benefits of thoracic epidural anaesthesia. Br J Anaesth. 2011;107(6):859&#x2013;868. doi: 10.1093/bja/aer339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aer339</ArticleId><ArticleId IdType="pubmed">22058144</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahnenkamp K, Theilmeier G, Van Aken HK, Hoenemann CW. The effects of local anesthetics on perioperative coagulation, inflammation, and microcirculation. Anesth Analg. 2002;94(6):1441&#x2013;1447. doi: 10.1213/00000539-200206000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/00000539-200206000-00011</ArticleId><ArticleId IdType="pubmed">12032003</ArticleId></ArticleIdList></Reference><Reference><Citation>Takita K, Uchida Y, Hase T, Kamiyama T, Morimoto Y. Co-existing liver disease increases the risk of postoperative thrombocytopenia in patients undergoing hepatic resection: implications for the risk of epidural hematoma associated with the removal of an epidural catheter. J Anesth. 2014;28(4):554&#x2013;558. doi: 10.1007/s00540-013-1776-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00540-013-1776-4</ArticleId><ArticleId IdType="pubmed">24375285</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamenkovic DM, Jankovic ZB, Toogood GJ, Lodge JP, Bellamy MC. Epidural analgesia and liver resection: postoperative coagulation disorders and epidural catheter removal. Minerva Anestesiol. 2011;77(7):671&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">19037193</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzimas P, Prout J, Papadopoulos G, Mallett SV. Epidural anaesthesia and analgesia for liver resection. Anaesthesia. 2013;68(6):628&#x2013;635. doi: 10.1111/anae.12191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/anae.12191</ArticleId><ArticleId IdType="pubmed">23662750</ArticleId></ArticleIdList></Reference><Reference><Citation>Siniscalchi A, Gamberini L, Bardi T, Laici C, Gamberini E, Francorsi L, et al. Role of epidural anesthesia in a fast track liver resection protocol for cirrhotic patients &#x2014; results after three years of practice. World J Hepatol. 2016;8(26):1097&#x2013;1104. doi: 10.4254/wjh.v8.i26.1097.</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/wjh.v8.i26.1097</ArticleId><ArticleId IdType="pmc">PMC5026992</ArticleId><ArticleId IdType="pubmed">27660677</ArticleId></ArticleIdList></Reference><Reference><Citation>Merath K, Hyer JM, Mehta R, Bagante F, Paredes A, Wu L, et al. Use of perioperative epidural analgesia among Medicare patients undergoing hepatic and pancreatic surgery. HPB (Oxford) 2019;21(8):1064&#x2013;1071. doi: 10.1016/j.hpb.2018.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hpb.2018.12.008</ArticleId><ArticleId IdType="pubmed">30718186</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes M, McNally S, McKeown DW, Wigmore S. Effect of analgesic modality on outcome following open liver surgery: a systematic review of postoperative analgesia. Minerva Anestesiol. 2015;81(5):541&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">24918191</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaak C, Spies C, Schneider A, Jara M, Vorderwulbecke G, Kuhlmann AD, et al. Epidural anesthesia in liver surgery&#x2014;a propensity score-matched analysis. Pain Med. 2020;21(11):2650&#x2013;2660. doi: 10.1093/pm/pnaa130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnaa130</ArticleId><ArticleId IdType="pubmed">32651587</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Pu Y, Zhao Z, Yang X. Influence of combined epidural anesthesia on cognitive function, inflammation and stress response in elderly liver cancer patients undergoing surgery. Oncol Lett. 2020;19(4):2733&#x2013;2738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7068239</ArticleId><ArticleId IdType="pubmed">32218825</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RD. Miller&#x2019;s anesthesia. 8. Philadelphia: Elsevier; 2015.</Citation></Reference><Reference><Citation>Clarke H, Chandy T, Srinivas C, Ladak S, Okubo N, Mitsakakis N, et al. Epidural analgesia provides better pain management after live liver donation: a retrospective study. Liver Transpl. 2011;17(3):315&#x2013;323. doi: 10.1002/lt.22221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.22221</ArticleId><ArticleId IdType="pubmed">21384514</ArticleId></ArticleIdList></Reference><Reference><Citation>Revie EJ, Massie LJ, McNally SJ, McKeown DW, Garden OJ, Wigmore SJ. Effectiveness of epidural analgesia following open liver resection. HPB (Oxford) 2011;13(3):206&#x2013;211. doi: 10.1111/j.1477-2574.2010.00274.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1477-2574.2010.00274.x</ArticleId><ArticleId IdType="pmc">PMC3048973</ArticleId><ArticleId IdType="pubmed">21309939</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S, DeRoche A, Adams L, Slocum KV, Clark CJ, Fino NF, et al. Effect of epidural compared to patient-controlled intravenous analgesia on outcomes for patients undergoing liver resection for neoplastic disease. J Surg Oncol. 2017;115(4):402&#x2013;406. doi: 10.1002/jso.24534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.24534</ArticleId><ArticleId IdType="pmc">PMC5400729</ArticleId><ArticleId IdType="pubmed">28185289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kambakamba P, Slankamenac K, Tschuor C, Kron P, Wirsching A, Maurer K, et al. Epidural analgesia and perioperative kidney function after major liver resection. Br J Surg. 2015;102(7):805&#x2013;812. doi: 10.1002/bjs.9810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.9810</ArticleId><ArticleId IdType="pubmed">25877255</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber KL, Chelly JE, Lang RS, Abuelkasem E, Geller DA, Marsh JW, et al. Epidural versus paravertebral nerve block for postoperative analgesia in patients undergoing open liver resection: a randomized clinical trial. Reg Anesth Pain Med. 2016;41(4):460&#x2013;468. doi: 10.1097/AAP.0000000000000422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AAP.0000000000000422</ArticleId><ArticleId IdType="pubmed">27281726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hausken J, Fretland AA, Edwin B, Andersen MH, Dagenborg VJ, Bjornelv GMW, et al. Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery: a prospective, randomized, controlled, noninferiority trial. Ann Surg. 2019;270(2):193&#x2013;199. doi: 10.1097/SLA.0000000000003209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000003209</ArticleId><ArticleId IdType="pubmed">30676382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell R, Ward D, Jeffery J, Toogood GJ, Lodge JA, Rao K, et al. A randomized controlled trial comparing epidural analgesia versus continuous local anesthetic infiltration via abdominal wound catheter in open liver resection. Ann Surg. 2019;269(3):413&#x2013;419. doi: 10.1097/SLA.0000000000002988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000002988</ArticleId><ArticleId IdType="pubmed">30080727</ArticleId></ArticleIdList></Reference><Reference><Citation>Guay J, Nishimori M, Kopp SL. Epidural local anesthetics versus opioid-based analgesic regimens for postoperative gastrointestinal paralysis, vomiting, and pain after abdominal surgery: a Cochrane review. Anesth Analg. 2016;123(6):1591&#x2013;1602. doi: 10.1213/ANE.0000000000001628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000001628</ArticleId><ArticleId IdType="pubmed">27870743</ArticleId></ArticleIdList></Reference><Reference><Citation>Elterman KG, Xiong Z. Coagulation profile changes and safety of epidural analgesia after hepatectomy: a retrospective study. J Anesth. 2015;29(3):367&#x2013;372. doi: 10.1007/s00540-014-1933-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00540-014-1933-4</ArticleId><ArticleId IdType="pubmed">25391365</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SJ, Gwak MS, Ko JS, Kim GS, Ahn HJ, Yang M, et al. The changes in coagulation profile and epidural catheter safety for living liver donors: a report on 6 years of our experience. Liver Transpl. 2007;13(1):62&#x2013;70. doi: 10.1002/lt.20933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.20933</ArticleId><ArticleId IdType="pubmed">17192873</ArticleId></ArticleIdList></Reference><Reference><Citation>Karna ST, Pandey CK, Sharma S, Singh A, Tandon M, Pandey VK. Postoperative coagulopathy after live related donor hepatectomy: incidence, predictors and implications for safety of thoracic epidural catheter. J Postgrad Med. 2015;61(3):176&#x2013;180. doi: 10.4103/0022-3859.159419.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0022-3859.159419</ArticleId><ArticleId IdType="pmc">PMC4943418</ArticleId><ArticleId IdType="pubmed">26119437</ArticleId></ArticleIdList></Reference><Reference><Citation>Koul A, Pant D, Rudravaram S, Sood J. Thoracic epidural analgesia in donor hepatectomy: an analysis. Liver Transpl. 2018;24(2):214&#x2013;221. doi: 10.1002/lt.24989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lt.24989</ArticleId><ArticleId IdType="pubmed">29205784</ArticleId></ArticleIdList></Reference><Reference><Citation>Volk T, Wolf A, Van Aken H, Burkle H, Wiebalck A, Steinfeldt T. Incidence of spinal haematoma after epidural puncture: analysis from the German network for safety in regional anaesthesia. Eur J Anaesthesiol. 2012;29(4):170&#x2013;176. doi: 10.1097/EJA.0b013e3283504fec.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0b013e3283504fec</ArticleId><ArticleId IdType="pubmed">22374389</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook TM, Counsell D, Wildsmith JA, Royal College of Anaesthetists Third National Audit Project Major complications of central neuraxial block: report on the Third National Audit Project of the Royal College of Anaesthetists. Br J Anaesth. 2009;102(2):179&#x2013;190. doi: 10.1093/bja/aen360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aen360</ArticleId><ArticleId IdType="pubmed">19139027</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell R, Pandanaboyana S, Prasad KR. Epidural versus local anaesthetic infiltration via wound catheters in open liver resection: a meta-analysis. ANZ J Surg. 2015;85(1-2):16&#x2013;21. doi: 10.1111/ans.12683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ans.12683</ArticleId><ArticleId IdType="pubmed">24888251</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriilidis P, Roberts KJ, Sutcliffe RP. Local anaesthetic infiltration via wound catheter versus epidural analgesia in open hepatectomy: a systematic review and meta-analysis of randomised controlled trials. HPB (Oxford) 2019;21(8):945&#x2013;952. doi: 10.1016/j.hpb.2019.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hpb.2019.02.007</ArticleId><ArticleId IdType="pubmed">30879991</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings KC, III, Zimmerman NM, Maheshwari K, Cooper GS, Cummings LC. Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: a retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth. 2018;47:12&#x2013;18. doi: 10.1016/j.jclinane.2018.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinane.2018.03.005</ArticleId><ArticleId IdType="pmc">PMC5936664</ArticleId><ArticleId IdType="pubmed">29544203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kampe S, Weinreich G, Darr C, Eicker K, Stamatis G, Hachenberg T. The impact of epidural analgesia compared to systemic opioid-based analgesia with regard to length of hospital stay and recovery of bowel function: retrospective evaluation of 1555 patients undergoing thoracotomy. J Cardiothorac Surg. 2014;9:175. doi: 10.1186/s13019-014-0175-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13019-014-0175-8</ArticleId><ArticleId IdType="pmc">PMC4246432</ArticleId><ArticleId IdType="pubmed">25417134</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25373840</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1436-2023</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association</Title><ISOAbbreviation>J Orthop Sci</ISOAbbreviation></Journal><ArticleTitle>Use of a tourniquet in total knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>110</StartPage><EndPage>123</EndPage><MedlinePgn>110-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00776-014-0664-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A tourniquet is commonly used in total knee arthroplasty (TKA). However, the effectiveness and safety of tourniquets are debated. We performed this study to investigate whether patients benefit from the use of tourniquets in TKA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The literature search was conducted using PubMed, Cochrane Library, MEDLINE, Embase, and other medical databases. After a literature search, 26 randomized controlled trials involving 1,450 knees were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Tourniquet use significantly decreased intraoperative blood loss, transfusion rate, and operation time but not postoperative blood loss, measurable total blood loss, calculated total blood loss, transfusion volume, incidence of pulmonary embolism, or duration of hospital stay. It also slowed down joint functional recovery in the short term and increased the incidence of deep vein thrombosis and other minor wound complications.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Data from this meta-analysis indicate that patients may benefit from the use of a tourniquet in TKA; however, it use is accompanied by disadvantages and complications. Because of the very low-evidence quality and lower grading of recommendations, assessment, development, and evaluation recommendation strength, no guidelines can be developed based on current evidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Fang-Zhen</ForeName><Initials>FZ</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, Second Affiliated Hospital, Zhejiang University, School of Medicine, No. 88 Jiefang road, Hangzhou, 310009, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Hui-Ming</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Yu-Cai</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Guang-Feng</ForeName><Initials>GF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>J Orthop Sci</MedlineTA><NlmUniqueID>9604934</NlmUniqueID><ISSNLinking>0949-2658</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="N">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006488" MajorTopicYN="N">Hemostasis, Surgical</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="Y">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019106" MajorTopicYN="N">Postoperative Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014111" MajorTopicYN="Y">Tourniquets</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25373840</ArticleId><ArticleId IdType="doi">10.1007/s00776-014-0664-6</ArticleId><ArticleId IdType="pii">S0949-2658(15)30156-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28149552</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2072-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>12</Issue><PubDate><Year>2016</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>MicroRNAs are novel non-invasive diagnostic biomarkers for pulmonary embolism: a meta-analysis.</ArticleTitle><Pagination><StartPage>3580</StartPage><EndPage>3587</EndPage><MedlinePgn>3580-3587</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/jtd.2016.12.98</ELocationID><Abstract><AbstractText Label="BACKGROUNDS" NlmCategory="BACKGROUND">The diagnosis of pulmonary embolism (PE) still remains difficult in clinical practice. MicroRNAs (miRNAs) have been widely investigated as biomarkers for various diseases. However, the diagnostic biomarker value of miRNAs in the diagnosis of PE is unclear. Therefore, we conducted this meta-analysis to establish the diagnostic power of miRNAs for PE diagnosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic literature search in PubMed and Embase was conducted to identify relevant studies dated up to July 22, 2016. Data on sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were pooled from those included studies. Summary receiver operating characteristic (SROC) curves were used to summarize overall diagnostic power of miRNAs for PE diagnosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of three studies with five types of miRNAs covering 254 participants were included in our meta-analysis. The overall pooled results for sensitivity, specificity, PLR, NLR, and DOR of miRNAs for PE diagnosis were 0.83 [95% confidence intervals (CI): 0.67-0.92], 0.85 (95% CI: 0.72-0.92), 5.4 (95% CI: 2.7-10.9), 0.20 (95% CI: 0.10-0.44), and 26.00 (95% CI: 7.00-101.00), respectively. The area under the SROC curve was 0.90 (95% CI: 0.87-0.92). Even though heterogeneity was observed in the analysis of sensitivity, there was no evidence of publication bias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MiRNAs could serve as novel non-invasive diagnostic biomarkers of PE with a relatively high diagnostic power. More researches, however, are needed to explore the diagnostic as well as therapeutic values of miRNAs for PE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Han-Yu</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China;; West China School of Medicine, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Gang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China;; West China School of Medicine, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China;; West China School of Medicine, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhi-Qiang</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China;; West China School of Medicine, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiao-Yan</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Information Center, West China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yi-Dan</ForeName><Initials>YD</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lun-Xu</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MicroRNA</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">pulmonary embolism (PE)</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28149552</ArticleId><ArticleId IdType="pmc">PMC5227248</ArticleId><ArticleId IdType="doi">10.21037/jtd.2016.12.98</ArticleId><ArticleId IdType="pii">jtd-08-12-3580</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lapner ST, Kearon C. Diagnosis and management of pulmonary embolism. BMJ 2013;346:f757. 10.1136/bmj.f757</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.f757</ArticleId><ArticleId IdType="pubmed">23427133</ArticleId></ArticleIdList></Reference><Reference><Citation>Monreal M, Mah&#xe9; I, Bura-Riviere A, et al. Pulmonary embolism: Epidemiology and registries. Presse Med 2015;44:e377-83. 10.1016/j.lpm.2015.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lpm.2015.10.006</ArticleId><ArticleId IdType="pubmed">26547675</ArticleId></ArticleIdList></Reference><Reference><Citation>Righini M, Robert-Ebadi H, Le Gal G. Diagnosis of pulmonary embolism. Presse Med 2015;44:e385-91. 10.1016/j.lpm.2015.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lpm.2015.10.007</ArticleId><ArticleId IdType="pubmed">26585743</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C. Diagnosis of pulmonary embolism. CMAJ 2003;168:183-94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140429</ArticleId><ArticleId IdType="pubmed">12538548</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Nisio M, van Es N, Buller HR. Deep vein thrombosis and pulmonary embolism. Lancet 2017;388:3060-3073. 10.1016/S0140-6736(16)30514-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)30514-1</ArticleId><ArticleId IdType="pubmed">27375038</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med 2004;140:589-602. 10.7326/0003-4819-140-8-200404200-00005</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-140-8-200404200-00005</ArticleId><ArticleId IdType="pubmed">15096330</ArticleId></ArticleIdList></Reference><Reference><Citation>Woller SC, Stevens SM, Adams DM, et al. Assessment of the safety and efficiency of using an age-adjusted D-dimer threshold to exclude suspected pulmonary embolism. Chest 2014;146:1444-51. 10.1378/chest.13-2386</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.13-2386</ArticleId><ArticleId IdType="pubmed">24831769</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhead S, Ferguson C. Towards evidence based emergency medicine: Best BETs from the Manchester Royal Infirmary. BET 2: Current evidence does support the use of a negative D-dimer to rule out suspected pulmonary embolism in pregnancy. Emerg Med J 2014;31:946-7. 10.1136/emermed-2014-204290.2</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/emermed-2014-204290.2</ArticleId><ArticleId IdType="pubmed">25326500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto E, Kuroda T, Fujita Y, et al. D-dimer testing cannot rule out thromboembolism after major lower extremity arthroplasties and thromboprophylaxis treatment. J Anesth 2015;29:686-9. 10.1007/s00540-015-2020-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00540-015-2020-1</ArticleId><ArticleId IdType="pubmed">25957116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schembri GP, Miller AE, Smart R. Radiation dosimetry and safety issues in the investigation of pulmonary embolism. Semin Nucl Med 2010;40:442-54. 10.1053/j.semnuclmed.2010.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semnuclmed.2010.07.007</ArticleId><ArticleId IdType="pubmed">20920634</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97. 10.1016/S0092-8674(04)00045-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(04)00045-5</ArticleId><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012;13:358-69. 10.1038/nrg3198</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3198</ArticleId><ArticleId IdType="pmc">PMC4517822</ArticleId><ArticleId IdType="pubmed">22510765</ArticleId></ArticleIdList></Reference><Reference><Citation>Inamura K, Ishikawa Y. MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment. J Clin Med 2016;5. pii: E36. 10.3390/jcm5030036</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm5030036</ArticleId><ArticleId IdType="pmc">PMC4810107</ArticleId><ArticleId IdType="pubmed">27005669</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada K, Baba Y, Ishimoto T, et al. The role of microRNA in esophageal squamous cell carcinoma. J Gastroenterol 2016;51:520-30. 10.1007/s00535-016-1161-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-016-1161-9</ArticleId><ArticleId IdType="pubmed">26794004</ArticleId></ArticleIdList></Reference><Reference><Citation>Basak I, Patil KS, Alves G, et al. microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases. Cell Mol Life Sci 2016;73:811-27. 10.1007/s00018-015-2093-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-015-2093-x</ArticleId><ArticleId IdType="pmc">PMC11108480</ArticleId><ArticleId IdType="pubmed">26608596</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Zhang J. Circulating MicroRNAs: Potential and Emerging Biomarkers for Diagnosis of Cardiovascular and Cerebrovascular Diseases. Biomed Res Int 2015;2015:730535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4477423</ArticleId><ArticleId IdType="pubmed">26180810</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao J, Jing ZC, Ellinor PT, et al. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med 2011;9:159. 10.1186/1479-5876-9-159</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-9-159</ArticleId><ArticleId IdType="pmc">PMC3189884</ArticleId><ArticleId IdType="pubmed">21943159</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Wen W, Shan X, et al. MiR-28-3p as a potential plasma marker in diagnosis of pulmonary embolism. Thromb Res 2016;138:91-5. 10.1016/j.thromres.2015.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2015.12.006</ArticleId><ArticleId IdType="pubmed">26702486</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler T, Erdmann J, Vilne B, et al. Serum microRNA-1233 is a specific biomarker for diagnosing acute pulmonary embolism. J Transl Med 2016;14:120. 10.1186/s12967-016-0886-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-016-0886-9</ArticleId><ArticleId IdType="pmc">PMC4858885</ArticleId><ArticleId IdType="pubmed">27150028</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36. 10.7326/0003-4819-155-8-201110180-00009</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-155-8-201110180-00009</ArticleId><ArticleId IdType="pubmed">22007046</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31. 10.1186/1471-2288-6-31</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-6-31</ArticleId><ArticleId IdType="pmc">PMC1552081</ArticleId><ArticleId IdType="pubmed">16836745</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882-93. 10.1016/j.jclinepi.2005.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2005.01.016</ArticleId><ArticleId IdType="pubmed">16085191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoletti L, Humbert M. Pulmonary embolism: An update. Presse Med 2015;44:e373-6. 10.1016/j.lpm.2015.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lpm.2015.10.005</ArticleId><ArticleId IdType="pubmed">26547677</ArticleId></ArticleIdList></Reference><Reference><Citation>Remy-Jardin M, Pistolesi M, Goodman LR, et al. Management of suspected acute pulmonary embolism in the era of CT angiography: a statement from the Fleischner Society. Radiology 2007;245:315-29. 10.1148/radiol.2452070397</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2452070397</ArticleId><ArticleId IdType="pubmed">17848685</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Q, Wang W, Yu X, et al. Upregulation of MicroRNA-126 Contributes to Endothelial Progenitor Cell Function in Deep Vein Thrombosis via Its Target PIK3R2. J Cell Biochem 2015;116:1613-23. 10.1002/jcb.25115</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.25115</ArticleId><ArticleId IdType="pubmed">25652288</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Wang J, Wang B, et al. MiR-126 inhibits vascular endothelial cell apoptosis through targeting PI3K/Akt signaling. Ann Hematol 2016;95:365-74. 10.1007/s00277-015-2567-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-015-2567-9</ArticleId><ArticleId IdType="pubmed">26659078</ArticleId></ArticleIdList></Reference><Reference><Citation>Gareri C, De Rosa S, Indolfi C. MicroRNAs for Restenosis and Thrombosis After Vascular Injury. Circ Res 2016;118:1170-84. 10.1161/CIRCRESAHA.115.308237</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.115.308237</ArticleId><ArticleId IdType="pubmed">27034278</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26504150</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Incidence of Venous Thromboembolism and Benefits and Risks of Thromboprophylaxis After Cardiac Surgery: A Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>e002652</StartPage><MedlinePgn>e002652</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e002652</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.115.002652</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Optimal thromboprophylaxis after cardiac surgery is uncertain. This systematic review aimed to define the incidence and risk factors for deep vein thrombosis (DVT), fatal and nonfatal pulmonary embolism (PE), and assess whether venous thromboembolism (VTE) prophylaxis was effective in reducing VTE without complications after cardiac surgery.</AbstractText><AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Two reviewers independently searched and assessed the quality and outcomes of randomized, controlled trials (RCTs) and observational studies on VTE after cardiac surgery in the MEDLINE, EMBASE, and Cochrane controlled trial register (1966 to December 2014). Sixty-eight studies provided data on VTE outcomes or complications related to thromboprophylaxis after cardiac surgery. The majority of the studies were observational studies (n=49), 16 studies were RCTs, and 3 were meta-analyses. VTE prophylaxis was associated with a reduced risk of PE (relative risk [RR], 0.45; 95% confidence interval [CI], 0.28-0.72; P=0.0008) or symptomatic VTE (RR, 0.44; 95% CI, 0.28-0.71; P=0.0006) compared to the control without significant heterogeneity. Median incidence (interquartile range) of symptomatic DVT, PE, and fatal PE were 3.2% (0.6-8.1), 0.6% (0.3-2.9), and 0.3% (0.08-1.7), respectively. Previous history of VTE, obesity, left or right ventricular failure, and prolonged bed rest, mechanical ventilation, or use of a central venous catheter were common risk factors for VTE. Bleeding or cardiac tamponade requiring reoperation owing to pharmacological VTE prophylaxis alone, without systemic anticoagulation, was not observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Unless proven otherwise by adequately powered RCTs, initiating pharmacological VTE prophylaxis as soon as possible after cardiac surgery for patients who have no active bleeding is highly recommended.</AbstractText><CopyrightInformation>&#xa9; 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Kwok M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Royal Perth Hospital, Perth, WA, Australia (K.M.H.) School of Population Health, University of Western Australia, Perth, WA, Australia (K.M.H.) School of Veterinary and Life Sciences, Murdoch University, Perth, WA, Australia (K.M.H., W.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bham</LastName><ForeName>Ebrahim</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Fiona Stanley Hospital, Perth, WA, Australia (E.B., W.P.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavey</LastName><ForeName>Warren</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Veterinary and Life Sciences, Murdoch University, Perth, WA, Australia (K.M.H., W.P.) Department of Anesthesia, Fiona Stanley Hospital, Perth, WA, Australia (E.B., W.P.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">deep vein thrombosis</Keyword><Keyword MajorTopicYN="N">heart surgery</Keyword><Keyword MajorTopicYN="N">prevention</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26504150</ArticleId><ArticleId IdType="pmc">PMC4845147</ArticleId><ArticleId IdType="doi">10.1161/JAHA.115.002652</ArticleId><ArticleId IdType="pii">JAHA.115.002652</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention (CDC) . Venous thromboembolism in adult hospitalizations&#x2014;United States, 2007&#x2013;2009. MMWR Morb Mortal Wkly Rep. 2012;61:401&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">22672974</ArticleId></ArticleIdList></Reference><Reference><Citation>
The burden of venous thromboembolism in Australia. Report by Access Economics Pty Limited for the Australian and New Zealand Working Party on the management and prevention of venous thromboembolism in Australia. 2008.  May. Available at: https://www.google.com.au/?gws_rd=ssl#q=The+burden+of+venous+thromboembolism+in+Australia.+Report+by+Access. Accessed October 15, 2015.</Citation></Reference><Reference><Citation>Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U, Nashef SA; EACTS Audit and Guidelines Committee . Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008;34:73&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18375137</ArticleId></ArticleIdList></Reference><Reference><Citation>Cikirikcioglu M, Myers PO, Kalangos A. First do no harm: postoperative thromboprophylaxis following open heart surgery. Eur J Cardiothorac Surg. 2013;44:184.</Citation><ArticleIdList><ArticleId IdType="pubmed">23295448</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM; American College of Chest Physicians . Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence&#x2010;Based Clinical Practice Guidelines. Chest. 2012;141:e227S&#x2013;e277S.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278061</ArticleId><ArticleId IdType="pubmed">22315263</ArticleId></ArticleIdList></Reference><Reference><Citation>Parolari A, Mussoni L, Frigerio M, Naliato M, Alamanni F, Galanti A, Fiore G, Veglia F, Tremoli E, Biglioli P, Camera M. Increased prothrombotic state lasting as long as one month after on&#x2010;pump and off&#x2010;pump coronary surgery. J Thorac Cardiovasc Surg. 2005;130:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">16077391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lison S, Dietrich W, Braun S, Boehm J, Schuster T, Englhard A, Perchuc A, Spannagl M, Busley R. Enhanced thrombin generation after cardiopulmonary bypass surgery. Anesth Analg. 2011;112:37&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21127274</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallely MP, Bannon PG, Bayfield MS, Hughes CF, Kritharides L. Quantitative and temporal differences in coagulation, fibrinolysis and platelet activation after on&#x2010;pump and off&#x2010;pump coronary artery bypass surgery. Heart Lung Circ. 2009;18:123&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">19081297</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelman JJ, Reddel CJ, Kritharides L, Bannon PG, Fraser JF, Curnow JL, Vallely MP. Natural history of hypercoagulability in patients undergoing coronary revascularization and effect of preoperative myocardial infarction. J Thorac Cardiovasc Surg. 2014;148:536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">24280714</ArticleId></ArticleIdList></Reference><Reference><Citation>Romlin BS, S&#xf6;derlund F, W&#xe5;hlander H, Nilsson B, Baghaei F, Jeppsson A. Platelet count and function in paediatric cardiac surgery: a prospective observational study. Br J Anaesth. 2014;113:847&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">25012582</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla M, Parolari A, Camera M, Colli S, Eligini S, Centenaro C, Anselmo A, Alamanni F, Tremoli E. Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery. Thromb Haemost. 2010;103:516&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">20076848</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schr&#xf6;r K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003;108:542&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">12874188</ArticleId></ArticleIdList></Reference><Reference><Citation>Emani S, Trainor B, Zurakowski D, Baird CW, Fynn&#x2010;Thompson FE, Pigula FA, Emani SM. Aspirin unresponsiveness predicts thrombosis in high&#x2010;risk pediatric patients after cardiac surgery. J Thorac Cardiovasc Surg. 2014;148:810&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pubmed">25129584</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta&#x2010;analyses. BMJ. 2003;327:557&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos RS, Salem BI, Haikal M, Gowda S, Coordes C, Leidenfrost R. Critical role of pulmonary angiography in the diagnosis of pulmonary emboli following cardiac surgery. Cathet Cardiovasc Diagn. 1995;36:112&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">8829830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos R, Salem BI, De Pawlikowski MP, Coordes C, Eisenberg S, Leidenfrost R. The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest. 1996;109:82&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">8549224</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirhosseini SJ, Forouzannia SK, Mostafavi Pour Manshadi SM, Ali&#x2010;Hassan&#x2010;Sayegh S, Naderi N, Sanatkar M. Comparison of aspirin plus heparin with heparin alone on asymptomatic perioperative deep vein thrombosis in candidates for elective off&#x2010;pump coronary artery bypass graft: a randomized clinical trial. Cardiol J. 2013;20:139&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">23558871</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4&#x2010;heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low&#x2010;molecular&#x2010;weight heparin: clinical implications for heparin&#x2010;induced thrombocytopenia. Circulation. 1999;99:2530&#x2013;2536.</Citation><ArticleIdList><ArticleId IdType="pubmed">10330384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulik A, Rassen JA, Myers J, Schneeweiss S, Gagne J, Polinski JM, Liu J, Fischer MA, Choudhry NK. Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery. Circ Cardiovasc Interv. 2012;5:590&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pubmed">22739788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosetti M, Salerno M, Zambelli M, Mastropasqua F, Tramarin R, Pedretti RF. Deep vein thrombosis among patients entering cardiac rehabilitation after coronary artery bypass surgery. Chest. 2004;125:191&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">14718440</ArticleId></ArticleIdList></Reference><Reference><Citation>Frizzelli R, Tortelli O, Di Comite V, Ghirardi R, Pinzi C, Scarduelli C. Deep venous thrombosis of the neck and pulmonary embolism in patients with a central venous catheter admitted to cardiac rehabilitation after cardiac surgery: a prospective study of 815 patients. Intern Emerg Med. 2008;3:325&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">18357502</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLaria GA, Hunter JA. Deep venous thrombosis. Implications after open heart surgery. Chest. 1991;99:284&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">1989784</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM, Bertenshaw C, Same S, Schneider M, Williams KA, Godsell T, Hird K. Differential associations between body mass index and outcomes after elective adult cardiac surgery: a linked data cohort study. Anaesth Intensive Care. 2013;41:573&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">23977907</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson EC, Levine FH. Hyperlipoproteinemia as a significant risk factor for pulmonary embolism in patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 1982;33:593&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">6979985</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwann TA, Kistler L, Engoren MC, Habib RH. Incidence and predictors of postoperative deep vein thrombosis in cardiac surgery in the era of aggressive thromboprophylaxis. Ann Thorac Surg. 2010;90:760&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">20732491</ArticleId></ArticleIdList></Reference><Reference><Citation>Saranteas T, Kostopanagiotou G, Tzoufi M, Drachtidi K, Knox GM, Panou F. Incidence of inferior vena cava thrombosis detected by transthoracic echocardiography in the immediate postoperative period after adult cardiac and general surgery. Anaesth Intensive Care. 2013;41:782&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">24180720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosetti M, Ageno W, Salerno M, Pedretti RF. Postoperative pericardial effusion in patients receiving anticoagulants for deep vein thrombosis after coronary artery bypass graft surgery. J Thromb Haemost. 2005;3:2367&#x2013;2368.</Citation><ArticleIdList><ArticleId IdType="pubmed">16194218</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao G, Zikria EA, Miller WH, Samadani SR, Ford WB. Incidence and prevention of pulmonary embolism after coronary artery surgery. Vasc Surg. 1975;9:37&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">1079102</ArticleId></ArticleIdList></Reference><Reference><Citation>Josa M, Siouffi SY, Silverman AB, Barsamian EM, Khuri SF, Sharma GV. Pulmonary embolism after cardiac surgery. J Am Coll Cardiol. 1993;21:990&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">8450170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillinov AM, Davis EA, Alberg AJ, Rykiel M, Gardner TJ, Cameron DE. Pulmonary embolism in the cardiac surgical patient. Ann Thorac Surg. 1992;53:988&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">1596161</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis SE, Polak JF, Hirsch DR, Cohn LH, Creager MA, Donovan BC, Goldhaber SZ. Frequency of deep venous thrombosis in asymptomatic patients with coronary artery bypass grafts. Am Heart J. 1991;122:478&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">1858629</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N, Hiromatsu S, Shintani Y, Kanaya K, Fukunaga S, Aoyagi S. Prevention of venous thromboembolism in thoracic and cardiovascular surgery. Asian Cardiovasc Thorac Ann. 2009;17:505&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">19917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahtinen J, Ahvenj&#xe4;rvi L, Biancari F, Ojala R, Mosorin M, Cresti R, Lepoj&#xe4;rvi M, Juvonen T. Pulmonary embolism after off&#x2010;pump coronary artery bypass surgery as detected by computed tomography. Am J Surg. 2006;192:396&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920438</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra B, Phillips L, Cameron PA, Billah B, Reid C. The safety of recombinant factor VIIa in cardiac surgery. Anaesth Intensive Care. 2010;38:671&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">20715730</ArticleId></ArticleIdList></Reference><Reference><Citation>Canver CC, Fiedler RC. Venous thromboembolic complications after open heart surgery. Vasc Endovascular Surg. 1992;26:213&#x2013;217.</Citation></Reference><Reference><Citation>Ayatollahzade&#x2010;Isfahani F, Pashang M, Omran AS, Saadat S, Shirani S, Fathollahi MS. Comparing the impact of supine and leg elevation positions during coronary artery bypass graft on deep vein thrombosis occurrence: a randomized clinical trial study. J Vasc Nurs. 2013;31:64&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">23683764</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi MJ, Pierce RA, Zhang L, Moon MR, Despotis GJ, Moazami N. Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant. J Cardiothorac Surg. 2007;2:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1939840</ArticleId><ArticleId IdType="pubmed">17617902</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller J, Jeudy J, Poston R, White CS. Cardiac CT angiography after coronary bypass surgery: prevalence of incidental findings. AJR Am J Roentgenol. 2007;189:414&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4146433</ArticleId><ArticleId IdType="pubmed">17646469</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM. Complications of the COX&#x2010;2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713945</ArticleId></ArticleIdList></Reference><Reference><Citation>Belczak CE, Tyszka AL, Godoy JM, Ramos RN, Belczak SQ, Caffaro RA. Clinical complications of limb undergone harvesting of great saphenous vein for coronary artery bypass grafting using bridge technique. Rev Bras Cir Cardiovasc. 2009;24:68&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">19504022</ArticleId></ArticleIdList></Reference><Reference><Citation>ElBardissi AW, Shekar P, Couper GS, Cohn LH. Minimally invasive aortic valve replacement in octogenarian, high&#x2010;risk, transcatheter aortic valve implantation candidates. J Thorac Cardiovasc Surg. 2011;141:328&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">21047646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, Sellke F, Booth F, Schmidt TA. Safety and efficacy of recombinant activated factor VII: a randomized placebo&#x2010;controlled trial in the setting of bleeding after cardiac surgery. Circulation. 2009;120:21&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">19546387</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfirevic A, Duncan A, You J, Lober C, Soltesz E. Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg. 2014;98:618&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122638</ArticleId><ArticleId IdType="pubmed">24968771</ArticleId></ArticleIdList></Reference><Reference><Citation>White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90:446&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">12958614</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrindle BW, Manlhiot C, Cochrane A, Roberts R, Hughes M, Szechtman B, Weintraub R, Andrew M, Monagle P; Fontan Anticoagulation Study Group . Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2&#xa0;years after the Fontan procedure. J Am Coll Cardiol. 2013;61:346&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">23246393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahn R, Gerckens U, Linke A, Sievert H, Kahlert P, Hambrecht R, Sack S, Abdel&#x2010;Wahab M, Hoffmann E, Schiele R, Schneider S, Senges J; German Transcatheter Aortic Valve Interventions&#x2010;Registry Investigators . Predictors of one&#x2010;year mortality after transcatheter aortic valve implantation for severe symptomatic aortic stenosis. Am J Cardiol. 2013;112:272&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">23578349</ArticleId></ArticleIdList></Reference><Reference><Citation>Iribarne A, Burgener JD, Hong K, Raman J, Akhter S, Easterwood R, Jeevanandam V, Russo MJ. Quantifying the incremental cost of complications associated with mitral valve surgery in the United States. J Thorac Cardiovasc Surg. 2012;143:864&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">22424521</ArticleId></ArticleIdList></Reference><Reference><Citation>Thielmann M, Bunschkowski M, Tossios P, Selleng S, Marggraf G, Greinacher A, Jakob H, Massoudy P. Perioperative thrombocytopenia in cardiac surgical patients&#x2014;incidence of heparin&#x2010;induced thrombocytopenia, morbidities and mortality. Eur J Cardiothorac Surg. 2010;37:1391&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pubmed">20138779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal DN, Friedman AH, Kleinman CS, Kopf GS, Rosenfeld LE, Hellenbrand WE. Thromboembolic complications after Fontan operations. Circulation. 1995;92:II287&#x2013;II293.</Citation><ArticleIdList><ArticleId IdType="pubmed">7586425</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalopoulos A, Tzelepis G, Dafni U, Geroulanos S. Determinants of hospital mortality after coronary artery bypass grafting. Chest. 1999;115:1598&#x2013;1603.</Citation><ArticleIdList><ArticleId IdType="pubmed">10378555</ArticleId></ArticleIdList></Reference><Reference><Citation>Briffa N, Large SR. Venous thromboembolism in coronary artery surgery. Heart. 1996;75:433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC484334</ArticleId><ArticleId IdType="pubmed">8665330</ArticleId></ArticleIdList></Reference><Reference><Citation>Doss M, Wood JP, Kiessling AH, Moritz A. Comparative evaluation of left ventricular mass regression after aortic valve replacement: a prospective randomized analysis. J Cardiothorac Surg. 2011;6:136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199244</ArticleId><ArticleId IdType="pubmed">21992565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucci C, Geerts WH, Sinclair A, Fremes SE. Comparison of the effectiveness and safety of low&#x2010;molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery. Am J Cardiol. 2011;107:591&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">21184996</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalescot G, Polle V, Collet JP, Leprince P, Bellanger A, Gandjbakhch I, Thomas D. Low molecular weight heparin after mechanical heart valve replacement. Circulation. 2000;101:1083&#x2013;1086.</Citation><ArticleIdList><ArticleId IdType="pubmed">10715251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Lee SJ, Tsushima WT, Yamauchi H, Lau WT, Popper J, Stein A, Johnson D, Lee D, Petrovitch H, Dang CR. Benefits of off&#x2010;pump bypass on neurologic and clinical morbidity: a prospective randomized trial. Ann Thorac Surg. 2003;76:18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">12842506</ArticleId></ArticleIdList></Reference><Reference><Citation>Riess FC, Poetzsch B, Madlener K, Cramer E, Doll KN, Doll S, Lorke DE, Kormann J, Mueller&#x2010;Berghaus G. Recombinant hirudin for cardiopulmonary bypass anticoagulation: a randomized, prospective, and heparin&#x2010;controlled pilot study. Thorac Cardiovasc Surg. 2007;55:233&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">17546553</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastan AJ, Gummert JF, Lachmann N, Walther T, Schmitt DV, Falk V, Doll N, Caffier P, Richter MM, Wittekind C, Mohr FW. Significant value of autopsy for quality management in cardiac surgery. J Thorac Cardiovasc Surg. 2005;129:1292&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15942569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zehr KJ, Liddicoat JR, Salazar JD, Gillinov AM, Hruban RH, Hutchins GM, Cameron DE. The autopsy: still important in cardiac surgery. Ann Thorac Surg. 1997;64:380&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">9262579</ArticleId></ArticleIdList></Reference><Reference><Citation>Heard BE. Pathology of hearts after aortocoronary saphenous vein bypass grafting for coronary artery disease, studied by post&#x2010;mortem coronary angiography. Br Heart J. 1976;38:838&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC483096</ArticleId><ArticleId IdType="pubmed">1086091</ArticleId></ArticleIdList></Reference><Reference><Citation>Song HK, Tibayan FA, Kahl EA, Sera VA, Slater MS, Deloughery TG, Scanlan MM. Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. J Thorac Cardiovasc Surg. 2014;147:1036&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">24365268</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez R, Haft JI. Temporal relationship of complications after coronary artery bypass graft surgery: scheduling for safe discharge. Am Heart J. 1994;127:282&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">8296694</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler Ma SC, Brindle W, Burton G, Gallacher S, Hong FC, Manelius I, Smith A, Ho W, Alston RP, Bhattacharya K. Tranexamic acid is associated with less blood transfusion in off&#x2010;pump coronary artery bypass graft surgery: a systematic review and meta&#x2010;analysis. J Cardiothorac Vasc Anesth. 2011;25:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">21115366</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone C, Galasso G, Piccolo R, de Leva F, Paladini R, Piscione F, Santoro G. Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta&#x2010;analysis. Pediatr Cardiol. 2011;32:32&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">20967441</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi C, Fragnito C, Antonelli A, Reverberi C, Ferrari P, Saccani S, Fesani F. Prevention of deep venous thrombosis by a new low molecular weight heparin (Fluxum) in cardiac surgery. Int Angiol. 1993;12:383&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">8207317</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark KB, Kon ND, Hammon JW Jr, MacGregor DA, Kincaid EH, Reichert MG. Factor IX complex for the treatment of severe bleeding after cardiac surgery. J Cardiovasc Pharmacol. 2013;62:67&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">23519139</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Hirsch DR, MacDougall RC, Polak JF, Creager MA, Cohn LH. Prevention of venous thrombosis after coronary artery bypass surgery (a randomized trial comparing two mechanical prophylaxis strategies). Am J Cardiol. 1995;76:993&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">7484878</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibodeau JT, Mishkin JD, Patel PC, Kaiser PA, Ayers CR, Mammen PP, Markham DW, Ring WS, Peltz M, Drazner MH. Sirolimus use and incidence of venous thromboembolism in cardiac transplant recipients. Clin Transplant. 2012;26:953&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">22775970</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantely GA, Goodnight SH Jr, Rahimtoola SH, Harlan BJ, DeMots H, Calvin L, R&#xf6;sch J. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary&#x2010;artery bypass: a controlled, randomized study. N Engl J Med. 1979;301:962&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">386118</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder AR, Axelrod DM, Silverman NH, Rubesova E, Merkel E, Roth SJ. A continuous heparin infusion does not prevent catheter&#x2010;related thrombosis in infants after cardiac surgery. Pediatr Crit Care Med. 2010;11:489&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">20101197</ArticleId></ArticleIdList></Reference><Reference><Citation>Weltert L, Nardella S, Rondinelli MB, Pierelli L, De Paulis R. Reduction of allogeneic red blood cell usage during cardiac surgery by an integrated intra&#x2010; and postoperative blood salvage strategy: results of a randomized comparison. Transfusion. 2013;53:790&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">22882381</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbanski PP, Dinstak W, Rents W, Heinz N, Diegeler A. Long&#x2010;term results after aortic root replacement using self&#x2010;assembled valve composite grafts in patients with small aortic annulus. Interact Cardiovasc Thorac Surg. 2014;18:159&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3895059</ArticleId><ArticleId IdType="pubmed">24179177</ArticleId></ArticleIdList></Reference><Reference><Citation>Manlhiot C, Menjak IB, Brand&#xe3;o LR, Gruenwald CE, Schwartz SM, Sivarajan VB, Yoon H, Maratta R, Carew CL, McMullen JA, Clarizia NA, Holtby HM, Williams S, Caldarone CA, Van Arsdell GS, Chan AK, McCrindle BW. Risk, clinical features, and outcomes of thrombosis associated with pediatric cardiac surgery. Circulation. 2011;124:1511&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pubmed">21911785</ArticleId></ArticleIdList></Reference><Reference><Citation>Manlhiot C, Brand&#xe3;o LR, Kwok J, Kegel S, Menjak IB, Carew CL, Chan AK, Schwartz SM, Sivarajan VB, Caldarone CA, Van Arsdell GS, McCrindle BW. Thrombotic complications and thromboprophylaxis across all three stages of single ventricle heart palliation. J Pediatr. 2012;161:513&#x2013;519.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">22513267</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponschab M, Landoni G, Biondi&#x2010;Zoccai G, Bignami E, Frati E, Nicolotti D, Monaco F, Pappalardo F, Zangrillo A. Recombinant activated factor VII increases stroke in cardiac surgery: a meta&#x2010;analysis. J Cardiothorac Vasc Anesth. 2011;25:804&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">21596585</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman IA, Hussain A, Davies A, Bryan AJ. NICE thromboprophylaxis guidelines are not associated with increased pericardial effusion after surgery of the proximal thoracic aorta. Ann R Coll Surg Engl. 2013;95:433&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4188293</ArticleId><ArticleId IdType="pubmed">24025294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ik&#xe4;heimo MJ, Huikuri HV, Airaksinen KE, Korhonen UR, Linnaluoto MK, Tarkka MR, Takkunen JT. Pericardial effusion after cardiac surgery: incidence, relation to the type of surgery, antithrombotic therapy, and early coronary bypass graft patency. Am Heart J. 1988;116:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">3260740</ArticleId></ArticleIdList></Reference><Reference><Citation>Alassar A, Roy D, Valencia O, Brecker S, Jahangiri M. Survival, predictive factors, and causes of mortality following transcatheter aortic valve implantation. Innovations (Phila). 2013;8:359&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">24346585</ArticleId></ArticleIdList></Reference><Reference><Citation>McEnany MT, Salzman EW, Mundth ED, DeSanctis RW, Harthorne JW, Weintraub RM, Gates S, Austen WG. The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg. 1982;83:81&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">7033673</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvin S, Muehlschlegel JD, Perry TE, Chen J, Liu KY, Fox AA, Collard CD, Aranki SF, Shernan SK, Body SC. Postoperative activity, but not preoperative activity, of antithrombin is associated with major adverse cardiac events after coronary artery bypass graft surgery. Anesth Analg. 2010;111:862&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3010354</ArticleId><ArticleId IdType="pubmed">19820236</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen L, Yang L. Risk factors for postoperative pulmonary complications in coronary artery bypass graft surgery patients. Eur J Cardiovasc Nurs. 2007;6:241&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">17347049</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisoff BG, Hartstein ML, Aintablian A, Hamby RI. Risk of coronary surgery. Two hundred consecutive patients with no hospital deaths. J Thorac Cardiovasc Surg. 1975;69:669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">1079291</ArticleId></ArticleIdList></Reference><Reference><Citation>Parenti C. Pulmonary embolism after coronary artery bypass surgery. Crit Care Nurs Q. 1994;17:48&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">8000937</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Terada Y, Fukuda S, Sakao Y, Takayama T, Suma H, Wanibuchi Y, Furuta S. Acute pulmonary thromboembolism after coronary artery bypass grafting. Kyobu Geka. 1991;44:1003&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">1758099</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorros G, Lewin RF, Daley P, Assa J. Coronary artery bypass surgery in patients over age 70&#xa0;years: report from the Milwaukee Cardiovascular Data Registry. Clin Cardiol. 1987;10:377&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">3497001</ArticleId></ArticleIdList></Reference><Reference><Citation>Malouf JF, Alam S, Gharzeddine W, Stefadouros MA. The role of anticoagulation in the development of pericardial effusion and late tamponade after cardiac surgery. Eur Heart J. 1993;14:1451&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pubmed">8299624</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM. Determinants of the relationship between cost and survival time after elective adult cardiac surgery. Anaesth Intensive Care. 2014;42:303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">24794468</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet. 2000;355:1295&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pubmed">10776741</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RC. Aspirin and the prevention of venous thromboembolism. N Engl J Med. 2012;366:2028&#x2013;2030.</Citation><ArticleIdList><ArticleId IdType="pubmed">22621631</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM, Yip CB, Duff O. Reactive thrombocytosis and risk of subsequent venous thromboembolism: a cohort study. J Thromb Haemost. 2012;10:1768&#x2013;1774.</Citation><ArticleIdList><ArticleId IdType="pubmed">22784217</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM, Chavan S. Prevalence of thrombocytosis in critically ill patients and its association with symptomatic acute pulmonary embolism. A multicentre registry study. Thromb Haemost. 2013;109:272&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pubmed">23238075</ArticleId></ArticleIdList></Reference><Reference><Citation>Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P; WARFASA Investigators . Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959&#x2013;1967.</Citation><ArticleIdList><ArticleId IdType="pubmed">22621626</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM, Chavan S, Pilcher D. Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest. 2011;140:1436&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">21940768</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM, Tan JA. Stratified meta&#x2010;analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 2013;128:1003&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pubmed">23852609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KM. Benefit of intermittent pneumatic compression of lower limbs in reducing venous thromboembolism in hospitalised patients: interactions between risk and effectiveness. Anaesth Intensive Care. 2014;42:140&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">24471679</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepi M, Muratori M, Barbier P, Doria E, Arena V, Berti M, Celeste F, Guazzi M, Tamborini G. Pericardial effusion after cardiac surgery: incidence, site, size, and haemodynamic consequences. Br Heart J. 1994;72:327&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1025541</ArticleId><ArticleId IdType="pubmed">7833189</ArticleId></ArticleIdList></Reference><Reference><Citation>Pompilio G, Filippini S, Agrifoglio M, Merati E, Lauri G, Salis S, Alamanni F, Parolari A. Determinants of pericardial drainage for cardiac tamponade following cardiac surgery. Eur J Cardiothorac Surg. 2011;39:e107&#x2013;e113.</Citation><ArticleIdList><ArticleId IdType="pubmed">21295488</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36547010</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2543-6031</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>23</Day></PubDate></JournalIssue><Title>Advances in respiratory medicine</Title><ISOAbbreviation>Adv Respir Med</ISOAbbreviation></Journal><ArticleTitle>Using a Fibrinolysis Delivery Catheter in Pulmonary Embolism Treatment for Measurement of Pulmonary Artery Hemodynamics.</ArticleTitle><Pagination><StartPage>483</StartPage><EndPage>499</EndPage><MedlinePgn>483-499</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/arm90060055</ELocationID><Abstract><AbstractText>Background: Ultrasound-facilitated and catheter-directed low-dose fibrinolysis (EKOS) has shown favorable hemodynamic and safety outcomes in intermediate- to high-risk pulmonary embolism (PE) cases. Objectives: This prospective single-arm monocentric study assessed the effects of using a delivery catheter for fibrinolysis as a novel approach for acute intermediate- to high-risk patients on pulmonary artery hemodynamics PE. Methods: Forty-five patients (41 intermediate&#x2212;high and 4 high risk) with computer tomography (CT)-confirmed PE underwent EKOS therapy. By protocol, a total of 6 mg of tissue-plasminogen activator (t-PA) was administered over 6 h in the pulmonary artery (unilateral 6 mg or bilateral 12 mg). Unfractionated heparin was provided periprocedurally. The primary safety outcome was death, as well as major and minor bleeding within 48 of procedure initiation and at 90 days. The primary effectiveness outcomes were: 1. to assess the difference in pulmonary artery pressure from baseline to 6 h post-treatment as a primary precise surrogate marker, and 2. to determine the echocardiographic RV/LV ratio from baseline to 48 h and at 90 days post-delivery. Results: Pulmonary artery pressure decreased by 15/6/10 mmHg (p &lt; 0.001). The mean RV/LV ratio decreased from 1.2 &#xb1; 0.85 at baseline to 0.85 &#xb1; 0.12 at 48 and to 0.76 &#xb1; 0.13 at 90 days (p &lt; 0.001). Five patients (11%) died within 90 days of therapy. Conclusions and Highlights: Pulmonary artery hemodynamics were assessed using a delivery catheter for fibrinolysis, which is reproducible for identifying PE at risk of adverse outcomes. The results matched the right heart catheter results in EKOS and Heparin arm of Ultima trial, thereby confirming the validity of this potential diagnostic tool to assess therapy effectiveness and thereby reduce additional procedure-related complications, hospital residency, and economics. These results stress the importance of having an interdisciplinary team involved in the management of PE to evaluate the quality of life of these patients and this protocol shortens ICU admission to 6 h.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elhakim</LastName><ForeName>Abdelrahman</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3315-4167</Identifier><AffiliationInfo><Affiliation>Cardiology Department, Schoen Hospital, 23730 Neustadt in Holstein, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knauth</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Department, Schoen Hospital, 23730 Neustadt in Holstein, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elhakim</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Critical Care and Anesthesia, Nepean Hospital, Kingswood, Sydney, NSW 2747, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xf6;hmer</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Cardiology Department, Schoen Hospital, 23730 Neustadt in Holstein, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patzelt</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology Department, Schoen Hospital, 23730 Neustadt in Holstein, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radke</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiology Department, Schoen Hospital, 23730 Neustadt in Holstein, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Adv Respir Med</MedlineTA><NlmUniqueID>101697329</NlmUniqueID><ISSNLinking>2451-4934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005342" MajorTopicYN="Y">Fibrinolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011651" MajorTopicYN="N">Pulmonary Artery</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057785" MajorTopicYN="N">Catheters</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">catheter-directed</Keyword><Keyword MajorTopicYN="N">cohort study</Keyword><Keyword MajorTopicYN="N">intermediate- to high-risk thrombotic pulmonary embolism</Keyword><Keyword MajorTopicYN="N">low-dose fibrinolysis</Keyword><Keyword MajorTopicYN="N">pulmonary artery pressure</Keyword><Keyword MajorTopicYN="N">pulmonary embolism hemodynamics</Keyword><Keyword MajorTopicYN="N">ultrasound-facilitated</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The authors whose names are listed in this article certify that they have no affiliations with or involvement in any organization or entity with a financial or nonfinancial interest in the subject matter or materials discussed in this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36547010</ArticleId><ArticleId IdType="pmc">PMC9774279</ArticleId><ArticleId IdType="doi">10.3390/arm90060055</ArticleId><ArticleId IdType="pii">arm90060055</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hobohm L., Lankeit M. Lungenembolie. Pneumologie. 2021;75:800&#x2013;818. doi: 10.1055/a-1029-9937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1029-9937</ArticleId><ArticleId IdType="pubmed">34662916</ArticleId></ArticleIdList></Reference><Reference><Citation>Triantafyllidi H., Iordanidis D., Mpahara A., Mademli M., Birmpa D., Argentos S., Benas D., Trivilou P., Anagnostopoulos K., Mayer E., et al. Giant Pulmonary Artery Thrombotic Material, Due to Chronic Thromboembolic Pulmonary Hypertension, Mimics Pulmonary Artery Sarcoma. Medicina. 2021;57:992. doi: 10.3390/medicina57090992.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57090992</ArticleId><ArticleId IdType="pmc">PMC8465601</ArticleId><ArticleId IdType="pubmed">34577914</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides S.V., Meyer G., Becat C., Bueno H., Geersing G.J., Harjola V.-P., Huisman M.V., Humbert M., Jennings C.S., Jim&#xe9;nez D., et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) Eur. Heart J. 2020;41:543&#x2013;603. doi: 10.1093/eurheartj/ehz405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz405</ArticleId><ArticleId IdType="pubmed">31504429</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes G.D., Kabrhel C., Courtney D.M., Naydenov S., Wood T., Rosovsky R., Rosenfield K., Giri J., Balan P., Barnes G., et al. Diversity in the Pulmonary Embolism Response Team Model: An Organizational Survey of the National PERT Consortium Members. Chest. 2016;150:1414&#x2013;1417. doi: 10.1016/j.chest.2016.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2016.09.034</ArticleId><ArticleId IdType="pubmed">27938758</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaff M.R., McMurtry M.S., Archer S.L., Cushman M., Goldenberg N., Goldhaber S.Z., Jenkins J.S., Kline J.A., Michaels A.D., Thistlethwaite P., et al. Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. Circulation. 2011;123:1788&#x2013;1830. doi: 10.1161/CIR.0b013e318214914f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0b013e318214914f</ArticleId><ArticleId IdType="pubmed">21422387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C., Akl E.A., Ornelas J., Blaivas A., Jimenez D., Bounameaux H., Huisman M., King C.S., Morris T.A., Sood N., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315&#x2013;352. doi: 10.1016/j.chest.2015.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2015.11.026</ArticleId><ArticleId IdType="pubmed">26867832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucher N., Boekstegers P., M&#xfc;ller O.J., Kupatt C., Beyer-Westendorf J., Heitzer T., Tebbe U., Horstkotte J., M&#xfc;ller R., Blessing E., et al. Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism. Circulation. 2014;129:479&#x2013;486. doi: 10.1161/CIRCULATIONAHA.113.005544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.005544</ArticleId><ArticleId IdType="pubmed">24226805</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis C.W., Blinc A., Lee S., Cox C. Ultrasound Accelerates Transport of Recombinant Tissue Plasminogen Activator into Clots. Ultrasound Med. Biol. 1995;21:419&#x2013;424. doi: 10.1016/0301-5629(94)00119-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0301-5629(94)00119-X</ArticleId><ArticleId IdType="pubmed">7645133</ArticleId></ArticleIdList></Reference><Reference><Citation>GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N. Engl. J. Med. 1993;329:673&#x2013;682. doi: 10.1056/NEJM199309023291001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199309023291001</ArticleId><ArticleId IdType="pubmed">8204123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig K., von der Schulenburg J.-M.G., Greiner W. German Value Set for the EQ-5D-5L. Pharmacoeconomics. 2018;36:663&#x2013;674. doi: 10.1007/s40273-018-0615-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-018-0615-8</ArticleId><ArticleId IdType="pmc">PMC5954069</ArticleId><ArticleId IdType="pubmed">29460066</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruaro B., Baratella E., Caforio G., Confalonieri P., Wade B., Marrocchio C., Geri P., Pozzan R., Andrisano A.G., Cova M.A., et al. Chronic Thromboembolic Pulmonary Hypertension: An Update. Diagnostics. 2022;12:235. doi: 10.3390/diagnostics12020235.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12020235</ArticleId><ArticleId IdType="pmc">PMC8871284</ArticleId><ArticleId IdType="pubmed">35204326</ArticleId></ArticleIdList></Reference><Reference><Citation>Banaszkiewicz M., Pietrasik A., Florczyk M., K&#x119;dzierski P., Pi&#x142;ka M., Ma&#x144;czak R., Kochman J., Opolski G., Torbicki A., Kurzyna M., et al. Soluble ST2 as a Biomarker for Early Complications in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty. Diagnostics. 2021;11:133. doi: 10.3390/diagnostics11010133.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11010133</ArticleId><ArticleId IdType="pmc">PMC7830401</ArticleId><ArticleId IdType="pubmed">33467121</ArticleId></ArticleIdList></Reference><Reference><Citation>Piazza G., Hohlfelder B., Jaff M.R., Ouriel K., Engelhardt T.C., Sterling K.M., Jones N.J., Gurley J.C., Bhatheja R., Kennedy R.J., et al. SEATTLE II Investigators. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmo. JACC Cardiovasc. Interv. 2015;8:1382&#x2013;1392. doi: 10.1016/j.jcin.2015.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2015.04.020</ArticleId><ArticleId IdType="pubmed">26315743</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapson V.F., Sterling K., Jones N., Elder M., Tripathy U., Brower J., Maholic R.L., Ross C.B., Natarajan K., Fong P., et al. A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial. JACC Cardiovasc. Interv. 2018;11:1401&#x2013;1410. doi: 10.1016/j.jcin.2018.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2018.04.008</ArticleId><ArticleId IdType="pubmed">30025734</ArticleId></ArticleIdList></Reference><Reference><Citation>Brass L.M., Lichtman J.H., Wang Y., Gurwitz J.H., Radford M.J., Krumholz H.M. Intracranial Hemorrhage Associated With Thrombolytic Therapy for Elderly Patients With Acute Myocardial Infarction. Stroke. 2000;31:1802&#x2013;1811. doi: 10.1161/01.STR.31.8.1802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.31.8.1802</ArticleId><ArticleId IdType="pubmed">10926938</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer G., Vicaut E., Danays T., Agnelli G., Becattini C., Beyer-Westendorf J., Bluhmki E., Bouvaist H., Brenner B., Couturaud F., et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N. Engl. J. Med. 2014;370:1402&#x2013;1411. doi: 10.1056/NEJMoa1302097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1302097</ArticleId><ArticleId IdType="pubmed">24716681</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S., Chakraborty A., Weinberg I., Kadakia M., Wilensky R.L., Sardar P., Kumbhani D.J., Mukherjee D., Jaff M.R., Giri J. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: A meta-analysis. JAMA. 2014;311:2414&#x2013;2421. doi: 10.1001/jama.2014.5990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.5990</ArticleId><ArticleId IdType="pubmed">24938564</ArticleId></ArticleIdList></Reference><Reference><Citation>Marti C., John G., Konstantinides S., Combescure C., Sanchez O., Lankeit M., Meyer G., Perrier A. Systemic thrombolytic therapy for acute pulmonary embolism: A systematic review and meta-analysis. Eur. Heart J. 2015;36:605&#x2013;614. doi: 10.1093/eurheartj/ehu218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehu218</ArticleId><ArticleId IdType="pmc">PMC4352209</ArticleId><ArticleId IdType="pubmed">24917641</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides S., Rosenfield K.U.S. National Library of Medicine.  [(accessed on 30 June 2022)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04790370.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29044295</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2567-689X</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Thrombosis and haemostasis</Title><ISOAbbreviation>Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Clinical Decision Rules for Pulmonary Embolism in Hospitalized Patients: A Systematic Literature Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>2176</StartPage><EndPage>2185</EndPage><MedlinePgn>2176-2185</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1160/TH17-06-0395</ELocationID><Abstract><AbstractText><b>Background</b>&#x2003;Clinical decision rules (CDRs) for pulmonary embolism (PE) have been validated in outpatients, but their performance in hospitalized patients is not well characterized. <b>Objectives</b>&#x2003;The goal of this systematic literature review was to assess the performance of CDRs for PE in hospitalized patients. <b>Methods</b>&#x2003;We performed a structured literature search using Medline, EMBASE and the Cochrane library for articles published on or before January 18, 2017. Two authors reviewed all titles, abstracts and full texts. We selected prospective studies of symptomatic hospitalized patients in which a CDR was used to estimate the likelihood of PE. The diagnosis of PE had to be confirmed using an accepted reference standard. Data on hospitalized patients were solicited from authors of studies in mixed populations of outpatients and hospitalized patients. Study characteristics, PE prevalence and CDR performance were extracted. The methodological quality of the studies was assessed using the QUADAS instrument. <b>Results</b>&#x2003;Twelve studies encompassing 3,942 hospitalized patients were included. Studies varied in methodology (randomized controlled trials and observational studies) and reference standards used. The pooled sensitivity of the modified Wells rule (cut-off&#x2009;&#x2264;&#x2009;4) in hospitalized patients was 72.1% (95% confidence interval [CI], 63.7-79.2) and the pooled specificity was 62.2% (95% CI, 52.6-70.9). The modified Wells rule (cut-off&#x2009;&#x2264;&#x2009;4) plus D-dimer testing had a pooled sensitivity 99.7% (95% CI, 96.7-100) and pooled specificity 10.8% (95% CI, 6.7-16.9). The efficiency (proportion of patients stratified into the 'PE unlikely' group) was 8.4% (95% CI, 4.1-16.5), and the failure rate (proportion of low likelihood patients who were diagnosed with PE during follow-up) was 0.1% (95% CI, 0-5.3). <b>Conclusion</b>&#x2003;In symptomatic hospitalized patients, use of the Wells rule plus D-dimer to rule out PE is safe, but allows very few patients to forgo imaging.</AbstractText><CopyrightInformation>Schattauer GmbH Stuttgart.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bass</LastName><ForeName>Anne R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hospital for Special Surgery, New York, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fields</LastName><ForeName>Kara G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Healthcare Research Institute, Hospital for Special Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goto</LastName><ForeName>Rie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Kim Barrett Memorial Library, Education and Academic Affairs Division, Hospital for Special Surgery.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turissini</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hospital for Special Surgery, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dey</LastName><ForeName>Shirin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hospital for Special Surgery, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Linda A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hospital for Special Surgery, New York, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, New York, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Thromb Haemost</MedlineTA><NlmUniqueID>7608063</NlmUniqueID><ISSNLinking>0340-6245</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000066491" MajorTopicYN="Y">Clinical Decision-Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="Y">Decision Support Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29044295</ArticleId><ArticleId IdType="doi">10.1160/TH17-06-0395</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19130163</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-1132</ISSN><JournalIssue CitedMedium="Internet"><Volume>467</Volume><Issue>9</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical orthopaedics and related research</Title><ISOAbbreviation>Clin Orthop Relat Res</ISOAbbreviation></Journal><ArticleTitle>Does regional anesthesia improve outcome after total knee arthroplasty?</ArticleTitle><Pagination><StartPage>2379</StartPage><EndPage>2402</EndPage><MedlinePgn>2379-402</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11999-008-0666-9</ELocationID><Abstract><AbstractText>Total knee arthroplasty (TKA) is amenable to various regional anesthesia techniques that may improve patient outcome. We sought to answer whether regional anesthesia decreased mortality, cardiovascular morbidity, deep venous thrombosis and pulmonary embolism, blood loss, duration of surgery, pain, opioid-related adverse effects, cognitive defects, and length of stay. We also questioned whether regional anesthesia improved rehabilitation. To do so, we performed a systematic review of the contemporary literature comparing general anesthesia and/or systemic analgesia with regional anesthesia and/or regional analgesia for TKA. To reflect contemporary surgical and anesthetic practice, only randomized, controlled trials from 1990 onward were included. We identified 28 studies involving 1538 patients. There was insufficient evidence from randomized, controlled trials alone to conclude if anesthetic technique influenced mortality, cardiovascular morbidity other than postoperative hypotension, or the incidence of deep venous thrombosis and pulmonary embolism when using thromboprophylaxis. Our review suggests there was no difference in perioperative blood loss or duration of surgery in patients who received general anesthesia versus regional anesthesia. Compared with general anesthesia and/or systemic analgesia, regional anesthesia and/or analgesia reduced postoperative pain, morphine consumption, and opioid-related adverse effects. Length of stay may be reduced and rehabilitation facilitated for patients undergoing regional anesthesia and analgesia for TKA.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Macfarlane</LastName><ForeName>Alan J R</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Pain Management, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasad</LastName><ForeName>Govindarajulu Arun</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Vincent W S</ForeName><Initials>VW</Initials></Author><Author ValidYN="Y"><LastName>Brull</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Orthop Relat Res</MedlineTA><NlmUniqueID>0075674</NlmUniqueID><ISSNLinking>0009-921X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000698" MajorTopicYN="N">Analgesia</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000765" MajorTopicYN="Y">Anesthesia, Conduction</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000768" MajorTopicYN="Y">Anesthesia, General</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019645" MajorTopicYN="N">Arthroplasty, Replacement, Knee</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016206" MajorTopicYN="N">Databases, Bibliographic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19130163</ArticleId><ArticleId IdType="pmc">PMC2866929</ArticleId><ArticleId IdType="doi">10.1007/s11999-008-0666-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams HA, Saatweber P, Schmitz CS, Hecker H. Postoperative pain management in orthopaedic patients: no differences in pain score, but improved stress control by epidural anaesthesia. Eur J Anaesthesiol. 2002;19:658&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243289</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen HW, Liu SS, Ware PD, Nairn CS, Owens BD. Peripheral nerve blocks improve analgesia after total knee replacement surgery. Anesth Analg. 1998;87:93&#x2013;97. doi: 10.1097/00000539-199807000-00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000539-199807000-00020</ArticleId><ArticleId IdType="pubmed">9661553</ArticleId></ArticleIdList></Reference><Reference><Citation>Aromaa U, Lahdensuu M, Cozanitis DA. Severe complications associated with epidural and spinal anaesthesias in Finland 1987&#x2013;1993: a study based on patient insurance claims [see comment] Acta Anaesthesiol Scand. 1997;41:445&#x2013;452. doi: 10.1111/j.1399-6576.1997.tb04722.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.1997.tb04722.x</ArticleId><ArticleId IdType="pubmed">9150770</ArticleId></ArticleIdList></Reference><Reference><Citation>Auroy Y, Benhamou D, Bargues L, Ecoffey C, Falissard B, Mercier FJ, Bouaziz H, Samii K. Major complications of regional anesthesia in France: The SOS Regional Anesthesia Hotline Service. Anesthesiology. 2002;97:1274&#x2013;1280. doi: 10.1097/00000542-200211000-00034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200211000-00034</ArticleId><ArticleId IdType="pubmed">12411815</ArticleId></ArticleIdList></Reference><Reference><Citation>Auroy Y, Narchi P, Messiah A, Litt L, Rouvier B, Samii K. Serious complications related to regional anesthesia: results of a prospective survey in France. Anesthesiology. 1997;87:479&#x2013;486. doi: 10.1097/00000542-199709000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-199709000-00005</ArticleId><ArticleId IdType="pubmed">9316950</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelsson K, Johanzon E, Essving P, Weckstrom J, Ekback G. Postoperative extradural analgesia with morphine and ropivacaine: a double-blind comparison between placebo and ropivacaine 10&#xa0;mg/h or 16&#xa0;mg/h. Acta Anaesthesiol Scand. 2005;49:1191&#x2013;1199. doi: 10.1111/j.1399-6576.2005.00715.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.2005.00715.x</ArticleId><ArticleId IdType="pubmed">16095462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagry H, a Fontaine JC, Asenjo JF, Bracco D, Carli F. Effect of a continuous peripheral nerve block on the inflammatory response in knee arthroplasty. Reg Anesth Pain Med. 2008;33:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">18155052</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrington MJ, Olive D, Low K, Scott DA, Brittain J, Choong P. Continuous femoral nerve blockade or epidural analgesia after total knee replacement: a prospective randomized controlled trial. Anesth Analg. 2005;101:1824&#x2013;1829. doi: 10.1213/01.ANE.0000184113.57416.DD.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ANE.0000184113.57416.DD</ArticleId><ArticleId IdType="pubmed">16301267</ArticleId></ArticleIdList></Reference><Reference><Citation>Block BM, Liu SS, Rowlingson AJ, Cowan AR, Cowan JA, Jr., Wu CL. Efficacy of postoperative epidural analgesia: a meta-analysis. JAMA. 2003;290:2455&#x2013;2463. doi: 10.1001/jama.290.18.2455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.290.18.2455</ArticleId><ArticleId IdType="pubmed">14612482</ArticleId></ArticleIdList></Reference><Reference><Citation>Boezaart AP. Perineural infusion of local anesthetics. Anesthesiology. 2006;104:872&#x2013;880. doi: 10.1097/00000542-200604000-00033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200604000-00033</ArticleId><ArticleId IdType="pubmed">16571984</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogoch ER, Henke M, Mackenzie T, Olschewski E, Mahomed NN. Lumbar paravertebral nerve block in the management of pain after total hip and knee arthroplasty: a randomized controlled clinical trial. J Arthroplasty. 2002;17:398&#x2013;401. doi: 10.1054/arth.2002.31079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/arth.2002.31079</ArticleId><ArticleId IdType="pubmed">12066266</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgeat A, Ekatodramis G, Kalberer F, Benz C. Acute and nonacute complications associated with interscalene block and shoulder surgery: a prospective study. Anesthesiology. 2001;95:875&#x2013;880. doi: 10.1097/00000542-200110000-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200110000-00015</ArticleId><ArticleId IdType="pubmed">11605927</ArticleId></ArticleIdList></Reference><Reference><Citation>Brull R, McCartney CJ, Chan VW, El-Beheiry H. Neurological complications after regional anesthesia: contemporary estimates of risk. Anesth Analg. 2007;104:965&#x2013;974. doi: 10.1213/01.ane.0000258740.17193.ec.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ane.0000258740.17193.ec</ArticleId><ArticleId IdType="pubmed">17377115</ArticleId></ArticleIdList></Reference><Reference><Citation>Capdevila X, Barthelet Y, Biboulet P, Ryckwaert Y, Rubenovitch J, d&#x2019;Athis F. Effects of perioperative analgesic technique on the surgical outcome and duration of rehabilitation after major knee surgery. Anesthesiology. 1999;91:8&#x2013;15. doi: 10.1097/00000542-199907000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-199907000-00006</ArticleId><ArticleId IdType="pubmed">10422923</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi PT, Bhandari M, Scott J, Douketis J. Epidural analgesia for pain relief following hip or knee replacement. Cochrane Database Syst Rev. 2003:CD003071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10710280</ArticleId><ArticleId IdType="pubmed">12917945</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu CP, Yap JC, Chen PP, Hung HH. Postoperative outcome in Chinese patients having primary total knee arthroplasty under general anaesthesia/intravenous patient-controlled analgesia compared to spinal-epidural anaesthesia/analgesia. Hong Kong Med J. 2006;12:442&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">17148797</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies AF, Segar EP, Murdoch J, Wright DE, Wilson IH. Epidural infusion or combined femoral and sciatic nerve blocks as perioperative analgesia for knee arthroplasty. Br J Anaesth. 2004;93:368&#x2013;374. doi: 10.1093/bja/aeh224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aeh224</ArticleId><ArticleId IdType="pubmed">15247111</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards ND, Wright EM. Continuous low-dose 3-in-1 nerve blockade for postoperative pain relief after total knee replacement. Anesth Analg. 1992;75:265&#x2013;267. doi: 10.1213/00000539-199208000-00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/00000539-199208000-00020</ArticleId><ArticleId IdType="pubmed">1632541</ArticleId></ArticleIdList></Reference><Reference><Citation>Enneking FK, Chan V, Greger J, Hadzic A, Lang SA, Horlocker TT. Lower-extremity peripheral nerve blockade: essentials of our current understanding. Reg Anesth Pain Med. 2005;30:4&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15690265</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanelli G, Casati A, Garancini P, Torri G. Nerve stimulator and multiple injection technique for upper and lower limb blockade: failure rate, patient acceptance, and neurologic complications. Study Group on Regional Anesthesia. Anesth Analg. 1999;88:847&#x2013;852. doi: 10.1097/00000539-199904000-00031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000539-199904000-00031</ArticleId><ArticleId IdType="pubmed">10195536</ArticleId></ArticleIdList></Reference><Reference><Citation>Farag E, Dilger J, Brooks P, Tetzlaff JE. Epidural analgesia improves early rehabilitation after total knee replacement. J Clin Anesth. 2005;17:281&#x2013;285. doi: 10.1016/j.jclinane.2004.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinane.2004.08.008</ArticleId><ArticleId IdType="pubmed">15950853</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer HB, Simanski CJ, Sharp C, Bonnet F, Camu F, Neugebauer EA, Rawal N, Joshi GP, Schug SA, Kehlet H. A procedure-specific systematic review and consensus recommendations for postoperative analgesia following total knee arthroplasty. Anaesthesia. 2008;63:1105&#x2013;1123. doi: 10.1111/j.1365-2044.2008.05565.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2044.2008.05565.x</ArticleId><ArticleId IdType="pubmed">18627367</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler SJ, Symons J, Sabato S, Myles PS. Epidural analgesia compared with peripheral nerve blockade after major knee surgery: a systematic review and meta-analysis of randomized trials. Br J Anaesth. 2008;100:154&#x2013;164. doi: 10.1093/bja/aem373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aem373</ArticleId><ArticleId IdType="pubmed">18211990</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa TA, Streiner DL, Hori S. Discrepancies among megatrials. J Clin Epidemiol. 2000;53:1193&#x2013;1199. doi: 10.1016/S0895-4356(00)00250-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(00)00250-X</ArticleId><ArticleId IdType="pubmed">11146264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganapathy S, Wasserman RA, Watson JT, Bennett J, Armstrong KP, Stockall CA, Chess DG, MacDonald C. Modified continuous femoral three-in-one block for postoperative pain after total knee arthroplasty. Anesth Analg. 1999;89:1197&#x2013;1202. doi: 10.1097/00000539-199911000-00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000539-199911000-00021</ArticleId><ArticleId IdType="pubmed">10553834</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Jr., Wheeler HB. Prevention of venous thromboembolism. Chest. 2001;119:132S&#x2013;175S. doi: 10.1378/chest.119.1_suppl.132S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.119.1_suppl.132S</ArticleId><ArticleId IdType="pubmed">11157647</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonano C, Leitgeb U, Sitzwohl C, Ihra G, Weinstabl C, Kettner SC. Spinal versus general anesthesia for orthopedic surgery: anesthesia drug and supply costs. Anesth Analg. 2006;102:524&#x2013;529. doi: 10.1213/01.ane.0000194292.81614.c6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ane.0000194292.81614.c6</ArticleId><ArticleId IdType="pubmed">16428554</ArticleId></ArticleIdList></Reference><Reference><Citation>Good RP, Snedden MH, Schieber FC, Polachek A. Effects of a preoperative femoral nerve block on pain management and rehabilitation after total knee arthroplasty. Am J Orthop. 2007;36:554&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">18033568</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossi P, Urmey WF. Peripheral nerve blocks for anaesthesia and postoperative analgesia. Curr Opin Anaesth. 2003;16:493&#x2013;501. doi: 10.1097/00001503-200310000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001503-200310000-00009</ArticleId><ArticleId IdType="pubmed">17021502</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas SB. Effects of epidural anesthesia on incidence of venous thromboembolism following joint replacement. Orthopedics. 1994;17(suppl):18&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7937384</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpern S. Why meta-analysis? Reg Anesth Pain Med. 2002;27:3&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11799497</ArticleId></ArticleIdList></Reference><Reference><Citation>Hantler C, Despotis GJ, Sinha R, Chelly JE. Guidelines and alternatives for neuraxial anesthesia and venous thromboembolism prophylaxis in major orthopedic surgery. J Arthroplasty. 2004;19:1004&#x2013;1016. doi: 10.1016/j.arth.2004.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2004.04.018</ArticleId><ArticleId IdType="pubmed">15586337</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebl JR, Kopp SL, Ali MH, Horlocker TT, Dilger JA, Lennon RL, Williams BA, Hanssen AD, Pagnano MW. A comprehensive anesthesia protocol that emphasizes peripheral nerve blockade for total knee and total hip arthroplasty. J Bone Joint Surg Am. 2005;87(suppl 2):63&#x2013;70. doi: 10.2106/JBJS.E.00491.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.E.00491</ArticleId><ArticleId IdType="pubmed">16326725</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins MS, Stiff JL. Pitfalls in performing meta-analysis: I. Anesthesiology. 1993;79:405. doi: 10.1097/00000542-199308000-00038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-199308000-00038</ArticleId><ArticleId IdType="pubmed">8342859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirst GC, Lang SA, Dust WN, Cassidy JD, Yip RW. Femoral nerve block: single injection versus continuous infusion for total knee arthroplasty. Reg Anesth. 1996;21:292&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">8837185</ArticleId></ArticleIdList></Reference><Reference><Citation>Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA, Mulroy MF, Rosenquist RW, Rowlingson J, Tryba M, Yuan CS. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation) Reg Anesth Pain Med. 2003;28:172&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">12772135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilfeld BM, Gearen PF, Enneking FK, Berry LF, Spadoni EH, George SZ, Vandenborne K. Total knee arthroplasty as an overnight-stay procedure using continuous femoral nerve blocks at home: a prospective feasibility study. Anesth Analg. 2006;102:87&#x2013;90. doi: 10.1213/01.ane.0000189562.86969.9f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ane.0000189562.86969.9f</ArticleId><ArticleId IdType="pubmed">16368810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilfeld BM, Le LT, Meyer RS, Mariano ER, Vandenborne K, Duncan PW, Sessler DI, Enneking FK, Shuster JJ, Theriaque DW, Berry LF, Spadoni EH, Gearen PF. Ambulatory continuous femoral nerve blocks decrease time to discharge readiness after tricompartment total knee arthroplasty: a randomized, triple-masked, placebo-controlled study. Anesthesiology. 2008;108:703&#x2013;713. doi: 10.1097/ALN.0b013e318167af46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0b013e318167af46</ArticleId><ArticleId IdType="pmc">PMC2643303</ArticleId><ArticleId IdType="pubmed">18362603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1&#x2013;12. doi: 10.1016/0197-2456(95)00134-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(95)00134-4</ArticleId><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MJ, Piggott SE, Vaughan RS, Bayer AJ, Newcombe RG, Twining TC, Pathy J, Rosen M. Cognitive and functional competence after anaesthesia in patients aged over 60: controlled trial of general and regional anaesthesia for elective hip or knee replacement. BMJ. 1990;300:1683&#x2013;1687. doi: 10.1136/bmj.300.6741.1683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.300.6741.1683</ArticleId><ArticleId IdType="pmc">PMC1663336</ArticleId><ArticleId IdType="pubmed">2390547</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen LN, Rasmussen LS, Nielsen PT, Leffers A, Albrecht-Beste E. Antithrombotic efficacy of continuous extradural analgesia after knee replacement. Br J Anaesth. 1991;66:8&#x2013;12. doi: 10.1093/bja/66.1.8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/66.1.8</ArticleId><ArticleId IdType="pubmed">1997063</ArticleId></ArticleIdList></Reference><Reference><Citation>Juni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol. 2002;31:115&#x2013;123. doi: 10.1093/ije/31.1.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/31.1.115</ArticleId><ArticleId IdType="pubmed">11914306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalairajah Y, Simpson D, Cossey AJ, Verrall GM, Spriggins AJ. Blood loss after total knee replacement: effects of computer-assisted surgery. J Bone Joint Surg Br. 2005;87:1480&#x2013;1482. doi: 10.1302/0301-620X.87B11.16474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.87B11.16474</ArticleId><ArticleId IdType="pubmed">16260662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaloul I, Guay J, Cote C, Fallaha M. The posterior lumbar plexus (psoas compartment) block and the three-in-one femoral nerve block provide similar postoperative analgesia after total knee replacement. Can J Anaesth. 2004;51:45&#x2013;51. doi: 10.1007/BF03018546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03018546</ArticleId><ArticleId IdType="pubmed">14709460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kardash K, Hickey D, Tessler MJ, Payne S, Zukor D, Velly AM. Obturator versus femoral nerve block for analgesia after total knee arthroplasty. Anesth Analg. 2007;105:853&#x2013;858. doi: 10.1213/01.ane.0000278158.36843.f7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ane.0000278158.36843.f7</ArticleId><ArticleId IdType="pubmed">17717250</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz J. A survey of anesthetic choice among anesthesiologists. Anesth Analg. 1973;52:373&#x2013;375. doi: 10.1213/00000539-197352030-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/00000539-197352030-00015</ArticleId><ArticleId IdType="pubmed">4145266</ArticleId></ArticleIdList></Reference><Reference><Citation>Klasen JA, Opitz SA, Melzer C, Thiel A, Hempelmann G. Intraarticular, epidural, and intravenous analgesia after total knee arthroplasty. Acta Anaesthesiol Scand. 1999;43:1021&#x2013;1026. doi: 10.1034/j.1399-6576.1999.431009.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-6576.1999.431009.x</ArticleId><ArticleId IdType="pubmed">10593465</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohro S, Yamakage M, Arakawa J, Kotaki M, Omote T, Namiki A. Surgical/tourniquet pain accelerates blood coagulability but not fibrinolysis. Br J Anaesth. 1998;80:460&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">9640150</ArticleId></ArticleIdList></Reference><Reference><Citation>LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997;337:536&#x2013;542. doi: 10.1056/NEJM199708213370806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199708213370806</ArticleId><ArticleId IdType="pubmed">9262498</ArticleId></ArticleIdList></Reference><Reference><Citation>Macalou D, Trueck S, Meuret P, Heck M, Vial F, Ouologuem S, Capdevila X, Virion JM, Bouaziz H. Postoperative analgesia after total knee replacement: the effect of an obturator nerve block added to the femoral 3-in-1 nerve block. Anesth Analg. 2004;99:251&#x2013;254. doi: 10.1213/01.ANE.0000121350.09915.84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ANE.0000121350.09915.84</ArticleId><ArticleId IdType="pubmed">15281539</ArticleId></ArticleIdList></Reference><Reference><Citation>Macario A, Weinger M, Truong P, Lee M. Which clinical anesthesia outcomes are both common and important to avoid? The perspective of a panel of expert anesthesiologists. Anesth Analg. 1999;88:1085&#x2013;1091. doi: 10.1097/00000539-199905000-00023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000539-199905000-00023</ArticleId><ArticleId IdType="pubmed">10320175</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariano ER, Ilfeld BM, Neal JM. &#x201c;Going fishing&#x201d;: the practice of reporting secondary outcomes as separate studies. Reg Anesth Pain Med. 2007;32:183&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">17543811</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthey PW, Finegan BA, Finucane BT. The public&#x2019;s fears about and perceptions of regional anesthesia. Reg Anesth Pain Med. 2004;29:96&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">15029543</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauermann WJ, Shilling AM, Zuo Z. A comparison of neuraxial block versus general anesthesia for elective total hip replacement: a meta-analysis. Anesth Analg. 2006;103:1018&#x2013;1025. doi: 10.1213/01.ane.0000237267.75543.59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ane.0000237267.75543.59</ArticleId><ArticleId IdType="pubmed">17000823</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie PJ. Pitfalls in performing meta-analysis: II. Anesthesiology. 1993;79:406&#x2013;408. doi: 10.1097/00000542-199308000-00039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-199308000-00039</ArticleId><ArticleId IdType="pubmed">8380047</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamee DA, Convery PN, Milligan KR. Total knee replacement: a comparison of ropivacaine and bupivacaine in combined femoral and sciatic block. Acta Anaesthesiol Scand. 2001;45:477&#x2013;481. doi: 10.1034/j.1399-6576.2001.045004477.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-6576.2001.045004477.x</ArticleId><ArticleId IdType="pubmed">11300387</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell D, Friedman RJ, Baker JD, III, Cooke JE, Darcy MD, Miller MC., III Prevention of thromboembolic disease following total knee arthroplasty: epidural versus general anesthesia. Clin Orthop Relat Res. 1991;269:109&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">1864027</ArticleId></ArticleIdList></Reference><Reference><Citation>Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990&#x2013;1999. Anesthesiology. 2004;101:950&#x2013;959. doi: 10.1097/00000542-200410000-00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-200410000-00021</ArticleId><ArticleId IdType="pubmed">15448529</ArticleId></ArticleIdList></Reference><Reference><Citation>Moiniche S, Hjortso NC, Hansen BL, Dahl JB, Rosenberg J, Gebuhr P, Kehlet H. The effect of balanced analgesia on early convalescence after major orthopaedic surgery. Acta Anaesthesiol Scand. 1994;38:328&#x2013;335. doi: 10.1111/j.1399-6576.1994.tb03902.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.1994.tb03902.x</ArticleId><ArticleId IdType="pubmed">8067218</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin AM, Kratz CD, Eberhart LH, Dinges G, Heider E, Schwarz N, Eisenhardt G, Geldner G, Wulf H. Postoperative analgesia and functional recovery after total-knee replacement: comparison of a continuous posterior lumbar plexus (psoas compartment) block, a continuous femoral nerve block, and the combination of a continuous femoral and sciatic nerve block. Reg Anesth Pain Med. 2005;30:434&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">16135347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng HP, Cheong KF, Lim A, Lim J, Puhaindran ME. Intraoperative single-shot &#x201c;3-in-1&#x201d; femoral nerve block with ropivacaine 0.25%, ropivacaine 0.5% or bupivacaine 0.25% provides comparable 48-hr analgesia after unilateral total knee replacement. Can J Anaesth. 2001;48:1102&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">11744586</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen KC, Steele SM. Outcome after regional anaesthesia in the ambulatory setting: is it really worth it? Best Pract Res Clin Anaesthesiol. 2002;16:145&#x2013;157. doi: 10.1053/bean.2002.0244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/bean.2002.0244</ArticleId><ArticleId IdType="pubmed">12491549</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielson WR, Gelb AW, Casey JE, Penny FJ, Merchant RN, Manninen PH. Long-term cognitive and social sequelae of general versus regional anesthesia during arthroplasty in the elderly. Anesthesiology. 1990;73:1103&#x2013;1109. doi: 10.1097/00000542-199012000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000542-199012000-00006</ArticleId><ArticleId IdType="pubmed">2248389</ArticleId></ArticleIdList></Reference><Reference><Citation>Niskanen RO, Strandberg N. Bedside femoral block performed on the first postoperative day after unilateral total knee arthroplasty: a randomized study of 49 patients. J Knee Surg. 2005;18:192&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">16152867</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldman M, McCartney CJ, Leung A, Rawson R, Perlas A, Gadsden J, Chan VW. A survey of orthopedic surgeons&#x2019; attitudes and knowledge regarding regional anesthesia. Anesth Analg. 2004;98:1486&#x2013;1490. doi: 10.1213/01.ANE.0000113549.98873.B1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ANE.0000113549.98873.B1</ArticleId><ArticleId IdType="pubmed">15105236</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlin DJ, Rapp SE, Polissar NL, Malmgren JA, Koerschgen M, Keyes H. Factors affecting discharge time in adult outpatients. Anesth Analg. 1998;87:816&#x2013;826. doi: 10.1097/00000539-199810000-00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000539-199810000-00014</ArticleId><ArticleId IdType="pubmed">9768776</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers A, Walker N, Schug S, McKee A, Kehlet H, Zundert A, Sage D, Futter M, Saville G, Clark T, MacMahon S. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ. 2000;321:1493. doi: 10.1136/bmj.321.7275.1493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.321.7275.1493</ArticleId><ArticleId IdType="pmc">PMC27550</ArticleId><ArticleId IdType="pubmed">11118174</ArticleId></ArticleIdList></Reference><Reference><Citation>Salinas FV, Liu SS, Mulroy MF. The effect of single-injection femoral nerve block versus continuous femoral nerve block after total knee arthroplasty on hospital length of stay and long-term functional recovery within an established clinical pathway. Anesth Analg. 2006;102:1234&#x2013;1239. doi: 10.1213/01.ane.0000198675.20279.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ane.0000198675.20279.81</ArticleId><ArticleId IdType="pubmed">16551930</ArticleId></ArticleIdList></Reference><Reference><Citation>Seet E, Leong WL, Yeo AS, Fook-Chong S. Effectiveness of 3-in-1 continuous femoral block of differing concentrations compared to patient controlled intravenous morphine for post total knee arthroplasty analgesia and knee rehabilitation. Anaesth Intensive Care. 2006;34:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">16494145</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpell MG, Millar FA, Thomson MF. Comparison of lumbar plexus block versus conventional opioid analgesia after total knee replacement. Anaesthesia. 1991;46:275&#x2013;277. doi: 10.1111/j.1365-2044.1991.tb11495.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2044.1991.tb11495.x</ArticleId><ArticleId IdType="pubmed">2024744</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharrock NE, Cazan MG, Hargett MJ, Williams-Russo P, Wilson PD., Jr. Changes in mortality after total hip and knee arthroplasty over a ten-year period. Anesth Analg. 1995;80:242&#x2013;248. doi: 10.1097/00000539-199502000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000539-199502000-00008</ArticleId><ArticleId IdType="pubmed">7818108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharrock NE, Go G, Williams-Russo P, Haas SB, Harpel PC. Comparison of extradural and general anaesthesia on the fibrinolytic response to total knee arthroplasty. Br J Anaesth. 1997;79:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9301385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharrock NE, Urquhart BL, Ganz S, Williams-Russo PG. Epidural infusions of bupivacaine and fentanyl do not improve rehabilitation following one-stage bilateral total knee arthroplasty. Ann Acad Med Singapore. 1994;23:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7710234</ArticleId></ArticleIdList></Reference><Reference><Citation>Singelyn FJ, Deyaert M, Joris D, Pendeville E, Gouverneur JM. Effects of intravenous patient-controlled analgesia with morphine, continuous epidural analgesia, and continuous three-in-one block on postoperative pain and knee rehabilitation after unilateral total knee arthroplasty. Anesth Analg. 1998;87:88&#x2013;92. doi: 10.1097/00000539-199807000-00019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000539-199807000-00019</ArticleId><ArticleId IdType="pubmed">9661552</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele SM, Klein SM, D&#x2019;Ercole FJ, Greengrass RA, Gleason D. A new continuous catheter delivery system. Anesth Analg. 1998;87:228. doi: 10.1097/00000539-199807000-00047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000539-199807000-00047</ArticleId><ArticleId IdType="pubmed">9661580</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczukowski MJ, Jr., Hines JA, Snell JA, Sisca TS. Femoral nerve block for total knee arthroplasty patients: a method to control postoperative pain. J Arthroplasty. 2004;19:720&#x2013;725. doi: 10.1016/j.arth.2004.02.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2004.02.043</ArticleId><ArticleId IdType="pubmed">15343531</ArticleId></ArticleIdList></Reference><Reference><Citation>Tugay N, Saricoaglu F, Satilmis T, Alpar U, Akarcali I, Citaker S, Tugay U, Atilla B, Tokgozoglu M. Single-injection femoral nerve block: effects of the independence level in functional activities in the early postoperative period in patients with total knee arthroplasty. Neurosciences. 2006;11:175&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">22266616</ArticleId></ArticleIdList></Reference><Reference><Citation>Urwin SC, Parker MJ, Griffiths R. General versus regional anaesthesia for hip fracture surgery: a meta-analysis of randomized trials. Br J Anaesth. 2000;84:450&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">10823094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Boctor B, Verner J. The effect of single-injection femoral nerve block on rehabilitation and length of hospital stay after total knee replacement. Reg Anesth Pain Med. 2002;27:139&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">11915059</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson MW, Mitra D, McLintock TC, Grant SA. Continuous versus single-injection lumbar plexus blocks: comparison of the effects on morphine use and early recovery after total knee arthroplasty. Reg Anesth Pain Med. 2005;30:541&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">16326339</ArticleId></ArticleIdList></Reference><Reference><Citation>Weller R, Rosenblum M, Conard P, Gross JB. Comparison of epidural and patient-controlled intravenous morphine following joint replacement surgery. Can J Anaesth. 1991;38:582&#x2013;586. doi: 10.1007/BF03008188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03008188</ArticleId><ArticleId IdType="pubmed">1934205</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams-Russo P, Sharrock NE, Haas SB, Insall J, Windsor RE, Laskin RS, Ranawat CS, Go G, Ganz SB. Randomized trial of epidural versus general anesthesia: outcomes after primary total knee replacement. Clin Orthop Relat Res. 1996;331:199&#x2013;208. doi: 10.1097/00003086-199610000-00028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003086-199610000-00028</ArticleId><ArticleId IdType="pubmed">8895639</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams-Russo P, Sharrock NE, Mattis S, Szatrowski TP, Charlson ME. Cognitive effects after epidural vs general anesthesia in older adults: a randomized trial. JAMA. 1995;274:44&#x2013;50. doi: 10.1001/jama.274.1.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.274.1.44</ArticleId><ArticleId IdType="pubmed">7791257</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CL, Hurley RW, Anderson GF, Herbert R, Rowlingson AJ, Fleisher LA. Effect of postoperative epidural analgesia on morbidity and mortality following surgery in Medicare patients. Reg Anesth Pain Med. 2004;29:525&#x2013;533; discussion 515&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">15635510</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaric D, Boysen K, Christiansen C, Christiansen J, Stephensen S, Christensen B. A comparison of epidural analgesia with combined continuous femoral-sciatic nerve blocks after total knee replacement. Anesth Analg. 2006;102:1240&#x2013;1246. doi: 10.1213/01.ane.0000198561.03742.50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/01.ane.0000198561.03742.50</ArticleId><ArticleId IdType="pubmed">16551931</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32958029</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1749-799X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of orthopaedic surgery and research</Title><ISOAbbreviation>J Orthop Surg Res</ISOAbbreviation></Journal><ArticleTitle>The choice of screw internal fixation and hemiarthroplasty in the treatment of femoral neck fractures in the elderly: a meta-analysis.</ArticleTitle><Pagination><StartPage>433</StartPage><MedlinePgn>433</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">433</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13018-020-01958-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Femoral neck fractures are common fractures in the elderly. Common treatment options include internal fixation (IF) and hemiarthroplasty (HA). However, the clinical application of these two options is always controversial due to the potential clinical trauma, postoperative function, early complications, and other factors.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Randomized controlled trials and cohort studies comparing screw fixation and hemiarthroplasty in elderly patients with displaced femoral neck fractures were extracted from databases such as PubMed, Web of Science, EMBASE, and Cochrane. The revised Jadad scale or NOS treatment evaluation form was used to evaluate the quality of the included studies. After extracting the data, the standard deviation of continuous data and the relative risk of binary data were used. The operation time, blood loss during operation, EQ-5D (EuroQol-5 Dimension) score, mortality rate, reoperation rate, and postoperative common complications were reviewed using Review Manager software (RevMan 5.3) were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 7 randomized controlled trials and 5 cohort studies. The results showed that the operation time, intraoperative blood loss, and short-term EQ-5D score of the internal fixation group were lower than those of the hemi-hip replacement group, but the reoperation rate was higher. There was no statistically significant difference in mortality and common complications such as deep vein thrombosis, pulmonary embolism, infection, and pressure sores during short-term follow-up.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In the treatment of elderly femoral neck fractures, the screw internal fixation group has shorter operation time and less intraoperative bleeding, and the perioperative advantage is more obvious. However, the hemi-hip replacement group had more advantages in postoperative functional scoring and reoperation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Shuai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Mathematics, Jilin University, Changchun, Jilin Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dehui</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Mathematics, Jilin University, Changchun, Jilin Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xuejie</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zehui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hand Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Wenlai</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-3494-9076</Identifier><AffiliationInfo><Affiliation>Department of Hand Surgery, The Second Hospital of Jilin University, Changchun, Jilin Province, China. 1031557032@qq.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Orthop Surg Res</MedlineTA><NlmUniqueID>101265112</NlmUniqueID><ISSNLinking>1749-799X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016063" MajorTopicYN="N">Blood Loss, Surgical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001863" MajorTopicYN="Y">Bone Screws</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005265" MajorTopicYN="N">Femoral Neck Fractures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005593" MajorTopicYN="N">Fracture Fixation, Internal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062785" MajorTopicYN="N">Hemiarthroplasty</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012086" MajorTopicYN="N">Reoperation</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020246" MajorTopicYN="N">Venous Thrombosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Femoral neck fractures</Keyword><Keyword MajorTopicYN="N">Hemiarthroplasty</Keyword><Keyword MajorTopicYN="N">Internal fixation</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">The elderly</Keyword></KeywordList><CoiStatement>The authors of this manuscript have no conflict of interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>22</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32958029</ArticleId><ArticleId IdType="pmc">PMC7507610</ArticleId><ArticleId IdType="doi">10.1186/s13018-020-01958-2</ArticleId><ArticleId IdType="pii">10.1186/s13018-020-01958-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sterling RS. Gender and race/ethnicity differences in hip fracture incidence, morbidity, mortality, and function[J] Clin Orthop Relat Res. 2011;469(7):1913&#x2013;1918. doi: 10.1007/s11999-010-1736-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-010-1736-3</ArticleId><ArticleId IdType="pmc">PMC3111795</ArticleId><ArticleId IdType="pubmed">21161737</ArticleId></ArticleIdList></Reference><Reference><Citation>Frihagen F, Nordsletten, et al. Hemiarthroplasty or internal fixation for intracapsular displaced femoral neck fractures: randomised controlled trial[J]. BMJ. 2007;335(7632):1251&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2137068</ArticleId><ArticleId IdType="pubmed">18056740</ArticleId></ArticleIdList></Reference><Reference><Citation>Damany DS, Parker MJ, Chojnowski A. Complications after intracapsular hip fractures in young adults. A meta-analysis of 18 published studies involving 564 fractures. Injury. 2005;36:131&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">15589931</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiontkowski MF. Comparison of internal fixation with total hip replacement for displaced femoral neck fractures: randomized, controlled trial performed at four years[J] Yearbook Orthopedics. 2006;2006:80&#x2013;81. doi: 10.1016/S0276-1092(08)70381-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0276-1092(08)70381-X</ArticleId><ArticleId IdType="pubmed">16085605</ArticleId></ArticleIdList></Reference><Reference><Citation>van Balen R, Steyerberg EW, Polder JJ, Ribbers TL, Habbema JD, Cools HJ. Hip fracture in elderly patients: outcomes for function, quality of life, and type of residence. Clin Orthop Relat Res. 2001;390:232&#x2013;243. doi: 10.1097/00003086-200109000-00027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003086-200109000-00027</ArticleId><ArticleId IdType="pubmed">11550871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Yao GL, Keller RB, Littenberg B, Wennberg JE. Outcomes after displaced fractures of the femoral neck. A meta-analysis of one hundred and six published reports. J Bone Joint Surg Am. 1994;76:15&#x2013;25. doi: 10.2106/00004623-199401000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-199401000-00003</ArticleId><ArticleId IdType="pubmed">8288658</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson T, Jacobsson SA, Ivarsson I, Knutsson A, Wahlstr&#xf6;m O. Internal fixation versus total hip arthroplasty in the treatment of displaced femoral neck fractures: A prospective randomized study of 100 hips. Acta Orthop Scand. 2000;71:597&#x2013;602. doi: 10.1080/000164700317362235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/000164700317362235</ArticleId><ArticleId IdType="pubmed">11145387</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari M, Devereaux PJ, Swiontkowski MF, Tornetta P, 3rd, Obremskey W, Koval KJ, et al. Internal fixation compared with arthroplasty for displaced fractures of the femoral neck. A meta-analysis. J Bone Joint Surg Am. 2003;85-A:1673&#x2013;1681. doi: 10.2106/00004623-200309000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/00004623-200309000-00004</ArticleId><ArticleId IdType="pubmed">12954824</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;10:1006&#x2013;1012. doi: 10.1016/j.jclinepi.2009.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2009.06.005</ArticleId><ArticleId IdType="pubmed">19631508</ArticleId></ArticleIdList></Reference><Reference><Citation>Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1. doi: 10.1016/0197-2456(95)00134-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(95)00134-4</ArticleId><ArticleId IdType="pubmed">8721797</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuyu MA, Qing HAN. Choose Model for Meta.[J] J Nanhua Univ (Science &amp; Engineering Edition) 2002;016(002):6&#x2013;13.</Citation></Reference><Reference><Citation>Higgins JPT. Green Se. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. (updated March 2011).</Citation></Reference><Reference><Citation>Puolakka TJ, Laine HJ, Tarvainen T, Aho H. Thompson hemiarthroplasty is superior to Ullevaal screws in treating displaced femoral neck fractures in patient over 75&#x2009;years: a prospective randomized study with two-year follow-up. Ann Chir Gynaecol. 2001;90:225&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">11695801</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker MJ, Khan RJK, Crawford J, et al. Hemiarthroplasty versus internal fixation for displaced intracapsular hip fractures in the elderly[J] J Bone Joint Surg Br Vol. 2002;84(8):1150&#x2013;1155. doi: 10.1302/0301-620X.84B8.0841150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.84B8.0841150</ArticleId><ArticleId IdType="pubmed">12463661</ArticleId></ArticleIdList></Reference><Reference><Citation>Frihagen F, Nordsletten L, Madsen JE. Hemiarthroplasty or internal fixation for intracapsular displaced femoral neck fractures: randomised controlled trial. BMJ. 2007;335:1251&#x2013;1254. doi: 10.1136/bmj.39399.456551.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39399.456551.25</ArticleId><ArticleId IdType="pmc">PMC2137068</ArticleId><ArticleId IdType="pubmed">18056740</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedbeck CJ, Inngul C, Blomfeldt R, Ponzer S, T&#xf6;rnkvist H, Enocson A. Internal fixation versus cemented hemiarthroplasty for displaced femoral neck fractures in patients with severe cognitive dysfunction: a randomized controlled trial. J Orthop Trauma. 2013;27:690&#x2013;695. doi: 10.1097/BOT.0b013e318291f544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOT.0b013e318291f544</ArticleId><ArticleId IdType="pubmed">23515127</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, He L, Zhang G, et al. Comparison of total costs between internal fixation and hemiarthroplasty for displaced femoral neck fractures[J]. J Orthop Sci Official J Japanese Orthop Assoc. 2016;22(1):75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">27693203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q, Tang G, Zhao X, et al. Hemiarthroplasty versus internal fixation in super-aged patients with undisplaced femoral neck fractures: a 5-year follow-up of randomized controlled trial[J]. Arch Orthop Trauma Surg. 2017;137:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">27837321</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolatowski FC, Frihagen F, Bartels S, et al. Screw fixation versus hemiarthroplasty for nondisplaced femoral neck fractures in elderly patients: a multicenter randomized controlled trial [J] J Bone Joint Surg Am. 2019;101:136&#x2013;144. doi: 10.2106/JBJS.18.00316.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.18.00316</ArticleId><ArticleId IdType="pubmed">30653043</ArticleId></ArticleIdList></Reference><Reference><Citation>Partanen J, Jalovaara P. Functional comparison between uncemented Austin-Moore hemiarthroplasty and osteosynthesis with three screws in displaced femoral neck fractures&#x2014;a matched-pair study of 168 patients[J] Int Orthop. 2004;28(1):28&#x2013;31. doi: 10.1007/s00264-003-0517-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00264-003-0517-y</ArticleId><ArticleId IdType="pmc">PMC3466578</ArticleId><ArticleId IdType="pubmed">14586571</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikand M, Wenn R, Moran CG. Mortality following surgery for undisplaced intracapsular hip fractures. Injury. 2004;35:1015&#x2013;1019. doi: 10.1016/j.injury.2004.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2004.01.004</ArticleId><ArticleId IdType="pubmed">15351669</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf8;rgul K, Reiker&#xe5;s O. Hemiarthroplasty in worst cases is better than internal fixation in best cases of displaced femoral neck fractures: a prospective study of 683 patients treated with hemiarthroplasty or internal fixation [J] Acta Orthopaedica. 2006;77(3):368&#x2013;374. doi: 10.1080/17453670610046271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17453670610046271</ArticleId><ArticleId IdType="pubmed">16819673</ArticleId></ArticleIdList></Reference><Reference><Citation>Gjertsen JE, Vinje T, Enges&#xe6;ter LB, et al. Internal screw fixation compared with bipolar hemiarthroplasty for treatment of displaced femoral neck fractures in elderly patients [J] J Bone Joint Surg Am Vol. 2010;92(3):619&#x2013;628. doi: 10.2106/JBJS.H.01750.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.H.01750</ArticleId><ArticleId IdType="pubmed">20194320</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels S, Gjertsen J-E, Frihagen F, et al. High failure rate after internal fixation and beneficial outcome after arthroplasty in treatment of displaced femoral neck fractures in patients between 55 and 70&#x2009;years[J]. Acta Orthopaedica. 2018;89:53&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5810833</ArticleId><ArticleId IdType="pubmed">28914130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedlund R, Lindgren U, Ahlbom A. Age- and sex-specific incidence of femoral neck and trochanteric fractures. An analysis based on 20,538 fractures in Stockholm County, Sweden, 1972- 1981. Clin Orthop Relat Res. 1987;222:132&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">3621713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lofthus CM, Osnes EK, Falch JA, Kaastad TS, Kristiansen IS, Nordsletten L, Stensvold I. Meyer HE Epidemiology of hip fractures in Oslo. Norway Bone. 2001;29:413&#x2013;418. doi: 10.1016/S8756-3282(01)00603-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S8756-3282(01)00603-2</ArticleId><ArticleId IdType="pubmed">11704490</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker MJ, Gurusamy K. Internal fixation versus arthroplasty for intracapsular proximal femoral fractures in adults. Cochrane Database Syst Rev. 2006;4:CD001708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8407320</ArticleId><ArticleId IdType="pubmed">17054139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Jiang B, Marshall RJ, Zhang P. Arthroplasty or internal fixation for displaced femoral neck fractures: which is the optimal alternative for elderly patients? A meta-analysis. Int Orthop. 2009;33:1179&#x2013;1187. doi: 10.1007/s00264-009-0763-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00264-009-0763-8</ArticleId><ArticleId IdType="pmc">PMC2899139</ArticleId><ArticleId IdType="pubmed">19343344</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Yang CH, Lin Q, et al. Does arthroplasty provide better outcomes than internal fixation at mid- and long-term followup? A meta-analysis[J] Clin Orthop Relat Res? 2015;473(8):2672&#x2013;2679. doi: 10.1007/s11999-015-4345-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-015-4345-3</ArticleId><ArticleId IdType="pmc">PMC4488202</ArticleId><ArticleId IdType="pubmed">25981713</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao H, Liu Z, Xing D, Gong M. Which is the best alternative for displaced femoral neck fractures in the elderly?: a meta-analysis. Clin Orthop Relat Res. 2012;470:1782&#x2013;1791. doi: 10.1007/s11999-012-2250-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-012-2250-6</ArticleId><ArticleId IdType="pmc">PMC3348330</ArticleId><ArticleId IdType="pubmed">22278852</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Yi Y, An L, Ming-Yuan X, et al. Arthroplasty versus internal fixation for displaced intracapsular femoral neck fracture in the elderly: systematic review and meta-analysis of short- and long-term effectiveness[J] Chin Med J. 2016;129(21):2630&#x2013;2638. doi: 10.4103/0366-6999.192788.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.192788</ArticleId><ArticleId IdType="pmc">PMC5125344</ArticleId><ArticleId IdType="pubmed">27779172</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng FJ, Chia WT, Pan RY, et al. Comparison of arthroplasty vs. osteosynthesis for displaced femoral neck fractures: a meta-analysis[J] J Orthop Surg Res. 2017;12(1):131. doi: 10.1186/s13018-017-0629-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13018-017-0629-5</ArticleId><ArticleId IdType="pmc">PMC5602948</ArticleId><ArticleId IdType="pubmed">28915928</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher MA, Matthei JD, Obirieze A, Ortega G, Tran DD, Carnegie DA, et al. Open reduction internal fixation versus hemiarthroplasty versus total hip arthroplasty in the elderly: a review of the National Surgical Quality Improvement Program database. J Surg Res. 2013;181:193&#x2013;198. doi: 10.1016/j.jss.2012.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2012.07.004</ArticleId><ArticleId IdType="pubmed">23122668</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36384306</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1938-2723</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><PubDate><Year>2022</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis</Title><ISOAbbreviation>Clin Appl Thromb Hemost</ISOAbbreviation></Journal><ArticleTitle>Prevalence, Outcome, and Optimal Management of Free-Floating Right Heart Thrombi in the Context of Pulmonary Embolism, a Systematic Review and Meta-Analysis.</ArticleTitle><Pagination><StartPage>10760296221140114</StartPage><MedlinePgn>10760296221140114</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10760296221140114</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/10760296221140114</ELocationID><Abstract><AbstractText>Free-floating right-heart thrombus (FFRHT) in the context of a pulmonary embolism (PE) is a rare but serious encounter with no guidelines addressing its management. We performed a systematic review and meta-analysis addressing prevalence, clinical behavior, and outcomes of FFRHT associated with PE. Among the included 397 patients with FFRHT and PE, dyspnea was the main presenting symptom (73.3%). Obstructive shock was documented in 48.9% of cases. Treatment with thrombolytic therapy, surgical thrombectomy, and percutaneous thrombectomy was documented in 43.8%, 32.7%, and 6.5% of patients, respectively. The overall mortality rate was 20.4%. Syncope (<i>p</i>: 0.027), chest pain (<i>p</i>: 0.006), and obstructive shock (<i>p</i>: 0.037) were significantly associated with mortality. Use of thrombolytic therapy was significantly associated with survival (<i>p</i>: 0.008). A multivariate logistic regression model to determine mortality predictors revealed that syncope (OR: 1.97, 95% CI: 1.06-3.65, <i>p</i>: 0.03), and obstructive shock (OR: 2.23, 95% CI: 1.20-4.14, <i>p</i>: 0.01) were associated with increased death odds. Treatment with thrombolytic therapy (OR: 0.22, 95% CI: 0.086-0.57, <i>p</i>: 0.002) or surgical thrombectomy (OR: 0.35, 95% CI: 0.137-0.9, <i>p</i>: 0.03) were associated with reduced death odds. Meta-analysis of observational studies revealed a pooled prevalence of FFRHT among all PE cases of 8.1%, and overall mortality of 23%. Although uncommon, the presence of FFRHT in the context of PE is associated with high obstructive shock and mortality rates. Favorable survival odds are observed with thrombolytic therapy and surgical thrombectomy. Data are derived from case reports and observational studies. Clinical trials elucidating these findings are needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Wanis H</ForeName><Initials>WH</Initials><Identifier Source="ORCID">0000-0001-6298-9959</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology and Internal Medicine, Weill-Cornell Medicine &amp; Hamad General Hospital, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ata</LastName><ForeName>Fateen</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7121-8574</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, 62849Hamad General Hospital, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choudry</LastName><ForeName>Hassan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, University Hospital of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Javed</LastName><ForeName>Huzaifa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medicine, 57979Cavan General Hospital, Cavan, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shunnar</LastName><ForeName>Khaled M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Heart Hospital, 36977Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shams</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, 62849Hamad General Hospital, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arshad</LastName><ForeName>Abdullah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, 62849Hamad General Hospital, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosom</LastName><ForeName>Adel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, 62849Hamad General Hospital, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elkahlout</LastName><ForeName>Mohammed H A</ForeName><Initials>MHA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, 62849Hamad General Hospital, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawaf</LastName><ForeName>Bisher</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, 62849Hamad General Hospital, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Shahda M A</ForeName><Initials>SMA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, 62849Hamad General Hospital, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olajide</LastName><ForeName>Tinuola</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0774-5860</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, 62849Hamad General Hospital, Doha, Qatar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Appl Thromb Hemost</MedlineTA><NlmUniqueID>9508125</NlmUniqueID><ISSNLinking>1076-0296</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013575" MajorTopicYN="N">Syncope</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">free-Floating right heart thrombi</Keyword><Keyword MajorTopicYN="N">pulmonary embolism</Keyword><Keyword MajorTopicYN="N">right heart thrombi</Keyword></KeywordList><CoiStatement>The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>17</Day><Hour>9</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36384306</ArticleId><ArticleId IdType="pmc">PMC9677292</ArticleId><ArticleId IdType="doi">10.1177/10760296221140114</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bellou E, Keramida E, Karampinis I, et al. Outpatient treatment of pulmonary embolism. Breathe (Sheff). 2020;16(3):200069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792861</ArticleId><ArticleId IdType="pubmed">33447272</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340-1347.</Citation><ArticleIdList><ArticleId IdType="pubmed">27126645</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffett L, Castellucci LA, Forgie MA. Pulmonary embolism: update on management and controversies. Br Med J. 2020;370:m2177.</Citation><ArticleIdList><ArticleId IdType="pubmed">32759284</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603.</Citation><ArticleIdList><ArticleId IdType="pubmed">31504429</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez Licha CR, McCurdy CM, Maldonado SM, Lee LS. Current management of acute pulmonary embolism. Ann Thorac Cardiovasc Surg. 2020;26(2):65-71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184035</ArticleId><ArticleId IdType="pubmed">31588070</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Elliott CG. Acute pulmonary embolism: Part I: epidemiology, pathophysiology, and diagnosis. Circulation. 2003;108(22):2726-2729.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656907</ArticleId></ArticleIdList></Reference><Reference><Citation>The European cooperative study on the clinical significance of right heart thrombi. European working group on echocardiography. Eur Heart J. 1989;10(12):1046-1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">2606115</ArticleId></ArticleIdList></Reference><Reference><Citation>Farfel Z, Shechter M, Vered Z, Rath S, Goor D, Gafni J. Review of echocardiographically diagnosed right heart entrapment of pulmonary emboli-in-transit with emphasis on management. Am Heart J. 1987;113(1):171-178.</Citation><ArticleIdList><ArticleId IdType="pubmed">3541555</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes CJ, Luppino Assad AP, Alves-Jr JL, Jardim C, de Souza R. Pulmonary embolism and gas exchange. Respiration. 2019;98(3):253-262.</Citation><ArticleIdList><ArticleId IdType="pubmed">31390642</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vrey EA, Bax JJ, Poldermans D, van der Wall EE, Holman ER. Mobile right heart thrombus and massive pulmonary embolism. Eur J Echocardiogr. 2007;8(3):229-231.</Citation><ArticleIdList><ArticleId IdType="pubmed">16716753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabrhel C, Rosovsky R, Garvey S. Special considerations in pulmonary embolism: clot-in-transit and incidental pulmonary embolism. Crit Care Clin. 2020;36(3):531-546.</Citation><ArticleIdList><ArticleId IdType="pubmed">32473697</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeano-Valle F, Demelo-Rodr&#xed;guez P, Garc&#xed;a-Fern&#xe1;ndez-Bravo I, et al. Early surgical treatment in patients with pulmonary embolism and thrombus-in-transit. J Thorac Dis. 2018;10(4):2338-2345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5949483</ArticleId><ArticleId IdType="pubmed">29850139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier L, B&#xe9;ra J, Delomez M, et al. Free-floating thrombi in the right heart: Diagnosis, management, and prognostic indexes in 38 consecutive patients. Circulation. 1999;99(21):2779-2783.</Citation><ArticleIdList><ArticleId IdType="pubmed">10351972</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine MN. Thrombolytic therapy in acute pulmonary embolism. Can J Cardiol. 1993;9(2):158-159.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490784</ArticleId></ArticleIdList></Reference><Reference><Citation>Athappan G, Sengodan P, Chacko P, Gandhi S. Comparative efficacy of different modalities for treatment of right heart thrombi in transit: a pooled analysis. Vasc Med. 2015;20(2):131-138.</Citation><ArticleIdList><ArticleId IdType="pubmed">25832601</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam M, Nesheim D, Acquah S, et al. Right heart thrombi: Patient outcomes by treatment modality and predictors of mortality: a pooled analysis. J Intensive Care Med. 2019;34(11-12):930-937.</Citation><ArticleIdList><ArticleId IdType="pubmed">30373436</ArticleId></ArticleIdList></Reference><Reference><Citation>Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712-716.</Citation><ArticleIdList><ArticleId IdType="pubmed">12956787</ArticleId></ArticleIdList></Reference><Reference><Citation>Moola S, Munn Z, Tufanaru C, et al.
Chapter 7: Systematic reviews of etiology and
risk. In: Aromataris E, Munn Z, eds. JBI Manual for Evidence
Synthesis. JBI; 2020.
Available from
https://synthesismanual.jbi.global.
10.46658/JBIMES-20-08. Accessed:
19-July-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.46658/JBIMES-20-08</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembcke A, Grubitzsch H, Hein PA. Pulmonary embolism and thrombus-in-transit crossing a patent foramen ovale: comprehensive diagnosis using cardiac multi-slice computed tomography. Eur J Cardiothorac Surg. 2016;49(1):356.</Citation><ArticleIdList><ArticleId IdType="pubmed">25732969</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariyanna PT, Hossain NA, Jayarangaiah A, et al. Thrombus in transit and impending pulmonary embolism detected on POCUS in a patient with COVID-19 pneumonia. Am J Med Case Rep. 2020;8(8):225-228.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko&#x107; M, Kostrubiec M, Elikowski W, et al. RiHTER Investigators. Outcome of patients with right heart thrombi: the right Heart Thrombi European Registry. Eur Respir J. 2016;47(3):869-875.</Citation><ArticleIdList><ArticleId IdType="pubmed">26797032</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivetti S, Aluffi E, Bonino L, et al. Obstructive shock in pulmonary embolism: thrombolytic therapy and survival. Crit Care. 2000;3(1):P242.</Citation></Reference><Reference><Citation>Perrier A, Bounameaux H. Ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med. 1998;128(3):243-243.</Citation><ArticleIdList><ArticleId IdType="pubmed">9454536</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med. 1998;129(12):1044-1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">9867760</ArticleId></ArticleIdList></Reference><Reference><Citation>Righini M, Le Gal G, Aujesky D, et al. Diagnosis of pulmonary embolism by multi-detector CT alone or combined with venous ultrasonography of the leg: a randomized non-inferiority trial. Lancet. 2008;371(9621):1343-1352.</Citation><ArticleIdList><ArticleId IdType="pubmed">18424324</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med. 1983;98(6):891-899.</Citation><ArticleIdList><ArticleId IdType="pubmed">6859705</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack CV, Schreiber D, Goldhaber SZ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter emergency medicine pulmonary embolism in the real world registry). J Am Coll Cardiol. 2011;57(6):700-706.</Citation><ArticleIdList><ArticleId IdType="pubmed">21292129</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharthy A, Faqihi F, Papanikolaou J, et al. Thrombolysis in severe COVID-19 pneumonia with massive pulmonary embolism. Am J Emerg Med. 2021;41:261.e1-261.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392155</ArticleId><ArticleId IdType="pubmed">32763101</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujikura K, Fontes JD, Taub CC. Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset. Echocardiography. 2020;37(8):1296-1299.</Citation><ArticleIdList><ArticleId IdType="pubmed">32735050</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus SE, Hajjari J, Cunningham MJ, et al. COVID-19: a case report of thrombus in transit. European Heart Journal - Case Reports. 2020;4(FI1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337692</ArticleId><ArticleId IdType="pubmed">33089047</ArticleId></ArticleIdList></Reference><Reference><Citation>Pla JJ, Rodriguez BF, Tirado CF. Free-floating right heart thrombus with pulmonary embolism in SARS-CoV-2 patient. Med Clin (Barc). 2020;155(9):415-416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836897</ArticleId><ArticleId IdType="pubmed">33521305</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan HMW, Khan MR, Munir A, Moughrabieh A, Changezi HU. A giant right-heart thrombus-in-transit in a patient with COVID-19 pneumonia. Am J Case Rep. 2020;21:e927380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680708</ArticleId><ArticleId IdType="pubmed">33201863</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Huerta MT, P&#xe9;rez-Santiago AD, P&#xe9;rez-Campos Mayoral L, et al. Mechanisms of immunothrombosis by SARS-CoV-2. Biomolecules. 2021;11(11):1550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8615366</ArticleId><ArticleId IdType="pubmed">34827548</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson T, S&#xf6;derberg S. Incidence of acute pulmonary embolism, related comorbidities, and survival; analysis of a Swedish national cohort. BMC Cardiovasc Disord. 2017;17(1):155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5471722</ArticleId><ArticleId IdType="pubmed">28615009</ArticleId></ArticleIdList></Reference><Reference><Citation>Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005;112(7):1063-1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103257</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinides S, Geibel A, Kasper W, Olschewski M, Bl&#xfc;mel L, Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation. 1998;97(19):1946-1951.</Citation><ArticleIdList><ArticleId IdType="pubmed">9609088</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrone D, Morrone V. Acute pulmonary embolism: focus on the clinical picture. Korean Circ J. 2018;48(5):365-381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5940642</ArticleId><ArticleId IdType="pubmed">29737640</ArticleId></ArticleIdList></Reference><Reference><Citation>Alt&#x131;nsoy B, Erboy F, Tanr&#x131;vedi H, et al. Syncope as a presentation of acute pulmonary embolism. Ther Clin Risk Manag. 2016;27(12):1023-1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930221</ArticleId><ArticleId IdType="pubmed">27390523</ArticleId></ArticleIdList></Reference><Reference><Citation>de Winter MA, van Bergen EDP, Welsing PMJ, Kraaijeveld AO, Kaasjager KHAH, Nijkeuter M. The prognostic value of syncope on mortality in patients with pulmonary embolism: a systematic review and meta-analysis. Ann Emerg Med. 2020;76(4):527-541.</Citation><ArticleIdList><ArticleId IdType="pubmed">32461009</ArticleId></ArticleIdList></Reference><Reference><Citation>Do&#x11f;an H, de Roos A, Geleijins J, Huisman MV, Kroft LJ. The role of computed tomography in the diagnosis of acute and chronic pulmonary embolism. Diagn Interv Radiol. 2015;21(4):307-316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4498425</ArticleId><ArticleId IdType="pubmed">26133321</ArticleId></ArticleIdList></Reference><Reference><Citation>Qanadli SD, Hajjam ME, Mesurolle B, et al. Pulmonary embolism detection: prospective evaluation of dual-section helical CT versus selective pulmonary arteriography in 157 patients. Radiology. 2000;217(2):447-455.</Citation><ArticleIdList><ArticleId IdType="pubmed">11058644</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein PD, Fowler SE, Goodman LR, et al. Multi-detector computed tomography for acute pulmonary embolism. N Engl J Med. 2006;354(22):2317-2327.</Citation><ArticleIdList><ArticleId IdType="pubmed">16738268</ArticleId></ArticleIdList></Reference><Reference><Citation>Winer-Muram HT, Boone JM, Brown HL, Jennings SG, Mabie WC, Lombardo GT. Pulmonary embolism in pregnant patients: fetal radiation dose with helical CT. Radiology. 2002;224(2):487-492.</Citation><ArticleIdList><ArticleId IdType="pubmed">12147847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim WH, Al-Shokri SD, Hussein MS, et al. Saddle versus non-saddle pulmonary embolism: differences in the clinical, echocardiographic, and outcome characteristics. Libyan J Med. 2022;17(1):2044597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8890508</ArticleId><ArticleId IdType="pubmed">35227164</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbagallo M, Naef D, K&#xf6;pfli P, et al. Right ventricular thrombus, a challenge in imaging diagnostics: a case series. Eur Heart J Case Rep. 2021;5(9):ytab340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491024</ArticleId><ArticleId IdType="pubmed">34622134</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest. 2002;121(3):806-814.</Citation><ArticleIdList><ArticleId IdType="pubmed">11888964</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney EL, Wright RJ. Efficacy of treatment of patients with echocardiographically detected right-sided heart thrombi: a meta-analysis. Am Heart J. 1989;118(3):569.</Citation><ArticleIdList><ArticleId IdType="pubmed">2773775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T, Itagaki S, Chiang YP, Egorova NN, Adams DH, Chikwe J. Survival and recurrence after acute pulmonary embolism treated with pulmonary embolectomy or thrombolysis in New York State, 1999 to 2013. J Thorac Cardiovasc Surg. 2018;155(3):1084-1090.e12.</Citation><ArticleIdList><ArticleId IdType="pubmed">28942971</ArticleId></ArticleIdList></Reference><Reference><Citation>Tafur AJ, Shamoun FE, Patel SI, Tafur D, Donna F, Murad MH. Catheter-directed treatment of pulmonary embolism: a systematic review and meta-analysis of modern literature. Clin Appl Thromb Hemost. 2017;23(7):821-829.</Citation><ArticleIdList><ArticleId IdType="pubmed">27481877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaymaz C, Akbal OY, Tanboga IH, et al. Ultrasound-assisted catheter-directed thrombolysis in high-risk and intermediate-high-risk pulmonary embolism: a meta-analysis. Curr Vasc Pharmacol. 2018;16(2):179-189.</Citation><ArticleIdList><ArticleId IdType="pubmed">28393706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando T, Abe H, Nagata T, et al. Reports of four surgical treatments of acute pulmonary embolism with a floating thrombus in the right atrium. Gen Thorac Cardiovasc Surg. 2011;59(10):705-708.</Citation><ArticleIdList><ArticleId IdType="pubmed">21984139</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltalarli A, Sirin BH, G&#xf6;k&#x15f;in I. Surgical treatment of cardiogenic shock due to huge right atrial thromboembolus. Acta Cardiol. 2000;55(4):261-263.</Citation><ArticleIdList><ArticleId IdType="pubmed">11041125</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui T, Shimizu Y, Takanashi S, et al. Acute pulmonary thromboembolism with a floating right-heart thrombus. 4 surgical cases. Jpn J Thorac Cardiovasc Surg. 2001;49(2):113-116.</Citation><ArticleIdList><ArticleId IdType="pubmed">11257766</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestico PF, Panidis IP, Kotler MN, Mintz GS, Ross J. Surgical removal of right atrial thromboembolus detected by two-dimensional echocardiography in pulmonary embolism. Am Heart J. 1984;107(6):1278-1280.</Citation><ArticleIdList><ArticleId IdType="pubmed">6720560</ArticleId></ArticleIdList></Reference><Reference><Citation>Moosavi J, Shafe O, Alizadehasl A, et al. Half-dose thrombolytic therapy in patients with right heart thrombi. J Int Med Res. 2019;47(7):3400-3407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6683889</ArticleId><ArticleId IdType="pubmed">31142170</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldhaber SZ, Nagel JS, Th&#xe9;ard M, Levine JD, Sutton MG. Treatment of right atrial thrombus with urokinase. Am Heart J. 1988;115(4):894-897.</Citation><ArticleIdList><ArticleId IdType="pubmed">3354417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso L, March&#xec; S, Mizio G, Iacona MA, Celona G. Echocardiographic detection of right-sided cardiac thrombi in pulmonary embolism. Chest. 1987;92(1):23-26.</Citation><ArticleIdList><ArticleId IdType="pubmed">3595245</ArticleId></ArticleIdList></Reference><Reference><Citation>Nkoke C, Faucher O, Camus L, Flork L. Free-floating right heart thrombus associated with acute pulmonary embolism: an unsettled therapeutic difficulty. Case Rep Cardiol. 2015;2015:364780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4442267</ArticleId><ArticleId IdType="pubmed">26078887</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernat A, Logar M, Zorman SK. Two cases of complications of the thrombolysis of right heart free-floating thrombi with pulmonary embolism: important role of echocardiographically-based management. Int J Clin Pract. 2004;58(6):628-631.</Citation><ArticleIdList><ArticleId IdType="pubmed">15311565</ArticleId></ArticleIdList></Reference><Reference><Citation>Martires JS, Stein SJ, Kamangar N. Right heart thrombus in transit diagnosed by bedside ultrasound. J Emerg Med. 2015;48(4):e105-e108.</Citation><ArticleIdList><ArticleId IdType="pubmed">25605322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ak&#x131;ll&#x131; H, G&#xfc;l EE, Ar&#x131;ba&#x15f; A, &#xd6;zdemir K, Kayrak M, Erdo&#x11f;an HI. Management of right heart thrombi associated with acute pulmonary embolism: A retrospective, single-center experience. Anadolu Kardiyol Derg. 2013;13(6):528-533.</Citation><ArticleIdList><ArticleId IdType="pubmed">23835298</ArticleId></ArticleIdList></Reference><Reference><Citation>Aujesky D, Stone RA, Kim S, Crick EJ, Fine MJ. Length of hospital stay and post-discharge mortality in patients with pulmonary embolism: a statewide perspective. Arch Intern Med. 2008;168(7):706-712.</Citation><ArticleIdList><ArticleId IdType="pubmed">18413552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasper W, Meinertz T, Henkel B, et al. Echocardiographic findings in patients with proved pulmonary embolism. Am Heart J. 1986;112(6):1284-1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">3788776</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Okada K, Matsumori M, Kano H, Kitagawa A, Okita Y. Aggressive surgical treatment of acute pulmonary embolism with circulatory collapse. Ann Thorac Surg. 2012;94(3):785-791.</Citation><ArticleIdList><ArticleId IdType="pubmed">22698769</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrios D, Rosa-Salazar V, Jim&#xe9;nez D, et al. RIETE Investigators. Right heart thrombi in pulmonary embolism. Eur Respir J. 2016;48(5):1377-1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">27799388</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26419832</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Issue>9</Issue><PubDate><Year>2015</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Thrombolytic therapy for pulmonary embolism.</ArticleTitle><Pagination><StartPage>CD004437</StartPage><MedlinePgn>CD004437</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/14651858.CD004437.pub4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Thrombolytic therapy (powerful anticoagulation drugs) is usually reserved for patients with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages. This is the second update of the Cochrane review first published in 2006.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the effects of thrombolytic therapy in patients with acute pulmonary embolism.</AbstractText><AbstractText Label="SEARCH METHODS" NlmCategory="METHODS">For this update the Cochrane Vascular Group searched their Specialised Register (last searched September 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (last searched Issue 8, 2014). We also searched individual trial collections and private databases, along with bibliographies of relevant articles. We handsearched relevant medical journals.</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomised controlled trials (RCTs) that compared thrombolytic therapy followed by heparin versus heparin alone, heparin plus placebo or surgical intervention in patients with acute PE. We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two authors (BD and QH) assessed the eligibility and quality of trials and extracted data.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">We identified 18 trials with a total of 2197 participants for inclusion in the review. We were not able to include one study in the meta-analysis because it had no data to extract. Most of the studies carried a high risk of bias because of high or unclear risk relating to randomisation and blinding. Meta-analysis showed that, compared with heparin alone, or heparin plus placebo, thrombolytics plus heparin can reduce the odds of death (odds ratio (OR) 0.57, 95% confidence interval (CI) 0.37 to 0.87, P = 0.02, low quality evidence) and recurrence of PE (OR 0.51; 95% CI 0.29 to 0.89, P = 0.02, low quality evidence). The effects of death weakened when we excluded four studies at high risk of bias from analysis: OR 0.66, 95% CI 0.42 to 1.06, P = 0.08. The incidence of major and minor haemorrhagic events was higher in the thrombolytics group than in the control group, and this difference was statistically significant (OR 2.90, 95% CI 1.95 to 4.31, P &lt; 0.001, low quality evidence; OR 3.09, 95% CI 1.58 to 6.06, P = 0.001, very low quality evidence, respectively). Length of hospital stay (mean difference (MD) -1.35, 95% CI -4.27 to 1.58) and quality of life were similar between the two treatment groups. Stroke was reported in one study and occurred more often in the thrombolytics group than in the control group, although the confidence interval was wide (OR 12.10, 95% CI 1.57 to 93.39). Limited information from a small number of trials indicated that thrombolytics may improve haemodynamic outcomes, perfusion lung scanning, pulmonary angiogram assessment, echocardiograms, pulmonary hypertension, coagulation parameters, clinical outcomes and survival time to a greater extent than heparin alone. However, the heterogeneity of the studies and small number of participants involved warrant caution when interpreting results. Similarily, fewer patients from the thrombolytics group required escalation of treatment. None of the included studies reported on post-thrombotic syndrome or compared the cost of the different treatments.</AbstractText><AbstractText Label="AUTHORS' CONCLUSIONS" NlmCategory="CONCLUSIONS">There is low quality evidence that thrombolytics reduce death following acute pulmonary embolism compared with heparin. Furthermore, thrombolytic therapies included in the review were heterogeneous. Thrombolytic therapy may be helpful in reducing the recurrence of pulmonary emboli but may cause more major and minor haemorrhagic events and stroke. More high quality double blind RCTs assessing safety and cost-effectiveness are required.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Qiukui</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Center of Geriatrics and Gerontology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Bi Rong</ForeName><Initials>BR</Initials></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Jirong</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Taixiang</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guan J</ForeName><Initials>GJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CZB/4/788</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ETM/442</GrantID><Acronym>CSO_</Acronym><Agency>Chief Scientist Office</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-49-6</RegistryNumber><NameOfSubstance UI="D006493">Heparin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Cochrane Database Syst Rev. 2009 Jul 08;(3):CD004437. doi: 10.1002/14651858.CD004437.pub3.</RefSource><PMID Version="1">19588357</PMID></CommentsCorrections><CommentsCorrections RefType="UpdateIn"><RefSource>Cochrane Database Syst Rev. 2018 Dec 18;12:CD004437. doi: 10.1002/14651858.CD004437.pub5.</RefSource><PMID Version="1">30560579</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006493" MajorTopicYN="N">Heparin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="N">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015912" MajorTopicYN="N">Thrombolytic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26419832</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD004437.pub4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>